nitrophila O
be O
a O
small O
genus O
of O
flower O
B-Plant O
in O
the O
amaranth O
family O
sometimes O
know O
by O
the O
common O
name O
niterwort B-Plant
. O

labdanum B-Plant
, O
also O
call O
ladanum O
, O
laudanum B-Plant
, O
ladan O
or O
ladanon O
, O
be O
a O
sticky O
brown O
resin O
obtain O
from O
the O
shrub O
cistus B-Plant
ladanifer I-Plant
( O
western O
mediterranean O
) O
and O
cistus B-Plant
creticus I-Plant
( O
eastern O
mediterranean O
) O
, O
specie O
of O
rockrose B-Plant
. O

capnoides B-Plant
semperviren I-Plant
, O
the O
harlequin B-Plant
corydalis O
, O
rock B-Plant
harlequin I-Plant
, O
pale B-Plant
corydalis I-Plant
or O
pink B-Plant
corydalis I-Plant
, O
be O
an O
annual O
or O
biennial O
B-Plant O
native O
to O
rocky O
woodland O
and O
burn O
or O
disturbed O
place O
in O
northern O
north O
america O
. O

capnoides B-Plant
semperviren I-Plant
be O
the O
only O
specie O
in O
the O
genus O
capnoides O
. O

capnoide O
elegan O
kuntze O
, O
a O
synonym O
for O
corydalis B-Plant
elegan I-Plant
cunila B-Plant
origanoid I-Plant
-- O
common O
name O
stone B-Plant
mint I-Plant
, O
frost B-Plant
mint I-Plant
, O
dittany B-Plant
, O
and O
american B-Plant
dittany I-Plant
-- O
be O
a O
perennial O
late O
- O
summer O
- O
flower O
subshrub O
with O
small O
purple O
flower O
, O
which O
be O
native O
to O
the O
eastern O
united O
states O
. O

this O
species O
have O
historically O
be O
cultivate O
for O
use O
as O
a O
medicinal O
herb O
, O
tea B-Plant
, O
and O
ornamental O
B-Plant O
. O

the O
genus O
androstephium O
be O
a O
group O
of O
north O
american O
B-Plant O
in O
the O
cluster O
lily B-Plant
subfamily O
within O
the O
asparagus O
family O
. O

cyperus O
be O
a O
large O
genus O
of O
about O
700 O
specie O
of O
sedge B-Plant
, O
distribute O
throughout O
all O
continent O
in O
both O
tropical O
and O
temperate O
region O
. O

cimicifuga O
( O
bugbane B-Plant
or O
cohosh B-Plant
) O
be O
a O
genus O
of O
between O
12 O
- O
18 O
specie O
of O
flower O
B-Plant O
belong O
to O
the O
family O
ranunculaceae O
, O
native O
to O
temperate O
region O
of O
the O
northern O
hemisphere O
. O

the O
white B-Plant
meadowfoam I-Plant
limnanthes B-Plant
alba I-Plant
be O
of O
commercial O
interest O
for O
oil O
, O
while O
several O
other O
specie O
be O
rare O
or O
endanger O
. O

l. B-Plant
douglasii I-Plant
be O
widely O
cultivate O
as O
a O
hardy O
annual O
, O
-PRON- O
white O
and O
yellow O
flower O
colour O
give O
-PRON- O
the O
common O
name O
of O
poached O
egg O
B-Plant O
. O

tillandsia B-Plant
flabellata I-Plant
be O
a O
species O
in O
the O
genus O
tillandsia O
. O

bulbophyllum B-Plant
dolichoglottis I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
, O
section O
codonosiphon O
schlechter O
1913 O
. O

haloxylon O
and O
-PRON- O
specie O
be O
know O
by O
the O
common O
name O
saxaul B-Plant
. O

allium O
be O
a O
genus O
of O
monocotyledonous O
flower O
B-Plant O
that O
include O
hundred O
of O
specie O
, O
include O
the O
cultivate O
onion B-Plant
, O
garlic B-Plant
, O
scallion B-Plant
, O
shallot B-Plant
, O
leek B-Plant
, O
and O
chive B-Plant
. O

the O
generic O
name O
allium O
be O
the O
latin O
word O
for O
garlic B-Plant
, O
and O
the O
type O
specie O
for O
the O
genus O
be O
allium B-Plant
sativum I-Plant
which O
mean O
cultivate O
first O
describe O
the O
genus O
allium O
in O
1753 O
. O

some O
source O
refer O
to O
greek O
αλεω O
( O
aleo O
, O
to O
avoid O
) O
by O
reason O
of O
the O
smell O
of O
garlic B-Plant
. O

estimate O
of O
the O
number O
of O
specie O
be O
as O
low O
as O
260 O
, O
and O
as O
high O
as O
979 O
allium O
specie O
occur O
in O
temperate O
climate O
of O
the O
northern O
hemisphere O
, O
except O
for O
a O
few O
specie O
occur O
in O
chile O
( O
such O
as O
a. B-Plant
juncifolium I-Plant
) O
, O
brazil O
( O
a. B-Plant
sellovianum I-Plant
) O
, O
and O
tropical O
africa O
( O
a. B-Plant
spathaceum I-Plant
) O
. O

some O
specie O
( O
such O
as O
welsh B-Plant
onion I-Plant
a. B-Plant
fistulosum I-Plant
) O
develop O
thickened O
leaf O
- O
base O
rather O
than O
form O
bulb O
as O
such O
. O

B-Plant O
of O
the O
genus O
allium O
produce O
chemical O
compound O
, O
mostly O
derive O
from O
cysteine O
sulfoxide O
, O
that O
give O
a O
characteristic O
onion B-Plant
, O
or O
garlic B-Plant
, O
taste O
and O
odor O
. O

bulbophyllum B-Plant
minutum I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

the O
venus O
comb B-Plant
murex O
, O
after O
scientific O
name O
murex O
pecten O
juglans B-Plant
ailantifolia I-Plant
( O
synonym O
j. B-Plant
cordiformis I-Plant
and O
j. B-Plant
sieboldiana I-Plant
and O
j. B-Plant
mandshurica I-Plant
var I-Plant
sachalinensis I-Plant
) O
, O
the O
japanese B-Plant
walnut I-Plant
( O
japanese O
: O
oni O
- O
gurumi O
) O
, O
be O
a O
species O
of O
walnut B-Plant
native O
to O
japan O
and O
sakhalin O
. O

xylopia B-Plant
aethiopica I-Plant
be O
an O
evergreen O
, O
aromatic O
tree O
, O
of O
the O
annonaceae O
family O
that O
can O
grow O
up O
to O
20 O
m O
high O
. O

be O
a O
native O
to O
the O
lowland O
rainfor O
and O
moist O
fringe B-Plant
forest O
in O
the O
savanna O
zone O
of O
africa O
. O

the O
dry O
fruit O
of O
x. B-Plant
aethiopica I-Plant
( O
grain O
of O
selim O
) O
be O
use O
as O
a O
spice O
and O
an O
herbal O
medicine O
. O

be O
sometimes O
employ O
as O
honey O
B-Plant O
, O
notably O
c. B-Plant
decandra I-Plant
and O
c. B-Plant
sylvestris I-Plant
. O

some O
appear O
close O
to O
extinction O
, O
and O
c. B-Plant
quinduensis I-Plant
of O
colombia O
and O
c. B-Plant
tinifolia I-Plant
from O
mauritius O
seem O
to O
be O
extinct O
since O
some O
time O
in O
the O
20th O
century O
and O
about O
1976 O
, O
respectively O
. O

these O
B-Plant O
often O
parasitize O
alder B-Plant
but O
be O
find O
on O
many O
other O
B-Plant O
. O

b. B-Plant
hookeri I-Plant
may O
be O
find O
on O
salal B-Plant
and O
huckleberry O
, O
and O
b. B-Plant
strobilacea I-Plant
grow O
on O
manzanita B-Plant
and O
madrone O
. O

groundcone O
often O
look O
at O
first O
glance O
like O
pine B-Plant
cone O
lie O
on O
the O
ground O
, O
especially O
when O
-PRON- O
be O
brown O
in O
color O
. O

each O
B-Plant O
may O
be O
a O
few O
inch O
tall O
, O
and O
pine B-Plant
- O
cone O
- O
shape O
or O
cylindrical O
. O

vanda B-Plant
be O
a O
genus O
in O
the O
orchid O
family O
, O
orchidaceae O
. O

this O
genus O
and O
ally O
be O
consider O
to O
be O
among O
the O
most O
specifically O
adapt O
of O
all O
orchid B-Plant
within O
the O
orchidaceae O
. O

vanda B-Plant
specie O
be O
widespread O
across O
east O
asia O
, O
southeast O
asia O
, O
and O
new O
guinea O
, O
with O
a O
few O
specie O
extend O
into O
queensland O
and O
some O
of O
the O
island O
of O
the O
western O
pacific O
. O

the O
oat B-Plant
( O
avena B-Plant
sativa I-Plant
) O
, O
sometimes O
call O
the O
common B-Plant
oat I-Plant
, O
be O
a O
species O
of O
cereal O
grain O
grow O
for O
seed O
, O
which O
be O
know O
by O
the O
same O
name O
( O
usually O
in O
the O
plural O
, O
unlike O
other O
cereal O
and O
pseudocereal O
) O
. O

while O
oat B-Plant
be O
suitable O
for O
human O
consumption O
as O
oatmeal O
and O
roll O
oats B-Plant
, O
one O
of O
the O
most O
common O
us O
be O
as O
livestock O
feed O
. O

oat B-Plant
be O
a O
nutrient O
- O
rich O
food O
associate O
with O
low O
blood O
cholesterol O
when O
consume O
regularly O
. O

avenin O
present O
in O
oats B-Plant
( O
protein O
similar O
to O
gliadin O
from O
wheat B-Plant
) O
can O
trigger O
celiac O
disease O
in O
a O
small O
proportion O
of O
people O
. O

also O
, O
oat B-Plant
product O
be O
frequently O
contaminate O
by O
other O
gluten O
- O
contain O
grain O
, O
mainly O
wheat B-Plant
and O
barley B-Plant
. O

sporobolus B-Plant
heterolepis I-Plant
, O
commonly O
know O
as O
prairie B-Plant
dropseed I-Plant
, O
be O
a O
species O
of O
prairie B-Plant
grass I-Plant
native O
to O
the O
tallgrass O
and O
mixed O
grass O
prairie O
of O
central O
north O
america O
from O
texas O
to O
southern O
canada O
. O

bolbocoleon O
be O
a O
genus O
of O
green O
algae B-Plant
, O
in O
the O
family O
bolbocoleonaceae O
. O

senecio B-Plant
vernali I-Plant
be O
one O
of O
the O
european O
specie O
of O
senecio O
, O
an O
annual O
that O
be O
also O
know O
as O
eastern B-Plant
groundsel I-Plant
. O

while O
have O
be O
long O
classify O
as O
senecio B-Plant
vernali I-Plant
, O
this O
species O
have O
more O
recently O
be O
describe O
as O
a O
subspecie O
of O
senecio B-Plant
leucanthemifolius I-Plant
and O
be O
now O
include O
by O
some O
in O
that O
specie O
. O

cleisostoma O
be O
a O
genus O
of O
orchid B-Plant
with O
approximately O
90 O
accept O
specie O
widely O
distribute O
through O
much O
of O
the O
indian O
subcontinent O
, O
southeast O
asia O
, O
china O
, O
new O
guinea O
, O
and O
some O
of O
the O
island O
of O
the O
western O
pacific O
. O

salvia B-Plant
be O
the O
large O
genus O
of O
B-Plant O
in O
the O
mint O
family O
, O
lamiaceae O
, O
with O
nearly O
1000 O
specie O
of O
shrub O
, O
herbaceous O
perennial O
, O
and O
annual O
. O

within O
the O
lamiaceae O
, O
salvia B-Plant
be O
part O
of O
the O
tribe O
mentheae O
within O
the O
subfamily O
nepetoideae O
. O

be O
one O
of O
several O
genera O
commonly O
refer O
to O
as O
sage B-Plant
, O
-PRON- O
include O
the O
widely O
produce O
herb O
use O
in O
cooking O
, O
salvia B-Plant
officinali I-Plant
( O
common B-Plant
sage I-Plant
, O
or O
just O
sage B-Plant
) O
. O

gennaria B-Plant
diphylla I-Plant
be O
a O
species O
of O
flower O
B-Plant O
from O
the O
orchid O
family O
, O
orchidaceae O
, O
native O
to O
the O
region O
from O
the O
western O
mediterranean O
and O
macaronesia O
( O
canary O
islands O
, O
madeira O
, O
portugal O
, O
spain O
, O
the O
balearic O
islands O
, O
morocco O
, O
algeria O
, O
tunisia O
, O
sardinia O
, O
tuscany O
) O
. O

gennaria B-Plant
diphylla I-Plant
be O
illustrate O
( O
as O
habenaria B-Plant
cordata I-Plant
) O
in O
plate O
3164 O
of O
curtis O
' O
botanical O
magazine O
, O
1832 O
. O

rigiopappus B-Plant
be O
a O
genus O
of O
north O
american O
B-Plant O
in O
the O
aster B-Plant
tribe O
within O
the O
sunflower O
family O
. O

speciesthe O
only O
know O
specie O
be O
rigiopappus B-Plant
leptocladus I-Plant
, O
sometimes O
know O
as O
wireweed B-Plant
. O

anthurium B-Plant
acaule I-Plant
be O
a O
herbaceous O
B-Plant O
native O
to O
the O
lesser O
antilles O
. O

the O
B-Plant O
have O
a O
complicated O
taxonomic O
history O
, O
and O
the O
name O
anthurium B-Plant
acaule I-Plant
have O
be O
apply O
to O
several O
other O
B-Plant O
. O

coryphothamnus B-Plant
auyantepuiensis I-Plant
, O
which O
be O
endemic O
to O
southern O
venezuela O
. O

astronium B-Plant
fraxinifolium I-Plant
be O
a O
timber O
tree O
, O
which O
be O
native O
to O
amazon O
rainforest O
, O
atlantic O
forest O
, O
caatinga O
, O
and O
cerrado O
vegetation O
in O
brazil O
. O

common O
name O
include O
kingwood B-Plant
, O
locustwood B-Plant
, O
tigerwood B-Plant
, O
and O
zebrawood B-Plant
. O

be O
also O
use O
to O
make O
hardwood O
such O
as O
tigerwood B-Plant
. O

the O
torrey B-Plant
pine I-Plant
, O
pinus B-Plant
torreyana I-Plant
, O
be O
a O
rare O
pine B-Plant
specie O
in O
the O
united O
states O
. O

be O
an O
endanger O
specie O
grow O
only O
in O
the O
torrey O
pines B-Plant
state O
natural O
reserve O
, O
coastal O
northern O
san O
diego O
county O
, O
and O
on O
santa O
rosa O
island O
. O

this O
species O
be O
endemic O
to O
the O
coastal O
sage B-Plant
and O
chaparral O
ecoregion O
in O
the O
u.s. O
state O
of O
california O
. O

helenium O
be O
a O
genus O
of O
annual O
and O
herbaceous O
perennial O
in O
the O
sunflower O
family O
native O
to O
the O
americas O
. O

bear O
yellow O
or O
orange B-Plant
daisy I-Plant
- O
like O
composite O
flower O
. O

a O
number O
of O
these O
specie O
( O
particularly O
helenium B-Plant
autumnale I-Plant
) O
have O
the O
common O
name O
sneezeweed B-Plant
, O
base O
on O
the O
former O
use O
of O
dry O
leaf O
in O
make O
snuff O
. O

prunus B-Plant
laurocerasus I-Plant
, O
also O
know O
as O
cherry B-Plant
laurel I-Plant
, O
common O
laurel B-Plant
and O
sometimes O
english B-Plant
laurel I-Plant
in O
north O
america O
, O
be O
an O
evergreen O
specie O
of O
cherry B-Plant
( O
prunus O
) O
, O
native O
to O
region O
border O
the O
black O
sea O
in O
southwestern O
asia O
and O
southeastern O
europe O
, O
from O
albania O
and O
bulgaria O
east O
through O
turkey O
to O
the O
caucasus O
mountains O
and O
northern O
iran O
. O

the O
common O
name O
of O
p. B-Plant
laurocerasus I-Plant
refer O
to O
the O
similarity O
of O
foliage O
and O
appearance O
to O
bay B-Plant
laurel I-Plant
( O
laurus B-Plant
nobili I-Plant
, O
the O
laurel B-Plant
, O
in O
the O
lauraceae O
family O
) O
, O
and O
like O
the O
bay B-Plant
laurel I-Plant
, O
prunus B-Plant
laurocerasus I-Plant
be O
use O
for O
make O
laurel B-Plant
wreath O
, O
but O
the O
two O
B-Plant O
be O
unrelated O
. O

be O
not O
to O
be O
confuse O
with O
american O
relative O
prunus B-Plant
caroliniana I-Plant
, O
which O
be O
also O
call O
cherry B-Plant
laurel I-Plant
. O

quassia B-Plant
( O
or O
) O
be O
a O
flora O
genus O
in O
the O
family O
simaroubaceae O
. O

some O
botanist O
treat O
as O
consist O
of O
only O
one O
specie O
, O
quassia B-Plant
amara I-Plant
from O
tropical O
south O
america O
, O
while O
other O
treat O
-PRON- O
in O
a O
wide O
circumscription O
as O
a O
pantropical O
genus O
contain O
up O
to O
40 O
specie O
of O
tree O
and O
shrub O
. O

discover O
the O
medicinal O
property O
of O
the O
bark O
of O
quassia B-Plant
amara I-Plant
. O

quassia B-Plant
undulatait O
be O
the O
source O
of O
the O
quassinoid O
quassin O
and O
neo O
- O
quassin O
. O

chamaecyparis B-Plant
obtusa I-Plant
( O
japanese O
cypress B-Plant
, O
hinoki B-Plant
cypress I-Plant
or O
hinoki O
japanese O
: O
or O
hinoki O
) O
be O
a O
species O
of O
cypress B-Plant
native O
to O
central O
japan O
. O

be O
a O
slow O
- O
grow O
tree O
which O
grow O
to O
35 O
m O
tall O
with O
a O
trunk O
up O
to O
1 O
m O
in O
diameter O
. O

the O
related O
chamaecyparis B-Plant
pisifera I-Plant
( O
sawara B-Plant
cypress I-Plant
) O
can O
be O
readily O
distinguish O
in O
have O
pointed O
tip O
to O
the O
leaf O
and O
small O
cone O
. O

speciesthe O
only O
know O
specie O
be O
lamarckia B-Plant
aurea I-Plant
, O
the O
golden B-Plant
dog's I-Plant
- I-Plant
tail I-Plant
or O
goldentop B-Plant
grass I-Plant
camaridium O
be O
a O
genus O
of O
epiphytic O
orchid B-Plant
widespread O
across O
the O
west O
indies O
and O
through O
latin O
america O
from O
mexico O
to O
bolivia O
. O

one O
species O
extend O
into O
florida O
( O
c. B-Plant
vestitum I-Plant
, O
list O
in O
flora O
of O
north O
america O
under O
the O
synonym O
, O
maxillaria O
parviflora O
) O
the O
genus O
be O
long O
include O
as O
part O
of O
maxillaria O
but O
recent O
molecular O
study O
have O
indicate O
that O
maxillaria O
should O
be O
split O
into O
several O
genera O
. O

doronicum B-Plant
grandiflorum I-Plant
be O
a O
european O
specie O
of O
doronicum O
, O
a O
member O
of O
the O
aster O
family O
. O

doronicum B-Plant
grandiflorum I-Plant
be O
a O
perennial O
herb O
grow O
10–40 O
cm O
. O

epacris B-Plant
longiflora I-Plant
, O
commonly O
know O
as O
the O
fuchsia O
heath O
, O
be O
a O
B-Plant O
in O
the O
family O
ericaceae O
and O
be O
endemic O
to O
eastern O
australia O
. O

damasonium B-Plant
californicum I-Plant
be O
a O
species O
of O
perennial O
wildflower O
in O
the O
water O
B-Plantain O
family O
which O
be O
know O
by O
the O
common O
name O
fringe B-Plant
water I-Plant
- I-Plant
B-Plantain I-Plant
, O
or O
star B-Plant
water I-Plant
- I-Plant
B-Plantain I-Plant
. O

damasonium B-Plant
californicum I-Plant
be O
a O
resident O
of O
pond O
, O
riverside O
, O
and O
vernal O
pool O
. O

comparettia O
, O
abbreviate O
comp O
in O
the O
horticultural O
trade O
, O
be O
a O
genus O
of O
orchid B-Plant
. O

huperzia O
be O
a O
genus O
of O
lycophyte O
B-Plant O
, O
sometimes O
know O
as O
the O
firmoss O
or O
fir B-Plant
clubmoss O
. O

the O
common O
name O
firmoss O
, O
use O
for O
some O
of O
the O
north O
temperate O
specie O
, O
refer O
to O
superficial O
resemblance O
to O
branch O
of O
fir B-Plant
( O
abies O
) O
, O
a O
conifer B-Plant
. O

in O
australia O
, O
the O
epiphytic O
specie O
be O
commonly O
know O
as O
tassel B-Plant
fern I-Plant
. O

two O
specie O
( O
m. B-Plant
oppositifolius I-Plant
and O
m. B-Plant
subulatus I-Plant
) O
be O
find O
in O
tropical O
africa O
and O
madagascar O
. O

quebracho B-Plant
blanco O
, O
call O
kebrako B-Plant
or O
white B-Plant
quebracho I-Plant
, O
be O
a O
south O
american O
tree O
specie O
, O
native O
to O
brazil O
, O
n O
argentina O
, O
bolivia O
, O
paraguay O
, O
and O
uruguay O
. O

must O
not O
be O
confuse O
with O
other O
specie O
also O
know O
as O
quebracho B-Plant
, O
but O
belong O
to O
the O
genus O
schinopsis B-Plant
. O

malacothrix O
be O
a O
genus O
of O
B-Plant O
in O
the O
dandelion B-Plant
tribe O
within O
the O
sunflower O
family O
. O

be O
know O
generally O
as O
desert O
dandelion B-Plant
or O
desertdandelion O
. O

eucalyptus B-Plant
websteriana I-Plant
, O
commonly O
know O
as O
webster B-Plant
's I-Plant
mallee I-Plant
, O
be O
a O
mallee B-Plant
that O
be O
native O
to O
the O
goldfields O
- O
esperance O
region O
of O
western O
australia O
. O

the O
mallee B-Plant
typically O
grow O
to O
a O
height O
of O
around O
4 O
metre O
( O
13 O
ft O
) O
and O
have O
a O
spread O
habit O
and O
minni B-Plant
ritchi O
type O
bark O
. O

typha B-Plant
angustifolia I-Plant
l. I-Plant
( O
also O
less B-Plant
bulrush I-Plant
, O
narrowleaf B-Plant
cattail I-Plant
or O
less O
reedmace O
) O
be O
a O
perennial O
herbaceous O
B-Plant O
of O
genus O
typha O
. O

this O
cattail B-Plant
be O
an O
obligate O
wetland O
specie O
that O
be O
commonly O
find O
in O
the O
northern O
hemisphere O
in O
brackish O
location O
. O

the O
geographic O
range O
of O
typha B-Plant
angustifolia I-Plant
overlap O
with O
the O
very O
similar O
specie O
typha B-Plant
latifolia I-Plant
( O
broadleaf B-Plant
or O
common B-Plant
cattail I-Plant
) O
. O

t. B-Plant
angustifolia I-Plant
can O
be O
distinguish O
from O
t. B-Plant
latifolia I-Plant
by O
narrow O
leaf O
and O
by O
a O
clear O
separation O
of O
two O
different O
region O
( O
staminate O
flower O
above O
and O
pistilate O
flower O
below O
) O
on O
the O
flower O
head O
. O

the O
species O
hybridize O
as O
typha B-Plant
x I-Plant
glauca O
( O
typha B-Plant
angustifolia I-Plant
x O
t. B-Plant
latifolia I-Plant
) O
( O
white O
cattail B-Plant
) O
typha B-Plant
x I-Plant
glauca O
be O
not O
a O
distinct O
specie O
, O
but O
be O
rather O
a O
sterile O
f1 O
hybrid O
. O

broadleaf B-Plant
cattail I-Plant
be O
usually O
find O
in O
shallow O
water O
than O
narrowleaf B-Plant
cattail I-Plant
. O

hornwort B-Plant
be O
a O
group O
of O
non O
- O
vascular O
B-Plant O
constitute O
the O
division O
anthocerotophyta O
. O

as O
in O
moss B-Plant
and O
liverwort B-Plant
, O
the O
flattened O
, O
green O
B-Plant O
body O
of O
a O
hornwort B-Plant
be O
the O
gametophyte O
B-Plant O
. O

hornwort B-Plant
may O
be O
find O
worldwide O
, O
though O
tend O
to O
grow O
only O
in O
place O
that O
be O
damp O
or O
humid O
. O

many O
be O
know O
by O
the O
general O
common O
name O
indigo B-Plant
bush I-Plant
. O

tasmannia B-Plant
lanceolata I-Plant
( O
syn O
drimys B-Plant
lanceolata I-Plant
) O
, O
commonly O
know O
as O
the O
mountain B-Plant
pepper I-Plant
( O
aus O
) O
, O
or O
cornish O
pepper B-Plant
leaf O
( O
uk O
) O
, O
be O
a O
shrub O
native O
to O
woodland O
and O
cool O
temperate O
rainforest O
of O
south O
- O
eastern O
australia O
. O

have O
be O
know O
for O
many O
year O
as O
drimys B-Plant
lanceolata I-Plant
. O

iwanoffia O
be O
a O
genus O
of O
green O
algae B-Plant
in O
the O
family O
chaetophoraceae O
. O

passiflora B-Plant
sanguinolenta I-Plant
, O
common O
name O
blood O
red O
passion B-Plant
flower I-Plant
, O
be O
a O
species O
of O
passion B-Plant
flower I-Plant
from O
ecuador O
. O

c. B-Plant
complecten I-Plant
be O
a O
shrub O
find O
in O
the O
neotropic O
. O

vriesea B-Plant
ensiformis I-Plant
be O
a O
species O
in O
the O
genus O
vriesea B-Plant
. O

gongora B-Plant
irmgardiae I-Plant
be O
a O
species O
of O
orchid B-Plant
find O
in O
colombia O
. O

daphne B-Plant
gnidium I-Plant
( O
commonly O
know O
as O
the O
flax B-Plant
- I-Plant
leaved I-Plant
daphne I-Plant
) O
be O
a O
poisonous O
evergreen O
shrub O
from O
the O
mediterranean O
region O
with O
narrow O
, O
dense O
dark O
- O
green O
foliage O
and O
white O
fragrant O
flower O
. O

bulbophyllum B-Plant
schimperianum I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

zanthoxylum B-Plant
flavum I-Plant
be O
a O
medium O
- O
sized O
tree O
in O
the O
citrus O
family O
, O
rutaceae O
. O

common O
name O
include O
noyer B-Plant
, O
west B-Plant
indian I-Plant
satinwood I-Plant
, O
yellow B-Plant
sander I-Plant
, O
tembetaria O
, O
and O
yellow B-Plant
sandalwood I-Plant
. O

be O
threaten O
by O
habitat O
loss O
and O
harvesting O
for O
-PRON- O
dense O
, O
durable O
wood O
use O
in O
fine O
woodworking O
. O

in O
-PRON- O
native O
subtropical O
range O
z. B-Plant

flavum I-Plant
grow O
in O
area O
with O
average O
to O
high O
rainfall O
year O
- O
round O
or O
with O
define O
dry O
season O
. O

pollination O
be O
probably O
from O
bee O
, O
and O
the O
seed O
be O
think O
to O
be O
disperse O
by O
bird O
and O
bat O
as O
with O
the O
closely O
related O
specie O
, O
z. B-Plant
martinicense I-Plant
. O

like O
the O
curia B-Plant
be O
destroy O
and O
rebuild O
several O
time O
, O
as O
far O
back O
as O
the O
roman O
monarchy O
. O

oxybasis B-Plant
glauca I-Plant
( O
syn O
chenopodium B-Plant
glaucum I-Plant
) O
, O
common O
name O
oak B-Plant
- I-Plant
leave I-Plant
goosefoot I-Plant
, O
be O
a O
species O
of O
goosefoot B-Plant
B-Plant O
native O
to O
europe O
. O

the O
type O
species O
be O
c. B-Plant
capitatus I-Plant
. O

in O
the O
horticultural O
trade O
, O
be O
a O
genus O
that O
contain O
about O
330 O
specie O
of O
orchid B-Plant
from O
the O
subtribe O
oncidiinae O
of O
the O
orchid O
family O
( O
orchidaceae O
) O
. O

as O
presently O
conceive O
( O
may O
2014 O
) O
, O
-PRON- O
be O
distribute O
across O
much O
of O
south O
america O
, O
central O
america O
, O
mexico O
and O
the O
west O
indies O
, O
with O
one O
specie O
( O
o. B-Plant
ensatum I-Plant
) O
extend O
into O
florida O
. O

common O
name O
for O
B-Plant O
in O
this O
genus O
include O
dance B-Plant
- I-Plant
lady I-Plant
orchid I-Plant
and O
golden B-Plant
shower I-Plant
orchid I-Plant
. O

the O
american O
orchid B-Plant
society O
label O
this O
genu O
a O
dump O
ground O
. O

the O
royal O
horticultural O
society O
system O
, O
the O
world O
checklist O
of O
monocots O
database O
and O
the O
american O
orchid B-Plant
society O
have O
already O
update O
-PRON- O
database O
to O
reflect O
most O
of O
these O
change O
. O

monotropa O
hypopity O
-- O
call O
dutchman B-Plant
's I-Plant
pipe I-Plant
, O
FALSE B-Plant
beech I-Plant
- I-Plant
drop I-Plant
, O
pinesap B-Plant
, O
or O
yellow B-Plant
bird's I-Plant
- I-Plant
nest I-Plant
-- O
be O
a O
herbaceous O
perennial O
B-Plant O
, O
formerly O
classify O
in O
the O
family O
monotropaceae O
or O
pyrolaceae O
, O
but O
now O
include O
within O
the O
subfamily O
monotropoideae O
of O
the O
blueberry O
family O
( O
ericaceae O
) O
. O

while O
currently O
include O
in O
the O
genus O
monotropa O
, O
recent O
genetic O
evidence O
strongly O
suggest O
that O
monotropa O
hypopity O
should O
be O
place O
in O
-PRON- O
own O
genus O
, O
hypopitys O
, O
with O
the O
single O
specie O
hypopitys B-Plant
monotropa I-Plant
crantz I-Plant
, O
but O
possibly O
contain O
several O
other O
specie O
. O

have O
be O
suggest O
that O
yellow O
individual O
be O
largely O
self O
- O
pollinate O
. O

the O
species O
name O
be O
from O
latinized O
greek O
hypo- O
, O
under O
, O
and O
pity O
, O
pine B-Plant
, O
refer O
to O
where O
pinesap B-Plant
often O
grow O
. O

some O
of O
which O
include O
hypopitys B-Plant
americana I-Plant
, O
h. B-Plant
fimbriata I-Plant
, O
h. B-Plant
insignata I-Plant
, O
h. B-Plant
lanuginosa I-Plant
, O
h. B-Plant
latisquama I-Plant
, O
h. B-Plant
monotropa I-Plant
, O
monotropa B-Plant
chinensis I-Plant
, O
m. B-Plant
hypophegea I-Plant
, O
m. B-Plant
lanuginosa I-Plant
, O
m. B-Plant
latisquama I-Plant
, O
m. B-Plant
multiflora I-Plant
and O
m. B-Plant
taiwaniana I-Plant
. O

bryopsis O
be O
a O
genus O
of O
marine O
green O
algae B-Plant
in O
the O
family O
bryopsidaceae O
. O

be O
frequently O
a O
pest O
in O
aquarium O
, O
where O
be O
commonly O
refer O
to O
as O
hair O
algae B-Plant
. O

the O
only O
know O
specie O
be O
lagurus B-Plant
ovatus I-Plant
, O
commonly O
call O
hare B-Plant
- I-Plant
tail I-Plant
, O
hare B-Plant
- I-Plant
tail I-Plant
grass I-Plant
or O
bunnytail B-Plant
. O

tillandsia B-Plant
emergen I-Plant
be O
a O
species O
of O
B-Plant O
in O
the O
bromeliaceae O
family O
. O

hacquetia B-Plant
epipactis I-Plant
( O
syn O
dondia B-Plant
epipactis I-Plant
spreng O
. O

) O
the O
flower O
, O
appear O
late O
winter O
and O
early O
spring O
, O
consist O
of O
multiple O
tiny O
yellow O
floret O
frame O
by O
lime B-Plant
green O
bract O
, O
and O
carry O
in O
dense O
spherical O
umbel O
4 O
cm O
in O
diameter O
. O

robinia B-Plant
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
family O
fabaceae O
, O
subfamily O
faboideae O
, O
native O
to O
north O
america O
and O
northern O
mexico O
. O

commonly O
know O
as O
locust B-Plant
, O
be O
deciduous O
tree O
and O
shrub O
grow O
4–25 O
metre O
( O
13–82 O
ft O
) O
tall O
. O

some O
specie O
of O
robinia B-Plant
be O
use O
as O
food O
by O
larvae O
of O
lepidoptera O
, O
include O
such O
moth O
as O
the O
brown B-Plant
- I-Plant
tail I-Plant
( O
euproctis O
chrysorrhoea O
) O
, O
the O
buff B-Plant
- I-Plant
tip I-Plant
( O
phalera O
bucephala O
) O
, O
the O
engrail O
( O
ectropis O
crepuscularia O
) O
, O
the O
giant O
leopard O
moth O
( O
hypercompe O
scribonia O
) O
, O
the O
locust B-Plant
underwing O
( O
euparthenos O
nubili O
) O
, O
and O
chrysaster O
ostensackenella O
. O

florideophyceae O
, O
demote O
to O
subclass O
florideae O
in O
some O
classification O
system O
, O
be O
a O
class O
of O
red O
algae B-Plant
. O

be O
once O
think O
to O
be O
the O
only O
algae B-Plant
to O
bear O
pit O
connection O
, O
but O
these O
have O
since O
be O
find O
in O
the O
filamentous O
stage O
of O
the O
bangiaceae O
. O

gnaphalium O
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
sunflower O
family O
, O
commonly O
call O
cudweed B-Plant
. O

cudweed B-Plant
be O
important O
foodB-Plant O
for O
american O
paint B-Plant
lady I-Plant
caterpillar O
. O

include O
the O
major O
food O
crop O
rice B-Plant
( O
specie O
oryza B-Plant
sativa I-Plant
and O
oryza B-Plant
glaberrima I-Plant
) O
. O

one O
species O
, O
asian B-Plant
rice I-Plant
( O
o. B-Plant
sativa I-Plant
) O
, O
provide O
20 O
% O
of O
global O
grain O
and O
be O
a O
food O
crop O
of O
major O
global O
importance O
. O

the O
better O
know O
specie O
be O
the O
pomegranate B-Plant
( O
punica B-Plant
granatum I-Plant
) O
. O

the O
other O
specie O
, O
the O
socotra O
pomegranate B-Plant
( O
punica B-Plant
protopunica I-Plant
) O
, O
be O
endemic O
to O
the O
island O
of O
socotra O
. O

the O
name O
be O
derive O
from O
the O
latin O
word O
for O
the O
pomegranate B-Plant
, O
malum O
punicum O
, O
mean O
carthaginian O
apple B-Plant
. O

salvia B-Plant
verbenaca I-Plant
, O
also O
know O
as O
wild B-Plant
clary I-Plant
or O
wild B-Plant
sage I-Plant
, O
be O
native O
to O
the O
british O
isles O
, O
the O
mediterranean O
region O
in O
southern O
europe O
, O
north O
africa O
, O
and O
near O
east O
, O
and O
in O
the O
caucasus O
. O

s. B-Plant
verbenaca I-Plant
be O
a O
tall O
perennial O
herb O
with O
hairy O
stem O
and O
branch O
that O
erectly O
sprawl O
out O
. O

have O
soft O
purple O
to O
violet B-Plant
flower O
in O
mid O
summer O
. O

this O
aromatic O
sage B-Plant
be O
use O
as O
a O
flavoring O
in O
food O
and O
to O
make O
tea B-Plant
gladiolus O
( O
from O
latin O
, O
the O
diminutive O
of O
gladius O
, O
a O
sword O
, O
) O
be O
a O
genus O
of O
perennial O
cormous O
flower O
B-Plant O
in O
the O
iris O
family O
( O
iridaceae O
it O
be O
sometimes O
call O
the O
' O
sword B-Plant
lily I-Plant
' O
, O
but O
be O
usually O
call O
by O
generic O
name O
( O
plural O
gladioli O
the O
genus O
occur O
in O
asia O
, O
mediterranean O
europe O
, O
south O
africa O
, O
and O
tropical O
africa O
. O

diospyro B-Plant
kaki I-Plant
, O
also O
call O
persimmon B-Plant
, O
be O
the O
most O
widely O
cultivate O
specie O
of O
the O
genus O
diospyros O
. O

although O
first O
publish O
botanical O
description O
be O
not O
until O
1780 O
, O
the O
kaki B-Plant
be O
among O
the O
old O
B-Plant O
in O
cultivation O
, O
know O
for O
use O
in O
china O
for O
more O
than O
2000 O
year O
. O

in O
some O
rural O
chinese O
community O
, O
the O
kaki B-Plant
fruit O
be O
see O
as O
have O
a O
great O
mystical O
power O
that O
can O
be O
harness O
to O
solve O
headache O
, O
back O
pain O
and O
foot O
ache O
. O

the O
persimmon B-Plant
( O
kaki B-Plant
) O
be O
a O
sweet O
, O
slightly O
tangy O
fruit O
with O
a O
soft O
to O
occasionally O
fibrous O
texture O
. O

a O
variety O
be O
diospyros B-Plant
kaki I-Plant
var I-Plant
sylvestris I-Plant
makino O
. O

those O
can O
be O
eat O
like O
an O
apple B-Plant
or O
can O
be O
allow O
to O
go O
to O
any O
stage O
of O
ripeness O
, O
include O
to O
the O
jelly O
- O
like O
stage O
. O

sharon O
fruit O
( O
name O
originally O
after O
sharon O
plain O
in O
israel O
) O
be O
a O
trade O
name O
for O
non O
- O
astringent O
d. B-Plant
kaki I-Plant
fruit O
. O

strophanthus B-Plant
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
family O
apocynaceae O
, O
first O
describe O
as O
a O
genus O
in O
1802 O
. O

the O
name O
( O
strophos O
anthos O
, O
twisted O
flower O
) O
derive O
from O
the O
long O
, O
twisted O
, O
threadlike O
segment O
of O
the O
corolla O
, O
which O
attain O
a O
length O
of O
30–35 O
cm O
in O
s. B-Plant
preussii I-Plant
. O

several O
african O
tribe O
use O
strophanthus B-Plant
as O
the O
principal O
ingredient O
in O
arrow B-Plant
poison I-Plant
. O

B-Plant O
from O
this O
genus O
produce O
toxic O
alkaloid O
and O
cardiac O
glycosid O
g O
- O
strophanthin O
( O
syn O
ouabain B-Plant
) O
, O
k O
- O
strophanthin O
, O
and O
e O
- O
strophanthin O
. O

some O
of O
the O
chemical O
in O
the O
B-Plant O
be O
use O
to O
produce O
the O
drug O
ouabain B-Plant
, O
which O
be O
take O
as O
a O
cardiac O
stimulant O
to O
treat O
heart O
failure O
and O
sometimes O
g O
- O
strophanthin O
be O
advocate O
as O
an O
alternative O
treatment O
to O
more O
contemporary O
practice O
. O

the O
effect O
be O
similar O
to O
that O
of O
the O
drug O
digoxin O
, O
which O
be O
produce O
from O
digitalis B-Plant
purpurea I-Plant
. O

formerly O
include O
in O
genusstrophanthus O
aambe O
= O
papuechites B-Plant
aambe I-Plant
ginkgo B-Plant
biloba I-Plant
, O
commonly O
know O
as O
ginkgo O
or O
gingko O
( O
both O
pronounce O
) O
, O
also O
know O
as O
the O
maidenhair B-Plant
tree I-Plant
, O
be O
the O
only O
living O
specie O
in O
the O
division O
ginkgophyta O
, O
all O
other O
be O
extinct O
. O

dipsacus B-Plant
fullonum I-Plant
, O
syn O
dipsacus B-Plant
sylvestris I-Plant
, O
be O
a O
species O
of O
flower O
B-Plant O
know O
by O
the O
common O
name O
wild B-Plant
teasel I-Plant
or O
full B-Plant
's I-Plant
teasel I-Plant
, O
although O
the O
latter O
name O
be O
usually O
apply O
to O
the O
cultivate O
species O
dipsacus B-Plant
sativus I-Plant
. O

the O
inflorescence O
be O
a O
cylindrical O
array O
of O
lavender B-Plant
flower O
which O
dry O
to O
a O
cone O
of O
spine O
- O
tip O
hard O
bract O
. O

bulbophyllum B-Plant
absconditum I-Plant
, O
know O
as O
the O
' O
hidden O
bulbophyllum O
, O
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

betula B-Plant
michauxii I-Plant
, O
newfoundland B-Plant
dwarf I-Plant
birch I-Plant
, O
be O
a O
species O
of O
birch B-Plant
which O
be O
native O
to O
newfoundland O
from O
which O
-PRON- O
get O
introduce O
to O
nova O
scotia O
and O
quebec O
. O

plinia B-Plant
cauliflora I-Plant
, O
the O
brazilian B-Plant
grapetree I-Plant
, O
jaboticaba B-Plant
or O
jabuticaba O
, O
be O
a O
tree O
in O
the O
family O
myrtaceae O
, O
native O
to O
minas O
gerais O
, O
goiás O
and O
são O
paulo O
state O
in O
brazil O
. O

three O
specie O
( O
g. B-Plant
odorata I-Plant
, O
g. B-Plant
scabra I-Plant
, O
g. B-Plant
speciosa I-Plant
) O
be O
know O
in O
cultivation O
. O

guettarda B-Plant
argentea I-Plant
provide O
edible O
fruit O
. O

the O
type O
specie O
for O
the O
genus O
be O
guettarda B-Plant
speciosa I-Plant
. O

fir O
be O
most O
closely O
related O
to O
the O
genus O
cedrus O
( O
cedar B-Plant
) O
. O

douglas B-Plant
fir I-Plant
be O
not O
TRUE O
fir O
, O
be O
of O
the O
genus O
pseudotsuga O
. O

fir O
can O
be O
distinguish O
from O
other O
member O
of O
the O
pine O
family O
by O
the O
way O
in O
which O
needle O
- O
like O
leaf O
be O
attach O
singly O
to O
the O
branch O
with O
a O
base O
resemble O
a O
suction O
cup O
, O
and O
by O
-PRON- O
cone O
, O
which O
, O
like O
those O
of O
TRUE B-Plant
cedar I-Plant
( O
cedrus O
) O
, O
stand O
upright O
on O
the O
branch O
like O
candle O
and O
disintegrate O
at O
maturity O
. O

cryptarrhena O
be O
a O
genus O
of O
orchid B-Plant
( O
family O
orchidaceae O
) O
. O

bonnemaisoniaceae O
be O
a O
family O
of O
red O
algae B-Plant
in O
the O
order O
bonnemaisoniales O
. O

kelloggia O
be O
a O
B-Plant O
genus O
in O
the O
bedstraw B-Plant
and O
madder O
family O
rubiaceae O
. O

be O
know O
by O
the O
native O
hawaiians O
as O
hau B-Plant
kuahiwi I-Plant
which O
mean O
mountain O
hibiscus O
. O

mirabilis B-Plant
longiflora I-Plant
, O
sweet B-Plant
four I-Plant
o'clock I-Plant
, O
be O
a O
species O
of O
flower O
B-Plant O
native O
to O
the O
southwestern O
united O
states O
from O
arizona O
to O
texas O
and O
northern O
mexico O
. O

specie O
include O
gomesa B-Plant
radican I-Plant
. O

when O
carl O
linnaeus O
name O
this O
genus O
in O
1763 O
, O
include O
in O
this O
genus O
all O
the O
epiphytic O
orchid B-Plant
know O
to O
. O

although O
few O
of O
these O
orchid B-Plant
be O
still O
include O
in O
the O
genus O
epidendrum O
, O
some O
specie O
of O
epidendrum O
be O
nevertheless O
not O
epiphytic O
. O

lemon B-Plant
balm O
( O
melissa B-Plant
officinali I-Plant
) O
, O
balm O
, O
common B-Plant
balm I-Plant
, O
or O
balm O
mint B-Plant
, O
be O
a O
perennial O
herbaceous O
B-Plant O
in O
the O
mint O
family O
lamiaceae O
and O
native O
to O
south O
- O
central O
europe O
, O
the O
mediterranean O
basin O
, O
iran O
, O
and O
central O
asia O
, O
but O
now O
naturalize O
in O
the O
americas O
and O
elsewhere O
. O

the O
leaf O
have O
a O
mild O
lemon B-Plant
scent O
similar O
to O
mint B-Plant
. O

the O
tea B-Plant
of O
lemon B-Plant
balm O
, O
the O
essential O
oil O
, O
and O
the O
extract O
be O
use O
in O
traditional O
and O
alternative O
medicine O
, O
include O
aromatherapy O
. O

the O
B-Plant O
have O
be O
cultivate O
at O
least O
since O
the O
16th O
century O
, O
but O
research O
be O
still O
be O
conduct O
to O
establish O
the O
safety O
and O
effect O
of O
lemon B-Plant
balm O
. O

crobylanthe B-Plant
pellacalyx I-Plant
, O
which O
be O
endemic O
to O
sarawak O
. O

asphodelus B-Plant
aestivus I-Plant
, O
the O
summer O
asphodel B-Plant
, O
be O
a O
species O
of O
asphodel B-Plant
, O
a O
common O
western O
mediterranean O
geophyte O
with O
a O
short O
vertical O
rhizome O
and O
basal O
leaf O
. O

there O
have O
be O
a O
lot O
of O
confusion O
over O
the O
nomenclature O
and O
taxonomy O
of O
the O
specie O
, O
especially O
in O
confusion O
with O
asphodelus B-Plant
ramosus I-Plant
. O

satyrium O
be O
a O
genus O
of O
orchid B-Plant
. O

elymus O
be O
a O
genus O
of O
perennial O
B-Plant O
with O
approximately O
150 O
specie O
in O
the O
grass O
family O
, O
relate O
to O
rye B-Plant
, O
wheat B-Plant
, O
and O
other O
widely O
grow O
cereal O
grain O
. O

elymus O
be O
a O
cosmopolitan O
genus O
, O
represent O
by O
specie O
across O
all O
continent O
of O
the O
world O
. O

common O
name O
include O
couch B-Plant
grass I-Plant
, O
wildrye B-Plant
and O
wheatgrass B-Plant
. O

many O
specie O
once O
consider O
member O
of O
elymus O
be O
now O
regard O
as O
better O
suit O
to O
other O
genera O
: O
agropyron O
, O
anthosachne O
, O
brachypodium O
, O
cenchrus O
, O
crithopsis O
, O
heteranthelium O
, O
jouvea O
, O
kengyilia O
, O
leymus O
, O
psathyrostachys O
, O
stenostachys O
, O
taeniatherum O
, O
thinopyrum O
etc O
. O

the O
following O
specie O
be O
recognise O
by O
the O
B-Plant O
list O
: O
moreover O
, O
scleroderma O
citrinum O
have O
much O
firm O
flesh O
and O
a O
dark O
gleba O
( O
interior O
) O
much O
earlier O
in O
development O
than O
puffball B-Plant
. O

pinellia B-Plant
ternata I-Plant
( O
chinese O
: O
半夏 O
, O
japanese O
: O
) O
, O
crow B-Plant
- I-Plant
dipper I-Plant
, O
be O
a O
B-Plant O
native O
to O
china O
, O
japan O
, O
and O
korea O
, O
but O
also O
grow O
as O
an O
invasive O
weed O
in O
part O
of O
europe O
( O
austria O
, O
germany O
) O
and O
north O
america O
( O
california O
, O
ontario O
, O
northeastern O
united O
states O
) O
. O

general O
common O
name O
include O
indian B-Plant
mallow I-Plant
and O
velvetleaf B-Plant
in O
russian O
, O
ornamental O
variety O
be O
commonly O
know O
as O
the O
room B-Plant
maple I-Plant
. O

the O
generic O
name O
be O
derive O
from O
the O
latin O
word O
moru O
mulberry B-Plant
, O
from O
the O
appearance O
of O
the O
fruit O
, O
and O
indica O
, O
mean O
of O
india O
. O

grow O
in O
acidic O
soil O
, O
with O
different O
specie O
in O
wet O
acid O
bog O
habitat O
( O
k. B-Plant
angustifolia I-Plant
, O
k. B-Plant
polifolia I-Plant
) O
and O
dry O
, O
sandy O
soil O
( O
k. B-Plant
ericoide I-Plant
, O
k. B-Plant
latifolia I-Plant
) O
. O

describe O
, O
a O
costly O
rarity O
, O
in O
-PRON- O
natural O
history O
of O
carolina O
, O
as O
chamaedaphne O
foliis O
tini O
, O
that O
be O
to O
say O
with O
leaf O
like O
the O
laurustinus B-Plant
the O
foliage O
be O
toxic O
if O
eat O
, O
with O
sheep O
be O
particularly O
prone O
to O
poisoning O
, O
hence O
the O
name O
lambkill B-Plant
use O
for O
some O
of O
the O
specie O
. O

other O
name O
for O
kalmia O
, O
particularly O
kalmia B-Plant
angustifolia I-Plant
, O
be O
sheep B-Plant
- I-Plant
laurel I-Plant
, O
lamb B-Plant
- I-Plant
kill I-Plant
, O
calf B-Plant
- I-Plant
kill I-Plant
, O
kill B-Plant
- I-Plant
kid I-Plant
, O
and O
sheep B-Plant
- I-Plant
poison I-Plant
, O
which O
may O
be O
write O
with O
or O
without O
the O
hyphen O
. O

have O
also O
be O
call O
spoonwood B-Plant
because O
kalm O
be O
tell O
by O
dutch O
settler O
of O
north O
america O
that O
native O
americans O
make O
spoon O
from O
the O
wood O
. O

impatien B-Plant
noli I-Plant
- I-Plant
tangere I-Plant
( O
touch B-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
balsam I-Plant
also O
call O
touch B-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
, O
yellow B-Plant
balsam I-Plant
, O
jewelwe B-Plant
, O
western B-Plant
touch I-Plant
- I-Plant
-PRON- I-Plant
- I-Plant
not I-Plant
or O
wild B-Plant
balsam I-Plant
. O

guthriea B-Plant
capensis I-Plant
be O
an O
acaulescent O
perennial O
herb O
endemic O
to O
south O
africa O
and O
occur O
in O
cool O
and O
damp O
site O
face O
south O
or O
east O
in O
the O
mountain O
of O
the O
cape O
province O
, O
lesotho O
and O
kwazulu O
- O
natal O
. O

this O
ground O
- O
hugging O
specie O
with O
a O
rhizome O
and O
fleshy O
root O
form O
a O
compact O
rosette O
of O
some O
20 O
- O
30 O
broadly O
elliptic O
or O
cordate O
discolorous O
leaf O
with O
crenate O
margin O
, O
measure O
about O
50 O
x O
75 O
mm O
, O
glossy O
above O
with O
deeply O
indented O
venation O
hide O
creamy O
- O
green O
flower O
which O
be O
solitary O
and O
stalk O
. O

guthriea O
belong O
to O
the O
family O
achariaceae O
, O
a O
family O
which O
now O
include O
various O
specie O
previously O
place O
in O
the O
flacourtiaceae O
, O
such O
as O
kiggelaria B-Plant
africana I-Plant
, O
rawsonia B-Plant
lucida I-Plant
and O
xylotheca B-Plant
kraussiana I-Plant
. O

several O
specie O
be O
grow O
in O
garden O
, O
especially O
b. B-Plant
frutescen I-Plant
. O

the O
genus O
include O
the O
important O
group O
of O
culinary O
herb O
: O
marjoram B-Plant
( O
origanum B-Plant
majorana I-Plant
) O
and O
oregano B-Plant
( O
origanum O
vulgare).origanum O

specie O
be O
use O
as O
food O
B-Plant O
by O
the O
larvae O
of O
some O
lepidoptera O
specie O
, O
include O
coleophora O
albitarsella O
. O

-PRON- O
be O
sometimes O
call O
cottonros O
or O
cudweed B-Plant
. O

the O
name O
cudweed B-Plant
come O
from O
the O
fact O
that O
-PRON- O
be O
once O
use O
to O
feed O
cow O
that O
have O
lose O
the O
ability O
to O
chew O
the O
cud O
. O

several O
specie O
be O
sometimes O
treat O
as O
member O
of O
genus O
logfia O
. O

jensenia O
be O
a O
bryophyte O
B-Plant O
genus O
in O
the O
liverwort B-Plant
family O
pallaviciniaceae O
. O

one O
of O
the O
specie O
, O
catopsis B-Plant
berteroniana I-Plant
, O
be O
think O
to O
be O
carnivorous O
. O

phlox B-Plant
hoodii I-Plant
, O
the O
spiny B-Plant
phlox I-Plant
or O
carpet B-Plant
phlox I-Plant
, O
be O
a O
species O
of O
phlox B-Plant
. O

be O
a O
B-Plant O
of O
western O
north O
america O
, O
where O
be O
a O
common O
flower O
in O
sagebrush B-Plant
country O
. O

gastrodia O
be O
a O
genus O
of O
achlorophyllous O
orchid B-Plant
with O
64 O
currently O
accept O
specie O
. O

be O
native O
to O
asia O
( O
china O
, O
the O
russian O
far O
east O
, O
japan O
, O
korea O
, O
southeast O
asia O
, O
the O
indian O
subcontinent O
) O
, O
australia O
, O
new O
zealand O
, O
central O
africa O
, O
and O
various O
island O
of O
the O
indian O
and O
pacific O
oceans O
. O

gastrodia B-Plant
elata I-Plant
be O
a O
traditional O
chinese O
herb O
, O
tian O
ma O
chinese O
and O
be O
commonly O
use O
in O
china O
to O
treat O
hypertension O
, O
improve O
circulation O
and O
resolve O
headache O
. O

anthoceros O
be O
a O
genus O
of O
hornwort B-Plant
in O
the O
family O
anthocerotaceae O
. O

name O
mean O
' O
flower O
horn O
' O
, O
and O
refer O
to O
the O
characteristic O
horn O
- O
shape O
sporophyte O
that O
all O
hornwort B-Plant
produce O
. O

rumex B-Plant
dentatus I-Plant
be O
a O
species O
of O
flower O
B-Plant O
in O
the O
knotweed O
family O
know O
by O
the O
common O
name O
tooth B-Plant
dock I-Plant
and O
aegean O
dock O
. O

the O
group O
include O
many O
well O
- O
know O
desert O
and O
dry O
zone O
type O
such O
as O
the O
agave O
, O
yucca B-Plant
, O
and O
joshua B-Plant
tree I-Plant
. O

cryptocoryne B-Plant
beckettii I-Plant
( O
also O
know O
as O
beckett B-Plant
's I-Plant
water I-Plant
trumpet I-Plant
) O
be O
a O
B-Plant O
specie O
belong O
to O
the O
aroid O
genus O
cryptocoryne O
. O

crataegus B-Plant
× I-Plant
lavalleei O
, O
sometimes O
know O
as O
hybrid O
cockspurthorn B-Plant
or O
lavallée B-Plant
's I-Plant
hawthorn I-Plant
, O
be O
a O
hybrid O
that O
arise O
between O
cultivate O
specimen O
of O
two O
specie O
in O
the O
genus O
crataegus O
( O
hawthorn B-Plant
) O
. O

the O
female O
parent O
be O
c. B-Plant
mexicana I-Plant
( O
sometimes O
mistakenly O
call O
c. B-Plant
pubescen I-Plant
) O
, O
and O
the O
male O
parent O
be O
think O
to O
be O
c. B-Plant
calpodendron I-Plant
( O
which O
be O
sometimes O
mistakenly O
call O
c. O
crus O
- O
galli O
) O
's O
hawthorn B-Plant
, O
c. B-Plant
× I-Plant
carrierei O
have O
the O
same O
parentage O
, O
and O
be O
therefore O
a O
synonym O
, O
i.e. O
there O
be O
minor O
difference O
between O
lavallée B-Plant
's I-Plant
hawthorn I-Plant
and O
carrière B-Plant
's I-Plant
hawthorn I-Plant
, O
and O
the O
latter O
be O
consider O
a O
separate O
cultivar O
, O
which O
be O
formally O
write O
as O
crataegus O
' O
carrierei O
' O
. O

crataegus B-Plant
× I-Plant
lavalleei O
be O
an O
ornamental O
small O
tree O
with O
glossy O
dark O
green O
unlob O
leaf O
that O
be O
use O
horticulturally O
. O

cedronella O
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
mentheae O
tribe O
of O
family O
lamiaceae O
, O
comprise O
a O
single O
specie O
, O
cedronella B-Plant
canariensis I-Plant
, O
native O
to O
the O
canary O
islands O
, O
the O
azores O
, O
and O
madeira O
. O

common O
name O
include O
canary B-Plant
islands I-Plant
- I-Plant
balm I-Plant
, O
canary B-Plant
balm I-Plant
, O
and O
balm B-Plant
- I-Plant
of I-Plant
- I-Plant
gilead I-Plant
. O
be O
a O
perennial O
herbaceous O
B-Plant O
grow O
to O
1 O
- O
1.5 O
m O
tall O
. O

the O
genus O
name O
be O
a O
diminutive O
of O
cedrus O
, O
though O
the O
only O
connection O
between O
this O
herb O
and O
the O
large O
conifer B-Plant
of O
cedrus O
be O
a O
vaguely O
similar O
resinous O
scent O
of O
the O
foliage O
. O

the O
genus O
platanthera O
belong O
to O
the O
subfamily O
orchidoideae O
of O
the O
family O
orchidaceae O
, O
and O
comprise O
about O
100 O
specie O
of O
orchid B-Plant
. O

the O
member O
of O
this O
genus O
, O
know O
as O
the O
butterfly B-Plant
orchid I-Plant
or O
fringed B-Plant
orchid I-Plant
, O
be O
previously O
include O
in O
the O
genus O
orchis O
, O
which O
be O
a O
close O
relative O
( O
along O
with O
the O
genus O
habenaria O
) O
. O

one O
specie O
, O
pitcairnia B-Plant
feliciana I-Plant
be O
find O
in O
tropical O
west O
africa O
and O
be O
the O
only O
member O
of O
the O
bromeliaceae O
family O
not O
native O
to O
the O
western O
hemisphere O
. O

almost O
all O
pitcairnia O
be O
terrestrial O
or O
saxicolous O
, O
and O
prefer O
moist O
area O
. O

marchantiopsida O
be O
one O
of O
three O
class O
within O
the O
liverwort B-Plant
phylum O
marchantiophyta O
. O

quercus B-Plant
garryana I-Plant
, O
the O
garry B-Plant
oak I-Plant
, O
oregon B-Plant
white I-Plant
oak I-Plant
, O
oregon B-Plant
oak I-Plant
, O
or O
hu'dshnam O
, O
from O
the O
traditional O
klamath O
language O
, O
be O
a O
tree O
specie O
with O
a O
range O
stretch O
from O
southern O
california O
to O
southwestern O
british O
columbia O
. O

the O
tree O
get O
one O
of O
name O
from O
nicholas O
garry O
, O
deputy O
governor O
of O
the O
hudson B-Plant
's O
bay O
company O
, O
1822–35 O
. O

alligator B-Plant
- I-Plant
flag I-Plant
be O
a O
common O
name O
for O
B-Plant O
in O
this O
genus O
. O

drosophyllum O
( O
, O
rarely O
) O
be O
a O
genus O
of O
carnivorous O
B-Plant O
contain O
the O
single O
specie O
drosophyllum B-Plant
lusitanicum I-Plant
( O
portuguese O
sundew B-Plant
or O
dewy O
pine B-Plant
) O
. O

drosophyllum B-Plant
lusitanicum I-Plant
bear O
bright O
- O
yellow O
flower O
, O
4 O
cm O
( O
1.6 O
in O
) O
in O
diameter O
, O
bear O
in O
group O
of O
3–15 O
between O
february O
and O
May O
the O
translucent O
seedpod O
bear O
3–10 O
opaque O
black O
, O
pear B-Plant
- O
shape O
seed O
, O
2.5 O
mm O
( O
98 O
in O
) O
in O
diameter O
. O

drosera B-Plant
paradoxa I-Plant
be O
a O
carnivorous O
B-Plant O
in O
the O
genus O
drosera O
and O
be O
endemic O
to O
the O
northern O
territory O
and O
western O
australia O
. O

drosera B-Plant
paradoxa I-Plant
be O
find O
in O
skeletal O
sandy O
soil O
over O
sandstone O
in O
or O
along O
the O
bank O
of O
seasonally O
dry O
creek O
or O
in O
sandstone O
crack O
. O

drosera B-Plant
paradoxa I-Plant
be O
native O
to O
the O
west O
and O
north O
coast O
of O
the O
kimberley O
region O
inland O
to O
beverley O
springs O
, O
western O
australia O
and O
east O
to O
arnhem O
land O
and O
kakadu O
national O
park O
in O
the O
northern O
territory O
. O

be O
first O
describe O
by O
australian O
botanist O
allen O
lowrie O
in O
a O
1997 O
issue O
of O
nuytsia O
, O
the O
journal O
of O
the O
western O
australian O
herbarium O
. O

several O
trip O
into O
the O
field O
from O
1993 O
to O
1997 O
be O
require O
to O
reveal O
these O
different O
form O
to O
be O
only O
stage O
in O
this O
specie O
' O
perennial O
growth O
cycle O
from O
seedl O
to O
pincushion B-Plant
basal O
rosette O
to O
erect O
woody O
- O
stemmed O
speciman O
. O

be O
closely O
related O
to O
d. B-Plant
petiolaris I-Plant
, O
but O
differ O
from O
that O
specie O
most O
notably O
by O
-PRON- O
tall O
woody O
stem O
whereas O
d. B-Plant
petiolaris I-Plant
form O
clump O
of O
many O
basal O
rosette B-Plant
from O
a O
common O
perennial O
rootstock O
. O

illicium B-Plant
anisatum I-Plant
, O
with O
common O
name O
japanese B-Plant
star I-Plant
anise I-Plant
, O
aniseed O
tree O
, O
and O
sacred O
anise B-Plant
tree I-Plant
, O
know O
in O
japan O
as O
shikimi O
( O
樒 O
, O
シキミ O
) O
, O
be O
a O
tree O
closely O
related O
to O
the O
chinese B-Plant
star I-Plant
anise I-Plant
( O
illicium B-Plant
verum I-Plant
) O
. O

instead O
, O
the O
dry O
and O
powdered O
leaf O
be O
burn O
as O
incense B-Plant
in O
japan O
. O

akris O
, O
a O
locust B-Plant
and O
carpos O
, O
a O
fruit O
, O
allude O
to O
the O
winged O
fruit O
) O
be O
a O
genus O
of O
B-Plant O
in O
family O
malpighiaceae O
. O

acridocarpus B-Plant
monodii I-Plant
arènes I-Plant
& I-Plant
p.jaeger I-Plant
ex I-Plant
birnbaum I-Plant
& I-Plant
j.florence I-Plant
pluchea O
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
stinkwort B-Plant
tribe O
within O
the O
sunflower O
family O
. O

member O
of O
this O
genus O
may O
be O
know O
as O
camphorweed B-Plant
, O
pluchea B-Plant
, O
or O
less O
uniquely O
fleabane B-Plant
. O

some O
, O
such O
as O
p. B-Plant
carolinensis I-Plant
and O
p. B-Plant
odorata I-Plant
, O
be O
call O
sourbush O
. O

pluchea B-Plant
laxiflora I-Plant
hook O
. O

baccharis B-Plant
decussata I-Plant
( O
klatt O
) O
hieron O
. O

( O
as O
p. B-Plant
decussata I-Plant
klatt O
) O
cratystylis B-Plant
conocephala I-Plant
( O
f.muell O
. O

) O
s.moore O
( O
as O
p. B-Plant
conocephala I-Plant
( O
f.muell O
. O

) O
neurolaena B-Plant
lobata I-Plant
( O
l. O
) O
cass B-Plant
. O

( O
as O
p. B-Plant
symphytifolia I-Plant
( O
mill O
. O

) O
streptoglossa B-Plant
liatroide I-Plant
( O
turcz O
. O

) O
dunlop O
( O
as O
p. B-Plant
ligulata I-Plant
f.muell O
. O

) O
streptoglossa B-Plant
macrocephala I-Plant
( O
f.muell O
. O

) O
dunlop O
( O
as O
p. B-Plant
macrocephala I-Plant
f.muell O
. O

) O
streptoglossa B-Plant
odora I-Plant
( O
f.muell O
. O

) O
dunlop O
( O
as O
p. B-Plant
odora I-Plant
f.muell O
. O

) O
thespidium B-Plant
basiflorum I-Plant
( O
f.muell O
. O

) O
( O
as O
p. B-Plant
basiflora I-Plant
f.muell O
. O

) O
nothotsuga O
contain O
only O
one O
specie O
, O
nothotsuga B-Plant
longibracteata I-Plant
, O
commonly O
know O
as O
the O
bristlecone B-Plant
hemlock I-Plant
, O
which O
be O
find O
in O
southeastern O
china O
, O
in O
southern O
fujian O
, O
northern O
guangdong O
, O
northeast O
guangxi O
, O
northeast O
guizhou O
, O
and O
southwest O
hunan O
. O

artemisia B-Plant
chamaemelifolia I-Plant
be O
a O
european O
and O
middle O
eastern O
specie O
of O
B-Plant O
in O
the O
daisy O
family O
. O

ponthieva O
( O
commonly O
call O
shadow B-Plant
witch I-Plant
) O
be O
a O
genus O
form O
the O
orchid O
family O
( O
orchidaceae O
) O
. O

platanus B-Plant
orientalis I-Plant
, O
the O
old O
world O
sycamore B-Plant
, O
or O
oriental B-Plant
plane I-Plant
, O
be O
a O
large O
, O
deciduous O
tree O
of O
the O
platanaceae O
family O
, O
grow O
to O
30 O
m O
( O
98 O
ft O
) O
or O
more O
, O
and O
know O
for O
longevity O
and O
spread O
crown O
. O

the O
fruit O
of O
several O
specie O
be O
use O
to O
make O
the O
spice O
sichuan B-Plant
pepper I-Plant
. O

common O
name O
include O
prickly B-Plant
ash I-Plant
and O
hercule B-Plant
club I-Plant
. O

acineta B-Plant
chrysantha I-Plant
be O
a O
species O
of O
orchid B-Plant
find O
in O
the O
forest O
of O
guatemala O
, O
el O
salvador O
, O
costa O
rica O
and O
panama O
. O

the O
specie O
be O
first O
collect O
by O
humboldt O
and O
bonpland O
on O
the O
outskirt O
of O
mina O
de O
morán O
in O
the O
sierra B-Plant
de O
pachuca O
of O
the O
modern O
- O
day O
mexican O
state O
of O
hidalgo O
on O
latin O
american O
expedition O
of O
1799–1804 O
. O

p. B-Plant
moranensis I-Plant
remain O
the O
most O
common O
and O
most O
widely O
distribute O
member O
of O
the O
section O
orcheosanthus O
. O

-PRON- O
have O
long O
be O
cultivate O
for O
-PRON- O
carnivorous O
nature O
and O
attractive O
flower O
, O
and O
be O
one O
of O
the O
most O
common O
butterwort B-Plant
in O
cultivation O
. O

octomeria B-Plant
tricolor I-Plant
be O
a O
species O
of O
orchid B-Plant
endemic O
to O
southeastern O
brazil O
. O

bulbophyllum B-Plant
resupinatum I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

haptanthus O
be O
a O
monotypic O
genus O
contain O
the O
sole O
specie O
haptanthus B-Plant
hazlettii I-Plant
, O
a O
shrub O
or O
small O
tree O
know O
only O
from O
the O
locality O
of O
matarras O
in O
the O
arizona O
municipality O
in O
honduras O
. O

the O
common O
name O
for O
this O
genus O
be O
rushfoil O
and O
croton O
, O
but O
the O
latter O
also O
refer O
to O
codiaeum B-Plant
variegatum I-Plant
. O

siraitia B-Plant
grosvenorii I-Plant
( O
luo O
han O
guo O
, O
monk B-Plant
's I-Plant
fruit I-Plant
) O
, O
from O
china O
and O
thailand O
siraitia B-Plant
taiwaniana I-Plant
, O
from O
taiwan O
, O
see O
sinobaijiania B-Plant
taiwaniana I-Plant
lathyrus B-Plant
tuberosus I-Plant
, O
also O
know O
as O
the O
tuberous B-Plant
pea I-Plant
, O
tuberous B-Plant
vetchling I-Plant
, O
earthnut B-Plant
pea I-Plant
, O
aardaker B-Plant
or O
tine B-Plant
- I-Plant
tare I-Plant
, O
be O
a O
small O
, O
climb O
perennial O
B-Plant O
, O
native O
in O
moist O
temperate O
part O
of O
europe O
and O
western O
asia O
. O

the O
B-Plant O
be O
a O
trailer O
or O
weak O
climber B-Plant
, O
support O
by O
tendril O
, O
grow O
to O
1.2 O
m O
tall O
. O

aralia B-Plant
racemosa I-Plant
, O
with O
common O
name O
american B-Plant
spikenard I-Plant
, O
small B-Plant
spikenard I-Plant
, O
indian B-Plant
root I-Plant
, O
spice B-Plant
berry I-Plant
, O
spignet B-Plant
, O
life B-Plant
- I-Plant
of I-Plant
- I-Plant
man I-Plant
, O
petty B-Plant
morel I-Plant
, O
be O
an O
ornamental O
B-Plant O
in O
the O
araliaceae O
family O
native O
to O
the O
united O
states O
and O
canada O
. O

ampelodesmo B-Plant
mauritanicus I-Plant
be O
a O
large O
clumping O
perennial O
bunchgrass B-Plant
, O
which O
be O
native O
to O
the O
mediterranean O
region O
. O

in O
native O
area O
be O
use O
as O
a O
fiber O
for O
make O
mat O
, O
broom O
, O
and O
twine O
. O

the O
genus O
name O
come O
from O
the O
greek O
ampelo O
, O
vine B-Plant
, O
and O
desmo O
, O
bond O
, O
from O
-PRON- O
former O
use O
as O
a O
string O
to O
tie O
up O
grapevine O
. O

euphorbia B-Plant
pachypodioid I-Plant
be O
a O
species O
of O
B-Plant O
in O
the O
euphorbiaceae O
family O
. O

also O
have O
the O
binomial O
synonym O
euphorbia B-Plant
antankara I-Plant
( O
leandri O
, O
1946 O
) O
. O

crowea O
be O
a O
genus O
of O
small O
evergreen O
shrub O
in O
the O
B-Plant O
family O
rutaceae O
sometimes O
know O
as O
waxflowers B-Plant
. O

helianthella B-Plant
quinquenervi I-Plant
, O
fivenerve B-Plant
helianthella I-Plant
, O
be O
a O
north O
american O
B-Plant O
specie O
in O
the O
sunflower O
family O
. O

this O
include O
the O
rockies O
, O
the O
black O
hills O
, O
the O
range O
of O
the O
great O
basin O
, O
and O
the O
northern O
sierra B-Plant
madre O
, O
from O
montana O
, O
oregon O
, O
and O
south O
dakota O
south O
as O
far O
as O
western O
chihuahua O
and O
coahuila O
. O

helianthella B-Plant
quinquenervis I-Plant
be O
a O
herbaceous O
B-Plant O
up O
to O
150 O
cm O
( O
4.9 O
ft O
) O
tall O
. O

lepismium B-Plant
houlletianum I-Plant
be O
a O
species O
of O
B-Plant O
in O
the O
family O
cactaceae O
. O

chaetonema O
be O
a O
genus O
of O
green O
algae B-Plant
in O
the O
family O
aphanochaetaceae O
. O

notable O
culprit O
be O
c. B-Plant

fragran I-Plant
( O
inch B-Plant
B-Plant I-Plant
) O
and O
c. B-Plant
repen I-Plant
( O
turtle B-Plant
vine I-Plant
) O
. O

selenicereus O
, O
or O
moonlight O
cacti B-Plant
, O
be O
an O
epiphytic O
, O
lithophytic O
, O
and O
terrestrial O
cactus B-Plant
genus O
find O
in O
central O
america O
, O
the O
caribbean O
and O
northern O
south O
america O
. O

grevillea B-Plant
preissii I-Plant
be O
a O
small O
shrub O
which O
be O
endemic O
to O
western O
australia O
. O

alkali B-Plant
grass I-Plant
redirect O
here O
. O

this O
name O
be O
also O
use O
for O
the O
mountain B-Plant
deathcama I-Plant
( O
anticlea B-Plant
elegan I-Plant
) O
which O
be O
not O
a O
grass O
. O

puccinellia O
be O
a O
genus O
of O
B-Plant O
in O
the O
grass O
family O
, O
know O
as O
alkali B-Plant
grass I-Plant
or O
salt B-Plant
grass I-Plant
. O

these O
grass O
grow O
in O
wet O
environment O
, O
often O
in O
saline O
or O
alkaline O
condition O
. O

scyphiphora B-Plant
hydrophyllacea I-Plant
, O
which O
have O
a O
large O
distribution O
range O
from O
madagascar O
, O
to O
tropical O
asia O
and O
the O
western O
pacific O
. O

be O
a O
shrub O
of O
about O
3 O
m O
( O
10 O
ft O
) O
and O
be O
often O
find O
in O
mangrove B-Plant
forest O
or O
sandy O
beach O
. O

engelmannia O
( O
engelmann B-Plant
's B-Plant
daisy I-Plant
) O
be O
a O
genus O
of O
north O
american O
flower O
B-Plant O
in O
the O
daisy O
family O
. O

pinus B-Plant
heldreichii I-Plant
( O
synonym O
p. B-Plant
leucodermis I-Plant
family O
pinaceae O
) O
, O
the O
heldreich O
’s O
pine B-Plant
or O
bosnian B-Plant
pine I-Plant
, O
be O
a O
species O
of O
pine B-Plant
native O
to O
mountainous O
area O
of O
the O
balkans O
and O
southern O
italy O
. O

be O
a O
member O
of O
the O
hard B-Plant
pine I-Plant
group O
, O
pinus O
subgenus O
pinus O
, O
with O
leaf O
( O
' O
needle O
' O
) O
in O
fascicle O
( O
bundle O
) O
of O
two O
, O
with O
a O
persistent O
sheath O
. O

the O
best O
- O
know O
member O
of O
the O
genus O
be O
the O
avocado B-Plant
, O
p. B-Plant
americana I-Plant
, O
widely O
cultivate O
in O
subtropical O
region O
for O
-PRON- O
large O
, O
edible O
fruit O
. O

ilex B-Plant
canariensis I-Plant
, O
the O
small B-Plant
- I-Plant
leave I-Plant
holly O
, O
be O
an O
endemic O
specie O
of O
holly O
native O
to O
macaronesian O
island O
. O

goldenseal B-Plant
( O
hydrastis B-Plant
canadensis I-Plant
) O
, O
also O
call O
orangeroot B-Plant
or O
yellow B-Plant
puccoon I-Plant
, O
be O
a O
perennial O
herb O
in O
the O
buttercup O
family O
ranunculaceae O
, O
native O
to O
southeastern O
canada O
and O
the O
eastern O
united O
states O
. O

goldenseal B-Plant
mostly O
reproduce O
clonally O
through O
the O
rhizome O
. O

in O
summer O
, O
bear O
a O
single O
berry O
the O
size O
of O
a O
large O
raspberry B-Plant
with O
10–30 O
seed O
. O

in O
herbal O
medicine O
, O
goldenseal B-Plant
's O
root O
and O
rhizome O
be O
harvest O
and O
use O
as O
a O
multi O
- O
purpose O
remedy O
because O
of O
high O
concentration O
of O
berberine O
and O
hydrastine O
. O

however O
, O
there O
be O
little O
scientific O
evidence O
that O
goldenseal B-Plant
be O
effective O
. O

goldenseal B-Plant
be O
use O
to O
control O
muscle O
spasm O
, O
treat O
cancer O
, O
stimulate O
the O
heart O
and O
increase O
blood O
pressure O
, O
treat O
gastrointestinal O
disorder O
, O
treat O
conjunctivitis O
, O
manage O
painful O
and O
heavy O
menstruation O
, O
treat O
infection O
topically O
, O
reduce O
swell O
and O
alleviate O
edema O
. O

goldenseal B-Plant
may O
be O
purchase O
in O
salve O
, O
tablet O
, O
tincture O
form O
or O
as O
a O
bulk O
powder O
. O

a O
second O
specie O
from O
japan O
, O
previously O
list O
as O
hydrastis O
palmatum O
, O
be O
sufficiently O
distinct O
that O
be O
now O
usually O
treat O
in O
a O
separate O
genus O
, O
as O
glaucidium B-Plant
palmatum I-Plant
. O

piper B-Plant
auritum I-Plant
( O
hoja B-Plant
santa I-Plant
) O
be O
an O
aromatic O
herb O
with O
a O
heart O
- O
shape O
, O
velvety O
leaf O
which O
grow O
in O
tropic O
mesoamerica O
. O

the O
name O
hoja B-Plant
santa I-Plant
mean O
sacred O
leaf O
in O
spanish O
. O

be O
also O
know O
as O
yerba B-Plant
santa I-Plant
, O
hierba B-Plant
santa I-Plant
, O
mexican B-Plant
pepperleaf I-Plant
, O
acuyo O
, O
tlanepa O
, O
anisillo B-Plant
, O
root B-Plant
beer I-Plant
B-Plant I-Plant
, O
vera B-Plant
cruz I-Plant
pepper I-Plant
and O
sacred B-Plant
pepper I-Plant
. O

melaleuca B-Plant
pulchella I-Plant
, O
commonly O
know O
as O
claw B-Plant
flower I-Plant
and O
claw B-Plant
honey I-Plant
- I-Plant
myrtle I-Plant
, O
be O
a O
B-Plant O
in O
the O
myrtle O
family O
, O
myrtaceae O
and O
be O
endemic O
to O
the O
south O
of O
western O
australia O
. O

( O
the O
other O
be O
melaleuca B-Plant
violacea I-Plant
) O
. O

the O
outer O
stamen O
be O
long O
and O
curve O
, O
give O
the O
appearance O
of O
a O
claw B-Plant
to O
the O
flower O
. O

amentotaxus O
be O
a O
genus O
of O
conifer B-Plant
( O
catkin B-Plant
- I-Plant
yew I-Plant
) O
comprise O
five O
specie O
, O
treat O
in O
either O
the O
cephalotaxaceae O
, O
or O
in O
the O
taxaceae O
when O
that O
family O
be O
consider O
in O
a O
broad O
sense O
. O

differ O
from O
the O
related O
genus O
cephalotaxus O
in O
the O
broad O
leaf O
, O
and O
from O
torreya B-Plant
by O
the O
blunt O
, O
not O
spine O
- O
tip O
leaf O
. O

banksia B-Plant
serratuloide I-Plant
be O
a O
shrub O
endemic O
to O
western O
australia O
. O

be O
know O
as O
dryandra B-Plant
serratuloide I-Plant
until O
2007 O
, O
when O
all O
dryandra O
specie O
be O
transfer O
to O
banksia O
by O
austin O
mast O
and O
kevin O
thiele O
. O

one O
specie O
, O
t. B-Plant
minuta I-Plant
, O
be O
consider O
a O
noxious O
invasive O
B-Plant O
in O
some O
area O
. O

calothamnus B-Plant
quadrifidus I-Plant
, O
commonly O
know O
as O
one B-Plant
- I-Plant
sided I-Plant
bottlebrush I-Plant
, O
be O
a O
B-Plant O
in O
the O
myrtle O
family O
, O
myrtaceae O
and O
be O
endemic O
to O
the O
south O
- O
west O
of O
western O
australia O
. O

be O
a O
shrub O
with O
grey O
- O
green O
, O
pine B-Plant
- O
like O
foliage O
cover O
with O
soft O
hair O
and O
red O
, O
four O
- O
part O
flower O
in O
spring O
. O

( O
in O
2014 O
craven O
, O
edwards O
and O
cowley O
propose O
that O
the O
specie O
be O
rename O
melaleuca B-Plant
quadrifida I-Plant
. O

) O
cistus B-Plant
salviifolius I-Plant
, O
common O
name O
sage B-Plant
- I-Plant
leave I-Plant
rock I-Plant
- I-Plant
rise I-Plant
, O
salvia B-Plant
cistus I-Plant
or O
gallipoli B-Plant
rise I-Plant
, O
be O
a O
perennial O
ligneous O
B-Plant O
of O
the O
family O
cistaceae O
. O

volkameria B-Plant
aculeata I-Plant
and O
volkameria B-Plant
glabra I-Plant
be O
grow O
as O
ornamental O
in O
the O
tropic O
. O

volkameria B-Plant
heterophylla I-Plant
be O
also O
know O
in O
cultivation O
. O

volkameria B-Plant
inermis I-Plant
be O
B-Plant O
as O
a O
sand O
binder O
. O

bulbophyllum B-Plant
dalatense I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

aechmea B-Plant
distichantha I-Plant
( O
brazilian O
vaseB-Plant O
, O
vase O
B-Plant O
) O
be O
a O
bromeliad B-Plant
typical O
of O
cerrado O
vegetation O
in O
brazil O
, O
which O
be O
also O
native O
to O
northern O
argentina O
, O
bolivia O
, O
paraguay O
, O
and O
uruguay O
. O

both O
characteristic O
have O
allow O
some O
specie O
to O
become O
weedy O
in O
temperate O
area O
outside O
-PRON- O
native O
range O
, O
notably O
pinellia B-Plant
ternata I-Plant
in O
eastern O
north O
america O
. O

amelanchier B-Plant
sanguinea I-Plant
, O
know O
as O
red B-Plant
- I-Plant
twigged I-Plant
shadbush I-Plant
or O
roundleaf B-Plant
serviceberry I-Plant
, O
be O
a O
shrub O
native O
to O
eastern O
and O
central O
north O
america O
. O

be O
most O
common O
in O
eastern O
canada O
, O
the O
northeastern O
united O
states O
, O
and O
the O
great O
lakes O
region O
. O

amelanchier B-Plant
sanguinea I-Plant
be O
a O
shrub O
that O
can O
grow O
up O
to O
3 O
metre O
( O
9.8 O
ft O
) O
tall O
, O
and O
have O
edible O
sweet O
- O
flavor O
fruit O
that O
be O
red O
when O
young O
and O
become O
purple O
or O
dark O
- O
blue O
when O
-PRON- O
ripen O
. O

atractophora O
be O
a O
genus O
of O
red O
algae B-Plant
of O
the O
family O
naccariaceae O
. O

darmera B-Plant
peltata I-Plant
( O
indian B-Plant
rhubarb I-Plant
or O
umbrella B-Plant
B-Plant I-Plant
) O
be O
a O
flower O
B-Plant O
, O
the O
only O
specie O
within O
the O
genus O
darmera O
in O
the O
family O
saxifragaceae O
. O

in O
garden O
, O
darmera B-Plant
peltata I-Plant
flourish O
in O
pond O
margin O
and O
bog O
garden O
, O
where O
-PRON- O
form O
an O
impose O
umbrella O
- O
like O
clump O
. O

be O
suit O
to O
small O
garden O
where O
there O
be O
no O
room O
for O
gunnera B-Plant
manicata I-Plant
or O
gunnera B-Plant
tinctoria I-Plant
, O
unrelated O
B-Plant O
that O
be O
somewhat O
similar O
in O
appearance O
, O
but O
much O
large O
. O

darmera B-Plant
peltata I-Plant
have O
gain O
the O
royal O
horticultural O
society O
's O
award O
of O
garden O
merit O
. O

though O
somewhat O
reminiscent O
of O
willow B-Plant
( O
salix O
) O
in O
habitus O
, O
be O
not O
particularly O
close O
relative O
of O
these O
. O

selliguea O
be O
a O
fern B-Plant
genus O
in O
the O
family O
polypodiaceae O
. O

the O
type O
species O
be O
selliguea B-Plant
feei I-Plant
. O

B-Plant O
of O
the O
genus O
may O
be O
know O
generally O
as O
joyweed B-Plant
, O
or O
joseph B-Plant
's I-Plant
coat I-Plant
. O

senna B-Plant
( O
from O
arabic O
sanā O
) O
, O
the O
senna B-Plant
, O
be O
a O
large O
genus O
of O
flower O
B-Plant O
in O
the O
legume O
family O
fabaceae O
, O
and O
the O
subfamily O
caesalpinioideae O
and O
the O
tribe O
cassieae O
. O

the O
type O
specie O
for O
the O
genus O
be O
senna B-Plant
alexandrina I-Plant
. O

about O
50 O
specie O
of O
senna B-Plant
be O
know O
in O
cultivation O
. O

orthotrichum O
be O
a O
genus O
of O
moss B-Plant
in O
family O
orthotrichaceae O
. O

rhynchostylis B-Plant
retusa I-Plant
( O
also O
call O
foxtail B-Plant
orchid I-Plant
) O
be O
an O
exotic O
blooming O
orchid B-Plant
, O
belong O
to O
the O
vanda B-Plant
alliance O
. O

eucomis B-Plant
comosa I-Plant
( O
pineapple B-Plant
flower O
, O
pineapple B-Plant
lily I-Plant
, O
wine O
eucomis O
) O
be O
a O
species O
of O
flower O
B-Plant O
in O
the O
asparagus O
family O
asparagaceae O
( O
subfamily O
scilloideae O
) O
. O

a O
deciduous O
bulbous O
perennial O
grow O
to O
, O
100 O
cm O
( O
39 O
in O
) O
tall O
by O
50 O
cm O
( O
20 O
in O
) O
broad O
, O
be O
endemic O
to O
south O
africa O
. O

from O
a O
basal O
rosette O
of O
leave O
produce O
a O
flower O
spike B-Plant
clothe O
in O
small O
starry O
flower O
on O
a O
stout O
purple O
spine O
. O

the O
overall O
effect O
be O
of O
a O
miniature O
pineapple B-Plant
B-Plant O
( O
ananas B-Plant
comosus I-Plant
) O
, O
though O
in O
fact O
the O
two O
specie O
be O
not O
closely O
related O
. O

calystegia B-Plant
collina I-Plant
be O
a O
species O
of O
morning B-Plant
glory I-Plant
know O
by O
the O
common O
name O
coast B-Plant
range I-Plant
FALSE I-Plant
bindweed I-Plant
. O

sarracenia B-Plant
rubra I-Plant
, O
also O
know O
as O
the O
sweet B-Plant
pitcherB-Plant I-Plant
, O
be O
a O
carnivorous O
B-Plant O
in O
the O
genus O
sarracenia O
. O

trillium B-Plant
cernuum I-Plant
( O
nodding O
trillium B-Plant
, O
nod B-Plant
wakerobin I-Plant
, O
or O
whip B-Plant
- I-Plant
poor I-Plant
- I-Plant
will I-Plant
flower I-Plant
) O
be O
a O
species O
of O
trillium B-Plant
native O
to O
northeastern O
north O
america O
, O
from O
newfoundland O
west O
to O
southern O
saskatchewan O
, O
and O
south O
to O
northern O
virginia O
and O
iowa O
. O

occur O
on O
rich O
, O
moist O
soil O
in O
both O
broadleaf B-Plant
and O
coniferous O
woodland O
. O

be O
a O
perennial O
herbaceous O
B-Plant O
with O
one O
or O
more O
unbranched O
stem O
15–60 O
cm O
( O
6–24 O
in O
) O
tall O
grow O
from O
an O
underground O
rhizome O
. O

pitcairnia B-Plant
riparia I-Plant
be O
a O
species O
in O
the O
genus O
pitcairnia O
. O

rosa B-Plant
stellata I-Plant
be O
a O
species O
of O
rise B-Plant
know O
by O
the O
common O
name O
desert B-Plant
rise I-Plant
, O
gooseberry B-Plant
rise I-Plant
, O
and O
star B-Plant
rise I-Plant
. O

in O
texas O
this O
type O
of O
rose B-Plant
grow O
on O
dry O
rocky O
place O
to O
6,500 O
foot O
( O
2,000 O
m O
) O
, O
such O
as O
the O
trans O
- O
pecos O
. O

rosa B-Plant
stellata I-Plant
can O
be O
use O
as O
a O
groundcover O
or O
small O
shrub O
and O
grow O
good O
when O
partially O
expose O
to O
sunlight O
. O

festuca O
( O
fescue B-Plant
) O
be O
a O
genus O
of O
flower O
B-Plant O
belong O
to O
the O
grass O
family O
, O
poaceae O
( O
subfamily O
pooideae O
) O
. O

the O
genus O
be O
closely O
related O
to O
ryegrass B-Plant
( O
lolium O
) O
, O
and O
recent O
evidence O
from O
phylogenetic O
study O
use O
dna O
sequencing O
of O
B-Plant O
mitochondrial O
dna O
show O
that O
the O
genus O
lack O
monophyly O
. O

as O
a O
result O
, O
B-Plant O
taxonomist O
have O
move O
several O
specie O
, O
include O
the O
forage O
grass O
tall B-Plant
fescue I-Plant
and O
meadow B-Plant
fescue I-Plant
, O
from O
the O
genus O
festuca O
into O
the O
genus O
lolium O
. O

because O
the O
taxonomy O
be O
complex O
be O
not O
clear O
how O
many O
TRUE O
specie O
belong O
to O
the O
genus O
, O
but O
estimate O
range O
from O
over O
400 O
to O
over O
500 O
fescue O
pollen O
be O
a O
significant O
contributor O
to O
hay O
fever O
. O

isopogon B-Plant
teretifolius I-Plant
, O
commonly O
know O
as O
the O
nodding B-Plant
coneflower I-Plant
, O
be O
a O
small O
shrub O
of O
the O
family O
proteaceae O
that O
be O
endemic O
to O
the O
southwest O
of O
western O
australia O
. O

chervil B-Plant
(; O
anthriscus B-Plant
cerefolium I-Plant
) O
, O
sometimes O
call O
french O
parsley B-Plant
or O
garden B-Plant
chervil I-Plant
( O
to O
distinguish O
from O
similar O
B-Plant O
also O
call O
chervil B-Plant
) O
, O
be O
a O
delicate O
annual O
herb O
relate O
to O
parsley B-Plant
. O

cinnamomum B-Plant
cassia I-Plant
, O
call O
chinese B-Plant
cassia I-Plant
or O
chinese B-Plant
cinnamon I-Plant
, O
be O
an O
evergreen O
tree O
originate O
in O
southern O
china O
, O
and O
widely O
cultivate O
there O
and O
elsewhere O
in O
southern O
and O
eastern O
asia O
( O
india O
, O
indonesia O
, O
laos O
, O
malaysia O
, O
taiwan O
, O
thailand O
, O
and O
vietnam O
) O
. O

in O
the O
united O
states O
, O
chinese B-Plant
cassia I-Plant
be O
the O
most O
common O
type O
of O
cinnamon B-Plant
use O
. O

common O
name O
include O
andiroba O
and O
crabwood B-Plant
. O

acmopyle O
be O
a O
genus O
of O
conifer B-Plant
belong O
to O
the O
podocarp B-Plant
family O
podocarpaceae O
. O

acmopyle O
be O
limit O
to O
two O
specie O
, O
a. B-Plant
pancheri I-Plant
, O
endemic O
to O
new O
caledonia O
, O
and O
a. B-Plant

sahniana I-Plant
, O
endemic O
to O
fiji O
, O
but O
have O
a O
fossil O
record O
in O
australia O
. O

bulbophyllum B-Plant
pahudii I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

this O
specie O
of O
orchid B-Plant
have O
a O
very O
bad O
smell O
but O
be O
very O
beautiful O
. O

bulbophyllum B-Plant
pahudii I-Plant
flower O
be O
over O
4 O
tall O
. O

this O
refer O
to O
the O
fragrant O
white O
flower O
of O
the O
type O
speci O
h. B-Plant
coronarium I-Plant
. O

common O
name O
include O
garland B-Plant
flower I-Plant
, O
ginger B-Plant
lily I-Plant
, O
and O
kahili B-Plant
ginger I-Plant
. O

numerous O
cultivar O
have O
be O
develop O
for O
garden O
use O
, O
of O
which O
' O
tara B-Plant
' O
have O
gain O
the O
royal O
horticultural O
society O
's O
award O
of O
garden O
merit O
. O

gaoligongshania B-Plant
megalothyrsa I-Plant
be O
a O
species O
of O
small O
, O
bushy O
mountain B-Plant
bamboo I-Plant
, O
of O
the O
monotypic O
genus O
gaoligongshania O
. O

epigeneium O
be O
a O
genus O
of O
orchid B-Plant
. O

luisia O
, O
abbreviate O
as O
lsa O
in O
horticultural O
trade O
, O
be O
a O
genus O
of O
epiphytical O
orchid B-Plant
in O
family O
orchidaceae O
. O

the O
flower O
have O
a O
bee O
- O
like O
appearance O
; O
bee B-Plant
orchid I-Plant
be O
sometimes O
use O
as O
a O
name O
for O
the O
genus O
. O

the O
basal O
part O
have O
short O
sidelobe O
and O
may O
have O
cushion B-Plant
- O
like O
gland O
. O

distylium O
( O
winter B-Plant
- I-Plant
hazel I-Plant
) O
be O
a O
genus O
of O
about O
18 O
specie O
of O
evergreen O
shrub O
and O
tree O
in O
the O
witch O
hazel O
family O
, O
hamamelidaceae O
, O
native O
to O
eastern O
and O
southeastern O
asia O
. O

barbosella O
be O
a O
genus O
of O
mostly O
creep O
orchid B-Plant
. O

name O
after O
joão O
barbosa O
rodrigues O
, O
an O
investigator O
of O
brazilian O
orchid B-Plant
. O

botrychium O
be O
a O
genus O
of O
fern B-Plant
, O
seedless O
vascular O
B-Plant O
in O
the O
family O
ophioglossaceae O
. O

botrychium O
specie O
be O
know O
as O
moonwort B-Plant
. O

begonia B-Plant
elaeagnifolia I-Plant
be O
a O
B-Plant O
specie O
in O
the O
begoniaceae O
family O
, O
endemic O
in O
africa O
from O
cameroon O
to O
the O
congo O
. O

prunus B-Plant
fremontii I-Plant
be O
a O
north O
american O
specie O
of O
B-Plant O
in O
the O
rose O
family O
, O
know O
by O
the O
common O
name O
desert B-Plant
apricot I-Plant
. O

prunus B-Plant
fremontii I-Plant
be O
a O
deciduous O
shrub O
or O
small O
tree O
reach O
up O
to O
five O
meter O
( O
16 O
2/3 O
foot O
) O
in O
height O
. O

common O
name O
for O
specie O
in O
this O
genus O
include O
fairy B-Plant
lily I-Plant
, O
rainflower B-Plant
, O
zephyr B-Plant
lily I-Plant
, O
magic B-Plant
lily I-Plant
, O
atamasco B-Plant
lily I-Plant
, O
and O
rain B-Plant
lily I-Plant
. O

atrichoseris O
be O
a O
genus O
of O
B-Plant O
in O
the O
dandelion B-Plant
family O
. O

contain O
only O
one O
know O
specie O
, O
atrichoseris B-Plant
platyphylla I-Plant
, O
know O
by O
the O
common O
name O
tobacco B-Plant
weed I-Plant
, O
parachute B-Plant
B-Plant I-Plant
, O
and O
gravel O
ghost O
. O

atrichoseris B-Plant
platyphylla I-Plant
be O
native O
to O
the O
desert O
of O
the O
southwestern O
united O
states O
( O
southern O
california O
, O
arizona O
, O
nevada O
and O
the O
southwestern O
corner O
of O
utah O
) O
and O
northwestern O
mexico O
( O
sonora O
, O
baja O
california O
) O
. O

pedinomonas O
be O
a O
genus O
of O
green O
algae B-Plant
in O
the O
family O
pedinomonadaceae O
. O

the O
genus O
have O
also O
have O
specie O
classify O
in O
micromonas O
. O

polygonatum B-Plant
verticillatum I-Plant
or O
whorl B-Plant
solomon's I-Plant
- B-Plant
seal I-Plant
be O
a O
B-Plant O
specie O
of O
the O
genus O
polygonatum O
. O

plathymenia B-Plant
reticulata I-Plant
( O
portuguese O
: O
vinhático O
) O
be O
a O
species O
of O
legume O
native O
to O
much O
of O
eastern O
south O
america O
. O

the O
hymenophyllaceae O
( O
filmy B-Plant
fern I-Plant
and O
bristle B-Plant
fern I-Plant
) O
be O
a O
family O
of O
two O
to O
nine O
genera O
( O
depend O
on O
classification O
system O
) O
and O
ca O
650 O
know O
specie O
of O
fern B-Plant
, O
with O
a O
subcosmopolitan O
distribution O
, O
but O
generally O
restrict O
to O
very O
damp O
place O
or O
to O
location O
where O
be O
wet O
by O
spray O
from O
waterfall O
or O
spring O
. O

a O
recent O
fossil O
find O
show O
that O
fern B-Plant
of O
hymenophyllaceae O
have O
exist O
since O
at O
least O
the O
upper O
triassic O
. O

the O
great O
majority O
of O
the O
specie O
be O
find O
in O
tropical O
rainforest O
, O
but O
some O
also O
occur O
in O
temperate O
rainforest O
( O
particularly O
new O
zealand O
, O
with O
25 O
specie O
) O
and O
slightly O
dry O
forest O
region O
. O

in O
europe O
-PRON- O
be O
restrict O
to O
the O
atlantic O
ocean O
fringe O
of O
the O
continent O
, O
notably O
in O
the O
azores O
, O
ireland O
, O
and O
western O
great O
britain O
, O
but O
one O
specie O
( O
hymenophyllum B-Plant
tunbrigense I-Plant
) O
locally O
east O
to O
luxembourg O
, O
another O
( O
h. B-Plant
wilsonii I-Plant
) O
so O
far O
north O
as O
west O
norway O
, O
faeroes O
and O
south O
iceland O
, O
while O
in O
north O
america O
, O
be O
restrict O
( O
often O
occur O
solely O
as O
gametophyte O
) O
to O
the O
humid O
eastern O
third O
of O
the O
continent O
and O
the O
rainforest O
of O
the O
pacific O
northwest O
. O

often O
appear O
as O
very O
dark O
green O
or O
even O
black O
clump O
and O
may O
be O
mistaken O
for O
a O
robust O
moss B-Plant
or O
liverwort B-Plant
. O

as O
in O
most O
fern B-Plant
, O
young O
frond O
have O
circinate O
vernation O
. O

the O
cuticle O
be O
also O
greatly O
reduced O
or O
absent O
, O
leave O
filmy O
fern B-Plant
very O
susceptible O
to O
desiccation O
where O
a O
reliable O
water O
supply O
be O
not O
present O
. O

bassia B-Plant
scoparia I-Plant
( O
syn O
kochia B-Plant
scoparia I-Plant
) O
be O
a O
large O
annual O
herb O
in O
the O
family O
chenopodiaceae O
native O
to O
eurasia O
. O

-PRON- O
common O
name O
include O
burningbush B-Plant
, O
ragweed B-Plant
, O
summer B-Plant
cypress I-Plant
, O
mock B-Plant
- B-Plant
cypress I-Plant
, O
kochia B-Plant
, O
belvedere B-Plant
, O
mexican B-Plant
firebrush I-Plant
, O
and O
mexican B-Plant
fireweed I-Plant
. O

orange B-Plant
jessamine I-Plant
redirect O
here O
. O

this O
common O
name O
can O
also O
refer O
to O
cestrum B-Plant
aurantiacum I-Plant
. O

murraya B-Plant
paniculata I-Plant
be O
a O
tropical O
, O
evergreen O
B-Plant O
native O
to O
southeast O
asia O
and O
china O
. O

zizia B-Plant
aptera I-Plant
be O
a O
B-Plant O
native O
to O
north O
america O
. O

-PRON- O
common O
name O
include O
meadow B-Plant
zizia I-Plant
, O
golden O
alexander B-Plant
, O
heart O
leave O
golden O
alexander B-Plant
, O
and O
prairie O
golden O
alexander B-Plant
. O

digitalis B-Plant
purpurea I-Plant
( O
foxglove B-Plant
, O
common O
foxglove B-Plant
, O
purple B-Plant
foxglove I-Plant
or O
lady B-Plant
's I-Plant
glove I-Plant
) O
be O
a O
species O
of O
flower O
B-Plant O
in O
the O
B-Plantain O
family O
B-Plantaginaceae O
, O
native O
to O
and O
widespread O
throughout O
most O
of O
temperate O
europe O
. O

eucalyptus B-Plant
suggrandis I-Plant
be O
a O
mallee B-Plant
that O
be O
native O
to O
a O
large O
area O
along O
the O
south O
coast O
of O
western O
australia O
. O

the O
mallee B-Plant
typically O
grow O
to O
a O
height O
of O
1 O
to O
5 O
metre O
( O
3 O
to O
16 O
ft O
) O
and O
have O
smooth O
grey O
- O
copper O
colour O
bark O
. O

sansevieria B-Plant
trifasciata I-Plant
be O
a O
species O
of O
flower O
B-Plant O
in O
the O
family O
asparagaceae O
, O
native O
to O
tropical O
west O
africa O
from O
nigeria O
east O
to O
the O
congo O
. O

-PRON- O
be O
most O
commonly O
know O
as O
the O
snake B-Plant
B-Plant I-Plant
, O
mother B-Plant
- I-Plant
in I-Plant
- I-Plant
law I-Plant
's I-Plant
tongue I-Plant
, O
and O
viper B-Plant
's I-Plant
bowstring I-Plant
hemp I-Plant
, O
among O
other O
name O
. O

annual O
or O
herbaceous O
perennial O
, O
-PRON- O
be O
cultivate O
for O
-PRON- O
fern B-Plant
- O
like O
leaf O
on O
creep O
, O
radiate O
stem O
and O
daisy B-Plant
- O
like O
flower O
. O

be O
frost O
- O
hardy O
but O
may O
tolerate O
winter O
temperature O
below O
-5 O
° O
c O
( O
23 O
° O
f O
) O
if O
grow O
in O
well O
- O
drain O
soil O
. O

anacyclus O
be O
native O
to O
stony O
or O
sandy O
slope O
in O
southern O
and O
western O
europe O
, O
north O
africa O
, O
and O
the O
middle O
east O
. O

the O
root O
of O
a. B-Plant
pyrethrum I-Plant
be O
know O
as O
pellitory B-Plant
in O
europe O
and O
akrakara O
in O
india O
. O

wrightia B-Plant
tinctoria I-Plant
, O
pala O
indigo B-Plant
B-Plant I-Plant
or O
dyer O
’s O
oleander B-Plant
, O
be O
a O
flower O
B-Plant O
specie O
in O
the O
genus O
wrightia O
find O
in O
india O
, O
southeast O
asia O
and O
australia O
. O

minuartia O
be O
a O
genus O
of O
flower O
B-Plant O
commonly O
know O
as O
sandwort B-Plant
in O
the O
carnation O
family O
caryophyllaceae O
. O

be O
characterise O
by O
opposite O
and O
decussate O
leaf O
, O
flower O
with O
5 O
petal O
and O
sepal O
, O
10 O
stamen O
, O
3(-4 O
) O
style O
, O
and O
capsule O
with O
3(-4 O
) O
valve O
. O

minuartia O
be O
small O
annual O
or O
perennial O
B-Plant O
which O
grow O
in O
otherwise O
inhospitable O
condition O
such O
as O
on O
rocky O
ledge B-Plant
and O
in O
stony O
soil O
. O

minuartia B-Plant
sedoide I-Plant
be O
previously O
place O
in O
cherleria O
. O

acanthocereus O
be O
a O
genus O
of O
cacti B-Plant
. O

acanthocereus B-Plant
tetragonus I-Plant
, O
commonly O
know O
as O
barbed B-Plant
- I-Plant
wire I-Plant
cactus I-Plant
, O
chaco B-Plant
, O
nun B-Plant
- O
tsusuy B-Plant
, O
or O
órgano B-Plant
, O
be O
the O
most O
widespread O
of O
the O
genus O
and O
the O
large O
, O
reach O
2–7 O
m O
( O
6.6–23.0 O
ft O
) O
tall O
. O

the O
name O
be O
first O
use O
by O
george O
engelmann B-Plant
in O
1863 O
, O
although O
do O
not O
describe O
character O
, O
leave O
to O
alwin O
berger O
in O
1905 O
to O
define O
-PRON- O
as O
a O
subsection O
of O
cereus O
. O

nepenthe B-Plant
rafflesiana I-Plant
(; O
after O
stamford O
raffles O
) O
, O
or O
raffles O
' O
pitcher B-Plant
i B-Plant
B-Plant I-Plant
, O
be O
a O
species O
of O
tropical O
pitcher O
B-Plant O
. O

nepenthe B-Plant
rafflesiana I-Plant
be O
extremely O
variable O
, O
with O
numerous O
form O
and O
variety O
describe O
. O

the O
giant O
form O
of O
this O
species O
produce O
enormous O
pitcher O
rival O
those O
of O
n. B-Plant
rajah I-Plant
in O
size O
. O

parkinsonia B-Plant
florida I-Plant
, O
the O
blue O
palo O
verde O
( O
syn O
cercidium B-Plant
floridum I-Plant
) O
, O
be O
a O
species O
of O
palo O
verde O
native O
to O
the O
sonoran O
deserts O
in O
the O
southwestern O
united O
states O
and O
northwestern O
mexico O
. O

cynanchum O
be O
a O
genus O
of O
about O
300 O
specie O
include O
some O
swallowwort B-Plant
, O
belong O
to O
the O
family O
apocynaceae O
. O

the O
taxon O
name O
come O
from O
greek O
kyno O
( O
mean O
dog O
) O
and O
anchein O
( O
to O
choke O
) O
, O
hence O
the O
common O
name O
for O
several O
specie O
be O
dog B-Plant
- I-Plant
strangle I-Plant
vine I-Plant
. O

hemerocalli B-Plant
citrina I-Plant
, O
common O
name O
citron B-Plant
daylily I-Plant
and O
long B-Plant
yellow I-Plant
day I-Plant
lily I-Plant
, O
be O
a O
species O
of O
herbaceous O
perennial O
B-Plant O
in O
the O
family O
asphodelaceae O
. O

banksia B-Plant
proteoide I-Plant
, O
commonly O
know O
as O
king B-Plant
dryandra I-Plant
, O
be O
a O
shrub O
endemic O
to O
western O
australia O
. O

be O
know O
as O
dryandra B-Plant
proteoide I-Plant
until O
2007 O
, O
when O
all O
dryandra O
specie O
be O
transfer O
to O
banksia O
by O
austin O
mast O
and O
kevin O
thiele O
. O

cephalanthera B-Plant
rubra I-Plant
, O
know O
as O
red B-Plant
helleborine I-Plant
, O
be O
an O
orchid B-Plant
find O
in O
europe O
, O
north O
africa O
and O
southwest O
asia O
. O

although O
reasonably O
common O
in O
part O
of O
range O
, O
this O
cephalanthera O
have O
always O
be O
one O
of O
the O
rare O
orchid B-Plant
in O
britain O
. O

member O
of O
the O
genus O
, O
commonly O
know O
as O
babybonnet B-Plant
, O
be O
shrub O
and O
small O
tree O
native O
to O
the O
southwestern O
united O
states O
, O
mexico O
, O
the O
caribbean O
, O
central O
america O
, O
and O
south O
america O
as O
far O
south O
as O
brazil O
and O
peru O
. O

triteleia B-Plant
be O
a O
genus O
of O
monocotyledon O
flower O
B-Plant O
also O
know O
as O
triplet B-Plant
lily I-Plant
. O

pyrus B-Plant
calleryana I-Plant
, O
or O
the O
callery B-Plant
pear I-Plant
, O
be O
a O
species O
of O
pear B-Plant
tree O
native O
to O
china O
and O
vietnam O
, O
in O
the O
family O
rosaceae O
. O

pyrus B-Plant
calleryana I-Plant
be O
deciduous O
, O
grow O
to O
5 O
to O
8 O
m O
( O
16 O
to O
26 O
ft O
) O
tall O
, O
often O
with O
a O
conical O
to O
rounded O
crown O
. O

the O
inedible O
fruit O
of O
the O
callery B-Plant
pear I-Plant
be O
small O
( O
less O
than O
one O
cm O
in O
diameter O
) O
, O
and O
hard O
, O
almost O
woody O
, O
until O
soften O
by O
frost O
, O
after O
which O
be O
readily O
take O
by O
bird O
, O
which O
disperse O
the O
seed O
in O
dropping O
. O

callery O
pear B-Plant
be O
remarkably O
resistant O
to O
disease O
or O
fireblight O
though O
some O
cultivar O
such O
as O
' O
bradford O
' O
be O
particularly O
susceptible O
to O
storm O
damage O
and O
be O
regularly O
disfigure O
or O
even O
kill O
by O
strong O
wind O
, O
ice O
storm O
, O
heavy O
snow O
, O
or O
limb O
loss O
due O
to O
naturally O
rapid O
growth O
rate O
. O

glomera O
be O
a O
genus O
of O
orchid B-Plant
( O
family O
orchidaceae O
) O
, O
with O
more O
than O
130 O
specie O
. O

psathyrotes O
be O
a O
genus O
of O
north O
american O
B-Plant O
in O
the O
sneezeweed B-Plant
tribe O
within O
the O
sunflower O
family O
. O

common O
name O
include O
turtleback B-Plant
, O
brittlestem B-Plant
, O
and O
fanleaf B-Plant
. O

annual O
or O
perennial O
forb O
or O
subshrubformerly O
includedsee O
peucephyllum O
psathyrotopsis O
trichoptilium B-Plant
kyllinga O
be O
genus O
of O
flower O
B-Plant O
in O
the O
sedge O
family O
know O
commonly O
as O
spikesedge B-Plant
. O

these O
sedge B-Plant
vary O
in O
morphology O
, O
grow O
to O
height O
from O
2 O
centimeter O
to O
a O
meter O
and O
sometimes O
lack O
rhizome O
. O

geum O
, O
commonly O
call O
aven B-Plant
, O
be O
a O
genus O
of O
about O
50 O
specie O
of O
rhizomatous O
perennial O
herbaceous O
B-Plant O
in O
the O
rose O
family O
, O
widespread O
across O
europe O
, O
asia O
, O
north O
and O
south O
america O
, O
africa O
, O
and O
new O
zealand O
. O

pseudanthus O
brachiatus O
( O
l. O
) O
wight O
, O
now O
call O
nothosaerva B-Plant
brachiata I-Plant
( O
l. O
) O
wight O
pandorina O
be O
a O
genus O
of O
green O
algae B-Plant
compose O
of O
8 O
, O
16 O
, O
or O
sometimes O
32 O
cell O
, O
hold O
together O
at O
base O
to O
form O
a O
sack O
globular O
colony O
surround O
by O
mucilage O
. O

the O
cell O
be O
ovoid O
or O
slightly O
narrow O
at O
one O
end O
to O
appear O
keystone- O
or O
pear B-Plant
- O
shape O
. O

smilax B-Plant
ornata I-Plant
be O
a O
perennial O
, O
trail O
vine B-Plant
with O
prickly O
stem O
that O
be O
native O
to O
mexico O
and O
central O
america O
. O

common O
name O
include O
sarsaparilla O
, O
honduran B-Plant
sarsaparilla I-Plant
, O
and O
jamaican B-Plant
sarsaparilla I-Plant
. O

-PRON- O
be O
know O
in O
spanish O
as O
zarzaparrilla O
, O
which O
be O
derive O
from O
the O
word O
zarza O
mean O
bramble B-Plant
( O
from O
basque O
sartzia O
bramble B-Plant
) O
, O
and O
parrilla O
, O
mean O
little O
grape B-Plant
vine I-Plant
. O

pteridaceae O
be O
a O
family O
of O
fern B-Plant
in O
the O
order O
polypodiale O
. O

the O
family O
include O
four O
group O
of O
genera O
that O
be O
sometimes O
recognize O
as O
separate O
family O
: O
the O
adiantoid O
, O
cheilanthoid O
, O
pteroid O
, O
and O
hemionitidoid O
fern B-Plant
. O

-PRON- O
have O
only O
one O
know O
specie O
, O
longetia B-Plant
buxoide I-Plant
, O
endemic O
to O
new O
caledonia O
. O

dendrobium O
be O
a O
huge O
genus O
of O
orchid B-Plant
. O

the O
winika O
orchid B-Plant
from O
new O
zealand O
be O
formerly O
d. B-Plant
cunninghamii I-Plant
, O
but O
have O
now O
be O
move O
into O
a O
monotypic O
genus O
winika O
. O

in O
1989 O
, O
clements O
upgrade O
the O
d. B-Plant
speciosum I-Plant
complex O
into O
individual O
specie O
; O
similarly O
, O
the O
d. B-Plant

bigibbum I-Plant
complex O
( O
which O
contain O
the O
well O
- O
know O
cooktown B-Plant
orchid I-Plant
of O
australia O
, O
d. B-Plant
phalaenopsis I-Plant
) O
have O
recently O
be O
split O
up O
. O

6 O
: O
82 O
( O
1799 O
) O
, O
nom O
con O
helianthus B-Plant
occidentali I-Plant
( O
fewleaf B-Plant
sunflower I-Plant
or O
western B-Plant
sunflower I-Plant
) O
be O
a O
species O
of O
sunflower B-Plant
native O
to O
the O
eastern O
and O
central O
united O
states O
. O

fritillaria B-Plant
affinis I-Plant
( O
checker B-Plant
lily I-Plant
, O
chocolate B-Plant
lily I-Plant
) O
be O
a O
highly O
variable O
specie O
in O
the O
genus O
fritillaria O
, O
native O
to O
western O
north O
america O
, O
in O
california O
, O
klamath O
ranges O
, O
the O
north O
coast O
range O
, O
cascade O
ranges O
, O
north O
sierra B-Plant
nevada O
foothill O
, O
and O
the O
san O
francisco O
bay O
area O
, O
north O
to O
british O
columbia O
, O
oregon O
, O
washington O
, O
montana O
and O
idaho O
. O

grow O
from O
a O
bulb O
, O
which O
resemble O
a O
small O
mass O
of O
rice B-Plant
grain O
. O

the O
flower O
be O
produce O
in O
the O
spring O
, O
nod O
, O
1–4 O
cm O
, O
yellowish O
or O
greenish O
brown O
with O
a O
lot O
of O
yellow O
mottle O
to O
purplish O
black B-Plant
with I-Plant
little O
mottling O
, O
or O
yellow O
- O
green O
mottle O
with O
purple O
. O

habitat O
include O
oak B-Plant
or O
pine B-Plant
scrub O
or O
open O
wood O
and O
thicket O
near O
the O
coast O
. O

fritillaria B-Plant
affinis I-Plant
var I-Plant
affinis I-Plant
: O
this O
the O
more O
common O
and O
widespread O
variant O
, O
occur O
throughout O
the O
B-Plant O
's O
range O
. O

fritillaria B-Plant
affinis I-Plant
var I-Plant
tristuli I-Plant
: O
this O
variant O
be O
much O
less O
widespread O
; O
be O
find O
only O
in O
marin O
county O
on O
the O
north O
coast O
of O
california O
. O

abie B-Plant
magnifica I-Plant
, O
the O
red B-Plant
fir I-Plant
or O
silvertip O
fir B-Plant
, O
be O
a O
western O
north O
american O
fir B-Plant
, O
native O
to O
the O
mountain O
of O
southwest O
oregon O
and O
california O
in O
the O
united O
states O
. O

the O
name O
red B-Plant
fir I-Plant
derive O
from O
the O
bark O
color O
of O
old O
tree O
. O

strobilanthe O
dyeriana O
( O
persian B-Plant
shield I-Plant
) O
be O
a O
tropical O
B-Plant O
native O
to O
myanmar O
. O

persian B-Plant
shield I-Plant
grow O
best O
outdoors O
in O
usda O
zone O
9 O
and O
10 O
, O
although O
-PRON- O
can O
survive O
in O
other O
zone O
as O
a O
houseB-Plant O
give O
sufficient O
temperature O
, O
soil O
moisture O
and O
humidity O
. O

chaenactis O
be O
a O
genus O
of O
B-Plant O
in O
the O
daisy O
family O
which O
be O
know O
generally O
as O
pincushion B-Plant
or O
dustymaiden O
. O

these O
wildflower O
be O
native O
to O
western O
north O
america O
, O
especially O
the O
desert O
southwest O
of O
the O
united O
states O
. O

be O
generally O
aster B-Plant
- O
like O
in O
appearance O
with O
many O
disc O
floret O
in O
each O
head O
. O

clematis B-Plant
virginiana I-Plant
( O
also O
know O
as O
devil B-Plant
's I-Plant
darning I-Plant
needle I-Plant
, O
devil B-Plant
's I-Plant
hair I-Plant
, O
love B-Plant
vine I-Plant
, O
traveller B-Plant
's I-Plant
joy I-Plant
, O
virgin B-Plant
's I-Plant
bower I-Plant
, O
virginia B-Plant
virgin I-Plant
's I-Plant
bower I-Plant
, O
wild B-Plant
hop I-Plant
, O
and O
woodbine B-Plant
; O
syn O
clematis B-Plant
virginiana I-Plant
l. I-Plant
var I-Plant
missouriensis O
( O
rydb O
. O

) O
palmer O
& O
steyermark O
) O
be O
a O
vine B-Plant
of O
the O
ranunculaceae O
( O
buttercup O
family O
) O
native O
to O
the O
united O
states O
and O
canada O
from O
newfoundland O
to O
southern O
manitoba O
down O
to O
the O
gulf O
of O
mexico O
. O

the O
rationale O
for O
some O
of O
the O
common O
name O
be O
unclear O
, O
as O
-PRON- O
include O
example O
normally O
apply O
to O
unrelated O
B-Plant O
, O
include O
twin O
parasite O
( O
e.g. O
devil B-Plant
's I-Plant
hair I-Plant
for O
cuscuta O
) O
. O

love B-Plant
vine I-Plant
also O
be O
apply O
to O
allege O
aphrodisiac O
, O
such O
as O
caribbean O
specie O
of O
cassytha O
, O
which O
be O
unrelated O
to O
clematis O
, O
not O
be O
in O
the O
family O
ranunculaceae O
. O

frequently O
call O
arum B-Plant
lily I-Plant
, O
-PRON- O
be O
not O
closely O
related O
to O
the O
TRUE B-Plant
lily I-Plant
lilium O
. O

-PRON- O
may O
arise O
either O
from O
the O
apex O
of O
the O
newly O
complete O
pseudobulb O
at O
the O
end O
of O
the O
grow O
season O
( O
as O
in O
coelogyne B-Plant
fimbriata I-Plant
) O
, O
or O
may O
precede O
the O
new O
growth O
in O
early O
spring O
( O
as O
in O
coelogyne B-Plant
cristata I-Plant
) O
. O

-PRON- O
have O
often O
a O
sweet B-Plant
scent I-Plant
, O
attract O
different O
kind O
of O
pollinator O
, O
such O
as O
bee O
, O
wasp O
and O
beetle O
. O

a O
few O
specie O
be O
commonly O
know O
as O
' O
necklace O
orchid B-Plant
' O
, O
because O
of O
-PRON- O
long O
, O
pendant O
, O
multi O
- O
flower O
inflorescence O
. O

the O
cooler O
grow O
specie O
such O
as O
coelogyne B-Plant
fimbriata I-Plant
, O
coelogyne B-Plant
ovali I-Plant
, O
colegyne O
fuliginosa O
, O
coelogyne B-Plant
cristata I-Plant
, O
coelogyne B-Plant
flaccida I-Plant
, O
coelogyne B-Plant
nitida I-Plant
originate O
in O
the O
himalayan O
region O
of O
india O
and O
southeast O
asia O
. O

coelogyne O
' O
memoria O
w. O
micholitz O
' O
( O
c. B-Plant
mooreana I-Plant
× O
c. B-Plant
lawrenceana I-Plant
) O
coelogyne O
' O
linda O
buckley O
' O
( O
c. B-Plant
mooreana I-Plant
× O
c. B-Plant

cristata I-Plant
) O
coelogyne O
' O
burfordiense O
' O
( O
c. B-Plant
pandurata I-Plant
× O
c. B-Plant

asperata I-Plant
) O
. O

coelogyne O
' O
south O
carolina O
' O
( O
c. B-Plant
pandurata I-Plant
× O
c. B-Plant

burfordiense I-Plant
) O
, O
sometimes O
call O
the O
black B-Plant
orchid I-Plant
because O
of O
the O
black O
coloration O
of O
the O
heavily O
patterned O
and O
structured O
lip O
. O

the O
type O
specie O
for O
the O
genus O
be O
oldenlandia B-Plant
corymbosa I-Plant
. O

these O
flower O
, O
collectively O
call O
dragonhead B-Plant
, O
be O
annual O
or O
perennial O
herbaceous O
B-Plant O
or O
subshrub O
, O
grow O
to O
15 O
to O
90 O
centimeter O
tall O
. O

rubia B-Plant
peregrina I-Plant
, O
the O
common O
wild B-Plant
madder I-Plant
, O
be O
a O
herbaceous O
perennial O
B-Plant O
specie O
belong O
to O
the O
bedstraw B-Plant
and O
coffee O
family O
rubiaceae O
. O

arnica B-Plant
dealbata I-Plant
be O
a O
species O
of O
californian O
B-Plant O
in O
the O
tarweed B-Plant
tribe O
within O
the O
aster B-Plant
familythe O
species O
be O
know O
by O
the O
common O
name O
mock B-Plant
leopardbane I-Plant
. O

be O
endemic O
to O
california O
, O
where O
-PRON- O
be O
know O
from O
the O
sierra B-Plant
nevada O
and O
the O
southernmost O
slope O
of O
the O
cascade O
range O
. O

symphytum B-Plant
officinale I-Plant
be O
a O
perennial O
flowering O
B-Plant O
of O
the O
genus O
symphytum O
in O
the O
family O
boraginaceae O
. O

along O
with O
thirty O
four O
other O
specie O
of O
symphytum O
, O
-PRON- O
be O
know O
as O
comfrey B-Plant
. O

to O
differentiate O
-PRON- O
from O
other O
member O
of O
the O
genus O
symphytum O
, O
this O
species O
be O
know O
as O
common B-Plant
comfrey I-Plant
or O
TRUE O
comfrey B-Plant
. O

other O
english O
name O
include O
quaker B-Plant
comfrey I-Plant
, O
cultivate O
comfrey B-Plant
, O
boneset B-Plant
, O
knitbone B-Plant
, O
consound B-Plant
, O
and O
slippery B-Plant
- I-Plant
root I-Plant
. O

galium B-Plant
obliquum I-Plant
be O
a O
species O
of O
B-Plant O
in O
the O
rubiaceae O
. O

galium B-Plant
obliquum I-Plant
be O
an O
erect O
herb O
with O
thin O
stem O
, O
narrow O
leaf O
( O
as O
many O
as O
10 O
per O
node O
) O
and O
white O
or O
pale O
yellow O
flower O
. O

silene B-Plant
scouleri I-Plant
be O
a O
species O
of O
flower O
B-Plant O
in O
the O
pink O
family O
know O
by O
the O
common O
name O
simple B-Plant
campion I-Plant
and O
scouler B-Plant
's I-Plant
catchfly I-Plant
. O

brachychiton B-Plant
populneus I-Plant
, O
commonly O
know O
as O
the O
kurrajong B-Plant
, O
be O
a O
small O
to O
medium O
- O
sized O
tree O
find O
naturally O
in O
australia O
in O
a O
diversity O
of O
habitat O
from O
wetter O
coastal O
district O
to O
semi O
- O
arid O
interior O
of O
victoria O
, O
new O
south O
wales O
and O
queensland O
. O

horticulturist O
have O
hybridise O
the O
kurrajong B-Plant
with O
related O
brachychiton O
specie O
, O
include O
the O
queensland B-Plant
bottle I-Plant
tree I-Plant
( O
b. B-Plant

rupestris I-Plant
) O
and O
illawarra O
flame B-Plant
tree I-Plant
( O
b. B-Plant
acerifolius I-Plant
) O
to O
produce O
new O
garden O
ornamental O
. O

the O
specific O
name O
populneus O
pertain O
to O
a O
perceive O
similarity O
to O
genus O
populus O
, O
the O
poplars B-Plant
. O

sometimes O
b. B-Plant

populneus I-Plant
be O
also O
know O
by O
the O
name O
and O
bottle B-Plant
tree I-Plant
( O
usa O
) O
. O

however O
, O
b. B-Plant
discolor I-Plant
be O
also O
refer O
to O
as O
the O
lacebark B-Plant
kurrajong I-Plant
, O
and O
bottle B-Plant
tree I-Plant
be O
a O
term O
commonly O
apply O
not O
only O
to O
other O
specie O
of O
brachychiton O
but O
to O
member O
of O
other O
genera O
around O
the O
world O
. O

the O
kurrajong B-Plant
have O
be O
record O
as O
a O
host O
B-Plant O
for O
the O
mistletoe B-Plant
speci O
dendrophthoe B-Plant
glabrescen I-Plant
. O

anacyclus B-Plant
pyrethrum I-Plant
( O
pellitory B-Plant
, O
spanish B-Plant
chamomile I-Plant
, O
or O
mount O
atlas B-Plant
daisy I-Plant
) O
be O
a O
perennial O
herb O
much O
like O
chamomile B-Plant
in O
habitat O
and O
appearance O
. O

be O
in O
a O
different O
family O
( O
asteraceae O
) O
from O
the O
B-Plant O
know O
as O
pellitory B-Plant
- I-Plant
of I-Plant
- I-Plant
the I-Plant
- I-Plant
wall I-Plant
( O
parietaria B-Plant
officinali I-Plant
) O
and O
spread B-Plant
pellitory I-Plant
( O
parietaria B-Plant
judaica I-Plant
) O
. O

wyethia O
be O
a O
genus O
of O
north O
american O
flower O
B-Plant O
in O
the O
sunflower O
family O
. O

these O
B-Plant O
be O
commonly O
refer O
to O
as O
mule B-Plant
's I-Plant
ear I-Plant
. O

be O
short O
, O
low O
to O
the O
ground O
golden O
- O
rayed O
wildflower O
that O
resemble O
miniature O
sunflower B-Plant
. O

galaxaura O
be O
a O
genus O
of O
thalloid O
red O
algae B-Plant
. O

potentilla B-Plant
erecta I-Plant
( O
syn O
tormentilla B-Plant
erecta I-Plant
, O
potentilla B-Plant
laeta I-Plant
, O
potentilla B-Plant
tormentilla I-Plant
, O
know O
as O
the O
( O
common O
) O
tormentil O
, O
septfoil B-Plant
or O
erect B-Plant
cinquefoil I-Plant
) O
be O
a O
herbaceous O
perennial O
B-Plant O
belong O
to O
the O
rose O
family O
( O
rosaceae O
) O
. O

oestlundia O
be O
a O
validly O
publish O
genus O
of O
orchid B-Plant
within O
the O
subtribe O
laeliinae O
. O

picea B-Plant
omorika I-Plant
, O
common O
name O
serbian B-Plant
spruce I-Plant
( O
serbian O
: O
панчићева O
оморика O
, O
bosnian O
: O
pančićeva O
omorika O
, O
pronounce O
[ O
] O
) O
, O
be O
a O
species O
of O
coniferous O
tree O
endemic O
to O
the O
drina O
river O
valley O
in O
western O
serbia O
, O
and O
eastern O
bosnia O
and O
herzegovina O
, O
with O
a O
total O
range O
of O
only O
about O
60 O
ha O
, O
at O
800–1,600 O
m O
( O
2,625–5,249 O
ft O
) O
altitude O
. O

be O
originally O
discover O
near O
the O
village O
of O
zaovine O
( O
serbia O
) O
on O
the O
tara B-Plant
mountain O
in O
1875 O
, O
and O
name O
by O
the O
serbian O
botanist O
josif O
pančić O
; O
the O
specific O
epithet O
omorika O
be O
simply O
the O
serbian O
word O
for O
serbian B-Plant
spruce I-Plant
. O

all O
other O
spruce B-Plant
be O
smrča O
( O
смрча O
) O
. O

one O
be O
mimosa B-Plant
pudica I-Plant
, O
because O
of O
the O
way O
-PRON- O
fold O
-PRON- O
leaf O
when O
touch O
or O
expose O
to O
heat O
. O

the O
other O
be O
mimosa B-Plant
tenuiflora I-Plant
, O
which O
be O
best O
know O
use O
in O
shamanic O
ayahuasca B-Plant
brew O
due O
to O
the O
psychedelic O
drug O
dimethyltryptamine O
find O
in O
root O
bark O
. O

layia O
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
daisy O
family O
know O
generally O
as O
tidy B-Plant
tip I-Plant
, O
native O
to O
western O
north O
america O
. O

the O
genus O
be O
name O
for O
naturalist O
george O
tradescant O
lay O
, O
who O
be O
one O
of O
the O
discoverer O
of O
layia B-Plant
gaillardioid I-Plant
. O

protea B-Plant
aurea I-Plant
( O
long B-Plant
- I-Plant
bud I-Plant
sugarbush I-Plant
) O
be O
a O
shrub O
or O
small O
tree O
with O
a O
single O
trunk O
occur O
in O
mountain O
fynbo O
, O
usually O
on O
cool O
, O
moist O
, O
southern O
slope O
. O

resemble O
palm B-Plant
, O
but O
be O
not O
closely O
related O
to O
palm B-Plant
. O

amaranthus B-Plant
blitoide I-Plant
, O
commonly O
call O
mat B-Plant
amaranth I-Plant
, O
prostrate B-Plant
pigweed I-Plant
, O
procumbent O
pigweed B-Plant
, O
prostrate B-Plant
amaranth I-Plant
, O
or O
matwe B-Plant
, O
be O
a O
glabrous O
annual O
B-Plant O
specie O
. O

phlomoide B-Plant
tuberosa I-Plant
be O
a O
perennial O
flowering O
B-Plant O
in O
the O
family O
lamiaceae O
native O
to O
china O
, O
kazakhstan O
, O
kyrgyzstan O
, O
mongolia O
, O
russia O
; O
sw O
asia O
and O
europe O
. O

the O
genus O
have O
a O
wide O
distribution O
primarily O
in O
the O
tropic O
and O
subtropic O
, O
but O
with O
three O
specie O
extend O
north O
into O
temperate O
region O
, O
one O
( O
c. B-Plant
retusus I-Plant
) O
in O
eastern O
asia O
and O
two O
( O
c. B-Plant
virginicus I-Plant
and O
c. B-Plant
henryae I-Plant
) O
in O
eastern O
north O
america O
. O

launaea O
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
dandelion B-Plant
family O
. O

carduus B-Plant
acanthoid I-Plant
, O
know O
as O
the O
spiny B-Plant
plumeless I-Plant
thistle I-Plant
, O
welt B-Plant
thistle I-Plant
, O
and O
plumeless B-Plant
thistle I-Plant
, O
be O
a O
biennial O
B-Plant O
specie O
of O
thistle B-Plant
in O
the O
asteraceae O
— O
sunflower O
family O
. O

acer B-Plant
barbinerve I-Plant
, O
commonly O
know O
as O
bearded B-Plant
maple I-Plant
, O
be O
an O
asian O
specie O
of O
maple B-Plant
find O
in O
korea O
, O
eastern O
russia O
, O
and O
northeastern O
china O
( O
heilongjiang O
, O
jilin O
, O
liaoning O
) O
acer O
barbinerve O
be O
a O
shrub O
up O
multi O
- O
stemmed O
tree O
up O
to O
7 O
meter O
tall O
, O
with O
smooth O
gray O
bark O
. O

equisetum B-Plant
pratense I-Plant
, O
commonly O
know O
as O
meadow B-Plant
horsetail I-Plant
, O
shade O
horsetail B-Plant
or O
shady O
horsetail B-Plant
, O
be O
a O
widespread O
horsetail B-Plant
( O
equisetophyta O
) O
fern B-Plant
. O

shade O
horsetail B-Plant
can O
be O
commonly O
find O
in O
forest O
with O
tall O
tree O
or O
very O
thick O
foliage O
that O
can O
provide O
shade O
and O
tend O
to O
grow O
close O
and O
thick O
around O
stream O
, O
pond O
and O
river O
. O

ammobium B-Plant
alatum I-Plant
( O
wing B-Plant
everlasting I-Plant
) O
be O
a O
perennial O
asteraceae O
specie O
native O
to O
eastern O
australia O
. O

-PRON- O
be O
an O
important O
foodB-Plant O
for O
australian O
paint B-Plant
lady I-Plant
caterpillar O
. O

eucalyptus B-Plant
conferruminata I-Plant
, O
commonly O
know O
as O
bald B-Plant
island I-Plant
marlock I-Plant
or O
bushy B-Plant
yate I-Plant
, O
be O
a O
small O
tree O
or O
mallee B-Plant
native O
to O
the O
south O
coast O
of O
western O
australia O
. O

-PRON- O
contain O
only O
one O
know O
specie O
, O
cyanixia B-Plant
socotrana I-Plant
, O
a O
perennial O
, O
herbaceous O
and O
bulbous O
B-Plant O
specie O
endemic O
to O
the O
island O
of O
socotra O
in O
the O
indian O
ocean O
, O
part O
of O
the O
republic O
of O
yemen O
. O

the O
genus O
name O
be O
derive O
from O
greek O
word O
ixia O
, O
refer O
to O
the O
radially O
symmetrical O
flower O
in O
the O
genus O
of O
that O
name O
, O
as O
well O
as O
cyano O
, O
mean O
blue O
. O

the O
most O
widely O
know O
specie O
be O
aloe B-Plant
vera I-Plant
, O
or O
TRUE B-Plant
aloe I-Plant
, O
so O
call O
because O
be O
cultivate O
as O
the O
standard O
source O
of O
so O
- O
call O
aloe B-Plant
vera I-Plant
for O
assorted O
pharmaceutical O
purpose O
. O

other O
specie O
, O
such O
as O
aloe B-Plant
ferox I-Plant
, O
also O
be O
cultivate O
or O
harvest O
from O
the O
wild O
for O
similar O
application O
. O

the O
B-Plant O
agave B-Plant
americana I-Plant
, O
which O
be O
sometimes O
call O
american B-Plant
aloe I-Plant
, O
belong O
to O
the O
asparagaceae O
, O
a O
different O
family O
. O

platycladus O
be O
a O
distinct O
genus O
of O
evergreen O
coniferous O
tree O
in O
the O
cypress O
family O
cupressaceae O
, O
contain O
only O
one O
specie O
, O
platycladus B-Plant
orientalis I-Plant
, O
also O
know O
as O
chinese B-Plant
thuja I-Plant
, O
oriental B-Plant
arborvitae I-Plant
, O
chinese B-Plant
arborvitae I-Plant
, O
biota O
or O
oriental B-Plant
thuja I-Plant
. O

in O
the O
horticultural O
trade O
, O
be O
a O
genus O
of O
orchid B-Plant
( O
family O
orchidaceae O
) O
and O
the O
only O
genus O
of O
alliance O
lockhartia O
. O

boronia B-Plant
deanei I-Plant
, O
commonly O
know O
as O
deane B-Plant
's I-Plant
boronia I-Plant
, O
be O
a O
B-Plant O
in O
the O
citrus O
family O
rutaceae O
and O
be O
endemic O
to O
the O
central O
and O
southern O
highland O
of O
new O
south O
wales O
. O

eulophia B-Plant
streptopetala I-Plant
be O
a O
species O
of O
orchid B-Plant
. O

matteuccia O
be O
a O
genus O
of O
fern B-Plant
with O
one O
specie O
, O
matteuccia B-Plant
struthiopteris I-Plant
( O
common O
name O
ostrich B-Plant
fern I-Plant
, O
fiddlehead B-Plant
fern I-Plant
or O
shuttlecock B-Plant
fern I-Plant
) O
. O

the O
specie O
epithet O
struthiopteris O
come O
from O
ancient O
greek O
word O
, O
στρουθίων O
( O
strouthíōn O
) O
ostrich O
and O
πτερίς O
( O
pterís O
) O
fern B-Plant
. O

these O
palm B-Plant
be O
canopy O
tree O
grow O
to O
20–35 O
m O
tall O
. O

i. B-Plant
deltoidea I-Plant
be O
easily O
recognize O
by O
the O
prominent O
bulge O
in O
the O
center O
of O
-PRON- O
trunk O
, O
and O
the O
stilt O
root O
, O
which O
form O
a O
dense O
cone O
up O
to O
1 O
m O
in O
diameter O
at O
the O
base O
. O

-PRON- O
can O
thus O
be O
easily O
be O
distinguish O
from O
socratea B-Plant
exorrhiza I-Plant
( O
which O
also O
bear O
stilt O
root O
) O
, O
as O
the O
stilt O
root O
of O
the O
former O
be O
much O
less O
tightly O
appress O
upon O
one O
another O
. O

stellaria B-Plant
graminea I-Plant
be O
a O
species O
of O
flower O
B-Plant O
in O
the O
caryophyllaceae O
family O
( O
like O
pink O
) O
know O
by O
the O
common O
name O
common B-Plant
starwort I-Plant
, O
grass B-Plant
- I-Plant
leave I-Plant
stitchwort I-Plant
, O
less B-Plant
stitchwort I-Plant
and O
grass B-Plant
- I-Plant
like I-Plant
starwort I-Plant
. O

lycopodium B-Plant
lagopus I-Plant
( O
one B-Plant
- I-Plant
cone I-Plant
club I-Plant
- I-Plant
moss I-Plant
) O
be O
an O
arctic O
and O
subarctic O
specie O
of O
B-Plant O
in O
the O
genus O
lycopodium O
in O
the O
clubmoss O
family O
. O

be O
widespread O
in O
cold O
, O
northerly O
region O
: O
canada O
, O
greenland O
, O
russia O
, O
scandinavia O
, O
and O
the O
northern O
united O
states O
include O
alaska O
. O

lycopodium B-Plant
lagopus I-Plant
be O
very O
similar O
to O
l. B-Plant
clavatum I-Plant
except O
that O
-PRON- O
rarely O
have O
more O
than O
one O
cone O
per O
stem O
. O

the O
name O
come O
from O
the O
ancient O
greek O
aria O
( O
an O
oak B-Plant
type O
) O
and O
carpos O
( O
= O
fruit O
) O
because O
of O
the O
resemblance O
of O
the O
fruit O
of O
the O
two O
genus O
in O
acorn O
form O
. O

another O
possibility O
for O
the O
origin O
of O
the O
name O
be O
the O
work O
scheidweiler O
do O
on O
the O
tree O
sorbus B-Plant
aria I-Plant
at O
the O
time O
-PRON- O
describe O
the O
genus O
ariocarpus O
. O

-PRON- O
may O
have O
mean O
the O
fruit O
of O
ariocarpus O
B-Plant O
look O
like O
the O
fruit O
of O
the O
sorbus B-Plant
aria I-Plant
. O

come O
from O
limestone O
hill O
of O
rio O
grande O
in O
the O
south O
of O
texas O
( O
ariocarpus B-Plant
fissuratus I-Plant
) O
and O
also O
the O
north O
and O
the O
center O
of O
mexico O
( O
all O
other O
specie O
include O
a. B-Plant
fissuratus I-Plant
form O
know O
as O
a. O
loydii O
and O
a. B-Plant
fissuratus I-Plant
var I-Plant
intermedius I-Plant
) O
with O
strong O
sunshine O
exposure O
. O

asterarcys O
be O
a O
genus O
of O
green O
algae B-Plant
in O
the O
family O
scenedesmaceae O
. O

anisoptera B-Plant
thurifera I-Plant
be O
a O
tree O
specie O
in O
the O
family O
dipterocarpaceae O
. O

include O
the O
canistel B-Plant
( O
p. B-Plant
campechiana I-Plant
) O
, O
the O
mamey B-Plant
sapote I-Plant
( O
p. B-Plant
sapota I-Plant
) O
and O
the O
lucuma O
( O
p. B-Plant
lucuma I-Plant
) O
. O

balatá O
, O
m. B-Plant
bidentata I-Plant
) O
much O
use O
in O
heavy O
or O
outdoors O
construction O
, O
as O
well O
as O
edible O
fruit O
( O
such O
as O
sapodilla B-Plant
, O
m. B-Plant
zapota I-Plant
) O
. O

common O
name O
include O
meadow B-Plant
- I-Plant
grass I-Plant
( O
mainly O
in O
europe O
and O
asia O
) O
, O
bluegrass B-Plant
( O
mainly O
in O
north O
america O
) O
, O
tussock B-Plant
( O
some O
new O
zealand O
specie O
) O
, O
and O
speargrass B-Plant
. O

poa O
be O
member O
of O
the O
pooideae O
subfamily O
of O
the O
poaceae O
family O
. O

bluegrass B-Plant
, O
which O
have O
green O
leaf O
, O
derive O
-PRON- O
name O
from O
the O
seed O
head O
, O
which O
be O
blue O
when O
the O
B-Plant O
be O
allow O
to O
grow O
to O
natural O
height O
of O
two O
to O
three O
foot O
( O
0.6 O
to O
0.9 O
meters O
) O
the O
genus O
poa O
include O
both O
annual O
and O
perennial O
specie O
. O

sonchus O
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
dandelion B-Plant
tribe O
within O
the O
sunflower O
family O
. O

most O
of O
the O
specie O
be O
annual O
herb O
, O
a O
few O
be O
perennial O
, O
and O
a O
few O
be O
even O
woody O
( O
subgenus O
dendrosonchus O
, O
restrict O
to O
the O
canary O
islands O
) O
annual O
herb O
in O
the O
genus O
be O
know O
as O
sow O
thistle B-Plant
( O
less O
commonly O
hare O
thistle B-Plant
or O
hare O
lettuce O
) O
. O

sow O
thistle B-Plant
be O
common O
roadside O
B-Plant O
, O
and O
while O
native O
to O
eurasia O
and O
tropical O
africa O
, O
be O
find O
almost O
worldwide O
in O
temperate O
region O
. O

mature O
sow B-Plant
thistle I-Plant
stem O
can O
range O
from O
30 O
cm O
to O
2 O
m O
( O
1 O
to O
6 O
foot O
) O
tall O
, O
depend O
upon O
specie O
and O
grow O
condition O
. O

sow O
thistle B-Plant
exude O
a O
milky O
latex O
when O
any O
part O
of O
the O
B-Plant O
be O
cut O
or O
damage O
, O
and O
be O
from O
this O
fact O
that O
the O
B-Plant O
obtain O
the O
common O
name O
, O
sow B-Plant
thistle I-Plant
, O
as O
be O
feed O
to O
lactating O
sow O
in O
the O
belief O
that O
milk O
production O
would O
increase O
. O

sow O
thistle B-Plant
be O
know O
as O
milk O
thistle B-Plant
in O
some O
region O
, O
although O
TRUE O
milk O
thistle B-Plant
belong O
to O
the O
genus O
silybum O
. O

sow O
thistle B-Plant
have O
be O
use O
as O
fodder O
, O
particularly O
for O
rabbit O
, O
hence O
the O
other O
common O
name O
of O
hare O
thistle B-Plant
or O
hare O
lettuce B-Plant
. O

be O
also O
edible O
to O
human O
as O
a O
leaf O
vegetable O
; O
old O
leaf O
and O
stalk O
can O
be O
bitter O
but O
young O
leaf O
have O
a O
flavour O
similar O
to O
lettuce B-Plant
. O

when O
cook O
the O
flavour O
be O
reminiscent O
of O
chard B-Plant
. O

in O
many O
area O
sow O
thistle B-Plant
be O
consider O
noxious O
weed O
, O
as O
-PRON- O
grow O
quickly O
in O
a O
wide O
range O
of O
condition O
and O
-PRON- O
wind O
- O
bear O
seed O
allow O
-PRON- O
to O
spread O
rapidly O
. O

sonchus B-Plant
arvensis I-Plant
, O
the O
perennial B-Plant
sow I-Plant
thistle I-Plant
, O
be O
consider O
the O
most O
economically O
detrimental O
, O
as O
can O
crowd O
commercial O
crop O
, O
be O
a O
heavy O
consumer O
of O
nitrogen O
in O
soil O
, O
may O
deplete O
soil O
water O
of O
land O
leave O
to O
fallow O
, O
and O
can O
regrow O
and O
sprout O
additional O
B-Plant O
from O
creep O
root O
. O

however O
, O
sow O
thistle B-Plant
be O
easily O
uproot O
by O
hand O
, O
and O
-PRON- O
soft O
stem O
present O
little O
resistance O
to O
slash O
or O
mow O
. O

most O
livestock O
will O
readily O
devour O
sow B-Plant
thistle I-Plant
in O
preference O
to O
grass O
, O
and O
this O
lettuce B-Plant
- O
relative O
be O
edible O
and O
nutritious O
to O
human O
— O
in O
fact O
this O
be O
the O
meaning O
of O
the O
second O
part O
of O
the O
latin O
name O
of O
the O
common B-Plant
sow I-Plant
thistle I-Plant
, O
oleraceus O
. O

attempt O
at O
weed O
control O
by O
herbicidal O
use O
, O
to O
the O
neglect O
of O
other O
method O
, O
may O
have O
lead O
to O
a O
proliferation O
of O
this O
specie O
in O
some O
environment O
. O

sow O
thistle B-Plant
be O
common O
host O
B-Plant O
for O
aphid O
. O

gardener O
may O
consider O
this O
a O
benefit O
or O
a O
curse O
; O
aphid O
may O
spread O
from O
sow B-Plant
thistle I-Plant
to O
other O
B-Plant O
, O
but O
alternatively O
the O
sow B-Plant
thistle I-Plant
can O
encourage O
the O
growth O
of O
beneficial O
predator O
such O
as O
hoverflie O
. O

in O
this O
regard O
sow O
thistle B-Plant
make O
excellent O
sacrificial O
B-Plant O
. O

sonchus O
specie O
be O
use O
as O
food O
B-Plant O
by O
the O
larvae O
of O
some O
lepidoptera O
include O
celypha O
rufana O
and O
the O
broad O
- O
bar O
white O
, O
grey O
chi O
, O
nutmeg B-Plant
, O
and O
shark O
moth O
. O

the O
fly O
tephritis O
formosa B-Plant
be O
know O
to O
attack O
the O
capitula O
of O
this O
B-Plant O
. O

anthemis O
be O
a O
genus O
of O
aromatic O
flower O
B-Plant O
in O
the O
family O
asteraceae O
, O
closely O
related O
to O
chamaemelum O
, O
and O
like O
that O
genus O
, O
know O
by O
the O
common O
name O
chamomile B-Plant
; O
some O
specie O
be O
also O
call O
dog B-Plant
- I-Plant
fennel I-Plant
or O
mayweed B-Plant
. O

a O
number O
of O
specie O
have O
also O
become O
naturalize O
in O
the O
united O
kingdom O
and O
other O
part O
of O
the O
world O
. O

anthemis O
specie O
be O
use O
as O
food O
B-Plant O
by O
the O
larvae O
of O
some O
lepidoptera O
specie O
include O
orthonama O
obstipata O
( O
the O
gem O
) O
and O
bucculatrix O
anthemidella O
, O
a O
leaf O
- O
miner O
which O
feed O
exclusively O
on O
anthemis B-Plant
tinctoria I-Plant
. O

actinocladum O
be O
a O
south O
american O
specie O
of O
bamboo B-Plant
in O
the O
grass O
family O
. O

speciesthe O
only O
know O
specie O
be O
actinocladum B-Plant
verticillatum I-Plant
. O

crassula B-Plant
muscosa I-Plant
, O
synonym O
crassula B-Plant
lycopodioide I-Plant
and O
crassula B-Plant
pseudolycopodioide I-Plant
, O
be O
a O
succulent O
B-Plant O
native O
to O
south O
africa O
and O
namibia O
, O
belong O
to O
the O
family O
of O
crassulaceae O
and O
to O
the O
genus O
crassula O
. O

-PRON- O
be O
a O
houseB-Plant O
grow O
worldwide O
and O
commonly O
know O
as O
rattail B-Plant
crassula O
, O
watch B-Plant
chain I-Plant
, O
lizard B-Plant
's I-Plant
tail I-Plant
, O
zipper B-Plant
B-Plant I-Plant
and O
princess B-Plant
pine I-Plant
. O

petitia O
, O
call O
the O
bastard B-Plant
stopper I-Plant
, O
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
mint O
family O
, O
lamiaceae O
, O
first O
describe O
in O
1760 O
. O

polanisia B-Plant
erosa I-Plant
be O
a O
sticky O
, O
small O
to O
large O
10–60 O
cm O
( O
3.9–23.6 O
in O
) O
high O
annual O
herbaceous O
specie O
of O
flower O
B-Plant O
in O
the O
cleome O
family O
, O
cleomaceae O
, O
know O
by O
the O
common O
name O
large B-Plant
clammyweed I-Plant
. O

have O
narrow B-Plant
clover I-Plant
- O
like O
leaf O
, O
and O
cream O
- O
colour O
, O
frilly O
flower O
with O
a O
yellowish O
centre O
, O
look O
a O
bit O
like O
a O
small O
butterfly O
or O
a O
set O
of O
elk O
antler O
. O

edraianthus B-Plant
dalmaticus I-Plant
( O
syn O
wahlenbergia B-Plant
dalmatica I-Plant
a.dc O
. O

) O
or O
dalmatian O
rockbell O
be O
an O
ornamental O
B-Plant O
in O
the O
campanulaceae O
( O
bellflower B-Plant
) O
family O
. O

-PRON- O
be O
a O
tuft O
specie O
with O
narrow O
grass O
- O
like O
leaf O
, O
2 O
to O
4 O
inch O
in O
length O
, O
and O
flower O
- O
stem O
at O
first O
drooping O
, O
afterwards O
erect O
, O
4 O
to O
6 O
inch O
high O
, O
with O
large O
flower O
of O
a O
violet B-Plant
- O
blue O
color O
, O
in O
cluster O
which O
appear O
in O
july O
and O
august O
. O

nothofagus O
, O
also O
know O
as O
the O
southern B-Plant
beech I-Plant
, O
be O
a O
genus O
of O
43 O
specie O
of O
tree O
and O
shrub O
native O
to O
the O
southern O
hemisphere O
in O
southern O
south O
america O
( O
chile O
, O
argentina O
) O
and O
australasia O
( O
east O
and O
southeast O
australia O
, O
new O
zealand O
, O
new O
guinea O
and O
new O
caledonia O
) O
. O

in O
the O
past O
, O
be O
include O
in O
the O
family O
fagaceae O
, O
but O
genetic O
test O
reveal O
-PRON- O
to O
be O
genetically O
distinct O
, O
and O
be O
now O
include O
in O
-PRON- O
own O
family O
, O
the O
nothofagaceae O
( O
literally O
mean O
beech B-Plant
or O
bastard O
. O

nitrophila O
be O
a O
small O
genus O
of O
flower O
B-Plant O
in O
the O
amaranth O
family O
sometimes O
know O
by O
the O
common O
name O
niterwort B-Plant
. O

labdanum B-Plant
, O
also O
call O
ladanum O
, O
laudanum B-Plant
, O
ladan O
or O
ladanon O
, O
be O
a O
sticky O
brown O
resin O
obtain O
from O
the O
shrub O
cistus B-Plant
ladanifer I-Plant
( O
western O
mediterranean O
) O
and O
cistus B-Plant
creticus I-Plant
( O
eastern O
mediterranean O
) O
, O
specie O
of O
rockrose B-Plant
. O

capnoides B-Plant
semperviren I-Plant
, O
the O
harlequin B-Plant
corydalis O
, O
rock B-Plant
harlequin I-Plant
, O
pale B-Plant
corydalis I-Plant
or O
pink B-Plant
corydalis I-Plant
, O
be O
an O
annual O
or O
biennial O
B-Plant O
native O
to O
rocky O
woodland O
and O
burn O
or O
disturbed O
place O
in O
northern O
north O
america O
. O

capnoides B-Plant
semperviren I-Plant
be O
the O
only O
specie O
in O
the O
genus O
capnoides O
. O

capnoide O
elegan O
kuntze O
, O
a O
synonym O
for O
corydalis B-Plant
elegan I-Plant
cunila B-Plant
origanoid I-Plant
-- O
common O
name O
stone B-Plant
mint I-Plant
, O
frost B-Plant
mint I-Plant
, O
dittany B-Plant
, O
and O
american B-Plant
dittany I-Plant
-- O
be O
a O
perennial O
late O
- O
summer O
- O
flower O
subshrub O
with O
small O
purple O
flower O
, O
which O
be O
native O
to O
the O
eastern O
united O
states O
. O

this O
species O
have O
historically O
be O
cultivate O
for O
use O
as O
a O
medicinal O
herb O
, O
tea B-Plant
, O
and O
ornamental O
B-Plant O
. O

the O
genus O
androstephium O
be O
a O
group O
of O
north O
american O
B-Plant O
in O
the O
cluster O
lily B-Plant
subfamily O
within O
the O
asparagus O
family O
. O

cyperus O
be O
a O
large O
genus O
of O
about O
700 O
specie O
of O
sedge B-Plant
, O
distribute O
throughout O
all O
continent O
in O
both O
tropical O
and O
temperate O
region O
. O

cimicifuga O
( O
bugbane B-Plant
or O
cohosh B-Plant
) O
be O
a O
genus O
of O
between O
12 O
- O
18 O
specie O
of O
flower O
B-Plant O
belong O
to O
the O
family O
ranunculaceae O
, O
native O
to O
temperate O
region O
of O
the O
northern O
hemisphere O
. O

the O
white B-Plant
meadowfoam I-Plant
limnanthes B-Plant
alba I-Plant
be O
of O
commercial O
interest O
for O
-PRON- O
oil O
, O
while O
several O
other O
specie O
be O
rare O
or O
endanger O
. O

l. B-Plant
douglasii I-Plant
be O
widely O
cultivate O
as O
a O
hardy O
annual O
, O
-PRON- O
white O
and O
yellow O
flower O
colour O
give O
the O
common O
name O
of O
poached O
egg O
B-Plant O
. O

tillandsia B-Plant
flabellata I-Plant
be O
a O
species O
in O
the O
genus O
tillandsia O
. O

bulbophyllum B-Plant
dolichoglottis I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
, O
section O
codonosiphon O
schlechter O
1913 O
. O

haloxylon O
and O
-PRON- O
specie O
be O
know O
by O
the O
common O
name O
saxaul B-Plant
. O

allium O
be O
a O
genus O
of O
monocotyledonous O
flower O
B-Plant O
that O
include O
hundred O
of O
specie O
, O
include O
the O
cultivate O
onion B-Plant
, O
garlic B-Plant
, O
scallion B-Plant
, O
shallot B-Plant
, O
leek B-Plant
, O
and O
chive B-Plant
. O

the O
generic O
name O
allium O
be O
the O
latin O
word O
for O
garlic B-Plant
, O
and O
the O
type O
specie O
for O
the O
genus O
be O
allium B-Plant
sativum I-Plant
which O
mean O
cultivate O
. O

some O
source O
refer O
to O
greek O
αλεω O
( O
aleo O
, O
to O
avoid O
) O
by O
reason O
of O
the O
smell O
of O
garlic B-Plant
. O

estimate O
of O
the O
number O
of O
specie O
be O
as O
low O
as O
260 O
, O
and O
as O
high O
as O
979 O
allium O
specie O
occur O
in O
temperate O
climate O
of O
the O
northern O
hemisphere O
, O
except O
for O
a O
few O
specie O
occur O
in O
chile O
( O
such O
as O
a. B-Plant
juncifolium I-Plant
) O
, O
brazil O
( O
a. B-Plant
sellovianum I-Plant
) O
, O
and O
tropical O
africa O
( O
a. B-Plant
spathaceum I-Plant
) O
. O

some O
specie O
( O
such O
as O
welsh B-Plant
onion I-Plant
a. B-Plant
fistulosum I-Plant
) O
develop O
thickened O
leaf O
- O
base O
rather O
than O
form O
bulb O
as O
such O
. O

B-Plant O
of O
the O
genus O
allium O
produce O
chemical O
compound O
, O
mostly O
derive O
from O
cysteine O
sulfoxide O
, O
that O
give O
-PRON- O
a O
characteristic O
onion B-Plant
, O
or O
garlic B-Plant
, O
taste O
and O
odor O
. O

bulbophyllum B-Plant
minutum I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

the O
venus O
comb B-Plant
murex O
, O
after O
-PRON- O
scientific O
name O
murex O
pecten O
juglans B-Plant
ailantifolia I-Plant
( O
synonym O
j. B-Plant
cordiformis I-Plant
and O
j. B-Plant
sieboldiana I-Plant
and O
j. B-Plant
mandshurica I-Plant
var I-Plant
sachalinensis I-Plant
) O
, O
the O
japanese B-Plant
walnut I-Plant
( O
japanese O
: O
鬼胡桃 O
oni O
- O
gurumi O
) O
, O
be O
a O
species O
of O
walnut B-Plant
native O
to O
japan O
and O
sakhalin O
. O

xylopia B-Plant
aethiopica I-Plant
be O
an O
evergreen O
, O
aromatic O
tree O
, O
of O
the O
annonaceae O
family O
that O
can O
grow O
up O
to O
20 O
m O
high O
. O

be O
a O
native O
to O
the O
lowland O
rainfor O
and O
moist O
fringe B-Plant
forest O
in O
the O
savanna O
zone O
of O
africa O
. O

the O
dry O
fruit O
of O
x. B-Plant
aethiopica I-Plant
( O
grain O
of O
selim O
) O
be O
use O
as O
a O
spice O
and O
an O
herbal O
medicine O
. O

be O
sometimes O
employ O
as O
honey O
B-Plant O
, O
notably O
c. B-Plant
decandra I-Plant
and O
c. B-Plant
sylvestris I-Plant
. O

some O
appear O
close O
to O
extinction O
, O
and O
c. B-Plant
quinduensis I-Plant
of O
colombia O
and O
c. B-Plant
tinifolia I-Plant
from O
mauritius O
seem O
to O
be O
extinct O
since O
some O
time O
in O
the O
20th O
century O
and O
about O
1976 O
, O
respectively O
. O

these O
B-Plant O
often O
parasitize O
alder B-Plant
but O
be O
find O
on O
many O
other O
B-Plant O
. O

b. B-Plant
hookeri I-Plant
may O
be O
find O
on O
salal B-Plant
and O
huckleberry O
, O
and O
b. B-Plant
strobilacea I-Plant
grow O
on O
manzanita B-Plant
and O
madrone O
. O

groundcone O
often O
look O
at O
first O
glance O
like O
pine B-Plant
cone O
lie O
on O
the O
ground O
, O
especially O
when O
-PRON- O
be O
brown O
in O
color O
. O

each O
B-Plant O
may O
be O
a O
few O
inch O
tall O
, O
and O
pine B-Plant
- O
cone O
- O
shape O
or O
cylindrical O
. O

vanda B-Plant
be O
a O
genus O
in O
the O
orchid O
family O
, O
orchidaceae O
. O

this O
genus O
and O
ally O
be O
consider O
to O
be O
among O
the O
most O
specifically O
adapt O
of O
all O
orchid B-Plant
within O
the O
orchidaceae O
. O

vanda B-Plant
specie O
be O
widespread O
across O
east O
asia O
, O
southeast O
asia O
, O
and O
new O
guinea O
, O
with O
a O
few O
specie O
extend O
into O
queensland O
and O
some O
of O
the O
island O
of O
the O
western O
pacific O
. O

the O
oat B-Plant
( O
avena B-Plant
sativa I-Plant
) O
, O
sometimes O
call O
the O
common B-Plant
oat I-Plant
, O
be O
a O
species O
of O
cereal O
grain O
grow O
for O
seed O
, O
which O
be O
know O
by O
the O
same O
name O
( O
usually O
in O
the O
plural O
, O
unlike O
other O
cereal O
and O
pseudocereal O
) O
. O

while O
oat B-Plant
be O
suitable O
for O
human O
consumption O
as O
oatmeal O
and O
roll O
oats B-Plant
, O
one O
of O
the O
most O
common O
us O
be O
as O
livestock O
feed O
. O

oat B-Plant
be O
a O
nutrient O
- O
rich O
food O
associate O
with O
low O
blood O
cholesterol O
when O
consume O
regularly O
. O

avenin O
present O
in O
oats B-Plant
( O
protein O
similar O
to O
gliadin O
from O
wheat B-Plant
) O
can O
trigger O
celiac O
disease O
in O
a O
small O
proportion O
of O
people O
. O

also O
, O
oat B-Plant
product O
be O
frequently O
contaminate O
by O
other O
gluten O
- O
contain O
grain O
, O
mainly O
wheat B-Plant
and O
barley B-Plant
. O

sporobolus B-Plant
heterolepis I-Plant
, O
commonly O
know O
as O
prairie B-Plant
dropseed I-Plant
, O
be O
a O
species O
of O
prairie B-Plant
grass I-Plant
native O
to O
the O
tallgrass O
and O
mixed O
grass O
prairie O
of O
central O
north O
america O
from O
texas O
to O
southern O
canada O
. O

bolbocoleon O
be O
a O
genus O
of O
green O
algae B-Plant
, O
in O
the O
family O
bolbocoleonaceae O
. O

senecio B-Plant
vernali I-Plant
be O
one O
of O
the O
european O
specie O
of O
senecio O
, O
an O
annual O
that O
be O
also O
know O
as O
eastern B-Plant
groundsel I-Plant
. O

while O
have O
be O
long O
classify O
as O
senecio B-Plant
vernali I-Plant
, O
this O
species O
have O
more O
recently O
be O
describe O
as O
a O
subspecie O
of O
senecio B-Plant
leucanthemifolius I-Plant
and O
be O
now O
include O
by O
some O
in O
that O
specie O
. O

cleisostoma O
be O
a O
genus O
of O
orchid B-Plant
with O
approximately O
90 O
accept O
specie O
widely O
distribute O
through O
much O
of O
the O
indian O
subcontinent O
, O
southeast O
asia O
, O
china O
, O
new O
guinea O
, O
and O
some O
of O
the O
island O
of O
the O
western O
pacific O
. O

salvia B-Plant
be O
the O
large O
genus O
of O
B-Plant O
in O
the O
mint O
family O
, O
lamiaceae O
, O
with O
nearly O
1000 O
specie O
of O
shrub O
, O
herbaceous O
perennial O
, O
and O
annual O
. O

within O
the O
lamiaceae O
, O
salvia B-Plant
be O
part O
of O
the O
tribe O
mentheae O
within O
the O
subfamily O
nepetoideae O
. O

be O
one O
of O
several O
genera O
commonly O
refer O
to O
as O
sage B-Plant
, O
include O
the O
widely O
produce O
herb O
use O
in O
cooking O
, O
salvia B-Plant
officinali I-Plant
( O
common B-Plant
sage I-Plant
, O
or O
just O
sage B-Plant
) O
. O

gennaria B-Plant
diphylla I-Plant
be O
a O
species O
of O
flower O
B-Plant O
from O
the O
orchid O
family O
, O
orchidaceae O
, O
native O
to O
the O
region O
from O
the O
western O
mediterranean O
and O
macaronesia O
( O
canary O
islands O
, O
madeira O
, O
portugal O
, O
spain O
, O
the O
balearic O
islands O
, O
morocco O
, O
algeria O
, O
tunisia O
, O
sardinia O
, O
tuscany O
) O
. O

gennaria B-Plant
diphylla I-Plant
be O
illustrate O
( O
as O
habenaria B-Plant
cordata I-Plant
) O
in O
plate O
3164 O
of O
curtis O
' O
botanical O
magazine O
, O
1832 O
. O

rigiopappus B-Plant
be O
a O
genus O
of O
north O
american O
B-Plant O
in O
the O
aster B-Plant
tribe O
within O
the O
sunflower O
family O
. O

speciesthe O
only O
know O
specie O
be O
rigiopappus B-Plant
leptocladus I-Plant
, O
sometimes O
know O
as O
wireweed B-Plant
. O

anthurium B-Plant
acaule I-Plant
be O
a O
herbaceous O
B-Plant O
native O
to O
the O
lesser O
antilles O
. O

the O
B-Plant O
have O
a O
complicated O
taxonomic O
history O
, O
and O
the O
name O
anthurium B-Plant
acaule I-Plant
have O
be O
apply O
to O
several O
other O
B-Plant O
. O

coryphothamnus B-Plant
auyantepuiensis I-Plant
, O
which O
be O
endemic O
to O
southern O
venezuela O
. O

astronium B-Plant
fraxinifolium I-Plant
be O
a O
timber O
tree O
, O
which O
be O
native O
to O
amazon O
rainforest O
, O
atlantic O
forest O
, O
caatinga O
, O
and O
cerrado O
vegetation O
in O
brazil O
. O

common O
name O
include O
kingwood B-Plant
, O
locustwood B-Plant
, O
tigerwood B-Plant
, O
and O
zebrawood B-Plant
. O

be O
also O
use O
to O
make O
hardwood O
such O
as O
tigerwood B-Plant
. O

the O
torrey B-Plant
pine I-Plant
, O
pinus B-Plant
torreyana I-Plant
, O
be O
a O
rare O
pine B-Plant
specie O
in O
the O
united O
states O
. O

be O
an O
endanger O
specie O
grow O
only O
in O
the O
torrey O
pines B-Plant
state O
natural O
reserve O
, O
coastal O
northern O
san O
diego O
county O
, O
and O
on O
santa O
rosa O
island O
. O

this O
species O
be O
endemic O
to O
the O
coastal O
sage B-Plant
and O
chaparral O
ecoregion O
in O
the O
u.s. O
state O
of O
california O
. O

bear O
yellow O
or O
orange B-Plant
daisy I-Plant
- O
like O
composite O
flower O
. O

a O
number O
of O
these O
specie O
( O
particularly O
helenium B-Plant
autumnale I-Plant
) O
have O
the O
common O
name O
sneezeweed B-Plant
, O
base O
on O
the O
former O
use O
of O
-PRON- O
dry O
leaf O
in O
make O
snuff O
. O

prunus B-Plant
laurocerasus I-Plant
, O
also O
know O
as O
cherry B-Plant
laurel I-Plant
, O
common O
laurel B-Plant
and O
sometimes O
english B-Plant
laurel I-Plant
in O
north O
america O
, O
be O
an O
evergreen O
specie O
of O
cherry B-Plant
( O
prunus O
) O
, O
native O
to O
region O
border O
the O
black O
sea O
in O
southwestern O
asia O
and O
southeastern O
europe O
, O
from O
albania O
and O
bulgaria O
east O
through O
turkey O
to O
the O
caucasus O
mountains O
and O
northern O
iran O
. O

the O
common O
name O
of O
p. B-Plant
laurocerasus I-Plant
refer O
to O
the O
similarity O
of O
foliage O
and O
appearance O
to O
bay B-Plant
laurel I-Plant
( O
laurus B-Plant
nobili I-Plant
, O
the O
TRUE O
laurel B-Plant
, O
in O
the O
lauraceae O
family O
) O
, O
and O
like O
the O
bay B-Plant
laurel I-Plant
, O
prunus B-Plant
laurocerasus I-Plant
be O
use O
for O
make O
laurel B-Plant
wreath O
, O
but O
the O
two O
B-Plant O
be O
unrelated O
. O

-PRON- O
be O
not O
to O
be O
confuse O
with O
-PRON- O
american O
relative O
prunus B-Plant
caroliniana I-Plant
, O
which O
be O
also O
call O
cherry B-Plant
laurel I-Plant
. O

quassia B-Plant
( O
or O
) O
be O
a O
flora O
genus O
in O
the O
family O
simaroubaceae O
. O

some O
botanist O
treat O
-PRON- O
as O
consist O
of O
only O
one O
specie O
, O
quassia B-Plant
amara I-Plant
from O
tropical O
south O
america O
, O
while O
other O
treat O
-PRON- O
in O
a O
wide O
circumscription O
as O
a O
pantropical O
genus O
contain O
up O
to O
40 O
specie O
of O
tree O
and O
shrub O
. O

-PRON- O
discover O
the O
medicinal O
property O
of O
the O
bark O
of O
quassia B-Plant
amara I-Plant
. O

quassia B-Plant
undulatait O
be O
the O
source O
of O
the O
quassinoid O
quassin O
and O
neo O
- O
quassin O
. O

chamaecyparis B-Plant
obtusa I-Plant
( O
japanese O
cypress B-Plant
, O
hinoki B-Plant
cypress I-Plant
or O
hinoki O
japanese O
: O
檜 O
or O
桧 O
hinoki O
) O
be O
a O
species O
of O
cypress B-Plant
native O
to O
central O
japan O
. O

the O
related O
chamaecyparis B-Plant
pisifera I-Plant
( O
sawara B-Plant
cypress I-Plant
) O
can O
be O
readily O
distinguish O
in O
-PRON- O
have O
pointed O
tip O
to O
the O
leaf O
and O
small O
cone O
. O

speciesthe O
only O
know O
specie O
be O
lamarckia B-Plant
aurea I-Plant
, O
the O
golden B-Plant
dog's I-Plant
- I-Plant
tail I-Plant
or O
goldentop B-Plant
grass I-Plant
camaridium O
be O
a O
genus O
of O
epiphytic O
orchid B-Plant
widespread O
across O
the O
west O
indies O
and O
through O
latin O
america O
from O
mexico O
to O
bolivia O
. O

one O
species O
extend O
into O
florida O
( O
c. B-Plant
vestitum I-Plant
, O
list O
in O
flora O
of O
north O
america O
under O
the O
synonym O
, O
maxillaria O
parviflora).the O

doronicum B-Plant
grandiflorum I-Plant
be O
a O
european O
specie O
of O
doronicum O
, O
a O
member O
of O
the O
aster O
family O
. O

doronicum B-Plant
grandiflorum I-Plant
be O
a O
perennial O
herb O
grow O
10–40 O
cm O
. O

epacris B-Plant
longiflora I-Plant
, O
commonly O
know O
as O
the O
fuchsia O
heath O
, O
be O
a O
B-Plant O
in O
the O
family O
ericaceae O
and O
be O
endemic O
to O
eastern O
australia O
. O

damasonium B-Plant
californicum I-Plant
be O
a O
species O
of O
perennial O
wildflower O
in O
the O
water O
B-Plantain O
family O
which O
be O
know O
by O
the O
common O
name O
fringe B-Plant
water I-Plant
- I-Plant
B-Plantain I-Plant
, O
or O
star B-Plant
water I-Plant
- I-Plant
B-Plantain I-Plant
. O

damasonium B-Plant
californicum I-Plant
be O
a O
resident O
of O
pond O
, O
riverside O
, O
and O
vernal O
pool O
. O

comparettia O
, O
abbreviate O
comp O
in O
the O
horticultural O
trade O
, O
be O
a O
genus O
of O
orchid B-Plant
. O

huperzia O
be O
a O
genus O
of O
lycophyte O
B-Plant O
, O
sometimes O
know O
as O
the O
firmoss O
or O
fir B-Plant
clubmoss O
. O

the O
common O
name O
firmoss O
, O
use O
for O
some O
of O
the O
north O
temperate O
specie O
, O
refer O
to O
-PRON- O
superficial O
resemblance O
to O
branch O
of O
fir B-Plant
( O
abies O
) O
, O
a O
conifer B-Plant
. O

in O
australia O
, O
the O
epiphytic O
specie O
be O
commonly O
know O
as O
tassel B-Plant
fern I-Plant
. O

two O
specie O
( O
m. B-Plant
oppositifolius I-Plant
and O
m. B-Plant
subulatus I-Plant
) O
be O
find O
in O
tropical O
africa O
and O
madagascar O
. O

quebracho B-Plant
blanco O
, O
call O
kebrako B-Plant
or O
white B-Plant
quebracho I-Plant
, O
be O
a O
south O
american O
tree O
specie O
, O
native O
to O
brazil O
, O
n O
argentina O
, O
bolivia O
, O
paraguay O
, O
and O
uruguay O
. O

must O
not O
be O
confuse O
with O
other O
specie O
also O
know O
as O
quebracho B-Plant
, O
but O
belong O
to O
the O
genus O
schinopsis B-Plant
. O

malacothrix O
be O
a O
genus O
of O
B-Plant O
in O
the O
dandelion B-Plant
tribe O
within O
the O
sunflower O
family O
. O

-PRON- O
be O
know O
generally O
as O
desert O
dandelion B-Plant
or O
desertdandelion O
. O

eucalyptus B-Plant
websteriana I-Plant
, O
commonly O
know O
as O
webster B-Plant
's I-Plant
mallee I-Plant
, O
be O
a O
mallee B-Plant
that O
be O
native O
to O
the O
goldfields O
- O
esperance O
region O
of O
western O
australia O
. O

the O
mallee B-Plant
typically O
grow O
to O
a O
height O
of O
around O
4 O
metre O
( O
13 O
ft O
) O
and O
have O
a O
spread O
habit O
and O
minni B-Plant
ritchi O
type O
bark O
. O

typha B-Plant
angustifolia I-Plant
l. I-Plant
( O
also O
less B-Plant
bulrush I-Plant
, O
narrowleaf B-Plant
cattail I-Plant
or O
less O
reedmace O
) O
be O
a O
perennial O
herbaceous O
B-Plant O
of O
genus O
typha O
. O

this O
cattail B-Plant
be O
an O
obligate O
wetland O
specie O
that O
be O
commonly O
find O
in O
the O
northern O
hemisphere O
in O
brackish O
location O
. O

the O
geographic O
range O
of O
typha B-Plant
angustifolia I-Plant
overlap O
with O
the O
very O
similar O
specie O
typha B-Plant
latifolia I-Plant
( O
broadleaf B-Plant
or O
common B-Plant
cattail I-Plant
) O
. O

t. B-Plant
angustifolia I-Plant
can O
be O
distinguish O
from O
t. B-Plant
latifolia I-Plant
by O
-PRON- O
narrow O
leaf O
and O
by O
a O
clear O
separation O
of O
two O
different O
region O
( O
staminate O
flower O
above O
and O
pistilate O
flower O
below O
) O
on O
the O
flower O
head O
. O

the O
species O
hybridize O
as O
typha B-Plant
x I-Plant
glauca O
( O
typha B-Plant
angustifolia I-Plant
x O
t. B-Plant

latifolia I-Plant
) O
( O
white O
cattail B-Plant
) O
typha B-Plant
x I-Plant
glauca O
be O
not O
a O
distinct O
specie O
, O
but O
be O
rather O
a O
sterile O
f1 O
hybrid O
. O

broadleaf B-Plant
cattail I-Plant
be O
usually O
find O
in O
shallow O
water O
than O
narrowleaf B-Plant
cattail I-Plant
. O

hornwort B-Plant
be O
a O
group O
of O
non O
- O
vascular O
B-Plant O
constitute O
the O
division O
anthocerotophyta O
. O

as O
in O
moss B-Plant
and O
liverwort B-Plant
, O
the O
flattened O
, O
green O
B-Plant O
body O
of O
a O
hornwort B-Plant
be O
the O
gametophyte O
B-Plant O
. O

hornwort B-Plant
may O
be O
find O
worldwide O
, O
though O
-PRON- O
tend O
to O
grow O
only O
in O
place O
that O
be O
damp O
or O
humid O
. O

many O
be O
know O
by O
the O
general O
common O
name O
indigo B-Plant
bush I-Plant
. O

tasmannia B-Plant
lanceolata I-Plant
( O
syn O
drimys B-Plant
lanceolata I-Plant
) O
, O
commonly O
know O
as O
the O
mountain B-Plant
pepper I-Plant
( O
aus O
) O
, O
or O
cornish O
pepper B-Plant
leaf O
( O
uk O
) O
, O
be O
a O
shrub O
native O
to O
woodland O
and O
cool O
temperate O
rainforest O
of O
south O
- O
eastern O
australia O
. O

-PRON- O
have O
be O
know O
for O
many O
year O
as O
drimys B-Plant
lanceolata I-Plant
. O

iwanoffia O
be O
a O
genus O
of O
green O
algae B-Plant
in O
the O
family O
chaetophoraceae O
. O

passiflora B-Plant
sanguinolenta I-Plant
, O
common O
name O
blood O
red O
passion B-Plant
flower I-Plant
, O
be O
a O
species O
of O
passion B-Plant
flower I-Plant
from O
ecuador O
. O

c. B-Plant
complecten I-Plant
be O
a O
shrub O
find O
in O
the O
neotropic O
. O

vriesea B-Plant
ensiformis I-Plant
be O
a O
species O
in O
the O
genus O
vriesea B-Plant
. O

gongora B-Plant
irmgardiae I-Plant
be O
a O
species O
of O
orchid B-Plant
find O
in O
colombia O
. O

daphne B-Plant
gnidium I-Plant
( O
commonly O
know O
as O
the O
flax B-Plant
- I-Plant
leaved I-Plant
daphne I-Plant
) O
be O
a O
poisonous O
evergreen O
shrub O
from O
the O
mediterranean O
region O
with O
narrow O
, O
dense O
dark O
- O
green O
foliage O
and O
white O
fragrant O
flower O
. O

bulbophyllum B-Plant
schimperianum I-Plant
be O
a O
species O
of O
orchid B-Plant
in O
the O
genus O
bulbophyllum O
. O

zanthoxylum B-Plant
flavum I-Plant
be O
a O
medium O
- O
sized O
tree O
in O
the O
citrus O
family O
, O
rutaceae O
. O

common O
name O
include O
noyer B-Plant
, O
west B-Plant
indian I-Plant
satinwood I-Plant
, O
yellow B-Plant
sander I-Plant
, O
tembetaria O
, O
and O
yellow B-Plant
sandalwood I-Plant
. O

-PRON- O
be O
threaten O
by O
habitat O
loss O
and O
harvesting O
for O
-PRON- O
dense O
, O
durable O
wood O
use O
in O
fine O
woodworking O
. O

in O
-PRON- O
native O
subtropical O
range O
z. B-Plant
flavum I-Plant
grow O
in O
area O
with O
average O
to O
high O
rainfall O
year O
- O
round O
or O
with O
define O
dry O
season O
. O

pollination O
be O
probably O
from O
bee O
, O
and O
the O
seed O
be O
think O
to O
be O
disperse O
by O
bird O
and O
bat O
as O
with O
the O
closely O
related O
specie O
, O
z. B-Plant
martinicense I-Plant
. O

like O
the O
curia B-Plant
-PRON- O
be O
destroy O
and O
rebuild O
several O
time O
, O
as O
far O
back O
as O
the O
roman O
monarchy O
. O

oxybasis B-Plant
glauca I-Plant
( O
syn O
chenopodium B-Plant
glaucum I-Plant
) O
, O
common O
name O
oak B-Plant
- I-Plant
leave I-Plant
goosefoot I-Plant
, O
be O
a O
species O
of O
goosefoot B-Plant
B-Plant O
native O
to O
europe O
. O

the O
type O
species O
be O
c. B-Plant
capitatus I-Plant
. O

in O
the O
horticultural O
trade O
, O
be O
a O
genus O
that O
contain O
about O
330 O
specie O
of O
orchid B-Plant
from O
the O
subtribe O
oncidiinae O
of O
the O
orchid O
family O
( O
orchidaceae O
) O
. O

as O
presently O
conceive O
( O
may O
2014 O
) O
, O
-PRON- O
be O
distribute O
across O
much O
of O
south O
america O
, O
central O
america O
, O
mexico O
and O
the O
west O
indies O
, O
with O
one O
specie O
( O
o. B-Plant

ensatum I-Plant
) O
extend O
into O
florida O
. O

common O
name O
for O
B-Plant O
in O
this O
genus O
include O
dance B-Plant
- I-Plant
lady I-Plant
orchid I-Plant
and O
golden B-Plant
shower I-Plant
orchid I-Plant
. O

the O
american O
orchid B-Plant
society O
label O
this O
genu O
a O
dump O
ground O
. O

the O
royal O
horticultural O
society O
system O
, O
the O
world O
checklist O
of O
monocots O
database O
and O
the O
american O
orchid B-Plant
society O
have O
already O
update O
-PRON- O
database O
to O
reflect O
most O
of O
these O
change O
. O

monotropa O
hypopity O
-- O
call O
dutchman B-Plant
's I-Plant
pipe I-Plant
, O
FALSE B-Plant
beech I-Plant
- I-Plant
drop I-Plant
, O
pinesap B-Plant
, O
or O
yellow B-Plant
bird's I-Plant
- I-Plant
nest I-Plant
-- O
be O
a O
herbaceous O
perennial O
B-Plant O
, O
formerly O
classify O
in O
the O
family O
monotropaceae O
or O
pyrolaceae O
, O
but O
now O
include O
within O
the O
subfamily O
monotropoideae O
of O
the O
blueberry O
family O
( O
ericaceae O
) O
. O

while O
currently O
include O
in O
the O
genus O
monotropa O
, O
recent O
genetic O
evidence O
strongly O
suggest O
that O
monotropa O
hypopity O
should O
be O
place O
in O
-PRON- O
own O
genus O
, O
hypopitys O
, O
with O
the O
single O
specie O
hypopitys B-Plant
monotropa I-Plant
crantz I-Plant
, O
but O
possibly O
contain O
several O
other O
specie O
. O

-PRON- O
have O
be O
suggest O
that O
yellow O
individual O
be O
largely O
self O
- O
pollinate O
. O

the O
species O
name O
be O
from O
latinized O
greek O
hypo- O
, O
under O
, O
and O
pity O
, O
pine B-Plant
, O
refer O
to O
where O
pinesap B-Plant
often O
grow O
. O

some O
of O
which O
include O
hypopitys B-Plant
americana I-Plant
, O
h. B-Plant
fimbriata I-Plant
, O
h. B-Plant
insignata I-Plant
, O
h. B-Plant
lanuginosa I-Plant
, O
h. B-Plant
latisquama I-Plant
, O
h. B-Plant
monotropa I-Plant
, O
monotropa B-Plant
chinensis I-Plant
, O
m. B-Plant
hypophegea I-Plant
, O
m. B-Plant
lanuginosa I-Plant
, O
m. B-Plant
latisquama I-Plant
, O
m. B-Plant
multiflora I-Plant
and O
m. B-Plant

taiwaniana I-Plant
. O

bryopsis O
be O
a O
genus O
of O
marine O
green O
algae B-Plant
in O
the O
family O
bryopsidaceae O
. O

-PRON- O
be O
frequently O
a O
pest O
in O
aquarium O
, O
where O
-PRON- O
be O
commonly O
refer O
to O
as O
hair O
algae B-Plant
. O

the O
only O
know O
specie O
be O
lagurus B-Plant
ovatus I-Plant
, O
commonly O
call O
hare' B-Plant
- I-Plant
tail I-Plant
, O
hare' B-Plant
- I-Plant
tail I-Plant
grass I-Plant
or O
bunnytail B-Plant
. O

tillandsia B-Plant
emergen I-Plant
be O
a O
species O
of O
B-Plant O
in O
the O
bromeliaceae O
family O
. O

hacquetia B-Plant
epipactis I-Plant
( O
syn O
dondia B-Plant
epipactis I-Plant
spreng O
. O

) O
the O
flower O
, O
appear O
late O
winter O
and O
early O
spring O
, O
consist O
of O
multiple O
tiny O
yellow O
floret O
frame O
by O
lime B-Plant
green O
bract O
, O
and O
carry O
in O
dense O
spherical O
umbel O
4 O
cm O
in O
diameter O
. O

robinia B-Plant
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
family O
fabaceae O
, O
subfamily O
faboideae O
, O
native O
to O
north O
america O
and O
northern O
mexico O
. O

commonly O
know O
as O
locust B-Plant
, O
-PRON- O
be O
deciduous O
tree O
and O
shrub O
grow O
4–25 O
metre O
( O
13–82 O
ft O
) O
tall O
. O

some O
specie O
of O
robinia B-Plant
be O
use O
as O
food O
by O
larvae O
of O
lepidoptera O
, O
include O
such O
moth O
as O
the O
brown B-Plant
- I-Plant
tail I-Plant
( O
euproctis O
chrysorrhoea O
) O
, O
the O
buff B-Plant
- I-Plant
tip I-Plant
( O
phalera O
bucephala O
) O
, O
the O
engrail O
( O
ectropis O
crepuscularia O
) O
, O
the O
giant O
leopard O
moth O
( O
hypercompe O
scribonia O
) O
, O
the O
locust B-Plant
underwing O
( O
euparthenos O
nubili O
) O
, O
and O
chrysaster O
ostensackenella O
. O

florideophyceae O
, O
demote O
to O
subclass O
florideae O
in O
some O
classification O
system O
, O
be O
a O
class O
of O
red O
algae B-Plant
. O

-PRON- O
be O
once O
think O
to O
be O
the O
only O
algae B-Plant
to O
bear O
pit O
connection O
, O
but O
these O
have O
since O
be O
find O
in O
the O
filamentous O
stage O
of O
the O
bangiaceae O
. O

gnaphalium O
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
sunflower O
family O
, O
commonly O
call O
cudweed B-Plant
. O

cudweed B-Plant
be O
important O
foodB-Plant O
for O
american O
paint B-Plant
lady I-Plant
caterpillar O
. O

-PRON- O
include O
the O
major O
food O
crop O
rice B-Plant
( O
specie O
oryza B-Plant
sativa I-Plant
and O
oryza B-Plant
glaberrima I-Plant
) O
. O

the O
most O
distinctive O
leaf O
characteristic O
of O
this O
subfamily O
be O
the O
arm O
cell O
and O
fusoid O
cell O
find O
in O
-PRON- O
leaf O
. O

one O
specie O
, O
asian B-Plant
rice I-Plant
( O
o. B-Plant
sativa I-Plant
) O
, O
provide O
20 O
% O
of O
global O
grain O
and O
be O
a O
food O
crop O
of O
major O
global O
importance O
. O

the O
better O
know O
specie O
be O
the O
pomegranate B-Plant
( O
punica B-Plant
granatum I-Plant
) O
. O

the O
other O
specie O
, O
the O
socotra O
pomegranate B-Plant
( O
punica B-Plant
protopunica I-Plant
) O
, O
be O
endemic O
to O
the O
island O
of O
socotra O
. O

the O
name O
be O
derive O
from O
the O
latin O
word O
for O
the O
pomegranate B-Plant
, O
malum O
punicum O
, O
mean O
carthaginian O
apple B-Plant
. O

salvia B-Plant
verbenaca I-Plant
, O
also O
know O
as O
wild B-Plant
clary I-Plant
or O
wild B-Plant
sage I-Plant
, O
be O
native O
to O
the O
british O
isles O
, O
the O
mediterranean O
region O
in O
southern O
europe O
, O
north O
africa O
, O
and O
near O
east O
, O
and O
in O
the O
caucasus O
. O

s. B-Plant
verbenaca I-Plant
be O
a O
tall O
perennial O
herb O
with O
hairy O
stem O
and O
branch O
that O
erectly O
sprawl O
out O
. O

-PRON- O
have O
soft O
purple O
to O
violet B-Plant
flower O
in O
mid O
summer O
. O

this O
aromatic O
sage B-Plant
be O
use O
as O
a O
flavoring O
in O
food O
and O
to O
make O
tea B-Plant
gladiolus O
( O
from O
latin O
, O
the O
diminutive O
of O
gladius O
, O
a O
sword O
, O
) O
be O
a O
genus O
of O
perennial O
cormous O
flower O
B-Plant O
in O
the O
iris O
family O
( O
iridaceae O
it O
be O
sometimes O
call O
the O
' O
sword B-Plant
lily I-Plant
' O
, O
but O
be O
usually O
call O
by O
-PRON- O
generic O
name O
( O
plural O
gladioli).the O

genus O
occur O
in O
asia O
, O
mediterranean O
europe O
, O
south O
africa O
, O
and O
tropical O
africa O
. O

diospyro B-Plant
kaki I-Plant
, O
also O
call O
persimmon B-Plant
, O
be O
the O
most O
widely O
cultivate O
specie O
of O
the O
genus O
diospyros O
. O

although O
-PRON- O
first O
publish O
botanical O
description O
be O
not O
until O
1780 O
, O
the O
kaki B-Plant
be O
among O
the O
old O
B-Plant O
in O
cultivation O
, O
know O
for O
-PRON- O
use O
in O
china O
for O
more O
than O
2000 O
year O
. O

in O
some O
rural O
chinese O
community O
, O
the O
kaki B-Plant
fruit O
be O
see O
as O
have O
a O
great O
mystical O
power O
that O
can O
be O
harness O
to O
solve O
headache O
, O
back O
pain O
and O
foot O
ache O
. O

the O
persimmon B-Plant
( O
kaki B-Plant
) O
be O
a O
sweet O
, O
slightly O
tangy O
fruit O
with O
a O
soft O
to O
occasionally O
fibrous O
texture O
. O

a O
variety O
be O
diospyros B-Plant
kaki I-Plant
var I-Plant
sylvestris I-Plant
makino O
. O

those O
can O
be O
eat O
like O
an O
apple B-Plant
or O
can O
be O
allow O
to O
go O
to O
any O
stage O
of O
ripeness O
, O
include O
to O
the O
jelly O
- O
like O
stage O
. O

sharon O
fruit O
( O
name O
originally O
after O
sharon O
plain O
in O
israel O
) O
be O
a O
trade O
name O
for O
non O
- O
astringent O
d. B-Plant
kaki I-Plant
fruit O
. O

strophanthus B-Plant
be O
a O
genus O
of O
flower O
B-Plant O
in O
the O
family O
apocynaceae O
, O
first O
describe O
as O
a O
genus O
in O
1802 O
. O

the O
name O
( O
strophos O
anthos O
, O
twisted O
flower O
) O
derive O
from O
the O
long O
, O
twisted O
, O
threadlike O
segment O
of O
the O
corolla O
, O
which O
attain O
a O
length O
of O
30–35 O
cm O
in O
s. B-Plant
preussii I-Plant
. O

several O
african O
tribe O
use O
strophanthus B-Plant
as O
the O
principal O
ingredient O
in O
arrow B-Plant
poison I-Plant
. O

isolation O
and O
characterization O
of O
mat O
gene O
in O
the O
symbiotic O
ascomycete O
tuber B-Plant
melanosporum I-Plant
. O

the O
genome O
of O
tuber B-Plant
melanosporum I-Plant
have O
recently O
be O
sequence O
. O

here O
, O
use O
this O
information O
to O
identify O
gene O
involve O
in O
the O
reproductive O
process O
of O
this O
edible O
fungus B-Plant
. O

the O
sequenced O
strain O
( O
mel28 O
) O
possess O
only O
one O
of O
the O
two O
master O
gene O
require O
for O
mating O
, O
that O
is O
, O
the O
gene O
that O
code O
for O
the O
high O
mobility O
group O
( O
hmg O
) O
transcription O
factor O
( O
mat1 O
- O
2 O
- O
1 O
) O
, O
whereas O
lack O
the O
gene O
that O
code O
for O
the O
protein O
contain O
the O
alpha O
- O
box- O
domain O
( O
mat1 O
- O
1 O
- O
1 O
) O
, O
suggest O
that O
this O
fungus B-Plant
be O
heterothallic O
. O

these O
analysis O
provide O
definitive O
evidence O
that O
t. B-Plant
melanosporum I-Plant
be O
a O
heterothallic O
specie O
with O
a O
mat O
locus O
that O
be O
organize O
similarly O
to O
those O
of O
ancient O
fungal O
lineage O
. O

apical O
bud O
of O
norway B-Plant
spruce I-Plant
( O
picea B-Plant
abie I-Plant
) O
tree O
at O
high O
and O
low O
elevation O
be O
heat O
during O
2006 O
and O
2007 O
. O

physiological O
and O
morphological O
adaptation O
in O
relation O
to O
water O
use O
efficiency O
in O
mediterranean O
accession O
of O
solanum B-Plant
lycopersicum I-Plant
. O

the O
physiological O
trait O
underlie O
the O
apparent O
drought O
resistance O
of O
' O
tomatiga O
de O
ramellet O
' O
( O
tr O
) O
cultivar O
, O
a O
population O
of O
mediterranean O
tomato B-Plant
cultivar O
with O
delay O
fruit O
deterioration O
( O
dfd O
) O
phenotype O
and O
typically O
grow O
under O
non O
- O
irrigation O
condition O
, O
be O
evaluate O
. O

eight O
different O
tomato B-Plant
accession O
be O
select O
and O
include O
six O
tr O
accession O
, O
one O
mediterranean O
non O
- O
tr O
accession O
( O
ntr(m O
) O
) O
and O
a O
processing O
cultivar O
( O
ntr(o O
) O
) O
. O

among O
the O
tr O
accession O
two O
leaf O
morphology O
type O
, O
normal O
divided O
leaf O
and O
potato B-Plant
- O
leaf O
, O
be O
select O
. O

the O
result O
confirm O
the O
existence O
of O
differential O
trait O
in O
the O
response O
to O
drought O
stress O
in O
mediterranean O
accession O
of O
tomato B-Plant
, O
and O
demonstrate O
that O
increase O
in O
the O
g(m)/g(s O
) O
ratio O
would O
allow O
improvement O
in O
a(n)/g(s O
) O
in O
horticultural O
crop O
. O

the O
ubiquitous O
marine O
chlorophyte O
alga O
dunaliella B-Plant
tertiolecta I-Plant
be O
test O
under O
identical O
uv O
- O
b O
flux O
density O
couple O
with O
ecologically O
realistic O
flux O
of O
uv O
- O
a O
and O
visible O
radiation O
for O
6 O
and O
12 O
h O
exposure O
. O

the O
13c/12c O
isotopic O
signal O
of O
day O
- O
respire O
co2 O
in O
variegated O
leaf O
of O
pelargonium B-Plant
x I-Plant
hortorum I-Plant
. O

here O
, O
apply O
equation O
describe O
previously O
for O
mesocosm O
co(2 O
) O
exchange O
to O
investigate O
the O
carbon O
isotope O
composition O
of O
co(2 O
) O
respire O
by O
autotrophic O
and O
heterotrophic O
tissue O
of O
pelargonium B-Plant
x I-Plant
hortorum I-Plant
leaf O
, O
take O
advantage O
of O
leaf O
variegation O
. O

auxin O
depletion O
in O
barley B-Plant
B-Plant O
under O
high O
- O
temperature O
condition O
repress O
dna O
proliferation O
in O
organelle O
and O
nucleus O
via O
transcriptional O
alteration O
. O

recently O
demonstrate O
that O
ht O
repress O
the O
expression O
of O
yucca B-Plant
auxin O
biosynthesis O
gene O
and O
reduce O
endogenous O
auxin O
in O
the O
develop O
anther O
of O
barley B-Plant
and O
arabidopsis O
. O

here O
, O
show O
that O
dna O
proliferation O
in O
mitochondria O
, O
chloroplast O
and O
nucleus O
of O
develop O
panicle O
be O
inhibit O
with O
increase O
temperature O
in O
barley B-Plant
. O

experiment O
with O
wild O
- O
type O
arabidopsis B-Plant
thaliana I-Plant
be O
design O
to O
quantify O
the O
influence O
of O
parental O
environment O
and O
seed O
size O
on O
growth O
and O
development O
in O
the O
next O
generation O
. O

here O
, O
examine O
how O
the O
vulnerability O
of O
xylem O
to O
water O
stress O
- O
induce O
cavitation O
and O
the O
coordination O
between O
water O
transport O
capacity O
and O
assimilation O
( O
a O
) O
influence O
diurnal O
water O
- O
use O
efficiency O
( O
wue O
) O
and O
dry O
- O
matter O
production O
in O
lolium B-Plant
perenne I-Plant
l. I-Plant
- O
a O
commercial O
forage O
grass O
. O

mannitol O
permeation O
and O
radial O
flow O
of O
water O
in O
maize B-Plant
root O
. O

therefore O
, O
mannitol O
transport O
from O
the O
medium O
to O
the O
shoot O
of O
young O
maize B-Plant
B-Plant O
be O
study O
at O
different O
rate O
of O
transpiration O
in O
hydroculture O
. O

to O
resolve O
this O
, O
investigate O
the O
mechanism O
by O
which O
the O
root O
herbivore O
diabrotica O
virgifera O
induce O
resistance O
against O
lepidopteran O
herbivore O
in O
the O
leaf O
of O
zea B-Plant
may I-Plant
. O

the O
induction O
of O
aba O
by O
be O
partly O
responsible O
for O
the O
induction O
of O
leaf O
defense O
, O
but O
not O
for O
the O
resistance O
against O
s. B-Plant
littorali I-Plant
. O

improve O
nitrogen O
nutrition O
enhance O
root O
uptake O
, O
root O
- O
to O
- O
shoot O
translocation O
and O
remobilization O
of O
zinc O
( O
( O
65 O
) O
zn O
) O
in O
wheat B-Plant
. O

this O
study O
focuss O
on O
the O
effect O
of O
increase O
nitrogen O
( O
n O
) O
supply O
on O
root O
uptake O
and O
root O
- O
to O
- O
shoot O
translocation O
of O
zinc O
( O
zn O
) O
as O
well O
as O
retranslocation O
of O
foliar O
- O
apply O
zn O
in O
durum B-Plant
wheat I-Plant
( O
triticum B-Plant
durum I-Plant
) O
. O

the O
result O
demonstrate O
that O
the O
n O
- O
nutritional O
status O
of O
wheat B-Plant
affect O
major O
step O
in O
the O
route O
of O
zn O
from O
the O
growth O
medium O
to O
the O
grain O
, O
include O
uptake O
, O
xylem O
transport O
and O
remobilization O
via O
phloem O
. O

investigate O
response O
of O
a(n O
) O
, O
dark O
respiration O
and O
chlorophyll O
fluorescence O
to O
supraoptimal O
temperature O
of O
vary O
duration O
and O
kinetic O
in O
phaseolus B-Plant
vulgaris I-Plant
ask O
whether O
the O
instability O
of O
photosynthesis O
under O
severe O
heat O
stress O
be O
associate O
with O
cellular O
damage O
. O

here O
, O
report O
the O
effect O
of O
short O
- O
term O
variation O
of O
co2 O
concentration O
on O
canopy O
- O
scale O
g(m O
) O
and O
other O
co2 O
exchange O
parameter O
of O
sunflower B-Plant
( O
helianthus B-Plant
annuus I-Plant
l. I-Plant
) O
stand O
in O
the O
presence O
and O
absence O
of O
abscisic O
acid O
( O
aba O
) O
in O
nutrient O
solution O
. O

functional O
characterization O
of O
arabidopsis B-Plant
thaliana I-Plant
isopropylmalate O
dehydrogenas O
reveal O
important O
role O
in O
gametophyte O
development O
. O

the O
arabidopsis B-Plant
thaliana I-Plant
genome O
contain O
three O
putative O
ipmdh O
gene O
. O

bud O
set O
in O
poplar B-Plant
-- O
genetic O
dissection O
of O
a O
complex O
trait O
in O
natural O
and O
hybrid O
population O
. O

quantitative O
trait O
loci O
( O
qtl O
) O
be O
identify O
for O
the O
most O
discriminative O
phenotypic O
bud O
- O
set O
component O
across O
four O
poplar B-Plant
pedigree O
. O

the O
qtl O
from O
different O
pedigree O
be O
recurrently O
detect O
in O
six O
region O
of O
the O
poplar B-Plant
genome O
. O

intraspecific O
trait O
variation O
and O
covariation O
in O
a O
widespread O
tree O
specie O
( O
nothofagus B-Plant
pumilio I-Plant
) O
in O
southern O
chile O
. O

here O
quantify O
intraspecific O
variation O
and O
covariation O
of O
leaf O
mass O
per O
area O
( O
lma O
) O
and O
wood O
density O
( O
wd O
) O
in O
monospecific O
forest O
of O
the O
widespread O
tree O
speci O
nothofagus B-Plant
pumilio I-Plant
to O
determine O
magnitude O
and O
whether O
be O
relate O
to O
environmental O
condition O
and O
ontogeny O
. O

functional O
trait O
of O
n. B-Plant
pumilio I-Plant
exhibit O
nonnegligible O
variation O
; O
lma O
vary O
for O
the O
most O
part O
with O
temperature O
, O
while O
wd O
mostly O
vary O
with O
moisture O
and O
ontogeny O
. O

systemic O
virus O
- O
induce O
gene O
silencing O
allow O
functional O
characterization O
of O
maize B-Plant
gene O
during O
biotrophic O
interaction O
with O
ustilago O
maydis O
. O

infection O
of O
maize B-Plant
( O
zea B-Plant
may I-Plant
) O
B-Plant O
with O
the O
corn B-Plant
smut I-Plant
fungus I-Plant
ustilago B-Plant
maydis I-Plant
lead O
to O
the O
formation O
of O
large O
tumor O
on O
the O
stem O
, O
leaf O
and O
inflorescence O
. O

in O
this O
biotrophic O
interaction O
, O
B-Plant O
defense O
response O
be O
actively O
suppress O
by O
the O
pathogen O
, O
and O
previous O
transcriptome O
analysis O
of O
infected O
maize B-Plant
B-Plant O
show O
massive O
and O
stage O
- O
specific O
change O
in O
host O
gene O
expression O
during O
disease O
progression O
. O

to O
identify O
maize B-Plant
gene O
that O
be O
functionally O
involve O
in O
the O
interaction O
with O
u. B-Plant
maydis I-Plant
, O
adapt O
a O
virus O
- O
induce O
gene O
silencing O
( O
vigs O
) O
system O
base O
on O
the O
brome B-Plant
mosaic O
virus O
( O
bmv O
) O
for O
maize B-Plant
. O

condition O
be O
establish O
that O
allow O
successful O
u. B-Plant
maydis I-Plant
infection O
of O
bmv O
- O
preinfect O
maize B-Plant
B-Plant O
. O

this O
set O
- O
up O
enable O
quantification O
of O
vig O
and O
impact O
on O
u. B-Plant

maydis I-Plant
infection O
use O
a O
quantitative O
real O
- O
time O
pcr O
( O
qrt O
- O
pcr)-bas O
readout O
. O

in O
proof O
- O
of O
- O
principle O
experiment O
, O
an O
u. B-Plant

maydis I-Plant
- O
induce O
terpene O
synthase O
be O
show O
to O
negatively O
regulate O
disease O
development O
while O
a O
protein O
involve O
in O
cell O
death O
inhibition O
be O
require O
for O
full O
virulence O
of O
u. B-Plant
maydis I-Plant
. O

the O
result O
suggest O
that O
this O
system O
be O
a O
versatile O
tool O
for O
the O
rapid O
identification O
of O
maize B-Plant
gene O
that O
determine O
compatibility O
with O
u. B-Plant
maydis I-Plant
. O

stable O
expression O
of O
the O
potato B-Plant
leaf O
roll O
virus O
movement O
protein O
mp17 O
in O
arabidopsis O
result O
in O
a O
carbohydrate O
export O
block O
and O
stunt O
growth O
. O

two O
suppressor O
mutant O
show O
decrease O
susceptibility O
against O
turnip B-Plant
mosaic O
virus O
and O
post O
- O
transcriptional O
silencing O
of O
mp17:gfp O
rna O
in O
source O
leaf O
. O

in O
this O
study O
, O
examine O
the O
preference O
and O
performance O
of O
a O
herbivorous O
leafminer O
( O
liriomyza O
huidobrensis O
) O
and O
parasitic O
wasp O
( O
opius O
dissitus O
) O
on O
three O
tomato B-Plant
genotype O
: O
a O
wild O
- O
type O
( O
wt O
) O
B-Plant O
, O
a O
ja O
biosynthesis O
( O
spr2 O
) O
mutant O
, O
and O
a O
ja O
- O
overexpression O
35s::prosys O
B-Plant O
. O

haplotype O
analysis O
of O
the O
gene O
encode O
glutamine O
synthetase O
plastic O
isoform O
and O
association O
with O
nitrogen O
- O
use- O
and O
yield O
- O
relate O
trait O
in O
bread B-Plant
wheat I-Plant
. O

investigate O
the O
haplotype O
variation O
of O
gs O
gene O
and O
association O
with O
agronomic O
trait O
may O
provide O
useful O
information O
for O
improve O
wheat B-Plant
n O
- O
use O
efficiency O
and O
yield O
. O

isolate O
the O
promoter O
and O
cod O
region O
sequence O
of O
the O
plastic O
glutamine O
synthetase O
isoform O
( O
gs2 O
) O
gene O
locate O
on O
chromosome O
2a O
, O
2b O
and O
2d O
in O
bread B-Plant
wheat I-Plant
. O

datum O
suggest O
that O
certain O
tags2 O
haplotype O
may O
be O
valuable O
in O
breed O
wheat B-Plant
variety O
with O
improve O
agronomic O
performance O
and O
n O
- O
use O
efficiency O
. O

pollinator O
preference O
be O
measure O
by O
field O
test O
with O
antirrhinum B-Plant
maju I-Plant
. O

high O
homologous O
gene O
conservation O
despite O
extreme O
autopolyploid O
redundancy O
in O
sugarcane B-Plant
. O

modern O
sugarcane B-Plant
( O
saccharum B-Plant
spp. I-Plant
) O
be O
the O
lead O
sugar O
crop O
and O
a O
primary O
energy O
crop O
. O

be O
produce O
about O
a O
century O
ago O
through O
hybridization O
between O
two O
autopolyploid O
specie O
, O
namely O
s. B-Plant
officinarum I-Plant
and O
s. B-Plant
spontaneum I-Plant
. O

by O
contrast O
, O
transposable O
element O
display O
a O
general O
absence O
of O
colinearity O
among O
hom(oe)ologous O
haplotype O
and O
appear O
to O
have O
undergo O
dynamic O
expansion O
in O
saccharum O
, O
compare O
with O
sorghum B-Plant
, O
close O
relative O
in O
the O
andropogonea O
tribe O
. O

nitric O
oxide O
participate O
in O
cold O
- O
responsive O
phosphosphingolipid O
formation O
and O
gene O
expression O
in O
arabidopsis B-Plant
thaliana I-Plant
. O

the O
participation O
of O
no O
in O
the O
early O
transduction O
of O
the O
cold O
signal O
in O
arabidopsis B-Plant
thaliana I-Plant
be O
investigate O
. O

moreover O
, O
no O
accumulation O
be O
not O
observe O
in O
h7 O
B-Plant O
overexpress O
the O
a. B-Plant
thaliana I-Plant
nonsymbiotic O
hemoglobin O
arabidopsis O
haemoglobin O
1 O
( O
ahb1 O
) O
. O

identification O
of O
a O
novel O
mitochondrial O
protein O
, O
short O
postembryonic O
root O
1 O
( O
spr1 O
) O
, O
involve O
in O
root O
development O
and O
iron O
homeostasis O
in O
oryza B-Plant
sativa I-Plant
. O

a O
rice B-Plant
mutant O
, O
oryza B-Plant
sativa I-Plant
short O
postembryonic O
root O
1 O
( O
osspr1 O
) O
, O
have O
be O
characterize O
. O

complementation O
of O
the O
mutant O
confirm O
that O
osspr1 O
be O
involve O
in O
post O
- O
embryonic O
root O
elongation O
and O
iron O
homeostasis O
in O
rice B-Plant
. O

genomic O
profiling O
of O
carbohydrate O
metabolism O
in O
the O
ectomycorrhizal O
fungus O
tuber B-Plant
melanosporum I-Plant
. O

in O
this O
study O
, O
use O
information O
retrieve O
from O
the O
recently O
sequence O
tuber B-Plant
melanosporum I-Plant
genome O
, O
together O
with O
transcriptome O
analysis O
datum O
and O
target O
validation O
experiment O
, O
to O
construct O
the O
first O
genome O
- O
wide O
catalogue O
of O
the O
protein O
support O
carbohydrate O
metabolism O
in O
a O
B-Plant O
- O
symbiotic O
ascomycete O
. O

transcriptional O
regulation O
of O
these O
pathway O
in O
different O
stage O
of O
the O
t. B-Plant
melanosporum I-Plant
lifecycle O
be O
investigate O
use O
whole O
- O
genome O
oligoarray O
expression O
datum O
together O
with O
real O
- O
time O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
analysis O
of O
select O
gene O
. O

the O
most O
significant O
result O
be O
the O
identification O
of O
methylcitrate O
cycle O
gene O
and O
of O
an O
acid O
invertase O
, O
the O
first O
enzyme O
of O
this O
kind O
to O
be O
describe O
in O
a O
B-Plant O
- O
symbiotic O
filamentous O
fungus B-Plant
. O

these O
datum O
indicate O
a O
high O
degree O
of O
lifecycle O
stage O
specialization O
for O
particular O
branch O
of O
carbohydrate O
metabolism O
in O
t. B-Plant
melanosporum I-Plant
. O

cold O
stress O
contribute O
to O
aberrant O
cytokinesis O
during O
male O
meiosis O
in O
a O
wheat B-Plant
thermosensitive O
genic O
male O
sterile O
line O
. O

the O
male O
sterility O
of O
a O
wheat B-Plant
thermosensitive O
genic O
male O
sterile O
( O
tgms O
) O
line O
be O
strictly O
control O
by O
temperature O
. O

report O
here O
a O
large O
- O
scale O
transcriptomic O
study O
use O
the O
affymetrix O
wheat B-Plant
genechip O
to O
follow O
gene O
expression O
in O
bs366 O
line O
anther O
in O
response O
to O
cold O
stress O
. O

the O
result O
may O
explain O
the O
male O
sterility O
cause O
by O
low O
temperature O
in O
wheat B-Plant
tgms O
line O
. O

nicotiana B-Plant
benthamiana I-Plant
B-Plant O
be O
infect O
with O
potato B-Plant
virus O
x O
( O
pvx O
) O
and O
expose O
to O
oxidative O
[ O
either O
ultraviolet O
( O
uv O
- O
c O
) O
or O
h2o2 O
] O
stress O
. O

dual O
delta^1 O
^ O
3c O
/ O
delta^1 O
^ O
8o O
response O
to O
water O
and O
nitrogen O
availability O
and O
relationship O
with O
yield O
in O
field O
- O
grow O
durum B-Plant
wheat I-Plant
. O

however O
, O
this O
method O
have O
not O
be O
apply O
to O
wheat B-Plant
grow O
under O
real O
field O
condition O
. O

here O
, O
B-Plant O
growth O
, O
grain O
yield O
( O
gy O
) O
and O
the O
associate O
agronomic O
component O
, O
carbon O
isotope O
discrimination O
( O
delta^1 O
^ O
3c O
) O
plus O
oxygen O
isotope O
composition O
( O
delta^1 O
^ O
8o O
) O
as O
well O
as O
leaf O
and O
canopy O
gas O
exchange O
be O
measure O
in O
field O
- O
grow O
wheat B-Plant
subject O
to O
different O
water O
and O
n O
availability O
. O

effect O
of O
soil O
acidity O
, O
soil O
strength O
and O
macropore O
on O
root O
growth O
and O
morphology O
of O
perennial B-Plant
grass I-Plant
specie O
differ O
in O
acid O
- O
soil O
resistance O
. O

the O
response O
of O
root O
growth O
and O
morphology O
to O
soil O
acidity O
, O
soil O
strength O
and O
macropore O
by O
seedling O
of O
five O
perennial B-Plant
grass I-Plant
genotype O
differ O
in O
acid O
- O
soil O
resistance O
be O
determine O
, O
and O
the O
interaction O
of O
soil O
acidity O
and O
strength O
for O
growth O
and O
morphology O
of O
root O
be O
investigate O
. O

generation O
of O
se O
- O
fortify O
broccoli B-Plant
as O
functional O
food O
: O
impact O
of O
se O
fertilization O
on O
s O
metabolism O
. O

selenium O
( O
se)-fortified O
broccoli B-Plant
( O
brassica B-Plant
oleracea I-Plant
var I-Plant
italica I-Plant
) O
have O
be O
propose O
as O
a O
functional O
food O
for O
cancer O
prevention O
, O
base O
on O
high O
glucosinolate O
( O
gsl O
) O
content O
and O
capacity O
for O
se O
accumulation O
. O

to O
evaluate O
these O
potentially O
adverse O
effect O
of O
se O
fertilization O
, O
perform O
a O
comprehensive O
study O
on O
sand O
- O
grow O
young O
broccoli B-Plant
B-Plant O
( O
weekly O
selenate O
application O
of O
0.8 O
mumol O
B-Plant(-1 O
) O
via O
the O
root O
) O
and O
field O
- O
grow O
adult O
broccoli B-Plant
B-Plant O
during O
head O
formation O
( O
single O
foliar O
selenate O
application O
: O
25.3 O
or O
253 O
mumol O
B-Plant(-1 O
) O
) O
. O

conclude O
that O
broccoli B-Plant
can O
be O
fertilize O
with O
se O
without O
reduction O
in O
gsl O
content O
, O
even O
with O
se O
accumulation O
exceed O
the O
level O
recommend O
for O
human O
consumption O
. O

factor O
require O
for O
the O
high O
co2 O
specificity O
of O
the O
anaerobically O
induce O
maize B-Plant
gapc4 O
promoter O
in O
transgenic O
tobacco B-Plant
. O

strong O
anaerobic O
reporter O
gene O
activity O
in O
tobacco B-Plant
( O
nicotiana B-Plant
tabacum I-Plant
) O
control O
by O
the O
glycolytic O
glyceraldehyde-3-phosphate O
dehydrogenase O
( O
gapc4 O
) O
promoter O
from O
maize B-Plant
( O
zea B-Plant
may I-Plant
) O
depend O
on O
the O
presence O
of O
co(2 O
) O
and O
light O
. O

to O
identify O
factor O
require O
for O
co(2 O
) O
regulate O
gene O
expression O
, O
promoter O
deletion O
fuse O
to O
the O
beta O
- O
glucuronidase O
reporter O
gene O
be O
study O
in O
transgenic O
tobacco B-Plant
. O

electrophoretic O
mobility O
shift O
experiment O
indicate O
that O
tobacco B-Plant
nuclear O
extract O
harbour O
protein O
that O
bind O
to O
part O
of O
the O
40 O
bp O
fragment O
. O

database O
assist O
as O
well O
as O
experimental O
analysis O
reveal O
a O
role O
for O
ap2/erebp O
transcription O
factor O
for O
confer O
the O
high O
co(2 O
) O
specificity O
to O
the O
gapc4 O
promoter O
in O
tobacco B-Plant
leaf O
. O

root O
organ O
culture O
of O
both O
medicago B-Plant
truncatula I-Plant
and O
daucus B-Plant
carota I-Plant
, O
express O
the O
nuclear O
- O
localize O
cameleon O
reporter O
nupyc2.1 O

, O
be O
use O
to O
monitor O
am O
- O
elicit O
ca(2 O
+ O
) O
response O
in O
host O
root O
tissue O
. O

treatment O
with O
am O
spore O
exudate O
also O
elicit O
ca(2 O
+ O
) O
spike O
within O
the O
am O
- O
responsive O
zone O
of O
the O
root O
and O
, O
in O
both O
case O
, O
spiking O
be O
dependent O
on O
the O
m. B-Plant
truncatula I-Plant
common O
sym O
gene O
dmi1/2 O
, O
but O
not O
on O
the O
rhizobial O
nod O
factor O
perception O
gene O
nfp O
. O

arabidopsis B-Plant
thaliana I-Plant
population O
show O
clinal O
variation O
in O
a O
climatic O
gradient O
associate O
with O
altitude O
. O

here O
, O
test O
for O
clinal O
variation O
in O
life O
history O
and O
associated O
trait O
along O
an O
environmental O
and O
altitudinal O
gradient O
in O
the O
model O
speci O
arabidopsis B-Plant
thaliana I-Plant
. O

seventeen O
natural O
population O
of O
a. B-Plant
thaliana I-Plant
be O
geo O
- O
reference O
in O
north O
- O
eastern O
spain O
on O
a O
gradient O
in O
which O
precipitation O
increase O
but O
maximum O
spring O
temperature O
and O
minimum O
winter O
temperature O
decrease O
with O
altitude O
. O

structural O
and O
hydraulic O
correlate O
of O
heterophylly O
in O
ginkgo B-Plant
biloba I-Plant
. O

this O
study O
investigate O
the O
functional O
significance O
of O
heterophylly O
in O
ginkgo B-Plant
biloba I-Plant
, O
where O
leaf O
bear O
on O
short O
shoot O
be O
ontogenetically O
distinct O
from O
those O
on O
long O
shoot O
. O

propose O
that O
structural O
difference O
between O
the O
two O
g. B-Plant
biloba I-Plant
leaf O
type O
reflect O
great O
hydraulic O
limitation O
of O
long O
- O
shoot O
leaf O
during O
expansion O
. O

possible O
contribution O
of O
terminal O
flower O
1 O
to O
the O
evolution O
of O
rosette O
flower O
in O
leavenworthia O
( O
brassicaceae B-Plant
) O
. O

leavenworthia B-Plant
crassa I-Plant
be O
a O
rosette O
flowering O
specie O
that O
differ O
from O
inflorescence O
flowering O
specie O
, O
such O
as O
arabidopsis B-Plant
thaliana I-Plant
, O
in O
have O
elongate O
pedicel O
and O
shorten O
interfloral O
internode O
on O
the O
main O
axis O
. O

base O
on O
previous O
experiment O
, O
hypothesize O
that O
change O
to O
the O
l. B-Plant
crassa I-Plant
tfl1 O
ortholog O
, O
lcrtfl1 O
, O
be O
important O
in O
the O
evolution O
of O
rosette O
flowering O
. O

isolate O
lcrtfl1 O
and O
introduce O
a O
genomic O
construct O
into O
tfl1 O
mutant O
a. B-Plant
thaliana I-Plant
B-Plant O
. O

datum O
show O
that O
there O
be O
substantive O
difference O
in O
the O
regulation O
and/or O
function O
of O
tfl1 O
ortholog O
between O
a. B-Plant
thaliana I-Plant
and O
l. B-Plant
crassa I-Plant
. O

here O
, O
use O
a O
combination O
of O
ionomic O
and O
gas O
chromatography O
- O
mass O
spectrometry O
( O
gc O
- O
ms)-based O
metabolite O
profiling O
of O
complete O
shoot O
( O
pool O
leaf O
, O
petiole O
and O
stem O
) O
to O
compare O
the O
extremophile O
lotus B-Plant
creticus I-Plant
, O
adapt O
to O
highly O
saline O
coastal O
region O
, O
and O
two O
cultivate O
glycophytic O
grassland O
forage O
specie O
, O
lotus B-Plant
corniculatus I-Plant
and O
lotus B-Plant
tenuis I-Plant
. O

l. B-Plant
creticus I-Plant
exhibit O
good O
survival O
after O
exposure O
to O
long O
- O
term O
lethal O
salinity O
and O
be O
more O
efficient O
at O
exclude O
cl- O
from O
the O
shoot O
than O
the O
glycophyte O
. O

metabolite O
profiling O
show O
that O
response O
to O
nacl O
in O
l. B-Plant
creticus I-Plant
shoot O
be O
globally O
similar O
to O
those O
of O
the O
glycophyte O
, O
provide O
little O
evidence O
for O
metabolic O
pre O
- O
adaptation O
to O
salinity O
. O

acclimation O
to O
high O
co2 O
in O
maize B-Plant
be O
relate O
to O
water O
status O
and O
dependent O
on O
leaf O
rank O
. O

in O
this O
study O
, O
the O
effect O
of O
atmospheric O
co(2 O
) O
availability O
on O
the O
transcriptome O
, O
proteome O
and O
metabolome O
profile O
of O
two O
rank O
of O
source O
leaf O
in O
maize B-Plant
( O
zea B-Plant
may I-Plant
l. I-Plant
) O
be O
study O
in O
B-Plant O
grow O
under O
ambient O
co(2 O
) O
condition O
( O
350 O
+ O
/- O
20 O
mul O
l(-1 O
) O
co(2 O
) O
) O
or O
with O
co(2 O
) O
enrichment O
( O
700 O
+ O
/- O
20 O
mul O
l(-1 O
) O
co(2 O
) O
) O
. O

seasonal O
dynamic O
in O
the O
stable O
carbon O
isotope O
composition O
delta^1 O
^ O
3c O
from O
non O
- O
leafy O
branch O
, O
trunk O
and O
coarse O
root O
co2 O
efflux O
of O
adult O
deciduous O
( O
fagus B-Plant
sylvatica I-Plant
) O
and O
evergreen O
( O
picea B-Plant
abie I-Plant
) O
tree O
. O

study O
seasonal O
dynamic O
in O
delta^1 O
^ O
3c O
of O
co2 O
efflux O
( O
delta^1 O
^ O
3c(e O
) O
) O
from O
non O
- O
leafy O
branch O
, O
upper O
and O
low O
trunk O
and O
coarse O
root O
of O
adult O
tree O
, O
compare O
deciduous O
fagus B-Plant
sylvatica I-Plant
( O
european B-Plant
beech I-Plant
) O
with O
evergreen O
picea B-Plant
abie I-Plant
( O
norway B-Plant
spruce I-Plant
) O
. O

during O
summer O
, O
delta^1 O
^ O
3c(e O
) O
of O
trunk O
be O
about O
-28.2 O
% O
( O
beech B-Plant
) O
and O
-26.8 O
% O
( O
spruce B-Plant
) O
. O

the O
seasonal O
delta^1 O
^ O
3c(e O
) O
pattern O
of O
branch O
of O
beech B-Plant
and O
upper O
trunk O
of O
spruce B-Plant
be O
less O
variable O
, O
probably O
because O
these O
organ O
be O
additionally O
supply O
by O
winter O
photosynthesis O
. O

gene O
expression O
change O
during O
short O
day O
induce O
terminal O
bud O
formation O
in O
norway B-Plant
spruce I-Plant
. O

the O
molecular O
basis O
for O
terminal O
bud O
formation O
in O
autumn O
be O
not O
well O
understand O
in O
conifer B-Plant
. O

by O
combine O
suppression O
subtractive O
hybridization O
and O
monitoring O
of O
gene O
expression O
by O
qrt O
- O
pcr O
analysis O
, O
aim O
to O
identify O
gene O
involve O
in O
photoperiodic O
control O
of O
growth O
cessation O
and O
bud O
set O
in O
norway B-Plant
spruce I-Plant
. O

role O
of O
nitric O
oxide O
in O
hydrogen O
peroxide O
- O
dependent O
induction O
of O
abiotic O
stress O
tolerance O
by O
brassinosteroid O
in O
cucumber B-Plant
. O

brassinosteroid O
( O
br O
) O
can O
induce O
B-Plant O
tolerance O
to O
a O
variety O
of O
abiotic O
stress O
by O
trigger O
the O
generation O
of O
h(2 O
) O
o(2 O
) O
as O
a O
signal O
molecule O
in O
cucumber B-Plant
leaf O
. O

recovery O
of O
ectomycorrhiza O
after O
' O
nitrogen O
saturation O
' O
of O
a O
conifer B-Plant
forest O
. O

here O
, O
report O
the O
long O
- O
term O
impact O
of O
n O
loading O
and O
the O
recovery O
of O
ectomycorrhiza O
after O
high O
n O
loading O
on O
a O
pinus B-Plant
sylvestris I-Plant
forest O
. O

host O
B-Plant O
secondary O
metabolite O
profiling O
show O
a O
complex O
, O
strain O
- O
dependent O
response O
of O
maize B-Plant
to O
B-Plant O
growth O
- O
promote O
rhizobacteria O
of O
the O
genus O
azospirillum O
. O

these O
effect O
be O
assess O
by O
compare O
the O
early O
impact O
of O
three O
azospirillum O
inoculant O
strain O
on O
secondary O
metabolite O
profile O
of O
two O
different O
maize B-Plant
( O
zea B-Plant
may I-Plant
) O
cultivar O
. O

after O
10d O
of O
growth O
in O
nonsterile O
soil O
, O
maize B-Plant
methanolic O
extract O
be O
analyze O
by O
reverse O
- O
phase O
high O
- O
performance O
liquid O
chromatography O
( O
rp O
- O
hplc O
) O
and O
secondary O
metabolite O
identify O
by O
liquid O
chromatography O
/ O
mass O
spectrometry O
( O
lc O
/ O
ms O
) O
and O
nuclear O
magnetic O
resonance O
( O
nmr O
) O
. O

in O
parallel O
, O
azospirillum O
inoculation O
lead O
to O
major O
qualitative O
and O
quantitative O
modification O
of O
the O
content O
of O
secondary O
metabolite O
, O
especially O
benzoxazinoid O
, O
in O
the O
maize B-Plant
B-Plant O
. O

thus O
, O
azospirillum O
inoculation O
result O
in O
early O
, O
strain O
- O
dependent O
modification O
in O
the O
biosynthetic O
pathway O
of O
benzoxazine O
derivative O
in O
maize B-Plant
in O
compatible O
interaction O
. O

this O
be O
the O
first O
study O
document O
a O
pgpr O
effect O
on O
B-Plant O
secondary O
metabolite O
profile O
, O
and O
suggest O
the O
establishment O
of O
complex O
interaction O
between O
azospirillum O
pgpr O
and O
maize B-Plant
. O

physiological O
performance O
of O
an O
alaskan O
shrub O
( O
alnus B-Plant
fruticosa I-Plant
) O
in O
response O
to O
disease O
( O
valsa O
melanodiscus O
) O
and O
water O
stress O
. O

for O
alnus B-Plant
fruticosa I-Plant
, O
examine O
the O
effect O
of O
water O
stress O
on O
disease O
predisposition O
, O
and O
the O
effect O
of O
disease O
and O
water O
stress O
on O
host O
physiology O
. O

in O
order O
to O
understand O
the O
spatial O
distribution O
of O
ja O
biosynthetic O
capacity O
in O
nodule O
of O
two O
actinorhizal O
specie O
, O
casaurina O
glauca O
and O
datisca B-Plant
glomerata I-Plant
, O
and O
one O
legume O
, O
medicago B-Plant
truncatula I-Plant
, O
determine O
the O
localization O
of O
allene O
oxide O
cyclase O
( O
aoc O
) O
which O
catalyse O
a O
committed O
step O
in O
ja O
biosynthesis O
. O

the O
nodule O
and O
noninoculated O
root O
of O
the O
two O
actinorhizal O
specie O
, O
and O
the O
root O
system O
of O
m. B-Plant
truncatula I-Plant
, O
noninoculat O
or O
nodulat O
with O
wild O
- O
type O
sinorhizobium O
meliloti O
or O
with O
mutant O
unable O
to O
fix O
nitrogen O
, O
do O
not O
show O
significant O
difference O
in O
ja O
level O
. O

to O
study O
whether O
ja O
play O
a O
regulatory O
role O
in O
the O
nodule O
of O
m. B-Plant
truncatula I-Plant
, O
composite O
B-Plant O
contain O
root O
express O
an O
mtaoc1-sense O
or O
mtaoc1-rnai O
construct O
be O
inoculate O
with O
s. O
meliloti O
. O

the O
degree O
of O
mycoheterotrophic O
carbon O
gain O
in O
green O
, O
variegated O
and O
vegetative O
albino O
individual O
of O
cephalanthera B-Plant
damasonium I-Plant
be O
relate O
to O
leaf O
chlorophyll O
concentration O
. O

achlorophyllous O
variant O
of O
some O
forest O
orchid B-Plant
be O
know O
to O
reach O
almost O
the O
same O
size O
as O
green O
form O
. O

the O
discovery O
of O
two O
cephalanthera B-Plant
damasonium I-Plant
population O
with O
variegate O
leaf O
enable O
a O
continuous O
bridging O
of O
leaf O
chlorophyll O
concentration O
between O
green O
and O
albino O
form O
. O

leaf O
of O
27 O
green O
, O
variegate O
and O
albino O
individual O
of O
c. B-Plant
damasonium I-Plant
be O
compare O
for O
chlorophyll O
concentration O
, O
c O
source O
( O
as O
characterize O
by O
( O
13)c O
abundance O
) O
and O
total O
c O
and O
nitrogen O
( O
n O
) O
concentration O
. O

result O
document O
that O
partial O
mycoheterotrophy O
in O
c. B-Plant
damasonium I-Plant
be O
not O
a O
static O
nutritional O
mode O
but O
a O
flexible O
mechanism O
relate O
inter O
alia O
to O
leaf O
chlorophyll O
concentration O
. O

( O
brassicaceae B-Plant
) O
and O
misleading O
assessment O
of O
host O
suitability O
by O
a O
specialist O
herbivore O
. O

glucosinolate O
be O
B-Plant O
secondary O
metabolite O
use O
in O
host O
B-Plant O
recognition O
by O
insect O
specialize O
on O
brassicaceae B-Plant
, O
such O
as O
the O
diamondback O
moth O
( O
dbm O
) O
, O
plutella O
xylostella O
. O

dbm O
oviposit O
extensively O
on O
barbarea B-Plant
vulgaris I-Plant
, O
despite O
larvae O
not O
be O
able O
to O
survive O
on O
this O
B-Plant O
because O
of O
content O
of O
feeding O
- O
deterrent O
saponin O
. O

glucosinolate O
and O
saponin O
in O
B-Plant O
tissue O
and O
mechanically O
remove O
surface O
wax O
from O
leaf O
of O
barbarea B-Plant
spp. I-Plant
be O
analyze O
with O
high O
- O
performance O
liquid O
chromatography O
( O
hplc O
) O
and O
liquid O
chromatography O
- O
mass O
spectrometry O
( O
lc O
- O
ms O
) O
. O

surface O
wax O
from O
leaf O
of O
barbarea B-Plant
spp. I-Plant
contain O
glucosinolate O
, O
but O
not O
feed O
- O
deterrent O
saponin O
. O

research O
be O
also O
the O
first O
to O
quantify O
glucosinolate O
on O
the O
leaf O
surface O
of O
a O
crucifer O
, O
and O
to O
show O
that O
the O
concentration O
of O
glucosinolate O
find O
on O
the O
leaf O
surface O
of O
barbarea B-Plant
spp. I-Plant
be O
sufficient O
to O
be O
perceive O
by O
oviposit O
dbm O
. O

floret O
initiation O
, O
tissue O
expansion O
and O
carbon O
availability O
at O
the O
meristem O
of O
the O
sunflower B-Plant
capitulum O
as O
affect O
by O
water O
or O
light O
deficit O
. O

the O
co O
- O
ordination O
between O
floret O
initiation O
and O
meristem O
expansion O
, O
and O
relationship O
with O
carbon O
availability O
, O
be O
study O
and O
quantify O
in O
sunflower B-Plant
( O
helianthus B-Plant
annuus I-Plant
) O
B-Plant O
subject O
to O
light O
or O
water O
shortage O
. O

molecular O
event O
of O
apical O
bud O
formation O
in O
white B-Plant
spruce I-Plant
, O
picea B-Plant
glauca I-Plant
. O

have O
characterize O
transcriptome O
- O
level O
change O
that O
occur O
during O
bud O
formation O
of O
white B-Plant
spruce I-Plant
[ O
picea B-Plant
glauca I-Plant
( O
moench O
) O
voss O
] O
, O
a O
primarily O
determinate O
specie O
in O
which O
preform O
stem O
unit O
contain O
within O
the O
apical O
bud O
constitute O
most O
of O
next O
season O
's O
growth O
. O

these O
finding O
provide O
a O
temporal O
roadmap O
of O
bud O
formation O
in O
white B-Plant
spruce I-Plant
. O

the O
effect O
of O
shade O
on O
xylem O
hydraulic O
trait O
and O
xylem O
anatomy O
be O
study O
in O
hybrid O
poplar B-Plant
( O
populus B-Plant
trichocarpa I-Plant
x I-Plant
deltoide I-Plant
, O
clone O
h11 O
- O
11 O
) O
. O

dry O
through O
a O
gradual O
ethanol O
series O
seem O
to O
be O
a O
good O
alternative O
to O
dry O
directly O
from O
a O
hydrated O
state O
for O
pit O
membrane O
observation O
in O
poplar B-Plant
. O

analysis O
of O
populus B-Plant
trichocarpa I-Plant
's O
response O
to O
infiltration O
of O
sucrose O
, O
monosaccharide O
, O
polyethylene O
glycol O
and O
potassium O
chloride O
into O
the O
xylem O
reveal O
that O
only O
presence O
of O
sucrose O
result O
in O
a O
simultaneous O
physiological O
and O
molecular O
response O
similar O
to O
that O
induce O
by O
embolism O
. O

drought O
increase O
freeze O
tolerance O
of O
both O
leaf O
and O
xylem O
of O
larrea B-Plant
tridentata I-Plant
. O

to O
test O
this O
hypothesis O
, O
subject O
larrea B-Plant
tridentata I-Plant
juvenile O
grow O
in O
a O
greenhouse O
under O
well O
- O
water O
or O
drought O
condition O
to O
minimum O
temperature O
range O
from O
-8 O
to O
-24 O
^0c O
. O

by O
document O
the O
combine O
effect O
of O
drought O
and O
freezing O
stress O
, O
datum O
provide O
insight O
into O
the O
mechanism O
determine O
B-Plant O
survival O
and O
performance O
follow O
freezing O
and O
the O
potential O
for O
shift O
in O
l. B-Plant
tridentata I-Plant
abundance O
and O
range O
in O
the O
face O
of O
change O
temperature O
and O
precipitation O
regime O
. O

stable O
isotope O
labelling O
and O
zinc O
distribution O
in O
grain O
study O
by O
laser O
ablation O
icp O
- O
ms O
in O
an O
ear O
culture O
system O
reveal O
zinc O
transport O
barrier O
during O
grain O
fill O
in O
wheat B-Plant
. O

the O
transfer O
of O
zn O
from O
the O
growth O
medium O
to O
wheat B-Plant
( O
triticum B-Plant
aestivum I-Plant
) O
grain O
in O
an O
ear O
culture O
system O
be O
investigate O
by O
use O
the O
stable O
zn O
isotope O
( O
70 O
) O
zn O
, O
and O
the O
spatial O
distribution O
of O
zn O
within O
the O
grain O
be O
study O
by O
laser O
ablation O
- O
inductively O
couple O
plasma O
- O
mass O
spectrometry O
( O
la O
- O
icp O
- O
ms O
) O
. O

these O
result O
suggest O
that O
two O
barrier O
of O
zn O
transport O
into O
wheat B-Plant
grain O
may O
exist O
: O
between O
the O
stem O
tissue O
rachis O
and O
the O
grain O
, O
and O
the O
maternal O
and O
filial O
tissue O
in O
the O
grain O
. O

association O
between O
nonsynonymous O
mutation O
of O
starch O
synthase O
iia O
and O
starch O
quality O
in O
rice B-Plant
( O
oryza B-Plant
sativa I-Plant
) O
. O

starch O
quality O
be O
one O
of O
the O
most O
important O
agronomic O
trait O
in O
asian B-Plant
rice I-Plant
, O
oryza B-Plant
sativa I-Plant
. O

to O
search O
for O
the O
variation O
in O
ssiia O
that O
be O
responsible O
for O
starch O
quality O
variation O
in O
rice B-Plant
, O
sequence O
the O
ssiia O
exon O
8 O
region O
and O
measure O
starch O
quality O
as O
starch O
disintegration O
in O
alkali O
for O
289 O
accession O
of O
cultivate O
rice B-Plant
and O
57 O
accession O
of O
wild O
ancestor O
, O
oryza B-Plant
rufipogon I-Plant
. O

variation O
in O
ssiia O
enzyme O
activity O
be O
associate O
with O
the O
cohesiveness O
of O
rice B-Plant
grain O
when O
cook O
, O
and O
finding O
be O
consistent O
with O
selection O
for O
more O
cohesive O
grain O
during O
the O
domestication O
of O
tropical O
japonica B-Plant
rice I-Plant
. O

dissection O
of O
the O
phytohormonal O
regulation O
of O
trichome O
formation O
and O
biosynthesis O
of O
the O
antimalarial O
compound O
artemisinin O
in O
artemisia B-Plant
annua I-Plant
B-Plant O
. O

biosynthesis O
of O
the O
sesquiterpene O
lactone O
and O
potent O
antimalarial O
drug O
artemisinin O
occur O
in O
glandular O
trichome O
of O
artemisia B-Plant
annua I-Plant
B-Plant O
and O
be O
subject O
to O
a O
strict O
network O
of O
developmental O
and O
other O
regulatory O
cue O
. O

the O
effect O
of O
three O
hormone O
, O
jasmonate O
, O
gibberellin O
and O
cytokinin O
, O
be O
study O
at O
the O
structural O
and O
molecular O
level O
in O
two O
different O
a. B-Plant
annua I-Plant
chemotype O
by O
microscopic O
analysis O
of O
gland O
development O
, O
and O
by O
targeted O
metabolite O
and O
transcript O
profiling O
. O

tfar1 O
be O
potentially O
involve O
in O
cuticular O
wax O
formation O
during O
glandular O
trichome O
expansion O
in O
leaf O
and O
flower O
of O
a. B-Plant
annua I-Plant
B-Plant O
. O

aerenchyma O
formation O
in O
the O
rice B-Plant
stem O
and O
promotion O
by O
h2o2 O
. O

in O
rice B-Plant
( O
oryza B-Plant
sativa I-Plant
) O
, O
aerenchyma O
develop O
by O
cell O
death O
and O
lysis O
, O
which O
be O
poorly O
understand O
at O
the O
cellular O
level O
. O

aerenchyma O
formation O
be O
study O
in O
rice B-Plant
stem O
by O
light O
microscopy O
. O

aerenchyma O
develop O
constitutively O
in O
all O
internode O
of O
the O
deep O
- O
water B-Plant
rice I-Plant
variety O
pin O
gaew O
56 O
, O
but O
be O
absent O
from O
the O
node O
. O

constitutive O
aerenchyma O
formation O
be O
also O
observe O
in O
two O
lowland B-Plant
rice I-Plant
variety O
, O
albeit O
to O
a O
less O
degree O
. O

cryptogein O
, O
a O
fungal O
elicitor O
, O
remodel O
the O
phenylpropanoid O
metabolism O
of O
tobacco B-Plant
cell O
suspension O
culture O
in O
a O
calcium O
- O
dependent O
manner O
. O

to O
understand O
these O
relationship O
better O
, O
challenge O
tobacco B-Plant
by-2 O
cell O
with O
cryptogein O
and O
evaluate O
how O
calcium O
transient O
( O
monitor O
through O
the O
calcium O
sensor O
aequorin O
) O
impact O
( O
1 O
) O
transcript O
level O
of O
phenylpropanoid O
gene O
( O
assess O
by O
rt O
- O
qpcr O
) O
; O
and O
( O
2 O
) O
derive O
- O
phenolic O
compound O
( O
analyse O
by O
mass O
spectrometry O
) O
. O

investigate O
the O
response O
of O
g(m O
) O
to O
change O
in O
co2 O
in O
two O
arabidopsis O
genotype O
( O
include O
a O
mutant O
with O
open O
stoma O
, O
ost1 O
) O
, O
tobacco B-Plant
and O
wheat B-Plant
. O

osedr1 O
negatively O
regulate O
rice B-Plant
bacterial O
resistance O
via O
activation O
of O
ethylene O
biosynthesis O
. O

rice B-Plant
osedr1 O
be O
a O
sequence O
ortholog O
of O
arabidopsis O
edr1 O
. O

show O
here O
that O
osedr1-suppress O
/ O
knockout O
( O
ko O
) O
B-Plant O
, O
which O
develop O
spontaneous O
lesion O
on O
the O
leaf O
, O
have O
enhance O
resistance O
to O
xanthomonas O
oryzae O
pv. O
oryzae O
( O
xoo O
) O
cause O
bacterial O
blight B-Plant
disease O
. O

these O
result O
suggest O
that O
ethylene O
be O
a O
negative O
signalling O
molecule O
in O
rice B-Plant
bacterial O
resistance O
. O

in O
the O
rice B-Plant
- O
xoo O
interaction O
, O
osedr1 O
transcriptionally O
promote O
the O
synthesis O
of O
ethylene O
that O
, O
in O
turn O
, O
suppress O
sa- O
and O
ja O
- O
associate O
defence O
signalling O
. O

role O
of O
lupeol O
synthase O
in O
lotus B-Plant
japonicus I-Plant
nodule O
formation O
. O

here O
, O
investigate O
the O
role O
of O
lupeol O
synthase O
, O
encode O
by O
osc3 O
, O
and O
product O
, O
lupeol O
, O
in O
develop O
root O
and O
nodule O
of O
the O
model O
legume O
lotus B-Plant
japonicus I-Plant
. O

functional O
analysis O
, O
in O
which O
transgenic O
l. B-Plant
japonicus I-Plant
root O
silence O
for O
osc3 O
be O
generate O
, O
be O
perform O
. O

the O
synthesis O
of O
lupeol O
in O
l. B-Plant
japonicus I-Plant
root O
and O
nodule O
can O
be O
solely O
attribute O
to O
osc3 O
. O

ginger B-Plant
is O
one O
spice O
that O
i O
recommend O
keeping O
on O
hand O
in O
your O
kitchen O
at O
all O
times O
. O

not O
only O
is O
it O
a O
wonderful O
addition O
to O
your O
cooking O
( O
especially O
paired O
with O
garlic B-Plant
) O
but O
it O
also O
has O
enough O
medicinal O
properties O
to O
fill O
several O
books O
. O

ginger B-Plant
is O
best O
known O
for O
its O
antinausea O
effects O
but O
also O
has O
broad O
- O
spectrum O
antibacterial O
, O
antiviral O
, O
antioxidant O
, O
and O
anti O
- O
parasitic O
properties O
, O
to O
name O
just O
several O
of O
its O
more O
than O
40 O
scientifically O
confirmed O
pharmacological O
actions O
. O

the O
pain O
- O
relieving O
potential O
of O
ginger B-Plant
appears O
to O
be O
far O
- O
reaching O
. O

along O
with O
help O
for O
muscle O
and O
joint O
pain O
, O
ginger B-Plant
has O
been O
found O
to O
reduce O
the O
severity O
of O
migraine O
headaches O
as O
well O
as O
the O
migraine O
medication O
sumatriptan O
96 O
with O
fewer O
side O
effects.4 O

ginger B-Plant
also O
shows O
promise O
for O
fighting O
cancer O
, O
diabetes O
, O
non O
- O
alcoholic O
fatty O
liver O
disease O
, O
asthma O
, O
bacterial O
and O
fungal O
infections O
, O
and O
it O
is O
one O
of O
the O
best O
natural O
remedies O
available O
for O
motion O
sickness O
or O
nausea O
( O
from O
pregnancy O
or O
chemotherapy O
, O
for O
example O
) O
. O

taking O
one O
gram O
of O
ginger B-Plant
daily O
may O
help O
reduce O
nausea O
and O
vomiting O
in O
pregnant O
women O
, O
or O
those O
with O
migraines O
and O
ginger B-Plant
has O
been O
shown O
to O
work O
better O
than O
a O
placebo O
in O
relieving O
morning O
sickness O
. O

eating O
a O
clove O
or O
two O
of O
fresh O
garlic B-Plant
a O
day O
may O
indeed O
keep O
the O
doctor O
away O
, O
in O
part O
because O
it O
has O
immune O
- O
boosting O
, O
antibacterial O
, O
antiviral O
, O
and O
anti O
- O
fungal O
effects O
. O

many O
of O
garlic B-Plant
's O
therapeutic O
effects O
are O
derived O
from O
its O
sulfur O
- O
containing O
compounds O
, O
such O
as O
allicin O
, O
which O
are O
also O
what O
give O
it O
its O
characteristic O
smell O
. O

in O
general O
, O
garlic B-Plant
's O
benefits O
fall O
into O
four O
main O
categories O
: O
peppermint B-Plant
offers O
benefits O
to O
the O
respiratory O
system O
, O
including O
for O
coughs O
, O
colds O
, O
asthma O
, O
allergies O
, O
and O
tuberculosis O
. O

in O
terms O
of O
digestive O
health O
, O
peppermint B-Plant
oil O
capsules O
have O
been O
described O
as O
the O
drug O
of O
first O
choice O
in O
ibs O
patients,7 O
and O
peppermint B-Plant
oil O
is O
an O
effective O
alternative O
to O
drugs O
like O
buscopan O
for O
reducing O
colonic O
spasms.8 O

try O
peppermint B-Plant
oil O
or O
leaves O
added O
to O
tea B-Plant
for O
gas O
relief O
. O

inhaling O
the O
peppermint B-Plant
aroma O
may O
offer O
memory O
enhancement O
and O
stress O
relief O
, O
and O
peppermint B-Plant
oil O
acts O
as O
an O
expectorant O
and O
decongestant O
, O
and O
may O
help O
clear O
your O
respiratory O
tract O
. O

lavender B-Plant
oil O
has O
a O
chemically O
complex O
structure O
with O
over O
150 O
active O
constituents.9 O

this O
oil O
is O
rich O
in O
esters O
, O
which O
are O
aromatic O
molecules O
with O
antispasmodic O
( O
suppressing O
spasms O
and O
pain O
) O
, O
calming O
, O
and O
stimulating O
properties O
. O

the O
chief O
botanical O
constituents O
of O
lavender B-Plant
oil O
are O
linalyl O
acetate O
, O
linalool O
( O
a O
non O
- O
toxic O
terpene O
alcohol O
that O
has O
natural O
germicidal O
properties O
) O
, O
terpinen-4-ol O
, O
and O
camphor B-Plant
. O

other O
constituents O
in O
lavender B-Plant
oil O
that O
are O
responsible O
for O
its O
antibacterial O
, O
antiviral O
, O
and O
anti O
- O
inflammatory O
properties O
include O
cis O
- O
ocimene O
, O
lavandulyl O
acetate O
, O
1,8-cineole O
, O
limonene O
, O
and O
geraniol O
. O

lavender B-Plant
essential O
oil O
useslavender O
oil O
is O
known O
for O
its O
calming O
and O
relaxing O
properties O
, O
and O
has O
been O
used O
aromatherapeutically O
for O
alleviating O
insomnia O
, O
anxiety O
, O
depression O
, O
restlessness O
, O
dental O
anxiety O
, O
and O
stress O
. O

thyme B-Plant
is O
a O
fragrant O
herb O
that O
makes O
a O
wonderful O
addition O
to O
your O
cooking O
, O
in O
part O
because O
it O
is O
rich O
in O
antioxidants O
. O

thyme B-Plant
contains O
health O
- O
boosting O
flavonoids O
including O
apigenin O
, O
naringenin O
, O
luteolin O
, O
and O
thymonin O
, O
and O
has O
been O
shown O
to O
protect O
and O
increase O
the O
percentage O
of O
healthy O
fats O
found O
in O
cell O
membranes O
. O

thyme B-Plant
is O
also O
nutrient O
dense O
, O
containing O
vitamin O
c O
, O
vitamin O
a O
, O
iron O
, O
manganese O
, O
copper O
, O
and O
dietary O
fiber O
. O

chamomile B-Plant
is O
most O
popular O
in O
tea B-Plant
form O
for O
use O
to O
calm O
upset O
stomach O
and O
help O
support O
restful O
sleep O
. O

germany O
's O
commission O
e O
( O
a O
government O
organization O
) O
has O
even O
approved O
the O
use O
of O
chamomile B-Plant
for O
reducing O
swelling O
on O
your O
skin O
and O
fighting O
bacteria O
. O

chamomile B-Plant
is O
a O
powerful O
anti O
- O
inflammatory O
that O
also O
has O
antibacterial O
, O
anti O
- O
spasmodic O
, O
anti O
- O
allergenic O
, O
muscle O
relaxant O
, O
and O
sedative O
properties O
. O

the O
soothing O
mentholated O
flavor O
that O
mint B-Plant
adds O
to O
a O
cough O
syrup O
ca O
n't O
be O
beat O
. O

i O
add O
mint B-Plant
to O
almost O
all O
my O
herbal O
syrups O
. O

not O
as O
commonly O
known O
as O
a O
medicinal O
herb O
, O
hyssop B-Plant
is O
usually O
grown O
as O
a O
landscape O
addition O
. O

hyssop B-Plant
is O
at O
the O
top O
of O
the O
list O
for O
useful O
cough O
syrup O
herbs O
. O

at O
the O
same O
time O
, O
it O
has O
been O
my O
experience O
that O
hyssop B-Plant
is O
an O
herb O
that O
is O
best O
harvested O
and O
used O
right O
away O
, O
instead O
of O
purchased O
dried O
. O

in O
fact O
, O
i O
use O
the O
tea B-Plant
for O
that O
post O
nasal O
issue O
that O
we O
sometimes O
get O
from O
winter O
allergies O
. O

often O
viewed O
as O
just O
a O
tree O
, O
white B-Plant
pine I-Plant
is O
actually O
an O
extremely O
useful O
B-Plant O
to O
get O
to O
know O
. O

yarrow B-Plant
once O
again O
delivers O
. O

sage B-Plant
is O
often O
referred O
to O
as O
the O
throat O
herb O
, O
with O
good O
reason O
. O

i O
have O
found O
that O
sage B-Plant
is O
a O
bit O
too O
medicinal O
tasting O
on O
it O
's O
own O
, O
especially O
for O
the O
younger O
ones O
. O

i O
like O
to O
mix O
sage B-Plant
lightly O
into O
my O
basic O
herb O
mix O
before O
making O
the O
syrup O
. O

mullein B-Plant
once O
again O
makes O
the O
list O
as O
an O
important O
herb O
to O
have O
in O
your O
herbal O
medicine O
chest O
. O

be O
sure O
to O
consider O
mullein B-Plant
in O
your O
cough O
syrup O
mix O
. O

ginger B-Plant
is O
a O
wonderful O
addition O
to O
your O
herbal O
mix O
. O

borage B-Plant
is O
a O
good O
ingredient O
to O
include O
in O
a O
cream O
for O
dry O
or O
sensitive O
skin O
. O

use O
borage B-Plant
for O
regulation O
of O
metabolism O
and O
the O
hormonal O
system O
. O

another O
gentle O
herb O
, O
chamomile B-Plant
is O
useful O
for O
any O
recipe O
that O
is O
going O
to O
be O
soothing O
and O
calming O
the O
skin O
. O

perfect O
for O
babies O
and O
the O
thin O
skin O
of O
the O
elderly O
, O
chamomile B-Plant
is O
lightly O
scented O
and O
blends O
well O
with O
all O
other O
herbs O
. O

use O
chamomile B-Plant
if O
you O
are O
specifically O
trying O
to O
soften O
the O
skin O
, O
when O
there O
is O
redness O
from O
chafing O
and O
irritation O
. O

often O
misunderstood O
, O
comfrey B-Plant
deserves O
a O
place O
in O
this O
list O
of O
herbs O
for O
salves O
. O

comfrey B-Plant
heals O
the O
skin O
, O
a O
fact O
that O
no O
one O
denies O
. O

the O
problem O
lies O
in O
that O
comfrey B-Plant
heals O
so O
well O
, O
it O
can O
heal O
over O
an O
infected O
area O
, O
trapping O
the O
infection O
under O
healthy O
skin O
. O

use O
comfrey B-Plant
in O
any O
cream O
that O
you O
wish O
to O
use O
on O
healing O
skin O
; O
skin O
that O
has O
no O
sign O
of O
infection O
present O
, O
and O
needs O
only O
to O
heal O
. O

you O
can O
also O
use O
comfrey B-Plant
cream O
on O
skin O
that O
is O
irritated O
check O
out O
some O
more O
uses O
with O
comfrey B-Plant
: O
dandelion B-Plant
is O
amazing O
as O
an O
emollient O
herb O
, O
perfect O
for O
the O
driest O
of O
skin O
. O

dandelion B-Plant
has O
so O
many O
uses O
, O
it O
is O
hard O
to O
narrow O
down O
just O
the O
top O
few O
. O

used O
for O
any O
type O
of O
skin O
, O
elderflowers B-Plant
and O
especially O
nice O
for O
creams O
that O
will O
be O
used O
on O
mature O
skin O
. O

check O
out O
more O
uses O
with O
elderflowers B-Plant
: O
once O
again O
, O
fennel B-Plant
surprises O
many O
of O
us O
. O

not O
always O
used O
to O
the O
fullest O
potential O
, O
fennel B-Plant
is O
great O
for O
a O
cleansing O
cream O
. O

check O
out O
more O
uses O
with O
fennel B-Plant
: O
lavender B-Plant
is O
a O
gentle O
herb O
, O
great O
for O
any O
type O
of O
skin O
. O

i O
prefer O
using O
lavender B-Plant
as O
a O
common O
herb O
in O
almost O
all O
my O
creams O
. O

check O
out O
more O
uses O
with O
lavender B-Plant
: O
burdock B-Plant
makes O
the O
list O
to O
help O
soothe O
and O
improve O
the O
scalp O
. O

buy O
burdock B-Plant
root O
at O
you O
local O
asian O
market O
. O

it O
is O
sold O
as O
gobo B-Plant
root I-Plant
and O
is O
quite O
inexpensive O
. O

parsley B-Plant
will O
add O
a O
refreshing O
aspect O
to O
your O
hair O
rinses O
. O

dried O
parsley B-Plant
does O
n't O
add O
as O
much O
kick O
, O
however O
, O
if O
that O
's O
all O
you O
have O
available O
, O
be O
sure O
to O
add O
it O
. O

rosemary B-Plant
is O
a O
definite O
scalp O
stimulator O
. O

traditionally O
, O
rosemary B-Plant
has O
been O
known O
to O
help O
stimulate O
the O
memory O
as O
well O
, O
so O
think O
of O
it O
as O
food O
for O
the O
head O
- O
both O
inside O
and O
out O
. O

the O
scent O
of O
rosemary B-Plant
is O
enjoyed O
by O
adults O
, O
especially O
men O
. O

another O
resinous O
herb O
, O
thyme B-Plant
is O
not O
only O
fragrant O
and O
pleasing O
to O
the O
nose O
, O
it O
also O
makes O
a O
great O
herb O
to O
create O
a O
dandruff O
hair O
rinse O
. O

if O
you O
want O
to O
experiment O
with O
scents O
, O
try O
lemon B-Plant
thyme I-Plant
and O
rosemary B-Plant
, O
lemon B-Plant
peel O
and O
thyme B-Plant
, O
rosemary B-Plant
and O
thyme B-Plant
and O
orange B-Plant
peel O
.. O

all O
make O
wonderful O
hair O
rinses O
that O
can O
be O
dried O
directly O
on O
the O
scalp O
and O
help O
a O
scalp O
recover O
from O
dandruff O
. O

burdock B-Plant
root O
is O
a O
must O
have O
for O
dry O
hair O
treatment O
. O

burdock B-Plant
root O
is O
found O
at O
many O
herbal O
shops O
, O
and O
remember O
that O
it O
is O
also O
sold O
in O
asian O
markets O
, O
as O
gobo B-Plant
root I-Plant
. O

if O
you O
think O
about O
it O
, O
comfrey B-Plant
makes O
sense O
on O
this O
list O
. O

remember O
that O
comfrey B-Plant
grows O
very O
fast O
, O
and O
can O
be O
harvested O
numerous O
times O
throughout O
the O
growing O
season O
, O
so O
save O
plenty O
, O
and O
use O
it O
in O
your O
daily O
hair O
rinse O
. O

i O
find O
that O
i O
have O
much O
less O
hair O
breakage O
when O
including O
comfrey B-Plant
in O
my O
herbal O
hair O
rinse O
recipe O
. O

the O
sweet O
fragrance O
of O
the O
elderflower B-Plant
is O
much O
more O
than O
a O
pretty O
scent O
. O

freeze O
elderflowers B-Plant
in O
the O
early O
spring O
, O
to O
use O
throughout O
the O
rest O
of O
the O
year O
for O
this O
remedy O
, O
or O
juice O
and O
freeze O
the O
juice O
in O
ice O
cube O
trays O
. O

mallow B-Plant
's O
soothing O
, O
moistening O
properties O
make O
it O
an O
obvious O
choice O
for O
dry O
hair O
. O

we O
like O
to O
use O
lavender B-Plant
blooms O
of O
course O
, O
but O
the O
leaves O
and O
stems O
work O
well O
here O
also O
. O

for O
a O
naturally O
soothing O
boost O
to O
go O
along O
with O
the O
lavender B-Plant
, O
try O
whisking O
1/4 O
cup O
of O
dry O
oats B-Plant
in O
a O
coffee B-Plant
grinder O
, O
until O
powdery O
and O
add O
that O
to O
the O
lavender B-Plant
in O
the O
water O
. O

sage B-Plant
is O
wonderfully O
soothing O
for O
an O
herbal O
foot O
bath O
. O

sage B-Plant
makes O
a O
great O
base O
for O
your O
herbal O
foot O
bath O
for O
feet O
that O
have O
an O
odor O
due O
to O
excessive O
sweating O
. O

adding O
sage B-Plant
and O
cider O
vinegar O
to O
the O
footbath O
is O
a O
great O
way O
to O
combat O
this O
. O

sweet B-Plant
marjoram I-Plant
is O
perfect O
for O
a O
soothing O
foot O
bath O
. O

add O
some O
sea O
salt O
to O
the O
water O
and O
sprinkle O
in O
your O
sweet B-Plant
marjoram I-Plant
. O

for O
a O
herb O
with O
such O
a O
rich O
history O
in O
herbal O
healing O
, O
lovage B-Plant
certainly O
needs O
some O
more O
kudos O
. O

used O
in O
soothing O
foot O
bath O
recipes O
, O
lovage B-Plant
is O
an O
impressive O
addition O
. O

fabulous O
and O
huge O
, O
russian B-Plant
sage I-Plant
is O
a O
stunning O
herb O
for O
your O
landscape O
. O

the O
lavender B-Plant
- O
blue O
flowers O
tower O
over O
the O
softly O
silvered O
foliage O
. O

fennel B-Plant
is O
a O
fantastic O
B-Plant O
, O
with O
a O
soft O
green O
color O
. O

useful O
for O
cooking O
, O
of O
course O
, O
many O
people O
never O
realize O
that O
fennel B-Plant
can O
grow O
to O
magnificent O
proportions O
. O

grow O
it O
for O
blocking O
an O
unsightly O
area O
in O
your O
yard O
, O
fennel B-Plant
grows O
thickly O
and O
is O
very O
forgiving O
. O

fennel B-Plant
also O
makes O
a O
temporary O
screen O
against O
neighbors O
who O
are O
a O
bit O
too O
curious O
. O

borage B-Plant
is O
much O
more O
than O
a O
big O
, O
fuzzy O
herb O
B-Plant O
. O

borage B-Plant
is O
delicious O
and O
fast O
growing O
. O

for O
more O
interesting O
ideas O
for O
borage B-Plant
, O
check O
out O
: O
thyme B-Plant
loves O
the O
books O
that O
a O
wall O
provides O
, O
making O
them O
a O
great O
filler O
for O
even O
the O
most O
rugged O
rocky O
location O
. O

if O
you O
love O
rosemary B-Plant
, O
try O
tucking O
a O
prostrate O
( O
trailing O
) O
variety O
into O
your O
rock O
wall O
herb O
garden O
. O

although O
many O
of O
us O
do O
n't O
live O
in O
the O
mediterranean O
environment O
that O
rosemary B-Plant
requires O
to O
be O
a O
perennial O
, O
with O
the O
protection O
that O
a O
rock O
wall O
provides O
, O
it O
can O
add O
at O
least O
a O
full O
zone O
to O
the O
range O
of O
temperatures O
that O
help O
rosemary B-Plant
survive O
the O
winter O
. O

savory B-Plant
is O
another O
herb O
that O
should O
be O
added O
to O
your O
rock O
wall O
herb O
garden O
. O

use O
winter B-Plant
savory I-Plant
and O
although O
it O
is O
said O
to O
be O
hardy O
only O
to O
zone O
6 O
, O
tucked O
into O
a O
wall O
for O
protection O
might O
give O
it O
the O
extra O
help O
it O
needs O
to O
live O
in O
colder O
zones O
. O

it O
may O
be O
surprising O
to O
note O
that O
sage B-Plant
likes O
to O
grow O
in O
a O
rock O
wall O
garden O
, O
but O
if O
you O
consider O
its O
needs O
: O
bright O
sun O
, O
good O
drainage O
and O
plenty O
of O
room O
. O

of O
course O
, O
lavender B-Plant
will O
fit O
in O
well O
with O
a O
walled O
garden O
. O

lavender B-Plant
loves O
full O
sun O
and O
not O
so O
fertile O
soil O
, O
so O
the O
requirements O
fall O
well O
within O
what O
a O
wall O
herb O
garden O
can O
offer O
. O

lavender B-Plant
especially O
loves O
the O
warmth O
that O
a O
rock O
wall O
will O
provide O
, O
so O
again O
you O
may O
find O
that O
it O
is O
the O
perfect O
place O
to O
grow O
an O
otherwise O
fussy O
B-Plant O
. O

B-Plant O
lavender B-Plant
along O
the O
top O
of O
the O
rock O
wall O
for O
a O
stunning O
look O
. O

hyssop B-Plant
will O
love O
being O
B-Planted O
on O
top O
of O
, O
or O
in O
front O
of O
a O
rock O
wall O
. O

chamomile B-Plant
is O
especially O
suited O
for O
a O
rock O
wall O
garden O
. O

it O
's O
light O
, O
and O
airy O
growth O
habit O
will O
look O
attractive O
against O
the O
solid O
background O
, O
and O
if O
your O
rock O
wall O
is O
tall O
enough O
, O
this O
will O
raise O
the O
chamomile B-Plant
up O
to O
an O
easier O
to O
harvest O
height O
. O

remember O
, O
houseleeks O
can O
be O
used O
for O
soothing O
burns O
, O
just O
like O
aloe B-Plant
. O

if O
you O
have O
ever O
tasted O
the O
richness O
of O
basil B-Plant
, O
it O
will O
come O
as O
no O
surprise O
that O
basil B-Plant
enhances O
the O
flavor O
of O
your O
favorite O
tomato B-Plant
as O
it O
grows O
. O

this O
companion O
is O
not O
only O
easy O
to O
tuck O
in O
alongside O
your O
favorite O
tomato B-Plant
B-Plant O
, O
it O
also O
makes O
a O
lovely O
complimentary O
B-Planting O
. O

borage B-Plant
B-Plants O
growing O
at O
park O
borage B-Plant
offers O
a O
lovely O
companion O
B-Planting O
for O
tomatoes B-Plant
. O

the O
purple O
flowers O
and O
fuzzy O
, O
silvery B-Plant
green O
leaves O
make O
a O
super O
neighbor O
for O
the O
lush O
foliage O
for O
the O
tomato B-Plant
B-Plants O
. O

add O
to O
that O
the O
improvement O
to O
the O
tomato B-Plant
's O
taste O
and O
you O
have O
a O
sure O
- O
fire O
winner O
. O

green O
chives B-Plant
with O
pink O
flowers O
another O
fabulous O
companion O
herb O
for O
tomatoes B-Plant
, O
chives B-Plant
not O
only O
help O
the O
tomato B-Plant
's O
taste O
, O
they O
season O
tomato B-Plant
dishes O
just O
wonderfully O
. O

since O
chives B-Plant
are O
perennial O
, O
think O
of O
them O
as O
the O
backdrop O
for O
your O
tomato B-Plant
garden O
. O

close O
- O
up O
of O
orange B-Plant
marigold I-Plant
blooming O
outdoors O
everyone O
recognizes O
the O
brightly O
colored O
blossoms O
of O
the O
marigold B-Plant
. O

from O
rich O
reds O
and O
bronzes O
to O
bright O
yellows O
, O
marigolds B-Plant
offer O
a O
pop O
of O
color O
and O
insect O
control O
to O
any O
garden O
. O

did O
you O
know O
that O
they O
are O
said O
to O
improve O
tomato B-Plant
flavor O
as O
well O
? O
leaves O
on O
a O
mint B-Plant
B-Plant O
( O
lamiaceae B-Plant
) O
, O
close O
- O
up O
mint B-Plant
makes O
a O
wonderful O
companion O
to O
your O
tomatoes B-Plant
. O

if O
B-Planting O
tomatoes B-Plant
in O
a O
container O
garden O
, O
this O
is O
not O
a O
problem O
and O
you O
can O
B-Plant O
your O
mint B-Plant
right O
under O
the O
tomato B-Plant
vines O
. O

close O
- O
up O
of O
sage B-Plant
growing O
in O
garden O
sage B-Plant
is O
simply O
delicious O
! O
it O
offers O
the O
added O
benefit O
of O
being O
a O
good O
companion O
B-Plant O
for O
tomato B-Plant
growers O
. O

with O
all O
of O
the O
colors O
and O
sizes O
that O
sage B-Plant
comes O
in O
, O
you O
will O
be O
sure O
to O
find O
the O
unique O
look O
you O
want O
for O
the O
garden O
. O

fresh O
thyme B-Plant
herb O
B-Plants O
growing O
in O
a O
herb O
garden O
thyme B-Plant
is O
so O
delicate O
, O
it O
is O
amazing O
how O
much O
scent O
and O
taste O
there O
is O
in O
each O
leaf O
. O

thyme B-Plant
is O
also O
wonderful O
for O
improving O
the O
taste O
of O
tomatoes B-Plant
. O

try O
adding O
a O
creeping B-Plant
thyme I-Plant
to O
the O
front O
edge O
of O
your O
container O
garden O
. O

while O
it O
spills O
over O
the O
side O
in O
a O
lovely O
wave O
of O
tiny O
flowers O
and O
leaves O
, O
know O
that O
it O
is O
also O
helping O
your O
tomatoes B-Plant
taste O
the O
very O
best O
. O

catmint B-Plant
- O
catnip B-Plant
B-Plant- O
catswort B-Plant
- O
nepeta O
cataria I-Plant
you O
may O
be O
surprised O
to O
know O
that O
catnip B-Plant
makes O
a O
good O
companion O
B-Plant O
for O
tomatoes B-Plant
. O

the O
truth O
is O
, O
it O
makes O
a O
great O
B-Plant O
for O
beneficial O
insects O
that O
help O
protect O
your O
tomatoes B-Plant
. O

try O
keeping O
this O
member O
of O
the O
mint B-Plant
family I-Plant
in O
check O
by O
B-Planting O
in O
a O
pot O
. O

anise B-Plant
is O
another O
herb O
that O
is O
an O
excellent O
companion O
for O
tomatoes B-Plant
. O

it O
attracts O
and O
feeds O
many O
beneficial O
insects O
that O
will O
protect O
your O
tomatoes B-Plant
. O

fresh O
organic O
dill B-Plant
on O
new O
wood O
surface O
dill B-Plant
is O
yet O
another O
wonderful O
herb O
for O
a O
beneficial O
insect O
's O
home O
near O
your O
tomatoes B-Plant
. O

do O
not O
B-Plant O
dill B-Plant
right O
next O
to O
the O
vines B-Plant
, O
however O
. O

neither O
the O
tomato B-Plant
nor O
the O
dill B-Plant
will O
grow O
well O
. O

leave O
dill B-Plant
's O
frilly O
, O
light O
structure O
to O
grow O
in O
your O
beneficial O
insect O
garden O
, O
right O
near O
the O
tomatoes B-Plant
and O
you O
will O
be O
inviting O
the O
very O
insects O
that O
will O
help O
protect O
your O
precious O
fruits O
. O

lemon B-Plant
verbena I-Plant
( O
aloysia B-Plant
triphylla I-Plant
) O
has O
a O
powerfully O
strong O
lemon B-Plant
scent O
. O

it O
is O
fantastic O
to O
grow O
for O
the O
' O
clean O
lemon B-Plant
' O
fragrance O
that O
it O
has O
. O

lemon B-Plant
verbena I-Plant
is O
not O
just O
for O
room O
cleaning O
and O
freshening O
. O

its O
calming O
lemon B-Plant
flavor O
holds O
up O
very O
well O
when O
dried O
, O
so O
it O
stands O
up O
nicely O
in O
a O
tea B-Plant
... O

a O
cup O
of O
lemon B-Plant
balm O
tea B-Plant
perhaps O
the O
most O
well O
known O
of O
the O
lemon B-Plant
- O
scented O
herbs O
, O
lemon B-Plant
balm O
( O
melissa B-Plant
officinalis I-Plant
) O
is O
a O
juicy O
, O
lemony O
herb O
that O
is O
in O
the O
mint B-Plant
family I-Plant
. O

as O
is O
common O
with O
most O
mints O
, O
lemon B-Plant
balm O
will O
grow O
like O
crazy O
and O
can O
take O
over O
a O
yard O
if O
it O
is O
not O
kept O
contained O
. O

luckily O
, O
it O
is O
as O
easy O
as O
any O
mint B-Plant
to O
grow O
, O
so O
place O
it O
in O
a O
pot O
and O
then O
B-Plant O
that O
into O
the O
ground O
. O

lemon B-Plant
balm O
can O
be O
cut O
numerous O
times O
during O
the O
season O
. O

a O
pile O
of O
lemongrass B-Plant
( O
cymbopogon O
) O
lemongrass B-Plant
( O
cymbopogon B-Plant
citratus I-Plant
) O
is O
an O
unusual O
herb O
that O
does O
n't O
get O
as O
much O
attention O
as O
it O
deserves O
in O
north O
america O
. O

this O
is O
too O
bad O
because O
lemongrass B-Plant
is O
certainly O
delicious O
. O

to O
use O
lemongrass B-Plant
over O
the O
winter O
, O
freeze O
the O
entire O
thing O
, O
and O
use O
it O
as O
you O
would O
fresh O
, O
as O
needed O
. O

a O
close O
- O
up O
of O
lemon B-Plant
basil I-Plant
lemon B-Plant
basil I-Plant
( O
ocimum B-Plant
americanum I-Plant
) O
is O
lovely O
, O
lemon B-Plant
- O
scented O
basil B-Plant
that O
is O
an O
exciting O
flavor O
to O
explore O
. O

if O
you O
love O
basil B-Plant
, O
then O
you O
know O
that O
lemon B-Plant
is O
a O
wonderful O
partner O
to O
this O
flavorful O
herb O
. O

why O
not O
grow O
a O
type O
of O
basil B-Plant
that O
combines O
both O
flavors O
in O
one O
? O
try O
substituting O
lemon B-Plant
basil I-Plant
for O
any O
recipe O
that O
calls O
for O
sweet B-Plant
basil I-Plant
. O

a O
cluster O
of O
lemon B-Plant
thyme I-Plant
seedlings O
TRUE O
to O
its O
name O
, O
lemon B-Plant
thyme I-Plant
( O
thymus B-Plant
x I-Plant
citriodorus I-Plant
' O
aureus O
' O
) O
has O
all O
the O
resinous O
flavor O
of O
thyme B-Plant
that O
we O
love O
, O
yet O
it O
also O
has O
the O
genuine O
citrus O
scent O
of O
lemon B-Plant
in O
every O
leaf O
. O

lemon B-Plant
thyme I-Plant
also O
has O
a O
pretty O
variegated O
leaf O
that O
adds O
interest O
to O
your O
borders O
and O
container O
herb O
gardens O
. O

the O
pronounced O
and O
cheerful O
lemon B-Plant
flavor O
adds O
a O
unique O
touch O
to O
your O
summer O
dishes O
, O
and O
wait O
until O
you O
try O
it O
on O
grilled O
fish O
and O
asparagus O
. O

what O
would O
a O
list O
of O
hardy O
herbs O
be O
without O
mint B-Plant
? O
no O
matter O
how O
high O
of O
an O
altitude O
, O
or O
harsh O
of O
weather O
, O
you O
will O
never O
be O
rid O
of O
unwanted O
mint B-Plant
. O

then O
, O
by O
the O
end O
of O
the O
season O
, O
lift O
your O
mint B-Plant
pot O
up O
and O
out O
of O
the O
ground O
, O
roots O
and O
all O
. O

fennel B-Plant
is O
on O
the O
list O
of O
hardy O
herbs O
for O
tough O
gardens O
. O

fennel B-Plant
is O
not O
only O
delicious O
; O
it O
makes O
a O
lovely O
B-Plant O
to O
see O
growing O
in O
the O
herb O
garden O
. O

for O
a O
pretty O
punch O
of O
color O
, O
grow O
bronze O
fennel B-Plant
and O
enjoy O
the O
unusual O
shade O
of O
deep O
purple O
. O

fennel B-Plant
keeps O
blooming O
, O
despite O
the O
temperatures O
. O

collect O
the O
fennel B-Plant
pollen O
for O
a O
tasty O
culinary O
treat O
. O

some O
fennel B-Plant
grows O
well O
over O
stones O
. O

as O
useful O
as O
sage B-Plant
is O
for O
colds O
and O
flu O
remedies O
, O
it O
just O
makes O
sense O
that O
sage B-Plant
can O
withstand O
rough O
weather O
as O
well O
. O

for O
short O
season O
or O
high O
altitude O
gardeners O
, O
sage B-Plant
is O
a O
colorful O
addition O
to O
sometimes O
less O
than O
fancy O
looking O
herb O
gardens O
. O

you O
can O
grow O
sage B-Plant
in O
nasty O
weather O
, O
but O
do O
n't O
soak O
its O
roots O
. O

if O
you O
live O
in O
an O
area O
of O
cold O
and O
wet O
( O
poor O
you O
) O
, O
grow O
sage B-Plant
in O
pots O
that O
have O
great O
drainage O
. O

cilantro B-Plant
should O
be O
called O
the O
wonder O
herb O
. O

it O
can O
be O
snowing O
like O
crazy O
, O
and O
you O
can O
wander O
through O
the O
garden O
and O
tiny O
cilantro B-Plant
B-Plants O
sprouting O
. O

it O
is O
one O
of O
the O
first O
markers O
of O
spring O
on O
a O
farm O
, O
even O
germinating O
before O
some O
of O
the O
early O
wild O
B-Plants O
like O
catmint B-Plant
and O
dock O
. O

it O
is O
funny O
that O
cilantro B-Plant
likes O
the O
cold O
weather O
so O
much O
when O
it O
is O
such O
a O
cooling O
herb O
for O
spicy O
dishes O
. O

even O
young O
children O
can O
enjoy O
mexican O
food O
with O
some O
cilantro B-Plant
added O
. O

grow O
cilantro B-Plant
in O
a O
pot O
for O
short O
season O
gardeners O
. O

chives B-Plant
are O
the O
perfect O
choice O
for O
difficult O
growing O
areas O
. O

choose O
chives B-Plant
for O
any O
fussy O
conditions O
, O
because O
it O
stays O
where O
you O
put O
it O
, O
growing O
in O
a O
clumping O
habit O
. O

you O
wo O
n't O
suddenly O
find O
chives B-Plant
growing O
in O
your O
lavender B-Plant
unless O
you O
put O
them O
there O
. O

the O
flowers O
are O
lovely O
and O
edible O
; O
you O
can O
cut O
the O
leaves O
again O
and O
again O
( O
freeze O
them O
whole O
and O
snip O
into O
dishes O
all O
winter O
) O
, O
and O
enjoy O
the O
taste O
of O
onion B-Plant
. O

angelica O
: O
herbalists O
recommend O
making O
tea B-Plant
from O
angelica O
leaves O
to O
remedy O
colds O
and O
digestive O
issues O
. O

bee O
balm O
: O
this O
herbaceous O
perennial O
in O
the O
mint B-Plant
family I-Plant
produces O
brightly O
colored O
flowers O
and O
has O
many O
uses O
in O
cooking O
. O

calendula O
( O
pot B-Plant
marigold I-Plant
) O
: O
calendula O
is O
a O
flowering O
annual O
B-Plant O
that O
produces O
colorful O
blooms O
and O
has O
multiple O
medicinal O
uses O
. O

catnip B-Plant
: O
catmint B-Plant
, O
the O
most O
famous O
type O
of O
which O
is O
catnip B-Plant
, O
is O
often O
grown O
for O
its O
beautiful O
ornamental O
properties O
, O
though O
feline O
owners O
may O
have O
additional O
motives O
. O

chamomile B-Plant
: O
this O
delicate O
but O
surprisingly O
tough O
B-Plant O
makes O
a O
popular O
and O
delicious O
tea B-Plant
, O
made O
from O
both O
its O
leaves O
and O
stems O
. O

chervil B-Plant
: O
a O
delicate O
spring O
herb O
that O
's O
great O
in O
salads O
and O
particularly O
delicious O
in O
omelets O
and O
other O
egg O
dishes O
, O
chervil B-Plant
is O
one O
of O
the O
four O
key O
herbs O
to O
the O
french O
blend O
called O
fines O
herbes O
( O
the O
others O
are O
parsley B-Plant
, O
tarragon B-Plant
, O
and O
chives B-Plant
) O
. O

chives B-Plant
: O
chives B-Plant
are O
a O
clumping O
herb O
, O
meaning O
that O
they O
grow O
tightly O
packed O
, O
which O
makes O
them O
a O
great O
choice O
for O
small O
spaces O
. O

the O
mild O
onion B-Plant
flavor O
works O
well O
in O
vinaigrettes O
and O
herb O
butter O
and O
pairs O
nicely O
with O
egg O
dishes O
. O

cilantro B-Plant
/ O
coriander B-Plant
: O
this O
double O
- O
duty O
herb O
can O
be O
eaten O
as O
fresh O
leaves O
( O
cilantro B-Plant
) O
or O
dried O
seeds O
( O
coriander B-Plant
) O
. O

garlic B-Plant
: O
garlic B-Plant
is O
easy O
to O
grow O
and O
easy O
to O
use O
in O
any O
number O
of O
dishes O
from O
nearly O
every O
cuisine O
. O

lovage B-Plant
: O
related O
to O
carrots O
, O
dill B-Plant
, O
and O
caraway B-Plant
, O
lovage B-Plant
is O
used O
in O
many O
european O
and O
mediterranean O
cuisines O
. O

lemon B-Plant
balm O
: O
not O
to O
be O
confused O
with O
its O
close O
cousin O
lemon B-Plant
verbena I-Plant
, O
lemon B-Plant
balm O
is O
thought O
by O
herbalists O
to O
help O
combat O
a O
variety O
of O
woes O
, O
including O
anxiety O
and O
stress O
. O

mint B-Plant
: O
mint B-Plant
is O
a O
hardy O
perennial O
that O
will O
spread O
quickly O
if O
left O
untended O
. O

oregano B-Plant
: O
another O
easy O
- O
to O
- O
grow O
perennial O
, O
oregano B-Plant
is O
a O
popular O
herb O
that O
finds O
a O
home O
in O
numerous O
italian O
, O
mexican O
and O
spanish O
dishes O
. O

parsley B-Plant
: O
a O
ubiquitous O
garnish O
, O
parsley B-Plant
is O
also O
a O
delicious O
fresh O
herb O
that O
incorporates O
beautifully O
with O
many O
dishes O
. O

italian O
flat O
leaf O
parsley B-Plant
is O
a O
little O
sweeter O
than O
the O
curly O
variety O
. O

sweet B-Plant
woodruff I-Plant
: O
a O
perennial O
often O
used O
as O
pretty O
ground O
cover O
, O
due O
to O
its O
clusters O
of O
small O
, O
white O
, O
star O
- O
shaped O
flowers O
, O
sweet B-Plant
woodruff I-Plant
also O
boasts O
both O
medicinal O
and O
culinary O
uses O
. O

thyme B-Plant
: O
this O
woody O
mediterranean O
herb O
is O
associated O
with O
the O
flavors O
of O
the O
region O
: O
garlic B-Plant
, O
olive B-Plant
oil O
, O
and O
tomatoes B-Plant
. O

chamomile B-Plant
is O
notorious O
for O
being O
gentle O
and O
soothing O
. O

chamomile B-Plant
can O
also O
help O
with O
eyes O
that O
are O
tired O
from O
overuse O
. O

the O
part O
of O
fennel B-Plant
used O
in O
this O
application O
is O
the O
seed O
. O

fennel B-Plant
seed O
is O
especially O
good O
for O
inflamed O
eyes O
. O

mallow B-Plant
continues O
to O
be O
a O
useful O
herb O
to O
keep O
. O

using O
it O
as O
a O
decoction O
around O
the O
eyes O
, O
and O
mallow B-Plant
will O
help O
soften O
that O
delicate O
skin O
. O

dab O
it O
on O
with O
a O
piece O
of O
flannel O
or O
cotton B-Plant
ball O
, O
being O
careful O
not O
to O
stretch O
or O
pull O
the O
skin O
. O

mint B-Plant
is O
said O
to O
help O
reduce O
the O
dark O
circles O
under O
the O
eye O
. O

use O
a O
cotton B-Plant
ball O
or O
flannel O
square O
to O
dab O
it O
carefully O
on O
the O
dark O
area O
. O

roses B-Plant
are O
much O
more O
than O
a O
pretty O
face O
. O

use O
only O
your O
own O
roses B-Plant
or O
certified O
organic O
/ O
wild B-Plant
rose I-Plant
petals O
for O
this O
. O

the O
second O
one O
with O
the O
lilac B-Plant
flowers O
is O
, O
i O
think O
, O
a O
lemon B-Plant
verbena I-Plant
. O

closely O
related O
to O
poison B-Plant
hemlock I-Plant
( O
the O
B-Plant O
that O
famously O
killed O
socrates O
) O
, O
water B-Plant
hemlock I-Plant
has O
been O
deemed O
the O
most O
violently O
toxic O
B-Plant O
in O
north O
america O
. O

a O
large O
wildflower O
in O
the O
carrot B-Plant
family I-Plant
, O
water B-Plant
hemlock I-Plant
resembles O
queen O
anne O
92s O
lace O
and O
is O
sometimes O
confused O
with O
edible O
parsnips B-Plant
or O
celery B-Plant
. O

however O
, O
water B-Plant
hemlock I-Plant
is O
infused O
with O
deadly O
cicutoxin O
, O
especially O
in O
its O
roots O
, O
and O
will O
rapidly O
generate O
potentially O
fatal O
symptoms O
in O
anyone O
unlucky O
enough O
to O
eat O
it O
. O

belladonna B-Plant
( O
atropa B-Plant
belladonna I-Plant
) O
showing O
details O
of O
( O
above O
) O
the O
flower O
, O
( O
below O
) O
the O
fruit O
, O
and O
( O
right O
) O
the O
root O
. O

according O
to O
legend O
, O
macbeth O
92s O
soldiers O
poisoned O
the O
invading O
danes O
with O
wine O
made O
from O
the O
sweet O
fruit O
of O
deadly B-Plant
nightshade I-Plant
. O

a O
native O
of O
wooded O
or O
waste O
areas O
in O
central O
and O
southern O
eurasia O
, O
deadly B-Plant
nightshade I-Plant
has O
dull O
green O
leaves O
and O
shiny O
black O
berries O
about O
the O
size O
of O
cherries B-Plant
. O

nightshade B-Plant
contains O
atropine O
and O
scopolamine O
in O
its O
stems O
, O
leaves O
, O
berries O
, O
and O
roots O
, O
and O
causes O
paralysis O
in O
the O
involuntary O
muscles O
of O
the O
body O
, O
including O
the O
heart O
. O

white B-Plant
snakeroot I-Plant
( O
ageratina B-Plant
altissima I-Plant
) O
. O

earlier O
taxonomy O
name O
was O
eupatorium B-Plant
rugosum I-Plant
. O

an O
innocuous O
B-Plant O
, O
white B-Plant
snakeroot I-Plant
was O
responsible O
for O
the O
death O
of O
abraham O
lincoln O
92s O
mother O
, O
nancy B-Plant
hanks O
. O

white B-Plant
snakeroot I-Plant
is O
a O
north O
american O
herb O
with O
flat O
- O
topped O
clusters O
of O
small O
white O
flowers O
and O
contains O
a O
toxic O
alcohol O
known O
as O
trematol O
. O

unlike O
those O
who O
have O
died O
from O
directly O
ingesting O
deadly O
B-Plants O
, O
poor O
nancy B-Plant
hanks O
was O
poisoned O
by O
simply O
drinking O
the O
milk O
of O
a O
cow O
who O
had O
grazed O
on O
the O
B-Plant O
. O

castor B-Plant
bean I-Plant
( O
ricinus B-Plant
communis I-Plant
) O
with O
details O
of O
( O
left O
) O
seeds O
and O
( O
right O
) O
fruit O
. O

widely O
grown O
as O
an O
ornamental O
, O
the O
castor B-Plant
bean I-Plant
is O
an O
attractive O
B-Plant O
native O
to O
africa O
. O

while O
the O
processed O
seeds O
are O
the O
source O
of O
castor B-Plant
oil I-Plant
, O
they O
naturally O
contain O
the O
poison O
ricin B-Plant
and O
are O
deadly O
in O
small O
amounts O
. O

ricin B-Plant
works O
by O
inhibiting O
the O
synthesis O
of O
proteins O
within O
cells O
and O
can O
cause O
severe O
vomiting O
, O
diarrhea O
, O
seizures O
, O
and O
even O
death O
. O

rosary B-Plant
pea I-Plant
( O
abrus B-Plant
precatorius I-Plant
) O
with O
enlarged O
view O
of O
the O
poisonous O
seeds O
. O

also O
called O
jequirity B-Plant
beans I-Plant
, O
these O
piously O
- O
named O
seeds O
contain O
abrin O
, O
an O
extremely O
deadly O
ribosome O
- O
inhibiting O
protein O
. O

like O
ricin B-Plant
, O
abrin O
prevents O
protein O
synthesis O
within O
cells O
and O
can O
cause O
organ O
failure O
within O
four O
days O
. O

common O
oleander B-Plant
, O
or O
rosebay O
( O
nerium B-Plant
oleander I-Plant
) O
. O

described O
by O
pliny O
the O
elder O
in O
ancient O
rome O
, O
oleander B-Plant
is O
a O
beautiful O
B-Plant O
known O
for O
its O
striking O
flowers O
. O

though O
commonly O
grown O
as O
a O
hedge O
and O
ornamental O
, O
all O
parts O
of O
the O
oleander B-Plant
B-Plant O
are O
deadly O
and O
contain O
lethal O
cardiac O
glycosides O
known O
as O
oleandrin O
and O
neriine O
. O

if O
eaten O
, O
oleander B-Plant
can O
cause O
vomiting O
, O
diarrhea O
, O
erratic O
pulse O
, O
seizures O
, O
coma B-Plant
, O
and O
death O
, O
and O
contact O
with O
the O
leaves O
and O
sap O
is O
known O
to O
be O
a O
skin O
irritant O
to O
some O
people O
. O

indeed O
, O
the O
toxins O
in O
oleander B-Plant
are O
so O
strong O
that O
people O
have O
become O
ill O
after O
eating O
honey O
made O
by O
bees O
that O
visited O
the O
flowers O
! O
fortunately O
, O
fatalities O
from O
oleander B-Plant
poisoning O
are O
rare O
, O
as O
the O
B-Plant O
is O
very O
bitter O
and O
thus O
quickly O
deters O
anyone O
sampling O
the O
vegetation O
. O

tobacco B-Plant
is O
the O
most O
widely O
grown O
commercial O
non O
- O
food O
B-Plant O
in O
the O
world O
. O

despite O
its O
designation O
as O
a O
cardiac O
poison O
, O
nicotine O
from O
tobacco B-Plant
is O
widely O
consumed O
around O
the O
world O
and O
is O
both O
psychoactive O
and O
addictive O
. O

tobacco B-Plant
use O
causes O
more O
than O
5 O
million O
deaths O
per O
year O
, O
making O
it O
perhaps O
the O
most O
deadly O
B-Plant O
in O
the O
world O
. O

if O
we O
're O
going O
to O
talk O
about O
poisonous O
B-Plants O
, O
then O
right O
at O
the O
top O
of O
the O
list O
should O
be O
hemlock B-Plant
, O
do O
n't O
you O
think O
? O
widely O
known O
for O
its O
uses O
in O
ancient O
greece O
as O
a O
means O
of O
execution O
, O
hemlock B-Plant
's O
most O
famous O
victim O
was O
the O
philosopher O
socrates O
, O
who O
suffered O
the O
effects O
of O
the O
B-Plant O
's O
most O
potent O
toxin O
, O
coniine O
. O

hemlock B-Plant
again O
: O
cicuta O
( O
aka O
water B-Plant
hemlock I-Plant
, O
death B-Plant
- I-Plant
of I-Plant
- I-Plant
man I-Plant
, O
poison B-Plant
parsnip I-Plant
) O
members O
of O
the O
genus O
cicuta O
belong O
to O
the O
same O
family O
of O
B-Plants O
as O
the O
hemlock B-Plant
that O
did O
in O
socrates O
; O
and O
their O
toxic O
effects O
are O
so O
harrowing O
they O
warrant O
an O
appearance O
on O
this O
list O
as O
well O
. O

these O
roots O
, O
when O
pulled O
freshly O
out O
of O
the O
ground O
, O
are O
often O
mistaken O
for O
edible O
B-Plants O
like O
parsnip B-Plant
. O

aconitum O
( O
aka O
monkshood B-Plant
, O
wolfsbane B-Plant
, O
and O
devil B-Plant
's I-Plant
helmet I-Plant
) O
ageratina B-Plant
altissima I-Plant
( O
aka O
white B-Plant
snakeroot I-Plant
) O
white B-Plant
snakeroot I-Plant
is O
so O
potent O
that O
just O
drinking O
the O
milk O
or O
eating O
the O
meat O
of O
a O
cow O
that O
's O
ingested O
the O
B-Plant O
can O
lead O
to O
severe O
sickness O
and O
even O
death O
. O

the O
illness O
brought O
on O
by O
secondary O
tremetol O
ingestion O
was O
so O
widespread O
in O
the O
early O
19th O
century O
that O
it O
became O
known O
as O
milk O
sickness O
, O
and O
is O
estimated O
to O
be O
responsible O
for O
thousands O
of O
deaths O
at O
the O
time O
97 O
including O
that O
of O
abraham O
lincoln O
's O
mother O
, O
nancy B-Plant
hanks O
lincoln O
. O

brugmansia O
( O
aka O
angel B-Plant
's I-Plant
trumpet I-Plant
) O
botanists O
will O
tell O
you O
that O
members O
of O
the O
genus O
brugmansia O
get O
their O
nickname O
, O
angel B-Plant
's I-Plant
trumpet I-Plant
, O
from O
their O
large O
, O
hanging O
, O
trumpet O
- O
shaped O
flowers O
, O
which O
can O
measure O
up O
to O
50 O
cm O
long O
and O
35 O
cm O
wide O
at O
their O
openings O
. O

dieffenbachia O
( O
aka O
dumbcane B-Plant
) O
abrus B-Plant
precatorius I-Plant
( O
aka O
jequirity B-Plant
, O
crab B-Plant
's I-Plant
eye I-Plant
, O
rosary B-Plant
pea I-Plant
) O
abrus B-Plant
precatorius I-Plant
is O
native O
to O
indonesia O
, O
where O
its O
vibrant O
black O
, O
red O
, O
and O
white O
beads O
are O
often O
used O
in O
the O
region O
's O
percussion O
instruments O
. O

abrin O
, O
which O
is O
chemically O
similar O
to O
the O
ricin B-Plant
found O
in O
castor B-Plant
seeds O
( O
see O
below O
) O
, O
sabotages O
your O
body O
's O
functions O
at O
the O
cellular O
level O
by O
inactivating O
ribosomes O
, O
the O
molecular O
machines O
in O
your O
body O
responsible O
for O
synthesizing O
proteins O
. O

hippomane B-Plant
mancinella I-Plant
( O
aka O
manchineel B-Plant
, O
manzanilla O
de O
la O
muerte O
[ O
little O
apple B-Plant
of O
death O
] O
) O
the O
manchineel B-Plant
tree O
does O
not O
like O
company O
. O

basically O
, O
do O
n't O
mess O
with O
the O
manchineel B-Plant
; O
there O
's O
a O
reason O
it O
's O
called O
the O
little O
apple B-Plant
of O
death O
. O

cerbera B-Plant
odollam I-Plant
( O
aka O
the O
suicide O
tree O
) O
this O
species O
of O
tree O
belongs O
to O
the O
same O
family O
as O
oleander B-Plant
, O
and O
is O
also O
quite O
toxic O
to O
humans O
. O

it O
may O
not O
come O
as O
a O
surprise O
, O
therefore O
, O
that O
a O
team O
of O
french O
forensic O
toxicologists O
concluded O
that O
cerbera B-Plant
odollam I-Plant
is O
used O
by O
more O
people O
to O
commit O
suicide O
and O
murder O
than O
any O
other O
B-Plant O
, O
having O
identified O
more O
than O
500 O
cases O
of O
fatal O
cerbera O
poisoning O
between O
1989 O
and O
1999 O
in O
the O
south O
- O
west O
indian O
state O
of O
kerala O
alone O
. O

ricinus B-Plant
communis I-Plant
( O
aka O
the O
castor B-Plant
oil I-Plant
B-Plant I-Plant
) O
much O
like O
oleander B-Plant
, O
castor B-Plant
oil I-Plant
B-Plants O
can O
be O
found O
in O
houses O
and O
gardens O
all O
over O
the O
world O
, O
despite O
the O
fact O
that O
their O
seeds O
are O
actually O
very O
dangerous O
97 O
so O
dangerous O
, O
in O
fact O
, O
that O
the O
B-Plant O
is O
the O
current O
holder O
of O
the O
guinness O
book O
of O
world O
records O
title O
for O
world O
's O
most O
poisonous O
B-Plant O
. O

the O
seeds O
harbor O
an O
incredibly O
toxic O
chemical O
called O
ricin B-Plant
, O
and O
a O
lethal O
dose O
is O
considered O
to O
be O
in O
the O
range O
of O
4 O
to O
8 O
seeds O
. O

several O
species O
including O
asparagus B-Plant
officinalis I-Plant
and O
asparagus B-Plant
densiflorus I-Plant
. O

these O
are O
decomposed O
by O
linamarase O
, O
a O
naturally O
occurring O
enzyme O
in O
cassava B-Plant
, O
liberating O
hydrogen O
cyanide O
. O

[ O
6 O
] O
cassava B-Plant
varieties O
are O
often O
categorized O
as O
either O
sweet O
or O
bitter O
, O
respectively O
signifying O
the O
absence O
or O
presence O
of O
toxic O
levels O
of O
cyanogenic O
glycosides O
. O

[ O
7][8 O
] O
a O
dose O
of O
40 O
mg O
of O
pure O
cassava B-Plant
cyanogenic O
glycoside O
is O
sufficient O
to O
kill O
a O
cow O
. O

processing O
( O
soaking O
, O
cooking O
, O
fermentation O
, O
etc. O
) O
of O
cassava B-Plant
root O
is O
necessary O
to O
remove O
the O
toxins O
and O
avoid O
getting O
sick O
. O

despite O
its O
appearance O
and O
common O
name O
, O
c. B-Plant
cinnabarinum I-Plant
is O
not O
related O
to O
the O
TRUE B-Plant
puffballs I-Plant
or O
to O
species O
in O
the O
genus O
podaxis O
( O
also O
commonly O
called O
stalked B-Plant
puffballs I-Plant
) O
. O

it O
is O
also O
unrelated O
to O
earthstars B-Plant
and O
stinkhorns B-Plant
. O

however O
, O
c. B-Plant
cinnabarinum I-Plant
has O
had O
a O
complex O
taxonomic O
history O
that O
at O
various O
times O
confused O
it O
with O
each O
of O
those O
groups O
, O
until O
the O
advent O
of O
molecular O
phylogenetics O
. O

calostoma B-Plant
fuhreri I-Plant
is O
a O
species O
of O
gasteroid B-Plant
fungus I-Plant
in O
the O
family O
sclerodermataceae B-Plant
. O

calostoma B-Plant
fuscum I-Plant
is O
a O
species O
of O
gasteroid B-Plant
fungus I-Plant
in O
the O
family O
sclerodermataceae B-Plant
. O

found O
in O
australia O
, O
where O
it O
grows O
mainly O
in O
eucalyptus B-Plant
forests O
, O
it O
was O
originally O
described O
by O
miles O
joseph O
berkeley O
in O
1839 O
as O
mitremyces B-Plant
fuscus I-Plant
. O

chlorogaster O
( O
literally O
green O
stomach O
) O
is O
a O
genus O
of O
fungi B-Plant
thought O
to O
belong O
to O
the O
sclerodermataceae B-Plant
family O
, O
but O
this O
has O
been O
not O
molecularly O
confirmed O
. O

a O
monotypic O
genus O
, O
it O
contains O
the O
single O
mycorrhizal O
species O
chlorogaster B-Plant
dipterocarpi I-Plant
. O

chroogomphus O
is O
a O
genus O
of O
mushrooms B-Plant
commonly O
known O
as O
pine B-Plant
- I-Plant
spikes I-Plant
or O
spike B-Plant
- I-Plant
caps I-Plant
based O
on O
their O
shape O
and O
because O
they O
are O
often O
found O
growing O
in O
association O
with O
pine B-Plant
trees O
. O

chroogomphus B-Plant
vinicolor I-Plant
, O
commonly O
known O
as O
the O
wine B-Plant
- I-Plant
cap I-Plant
chroogomphus O
or O
the O
pine B-Plant
spike I-Plant
, O
is O
a O
species O
of O
mushroom B-Plant
in O
the O
family O
gomphidiaceae B-Plant
. O

found O
in O
north O
america O
and O
the O
dominican O
republic O
, O
mushrooms B-Plant
grow O
on O
the O
ground O
under O
pine B-Plant
trees O
. O

c. B-Plant
vinicolor I-Plant
is O
differentiated O
from O
the O
european O
c. B-Plant
rutilus I-Plant
and O
the O
north O
american O
c. B-Plant
ochraceus I-Plant
by O
the O
thickness O
of O
its O
cystidial O
walls O
. O

chrysoconia O
is O
a O
genus O
of O
fungi B-Plant
within O
the O
coniophoraceae B-Plant
family O
. O

coniophora B-Plant
elegans I-Plant
is O
a O
species O
of O
fungi B-Plant
within O
the O
coniophoraceae B-Plant
family O
. O

coniophoropsis O
is O
a O
fungal O
genus O
in O
the O
family O
coniophoraceae B-Plant
. O

it O
is O
a O
monotypic O
genus O
, O
containing O
the O
single O
species O
coniophoropsis B-Plant
obscura I-Plant
, O
found O
in O
argentina O
. O

cystogomphus O
is O
a O
fungal O
genus O
in O
the O
family O
gomphidiaceae B-Plant
. O

circumscribed O
by O
american O
mycologist O
rolf O
singer O
in O
1942 O
, O
the O
genus O
is O
monotypic O
, O
containing O
the O
single O
species O
cystogomphus B-Plant
humblotii I-Plant
, O
originally O
described O
from O
france O
. O

durianella O
is O
a O
fungal O
genus O
in O
the O
suborder O
boletineae O
, O
family O
boletaceae B-Plant
of O
the O
order O
boletales O
. O

it O
contains O
the O
single O
species O
durianella B-Plant
echinulata I-Plant
, O
described O
in O
2008 O
and O
found O
in O
peninsular O
malaysia O
and O
borneo O
. O

endogonopsis B-Plant
is O
a O
poorly O
known O
fungal O
genus O
, O
provisionally O
placed O
in O
the O
diplocystaceae B-Plant
family O
. O

a O
monotypic O
genus O
, O
it O
contains O
the O
single O
species O
endogonopsis B-Plant
sacramentarium I-Plant
, O
known O
from O
southern O
asia O
. O

favillea B-Plant
is O
a O
genus O
of O
fungi O
within O
the O
sclerodermataceae B-Plant
family O
. O

the O
gomphidiaceae B-Plant
are O
a O
family O
of O
mushroom O
- O
forming O
fungi B-Plant
in O
the O
order O
boletales O
. O

unlike O
other O
boletes B-Plant
, O
all O
members O
of O
gomphidiaceae B-Plant
( O
except O
for O
gomphogaster O
) O
are O
agarics B-Plant
, O
having O
gills O
instead O
of O
pores O
. O

like O
all O
agarics B-Plant
, O
this O
group O
was O
formerly O
classified O
in O
agaricales O
. O

nonetheless O
, O
many O
of O
the O
microscopic O
features O
of O
these O
fungi B-Plant
, O
such O
as O
spore O
shape O
, O
strongly O
suggested O
an O
affinity O
with O
boletales O
. O

this O
was O
later O
confirmed O
through O
molecular O
phylogenetic O
investigation O
, O
which O
demonstrated O
that O
gomphidiaceae O
are O
more O
closely O
related O
to O
boletes O
than O
the O
TRUE O
agarics B-Plant
of O
the O
agaricales O
and O
that O
the O
development O
of O
gills O
in O
this O
group O
was O
an O
independent O
evolutionary O
event O
from O
the O
development O
of O
gills O
in O
the O
agaricales O
. O

molecular O
phylogenetic O
investigations O
have O
also O
demonstrated O
gomphidiaceae B-Plant
are O
nested O
well O
within O
boletales O
, O
being O
more O
closely O
related O
to O
suillaceae B-Plant
than O
to O
boletaceae B-Plant
, O
a O
finding O
that O
is O
supported O
by O
chemotaxonomic O
investigation O
of O
these O
groups O
. O

this O
family O
of O
fungi B-Plant
has O
been O
thought O
to O
be O
ectomycorrhizal O
, O
forming O
symbiotic O
relationship O
with O
their O
host O
trees O
, O
however O
, O
there O
is O
now O
evidence O
that O
many O
( O
and O
perhaps O
all O
) O
species O
in O
this O
group O
are O
parasitic O
upon O
ectomycorrhizal O
boletes B-Plant
, O
in O
relationships O
that O
are O
often O
highly O
species O
- O
specific O
. O

gomphidius O
is O
a O
genus O
of O
mushrooms B-Plant
, O
commonly O
known O
as O
spike B-Plant
- I-Plant
caps I-Plant
, O
that O
are O
members O
of O
the O
boletales O
( O
suborder O
suillineae O
) O
, O
or O
pored B-Plant
fungi I-Plant
. O

they O
appear O
to O
have O
gill O
- O
like O
structures O
which O
resemble O
those O
of O
agarics B-Plant
, O
however O
the O
similarity O
is O
superficial O
only O
. O

the O
best O
- O
known O
member O
is O
the O
slimy B-Plant
spike I-Plant
- I-Plant
cap I-Plant
( O
gomphidius B-Plant
glutinosus I-Plant
) O
. O

gomphidius B-Plant
borealis I-Plant
is O
a O
mushroom B-Plant
in O
the O
family O
gomphidiaceae B-Plant
that O
is O
found O
in O
siberia O
. O

gomphidius B-Plant
glutinosus I-Plant
, O
commonly O
known O
as O
the O
slimy B-Plant
spike I-Plant
- I-Plant
cap I-Plant
, O
is O
a O
gilled B-Plant
mushroom I-Plant
found O
in O
europe O
& O
north O
america O
. O

although O
it O
has O
gills O
, O
it O
is O
a O
member O
of O
the O
order O
boletales O
, O
along O
with O
the O
boletes B-Plant
. O

the O
fruiting O
bodies O
sprout O
in O
pine B-Plant
, O
fir B-Plant
and O
spruce B-Plant
woodland O
in O
europe O
in O
autumn O
. O

initially O
, O
are O
completely O
covered O
with O
a O
slimy O
veil O
, O
breaking O
through O
to O
reveal O
a O
greyish O
or O
brownish O
- O
capped O
mushroom B-Plant
with O
decurrent O
greyish O
gills O
which O
sometimes O
resembles O
a O
child O
's O
top O
. O

opinions O
differ O
on O
the O
suitability O
of O
this O
mushroom B-Plant
for O
the O
table O
, O
some O
guides O
hold O
it O
in O
high O
regard O
, O
while O
others O
view O
it O
with O
caution O
. O

gomphidius B-Plant
largus I-Plant
is O
a O
fungus B-Plant
native O
to O
north O
america O
. O

gomphidius B-Plant
maculatus I-Plant
is O
an O
edible O
mushroom B-Plant
in O
the O
family O
gomphidiaceae O
that O
is O
found O
in O
europe O
and O
north O
america O
. O

gomphidius B-Plant
nigricans I-Plant
is O
a O
mushroom B-Plant
in O
the O
family O
gomphidiaceae B-Plant
that O
is O
found O
in O
eastern O
north O
america O
to O
as O
far O
west O
as O
michigan O
. O

gomphidius B-Plant
oregonensis I-Plant
, O
commonly O
known O
as O
insidious B-Plant
gomphidius I-Plant
is O
a O
mushroom B-Plant
found O
only O
in O
western O
north O
america O
, O
most O
commonly O
on O
the O
pacific O
coast O
. O

g. B-Plant
oregonensis I-Plant
can O
be O
distinguished O
by O
its O
spores O
which O
are O
the O
shortest O
in O
the O
genus O
, O
typically O
less O
than O
14 O
m O
long O
. O

earlier O
in O
growth O
, O
g. B-Plant
oregonensis I-Plant
can O
be O
difficult O
to O
distinguish O
from O
other O
members O
of O
the O
genus O
gomphidius O
, O
such O
as O
g. B-Plant
glutinosus I-Plant
which O
is O
the O
most O
common O
and O
widespread O
species O
. O

gomphidius B-Plant
pseudoflavipes I-Plant
is O
a O
mushroom B-Plant
in O
the O
family O
gomphidiaceae B-Plant
that O
is O
found O
in O
california O
in O
north O
america O
. O

gomphidius B-Plant
pseudomaculatus I-Plant
is O
a O
mushroom B-Plant
in O
the O
family O
gomphidiaceae B-Plant
that O
is O
found O
in O
idaho O
in O
north O
america O
. O

gomphidius B-Plant
roseus I-Plant
, O
commonly O
known O
as O
the O
rosy B-Plant
spike I-Plant
- I-Plant
cap I-Plant
or O
pink B-Plant
gomphidius I-Plant
, O
is O
a O
gilled B-Plant
mushroom I-Plant
found O
in O
europe O
. O

although O
it O
has O
gills O
, O
it O
is O
a O
member O
of O
the O
order O
boletales O
, O
along O
with O
the O
boletes B-Plant
. O

it O
is O
a O
coral O
pink O
- O
capped O
mushroom B-Plant
which O
appears O
in O
pine O
forests O
in O
autumn O
, O
always O
near O
the O
related O
mushroom B-Plant
suillus B-Plant
bovinus I-Plant
, O
on O
which O
it O
appears O
to O
be O
parasitic O
. O

gomphidius B-Plant
smithii I-Plant
is O
a O
mushroom B-Plant
in O
the O
family O
gomphidiaceae B-Plant
that O
is O
found O
in O
the O
pacific O
northwest O
in O
north O
america O
. O

gomphidius B-Plant
subroseus I-Plant
is O
a O
gilled B-Plant
mushroom I-Plant
found O
in O
europe O
and O
north O
america O
. O

it O
was O
once O
thought O
to O
be O
mycorrhizal O
with O
pinus B-Plant
sylvestris I-Plant
. O

however O
, O
olson O
et O
al. O
( O
2002 O
) O
found O
it O
to O
be O
more O
likely O
to O
be O
parasitic O
on O
suillus B-Plant
bovinus I-Plant
, O
which O
is O
mycorrhizal O
with O
pinus B-Plant
sylvestris I-Plant
, O
pinus B-Plant
sylvestris I-Plant
or O
both O
. O

gomphogaster O
is O
a O
fungal O
genus O
in O
the O
family O
gomphidiaceae B-Plant
. O

circumscribed O
in O
1972 O
by O
american O
mycologist O
orson O
k. O
miller O
, O
jr. O
, O
the O
genus O
is O
monotypic O
, O
containing O
the O
single O
gasteroid O
species O
gomphogaster B-Plant
leucosarx I-Plant
, O
found O
in O
the O
united O
states O
. O

gymnopaxillus O
is O
a O
genus O
of O
fungi B-Plant
in O
the O
family O
serpulaceae B-Plant
. O

according O
to O
the O
dictionary O
of O
the O
fungi B-Plant
( O
10th O
edition O
, O
2008 O
) O
, O
the O
family O
contains O
four O
species O
found O
in O
temperate O
south O
america O
and O
australia O
. O

gymnopaxillus O
was O
circumscribed O
by O
mycologist O
egon O
horak O
in O
1966 O
with O
g. B-Plant
morchelliformis I-Plant
as O
the O
type O
species O
. O

g. B-Plant

crubensis I-Plant
, O
described O
from O
argentina O
, O
was O
added O
in O
1989 O
, O
while O
the O
australasian O
species O
g. B-Plant

nudus I-Plant
and O
g. B-Plant

vestitus I-Plant
were O
added O
to O
the O
genus O
in O
2001 O
. O

gyroporus B-Plant
brunneofloccosus I-Plant
is O
a O
species O
of O
bolete B-Plant
fungus I-Plant
in O
the O
family O
gyroporaceae B-Plant
. O

gyroporus B-Plant
castaneus I-Plant
, O
or O
commonly O
the O
chestnut B-Plant
bolete I-Plant
, O
is O
a O
small O
, O
white O
- O
pored O
relation O
of O
the O
boletus O
mushrooms O
. O

it O
has O
a O
brown O
cap O
, O
and O
is O
usually O
found O
with O
oak B-Plant
trees O
. O

it O
differs O
from O
the O
TRUE B-Plant
boletes I-Plant
in O
that O
the O
spores O
are O
a O
pale O
straw O
colour O
. O

gyroporus B-Plant
cyanescens I-Plant
, O
commonly O
known O
as O
the O
bluing B-Plant
bolete I-Plant
or O
the O
cornflower B-Plant
bolete I-Plant
, O
is O
a O
species O
of O
bolete B-Plant
fungus I-Plant
in O
the O
family O
gyroporaceae B-Plant
. O

scleroderma B-Plant
polyrhizum I-Plant
, O
commonly O
known O
as O
the O
star B-Plant
earthball I-Plant
or O
dead B-Plant
man I-Plant
's I-Plant
hand I-Plant
, O
is O
a O
basidiomycete B-Plant
fungus I-Plant
and O
a O
member O
of O
the O
genus O
scleroderma O
, O
or O
earthballs B-Plant
. O

scleroderma B-Plant
verrucosum I-Plant
is O
a O
basidiomycete B-Plant
fungus I-Plant
and O
a O
member O
of O
the O
genus O
scleroderma O
, O
or O
earth B-Plant
balls I-Plant
. O

the O
sclerodermataceae B-Plant
are O
a O
family O
of O
fungi O
in O
the O
order O
boletales O
, O
containing O
several O
genera O
of O
unusual O
fungi B-Plant
that O
little O
resemble O
boletes B-Plant
. O

taxa O
, O
which O
include O
species O
commonly O
known O
as O
the O
1 O
hard B-Plant
- I-Plant
skinned I-Plant
puffballs'92 I-Plant
, O
1 O
earthballs'92 B-Plant
, O
or O
' O
earthstars B-Plant
' O
, O
are O
widespread O
in O
both O
temperate O
and O
tropical O
regions O
. O

the O
best O
known O
members O
include O
the O
earthball B-Plant
scleroderma B-Plant
citrinum I-Plant
, O
the O
dye B-Plant
fungus I-Plant
pisolithus B-Plant
tinctorius I-Plant
and O
the O
' O
prettymouths B-Plant
' O
of O
the O
genus O
calostoma O
. O

the O
suborder O
contains O
a O
diverse O
assemblage O
fruit O
body O
morphologies O
, O
including O
boletes B-Plant
, O
gasteroid O
forms O
, O
earthstars B-Plant
( O
genus O
astraeus O
) O
, O
and O
puffballs B-Plant
. O

serpula O
is O
a O
genus O
of O
fungi B-Plant
in O
the O
family O
serpulaceae B-Plant
. O

serpula B-Plant
himantioides I-Plant
is O
a O
species O
of O
fungus B-Plant
that O
causes O
damage O
to O
timber O
referred O
to O
as O
dry O
rot O
. O

it O
is O
a O
basidiomycete B-Plant
in O
the O
order O
boletales O
. O

recent O
molecular O
work O
demonstrates O
that O
s. B-Plant
himantioides I-Plant
is O
a O
species O
complex O
including O
multiple O
cryptic O
lineages O
. O

serpula B-Plant
lacrymans I-Plant
is O
one O
of O
the O
fungi B-Plant
that O
cause O
damage O
to O
timber O
referred O
to O
as O
dry O
rot O
. O

it O
is O
a O
basidiomycete B-Plant
in O
the O
order O
boletales O
. O

the O
suillaceae B-Plant
are O
a O
family O
of O
fungi B-Plant
in O
the O
order O
boletales O
( O
suborder O
suillineae O
) O
, O
containing O
the O
boletus B-Plant
- I-Plant
like I-Plant
suillus I-Plant
, O
the O
small B-Plant
truffle I-Plant
- I-Plant
like I-Plant
truncocolumella I-Plant
, O
as O
well O
as O
the O
monotypic O
genus O
psiloboletinus O
. O

tapinella B-Plant
atrotomentosa I-Plant
, O
commonly O
known O
as O
the O
velvet B-Plant
roll I-Plant
- I-Plant
rim I-Plant
or O
velvet B-Plant
- I-Plant
footed I-Plant
pax I-Plant
, O
is O
a O
species O
of O
fungus B-Plant
in O
the O
family O
tapinellaceae B-Plant
. O

although O
it O
has O
gills O
, O
it O
is O
a O
member O
of O
the O
pored O
mushroom B-Plant
order O
boletales O
. O

the O
mushroom B-Plant
contains O
several O
compounds O
that O
act O
as O
deterrents O
to O
deter O
feeding O
by O
insects O
. O

tapinella B-Plant
panuoides I-Plant
is O
a O
fungus B-Plant
species O
in O
the O
genus O
tapinella O
. O

the O
first O
enzymes O
in O
its O
biosynthesis O
have O
been O
characterised O
in O
t. B-Plant
panuoides I-Plant
. O

the O
fungal O
order O
agaricales O
, O
also O
known O
as O
gilled B-Plant
mushrooms I-Plant
( O
for O
their O
distinctive O
gills O
) O
or O
euagarics O
, O
contains O
some O
of O
the O
most O
familiar O
types O
of O
mushrooms B-Plant
. O

they O
range O
from O
the O
ubiquitous O
common B-Plant
mushroom I-Plant
to O
the O
deadly B-Plant
destroying I-Plant
angel I-Plant
and O
the O
hallucinogenic O
fly B-Plant
agaric I-Plant
to O
the O
bioluminescent O
jack B-Plant
- I-Plant
o I-Plant
- I-Plant
lantern I-Plant
mushroom I-Plant
. O

basidiolichens B-Plant
are O
lichenized O
members O
of O
the O
basidiomycota O
, O
a O
much O
smaller O
group O
of O
lichens B-Plant
than O
the O
far O
more O
common O
ascolichens B-Plant
in O
the O
ascomycota O
. O

in O
arctic O
, O
alpine O
, O
and O
temperate O
forests O
, O
the O
most O
common O
basidiolichens B-Plant
are O
in O
the O
agaric O
genus O
lichenomphalia O
( O
including O
former O
members O
of O
omphalina O
or O
gerronema O
) O
and O
the O
clavarioid O
genus O
multiclavula O
. O

previously O
basidiolichens B-Plant
had O
been O
classified O
in O
their O
own O
subclass O
, O
basidiolichenes O
. O

the O
broomeiaceae B-Plant
are O
a O
family O
of O
fungi O
in O
the O
agaricales O
order O
. O

berkeley O
designated O
the O
type O
species O
to O
be O
broomeia B-Plant
congregata I-Plant
. O

calcarisporium B-Plant
elegans I-Plant
is O
a O
species O
of O
fungi B-Plant
known O
from O
s'e3o O
tom'e9 O
and O
pr'edncipe O
. O

dictyocephalos O
is O
a O
genus O
of O
fungi B-Plant
in O
the O
phelloriniaceae B-Plant
family O
of O
the O
agaricales O
order O
. O

the O
genus O
is O
monotypic O
, O
and O
contains O
the O
single O
species O
dictyocephalos B-Plant
attenuatus I-Plant
, O
described O
by O
the O
american O
botanist O
lucien O
marcus O
underwood O
in O
1901 O
( O
as O
d. B-Plant
curvatus I-Plant
) O
. O

limnoperdon O
is O
a O
fungal O
genus O
in O
the O
monotypic O
family O
limnoperdaceae B-Plant
. O

the O
genus O
is O
also O
monotypic O
, O
as O
it O
contains O
a O
single O
species O
, O
the O
aquatic O
fungus O
limnoperdon B-Plant
incarnatum I-Plant
. O

the O
species O
, O
described O
as O
new O
to O
science O
in O
1976 O
, O
produces O
fruit O
bodies O
that O
lack O
specialized O
structures O
such O
as O
a O
stem O
, O
cap O
and O
gills O
common O
in O
mushrooms B-Plant
. O

rather O
, O
the O
fruit O
bodies O
7 O
described O
as O
aquatic O
or O
floating B-Plant
puffballs I-Plant
7 O
are O
small O
balls O
( O
0.5'961 O
mm O
diameter O
) O
of O
loosely O
interwoven O
hyphae O
. O

because O
they O
are O
often O
studied O
as O
a O
group O
, O
it O
has O
been O
convenient O
to O
retain O
the O
informal O
( O
non O
- O
taxonomic O
) O
name O
of O
gasteroid B-Plant
fungi I-Plant
. O

jelly B-Plant
fungi I-Plant
are O
a O
paraphyletic O
group O
of O
several O
heterobasidiomycete O
fungal O
orders O
from O
different O
classes O
of O
the O
subphylum O
agaricomycotina O
: O
tremellales O
, O
dacrymycetales O
, O
auriculariales O
and O
sebacinales O
. O

these O
fungi B-Plant
are O
so O
named O
because O
their O
foliose O
, O
irregularly O
branched O
fruiting O
body O
is O
, O
or O
appears O
to O
be O
, O
the O
consistency O
of O
jelly O
. O

the O
slabs O
and O
walls O
are O
dotted O
with O
grass O
tufts O
and O
a O
woody O
, O
liliaceous O
, O
antler O
- O
like O
B-Plant O
vellozia B-Plant
splendens I-Plant
( O
xerophyta O
) O
. O

the O
higher O
moorlands O
in O
spring O
and O
early O
summer O
may O
be O
a O
blaze O
of O
colour O
from O
the O
flowers O
of O
a O
variety O
of O
endemic O
tasmanian O
B-Plants O
and O
even O
the O
painfully O
prickly O
grass O
( O
richea B-Plant
scoparia I-Plant
) O
has O
brilliant O
flowers O
of O
red O
, O
orange B-Plant
or O
pale O
yellow O
. O

in O
places O
where O
the O
biotopic O
and O
climatic O
conditions O
allow O
, O
specimens O
of O
104 O
ma1 O
tabun O
60 O
gd0 O
ttonskhe O
khayrkhan O
3 O
turgen4 O
kmarkhyra O
' O
5 O
barun O
bo'f4do O
6 O
3 O
n O
tenser O
-15 O
siberian B-Plant
larch I-Plant
( O
larix B-Plant
sibirica I-Plant
) O
are O
frequent O
while O
the O
prevailing O
B-Plant O
community O
comprises O
the O
vast O
meadows O
of O
mountain O
steppes O
. O

the O
valleys O
' O
( O
entrai O
sections O
are O
covered O
with O
typical O
tundra O
B-Plants O
including O
some O
llora O
of O
so O
( O
ailed O
divas O
character O
' O
represented O
by O
betula B-Plant
nana I-Plant
and O
divas O
oelopetala O
among O
others O
, O
and O
some O
species O
of O
grouse O
( O
i.agopus O
lagopus O
) O
which O
recall O
the O
far O
n O
regions O
, O
can O
be O
seen O
lref)iiently O
. O

there O
were O
many O
B-Plants O
growing O
in O
the O
wetter O
pastures O
including O
purple O
and O
pink O
marsh O
orchids B-Plant
( O
dactylorhiza O
spp O
. O

) O
, O
a O
slender O
pink O
primrose B-Plant
200 O
mm O
tall O
( O
primula B-Plant
pamirica I-Plant
) O
, O
several O
deep O
blue O
gentians B-Plant
( O
gentiana B-Plant
longicarpa I-Plant
, O
g. B-Plant
minutissima I-Plant
and O
g. O
prostratd O
) O
, O
as O
well O
as O
the O
closely O
related O
white B-Plant
- I-Plant
flowered I-Plant
felwort I-Plant
( O
swertia B-Plant
lactea I-Plant
) O
forming O
tufts O
600 O
mm O
tall O
. O

common O
meadow O
B-Plants O
here O
were O
a O
pasque B-Plant
- I-Plant
flower I-Plant
( O
pulsatilla B-Plant
albana I-Plant
) O
in O
fruit O
with O
feathery O
seedheads O
and O
growing O
in O
similar O
places O
to O
the O
closely O
related O
species O
found O
in O
the O
european O
mountains O
, O
a O
small O
, O
yellow O
- O
flowered O
, O
whitlow B-Plant
grass I-Plant
( O
draba B-Plant
oreades I-Plant
) O
not O
previously O
recorded O
from O
afghanistan O
and O
yellow O
or O
orange B-Plant
poppies O
( O
papaver O
involucrata O
) O
almost O
too O
delicate O
for O
such O
an O
exposed O
place O
. O

in O
the O
rock O
gullies O
on O
the O
east O
side O
of O
the O
pass O
a O
small O
matted O
bistort B-Plant
( O
polygonum B-Plant
chitralicum I-Plant
) O
, O
new O
to O
the O
flora O
of O
afghanistan O
, O
proved O
uncommon O
, O
though O
the O
most O
interesting O
B-Plant O
here O
was O
a O
shrubby B-Plant
cinquefoil I-Plant
( O
potentilla B-Plant
phyllocalyx I-Plant
) O
, O
a O
prostrate O
cousin O
of O
the O
species O
( O
p. B-Plant
fruticosa I-Plant
) O
that O
occurs O
in O
teesdale O
and O
indeed O
across O
much O
of O
the O
northern O
temperate O
old O
world O
. O

the O
most O
characteristic O
B-Plant O
of O
the O
dry O
valley O
slopes O
above O
( O
acantholimon B-Plant
diapensioides I-Plant
) O
forms O
hard O
flat O
cushions O
up O
to O
0.5 O
m O
in O
diameter O
and O
studded O
with O
small O
stemless O
pale O
pink O
flowers O
in O
mid O
- O
summer O
. O

this O
B-Plant O
is O
a O
cousin O
of O
the O
thrift B-Plant
( O
armeria O
) O
and O
sea B-Plant
lavender I-Plant
( O
limonium O
) O
common O
to O
british O
coastal O
areas O
. O

however O
, O
one O
tiny O
B-Plant O
, O
scarcely O
20 O
mm O
tall O
, O
proved O
of O
interest O
and O
later O
identified O
as O
koenigia B-Plant
islandica I-Plant
, O
new O
to O
the O
flora O
of O
afghanistan O
and O
a O
species O
primarily O
with O
a O
northern O
arctic O
distribution O
. O

the O
most O
conspicuous O
B-Plants O
found O
amongst O
the O
thick O
growth O
of O
sedges B-Plant
were O
the O
yellowish O
edelweiss B-Plant
previously O
noted O
, O
a O
small O
yellow O
dandelion B-Plant
( O
taraxacum B-Plant
leucanthuni I-Plant
) O
, O
a O
widespread O
starry O
white B-Plant
- I-Plant
flowered I-Plant
mouse I-Plant
- I-Plant
ear I-Plant
( O
cerastium B-Plant
trigynum I-Plant
) O
, O
a O
rather O
elegant O
gentian B-Plant
( O
g. B-Plant
stricta I-Plant
) O
300 O
mm O
tall O
and O
the O
related O
lomatogonium B-Plant
carinthiacum I-Plant
, O
a O
long O
name O
for O
a O
small O
B-Plant O
with O
pretty O
pale O
blue O
flowers O
. O

here O
there O
were O
stonecrops B-Plant
( O
3 O
species O
) O
nestling O
amongst O
the O
rocks O
and O
two O
tiny O
ferns B-Plant
( O
cystopteris B-Plant
fragilis I-Plant
and O
distichium B-Plant
capillaceum I-Plant
) O
not O
previously O
noted O
, O
but O
besides O
these O
there O
were O
many O
of O
the O
B-Plants O
seen O
earlier O
on O
in O
the O
trip O
. O

the O
generic O
name O
meconopsis O
signifies O
in O
greek O
that O
the O
flower O
bears O
a O
resemblance O
to O
a O
poppy B-Plant
and O
the O
B-Plant O
is O
of O
the O
poppy B-Plant
family I-Plant
, O
it O
being O
of O
the O
natural O
order O
papaveraceae B-Plant
. O

the O
chestnut B-Plant
blackbird O
is O
unique O
and O
the O
nepenthes O
, O
or O
pitcher O
B-Plants O
, O
occurring O
at O
around O
3000 O
m O
on O
the O
mountain O
have O
their O
counterparts O
in O
madagascar O
, O
sri O
lanka O
, O
new O
guinea O
and O
the O
northern O
tip O
of O
australia O
, O
providing O
botanical O
evidence O
for O
continental O
drift O
. O

the O
B-Plant O
for O
which O
he O
is O
best O
known O
is O
the O
himalayan B-Plant
blue I-Plant
poppy I-Plant
, O
meconopsis B-Plant
baileyi I-Plant
, O
originally O
named O
in O
honour O
of O
colonel O
f O
m O
bailey O
who O
with O
morshead O
confirmed O
that O
the O
tsangpo O
and O
dihang O
were O
the O
same O
river O
. O

( O
ligularia B-Plant
przewalskii I-Plant
is O
but O
one O
B-Plant O
named O
in O
his O
honour O
. O

) O
books O
a O
franchet B-Plant
, O
B-Plantae O
yunnanensis O
. O

they O
visited O
wager O
's O
1936 O
food O
dump O
and O
collected O
B-Plant O
and O
lichen O
samples O
from O
the O
lindberg O
and O
lemon B-Plant
mountains O
. O

two O
of O
us O
climbed O
kavringtind O
, O
south O
of O
lyngseidet O
, O
and O
found O
drooping O
saxifrage B-Plant
, O
a O
B-Plant O
which O
our O
book O
did O
not O
place O
in O
scandinavia O
. O

other O
B-Plants O
found O
also O
in O
ireland O
include O
large O
butterwort B-Plant
( O
pinguicula B-Plant
grandiflora I-Plant
) O
and O
st O
dabeoc O
's O
heath O
( O
daboecia B-Plant
cantabrica I-Plant
) O
. O

we O
walked O
and O
scrambled O
up O
a O
series O
of O
vegetated O
ledges B-Plant
covered O
with O
strange O
martian O
- O
looking O
B-Plants O
, O
their O
purple O
flowers O
( O
saussurea B-Plant
simpsoniana I-Plant
) O
festooned O
with O
what O
looked O
like O
thick O
cobwebs O
. O

and O
again O
when O
we O
spotted O
bryocarpum B-Plant
himalaicum I-Plant
, O
a O
charming O
B-Plant O
looking O
like O
a O
yellow O
soldanella O
. O

the O
season O
was O
late O
, O
and O
flowering O
B-Plants O
were O
sparse O
in O
the O
clearings O
, O
but O
creeping O
scarlet O
rhododendron B-Plant
forrestii I-Plant
remains O
in O
the O
memory O
. O

B-Plants O
seen O
on O
this O
trek O
included O
blood O
- O
red O
rhododendron B-Plant
sanguineum I-Plant
, O
the O
yellow O
poppy B-Plant
meconopsispseudo O
- O
integrifolia O
, O
the O
remarkable O
striped O
daiswa B-Plant
violacea I-Plant
and O
the O
woodland B-Plant
orchid I-Plant
calanthe B-Plant
tricarinata I-Plant
. O

on O
the O
long O
descent O
there O
were O
more O
lovely O
B-Plants O
, O
including O
the O
dark O
red O
, O
striped O
ladies O
' O
slipper B-Plant
orchid I-Plant
cypripedium B-Plant
tibeticum I-Plant
, O
a O
clump O
of O
blue O
poppies O
by O
a O
stream O
( O
meconopsis O
betonidfolia O
, O
the O
emblem O
of O
the O
himalaya O
) O
, O
and O
beautiful O
primula B-Plant
cawdoriana I-Plant
, O
with O
downward O
- O
pointing O
mauve B-Plant
tubular O
flowers O
, O
named O
after O
the O
earl O
of O
cawdor O
who O
accompanied O
kingdon O
- O
ward O
on O
his O
1924 O
expedition O
. O

sparrman O
did O
return O
with O
some O
new O
B-Plant O
specimens O
, O
including O
the O
common O
south O
island O
forstera O
( O
forstera B-Plant
sedifolia I-Plant
) O
and O
a O
verbal O
description O
of O
the O
view O
from O
the O
summit O
which O
was O
repeated O
accurately O
in O
more O
than O
one O
journal O
it O
would O
be O
easy O
to O
say O
that O
the O
motive O
for O
such O
an O
ascent O
was O
simply O
exploration O
, O
but O
after O
four O
months O
at O
sea O
a O
day O
spent O
in O
the O
mountains O
might O
be O
considered O
as O
recreation O
. O

between O
namche O
bazar O
and O
phortse O
were O
numerous O
patches O
of O
gentiana B-Plant
depressa I-Plant
but O
we O
saw O
one O
B-Plant O
which O
no O
member O
of O
the O
party O
could O
identify O
. O

lowndes O
had O
a O
number O
of O
B-Plants O
, O
such O
as O
rhododendron B-Plant
lowndesii I-Plant
and O
gentianella B-Plant
lowndesii I-Plant
named O
after O
him O
, O
but O
the O
flower O
gentiana B-Plant
tilmanii I-Plant
does O
not O
appear O
in O
any O
of O
his O
papers O
. O

searching O
for O
it O
has O
been O
an O
interesting O
exercise O
, O
and O
it O
would O
appear O
that O
our O
only O
hope O
of O
growing O
this O
B-Plant O
at O
home O
is O
to O
search O
for O
gentiana B-Plant
marginata I-Plant
, O
as O
an O
alternative O
in O
specialist O
seed O
catalogues O
. O

a O
5 O
km O
strip O
of O
rocky O
bog O
, O
the O
alp O
is O
dominated O
by O
the O
heath O
empetrum B-Plant
rubrum I-Plant
, O
areas O
of O
cushion B-Plant
B-Plants O
, O
such O
as O
asti'lia O
pumihi O
, O
and O
the O
bizarre O
globes O
of O
bolax O
aiespitose O
. O

in O
1885 O
he O
published O
flowering O
B-Plants O
and O
ferns B-Plant
of O
the O
riviera O
, O
illustrated O
with O
many O
of O
his O
own O
paintings O
, O
but O
after O
visiting O
the O
merveilles O
in O
1881 O
his O
sphere O
of O
interest O
changed O
to O
archaeology O
and O
he O
became O
obsessed O
with O
the O
rock O
engravings O
. O

1 O
banning O
the O
harvesting O
of O
all O
shrub O
juniper B-Plant
and O
alpine O
B-Plants O
( O
eg O
arenaria B-Plant
sp. I-Plant
) O
for O
fuelwood O
, O
agricultural O
purposes O
and O
incense B-Plant
throughout O
the O
imja O
khola O
valley O
( O
the O
equivalent O
of O
2000 O
doko O
( O
baskets O
) O
, O
or O
80,000 O
kg O
of O
wood O
saved O
for O
2007 O
alone O
) O
. O

this O
proved O
to O
be O
a O
species O
new O
to O
science O
and O
later O
named O
at O
kew O
, O
astragalus B-Plant
bahrakianus I-Plant
. O

other O
species O
in O
this O
association O
were O
two O
small O
gentians B-Plant
( O
gentiana B-Plant
falcata I-Plant
and O
g. O
minutissimd O
) O
both O
opening O
in O
the O
bright O
sunshine O
, O
and O
a O
starry O
white O
and O
pink O
felwort B-Plant
( O
swertia B-Plant
marginata I-Plant
) O
not O
previously O
seen O
and O
making O
small O
clumps O
150 O
- O
200 O
mm O
tall O
. O

especially O
combustible O
were O
the O
bushy O
leptospermum O
, O
the O
dwarf B-Plant
rhododendron I-Plant
ericoides O
and O
several O
species O
of O
tiny O
conifer B-Plant
. O

the O
two O
species O
of O
which O
i O
have O
seen O
the O
most O
are O
meconopsis B-Plant
aculeata I-Plant
( O
kashmir O
to O
kumaom O
) O
and O
meconopsis B-Plant
grandis I-Plant
151 O
the O
large O
himalayan B-Plant
blue I-Plant
poppy I-Plant
( O
nepal B-Plant
to O
tibet O
) O
. O

paeonia B-Plant
delavayi I-Plant
sp. I-Plant
nov O
[ O
new O
species O
] O
3,500 O
metres O
li O
- O
kiang O
9/7/84 O
delavay O
no O
. O

1142 O
these O
include O
several O
species O
of O
rhododendron O
, O
hypericum O
, O
buddleja O
, O
syringa B-Plant
, O
berberis O
, O
daphne O
and O
the O
delightful O
clematis B-Plant
montana I-Plant
, O
and O
much O
more O
besides O
. O

deciduous O
trees O
include O
forrest B-Plant
's I-Plant
maple I-Plant
acer B-Plant
forrestii I-Plant
, O
vilmorin B-Plant
's I-Plant
mountain I-Plant
ash I-Plant
sorbus B-Plant
vilmorinii I-Plant
and O
the O
two O
major O
birch B-Plant
species O
of O
the O
region O
, O
betula B-Plant
utilis I-Plant
and O
b. B-Plant
platyphylla I-Plant
var. I-Plant
sechuanica I-Plant
. O

these O
include O
a O
small O
blue O
and O
white O
species O
of O
columbine B-Plant
( O
aquilegia B-Plant
discolor I-Plant
) O
, O
a O
houseleek B-Plant
( O
sempervivum B-Plant
cantabricum I-Plant
) O
, O
a O
milkwort B-Plant
( O
polygala O
edmundii O
) O
, O
and O
a O
low O
- O
growing O
toadflax B-Plant
( O
linaria B-Plant
faucicola I-Plant
) O
, O
among O
others O
. O

some O
50 O
species O
of O
orchid B-Plant
have O
been O
recorded O
here O
, O
including O
the O
evocatively O
named O
pink O
butterfly B-Plant
( O
orchis B-Plant
papilionacea I-Plant
) O
( O
plate O
64 O
) O
, O
lizard B-Plant
( O
himantoglossum B-Plant
hircinum I-Plant
) O
, O
man B-Plant
( O
aceras B-Plant
anthropophorum I-Plant
) O
, O
woodcock B-Plant
( O
ophrys B-Plant
scolopax I-Plant
) O
, O
fly B-Plant
( O
ophrys B-Plant
insectifera I-Plant
) O
and O
sawfly B-Plant
( O
ophrys B-Plant
tenthredinifera I-Plant
) O
orchids B-Plant
, O
to O
name O
but O
a O
few O
. O

nine O
different O
kinds O
were O
found O
, O
one O
being O
a O
new O
species O
named O
primula B-Plant
jigmediana I-Plant
after O
jigme O
wangchuk O
, O
the O
king O
of O
bhutan O
. O

there O
are O
two O
dominant O
species O
of O
tree O
, O
lower O
down O
the O
evergreen O
nothofagus B-Plant
betuloides I-Plant
and O
higher O
up O
, O
the O
deciduous O
tv O
! O
veteran O
trees O
were O
of O
great O
girth O
, O
but O
i O
could O
not O
distinguish O
what O
they O
were O
except O
a O
species O
of O
oak B-Plant
, O
and O
another O
beautiful O
tree O
with O
large O
compound O
leaves O
which O
may O
have O
been O
either O
cedrela O
or O
alianthus O
. O

in O
wales O
, O
i O
can O
only O
remember O
, O
although O
there O
must O
have O
been O
others O
, O
the O
mysterious O
and O
unnecessary O
one O
on O
holly B-Plant
tree I-Plant
wall O
from O
which O
the O
piton O
route O
got O
its O
name O
; O
the O
holly B-Plant
tree I-Plant
wall O
on O
idwal O
slabs O
was O
worked O
out O
by O
him O
with O
c. O

f. O

holland O
. O

the O
tree O
- O
line O
is O
low O
, O
down O
at O
2800 O
m O
, O
and O
the O
forest O
151 O
bristling O
with O
mammals O
such O
as O
howler O
and O
spider O
monkeys O
, O
bears O
and O
a O
fierce O
blue O
carnivorous O
foxgives O
way O
to O
the O
' O
sabana O
rubia B-Plant
, O
a O
gently O
- O
sloping O
, O
marshy O
expanse O
of'pseudo O
- O
paramo O
' O
, O
leading O
up O
to O
the O
border O
. O

from O
april O
to O
august O
in O
1982 O
, O
i O
mounted O
a O
one O
- O
man O
expedition O
to O
kashmir O
to O
study O
fir B-Plant
trees I-Plant
( O
abies B-Plant
pindrow I-Plant
) O
. O

he O
led O
six O
of O
us O
up O
the O
holly B-Plant
tree I-Plant
wall O
which O
in O
1931 O
was O
considered O
extremely O
difficult O
. O

selegiline O
- O
induced O
postural B-Disease
hypotension I-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
: O
a O
longitudinal O
study O
on O
the O
effects O
of O
drug O
withdrawal O
. O

objectives O
: O
the O
united O
kingdom O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
research O
group O
( O
ukpdrg O
) O
trial O
found O
an O
increased O
mortality O
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
randomized O
to O
receive O
10 O
mg O
selegiline O
per O
day O
and O
l O
- O
dopa O
compared O
with O
those O
taking O
l O
- O
dopa O
alone O
. O

recently O
, O
we O
found O
that O
therapy O
with O
selegiline O
and O
l O
- O
dopa O
was O
associated O
with O
selective O
systolic B-Disease
orthostatic I-Disease
hypotension I-Disease
which O
was O
abolished O
by O
withdrawal O
of O
selegiline O
. O

the O
aims O
of O
this O
study O
were O
to O
confirm O
our O
previous O
findings O
in O
a O
separate O
cohort O
of O
patients O
and O
to O
determine O
the O
time O
course O
of O
the O
cardiovascular O
consequences O
of O
stopping O
selegiline O
in O
the O
expectation O
that O
this O
might O
shed O
light O
on O
the O
mechanisms O
by O
which O
the O
drug O
causes O
orthostatic B-Disease
hypotension I-Disease
. O

methods O
: O
the O
cardiovascular O
responses O
to O
standing O
and O
head O
- O
up O
tilt O
were O
studied O
repeatedly O
in O
pd B-Disease
patients O
receiving O
selegiline O
and O
as O
the O
drug O
was O
withdrawn O
. O

results O
: O
head O
- O
up O
tilt O
caused O
systolic B-Disease
orthostatic I-Disease
hypotension I-Disease
which O
was O
marked O
in O
six O
of O
20 O
pd B-Disease
patients O
on O
selegiline O
, O
one O
of O
whom O
lost O
consciousness O
with O
unrecordable O
blood O
pressures O
. O

a O
lesser O
degree O
of O
orthostatic B-Disease
hypotension I-Disease
occurred O
with O
standing O
. O

orthostatic B-Disease
hypotension I-Disease
was O
ameliorated O
4 O
days O
after O
withdrawal O
of O
selegiline O
and O
totally O
abolished O
7 O
days O
after O
discontinuation O
of O
the O
drug O
. O

stopping O
selegiline O
also O
significantly O
reduced B-Disease
the I-Disease
supine I-Disease
systolic I-Disease
and I-Disease
diastolic I-Disease
blood I-Disease
pressures I-Disease
consistent O
with O
a O
previously O
undescribed O
supine O
pressor O
action O
. O

conclusion O
: O
this O
study O
confirms O
our O
previous O
finding O
that O
selegiline O
in O
combination O
with O
l O
- O
dopa O
is O
associated O
with O
selective O
orthostatic B-Disease
hypotension I-Disease
. O

the O
results O
have O
shown O
that O
the O
degradation O
product O
p O
- O
choloroaniline O
is O
not O
a O
significant O
factor O
in O
chlorhexidine O
- O
digluconate O
associated O
erosive O
cystitis B-Disease
. O

a O
high O
percentage O
of O
kanamycin O
- O
colistin O
and O
povidone O
- O
iodine O
irrigations O
were O
associated O
with O
erosive O
cystitis B-Disease
and O
suggested O
a O
possible O
complication O
with O
human O
usage O
. O

picloxydine O
irrigations O
appeared O
to O
have O
a O
lower O
incidence O
of O
erosive O
cystitis B-Disease
but O
further O
studies O
would O
have O
to O
be O
performed O
before O
it O
could O
be O
recommended O
for O
use O
in O
urological O
procedures O
. O

effects O
of O
tetrandrine O
and O
fangchinoline O
on O
experimental O
thrombosis B-Disease
in O
mice O
and O
human O
platelet B-Disease
aggregation I-Disease
. O

the O
present O
study O
was O
undertaken O
to O
investigate O
the O
effects O
of O
tet O
and O
fan O
on O
the O
experimental O
thrombosis B-Disease
induced O
by O
collagen O
plus O
epinephrine O
( O
ep O
) O
in O
mice O
, O
and O
platelet B-Disease
aggregation I-Disease
and O
blood B-Disease
coagulation I-Disease
in O
vitro O
. O

in O
the O
in O
vivo O
study O
, O
the O
administration O
( O
50 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
of O
tet O
and O
fan O
in O
mice O
showed O
the O
inhibition O
of O
thrombosis B-Disease
by O
55 O
% O
and O
35 O
% O
, O
respectively O
, O
while O
acetylsalicylic O
acid O
( O
asa O
, O
50 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
, O
a O
positive O
control O
, O
showed O
only O
30 O
% O
inhibition O
. O

in O
the O
vitro O
human O
platelet B-Disease
aggregations I-Disease
induced O
by O
the O
agonists O
used O
in O
tests O
, O
tet O
and O
fan O
showed O
the O
inhibitions O
dose O
dependently O
. O

angioedema B-Disease
due O
to O
ace O
inhibitors O
: O
common O
and O
inadequately O
diagnosed O
. O

the O
estimated O
incidence O
of O
angioedema B-Disease
during O
angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitor O
treatment O
is O
between O
1 O
and O
7 O
per O
thousand O
patients O
. O

cocaine O
- O
induced O
mood B-Disease
disorder I-Disease
: O
prevalence O
rates O
and O
psychiatric B-Disease
symptoms O
in O
an O
outpatient O
cocaine O
- O
dependent O
sample O
. O

this O
paper O
attempts O
to O
examine O
and O
compare O
prevalence O
rates O
and O
symptom O
patterns O
of O
dsm O
substance O
- O
induced O
and O
other O
mood B-Disease
disorders I-Disease
. O

243 O
cocaine O
- O
dependent O
outpatients O
with O
cocaine O
- O
induced O
mood B-Disease
disorder I-Disease
( O
cimd B-Disease
) O
, O
other O
mood B-Disease
disorders I-Disease
, O
or O
no O
mood B-Disease
disorder I-Disease
were O
compared O
on O
measures O
of O
psychiatric B-Disease
symptoms O
. O

the O
prevalence O
rate O
for O
cimd B-Disease
was O
12 O
% O
at O
baseline O
. O

introduction O
of O
the O
dsm O
- O
iv O
diagnosis O
of O
cimd B-Disease
did O
not O
substantially O
affect O
rates O
of O
the O
other O
depressive B-Disease
disorders I-Disease
. O

patients O
with O
cimd B-Disease
had O
symptom O
severity O
levels O
between O
those O
of O
patients O
with O
and O
without O
a O
mood B-Disease
disorder I-Disease
. O

these O
findings O
suggest O
some O
validity O
for O
the O
new O
dsm O
- O
iv O
diagnosis O
of O
cimd B-Disease
, O
but O
also O
suggest O
that O
it O
requires O
further O
specification O
and O
replication O
. O

effect O
of O
fucoidan O
treatment O
on O
collagenase O
- O
induced O
intracerebral B-Disease
hemorrhage I-Disease
in O
rats O
. O

inflammatory O
cells O
are O
postulated O
to O
mediate O
some O
of O
the O
brain B-Disease
damage I-Disease
following O
ischemic B-Disease
stroke I-Disease
. O

intracerebral B-Disease
hemorrhage I-Disease
is O
associated O
with O
more O
inflammation B-Disease
than O
ischemic B-Disease
stroke I-Disease
. O

we O
tested O
the O
sulfated O
polysaccharide O
fucoidan O
, O
which O
has O
been O
reported O
to O
reduce O
inflammatory O
brain B-Disease
damage I-Disease
, O
in O
a O
rat O
model O
of O
intracerebral B-Disease
hemorrhage I-Disease
induced O
by O
injection O
of O
bacterial O
collagenase O
into O
the O
caudate O
nucleus O
. O

the O
hematoma B-Disease
was O
assessed O
in O
vivo O
by O
magnetic O
resonance O
imaging O
. O

fucoidan O
- O
treated O
rats O
exhibited O
evidence O
of O
impaired B-Disease
blood I-Disease
clotting I-Disease
and O
hemodilution B-Disease
, O
had O
larger O
hematomas B-Disease
, O
and O
tended O
to O
have O
less O
inflammation B-Disease
in O
the O
vicinity O
of O
the O
hematoma B-Disease
after O
three O
days O
. O

they O
showed O
significantly O
more O
rapid O
improvement O
of O
motor O
function O
in O
the O
first O
week O
following O
hemorrhage B-Disease
and O
better O
memory O
retention O
in O
the O
passive O
avoidance O
test O
. O

acute O
white B-Disease
matter I-Disease
edema I-Disease
and O
eventual O
neuronal B-Disease
loss I-Disease
in O
the O
striatum O
adjacent O
to O
the O
hematoma B-Disease
did O
not O
differ O
between O
the O
two O
groups O
. O

investigation O
of O
more O
specific O
anti O
- O
inflammatory O
agents O
and O
hemodiluting O
agents O
are O
warranted O
in O
intracerebral B-Disease
hemorrhage I-Disease
. O

a O
respiratory B-Disease
arrest I-Disease
with O
severe O
desaturation B-Disease
and O
bradycardia B-Disease
occurred O
. O

circumstances O
leading O
to O
this O
event O
and O
the O
mechanisms O
enabling O
a O
neuromuscular B-Disease
blockade I-Disease
to O
occur O
, O
following O
the O
administration O
of O
a O
small O
dose O
of O
relaxant O
, O
are O
discussed O
. O

we O
investigated O
the O
safety O
and O
efficacy O
of O
adding O
different O
doses O
of O
ephedrine O
to O
propofol O
in O
order O
to O
obtund O
the O
hypotensive B-Disease
response O
. O

the O
addition O
of O
ephedrine O
to O
propofol O
appears O
to O
be O
an O
effective O
method O
of O
obtunding O
the O
hypotensive B-Disease
response O
to O
propofol O
at O
all O
doses O
used O
in O
this O
study O
. O

however O
, O
marked O
tachycardia B-Disease
associated O
with O
the O
use O
of O
ephedrine O
in O
combination O
with O
propofol O
occurred O
in O
the O
majority O
of O
patients O
, O
occasionally O
reaching O
high O
levels O
in O
individual O
patients O
. O

due O
to O
the O
risk O
of O
this O
tachycardia B-Disease
inducing O
myocardial B-Disease
ischemia I-Disease
, O
we O
would O
not O
recommend O
the O
use O
in O
elderly O
patients O
of O
any O
of O
the O
ephedrine O
/ O
propofol O
/ O
mixtures O
studied O
. O

gemcitabine O
plus O
vinorelbine O
in O
nonsmall B-Disease
cell I-Disease
lung I-Disease
carcinoma I-Disease
patients O
age O
70 O
years O
or O
older O
or O
patients O
who O
cannot O
receive O
cisplatin O
. O

background O
: O
although O
the O
prevalence O
of O
nonsmall B-Disease
cell I-Disease
lung I-Disease
carcinoma I-Disease
( O
nsclc B-Disease
) O
is O
high O
among O
elderly O
patients O
, O
few O
data O
are O
available O
regarding O
the O
efficacy O
and O
toxicity B-Disease
of O
chemotherapy O
in O
this O
group O
of O
patients O
. O

recent O
reports O
indicate O
that O
single O
agent O
therapy O
with O
vinorelbine O
( O
vnb O
) O
or O
gemcitabine O
( O
gem O
) O
may O
obtain O
a O
response O
rate O
of O
20 O
- O
30 O
% O
in O
elderly O
patients O
, O
with O
acceptable O
toxicity B-Disease
and O
improvement O
in O
symptoms O
and O
quality O
of O
life O
. O

in O
the O
current O
study O
the O
efficacy O
and O
toxicity B-Disease
of O
the O
combination O
of O
gem O
and O
vnb O
in O
elderly O
patients O
with O
advanced O
nsclc B-Disease
or O
those O
with O
some O
contraindication O
to O
receiving O
cisplatin O
were O
assessed O
. O

methods O
: O
forty O
- O
nine O
patients O
with O
advanced O
nsclc B-Disease
were O
included O
, O
38 O
of O
whom O
were O
age O
> O
/ O
= O
70 O
years O
and O
11 O
were O
age O
< O
70 O
years O
but O
who O
had O
some O
contraindication O
to O
receiving O
cisplatin O
. O

all O
patients O
were O
evaluable O
for O
response O
and O
toxicity B-Disease
. O

toxicity B-Disease
was O
mild O
. O

six O
patients O
( O
12 O
% O
) O
had O
world O
health O
organization O
grade O
3 O
- O
4 O
neutropenia B-Disease
, O
2 O
patients O
( O
4 O
% O
) O
had O
grade O
3 O
- O
4 O
thrombocytopenia B-Disease
, O
and O
2 O
patients O
( O
4 O
% O
) O
had O
grade O
3 O
neurotoxicity B-Disease
. O

three O
patients O
with O
severe O
neutropenia B-Disease
( O
6 O
% O
) O
died O
of O
sepsis B-Disease
. O

the O
median O
age O
of O
those O
patients O
developing O
grade O
3 O
- O
4 O
neutropenia B-Disease
was O
significantly O
higher O
than O
that O
of O
the O
remaining O
patients O
( O
75 O
years O
vs O
. O

72 O
years O
; O
p O
= O
0 O
. O

47 O
) O
. O

this O
age O
group O
had O
an O
increased O
risk O
of O
myelosuppression B-Disease
. O

new O
chemotherapy O
combinations O
with O
higher O
activity O
and O
lower O
toxicity B-Disease
are O
needed O
for O
elderly O
patients O
with O
advanced O
nsclc B-Disease
. O

nra0160 O
and O
clozapine O
antagonized O
locomotor O
hyperactivity B-Disease
induced O
by O
methamphetamine O
( O
map O
) O
in O
mice O
. O

nra0160 O
and O
clozapine O
significantly O
induced O
catalepsy B-Disease
in O
rats O
, O
although O
their O
effects O
did O
not O
exceed O
50 O
% O
induction O
even O
at O
the O
highest O
dose O
given O
. O

warfarin O
- O
induced O
artery B-Disease
calcification I-Disease
is O
accelerated O
by O
growth O
and O
vitamin O
d O
. O

the O
present O
studies O
demonstrate O
that O
growth O
and O
vitamin O
d O
treatment O
enhance O
the O
extent O
of O
artery B-Disease
calcification I-Disease
in O
rats O
given O
sufficient O
doses O
of O
warfarin O
to O
inhibit O
gamma O
- O
carboxylation O
of O
matrix O
gla O
protein O
, O
a O
calcification B-Disease
inhibitor O
known O
to O
be O
expressed O
by O
smooth O
muscle O
cells O
and O
macrophages O
in O
the O
artery O
wall O
. O

the O
first O
series O
of O
experiments O
examined O
the O
influence O
of O
age O
and O
growth O
status O
on O
artery B-Disease
calcification I-Disease
in O
warfarin O
- O
treated O
rats O
. O

treatment O
for O
2 O
weeks O
with O
warfarin O
caused O
massive O
focal O
calcification B-Disease
of I-Disease
the I-Disease
artery I-Disease
media O
in O
20 O
- O
day O
- O
old O
rats O
and O
less O
extensive O
focal O
calcification B-Disease
in O
42 O
- O
day O
- O
old O
rats O
. O

in O
contrast O
, O
no O
artery B-Disease
calcification I-Disease
could O
be O
detected O
in O
10 O
- O
month O
- O
old O
adult O
rats O
even O
after O
4 O
weeks O
of O
warfarin O
treatment O
. O

to O
directly O
examine O
the O
importance O
of O
growth O
to O
warfarin O
- O
induced O
artery B-Disease
calcification I-Disease
in O
animals O
of O
the O
same O
age O
, O
20 O
- O
day O
- O
old O
rats O
were O
fed O
for O
2 O
weeks O
either O
an O
ad O
libitum O
diet O
or O
a O
6 O
- O
g O
/ O
d O
restricted O
diet O
that O
maintains O
weight O
but O
prevents O
growth O
. O

concurrent O
treatment O
of O
both O
dietary O
groups O
with O
warfarin O
produced O
massive O
focal O
calcification B-Disease
of I-Disease
the I-Disease
artery I-Disease
media O
in O
the O
ad O
libitum O
- O
fed O
rats O
but O
no O
detectable O
artery B-Disease
calcification I-Disease
in O
the O
restricted O
- O
diet O
, O
growth O
- O
inhibited O
group O
. O

although O
the O
explanation O
for O
the O
association O
between O
artery B-Disease
calcification I-Disease
and O
growth O
status O
cannot O
be O
determined O
from O
the O
present O
study O
, O
there O
was O
a O
relationship O
between O
higher O
serum O
phosphate O
and O
susceptibility O
to O
artery B-Disease
calcification I-Disease
, O
with O
30 O
% O
higher O
levels O
of O
serum O
phosphate O
in O
young O
, O
ad O
libitum O
- O
fed O
rats O
compared O
with O
either O
of O
the O
groups O
that O
was O
resistant O
to O
warfarin O
- O
induced O
artery B-Disease
calcification I-Disease
, O
ie O
, O
the O
10 O
- O
month O
- O
old O
rats O
and O
the O
restricted O
- O
diet O
, O
growth O
- O
inhibited O
young O
rats O
. O

this O
observation O
suggests O
that O
increased O
susceptibility O
to O
warfarin O
- O
induced O
artery B-Disease
calcification I-Disease
could O
be O
related O
to O
higher O
serum O
phosphate O
levels O
. O

the O
second O
set O
of O
experiments O
examined O
the O
possible O
synergy O
between O
vitamin O
d O
and O
warfarin O
in O
artery B-Disease
calcification I-Disease
. O

high O
doses O
of O
vitamin O
d O
are O
known O
to O
cause O
calcification B-Disease
of I-Disease
the I-Disease
artery I-Disease
media O
in O
as O
little O
as O
3 O
to O
4 O
days O
. O

high O
doses O
of O
the O
vitamin O
k O
antagonist O
warfarin O
are O
also O
known O
to O
cause O
calcification B-Disease
of I-Disease
the I-Disease
artery I-Disease
media O
, O
but O
at O
treatment O
times O
of O
2 O
weeks O
or O
longer O
yet O
not O
at O
1 O
week O
. O

in O
the O
current O
study O
, O
we O
investigated O
the O
synergy O
between O
these O
2 O
treatments O
and O
found O
that O
concurrent O
warfarin O
administration O
dramatically O
increased O
the O
extent O
of O
calcification B-Disease
in O
the O
media O
of O
vitamin O
d O
- O
treated O
rats O
at O
3 O
and O
4 O
days O
. O

there O
was O
a O
close O
parallel O
between O
the O
effect O
of O
vitamin O
d O
dose O
on O
artery B-Disease
calcification I-Disease
and O
the O
effect O
of O
vitamin O
d O
dose O
on O
the O
elevation O
of O
serum O
calcium O
, O
which O
suggests O
that O
vitamin O
d O
may O
induce O
artery B-Disease
calcification I-Disease
through O
its O
effect O
on O
serum O
calcium O
. O

because O
warfarin O
treatment O
had O
no O
effect O
on O
the O
elevation O
in O
serum O
calcium O
produced O
by O
vitamin O
d O
, O
the O
synergy O
between O
warfarin O
and O
vitamin O
d O
is O
probably O
best O
explained O
by O
the O
hypothesis O
that O
warfarin O
inhibits O
the O
activity O
of O
matrix O
gla O
protein O
as O
a O
calcification B-Disease
inhibitor O
. O

high O
levels O
of O
matrix O
gla O
protein O
are O
found O
at O
sites O
of O
artery B-Disease
calcification I-Disease
in O
rats O
treated O
with O
vitamin O
d O
plus O
warfarin O
, O
and O
chemical O
analysis O
showed O
that O
the O
protein O
that O
accumulated O
was O
indeed O
not O
gamma O
- O
carboxylated O
. O

these O
observations O
indicate O
that O
although O
the O
gamma O
- O
carboxyglutamate O
residues O
of O
matrix O
gla O
protein O
are O
apparently O
required O
for O
its O
function O
as O
a O
calcification B-Disease
inhibitor O
, O
they O
are O
not O
required O
for O
its O
accumulation O
at O
calcification B-Disease
sites O
. O

apomorphine O
, O
a O
nonselective O
dopamine O
agonist O
, O
was O
selected O
due O
to O
its O
biphasic O
behavioral O
effects O
, O
its O
ability O
to O
induce O
hypothermia B-Disease
, O
and O
to O
produce O
distinct O
changes O
to O
dopamine O
turnover O
in O
the O
rodent O
brain O
. O

in O
rats O
, O
detection O
of O
apomorphine O
- O
induced O
hyperactivity B-Disease
was O
facilitated O
by O
a O
period O
of O
acclimatization O
to O
the O
test O
conditions O
. O

moreover O
, O
test O
conditions O
can O
impact O
upon O
other O
physiological O
responses O
to O
apomorphine O
such O
as O
drug O
- O
induced O
hypothermia B-Disease
. O

hemolysis B-Disease
of O
human O
erythrocytes O
induced O
by O
tamoxifen O
is O
related O
to O
disruption O
of O
membrane O
structure O
. O

tamoxifen O
( O
tam O
) O
, O
the O
antiestrogenic O
drug O
most O
widely O
prescribed O
in O
the O
chemotherapy O
of O
breast B-Disease
cancer I-Disease
, O
induces O
changes O
in O
normal O
discoid O
shape O
of O
erythrocytes O
and O
hemolytic B-Disease
anemia I-Disease
. O

this O
work O
evaluates O
the O
effects O
of O
tam O
on O
isolated O
human O
erythrocytes O
, O
attempting O
to O
identify O
the O
underlying O
mechanisms O
on O
tam O
- O
induced O
hemolytic B-Disease
anemia I-Disease
and O
the O
involvement O
of O
biomembranes O
in O
its O
cytostatic O
action O
mechanisms O
. O

tam O
induces O
hemolysis B-Disease
of O
erythrocytes O
as O
a O
function O
of O
concentration O
. O

the O
extension O
of O
hemolysis B-Disease
is O
variable O
with O
erythrocyte O
samples O
, O
but O
12 O
. O

5 O
microm O
tam O
induces O
total O
hemolysis B-Disease
of O
all O
tested O
suspensions O
. O

the O
hemolytic B-Disease
effect O
of O
tam O
is O
prevented O
by O
low O
concentrations O
of O
alpha O
- O
tocopherol O
( O
alpha O
- O
t O
) O
and O
alpha O
- O
tocopherol O
acetate O
( O
alpha O
- O
tac O
) O
( O
inactivated O
functional O
hydroxyl O
) O
indicating O
that O
tam O
- O
induced O
hemolysis B-Disease
is O
not O
related O
to O
oxidative O
membrane O
damage O
. O

this O
was O
further O
evidenced O
by O
absence O
of O
oxygen O
consumption O
and O
hemoglobin O
oxidation O
both O
determined O
in O
parallel O
with O
tam O
- O
induced O
hemolysis B-Disease
. O

hemolysis B-Disease
caused O
by O
tam O
was O
not O
preceded O
by O
the O
leakage O
of O
k O
( O
+ O
) O
from O
the O
cells O
, O
also O
excluding O
a O
colloid O
- O
osmotic O
type O
mechanism O
of O
hemolysis B-Disease
, O
according O
to O
the O
effects O
on O
osmotic O
fragility O
curves O
. O

these O
effects O
suggest O
that O
the O
protection O
from O
hemolysis B-Disease
by O
tocopherols O
is O
related O
to O
a O
decreased O
tam O
incorporation O
in O
condensed O
membranes O
and O
the O
structural O
damage O
of O
the O
erythrocyte O
membrane O
is O
consequently O
avoided O
. O

therefore O
, O
tam O
- O
induced O
hemolysis B-Disease
results O
from O
a O
structural O
perturbation O
of O
red O
cell O
membrane O
, O
leading O
to O
changes O
in O
the O
framework O
of O
the O
erythrocyte O
membrane O
and O
its O
cytoskeleton O
caused O
by O
its O
high O
partition O
in O
the O
membrane O
. O

these O
defects O
explain O
the O
abnormal O
erythrocyte O
shape O
and O
decreased O
mechanical O
stability O
promoted O
by O
tam O
, O
resulting O
in O
hemolytic B-Disease
anemia I-Disease
. O

changes O
of O
sodium O
and O
atp O
affinities O
of O
the O
cardiac O
( O
na O
, O
k O
) O
- O
atpase O
during O
and O
after O
nitric O
oxide O
deficient O
hypertension B-Disease
. O

inhibition O
of O
no O
synthesis O
induces O
sustained O
hypertension B-Disease
. O

in O
several O
models O
of O
hypertension B-Disease
, O
elevation O
of O
intracellular O
sodium O
level O
was O
documented O
in O
cardiac O
tissue O
. O

to O
assess O
the O
molecular O
basis O
of O
disturbances O
in O
transmembraneous O
transport O
of O
na O
+ O
, O
we O
studied O
the O
response O
of O
cardiac O
( O
na O
, O
k O
) O
- O
atpase O
to O
no O
- O
deficient O
hypertension B-Disease
induced O
in O
rats O
by O
no O
- O
synthase O
inhibition O
with O
40 O
mg O
/ O
kg O
/ O
day O
n O
( O
g O
) O
- O
nitro O
- O
l O
- O
arginine O
methyl O
ester O
( O
l O
- O
name O
) O
for O
4 O
four O
weeks O
. O

after O
recovery O
from O
hypertension B-Disease
, O
the O
activity O
of O
( O
na O
, O
k O
) O
- O
atpase O
increased O
, O
due O
to O
higher O
affinity O
of O
the O
atp O
- O
binding O
site O
, O
as O
revealed O
from O
the O
lowered O
km O
value O
for O
atp O
. O

inhibition O
of O
no O
- O
synthase O
induced O
a O
reversible O
hypertension B-Disease
accompanied O
by O
depressed B-Disease
na O
+ O
- O
extrusion O
from O
cardiac O
cells O
as O
a O
consequence O
of O
deteriorated O
na O
+ O
- O
binding O
properties O
of O
the O
( O
na O
, O
k O
) O
- O
atpase O
. O

effects O
of O
long O
- O
term O
pretreatment O
with O
isoproterenol O
on O
bromocriptine O
- O
induced O
tachycardia B-Disease
in O
conscious O
rats O
. O

it O
has O
been O
shown O
that O
bromocriptine O
- O
induced O
tachycardia B-Disease
, O
which O
persisted O
after O
adrenalectomy O
, O
is O
( O
i O
) O
mediated O
by O
central O
dopamine O
d2 O
receptor O
activation O
and O
( O
ii O
) O
reduced O
by O
5 O
- O
day O
isoproterenol O
pretreatment O
, O
supporting O
therefore O
the O
hypothesis O
that O
this O
effect O
is O
dependent O
on O
sympathetic O
outflow O
to O
the O
heart O
. O

this O
study O
was O
conducted O
to O
examine O
whether O
prolonged O
pretreatment O
with O
isoproterenol O
could O
abolish O
bromocriptine O
- O
induced O
tachycardia B-Disease
in O
conscious O
rats O
. O

isoproterenol O
pretreatment O
for O
15 O
days O
caused O
cardiac B-Disease
hypertrophy I-Disease
without O
affecting O
baseline O
blood O
pressure O
and O
heart O
rate O
. O

in O
control O
rats O
, O
intravenous O
bromocriptine O
( O
150 O
microg O
/ O
kg O
) O
induced O
significant O
hypotension B-Disease
and O
tachycardia B-Disease
. O

bromocriptine O
- O
induced O
hypotension B-Disease
was O
unaffected O
by O
isoproterenol O
pretreatment O
, O
while O
tachycardia B-Disease
was O
reversed O
to O
significant O
bradycardia B-Disease
, O
an O
effect O
that O
was O
partly O
reduced O
by O
i O
. O

v O
. O

domperidone O
( O
0 O
. O

5 O
mg O
/ O
kg O
) O
. O

these O
results O
show O
that O
15 O
- O
day O
isoproterenol O
pretreatment O
not O
only O
abolished O
but O
reversed O
bromocriptine O
- O
induced O
tachycardia B-Disease
to O
bradycardia B-Disease
, O
an O
effect O
that O
is O
mainly O
related O
to O
further O
cardiac O
beta O
- O
adrenoceptor O
desensitization O
rather O
than O
to O
impairment O
of O
autonomic O
regulation O
of O
the O
heart O
. O

they O
suggest O
that O
, O
in O
normal O
conscious O
rats O
, O
the O
central O
tachycardia B-Disease
of O
bromocriptine O
appears O
to O
predominate O
and O
to O
mask O
the O
bradycardia B-Disease
of O
this O
agonist O
at O
peripheral O
dopamine O
d2 O
receptors O
. O

given O
that O
sympathetic O
neural O
dominance O
exhibits O
a O
similar O
developmental O
pattern O
, O
and O
given O
that O
clonidine O
induces O
sympathetic O
withdrawal O
and O
bradycardia B-Disease
, O
we O
hypothesized O
that O
clonidine O
' O
s O
developmental O
effects O
on O
cardiac O
rate O
and O
ultrasound O
production O
would O
mirror O
each O
other O
. O

age O
- O
related O
changes O
in O
ultrasound O
production O
corresponded O
with O
changes O
in O
cardiovascular O
variables O
, O
including O
baseline O
cardiac O
rate O
and O
clonidine O
- O
induced O
bradycardia B-Disease
. O

recurrent O
use O
of O
newer O
oral O
contraceptives O
and O
the O
risk O
of O
venous B-Disease
thromboembolism I-Disease
. O

the O
epidemiological O
studies O
that O
assessed O
the O
risk O
of O
venous B-Disease
thromboembolism I-Disease
( O
vte B-Disease
) O
associated O
with O
newer O
oral O
contraceptives O
( O
oc O
) O
did O
not O
distinguish O
between O
patterns O
of O
oc O
use O
, O
namely O
first O
- O
time O
users O
, O
repeaters O
and O
switchers O
. O

data O
from O
a O
transnational O
case O
- O
control O
study O
were O
used O
to O
assess O
the O
risk O
of O
vte B-Disease
for O
the O
latter O
patterns O
of O
use O
, O
while O
accounting O
for O
duration O
of O
use O
. O

over O
the O
period O
1993 O
- O
1996 O
, O
551 O
cases O
of O
vte B-Disease
were O
identified O
in O
germany O
and O
the O
uk O
along O
with O
2066 O
controls O
. O

the O
adjusted O
rate O
ratio O
of O
vte B-Disease
for O
repeat O
users O
of O
third O
generation O
oc O
was O
0 O
. O

6 O
( O
95 O
% O
ci O
: O
0 O
. O

3 O
- O
1 O
. O

2 O
) O
relative O
to O
repeat O
users O
of O
second O
generation O
pills O
, O
whereas O
it O
was O
1 O
. O

3 O
( O
95 O
% O
ci O
: O
0 O
. O

7 O
- O
2 O
. O

4 O
) O
for O
switchers O
from O
second O
to O
third O
generation O
pills O
relative O
to O
switchers O
from O
third O
to O
second O
generation O
pills O
. O

we O
conclude O
that O
second O
and O
third O
generation O
agents O
are O
associated O
with O
equivalent O
risks O
of O
vte B-Disease
when O
the O
same O
agent O
is O
used O
repeatedly O
after O
interruption O
periods O
or O
when O
users O
are O
switched O
between O
the O
two O
generations O
of O
pills O
. O

differential O
effects O
of O
systemically O
administered O
ketamine O
and O
lidocaine O
on O
dynamic O
and O
static O
hyperalgesia B-Disease
induced O
by O
intradermal O
capsaicin O
in O
humans O
. O

we O
have O
examined O
the O
effect O
of O
systemic O
administration O
of O
ketamine O
and O
lidocaine O
on O
brush O
- O
evoked O
( O
dynamic O
) O
pain B-Disease
and O
punctate O
- O
evoked O
( O
static O
) O
hyperalgesia B-Disease
induced O
by O
capsaicin O
. O

the O
following O
were O
measured O
: O
spontaneous O
pain B-Disease
, O
pain B-Disease
evoked O
by O
punctate O
and O
brush O
stimuli O
( O
vas O
) O
, O
and O
areas O
of O
brush O
- O
evoked O
and O
punctate O
- O
evoked O
hyperalgesia B-Disease
. O

ketamine O
reduced O
both O
the O
area O
of O
brush O
- O
evoked O
and O
punctate O
- O
evoked O
hyperalgesia B-Disease
significantly O
and O
it O
tended O
to O
reduce O
brush O
- O
evoked O
pain B-Disease
. O

lidocaine O
reduced O
the O
area O
of O
punctate O
- O
evoked O
hyperalgesia B-Disease
significantly O
. O

it O
tended O
to O
reduce O
vas O
scores O
of O
spontaneous O
pain B-Disease
but O
had O
no O
effect O
on O
evoked O
pain B-Disease
. O

the O
differential O
effects O
of O
ketamine O
and O
lidocaine O
on O
static O
and O
dynamic O
hyperalgesia B-Disease
suggest O
that O
the O
two O
types O
of O
hyperalgesia B-Disease
are O
mediated O
by O
separate O
mechanisms O
and O
have O
a O
distinct O
pharmacology O
. O

development O
of O
apomorphine O
- O
induced O
aggressive B-Disease
behavior I-Disease
: O
comparison O
of O
adult O
male O
and O
female O
wistar O
rats O
. O

the O
development O
of O
apomorphine O
- O
induced O
( O
1 O
. O

0 O
mg O
/ O
kg O
s O
. O

c O
. O

once O
daily O
) O
aggressive B-Disease
behavior I-Disease
of O
adult O
male O
and O
female O
wistar O
rats O
obtained O
from O
the O
same O
breeder O
was O
studied O
in O
two O
consecutive O
sets O
. O

in O
male O
animals O
, O
repeated O
apomorphine O
treatment O
induced O
a O
gradual O
development O
of O
aggressive B-Disease
behavior I-Disease
as O
evidenced O
by O
the O
increased O
intensity O
of O
aggressiveness B-Disease
and O
shortened O
latency O
before O
the O
first O
attack O
toward O
the O
opponent O
. O

in O
female O
rats O
, O
only O
a O
weak O
tendency O
toward O
aggressiveness B-Disease
was O
found O
. O

in O
conclusion O
, O
the O
present O
study O
demonstrates O
gender O
differences O
in O
the O
development O
of O
the O
apomorphine O
- O
induced O
aggressive B-Disease
behavior I-Disease
and O
indicates O
that O
the O
female O
rats O
do O
not O
fill O
the O
validation O
criteria O
for O
use O
in O
this O
method O
. O

intracranial B-Disease
aneurysms I-Disease
and O
cocaine B-Disease
abuse I-Disease
: O
analysis O
of O
prognostic O
indicators O
. O

objective O
: O
the O
outcome O
of O
subarachnoid B-Disease
hemorrhage I-Disease
associated O
with O
cocaine B-Disease
abuse I-Disease
is O
reportedly O
poor O
. O

methods O
: O
a O
review O
of O
admissions O
during O
a O
6 O
- O
year O
period O
revealed O
14 O
patients O
with O
cocaine O
- O
related O
aneurysms B-Disease
. O

this O
group O
was O
compared O
with O
a O
control O
group O
of O
135 O
patients O
with O
ruptured B-Disease
aneurysms I-Disease
and O
no O
history O
of O
cocaine B-Disease
abuse I-Disease
. O

age O
at O
presentation O
, O
time O
of O
ictus O
after O
intoxication O
, O
hunt O
and O
hess O
grade O
of O
subarachnoid B-Disease
hemorrhage I-Disease
, O
size O
of O
the O
aneurysm B-Disease
, O
location O
of O
the O
aneurysm B-Disease
, O
and O
the O
glasgow O
outcome O
scale O
score O
were O
assessed O
and O
compared O
. O

in O
patients O
in O
the O
study O
group O
, O
all O
aneurysms B-Disease
were O
located O
in O
the O
anterior O
circulation O
. O

the O
majority O
of O
these O
aneurysms B-Disease
were O
smaller O
than O
those O
of O
the O
control O
group O
( O
8 O
+ O
/ O
- O
6 O
. O

8 O
mm O
versus O
11 O
+ O
/ O
- O
5 O
. O

4 O
mm O
; O
p O
= O
0 O
. O

5 O
) O
. O

hunt O
and O
hess O
grade O
( O
p O
< O
0 O
. O

5 O
) O
and O
age O
( O
p O
< O
0 O
. O

7 O
) O
were O
significant O
predictors O
of O
outcome O
for O
the O
patients O
with O
cocaine O
- O
related O
aneurysms B-Disease
. O

conclusion O
: O
cocaine O
use O
predisposed O
aneurysmal B-Disease
rupture I-Disease
at O
a O
significantly O
earlier O
age O
and O
in O
much O
smaller O
aneurysms B-Disease
. O

effect O
of O
intravenous O
nimodipine O
on O
blood O
pressure O
and O
outcome O
after O
acute B-Disease
stroke I-Disease
. O

background O
and O
purpose O
: O
the O
intravenous O
nimodipine O
west O
european O
stroke B-Disease
trial O
( O
inwest O
) O
found O
a O
correlation O
between O
nimodipine O
- O
induced O
reduction B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
( O
bp O
) O
and O
an O
unfavorable O
outcome O
in O
acute B-Disease
stroke I-Disease
. O

we O
sought O
to O
confirm O
this O
correlation O
with O
and O
without O
adjustment O
for O
prognostic O
variables O
and O
to O
investigate O
outcome O
in O
subgroups O
with O
increasing O
levels O
of O
bp B-Disease
reduction I-Disease
. O

methods O
: O
patients O
with O
a O
clinical O
diagnosis O
of O
ischemic B-Disease
stroke I-Disease
( O
within O
24 O
hours O
) O
were O
consecutively O
allocated O
to O
receive O
placebo O
( O
n O
= O
100 O
) O
, O
1 O
mg O
/ O
h O
( O
low O
- O
dose O
) O
nimodipine O
( O
n O
= O
101 O
) O
, O
or O
2 O
mg O
/ O
h O
( O
high O
- O
dose O
) O
nimodipine O
( O
n O
= O
94 O
) O
. O

nimodipine O
treatment O
resulted O
in O
a O
statistically O
significant O
reduction B-Disease
in I-Disease
systolic I-Disease
bp I-Disease
( O
sbp O
) O
and O
diastolic O
bp O
( O
dbp O
) O
from O
baseline O
compared O
with O
placebo O
during O
the O
first O
few O
days O
. O

in O
multivariate O
analysis O
, O
a O
significant O
correlation O
between O
dbp B-Disease
reduction I-Disease
and O
worsening O
of O
the O
neurological O
score O
was O
found O
for O
the O
high O
- O
dose O
group O
( O
beta O
= O
0 O
. O

49 O
, O
p O
= O
0 O
. O

48 O
) O
. O

patients O
with O
a O
dbp B-Disease
reduction I-Disease
of O
> O
or O
= O
20 O
% O
in O
the O
high O
- O
dose O
group O
had O
a O
significantly O
increased O
adjusted O
or O
for O
the O
compound O
outcome O
variable O
death B-Disease
or O
dependency O
( O
barthel O
index O
< O
60 O
) O
( O
n O
/ O
n O
= O
25 O
/ O
26 O
, O
or O
10 O
. O

16 O
, O
95 O
% O
ci O
1 O
. O

2 O
to O
101 O
. O

74 O
) O
and O
death B-Disease
alone O
( O
n O
/ O
n O
= O
9 O
/ O
26 O
, O
or O
4 O
. O

336 O
, O
95 O
% O
ci O
1 O
. O

131 O
16 O
. O

619 O
) O
compared O
with O
all O
placebo O
patients O
( O
n O
/ O
n O
= O
62 O
/ O
92 O
and O
14 O
/ O
92 O
, O
respectively O
) O
. O

conclusions O
: O
dbp O
, O
but O
not O
sbp O
, O
reduction O
was O
associated O
with O
neurological O
worsening O
after O
the O
intravenous O
administration O
of O
high O
- O
dose O
nimodipine O
after O
acute B-Disease
stroke I-Disease
. O

neonatal O
pyridoxine O
responsive O
convulsions B-Disease
due O
to O
isoniazid O
therapy O
. O

a O
17 O
- O
day O
- O
old O
infant O
on O
isoniazid O
therapy O
13 O
mg O
/ O
kg O
daily O
from O
birth O
because O
of O
maternal O
tuberculosis B-Disease
was O
admitted O
after O
4 O
days O
of O
clonic B-Disease
fits I-Disease
. O

the O
fits B-Disease
ceased O
within O
4 O
hours O
of O
administering O
intramuscular O
pyridoxine O
, O
suggesting O
an O
aetiology O
of O
pyridoxine O
deficiency O
secondary O
to O
isoniazid O
medication O
. O

ketamine O
sedation O
for O
the O
reduction O
of O
children O
' O
s O
fractures B-Disease
in O
the O
emergency O
department O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
examine O
the O
safety O
and O
efficacy O
of O
ketamine O
for O
sedation O
in O
the O
treatment O
of O
children O
' O
s O
fractures B-Disease
in O
the O
emergency O
department O
. O

methods O
: O
one O
hundred O
and O
fourteen O
children O
( O
average O
age O
, O
5 O
. O

3 O
years O
; O
range O
, O
twelve O
months O
to O
ten O
years O
and O
ten O
months O
) O
who O
underwent O
closed O
reduction O
of O
an O
isolated O
fracture B-Disease
or O
dislocation B-Disease
in O
the O
emergency O
department O
at O
a O
level O
- O
i O
trauma B-Disease
center O
were O
prospectively O
evaluated O
. O

any O
pain B-Disease
during O
the O
reduction O
was O
rated O
by O
the O
orthopaedic O
surgeon O
treating O
the O
patient O
according O
to O
the O
children O
' O
s O
hospital O
of O
eastern O
ontario O
pain B-Disease
scale O
( O
cheops O
) O
. O

results O
: O
the O
average O
time O
from O
intravenous O
administration O
of O
ketamine O
to O
manipulation O
of O
the O
fracture B-Disease
or O
dislocation B-Disease
was O
one O
minute O
and O
thirty O
- O
six O
seconds O
( O
range O
, O
twenty O
seconds O
to O
five O
minutes O
) O
, O
and O
the O
average O
time O
from O
intramuscular O
administration O
to O
manipulation O
was O
four O
minutes O
and O
forty O
- O
two O
seconds O
( O
range O
, O
sixty O
seconds O
to O
fifteen O
minutes O
) O
. O

the O
average O
score O
according O
to O
the O
children O
' O
s O
hospital O
of O
eastern O
ontario O
pain B-Disease
scale O
was O
6 O
. O

4 O
points O
( O
range O
, O
5 O
to O
10 O
points O
) O
, O
reflecting O
minimal O
or O
no O
pain B-Disease
during O
fracture B-Disease
reduction O
. O

adequate O
fracture B-Disease
reduction O
was O
obtained O
in O
111 O
of O
the O
children O
. O

minor O
side O
effects O
included O
nausea B-Disease
( O
thirteen O
patients O
) O
, O
emesis B-Disease
( O
eight O
of O
the O
thirteen O
patients O
with O
nausea B-Disease
) O
, O
clumsiness B-Disease
( O
evident O
as O
ataxic B-Disease
movements I-Disease
in O
ten O
patients O
) O
, O
and O
dysphoric B-Disease
reaction I-Disease
( O
one O
patient O
) O
. O

no O
long O
- O
term O
sequelae O
were O
noted O
, O
and O
no O
patients O
had O
hallucinations B-Disease
or O
nightmares O
. O

conclusions O
: O
ketamine O
reliably O
, O
safely O
, O
and O
quickly O
provided O
adequate O
sedation O
to O
effectively O
facilitate O
the O
reduction O
of O
children O
' O
s O
fractures B-Disease
in O
the O
emergency O
department O
at O
our O
institution O
. O

cyclosporine O
and O
tacrolimus O
- O
associated O
thrombotic B-Disease
microangiopathy I-Disease
. O

the O
development O
of O
thrombotic B-Disease
microangiopathy I-Disease
( O
tma B-Disease
) O
associated O
with O
the O
use O
of O
cyclosporine O
has O
been O
well O
documented O
. O

as O
a O
result O
, O
switching O
to O
tacrolimus O
has O
been O
reported O
to O
be O
a O
viable O
therapeutic O
option O
in O
the O
setting O
of O
cyclosporine O
- O
induced O
tma B-Disease
. O

with O
the O
more O
widespread O
application O
of O
tacrolimus O
in O
organ O
transB-Plantation O
, O
tacrolimus O
- O
associated O
tma B-Disease
has O
also O
been O
recognized O
. O

however O
, O
literature O
regarding O
the O
incidence O
of O
the O
recurrence O
of O
tma B-Disease
in O
patients O
exposed O
sequentially O
to O
cyclosporine O
and O
tacrolimus O
is O
limited O
. O

we O
report O
a O
case O
of O
a O
living O
donor O
renal O
transB-Plant O
recipient O
who O
developed O
cyclosporine O
- O
induced O
tma B-Disease
that O
responded O
to O
the O
withdrawal O
of O
cyclosporine O
in O
conjunction O
with O
plasmapheresis O
and O
fresh O
frozen O
plasma O
replacement O
therapy O
. O

introduction O
of O
tacrolimus O
as O
an O
alternative O
immunosuppressive O
agent O
resulted O
in O
the O
recurrence O
of O
tma B-Disease
and O
the O
subsequent O
loss O
of O
the O
renal O
allograft O
. O

patients O
who O
are O
switched O
from O
cyclosporine O
to O
tacrolimus O
or O
vice O
versa O
should O
be O
closely O
monitored O
for O
the O
signs O
and O
symptoms O
of O
recurrent O
tma B-Disease
. O

analgesic O
effect O
of O
intravenous O
ketamine O
in O
cancer B-Disease
patients O
on O
morphine O
therapy O
: O
a O
randomized O
, O
controlled O
, O
double O
- O
blind O
, O
crossover O
, O
double O
- O
dose O
study O
. O

pain B-Disease
not O
responsive O
to O
morphine O
is O
often O
problematic O
. O

animal O
and O
clinical O
studies O
have O
suggested O
that O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
antagonists O
, O
such O
as O
ketamine O
, O
may O
be O
effective O
in O
improving O
opioid O
analgesia O
in O
difficult O
pain B-Disease
syndromes O
, O
such O
as O
neuropathic B-Disease
pain I-Disease
. O

a O
slow O
bolus O
of O
subhypnotic O
doses O
of O
ketamine O
( O
0 O
. O

25 O
mg O
/ O
kg O
or O
0 O
. O

50 O
mg O
/ O
kg O
) O
was O
given O
to O
10 O
cancer B-Disease
patients O
whose O
pain B-Disease
was O
unrelieved O
by O
morphine O
in O
a O
randomized O
, O
double O
- O
blind O
, O
crossover O
, O
double O
- O
dose O
study O
. O

pain B-Disease
intensity O
on O
a O
0 O
to O
10 O
numerical O
scale O
; O
nausea B-Disease
and O
vomiting B-Disease
, O
drowsiness O
, O
confusion B-Disease
, O
and O
dry B-Disease
mouth I-Disease
, O
using O
a O
scale O
from O
0 O
to O
3 O
( O
not O
at O
all O
, O
slight O
, O
a O
lot O
, O
awful O
) O
; O
mini O
- O
mental O
state O
examination O
( O
mmse O
) O
( O
0 O
- O
30 O
) O
; O
and O
arterial O
pressure O
were O
recorded O
before O
administration O
of O
drugs O
( O
t0 O
) O
and O
after O
30 O
minutes O
( O
t30 O
) O
, O
60 O
minutes O
( O
t60 O
) O
, O
120 O
minutes O
( O
t120 O
) O
, O
and O
180 O
minutes O
( O
t180 O
) O
. O

ketamine O
, O
but O
not O
saline O
solution O
, O
significantly O
reduced O
the O
pain B-Disease
intensity O
in O
almost O
all O
the O
patients O
at O
both O
doses O
. O

hallucinations B-Disease
occurred O
in O
4 O
patients O
, O
and O
an O
unpleasant O
sensation O
( O
nan O
empty O
head O
nan O
) O
was O
also O
reported O
by O
2 O
patients O
. O

ketamine O
can O
improve O
morphine O
analgesia O
in O
difficult O
pain B-Disease
syndromes O
, O
such O
as O
neuropathic B-Disease
pain I-Disease
. O

paclitaxel O
, O
cisplatin O
, O
and O
gemcitabine O
combination O
chemotherapy O
within O
a O
multidisciplinary O
therapeutic O
approach O
in O
metastatic O
nonsmall B-Disease
cell I-Disease
lung I-Disease
carcinoma I-Disease
. O

background O
: O
cisplatin O
- O
based O
chemotherapy O
combinations O
improve O
quality O
of O
life O
and O
survival O
in O
advanced O
nonsmall B-Disease
cell I-Disease
lung I-Disease
carcinoma I-Disease
( O
nsclc B-Disease
) O
. O

methods O
: O
the O
objective O
of O
this O
study O
was O
to O
determine O
the O
feasibility O
, O
response O
rate O
, O
and O
toxicity B-Disease
of O
a O
paclitaxel O
, O
cisplatin O
, O
and O
gemcitabine O
combination O
to O
treat O
metastatic O
nsclc B-Disease
. O

thirty O
- O
five O
consecutive O
chemotherapy O
- O
naive O
patients O
with O
stage O
iv O
nsclc B-Disease
and O
an O
eastern O
cooperative O
oncology O
group O
performance O
status O
of O
0 O
- O
2 O
were O
treated O
with O
a O
combination O
of O
paclitaxel O
( O
135 O
mg O
/ O
m O
( O
2 O
) O
given O
intravenously O
in O
3 O
hours O
) O
on O
day O
1 O
, O
cisplatin O
( O
120 O
mg O
/ O
m O
( O
2 O
) O
given O
intravenously O
in O
6 O
hours O
) O
on O
day O
1 O
, O
and O
gemcitabine O
( O
800 O
mg O
/ O
m O
( O
2 O
) O
given O
intravenously O
in O
30 O
minutes O
) O
on O
days O
1 O
and O
8 O
, O
every O
4 O
weeks O
. O

although O
responding O
patients O
were O
scheduled O
to O
receive O
consolidation O
radiotherapy O
and O
24 O
patients O
received O
preplanned O
second O
- O
line O
chemotherapy O
after O
disease O
progression O
, O
the O
response O
and O
toxicity B-Disease
rates O
reported O
refer O
only O
to O
the O
chemotherapy O
regimen O
given O
. O

results O
: O
all O
the O
patients O
were O
examined O
for O
toxicity B-Disease
; O
34 O
were O
examinable O
for O
response O
. O

world O
health O
organization O
grade O
3 O
- O
4 O
neutropenia B-Disease
and O
thrombocytopenia B-Disease
occurred O
in O
39 O
. O

9 O
% O
and O
11 O
. O

4 O
% O
of O
patients O
, O
respectively O
. O

there O
was O
one O
treatment O
- O
related O
death B-Disease
. O

nonhematologic O
toxicities B-Disease
were O
mild O
. O

conclusions O
: O
the O
combination O
of O
paclitaxel O
, O
cisplatin O
, O
and O
gemcitabine O
is O
well O
tolerated O
and O
shows O
high O
activity O
in O
metastatic O
nsclc B-Disease
. O

serotonergic O
antidepressants O
and O
urinary B-Disease
incontinence I-Disease
. O

although O
urinary B-Disease
incontinence I-Disease
is O
listed O
as O
one O
side O
effect O
of O
these O
drugs O
in O
their O
package O
inserts O
there O
is O
only O
one O
report O
in O
the O
literature O
. O

this O
concerns O
2 O
male O
patients O
who O
experienced O
incontinence B-Disease
while O
taking O
venlafaxine O
. O

in O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence B-Disease
secondary O
to O
the O
selective O
serotonin O
reuptake O
inhibitors O
paroxetine O
and O
sertraline O
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine O
. O

in O
2 O
of O
the O
3 O
cases O
the O
patients O
were O
also O
taking O
lithium O
carbonate O
and O
beta O
- O
blockers O
, O
both O
of O
which O
could O
have O
contributed O
to O
the O
incontinence B-Disease
. O

animal O
studies O
suggest O
that O
incontinence B-Disease
secondary O
to O
serotonergic O
antidepressants O
could O
be O
mediated O
by O
the O
5ht4 O
receptors O
found O
on O
the O
bladder O
. O

acute O
cocaine O
- O
induced O
seizures B-Disease
: O
differential O
sensitivity O
of O
six O
inbred O
mouse O
strains O
. O

mature O
male O
and O
female O
mice O
from O
six O
inbred O
stains O
were O
tested O
for O
susceptibility O
to O
behavioral O
seizures B-Disease
induced O
by O
a O
single O
injection O
of O
cocaine O
. O

seizure B-Disease
end O
points O
included O
latency O
to O
forelimb O
or O
hindlimb O
clonus O
, O
latency O
to O
clonic O
running O
seizure B-Disease
and O
latency O
to O
jumping O
bouncing O
seizure B-Disease
. O

additional O
studies O
of O
these O
murine O
strains O
may O
be O
useful O
for O
investigating O
genetic O
influences O
on O
cocaine O
- O
induced O
seizures B-Disease
. O

hypotension B-Disease
following O
the O
initiation O
of O
tizanidine O
in O
a O
patient O
treated O
with O
an O
angiotensin O
converting O
enzyme O
inhibitor O
for O
chronic O
hypertension B-Disease
. O

centrally O
acting O
alpha O
- O
2 O
adrenergic O
agonists O
are O
one O
of O
several O
pharmacologic O
agents O
used O
in O
the O
treatment O
of O
spasticity B-Disease
related O
to O
disorders B-Disease
of I-Disease
the I-Disease
central I-Disease
nervous I-Disease
system I-Disease
. O

in O
addition O
to O
their O
effects O
on O
spasticity B-Disease
, O
certain O
adverse O
cardiorespiratory O
effects O
have O
been O
reported O
. O

adults O
chronically O
treated O
with O
angiotensin O
converting O
enzyme O
inhibitors O
may O
have O
a O
limited O
ability O
to O
respond O
to O
hypotension B-Disease
when O
the O
sympathetic O
response O
is O
simultaneously O
blocked O
. O

the O
authors O
present O
a O
10 O
- O
year O
- O
old O
boy O
chronically O
treated O
with O
lisinopril O
, O
an O
angiotensin O
converting O
enzyme O
inhibitor O
, O
to O
control O
hypertension B-Disease
who O
developed O
hypotension B-Disease
following O
the O
addition O
of O
tizanidine O
, O
an O
alpha O
- O
2 O
agonist O
, O
for O
the O
treatment O
of O
spasticity B-Disease
. O

the O
possible O
interaction O
of O
tizanidine O
and O
other O
antihypertensive O
agents O
should O
be O
kept O
in O
mind O
when O
prescribing O
therapy O
to O
treat O
either O
hypertension B-Disease
or O
spasticity B-Disease
in O
such O
patients O
. O

two O
mouse O
lines O
selected O
for O
differential O
sensitivities O
to O
beta O
- O
carboline O
- O
induced O
seizures B-Disease
are O
also O
differentially O
sensitive O
to O
various O
pharmacological O
effects O
of O
other O
gaba O
( O
a O
) O
receptor O
ligands O
. O

two O
mouse O
lines O
were O
selectively O
bred O
according O
to O
their O
sensitivity O
( O
bs O
line O
) O
or O
resistance O
( O
br O
line O
) O
to O
seizures B-Disease
induced O
by O
a O
single O
i O
. O

p O
. O

injection O
of O
methyl O
beta O
- O
carboline O
- O
3 O
- O
carboxylate O
( O
beta O
- O
ccm O
) O
, O
an O
inverse O
agonist O
of O
the O
gaba O
( O
a O
) O
receptor O
benzodiazepine O
site O
. O

we O
measured O
diazepam O
- O
induced O
anxiolysis O
with O
the O
elevated O
plus O
- O
maze O
test O
, O
diazepam O
- O
induced O
sedation O
by O
recording O
the O
vigilance O
states O
, O
and O
picrotoxin O
- O
and O
pentylenetetrazol O
- O
induced O
seizures B-Disease
after O
i O
. O

p O
. O

injections O
. O

propylthiouracil O
- O
induced O
perinuclear O
- O
staining O
antineutrophil O
cytoplasmic O
autoantibody O
- O
positive O
vasculitis B-Disease
in O
conjunction O
with O
pericarditis B-Disease
. O

objective O
: O
to O
describe O
a O
case O
of O
propylthiouracil O
- O
induced O
vasculitis B-Disease
manifesting O
with O
pericarditis B-Disease
. O

methods O
: O
we O
present O
the O
first O
case O
report O
of O
a O
woman O
with O
hyperthyroidism B-Disease
treated O
with O
propylthiouracil O
in O
whom O
a O
syndrome O
of O
pericarditis B-Disease
, O
fever B-Disease
, O
and O
glomerulonephritis B-Disease
developed O
. O

results O
: O
a O
25 O
- O
year O
- O
old O
woman O
with O
graves B-Disease
' I-Disease
disease I-Disease
had O
a O
febrile B-Disease
illness I-Disease
and O
evidence O
of O
pericarditis B-Disease
, O
which O
was O
confirmed O
by O
biopsy O
. O

a O
literature O
review O
revealed O
no O
prior O
reports O
of O
pericarditis B-Disease
in O
anti O
- O
mpo O
panca O
- O
positive O
vasculitis B-Disease
associated O
with O
propylthio O
- O
uracil O
therapy O
. O

conclusion O
: O
pericarditis B-Disease
may O
be O
the O
initial O
manifestation O
of O
drug O
- O
induced O
vasculitis B-Disease
attributable O
to O
propylthio O
- O
uracil O
therapy O
. O

repeated O
transient O
anuria B-Disease
following O
losartan O
administration O
in O
a O
patient O
with O
a O
solitary O
kidney O
. O

we O
report O
the O
case O
of O
a O
70 O
- O
year O
- O
old O
hypertensive B-Disease
man O
with O
a O
solitary O
kidney O
and O
chronic B-Disease
renal I-Disease
insufficiency I-Disease
who O
developed O
two O
episodes O
of O
transient O
anuria B-Disease
after O
losartan O
administration O
. O

he O
was O
hospitalized O
for O
a O
myocardial B-Disease
infarction I-Disease
with O
pulmonary B-Disease
edema I-Disease
, O
treated O
with O
high O
- O
dose O
diuretics O
. O

due O
to O
severe O
systolic B-Disease
dysfunction I-Disease
losartan O
was O
prescribed O
. O

surprisingly O
, O
the O
first O
dose O
of O
50 O
mg O
of O
losartan O
resulted O
in O
a O
sudden O
anuria B-Disease
, O
which O
lasted O
eight O
hours O
despite O
high O
- O
dose O
furosemide O
and O
amine O
infusion O
. O

one O
week O
later O
, O
by O
mistake O
, O
losartan O
was O
prescribed O
again O
and O
after O
the O
second O
dose O
of O
50 O
mg O
, O
the O
patient O
developed O
a O
second O
episode O
of O
transient O
anuria B-Disease
lasting O
10 O
hours O
. O

during O
these O
two O
episodes O
, O
his O
blood O
pressure O
diminished O
but O
no O
severe O
hypotension B-Disease
was O
noted O
. O

ultimately O
, O
an O
arteriography O
showed O
a O
70 O
- O
80 O
% O
renal B-Disease
artery I-Disease
stenosis I-Disease
. O

in O
this O
patient O
, O
renal B-Disease
artery I-Disease
stenosis I-Disease
combined O
with O
heart B-Disease
failure I-Disease
and O
diuretic O
therapy O
certainly O
resulted O
in O
a O
strong O
activation O
of O
the O
renin O
- O
angiotensin O
system O
( O
ras O
) O
. O

this O
case O
report O
highlights O
the O
fact O
that O
the O
angiotensin O
ii O
receptor O
antagonist O
losartan O
can O
cause O
serious O
unexpected O
complications O
in O
patients O
with O
renovascular B-Disease
disease I-Disease
and O
should O
be O
used O
with O
extreme O
caution O
in O
this O
setting O
. O

calcineurin O
- O
inhibitor O
induced O
pain B-Disease
syndrome O
( O
cips B-Disease
) O
: O
a O
severe O
disabling O
complication O
after O
organ O
transB-Plantation O
. O

bone O
pain B-Disease
after O
transB-Plantation O
is O
a O
frequent O
complication O
that O
can O
be O
caused O
by O
several O
diseases O
. O

treatment O
strategies O
depend O
on O
the O
correct O
diagnosis O
of O
the O
pain B-Disease
. O

nine O
patients O
with O
severe O
pain B-Disease
in O
their O
feet O
, O
which O
was O
registered O
after O
transB-Plantation O
, O
were O
investigated O
. O

magnetic O
resonance O
imaging O
demonstrated O
bone B-Disease
marrow I-Disease
oedema I-Disease
in O
the O
painful O
bones O
. O

pain B-Disease
was O
not O
explained O
by O
other O
diseases O
causing O
foot O
pain B-Disease
, O
like O
reflex B-Disease
sympathetic I-Disease
dystrophy I-Disease
, O
polyneuropathy B-Disease
, O
morton B-Disease
' I-Disease
s I-Disease
neuralgia I-Disease
, O
gout B-Disease
, O
osteoporosis B-Disease
, O
avascular B-Disease
necrosis I-Disease
, O
intermittent B-Disease
claudication I-Disease
, O
orthopaedic O
foot B-Disease
deformities I-Disease
, O
stress B-Disease
fractures I-Disease
, O
and O
hyperparathyroidism B-Disease
. O

the O
reduction O
of O
cyclosporine O
- O
or O
tacrolimus O
trough O
levels O
and O
the O
administration O
of O
calcium O
channel O
blockers O
led O
to O
relief O
of O
pain B-Disease
. O

the O
calcineurin O
- O
inhibitor O
induced O
pain B-Disease
syndrome O
( O
cips B-Disease
) O
is O
a O
rare O
but O
severe O
side O
effect O
of O
cyclosporine O
or O
tacrolimus O
and O
is O
accurately O
diagnosed O
by O
its O
typical O
presentation O
, O
magnetic O
resonance O
imaging O
and O
bone O
scans O
. O

incorrect O
diagnosis O
of O
the O
syndrome O
will O
lead O
to O
a O
significant O
reduction O
of O
life O
quality O
in O
patients O
suffering O
from O
cips B-Disease
. O

brain O
natriuretic O
peptide O
is O
a O
predictor O
of O
anthracycline O
- O
induced O
cardiotoxicity B-Disease
. O

anthracyclines O
are O
effective O
antineoplastic O
drugs O
, O
but O
they O
frequently O
cause O
dose O
- O
related O
cardiotoxicity B-Disease
. O

the O
cardiotoxicity B-Disease
of O
conventional O
anthracycline O
therapy O
highlights O
a O
need O
to O
search O
for O
methods O
that O
are O
highly O
sensitive O
and O
capable O
of O
predicting O
cardiac B-Disease
dysfunction I-Disease
. O

we O
measured O
the O
plasma O
level O
of O
brain O
natriuretic O
peptide O
( O
bnp O
) O
to O
determine O
whether O
bnp O
might O
serve O
as O
a O
simple O
diagnostic O
indicator O
of O
anthracycline O
- O
induced O
cardiotoxicity B-Disease
in O
patients O
with O
acute B-Disease
leukemia I-Disease
treated O
with O
a O
daunorubicin O
( O
dnr O
) O
- O
containing O
regimen O
. O

thirteen O
patients O
with O
acute B-Disease
leukemia I-Disease
were O
treated O
with O
a O
dnr O
- O
containing O
regimen O
. O

three O
patients O
developed O
congestive B-Disease
heart I-Disease
failure I-Disease
after O
the O
completion O
of O
chemotherapy O
. O

five O
patients O
were O
diagnosed O
as O
having O
subclinical O
heart B-Disease
failure I-Disease
after O
the O
completion O
of O
chemotherapy O
. O

the O
plasma O
levels O
of O
bnp O
in O
all O
the O
patients O
with O
clinical O
and O
subclinical O
heart B-Disease
failure I-Disease
increased O
above O
the O
normal O
limit O
( O
40 O
pg O
/ O
ml O
) O
before O
the O
detection O
of O
clinical O
or O
subclinical O
heart B-Disease
failure I-Disease
by O
radionuclide O
angiography O
. O

on O
the O
other O
hand O
, O
bnp O
did O
not O
increase O
in O
the O
patients O
without O
heart B-Disease
failure I-Disease
given O
dnr O
, O
even O
at O
more O
than O
700 O
mg O
/ O
m O
( O
2 O
) O
. O

the O
plasma O
level O
of O
anp O
did O
not O
always O
increase O
in O
all O
the O
patients O
with O
clinical O
and O
subclinical O
heart B-Disease
failure I-Disease
. O

these O
preliminary O
results O
suggest O
that O
bnp O
may O
be O
useful O
as O
an O
early O
and O
sensitive O
indicator O
of O
anthracycline O
- O
induced O
cardiotoxicity B-Disease
. O

nephrotoxicity B-Disease
of O
combined O
cephalothin O
- O
gentamicin O
regimen O
. O

two O
patients O
developed O
acute B-Disease
tubular I-Disease
necrosis I-Disease
, O
characterized O
clinically O
by O
acute O
oliguric B-Disease
renal I-Disease
failure I-Disease
, O
while O
they O
were O
receiving O
a O
combination O
of O
cephalothin O
sodium O
and O
gentamicin O
sulfate O
therapy O
. O

patients O
who O
are O
given O
this O
drug O
regimen O
should O
be O
observed O
very O
carefully O
for O
early O
signs O
of O
nephrotoxicity B-Disease
. O

patients O
with O
renal B-Disease
insufficiency I-Disease
should O
not O
be O
given O
this O
regimen O
. O

in O
vivo O
protection O
of O
dna O
damage O
associated O
apoptotic O
and O
necrotic B-Disease
cell O
deaths O
during O
acetaminophen O
- O
induced O
nephrotoxicity B-Disease
, O
amiodarone O
- O
induced O
lung B-Disease
toxicity I-Disease
and O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
by O
a O
novel O
ih636 O
grape O
seed O
proanthocyanidin O
extract O
. O

this O
study O
assessed O
the O
ability O
of O
ih636 O
grape O
seed O
proanthocyanidin O
extract O
( O
gspe O
) O
to O
prevent O
acetaminophen O
( O
aap O
) O
- O
induced O
nephrotoxicity B-Disease
, O
amiodarone O
( O
ami O
) O
- O
induced O
lung B-Disease
toxicity I-Disease
, O
and O
doxorubicin O
( O
dox O
) O
- O
induced O
cardiotoxicity B-Disease
in O
mice O
. O

histopathological O
examination O
of O
kidney O
, O
heart O
and O
lung O
sections O
revealed O
moderate O
to O
massive O
tissue B-Disease
damage I-Disease
with O
a O
variety O
of O
morphological O
aberrations O
by O
all O
the O
three O
drugs O
in O
the O
absence O
of O
gspe O
preexposure O
than O
in O
its O
presence O
. O

interestingly O
, O
all O
the O
drugs O
, O
such O
as O
, O
aap O
, O
ami O
and O
dox O
induced O
apoptotic O
death O
in O
addition O
to O
necrosis B-Disease
in O
the O
respective O
organs O
which O
was O
very O
effectively O
blocked O
by O
gspe O
. O

antidepressant O
- O
induced O
mania B-Disease
in O
bipolar B-Disease
patients O
: O
identification O
of O
risk O
factors O
. O

background O
: O
concerns O
about O
possible O
risks O
of O
switching O
to O
mania B-Disease
associated O
with O
antidepressants O
continue O
to O
interfere O
with O
the O
establishment O
of O
an O
optimal O
treatment O
paradigm O
for O
bipolar B-Disease
depression I-Disease
. O

method O
: O
the O
response O
of O
44 O
patients O
meeting O
dsm O
- O
iv O
criteria O
for O
bipolar B-Disease
disorder I-Disease
to O
naturalistic O
treatment O
was O
assessed O
for O
at O
least O
6 O
weeks O
using O
the O
montgomery O
- O
asberg O
depression O
rating O
scale O
and O
the O
bech O
- O
rafaelson O
mania O
rating O
scale O
. O

patients O
who O
experienced O
a O
manic B-Disease
or O
hypomanic B-Disease
switch O
were O
compared O
with O
those O
who O
did O
not O
on O
several O
variables O
including O
age O
, O
sex O
, O
diagnosis O
( O
dsm B-Disease
- I-Disease
iv I-Disease
bipolar I-Disease
i I-Disease
vs O
. O

bipolar B-Disease
ii I-Disease
) O
, O
number O
of O
previous O
manic B-Disease
episodes O
, O
type O
of O
antidepressant O
therapy O
used O
( O
electroconvulsive O
therapy O
vs O
. O

antidepressant O
drugs O
and O
, O
more O
particularly O
, O
selective O
serotonin O
reuptake O
inhibitors O
[ O
ssris O
] O
) O
, O
use O
and O
type O
of O
mood O
stabilizers O
( O
lithium O
vs O
. O

anticonvulsants O
) O
, O
and O
temperament O
of O
the O
patient O
, O
assessed O
during O
a O
normothymic O
period O
using O
the O
hyperthymia O
component O
of O
the O
semi O
- O
structured O
affective O
temperament O
interview O
. O

results O
: O
switches O
to O
hypomania B-Disease
or O
mania B-Disease
occurred O
in O
27 O
% O
of O
all O
patients O
( O
n O
= O
12 O
) O
( O
and O
in O
24 O
% O
of O
the O
subgroup O
of O
patients O
treated O
with O
ssris O
[ O
8 O
/ O
33 O
] O
) O
; O
16 O
% O
( O
n O
= O
7 O
) O
experienced O
manic B-Disease
episodes O
, O
and O
11 O
% O
( O
n O
= O
5 O
) O
experienced O
hypomanic B-Disease
episodes O
. O

sex O
, O
age O
, O
diagnosis O
( O
bipolar B-Disease
i I-Disease
vs O
. O

bipolar B-Disease
ii I-Disease
) O
, O
and O
additional O
treatment O
did O
not O
affect O
the O
risk O
of O
switching O
. O

the O
number O
of O
previous O
manic B-Disease
episodes O
did O
not O
affect O
the O
probability O
of O
switching O
, O
whereas O
a O
high O
score O
on O
the O
hyperthymia O
component O
of O
the O
semistructured O
affective O
temperament O
interview O
was O
associated O
with O
a O
greater O
risk O
of O
switching O
( O
p O
= O
. O

8 O
) O
. O

peritubular O
capillary O
basement O
membrane O
reduplication O
in O
allografts O
and O
native O
kidney B-Disease
disease I-Disease
: O
a O
clinicopathologic O
study O
of O
278 O
consecutive O
renal O
specimens O
. O

background O
: O
an O
association O
has O
been O
found O
between O
transB-Plant B-Disease
glomerulopathy I-Disease
( O
tg B-Disease
) O
and O
reduplication O
of O
peritubular O
capillary O
basement O
membranes O
( O
ptcr O
) O
. O

in O
addition O
to O
renal O
allografts O
with O
tg B-Disease
, O
we O
also O
examined O
grafts O
with O
acute O
rejection O
, O
recurrent O
glomerulonephritis B-Disease
, O
chronic B-Disease
allograft I-Disease
nephropathy I-Disease
and O
stable O
grafts O
( O
nan O
protocol O
biopsies O
nan O
) O
. O

native O
kidney O
specimens O
included O
a O
wide O
range O
of O
glomerulopathies B-Disease
as O
well O
as O
cases O
of O
thrombotic B-Disease
microangiopathy I-Disease
, O
malignant B-Disease
hypertension I-Disease
, O
acute O
interstitial B-Disease
nephritis I-Disease
, O
and O
acute B-Disease
tubular I-Disease
necrosis I-Disease
. O

results O
: O
we O
found O
ptcr O
in O
14 O
of O
15 O
cases O
of O
tg B-Disease
, O
in O
7 O
transB-Plant O
biopsy O
specimens O
without O
tg B-Disease
, O
and O
in O
13 O
of O
143 O
native O
kidney O
biopsy O
specimens O
. O

these O
13 O
included O
cases O
of O
malignant B-Disease
hypertension I-Disease
, O
thrombotic B-Disease
microangiopathy I-Disease
, O
lupus B-Disease
nephritis I-Disease
, O
henoch B-Disease
- I-Disease
schonlein I-Disease
nephritis I-Disease
, O
crescentic O
glomerulonephritis B-Disease
, O
and O
cocaine O
- O
related O
acute B-Disease
renal I-Disease
failure I-Disease
. O

mild O
ptcr O
in O
allografts O
without O
tg B-Disease
did O
not O
predict O
renal B-Disease
failure I-Disease
or O
significant O
proteinuria B-Disease
after O
follow O
- O
up O
periods O
of O
between O
3 O
months O
and O
1 O
year O
. O

conclusions O
: O
we O
conclude O
that O
in O
transB-Plants O
, O
there O
is O
a O
strong O
association O
between O
well O
- O
developed O
ptcr O
and O
tg B-Disease
, O
while O
the O
significance O
of O
mild O
ptcr O
and O
its O
predictive O
value O
in O
the O
absence O
of O
tg B-Disease
is O
unclear O
. O

ptcr O
also O
occurs O
in O
certain O
native O
kidney B-Disease
diseases I-Disease
, O
though O
the O
association O
is O
not O
as O
strong O
as O
that O
for O
tg B-Disease
. O

we O
suggest O
that O
repeated O
endothelial B-Disease
injury I-Disease
, O
including O
immunologic B-Disease
injury I-Disease
, O
may O
be O
the O
cause O
of O
this O
lesion O
both O
in O
allografts O
and O
native O
kidneys O
. O

caffeine O
- O
induced O
cardiac B-Disease
arrhythmia I-Disease
: O
an O
unrecognised O
danger O
of O
healthfood O
products O
. O

we O
describe O
a O
25 O
- O
year O
- O
old O
woman O
with O
pre O
- O
existing O
mitral B-Disease
valve I-Disease
prolapse I-Disease
who O
developed O
intractable O
ventricular B-Disease
fibrillation I-Disease
after O
consuming O
a O
nan O
natural O
energy O
nan O
guarana O
health O
drink O
containing O
a O
high O
concentration O
of O
caffeine O
. O

in O
behavioral O
studies O
, O
pre O
- O
treatment O
of O
mice O
with O
bd1018 O
, O
bd1063 O
, O
or O
lr132 O
significantly O
attenuated O
cocaine O
- O
induced O
convulsions B-Disease
and O
lethality O
. O

in O
contrast O
to O
the O
protection O
provided O
by O
the O
putative O
antagonists O
, O
the O
well O
- O
characterized O
sigma O
receptor O
agonist O
di O
- O
o O
- O
tolylguanidine O
( O
dtg O
) O
and O
the O
novel O
sigma O
receptor O
agonist O
bd1031 O
( O
3r O
- O
1 O
- O
[ O
2 O
- O
( O
3 O
, O
4 O
- O
dichlorophenyl O
) O
ethyl O
] O
- O
1 O
, O
4 O
- O
diazabicyclo O
[ O
4 O
. O

3 O
. O

0 O
] O
nonane O
) O
each O
worsened O
the O
behavioral O
toxicity B-Disease
of O
cocaine O
. O

to O
further O
validate O
the O
hypothesis O
that O
the O
anti O
- O
cocaine O
effects O
of O
the O
novel O
ligands O
involved O
antagonism O
of O
sigma O
receptors O
, O
an O
antisense O
oligodeoxynucleotide O
against O
sigma1 O
receptors O
was O
also O
shown O
to O
significantly O
attenuate O
the O
convulsive B-Disease
and O
locomotor O
stimulatory O
effects O
of O
cocaine O
. O

ranitidine O
- O
induced O
acute O
interstitial B-Disease
nephritis I-Disease
in O
a O
cadaveric O
renal O
allograft O
. O

this O
drug O
occasionally O
has O
been O
associated O
with O
acute O
interstitial B-Disease
nephritis I-Disease
in O
native O
kidneys O
. O

we O
report O
a O
case O
of O
ranitidine O
- O
induced O
acute O
interstitial B-Disease
nephritis I-Disease
in O
a O
recipient O
of O
a O
cadaveric O
renal O
allograft O
presenting O
with O
acute O
allograft O
dysfunction O
within O
48 O
hours O
of O
exposure O
to O
the O
drug O
. O

liver B-Disease
disease I-Disease
caused O
by O
propylthiouracil O
. O

this O
report O
presents O
the O
clinical O
, O
laboratory O
, O
and O
light O
and O
electron O
microscopic O
observations O
on O
a O
patient O
with O
chronic B-Disease
active I-Disease
( I-Disease
aggressive I-Disease
) I-Disease
hepatitis I-Disease
caused O
by O
the O
administration O
of O
propylthiouracil O
. O

this O
is O
an O
addition O
to O
the O
list O
of O
drugs O
that O
must O
be O
considered O
in O
the O
evaluation O
of O
chronic O
liver B-Disease
disease I-Disease
. O

withdrawal B-Disease
- I-Disease
emergent I-Disease
rabbit I-Disease
syndrome I-Disease
during O
dose O
reduction O
of O
risperidone O
. O

rabbit B-Disease
syndrome I-Disease
( O
rs B-Disease
) O
is O
a O
rare O
extrapyramidal O
side O
effect O
caused O
by O
prolonged O
neuroleptic O
medication O
. O

here O
we O
present O
a O
case O
of O
withdrawal B-Disease
- I-Disease
emergent I-Disease
rs I-Disease
, O
which O
is O
the O
first O
of O
its O
kind O
to O
be O
reported O
. O

the O
patient O
developed O
rs B-Disease
during O
dose O
reduction O
of O
risperidone O
. O

the O
underlying O
mechanism O
of O
withdrawal B-Disease
- I-Disease
emergent I-Disease
rs I-Disease
in O
the O
present O
case O
may O
have O
been O
related O
to O
the O
pharmacological O
profile O
of O
risperidone O
, O
a O
serotonin O
- O
dopamine O
antagonist O
, O
suggesting O
the O
pathophysiologic O
influence O
of O
the O
serotonin O
system O
in O
the O
development O
of O
rs B-Disease
. O

torsades B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
is O
a O
potentially O
fatal O
ventricular B-Disease
tachycardia I-Disease
associated O
with O
increases O
in O
qt O
interval O
and O
monophasic O
action O
potential O
duration O
( O
mapd O
) O
. O

tdp B-Disease
is O
a O
side O
- O
effect O
that O
has O
led O
to O
withdrawal O
of O
several O
drugs O
from O
the O
market O
( O
e O
. O

g O
. O

terfenadine O
and O
terodiline O
) O
. O

the O
potential O
of O
compounds O
to O
cause O
tdp B-Disease
was O
evaluated O
by O
monitoring O
their O
effects O
on O
mapd O
in O
dog O
. O

four O
compounds O
known O
to O
increase O
qt O
interval O
and O
cause O
tdp B-Disease
were O
investigated O
: O
terfenadine O
, O
terodiline O
, O
cisapride O
and O
e4031 O
. O

for O
compounds O
that O
have O
shown O
tdp B-Disease
in O
the O
clinic O
( O
terfenadine O
, O
terodiline O
, O
cisapride O
) O
there O
is O
little O
differentiation O
between O
the O
dog O
ed50 O
and O
the O
efficacious O
free O
plasma O
concentrations O
in O
man O
( O
< O
10 O
- O
fold O
) O
reflecting O
their O
limited O
safety O
margins O
. O

these O
data O
underline O
the O
need O
to O
maximize O
the O
therapeutic O
ratio O
with O
respect O
to O
tdp B-Disease
in O
potential O
development O
candidates O
and O
the O
importance O
of O
using O
free O
drug O
concentrations O
in O
pharmacokinetic O
/ O
pharmacodynamic O
studies O
. O

bladder O
retention B-Disease
of I-Disease
urine I-Disease
as O
a O
result O
of O
continuous O
intravenous O
infusion O
of O
fentanyl O
: O
2 O
case O
reports O
. O

sedation O
has O
been O
commonly O
used O
in O
the O
neonate O
to O
decrease O
the O
stress O
and O
pain B-Disease
from O
the O
noxious O
stimuli O
and O
invasive O
procedures O
in O
the O
neonatal O
intensive O
care O
unit O
, O
as O
well O
as O
to O
facilitate O
synchrony O
between O
ventilator O
and O
spontaneous O
breaths O
. O

various O
reported O
side O
effects O
of O
fentanyl O
administration O
include O
chest B-Disease
wall I-Disease
rigidity I-Disease
, O
hypotension B-Disease
, O
respiratory B-Disease
depression I-Disease
, O
and O
bradycardia B-Disease
. O

here O
, O
2 O
cases O
of O
urinary B-Disease
bladder I-Disease
retention I-Disease
leading O
to O
renal O
pelvocalyceal O
dilatation O
mimicking O
hydronephrosis B-Disease
as O
a O
result O
of O
continuous O
infusion O
of O
fentanyl O
are O
reported O
. O

fatal O
myeloencephalopathy B-Disease
due O
to O
accidental O
intrathecal O
vincristin O
administration O
: O
a O
report O
of O
two O
cases O
. O

we O
report O
on O
two O
fatal O
cases O
of O
accidental O
intrathecal O
vincristine O
instillation O
in O
a O
5 O
- O
year O
old O
girl O
with O
recurrent O
acute B-Disease
lymphoblastic I-Disease
leucemia I-Disease
and O
a O
57 O
- O
year O
old O
man O
with O
lymphoblastic B-Disease
lymphoma I-Disease
. O

clinically O
, O
the O
onset O
was O
characterized O
by O
the O
signs O
of O
opistothonus B-Disease
, I-Disease
sensory I-Disease
and I-Disease
motor I-Disease
dysfunction I-Disease
and O
ascending O
paralysis B-Disease
. O

histological O
and O
immunohistochemical O
investigations O
( O
he O
- O
lfb O
, O
cd O
- O
68 O
, O
neurofilament O
) O
revealed O
degeneration B-Disease
of I-Disease
myelin I-Disease
and I-Disease
axons I-Disease
as O
well O
as O
pseudocystic B-Disease
transformation I-Disease
in O
areas O
exposed O
to O
vincristine O
, O
accompanied O
by O
secondary O
changes O
with O
numerous O
prominent O
macrophages O
. O

palpebral B-Disease
twitching I-Disease
in O
a O
depressed B-Disease
adolescent O
on O
citalopram O
. O

current O
estimates O
suggest O
that O
between O
0 O
. O

4 O
% O
and O
8 O
. O

3 O
% O
of O
children O
and O
adolescents O
are O
affected O
by O
major B-Disease
depression I-Disease
. O

we O
report O
a O
favorable O
response O
to O
treatment O
with O
citalopram O
by O
a O
15 O
- O
year O
- O
old O
boy O
with O
major B-Disease
depression I-Disease
who O
exhibited O
palpebral B-Disease
twitching I-Disease
during O
his O
first O
2 O
weeks O
of O
treatment O
. O

a O
34 O
- O
year O
- O
old O
lady O
developed O
a O
constellation O
of O
dermatitis B-Disease
, O
fever B-Disease
, O
lymphadenopathy B-Disease
and O
hepatitis B-Disease
, O
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine O
for O
sero O
- O
negative O
rheumatoid B-Disease
arthritis I-Disease
. O

cervical O
and O
inguinal O
lymph O
node O
biopsies O
showed O
the O
features O
of O
severe O
necrotising O
lymphadenitis B-Disease
, O
associated O
with O
erythrophagocytosis O
and O
prominent O
eosinophilic O
infiltrates O
, O
without O
viral O
inclusion O
bodies O
, O
suggestive O
of O
an O
adverse B-Disease
drug I-Disease
reaction I-Disease
. O

a O
week O
later O
, O
fulminant O
drug B-Disease
- I-Disease
induced I-Disease
hepatitis I-Disease
, O
associated O
with O
the O
presence O
of O
anti O
- O
nuclear O
autoantibodies O
( O
but O
not O
with O
other O
markers O
of O
autoimmunity B-Disease
) O
, O
and O
accompanied O
by O
multi B-Disease
- I-Disease
organ I-Disease
failure I-Disease
and O
sepsis B-Disease
, O
supervened O
. O

she O
subsequently O
died O
some O
5 O
weeks O
after O
the O
commencement O
of O
her O
drug O
therapy O
. O

post O
- O
mortem O
examination O
showed O
evidence O
of O
massive B-Disease
hepatocellular I-Disease
necrosis I-Disease
, O
acute O
hypersensitivity O
myocarditis B-Disease
, O
focal O
acute O
tubulo O
- O
interstitial O
nephritis B-Disease
and O
extensive O
bone B-Disease
marrow I-Disease
necrosis I-Disease
, O
with O
no O
evidence O
of O
malignancy B-Disease
. O

intravenous O
administration O
of O
prochlorperazine O
by O
15 O
- O
minute O
infusion O
versus O
2 O
- O
minute O
bolus O
does O
not O
affect O
the O
incidence O
of O
akathisia B-Disease
: O
a O
prospective O
, O
randomized O
, O
controlled O
trial O
. O

study O
objective O
: O
we O
sought O
to O
compare O
the O
rate O
of O
akathisia B-Disease
after O
administration O
of O
intravenous O
prochlorperazine O
as O
a O
2 O
- O
minute O
bolus O
or O
15 O
- O
minute O
infusion O
. O

patients O
aged O
18 O
years O
or O
older O
treated O
with O
prochlorperazine O
for O
headache B-Disease
, O
nausea B-Disease
, O
or O
vomiting B-Disease
were O
eligible O
for O
inclusion O
. O

the O
main O
outcome O
was O
the O
number O
of O
study O
participants O
experiencing O
akathisia B-Disease
within O
60 O
minutes O
of O
administration O
. O

akathisia O
was O
defined O
as O
either O
a O
spontaneous O
report O
of O
restlessness O
or O
agitation B-Disease
or O
a O
change O
of O
2 O
or O
more O
in O
the O
patient O
- O
reported O
akathisia B-Disease
rating O
scale O
and O
a O
change O
of O
at O
least O
1 O
in O
the O
investigator O
- O
observed O
akathisia B-Disease
rating O
scale O
. O

the O
intensity O
of O
headache B-Disease
and O
nausea B-Disease
was O
measured O
with O
a O
100 O
- O
mm O
visual O
analog O
scale O
. O

seventy O
- O
three O
percent O
( O
73 O
/ O
99 O
) O
of O
the O
study O
participants O
were O
treated O
for O
headache B-Disease
and O
70 O
% O
( O
70 O
/ O
99 O
) O
for O
nausea B-Disease
. O

in O
the O
bolus O
group O
, O
26 O
. O

0 O
% O
( O
13 O
/ O
50 O
) O
had O
akathisia B-Disease
compared O
with O
32 O
. O

7 O
% O
( O
16 O
/ O
49 O
) O
in O
the O
infusion O
group O
( O
delta O
= O
- O
6 O
. O

7 O
% O
; O
95 O
% O
confidence O
interval O
[ O
ci O
] O
- O
24 O
. O

6 O
% O
to O
11 O
. O

2 O
% O
) O
. O

the O
difference O
between O
the O
bolus O
and O
infusion O
groups O
in O
the O
percentage O
of O
participants O
who O
saw O
a O
50 O
% O
reduction O
in O
their O
headache B-Disease
intensity O
within O
30 O
minutes O
was O
11 O
. O

8 O
% O
( O
95 O
% O
ci O
- O
9 O
. O

6 O
% O
to O
33 O
. O

3 O
% O
) O
. O

the O
difference O
in O
the O
percentage O
of O
patients O
with O
a O
50 O
% O
reduction O
in O
their O
nausea B-Disease
was O
12 O
. O

6 O
% O
( O
95 O
% O
ci O
- O
4 O
. O

6 O
% O
to O
29 O
. O

8 O
% O
) O
. O

conclusion O
: O
a O
50 O
% O
reduction O
in O
the O
incidence O
of O
akathisia B-Disease
when O
prochlorperazine O
was O
administered O
by O
means O
of O
15 O
- O
minute O
intravenous O
infusion O
versus O
a O
2 O
- O
minute O
intravenous O
push O
was O
not O
detected O
. O

the O
efficacy O
of O
prochlorperazine O
in O
the O
treatment O
of O
headache B-Disease
and O
nausea B-Disease
likewise O
did O
not O
appear O
to O
be O
affected O
by O
the O
rate O
of O
administration O
, O
although O
no O
formal O
statistical O
comparisons O
were O
made O
. O

combined O
antiretroviral O
therapy O
causes O
cardiomyopathy B-Disease
and O
elevates O
plasma O
lactate O
in O
transgenic O
aids B-Disease
mice O
. O

highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
is O
implicated O
in O
cardiomyopathy B-Disease
( O
cm B-Disease
) O
and O
in O
elevated O
plasma O
lactate O
( O
la O
) O
in O
aids B-Disease
through O
mechanisms O
of O
mitochondrial B-Disease
dysfunction I-Disease
. O

to O
determine O
mitochondrial O
events O
from O
haart O
in O
vivo O
, O
8 O
- O
week O
- O
old O
hemizygous O
transgenic O
aids B-Disease
mice O
( O
nl4 O
- O
3delta O
gag O
/ O
pol O
; O
tg O
) O
and O
wild O
- O
type O
fvb O
/ O
n O
littermates O
were O
treated O
with O
the O
haart O
combination O
of O
zidovudine O
, O
lamivudine O
, O
and O
indinavir O
or O
vehicle O
control O
for O
10 O
days O
or O
35 O
days O
. O

at O
termination O
of O
the O
experiments O
, O
mice O
underwent O
echocardiography O
, O
quantitation O
of O
abundance O
of O
molecular O
markers O
of O
cm B-Disease
( O
ventricular O
mrna O
encoding O
atrial O
natriuretic O
factor O
[ O
anf O
] O
and O
sarcoplasmic O
calcium O
atpase O
[ O
serca2 O
] O
) O
, O
and O
determination O
of O
plasma O
la O
. O

results O
show O
that O
cumulative O
haart O
caused O
mitochondrial O
cm B-Disease
with O
elevated O
la O
in O
aids B-Disease
transgenic O
mice O
. O

a O
phase O
ii O
trial O
of O
cisplatin O
plus O
wr O
- O
2721 O
( O
amifostine O
) O
for O
metastatic O
breast B-Disease
carcinoma I-Disease
: O
an O
eastern O
cooperative O
oncology O
group O
study O
( O
e8188 O
) O
. O

background O
: O
cisplatin O
has O
minimal O
antitumor O
activity O
when O
used O
as O
second O
- O
or O
third O
- O
line O
treatment O
of O
metastatic O
breast B-Disease
carcinoma I-Disease
. O

although O
a O
dose O
- O
response O
effect O
has O
been O
observed O
with O
cisplatin O
, O
the O
dose O
- O
limiting O
toxicities B-Disease
associated O
with O
cisplatin O
( O
e O
. O

g O
. O

, O
nephrotoxicity B-Disease
, O
ototoxicity B-Disease
, O
and O
neurotoxicity B-Disease
) O
have O
limited O
its O
use O
as O
a O
treatment O
for O
breast B-Disease
carcinoma I-Disease
. O

early O
trials O
of O
cisplatin O
and O
amifostine O
also O
suggested O
that O
the O
incidence O
and O
severity O
of O
cisplatin O
- O
induced O
nephrotoxicity B-Disease
, O
ototoxicity B-Disease
, O
and O
neuropathy B-Disease
were O
reduced O
. O

methods O
: O
a O
phase O
ii O
study O
of O
the O
combination O
of O
cisplatin O
plus O
amifostine O
was O
conducted O
in O
patients O
with O
progressive O
metastatic O
breast B-Disease
carcinoma I-Disease
who O
had O
received O
one O
, O
but O
not O
more O
than O
one O
, O
chemotherapy O
regimen O
for O
metastatic O
disease O
. O

neurologic B-Disease
toxicity I-Disease
was O
reported O
in O
52 O
% O
of O
patients O
. O

seven O
different O
life O
- O
threatening O
toxicities B-Disease
were O
observed O
in O
patients O
while O
receiving O
treatment O
. O

neither O
a O
tumor B-Disease
- O
protective O
effect O
nor O
reduced O
toxicity B-Disease
to O
normal O
tissues O
was O
observed O
with O
the O
addition O
of O
amifostine O
to O
cisplatin O
in O
this O
trial O
. O

oral O
contraceptives O
and O
the O
risk O
of O
myocardial B-Disease
infarction I-Disease
. O

background O
: O
an O
association O
between O
the O
use O
of O
oral O
contraceptives O
and O
the O
risk O
of O
myocardial B-Disease
infarction I-Disease
has O
been O
found O
in O
some O
, O
but O
not O
all O
, O
studies O
. O

we O
investigated O
this O
association O
, O
according O
to O
the O
type O
of O
progestagen O
included O
in O
third O
- O
generation O
( O
i O
. O

e O
. O

, O
desogestrel O
or O
gestodene O
) O
and O
second O
- O
generation O
( O
i O
. O

e O
. O

, O
levonorgestrel O
) O
oral O
contraceptives O
, O
the O
dose O
of O
estrogen O
, O
and O
the O
presence O
or O
absence O
of O
prothrombotic O
mutations O
methods O
: O
in O
a O
nationwide O
, O
population O
- O
based O
, O
case O
- O
control O
study O
, O
we O
identified O
and O
enrolled O
248 O
women O
18 O
through O
49 O
years O
of O
age O
who O
had O
had O
a O
first O
myocardial B-Disease
infarction I-Disease
between O
1990 O
and O
1995 O
and O
925 O
control O
women O
who O
had O
not O
had O
a O
myocardial B-Disease
infarction I-Disease
and O
who O
were O
matched O
for O
age O
, O
calendar O
year O
of O
the O
index O
event O
, O
and O
area O
of O
residence O
. O

an O
analysis O
for O
factor O
v O
leiden O
and O
the O
g20210a O
mutation O
in O
the O
prothrombin O
gene O
was O
conducted O
in O
217 O
patients O
and O
763 O
controls O
results O
: O
the O
odds O
ratio O
for O
myocardial B-Disease
infarction I-Disease
among O
women O
who O
used O
any O
type O
of O
combined O
oral O
contraceptive O
, O
as O
compared O
with O
nonusers O
, O
was O
2 O
. O

0 O
( O
95 O
percent O
confidence O
interval O
, O
1 O
. O

5 O
to O
2 O
. O

8 O
) O
. O

among O
women O
who O
used O
oral O
contraceptives O
, O
the O
odds O
ratio O
was O
2 O
. O

1 O
( O
95 O
percent O
confidence O
interval O
, O
1 O
. O

5 O
to O
3 O
. O

0 O
) O
for O
those O
without O
a O
prothrombotic O
mutation O
and O
1 O
. O

9 O
( O
95 O
percent O
confidence O
interval O
, O
0 O
. O

6 O
to O
5 O
. O

5 O
) O
for O
those O
with O
a O
mutation O
conclusions O
: O
the O
risk O
of O
myocardial B-Disease
infarction I-Disease
was O
increased O
among O
women O
who O
used O
second O
- O
generation O
oral O
contraceptives O
. O

the O
risk O
of O
myocardial B-Disease
infarction I-Disease
was O
similar O
among O
women O
who O
used O
oral O
contraceptives O
whether O
or O
not O
they O
had O
a O
prothrombotic O
mutation O
. O

end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
( O
esrd B-Disease
) O
after O
orthotopic O
liver O
transB-Plantation O
( O
oltx O
) O
using O
calcineurin O
- O
based O
immunotherapy O
: O
risk O
of O
development O
and O
treatment O
. O

background O
: O
the O
calcineurin O
inhibitors O
cyclosporine O
and O
tacrolimus O
are O
both O
known O
to O
be O
nephrotoxic B-Disease
. O

recently O
, O
however O
, O
we O
have O
had O
an O
increase O
of O
patients O
who O
are O
presenting O
after O
oltx O
with O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
( O
esrd B-Disease
) O
. O

this O
retrospective O
study O
examines O
the O
incidence O
and O
treatment O
of O
esrd B-Disease
and O
chronic B-Disease
renal I-Disease
failure I-Disease
( O
crf B-Disease
) O
in O
oltx O
patients O
. O

patients O
were O
divided O
into O
three O
groups O
: O
controls O
, O
no O
crf B-Disease
or O
esrd B-Disease
, O
n O
= O
748 O
; O
crf B-Disease
, O
sustained O
serum O
creatinine O
> O
2 O
. O

5 O
mg O
/ O
dl O
, O
n O
= O
41 O
; O
and O
esrd B-Disease
, O
n O
= O
45 O
. O

groups O
were O
compared O
for O
preoperative O
laboratory O
variables O
, O
diagnosis O
, O
postoperative O
variables O
, O
survival O
, O
type O
of O
esrd B-Disease
therapy O
, O
and O
survival O
from O
onset O
of O
esrd B-Disease
. O

results O
: O
at O
13 O
years O
after O
oltx O
, O
the O
incidence O
of O
severe O
renal B-Disease
dysfunction I-Disease
was O
18 O
. O

1 O
% O
( O
crf B-Disease
8 O
. O

6 O
% O
and O
esrd B-Disease
9 O
. O

5 O
% O
) O
. O

compared O
with O
control O
patients O
, O
crf B-Disease
and O
esrd B-Disease
patients O
had O
higher O
preoperative O
serum O
creatinine O
levels O
, O
a O
greater O
percentage O
of O
patients O
with O
hepatorenal B-Disease
syndrome I-Disease
, O
higher O
percentage O
requirement O
for O
dialysis O
in O
the O
first O
3 O
months O
postoperatively O
, O
and O
a O
higher O
1 O
- O
year O
serum O
creatinine O
. O

multivariate O
stepwise O
logistic O
regression O
analysis O
using O
preoperative O
and O
postoperative O
variables O
identified O
that O
an O
increase O
of O
serum O
creatinine O
compared O
with O
average O
at O
1 O
year O
, O
3 O
months O
, O
and O
4 O
weeks O
postoperatively O
were O
independent O
risk O
factors O
for O
the O
development O
of O
crf B-Disease
or O
esrd B-Disease
with O
odds O
ratios O
of O
2 O
. O

6 O
, O
2 O
. O

2 O
, O
and O
1 O
. O

6 O
, O
respectively O
. O

overall O
survival O
from O
the O
time O
of O
oltx O
was O
not O
significantly O
different O
among O
groups O
, O
but O
by O
year O
13 O
, O
the O
survival O
of O
the O
patients O
who O
had O
esrd B-Disease
was O
only O
28 O
. O

2 O
% O
compared O
with O
54 O
. O

6 O
% O
in O
the O
control O
group O
. O

patients O
developing O
esrd B-Disease
had O
a O
6 O
- O
year O
survival O
after O
onset O
of O
esrd B-Disease
of O
27 O
% O
for O
the O
patients O
receiving O
hemodialysis O
versus O
71 O
. O

4 O
% O
for O
the O
patients O
developing O
esrd B-Disease
who O
subsequently O
received O
kidney O
transB-Plants O
. O

conclusions O
: O
patients O
who O
are O
more O
than O
10 O
years O
post O
- O
oltx O
have O
crf B-Disease
and O
esrd B-Disease
at O
a O
high O
rate O
. O

the O
development O
of O
esrd B-Disease
decreases O
survival O
, O
particularly O
in O
those O
patients O
treated O
with O
dialysis O
only O
. O

patients O
who O
develop O
esrd B-Disease
have O
a O
higher O
preoperative O
and O
1 O
- O
year O
serum O
creatinine O
and O
are O
more O
likely O
to O
have O
hepatorenal B-Disease
syndrome I-Disease
. O

however O
, O
an O
increase O
of O
serum O
creatinine O
at O
various O
times O
postoperatively O
is O
more O
predictive O
of O
the O
development O
of O
crf B-Disease
or O
esrd B-Disease
. O

epileptic B-Disease
seizures I-Disease
following O
cortical O
application O
of O
fibrin O
sealants O
containing O
tranexamic O
acid O
in O
rats O
. O

however O
, O
tamca O
has O
been O
shown O
to O
cause O
epileptic B-Disease
seizures I-Disease
. O

we O
wanted O
to O
study O
whether O
tamca O
retains O
its O
convulsive B-Disease
action O
if O
incorporated O
into O
a O
fs O
. O

findings O
: O
fs O
containing O
tamca O
caused O
paroxysmal O
brain O
activity O
which O
was O
associated O
with O
distinct O
convulsive B-Disease
behaviours O
. O

the O
degree O
of O
these O
seizures B-Disease
increased O
with O
increasing O
concentration O
of O
tamca O
. O

thus O
, O
fs O
containing O
47 O
. O

5 O
mg O
/ O
ml O
tamca O
evoked O
generalized B-Disease
seizures I-Disease
in O
all O
tested O
rats O
( O
n O
= O
6 O
) O
while O
the O
lowest O
concentration O
of O
tamca O
( O
0 O
. O

5 O
mg O
/ O
ml O
) O
only O
evoked O
brief O
episodes O
of O
jerk O
- O
correlated O
convulsive B-Disease
potentials O
in O
1 O
of O
6 O
rats O
. O

interpretation O
: O
tranexamic O
acid O
retains O
its O
convulsive B-Disease
action O
within O
fs O
. O

sequential O
observations O
of O
exencephaly B-Disease
and O
subsequent O
morphological O
changes O
by O
mouse O
exo O
utero O
development O
system O
: O
analysis O
of O
the O
mechanism O
of O
transformation O
from O
exencephaly B-Disease
to O
anencephaly B-Disease
. O

anencephaly B-Disease
has O
been O
suggested O
to O
develop O
from O
exencephaly B-Disease
; O
however O
, O
there O
is O
little O
direct O
experimental O
evidence O
to O
support O
this O
, O
and O
the O
mechanism O
of O
transformation O
remains O
unclear O
. O

we O
observed O
the O
exencephaly B-Disease
induced O
by O
5 O
- O
azacytidine O
at O
embryonic O
day O
13 O
. O

5 O
( O
e13 O
. O

5 O
) O
, O
let O
the O
embryos O
develop O
exo O
utero O
until O
e18 O
. O

5 O
, O
and O
re O
- O
observed O
the O
same O
embryos O
at O
e18 O
. O

5 O
. O

we O
confirmed O
several O
cases O
of O
transformation O
from O
exencephaly B-Disease
to O
anencephaly B-Disease
. O

however O
, O
in O
many O
cases O
, O
the O
exencephalic B-Disease
brain O
tissue O
was O
preserved O
with O
more O
or O
less O
reduction O
during O
this O
period O
. O

to O
analyze O
the O
transformation O
patterns O
, O
we O
classified O
the O
exencephaly B-Disease
by O
size O
and O
shape O
of O
the O
exencephalic B-Disease
tissue O
into O
several O
types O
at O
e13 O
. O

5 O
and O
e18 O
. O

5 O
. O

it O
was O
found O
that O
the O
transformation O
of O
exencephalic B-Disease
tissue O
was O
not O
simply O
size O
- O
dependent O
, O
and O
all O
cases O
of O
anencephaly B-Disease
at O
e18 O
. O

5 O
resulted O
from O
embryos O
with O
a O
large O
amount O
of O
exencephalic B-Disease
tissue O
at O
e13 O
. O

5 O
. O

microscopic O
observation O
showed O
the O
configuration O
of O
exencephaly B-Disease
at O
e13 O
. O

5 O
, O
frequent O
hemorrhaging B-Disease
and O
detachment O
of O
the O
neural O
plate O
from O
surface O
ectoderm O
in O
the O
exencephalic B-Disease
head O
at O
e15 O
. O

5 O
, O
and O
multiple O
modes O
of O
reduction O
in O
the O
exencephalic B-Disease
tissue O
at O
e18 O
. O

5 O
. O

from O
observations O
of O
the O
vasculature O
, O
altered O
distribution O
patterns O
of O
vessels O
were O
identified O
in O
the O
exencephalic B-Disease
head O
. O

these O
findings O
suggest O
that O
overgrowth O
of O
the O
exencephalic B-Disease
neural O
tissue O
causes O
the O
altered O
distribution O
patterns O
of O
vessels O
, O
subsequent O
peripheral O
circulatory B-Disease
failure I-Disease
and O
/ O
or O
hemorrhaging B-Disease
in O
various O
parts O
of O
the O
exencephalic B-Disease
head O
, O
leading O
to O
the O
multiple O
modes O
of O
tissue O
reduction O
during O
transformation O
from O
exencephaly B-Disease
to O
anencephaly B-Disease
. O

99mtc O
- O
glucarate O
for O
detection O
of O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

infarct B-Disease
- O
avid O
radiopharmaceuticals O
are O
necessary O
for O
rapid O
and O
timely O
diagnosis O
of O
acute O
myocardial B-Disease
infarction I-Disease
. O

the O
animal O
model O
used O
to O
produce O
infarction B-Disease
implies O
artery O
ligation O
but O
chemical O
induction O
can O
be O
easily O
obtained O
with O
isoproterenol O
. O

a O
new O
infarct B-Disease
- O
avid O
radiopharmaceutical O
based O
on O
glucaric O
acid O
was O
prepared O
in O
the O
hospital O
radiopharmacy O
of O
the O
incmnsz O
. O

99mtc O
- O
glucarate O
was O
easy O
to O
prepare O
, O
stable O
for O
96 O
h O
and O
was O
used O
to O
study O
its O
biodistribution O
in O
rats O
with O
isoproterenol O
- O
induced O
acute O
myocardial B-Disease
infarction I-Disease
. O

histological O
studies O
demonstrated O
that O
the O
rats O
developed O
an O
infarct B-Disease
18 O
h O
after O
isoproterenol O
administration O
. O

the O
high O
image O
quality O
suggests O
that O
high O
contrast O
images O
can O
be O
obtained O
in O
humans O
and O
the O
96 O
h O
stability O
makes O
it O
an O
ideal O
agent O
to O
detect O
, O
in O
patients O
, O
early O
cardiac B-Disease
infarction I-Disease
. O

bupropion O
( O
zyban O
) O
toxicity B-Disease
. O

in O
the O
initial O
6 O
months O
since O
it O
' O
s O
introduction O
, O
12 O
overdose B-Disease
cases O
have O
been O
reported O
to O
the O
national O
poisons O
information O
centre O
. O

8 O
patients O
developed O
symptoms O
of O
toxicity B-Disease
. O

common O
features O
included O
tachycardia B-Disease
, O
drowsiness O
, O
hallucinations B-Disease
and O
convulsions B-Disease
. O

two O
patients O
developed O
severe O
cardiac B-Disease
arrhythmias I-Disease
, O
including O
one O
patient O
who O
was O
resuscitated O
following O
a O
cardiac B-Disease
arrest I-Disease
. O

recurrent O
seizures B-Disease
were O
treated O
with O
diazepam O
and O
broad O
complex O
tachycardia B-Disease
was O
successfully O
treated O
with O
adenosine O
. O

zyban O
caused O
significant O
neurological B-Disease
and I-Disease
cardiovascular I-Disease
toxicity I-Disease
in O
overdose B-Disease
. O

glepp1 O
receptor O
tyrosine O
phosphatase O
( O
ptpro O
) O
in O
rat O
pan O
nephrosis B-Disease
. O

to O
better O
understand O
the O
utility O
of O
glepp1 O
as O
a O
marker O
of O
glomerular B-Disease
injury I-Disease
, O
the O
amount O
and O
distribution O
of O
glepp1 O
protein O
and O
mrna O
were O
examined O
by O
immunohistochemistry O
, O
western O
blot O
and O
rnase O
protection O
assay O
in O
a O
model O
of O
podocyte O
injury O
in O
the O
rat O
. O

puromycin O
aminonucleoside O
nephrosis B-Disease
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
puromycin O
aminonucleoside O
( O
pan O
, O
20 O
mg O
/ O
100g O
bw O
) O
. O

tissues O
were O
analyzed O
at O
0 O
, O
5 O
, O
7 O
, O
11 O
, O
21 O
, O
45 O
, O
80 O
and O
126 O
days O
after O
pan O
injection O
so O
as O
to O
include O
both O
the O
acute O
phase O
of O
proteinuria B-Disease
associated O
with O
foot O
process O
effacement O
( O
days O
5 O
- O
11 O
) O
and O
the O
chronic O
phase O
of O
proteinuria B-Disease
associated O
with O
glomerulosclerosis B-Disease
( O
days O
45 O
- O
126 O
) O
. O

antithymocyte O
globulin O
in O
the O
treatment O
of O
d O
- O
penicillamine O
- O
induced O
aplastic B-Disease
anemia I-Disease
. O

a O
patient O
who O
received O
antithymocyte O
globulin O
therapy O
for O
aplastic B-Disease
anemia I-Disease
due O
to O
d O
- O
penicillamine O
therapy O
is O
described O
. O

use O
of O
antithymocyte O
globulin O
may O
be O
the O
optimal O
treatment O
of O
d O
- O
penicillamine O
- O
induced O
aplastic B-Disease
anemia I-Disease
. O

metamizol O
potentiates O
morphine O
antinociception O
but O
not O
constipation B-Disease
after O
chronic O
treatment O
. O

this O
work O
evaluates O
the O
antinociceptive O
and O
constipating B-Disease
effects O
of O
the O
combination O
of O
3 O
. O

2 O
mg O
/ O
kg O
s O
. O

c O
. O

morphine O
with O
177 O
. O

8 O
mg O
/ O
kg O
s O
. O

c O
. O

metamizol O
in O
acutely O
and O
chronically O
treated O
( O
once O
a O
day O
for O
12 O
days O
) O
rats O
. O

on O
the O
13th O
day O
, O
antinociceptive O
effects O
were O
assessed O
using O
a O
model O
of O
inflammatory O
nociception O
, O
pain B-Disease
- O
induced O
functional O
impairment O
model O
, O
and O
the O
charcoal O
meal O
test O
was O
used O
to O
evaluate O
the O
intestinal O
transit O
. O

in O
independent O
groups O
, O
morphine O
inhibited O
the O
intestinal O
transit O
in O
48 O
+ O
/ O
- O
4 O
% O
and O
38 O
+ O
/ O
- O
4 O
% O
after O
acute O
and O
chronic O
treatment O
, O
respectively O
, O
suggesting O
that O
tolerance O
did O
not O
develop O
to O
the O
constipating B-Disease
effects O
. O

the O
combination O
inhibited O
intestinal O
transit O
similar O
to O
that O
produced O
by O
morphine O
regardless O
of O
the O
time O
of O
treatment O
, O
suggesting O
that O
metamizol O
did O
not O
potentiate O
morphine O
- O
induced O
constipation B-Disease
. O

these O
findings O
show O
a O
significant O
interaction O
between O
morphine O
and O
metamizol O
in O
chronically O
treated O
rats O
, O
suggesting O
that O
this O
combination O
could O
be O
useful O
for O
the O
treatment O
of O
chronic B-Disease
pain I-Disease
. O

ifosfamide O
encephalopathy B-Disease
presenting O
with O
asterixis B-Disease
. O

we O
report O
a O
case O
of O
a O
51 O
- O
year O
- O
old O
man O
who O
developed O
severe O
, O
disabling O
negative O
myoclonus B-Disease
of O
the O
upper O
and O
lower O
extremities O
after O
the O
infusion O
of O
ifosfamide O
for O
plasmacytoma B-Disease
. O

cranial O
magnetic O
resonance O
imaging O
and O
extensive O
laboratory O
studies O
failed O
to O
reveal O
structural B-Disease
lesions I-Disease
of I-Disease
the I-Disease
brain I-Disease
and O
metabolic B-Disease
abnormalities I-Disease
. O

an O
electroencephalogram O
showed O
continuous O
, O
generalized O
irregular O
slowing O
with O
admixed O
periodic O
triphasic O
waves O
indicating O
symptomatic O
encephalopathy B-Disease
. O

the O
administration O
of O
ifosfamide O
was O
discontinued O
and O
within O
12 O
h O
the O
asterixis B-Disease
resolved O
completely O
. O

in O
the O
patient O
described O
, O
the O
presence O
of O
asterixis B-Disease
during O
infusion O
of O
ifosfamide O
, O
normal O
laboratory O
findings O
and O
imaging O
studies O
and O
the O
resolution O
of O
symptoms O
following O
the O
discontinuation O
of O
the O
drug O
suggest O
that O
negative O
myoclonus B-Disease
is O
associated O
with O
the O
use O
of O
ifx O
. O

antagonism O
between O
interleukin O
3 O
and O
erythropoietin O
in O
mice O
with O
azidothymidine O
- O
induced O
anemia B-Disease
and O
in O
bone O
marrow O
endothelial O
cells O
. O

azidothymidine O
( O
azt O
) O
- O
induced O
anemia B-Disease
in O
mice O
can O
be O
reversed O
by O
the O
administration O
of O
igf O
- O
il O
- O
3 O
( O
fusion O
protein O
of O
insulin O
- O
like O
growth O
factor O
ii O
( O
igf O
ii O
) O
and O
interleukin O
3 O
) O
. O

the O
relationship O
between O
hippocampal O
acetylcholine O
release O
and O
cholinergic O
convulsant O
sensitivity O
in O
withdrawal O
seizure B-Disease
- O
prone O
and O
withdrawal O
seizure B-Disease
- O
resistant O
selected O
mouse O
lines O
. O

methods O
: O
cholinergic O
convulsant O
sensitivity O
was O
examined O
in O
alcohol O
- O
na O
ve O
withdrawal O
seizure B-Disease
- O
prone O
( O
wsp O
) O
and O
- O
resistant O
( O
wsr O
) O
mice O
. O

animals O
were O
administered O
nicotine O
, O
carbachol O
, O
or O
neostigmine O
via O
timed O
tail O
vein O
infusion O
, O
and O
the O
latencies O
to O
onset O
of O
tremor B-Disease
and O
clonus O
were O
recorded O
and O
converted O
to O
threshold O
dose O
. O

hippocampal O
ach O
also O
was O
measured O
during O
testing O
for O
handling O
- O
induced O
convulsions B-Disease
. O

results O
: O
sensitivity O
to O
several O
convulsion B-Disease
endpoints O
induced O
by O
nicotine O
, O
carbachol O
, O
and O
neostigmine O
were O
significantly O
greater O
in O
wsr O
versus O
wsp O
mice O
. O

when O
hippocampal O
ach O
was O
measured O
during O
testing O
for O
handling O
- O
induced O
convulsions B-Disease
, O
extracellular O
ach O
was O
significantly O
elevated O
( O
192 O
% O
) O
in O
wsp O
mice O
, O
but O
was O
nonsignificantly O
elevated O
( O
59 O
% O
) O
in O
wsr O
mice O
. O

conclusions O
: O
these O
results O
suggest O
that O
differences O
in O
cholinergic O
activity O
and O
postsynaptic O
sensitivity O
to O
cholinergic O
convulsants B-Disease
may O
be O
associated O
with O
ethanol O
withdrawal O
severity O
and O
implicate O
cholinergic O
mechanisms O
in O
alcohol O
withdrawal O
. O

specifically O
, O
wsp O
mice O
may O
have O
lower O
sensitivity O
to O
cholinergic O
convulsants B-Disease
compared O
with O
wsr O
because O
of O
postsynaptic O
receptor O
desensitization O
brought O
on O
by O
higher O
activity O
of O
cholinergic O
neurons O
. O

capsaicin O
- O
induced O
muscle B-Disease
pain I-Disease
alters O
the O
excitability O
of O
the O
human O
jaw O
- O
stretch O
reflex O
. O

the O
pathophysiology O
of O
painful O
temporomandibular B-Disease
disorders I-Disease
is O
not O
fully O
understood O
, O
but O
evidence O
suggests O
that O
muscle B-Disease
pain I-Disease
modulates O
motor O
function O
in O
characteristic O
ways O
. O

this O
study O
tested O
the O
hypothesis O
that O
activation O
of O
nociceptive B-Disease
muscle I-Disease
afferent O
fibers O
would O
be O
linked O
to O
an O
increased O
excitability O
of O
the O
human O
jaw O
- O
stretch O
reflex O
and O
whether O
this O
process O
would O
be O
sensitive O
to O
length O
and O
velocity O
of O
the O
stretch O
. O

capsaicin O
( O
10 O
micro O
g O
) O
was O
injected O
into O
the O
masseter O
muscle O
to O
induce O
pain B-Disease
in O
11 O
healthy O
volunteers O
. O

short O
- O
latency O
reflex O
responses O
were O
evoked O
in O
the O
masseter O
and O
temporalis O
muscles O
by O
a O
stretch O
device O
with O
different O
velocities O
and O
displacements O
before O
, O
during O
, O
and O
after O
the O
pain B-Disease
. O

the O
normalized O
reflex O
amplitude O
was O
significantly O
higher O
during O
pain B-Disease
, O
but O
only O
at O
faster O
stretches O
in O
the O
painful B-Disease
muscle I-Disease
. O

increased O
sensitivity O
of O
the O
fusimotor O
system O
during O
acute O
muscle B-Disease
pain I-Disease
could O
be O
one O
likely O
mechanism O
to O
explain O
the O
findings O
. O

effects O
of O
5 O
- O
ht1b O
receptor O
ligands O
microinjected O
into O
the O
accumbal O
shell O
or O
core O
on O
the O
cocaine O
- O
induced O
locomotor B-Disease
hyperactivity I-Disease
in O
rats O
. O

the O
present O
study O
was O
designed O
to O
examine O
the O
effect O
of O
5 O
- O
ht1b O
receptor O
ligands O
microinjected O
into O
the O
subregions O
of O
the O
nucleus O
accumbens O
( O
the O
shell O
and O
the O
core O
) O
on O
the O
locomotor B-Disease
hyperactivity I-Disease
induced O
by O
cocaine O
in O
rats O
. O

gr O
55562 O
( O
0 O
. O

1 O
- O
10 O
microg O
/ O
side O
) O
, O
administered O
intra O
- O
accumbens O
shell O
prior O
to O
cocaine O
, O
dose O
- O
dependently O
attenuated O
the O
psychostimulant O
- O
induced O
locomotor B-Disease
hyperactivity I-Disease
. O

our O
findings O
indicate O
that O
cocaine O
induced O
hyperlocomotion B-Disease
is O
modified O
by O
5 O
- O
ht1b O
receptor O
ligands O
microinjected O
into O
the O
accumbens O
shell O
, O
but O
not O
core O
, O
this O
modification O
consisting O
in O
inhibitory O
and O
facilitatory O
effects O
of O
the O
5 O
- O
ht1b O
receptor O
antagonist O
( O
gr O
55562 O
) O
and O
agonist O
( O
cp O
93129 O
) O
, O
respectively O
. O

cocaine O
related O
chest B-Disease
pain I-Disease
: O
are O
we O
seeing O
the O
tip O
of O
an O
iceberg O
? O
in O
particular O
, O
the O
tendency O
of O
cocaine O
to O
produce O
chest B-Disease
pain I-Disease
ought O
to O
be O
in O
the O
mind O
of O
the O
emergency O
nurse O
when O
faced O
with O
a O
young O
victim O
of O
chest B-Disease
pain I-Disease
who O
is O
otherwise O
at O
low O
risk O
. O

the O
mechanism O
of O
chest B-Disease
pain I-Disease
related O
to O
cocaine O
use O
is O
discussed O
and O
treatment O
dilemmas O
are O
discussed O
. O

crossover O
comparison O
of O
efficacy O
and O
preference O
for O
rizatriptan O
10 O
mg O
versus O
ergotamine O
/ O
caffeine O
in O
migraine B-Disease
. O

rizatriptan O
is O
a O
selective O
5 O
- O
ht O
( O
1b O
/ O
1d O
) O
receptor O
agonist O
with O
rapid O
oral O
absorption O
and O
early O
onset O
of O
action O
in O
the O
acute O
treatment O
of O
migraine B-Disease
. O

this O
randomized O
double O
- O
blind O
crossover O
outpatient O
study O
assessed O
the O
preference O
for O
1 O
rizatriptan O
10 O
mg O
tablet O
to O
2 O
ergotamine O
1 O
mg O
/ O
caffeine O
100 O
mg O
tablets O
in O
439 O
patients O
treating O
a O
single O
migraine B-Disease
attack O
with O
each O
therapy O
. O

faster O
relief O
of O
headache B-Disease
was O
the O
most O
important O
reason O
for O
preference O
, O
cited O
by O
67 O
. O

3 O
% O
of O
patients O
preferring O
rizatriptan O
and O
54 O
. O

2 O
% O
of O
patients O
who O
preferred O
ergotamine O
/ O
caffeine O
. O

the O
co O
- O
primary O
endpoint O
of O
being O
pain B-Disease
free O
at O
2 O
h O
was O
also O
in O
favor O
of O
rizatriptan O
. O

forty O
- O
nine O
percent O
of O
patients O
were O
pain B-Disease
free O
2 O
h O
after O
rizatriptan O
, O
compared O
with O
24 O
. O

3 O
% O
treated O
with O
ergotamine O
/ O
caffeine O
( O
p O
< O
or O
= O
0 O
. O

1 O
) O
, O
rizatriptan O
being O
superior O
within O
1 O
h O
of O
treatment O
. O

headache B-Disease
relief O
at O
2 O
h O
was O
75 O
. O

9 O
% O
for O
rizatriptan O
and O
47 O
. O

3 O
% O
for O
ergotamine O
/ O
caffeine O
( O
p O
< O
or O
= O
0 O
. O

1 O
) O
, O
with O
rizatriptan O
being O
superior O
to O
ergotamine O
/ O
caffeine O
within O
30 O
min O
of O
dosing O
. O

almost O
36 O
% O
of O
patients O
taking O
rizatriptan O
were O
pain B-Disease
free O
at O
2 O
h O
and O
had O
no O
recurrence O
or O
need O
for O
additional O
medication O
within O
24 O
h O
, O
compared O
to O
20 O
% O
of O
patients O
on O
ergotamine O
/ O
caffeine O
( O
p O
< O
or O
= O
0 O
. O

1 O
) O
. O

rizatriptan O
was O
also O
superior O
to O
ergotamine O
/ O
caffeine O
in O
the O
proportions O
of O
patients O
with O
no O
nausea B-Disease
, O
vomiting B-Disease
, O
phonophobia B-Disease
or O
photophobia B-Disease
and O
for O
patients O
with O
normal O
function O
2 O
h O
after O
drug O
intake O
( O
p O
< O
or O
= O
0 O
. O

1 O
) O
. O

the O
most O
common O
adverse O
events O
( O
incidence O
> O
or O
= O
5 O
% O
in O
one O
group O
) O
after O
rizatriptan O
and O
ergotamine O
/ O
caffeine O
, O
respectively O
, O
were O
dizziness B-Disease
( O
6 O
. O

7 O
and O
5 O
. O

3 O
% O
) O
, O
nausea B-Disease
( O
4 O
. O

2 O
and O
8 O
. O

5 O
% O
) O
and O
somnolence B-Disease
( O
5 O
. O

5 O
and O
2 O
. O

3 O
% O
) O
. O

severe O
ocular B-Disease
and I-Disease
orbital I-Disease
toxicity I-Disease
after O
intracarotid O
injection O
of O
carboplatin O
for O
recurrent O
glioblastomas B-Disease
. O

background O
: O
glioblastoma B-Disease
is O
a O
malignant B-Disease
tumor I-Disease
that O
occurs O
in O
the O
cerebrum O
during O
adulthood O
. O

therefore O
, O
patients O
with O
glioblastoma B-Disease
sometimes O
have O
intracarotid O
injection O
of O
carcinostatics O
added O
to O
the O
treatment O
regimen O
. O

generally O
, O
carboplatin O
is O
said O
to O
have O
milder O
side O
effects O
than O
cisplatin O
, O
whose O
ocular B-Disease
and I-Disease
orbital I-Disease
toxicity I-Disease
are O
well O
known O
. O

however O
, O
we O
experienced O
a O
case O
of O
severe O
ocular B-Disease
and I-Disease
orbital I-Disease
toxicity I-Disease
after O
intracarotid O
injection O
of O
carboplatin O
, O
which O
is O
infrequently O
reported O
. O

case O
: O
a O
58 O
- O
year O
- O
old O
man O
received O
an O
intracarotid O
injection O
of O
carboplatin O
for O
recurrent O
glioblastomas B-Disease
in O
his O
left O
temporal O
lobe O
. O

he O
complained O
of O
pain B-Disease
and I-Disease
visual I-Disease
disturbance I-Disease
in I-Disease
the I-Disease
ipsilateral I-Disease
eye I-Disease
30 O
h O
after O
the O
injection O
. O

various O
ocular O
symptoms O
and O
findings O
caused O
by O
carboplatin O
toxicity B-Disease
were O
seen O
. O

although O
the O
intraocular O
pressure O
elevation O
caused O
by O
secondary O
acute O
angle O
- O
closure O
glaucoma B-Disease
decreased O
and O
ocular B-Disease
pain I-Disease
diminished O
, O
inexorable O
papilledema B-Disease
and O
exudative O
retinal B-Disease
detachment I-Disease
continued O
for O
3 O
weeks O
. O

finally O
, O
6 O
weeks O
later O
, O
diffuse O
chorioretinal B-Disease
atrophy I-Disease
with O
optic B-Disease
atrophy I-Disease
occurred O
and O
the O
vision O
in O
his O
left O
eye O
was O
lost O
. O

conclusion O
: O
when O
performing O
intracarotid O
injection O
of O
carboplatin O
, O
we O
must O
be O
aware O
of O
its O
potentially O
blinding O
ocular B-Disease
toxicity I-Disease
. O

visual B-Disease
hallucinations I-Disease
associated O
with O
zonisamide O
. O

zonisamide O
is O
a O
broad O
- O
spectrum O
antiepileptic O
drug O
used O
to O
treat O
various O
types O
of O
seizures B-Disease
. O

although O
visual B-Disease
hallucinations I-Disease
have O
not O
been O
reported O
as O
an O
adverse O
effect O
of O
this O
agent O
, O
we O
describe O
three O
patients O
who O
experienced O
complex O
visual B-Disease
hallucinations I-Disease
and O
altered O
mental O
status O
after O
zonisamide O
treatment O
was O
begun O
or O
its O
dosage O
increased O
. O

all O
three O
had O
been O
diagnosed O
earlier O
with O
epilepsy B-Disease
, O
and O
their O
electroencephalogram O
( O
eeg O
) O
findings O
were O
abnormal O
. O

during O
monitoring O
, O
visual B-Disease
hallucinations I-Disease
did O
not O
correlate O
with O
eeg O
readings O
, O
nor O
did O
video O
recording O
capture O
any O
of O
the O
described O
events O
. O

none O
of O
the O
patients O
had O
experienced O
visual B-Disease
hallucinations I-Disease
before O
this O
event O
. O

anti O
- O
epileptic B-Disease
drugs O
- O
induced O
de O
novo O
absence B-Disease
seizures I-Disease
. O

the O
authors O
present O
three O
patients O
with O
de O
novo O
absence B-Disease
epilepsy I-Disease
after O
administration O
of O
carbamazepine O
and O
vigabatrin O
. O

despite O
the O
underlying O
diseases O
, O
the O
prognosis O
for O
drug O
- O
induced O
de O
novo O
absence B-Disease
seizure I-Disease
is O
good O
because O
it O
subsides O
rapidly O
after O
discontinuing O
the O
use O
of O
the O
offending O
drugs O
. O

the O
gamma O
- O
aminobutyric O
acid O
- O
transmitted O
thalamocortical O
circuitry O
accounts O
for O
a O
major O
part O
of O
the O
underlying O
neurophysiology O
of O
the O
absence B-Disease
epilepsy I-Disease
. O

because O
drug O
- O
induced O
de O
novo O
absence B-Disease
seizure I-Disease
is O
rare O
, O
pro O
- O
absence O
drugs O
can O
only O
be O
considered O
a O
promoting O
factor O
. O

the O
underlying O
epileptogenecity O
of O
the O
patients O
or O
the O
synergistic O
effects O
of O
the O
accompanying O
drugs O
is O
required O
to O
trigger O
the O
de O
novo O
absence B-Disease
seizure I-Disease
. O

the O
possibility O
of O
drug O
- O
induced O
aggravation O
should O
be O
considered O
whenever O
an O
unexpected O
increase O
in O
seizure B-Disease
frequency O
and O
/ O
or O
new O
seizure B-Disease
types O
appear O
following O
a O
change O
in O
drug O
treatment O
. O

by O
understanding O
the O
underlying O
mechanism O
of O
absence B-Disease
epilepsy I-Disease
, O
we O
can O
avoid O
the O
inappropriate O
use O
of O
anticonvulsants O
in O
children O
with O
epilepsy B-Disease
and O
prevent O
drug O
- O
induced O
absence B-Disease
seizures I-Disease
. O

prenatal O
dexamethasone O
programs O
hypertension B-Disease
and O
renal B-Disease
injury I-Disease
in O
the O
rat O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
prenatal O
dexamethasone O
programmed O
a O
progressive O
increase B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
and O
renal B-Disease
injury I-Disease
in O
rats O
. O

offspring O
of O
rats O
administered O
dexamethasone O
on O
days O
15 O
and O
16 O
gestation O
had O
a O
20 O
% O
reduction B-Disease
in I-Disease
glomerular I-Disease
number I-Disease
compared O
with O
control O
at O
6 O
to O
9 O
months O
of O
age O
( O
22 O
527 O
+ O
/ O
- O
509 O
versus O
28 O
50 O
+ O
/ O
- O
561 O
, O
p O
< O
0 O
. O

5 O
) O
, O
which O
was O
comparable O
to O
the O
percent O
reduction O
in O
glomeruli O
measured O
at O
3 O
weeks O
of O
age O
. O

male O
rats O
that O
received O
prenatal O
dexamethasone O
on O
days O
15 O
and O
16 O
, O
17 O
and O
18 O
, O
and O
13 O
and O
14 O
of O
gestation O
had O
elevated B-Disease
blood I-Disease
pressures I-Disease
at O
6 O
months O
of O
age O
; O
the O
latter O
group O
did O
not O
have O
a O
reduction B-Disease
in I-Disease
glomerular I-Disease
number I-Disease
. O

adult O
rats O
given O
dexamethasone O
on O
days O
15 O
and O
16 O
of O
gestation O
had O
more O
glomeruli O
with O
glomerulosclerosis B-Disease
than O
control O
rats O
. O

this O
study O
shows O
that O
prenatal O
dexamethasone O
in O
rats O
results O
in O
a O
reduction B-Disease
in I-Disease
glomerular I-Disease
number I-Disease
, O
glomerulosclerosis B-Disease
, O
and O
hypertension B-Disease
when O
administered O
at O
specific O
points O
during O
gestation O
. O

hypertension B-Disease
was O
observed O
in O
animals O
that O
had O
a O
reduction O
in O
glomeruli O
as O
well O
as O
in O
a O
group O
that O
did O
not O
have O
a O
reduction B-Disease
in I-Disease
glomerular I-Disease
number I-Disease
, O
suggesting O
that O
a O
reduction B-Disease
in I-Disease
glomerular I-Disease
number I-Disease
is O
not O
the O
sole O
cause O
for O
the O
development O
of O
hypertension B-Disease
. O

these O
are O
nephrotoxic B-Disease
, O
but O
srl O
seems O
to O
act O
differently O
displaying O
only O
minor O
nephrotoxic B-Disease
effects O
, O
although O
this O
question O
is O
still O
open O
. O

in O
a O
number O
of O
treatment O
protocols O
where O
srl O
was O
combined O
with O
a O
calcineurin O
inhibitor O
indications O
of O
a O
synergistic O
nephrotoxic B-Disease
effect O
were O
described O
. O

the O
morphological O
analysis O
of O
the O
kidneys O
included O
a O
semi O
- O
quantitative O
scoring O
system O
analysing O
the O
degree O
of O
striped O
fibrosis B-Disease
, O
subcapsular O
fibrosis B-Disease
and O
the O
number O
of O
basophilic O
tubules O
, O
plus O
an O
additional O
stereological O
analysis O
of O
the O
total O
grade O
of O
fibrosis B-Disease
in O
the O
cortex O
stained O
with O
sirius O
red O
. O

the O
semi O
- O
quantitative O
scoring O
was O
significantly O
worst O
in O
the O
group O
treated O
with O
csa O
plus O
srl O
( O
p O
< O
0 O
. O

1 O
compared O
with O
controls O
) O
and O
the O
analysis O
of O
the O
total O
grade O
of O
fibrosis B-Disease
also O
showed O
the O
highest O
proportion O
in O
the O
same O
group O
and O
was O
significantly O
different O
from O
controls O
( O
p O
< O
0 O
. O

2 O
) O
. O

the O
fk506 O
plus O
srl O
combination O
showed O
only O
a O
marginally O
higher O
degree O
of O
fibrosis B-Disease
as O
compared O
with O
controls O
( O
p O
= O
0 O
. O

5 O
) O
. O

conclusion O
: O
this O
rat O
study O
demonstrated O
a O
synergistic O
nephrotoxic B-Disease
effect O
of O
csa O
plus O
srl O
, O
whereas O
fk506 O
plus O
srl O
was O
better O
tolerated O
. O

evaluation O
of O
cardiac O
troponin O
i O
and O
t O
levels O
as O
markers O
of O
myocardial B-Disease
damage I-Disease
in O
doxorubicin O
- O
induced O
cardiomyopathy B-Disease
rats O
, O
and O
their O
relationship O
with O
echocardiographic O
and O
histological O
findings O
. O

background O
: O
cardiac O
troponins O
i O
( O
ctni O
) O
and O
t O
( O
ctnt O
) O
have O
been O
shown O
to O
be O
highly O
sensitive O
and O
specific O
markers O
of O
myocardial B-Disease
cell I-Disease
injury I-Disease
. O

we O
investigated O
the O
diagnostic O
value O
of O
ctni O
and O
ctnt O
for O
the O
diagnosis O
of O
myocardial B-Disease
damage I-Disease
in O
a O
rat O
model O
of O
doxorubicin O
( O
dox O
) O
- O
induced O
cardiomyopathy B-Disease
, O
and O
we O
examined O
the O
relationship O
between O
serial O
ctni O
and O
ctnt O
with O
the O
development O
of O
cardiac B-Disease
disorders I-Disease
monitored O
by O
echocardiography O
and O
histological O
examinations O
in O
this O
model O
. O

results O
: O
eighteen O
of O
the O
dox O
rats O
died O
prematurely O
of O
general O
toxicity B-Disease
during O
the O
9 O
- O
week O
period O
. O

histological O
evaluation O
of O
hearts O
from O
all O
rats O
given O
dox O
revealed O
significant O
slight O
degrees O
of O
perivascular O
and O
interstitial O
fibrosis B-Disease
. O

only O
five O
of O
the O
controls O
exhibited O
evidence O
of O
very O
slight O
perivascular O
fibrosis B-Disease
. O

conclusions O
: O
among O
markers O
of O
ischemic B-Disease
injury I-Disease
after O
dox O
in O
rats O
, O
ctnt O
showed O
the O
greatest O
ability O
to O
detect O
myocardial B-Disease
damage I-Disease
assessed O
by O
echocardiographic O
detection O
and O
histological O
changes O
. O

although O
there O
was O
a O
discrepancy O
between O
the O
amount O
of O
ctni O
and O
ctnt O
after O
dox O
, O
probably O
due O
to O
heterogeneity O
in O
cross O
- O
reactivities O
of O
mabs O
to O
various O
ctni O
and O
ctnt O
forms O
, O
it O
is O
likely O
that O
ctnt O
in O
rats O
after O
dox O
indicates O
cell O
damage O
determined O
by O
the O
magnitude O
of O
injury O
induced O
and O
that O
ctnt O
should O
be O
a O
useful O
marker O
for O
the O
prediction O
of O
experimentally O
induced O
cardiotoxicity B-Disease
and O
possibly O
for O
cardioprotective O
experiments O
. O

octreotide O
- O
induced O
hypoxemia B-Disease
and O
pulmonary B-Disease
hypertension I-Disease
in O
premature O
neonates O
. O

the O
authors O
report O
2 O
cases O
of O
premature O
neonates O
who O
had O
enterocutaneous O
fistula B-Disease
complicating O
necrotizing B-Disease
enterocolitis I-Disease
. O

pulmonary B-Disease
hypertension I-Disease
developed O
after O
administration O
of O
a O
somatostatin O
analogue O
, O
octreotide O
, O
to O
enhance O
resolution O
of O
the O
fistula B-Disease
. O

the O
risk O
of O
venous B-Disease
thromboembolism I-Disease
in O
women O
prescribed O
cyproterone O
acetate O
in O
combination O
with O
ethinyl O
estradiol O
: O
a O
nested O
cohort O
analysis O
and O
case O
- O
control O
study O
. O

background O
: O
cyproterone O
acetate O
combined O
with O
ethinyl O
estradiol O
( O
cpa O
/ O
ee O
) O
is O
licensed O
in O
the O
uk O
for O
the O
treatment O
of O
women O
with O
acne B-Disease
and O
hirsutism B-Disease
and O
is O
also O
a O
treatment O
option O
for O
polycystic B-Disease
ovary I-Disease
syndrome I-Disease
( O
pcos B-Disease
) O
. O

previous O
studies O
have O
demonstrated O
an O
increased O
risk O
of O
venous B-Disease
thromboembolism I-Disease
( O
vte B-Disease
) O
associated O
with O
cpa O
/ O
ee O
compared O
with O
conventional O
combined O
oral O
contraceptives O
( O
cocs O
) O
. O

methods O
: O
using O
the O
general O
practice O
research O
database O
we O
conducted O
a O
cohort O
analysis O
and O
case O
- O
control O
study O
nested O
within O
a O
population O
of O
women O
aged O
between O
15 O
and O
39 O
years O
with O
acne B-Disease
, O
hirsutism B-Disease
or O
pcos B-Disease
to O
estimate O
the O
risk O
of O
vte B-Disease
associated O
with O
cpa O
/ O
ee O
. O

conclusions O
: O
we O
have O
demonstrated O
an O
increased O
risk O
of O
vte B-Disease
associated O
with O
the O
use O
of O
cpa O
/ O
ee O
in O
women O
with O
acne B-Disease
, O
hirsutism B-Disease
or O
pcos B-Disease
although O
residual O
confounding O
by O
indication O
cannot O
be O
excluded O
. O

the O
effect O
of O
treatment O
with O
gum O
arabic O
on O
gentamicin O
nephrotoxicity B-Disease
in O
rats O
: O
a O
preliminary O
study O
. O

in O
the O
present O
work O
we O
assessed O
the O
effect O
of O
treatment O
of O
rats O
with O
gum O
arabic O
on O
acute B-Disease
renal I-Disease
failure I-Disease
induced O
by O
gentamicin O
( O
gm O
) O
nephrotoxicity B-Disease
. O

nephrotoxicity B-Disease
was O
assessed O
by O
measuring O
the O
concentrations O
of O
creatinine O
and O
urea O
in O
the O
plasma O
and O
reduced O
glutathione O
( O
gsh O
) O
in O
the O
kidney O
cortex O
, O
and O
by O
light O
microscopic O
examination O
of O
kidney O
sections O
. O

the O
results O
indicated O
that O
concomitant O
treatment O
with O
gum O
arabic O
and O
gm O
significantly O
increased O
creatinine O
and O
urea O
by O
about O
183 O
and O
239 O
% O
, O
respectively O
( O
compared O
to O
432 O
and O
346 O
% O
, O
respectively O
, O
in O
rats O
treated O
with O
cellulose O
and O
gm O
) O
, O
and O
decreased O
that O
of O
cortical O
gsh O
by O
21 O
% O
( O
compared O
to O
27 O
% O
in O
the O
cellulose O
plus O
gm O
group O
) O
the O
gm O
- O
induced O
proximal O
tubular B-Disease
necrosis I-Disease
appeared O
to O
be O
slightly O
less O
severe O
in O
rats O
given O
gm O
together O
with O
gum O
arabic O
than O
in O
those O
given O
gm O
and O
cellulose O
. O

it O
could O
be O
inferred O
that O
gum O
arabic O
treatment O
has O
induced O
a O
modest O
amelioration O
of O
some O
of O
the O
histological O
and O
biochemical O
indices O
of O
gm O
nephrotoxicity B-Disease
. O

further O
work O
is O
warranted O
on O
the O
effect O
of O
the O
treatments O
on O
renal O
functional O
aspects O
in O
models O
of O
chronic B-Disease
renal I-Disease
failure I-Disease
, O
and O
on O
the O
mechanism O
( O
s O
) O
involved O
. O

increased O
frequency O
of O
venous B-Disease
thromboembolism I-Disease
with O
the O
combination O
of O
docetaxel O
and O
thalidomide O
in O
patients O
with O
metastatic O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
. O

study O
objective O
: O
to O
evaluate O
the O
frequency O
of O
venous B-Disease
thromboembolism I-Disease
( O
vte B-Disease
) O
in O
patients O
with O
advanced O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
who O
were O
treated O
with O
docetaxel O
alone O
or O
in O
combination O
with O
thalidomide O
. O

patients O
: O
seventy O
men O
, O
aged O
50 O
- O
80 O
years O
, O
with O
advanced O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
. O

this O
4 O
- O
week O
cycle O
was O
repeated O
until O
there O
was O
evidence O
of O
excessive O
toxicity B-Disease
or O
disease O
progression O
. O

measurements O
and O
main O
results O
: O
none O
of O
23 O
patients O
who O
received O
docetaxel O
alone O
developed O
vte B-Disease
, O
whereas O
9 O
of O
47 O
patients O
( O
19 O
% O
) O
who O
received O
docetaxel O
plus O
thalidomide O
developed O
vte B-Disease
( O
p O
= O
0 O
. O

25 O
) O
. O

conclusion O
: O
the O
addition O
of O
thalidomide O
to O
docetaxel O
in O
the O
treatment O
of O
prostate B-Disease
cancer I-Disease
significantly O
increases O
the O
frequency O
of O
vte B-Disease
. O

ticlopidine O
- O
induced O
cholestatic B-Disease
hepatitis I-Disease
. O

objective O
: O
to O
report O
2 O
cases O
of O
ticlopidine O
- O
induced O
cholestatic B-Disease
hepatitis I-Disease
, O
investigate O
its O
mechanism O
, O
and O
compare O
the O
observed O
main O
characteristics O
with O
those O
of O
the O
published O
cases O
. O

case O
summaries O
: O
two O
patients O
developed O
prolonged O
cholestatic B-Disease
hepatitis I-Disease
after O
receiving O
ticlopidine O
following O
percutaneous O
coronary O
angioplasty O
, O
with O
complete O
remission O
during O
the O
follow O
- O
up O
period O
. O

discussion O
: O
cholestatic B-Disease
hepatitis I-Disease
is O
a O
rare O
complication O
of O
the O
antiplatelet O
agent O
ticlopidine O
; O
several O
cases O
have O
been O
reported O
but O
few O
in O
the O
english O
literature O
. O

our O
patients O
developed O
jaundice B-Disease
following O
treatment O
with O
ticlopidine O
and O
showed O
the O
clinical O
and O
laboratory O
characteristics O
of O
cholestatic B-Disease
hepatitis I-Disease
, O
which O
resolved O
after O
discontinuation O
of O
the O
drug O
. O

hepatitis B-Disease
may O
develop O
weeks O
after O
discontinuation O
of O
the O
drug O
and O
may O
run O
a O
prolonged O
course O
, O
but O
complete O
remission O
was O
observed O
in O
all O
reported O
cases O
. O

the O
mechanisms O
of O
this O
ticlopidine O
- O
induced O
cholestasis B-Disease
are O
unclear O
. O

immune O
mechanisms O
may O
be O
involved O
in O
the O
drug O
' O
s O
hepatotoxicity B-Disease
, O
as O
suggested O
by O
the O
t O
- O
cell O
stimulation O
study O
reported O
here O
. O

conclusions O
: O
cholestatic B-Disease
hepatitis I-Disease
is O
a O
rare O
adverse O
effect O
of O
ticlopidine O
that O
may O
be O
immune O
mediated O
. O

epithelial O
sodium O
channel O
( O
enac O
) O
subunit O
mrna O
and O
protein O
expression O
in O
rats O
with O
puromycin O
aminonucleoside O
- O
induced O
nephrotic B-Disease
syndrome I-Disease
. O

in O
experimental O
nephrotic B-Disease
syndrome I-Disease
, O
urinary O
sodium O
excretion O
is O
decreased O
during O
the O
early O
phase O
of O
the O
disease O
. O

we O
examined O
the O
abundance O
of O
enac O
subunit O
mrnas O
and O
proteins O
in O
puromycin O
aminonucleoside O
( O
pan O
) O
- O
induced O
nephrotic B-Disease
syndrome I-Disease
. O

the O
time O
courses O
of O
urinary O
sodium O
excretion O
, O
plasma O
aldosterone O
concentration O
and O
proteinuria B-Disease
were O
studied O
in O
male O
sprague O
- O
dawley O
rats O
treated O
with O
a O
single O
dose O
of O
either O
pan O
or O
vehicle O
. O

the O
kinetics O
of O
urinary O
sodium O
excretion O
and O
the O
appearance O
of O
proteinuria B-Disease
were O
comparable O
with O
those O
reported O
previously O
. O

in O
conclusion O
, O
enac O
mrna O
expression O
, O
especially O
alphaenac O
, O
is O
increased O
in O
the O
very O
early O
phase O
of O
the O
experimental O
model O
of O
pan O
- O
induced O
nephrotic B-Disease
syndrome I-Disease
in O
rats O
, O
but O
appears O
to O
escape O
from O
the O
regulation O
by O
aldosterone O
after O
day O
3 O
. O

objectives O
: O
given O
its O
preclinical O
success O
for O
treating O
substance B-Disease
abuse I-Disease
and O
the O
increased O
risk O
of O
visual B-Disease
field I-Disease
defects I-Disease
( O
vfd B-Disease
) O
associated O
with O
cumulative O
lifetime O
exposure O
, O
we O
explored O
the O
effects O
of O
sub O
- O
chronic O
low O
dose O
gvg O
on O
cocaine O
- O
induced O
increases O
in O
nucleus O
accumbens O
( O
nacc O
) O
dopamine O
( O
da O
) O
. O

mr O
imaging O
with O
quantitative O
diffusion O
mapping O
of O
tacrolimus O
- O
induced O
neurotoxicity B-Disease
in O
organ O
transB-Plant O
patients O
. O

brain O
mr O
studies O
, O
including O
dw O
imaging O
, O
were O
prospectively O
performed O
in O
14 O
organ O
transB-Plant O
patients O
receiving O
tacrolimus O
who O
developed O
neurologic B-Disease
complications I-Disease
. O

of O
the O
14 O
patients O
, O
5 O
( O
35 O
. O

7 O
% O
) O
had O
white B-Disease
matter I-Disease
abnormalities I-Disease
, O
1 O
( O
7 O
. O

1 O
% O
) O
had O
putaminal B-Disease
hemorrhage I-Disease
, O
and O
8 O
( O
57 O
. O

1 O
% O
) O
had O
normal O
findings O
on O
initial O
mr O
images O
. O

among O
the O
5 O
patients O
with O
white B-Disease
matter I-Disease
abnormalities I-Disease
, O
4 O
patients O
( O
80 O
. O

0 O
% O
) O
showed O
higher O
than O
normal O
adc O
values O
on O
initial O
mr O
images O
, O
and O
all O
showed O
complete O
resolution O
on O
follow O
- O
up O
images O
. O

the O
remaining O
1 O
patient O
( O
20 O
. O

0 O
% O
) O
showed O
lower O
than O
normal O
adc O
value O
and O
showed O
incomplete O
resolution O
with O
cortical B-Disease
laminar I-Disease
necrosis I-Disease
. O

diffusion O
- O
weighted O
imaging O
may O
be O
useful O
in O
predicting O
the O
outcomes O
of O
the O
lesions O
of O
tacrolimus O
- O
induced O
neurotoxicity B-Disease
. O

l O
- O
arginine O
transport O
in O
humans O
with O
cortisol O
- O
induced O
hypertension B-Disease
. O

a O
deficient O
l O
- O
arginine O
- O
nitric O
oxide O
system O
is O
implicated O
in O
cortisol O
- O
induced O
hypertension B-Disease
. O

we O
conclude O
that O
cortisol O
- O
induced O
increases B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
are O
not O
associated O
with O
abnormalities O
in O
the O
l O
- O
arginine O
transport O
system O
. O

amount O
of O
bleeding B-Disease
and O
hematoma B-Disease
size O
in O
the O
collagenase O
- O
induced O
intracerebral B-Disease
hemorrhage I-Disease
rat O
model O
. O

the O
aggravated O
risk O
on O
intracerebral B-Disease
hemorrhage I-Disease
( O
ich B-Disease
) O
with O
drugs O
used O
for O
stroke B-Disease
patients O
should O
be O
estimated O
carefully O
. O

we O
therefore O
established O
sensitive O
quantification O
methods O
and O
provided O
a O
rat O
ich B-Disease
model O
for O
detection O
of O
ich B-Disease
deterioration O
. O

in O
ich B-Disease
intrastriatally O
induced O
by O
0 O
. O

14 O
- O
unit O
, O
0 O
. O

70 O
- O
unit O
, O
and O
0 O
. O

350 O
- O
unit O
collagenase O
, O
the O
amount O
of O
bleeding B-Disease
was O
measured O
using O
a O
hemoglobin O
assay O
developed O
in O
the O
present O
study O
and O
was O
compared O
with O
the O
morphologically O
determined O
hematoma B-Disease
volume O
. O

the O
blood O
amounts O
and O
hematoma B-Disease
volumes O
were O
significantly O
correlated O
, O
and O
the O
hematoma B-Disease
induced O
by O
0 O
. O

14 O
- O
unit O
collagenase O
was O
adequate O
to O
detect O
ich B-Disease
deterioration O
. O

in O
ich B-Disease
induction O
using O
0 O
. O

14 O
- O
unit O
collagenase O
, O
heparin O
enhanced O
the O
hematoma B-Disease
volume O
3 O
. O

4 O
- O
fold O
over O
that O
seen O
in O
control O
ich B-Disease
animals O
and O
the O
bleeding B-Disease
7 O
. O

6 O
- O
fold O
. O

data O
suggest O
that O
this O
sensitive O
hemoglobin O
assay O
is O
useful O
for O
ich B-Disease
detection O
, O
and O
that O
a O
model O
with O
a O
small O
ich B-Disease
induced O
with O
a O
low O
- O
dose O
collagenase O
should O
be O
used O
for O
evaluation O
of O
drugs O
that O
may O
affect O
ich B-Disease
. O

estradiol O
reduces O
seizure B-Disease
- O
induced O
hippocampal B-Disease
injury I-Disease
in O
ovariectomized O
female O
but O
not O
in O
male O
rats O
. O

estrogens O
protect O
ovariectomized O
rats O
from O
hippocampal B-Disease
injury I-Disease
induced O
by O
kainic O
acid O
- O
induced O
status B-Disease
epilepticus I-Disease
( O
se B-Disease
) O
. O

we O
compared O
the O
effects O
of O
17beta O
- O
estradiol O
in O
adult O
male O
and O
ovariectomized O
female O
rats O
subjected O
to O
lithium O
- O
pilocarpine O
- O
induced O
se B-Disease
. O

se B-Disease
was O
induced O
20 O
h O
following O
the O
second O
injection O
and O
terminated O
3 O
h O
later O
. O

the O
extent O
of O
silver O
- O
stained O
ca3 O
and O
ca1 O
hippocampal O
neurons O
was O
evaluated O
2 O
days O
after O
se B-Disease
. O

these O
findings O
suggest O
that O
the O
effects O
of O
estradiol O
on O
seizure B-Disease
threshold O
and O
damage O
may O
be O
altered O
by O
sex O
- O
related O
differences O
in O
the O
hormonal O
environment O
. O

pseudoacromegaly B-Disease
induced O
by O
the O
long O
- O
term O
use O
of O
minoxidil O
. O

acromegaly B-Disease
is O
an O
endocrine B-Disease
disorder I-Disease
caused O
by O
chronic O
excessive O
growth O
hormone O
secretion O
from O
the O
anterior O
pituitary O
gland O
. O

significant O
disfiguring O
changes O
occur O
as O
a O
result O
of O
bone O
, O
cartilage O
, O
and O
soft O
tissue O
hypertrophy B-Disease
, O
including O
the O
thickening O
of O
the O
skin O
, O
coarsening O
of O
facial O
features O
, O
and O
cutis B-Disease
verticis I-Disease
gyrata I-Disease
. O

pseudoacromegaly B-Disease
, O
on O
the O
other O
hand O
, O
is O
the O
presence O
of O
similar O
acromegaloid O
features O
in O
the O
absence O
of O
elevated O
growth O
hormone O
or O
insulin O
- O
like O
growth O
factor O
levels O
. O

we O
present O
a O
patient O
with O
pseudoacromegaly B-Disease
that O
resulted O
from O
the O
long O
- O
term O
use O
of O
minoxidil O
at O
an O
unusually O
high O
dose O
. O

this O
is O
the O
first O
case O
report O
of O
pseudoacromegaly B-Disease
as O
a O
side O
effect O
of O
minoxidil O
use O
. O

combined O
androgen O
blockade O
- O
induced O
anemia B-Disease
in O
prostate B-Disease
cancer I-Disease
patients O
without O
bone O
involvement O
. O

background O
: O
to O
determine O
the O
onset O
and O
extent O
of O
combined O
androgen O
blockade O
( O
cab O
) O
- O
induced O
anemia B-Disease
in O
prostate B-Disease
cancer I-Disease
patients O
without O
bone O
involvement O
. O

patients O
and O
methods O
: O
forty O
- O
two O
patients O
with O
biopsy O
- O
proven O
prostatic B-Disease
adenocarcinoma I-Disease
[ O
26 O
with O
stage O
c O
( O
t3n0m0 O
) O
and O
16 O
with O
stage O
d1 O
( O
t3n1m0 O
) O
] O
were O
included O
in O
this O
study O
. O

all O
patients O
received O
cab O
[ O
leuprolide O
acetate O
( O
lhrh O
- O
a O
) O
3 O
. O

75 O
mg O
, O
intramuscularly O
, O
every O
28 O
days O
plus O
250 O
mg O
flutamide O
, O
tid O
, O
per O
os O
] O
and O
were O
evaluated O
for O
anemia B-Disease
by O
physical O
examination O
and O
laboratory O
tests O
at O
baseline O
and O
4 O
subsequent O
intervals O
( O
1 O
, O
2 O
, O
3 O
and O
6 O
months O
post O
- O
cab O
) O
. O

severe O
and O
clinically O
evident O
anemia B-Disease
of O
hb O
< O
11 O
g O
/ O
dl O
with O
clinical O
symptoms O
was O
detected O
in O
6 O
patients O
( O
14 O
. O

3 O
% O
) O
. O

this O
cab O
- O
induced O
anemia B-Disease
was O
normochromic O
and O
normocytic O
. O

at O
six O
months O
post O
- O
cab O
, O
patients O
with O
severe O
anemia B-Disease
had O
a O
hb O
mean O
value O
of O
10 O
. O

2 O
+ O
/ O
- O
0 O
. O

1 O
g O
/ O
dl O
( O
x O
+ O
/ O
- O
se O
) O
, O
whereas O
the O
other O
patients O
had O
mild O
anemia B-Disease
with O
hb O
mean O
value O
of O
13 O
. O

2 O
+ O
/ O
- O
0 O
. O

17 O
( O
x O
+ O
/ O
- O
se O
) O
. O

the O
development O
of O
severe O
anemia B-Disease
at O
6 O
months O
post O
- O
cab O
was O
predictable O
by O
the O
reduction O
of O
hb O
baseline O
value O
of O
more O
than O
2 O
. O

5 O
g O
/ O
dl O
after O
3 O
months O
of O
cab O
( O
p O
= O
0 O
. O

1 O
) O
. O

the O
development O
of O
severe O
cab O
- O
induced O
anemia B-Disease
in O
prostate B-Disease
cancer I-Disease
patients O
did O
not O
correlate O
with O
t O
baseline O
values O
( O
t O
< O
3 O
ng O
/ O
ml O
versus O
t O
> O
or O
= O
3 O
ng O
/ O
ml O
) O
, O
with O
age O
( O
< O
76 O
yrs O
versus O
> O
or O
= O
76 O
yrs O
) O
, O
and O
clinical O
stage O
( O
stage O
c O
versus O
stage O
d1 O
) O
. O

severe O
and O
clinically O
evident O
anemia B-Disease
was O
easily O
corrected O
by O
subcutaneous O
injections O
( O
3 O
times O
/ O
week O
for O
1 O
month O
) O
of O
recombinant O
erythropoietin O
( O
rhuepo O
- O
beta O
) O
. O

conclusion O
: O
our O
data O
suggest O
that O
rhuepo O
- O
beta O
correctable O
cab O
- O
induced O
anemia B-Disease
occurs O
in O
14 O
. O

3 O
% O
of O
prostate B-Disease
cancer I-Disease
patients O
after O
6 O
months O
of O
therapy O
. O

delirium B-Disease
during O
clozapine O
treatment O
: O
incidence O
and O
associated O
risk O
factors O
. O

background O
: O
incidence O
and O
risk O
factors O
for O
delirium B-Disease
during O
clozapine O
treatment O
require O
further O
clarification O
. O

methods O
: O
we O
used O
computerized O
pharmacy O
records O
to O
identify O
all O
adult O
psychiatric B-Disease
inpatients O
treated O
with O
clozapine O
( O
1995 O
- O
96 O
) O
, O
reviewed O
their O
medical O
records O
to O
score O
incidence O
and O
severity O
of O
delirium B-Disease
, O
and O
tested O
associations O
with O
potential O
risk O
factors O
. O

delirium B-Disease
was O
diagnosed O
in O
14 O
( O
10 O
. O

1 O
% O
incidence O
, O
or O
1 O
. O

48 O
cases O
/ O
person O
- O
years O
of O
exposure O
) O
; O
71 O
. O

4 O
% O
of O
cases O
were O
moderate O
or O
severe O
. O

conclusions O
: O
delirium B-Disease
was O
found O
in O
10 O
% O
of O
clozapine O
- O
treated O
inpatients O
, O
particularly O
in O
older O
patients O
exposed O
to O
other O
central O
anticholinergics O
. O

delirium B-Disease
was O
inconsistently O
recognized O
clinically O
in O
milder O
cases O
and O
was O
associated O
with O
increased O
length O
- O
of O
- O
stay O
and O
higher O
costs O
, O
and O
inferior O
clinical O
outcome O
. O

neuroprotective O
action O
of O
mpep O
, O
a O
selective O
mglur5 O
antagonist O
, O
in O
methamphetamine O
- O
induced O
dopaminergic O
neurotoxicity B-Disease
is O
associated O
with O
a O
decrease O
in O
dopamine O
outflow O
and O
inhibition O
of O
hyperthermia B-Disease
in O
rats O
. O

moreover O
, O
it O
transiently O
diminished O
the O
methamphetamine O
( O
10 O
mg O
/ O
kg O
sc O
) O
- O
induced O
hyperthermia B-Disease
and O
reduced O
basal O
body O
temperature O
. O

the O
results O
of O
this O
study O
suggest O
that O
the O
blockade O
of O
mglur5 O
by O
mpep O
may O
protect O
dopaminergic O
neurones O
against O
methamphetamine O
- O
induced O
toxicity B-Disease
. O

neuroprotection O
rendered O
by O
mpep O
may O
be O
associated O
with O
the O
reduction O
of O
the O
methamphetamine O
- O
induced O
dopamine O
efflux O
in O
the O
striatum O
due O
to O
the O
blockade O
of O
extrastriatal O
mglur5 O
, O
and O
with O
a O
decrease O
in O
hyperthermia B-Disease
. O

protective O
efficacy O
of O
neuroactive O
steroids O
against O
cocaine O
kindled O
- O
seizures B-Disease
in O
mice O
. O

neuroactive O
steroids O
demonstrate O
pharmacological O
actions O
that O
have O
relevance O
for O
a O
host O
of O
neurological B-Disease
and I-Disease
psychiatric I-Disease
disorders I-Disease
. O

they O
offer O
protection O
against O
seizures B-Disease
in O
a O
range O
of O
models O
and O
seem O
to O
inhibit O
certain O
stages O
of O
drug B-Disease
dependence I-Disease
in O
preclinical O
assessments O
. O

the O
present O
study O
was O
designed O
to O
evaluate O
two O
endogenous O
and O
one O
synthetic O
neuroactive O
steroid O
that O
positively O
modulate O
the O
gamma O
- O
aminobutyric O
acid O
( O
gaba O
( O
a O
) O
) O
receptor O
against O
the O
increase O
in O
sensitivity O
to O
the O
convulsant O
effects O
of O
cocaine O
engendered O
by O
repeated O
cocaine O
administration O
( O
seizure B-Disease
kindling O
) O
. O

allopregnanolone O
( O
3alpha O
- O
hydroxy O
- O
5alpha O
- O
pregnan O
- O
20 O
- O
one O
) O
, O
pregnanolone O
( O
3alpha O
- O
hydroxy O
- O
5beta O
- O
pregnan O
- O
20 O
- O
one O
) O
and O
ganaxolone O
( O
a O
synthetic O
derivative O
of O
allopregnanolone O
3alpha O
- O
hydroxy O
- O
3beta O
- O
methyl O
- O
5alpha O
- O
pregnan O
- O
20 O
- O
one O
) O
were O
tested O
for O
their O
ability O
to O
suppress O
the O
expression O
( O
anticonvulsant O
effect O
) O
and O
development O
( O
antiepileptogenic O
effect O
) O
of O
cocaine O

- O
kindled O
seizures B-Disease
in O
male O
, O
swiss O
- O
webster O
mice O
. O

kindled O
seizures B-Disease
were O
induced O
by O
daily O
administration O
of O
60 O
mg O
/ O
kg O
cocaine O
for O
5 O
days O
. O

all O
of O
these O
positive O
gaba O
( O
a O
) O
modulators O
suppressed O
the O
expression O
of O
kindled O
seizures B-Disease
, O
whereas O
only O
allopregnanolone O
and O
ganaxolone O
inhibited O
the O
development O
of O
kindling O
. O

effect O
of O
humoral O
modulators O
of O
morphine O
- O
induced O
increase B-Disease
in I-Disease
locomotor I-Disease
activity I-Disease
of O
mice O
. O

the O
effect O
of O
humoral O
modulators O
on O
the O
morphine O
- O
induced O
increase B-Disease
in I-Disease
locomotor I-Disease
activity I-Disease
of O
mice O
was O
studied O
. O

the O
subcutaneous O
administration O
of O
10 O
mg O
/ O
kg O
of O
morphine O
- O
hc1 O
produced O
a O
marked O
increase B-Disease
in I-Disease
locomotor I-Disease
activity I-Disease
in O
mice O
. O

the O
morphine O
- O
induced O
hyperactivity B-Disease
was O
potentiated O
by O
scopolamine O
and O
attenuated O
by O
physostigmine O
. O

in O
contrast O
, O
both O
methscopolamine O
and O
neostigmine O
, O
which O
do O
not O
penetrate O
the O
blood O
- O
brain O
barrier O
, O
had O
no O
effect O
on O
the O
hyperactivity B-Disease
produced O
by O
morphine O
. O

on O
the O
other O
hand O
, O
pretreatment O
with O
p O
- O
chlorophenylalamine O
( O
3 O
x O
320 O
mg O
/ O
kg O
i O
. O

p O
. O

, O
24 O
hr O
) O
, O
a O
serotonin O
depletor O
, O
caused O
no O
significant O
change O
in O
the O
hyperactivity B-Disease
. O

effects O
of O
uninephrectomy O
and O
high O
protein O
feeding O
on O
lithium O
- O
induced O
chronic B-Disease
renal I-Disease
failure I-Disease
in O
rats O
. O

rats O
with O
lithium O
- O
induced O
nephropathy B-Disease
were O
subjected O
to O
high O
protein O
( O
hp O
) O
feeding O
, O
uninephrectomy O
( O
nx O
) O
or O
a O
combination O
of O
these O
, O
in O
an O
attempt O
to O
induce O
glomerular O
hyperfiltration O
and O
further O
progression O
of O
renal B-Disease
failure I-Disease
. O

lithium O
also O
caused O
proteinuria B-Disease
and O
systolic O
hypertension B-Disease
in O
absence O
of O
glomerulosclerosis B-Disease
. O

hp O
failed O
to O
accentuante O
progression O
of O
renal B-Disease
failure I-Disease
and O
in O
fact O
tended O
to O
increase O
gfr O
and O
decrease O
plasma O
creatinine O
levels O
in O
lithium O
pretreated O
rats O
. O

the O
results O
indicate O
that O
li O
- O
induced O
nephropathy B-Disease
, O
even O
when O
the O
gfr O
is O
only O
modestly O
reduced O
, O
is O
associated O
with O
proteinuria B-Disease
and O
arterial O
systolic O
hypertension B-Disease
. O

in O
this O
model O
of O
chronic B-Disease
renal I-Disease
failure I-Disease
the O
decline O
in O
gfr O
is O
not O
accompanied O
by O
a O
corresponding O
fall O
in O
effective O
renal O
plasma O
flow O
, O
which O
may O
be O
the O
functional O
expression O
of O
the O
formation O
of O
nonfiltrating O
atubular O
glomeruli O
. O

treatment O
of O
crohn B-Disease
' I-Disease
s I-Disease
disease I-Disease
with O
fusidic O
acid O
: O
an O
antibiotic O
with O
immunosuppressive O
properties O
similar O
to O
cyclosporin O
. O

because O
of O
the O
need O
for O
the O
development O
of O
new O
treatments O
for O
crohn B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
a O
pilot O
study O
was O
undertaken O
to O
estimate O
the O
pharmacodynamics O
and O
tolerability O
of O
fusidic O
acid O
treatment O
in O
chronic O
active O
, O
therapy O
- O
resistant O
patients O
. O

eight O
crohn B-Disease
' I-Disease
s I-Disease
disease I-Disease
patients O
were O
included O
. O

there O
were O
no O
serious O
clinical O
side O
effects O
, O
but O
dose O
reduction O
was O
required O
in O
two O
patients O
because O
of O
nausea B-Disease
. O

the O
results O
of O
this O
pilot O
study O
suggest O
that O
fusidic O
acid O
may O
be O
of O
benefit O
in O
selected O
chronic O
active O
crohn B-Disease
' I-Disease
s I-Disease
disease I-Disease
patients O
in O
whom O
conventional O
treatment O
is O
ineffective O
. O

because O
there O
seems O
to O
exist O
a O
scientific O
rationale O
for O
the O
use O
of O
fusidic O
acid O
at O
the O
cytokine O
level O
in O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
, O
we O
suggest O
that O
the O
role O
of O
this O
treatment O
should O
be O
further O
investigated O
. O

changes O
in O
depressive B-Disease
status O
associated O
with O
topical O
beta O
- O
blockers O
. O

depression B-Disease
and O
sexual B-Disease
dysfunction I-Disease
have O
been O
related O
to O
side O
effects O
of O
topical O
beta O
- O
blockers O
. O

eight O
glaucomatous B-Disease
patients O
chronically O
treated O
with O
timolol O
0 O
. O

5 O
% O
/ O
12h O
, O
suffering O
from O
depression B-Disease
diagnosed O
through O
dms O
- O
iii O
- O
r O
criteria O
, O
were O
included O
in O
the O
study O
. O

during O
the O
six O
- O
month O
follow O
up O
, O
depression B-Disease
was O
quantified O
through O
the O
beck O
and O
zung O
- O
conde O
scales O
every O
two O
months O
. O

in O
a O
double O
blind O
cross O
- O
over O
study O
with O
control O
group O
, O
the O
patients O
under O
timolol O
treatment O
presented O
higher O
depression B-Disease
values O
measured O
through O
the O
beck O
and O
the O
zung O
- O
conde O
scales O
( O
p O
< O
0 O
. O

1 O
vs O
control O
) O
. O

these O
results O
suggest O
that O
betaxolol O
could O
be O
less O
of O
a O
depression B-Disease
- O
inducer O
than O
timolol O
in O
predisposed O
patients O
. O

protection O
against O
amphetamine O
- O
induced O
neurotoxicity B-Disease
toward O
striatal O
dopamine O
neurons O
in O
rodents O
by O
ly274614 O
, O
an O
excitatory O
amino O
acid O
antagonist O
. O

the O
data O
strengthen O
the O
evidence O
that O
the O
neurotoxic B-Disease
effect O
of O
amphetamine O
and O
related O
compounds O
toward O
nigrostriatal O
dopamine O
neurons O
involves O
nmda O
receptors O
and O
that O
ly274614 O
is O
an O
nmda O
receptor O
antagonist O
with O
long O
- O
lasting O
in O
vivo O
effects O
in O
rats O
. O

ketoconazole O
- O
induced O
neurologic B-Disease
sequelae I-Disease
. O

a O
77 O
- O
y O
- O
old O
patient O
developed O
weakness B-Disease
of I-Disease
extremities I-Disease
, O
legs B-Disease
paralysis I-Disease
, O
dysarthria B-Disease
and O
tremor B-Disease
1 O
h O
after O
ingestion O
of O
200 O
mg O
ketoconazole O
for O
the O
first O
time O
in O
his O
life O
. O

this O
case O
illustrates O
the O
need O
for O
close O
vigilance O
in O
adverse B-Disease
drug I-Disease
reactions I-Disease
, O
particularly O
in O
the O
elderly O
. O

development O
of O
levodopa O
- O
induced O
dyskinesias B-Disease
in O
parkinsonian B-Disease
monkeys O
may O
depend O
upon O
rate O
of O
symptom O
onset O
and O
/ O
or O
duration O
of O
symptoms O
. O

levodopa O
- O
induced O
dyskinesias B-Disease
( O
lids B-Disease
) O
present O
a O
major O
problem O
for O
the O
long O
- O
term O
management O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
patients O
. O

due O
to O
the O
interdependence O
of O
risk O
factors O
in O
clinical O
populations O
, O
it O
is O
difficult O
to O
independently O
examine O
factors O
that O
may O
influence O
the O
development O
of O
lids B-Disease
. O

using O
macaque O
monkeys O
with O
different O
types O
of O
mptp O
- O
induced O
parkinsonism B-Disease
, O
the O
current O
study O
evaluated O
the O
degree O
to O
which O
rate O
of O
symptom O
progression O
, O
symptom O
severity O
, O
and O
response O
to O
and O
duration O
of O
levodopa O
therapy O
may O
be O
involved O
in O
the O
development O
of O
lids B-Disease
. O

monkeys O
with O
acute O
( O
short O
- O
term O
) O
mptp O
exposure O
, O
rapid O
symptom O
onset O
and O
short O
symptom O
duration O
prior O
to O
initiation O
of O
levodopa O
therapy O
developed O
dyskinesia B-Disease
between O
11 O
and O
24 O
days O
of O
daily O
levodopa O
administration O
. O

in O
contrast O
, O
monkeys O
with O
long O
- O
term O
mptp O
exposure O
, O
slow O
symptom O
progression O
and O
/ O
or O
long O
symptom O
duration O
prior O
to O
initiation O
of O
levodopa O
therapy O
were O
more O
resistant O
to O
developing O
lids B-Disease
( O
e O
. O

g O
. O

, O
dyskinesia B-Disease
developed O
no O
sooner O
than O
146 O
days O
of O
chronic O
levodopa O
administration O
) O
. O

these O
data O
suggest O
distinct O
differences O
in O
the O
propensity O
to O
develop O
lids B-Disease
in O
monkeys O
with O
different O
rates O
of O
symptom O
progression O
or O
symptom O
durations O
prior O
to O
levodopa O
and O
demonstrate O
the O
value O
of O
these O
models O
for O
further O
studying O
the O
pathophysiology O
of O
lids B-Disease
. O

a O
diet O
promoting O
sugar B-Disease
dependency I-Disease
causes O
behavioral B-Disease
cross I-Disease
- I-Disease
sensitization I-Disease
to O
a O
low O
dose O
of O
amphetamine O
. O

previous O
research O
in O
this O
laboratory O
has O
shown O
that O
a O
diet O
of O
intermittent O
excessive O
sugar O
consumption O
produces O
a O
state O
with O
neurochemical O
and O
behavioral O
similarities O
to O
drug B-Disease
dependency I-Disease
. O

the O
present O
study O
examined O
whether O
female O
rats O
on O
various O
regimens O
of O
sugar O
access O
would O
show O
behavioral B-Disease
cross I-Disease
- I-Disease
sensitization I-Disease
to O
a O
low O
dose O
of O
amphetamine O
. O

the O
animals O
that O
had O
experienced O
cyclic O
sucrose O
and O
chow O
were O
hyperactive B-Disease
in O
response O
to O
amphetamine O
compared O
with O
four O
control O
groups O
( O
ad O
libitum O
10 O
% O
sucrose O
and O
chow O
followed O
by O
amphetamine O
injection O
, O
cyclic O
chow O
followed O
by O
amphetamine O
injection O
, O
ad O
libitum O
chow O
with O
amphetamine O
, O
or O
cyclic O
10 O
% O
sucrose O
and O
chow O
with O
a O
saline O
injection O
) O
. O

reversible O
dilated B-Disease
cardiomyopathy I-Disease
related O
to O
amphotericin O
b O
therapy O
. O

we O
describe O
a O
patient O
who O
developed O
dilated B-Disease
cardiomyopathy I-Disease
and O
clinical O
congestive O
heart B-Disease
failure I-Disease
after O
2 O
months O
of O
therapy O
with O
amphotericin O
b O
( O
amb O
) O
for O
disseminated O
coccidioidomycosis B-Disease
. O

his O
echocardiographic O
abnormalities O
and O
heart B-Disease
failure I-Disease
resolved O
after O
posaconazole O
was O
substituted O
for O
amb O
. O

it O
is O
important O
to O
recognize O
the O
rare O
and O
potentially O
reversible O
toxicity B-Disease
of O
amb O
. O

no O
- O
induced O
migraine B-Disease
attack O
: O
strong O
increase O
in O
plasma O
calcitonin O
gene O
- O
related O
peptide O
( O
cgrp O
) O
concentration O
and O
negative O
correlation O
with O
platelet O
serotonin O
release O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
changes O
in O
the O
plasma O
calcitonin O
gene O
- O
related O
peptide O
( O
cgrp O
) O
concentration O
and O
platelet O
serotonin O
( O
5 O
- O
hydroxytriptamine O
, O
5 O
- O
ht O
) O
content O
during O
the O
immediate O
headache B-Disease
and O
the O
delayed O
genuine O
migraine B-Disease
attack O
provoked O
by O
nitroglycerin O
. O

fifteen O
female O
migraineurs B-Disease
( I-Disease
without I-Disease
aura I-Disease
) I-Disease
and O
eight O
controls O
participated O
in O
the O
study O
. O

blood O
was O
collected O
from O
the O
antecubital O
vein O
four O
times O
: O
60 O
min O
before O
and O
after O
the O
nitroglycerin O
application O
, O
and O
60 O
and O
120 O
min O
after O
the O
beginning O
of O
the O
migraine B-Disease
attack O
( O
mean O
344 O
and O
404 O
min O
; O
12 O
subjects O
) O
. O

in O
those O
subjects O
who O
had O
no O
migraine B-Disease
attack O
( O
11 O
subjects O
) O
a O
similar O
time O
schedule O
was O
used O
. O

plasma O
cgrp O
concentration O
increased O
significantly O
( O
p O
< O
0 O
. O

1 O
) O
during O
the O
migraine B-Disease
attack O
and O
returned O
to O
baseline O
after O
the O
cessation O
of O
the O
migraine B-Disease
. O

in O
addition O
, O
both O
change O
and O
peak O
, O
showed O
significant O
positive O
correlations O
with O
migraine B-Disease
headache B-Disease
intensity O
( O
p O
< O
0 O
. O

1 O
) O
. O

however O
, O
plasma O
cgrp O
concentrations O
failed O
to O
change O
during O
immediate O
headache B-Disease
and O
in O
the O
subjects O
with O
no O
migraine B-Disease
attack O
. O

basal O
cgrp O
concentration O
was O
significantly O
higher O
and O
platelet O
5 O
- O
ht O
content O
tended O
to O
be O
lower O
in O
subjects O
who O
experienced O
a O
migraine B-Disease
attack O
. O

platelet O
serotonin O
content O
decreased O
significantly O
( O
p O
< O
0 O
. O

1 O
) O
after O
nitroglycerin O
in O
subjects O
with O
no O
migraine B-Disease
attack O
but O
no O
consistent O
change O
was O
observed O
in O
patients O
with O
migraine B-Disease
attack O
. O

in O
conclusion O
, O
the O
fact O
that O
plasma O
cgrp O
concentration O
correlates O
with O
the O
timing O
and O
severity O
of O
a O
migraine B-Disease
headache B-Disease
suggests O
a O
direct O
relationship O
between O
cgrp O
and O
migraine B-Disease
. O

in O
contrast O
, O
serotonin O
release O
from O
platelets O
does O
not O
provoke O
migraine B-Disease
, O
it O
may O
even O
counteract O
the O
headache B-Disease
and O
the O
concomitant O
cgrp O
release O
in O
this O
model O
. O

hyperbaric O
oxygen O
therapy O
for O
control O
of O
intractable O
cyclophosphamide O
- O
induced O
hemorrhagic B-Disease
cystitis I-Disease
. O

we O
report O
a O
case O
of O
intractable O
hemorrhagic B-Disease
cystitis I-Disease
due O
to O
cyclophosphamide O
therapy O
for O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
. O

conservative O
treatment O
, O
including O
bladder O
irrigation O
with O
physiological O
saline O
and O
instillation O
of O
prostaglandin O
f2 O
alpha O
, O
failed O
to O
totally O
control O
hemorrhage B-Disease
. O

the O
bleeding B-Disease
ceased O
completely O
by O
the O
end O
of O
treatment O
and O
the O
patient O
remained O
free O
of O
hematuria B-Disease
thereafter O
. O

in O
future O
, O
this O
form O
of O
therapy O
can O
offer O
a O
safe O
alternative O
in O
the O
treatment O
of O
cyclophosphamide O
- O
induced O
hemorrhagic B-Disease
cystitis I-Disease
. O

acute B-Disease
psychosis I-Disease
due O
to O
treatment O
with O
phenytoin O
in O
a O
nonepileptic O
patient O
. O

the O
development O
of O
psychosis B-Disease
related O
to O
antiepileptic O
drug O
treatment O
is O
usually O
attributed O
to O
the O
interaction O
between O
the O
epileptic B-Disease
brain O
substratum O
and O
the O
antiepileptic O
drugs O
. O

the O
case O
of O
a O
nonepileptic O
patient O
who O
developed O
psychosis B-Disease
following O
phenytoin O
treatment O
for O
trigeminal B-Disease
neuralgia I-Disease
is O
described O
. O

this O
case O
suggests O
that O
the O
psychotic B-Disease
symptoms I-Disease
that O
occur O
following O
phenytoin O
treatment O
in O
some O
epileptic B-Disease
patients O
may O
be O
the O
direct O
result O
of O
medication O
, O
unrelated O
to O
seizures B-Disease
. O

although O
the O
united O
states O
food O
and O
drug O
administration O
banned O
its O
use O
for O
nocturnal B-Disease
leg I-Disease
cramps I-Disease
due O
to O
lack O
of O
safety O
and O
efficacy O
, O
quinine O
is O
widely O
available O
in O
beverages O
including O
tonic O
water O
and O
bitter O
lemon O
. O

numerous O
anecdotal O
reports O
suggest O
that O
products O
containing O
quinine O
may O
produce O
neurological B-Disease
complications I-Disease
, O
including O
confusion B-Disease
, O
altered O
mental O
status O
, O
seizures B-Disease
, O
and O
coma B-Disease
, O
particularly O
in O
older O
women O
. O

transient O
platypnea B-Disease
- I-Disease
orthodeoxia I-Disease
- I-Disease
like I-Disease
syndrome I-Disease
induced O
by O
propafenone O
overdose B-Disease
in O
a O
young O
woman O
with O
ebstein B-Disease
' I-Disease
s I-Disease
anomaly I-Disease
. O

in O
this O
report O
we O
describe O
the O
case O
of O
a O
37 O
- O
year O
- O
old O
white O
woman O
with O
ebstein B-Disease
' I-Disease
s I-Disease
anomaly I-Disease
, O
who O
developed O
a O
rare O
syndrome O
called O
platypnea B-Disease
- I-Disease
orthodeoxia I-Disease
, O
characterized O
by O
massive O
right O
- O
to O
- O
left O
interatrial O
shunting O
with O
transient O
profound O
hypoxia B-Disease
and O
cyanosis B-Disease
. O

this O
shunt O
of O
blood O
via O
a O
patent B-Disease
foramen I-Disease
ovale I-Disease
occurred O
in O
the O
presence O
of O
a O
normal O
pulmonary O
artery O
pressure O
, O
and O
was O
probably O
precipitated O
by O
a O
propafenone O
overdose B-Disease
. O

this O
drug O
caused O
biventricular B-Disease
dysfunction I-Disease
, O
due O
to O
its O
negative O
inotropic O
effect O
, O
and O
hypotension B-Disease
, O
due O
to O
its O
peripheral O
vasodilatory O
effect O
. O

noxious O
chemical O
stimulation O
of O
rat O
facial O
mucosa O
increases O
intracranial O
blood O
flow O
through O
a O
trigemino O
- O
parasympathetic O
reflex O
- O
- O
an O
experimental O
model O
for O
vascular B-Disease
dysfunctions I-Disease
in O
cluster B-Disease
headache I-Disease
. O

cluster B-Disease
headache I-Disease
is O
characterized O
by O
typical O
autonomic O
dysfunctions O
including O
facial O
and O
intracranial B-Disease
vascular I-Disease
disturbances I-Disease
. O

capsaicin O
( O
0 O
. O

1 O
- O
1 O
mm O
) O
applied O
to O
oral O
or O
nasal O
mucosa O
induced O
increases B-Disease
in I-Disease
dural I-Disease
and I-Disease
cortical I-Disease
blood I-Disease
flow I-Disease
and O
provoked O
lacrimation O
. O

the O
evoked O
increases B-Disease
in I-Disease
dural I-Disease
blood I-Disease
flow I-Disease
were O
also O
abolished O
by O
topical O
pre O
- O
administration O
of O
atropine O
( O
1 O
mm O
) O
and O
[ O
lys1 O
, O
pro2 O
, O
5 O
, O
arg3 O
, O
4 O
, O
tyr6 O
] O
- O
vip O
( O
0 O
. O

1 O
mm O
) O
, O
a O
vasoactive O
intestinal O
polypeptide O
( O
vip O
) O
antagonist O
, O
onto O
the O
exposed O
dura O
mater O
. O

similar O
mechanisms O
may O
be O
involved O
in O
the O
pathogenesis O
of O
cluster B-Disease
headache I-Disease
. O

organophosphate O
- O
induced O
convulsions B-Disease
and O
prevention O
of O
neuropathological B-Disease
damages I-Disease
. O

the O
acute O
toxicity B-Disease
of O
ops O
is O
the O
result O
of O
their O
irreversible O
binding O
with O
aches O
in O
the O
central O
nervous O
system O
( O
cns O
) O
, O
which O
elevates O
acetylcholine O
( O
ach O
) O
levels O
. O

the O
rats O
treated O
with O
dfp O
- O
atropine O
showed O
severe O
typical O
op O
- O
induced O
toxicity B-Disease
signs O
. O

when O
cpa O
, O
diazepam O
or O
2pam O
was O
given O
immediately O
after O
dfp O
- O
atropine O
, O
these O
treatments O
prevented O
, O
delayed O
or O
shortened O
the O
occurrence O
of O
serious O
signs O
of O
poisoning B-Disease
. O

atropine O
- O
mk801 O
did O
not O
offer O
any O
additional O
protection O
against O
dfp O
toxicity B-Disease
. O

in O
conclusion O
, O
cpa O
, O
diazepam O
and O
2pam O
in O
combination O
with O
atropine O
prevented O
the O
occurrence O
of O
serious O
signs O
of O
poisoning B-Disease
and O
thus O
reduced O
the O
toxicity B-Disease
of O
dfp O
in O
rat O
. O

a O
pyridoxine O
- O
dependent O
behavioral B-Disease
disorder I-Disease
unmasked O
by O
isoniazid O
. O

a O
3 O
- O
year O
- O
old O
girl O
had O
behavioral B-Disease
deterioration I-Disease
, O
with O
hyperkinesis B-Disease
, O
irritability B-Disease
, O
and O
sleeping B-Disease
difficulties I-Disease
after O
the O
therapeutic O
administration O
of O
isoniazid O
. O

periodic O
withdrawal O
of O
pyridoxine O
was O
associated O
with O
return O
of O
the O
hyperkinesis B-Disease
. O

recurrent O
excitation O
in O
the O
dentate O
gyrus O
of O
a O
murine O
model O
of O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
. O

similar O
to O
rats O
, O
systemic O
pilocarpine O
injection O
causes O
status B-Disease
epilepticus I-Disease
( O
se B-Disease
) O
and O
the O
eventual O
development O
of O
spontaneous O
seizures B-Disease
and O
mossy O
fiber O
sprouting O
in O
c57bl O
/ O
6 O
and O
cd1 O
mice O
, O
but O
the O
physiological O
correlates O
of O
these O
events O
have O
not O
been O
identified O
in O
mice O
. O

in O
mg O
( O
2 O
+ O
) O
- O
free O
bathing O
medium O
containing O
bicuculline O
, O
conditions O
designed O
to O
increase O
excitability O
in O
the O
slices O
, O
electrical O
stimulation O
of O
the O
hilus O
resulted O
in O
a O
single O
population O
spike O
in O
granule O
cells O
from O
control O
mice O
and O
pilocarpine O
- O
treated O
mice O
that O
did O
not O
experience O
se B-Disease
. O

in O
se B-Disease
survivors O
, O
similar O
stimulation O
resulted O
in O
a O
population O
spike O
followed O
, O
at O
a O
variable O
latency O
, O
by O
negative O
dc O
shifts O
and O
repetitive O
afterdischarges O
of O
3 O
- O
60 O
s O
duration O
, O
which O
were O
blocked O
by O
ionotropic O
glutamate O
receptor O
antagonists O
. O

focal O
glutamate O
photostimulation O
of O
the O
granule O
cell O
layer O
at O
sites O
distant O
from O
the O
recording O
pipette O
resulted O
in O
population O
responses O
of O
1 O
- O
30 O
s O
duration O
in O
slices O
from O
se B-Disease
survivors O
but O
not O
other O
groups O
. O

these O
data O
support O
the O
hypothesis O
that O
se B-Disease
- O
induced O
mossy O
fiber O
sprouting O
and O
synaptic O
reorganization O
are O
relevant O
characteristics O
of O
seizure B-Disease
development O
in O
these O
murine O
strains O
, O
resembling O
rat O
models O
of O
human O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
. O

urinary B-Disease
bladder I-Disease
cancer I-Disease
in O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
: O
risks O
and O
relation O
to O
cyclophosphamide O
. O

objective O
: O
to O
assess O
and O
characterise O
the O
risk O
of O
bladder B-Disease
cancer I-Disease
, O
and O
its O
relation O
to O
cyclophosphamide O
, O
in O
patients O
with O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
. O

methods O
: O
in O
the O
population O
based O
, O
nationwide O
swedish O
inpatient O
register O
a O
cohort O
of O
1065 O
patients O
with O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
, O
1969 O
- O
95 O
, O
was O
identified O
. O

through O
linkage O
with O
the O
swedish O
cancer B-Disease
register O
, O
all O
subjects O
in O
this O
cohort O
diagnosed O
with O
bladder B-Disease
cancer I-Disease
were O
identified O
. O

nested O
within O
the O
cohort O
, O
a O
matched O
case O
- O
control O
study O
was O
performed O
to O
estimate O
the O
association O
between O
cyclophosphamide O
and O
bladder B-Disease
cancer I-Disease
using O
odds O
ratios O
( O
ors O
) O
as O
relative O
risk O
. O

in O
the O
cohort O
the O
cumulative O
risk O
of O
bladder B-Disease
cancer I-Disease
after O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
, O
and O
the O
relative O
prevalence O
of O
a O
history O
of O
bladder B-Disease
cancer I-Disease
at O
the O
time O
of O
diagnosis O
of O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
, O
were O
also O
estimated O
. O

the O
risk O
of O
bladder B-Disease
cancer I-Disease
doubled O
for O
every O
10 O
g O
increment O
in O
cyclophosphamide O
( O
or O
= O
2 O
. O

0 O
, O
95 O
% O
confidence O
interval O
( O
ci O
) O
0 O
. O

8 O
to O
4 O
. O

9 O
) O
. O

the O
absolute O
risk O
for O
bladder B-Disease
cancer I-Disease
in O
the O
cohort O
reached O
10 O
% O
16 O
years O
after O
diagnosis O
of O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
, O
and O
a O
history O
of O
bladder B-Disease
cancer I-Disease
was O
( O
non O
- O
significantly O
) O
twice O
as O
common O
as O
expected O
at O
the O
time O
of O
diagnosis O
of O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
. O

conclusion O
: O
the O
results O
indicate O
a O
dose O
- O
response O
relationship O
between O
cyclophosphamide O
and O
the O
risk O
of O
bladder B-Disease
cancer I-Disease
, O
high O
cumulative O
risks O
in O
the O
entire O
cohort O
, O
and O
also O
the O
possibility O
of O
risk O
factors O
operating O
even O
before O
wegener B-Disease
' I-Disease
s I-Disease
granulomatosis I-Disease
. O

differential O
modulation O
by O
estrogen O
of O
alpha2 O
- O
adrenergic O
and O
i1 O
- O
imidazoline O
receptor O
- O
mediated O
hypotension B-Disease
in O
female O
rats O
. O

we O
have O
recently O
shown O
that O
estrogen O
negatively O
modulates O
the O
hypotensive B-Disease
effect O
of O
clonidine O
( O
mixed O
alpha2 O
- O
/ O
i1 O
- O
receptor O
agonist O
) O
in O
female O
rats O
and O
implicates O
the O
cardiovascular O
autonomic O
control O
in O
this O
interaction O
. O

in O
sham O
- O
operated O
rats O
, O
rilmenidine O
or O
alpha O
- O
methyldopa O
elicited O
similar O
hypotension B-Disease
that O
lasted O
at O
least O
5 O
h O
and O
was O
associated O
with O
reductions O
in O
standard O
deviation O
of O
mean O
arterial O
pressure O
. O

ovx O
significantly O
enhanced O
the O
hypotensive B-Disease
response O
to O
alpha O
- O
methyldopa O
, O
in O
contrast O
to O
no O
effect O
on O
rilmenidine O
hypotension B-Disease
. O

the O
enhanced O
alpha O
- O
methyldopa O
hypotension B-Disease
in O
ovx O
rats O
was O
paralleled O
with O
further O
reduction O
in O
sdrr O
and O
a B-Disease
reduced I-Disease
locomotor I-Disease
activity I-Disease
. O

these O
findings O
suggest O
that O
estrogen O
downregulates O
alpha2 O
- O
but O
not O
i1 O
- O
receptor O
- O
mediated O
hypotension B-Disease
and O
highlight O
a O
role O
for O
the O
cardiac O
autonomic O
control O
in O
alpha O
- O
methyldopa O
- O
estrogen O
interaction O
. O

severe O
reversible O
left B-Disease
ventricular I-Disease
systolic I-Disease
and I-Disease
diastolic I-Disease
dysfunction I-Disease
due O
to O
accidental O
iatrogenic O
epinephrine O
overdose B-Disease
. O

catecholamine O
- O
induced O
cardiomyopathy B-Disease
due O
to O
chronic O
excess O
of O
endogenous O
catecholamines O
has O
been O
recognized O
for O
decades O
as O
a O
clinical O
phenomenon O
. O

in O
contrast O
, O
reports O
of O
myocardial B-Disease
dysfunction I-Disease
due O
to O
acute O
iatrogenic O
overdose B-Disease
are O
rare O
. O

a O
35 O
- O
year O
- O
old O
woman O
whose O
cervix O
uteri O
was O
inadvertently O
injected O
with O
8 O
mg O
of O
epinephrine O
developed O
myocardial B-Disease
stunning I-Disease
that O
was O
characterized O
by O
severe O
hemodynamic O
compromise O
, O
profound O
, O
albeit O
transient O
, O
left B-Disease
ventricular I-Disease
systolic I-Disease
and I-Disease
diastolic I-Disease
dysfunction I-Disease
, O
and O
only O
modestly O
elevated O
biochemical O
markers O
of O
myocardial B-Disease
necrosis I-Disease
. O

cardioprotective O
effect O
of O
tincture O
of O
crataegus O
on O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

the O
present O
study O
was O
done O
to O
investigate O
the O
protective O
effect O
of O
tcr O
on O
experimentally O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

treatment O
of O
tinnitus B-Disease
by O
intratympanic O
instillation O
of O
lignocaine O
( O
lidocaine O
) O
2 O
per O
cent O
through O
ventilation O
tubes O
. O

idiopathic B-Disease
subjective I-Disease
tinnitus I-Disease
( O
ist B-Disease
) O
is O
one O
of O
the O
most O
obscure O
otological O
pathologies O
. O

this O
paper O
presents O
the O
results O
of O
treating O
ist B-Disease
by O
intratympanic O
instillation O
of O
lignocaine O
( O
lidocaine O
) O
2 O
per O
cent O
through O
a O
grommet O
, O
for O
five O
weekly O
courses O
. O

fifty O
- O
two O
patients O
suffering O
from O
intractable O
tinnitus B-Disease
entered O
this O
therapeutic O
trial O
, O
but O
only O
nine O
finished O
all O
five O
courses O
. O

in O
one O
patient O
, O
the O
tinnitus B-Disease
was O
almost O
completely O
abolished O
, O
but O
in O
all O
the O
nine O
patients O
the O
decompensated O
tinnitus B-Disease
changed O
to O
a O
compensated O
one O
. O

patients O
should O
be O
warned O
about O
the O
side O
effects O
of O
vertigo B-Disease
and O
vomiting B-Disease
, O
which O
subsides O
gradually O
with O
every O
new O
instillation O
, O
and O
that O
the O
tinnitus B-Disease
may O
not O
disappear O
but O
will O
be O
alleviated O
, O
enabling O
them O
to O
cope O
more O
easily O
with O
the O
disease O
and O
lead O
a O
more O
normal O
life O
. O

the O
alpha3 O
and O
beta4 O
nicotinic O
acetylcholine O
receptor O
subunits O
are O
necessary O
for O
nicotine O
- O
induced O
seizures B-Disease
and O
hypolocomotion B-Disease
in O
mice O
. O

binding O
of O
nicotine O
to O
nicotinic O
acetylcholine O
receptors O
( O
nachrs O
) O
elicits O
a O
series O
of O
dose O
- O
dependent O
behaviors O
that O
go O
from O
altered O
exploration O
, O
sedation O
, O
and O
tremors B-Disease
, O
to O
seizures B-Disease
and O
death B-Disease
. O

we O
examined O
the O
role O
of O
the O
beta4 O
subunits O
in O
nicotine O
- O
induced O
seizures B-Disease
and O
hypolocomotion B-Disease
in O
beta4 O
homozygous O
nan O
( O
beta4 O
- O
/ O
- O
) O
and O
alpha3 O
heterozygous O
( O
+ O
/ O
- O
) O
mice O
. O

beta4 O
- O
/ O
- O
mice O
were O
less O
sensitive O
to O
the O
effects O
of O
nicotine O
both O
at O
low O
doses O
, O
measured O
as O
decreased O
exploration O
in O
an O
open O
field O
, O
and O
at O
high O
doses O
, O
measured O
as O
sensitivity O
to O
nicotine O
- O
induced O
seizures B-Disease
. O

alpha3 O
+ O
/ O
- O
mice O
were O
partially O
resistant O
to O
nicotine O
- O
induced O
seizures B-Disease
when O
compared O
to O
wild O
- O
type O
littermates O
. O

together O
, O
these O
results O
suggest O
that O
the O
beta4 O
and O
the O
alpha3 O
subunits O
are O
mediators O
of O
nicotine O
- O
induced O
seizures B-Disease
and O
hypolocomotion B-Disease
. O

the O
effects O
of O
sevoflurane O
on O
lidocaine O
- O
induced O
convulsions B-Disease
. O

the O
influence O
of O
sevoflurane O
on O
lidocaine O
- O
induced O
convulsions B-Disease
was O
studied O
in O
cats O
. O

the O
convulsive B-Disease
threshold O
( O
mean O
+ O
/ O
- O
sd O
) O
was O
41 O
. O

4 O
+ O
/ O
- O
6 O
. O

5 O
mg O
. O

there O
was O
no O
significant O
difference O
in O
the O
convulsive B-Disease
threshold O
between O
sevoflurane O
and O
enflurane O
. O

the O
rise O
in O
blood O
pressure O
became O
less O
marked O
when O
higher O
concentrations O
of O
sevoflurane O
or O
enflurane O
were O
administered O
and O
the O
blood O
pressure O
at O
convulsions B-Disease
decreased O
significantly O
in O
1 O
. O

6 O
% O
sevoflurane O
, O
and O
in O
0 O
. O

8 O
% O
and O
1 O
. O

6 O
% O
enflurane O
. O

apamin O
( O
10 O
ng O
) O
had O
a O
tendency O
to O
decrease O
the O
convulsive B-Disease
threshold O
( O
21 O
. O

6 O
+ O
/ O
- O
2 O
. O

2 O
to O
19 O
. O

9 O
+ O
/ O
- O
2 O
. O

5 O
mg O
. O

l O
( O
- O
1 O
) O
) O
but O
this O
was O
not O
statistically O
significant O
. O

it O
is O
suggested O
that O
sevoflurane O
reduces O
the O
convulsive B-Disease
effect O
of O
lidocaine O
toxicity B-Disease
but O
carries O
some O
risk O
due O
to O
circulatory O
depression B-Disease
. O

cardiac B-Disease
toxicity I-Disease
observed O
in O
association O
with O
high O
- O
dose O
cyclophosphamide O
- O
based O
chemotherapy O
for O
metastatic O
breast B-Disease
cancer I-Disease
. O

in O
high O
doses O
, O
its O
nonhematological O
dose O
- O
limiting O
toxicity B-Disease
is O
cardiomyopathy B-Disease
. O

study O
design O
: O
we O
combined O
paclitaxel O
, O
melphalan O
and O
high O
- O
dose O
cyclophosphamide O
, O
thiotepa O
, O
and O
carboplatin O
in O
a O
triple O
sequential O
high O
- O
dose O
regimen O
for O
patients O
with O
metastatic O
breast B-Disease
cancer I-Disease
. O

analysis O
was O
performed O
on O
61 O
women O
with O
chemotherapy O
- O
responsive O
metastatic O
breast B-Disease
cancer I-Disease
receiving O
96 O
- O
h O
infusional O
cyclophosphamide O
as O
part O
of O
a O
triple O
sequential O
high O
- O
dose O
regimen O
to O
assess O
association O
between O
presence O
of O
peritransB-Plant O
congestive B-Disease
heart I-Disease
failure I-Disease
( O
chf B-Disease
) O
and O
the O
following O
pretreatment O
characteristics O
: O
presence O
of O
electrocardiogram O
( O
ekg O
) O
abnormalities O
, O
age O
, O
hypertension B-Disease
, O
prior O
cardiac O
history O
, O
smoking O
, O
diabetes B-Disease
mellitus I-Disease
, O
prior O
use O
of O
anthracyclines O
, O
and O
left O
- O
sided O
chest O
irradiation O

. O

results O
: O
six O
of O
61 O
women O
( O
10 O
% O
) O
developed O
clinically O
reversible O
grade O
3 O
chf B-Disease
following O
infusional O
cyclophosphamide O
with O
a O
median O
percent O
decline O
in O
ejection O
fraction O
of O
31 O
% O
. O

incidence O
of O
transient O
cyclophosphamide O
- O
related O
cardiac B-Disease
toxicity I-Disease
( O
10 O
% O
) O
is O
comparable O
to O
previous O
recorded O
literature O
. O

older O
age O
was O
significantly O
correlated O
with O
the O
chf B-Disease
development O
; O
with O
median O
ages O
for O
the O
entire O
group O
and O
for O
patients O
developing O
chf B-Disease
of O
45 O
and O
59 O
, O
respectively O
. O

routine O
ekg O
monitoring O
during O
infusional O
cyclophosphamide O
did O
not O
predict O
chf B-Disease
development O
. O

tremor B-Disease
side O
effects O
of O
salbutamol O
, O
quantified O
by O
a O
laser O
pointer O
technique O
. O

objective O
: O
to O
study O
tremor B-Disease
side O
effects O
of O
salbutamol O
an O
easily O
applicable O
, O
quick O
and O
low O
- O
priced O
method O
is O
needed O
. O

methods O
: O
tremor B-Disease
was O
measured O
using O
a O
laser O
pointer O
technique O
. O

to O
determine O
sensitivity O
we O
assessed O
tremor B-Disease
in O
44 O
patients O
with O
obstructive B-Disease
lung I-Disease
disease I-Disease
after O
administration O
of O
cumulative O
doses O
of O
salbutamol O
. O

in O
another O
series O
of O
measurements O
, O
reproducibility O
and O
reference O
values O
of O
the O
tremor B-Disease
was O
assessed O
in O
65 O
healthy O
subjects O
in O
three O
sessions O
, O
at O
9 O
a O
. O

m O
. O

, O
4 O
p O
. O

m O
. O

and O
9 O
a O
. O

m O
. O

, O
respectively O
, O
1 O
week O
later O
. O

postural O
tremor B-Disease
was O
measured O
with O
the O
arm O
horizontally O
outstretched O
rest O
tremor B-Disease
with O
the O
arm O
supported O
by O
an O
armrest O
and O
finally O
tremor B-Disease
was O
measured O
after O
holding O
a O
2 O
- O
kg O
weight O
until O
exhaustion O
. O

tremor B-Disease
was O
measured O
simultaneously O
by O
two O
independent O
observers O
. O

results O
: O
salbutamol O
significantly O
increased O
tremor B-Disease
severity O
in O
patients O
in O
a O
dose O
- O
dependent O
way O
. O

there O
was O
no O
agreement O
between O
the O
questionnaire O
and O
tremor B-Disease
severity O
( O
r O
= O
0 O
. O

93 O
; O
p O
= O
0 O
. O

53 O
) O
. O

postural O
tremor B-Disease
showed O
no O
significant O
difference O
between O
the O
first O
and O
third O
session O
( O
p O
= O
0 O
. O

7 O
) O
. O

support O
of O
the O
arm O
decreased O
tremor B-Disease
severity O
, O
exhaustion O
increased O
tremor B-Disease
severity O
significantly O
. O

discussion O
: O
quantifying O
tremor B-Disease
by O
using O
an O
inexpensive O
laser O
pointer O
is O
, O
with O
the O
exception O
of O
children O
( O
< O
12 O
years O
) O
a O
sensitive O
and O
reproducible O
method O
. O

methods O
: O
the O
multiple O
outcomes O
of O
raloxifene O
evaluation O
, O
a O
multicenter O
, O
randomized O
, O
double O
- O
blind O
trial O
, O
enrolled O
7 O
, O
705 O
postmenopausal O
women O
with O
osteoporosis B-Disease
. O

outcomes O
included O
venous B-Disease
thromboembolism I-Disease
, O
cataracts B-Disease
, O
gallbladder B-Disease
disease I-Disease
, O
and O
endometrial B-Disease
hyperplasia I-Disease
or I-Disease
cancer I-Disease
. O

results O
: O
during O
a O
mean O
follow O
- O
up O
of O
3 O
. O

3 O
years O
, O
raloxifene O
was O
associated O
with O
an O
increased O
risk O
for O
venous B-Disease
thromboembolism I-Disease
( O
relative O
risk O
[ O
rr O
] O
2 O
. O

1 O
; O
95 O
% O
confidence O
interval O
[ O
ci O
] O
1 O
. O

2 O
- O
3 O
. O

8 O
) O
. O

raloxifene O
did O
not O
increase O
risk O
for O
cataracts B-Disease
( O
rr O
0 O
. O

9 O
; O
95 O
% O
ci O
0 O
. O

8 O
- O
1 O
. O

1 O
) O
, O
gallbladder B-Disease
disease I-Disease
( O
rr O
1 O
. O

0 O
; O
95 O
% O
ci O
0 O
. O

7 O
- O
1 O
. O

3 O
) O
, O
endometrial B-Disease
hyperplasia I-Disease
( O
rr O
1 O
. O

3 O
; O
95 O
% O
ci O
0 O
. O

4 O
- O
5 O
. O

1 O
) O
, O
or O
endometrial B-Disease
cancer I-Disease
( O
rr O
0 O
. O

9 O
; O
95 O
% O
ci O
0 O
. O

3 O
- O
2 O
. O

7 O
) O
. O

conclusion O
: O
raloxifene O
was O
associated O
with O
an O
increased O
risk O
for O
venous B-Disease
thromboembolism I-Disease
, O
but O
there O
was O
no O
increased O
risk O
for O
cataracts B-Disease
, O
gallbladder B-Disease
disease I-Disease
, O
endometrial B-Disease
hyperplasia I-Disease
, O
or O
endometrial B-Disease
cancer I-Disease
. O

while O
there O
is O
no O
single O
correct O
starting O
dose O
for O
levodopa O
therapy O
, O
many O
individuals O
can O
be O
started O
on O
either O
the O
25 O
/ O
100 O
or O
controlled O
- O
release O
formula O
, O
following O
the O
general O
rule O
not O
to O
attempt O
to O
titrate O
carbidopa O
- O
levodopa O
to O
the O
point O
of O
nan O
normality O
, O
nan O
which O
can O
lead O
to O
toxicity B-Disease
. O

other O
possible O
adverse O
effects O
- O
- O
such O
as O
gastrointestinal B-Disease
disorders I-Disease
, O
orthostatic B-Disease
hypotension I-Disease
, O
levodopa O
- O
induced O
psychosis B-Disease
, O
sleep B-Disease
disturbances I-Disease
or O
parasomnias B-Disease
, O
or O
drug O
interactions O
- O
- O
also O
require O
carefully O
monitored O
individual O
treatment O
. O

nonpharmacologic O
concerns O
can O
help O
the O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
patient O
achieve O
and O
maintain O
optimal O
functioning O
, O
including O
daily O
exercise O
, O
physical O
therapy O
, O
and O
involvement O
with O
support O
groups O
. O

long O
term O
audiological O
evaluation O
of O
beta B-Disease
- I-Disease
thalassemic I-Disease
patients O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
identify O
the O
incidence O
and O
to O
monitor O
the O
progression O
of O
hearing B-Disease
loss I-Disease
in O
children O
and O
young O
adults O
with O
beta B-Disease
- I-Disease
thalassemia I-Disease
major O
. O

results O
: O
overall O
, O
21 O
out O
of O
104 O
patients O
( O
20 O
. O

2 O
% O
) O
presented O
with O
high O
frequency O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
( O
snhl B-Disease
) O
, O
either O
unilateral O
or O
bilateral O
. O

no O
ototoxic B-Disease
factor O
, O
other O
than O
dfo O
, O
was O
present O
in O
any O
of O
the O
patients O
. O

patients O
with O
snhl B-Disease
presented O
with O
relatively O
lower O
serum O
ferritin O
levels O
than O
those O
with O
normal O
hearing O
, O
however O
, O
no O
statistically O
significant O
difference O
was O
observed O
. O

subjects O
with O
snhl B-Disease
were O
submitted O
to O
dfo O
reduction O
or O
temporary O
withdrawal O
. O

conclusion O
: O
the O
findings O
are O
indicative O
of O
dfo O
' O
s O
contributing O
role O
in O
the O
development O
of O
hearing B-Disease
impairment I-Disease
. O

regular O
audiologic O
evaluation O
is O
imperative O
in O
all O
thalassemic B-Disease
patients O
so O
that O
early O
changes O
may O
be O
recognized O
and O
treatment O
may O
be O
judiciously O
adjusted O
in O
order O
to O
prevent O
or O
reverse O
hearing B-Disease
impairment I-Disease
. O

individual O
differences O
in O
renal O
ace O
activity O
in O
healthy O
rats O
predict O
susceptibility O
to O
adriamycin O
- O
induced O
renal B-Disease
damage I-Disease
. O

therefore O
, O
we O
studied O
the O
predictive O
effect O
of O
renal O
ace O
activity O
for O
the O
severity O
of O
renal B-Disease
damage I-Disease
induced O
by O
a O
single O
injection O
of O
adriamycin O
in O
rats O
. O

after O
1 O
week O
of O
recovery O
, O
proteinuria B-Disease
was O
induced O
by O
adriamycin O
[ O
1 O
. O

5 O
mg O
/ O
kg O
intravenously O
( O
i O
. O

v O
. O

) O
n O
= O
18 O
; O
controls O
, O
saline O
i O
. O

v O
. O

n O
= O
9 O
] O
. O

proteinuria B-Disease
was O
measured O
every O
2 O
weeks O
. O

results O
: O
as O
anticipated O
, O
adriamycin O
elicited O
nephrotic B-Disease
range O
proteinuria B-Disease
, O
renal B-Disease
interstitial I-Disease
damage I-Disease
and O
mild O
focal B-Disease
glomerulosclerosis I-Disease
. O

baseline O
renal O
ace O
positively O
correlated O
with O
the O
relative O
rise O
in O
proteinuria B-Disease
after O
adriamycin O
( O
r O
= O
0 O
. O

62 O
, O
p O
< O
0 O
. O

1 O
) O
, O
renal O
interstitial O
alpha O
- O
smooth O
muscle O
actin O
( O
r O
= O
0 O
. O

49 O
, O
p O
< O
0 O
. O

5 O
) O
, O
interstitial O
macrophage O
influx O
( O
r O
= O
0 O
. O

56 O
, O
p O
< O
0 O
. O

5 O
) O
, O
interstitial O
collagen O
iii O
( O
r O
= O
0 O
. O

53 O
, O
p O
< O
0 O
. O

5 O
) O
, O
glomerular O
alpha O
- O
smooth O
muscle O
actin O
( O
r O
= O
0 O
. O

74 O
, O
p O
< O
0 O
. O

1 O
) O
and O
glomerular O
desmin O
( O
r O
= O
0 O
. O

48 O
, O
p O
< O
0 O
. O

5 O
) O
. O

baseline O
renal O
ace O
did O
not O
correlate O
with O
focal B-Disease
glomerulosclerosis I-Disease
( O
r O
= O
0 O
. O

22 O
, O
ns O
) O
. O

conclusion O
: O
individual O
differences O
in O
renal O
ace O
activity O
predict O
the O
severity O
of O
adriamycin O
- O
induced O
renal B-Disease
damage I-Disease
in O
this O
outbred O
rat O
strain O
. O

this O
supports O
the O
assumption O
that O
differences O
in O
renal O
ace O
activity O
predispose O
to O
a O
less O
favourable O
course O
of O
renal B-Disease
damage I-Disease
. O

recurrent O
acute O
interstitial B-Disease
nephritis I-Disease
induced O
by O
azithromycin O
. O

a O
14 O
- O
year O
- O
old O
girl O
is O
reported O
with O
recurrent O
, O
azithromycin O
- O
induced O
, O
acute O
interstitial B-Disease
nephritis I-Disease
. O

although O
most O
cases O
of O
antibiotic O
induced O
acute O
interstitial B-Disease
nephritis I-Disease
are O
benign O
and O
self O
- O
limited O
, O
some O
patients O
are O
at O
risk O
for O
permanent O
renal B-Disease
injury I-Disease
. O

spironolactone O
- O
induced O
renal B-Disease
insufficiency I-Disease
and O
hyperkalemia B-Disease
in O
patients O
with O
heart B-Disease
failure I-Disease
. O

background O
: O
a O
previous O
randomized O
controlled O
trial O
evaluating O
the O
use O
of O
spironolactone O
in O
heart B-Disease
failure I-Disease
patients O
reported O
a O
low O
risk O
of O
hyperkalemia B-Disease
( O
2 O
% O
) O
and O
renal B-Disease
insufficiency I-Disease
( O
0 O
% O
) O
. O

because O
treatments O
for O
heart B-Disease
failure I-Disease
have O
changed O
since O
the O
benefits O
of O
spironolactone O
were O
reported O
, O
the O
prevalence O
of O
these O
complications O
may O
differ O
in O
current O
clinical O
practice O
. O

we O
therefore O
sought O
to O
determine O
the O
prevalence O
and O
clinical O
associations O
of O
hyperkalemia B-Disease
and O
renal B-Disease
insufficiency I-Disease
in O
heart B-Disease
failure I-Disease
patients O
treated O
with O
spironolactone O
. O

methods O
: O
we O
performed O
a O
case O
control O
study O
of O
heart B-Disease
failure I-Disease
patients O
treated O
with O
spironolactone O
in O
our O
clinical O
practice O
. O

cases O
were O
patients O
who O
developed O
hyperkalemia B-Disease
( O
k O
( O
+ O
) O
> O
5 O
. O

0 O
meq O
/ O
l O
) O
or O
renal B-Disease
insufficiency I-Disease
( O
cr O
> O
or O
= O
2 O
. O

5 O
mg O
/ O
dl O
) O
, O
and O
they O
were O
compared O
to O
2 O
randomly O
selected O
controls O
per O
case O
. O

results O
: O
sixty O
- O
seven O
of O
926 O
patients O
( O
7 O
. O

2 O
% O
) O
required O
discontinuation O
of O
spironolactone O
due O
to O
hyperkalemia B-Disease
( O
n O
= O
33 O
) O
or O
renal B-Disease
failure I-Disease
( O
n O
= O
34 O
) O
. O

patients O
who O
developed O
hyperkalemia B-Disease
were O
older O
and O
more O
likely O
to O
have O
diabetes B-Disease
, O
had O
higher O
baseline O
serum O
potassium O
levels O
and O
lower O
baseline O
potassium O
supplement O
doses O
, O
and O
were O
more O
likely O
to O
be O
treated O
with O
beta O
- O
blockers O
than O
controls O
( O
n O
= O
134 O
) O
. O

patients O
who O
developed O
renal B-Disease
insufficiency I-Disease
had O
lower O
baseline O
body O
weight O
and O
higher O
baseline O
serum O
creatinine O
, O
required O
higher O
doses O
of O
loop O
diuretics O
, O
and O
were O
more O
likely O
to O
be O
treated O
with O
thiazide O
diuretics O
than O
controls O
. O

conclusions O
: O
spironolactone O
- O
induced O
hyperkalemia B-Disease
and O
renal B-Disease
insufficiency I-Disease
are O
more O
common O
in O
our O
clinical O
experience O
than O
reported O
previously O
. O

acute O
reserpine O
and O
subchronic O
haloperidol O
treatments O
change O
synaptosomal O
brain O
glutamate O
uptake O
and O
elicit O
orofacial B-Disease
dyskinesia I-Disease
in O
rats O
. O

reserpine O
- O
and O
haloperidol O
- O
induced O
orofacial B-Disease
dyskinesia I-Disease
are O
putative O
animal O
models O
of O
tardive B-Disease
dyskinesia I-Disease
( O
td B-Disease
) O
whose O
pathophysiology O
has O
been O
related O
to O
free O
radical O
generation O
and O
oxidative O
stress O
. O

in O
the O
present O
study O
, O
the O
authors O
induced O
orofacial B-Disease
dyskinesia I-Disease
by O
acute O
reserpine O
and O
subchronic O
haloperidol O
administration O
to O
rats O
. O

importantly O
, O
a O
decrease O
in O
glutamate O
uptake O
correlates O
negatively O
with O
an O
increase O
in O
the O
incidence O
of O
orofacial B-Disease
diskinesia I-Disease
. O

ceftriaxone O
- O
associated O
biliary B-Disease
pseudolithiasis I-Disease
in O
paediatric O
surgical O
patients O
. O

it O
is O
well O
known O
that O
ceftriaxone O
leads O
to O
pseudolithiasis B-Disease
in O
some O
patients O
. O

clinical O
and O
experimental O
studies O
also O
suggest O
that O
situations O
causing O
gallbladder B-Disease
dysfunction I-Disease
, O
such O
as O
fasting O
, O
may O
have O
a O
role O
for O
the O
development O
of O
pseudolithiasis B-Disease
. O

in O
this O
study O
, O
we O
prospectively O
evaluated O
the O
incidence O
and O
clinical O
importance O
of O
pseudolithiasis B-Disease
in O
paediatric O
surgical O
patients O
receiving O
ceftriaxone O
treatment O
, O
who O
often O
had O
to O
fast O
in O
the O
post O
- O
operative O
period O
. O

comparison O
of O
the O
patients O
with O
or O
without O
pseudolithiasis B-Disease
revealed O
no O
significant O
difference O
with O
respect O
to O
age O
, O
sex O
, O
duration O
of O
the O
treatment O
and O
starvation O
variables O
. O

after O
cessation O
of O
the O
treatment O
, O
pseudolithiasis B-Disease
resolved O
spontaneously O
within O
a O
short O
period O
. O

the O
incidence O
of O
pseudolithiasis B-Disease
is O
not O
affected O
by O
fasting O
. O

coronary B-Disease
aneurysm I-Disease
after O
imB-Plantation O
of O
a O
paclitaxel O
- O
eluting O
stent O
. O

formation O
of O
coronary B-Disease
aneurysm I-Disease
is O
a O
rare O
complication O
of O
stenting O
with O
bare O
metal O
stents O
, O
but O
based O
on O
experimental O
studies O
drug O
- O
eluting O
stents O
may O
induce O
toxic O
effects O
on O
the O
vessel O
wall O
with O
incomplete O
stent O
apposition O
, O
aneurysm B-Disease
formation O
and O
with O
the O
potential O
of O
stent O
thrombosis B-Disease
or O
vessel B-Disease
rupture I-Disease
. O

we O
present O
a O
43 O
- O
year O
- O
old O
man O
who O
developed O
a O
coronary B-Disease
aneurysm I-Disease
in O
the O
right O
coronary O
artery O
6 O
months O
after O
receiving O
a O
paclitaxel O
- O
eluting O
stent O
. O

the O
patient O
was O
asymptomatic O
and O
the O
aneurysm B-Disease
was O
detected O
in O
a O
routine O
control O
. O

angiography O
and O
intracoronary O
ultrasound O
demonstrated O
lack O
of O
contact O
between O
stent O
and O
vessel O
wall O
in O
a O
15 O
- O
mm O
long O
segment O
with O
maximal O
aneurysm B-Disease
diameter O
of O
6 O
. O

0 O
mm O
. O

causes O
of O
acute O
thrombotic B-Disease
microangiopathy I-Disease
in O
patients O
receiving O
kidney O
transB-Plantation O
. O

objectives O
: O
thrombotic B-Disease
microangiopathy I-Disease
is O
a O
well O
- O
known O
problem O
in O
patients O
following O
renal O
transB-Plantation O
. O

in O
postrenal O
transB-Plantation O
, O
thrombotic B-Disease
microangiopathy I-Disease
is O
often O
a O
reflection O
of O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
. O

we O
aimed O
to O
determine O
the O
causes O
of O
thrombotic B-Disease
microangiopathy I-Disease
in O
a O
population O
of O
renal O
transB-Plantation O
recipients O
and O
discuss O
the O
literature O
. O

materials O
and O
methods O
: O
we O
investigated O
the O
causes O
of O
thrombotic B-Disease
microangiopathy I-Disease
during O
a O
1 O
- O
year O
period O
, O
from O
june O
2003 O
to O
june O
2004 O
, O
at O
the O
king O
fahad O
national O
guard O
hospital O
in O
riyadh O
, O
saudi O
arabia O
, O
by O
reviewing O
the O
slides O
of O
all O
transB-Plant O
biopsies O
( O
n O
= O
25 O
) O
performed O
during O
this O
interval O
. O

results O
: O
five O
cases O
of O
thrombotic B-Disease
microangiopathy I-Disease
were O
found O
. O

the O
fifth O
case O
had O
features O
of O
thrombotic B-Disease
microangiopathy I-Disease
related O
to O
an O
antiphospholipid B-Disease
syndrome I-Disease
in O
a O
patient O
with O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
. O

conclusions O
: O
in O
the O
literature O
, O
the O
most O
- O
frequent O
cause O
of O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
in O
patients O
following O
renal O
transB-Plantation O
is O
recurrence O
of O
the O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
. O

other O
causes O
include O
drug O
- O
related O
( O
cyclosporine O
, O
tacrolimus O
) O
toxicity B-Disease
, O
procoagulant O
status O
, O
and O
antibody O
- O
mediated O
rejection O
. O

we O
found O
that O
the O
most O
- O
frequent O
cause O
of O
thrombotic B-Disease
microangiopathy I-Disease
was O
drug O
related O
, O
secondary O
mainly O
to O
cyclosporine O
. O

in O
the O
current O
study O
, O
the O
frequency O
of O
thrombotic B-Disease
microangiopathy I-Disease
was O
similar O
to O
the O
percentage O
reported O
in O
the O
literature O
( O
20 O
% O
) O
. O

comparison O
of O
developmental O
toxicity B-Disease
of O
selective O
and O
non O
- O
selective O
cyclooxygenase O
- O
2 O
inhibitors O
in O
crl O
: O
( O
wi O
) O
wubr O
wistar O
rats O
- O
- O
dfu O
and O
piroxicam O
study O
. O

unlike O
general O
toxicity B-Disease
data O
, O
their O
prenatal O
toxic O
effects O
were O
not O
extensively O
studied O
before O
. O

the O
aim O
of O
the O
experiment O
was O
to O
evaluate O
the O
developmental O
toxicity B-Disease
of O
the O
non O
- O
selective O
( O
piroxicam O
) O
and O
selective O
( O
dfu O
; O
5 O
, O
5 O
- O
dimethyl O
- O
3 O
- O
( O
3 O
- O
fluorophenyl O
) O
- O
4 O
- O
( O
4 O
- O
methylsulphonyl O
) O
phenyl O
- O
2 O
( O
5h O
) O
- O
furanon O
) O
cox O
- O
2 O
inhibitors O
. O

the O
pooled O
statistical O
analysis O
for O
ventricular B-Disease
septal I-Disease
( I-Disease
vsd I-Disease
) I-Disease
and I-Disease
midline I-Disease
( I-Disease
md I-Disease
) I-Disease
defects I-Disease
was O
performed O
for O
rat O
fetuses O
exposed O
to O
piroxicam O
, O
selective O
and O
non O
- O
selective O
cox O
- O
2 O
inhibitor O
based O
on O
present O
and O
historic O
data O
. O

results O
: O
maternal O
toxicity B-Disease
, O
intrauterine B-Disease
growth I-Disease
retardation I-Disease
, O
and O
increase B-Disease
of I-Disease
external I-Disease
and I-Disease
skeletal I-Disease
variations I-Disease
were O
found O
in O
rats O
treated O
with O
the O
highest O
dose O
of O
piroxicam O
. O

decrease O
of O
fetal O
length O
was O
the O
only O
signs O
of O
the O
dfu O
developmental O
toxicity B-Disease
observed O
in O
pups O
exposed O
to O
the O
highest O
compound O
dose O
. O

prenatal O
exposure O
to O
selective O
cox O
- O
2 O
inhibitors O
does O
not O
increase O
the O
risk O
of O
ventricular B-Disease
septal I-Disease
and I-Disease
midline I-Disease
defects I-Disease
in O
rat O
when O
compared O
to O
non O
- O
selective O
drugs O
and O
historic O
control O
. O

lone O
atrial B-Disease
fibrillation I-Disease
associated O
with O
creatine O
monohydrate O
supplementation O
. O

atrial B-Disease
fibrillation I-Disease
in O
young O
patients O
without O
structural O
heart B-Disease
disease I-Disease
is O
rare O
. O

therefore O
, O
when O
the O
arrhythmia B-Disease
is O
present O
in O
this O
population O
, O
reversible O
causes O
must O
be O
identified O
and O
resolved O
. O

thyroid B-Disease
disorders I-Disease
, O
illicit O
drug O
or O
stimulant O
use O
, O
and O
acute B-Disease
alcohol I-Disease
intoxication I-Disease
are O
among O
these O
causes O
. O

we O
report O
the O
case O
of O
a O
30 O
- O
year O
- O
old O
caucasian O
man O
who O
came O
to O
the O
emergency O
department O
in O
atrial B-Disease
fibrillation I-Disease
with O
rapid O
ventricular O
response O
. O

his O
medical O
history O
was O
unremarkable O
, O
except O
for O
minor O
fractures B-Disease
of O
the O
fingers O
and O
foot O
. O

previous O
anecdotal O
reports O
have O
linked O
creatine O
to O
the O
development O
of O
arrhythmia B-Disease
. O

seizures B-Disease
induced O
by O
the O
cocaine O
metabolite O
benzoylecgonine O
in O
rats O
. O

the O
half O
- O
life O
( O
t1 O
/ O
2 O
) O
of O
cocaine O
is O
relatively O
short O
, O
but O
some O
of O
the O
consequences O
of O
its O
use O
, O
such O
as O
seizures B-Disease
and O
strokes B-Disease
, O
can O
occur O
hours O
after O
exposure O
. O

we O
evaluated O
the O
potential O
of O
the O
major O
metabolite O
of O
cocaine O
, O
benzoylecgonine O
( O
be O
) O
, O
to O
cause O
seizures B-Disease
. O

treated O
rats O
were O
then O
evaluated O
for O
incidence O
, O
latency O
, O
and O
seizure B-Disease
pattern O
or O
for O
locomotor O
activity O
in O
animals O
without O
seizures B-Disease
. O

be O
- O
induced O
seizures B-Disease
occurred O
more O
frequently O
and O
had O
significantly O
longer O
latencies O
than O
those O
induced O
by O
equimolar O
amounts O
of O
cocaine O
. O

whereas O
cocaine O
- O
induced O
seizures B-Disease
were O
best O
characterized O
as O
brief O
, O
generalized O
, O
and O
tonic O
and O
resulted O
in O
death B-Disease
, O
those O
induced O
by O
be O
were O
prolonged O
, O
often O
multiple O
and O
mixed O
in O
type O
, O
and O
rarely O
resulted O
in O
death B-Disease
. O

electrical O
recordings O
from O
the O
hippocampus O
showed O
a O
rhythmic O
progression O
in O
eeg O
frequency O
and O
voltage O
with O
clinical O
seizure B-Disease
expression O
. O

be O
- O
injected O
rats O
that O
did O
not O
have O
seizures B-Disease
had O
significantly O
more O
locomotor O
activity O
than O
cocaine O
- O
injected O
animals O
without O
seizures B-Disease
. O

the O
finding O
that O
cocaine O
- O
and O
be O
- O
induced O
seizures B-Disease
differ O
in O
several O
respects O
suggests O
more O
than O
one O
mechanism O
for O
cocaine O
- O
induced O
seizures B-Disease
and O
emphasizes O
the O
importance O
of O
a O
cocaine O
metabolite O
, O
be O
. O

the O
selective O
5 O
- O
ht6 O
receptor O
antagonist O
ro4368554 O
restores O
memory O
performance O
in O
cholinergic O
and O
serotonergic O
models O
of O
memory B-Disease
deficiency I-Disease
in O
the O
rat O
. O

both O
, O
ro4368554 O
( O
3 O
and O
10 O
mg O
/ O
kg O
, O
intraperitoneally O
( O
i O
. O

p O
. O

) O
) O
and O
metrifonate O
( O
10 O
mg O
/ O
kg O
, O
p O
. O

o O
. O

, O
respectively O
) O
reversed O
memory B-Disease
deficits I-Disease
induced O
by O
scopolamine O
and O
trp O
depletion O
( O
10 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

, O
and O
3 O
mg O
/ O
kg O
, O
p O
. O

o O
. O

, O
respectively O
) O
. O

in O
conclusion O
, O
although O
ro4368554 O
did O
not O
improve O
a O
time O
- O
related O
retention O
deficit O
, O
it O
reversed O
a O
cholinergic O
and O
a O
serotonergic O
memory B-Disease
deficit I-Disease
, O
suggesting O
that O
both O
mechanisms O
may O
be O
involved O
in O
the O
facilitation O
of O
object O
memory O
by O
ro4368554 O
and O
, O
possibly O
, O
other O
5 O
- O
ht O
( O
6 O
) O
receptor O
antagonists O
. O

evaluation O
of O
the O
anticocaine O
monoclonal O
antibody O
gnc92h2 O
as O
an O
immunotherapy O
for O
cocaine B-Disease
overdose I-Disease
. O

the O
illicit O
use O
of O
cocaine O
continues O
in O
epidemic O
proportions O
and O
treatment O
for O
cocaine B-Disease
overdose I-Disease
remains O
elusive O
. O

the O
therapeutic O
potential O
of O
the O
anticocaine O
antibody O
gnc92h2 O
was O
examined O
using O
a O
model O
of O
cocaine B-Disease
overdose I-Disease
. O

significant O
blockade O
of O
cocaine O
toxicity B-Disease
was O
observed O
with O
the O
higher O
dose O
of O
gnc92h2 O
( O
190 O
mg O
/ O
kg O
) O
, O
where O
premorbid O
behaviors O
were O
reduced O
up O
to O
40 O
% O
, O
seizures B-Disease
up O
to O
77 O
% O
and O
death B-Disease
by O
72 O
% O
. O

importantly O
, O
gnc92h2 O
prevented O
death B-Disease
even O
post O
- O
cocaine O
injection O
. O

the O
results O
support O
the O
important O
potential O
of O
gnc92h2 O
as O
a O
therapeutic O
tool O
against O
cocaine B-Disease
overdose I-Disease
. O

electrocardiographic O
evidence O
of O
myocardial B-Disease
injury I-Disease
in O
psychiatrically O
hospitalized O
cocaine O
abusers O
. O

the O
electrocardiograms O
( O
ecg O
) O
of O
99 O
cocaine O
- O
abusing O
patients O
were O
compared O
with O
the O
ecgs O
of O
50 O
schizophrenic B-Disease
controls O
. O

eleven O
of O
the O
cocaine O
abusers O
and O
none O
of O
the O
controls O
had O
ecg O
evidence O
of O
significant O
myocardial B-Disease
injury I-Disease
defined O
as O
myocardial B-Disease
infarction I-Disease
, O
ischemia B-Disease
, O
and O
bundle B-Disease
branch I-Disease
block I-Disease
. O

intracerebroventricular O
( O
i O
. O

c O
. O

v O
. O

) O
injection O
of O
u O
- O
ii O
causes O
hypertension B-Disease
and O
bradycardia B-Disease
and O
stimulates O
prolactin O
and O
thyrotropin O
secretion O
. O

whatever O
was O
the O
dose O
, O
the O
central O
administration O
of O
u O
- O
ii O
had O
no O
effect O
on O
body O
temperature O
, O
nociception O
, O
apomorphine O
- O
induced O
penile B-Disease
erection I-Disease
and O
climbing O
behavior O
, O
and O
stress O
- O
induced O
plasma O
corticosterone O
level O
. O

these O
data O
suggest O
that O
u O
- O
ii O
may O
be O
involved O
in O
some O
aspects O
of O
psychiatric B-Disease
disorders I-Disease
. O

learning O
of O
rats O
under O
amnesia B-Disease
caused O
by O
pentobarbital O
. O

dissociated O
learning O
of O
rats O
in O
the O
normal O
state O
and O
the O
state O
of O
amnesia B-Disease
produced O
by O
pentobarbital O
( O
15 O
mg O
/ O
kg O
, O
ip O
) O
was O
carried O
out O
. O

it O
was O
shown O
that O
memory B-Disease
dissociation I-Disease
occurred O
in O
both O
groups O
. O

methods O
: O
thirty O
- O
nine O
postmenopausal O
women O
with O
osteopenia B-Disease
or O
osteoporosis B-Disease
were O
included O
in O
this O
prospective O
, O
controlled O
clinical O
study O
. O

a O
significant O
correlation O
was O
found O
between O
baseline O
tafi O
antigen O
concentrations O
and O
the O
duration O
of O
amenorrhea B-Disease
( O
p O
< O
0 O
. O

5 O
; O
r O
= O
0 O
. O

33 O
) O
. O

conclusion O
: O
we O
suggest O
that O
the O
increased O
risk O
of O
venous B-Disease
thromboembolism I-Disease
due O
to O
raloxifene O
treatment O
may O
be O
related O
to O
increased O
tpa O
levels O
, O
but O
not O
tafi O
levels O
. O

valproate O
- O
induced O
encephalopathy B-Disease
. O

valproate O
- O
induced O
encephalopathy B-Disease
is O
a O
rare O
syndrome O
that O
may O
manifest O
in O
otherwise O
normal O
epileptic B-Disease
individuals O
. O

it O
is O
usually O
but O
not O
necessarily O
associated O
with O
hyperammonemia B-Disease
. O

a O
case O
of O
valproate O
- O
induced O
encephalopathy B-Disease
is O
presented O
. O

recurrent O
dysphonia B-Disease
and O
acitretin O
. O

we O
report O
the O
case O
of O
a O
woman O
complaining O
of O
dysphonia B-Disease
while O
she O
was O
treated O
by O
acitretin O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
acitretin O
- O
induced O
dysphonia B-Disease
. O

nitro O
- O
l O
- O
arginine O
methyl O
ester O
: O
a O
potential O
protector O
against O
gentamicin O
ototoxicity B-Disease
. O

the O
nitric O
oxide O
( O
no O
) O
inhibitor O
nitro O
- O
l O
- O
arginine O
methyl O
ester O
( O
l O
- O
name O
) O
may O
act O
as O
an O
otoprotectant O
against O
high B-Disease
- I-Disease
frequency I-Disease
hearing I-Disease
loss I-Disease
caused O
by O
gentamicin O
, O
but O
further O
studies O
are O
needed O
to O
confirm O
this O
. O

aminoglycoside O
antibiotics O
are O
still O
widely O
used O
by O
virtue O
of O
their O
efficacy O
and O
low O
cost O
. O

their O
ototoxicity B-Disease
is O
a O
serious O
health O
problem O
and O
, O
as O
their O
ototoxic B-Disease
mechanism O
involves O
the O
production O
of O
no O
, O
we O
need O
to O
assess O
the O
use O
of O
no O
inhibitors O
for O
the O
prevention O
of O
aminoglycoside O
- O
induced O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
. O

its O
effect O
was O
determined O
in O
terms O
of O
attenuation O
of O
hearing B-Disease
loss I-Disease
, O
measured O
by O
shifts O
in O
the O
auditory O
brainstem O
response O
threshold O
. O

l O
- O
name O
reduced O
gentamicin O
- O
induced O
hearing B-Disease
loss I-Disease
in O
the O
high O
- O
frequency O
range O
, O
but O
gave O
no O
protection O
in O
the O
middle O
or O
low O
frequencies O
. O

methods O
: O
this O
was O
a O
multicenter O
, O
randomized O
, O
open O
- O
label O
study O
in O
adult O
smokers O
with O
heart B-Disease
disease I-Disease
, O
hypertension B-Disease
not O
controlled O
by O
medication O
, O
and O
/ O
or O
diabetes B-Disease
mellitus I-Disease
. O

the O
most O
common O
adverse O
events O
were O
nausea B-Disease
( O
17 O
. O

2 O
% O
and O
16 O
. O

1 O
% O
; O
95 O
% O
ci O
, O
- O
3 O
. O

7 O
to O
6 O
. O

0 O
) O
, O
hiccups B-Disease
( O
10 O
. O

7 O
% O
and O
6 O
. O

6 O
% O
; O
95 O
% O
ci O
, O
0 O
. O

5 O
to O
7 O
. O

8 O
) O
, O
and O
headache B-Disease
( O
8 O
. O

7 O
% O
and O
9 O
. O

9 O
% O
; O
95 O
% O
cl O
, O
- O
5 O
. O

0 O
to O
2 O
. O

6 O
) O
. O

pharmacological O
modulation O
of O
pain B-Disease
- O
related O
brain O
activity O
during O
normal O
and O
central O
sensitization O
states O
in O
humans O
. O

abnormal O
processing O
of O
somatosensory O
inputs O
in O
the O
central O
nervous O
system O
( O
central O
sensitization O
) O
is O
the O
mechanism O
accounting O
for O
the O
enhanced O
pain B-Disease
sensitivity O
in O
the O
skin O
surrounding O
tissue B-Disease
injury I-Disease
( O
secondary B-Disease
hyperalgesia I-Disease
) O
. O

secondary B-Disease
hyperalgesia I-Disease
shares O
clinical O
characteristics O
with O
neurogenic B-Disease
hyperalgesia I-Disease
in O
patients O
with O
neuropathic B-Disease
pain I-Disease
. O

abnormal O
brain O
responses O
to O
somatosensory O
stimuli O
have O
been O
found O
in O
patients O
with O
hyperalgesia B-Disease
as O
well O
as O
in O
normal O
subjects O
during O
experimental O
central O
sensitization O
. O

the O
aim O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
gabapentin O
, O
a O
drug O
effective O
in O
neuropathic B-Disease
pain I-Disease
patients O
, O
on O
brain O
processing O
of O
nociceptive O
information O
in O
normal O
and O
central O
sensitization O
states O
. O

using O
functional O
magnetic O
resonance O
imaging O
( O
fmri O
) O
in O
normal O
volunteers O
, O
we O
studied O
the O
gabapentin O
- O
induced O
modulation O
of O
brain O
activity O
in O
response O
to O
nociceptive O
mechanical O
stimulation O
of O
normal O
skin O
and O
capsaicin O
- O
induced O
secondary B-Disease
hyperalgesia I-Disease
. O

investigation O
of O
mitochondrial O
involvement O
in O
the O
experimental O
model O
of O
epilepsy B-Disease
induced O
by O
pilocarpine O
. O

mitochondrial B-Disease
abnormalities I-Disease
have O
been O
associated O
with O
several O
aspects O
of O
epileptogenesis O
, O
such O
as O
energy O
generation O
, O
control O
of O
cell O
death B-Disease
, O
neurotransmitter O
synthesis O
, O
and O
free O
radical O
( O
fr O
) O
production O
. O

in O
this O
study O
, O
we O
investigated O
whether O
increased O
generation O
of O
fr O
during O
status B-Disease
epilepticus I-Disease
would O
be O
sufficient O
to O
provoke O
abnormalities O
in O
mtdna O
and O
in O
the O
expression O
and O
activity O
of O
cytochrome O
c O
oxidase O
( O
cco O
) O
, O
complex O
iv O
of O
the O
respiratory O
chain O
, O
in O
the O
chronic O
phase O
of O
the O
pilocarpine O
model O
of O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
. O

although O
evidences O
of O
mitochondrial B-Disease
abnormalities I-Disease
were O
found O
in O
previously O
published O
studies O
, O
our O
results O
do O
not O
suggest O
that O
the O
frs O
, O
generated O
during O
the O
acute O
phase O
, O
determined O
important O
abnormalities O
in O
mtdna O
, O
in O
expression O
of O
cco O
- O
i O
, O
and O
in O
cco O
activity O
. O

adverse O
effect O
of O
the O
calcium O
channel O
blocker O
nitrendipine O
on O
nephrosclerosis B-Disease
in O
rats O
with O
renovascular B-Disease
hypertension I-Disease
. O

the O
effect O
of O
a O
6 O
- O
week O
treatment O
with O
the O
calcium O
channel O
blocker O
nitrendipine O
or O
the O
angiotensin O
converting O
enzyme O
inhibitor O
enalapril O
on O
blood O
pressure O
, O
albuminuria B-Disease
, O
renal O
hemodynamics O
, O
and O
morphology O
of O
the O
nonclipped O
kidney O
was O
studied O
in O
rats O
with O
two O
- O
kidney O
, O
one O
clip O
renovascular B-Disease
hypertension I-Disease
. O

six O
weeks O
after O
clipping O
of O
one O
renal O
artery O
, O
hypertensive B-Disease
rats O
( O
178 O
+ O
/ O
- O
4 O
mm O
hg O
) O
were O
randomly O
assigned O
to O
three O
groups O
: O
untreated O
hypertensive B-Disease
controls O
( O
n O
= O
8 O
) O
, O
enalapril O
- O
treated O
( O
n O
= O
8 O
) O
, O
or O
nitrendipine O
- O
treated O
( O
n O
= O
10 O
) O
. O

renal O
plasma O
flow O
increased O
, O
but O
albumin O
excretion O
and O
glomerulosclerosis B-Disease
did O
not O
change O
after O
enalapril O
treatment O
. O

in O
contrast O
, O
in O
the O
nitrendipine O
- O
treated O
group O
albuminuria B-Disease
increased O
from O
12 O
. O

8 O
+ O
/ O
- O
2 O
progressively O
to O
163 O
+ O
/ O
- O
55 O
compared O
with O
19 O
. O

2 O
+ O
/ O
- O
9 O
mg O
/ O
24 O
hr O
in O
the O
hypertensive B-Disease
controls O
. O

furthermore O
, O
glomerulosclerosis B-Disease
index O
was O
significantly O
increased O
in O
the O
nitrendipine O
- O
treated O
group O
compared O
with O
the O
hypertensive B-Disease
controls O
( O
0 O
. O

38 O
+ O
/ O
- O
0 O
. O

1 O
versus O
0 O
. O

13 O
+ O
/ O
- O
0 O
. O

4 O
) O
. O

in O
addition O
, O
glomerular O
size O
was O
higher O
in O
the O
nitrendipine O
- O
treated O
group O
( O
14 O
. O

9 O
+ O
/ O
- O
0 O
. O

17 O
10 O
( O
- O
3 O
) O
mm2 O
) O
but O
lower O
in O
the O
enalapril O
- O
treated O
group O
( O
11 O
. O

5 O
+ O
/ O
- O
0 O
. O

15 O
10 O
( O
- O
3 O
) O
mm2 O
) O
compared O
with O
the O
hypertensive B-Disease
controls O
( O
12 O
. O

1 O
+ O
/ O
- O
0 O
. O

17 O
10 O
( O
- O
3 O
) O
mm2 O
) O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
ketoconazole O
induced O
torsades B-Disease
de I-Disease
pointes I-Disease
without O
concomitant O
use O
of O
qt O
interval O
- O
prolonging O
drug O
. O

we O
report O
a O
woman O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
who O
developed O
a O
markedly O
prolonged B-Disease
qt I-Disease
interval I-Disease
and O
torsades B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
after O
taking O
ketoconazole O
for O
treatment O
of O
fungal B-Disease
infection I-Disease
. O

we O
postulate O
that O
by O
virtue O
of O
its O
direct O
blocking O
action O
on O
ikr O
, O
ketoconazole O
alone O
may O
prolong O
qt O
interval O
and O
induce O
tdp B-Disease
. O

this O
calls O
for O
attention O
when O
ketoconazole O
is O
administered O
to O
patients O
with O
risk O
factors O
for O
acquired O
long B-Disease
qt I-Disease
syndrome I-Disease
. O

cerebral B-Disease
vasculitis I-Disease
following O
oral O
methylphenidate O
intake O
in O
an O
adult O
: O
a O
case O
report O
. O

cerebral B-Disease
vasculitis I-Disease
associated O
with O
amphetamine B-Disease
abuse I-Disease
is O
well O
documented O
, O
and O
in O
rare O
cases O
ischaemic B-Disease
stroke I-Disease
has O
been O
reported O
after O
methylphenidate O
intake O
in O
children O
. O

we O
report O
the O
case O
of O
a O
63 O
- O
year O
- O
old O
female O
who O
was O
treated O
with O
methylphenidate O
due O
to O
hyperactivity B-Disease
and O
suffered O
from O
multiple O
ischaemic B-Disease
strokes I-Disease
. O

we O
consider O
drug O
- O
induced O
cerebral B-Disease
vasculitis I-Disease
as O
the O
most O
likely O
cause O
of O
recurrent O
ischaemic B-Disease
strokes I-Disease
in O
the O
absence O
of O
any O
pathological O
findings O
during O
the O
diagnostic O
work O
- O
up O
. O

we O
conclude O
that O
methylphenidate O
mediated O
vasculitis B-Disease
should O
be O
considered O
in O
patients O
with O
neurological O
symptoms O
and O
a O
history O
of O
methylphenidate O
therapy O
. O

mdma O
polydrug O
users O
show O
process O
- O
specific O
central O
executive O
impairments O
coupled O
with O
impaired B-Disease
social I-Disease
and I-Disease
emotional I-Disease
judgement I-Disease
processes I-Disease
. O

in O
recent O
years O
working O
memory B-Disease
deficits I-Disease
have O
been O
reported O
in O
users O
of O
mdma O
( O
3 O
, O
4 O
- O
methylenedioxymethamphetamine O
, O
ecstasy O
) O
. O

phase O
ii O
study O
of O
the O
amsacrine O
analogue O
ci O
- O
921 O
( O
nsc O
343499 O
) O
in O
non B-Disease
- I-Disease
small I-Disease
cell I-Disease
lung I-Disease
cancer I-Disease
. O

it O
was O
administered O
by O
15 O
min O
infusion O
to O
16 O
evaluable O
patients O
with O
non B-Disease
- I-Disease
small I-Disease
cell I-Disease
lung I-Disease
cancer I-Disease
( O
nsclc B-Disease
) O
( O
7 O
with O
no O
prior O
treatment O
, O
9 O
patients O
in O
relapse O
following O
surgery O
/ O
radiotherapy O
) O
at O
a O
dose O
( O
648 O
mg O
/ O
m2 O
divided O
over O
3 O
days O
, O
repeated O
every O
3 O
weeks O
) O
determined O
by O
phase O
i O
trial O
. O

the O
histology O
comprised O
squamous B-Disease
carcinoma I-Disease
( O
11 O
) O
, O
adenocarcinoma B-Disease
( O
1 O
) O
, O
mixed O
histology O
( O
2 O
) O
, O
bronchio B-Disease
- I-Disease
alveolar I-Disease
carcinoma I-Disease
( O
1 O
) O
and O
large O
cell O
undifferentiated B-Disease
carcinoma I-Disease
( O
1 O
) O
. O

neutropenia B-Disease
grade O
greater O
than O
or O
equal O
to O
3 O
was O
seen O
in O
15 O
patients O
, O
infections B-Disease
with O
recovery O
in O
3 O
, O
and O
grand O
mal O
seizures B-Disease
in O
1 O
patient O
. O

grade O
less O
than O
or O
equal O
to O
2 O
nausea B-Disease
and O
vomiting B-Disease
occurred O
in O
66 O
% O
courses O
and O
phlebitis B-Disease
in O
the O
infusion O
arm O
in O
37 O
% O
. O

1 O
patient O
with O
squamous B-Disease
cell I-Disease
carcinoma I-Disease
achieved O
a O
partial O
response O
lasting O
5 O
months O
. O

further O
testing O
in O
this O
and O
other O
tumour B-Disease
types O
using O
multiple O
daily O
schedules O
is O
warranted O
. O

fewer O
subjects O
reported O
adverse O
events O
following O
treatment O
with O
desipramine O
alone O
than O
when O
receiving O
desipramine O
with O
cinacalcet O
( O
33 O
versus O
86 O
% O
) O
, O
the O
most O
frequent O
of O
which O
( O
nausea B-Disease
and O
headache B-Disease
) O
have O
been O
reported O
for O
patients O
treated O
with O
either O
desipramine O
or O
cinacalcet O
. O

we O
report O
an O
interesting O
case O
investigating O
a O
( O
near O
) O
fatal O
poisoning B-Disease
. O

methods O
: O
the O
son O
of O
an O
84 O
- O
year O
- O
old O
male O
discovered O
a O
newspaper O
report O
stating O
clinical O
success O
with O
B-Plant O
extracts O
in O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

results O
: O
minutes O
after O
oral O
administration O
, O
the O
patient O
developed O
nausea B-Disease
, O
sweating O
and O
hypotension B-Disease
, O
and O
finally O
collapsed O
. O

bradycardia B-Disease
, O
cholinergic O
symptoms O
and O
asystole B-Disease
occurred O
. O

further O
signs O
were O
hyperhidrosis B-Disease
, O
hypersalivation B-Disease
, O
bronchorrhoea B-Disease
, O
and O
severe O
miosis B-Disease
; O
the O
electrocardiographic O
finding O
was O
atrio B-Disease
- I-Disease
ventricular I-Disease
dissociation I-Disease
. O

however O
, O
increased O
dyspnoea B-Disease
and O
bronchospasm B-Disease
necessitated O
reintubation O
. O

respiratory B-Disease
insufficiency I-Disease
was O
further O
worsened O
by O
proteus B-Disease
mirabilis I-Disease
infection I-Disease
and O
severe O
bronchoconstriction O
. O

on O
the O
next O
day O
he O
died O
, O
probably O
as O
a O
result O
of O
heart B-Disease
failure I-Disease
. O

especially O
in O
old O
patients O
, O
intensivists O
should O
consider O
intoxications O
( O
with O
cholinergics O
) O
as O
a O
cause O
of O
acute B-Disease
cardiovascular I-Disease
failure I-Disease
. O

pharmacological O
evidence O
for O
the O
potential O
of O
daucus O
carota O
in O
the O
management O
of O
cognitive B-Disease
dysfunctions I-Disease
. O

diazepam O
- O
, O
scopolamine O
- O
and O
ageing O
- O
induced O
amnesia B-Disease
served O
as O
the O
interoceptive O
behavioral O
models O
. O

furthermore O
, O
dce O
reversed O
the O
amnesia B-Disease
induced O
by O
scopolamine O
( O
0 O
. O

4 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
and O
diazepam O
( O
1 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
. O

therefore O
, O
dce O
may O
prove O
to O
be O
a O
useful O
remedy O
for O
the O
management O
of O
cognitive B-Disease
dysfunctions I-Disease
on O
account O
of O
its O
multifarious O
beneficial O
effects O
such O
as O
, O
memory O
improving O
property O
, O
cholesterol O
lowering O
property O
and O
anticholinesterase O
activity O
. O

valproic O
acid O
induced O
encephalopathy B-Disease
- O
- O
19 O
new O
cases O
in O
germany O
from O
1994 O
to O
2003 O
- O
- O
a O
side O
effect O
associated O
to O
vpa O
- O
therapy O
not O
only O
in O
young O
children O
. O

rare O
serious O
complications O
may O
occur O
in O
some O
patients O
, O
including O
haemorrhagic O
pancreatitis B-Disease
, O
bone B-Disease
marrow I-Disease
suppression I-Disease
, O
vpa O
- O
induced O
hepatotoxicity B-Disease
and O
vpa O
- O
induced O
encephalopathy B-Disease
. O

the O
typical O
signs O
of O
vpa O
- O
induced O
encephalopathy B-Disease
are O
impaired B-Disease
consciousness I-Disease
, O
sometimes O
marked O
eeg O
background O
slowing O
, O
increased O
seizure B-Disease
frequency O
, O
with O
or O
without O
hyperammonemia B-Disease
. O

there O
is O
still O
no O
proof O
of O
causative O
effect O
of O
vpa O
in O
patients O
with O
encephalopathy B-Disease
, O
but O
only O
of O
an O
association O
with O
an O
assumed O
causal O
relation O
. O

we O
report O
19 O
patients O
with O
vpa O
- O
associated O
encephalopathy B-Disease
in O
germany O
from O
the O
years O
1994 O
to O
2003 O
, O
none O
of O
whom O
had O
been O
published O
previously O
. O

cerebral B-Disease
haemorrhage I-Disease
induced O
by O
warfarin O
- O
the O
influence O
of O
drug O
- O
drug O
interactions O
. O

purpose O
: O
to O
evaluate O
the O
frequency O
, O
severity O
and O
preventability O
of O
warfarin O
- O
induced O
cerebral B-Disease
haemorrhages I-Disease
due O
to O
warfarin O
and O
warfarin O
- O
drug O
interactions O
in O
patients O
living O
in O
the O
county O
of O
osterg O
tland O
, O
sweden O
. O

methods O
: O
all O
patients O
with O
a O
diagnosed O
cerebral B-Disease
haemorrhage I-Disease
at O
three O
hospitals O
during O
the O
period O
2000 O
- O
2002 O
were O
identified O
. O

medical O
records O
were O
studied O
retrospectively O
to O
evaluate O
whether O
warfarin O
and O
warfarin O
- O
drug O
interactions O
could O
have O
caused O
the O
cerebral B-Disease
haemorrhage I-Disease
. O

results O
: O
among O
593 O
patients O
with O
cerebral B-Disease
haemorrhage I-Disease
, O
59 O
( O
10 O
% O
) O
were O
assessed O
as O
related O
to O
warfarin O
treatment O
. O

a O
warfarin O
- O
drug O
interaction O
could O
have O
contributed O
to O
the O
haemorrhage B-Disease
in O
24 O
( O
41 O
% O
) O
of O
the O
warfarin O
patients O
and O
in O
7 O
of O
these O
( O
12 O
% O
) O
the O
bleeding B-Disease
complication O
was O
considered O
being O
possible O
to O
avoid O
. O

conclusions O
: O
warfarin O
- O
induced O
cerebral B-Disease
haemorrhages I-Disease
are O
a O
major O
clinical O
problem O
with O
a O
high O
fatality O
rate O
. O

a O
significant O
proportion O
of O
warfarin O
- O
related O
cerebral B-Disease
haemorrhages I-Disease
might O
have O
been O
prevented O
if O
greater O
caution O
had O
been O
taken O
when O
prescribing O
drugs O
known O
to O
interact O
with O
warfarin O
. O

experimental O
and O
clinical O
evidence O
points O
to O
a O
role O
of O
central O
histaminergic O
system O
in O
the O
pathogenesis O
of O
schizophrenia B-Disease
. O

the O
present O
study O
was O
designed O
to O
study O
the O
effect O
of O
histamine O
h O
( O
3 O
) O
- O
receptor O
ligands O
on O
neuroleptic O
- O
induced O
catalepsy B-Disease
, O
apomorphine O
- O
induced O
climbing O
behavior O
and O
amphetamine O
- O
induced O
locomotor O
activities O
in O
mice O
. O

catalepsy B-Disease
was O
induced O
by O
haloperidol O
( O
2 O
mg O
/ O
kg O
p O
. O

o O
. O

) O
, O
while O
apomorphine O
( O
1 O
. O

5 O
mg O
/ O
kg O
s O
. O

c O
. O

) O
and O
amphetamine O
( O
2 O
mg O
/ O
kg O
s O
. O

c O
. O

) O
were O
used O
for O
studying O
climbing O
behavior O
and O
locomotor O
activities O
, O
respectively O
. O

( O
r O
) O
- O
alpha O
- O
methylhistamine O
( O
ramh O
) O
( O
5 O
microg O
i O
. O

c O
. O

v O
. O

) O
and O
thioperamide O
( O
thp O
) O
( O
15 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
, O
per O
se O
did O
not O
cause O
catalepsy B-Disease
. O

administration O
of O
thp O
( O
3 O
. O

75 O
, O
7 O
. O

5 O
and O
15 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
1 O
h O
prior O
to O
haloperidol O
resulted O
in O
a O
dose O
- O
dependent O
increase O
in O
the O
catalepsy B-Disease
times O
( O
p O
< O
0 O
. O

5 O
) O
. O

on O
amphetamine O
- O
induced O
hyperactivity B-Disease
, O
thp O
( O
3 O
. O

75 O
and O
7 O
. O

5 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
reduced O
locomotor O
time O
, O
distance O
traveled O
and O
average O
speed O
( O
p O
< O
0 O
. O

5 O
) O
. O

thp O
exhibited O
an O
antipsychotic O
- O
like O
profile O
by O
potentiating O
haloperidol O
- O
induced O
catalepsy B-Disease
, O
reducing O
amphetamine O
- O
induced O
hyperactivity B-Disease
and O
reducing O
apomorphine O
- O
induced O
climbing O
in O
mice O
. O

findings O
suggest O
a O
potential O
for O
h O
( O
3 O
) O
- O
receptor O
antagonists O
in O
improving O
the O
refractory O
cases O
of O
schizophrenia B-Disease
. O

cauda B-Disease
equina I-Disease
syndrome I-Disease
after O
epidural O
steroid O
injection O
: O
a O
case O
report O
. O

objective O
: O
conventional O
treatment O
methods O
of O
lumbusacral O
radiculopathy B-Disease
are O
physical O
therapy O
, O
epidural O
steroid O
injections O
, O
oral O
medications O
, O
and O
spinal O
manipulative O
therapy O
. O

cauda B-Disease
equina I-Disease
syndrome I-Disease
is O
a O
rare O
complication O
of O
epidural O
anesthesia O
. O

the O
following O
case O
is O
a O
report O
of O
cauda B-Disease
equina I-Disease
syndrome I-Disease
possibly O
caused O
by O
epidural O
injection O
of O
triamcinolone O
and O
bupivacaine O
. O

clinical O
features O
: O
a O
50 O
- O
year O
- O
old O
woman O
with O
low B-Disease
back I-Disease
and I-Disease
right I-Disease
leg I-Disease
pain I-Disease
was O
scheduled O
for O
epidural O
steroid O
injection O
. O

three O
hours O
later O
, O
she O
complained O
of O
perineal O
numbness B-Disease
and O
lower B-Disease
extremity I-Disease
weakness I-Disease
. O

the O
neurologic O
evaluation O
revealed O
loss B-Disease
of I-Disease
sensation I-Disease
in O
the O
saddle O
area O
and O
medial O
aspect O
of O
her O
right O
leg O
. O

clinical O
examination O
and O
continued O
vigilance O
for O
neurologic B-Disease
deterioration I-Disease
after O
epidural O
steroid O
injections O
is O
important O
. O

high O
- O
dose O
testosterone O
is O
associated O
with O
atherosclerosis B-Disease
in O
postmenopausal O
women O
. O

objectives O
: O
to O
study O
the O
long O
- O
term O
effects O
of O
androgen O
treatment O
on O
atherosclerosis B-Disease
in O
postmenopausal O
women O
. O

methods O
: O
in O
a O
population O
- O
based O
study O
in O
513 O
naturally O
postmenopausal O
women O
aged O
54 O
- O
67 O
years O
, O
we O
studied O
the O
association O
between O
self O
- O
reported O
intramuscularly O
administered O
high O
- O
dose O
estrogen O
- O
testosterone O
therapy O
( O
estradiol O
- O
and O
testosterone O
esters O
) O
and O
aortic O
atherosclerosis B-Disease
. O

aortic O
atherosclerosis B-Disease
was O
diagnosed O
by O
radiographic O
detection O
of O
calcified O
deposits O
in O
the O
abdominal O
aorta O
, O
which O
have O
been O
shown O
to O
reflect O
intima O
atherosclerosis B-Disease
. O

in O
almost O
half O
of O
these O
women O
severe O
atherosclerosis B-Disease
of O
the O
aorta O
was O
present O
( O
n O
= O
11 O
) O
, O
while O
in O
women O
without O
hormone O
use O
severe O
atherosclerosis B-Disease
of O
the O
aorta O
was O
present O
in O
less O
than O
20 O
% O
( O
or O
3 O
. O

1 O
; O
95 O
% O
ci O
, O
1 O
. O

1 O
- O
8 O
. O

5 O
, O
adjusted O
for O
age O
, O
years O
since O
menopause O
, O
smoking O
, O
and O
body O
mass O
index O
) O
. O

the O
association O
remained O
after O
additional O
adjustment O
for O
diabetes B-Disease
, O
cholesterol O
level O
, O
systolic O
blood O
pressure O
, O
or O
alcohol O
use O
. O

conclusion O
: O
our O
results O
suggest O
that O
high O
- O
dose O
testosterone O
therapy O
may O
adversely O
affect O
atherosclerosis B-Disease
in O
postmenopausal O
women O
and O
indicate O
that O
androgen O
replacement O
in O
these O
women O
may O
not O
be O
harmless O
. O

optimising O
stroke B-Disease
prevention O
in O
non O
- O
valvular O
atrial B-Disease
fibrillation I-Disease
. O

atrial B-Disease
fibrillation I-Disease
is O
associated O
with O
substantial O
morbidity O
and O
mortality O
. O

pooled O
data O
from O
trials O
comparing O
antithrombotic O
treatment O
with O
placebo O
have O
shown O
that O
warfarin O
reduces O
the O
risk O
of O
stroke B-Disease
by O
62 O
% O
, O
and O
that O
aspirin O
alone O
reduces O
the O
risk O
by O
22 O
% O
. O

overall O
, O
in O
high O
- O
risk O
patients O
, O
warfarin O
is O
superior O
to O
aspirin O
in O
preventing O
strokes B-Disease
, O
with O
a O
relative O
risk O
reduction O
of O
36 O
% O
. O

ximelagatran O
, O
an O
oral O
direct O
thrombin O
inhibitor O
, O
was O
found O
to O
be O
as O
efficient O
as O
vitamin O
k O
antagonist O
drugs O
in O
the O
prevention O
of O
embolic B-Disease
events I-Disease
, O
but O
has O
been O
recently O
withdrawn O
because O
of O
abnormal B-Disease
liver I-Disease
function I-Disease
tests O
. O

the O
active O
- O
w O
( O
atrial B-Disease
fibrillation I-Disease
clopidogrel O
trial O
with O
irbesartan O
for O
prevention O
of O
vascular O
events O
) O
study O
has O
demonstrated O
that O
warfarin O
is O
superior O
to O
platelet O
therapy O
( O
clopidogrel O
plus O
aspirin O
) O
in O
the O
prevention O
af O
embolic B-Disease
events I-Disease
. O

idraparinux O
, O
a O
factor O
xa O
inhibitor O
, O
is O
being O
evaluated O
in O
patients O
with O
atrial B-Disease
fibrillation I-Disease
. O

angiotensin O
- O
converting O
enzyme O
inhibitors O
and O
angiotensin O
ii O
receptor O
- O
blocking O
drugs O
hold O
promise O
in O
atrial B-Disease
fibrillation I-Disease
through O
cardiac B-Disease
remodelling I-Disease
. O

anti O
- O
oxidant O
effects O
of O
atorvastatin O
in O
dexamethasone O
- O
induced O
hypertension B-Disease
in O
the O
rat O
. O

dexamethasone O
( O
dex O
) O
- O
induced O
hypertension B-Disease
is O
characterized O
by O
endothelial O
dysfunction O
associated O
with O
nitric O
oxide O
( O
no O
) O
deficiency O
and O
increased O
superoxide O
( O
o2 O
- O
) O
production O
. O

atorvastatin O
( O
ato O
) O
possesses O
pleiotropic O
properties O
that O
have O
been O
reported O
to O
improve O
endothelial O
function O
through O
increased O
availability O
of O
no O
and O
reduced O
o2 O
- O
production O
in O
various O
forms O
of O
hypertension B-Disease
. O

severe O
citrate O
toxicity B-Disease
complicating O
volunteer O
apheresis O
platelet O
donation O
. O

we O
report O
a O
case O
of O
severe O
citrate O
toxicity B-Disease
during O
volunteer O
donor O
apheresis O
platelet O
collection O
. O

past O
medical O
history O
was O
remarkable O
for O
hypertension B-Disease
, O
hyperlipidemia B-Disease
, O
and O
depression B-Disease
. O

she O
then O
very O
rapidly O
developed O
acute O
onset O
of O
severe O
facial O
and O
extremity O
tetany B-Disease
. O

empirical O
treatment O
with O
intravenous O
calcium O
gluconate O
was O
initiated O
, O
and O
muscle B-Disease
contractions I-Disease
slowly O
subsided O
over O
approximately O
10 O
to O
15 O
minutes O
. O

the O
events O
are O
consistent O
with O
a O
severe O
reaction O
to O
calcium O
chelation O
by O
sodium O
citrate O
anticoagulant O
resulting O
in O
symptomatic O
systemic O
hypocalcemia B-Disease
. O

upon O
additional O
retrospective O
analysis O
, O
it O
was O
noted O
that O
bumetanide O
is O
a O
loop O
diuretic O
that O
may O
cause O
significant O
hypocalcemia B-Disease
. O

we O
conclude O
that O
careful O
screening O
for O
medications O
and O
underlying O
conditions O
predisposing O
to O
hypocalcemia B-Disease
is O
recommended O
to O
help O
prevent O
severe O
reactions O
due O
to O
citrate O
toxicity B-Disease
. O

sirolimus O
- O
associated O
proteinuria B-Disease
and O
renal B-Disease
dysfunction I-Disease
. O

sirolimus O
represents O
a O
major O
therapeutic O
advance O
in O
the O
prevention O
of O
acute O
renal O
allograft O
rejection O
and O
chronic O
allograft O
nephropathy B-Disease
. O

its O
role O
in O
the O
therapy O
of O
glomerulonephritis B-Disease
, O
autoimmunity B-Disease
, O
cystic B-Disease
renal I-Disease
diseases I-Disease
and O
renal B-Disease
cancer I-Disease
is O
under O
investigation O
. O

because O
sirolimus O
does O
not O
share O
the O
vasomotor O
renal O
adverse O
effects O
exhibited O
by O
calcineurin O
inhibitors O
, O
it O
has O
been O
designated O
a O
' O
non O
- O
nephrotoxic B-Disease
drug O
' O
. O

however O
, O
clinical O
reports O
suggest O
that O
, O
under O
some O
circumstances O
, O
sirolimus O
is O
associated O
with O
proteinuria B-Disease
and O
acute B-Disease
renal I-Disease
dysfunction I-Disease
. O

a O
common O
risk O
factor O
appears O
to O
be O
presence O
of O
pre O
- O
existing O
chronic B-Disease
renal I-Disease
damage I-Disease
. O

the O
mechanisms O
of O
sirolimus O
- O
associated O
proteinuria B-Disease
are O
multifactorial O
and O
may O
be O
due O
to O
an O
increase O
in O
glomerular O
capillary O
pressure O
following O
calcineurin O
inhibitor O
withdrawal O
. O

the O
acute B-Disease
renal I-Disease
dysfunction I-Disease
associated O
with O
sirolimus O
( O
such O
as O
in O
delayed O
graft O
function O
) O
may O
be O
due O
to O
suppression O
of O
compensatory O
renal O
cell O
proliferation O
and O
survival O
/ O
repair O
processes O
. O

although O
these O
adverse O
effects O
occur O
in O
some O
patients O
, O
their O
occurrence O
could O
be O
minimised O
by O
knowledge O
of O
the O
molecular O
effects O
of O
sirolimus O
on O
the O
kidney O
, O
the O
use O
of O
sirolimus O
in O
appropriate O
patient O
populations O
, O
close O
monitoring O
of O
proteinuria B-Disease
and O
renal O
function O
, O
use O
of O
angiotensin O
- O
converting O
enzyme O
inhibitors O
or O
angiotensin O
ii O
receptor O
blockers O
if O
proteinuria B-Disease
occurs O
and O
withdrawal O
if O
needed O
. O

proteinuria B-Disease
after O
conversion O
to O
sirolimus O
in O
renal O
transB-Plant O
recipients O
. O

more O
recently O
, O
proteinuria B-Disease
has O
been O
reported O
as O
a O
consequence O
of O
sirolimus O
therapy O
, O
although O
the O
mechanism O
has O
remained O
unclear O
. O

we O
retrospectively O
examined O
the O
records O
of O
25 O
renal O
transB-Plant O
patients O
, O
who O
developed O
or O
displayed O
increased O
proteinuria B-Disease
after O
srl O
conversion O
. O

the O
patient O
cohort O
( O
14 O
men O
, O
11 O
women O
) O
was O
treated O
with O
srl O
as O
conversion O
therapy O
, O
due O
to O
chronic B-Disease
allograft I-Disease
nephropathy I-Disease
( O
can B-Disease
) O
( O
n O
= O
15 O
) O
neoplasia B-Disease
( O
n O
= O
8 O
) O
; O
kaposi B-Disease
' I-Disease
s I-Disease
sarcoma I-Disease
, O
four O
skin B-Disease
cancers I-Disease
, O
one O
intestinal B-Disease
tumors I-Disease
, O
one O
renal B-Disease
cell I-Disease
carsinom I-Disease
) O
or O
bk O
virus O
nephropathy B-Disease
( O
n O
= O
2 O
) O
. O

proteinuria B-Disease
increased O
from O
0 O
. O

445 O
( O
0 O
to O
1 O
. O

5 O
) O
g O
/ O
d O
before O
conversion O
to O
3 O
. O

2 O
g O
/ O
dl O
( O
0 O
. O

2 O
to O
12 O
) O
after O
conversion O
( O
p O
= O
0 O
. O

1 O
) O
. O

before O
conversion O
8 O
( O
32 O
% O
) O
patients O
had O
no O
proteinuria B-Disease
, O
whereas O
afterwards O
all O
patients O
had O
proteinuria B-Disease
. O

in O
28 O
% O
of O
patients O
proteinuria B-Disease
remained O
unchanged O
, O
whereas O
it O
increased O
in O
68 O
% O
of O
patients O
. O

twenty O
- O
eight O
percent O
of O
patients O
showed O
increased O
proteinuria B-Disease
to O
the O
nephrotic B-Disease
range O
. O

biopsies O
performed O
in O
five O
patients O
revealed O
new O
pathological O
changes O
: O
one O
membranoproliferative B-Disease
glomerulopathy I-Disease
and O
interstitial B-Disease
nephritis I-Disease
. O

five O
patients O
displayed O
can B-Disease
and O
kaposi B-Disease
' I-Disease
s I-Disease
sarcoma I-Disease
. O

heavy O
proteinuria B-Disease
was O
common O
after O
the O
use O
of O
srl O
as O
rescue O
therapy O
for O
renal O
transB-Plantation O
. O

therefore O
, O
conversion O
should O
be O
considered O
for O
patients O
who O
have O
not O
developed O
advanced O
can B-Disease
and O
proteinuria B-Disease
. O

long O
- O
term O
follow O
- O
up O
of O
ifosfamide O
renal B-Disease
toxicity I-Disease
in O
children O
treated O
for O
malignant B-Disease
mesenchymal I-Disease
tumors I-Disease
: O
an O
international O
society O
of O
pediatric O
oncology O
report O
. O

the O
renal O
function O
of O
74 O
children O
with O
malignant B-Disease
mesenchymal I-Disease
tumors I-Disease
in O
complete O
remission O
and O
who O
have O
received O
the O
same O
ifosfamide O
chemotherapy O
protocol O
( O
international O
society O
of O
pediatric O
oncology O
malignant B-Disease
mesenchymal I-Disease
tumor I-Disease
study O
84 O
[ O
siop O
mmt O
84 O
] O
) O
were O
studied O
1 O
year O
after O
the O
completion O
of O
treatment O
. O

the O
most O
common O
primary O
tumor B-Disease
site O
was O
the O
head O
and O
neck O
. O

renal O
function O
was O
investigated O
by O
measuring O
plasma O
and O
urinary O
electrolytes O
, O
glucosuria B-Disease
, O
proteinuria B-Disease
, O
aminoaciduria B-Disease
, O
urinary O
ph O
, O
osmolarity O
, O
creatinine O
clearance O
, O
phosphate O
tubular O
reabsorption O
, O
beta O
2 O
microglobulinuria O
, O
and O
lysozymuria O
. O

fifty O
- O
eight O
patients O
( O
78 O
% O
) O
had O
normal O
renal O
tests O
, O
whereas O
16 O
patients O
( O
22 O
% O
) O
had O
renal B-Disease
abnormalities I-Disease
. O

two O
subsets O
of O
patients O
were O
identified O
from O
this O
latter O
group O
: O
the O
first O
included O
four O
patients O
( O
5 O
% O
of O
the O
total O
population O
) O
who O
developed O
major O
toxicity B-Disease
resulting O
in O
fanconi B-Disease
' I-Disease
s I-Disease
syndrome I-Disease
( O
tdfs B-Disease
) O
; O
and O
the O
second O
group O
included O
five O
patients O
with O
elevated O
beta O
2 O
microglobulinuria O
and O
low O
phosphate O
reabsorption O
. O

severe O
toxicity B-Disease
was O
correlated O
with O
the O
higher O
cumulative O
dose O
of O
60 O
g O
/ O
m2 O
of O
ifosfamide O
, O
a O
younger O
age O
( O
less O
than O
2 O
1 O
/ O
2 O
years O
old O
) O
, O
and O
a O
predominance O
of O
vesicoprostatic O
tumor B-Disease
involvement O
. O

this O
low O
percentage O
( O
5 O
% O
) O
of O
tdfs O
must O
be O
evaluated O
with O
respect O
to O
the O
efficacy O
of O
ifosfamide O
in O
the O
treatment O
of O
mesenchymal B-Disease
tumors I-Disease
in O
children O
. O

progressive O
myopathy B-Disease
with O
up O
- O
regulation O
of O
mhc O
- O
i O
associated O
with O
statin O
therapy O
. O

statins O
can O
cause O
a O
necrotizing O
myopathy B-Disease
and O
hyperckaemia B-Disease
which O
is O
reversible O
on O
cessation O
of O
the O
drug O
. O

what O
is O
less O
well O
known O
is O
a O
phenomenon O
whereby O
statins O
may O
induce O
a O
myopathy B-Disease
, O
which O
persists O
or O
may O
progress O
after O
stopping O
the O
drug O
. O

all O
had O
myofibre O
necrosis B-Disease
but O
only O
3 O
had O
an O
inflammatory O
infiltrate O
. O

in O
all O
cases O
there O
was O
diffuse O
or O
multifocal O
up O
- O
regulation O
of O
mhc O
- O
i O
expression O
even O
in O
non O
- O
necrotic B-Disease
fibres O
. O

these O
observations O
suggest O
that O
statins O
may O
initiate O
an O
immune O
- O
mediated O
myopathy B-Disease
that O
persists O
after O
withdrawal O
of O
the O
drug O
and O
responds O
to O
immunosuppressive O
therapy O
. O

the O
mechanism O
of O
this O
myopathy B-Disease
is O
uncertain O
but O
may O
involve O
the O
induction O
by O
statins O
of O
an O
endoplasmic O
reticulum O
stress O
response O
with O
associated O
up O
- O
regulation O
of O
mhc O
- O
i O
expression O
and O
antigen O
presentation O
by O
muscle O
fibres O
. O

use O
of O
chromosome O
substitution O
strains O
to O
identify O
seizure B-Disease
susceptibility O
loci O
in O
mice O
. O

seizure B-Disease
susceptibility O
varies O
among O
inbred O
mouse O
strains O
. O

chromosome O
substitution O
strains O
( O
css O
) O
, O
in O
which O
a O
single O
chromosome O
from O
one O
inbred O
strain O
( O
donor O
) O
has O
been O
transferred O
onto O
a O
second O
strain O
( O
host O
) O
by O
repeated O
backcrossing O
, O
may O
be O
used O
to O
identify O
quantitative O
trait O
loci O
( O
qtls O
) O
that O
contribute O
to O
seizure B-Disease
susceptibility O
. O

qtls O
for O
susceptibility O
to O
pilocarpine O
- O
induced O
seizures B-Disease
, O
a O
model O
of O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
, O
have O
not O
been O
reported O
, O
and O
css O
have O
not O
previously O
been O
used O
to O
localize O
seizure B-Disease
susceptibility O
genes O
. O

we O
report O
qtls O
identified O
using O
a O
b6 O
( O
host O
) O
x O
a O
/ O
j O
( O
donor O
) O
css O
panel O
to O
localize O
genes O
involved O
in O
susceptibility O
to O
pilocarpine O
- O
induced O
seizures B-Disease
. O

three O
hundred O
fifty O
- O
five O
adult O
male O
css O
mice O
, O
58 O
b6 O
, O
and O
39 O
a O
/ O
j O
were O
tested O
for O
susceptibility O
to O
pilocarpine O
- O
induced O
seizures B-Disease
. O

b6 O
mice O
were O
resistant O
to O
seizures B-Disease
and O
slower O
to O
reach O
stages O
compared O
to O
a O
/ O
j O
mice O
. O

css O
mapping O
suggests O
seizure B-Disease
susceptibility O
loci O
on O
mouse O
chromosomes O
10 O
and O
18 O
. O

this O
approach O
provides O
a O
framework O
for O
identifying O
potentially O
novel O
homologous O
candidate O
genes O
for O
human O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
. O

in O
vitro O
characterization O
of O
parasympathetic O
and O
sympathetic O
responses O
in O
cyclophosphamide O
- O
induced O
cystitis B-Disease
in O
the O
rat O
. O

in O
cyclophosphamide O
- O
induced O
cystitis B-Disease
in O
the O
rat O
, O
detrusor O
function O
is O
impaired O
and O
the O
expression O
and O
effects O
of O
muscarinic O
receptors O
altered O
. O

whether O
or O
not O
the O
neuronal O
transmission O
may O
be O
affected O
by O
cystitis B-Disease
was O
presently O
investigated O
. O

thus O
, O
in O
cystitis B-Disease
substantial O
changes O
of O
the O
efferent O
functional O
responses O
occur O
. O

background O
: O
inhibition O
of O
cardiac O
sympathetic O
tone O
represents O
an O
important O
strategy O
for O
treatment O
of O
cardiovascular B-Disease
disease I-Disease
, O
including O
arrhythmia B-Disease
, O
coronary B-Disease
heart I-Disease
disease I-Disease
, O
and O
chronic O
heart B-Disease
failure I-Disease
. O

clonidine O
- O
induced O
bradycardia B-Disease
in O
conscious O
alpha2abc O
- O
/ O
- O
mice O
was O
32 O
. O

3 O
% O
( O
10 O
microg O
/ O
kg O
) O
and O
26 O
. O

6 O
% O
( O
100 O
microg O
/ O
kg O
) O
of O
the O
effect O
in O
wild O
- O
type O
mice O
. O

granulomatous B-Disease
hepatitis I-Disease
due O
to O
combination O
of O
amoxicillin O
and O
clavulanic O
acid O
. O

we O
report O
the O
case O
of O
a O
patient O
with O
amoxicillin O
- O
clavulanic O
acid O
- O
induced O
hepatitis B-Disease
with O
histologic O
multiple O
granulomas B-Disease
. O

this O
type O
of O
lesion O
broadens O
the O
spectrum O
of O
liver B-Disease
injury I-Disease
due O
to O
this O
drug O
combination O
, O
mainly O
represented O
by O
a O
benign O
cholestatic B-Disease
syndrome I-Disease
. O

the O
association O
of O
granulomas B-Disease
and O
eosinophilia B-Disease
favor O
an O
immunoallergic O
mechanism O
. O

dobutamine O
stress O
echocardiography O
: O
a O
sensitive O
indicator O
of O
diminished O
myocardial O
function O
in O
asymptomatic O
doxorubicin O
- O
treated O
long O
- O
term O
survivors O
of O
childhood O
cancer B-Disease
. O

doxorubicin O
is O
an O
effective O
anticancer O
chemotherapeutic O
agent O
known O
to O
cause O
acute O
and O
chronic O
cardiomyopathy B-Disease
. O

to O
develop O
a O
more O
sensitive O
echocardiographic O
screening O
test O
for O
cardiac B-Disease
damage I-Disease
due O
to O
doxorubicin O
, O
a O
cohort O
study O
was O
performed O
using O
dobutamine O
infusion O
to O
differentiate O
asymptomatic O
long O
- O
term O
survivors O
of O
childhood O
cancer B-Disease
treated O
with O
doxorubicin O
from O
healthy O
control O
subjects O
. O

the O
influence O
of O
smoking O
during O
pregnancy O
on O
the O
developing O
cochlea O
has O
not O
been O
estimated O
, O
although O
smoking O
has O
been O
positively O
associated O
with O
hearing B-Disease
loss I-Disease
in O
adults O
. O

methods O
: O
this O
study O
was O
undertaken O
as O
part O
of O
neonatal O
screening O
for O
hearing B-Disease
impairment I-Disease
and O
involved O
both O
ears O
of O
200 O
newborns O
. O

however O
, O
by O
comparing O
each O
subgroup O
to O
control O
group O
, O
we O
found O
statistically O
significant O
decreases B-Disease
of I-Disease
teoaes I-Disease
amplitudes I-Disease
at O
4000hz O
for O
all O
three O
groups O
. O

simvastatin O
- O
induced O
bilateral O
leg O
compartment B-Disease
syndrome I-Disease
and O
myonecrosis B-Disease
associated O
with O
hypothyroidism B-Disease
. O

a O
54 O
- O
year O
- O
old O
hypothyroid B-Disease
male O
taking O
thyroxine O
and O
simvastatin O
presented O
with O
bilateral O
leg O
compartment B-Disease
syndrome I-Disease
and O
myonecrosis B-Disease
. O

it O
is O
likely O
that O
this O
complication O
will O
be O
seen O
more O
often O
with O
the O
increased O
worldwide O
use O
of O
this O
drug O
and O
its O
approval O
for O
all O
arteriopathic B-Disease
patients O
. O

neuroinflammation B-Disease
and O
behavioral B-Disease
abnormalities I-Disease
after O
neonatal O
terbutaline O
treatment O
in O
rats O
: O
implications O
for O
autism B-Disease
. O

autism B-Disease
is O
a O
neurodevelopmental B-Disease
disorder I-Disease
presenting O
before O
3 O
years O
of O
age O
with O
deficits B-Disease
in I-Disease
communication I-Disease
and I-Disease
social I-Disease
skills I-Disease
and O
repetitive B-Disease
behaviors I-Disease
. O

in O
addition O
to O
genetic O
influences O
, O
recent O
studies O
suggest O
that O
prenatal O
drug O
or O
chemical O
exposures O
are O
risk O
factors O
for O
autism B-Disease
. O

terbutaline O
, O
a O
beta2 O
- O
adrenoceptor O
agonist O
used O
to O
arrest O
preterm B-Disease
labor I-Disease
, O
has O
been O
associated O
with O
increased O
concordance O
for O
autism B-Disease
in O
dizygotic O
twins O
. O

our O
findings O
indicate O
that O
beta2 O
- O
adrenoceptor O
overstimulation O
during O
an O
early O
critical O
period O
results O
in O
microglial O
activation O
associated O
with O
innate O
neuroinflammatory O
pathways O
and O
behavioral B-Disease
abnormalities I-Disease
, O
similar O
to O
those O
described O
in O
autism B-Disease
. O

this O
study O
provides O
a O
useful O
animal O
model O
for O
understanding O
the O
neuropathological O
processes O
underlying O
autism B-Disease
spectrum I-Disease
disorders I-Disease
. O

upregulation O
of O
brain O
expression O
of O
p O
- O
glycoprotein O
in O
mrp2 O
- O
deficient O
tr O
( O
- O
) O
rats O
resembles O
seizure B-Disease
- O
induced O
up O
- O
regulation O
of O
this O
drug O
efflux O
transporter O
in O
normal O
rats O
. O

a O
comparable O
overexpression O
of O
pgp O
in O
the O
bbb O
was O
obtained O
after O
pilocarpine O
- O
induced O
seizures B-Disease
in O
wild O
- O
type O
wistar O
rats O
. O

because O
such O
a O
compensatory O
mechanism O
most O
likely O
occurs O
to O
reduce O
injury B-Disease
to I-Disease
the I-Disease
brain I-Disease
from O
cytotoxic O
compounds O
, O
the O
present O
data O
substantiate O
the O
concept O
that O
mrp2 O
performs O
a O
protective O
role O
in O
the O
bbb O
. O

furthermore O
, O
our O
data O
suggest O
that O
tr O
( O
- O
) O
rats O
are O
an O
interesting O
tool O
to O
study O
consequences O
of O
overexpression O
of O
pgp O
in O
the O
bbb O
on O
access O
of O
drugs O
in O
the O
brain O
, O
without O
the O
need O
of O
inducing O
seizures B-Disease
or O
other O
pgp O
- O
enhancing O
events O
for O
this O
purpose O
. O

role O
of O
xanthine O
oxidase O
in O
dexamethasone O
- O
induced O
hypertension B-Disease
in O
rats O
. O

glucocorticoid O
- O
induced O
hypertension B-Disease
( O
gc O
- O
ht B-Disease
) O
in O
the O
rat O
is O
associated O
with O
nitric O
oxide O
- O
redox O
imbalance O
. O

we O
studied O
the O
role O
of O
xanthine O
oxidase O
( O
xo O
) O
, O
which O
is O
implicated O
in O
the O
production O
of O
reactive O
oxygen O
species O
, O
in O
dexamethasone O
- O
induced O
hypertension B-Disease
( O
dex O
- O
ht B-Disease
) O
. O

dex O
increased B-Disease
sbp I-Disease
( O
110 O
+ O
/ O
- O
2 O
- O
126 O
+ O
/ O
- O
3 O
mmhg O
; O
p O
< O
0 O
. O

1 O
) O
and O
decreased B-Disease
thymus I-Disease
( I-Disease
p I-Disease
< I-Disease
0 I-Disease
. I-Disease

1 I-Disease
) I-Disease
and I-Disease
bodyweights I-Disease
( O
p O
nan O
< O
0 O
. O

1 O
) O
. O

allopurinol O
did O
not O
prevent O
dex O
- O
ht B-Disease
. O

this O
, O
together O
with O
our O
previous O
findings O
that O
allopurinol O
failed O
to O
prevent O
adrenocorticotrophic O
hormone O
induced O
hypertension B-Disease
, O
suggests O
that O
xo O
activity O
is O
not O
a O
major O
determinant O
of O
gc O
- O
ht B-Disease
in O
the O
rat O
. O

purpose O
: O
to O
assess O
the O
incidence O
of O
postoperative O
emetic O
side O
effects O
after O
the O
administration O
of O
methylprednisolone O
and O
gentamicin O
into O
the O
posterior O
sub O
- O
tenon O
' O
s O
space O
at O
the O
of O
routine O
cataract B-Disease
surgery O
. O

postoperatively O
, O
all O
patients O
were O
assessed O
for O
symptoms O
of O
nausea B-Disease
, I-Disease
vomiting I-Disease
, O
and O
headache B-Disease
. O

results O
: O
sixty O
percent O
in O
group O
a O
developed O
postoperative B-Disease
emetic I-Disease
symptoms I-Disease
, O
headache B-Disease
, O
or O
both O
; O
1 O
patient O
in O
group O
b O
developed O
symptoms O
. O

conclusions O
: O
the O
administration O
of O
methylprednisolone O
and O
gentamicin O
in O
the O
posterior O
sub O
- O
tenon O
' O
s O
space O
was O
related O
to O
a O
high O
incidence O
of O
side O
effects O
including O
nausea B-Disease
, I-Disease
vomiting I-Disease
, O
and O
headache B-Disease
. O

assessment O
of O
a O
new O
non O
- O
invasive O
index O
of O
cardiac O
performance O
for O
detection O
of O
dobutamine O
- O
induced O
myocardial B-Disease
ischemia I-Disease
. O

background O
: O
electrocardiography O
has O
a O
very O
low O
sensitivity O
in O
detecting O
dobutamine O
- O
induced O
myocardial B-Disease
ischemia I-Disease
. O

objectives O
: O
to O
assess O
the O
added O
diagnostic O
value O
of O
a O
new O
cardiac O
performance O
index O
( O
dp O
/ O
dtejc O
) O
measurement O
, O
based O
on O
brachial O
artery O
flow O
changes O
, O
as O
compared O
to O
standard O
12 O
- O
lead O
ecg O
, O
for O
detecting O
dobutamine O
- O
induced O
myocardial B-Disease
ischemia I-Disease
, O
using O
tc99m O
- O
sestamibi O
single O
- O
photon O
emission O
computed O
tomography O
as O
the O
gold O
standard O
of O
comparison O
to O
assess O
the O
presence O
or O
absence O
of O
ischemia B-Disease
. O

in O
19 O
of O
the O
40 O
patients O
perfusion O
defects O
compatible O
with O
ischemia B-Disease
were O
detected O
on O
spect O
. O

conclusions O
: O
if O
ecg O
alone O
is O
used O
for O
specificity O
, O
the O
combination O
with O
dp O
/ O
dtejc O
improved O
the O
sensitivity O
of O
the O
test O
and O
could O
be O
a O
cost O
- O
savings O
alternative O
to O
cardiac O
imaging O
or O
perfusion O
studies O
to O
detect O
myocardial B-Disease
ischemia I-Disease
, O
especially O
in O
patients O
unable O
to O
exercise O
. O

cocaine O
- O
induced O
myocardial B-Disease
infarction I-Disease
: O
clinical O
observations O
and O
pathogenetic O
considerations O
. O

clinical O
and O
experimental O
data O
published O
to O
date O
suggest O
several O
possible O
mechanisms O
by O
which O
cocaine O
may O
result O
in O
acute B-Disease
myocardial I-Disease
infarction I-Disease
. O

in O
individuals O
with O
preexisting O
, O
high O
- O
grade O
coronary O
arterial O
narrowing O
, O
acute B-Disease
myocardial I-Disease
infarction I-Disease
may O
result O
from O
an O
increase O
in O
myocardial O
oxygen O
demand O
associated O
with O
cocaine O
- O
induced O
increase O
in O
rate O
- O
pressure O
product O
. O

in O
other O
individuals O
with O
no O
underlying O
atherosclerotic B-Disease
obstruction I-Disease
, O
coronary B-Disease
occlusion I-Disease
may O
be O
due O
to O
spasm B-Disease
, O
thrombus B-Disease
, O
or O
both O
. O

with O
regard O
to O
spasm B-Disease
, O
the O
clinical O
findings O
are O
largely O
circumstantial O
, O
and O
the O
locus O
of O
cocaine O
- O
induced O
vasoconstriction O
remains O
speculative O
. O

although O
certain O
clinical O
and O
experimental O
findings O
support O
the O
hypothesis O
that O
spasm B-Disease
involves O
the O
epicardial O
, O
medium O
- O
size O
vessels O
, O
other O
data O
suggest O
intramural O
vasoconstriction O
. O

diffuse O
intramural O
vasoconstriction O
is O
not O
consistent O
with O
reports O
of O
segmental O
, O
discrete O
infarction B-Disease
. O

finally O
, O
the O
contribution O
of O
a O
primary O
, O
thrombotic B-Disease
effect O
of O
cocaine O
has O
not O
been O
excluded O
. O

proteomic O
analysis O
of O
striatal O
proteins O
in O
the O
rat O
model O
of O
l O
- O
dopa O
- O
induced O
dyskinesia B-Disease
. O

l O
- O
dopa O
- O
induced O
dyskinesia B-Disease
( O
lid B-Disease
) O
is O
among O
the O
motor O
complications O
that O
arise O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
patients O
after O
a O
prolonged O
treatment O
with O
l O
- O
dopa O
. O

to O
this O
day O
, O
transcriptome O
analysis O
has O
been O
performed O
in O
a O
rat O
model O
of O
lid B-Disease
[ O
neurobiol O
. O

dis O
. O

, O
17 O
( O
2004 O
) O
, O
219 O
] O
but O
information O
regarding O
the O
proteome O
is O
still O
lacking O
. O

in O
the O
present O
study O
, O
we O
investigated O
the O
changes O
occurring O
at O
the O
protein O
level O
in O
striatal O
samples O
obtained O
from O
the O
unilaterally O
6 O
- O
hydroxydopamine O
- O
lesion O
rat O
model O
of O
pd B-Disease
treated O
with O
saline O
, O
l O
- O
dopa O
or O
bromocriptine O
using O
two O
- O
dimensional O
difference O
gel O
electrophoresis O
and O
mass O
spectrometry O
( O
ms O
) O
. O

rats O
treated O
with O
l O
- O
dopa O
were O
allocated O
to O
two O
groups O
based O
on O
the O
presence O
or O
absence O
of O
lid B-Disease
. O

out O
of O
these O
67 O
proteins O
, O
lid B-Disease
significantly O
changed O
the O
expression O
level O
of O
five O
proteins O
: O
alphabeta O
- O
crystalin O
, O
gamma O
- O
enolase O
, O
guanidoacetate O
methyltransferase O
, O
vinculin O
, O
and O
proteasome O
alpha O
- O
2 O
subunit O
. O

in O
conclusion O
, O
this O
study O
provides O
new O
insights O
into O
the O
protein O
changes O
occurring O
in O
lid B-Disease
. O

cardiac O
angiography O
in O
renally O
impaired O
patients O
( O
care O
) O
study O
: O
a O
randomized O
double O
- O
blind O
trial O
of O
contrast O
- O
induced O
nephropathy B-Disease
in O
patients O
with O
chronic B-Disease
kidney I-Disease
disease I-Disease
. O

methods O
and O
results O
: O
the O
present O
study O
is O
a O
multicenter O
, O
randomized O
, O
double O
- O
blind O
comparison O
of O
iopamidol O
and O
iodixanol O
in O
patients O
with O
chronic B-Disease
kidney I-Disease
disease I-Disease
( O
estimated O
glomerular O
filtration O
rate O
, O
20 O
to O
59 O
ml O
/ O
min O
) O
who O
underwent O
cardiac O
angiography O
or O
percutaneous O
coronary O
interventions O
. O

in O
414 O
patients O
, O
contrast O
volume O
, O
presence O
of O
diabetes B-Disease
mellitus I-Disease
, O
use O
of O
n O
- O
acetylcysteine O
, O
mean O
baseline O
scr O
, O
and O
estimated O
glomerular O
filtration O
rate O
were O
comparable O
in O
the O
2 O
groups O
. O

in O
patients O
with O
diabetes B-Disease
, O
scr O
increases O
> O
or O
= O
0 O
. O

5 O
mg O
/ O
dl O
were O
5 O
. O

1 O
% O
( O
4 O
of O
78 O
patients O
) O
with O
iopamidol O
and O
13 O
. O

0 O
% O
( O
12 O
of O
92 O
patients O
) O
with O
iodixanol O
( O
p O
= O
0 O
. O

11 O
) O
, O
whereas O
scr O
increases O
> O
or O
= O
25 O
% O
were O
10 O
. O

3 O
% O
and O
15 O
. O

2 O
% O
, O
respectively O
( O
p O
= O
0 O
. O

37 O
) O
. O

mean O
post O
- O
scr O
increases O
were O
significantly O
less O
with O
iopamidol O
( O
all O
patients O
: O
0 O
. O

7 O
versus O
0 O
. O

12 O
mg O
/ O
dl O
, O
6 O
. O

2 O
versus O
10 O
. O

6 O
micromol O
/ O
l O
, O
p O
= O
0 O
. O

3 O
; O
patients O
with O
diabetes B-Disease
: O
0 O
. O

7 O
versus O
0 O
. O

16 O
mg O
/ O
dl O
, O
6 O
. O

2 O
versus O
14 O
. O

1 O
micromol O
/ O
l O
, O
p O
= O
0 O
. O

1 O
) O
. O

conclusions O
: O
the O
rate O
of O
contrast O
- O
induced O
nephropathy B-Disease
, O
defined O
by O
multiple O
end O
points O
, O
is O
not O
statistically O
different O
after O
the O
intraarterial O
administration O
of O
iopamidol O
or O
iodixanol O
to O
high O
- O
risk O
patients O
, O
with O
or O
without O
diabetes B-Disease
mellitus I-Disease
. O

a O
novel O
compound O
, O
maltolyl O
p O
- O
coumarate O
, O
attenuates O
cognitive B-Disease
deficits I-Disease
and O
shows O
neuroprotective O
effects O
in O
vitro O
and O
in O
vivo O
dementia B-Disease
models O
. O

in O
the O
present O
study O
, O
we O
investigated O
whether O
maltolyl O
p O
- O
coumarate O
could O
improve O
cognitive B-Disease
decline I-Disease
in O
scopolamine O
- O
injected O
rats O
and O
in O
amyloid O
beta O
peptide O
( O
1 O
- O
42 O
) O
- O
infused O
rats O
. O

maltolyl O
p O
- O
coumarate O
was O
found O
to O
attenuate O
cognitive B-Disease
deficits I-Disease
in O
both O
rat O
models O
using O
passive O
avoidance O
test O
and O
to O
reduce O
apoptotic O
cell O
death O
observed O
in O
the O
hippocampus O
of O
the O
amyloid O
beta O
peptide O
( O
1 O
- O
42 O
) O
- O
infused O
rats O
. O

taking O
these O
in O
vitro O
and O
in O
vivo O
results O
together O
, O
our O
study O
suggests O
that O
maltolyl O
p O
- O
coumarate O
is O
a O
potentially O
effective O
candidate O
against O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
that O
is O
characterized O
by O
wide O
spread O
neuronal B-Disease
death I-Disease
and O
progressive O
decline B-Disease
of I-Disease
cognitive I-Disease
function I-Disease
. O

attenuation O
of O
methamphetamine O
- O
induced O
nigrostriatal O
dopaminergic O
neurotoxicity B-Disease
in O
mice O
by O
lipopolysaccharide O
pretreatment O
. O

immunological O
activation O
has O
been O
proposed O
to O
play O
a O
role O
in O
methamphetamine O
- O
induced O
dopaminergic B-Disease
terminal I-Disease
damage I-Disease
. O

in O
this O
study O
, O
we O
examined O
the O
roles O
of O
lipopolysaccharide O
, O
a O
pro O
- O
inflammatory O
and O
inflammatory O
factor O
, O
treatment O
in O
modulating O
the O
methamphetamine O
- O
induced O
nigrostriatal O
dopamine O
neurotoxicity B-Disease
. O

lipopolysaccharide O
pretreatment O
did O
not O
affect O
the O
basal O
body O
temperature O
or O
methamphetamine O
- O
elicited O
hyperthermia B-Disease
three O
days O
later O
. O

we O
concluded O
a O
critical O
time O
window O
for O
systemic O
lipopolysaccharide O
pretreatment O
in O
exerting O
effective O
protection O
against O
methamphetamine O
- O
induced O
nigrostriatal O
dopamine O
neurotoxicity B-Disease
. O

acute O
myocarditis B-Disease
associated O
with O
clozapine O
. O

objective O
: O
a O
case O
of O
acute O
myocarditis B-Disease
associated O
with O
the O
commencement O
of O
clozapine O
is O
described O
, O
highlighting O
the O
onset O
, O
course O
and O
possible O
contributing O
factors O
. O

results O
: O
a O
20 O
- O
year O
- O
old O
male O
with O
schizophrenia B-Disease
developed O
a O
sudden O
onset O
of O
myocarditis B-Disease
after O
commencement O
of O
clozapine O
. O

conclusions O
: O
myocarditis B-Disease
is O
an O
increasingly O
recognized O
complication O
associated O
with O
the O
use O
of O
clozapine O
. O

considering O
that O
clozapine O
remains O
the O
gold O
standard O
in O
treatment O
of O
resistant O
psychosis B-Disease
, O
there O
is O
an O
urgent O
need O
to O
raise O
awareness O
among O
medical O
and O
paramedical O
staff O
involved O
in O
the O
care O
of O
these O
patients O
. O

severe O
rhabdomyolysis B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
secondary O
to O
concomitant O
use O
of O
simvastatin O
, O
amiodarone O
, O
and O
atazanavir O
. O

objective O
: O
to O
report O
a O
case O
of O
a O
severe O
interaction O
between O
simvastatin O
, O
amiodarone O
, O
and O
atazanavir O
resulting O
in O
rhabdomyolysis B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
. O

background O
: O
a O
72 O
- O
year O
- O
old O
white O
man O
with O
underlying O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
, O
atrial B-Disease
fibrillation I-Disease
, O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
and O
hyperlipidemia B-Disease
presented O
with O
generalized O
pain B-Disease
, O
fatigue B-Disease
, O
and O
dark O
orange O
urine O
for O
3 O
days O
. O

simvastatin O
, O
amiodarone O
, O
and O
the O
patient O
' O
s O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
medications O
were O
all O
temporarily O
discontinued O
and O
the O
patient O
was O
given O
forced O
alkaline O
diuresis O
and O
started O
on O
dialysis O
. O

discussion O
: O
the O
risk O
of O
rhabdomyolysis B-Disease
is O
increased O
in O
the O
presence O
of O
concomitant O
drugs O
that O
inhibit O
simvastatin O
metabolism O
. O

we O
report O
3 O
cases O
of O
serious O
bleeding B-Disease
complications O
that O
appear O
to O
be O
the O
result O
of O
the O
interaction O
between O
warfarin O
and O
levofloxacin O
. O

mutations O
associated O
with O
lamivudine O
- O
resistance O
in O
therapy O
- O
na O
ve O
hepatitis B-Disease
b I-Disease
virus I-Disease
( I-Disease
hbv I-Disease
) I-Disease
infected I-Disease
patients O
with O
and O
without O
hiv B-Disease
co I-Disease
- I-Disease
infection I-Disease
: O
implications O
for O
antiretroviral O
therapy O
in O
hbv B-Disease
and I-Disease
hiv I-Disease
co I-Disease
- I-Disease
infected I-Disease
south O
african O
patients O
. O

this O
was O
an O
exploratory O
study O
to O
investigate O
lamivudine O
- O
resistant O
hepatitis B-Disease
b I-Disease
virus O
( O
hbv O
) O
strains O
in O
selected O
lamivudine O
- O
na O
ve O
hbv O
carriers O
with O
and O
without O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
( I-Disease
hiv I-Disease
) I-Disease
co I-Disease
- I-Disease
infection I-Disease
in O
south O
african O
patients O
. O

thirty O
- O
five O
lamivudine O
- O
na O
ve O
hbv B-Disease
infected I-Disease
patients O
with O
or O
without O
hiv B-Disease
co I-Disease
- I-Disease
infection I-Disease
were O
studied O
: O
15 O
chronic O
hbv B-Disease
mono I-Disease
- I-Disease
infected I-Disease
patients O
and O
20 O
hbv B-Disease
- I-Disease
hiv I-Disease
co I-Disease
- I-Disease
infected I-Disease
patients O
. O

hbv O
lamivudine O
- O
resistant O
strains O
were O
detected O
in O
3 O
of O
15 O
mono O
- O
infected O
chronic O
hepatitis B-Disease
b I-Disease
patients O
and O
10 O
of O
20 O
hbv B-Disease
- I-Disease
hiv I-Disease
co I-Disease
- I-Disease
infected I-Disease
patients O
. O

to O
the O
best O
of O
our O
knowledge O
, O
this O
constitutes O
the O
first O
report O
of O
hbv O
lamivudine O
- O
resistant O
strains O
in O
therapy O
- O
na O
ve O
hbv B-Disease
- I-Disease
hiv I-Disease
co I-Disease
- I-Disease
infected I-Disease
patients O
. O

it O
remains O
to O
be O
seen O
whether O
such O
pre O
- O
existing O
antiviral O
mutations O
could O
result O
in O
widespread O
emergence O
of O
hbv O
resistant O
strains O
when O
lamivudine O
- O
containing O
highly O
active O
antiretroviral O
( O
arv O
) O
treatment O
( O
haart O
) O
regimens O
become O
widely O
applied O
in O
south O
africa O
, O
as O
this O
is O
likely O
to O
have O
potential O
implications O
in O
the O
management O
of O
hbv B-Disease
- I-Disease
hiv I-Disease
co I-Disease
- I-Disease
infected I-Disease
patients O
. O

rabbit B-Disease
syndrome I-Disease
, O
antidepressant O
use O
, O
and O
cerebral O
perfusion O
spect O
scan O
findings O
. O

the O
rabbit B-Disease
syndrome I-Disease
is O
an O
extrapyramidal O
side O
effect O
associated O
with O
chronic O
neuroleptic O
therapy O
. O

repeated O
cerebral O
perfusion O
spect O
scans O
revealed O
decreased B-Disease
basal I-Disease
ganglia I-Disease
perfusion I-Disease
while O
the O
movement B-Disease
disorder I-Disease
was O
present O
, O
and O
a O
return O
to O
normal O
perfusion O
when O
the O
rabbit B-Disease
syndrome I-Disease
resolved O
. O

many O
patients O
, O
however O
, O
develop O
negative O
long O
- O
term O
side O
effects O
such O
as O
premature B-Disease
atherosclerosis I-Disease
. O

we O
have O
previously O
demonstrated O
that O
ritonavir O
treatment O
increases O
atherosclerotic B-Disease
lesion I-Disease
formation O
in O
male O
mice O
to O
a O
greater O
extent O
than O
in O
female O
mice O
. O

acute O
hepatitis B-Disease
attack O
after O
exposure O
to O
telithromycin O
. O

introduction O
: O
antibiotic O
- O
associated O
hepatotoxicity B-Disease
is O
rare O
. O

with O
widespread O
use O
of O
antimicrobial O
agents O
, O
however O
, O
hepatic B-Disease
injury I-Disease
occurs O
frequently O
, O
and O
among O
adverse B-Disease
drug I-Disease
reactions I-Disease
, O
idiosyncratic O
reactions O
are O
the O
most O
serious O
. O

case O
summary O
: O
a O
25 O
- O
year O
- O
old O
male O
patient O
, O
with O
a O
height O
of O
175 O
cm O
and O
weight O
of O
72 O
kg O
presented O
to O
marmara O
university O
hospital O
emergency O
department O
, O
istanbul O
, O
turkey O
, O
with O
5 O
days O
' O
history O
of O
jaundice B-Disease
, O
malaise O
, O
nausea B-Disease
, O
and O
vomiting B-Disease
. O

he O
had O
been O
prescribed O
telithromycin O
400 O
mg O
/ O
d O
po O
to O
treat O
an O
upper B-Disease
respiratory I-Disease
tract I-Disease
infection I-Disease
7 O
days O
prior O
. O

the O
patient O
had O
suffered O
a O
previous O
episode O
of O
nan O
acute O
hepatitis B-Disease
of O
unknown O
origin O
, O
nan O
that O
occurred O
after O
telithromycin O
usage O
. O

it O
has O
been O
associated O
with O
infrequent O
and O
usually O
reversible O
severe O
hepatic B-Disease
dysfunction I-Disease
. O

based O
on O
a O
score O
of O
8 O
on O
the O
naranjo O
adverse B-Disease
drug I-Disease
reaction I-Disease
probability O
scale O
, O
telithromycin O
was O
the O
probable O
cause O
of O
acute O
hepatitis B-Disease
in O
this O
patient O
, O
and O
pathological O
findings O
suggested O
drug O
- O
induced O
toxic B-Disease
hepatitis I-Disease
. O

recurrence O
of O
hepatitis B-Disease
attack O
might O
have O
been O
avoided O
if O
the O
initial O
incident O
had O
been O
communicated O
to O
the O
attending O
physician O
who O
prescribed O
telithromycin O
the O
second O
time O
. O

conclusion O
: O
here O
we O
report O
a O
case O
of O
acute O
hepatitis B-Disease
probably O
associated O
with O
the O
administration O
of O
telithromycin O
. O

a O
study O
on O
the O
effect O
of O
the O
duration O
of O
subcutaneous O
heparin O
injection O
on O
bruising B-Disease
and O
pain B-Disease
. O

aim O
: O
this O
study O
was O
carried O
out O
to O
determine O
the O
effect O
of O
injection O
duration O
on O
bruising B-Disease
and O
pain B-Disease
following O
the O
administration O
of O
the O
subcutaneous O
injection O
of O
heparin O
. O

background O
: O
although O
different O
methods O
to O
prevent O
bruising B-Disease
and O
pain B-Disease
following O
the O
subcutaneous O
injection O
of O
heparin O
have O
been O
widely O
studied O
and O
described O
, O
the O
effect O
of O
injection O
duration O
on O
the O
occurrence O
of O
bruising B-Disease
and O
pain B-Disease
is O
little O
documented O
. O

injections O
areas O
were O
assessed O
for O
the O
presence O
of O
bruising B-Disease
at O
48 O
and O
72 O
hours O
after O
each O
injection O
. O

dimensions O
of O
the O
bruising B-Disease
on O
the O
heparin O
applied O
areas O
were O
measured O
using O
transparent O
millimetric O
measuring O
paper O
. O

the O
visual O
analog O
scale O
( O
vas O
) O
was O
used O
to O
measure O
pain B-Disease
intensity O
and O
a O
stop O
- O
watch O
was O
used O
to O
time O
the O
pain B-Disease
period O
. O

results O
: O
the O
percentage O
of O
bruising B-Disease
occurrence O
was O
64 O
% O
with O
the O
injection O
of O
10 O
seconds O
duration O
and O
42 O
% O
in O
the O
30 O
- O
second O
injection O
. O

it O
was O
determined O
that O
the O
size O
of O
the O
bruising B-Disease
was O
smaller O
in O
the O
30 O
- O
second O
injection O
. O

pain B-Disease
intensity O
and O
pain B-Disease
period O
were O
statistically O
significantly O
lower O
for O
the O
30 O
- O
second O
injection O
than O
for O
the O
10 O
- O
second O
injection O
. O

conclusions O
: O
it O
was O
determined O
that O
injection O
duration O
had O
an O
effect O
on O
bruising B-Disease
and O
pain B-Disease
following O
the O
subcutaneous O
administration O
of O
heparin O
. O

acute B-Disease
liver I-Disease
failure I-Disease
in O
two O
patients O
with O
regular O
alcohol O
consumption O
ingesting O
paracetamol O
at O
therapeutic O
dosage O
. O

background O
: O
the O
possible O
role O
of O
alcohol O
in O
the O
development O
of O
hepatotoxicity B-Disease
associated O
with O
therapeutic O
doses O
of O
paracetamol O
( O
acetaminophen O
) O
is O
currently O
debated O
. O

case O
report O
: O
we O
describe O
2 O
patients O
who O
were O
regular O
consumers O
of O
alcohol O
and O
who O
developed O
liver B-Disease
failure I-Disease
within O
3 O
- O
5 O
days O
after O
hospitalization O
and O
stopping O
alcohol O
consumption O
while O
being O
treated O
with O
4 O
g O
paracetamol O
/ O
day O
. O

possible O
risk O
factors O
for O
the O
development O
of O
hepatotoxicity B-Disease
in O
patients O
treated O
with O
therapeutic O
doses O
of O
paracetamol O
are O
discussed O
. O

conclusion O
: O
in O
patients O
with O
risk O
factors O
, O
e O
. O

g O
. O

regular O
consumption O
of O
alcohol O
, O
liver B-Disease
failure I-Disease
is O
possible O
when O
therapeutic O
doses O
are O
ingested O
. O

long O
- O
term O
use O
of O
these O
drugs O
was O
associated O
with O
female O
sex O
and O
use O
of O
a O
higher O
number O
of O
drugs O
with O
effects O
on O
the O
cns O
, O
which O
tended O
to O
be O
related O
to O
diagnosed O
dementia B-Disease
. O

however O
, O
use O
of O
bzds O
/ O
rds O
was O
associated O
with O
dizziness B-Disease
, O
inability B-Disease
to I-Disease
sleep I-Disease
after O
awaking O
at O
night O
and O
tiredness B-Disease
in O
the O
mornings O
during O
the O
week O
prior O
to O
admission O
and O
with O
stronger O
depressive B-Disease
symptoms I-Disease
measured O
at O
the O
beginning O
of O
the O
hospital O
stay O
. O

acute O
vocal B-Disease
fold I-Disease
palsy I-Disease
after O
acute O
disulfiram O
intoxication O
. O

acute O
peripheral B-Disease
neuropathy I-Disease
caused O
by O
a O
disulfiram O
overdose B-Disease
is O
very O
rare O
and O
there O
is O
no O
report O
of O
it O
leading O
to O
vocal B-Disease
fold I-Disease
palsy I-Disease
. O

a O
49 O
- O
year O
- O
old O
woman O
was O
transferred O
to O
our O
department O
because O
of O
quadriparesis B-Disease
, O
lancinating O
pain B-Disease
, O
sensory B-Disease
loss I-Disease
, O
and O
paresthesia B-Disease
of O
the O
distal O
limbs O
. O

for O
the O
first O
few O
days O
after O
ingestion O
, O
she O
was O
in O
a O
confused O
state O
and O
had O
mild O
to O
moderate O
ataxia B-Disease
and O
giddiness B-Disease
. O

she O
noticed O
hoarseness B-Disease
and O
distally O
accentuated O
motor O
and O
sensory O
dysfunction O
after O
she O
had O
recovered O
from O
this O
state O
. O

a O
nerve O
conduction O
study O
was O
consistent O
with O
severe O
sensorimotor O
axonal O
polyneuropathy B-Disease
. O

this O
was O
a O
case O
of O
acute O
palsy B-Disease
of O
the O
recurrent O
laryngeal O
nerve O
and O
superimposed O
severe O
acute O
sensorimotor O
axonal O
polyneuropathy B-Disease
caused O
by O
high O
- O
dose O
disulfiram O
intoxication O
. O

encephalopathy B-Disease
induced O
by O
levetiracetam O
added O
to O
valproate O
. O

background O
: O
we O
report O
on O
the O
manifestation O
of O
a O
levetiracetam O
( O
lev O
) O
- O
induced O
encephalopathy B-Disease
. O

findings O
: O
a O
28 O
- O
year O
- O
old O
man O
suffering O
from O
idiopathic B-Disease
epilepsy I-Disease
with O
generalized O
seizures B-Disease
was O
treated O
with O
lev O
( O
3000 O
mg O
) O
added O
to O
valproate O
( O
vpa O
) O
( O
2000 O
mg O
) O
. O

frequency O
of O
generalized O
tonic B-Disease
- I-Disease
clonic I-Disease
seizures I-Disease
increased O
from O
one O
per O
6 O
months O
to O
two O
per O
month O
. O

neuropsychological O
testing O
showed O
impaired B-Disease
word I-Disease
fluency I-Disease
, I-Disease
psychomotor I-Disease
speed I-Disease
and I-Disease
working I-Disease
memory I-Disease
. O

outcome O
: O
following O
discontinuation O
of O
lev O
, O
eeg O
and O
neuropsychological O
findings O
improved O
and O
seizure B-Disease
frequency O
decreased O
. O

norepinephrine O
signaling O
through O
beta O
- O
adrenergic O
receptors O
is O
critical O
for O
expression O
of O
cocaine O
- O
induced O
anxiety B-Disease
. O

while O
the O
mechanisms O
underlying O
cocaine O
' O
s O
rewarding O
effects O
have O
been O
studied O
extensively O
, O
less O
attention O
has O
been O
paid O
to O
the O
unpleasant O
behavioral O
states O
induced O
by O
cocaine O
, O
such O
as O
anxiety B-Disease
. O

methods O
: O
in O
this O
study O
, O
we O
evaluated O
the O
performance O
of O
dopamine O
beta O
- O
hydroxylase O
knockout O
( O
dbh O
- O
/ O
- O
) O
mice O
, O
which O
lack O
norepinephrine O
( O
ne O
) O
, O
in O
the O
elevated O
plus O
maze O
( O
epm O
) O
to O
examine O
the O
contribution O
of O
noradrenergic O
signaling O
to O
cocaine O
- O
induced O
anxiety B-Disease
. O

results O
: O
we O
found O
that O
cocaine O
dose O
- O
dependently O
increased O
anxiety B-Disease
- O
like O
behavior O
in O
control O
( O
dbh O
+ O
/ O
- O
) O
mice O
, O
as O
measured O
by O
a O
decrease O
in O
open O
arm O
exploration O
. O

cocaine O
- O
induced O
anxiety B-Disease
was O
also O
attenuated O
in O
dbh O
+ O
/ O
- O
mice O
following O
administration O
of O
disulfiram O
, O
a O
dopamine O
beta O
- O
hydroxylase O
( O
dbh O
) O
inhibitor O
. O

in O
experiments O
using O
specific O
adrenergic O
antagonists O
, O
we O
found O
that O
pretreatment O
with O
the O
beta O
- O
adrenergic O
receptor O
antagonist O
propranolol O
blocked O
cocaine O
- O
induced O
anxiety B-Disease
- O
like O
behavior O
in O
dbh O
+ O
/ O
- O
and O
wild O
- O
type O
c57bl6 O
/ O
j O
mice O
, O
while O
the O
alpha O
( O
1 O
) O
antagonist O
prazosin O
and O
the O
alpha O
( O
2 O
) O
antagonist O
yohimbine O
had O
no O
effect O
. O

conclusions O
: O
these O
results O
indicate O
that O
noradrenergic O
signaling O
via O
beta O
- O
adrenergic O
receptors O
is O
required O
for O
cocaine O
- O
induced O
anxiety B-Disease
in O
mice O
. O

hypothalamic O
prolactin O
receptor O
messenger O
ribonucleic O
acid O
levels O
, O
prolactin O
signaling O
, O
and O
hyperprolactinemic B-Disease
inhibition O
of O
pulsatile O
luteinizing O
hormone O
secretion O
are O
dependent O
on O
estradiol O
. O

hyperprolactinemia B-Disease
can O
reduce O
fertility O
and O
libido O
. O

we O
first O
tested O
whether O
chronic O
hyperprolactinemia B-Disease
inhibited O
two O
neuroendocrine O
parameters O
necessary O
for O
female O
fertility O
: O
pulsatile O
lh O
secretion O
and O
the O
estrogen O
- O
induced O
lh O
surge O
. O

chronic O
hyperprolactinemia B-Disease
induced O
by O
the O
dopamine O
antagonist O
sulpiride O
caused O
a O
40 O
% O
reduction O
lh O
pulse O
frequency O
in O
ovariectomized O
rats O
, O
but O
only O
in O
the O
presence O
of O
chronic O
low O
levels O
of O
estradiol O
. O

these O
data O
show O
that O
gnrh O
pulse O
frequency O
is O
inhibited O
by O
chronic O
hyperprolactinemia B-Disease
in O
a O
steroid O
- O
dependent O
manner O
. O

clonidine O
for O
attention B-Disease
- I-Disease
deficit I-Disease
/ I-Disease
hyperactivity I-Disease
disorder I-Disease
: O
ii O
. O

objective O
: O
to O
examine O
the O
safety O
and O
tolerability O
of O
clonidine O
used O
alone O
or O
with O
methylphenidate O
in O
children O
with O
attention B-Disease
- I-Disease
deficit I-Disease
/ I-Disease
hyperactivity I-Disease
disorder I-Disease
( O
adhd B-Disease
) O
. O

method O
: O
in O
a O
16 O
- O
week O
multicenter O
, O
double O
- O
blind O
trial O
, O
122 O
children O
with O
adhd B-Disease
were O
randomly O
assigned O
to O
clonidine O
( O
n O
= O
31 O
) O
, O
methylphenidate O
( O
n O
= O
29 O
) O
, O
clonidine O
and O
methylphenidate O
( O
n O
= O
32 O
) O
, O
or O
placebo O
( O
n O
= O
30 O
) O
. O

results O
: O
there O
were O
more O
incidents O
of O
bradycardia B-Disease
in O
subjects O
treated O
with O
clonidine O
compared O
with O
those O
not O
treated O
with O
clonidine O
( O
17 O
. O

5 O
% O
versus O
3 O
. O

4 O
% O
; O
p O
= O
. O

2 O
) O
, O
but O
no O
other O
significant O
group O
differences O
regarding O
electrocardiogram O
and O
other O
cardiovascular O
outcomes O
. O

drowsiness B-Disease
was O
common O
on O
clonidine O
, O
but O
generally O
resolved O
by O
6 O
to O
8 O
weeks O
. O

conclusions O
: O
clonidine O
, O
used O
alone O
or O
with O
methylphenidate O
, O
appears O
safe O
and O
well O
tolerated O
in O
childhood O
adhd B-Disease
. O

physicians O
prescribing O
clonidine O
should O
monitor O
for O
bradycardia B-Disease
and O
advise O
patients O
about O
the O
high O
likelihood O
of O
initial O
drowsiness B-Disease
. O

renal B-Disease
fanconi I-Disease
syndrome I-Disease
and O
myopathy B-Disease
after O
liver O
transB-Plantation O
: O
drug O
- O
related O
mitochondrial B-Disease
cytopathy I-Disease
? O
we O
describe O
a O
15 O
- O
yr O
- O
old O
girl O
who O
had O
orthotopic O
liver O
transB-Plantation O
because O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

lamivudine O
was O
added O
because O
of O
de O
nova O
hepatitis B-Disease
b I-Disease
infection I-Disease
during O
her O
follow O
- O
up O
. O

three O
yr O
after O
transB-Plantation O
she O
developed O
renal B-Disease
fanconi I-Disease
syndrome I-Disease
with O
severe O
metabolic B-Disease
acidosis I-Disease
, O
hypophosphatemia B-Disease
, O
glycosuria B-Disease
, O
and O
aminoaciduria B-Disease
. O

although O
tacrolimus O
was O
suspected O
to O
be O
the O
cause O
of O
late O
post O
- O
transB-Plant O
renal O
acidosis B-Disease
and O
was O
replaced O
by O
sirolimus O
, O
acidosis B-Disease
, O
and O
electrolyte O
imbalance O
got O
worse O
. O

proximal O
muscle B-Disease
weakness I-Disease
has O
developed O
during O
her O
follow O
- O
up O
. O

fanconi B-Disease
syndrome I-Disease
, O
as O
well O
as O
myopathy B-Disease
, O
is O
well O
recognized O
in O
patients O
with O
mitochondrial B-Disease
disorders I-Disease
and O
caused O
by O
depletion O
of O
mtdna O
. O

we O
suggest O
that O
our O
patient O
' O
s O
tubular B-Disease
dysfunction I-Disease
and O
myopathy B-Disease
may O
have O
resulted O
from O
mitochondrial B-Disease
dysfunction I-Disease
which O
is O
triggered O
by O
tacrolimus O
and O
augmented O
by O
lamivudine O
. O

higher O
optical O
density O
of O
an O
antigen O
assay O
predicts O
thrombosis B-Disease
in O
patients O
with O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

objectives O
: O
to O
correlate O
optical O
density O
and O
percent O
inhibition O
of O
a O
two O
- O
step O
heparin O
- O
induced O
thrombocytopenia B-Disease
( O
hit B-Disease
) O
antigen O
assay O
with O
thrombosis B-Disease
; O
the O
assay O
utilizes O
reaction O
inhibition O
characteristics O
of O
a O
high O
heparin O
concentration O
. O

patients O
and O
methods O
: O
patients O
with O
more O
than O
50 O
% O
decrease O
in O
platelet O
count O
or O
thrombocytopenia B-Disease
( O
< O
150 O
x O
10 O
( O
9 O
) O
/ O
l O
) O
after O
exposure O
to O
heparin O
, O
who O
had O
a O
positive O
two O
- O
step O
antigen O
assay O
[ O
optical O
density O
( O
od O
) O
> O
0 O
. O

4 O
and O
> O
50 O
inhibition O
with O
high O
concentration O
of O
heparin O
] O
were O
included O
in O
the O
study O
. O

results O
: O
forty O
of O
94 O
hit B-Disease
patients O
had O
thrombosis B-Disease
at O
diagnosis O
; O
54 O
/ O
94 O
had O
isolated O
- O
hit B-Disease
without O
thrombosis B-Disease
. O

eight O
of O
the O
isolated O
- O
hit B-Disease
patients O
developed O
thrombosis B-Disease
within O
the O
next O
30 O
d O
; O
thus O
, O
a O
total O
of O
48 O
patients O
had O
thrombosis B-Disease
at O
day O
30 O
. O

at O
diagnosis O
there O
was O
no O
significant O
difference O
in O
od O
between O
hit B-Disease
patients O
with O
thrombosis B-Disease
and O
those O
with O
isolated O
- O
hit B-Disease
. O

however O
, O
od O
was O
significantly O
higher O
in O
all O
patients O
with O
thrombosis B-Disease
( O
n O
= O
48 O
, O
1 O
. O

34 O
+ O
/ O
- O
0 O
. O

89 O
) O
, O
including O
isolated O
- O
hit B-Disease
patients O
who O
later O
developed O
thrombosis B-Disease
within O
30 O
d O
( O
n O
= O
8 O
, O
1 O
. O

84 O
+ O
/ O
- O
0 O
. O

64 O
) O
as O
compared O
to O
isolated O
- O
hit B-Disease
patients O
who O
did O
not O
develop O
thrombosis B-Disease
( O
0 O
. O

96 O
+ O
/ O
- O
0 O
. O

75 O
; O
p O
= O
0 O
. O

11 O
and O
p O
= O
0 O
. O

8 O
) O
. O

the O
receiver O
operative O
characteristic O
curve O
showed O
that O
od O
> O
1 O
. O

27 O
in O
the O
isolated O
- O
hit B-Disease
group O
had O
a O
significantly O
higher O
chance O
of O
developing O
thrombosis B-Disease
by O
day O
30 O
. O

multivariate O
analysis O
showed O
a O
2 O
. O

8 O
- O
fold O
increased O
risk O
of O
thrombosis B-Disease
in O
females O
. O

similarly O
, O
thrombotic B-Disease
risk O
increased O
with O
age O
and O
od O
values O
. O

conclusion O
: O
higher O
od O
is O
associated O
with O
significant O
risk O
of O
subsequent O
thrombosis B-Disease
in O
patients O
with O
isolated O
- O
hit B-Disease
; O
percent O
inhibition O
, O
however O
, O
was O
not O
predictive O
. O

thalidomide O
has O
limited O
single O
- O
agent O
activity O
in O
relapsed O
or O
refractory O
indolent O
non B-Disease
- I-Disease
hodgkin I-Disease
lymphomas I-Disease
: O
a O
phase O
ii O
trial O
of O
the O
cancer B-Disease
and O
leukemia B-Disease
group O
b O
. O

thalidomide O
is O
an O
immunomodulatory O
agent O
with O
demonstrated O
activity O
in O
multiple B-Disease
myeloma I-Disease
, O
mantle B-Disease
cell I-Disease
lymphoma I-Disease
and O
lymphoplasmacytic B-Disease
lymphoma I-Disease
. O

its O
activity O
is O
believed O
to O
be O
due O
modulation O
of O
the O
tumour B-Disease
milieu O
, O
including O
downregulation O
of O
angiogenesis O
and O
inflammatory O
cytokines O
. O

between O
july O
2001 O
and O
april O
2004 O
, O
24 O
patients O
with O
relapsed O
/ O
refractory O
indolent O
lymphomas B-Disease
received O
thalidomide O
200 O
mg O
daily O
with O
escalation O
by O
100 O
mg O
daily O
every O
1 O
- O
2 O
weeks O
as O
tolerated O
, O
up O
to O
a O
maximum O
of O
800 O
mg O
daily O
. O

grade O
3 O
- O
4 O
adverse O
effects O
included O
myelosuppression B-Disease
, O
fatigue B-Disease
, O
somnolence B-Disease
/ O
depressed B-Disease
mood I-Disease
, O
neuropathy B-Disease
and O
dyspnea B-Disease
. O

of O
concern O
was O
the O
occurrence O
of O
four O
thromboembolic B-Disease
events O
. O

our O
results O
failed O
to O
demonstrate O
an O
important O
response O
rate O
to O
single O
agent O
thalidomide O
in O
indolent O
lymphomas B-Disease
and O
contrast O
with O
the O
higher O
activity O
level O
reported O
with O
the O
second O
generation O
immunomodulatory O
agent O
, O
lenalidomide O
. O

sex O
differences O
in O
nmda O
antagonist O
enhancement O
of O
morphine O
antihyperalgesia O
in O
a O
capsaicin O
model O
of O
persistent O
pain B-Disease
: O
comparisons O
to O
two O
models O
of O
acute B-Disease
pain I-Disease
. O

in O
acute B-Disease
pain I-Disease
models O
, O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
antagonists O
enhance O
the O
antinociceptive O
effects O
of O
morphine O
to O
a O
greater O
extent O
in O
males O
than O
females O
. O

the O
purpose O
of O
this O
investigation O
was O
to O
extend O
these O
findings O
to O
a O
persistent O
pain B-Disease
model O
which O
could O
be O
distinguished O
from O
acute B-Disease
pain I-Disease
models O
on O
the O
basis O
of O
the O
nociceptive O
fibers O
activated O
, O
neurochemical O
substrates O
, O
and O
duration O
of O
the O
nociceptive O
stimulus O
. O

to O
this O
end O
, O
persistent O
hyperalgesia B-Disease
was O
induced O
by O
administration O
of O
capsaicin O
in O
the O
tail O
of O
gonadally O
intact O
f344 O
rats O
, O
following O
which O
the O
tail O
was O
immersed O
in O
a O
mildly O
noxious O
thermal O
stimulus O
, O
and O
tail O
- O
withdrawal O
latencies O
measured O
. O

for O
comparison O
, O
tests O
were O
conducted O
in O
two O
acute B-Disease
pain I-Disease
models O
, O
the O
hotplate O
and O
warm O
water O
tail O
- O
withdrawal O
procedures O
. O

enhancement O
of O
morphine O
antinociception O
by O
dextromethorphan O
was O
seen O
in O
both O
males O
and O
females O
in O
the O
acute B-Disease
pain I-Disease
models O
, O
with O
the O
magnitude O
of O
this O
effect O
being O
greater O
in O
males O
. O

these O
findings O
demonstrate O
a O
sexually O
- O
dimorphic O
interaction O
between O
nmda O
antagonists O
and O
morphine O
in O
a O
persistent O
pain B-Disease
model O
that O
can O
be O
distinguished O
from O
those O
observed O
in O
acute B-Disease
pain I-Disease
models O
. O

development O
of O
proteinuria B-Disease
after O
switch O
to O
sirolimus O
- O
based O
immunosuppression O
in O
long O
- O
term O
cardiac O
transB-Plant O
patients O
. O

calcineurin O
- O
inhibitor O
therapy O
can O
lead O
to O
renal B-Disease
dysfunction I-Disease
in O
heart O
transB-Plantation O
patients O
. O

the O
novel O
immunosuppressive O
( O
is O
) O
drug O
sirolmus O
( O
srl O
) O
lacks O
nephrotoxic B-Disease
effects O
; O
however O
, O
proteinuria B-Disease
associated O
with O
srl O
has O
been O
reported O
following O
renal O
transB-Plantation O
. O

in O
cardiac O
transB-Plantation O
, O
the O
incidence O
of O
proteinuria B-Disease
associated O
with O
srl O
is O
unknown O
. O

before O
the O
switch O
, O
11 O
. O

5 O
% O
of O
patients O
had O
high O
- O
grade O
proteinuria B-Disease
( O
> O
1 O
. O

0 O
g O
/ O
day O
) O
; O
this O
increased O
to O
22 O
. O

9 O
% O
postswitch O
( O
p O
= O
0 O
. O

6 O
) O
. O

ace O
inhibitor O
and O
angiotensin O
- O
releasing O
blocker O
( O
arb O
) O
therapy O
reduced O
proteinuria B-Disease
development O
. O

patients O
without O
proteinuria B-Disease
had O
increased O
renal O
function O
( O
median O
42 O
. O

5 O
vs O
. O

64 O
. O

1 O
, O
p O
= O
0 O
. O

25 O
) O
, O
whereas O
patients O
who O
developed O
high O
- O
grade O
proteinuria B-Disease
showed O
decreased O
renal O
function O
at O
the O
end O
of O
follow O
- O
up O
( O
median O
39 O
. O

6 O
vs O
. O

29 O
. O

2 O
, O
p O
= O
0 O
. O

125 O
) O
. O

thus O
, O
proteinuria B-Disease
may O
develop O
in O
cardiac O
transB-Plant O
patients O
after O
switch O
to O
srl O
, O
which O
may O
have O
an O
adverse O
effect O
on O
renal O
function O
in O
these O
patients O
. O

srl O
should O
be O
used O
with O
acei O
/ O
arb O
therapy O
and O
patients O
monitored O
for O
proteinuria B-Disease
and O
increased O
renal B-Disease
dysfunction I-Disease
. O

ginsenoside O
rg1 O
restores O
the O
impairment B-Disease
of I-Disease
learning I-Disease
induced O
by O
chronic O
morphine O
administration O
in O
rats O
. O

rg1 O
, O
as O
a O
ginsenoside O
extracted O
from O
panax O
ginseng O
, O
could O
ameliorate O
spatial O
learning B-Disease
impairment I-Disease
. O

the O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
rg1 O
on O
learning B-Disease
impairment I-Disease
by O
chronic O
morphine O
administration O
and O
the O
mechanism O
responsible O
for O
this O
effect O
. O

sar O
studies O
led O
to O
compound O
14 O
with O
excellent O
potency O
( O
k O
( O
i O
) O
= O
0 O
. O

4 O
nm O
) O
, O
selectivity O
( O
a O
( O
1 O
) O
/ O
a O
( O
2a O
) O
> O
100 O
) O
, O
and O
efficacy O
( O
med O
10 O
mg O
/ O
kg O
p O
. O

o O
. O

) O
in O
the O
rat O
haloperidol O
- O
induced O
catalepsy B-Disease
model O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

evidence O
for O
an O
involvement O
of O
d1 O
and O
d2 O
dopamine O
receptors O
in O
mediating O
nicotine O
- O
induced O
hyperactivity B-Disease
in O
rats O
. O

nicotine O
( O
1 O
. O

0 O
mg O
/ O
kg O
) O
caused O
a O
significant O
increase B-Disease
in I-Disease
locomotor I-Disease
activity I-Disease
in O
rats O
that O
were O
habituated O
to O
the O
test O
environment O
, O
but O
had O
only O
a O
weak O
and O
delayed O
stimulant O
action O
in O
rats O
that O
were O
unfamiliar O
with O
the O
test O
environment O
. O

nicotine O
- O
induced O
hyperactivity B-Disease
was O
blocked O
by O
the O
selective O
d1 O
antagonist O
sch O
23390 O
, O
the O
selective O
d2 O
antagonist O
raclopride O
and O
the O
d1 O
/ O
d2 O
antagonist O
fluphenazine O
. O

pretreatment O
with O
the O
d2 O
agonist O
phno O
enhanced O
nicotine O
- O
induced O
hyperactivity B-Disease
, O
whereas O
the O
d1 O
agonist O
skf O
38393 O
had O
no O
effect O
. O

the O
results O
indicate O
that O
acute O
nicotine O
injection O
induces O
a O
pronounced O
hyperactivity B-Disease
in O
rats O
habituated O
to O
the O
test O
environment O
. O

central O
retinal B-Disease
vein I-Disease
occlusion I-Disease
associated O
with O
clomiphene O
- O
induced O
ovulation O
. O

objective O
: O
to O
report O
a O
case O
of O
central O
retinal B-Disease
vein I-Disease
occlusion I-Disease
associated O
with O
clomiphene O
citrate O
( O
cc O
) O
. O

patient O
( O
s O
) O
: O
a O
36 O
- O
year O
- O
old O
woman O
referred O
from O
the O
infertility B-Disease
clinic O
for O
blurred B-Disease
vision I-Disease
. O

main O
outcome O
measure O
( O
s O
) O
: O
central O
retinal B-Disease
vein I-Disease
occlusion I-Disease
after O
ovulation O
induction O
with O
cc O
. O

result O
( O
s O
) O
: O
a O
36 O
- O
year O
- O
old O
chinese O
woman O
developed O
central O
retinal B-Disease
vein I-Disease
occlusion I-Disease
after O
eight O
courses O
of O
cc O
. O

a O
search O
of O
the O
literature O
on O
the O
thromboembolic B-Disease
complications O
of O
cc O
does O
not O
include O
this O
severe O
ophthalmic O
complication O
, O
although O
mild O
visual B-Disease
disturbance I-Disease
after O
cc O
intake O
is O
not O
uncommon O
. O

conclusion O
( O
s O
) O
: O
this O
is O
the O
first O
reported O
case O
of O
central O
retinal B-Disease
vein I-Disease
occlusion I-Disease
after O
treatment O
with O
cc O
. O

extra O
caution O
is O
warranted O
in O
treating O
infertility B-Disease
patients O
with O
cc O
, O
and O
patients O
should O
be O
well O
informed O
of O
this O
side O
effect O
before O
commencement O
of O
therapy O
. O

acute O
bronchodilating O
effects O
of O
ipratropium O
bromide O
and O
theophylline O
in O
chronic B-Disease
obstructive I-Disease
pulmonary I-Disease
disease I-Disease
. O

the O
bronchodilator O
effects O
of O
a O
single O
dose O
of O
ipratropium O
bromide O
aerosol O
( O
36 O
micrograms O
) O
and O
short O
- O
acting O
theophylline O
tablets O
( O
dose O
titrated O
to O
produce O
serum O
levels O
of O
10 O
- O
20 O
micrograms O
/ O
ml O
) O
were O
compared O
in O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
crossover O
study O
in O
21 O
patients O
with O
stable O
, O
chronic B-Disease
obstructive I-Disease
pulmonary I-Disease
disease I-Disease
. O

while O
side O
effects O
were O
rare O
, O
those O
experienced O
after O
theophylline O
use O
did O
involve O
the O
cardiovascular B-Disease
and I-Disease
gastrointestinal I-Disease
systems I-Disease
. O

these O
results O
show O
that O
ipratropium O
is O
a O
more O
potent O
bronchodilator O
than O
oral O
theophylline O
in O
patients O
with O
chronic B-Disease
airflow I-Disease
obstruction I-Disease
. O

methamphetamine O
- O
induced O
neurotoxicity B-Disease
and O
microglial O
activation O
are O
not O
mediated O
by O
fractalkine O
receptor O
signaling O
. O

[ O
nat O
. O

neurosci O
. O

9 O
( O
2006 O
) O
, O
917 O
] O
recently O
identified O
the O
microglial O
- O
specific O
fractalkine O
receptor O
( O
cx3cr1 O
) O
as O
an O
important O
mediator O
of O
mptp O
- O
induced O
neurodegeneration B-Disease
of O
da O
neurons O
. O

because O
the O
cns B-Disease
damage I-Disease
caused O
by O
meth O
and O
mptp O
is O
highly O
selective O
for O
the O
da O
neuronal O
system O
in O
mouse O
models O
of O
neurotoxicity B-Disease
, O
we O
hypothesized O
that O
the O
cx3cr1 O
plays O
a O
role O
in O
meth O
- O
induced O
neurotoxicity B-Disease
and O
microglial O
activation O
. O

mice O
in O
which O
the O
cx3cr1 O
gene O
has O
been O
deleted O
and O
replaced O
with O
a O
cdna O
encoding O
enhanced O
green O
fluorescent O
protein O
( O
egfp O
) O
were O
treated O
with O
meth O
and O
examined O
for O
striatal O
neurotoxicity B-Disease
. O

we O
conclude O
from O
these O
studies O
that O
cx3cr1 O
signaling O
does O
not O
modulate O
meth O
neurotoxicity B-Disease
or O
microglial O
activation O
. O

nicotine O
- O
induced O
nystagmus B-Disease
correlates O
with O
midpontine O
activation O
. O

the O
pathomechanism O
of O
nicotine O
- O
induced O
nystagmus B-Disease
( O
nin B-Disease
) O
is O
unknown O
. O

the O
aim O
of O
this O
study O
was O
to O
delineate O
brain O
structures O
that O
are O
involved O
in O
nin B-Disease
generation O
. O

nin B-Disease
correlated O
with O
blood O
oxygen O
level O
- O
dependent O
( O
bold O
) O
activity O
levels O
in O
a O
midpontine O
site O
in O
the O
posterior O
basis O
pontis O
. O

nin B-Disease
- O
induced O
midpontine O
activation O
may O
correspond O
to O
activation O
of O
the O
dorsomedial O
pontine O
nuclei O
and O
the O
nucleus O
reticularis O
tegmenti O
pontis O
, O
structures O
known O
to O
participate O
in O
the O
generation O
of O
multidirectional O
saccades O
and O
smooth O
pursuit O
eye O
movements O
. O

acute O
effects O
of O
n O
- O
( O
2 O
- O
propylpentanoyl O
) O
urea O
on O
hippocampal O
amino O
acid O
neurotransmitters O
in O
pilocarpine O
- O
induced O
seizure B-Disease
in O
rats O
. O

vpu O
was O
more O
potent O
than O
vpa O
, O
exhibiting O
the O
median O
effective O
dose O
( O
ed O
( O
50 O
) O
) O
of O
49 O
mg O
/ O
kg O
in O
protecting O
rats O
against O
pilocarpine O
- O
induced O
seizure B-Disease
whereas O
the O
corresponding O
value O
for O
vpa O
was O
322 O
mg O
/ O
kg O
. O

based O
on O
the O
finding O
that O
vpu O
and O
vpa O
could O
protect O
the O
animals O
against O
pilocarpine O
- O
induced O
seizure B-Disease
it O
is O
suggested O
that O
the O
reduction O
of O
inhibitory O
amino O
acid O
neurotransmitters O
was O
comparatively O
minor O
and O
offset O
by O
a O
pronounced O
reduction O
of O
glutamate O
and O
aspartate O
. O

therefore O
, O
like O
vpa O
, O
the O
finding O
that O
vpu O
could O
drastically O
reduce O
pilocarpine O
- O
induced O
increases O
in O
glutamate O
and O
aspartate O
should O
account O
, O
at O
least O
partly O
, O
for O
its O
anticonvulsant O
activity O
observed O
in O
pilocarpine O
- O
induced O
seizure B-Disease
in O
experimental O
animals O
. O

protective O
effect O
of O
verapamil O
on O
gastric B-Disease
hemorrhagic I-Disease
ulcers B-Disease
in O
severe O
atherosclerotic B-Disease
rats O
. O

studies O
concerning O
with O
pathogenesis O
of O
gastric B-Disease
hemorrhage I-Disease
and O
mucosal O
ulceration O
produced O
in O
atherosclerotic B-Disease
rats O
are O
lacking O
. O

the O
aim O
of O
this O
study O
is O
to O
examine O
the O
role O
of O
gastric O
acid O
back O
- O
diffusion O
, O
mast O
cell O
histamine O
release O
, O
lipid O
peroxide O
( O
lpo O
) O
generation O
and O
mucosal O
microvascular O
permeability O
in O
modulating O
gastric B-Disease
hemorrhage I-Disease
and O
ulcer B-Disease
in O
rats O
with O
atherosclerosis B-Disease
induced O
by O
coadministration O
of O
vitamin O
d2 O
and O
cholesterol O
. O

additionally O
, O
the O
protective O
effect O
of O
verapamil O
on O
this O
ulcer B-Disease
model O
was O
evaluated O
. O

male O
wistar O
rats O
were O
challenged O
intragastrically O
once O
daily O
for O
9 O
days O
with O
1 O
. O

0 O
ml O
/ O
kg O
of O
corn O
oil O
containing O
vitamin O
d2 O
and O
cholesterol O
to O
induce O
atherosclerosis B-Disease
. O

gastric O
acid O
back O
- O
diffusion O
, O
mucosal O
lpo O
generation O
, O
histamine O
concentration O
, O
microvascular O
permeability O
, O
luminal O
hemoglobin O
content O
and O
ulcer B-Disease
areas O
were O
determined O
. O

elevated O
atherosclerotic B-Disease
parameters O
, O
such O
as O
serum O
calcium O
, O
total O
cholesterol O
and O
low O
- O
density O
lipoprotein O
concentration O
were O
obtained O
in O
atherosclerotic B-Disease
rats O
. O

severe O
gastric O
ulcers B-Disease
accompanied O
with O
increased O
ulcerogenic O
factors O
, O
including O
gastric O
acid O
back O
- O
diffusion O
, O
histamine O
release O
, O
lpo O
generation O
and O
luminal O
hemoglobin O
content O
were O
also O
observed O
in O
these O
rats O
. O

moreover O
, O
a O
positive O
correlation O
of O
histamine O
to O
gastric B-Disease
hemorrhage I-Disease
and O
to O
ulcer B-Disease
was O
found O
in O
those O
atherosclerotic B-Disease
rats O
. O

this O
hemorrhagic B-Disease
ulcer B-Disease
and O
various O
ulcerogenic O
parameters O
were O
dose O
- O
dependently O
ameliorated O
by O
daily O
intragastric O
verapamil O
. O

atherosclerosis B-Disease
could O
produce O
gastric B-Disease
hemorrhagic I-Disease
ulcer B-Disease
via O
aggravation O
of O
gastric O
acid O
back O
- O
diffusion O
, O
lpo O
generation O
, O
histamine O
release O
and O
microvascular O
permeability O
that O
could O
be O
ameliorated O
by O
verapamil O
in O
rats O
. O

lamivudine O
for O
the O
prevention O
of O
hepatitis B-Disease
b I-Disease
virus O
reactivation O
in O
hepatitis O
- O
b O
surface O
antigen O
( O
hbsag O
) O
seropositive O
cancer B-Disease
patients O
undergoing O
cytotoxic O
chemotherapy O
. O

hepatitis B-Disease
b I-Disease
virus O
( O
hbv O
) O
is O
one O
of O
the O
major O
causes O
of O
chronic O
liver B-Disease
disease I-Disease
worldwide O
. O

cancer B-Disease
patients O
who O
are O
chronic O
carriers O
of O
hbv O
have O
a O
higher O
hepatic B-Disease
complication I-Disease
rate O
while O
receiving O
cytotoxic O
chemotherapy O
( O
ct O
) O
and O
this O
has O
mainly O
been O
attributed O
to O
hbv O
reactivation O
. O

in O
this O
study O
, O
cancer B-Disease
patients O
who O
have O
solid O
and O
hematological B-Disease
malignancies I-Disease
with O
chronic O
hbv B-Disease
infection I-Disease
received O
the O
antiviral O
agent O
lamivudine O
prior O
and O
during O
ct O
compared O
with O
historical O
control O
group O
who O
did O
not O
receive O
lamivudine O
. O

of O
our O
control O
group O
( O
n O
= O
50 O
) O
, O
21 O
patients O
( O
42 O
% O
) O
were O
established O
hepatitis B-Disease
. O

twelve O
( O
24 O
% O
) O
of O
them O
were O
evaluated O
as O
severe O
hepatitis B-Disease
. O

in O
the O
prophylactic O
lamivudine O
group O
severe O
hepatitis B-Disease
were O
observed O
only O
in O
1 O
patient O
( O
2 O
. O

7 O
% O
) O
of O
37 O
patients O
( O
p O
< O
0 O
. O

6 O
) O
. O

our O
study O
suggests O
that O
prophylactic O
lamivudine O
significantly O
decreases O
the O
incidence O
of O
hbv O
reactivation O
and O
overall O
morbidity O
in O
cancer B-Disease
patients O
during O
and O
after O
immunosuppressive O
therapy O
. O

recovery O
of O
tacrolimus O
- O
associated O
brachial B-Disease
neuritis I-Disease
after O
conversion O
to O
everolimus O
in O
a O
pediatric O
renal O
transB-Plant O
recipient O
- O
- O
case O
report O
and O
review O
of O
the O
literature O
. O

neurotoxicity B-Disease
is O
a O
potentially O
serious O
toxic O
effect O
. O

it O
is O
characterized O
by O
encephalopathy B-Disease
, O
headaches B-Disease
, O
seizures B-Disease
, O
or O
neurological B-Disease
deficits I-Disease
. O

mri O
demonstrated O
hyperintense O
t2 O
signals O
in O
the O
cervical O
cord O
and O
right O
brachial O
plexus O
roots O
indicative O
of O
both O
myelitis B-Disease
and O
right O
brachial B-Disease
plexitis I-Disease
. O

omitting O
fentanyl O
reduces O
nausea B-Disease
and O
vomiting B-Disease
, O
without O
increasing O
pain B-Disease
, O
after O
sevoflurane O
for O
day O
surgery O
. O

background O
and O
objective O
: O
despite O
advantages O
of O
induction O
and O
maintenance O
of O
anaesthesia O
with O
sevoflurane O
, O
postoperative B-Disease
nausea I-Disease
and I-Disease
vomiting I-Disease
occurs O
frequently O
. O

methods O
: O
this O
double O
- O
blind O
study O
examined O
the O
incidence O
and O
severity O
of O
postoperative B-Disease
nausea I-Disease
and I-Disease
vomiting I-Disease
and O
pain B-Disease
in O
the O
first O
24 O
h O
after O
sevoflurane O
anaesthesia O
in O
216 O
adult O
day O
surgery O
patients O
. O

results O
: O
omission O
of O
fentanyl O
did O
not O
reduce O
the O
overall O
incidence O
of O
postoperative B-Disease
nausea I-Disease
and I-Disease
vomiting I-Disease
, O
but O
did O
reduce O
the O
incidence O
of O
vomiting B-Disease
and O
/ O
or O
moderate O
to O
severe O
nausea B-Disease
prior O
to O
discharge O
from O
20 O
% O
and O
17 O
% O
with O
fentanyl O
and O
fentanyl O
- O
dexamethasone O
, O
respectively O
, O
to O
5 O
% O
( O
p O
= O
0 O
. O

13 O
) O
. O

dexamethasone O
had O
no O
significant O
effect O
on O
the O
incidence O
or O
severity O
of O
postoperative B-Disease
nausea I-Disease
and I-Disease
vomiting I-Disease
. O

combining O
the O
two O
fentanyl O
groups O
revealed O
further O
significant O
benefits O
from O
the O
avoidance O
of O
opioids O
, O
reducing O
postoperative B-Disease
nausea I-Disease
and I-Disease
vomiting I-Disease
and O
nausea B-Disease
prior O
to O
discharge O
from O
35 O
% O
and O
33 O
% O
to O
22 O
% O
and O
19 O
% O
( O
p O
= O
0 O
. O

49 O
and O
p O
= O
0 O
. O

35 O
) O
, O
respectively O
, O
while O
nausea B-Disease
in O
the O
first O
24 O
h O
was O
decreased O
from O
42 O
% O
to O
27 O
% O
( O
p O
= O
0 O
. O

34 O
) O
. O

pain B-Disease
severity O
and O
analgesic O
requirements O
were O
unaffected O
by O
the O
omission O
of O
fentanyl O
. O

fentanyl O
did O
reduce O
minor O
intraoperative O
movement O
but O
had O
no O
sevoflurane O
- O
sparing O
effect O
and O
increased O
respiratory B-Disease
depression I-Disease
, O
hypotension B-Disease
and O
bradycardia B-Disease
. O

conclusion O
: O
as O
fentanyl O
exacerbated O
postoperative B-Disease
nausea I-Disease
and I-Disease
vomiting I-Disease
without O
an O
improvement O
in O
postoperative B-Disease
pain I-Disease
and O
also O
had O
adverse O
cardiorespiratory O
effects O
, O
it O
appears O
to O
be O
an O
unnecessary O
and O
possibly O
detrimental O
supplement O
to O
sevoflurane O
in O
day O
surgery O
. O

valvular B-Disease
heart I-Disease
disease I-Disease
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
treated O
with O
pergolide O
. O

valvular B-Disease
heart I-Disease
abnormalities I-Disease
have O
been O
reported O
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
treated O
with O
pergolide O
. O

objectives O
: O
to O
estimate O
the O
frequency O
and O
severity O
of O
valvular B-Disease
heart I-Disease
abnormality I-Disease
and O
its O
possible O
reversibility O
after O
drug O
withdrawal O
in O
a O
case O
- O
control O
study O
. O

methods O
: O
all O
pd B-Disease
patients O
in O
the O
amiens O
area O
treated O
with O
pergolide O
were O
invited O
to O
attend O
a O
cardiologic O
assessment O
including O
transthoracic O
echocardiography O
. O

thirty O
pd B-Disease
patients O
participated O
in O
the O
study O
. O

controls O
were O
age O
- O
and O
sex O
- O
matched O
non O
- O
pd B-Disease
patients O
referred O
to O
the O
cardiology O
department O
. O

results O
: O
compared O
to O
controls O
, O
aortic B-Disease
regurgitation I-Disease
( O
or O
: O
3 O
. O

1 O
; O
95 O
% O
ic O
: O
1 O
. O

1 O
- O
8 O
. O

8 O
) O
and O
mitral B-Disease
regurgitation I-Disease
( O
or O
: O
10 O
. O

7 O
; O
95 O
% O
ic O
: O
2 O
. O

1 O
- O
53 O
) O
were O
more O
frequent O
in O
pd B-Disease
patients O
( O
tricuspid O
: O
ns O
) O
. O

a O
restrictive O
pattern O
of O
valvular B-Disease
regurgitation I-Disease
, O
suggestive O
of O
the O
role O
of O
pergolide O
, O
was O
observed O
in O
12 O
/ O
30 O
( O
40 O
% O
) O
patients O
including O
two O
with O
heart B-Disease
failure I-Disease
. O

pergolide O
was O
discontinued O
in O
10 O
patients O
with O
valvular B-Disease
heart I-Disease
disease I-Disease
, O
resulting O
in O
a O
lower O
regurgitation O
grade O
( O
p O
= O
0 O
. O

1 O
) O
at O
the O
second O
transthoracic O
echocardiography O
and O
the O
two O
patients O
with O
heart B-Disease
failure I-Disease
returned O
to O
nearly O
normal O
clinical O
examination O
. O

this O
study O
supports O
the O
high O
frequency O
of O
restrictive O
valve B-Disease
regurgitation I-Disease
in O
pd B-Disease
patients O
treated O
with O
pergolide O
and O
reveals O
that O
a O
significant O
improvement O
is O
usual O
when O
the O
treatment O
is O
converted O
to O
non O
- O
ergot O
dopamine O
agonists O
. O

adriamycin O
- O
induced O
autophagic O
cardiomyocyte O
death B-Disease
plays O
a O
pathogenic O
role O
in O
a O
rat O
model O
of O
heart B-Disease
failure I-Disease
. O

background O
: O
the O
mechanisms O
underlying O
heart B-Disease
failure I-Disease
induced O
by O
adriamycin O
are O
very O
complicated O
and O
still O
unclear O
. O

the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
autophagy O
was O
involved O
in O
the O
progression O
of O
heart B-Disease
failure I-Disease
induced O
by O
adriamycin O
, O
so O
that O
we O
can O
develop O
a O
novel O
treatment O
strategy O
for O
heart B-Disease
failure I-Disease
. O

methods O
: O
3 O
- O
methyladenine O
( O
3ma O
) O
, O
a O
specific O
inhibitor O
on O
autophagy O
was O
used O
in O
a O
heart B-Disease
failure I-Disease
model O
of O
rats O
induced O
by O
adriamycin O
. O

conclusion O
: O
autophagic O
cardiomyocyte O
death B-Disease
plays O
an O
important O
role O
in O
the O
pathogenesis O
of O
heart B-Disease
failure I-Disease
in O
rats O
induced O
by O
adriamycin O
. O

mitochondrial O
injury O
may O
be O
involved O
in O
the O
progression O
of O
heart B-Disease
failure I-Disease
caused O
by O
adriamycin O
via O
the O
autophagy O
pathway O
. O

mtor O
inhibitors O
- O
induced O
proteinuria B-Disease
: O
mechanisms O
, O
significance O
, O
and O
management O
. O

massive O
urinary O
protein O
excretion O
has O
been O
observed O
after O
conversion O
from O
calcineurin O
inhibitors O
to O
mammalian O
target O
of O
rapamycin O
( O
mtor O
) O
inhibitors O
, O
especially O
sirolimus O
, O
in O
renal O
transB-Plant O
recipients O
with O
chronic B-Disease
allograft I-Disease
nephropathy I-Disease
. O

because O
proteinuria B-Disease
is O
a O
major O
predictive O
factor O
of O
poor O
transB-Plantation O
outcome O
, O
many O
studies O
focused O
on O
this O
adverse O
event O
during O
the O
past O
years O
. O

whether O
proteinuria B-Disease
was O
due O
to O
sirolimus O
or O
only O
a O
consequence O
of O
calcineurin O
inhibitors O
withdrawal O
remained O
unsolved O
until O
high O
range O
proteinuria B-Disease
has O
been O
observed O
during O
sirolimus O
therapy O
in O
islet O
transB-Plantation O
and O
in O
patients O
who O
received O
sirolimus O
de O
novo O
. O

podocyte O
injury O
and O
focal O
segmental O
glomerulosclerosis B-Disease
have O
been O
related O
to O
mtor O
inhibition O
in O
some O
patients O
, O
but O
the O
pathways O
underlying O
these O
lesions O
remain O
hypothetic O
. O

we O
discuss O
herein O
the O
possible O
mechanisms O
and O
the O
significance O
of O
mtor O
blockade O
- O
induced O
proteinuria B-Disease
. O

reactions O
consisted O
mainly O
of O
seizures B-Disease
, O
acute O
psychoses B-Disease
, O
anxiety B-Disease
neurosis I-Disease
, O
and O
major O
disturbances B-Disease
of I-Disease
sleep I-Disease
- I-Disease
wake I-Disease
rhythm I-Disease
. O

therefore O
, O
certain O
limitations O
for O
malaria B-Disease
prophylaxis O
and O
treatment O
with O
mefloquine O
are O
recommended O
. O

epidemiological O
evidence O
indicates O
that O
prenatal O
nutritional O
deprivation O
may O
increase O
the O
risk O
of O
schizophrenia B-Disease
. O

the O
goal O
of O
these O
studies O
was O
to O
use O
an O
animal O
model O
to O
examine O
the O
effects O
of O
prenatal O
protein O
deprivation O
on O
behaviors O
and O
receptor O
binding O
with O
relevance O
to O
schizophrenia B-Disease
. O

no O
changes O
in O
haloperidol O
- O
induced O
catalepsy B-Disease
or O
mk O
- O
801 O
- O
induced O
locomotion O
were O
seen O
following O
pd O
. O

this O
animal O
model O
may O
be O
useful O
to O
explore O
the O
mechanisms O
by O
which O
prenatal O
nutritional B-Disease
deficiency I-Disease
enhances O
risk O
for O
schizophrenia B-Disease
in O
humans O
and O
may O
also O
have O
implications O
for O
developmental O
processes O
leading O
to O
differential O
sensitivity O
to O
drugs O
of O
abuse O
. O

background O
: O
papaverine O
hydrochloride O
is O
a O
direct O
- O
acting O
vasodilator O
used O
to O
manage O
vasospasm B-Disease
during O
various O
neurosurgical O
operations O
. O

transient O
cranial B-Disease
nerve I-Disease
dysfunction I-Disease
has O
been O
described O
in O
a O
few O
cases O
with O
topical O
papaverine O
. O

methods O
: O
we O
conducted O
a O
retrospective O
review O
of O
70 O
consecutive O
microvascular O
decompression O
operations O
and O
studied O
those O
patients O
who O
received O
topical O
papaverine O
for O
vasospasm B-Disease
. O

topical O
papaverine O
was O
used O
as O
a O
direct O
therapeutic O
action O
to O
manage O
vasospasm B-Disease
in O
a O
total O
of O
11 O
patients O
. O

one O
patient O
showed O
no O
recovery O
of O
later O
waves O
and O
a O
delayed O
profound O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
. O

conclusions O
: O
topical O
papaverine O
for O
the O
treatment O
of O
vasospasm B-Disease
was O
associated O
with O
the O
onset O
of O
a O
transient O
disturbance O
in O
neurophysiological O
function O
of O
the O
ascending O
auditory O
brainstem O
pathway O
. O

the O
complete O
disappearance O
of O
baep O
waveforms O
with O
a O
consistent O
temporal O
delay O
suggests O
a O
possible O
adverse B-Disease
effect I-Disease
on I-Disease
the I-Disease
proximal I-Disease
eighth I-Disease
nerve I-Disease
. O

recommendations O
to O
avoid O
potential O
cranial B-Disease
nerve I-Disease
deficits I-Disease
from O
papaverine O
are O
provided O
. O

simvastatin O
- O
ezetimibe O
- O
induced O
hepatic B-Disease
failure I-Disease
necessitating O
liver O
transB-Plantation O
. O

however O
, O
hepatotoxic B-Disease
events O
have O
not O
been O
widely O
published O
with O
ezetimibe O
or O
the O
combination O
agent O
simvastatin O
- O
ezetimibe O
. O

we O
describe O
a O
70 O
- O
year O
- O
old O
hispanic O
woman O
who O
developed O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
necessitating O
liver O
transB-Plantation O
10 O
weeks O
after O
conversion O
from O
simvastatin O
40 O
mg O
/ O
day O
to O
simvastatin O
10 O
mg O
- O
ezetimibe O
40 O
mg O
/ O
day O
. O

the O
patient O
' O
s O
lipid O
panel O
had O
been O
maintained O
with O
simvastatin O
for O
18 O
months O
before O
the O
conversion O
without O
evidence O
of O
hepatotoxicity B-Disease
. O

simvastatinezetimibe O
and O
escitalopram O
( O
which O
she O
was O
taking O
for O
depression B-Disease
) O
were O
discontinued O
, O
and O
other O
potential O
causes O
of O
hepatotoxicity B-Disease
were O
excluded O
. O

a O
repeat O
work O
- O
up O
revealed O
further O
elevations O
in O
aminotransferase O
levels O
, O
and O
liver O
biopsy O
revealed O
evidence O
of O
moderate O
- O
to O
- O
severe O
drug B-Disease
toxicity I-Disease
. O

ezetimibe O
undergoes O
extensive O
glucuronidation O
by O
uridine O
diphosphate O
glucoronosyltransferases O
( O
ugt O
) O
in O
the O
intestine O
and O
liver O
and O
may O
have O
inhibited O
the O
glucuronidation O
of O
simvastatin O
hydroxy O
acid O
, O
resulting O
in O
increased O
simvastatin O
exposure O
and O
subsequent O
hepatotoxicity B-Disease
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
of O
simvastatin O
- O
ezetimibe O
- O
induced O
liver B-Disease
failure I-Disease
that O
resulted O
in O
liver O
transB-Plantation O
. O

we O
postulate O
that O
the O
mechanism O
of O
the O
simvastatinezetimibe O
- O
induced O
hepatotoxicity B-Disease
is O
the O
increased O
simvastatin O
exposure O
by O
ezetimibe O
inhibition O
of O
ugt O
enzymes O
. O

clinicians O
should O
be O
aware O
of O
potential O
hepatotoxicity B-Disease
with O
simvastatin O
- O
ezetimibe O
especially O
in O
elderly O
patients O
and O
should O
carefully O
monitor O
serum O
aminotransferase O
levels O
when O
starting O
therapy O
and O
titrating O
the O
dosage O
. O

massive O
proteinuria B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
after O
oral O
bisphosphonate O
( O
alendronate O
) O
administration O
in O
a O
patient O
with O
focal B-Disease
segmental I-Disease
glomerulosclerosis I-Disease
. O

a O
61 O
- O
year O
- O
old O
japanese O
man O
with O
nephrotic B-Disease
syndrome I-Disease
due O
to O
focal B-Disease
segmental I-Disease
glomerulosclerosis I-Disease
was O
initially O
responding O
well O
to O
steroid O
therapy O
. O

within O
14 O
days O
of O
the O
oral O
bisphosphonate O
( O
alendronate O
sodium O
) O
administration O
, O
the O
amount O
of O
daily O
urinary O
protein O
increased O
rapidly O
up O
to O
12 O
. O

8 O
g O
with O
acute B-Disease
renal I-Disease
failure I-Disease
. O

this O
report O
demonstrates O
that O
not O
only O
intravenous O
, O
but O
also O
oral O
bisphosphonates O
can O
aggravate O
proteinuria B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
. O

serum O
- O
and O
glucocorticoid O
- O
inducible O
kinase O
1 O
in O
doxorubicin O
- O
induced O
nephrotic B-Disease
syndrome I-Disease
. O

doxorubicin O
- O
induced O
nephropathy B-Disease
leads O
to O
epithelial O
sodium O
channel O
( O
enac O
) O
- O
dependent O
volume B-Disease
retention I-Disease
and O
renal O
fibrosis B-Disease
. O

the O
aldosterone O
- O
sensitive O
serum O
- O
and O
glucocorticoid O
- O
inducible O
kinase O
sgk1 O
has O
been O
shown O
to O
participate O
in O
the O
stimulation O
of O
enac O
and O
to O
mediate O
renal O
fibrosis B-Disease
following O
mineralocorticoid O
and O
salt O
excess O
. O

the O
present O
study O
was O
performed O
to O
elucidate O
the O
role O
of O
sgk1 O
in O
the O
volume B-Disease
retention I-Disease
and O
fibrosis B-Disease
during O
nephrotic B-Disease
syndrome I-Disease
. O

doxorubicin O
treatment O
resulted O
in O
heavy O
proteinuria B-Disease
( O
> O
100 O
mg O
protein O
/ O
mg O
crea O
) O
in O
15 O
/ O
44 O
of O
sgk1 O
( O
+ O
/ O
+ O
) O
and O
15 O
/ O
44 O
of O
sgk1 O
( O
- O
/ O
- O
) O
mice O
leading O
to O
severe O
nephrotic B-Disease
syndrome I-Disease
with O
ascites B-Disease
, O
lipidemia B-Disease
, O
and O
hypoalbuminemia B-Disease
in O
both O
genotypes O
. O

plasma O
aldosterone O
levels O
increased O
in O
nephrotic B-Disease
mice O
of O
both O
genotypes O
and O
was O
followed O
by O
increased O
sgk1 O
protein O
expression O
in O
sgk1 O
( O
+ O
/ O
+ O
) O
mice O
. O

urinary O
sodium O
excretion O
reached O
signficantly O
lower O
values O
in O
sgk1 O
( O
+ O
/ O
+ O
) O
mice O
( O
15 O
+ O
/ O
- O
5 O
mumol O
/ O
mg O
crea O
) O
than O
in O
sgk1 O
( O
- O
/ O
- O
) O
mice O
( O
35 O
+ O
/ O
- O
5 O
mumol O
/ O
mg O
crea O
) O
and O
was O
associated O
with O
a O
significantly O
higher O
body O
weight B-Disease
gain I-Disease
in O
sgk1 O
( O
+ O
/ O
+ O
) O
compared O
with O
sgk1 O
( O
- O
/ O
- O
) O
mice O
( O
+ O
6 O
. O

6 O
+ O
/ O
- O
0 O
. O

7 O
vs O
. O

+ O
4 O
. O

1 O
+ O
/ O
- O
0 O
. O

8 O
g O
) O
. O

during O
the O
course O
of O
nephrotic B-Disease
syndrome I-Disease
, O
serum O
urea O
concentrations O
increased O
significantly O
faster O
in O
sgk1 O
( O
- O
/ O
- O
) O
mice O
than O
in O
sgk1 O
( O
+ O
/ O
+ O
) O
mice O
leading O
to O
uremia B-Disease
and O
a O
reduced O
median O
survival O
in O
sgk1 O
( O
- O
/ O
- O
) O
mice O
( O
29 O
vs O
. O

40 O
days O
in O
sgk1 O
( O
+ O
/ O
+ O
) O
mice O
) O
. O

in O
conclusion O
, O
gene O
- O
targeted O
mice O
lacking O
sgk1 O
showed O
blunted O
volume B-Disease
retention I-Disease
, O
yet O
were O
not O
protected O
against O
renal O
fibrosis B-Disease
during O
experimental O
nephrotic B-Disease
syndrome I-Disease
. O

severe O
thrombocytopenia B-Disease
and O
haemolytic B-Disease
anaemia I-Disease
associated O
with O
ciprofloxacin O
: O
a O
case O
report O
with O
fatal O
outcome O
. O

a O
30 O
- O
year O
old O
caucasian O
man O
reported O
with O
abdominal B-Disease
pain I-Disease
and O
jaundice B-Disease
after O
3 O
- O
day O
administration O
of O
oral O
ciprofloxacin O
for O
a O
suspect O
of O
urinary B-Disease
tract I-Disease
infection I-Disease
. O

clinical O
evaluations O
suggested O
an O
initial O
diagnosis O
of O
severe O
thrombocytopenia B-Disease
and O
haemolysis B-Disease
. O

the O
patient O
progressively O
developed O
petechiae B-Disease
and O
purpura B-Disease
on O
thorax O
and O
lower O
limbs O
. O

an O
accurate O
autopsy O
revealed O
most O
organs O
with O
diffuse O
petechial O
haemorrhages B-Disease
. O

no O
signs O
of O
bone B-Disease
marrow I-Disease
depression I-Disease
were O
found O
. O

no O
thrombi B-Disease
or O
signs O
of O
microangiopathies B-Disease
were O
observed O
in O
arterial O
vessels O
. O

this O
case O
report O
shows O
that O
ciprofloxacin O
may O
precipitate O
life O
- O
threatening O
thrombocytopenia B-Disease
and O
haemolytic B-Disease
anaemia I-Disease
, O
even O
in O
the O
early O
phases O
of O
treatment O
and O
without O
apparent O
previous O
exposures O
. O

alpha O
- O
lipoic O
acid O
prevents O
mitochondrial B-Disease
damage I-Disease
and O
neurotoxicity B-Disease
in O
experimental O
chemotherapy O
neuropathy B-Disease
. O

the O
study O
investigates O
if O
alpha O
- O
lipoic O
acid O
is O
neuroprotective O
against O
chemotherapy O
induced O
neurotoxicity B-Disease
, O
if O
mitochondrial B-Disease
damage I-Disease
plays O
a O
critical O
role O
in O
toxic B-Disease
neurodegenerative I-Disease
cascade I-Disease
, O
and O
if O
neuroprotective O
effects O
of O
alpha O
- O
lipoic O
acid O
depend O
on O
mitochondria O
protection O
. O

we O
used O
an O
in O
vitro O
model O
of O
chemotherapy O
induced O
peripheral B-Disease
neuropathy I-Disease
that O
closely O
mimic O
the O
in O
vivo O
condition O
by O
exposing O
primary O
cultures O
of O
dorsal O
root O
ganglion O
( O
drg O
) O
sensory O
neurons O
to O
paclitaxel O
and O
cisplatin O
, O
two O
widely O
used O
and O
highly O
effective O
chemotherapeutic O
drugs O
. O

this O
approach O
allowed O
investigating O
the O
efficacy O
of O
alpha O
- O
lipoic O
acid O
in O
preventing O
axonal B-Disease
damage I-Disease
and O
apoptosis O
and O
the O
function O
and O
ultrastructural O
morphology O
of O
mitochondria O
after O
exposure O
to O
toxic O
agents O
and O
alpha O
- O
lipoic O
acid O
. O

our O
results O
demonstrate O
that O
both O
cisplatin O
and O
paclitaxel O
cause O
early O
mitochondrial B-Disease
impairment I-Disease
with O
loss O
of O
membrane O
potential O
and O
induction O
of O
autophagic O
vacuoles O
in O
neurons O
. O

alpha O
- O
lipoic O
acid O
exerts O
neuroprotective O
effects O
against O
chemotherapy O
induced O
neurotoxicity B-Disease
in O
sensory O
neurons O
: O
it O
rescues O
the O
mitochondrial B-Disease
toxicity I-Disease
and O
induces O
the O
expression O
of O
frataxin O
, O
an O
essential O
mitochondrial O
protein O
with O
anti O
- O
oxidant O
and O
chaperone O
properties O
. O

in O
conclusion O
mitochondrial B-Disease
toxicity I-Disease
is O
an O
early O
common O
event O
both O
in O
paclitaxel O
and O
cisplatin O
induced O
neurotoxicity B-Disease
. O

these O
findings O
suggest O
that O
alpha O
- O
lipoic O
acid O
might O
reduce O
the O
risk O
of O
developing O
peripheral B-Disease
nerve I-Disease
toxicity I-Disease
in O
patients O
undergoing O
chemotherapy O
and O
encourage O
further O
confirmatory O
clinical O
trials O
. O

toxicity B-Disease
in O
rhesus O
monkeys O
following O
administration O
of O
the O
8 O
- O
aminoquinoline O
8 O
- O
[ O
( O
4 O
- O
amino O
- O
l O
- O
methylbutyl O
) O
amino O
] O
- O
5 O
- O
( O
l O
- O
hexyloxy O
) O
- O
6 O
- O
methoxy O
- O
4 O
- O
methylquinoline O
( O
wr242511 O
) O
. O

introduction O
: O
many O
substances O
that O
form O
methemoglobin O
( O
mhb O
) O
effectively O
counter O
cyanide O
( O
cn O
) O
toxicity B-Disease
. O

although O
mhb O
formers O
are O
generally O
applied O
as O
treatments O
for O
cn O
poisoning B-Disease
, O
it O
has O
been O
proposed O
that O
a O
stable O
, O
long O
- O
acting O
mhb O
former O
could O
serve O
as O
a O
cn O
pretreatment O
. O

results O
: O
the O
selected O
doses O
of O
wr242511 O
, O
which O
produced O
significant O
methemoglobinemia B-Disease
in O
beagle O
dogs O
in O
earlier O
studies O
conducted O
elsewhere O
, O
produced O
very O
little O
mhb O
( O
mean O
< O
2 O
. O

0 O
% O
) O
in O
the O
rhesus O
monkey O
. O

furthermore O
, O
transient O
hemoglobinuria B-Disease
was O
noted O
approximately O
60 O
minutes O
postinjection O
of O
wr242511 O
( O
3 O
. O

5 O
or O
7 O
. O

0 O
mg O
/ O
kg O
) O
, O
and O
2 O
lethalities O
occurred O
( O
one O
iv O
and O
one O
po O
) O
following O
the O
7 O
. O

0 O
mg O
/ O
kg O
dose O
. O

myoglobinuria B-Disease
was O
also O
observed O
following O
the O
7 O
. O

0 O
mg O
/ O
kg O
dose O
. O

histopathology O
analyses O
in O
the O
2 O
animals O
that O
died O
revealed O
liver B-Disease
and I-Disease
kidney I-Disease
toxicity I-Disease
, O
with O
greater O
severity O
in O
the O
orally O
- O
treated O
animal O
. O

conclusions O
: O
these O
data O
demonstrate O
direct O
and O
/ O
or O
indirect O
drug O
- O
induced O
toxicity B-Disease
. O

it O
is O
concluded O
that O
wr242511 O
should O
not O
be O
pursued O
as O
a O
pretreatment O
for O
cn O
poisoning B-Disease
unless O
the O
anti O
- O
cn O
characteristics O
of O
this O
compound O
can O
be O
successfully O
dissociated O
from O
those O
producing O
undesirable O
toxicity B-Disease
. O

repetitive O
transcranial O
magnetic O
stimulation O
for O
levodopa O
- O
induced O
dyskinesias B-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

in O
a O
placebo O
- O
controlled O
, O
single O
- O
blinded O
, O
crossover O
study O
, O
we O
assessed O
the O
effect O
of O
nan O
real O
nan O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rtms O
) O
versus O
nan O
sham O
nan O
rtms O
( O
placebo O
) O
on O
peak O
dose O
dyskinesias B-Disease
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
. O

ten O
patients O
with O
pd B-Disease
and O
prominent O
dyskinesias B-Disease
had O
rtms O
( O
1 O
, O
800 O
pulses O
; O
1 O
hz O
rate O
) O
delivered O
over O
the O
motor O
cortex O
for O
4 O
consecutive O
days O
twice O
, O
once O
real O
stimuli O
and O
once O
sham O
stimulation O
were O
used O
; O
evaluations O
were O
done O
at O
the O
baseline O
and O
1 O
day O
after O
the O
end O
of O
each O
of O
the O
treatment O
series O
. O

direct O
comparison O
between O
sham O
and O
real O
rtms O
effects O
showed O
no O
significant O
difference O
in O
clinician O
- O
assessed O
dyskinesia B-Disease
severity O
. O

however O
, O
comparison O
with O
the O
baseline O
showed O
small O
but O
significant O
reduction O
in O
dyskinesia B-Disease
severity O
following O
real O
rtms O
but O
not O
placebo O
. O

the O
major O
effect O
was O
on O
dystonia B-Disease
subscore O
. O

similarly O
, O
in O
patient O
diaries O
, O
although O
both O
treatments O
caused O
reduction O
in O
subjective O
dyskinesia B-Disease
scores O
during O
the O
days O
of O
intervention O
, O
the O
effect O
was O
sustained O
for O
3 O
days O
after O
the O
intervention O
for O
the O
real O
rtms O
only O
. O

following O
rtms O
, O
no O
side O
effects O
and O
no O
adverse O
effects O
on O
motor O
function O
and O
pd B-Disease
symptoms O
were O
noted O
. O

the O
results O
suggest O
the O
existence O
of O
residual O
beneficial O
clinical O
aftereffects O
of O
consecutive O
daily O
applications O
of O
low O
- O
frequency O
rtms O
on O
dyskinesias B-Disease
in O
pd B-Disease
. O

intracavernous O
epinephrine O
: O
a O
minimally O
invasive O
treatment O
for O
priapism B-Disease
in O
the O
emergency O
department O
. O

priapism B-Disease
is O
the O
prolonged O
erection O
of O
the O
penis O
in O
the O
absence O
of O
sexual O
arousal O
. O

a O
45 O
- O
year O
- O
old O
man O
, O
an O
admitted O
frequent O
cocaine O
user O
, O
presented O
to O
the O
emergency O
department O
( O
ed O
) O
on O
two O
separate O
occasions O
with O
a O
history O
of O
priapism B-Disease
after O
cocaine O
use O
. O

prophylactic O
use O
of O
lamivudine O
with O
chronic O
immunosuppressive O
therapy O
for O
rheumatologic B-Disease
disorders I-Disease
. O

the O
objective O
of O
this O
study O
was O
to O
report O
our O
experience O
concerning O
the O
effectiveness O
of O
the O
prophylactic O
administration O
of O
lamivudine O
in O
hepatitis O
b O
virus O
surface O
antigen O
( O
hbs O
ag O
) O
positive O
patients O
with O
rheumatologic B-Disease
disease I-Disease
. O

from O
june O
2004 O
to O
october O
2006 O
, O
11 O
hbs O
ag O
positive O
patients O
with O
rheumatologic B-Disease
diseases I-Disease
, O
who O
were O
on O
both O
immunosuppressive O
and O
prophylactic O
lamivudine O
therapies O
, O
were O
retrospectively O
assessed O
. O

liver O
function O
tests O
, O
hepatitis B-Disease
b I-Disease
virus O
( O
hbv O
) O
serologic O
markers O
, O
and O
hbv O
dna O
levels O
of O
the O
patients O
during O
follow O
- O
up O
were O
obtained O
from O
hospital O
file O
records O
. O

shortly O
after O
treatment O
their O
tests O
normalized O
and O
during O
follow O
- O
up O
period O
none O
of O
the O
patients O
had O
abnormal B-Disease
liver I-Disease
function I-Disease
tests O
. O

effect O
of O
green O
tea O
and O
vitamin O
e O
combination O
in O
isoproterenol O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

the O
present O
study O
was O
aimed O
to O
investigate O
the O
combined O
effects O
of O
green O
tea O
and O
vitamin O
e O
on O
heart O
weight O
, O
body O
weight O
, O
serum O
marker O
enzymes O
, O
lipid O
peroxidation O
, O
endogenous O
antioxidants O
and O
membrane O
bound O
atpases O
in O
isoproterenol O
( O
iso O
) O
- O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

these O
findings O
indicate O
the O
synergistic O
protective O
effect O
of O
green O
tea O
and O
vitamin O
e O
during O
iso O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

irreversible O
damage O
to O
the O
medullary O
interstitium O
in O
experimental O
analgesic O
nephropathy B-Disease
in O
f344 O
rats O
. O

renal B-Disease
papillary I-Disease
necrosis I-Disease
( O
rpn B-Disease
) O
and O
a O
decreased O
urinary O
concentrating O
ability O
developed O
during O
continuous O
long O
- O
term O
treatment O
with O
aspirin O
and O
paracetamol O
in O
female O
fischer O
344 O
rats O
. O

this O
study O
shows O
that O
prolonged O
analgesic O
treatment O
in O
fischer O
344 O
rats O
causes O
progressive O
and O
irreversible O
damage O
to O
the O
interstitial O
matrix O
and O
type O
1 O
interstitial O
cells O
leading O
to O
rpn B-Disease
. O

testosterone O
- O
dependent O
hypertension B-Disease
and O
upregulation O
of O
intrarenal O
angiotensinogen O
in O
dahl O
salt O
- O
sensitive O
rats O
. O

in O
this O
study O
, O
the O
hypothesis O
was O
tested O
that O
there O
is O
a O
sexual O
dimorphism O
in O
hs O
- O
induced O
upregulation O
of O
intrarenal O
angiotensinogen O
mediated O
by O
testosterone O
that O
also O
causes O
increases O
in O
bp O
and O
renal B-Disease
injury I-Disease
. O

hs O
diet O
for O
4 O
wk O
caused O
a O
progressive O
increase O
in O
bp O
, O
protein O
and O
albumin O
excretion O
, O
and O
glomerular B-Disease
sclerosis I-Disease
in O
male O
ds O
rats O
, O
which O
were O
attenuated O
by O
castration O
. O

testosterone O
replacement O
in O
castrated O
ds O
rats O
increased O
bp O
, O
renal B-Disease
injury I-Disease
, O
and O
upregulation O
of O
renal O
angiotensinogen O
associated O
with O
hs O
diet O
. O

testosterone O
contributes O
to O
the O
development O
of O
hypertension B-Disease
and O
renal B-Disease
injury I-Disease
in O
male O
ds O
rats O
on O
hs O
diet O
possibly O
through O
upregulation O
of O
the O
intrarenal O
renin O
- O
angiotensin O
system O
. O

explicit O
episodic O
memory O
for O
sensory O
- O
discriminative O
components O
of O
capsaicin O
- O
induced O
pain B-Disease
: O
immediate O
and O
delayed O
ratings O
. O

pain B-Disease
memory O
is O
thought O
to O
affect O
future O
pain B-Disease
sensitivity O
and O
thus O
contribute O
to O
clinical O
pain B-Disease
conditions O
. O

systematic O
investigations O
of O
the O
human O
capacity O
to O
remember O
sensory O
features O
of O
experimental O
pain B-Disease
are O
sparse O
. O

in O
order O
to O
address O
long O
- O
term O
pain B-Disease
memory O
, O
nine O
healthy O
male O
volunteers O
received O
intradermal O
injections O
of O
three O
doses O
of O
capsaicin O
( O
0 O
. O

5 O
, O
1 O
and O
20 O
microg O
, O
separated O
by O
15 O
min O
breaks O
) O
, O
each O
given O
three O
times O
in O
a O
balanced O
design O
across O
three O
sessions O
at O
one O
week O
intervals O
. O

pain B-Disease
rating O
was O
performed O
using O
a O
computerized O
visual O
analogue O
scale O
( O
0 O
- O
100 O
) O
digitized O
at O
1 O
/ O
s O
, O
either O
immediately O
online O
or O
one O
hour O
or O
one O
day O
after O
injection O
. O

subjects O
also O
recalled O
their O
pains B-Disease
one O
week O
later O
. O

the O
strong O
burning O
pain B-Disease
decayed O
exponentially O
within O
a O
few O
minutes O
. O

subjects O
were O
able O
to O
reliably O
discriminate O
pain B-Disease
magnitude O
and O
duration O
across O
capsaicin O
doses O
( O
both O
p O
< O
0 O
. O

1 O
) O
, O
regardless O
of O
whether O
first O
- O
time O
ratings O
were O
requested O
immediately O
, O
after O
one O
hour O
or O
after O
one O
day O
. O

pain B-Disease
recall O
after O
one O
week O
was O
similarly O
precise O
( O
magnitude O
: O
p O
< O
0 O
. O

1 O
, O
duration O
: O
p O
< O
0 O
. O

5 O
) O
. O

these O
results O
indicate O
a O
reliable O
memory O
for O
magnitude O
and O
duration O
of O
experimentally O
induced O
pain B-Disease
. O

severe O
and O
long O
lasting O
cholestasis B-Disease
after O
high O
- O
dose O
co O
- O
trimoxazole O
treatment O
for O
pneumocystis B-Disease
pneumonia I-Disease
in O
hiv B-Disease
- I-Disease
infected I-Disease
patients O
- O
- O
a O
report O
of O
two O
cases O
. O

pneumocystis B-Disease
pneumonia I-Disease
( O
pcp B-Disease
) O
, O
a O
common O
opportunistic B-Disease
infection I-Disease
in O
hiv B-Disease
- I-Disease
infected I-Disease
individuals O
, O
is O
generally O
treated O
with O
high O
doses O
of O
co O
- O
trimoxazole O
. O

here O
, O
we O
report O
two O
cases O
of O
severely O
immunocompromised O
hiv B-Disease
- I-Disease
infected I-Disease
patients O
who O
developed O
severe O
intrahepatic B-Disease
cholestasis I-Disease
, O
and O
in O
one O
patient O
lesions O
mimicking O
liver B-Disease
abscess I-Disease
formation O
on O
radiologic O
exams O
, O
during O
co O
- O
trimoxazole O
treatment O
for O
pcp B-Disease
. O

bradykinin O
receptors O
antagonists O
and O
nitric O
oxide O
synthase O
inhibitors O
in O
vincristine O
and O
streptozotocin O
induced O
hyperalgesia B-Disease
in O
chemotherapy O
and O
diabetic B-Disease
neuropathy I-Disease
rat O
model O
. O

purpose O
: O
the O
influence O
of O
an O
irreversible O
inhibitor O
of O
constitutive O
no O
synthase O
( O
l O
- O
noarg O
; O
1 O
. O

0 O
mg O
/ O
kg O
ip O
) O
, O
a O
relatively O
selective O
inhibitor O
of O
inducible O
no O
synthase O
( O
l O
- O
nil O
; O
1 O
. O

0 O
mg O
/ O
kg O
ip O
) O
and O
a O
relatively O
specific O
inhibitor O
of O
neuronal O
no O
synthase O
( O
7 O
- O
ni O
; O
0 O
. O

1 O
mg O
/ O
kg O
ip O
) O
, O
on O
antihyperalgesic O
action O
of O
selective O
antagonists O
of O
b2 O
and O
b1 O
receptors O
: O
d O
- O
arg O
- O
[ O
hyp3 O
, O
thi5 O
, O
d O
- O
tic7 O
, O
oic8 O
] O
bradykinin O
( O
hoe O
140 O
; O
70 O
nmol O
/ O
kg O
ip O
) O
or O
des O
arg10 O
hoe O
140 O
( O
70 O
nmol O
/ O
kg O
ip O
) O
respectively O
, O
in O
model O
of O
diabetic B-Disease
( I-Disease
streptozotocin I-Disease
- I-Disease
induced I-Disease
) I-Disease
and I-Disease
toxic I-Disease
( I-Disease
vincristine I-Disease
- I-Disease
induced I-Disease
) I-Disease
neuropathy I-Disease
was O
investigated O
. O

methods O
: O
the O
changes O
in O
pain B-Disease
thresholds O
were O
determined O
using O
mechanical O
stimuli O
- O
- O
the O
modification O
of O
the O
classic O
paw O
withdrawal O
test O
described O
by O
randall O
- O
selitto O
. O

results O
: O
the O
results O
of O
this O
paper O
confirm O
that O
inhibition O
of O
bradykinin O
receptors O
and O
inducible O
no O
synthase O
but O
not O
neuronal O
no O
synthase O
activity O
reduces O
diabetic B-Disease
hyperalgesia I-Disease
. O

it O
was O
also O
shown O
that O
both O
products O
of O
inducible O
no O
synthase O
and O
neuronal O
no O
synthase O
activation O
as O
well O
as O
bradykinin O
are O
involved O
in O
hyperalgesia B-Disease
produced O
by O
vincristine O
. O

moreover O
, O
l O
- O
noarg O
and O
7 O
- O
ni O
but O
not O
l O
- O
nil O
intensify O
antihyperalgesic O
activity O
of O
hoe O
140 O
or O
des O
- O
arg10hoe O
140 O
in O
toxic B-Disease
neuropathy I-Disease
. O

conclusions O
: O
results O
of O
these O
studies O
suggest O
that O
b1 O
and O
b2 O
receptors O
are O
engaged O
in O
transmission O
of O
nociceptive O
stimuli O
in O
both O
diabetic B-Disease
and I-Disease
toxic I-Disease
neuropathy I-Disease
. O

in O
streptozotocin O
- O
induced O
hyperalgesia B-Disease
, O
inducible O
no O
synthase O
participates O
in O
pronociceptive O
activity O
of O
bradykinin O
, O
whereas O
in O
vincristine O
- O
induced O
hyperalgesia B-Disease
bradykinin O
seemed O
to O
activate O
neuronal O
no O
synthase O
pathway O
. O

therefore O
, O
concomitant O
administration O
of O
small O
doses O
of O
bradykinin O
receptor O
antagonists O
and O
no O
synthase O
inhibitors O
can O
be O
effective O
in O
alleviation O
of O
neuropathic B-Disease
pain I-Disease
, O
even O
in O
hospital O
care O
. O

confusion B-Disease
, O
a O
rather O
serious O
adverse O
drug O
reaction O
with O
valproic O
acid O
: O
a O
review O
of O
the O
french O
pharmacovigilance O
database O
. O

introduction O
: O
confusion B-Disease
is O
an O
adverse O
drug O
reaction O
frequently O
observed O
with O
valproic O
acid O
. O

methods O
: O
using O
the O
french O
pharmacovigilance O
database O
, O
we O
selected O
the O
cases O
of O
confusion B-Disease
reported O
since O
1985 O
with O
valproic O
acid O
. O

results O
: O
272 O
cases O
of O
confusion B-Disease
were O
reported O
with O
valproic O
acid O
: O
153 O
women O
and O
119 O
men O
. O

confusion B-Disease
mostly O
occurred O
during O
the O
two O
first O
weeks O
following O
valproic O
acid O
exposure O
( O
39 O
. O

7 O
% O
) O
. O

conclusion O
: O
this O
work O
shows O
that O
confusion B-Disease
with O
valproic O
acid O
is O
a O
serious O
, O
rather O
frequent O
but O
reversible O
adverse O
drug O
reaction O
. O

reversible O
inferior B-Disease
colliculus I-Disease
lesion I-Disease
in O
metronidazole O
- O
induced O
encephalopathy B-Disease
: O
magnetic O
resonance O
findings O
on O
diffusion O
- O
weighted O
and O
fluid O
attenuated O
inversion O
recovery O
imaging O
. O

objective O
: O
this O
is O
to O
present O
reversible O
inferior B-Disease
colliculus I-Disease
lesions I-Disease
in O
metronidazole O
- O
induced O
encephalopathy B-Disease
, O
to O
focus O
on O
the O
diffusion O
- O
weighted O
imaging O
( O
dwi O
) O
and O
fluid O
attenuated O
inversion O
recovery O
( O
flair O
) O
imaging O
. O

materials O
and O
methods O
: O
from O
november O
2005 O
to O
september O
2007 O
, O
8 O
patients O
( O
5 O
men O
and O
3 O
women O
) O
were O
diagnosed O
as O
having O
metronidazole O
- O
induced O
encephalopathy B-Disease
( O
age O
range O
; O
43 O
- O
78 O
years O
) O
. O

they O
had O
been O
taking O
metronidazole O
( O
total O
dosage O
, O
45 O
- O
120 O
g O
; O
duration O
, O
30 O
days O
to O
2 O
months O
) O
to O
treat O
the O
infection B-Disease
in O
various O
organs O
. O

all O
the O
lesions O
in O
dentate O
, O
inferior O
colliculus O
, O
pons O
, O
and O
medullas O
had O
been O
resolved O
completely O
on O
follow O
- O
up O
mris O
in O
5 O
patients O
, O
but O
in O
1 O
patient O
of O
them O
, O
corpus O
callosal B-Disease
lesion I-Disease
persisted O
. O

conclusions O
: O
reversible O
inferior B-Disease
colliculus I-Disease
lesions I-Disease
could O
be O
considered O
as O
the O
characteristic O
for O
metronidazole O
- O
induced O
encephalopathy B-Disease
, O
next O
to O
the O
dentate O
nucleus O
involvement O
. O

clinically O
significant O
proteinuria B-Disease
following O
the O
administration O
of O
sirolimus O
to O
renal O
transB-Plant O
recipients O
. O

background O
: O
sirolimus O
is O
the O
latest O
immunosuppressive O
agent O
used O
to O
prevent O
rejection O
, O
and O
may O
have O
less O
nephrotoxicity B-Disease
than O
calcineurin O
inhibitor O
( O
cni O
) O
- O
based O
regimens O
. O

to O
date O
there O
has O
been O
little O
documentation O
of O
clinically O
significant O
proteinuria B-Disease
linked O
with O
the O
use O
of O
sirolimus O
. O

we O
have O
encountered O
several O
patients O
who O
developed O
substantial O
proteinuria B-Disease
associated O
with O
sirolimus O
use O
. O

in O
each O
patient O
, O
the O
close O
temporal O
association O
between O
the O
commencement O
of O
sirolimus O
therapy O
and O
proteinuria B-Disease
implicated O
sirolimus O
as O
the O
most O
likely O
etiology O
of O
the O
proteinuria B-Disease
. O

in O
these O
patients O
, O
the O
magnitude O
of O
proteinuria B-Disease
was O
assessed O
on O
morning O
urine O
samples O
by O
turbidometric O
measurement O
or O
random O
urine O
protein O
: O
creatinine O
ratios O
, O
an O
estimate O
of O
grams O
of O
proteinuria B-Disease
/ O
day O
. O

results O
: O
twenty O
- O
eight O
patients O
( O
24 O
% O
) O
developed O
increased O
proteinuria B-Disease
from O
baseline O
during O
their O
post O
- O
transB-Plantation O
course O
. O

in O
21 O
patients O
an O
alternative O
cause O
of O
proteinuria B-Disease
was O
either O
obvious O
or O
insufficient O
data O
was O
available O
to O
be O
conclusive O
. O

in O
7 O
of O
the O
28 O
patients O
there O
was O
a O
striking O
temporal O
association O
between O
the O
initiation O
of O
sirolimus O
and O
the O
development O
of O
nephrotic B-Disease
- O
range O
proteinuria B-Disease
. O

proteinuria B-Disease
correlated O
most O
strongly O
with O
sirolimus O
therapy O
when O
compared O
to O
other O
demographic O
and O
clinical O
variables O
. O

in O
most O
patients O
, O
discontinuation O
of O
sirolimus O
resulted O
in O
a O
decrease O
, O
but O
not O
resolution O
, O
of O
proteinuria B-Disease
. O

conclusions O
: O
sirolimus O
induces O
or O
aggravates O
pre O
- O
existing O
proteinuria B-Disease
in O
an O
unpredictable O
subset O
of O
renal O
allograft O
recipients O
. O

proteinuria B-Disease
may O
improve O
, O
but O
does O
not O
resolve O
, O
when O
sirolimus O
is O
withdrawn O
. O

components O
of O
lemon O
essential O
oil O
attenuate O
dementia B-Disease
induced O
by O
scopolamine O
. O

the O
anti O
- O
dementia B-Disease
effects O
of O
s O
- O
limonene O
and O
s O
- O
perillyl O
alcohol O
were O
observed O
using O
the O
passive O
avoidance O
test O
( O
pa O
) O
and O
the O
open O
field O
habituation O
test O
( O
ofh O
) O
. O

these O
lemon O
essential O
oils O
showed O
strong O
ability O
to O
improve O
memory B-Disease
impaired I-Disease
by O
scopolamine O
; O
however O
, O
s O
- O
perillyl O
alcohol O
relieved O
the O
deficit B-Disease
of I-Disease
associative I-Disease
memory I-Disease
in O
pa O
only O
, O
and O
did O
not O
improve O
non O
- O
associative O
memory O
significantly O
in O
ofh O
. O

attentional O
modulation O
of O
perceived O
pain B-Disease
intensity O
in O
capsaicin O
- O
induced O
secondary O
hyperalgesia B-Disease
. O

perceived O
pain B-Disease
intensity O
is O
modulated O
by O
attention O
. O

however O
, O
it O
is O
not O
known O
that O
how O
pain B-Disease
intensity O
ratings O
are O
affected O
by O
attention O
in O
capsaicin O
- O
induced O
secondary O
hyperalgesia B-Disease
. O

here O
we O
show O
that O
perceived O
pain B-Disease
intensity O
in O
secondary O
hyperalgesia B-Disease
is O
decreased O
when O
attention O
is O
distracted O
away O
from O
the O
painful O
pinprick O
stimulus O
with O
a O
visual O
task O
. O

furthermore O
, O
it O
was O
found O
that O
the O
magnitude O
of O
attentional O
modulation O
in O
secondary O
hyperalgesia B-Disease
is O
very O
similar O
to O
that O
of O
capsaicin O
- O
untreated O
, O
control O
condition O
. O

our O
findings O
, O
showing O
no O
interaction O
between O
capsaicin O
treatment O
and O
attentional O
modulation O
suggest O
that O
capsaicin O
- O
induced O
secondary O
hyperalgesia B-Disease
and O
attention O
might O
affect O
mechanical O
pain B-Disease
through O
independent O
mechanisms O
. O

cardioprotective O
effect O
of O
salvianolic O
acid O
a O
on O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

the O
present O
study O
was O
designed O
to O
evaluate O
the O
cardioprotective O
potential O
of O
salvianolic O
acid O
a O
on O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

in O
addition O
, O
mitochondrial O
respiratory B-Disease
dysfunction I-Disease
characterized O
by O
decreased O
respiratory O
control O
ratio O
and O
adp O
/ O
o O
was O
observed O
in O
isoproterenol O
- O
treated O
rats O
. O

administration O
of O
salvianolic O
acid O
a O
for O
a O
period O
of O
8 O
days O
significantly O
attenuated O
isoproterenol O
- O
induced O
cardiac B-Disease
dysfunction I-Disease
and O
myocardial B-Disease
injury I-Disease
and O
improved O
mitochondrial O
respiratory O
function O
. O

the O
protective O
role O
of O
salvianolic O
acid O
a O
against O
isoproterenol O
- O
induced O
myocardial B-Disease
damage I-Disease
was O
further O
confirmed O
by O
histopathological O
examination O
. O

the O
results O
of O
our O
study O
suggest O
that O
salvianolic O
acid O
a O
possessing O
antioxidant O
activity O
has O
a O
significant O
protective O
effect O
against O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
. O

long O
- O
term O
glutamate O
supplementation O
failed O
to O
protect O
against O
peripheral B-Disease
neurotoxicity I-Disease
of O
paclitaxel O
. O

toxic O
peripheral B-Disease
neuropathy I-Disease
is O
still O
a O
significant O
limiting O
factor O
for O
chemotherapy O
with O
paclitaxel O
( O
pac O
) O
, O
although O
glutamate O
and O
its O
closely O
related O
amino O
acid O
glutamine O
were O
claimed O
to O
ameliorate O
pac O
neurotoxicity B-Disease
. O

this O
pilot O
trial O
aimed O
to O
evaluate O
the O
role O
of O
glutamate O
supplementation O
for O
preventing O
pac O
- O
induced O
peripheral B-Disease
neuropathy I-Disease
in O
a O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blinded O
clinical O
and O
electro O
- O
diagnostic O
study O
. O

forty O
- O
three O
ovarian B-Disease
cancer I-Disease
patients O
were O
available O
for O
analysis O
following O
six O
cycles O
of O
the O
same O
pac O
- O
containing O
regimen O
: O
23 O
had O
been O
supplemented O
by O
glutamate O
all O
along O
the O
treatment O
period O
, O
at O
a O
daily O
dose O
of O
three O
times O
500 O
mg O
( O
group O
g O
) O
, O
and O
20 O
had O
received O
a O
placebo O
( O
group O
p O
) O
. O

there O
was O
no O
significant O
difference O
in O
the O
frequency O
of O
signs O
or O
symptoms O
between O
the O
two O
groups O
although O
neurotoxicity B-Disease
symptoms O
presented O
mostly O
with O
lower O
scores O
of O
severity O
in O
group O
g O
. O

however O
, O
this O
difference O
reached O
statistical O
significance O
only O
with O
regard O
to O
reported O
pain B-Disease
sensation O
( O
p O
= O
0 O
. O

11 O
) O
. O

this O
pilot O
study O
leads O
to O
the O
conclusion O
that O
glutamate O
supplementation O
at O
the O
chosen O
regimen O
fails O
to O
protect O
against O
peripheral B-Disease
neurotoxicity I-Disease
of O
pac O
. O

development O
of O
ocular B-Disease
myasthenia I-Disease
during O
pegylated O
interferon O
and O
ribavirin O
treatment O
for O
chronic B-Disease
hepatitis I-Disease
c I-Disease
. O

a O
63 O
- O
year O
- O
old O
male O
experienced O
sudden O
diplopia B-Disease
after O
9 O
weeks O
of O
administration O
of O
pegylated O
interferon O
( O
ifn O
) O
alpha O
- O
2b O
and O
ribavirin O
for O
chronic B-Disease
hepatitis I-Disease
c I-Disease
( O
chc B-Disease
) O
. O

ophthalmologic O
examinations O
showed O
ptosis B-Disease
on I-Disease
the I-Disease
right I-Disease
upper I-Disease
lid I-Disease
and O
restricted B-Disease
right I-Disease
eye I-Disease
movement I-Disease
without O
any O
other O
neurological O
signs O
. O

the O
ocular B-Disease
myasthenia I-Disease
associated O
with O
combination O
therapy O
of O
pegylated O
ifn O
alpha O
- O
2b O
and O
ribavirin O
for O
chc B-Disease
is O
very O
rarely O
reported O
; O
therefore O
, O
we O
present O
this O
case O
with O
a O
review O
of O
the O
various O
eye O
complications O
of O
ifn O
therapy O
. O

learning B-Disease
and I-Disease
memory I-Disease
deficits I-Disease
in O
ecstasy O
users O
and O
their O
neural O
correlates O
during O
a O
face O
- O
learning O
task O
. O

it O
has O
been O
consistently O
shown O
that O
ecstasy O
users O
display O
impairments B-Disease
in I-Disease
learning I-Disease
and I-Disease
memory I-Disease
performance O
. O

to O
address O
the O
potential O
confounding O
effects O
of O
the O
cannabis O
use O
of O
the O
ecstasy O
using O
group O
, O
a O
second O
analysis O
included O
14 O
previously O
tested O
cannabis O
users O
( O
nestor O
, O
l O
. O

, O
roberts O
, O
g O
. O

, O
garavan O
, O
h O
. O

, O
hester O
, O
r O
. O

, O
2008 O
. O

deficits B-Disease
in I-Disease
learning I-Disease
and I-Disease
memory I-Disease
: O
parahippocampal O
hyperactivity B-Disease
and O
frontocortical O
hypoactivity O
in O
cannabis O
users O
. O

neuroimage O
40 O
, O
1328 O
- O
1339 O
) O
. O

a O
conjunction O
analysis O
of O
the O
encode O
and O
recall O
phases O
of O
the O
task O
revealed O
ecstasy O
- O
specific O
hyperactivity B-Disease
in O
bilateral O
frontal O
regions O
, O
left O
temporal O
, O
right O
parietal O
, O
bilateral O
temporal O
, O
and O
bilateral O
occipital O
brain O
regions O
. O

these O
ecstasy O
- O
specific O
effects O
may O
be O
related O
to O
the O
vulnerability O
of O
isocortical O
and O
allocortical O
regions O
to O
the O
neurotoxic B-Disease
effects O
of O
ecstasy O
. O

in O
less O
than O
1 O
hour O
after O
the O
ingestion O
of O
alcohol O
, O
he O
developed O
malaise O
with O
flushing B-Disease
of I-Disease
the I-Disease
face I-Disease
, O
tachycardia B-Disease
, O
and O
dyspnea B-Disease
. O

five O
hours O
after O
exposure O
, O
he O
developed O
disulfiram O
- O
like O
syndrome O
with O
flushing B-Disease
, O
tachycardia B-Disease
, O
and O
arterial B-Disease
hypotension I-Disease
after O
consuming O
three O
glasses O
of O
wine O
. O

sulpiride O
- O
induced O
tardive B-Disease
dystonia I-Disease
. O

although O
initially O
thought O
to O
be O
free O
of O
extrapyramidal O
side O
effects O
, O
sulpiride O
- O
induced O
tardive B-Disease
dyskinesia I-Disease
and O
parkinsonism B-Disease
have O
been O
reported O
occasionally O
. O

we O
studied O
a O
37 O
- O
year O
- O
old O
man O
who O
developed O
persistent O
segmental O
dystonia B-Disease
within O
2 O
months O
after O
starting O
sulpiride O
therapy O
. O

we O
could O
not O
find O
any O
previous O
reports O
of O
sulpiride O
- O
induced O
tardive B-Disease
dystonia I-Disease
. O

this O
study O
measured O
the O
objective O
and O
subjective O
neurocognitive O
effects O
of O
a O
single O
10 O
- O
mg O
dose O
of O
immediate O
- O
release O
oxycodone O
in O
healthy O
, O
older O
( O
> O
65 O
years O
) O
, O
and O
middle O
- O
aged O
( O
35 O
to O
55 O
years O
) O
adults O
who O
were O
not O
suffering O
from O
chronic O
or O
significant O
daily O
pain B-Disease
. O

significant O
declines B-Disease
in I-Disease
simple I-Disease
and I-Disease
sustained I-Disease
attention I-Disease
, I-Disease
working I-Disease
memory I-Disease
, I-Disease
and I-Disease
verbal I-Disease
memory I-Disease
were O
observed O
at O
1 O
hour O
postdose O
compared O
to O
baseline O
for O
both O
age O
groups O
with O
a O
trend O
toward O
return O
to O
baseline O
by O
5 O
hours O
postdose O
. O

this O
study O
suggests O
that O
for O
healthy O
older O
adults O
who O
are O
not O
suffering O
from O
chronic B-Disease
pain I-Disease
, O
neurocognitive O
and O
pharmacodynamic O
changes O
in O
response O
to O
a O
10 O
- O
mg O
dose O
of O
immediate O
- O
release O
oxycodone O
are O
similar O
to O
those O
observed O
for O
middle O
- O
aged O
adults O
. O

schizophrenia B-Disease
has O
been O
initially O
associated O
with O
dysfunction O
in O
dopamine O
neurotransmission O
. O

however O
, O
the O
observation O
that O
antagonists O
of O
the O
glutamate O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptor O
produce O
schizophrenic B-Disease
- O
like O
symptoms O
in O
humans O
has O
led O
to O
the O
idea O
of O
a O
dysfunctioning O
of O
the O
glutamatergic O
system O
via O
its O
nmda O
receptor O
. O

this O
study O
aimed O
at O
investigating O
the O
potential O
antipsychotic O
- O
like O
properties O
of O
ssr103800 O
, O
with O
a O
particular O
focus O
on O
models O
of O
hyperactivity B-Disease
, O
involving O
either O
drug O
challenge O
( O
ie O
, O
amphetamine O
and O
mk O
- O
801 O
) O
or O
transgenic O
mice O
( O
ie O
, O
nmda O
nr1 O
( O
neo O
- O
/ O
- O
) O
and O
dat O
( O
- O
/ O
- O
) O
) O
. O

results O
showed O
that O
ssr103800 O
( O
10 O
- O
30 O
mg O
/ O
kg O
p O
. O

o O
. O

) O
blocked O
hyperactivity B-Disease
induced O
by O
the O
non O
- O
competitive O
nmda O
receptor O
antagonist O
, O
mk O
- O
801 O
and O
partially O
reversed O
spontaneous O
hyperactivity B-Disease
of O
nmda O
nr1 O
( O
neo O
- O
/ O
- O
) O
mice O
. O

in O
contrast O
, O
ssr103800 O
failed O
to O
affect O
hyperactivity B-Disease
induced O
by O
amphetamine O
or O
naturally O
observed O
in O
dopamine O
transporter O
( O
dat O
( O
- O
/ O
- O
) O
) O
knockout O
mice O
( O
10 O
- O
30 O
mg O
/ O
kg O
p O
. O

o O
. O

) O
. O

importantly O
, O
both O
classical O
( O
haloperidol O
) O
and O
atypical O
( O
olanzapine O
, O
clozapine O
and O
aripiprazole O
) O
antipsychotics O
were O
effective O
in O
all O
these O
models O
of O
hyperactivity B-Disease
. O

however O
, O
unlike O
these O
latter O
, O
ssr103800 O
did O
not O
produce O
catalepsy B-Disease
( O
retention O
on O
the O
bar O
test O
) O
up O
to O
30 O
mg O
/ O
kg O
p O
. O

o O
. O

pyrrolidine O
dithiocarbamate O
protects O
the O
piriform O
cortex O
in O
the O
pilocarpine O
status B-Disease
epilepticus I-Disease
model O
. O

both O
, O
production O
of O
reactive O
oxygen O
species O
as O
well O
as O
activation O
of O
nf O
- O
kappab O
have O
been O
implicated O
in O
severe O
neuronal B-Disease
damage I-Disease
in O
different O
sub O
- O
regions O
of O
the O
hippocampus O
as O
well O
as O
in O
the O
surrounding O
cortices O
. O

the O
effect O
of O
pdtc O
on O
status B-Disease
epilepticus I-Disease
- O
associated O
cell O
loss O
in O
the O
hippocampus O
and O
piriform O
cortex O
was O
evaluated O
in O
the O
rat O
fractionated O
pilocarpine O
model O
. O

treatment O
with O
150 O
mg O
/ O
kg O
pdtc O
before O
and O
following O
status B-Disease
epilepticus I-Disease
significantly O
increased O
the O
mortality O
rate O
to O
100 O
% O
. O

administration O
of O
50 O
mg O
/ O
kg O
pdtc O
( O
low O
- O
dose O
) O
did O
not O
exert O
major O
effects O
on O
the O
development O
of O
a O
status B-Disease
epilepticus I-Disease
or O
the O
mortality O
rate O
. O

in O
vehicle O
- O
treated O
rats O
, O
status B-Disease
epilepticus I-Disease
caused O
pronounced O
neuronal B-Disease
damage I-Disease
in O
the O
piriform O
cortex O
comprising O
both O
pyramidal O
cells O
and O
interneurons O
. O

a O
significant O
decrease O
in O
neuronal O
density O
of O
the O
hippocampal O
hilar O
formation O
was O
identified O
in O
vehicle O
- O
and O
pdtc O
- O
treated O
rats O
following O
status B-Disease
epilepticus I-Disease
. O

in O
conclusion O
, O
the O
nf O
- O
kappab O
inhibitor O
and O
antioxidant O
pdtc O
protected O
the O
piriform O
cortex O
, O
whereas O
it O
did O
not O
affect O
hilar O
neuronal B-Disease
loss I-Disease
. O

these O
data O
might O
indicate O
that O
the O
generation O
of O
reactive O
oxygen O
species O
and O
activation O
of O
nf O
- O
kappab O
plays O
a O
more O
central O
role O
in O
seizure B-Disease
- O
associated O
neuronal B-Disease
damage I-Disease
in O
the O
temporal O
cortex O
as O
compared O
to O
the O
hippocampal O
hilus O
. O

anaesthetists O
' O
nightmare O
: O
masseter B-Disease
spasm I-Disease
after O
induction O
in O
an O
undiagnosed O
case O
of O
myotonia B-Disease
congenita I-Disease
. O

we O
report O
an O
undiagnosed O
case O
of O
myotonia B-Disease
congenita I-Disease
in O
a O
24 O
- O
year O
- O
old O
previously O
healthy O
primigravida O
, O
who O
developed O
life O
threatening O
masseter B-Disease
spasm I-Disease
following O
a O
standard O
dose O
of O
intravenous O
suxamethonium O
for O
induction O
of O
anaesthesia O
. O

twin O
preterm O
neonates O
with O
cardiac B-Disease
toxicity I-Disease
related O
to O
lopinavir O
/ O
ritonavir O
therapy O
. O

we O
report O
twin O
neonates O
who O
were O
born O
prematurely O
at O
32 O
weeks O
of O
gestation O
to O
a O
mother O
with O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
infection I-Disease
. O

one O
of O
the O
twins O
developed O
complete O
heart B-Disease
block I-Disease
and O
dilated B-Disease
cardiomyopathy I-Disease
related O
to O
lopinavir O
/ O
ritonavir O
therapy O
, O
a O
boosted O
protease O
- O
inhibitor O
agent O
, O
while O
the O
other O
twin O
developed O
mild O
bradycardia B-Disease
. O

twenty O
- O
three O
hours O
after O
heart O
transB-Plantation O
, O
life O
- O
threatening O
acute O
right B-Disease
heart I-Disease
failure I-Disease
was O
diagnosed O
in O
a O
patient O
requiring O
continuous O
venovenous O
hemodiafiltration O
( O
cvvhdf O
) O
. O

however O
, O
a O
bolus O
of O
epinephrine O
injected O
through O
an O
alternative O
catheter O
provoked O
a O
hypertensive B-Disease
crisis O
. O

lithium O
- O
induced O
polyuria B-Disease
seems O
to O
be O
related O
to O
extrarenal O
as O
well O
as O
to O
renal O
effects O
. O

antibacterial O
medication O
use O
during O
pregnancy O
and O
risk O
of O
birth B-Disease
defects I-Disease
: O
national O
birth B-Disease
defects I-Disease
prevention O
study O
. O

objective O
: O
to O
estimate O
the O
association O
between O
antibacterial O
medications O
and O
selected O
birth B-Disease
defects I-Disease
. O

design O
, O
setting O
, O
and O
participants O
: O
population O
- O
based O
, O
multisite O
, O
case O
- O
control O
study O
of O
women O
who O
had O
pregnancies O
affected O
by O
1 O
of O
more O
than O
30 O
eligible O
major O
birth B-Disease
defects I-Disease
identified O
via O
birth B-Disease
defect I-Disease
surveillance O
programs O
in O
10 O
states O
( O
n O
= O
13 O
155 O
) O
and O
control O
women O
randomly O
selected O
from O
the O
same O
geographical O
regions O
( O
n O
= O
4941 O
) O
. O

main O
outcome O
measure O
: O
odds O
ratios O
( O
ors O
) O
measuring O
the O
association O
between O
antibacterial O
use O
and O
selected O
birth B-Disease
defects I-Disease
adjusted O
for O
potential O
confounders O
. O

sulfonamides O
were O
associated O
with O
anencephaly B-Disease
( O
adjusted O
or O
[ O
aor O
] O
= O
3 O
. O

4 O
; O
95 O
% O
confidence O
interval O
[ O
ci O
] O
, O
1 O
. O

3 O
- O
8 O
. O

8 O
) O
, O
hypoplastic B-Disease
left I-Disease
heart I-Disease
syndrome I-Disease
( O
aor O
= O
3 O
. O

2 O
; O
95 O
% O
ci O
, O
1 O
. O

3 O
- O
7 O
. O

6 O
) O
, O
coarctation B-Disease
of I-Disease
the I-Disease
aorta I-Disease
( O
aor O
= O
2 O
. O

7 O
; O
95 O
% O
ci O
, O
1 O
. O

3 O
- O
5 O
. O

6 O
) O
, O
choanal B-Disease
atresia I-Disease
( O
aor O
= O
8 O
. O

0 O
; O
95 O
% O
ci O
, O
2 O
. O

7 O
- O
23 O
. O

5 O
) O
, O
transverse B-Disease
limb I-Disease
deficiency I-Disease
( O
aor O
= O
2 O
. O

5 O
; O
95 O
% O
ci O
, O
1 O
. O

0 O
- O
5 O
. O

9 O
) O
, O
and O
diaphragmatic B-Disease
hernia I-Disease
( O
aor O
= O
2 O
. O

4 O
; O
95 O
% O
ci O
, O
1 O
. O

1 O
- O
5 O
. O

4 O
) O
. O

nitrofurantoins O
were O
associated O
with O
anophthalmia B-Disease
or O
microphthalmos B-Disease
( O
aor O
= O
3 O
. O

7 O
; O
95 O
% O
ci O
, O
1 O
. O

1 O
- O
12 O
. O

2 O
) O
, O
hypoplastic B-Disease
left I-Disease
heart I-Disease
syndrome I-Disease
( O
aor O
= O
4 O
. O

2 O
; O
95 O
% O
ci O
, O
1 O
. O

9 O
- O
9 O
. O

1 O
) O
, O
atrial B-Disease
septal I-Disease
defects I-Disease
( O
aor O
= O
1 O
. O

9 O
; O
95 O
% O
ci O
, O
1 O
. O

1 O
- O
3 O
. O

4 O
) O
, O
and O
cleft B-Disease
lip I-Disease
with O
cleft B-Disease
palate I-Disease
( O
aor O
= O
2 O
. O

1 O
; O
95 O
% O
ci O
, O
1 O
. O

2 O
- O
3 O
. O

9 O
) O
. O

conclusions O
: O
reassuringly O
, O
penicillins O
, O
erythromycins O
, O
and O
cephalosporins O
, O
although O
used O
commonly O
by O
pregnant O
women O
, O
were O
not O
associated O
with O
many O
birth B-Disease
defects I-Disease
. O

sulfonamides O
and O
nitrofurantoins O
were O
associated O
with O
several O
birth B-Disease
defects I-Disease
, O
indicating O
a O
need O
for O
additional O
scrutiny O
. O

immune O
escape O
variants O
of O
the O
hepatitis B-Disease
b I-Disease
virus O
( O
hbv O
) O
represent O
an O
emerging O
clinical O
challenge O
, O
because O
they O
can O
be O
associated O
with O
vaccine O
escape O
, O
hbv O
reactivation O
, O
and O
failure O
of O
diagnostic O
tests O
. O

hemolytic B-Disease
anemia I-Disease
associated O
with O
the O
use O
of O
omeprazole O
. O

it O
has O
been O
shown O
to O
be O
extremely O
effective O
in O
the O
treatment O
of O
peptic B-Disease
ulcer I-Disease
disease I-Disease
, O
reflux B-Disease
esophagitis I-Disease
, O
and O
the O
zollinger B-Disease
- I-Disease
ellison I-Disease
syndrome I-Disease
. O

we O
report O
the O
first O
case O
of O
a O
serious O
short O
- O
term O
adverse O
reaction O
with O
the O
use O
of O
omeprazole O
: O
hemolytic B-Disease
anemia I-Disease
. O

the O
patient O
developed O
weakness O
, O
lethargy B-Disease
, O
and O
shortness B-Disease
of I-Disease
breath I-Disease
2 O
days O
after O
starting O
therapy O
with O
omeprazole O
. O

the O
mechanism O
by O
which O
omeprazole O
caused O
the O
patient O
' O
s O
hemolytic B-Disease
anemia I-Disease
is O
uncertain O
, O
but O
physicians O
should O
be O
alerted O
to O
this O
possible O
adverse O
effect O
. O

phenylephrine O
but O
not O
ephedrine O
reduces B-Disease
frontal I-Disease
lobe I-Disease
oxygenation I-Disease
following O
anesthesia O
- O
induced O
hypotension B-Disease
. O

background O
: O
vasopressor O
agents O
are O
used O
to O
correct O
anesthesia O
- O
induced O
hypotension B-Disease
. O

we O
describe O
the O
effect O
of O
phenylephrine O
and O
ephedrine O
on O
frontal O
lobe O
oxygenation O
( O
s O
( O
c O
) O
o O
( O
2 O
) O
) O
following O
anesthesia O
- O
induced O
hypotension B-Disease
. O

heart O
rate O
( O
hr O
) O
, O
map O
, O
stroke B-Disease
volume O
( O
sv O
) O
, O
cardiac O
output O
( O
co O
) O
, O
and O
frontal O
lobe O
oxygenation O
( O
s O
( O
c O
) O
o O
( O
2 O
) O
) O
were O
registered O
. O

results O
: O
induction O
of O
anesthesia O
was O
followed O
by O
a B-Disease
decrease I-Disease
in I-Disease
map I-Disease
, I-Disease
hr I-Disease
, I-Disease
sv I-Disease
, I-Disease
and I-Disease
co I-Disease
concomitant O
with O
an O
elevation O
in O
s O
( O
c O
) O
o O
( O
2 O
) O
. O

conclusions O
: O
the O
utilization O
of O
phenylephrine O
to O
correct O
hypotension B-Disease
induced O
by O
anesthesia O
has O
a O
negative O
impact O
on O
s O
( O
c O
) O
o O
( O
2 O
) O
while O
ephedrine O
maintains O
frontal O
lobe O
oxygenation O
potentially O
related O
to O
an O
increase O
in O
co O
. O

prolonged O
elevation O
of O
plasma O
argatroban O
in O
a O
cardiac O
transB-Plant O
patient O
with O
a O
suspected O
history O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
with O
thrombosis B-Disease
. O

background O
: O
direct O
thrombin O
inhibitors O
( O
dtis O
) O
provide O
an O
alternative O
method O
of O
anticoagulation O
for O
patients O
with O
a O
history O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
( O
hit B-Disease
) O
or O
hit B-Disease
with O
thrombosis B-Disease
( O
hitt B-Disease
) O
undergoing O
cardiopulmonary O
bypass O
( O
cpb O
) O
. O

in O
the O
following O
report O
, O
a O
65 O
- O
year O
- O
old O
critically B-Disease
ill I-Disease
patient O
with O
a O
suspected O
history O
of O
hitt B-Disease
was O
administered O
argatroban O
for O
anticoagulation O
on O
bypass O
during O
heart O
transB-Plantation O
. O

the O
patient O
required O
massive O
transfusion O
support O
( O
55 O
units O
of O
red O
blood O
cells O
, O
42 O
units O
of O
fresh O
- O
frozen O
plasma O
, O
40 O
units O
of O
cryoprecipitate O
, O
40 O
units O
of O
platelets O
, O
and O
three O
doses O
of O
recombinant O
factor O
viia O
) O
for O
severe O
intraoperative B-Disease
and I-Disease
postoperative I-Disease
bleeding I-Disease
. O

results O
: O
unexpectedly O
high O
concentrations O
of O
argatroban O
were O
measured O
in O
these O
samples O
( O
range O
, O
0 O
- O
32 O
microg O
/ O
ml O
) O
, O
and O
a O
prolonged O
plasma O
argatroban O
half O
life O
( O
t O
( O
1 O
/ O
2 O
) O
) O
of O
514 O
minutes O
was O
observed O
( O
published O
elimination O
t O
( O
1 O
/ O
2 O
) O
is O
39 O
- O
51 O
minutes O
[ O
< O
or O
= O
181 O
minutes O
with O
hepatic B-Disease
impairment I-Disease
] O
) O
. O

conclusions O
: O
correlation O
of O
plasma O
argatroban O
concentration O
versus O
the O
patient O
' O
s O
coagulation O
variables O
and O
clinical O
course O
suggest O
that O
prolonged O
elevated O
levels O
of O
plasma O
argatroban O
may O
have O
contributed O
to O
the O
patient O
' O
s O
extended O
coagulopathy B-Disease
. O

this O
is O
the O
first O
report O
to O
measure O
plasma O
argatroban O
concentration O
in O
the O
context O
of O
cpb O
and O
extended O
coagulopathy B-Disease
. O

the O
effects O
of O
the O
adjunctive O
bupropion O
on O
male O
sexual B-Disease
dysfunction I-Disease
induced O
by O
a O
selective O
serotonin O
reuptake O
inhibitor O
: O
a O
double O
- O
blind O
placebo O
- O
controlled O
and O
randomized O
study O
. O

objective O
: O
to O
determine O
the O
safety O
and O
efficacy O
of O
adjunctive O
bupropion O
sustained O
- O
release O
( O
sr O
) O
on O
male O
sexual B-Disease
dysfunction I-Disease
( O
sd B-Disease
) O
induced O
by O
a O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
, O
as O
sd B-Disease
is O
a O
common O
side O
- O
effect O
of O
ssris O
and O
the O
most O
effective O
treatments O
have O
yet O
to O
be O
determined O
. O

efficacy O
was O
evaluated O
using O
the O
clinical O
global O
impression O
- O
sexual O
function O
( O
cgi O
- O
sf O
; O
the O
primary O
outcome O
measure O
) O
, O
the O
international O
index O
of O
erectile O
function O
( O
iief O
) O
, O
arizona O
sexual O
experience O
scale O
( O
asex O
) O
, O
and O
erectile B-Disease
dysfunction I-Disease
inventory O
of O
treatment O
satisfaction O
( O
edits O
) O
( O
secondary O
outcome O
measures O
) O
. O

in O
linear O
regression O
analyses O
the O
cgi O
- O
sf O
score O
was O
not O
affected O
significantly O
by O
the O
duration O
of O
sd B-Disease
, O
type O
of O
ssri O
used O
and O
age O
. O

conclusions O
: O
bupropion O
is O
an O
effective O
treatment O
for O
male O
sd B-Disease
induced O
by O
ssris O
. O

prevention O
of O
seizures B-Disease
and O
reorganization O
of O
hippocampal O
functions O
by O
transB-Plantation O
of O
bone O
marrow O
cells O
in O
the O
acute O
phase O
of O
experimental O
epilepsy B-Disease
. O

in O
this O
study O
, O
we O
investigated O
the O
therapeutic O
potential O
of O
bone O
marrow O
mononuclear O
cells O
( O
bmcs O
) O
in O
a O
model O
of O
epilepsy B-Disease
induced O
by O
pilocarpine O
in O
rats O
. O

bmcs O
obtained O
from O
green O
fluorescent O
protein O
( O
gfp O
) O
transgenic O
mice O
or O
rats O
were O
transB-Planted O
intravenously O
after O
induction O
of O
status B-Disease
epilepticus I-Disease
( O
se B-Disease
) O
. O

spontaneous B-Disease
recurrent I-Disease
seizures I-Disease
( O
srs B-Disease
) O
were O
monitored O
using O
racine O
' O
s O
seizure B-Disease
severity O
scale O
. O

all O
of O
the O
rats O
in O
the O
saline O
- O
treated O
epileptic B-Disease
control O
group O
developed O
srs B-Disease
, O
whereas O
none O
of O
the O
bmc O
- O
treated O
epileptic B-Disease
animals O
had O
seizures B-Disease
in O
the O
short O
term O
( O
15 O
days O
after O
transB-Plantation O
) O
, O
regardless O
of O
the O
bmc O
source O
. O

over O
the O
long O
- O
term O
chronic O
phase O
( O
120 O
days O
after O
transB-Plantation O
) O
, O
only O
25 O
% O
of O
bmc O
- O
treated O
epileptic B-Disease
animals O
had O
seizures B-Disease
, O
but O
with O
a O
lower O
frequency O
and O
duration O
compared O
to O
the O
epileptic B-Disease
control O
group O
. O

at O
hippocampal O
schaeffer O
collateral O
- O
ca1 O
synapses O
, O
long O
- O
term O
potentiation O
was O
preserved O
in O
bmc O
- O
transB-Planted O
rats O
compared O
to O
epileptic B-Disease
controls O
. O

the O
donor O
- O
derived O
gfp O
( O
+ O
) O
cells O
were O
rarely O
found O
in O
the O
brains O
of O
transB-Planted O
epileptic B-Disease
rats O
. O

in O
conclusion O
, O
treatment O
with O
bmcs O
can O
prevent O
the O
development O
of O
chronic O
seizures B-Disease
, O
reduce O
neuronal B-Disease
loss I-Disease
, O
and O
influence O
the O
reorganization O
of O
the O
hippocampal O
neuronal O
network O
. O

objective O
: O
the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
the O
effect O
of O
morning O
- O
dosed O
modafinil O
on O
sleep O
and O
daytime B-Disease
sleepiness I-Disease
in O
chronic O
cocaine O
users O
. O

modafinil O
was O
associated O
with O
increased O
daytime O
sleep O
latency O
, O
as O
measured O
by O
the O
multiple O
sleep O
latency O
test O
, O
and O
a O
nearly O
significant O
decrease O
in O
subjective O
daytime B-Disease
sleepiness I-Disease
. O

conclusions O
: O
morning O
- O
dosed O
modafinil O
promotes O
nocturnal O
sleep O
, O
normalizes O
sleep O
architecture O
, O
and O
decreases O
daytime B-Disease
sleepiness I-Disease
in O
abstinent O
cocaine O
users O
. O

uni O
- O
and O
multivariate O
analyses O
were O
used O
to O
test O
the O
influence O
of O
the O
clinical O
variables O
: O
age O
, O
sex O
, O
stroke B-Disease
, O
myocardiopathy B-Disease
( O
mp B-Disease
) O
, O
duration O
of O
the O
test O
, O
mitral B-Disease
regurgitation I-Disease
( O
mr B-Disease
) O
and O
the O
mz O
dose O
. O

mild O
hypoxia B-Disease
( O
so2 O
< O
90 O
% O
) O
was O
the O
most O
common O
event O
( O
11 O
patients O
) O
; O
3 O
patients O
( O
2 O
% O
) O
presented O
transient O
hypoxia B-Disease
due O
to O
upper O
airway B-Disease
obstruction I-Disease
by O
probe O
introduction O
and O
8 O
( O
5 O
. O

8 O
% O
) O
due O
to O
hypoxia B-Disease
caused O
by O
mz O
use O
. O

transient O
hypotension B-Disease
( O
sap O
< O
90mmhg O
) O
occurred O
in O
1 O
patient O
( O
0 O
. O

7 O
% O
) O
. O

the O
multivariate O
analysis O
showed O
that O
severe O
mr B-Disease
, O
mp B-Disease
( O
ef O
< O
45 O
% O
) O
and O
high O
doses O
of O
mz O
( O
> O
5mg O
) O
were O
associated O
with O
events O
( O
p O
< O
0 O
. O

1 O
) O
. O

the O
ef O
was O
40 O
% O
, O
in O
the O
group O
with O
mp B-Disease
and O
44 O
% O
in O
the O
group O
with O
severe O
mr B-Disease
and O
it O
can O
be O
a O
factor O
associated O
with O
clinical O
events O
in O
the O
last O
group O
. O

effect O
of O
direct O
intracoronary O
administration O
of O
methylergonovine O
in O
patients O
with O
and O
without O
variant B-Disease
angina I-Disease
. O

the O
effects O
of O
intracoronary O
administration O
of O
methylergonovine O
were O
studied O
in O
21 O
patients O
with O
variant B-Disease
angina I-Disease
and O
22 O
patients O
with O
atypical O
chest B-Disease
pain I-Disease
and O
in O
others O
without O
angina B-Disease
pectoris I-Disease
( O
control O
group O
) O
. O

in O
all O
patients O
with O
variant B-Disease
angina I-Disease
, O
coronary B-Disease
spasm I-Disease
was O
provoked O
at O
a O
mean O
dose O
of O
28 O
+ O
/ O
- O
13 O
micrograms O
( O
mean O
+ O
/ O
- O
sd O
) O
. O

in O
the O
control O
group O
neither O
ischemic O
st O
change O
nor O
localized O
spasm B-Disease
occurred O
. O

these O
results O
suggest O
that O
spasm B-Disease
provocation O
tests O
, O
which O
use O
an O
intracoronary O
injection O
of O
a O
relatively O
low O
dose O
of O
methylergonovine O
, O
have O
a O
high O
sensitivity O
in O
variant B-Disease
angina I-Disease
and O
the O
vasoreactivity O
of O
the O
right O
coronary O
artery O
may O
be O
greater O
than O
that O
of O
the O
other O
coronary O
arteries O
. O

oral O
manifestations O
of O
nan O
meth B-Disease
mouth I-Disease
nan O
: O
a O
case O
report O
. O

aim O
: O
the O
aim O
of O
the O
documentation O
of O
this O
clinical O
case O
is O
to O
make O
clinicians O
aware O
of O
nan O
meth B-Disease
mouth I-Disease
nan O
and O
the O
medical O
risks O
associated O
with O
this O
serious O
condition O
. O

background O
: O
methamphetamine O
is O
a O
very O
addictive O
, O
powerful O
stimulant O
that O
increases O
wakefulness O
and O
physical O
activity O
and O
can O
produce O
other O
effects O
such O
as O
cardiac B-Disease
dysrhythmias I-Disease
, O
hypertension B-Disease
, O
hallucinations B-Disease
, O
and O
violent B-Disease
behavior I-Disease
. O

dental O
patients O
abusing O
methamphetamine O
can O
present O
with O
poor O
oral O
hygiene O
, O
xerostomia B-Disease
, O
rampant O
caries B-Disease
( O
nan O
meth B-Disease
mouth I-Disease
nan O
) O
, O
and O
excessive O
tooth B-Disease
wear I-Disease
. O

case O
description O
: O
a O
30 O
- O
year O
- O
old O
caucasian O
woman O
presented O
with O
dental O
pain B-Disease
, O
bad B-Disease
breath I-Disease
, O
and O
self O
- O
reported O
poor O
esthetics O
. O

a O
comprehensive O
examination O
including O
her O
medical O
history O
, O
panoramic O
radiograph O
, O
and O
intraoral O
examination O
revealed O
19 O
carious B-Disease
lesions I-Disease
, O
which O
is O
not O
very O
common O
for O
a O
healthy O
adult O
. O

she O
reported O
her O
use O
of O
methamphetamine O
for O
five O
years O
and O
had O
not O
experienced O
any O
major O
carious B-Disease
episodes I-Disease
before O
she O
started O
using O
the O
drug O
. O

summary O
: O
the O
patient O
' O
s O
medical O
and O
dental O
histories O
along O
with O
radiographic O
and O
clinical O
findings O
lead O
to O
a O
diagnosis O
of O
nan O
meth B-Disease
mouth I-Disease
. O

nan O
although O
three O
different O
dental O
treatment O
modalities O
( O
either O
conventional O
or O
imB-Plant O
- O
supported O
) O
have O
been O
offered O
to O
the O
patient O
since O
august O
2007 O
, O
the O
patient O
has O
yet O
to O
initiate O
any O
treatment O
. O

clinical O
significance O
: O
this O
clinical O
case O
showing O
oral O
manifestations O
of O
meth B-Disease
mouth I-Disease
was O
presented O
to O
help O
dental O
practitioners O
recognize O
and O
manage O
patients O
who O
may O
be O
abusing O
methamphetamines O
. O

antituberculosis O
therapy O
- O
induced O
acute B-Disease
liver I-Disease
failure I-Disease
: O
magnitude O
, O
profile O
, O
prognosis O
, O
and O
predictors O
of O
outcome O
. O

antituberculosis O
therapy O
( O
att O
) O
- O
associated O
acute B-Disease
liver I-Disease
failure I-Disease
( O
att O
- O
alf B-Disease
) O
is O
the O
commonest O
drug O
- O
induced O
alf B-Disease
in O
south O
asia O
. O

prospective O
studies O
on O
att O
- O
alf B-Disease
are O
lacking O
. O

the O
current O
study O
prospectively O
evaluated O
the O
magnitude O
, O
clinical O
course O
, O
outcome O
, O
and O
prognostic O
factors O
in O
att O
- O
alf B-Disease
. O

from O
january O
1986 O
to O
january O
2009 O
, O
1223 O
consecutive O
alf B-Disease
patients O
were O
evaluated O
: O
att O
alone O
was O
the O
cause O
in O
70 O
( O
5 O
. O

7 O
% O
) O
patients O
. O

another O
15 O
( O
1 O
. O

2 O
% O
) O
had O
att O
and O
simultaneous O
hepatitis B-Disease
virus I-Disease
infection I-Disease
. O

in O
44 O
( O
62 O
. O

8 O
% O
) O
patients O
, O
att O
was O
prescribed O
empirically O
without O
definitive O
evidence O
of O
tuberculosis B-Disease
. O

att O
- O
alf B-Disease
patients O
were O
younger O
( O
32 O
. O

87 O
[ O
+ O
/ O
- O
15 O
. O

8 O
] O
years O
) O
, O
and O
49 O
( O
70 O
% O
) O
of O
them O
were O
women O
. O

most O
had O
hyperacute O
presentation O
; O
the O
median O
icterus B-Disease
encephalopathy B-Disease
interval O
was O
4 O
. O

5 O
( O
0 O
- O
30 O
) O
days O
. O

the O
median O
duration O
of O
att O
before O
alf B-Disease
was O
30 O
( O
7 O
- O
350 O
) O
days O
. O

at O
presentation O
, O
advanced O
encephalopathy B-Disease
and O
cerebral B-Disease
edema I-Disease
were O
present O
in O
51 O
( O
76 O
% O
) O
and O
29 O
( O
41 O
. O

4 O
% O
) O
patients O
, O
respectively O
. O

gastrointestinal B-Disease
bleed I-Disease
, O
seizures B-Disease
, O
infection B-Disease
, O
and O
acute B-Disease
renal I-Disease
failure I-Disease
were O
documented O
in O
seven O
( O
10 O
% O
) O
, O
five O
( O
7 O
. O

1 O
% O
) O
, O
26 O
( O
37 O
. O

1 O
% O
) O
, O
and O
seven O
( O
10 O
% O
) O
patients O
, O
respectively O
. O

compared O
with O
hepatitis B-Disease
e I-Disease
virus O
( O
hev O
) O
and O
non O
- O
a O
non O
- O
e O
- O
induced O
alf B-Disease
, O
att O
- O
alf B-Disease
patients O
had O
nearly O
similar O
presentations O
except O
for O
older O
age O
and O
less O
elevation O
of O
liver O
enzymes O
. O

the O
mortality O
rate O
among O
patients O
with O
att O
- O
alf B-Disease
was O
high O
( O
67 O
. O

1 O
% O
, O
n O
= O
47 O
) O
, O
and O
only O
23 O
( O
32 O
. O

9 O
% O
) O
patients O
recovered O
with O
medical O
treatment O
. O

in O
multivariate O
analysis O
, O
three O
factors O
independently O
predicted O
mortality O
: O
serum O
bilirubin O
( O
> O
or O
= O
10 O
. O

8 O
mg O
/ O
dl O
) O
, O
prothrombin O
time O
( O
pt O
) O
prolongation O
( O
> O
or O
= O
26 O
seconds O
) O
, O
and O
grade O
iii O
/ O
iv O
encephalopathy B-Disease
at O
presentation O
. O

conclusion O
: O
att O
- O
alf B-Disease
constituted O
5 O
. O

7 O
% O
of O
alf B-Disease
at O
our O
center O
and O
had O
a O
high O
mortality O
rate O
. O

design O
and O
analysis O
of O
the O
hypren O
- O
trial O
: O
safety O
of O
enalapril O
and O
prazosin O
in O
the O
initial O
treatment O
phase O
of O
patients O
with O
congestive B-Disease
heart I-Disease
failure I-Disease
. O

since O
the O
introduction O
of O
angiotensin O
converting O
enzyme O
( O
ace O
) O
inhibitors O
into O
the O
adjunctive O
treatment O
of O
patients O
with O
congestive B-Disease
heart I-Disease
failure I-Disease
, O
cases O
of O
severe O
hypotension B-Disease
, O
especially O
on O
the O
first O
day O
of O
treatment O
, O
have O
occasionally O
been O
reported O
. O

to O
assess O
the O
safety O
of O
the O
ace O
inhibitor O
enalapril O
a O
multicenter O
, O
randomized O
, O
prazosin O
- O
controlled O
trial O
was O
designed O
that O
compared O
the O
incidence O
and O
severity O
of O
symptomatic O
hypotension B-Disease
on O
the O
first O
day O
of O
treatment O
. O

patients O
who O
received O
enalapril O
experienced O
clinically O
and O
statistically O
significantly O
less O
symptomatic O
hypotension B-Disease
( O
5 O
. O

2 O
% O
) O
than O
the O
patients O
who O
received O
prazosin O
( O
12 O
. O

9 O
% O
) O
. O

central B-Disease
nervous I-Disease
system I-Disease
complications I-Disease
during O
treatment O
of O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
in O
a O
single O
pediatric O
institution O
. O

central B-Disease
nervous I-Disease
system I-Disease
( I-Disease
cns I-Disease
) I-Disease
complications I-Disease
during O
treatment O
of O
childhood O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
( O
all B-Disease
) O
remain O
a O
challenging O
clinical O
problem O
. O

this O
study O
analyzed O
the O
incidence O
of O
neurological B-Disease
complications I-Disease
during O
all B-Disease
treatment O
in O
a O
single O
pediatric O
institution O
, O
focusing O
on O
clinical O
, O
radiological O
, O
and O
electrophysiological O
findings O
. O

exclusion O
criteria O
included O
cns O
leukemic B-Disease
infiltration I-Disease
at O
diagnosis O
, O
therapy O
- O
related O
peripheral B-Disease
neuropathy I-Disease
, O
late O
- O
onset O
encephalopathy B-Disease
, O
or O
long O
- O
term O
neurocognitive B-Disease
defects I-Disease
. O

during O
a O
9 O
- O
year O
period O
, O
we O
retrospectively O
collected O
27 O
neurological O
events O
( O
11 O
% O
) O
in O
as O
many O
patients O
, O
from O
253 O
children O
enrolled O
in O
the O
all B-Disease
front O
- O
line O
protocol O
. O

cns O
complications O
included O
posterior O
reversible O
leukoencephalopathy B-Disease
syndrome O
( O
n O
= O
10 O
) O
, O
stroke B-Disease
( O
n O
= O
5 O
) O
, O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
( O
n O
= O
2 O
) O
, O
high O
- O
dose O
methotrexate O
toxicity B-Disease
( O
n O
= O
2 O
) O
, O
syndrome O
of O
inappropriate B-Disease
antidiuretic I-Disease
hormone I-Disease
secretion I-Disease
( O
n O
= O
1 O
) O
, O
and O
other O
unclassified O
events O
( O
n O
= O
7 O
) O
. O

in O
conclusion O
, O
cns O
complications O
are O
frequent O
events O
during O
all B-Disease
therapy O
, O
and O
require O
rapid O
detection O
and O
prompt O
treatment O
to O
limit O
permanent O
damage O
. O

cocaine O
causes O
memory B-Disease
and I-Disease
learning I-Disease
impairments I-Disease
in O
rats O
: O
involvement O
of O
nuclear O
factor O
kappa O
b O
and O
oxidative O
stress O
, O
and O
prevention O
by O
topiramate O
. O

different O
mechanisms O
have O
been O
suggested O
for O
cocaine O
toxicity B-Disease
including O
an O
increase O
in O
oxidative O
stress O
but O
the O
association O
between O
oxidative O
status O
in O
the O
brain O
and O
cocaine O
induced O
- O
behaviour O
is O
poorly O
understood O
. O

nuclear O
factor O
kappa O
b O
( O
nfkappab O
) O
is O
a O
sensor O
of O
oxidative O
stress O
and O
participates O
in O
memory O
formation O
that O
could O
be O
involved O
in O
drug O
toxicity B-Disease
and O
addiction O
mechanisms O
. O

therefore O
nfkappab O
activity O
, O
oxidative O
stress O
, O
neuronal O
nitric O
oxide O
synthase O
( O
nnos O
) O
activity O
, O
spatial O
learning O
and O
memory O
as O
well O
as O
the O
effect O
of O
topiramate O
, O
a O
previously O
proposed O
therapy O
for O
cocaine B-Disease
addiction I-Disease
, O
were O
evaluated O
in O
an O
experimental O
model O
of O
cocaine O
administration O
in O
rats O
. O

efficacy O
and O
safety O
of O
asenapine O
in O
a O
placebo O
- O
and O
haloperidol O
- O
controlled O
trial O
in O
patients O
with O
acute O
exacerbation O
of O
schizophrenia B-Disease
. O

asenapine O
is O
approved O
by O
the O
food O
and O
drugs O
administration O
in O
adults O
for O
acute O
treatment O
of O
schizophrenia B-Disease
or O
of O
manic B-Disease
or O
mixed O
episodes O
associated O
with O
bipolar B-Disease
i I-Disease
disorder I-Disease
with O
or O
without O
psychotic B-Disease
features O
. O

in O
a O
double O
- O
blind O
6 O
- O
week O
trial O
, O
458 O
patients O
with O
acute O
schizophrenia B-Disease
were O
randomly O
assigned O
to O
fixed O
- O
dose O
treatment O
with O
asenapine O
at O
5 O
mg O
twice O
daily O
( O
bid O
) O
, O
asenapine O
at O
10 O
mg O
bid O
, O
placebo O
, O
or O
haloperidol O
at O
4 O
mg O
bid O
( O
to O
verify O
assay O
sensitivity O
) O
. O

extrapyramidal B-Disease
symptoms I-Disease
reported O
as O
aes O
occurred O
in O
15 O
% O
and O
18 O
% O
, O
34 O
% O
, O
and O
10 O
% O
of O
the O
asenapine O
at O
5 O
and O
10 O
mg O
bid O
, O
haloperidol O
, O
and O
placebo O
groups O
, O
respectively O
. O

post O
hoc O
analyses O
indicated O
that O
efficacy O
was O
similar O
with O
asenapine O
and O
haloperidol O
; O
greater O
contrasts O
were O
seen O
in O
aes O
, O
especially O
extrapyramidal B-Disease
symptoms I-Disease
. O

salvage O
therapy O
with O
nelarabine O
, O
etoposide O
, O
and O
cyclophosphamide O
in O
relapsed O
/ O
refractory O
paediatric O
t B-Disease
- I-Disease
cell I-Disease
lymphoblastic I-Disease
leukaemia I-Disease
and I-Disease
lymphoma I-Disease
. O

a O
combination O
of O
5 O
d O
of O
nelarabine O
( O
arag O
) O
with O
5 O
d O
of O
etoposide O
( O
vp O
) O
and O
cyclophosphamide O
( O
cpm O
) O
and O
prophylactic O
intrathecal O
chemotherapy O
was O
used O
as O
salvage O
therapy O
in O
seven O
children O
with O
refractory O
or O
relapsed O
t B-Disease
- I-Disease
cell I-Disease
leukaemia I-Disease
or I-Disease
lymphoma I-Disease
. O

the O
most O
common O
side O
effects O
attributable O
to O
the O
arag O
included O
grade O
2 O
and O
3 O
sensory O
and O
motor O
neuropathy B-Disease
and O
musculoskeletal B-Disease
pain I-Disease
. O

haematological B-Disease
toxicity I-Disease
was O
greater O
for O
the O
combination O
than O
arag O
alone O
, O
although O
median O
time O
to O
neutrophil O
and O
platelet O
recovery O
was O
consistent O
with O
other O
salvage O
therapies O
. O

our O
experience O
supports O
the O
safety O
of O
giving O
arag O
as O
salvage O
therapy O
in O
synchrony O
with O
etoposide O
and O
cyclophosphamide O
, O
although O
neurological B-Disease
toxicity I-Disease
must O
be O
closely O
monitored O
. O

effect O
of O
adriamycin O
combined O
with O
whole O
body O
hyperthermia B-Disease
on O
tumor B-Disease
and O
normal O
tissues O
. O

thermal O
enhancement O
of O
adriamycin O
- O
mediated O
antitumor O
activity O
and O
normal O
tissue O
toxicities B-Disease
by O
whole O
body O
hyperthermia B-Disease
were O
compared O
using O
a O
f344 O
rat O
model O
. O

antitumor O
activity O
was O
studied O
using O
a O
tumor B-Disease
growth O
delay O
assay O
. O

acute O
normal O
tissue O
toxicities B-Disease
( O
i O
. O

e O
. O

, O
leukopenia B-Disease
and O
thrombocytopenia B-Disease
) O
and O
late O
normal O
tissue O
toxicities B-Disease
( O
i O
. O

e O
. O

, O
myocardial B-Disease
and I-Disease
kidney I-Disease
injury I-Disease
) O
were O
evaluated O
by O
functional O
/ O
physiological O
assays O
and O
by O
morphological O
techniques O
. O

whole O
body O
hyperthermia B-Disease
( O
120 O
min O
at O
41 O
. O

5 O
degrees O
c O
) O
enhanced O
both O
adriamycin O
- O
mediated O
antitumor O
activity O
and O
toxic O
side O
effects O
. O

thermal O
enhancement O
ratios O
estimated O
for O
nan O
acute O
nan O
hematological O
changes O
were O
1 O
. O

3 O
, O
whereas O
those O
estimated O
for O
nan O
late O
nan O
damage O
( O
based O
on O
morphological O
cardiac B-Disease
and I-Disease
renal I-Disease
lesions I-Disease
) O
varied O
between O
2 O
. O

4 O
and O
4 O
. O

3 O
. O

thus O
, O
while O
whole O
body O
hyperthermia B-Disease
enhances O
adriamycin O
- O
mediated O
antitumor O
effect O
, O
normal O
tissue O
toxicity B-Disease
is O
also O
increased O
, O
and O
the O
potential O
therapeutic O
gain O
of O
the O
combined O
modality O
treatment O
is O
eroded O
. O

permeability O
, O
ultrastructural O
changes O
, O
and O
distribution O
of O
novel O
proteins O
in O
the O
glomerular O
barrier O
in O
early O
puromycin O
aminonucleoside O
nephrosis B-Disease
. O

background O
/ O
aims O
: O
it O
is O
still O
unclear O
what O
happens O
in O
the O
glomerulus O
when O
proteinuria B-Disease
starts O
. O

using O
puromycin O
aminonucleoside O
nephrosis B-Disease
( O
pan O
) O
rats O
, O
we O
studied O
early O
ultrastructural O
and O
permeability O
changes O
in O
relation O
to O
the O
expression O
of O
the O
podocyte O
- O
associated O
molecules O
nephrin O
, O
a O
- O
actinin O
, O
dendrin O
, O
and O
plekhh2 O
, O
the O
last O
two O
of O
which O
were O
only O
recently O
discovered O
in O
podocytes O
. O

results O
: O
by O
day O
2 O
, O
some O
patchy O
foot O
process O
effacement O
, O
but O
no O
proteinuria B-Disease
, O
appeared O
. O

by O
day O
4 O
, O
foot O
process O
effacement O
was O
complete O
and O
proteinuria B-Disease
appeared O
in O
parallel O
with O
signs O
of O
size O
barrier O
damage O
. O

conclusions O
: O
pan O
glomeruli O
already O
showed O
significant O
pathology O
by O
day O
4 O
, O
despite O
relatively O
mild O
proteinuria B-Disease
. O

a O
novel O
, O
multiple O
symptom O
model O
of O
obsessive B-Disease
- I-Disease
compulsive I-Disease
- I-Disease
like I-Disease
behaviors I-Disease
in O
animals O
. O

background O
: O
current O
animal O
models O
of O
obsessive B-Disease
- I-Disease
compulsive I-Disease
disorder I-Disease
( O
ocd B-Disease
) O
typically O
involve O
acute O
, O
drug O
- O
induced O
symptom O
provocation O
or O
a O
genetic O
association O
with O
stereotypies O
or O
anxiety B-Disease
. O

none O
of O
these O
current O
models O
demonstrate O
multiple O
ocd B-Disease
- O
like O
behaviors O
. O

results O
: O
clomipramine O
exposure O
in O
immature O
rats O
produced O
significant O
behavioral O
and O
biochemical O
changes O
that O
include O
enhanced O
anxiety B-Disease
( O
elevated O
plus O
maze O
and O
marble O
burying O
) O
, O
behavioral B-Disease
inflexibility I-Disease
( O
perseveration O
in O
the O
spontaneous O
alternation O
task O
and O
impaired O
reversal O
learning O
) O
, O
working O
memory B-Disease
impairment I-Disease
( O
e O
. O

g O
. O

, O
win O
- O
shift O
paradigm O
) O
, O
hoarding B-Disease
, O
and O
corticostriatal B-Disease
dysfunction I-Disease
. O

conclusions O
: O
this O
is O
the O
first O
demonstration O
of O
multiple O
symptoms O
consistent O
with O
an O
ocd B-Disease
- O
like O
profile O
in O
animals O
. O

moreover O
, O
these O
behaviors O
are O
accompanied O
by O
biochemical O
changes O
in O
brain O
regions O
previously O
identified O
as O
relevant O
to O
ocd B-Disease
. O

this O
novel O
model O
of O
ocd B-Disease
demonstrates O
that O
drug O
exposure O
during O
a O
sensitive O
period O
can O
program O
disease O
- O
like O
systems O
permanently O
, O
which O
could O
have O
implications O
for O
current O
and O
future O
therapeutic O
strategies O
for O
this O
and O
other O
psychiatric B-Disease
disorders I-Disease
. O

elevation O
of O
adam10 O
, O
adam17 O
, O
mmp O
- O
2 O
and O
mmp O
- O
9 O
expression O
with O
media O
degeneration O
features O
cacl2 O
- O
induced O
thoracic B-Disease
aortic I-Disease
aneurysm I-Disease
in O
a O
rat O
model O
. O

purpose O
: O
this O
study O
was O
designed O
to O
establish O
a O
rat O
model O
of O
thoracic B-Disease
aortic I-Disease
aneurysm I-Disease
( O
taa B-Disease
) O
by O
calcium O
chloride O
( O
cacl O
( O
2 O
) O
) O
- O
induced O
arterial B-Disease
injury I-Disease
and O
to O
explore O
the O
potential O
role O
of O
a O
disintegrin O
and O
metalloproteinase O
( O
adam O
) O
, O
matrix O
metalloproteinases O
( O
mmps O
) O
and O
their O
endogenous O
inhibitors O
( O
timps O
) O
in O
taa B-Disease
formation O
. O

conclusion O
: O
this O
study O
establishes O
a O
taa B-Disease
model O
by O
periarterial O
cacl O
( O
2 O
) O
exposure O
in O
rats O
, O
and O
demonstrates O
a O
significant O
elevation O
of O
expression O
of O
mmp O
- O
2 O
, O
mmp O
- O
9 O
, O
adam10 O
and O
adam17 O
in O
the O
pathogenesis O
of O
vascular O
remodeling O
. O

suxamethonium O
induced O
prolonged O
apnea B-Disease
in O
a O
patient O
receiving O
electroconvulsive O
therapy O
. O

suxamethonium O
causes O
prolonged O
apnea B-Disease
in O
patients O
in O
whom O
pseudocholinesterase O
enzyme O
gets O
deactivated O
by O
organophosphorus O
( O
op O
) O
poisons O
. O

here O
, O
we O
present O
a O
similar O
incident O
in O
a O
severely O
depressed B-Disease
patient O
who O
received O
electroconvulsive O
therapy O
( O
ect O
) O
. O

prolonged O
apnea B-Disease
in O
our O
case O
ensued O
because O
the O
information O
about O
suicidal O
attempt O
by O
op O
compound O
was O
concealed O
from O
the O
treating O
team O
. O

curcumin O
ameliorates O
cognitive B-Disease
dysfunction I-Disease
and O
oxidative O
damage O
in O
phenobarbitone O
and O
carbamazepine O
administered O
rats O
. O

the O
antiepileptic O
drugs O
, O
phenobarbitone O
and O
carbamazepine O
are O
well O
known O
to O
cause O
cognitive B-Disease
impairment I-Disease
on O
chronic O
use O
. O

the O
increase O
in O
free O
radical O
generation O
has O
been O
implicated O
as O
one O
of O
the O
important O
mechanisms O
of O
cognitive B-Disease
impairment I-Disease
by O
antiepileptic O
drugs O
. O

therefore O
, O
the O
present O
study O
was O
carried O
out O
to O
investigate O
the O
effect O
of O
chronic O
curcumin O
administration O
on O
phenobarbitone O
- O
and O
carbamazepine O
- O
induced O
cognitive B-Disease
impairment I-Disease
and O
oxidative O
stress O
in O
rats O
. O

the O
administration O
of O
phenobarbitone O
and O
carbamazepine O
for O
21days O
caused O
a O
significant O
impairment B-Disease
of I-Disease
learning I-Disease
and I-Disease
memory I-Disease
as O
well O
as O
an O
increased O
oxidative O
stress O
. O

concomitant O
curcumin O
administration O
prevented O
the O
cognitive B-Disease
impairment I-Disease
and O
decreased O
the O
increased O
oxidative O
stress O
induced O
by O
these O
antiepileptic O
drugs O
. O

these O
results O
show O
that O
curcumin O
has O
beneficial O
effect O
in O
mitigating O
the O
deterioration B-Disease
of I-Disease
cognitive I-Disease
functions I-Disease
and O
oxidative O
damage O
in O
rats O
treated O
with O
phenobarbitone O
and O
carbamazepine O
without O
significantly O
altering O
their O
serum O
concentrations O
. O

the O
findings O
suggest O
that O
curcumin O
can O
be O
considered O
as O
a O
potential O
safe O
and O
effective O
adjuvant O
to O
phenobarbitone O
and O
carbamazepine O
therapy O
in O
preventing O
cognitive B-Disease
impairment I-Disease
associated O
with O
these O
drugs O
. O

can O
angiogenesis O
be O
a O
target O
of O
treatment O
for O
ribavirin O
associated O
hemolytic B-Disease
anemia I-Disease
? O
background O
/ O
aims O
: O
recently O
ribavirin O
has O
been O
found O
to O
inhibit O
angiogenesis O
and O
a O
number O
of O
angiogenesis O
inhibitors O
such O
as O
sunitinib O
and O
sorafenib O
have O
been O
found O
to O
cause O
acute O
hemolysis B-Disease
. O

we O
aimed O
to O
investigate O
whether O
there O
is O
a O
relation O
between O
hemoglobin O
, O
haptoglobin O
and O
angiogenesis O
soluble O
markers O
which O
are O
modifiable O
and O
can O
help O
in O
developing O
strategies O
against O
anemia B-Disease
. O

methods O
: O
fourteen O
patients O
chronically B-Disease
infected I-Disease
with I-Disease
hepatitis I-Disease
c I-Disease
virus I-Disease
were O
treated O
by O
pegylated O
interferon O
alpha O
2a O
and O
ribavirin O
. O

conclusion O
: O
this O
is O
the O
first O
study O
in O
the O
literature O
investigating O
a O
link O
between O
angiogenesis O
soluble O
markers O
and O
ribavirin O
induced O
anemia B-Disease
in O
patients O
with O
hepatitis B-Disease
c I-Disease
and O
we O
could O
not O
find O
any O
relation O
. O

reduction O
in O
injection O
pain B-Disease
using O
buffered O
lidocaine O
as O
a O
local O
anesthetic O
before O
cardiac O
catheterization O
. O

previous O
reports O
have O
suggested O
that O
pain B-Disease
associated O
with O
the O
injection O
of O
lidocaine O
is O
related O
to O
the O
acidic O
ph O
of O
the O
solution O
. O

to O
determine O
if O
the O
addition O
of O
a O
buffering O
solution O
to O
adjust O
the O
ph O
of O
lidocaine O
into O
the O
physiologic O
range O
would O
reduce O
pain B-Disease
during O
injection O
, O
we O
performed O
a O
blinded O
randomized O
study O
in O
patients O
undergoing O
cardiac O
catheterization O
. O

twenty O
patients O
were O
asked O
to O
quantify O
the O
severity O
of O
pain B-Disease
after O
receiving O
standard O
lidocaine O
in O
one O
femoral O
area O
and O
buffered O
lidocaine O
in O
the O
opposite O
femoral O
area O
. O

the O
mean O
pain B-Disease
score O
for O
buffered O
lidocaine O
was O
significantly O
lower O
than O
the O
mean O
score O
for O
standard O
lidocaine O
( O
2 O
. O

7 O
+ O
/ O
- O
1 O
. O

9 O
vs O
. O

3 O
. O

8 O
+ O
/ O
- O
2 O
. O

2 O
, O
p O
= O
0 O
. O

3 O
) O
. O

the O
ph O
adjustment O
of O
standard O
lidocaine O
can O
be O
accomplished O
easily O
in O
the O
catheterization O
laboratory O
before O
injection O
and O
results O
in O
a O
reduction O
of O
the O
pain B-Disease
occurring O
during O
the O
infiltration O
of O
tissues O
. O

effect O
of O
l O
- O
alpha O
- O
glyceryl O
- O
phosphorylcholine O
on O
amnesia B-Disease
caused O
by O
scopolamine O
. O

the O
present O
study O
was O
carried O
out O
to O
test O
the O
effects O
of O
l O
- O
alpha O
- O
glycerylphosphorylcholine O
( O
l O
- O
alpha O
- O
gfc O
) O
on O
memory B-Disease
impairment I-Disease
induced O
by O
scopolamine O
in O
man O
. O

the O
findings O
of O
this O
study O
indicate O
that O
the O
drug O
is O
able O
to O
antagonize O
impairment B-Disease
of I-Disease
attention I-Disease
and I-Disease
memory I-Disease
induced O
by O
scopolamine O
. O

importance O
of O
the O
field O
: O
fluoropyrimidines O
, O
in O
particular O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
, O
have O
been O
the O
mainstay O
of O
treatment O
for O
several O
solid O
tumors B-Disease
, O
including O
colorectal B-Disease
, I-Disease
breast I-Disease
and I-Disease
head I-Disease
and I-Disease
neck I-Disease
cancers I-Disease
, O
for O
> O
40 O
years O
. O

what O
the O
reader O
will O
gain O
: O
the O
reader O
will O
gain O
better O
insight O
into O
the O
safety O
of O
capecitabine O
in O
special O
populations O
such O
as O
patients O
with O
advanced O
age O
, O
renal B-Disease
and I-Disease
kidney I-Disease
disease I-Disease
. O

it O
has O
shown O
promising O
results O
alone O
or O
in O
combination O
with O
other O
chemotherapeutic O
agents O
in O
colorectal B-Disease
, I-Disease
breast I-Disease
, I-Disease
pancreaticobiliary I-Disease
, I-Disease
gastric I-Disease
, I-Disease
renal I-Disease
cell I-Disease
and I-Disease
head I-Disease
and I-Disease
neck I-Disease
cancers I-Disease
. O

the O
most O
commonly O
reported O
toxic O
effects O
of O
capecitabine O
are O
diarrhea B-Disease
, O
nausea B-Disease
, O
vomiting B-Disease
, O
stomatitis B-Disease
and O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
. O

capecitabine O
has O
a O
well O
- O
established O
safety O
profile O
and O
can O
be O
given O
safely O
to O
patients O
with O
advanced O
age O
, O
hepatic B-Disease
and I-Disease
renal I-Disease
dysfunctions I-Disease
. O

levodopa O
- O
induced O
dyskinesias B-Disease
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
: O
filling O
the O
bench O
- O
to O
- O
bedside O
gap O
. O

levodopa O
is O
the O
most O
effective O
drug O
for O
the O
treatment O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

however O
, O
the O
long O
- O
term O
use O
of O
this O
dopamine O
precursor O
is O
complicated O
by O
highly O
disabling O
fluctuations O
and O
dyskinesias B-Disease
. O

although O
preclinical O
and O
clinical O
findings O
suggest O
pulsatile O
stimulation O
of O
striatal O
postsynaptic O
receptors O
as O
a O
key O
mechanism O
underlying O
levodopa O
- O
induced O
dyskinesias B-Disease
, O
their O
pathogenesis O
is O
still O
unclear O
. O

in O
recent O
years O
, O
evidence O
from O
animal O
models O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
has O
provided O
important O
information O
to O
understand O
the O
effect O
of O
specific O
receptor O
and O
post O
- O
receptor O
molecular O
mechanisms O
underlying O
the O
development O
of O
dyskinetic B-Disease
movements I-Disease
. O

recent O
preclinical O
and O
clinical O
data O
from O
promising O
lines O
of O
research O
focus O
on O
the O
differential O
role O
of O
presynaptic O
versus O
postsynaptic O
mechanisms O
, O
dopamine O
receptor O
subtypes O
, O
ionotropic O
and O
metabotropic O
glutamate O
receptors O
, O
and O
non O
- O
dopaminergic O
neurotransmitter O
systems O
in O
the O
pathophysiology O
of O
levodopa O
- O
induced O
dyskinesias B-Disease
. O

effects O
of O
pallidal O
neurotensin O
on O
haloperidol O
- O
induced O
parkinsonian B-Disease
catalepsy I-Disease
: O
behavioral O
and O
electrophysiological O
studies O
. O

the O
present O
study O
aimed O
to O
investigate O
the O
effects O
of O
pallidal O
neurotensin O
on O
haloperidol O
- O
induced O
parkinsonian B-Disease
symptoms I-Disease
. O

results O
: O
bilateral O
infusions O
of O
neurotensin O
into O
the O
globus O
pallidus O
reversed O
haloperidol O
- O
induced O
parkinsonian B-Disease
catalepsy I-Disease
in O
rats O
. O

carmofur O
- O
induced O
organic B-Disease
mental I-Disease
disorders I-Disease
. O

organic B-Disease
mental I-Disease
disorder I-Disease
was O
observed O
in O
a O
29 O
- O
year O
- O
old O
female O
in O
the O
prognostic O
period O
after O
the O
onset O
of O
carmofur O
- O
induced O
leukoencephalopathy B-Disease
. O

symptoms O
such O
as O
euphoria O
, O
emotional O
lability O
and O
puerile O
attitude O
noted O
in O
the O
patient O
were O
diagnosed O
as O
organic B-Disease
personality I-Disease
syndrome I-Disease
according O
to O
the O
criteria O
defined O
in O
the O
dsm O
- O
iii O
- O
r O
. O

it O
is O
referred O
to O
as O
a O
frontal B-Disease
lobe I-Disease
syndrome I-Disease
. O

consequently O
, O
carmofur O
- O
induced O
leukoencephalopathy B-Disease
may O
uncommonly O
result O
in O
organic B-Disease
personality I-Disease
syndrome I-Disease
in O
the O
residual O
state O
. O

it O
may O
be O
attributed O
to O
the O
structural B-Disease
damage I-Disease
to I-Disease
the I-Disease
frontal I-Disease
lobe I-Disease
. O

butyrylcholinesterase O
gene O
mutations O
in O
patients O
with O
prolonged O
apnea B-Disease
after O
succinylcholine O
for O
electroconvulsive O
therapy O
. O

we O
determined O
the O
bche O
activity O
and O
the O
bche O
genotype O
using O
molecular O
genetic O
methods O
, O
the O
duration O
of O
apnea B-Disease
, O
time O
to O
sufficient O
spontaneous O
ventilation O
and O
whether O
neuromuscular O
monitoring O
was O
used O
. O

the O
duration O
of O
apnea B-Disease
was O
compared O
with O
published O
data O
on O
normal O
subjects O
. O

the O
duration O
of O
apnea B-Disease
was O
5 O
- O
15 O
min O
compared O
with O
3 O
- O
5 O
. O

3 O
min O
from O
the O
literature O
. O

conclusion O
: O
eleven O
of O
13 O
patients O
with O
a O
prolonged O
duration O
of O
action O
of O
succinylcholine O
had O
mutations O
in O
bche O
, O
indicating O
that O
this O
is O
the O
possible O
reason O
for O
a O
prolonged O
period O
of O
apnea B-Disease
. O

perhexiline O
maleate O
and O
peripheral B-Disease
neuropathy I-Disease
. O

peripheral B-Disease
neuropathy I-Disease
has O
been O
noted O
as O
a O
complication O
of O
therapy O
with O
perhexiline O
maleate O
, O
a O
drug O
widely O
used O
in O
france O
( O
and O
in O
clinical O
trials O
in O
the O
united O
states O
) O
for O
the O
prophylactic O
treatment O
of O
angina B-Disease
pectoris I-Disease
. O

in O
24 O
patients O
with O
this O
complication O
, O
the O
marked O
slowing O
of O
motor O
nerve O
conduction O
velocity O
and O
the O
electromyographic O
changes O
imply O
mainly O
a O
demyelinating B-Disease
disorder I-Disease
. O

the O
underlying O
mechanism O
causing O
the O
neuropathy B-Disease
is O
not O
yet O
fully O
known O
, O
although O
some O
evidence O
indicates O
that O
it O
may O
be O
a O
lipid O
storage O
process O
. O

a O
phase O
i O
study O
of O
intravenous O
( O
iv O
) O
bolus O
4 O
' O
- O
0 O
- O
tetrahydropyranyladriamycin O
( O
pirarubicin O
) O
was O
done O
in O
55 O
patients O
in O
good O
performance O
status O
with O
refractory O
tumors B-Disease
. O

twenty O
- O
six O
had O
minimal O
prior O
therapy O
( O
good O
risk O
) O
, O
23 O
had O
extensive O
prior O
therapy O
( O
poor O
risk O
) O
, O
and O
six O
had O
renal B-Disease
and I-Disease
/ I-Disease
or I-Disease
hepatic I-Disease
dysfunction I-Disease
. O

the O
dose O
- O
limiting O
toxic O
effect O
was O
transient O
noncumulative O
granulocytopenia B-Disease
. O

less O
frequent O
toxic O
effects O
included O
thrombocytopenia B-Disease
, O
anemia B-Disease
, O
nausea B-Disease
, O
mild O
alopecia B-Disease
, O
phlebitis B-Disease
, O
and O
mucositis B-Disease
. O

myelosuppression B-Disease
was O
more O
in O
patients O
with O
hepatic B-Disease
dysfunction I-Disease
. O

activity O
was O
noted O
in O
mesothelioma B-Disease
, O
leiomyosarcoma B-Disease
, O
and O
basal B-Disease
cell I-Disease
carcinoma I-Disease
. O

ocular B-Disease
and I-Disease
auditory I-Disease
toxicity I-Disease
in O
hemodialyzed O
patients O
receiving O
desferrioxamine O
. O

during O
an O
18 O
- O
month O
period O
of O
study O
41 O
hemodialyzed O
patients O
receiving O
desferrioxamine O
( O
10 O
- O
40 O
mg O
/ O
kg O
bw O
/ O
3 O
times O
weekly O
) O
for O
the O
first O
time O
were O
monitored O
for O
detection O
of O
audiovisual B-Disease
toxicity I-Disease
. O

6 O
patients O
presented O
clinical O
symptoms O
of O
visual B-Disease
or I-Disease
auditory I-Disease
toxicity I-Disease
. O

visual B-Disease
toxicity I-Disease
was O
of O
retinal O
origin O
and O
was O
characterized O
by O
a O
tritan O
- O
type O
dyschromatopsy B-Disease
, O
sometimes O
associated O
with O
a B-Disease
loss I-Disease
of I-Disease
visual I-Disease
acuity I-Disease
and O
pigmentary B-Disease
retinal I-Disease
deposits I-Disease
. O

auditory B-Disease
toxicity I-Disease
was O
characterized O
by O
a O
mid O
- O
to O
high O
- O
frequency O
neurosensorial B-Disease
hearing I-Disease
loss I-Disease
and O
the O
lesion O
was O
of O
the O
cochlear O
type O
. O

desferrioxamine O
withdrawal O
resulted O
in O
a O
complete O
recovery O
of O
visual O
function O
in O
1 O
patient O
and O
partial O
recovery O
in O
3 O
, O
and O
a O
complete O
reversal O
of O
hearing B-Disease
loss I-Disease
in O
3 O
patients O
and O
partial O
recovery O
in O
3 O
. O

this O
toxicity B-Disease
appeared O
in O
patients O
receiving O
the O
higher O
doses O
of O
desferrioxamine O
or O
coincided O
with O
the O
normalization O
of O
ferritin O
or O
aluminium O
serum O
levels O
. O

the O
data O
indicate O
that O
audiovisual B-Disease
toxicity I-Disease
is O
not O
an O
infrequent O
complication O
in O
hemodialyzed O
patients O
receiving O
desferrioxamine O
. O

serial O
epilepsy B-Disease
caused O
by O
levodopa O
/ O
carbidopa O
administration O
in O
two O
patients O
on O
hemodialysis O
. O

two O
patients O
with O
similar O
clinical O
features O
are O
presented O
: O
both O
patients O
had O
chronic B-Disease
renal I-Disease
failure I-Disease
, O
on O
hemodialysis O
for O
many O
years O
but O
recently O
begun O
on O
a O
high O
- O
flux O
dialyzer O
; O
both O
had O
been O
receiving O
a O
carbidopa O
/ O
levodopa O
preparation O
; O
and O
both O
had O
the O
onset O
of O
hallucinosis B-Disease
and O
recurrent O
seizures B-Disease
, O
which O
were O
refractory O
to O
anticonvulsants O
. O

randomized O
, O
double O
- O
blind O
trial O
of O
mazindol O
in O
duchenne B-Disease
dystrophy I-Disease
. O

there O
is O
evidence O
that O
growth O
hormone O
may O
be O
related O
to O
the O
progression O
of O
weakness B-Disease
in O
duchenne B-Disease
dystrophy I-Disease
. O

we O
conducted O
a O
12 O
- O
month O
controlled O
trial O
of O
mazindol O
, O
a O
putative O
growth O
hormone O
secretion O
inhibitor O
, O
in O
83 O
boys O
with O
duchenne B-Disease
dystrophy I-Disease
. O

the O
study O
was O
designed O
to O
have O
a O
power O
of O
greater O
than O
0 O
. O

90 O
to O
detect O
a O
slowing O
to O
25 O
% O
of O
the O
expected O
rate O
of O
progression O
of O
weakness B-Disease
at O
p O
less O
than O
0 O
. O

5 O
. O

side O
effects O
attributable O
to O
mazindol O
included O
decreased B-Disease
appetite I-Disease
( O
36 O
% O
) O
, O
dry B-Disease
mouth I-Disease
( O
10 O
% O
) O
, O
behavioral O
change O
( O
22 O
% O
) O
, O
and O
gastrointestinal B-Disease
symptoms I-Disease
( O
18 O
% O
) O
; O
mazindol O
dosage O
was O
reduced O
in O
43 O
% O
of O
patients O
. O

mazindol O
doses O
not O
slow O
the O
progression O
of O
weakness B-Disease
in O
duchenne B-Disease
dystrophy I-Disease
. O

amnesia B-Disease
produced O
by O
scopolamine O
and O
cycloheximide O
were O
reversed O
by O
morphine O
given O
30 O
min O
before O
the O
test O
trial O
( O
pre O
- O
test O
) O
, O
and O
pre O
- O
test O
morphine O
also O
facilitated O
the O
memory O
retrieval O
in O
the O
animals O
administered O
naloxone O
during O
the O
training O
trial O
. O

similarly O
, O
pre O
- O
test O
scopolamine O
partially O
reversed O
the O
scopolamine O
- O
induced O
amnesia B-Disease
, O
but O
not O
significantly O
; O
and O
pre O
- O
test O
cycloheximide O
failed O
to O
reverse O
the O
cycloheximide O
- O
induced O
amnesia B-Disease
. O

in O
unanesthetized O
, O
spontaneously O
hypertensive B-Disease
rats O
the O
decrease O
in O
blood O
pressure O
and O
heart O
rate O
produced O
by O
intravenous O
clonidine O
, O
5 O
to O
20 O
micrograms O
/ O
kg O
, O
was O
inhibited O
or O
reversed O
by O
nalozone O
, O
0 O
. O

2 O
to O
2 O
mg O
/ O
kg O
. O

the O
hypotensive B-Disease
effect O
of O
100 O
mg O
/ O
kg O
alpha O
- O
methyldopa O
was O
also O
partially O
reversed O
by O
naloxone O
. O

in O
brain O
membranes O
from O
spontaneously O
hypertensive B-Disease
rats O
clonidine O
, O
10 O
( O
- O
8 O
) O
to O
10 O
( O
- O
5 O
) O
m O
, O
did O
not O
influence O
stereoselective O
binding O
of O
[ O
3h O
] O
- O
naloxone O
( O
8 O
nm O
) O
, O
and O
naloxone O
, O
10 O
( O
- O
8 O
) O
to O
10 O
( O
- O
4 O
) O
m O
, O
did O
not O
influence O
clonidine O
- O
suppressible O
binding O
of O
[ O
3h O
] O
- O
dihydroergocryptine O
( O
1 O
nm O
) O
. O

these O
findings O
indicate O
that O
in O
spontaneously O
hypertensive B-Disease
rats O
the O
effects O
of O
central O
alpha O
- O
adrenoceptor O
stimulation O
involve O
activation O
of O
opiate O
receptors O
. O

neurotoxicity B-Disease
of O
halogenated O
hydroxyquinolines O
: O
clinical O
analysis O
of O
cases O
reported O
outside O
japan O
. O

an O
analysis O
is O
presented O
of O
220 O
cases O
of O
possible O
neurotoxic B-Disease
reactions O
to O
halogenated O
hydroxyquinolines O
reported O
from O
outside O
japan O
. O

in O
six O
of O
the O
probable O
cases O
the O
neurological B-Disease
disturbance I-Disease
consisted O
of O
an O
acute O
reversible O
encephalopathy B-Disease
usually O
related O
to O
the O
ingestion O
of O
a O
high O
dose O
of O
clioquinol O
over O
a O
short O
period O
. O

the O
most O
common O
manifestation O
, O
observed O
in O
15 O
further O
cases O
, O
was O
isolated O
optic B-Disease
atrophy I-Disease
. O

this O
was O
most O
frequently O
found O
in O
children O
, O
many O
of O
whom O
had O
received O
clioquinol O
as O
treatment O
for O
acrodermatitis B-Disease
enteropathica I-Disease
. O

in O
the O
remaining O
cases O
, O
a O
combination O
of O
myelopathy B-Disease
, O
visual B-Disease
disturbance I-Disease
, O
and O
peripheral B-Disease
neuropathy I-Disease
was O
the O
most O
common O
manifestation O
. O

isolated O
myelopathy B-Disease
or O
peripheral B-Disease
neuropathy I-Disease
, O
or O
these O
manifestations O
occurring O
together O
, O
were O
infrequent O
. O

the O
onset O
of O
all O
manifestations O
( O
except O
toxic O
encephalopathy B-Disease
) O
was O
usually O
subacute O
, O
with O
subsequent O
partial O
recovery O
. O

the O
full O
syndrome O
of O
subacute O
myelo B-Disease
- I-Disease
optic I-Disease
neuropathy I-Disease
was O
more O
frequent O
in O
women O
, O
but O
they O
tended O
to O
have O
taken O
greater O
quantities O
of O
the O
drug O
. O

prazosin O
- O
induced O
stress B-Disease
incontinence I-Disease
. O

a O
case O
of O
genuine O
stress B-Disease
incontinence I-Disease
due O
to O
prazosin O
, O
a O
common O
antihypertensive O
drug O
, O
is O
presented O
. O

her O
incontinence B-Disease
resolved O
with O
the O
change O
of O
medication O
. O

patients O
who O
present O
with O
stress B-Disease
incontinence I-Disease
while O
taking O
prazosin O
should O
change O
their O
antihypertensive O
medication O
before O
considering O
surgery O
, O
because O
their O
incontinence B-Disease
may O
resolve O
spontaneously O
with O
a O
change O
in O
drug O
therapy O
. O

myocardial B-Disease
infarction I-Disease
following O
sublingual O
administration O
of O
isosorbide O
dinitrate O
. O

a O
78 O
- O
year O
- O
old O
with O
healed O
septal O
necrosis B-Disease
suffered O
a O
recurrent O
myocardial B-Disease
infarction I-Disease
of O
the O
anterior O
wall O
following O
the O
administration O
of O
isosorbide O
dinitrate O
5 O
mg O
sublingually O
. O

after O
detailing O
the O
course O
of O
events O
, O
we O
discuss O
the O
role O
of O
paradoxical O
coronary O
spasm B-Disease
and O
hypotension B-Disease
- O
mediated O
myocardial B-Disease
ischemia I-Disease
occurring O
downstream O
to O
significant O
coronary B-Disease
arterial I-Disease
stenosis I-Disease
in O
the O
pathophysiology O
of O
acute B-Disease
coronary I-Disease
insufficiency I-Disease
. O

the O
incidence O
of O
postoperative O
respiratory O
apnoea B-Disease
was O
compared O
between O
five O
patients O
receiving O
a O
continuous O
i O
. O

v O
. O

infusion O
of O
morphine O
( O
mean O
73 O
. O

6 O
mg O
) O
and O
five O
patients O
receiving O
a O
continuous O
extradural O
infusion O
of O
0 O
. O

25 O
% O
bupivacaine O
( O
mean O
192 O
mg O
) O
in O
the O
24 O
- O
h O
period O
following O
upper O
abdominal O
surgery O
. O

both O
obstructive B-Disease
( I-Disease
p I-Disease
less I-Disease
than I-Disease
0 I-Disease
. I-Disease

5 I-Disease
) I-Disease
and I-Disease
central I-Disease
apnoea I-Disease
( O
p O
less O
than O
0 O
. O

5 O
) O
occurred O
more O
frequently O
in O
patients O
who O
had O
a O
morphine O
infusion O
. O

there O
was O
also O
a O
higher O
incidence O
of O
tachyarrhythmias B-Disease
( O
p O
less O
than O
0 O
. O

5 O
) O
and O
ventricular B-Disease
ectopic I-Disease
beats I-Disease
( O
p O
less O
than O
0 O
. O

5 O
) O
in O
the O
morphine O
infusion O
group O
. O

effects O
of O
aminophylline O
on O
the O
threshold O
for O
initiating O
ventricular B-Disease
fibrillation I-Disease
during O
respiratory B-Disease
failure I-Disease
. O

cardiac B-Disease
arrhythmias I-Disease
have O
frequently O
been O
reported O
in O
association O
with O
respiratory B-Disease
failure I-Disease
. O

the O
possible O
additive O
role O
of O
pharmacologic O
agents O
in O
precipitating O
cardiac B-Disease
disturbances I-Disease
in O
patients O
with O
respiratory B-Disease
failure I-Disease
has O
only O
recently O
been O
emphasized O
. O

the O
effects O
of O
aminophylline O
on O
the O
ventricular B-Disease
fibrillation I-Disease
threshold O
during O
normal O
acid O
- O
base O
conditions O
and O
during O
respiratory B-Disease
failure I-Disease
were O
studied O
in O
anesthetized O
open O
chest O
dogs O
. O

the O
ventricular B-Disease
fibrillation I-Disease
threshold O
was O
measured O
by O
passing O
a O
gated O
train O
of O
12 O
constant O
current O
pulses O
through O
the O
ventricular O
myocardium O
during O
the O
vulnerable O
period O
of O
the O
cardiac O
cycle O
. O

during O
the O
infusion O
of O
aminophylline O
, O
the O
ventricular B-Disease
fibrillation I-Disease
threshold O
was O
reduced O
by O
30 O
to O
40 O
percent O
of O
the O
control O
when O
ph O
and O
partial O
pressures O
of O
oxygen O
( O
po2 O
) O
and O
carbon O
dioxide O
( O
co2 O
) O
were O
kept O
within O
normal O
limits O
. O

when O
respiratory B-Disease
failure I-Disease
was O
produced O
by O
hypoventilation B-Disease
( O
ph O
7 O
. O

5 O
to O
7 O
. O

25 O
; O
pc02 O
70 O
to O
100 O
mm O
hg O
: O
p02 O
20 O
to O
40 O
mm O
hg O
) O
, O
infusion O
of O
aminophylline O
resulted O
in O
an O
even O
greater O
decrease O
in O
ventricular B-Disease
fibrillation I-Disease
threshold O
to O
60 O
percent O
of O
the O
control O
level O
. O

these O
experiments O
suggest O
that O
although O
many O
factors O
may O
contribute O
to O
the O
increased O
incidence O
of O
ventricular B-Disease
arrhythmias I-Disease
in O
respiratory B-Disease
failure I-Disease
, O
pharmacologic O
agents O
, O
particularly O
aminophylline O
, O
may O
play O
a O
significant O
role O
. O

pentoxifylline O
( O
trental O
) O
does O
not O
inhibit O
dipyridamole O
- O
induced O
coronary O
hyperemia B-Disease
: O
implications O
for O
dipyridamole O
- O
thallium O
- O
201 O
myocardial O
imaging O
. O

dipyridamole O
- O
thallium O
- O
201 O
imaging O
is O
often O
performed O
in O
patients O
unable O
to O
exercise O
because O
of O
peripheral B-Disease
vascular I-Disease
disease I-Disease
. O

many O
of O
these O
patients O
are O
taking O
pentoxifylline O
( O
trental O
) O
, O
a O
methylxanthine O
derivative O
which O
may O
improve O
intermittent B-Disease
claudication I-Disease
. O

whether O
pentoxifylline O
inhibits O
dipyridamole O
- O
induced O
coronary O
hyperemia B-Disease
like O
other O
methylxanthines O
such O
as O
theophylline O
and O
should O
be O
stopped O
prior O
to O
dipyridamole O
- O
thallium O
- O
201 O
imaging O
is O
unknown O
. O

neither O
dose O
of O
pentoxifylline O
significantly O
decreased O
the O
dipyridamole O
- O
induced O
hyperemia B-Disease
, O
while O
peak O
coronary O
blood O
flow O
was O
significantly O
lower O
after O
theophylline O
( O
p O
less O
than O
0 O
. O

1 O
) O
. O

we O
conclude O
that O
pentoxyifylline O
does O
not O
inhibit O
dipyridamole O
- O
induced O
coronary O
hyperemia B-Disease
even O
at O
high O
doses O
. O

cause O
of O
death B-Disease
among O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
: O
a O
rare O
mortality O
due O
to O
cerebral B-Disease
haemorrhage I-Disease
. O

causes O
of O
death B-Disease
, O
with O
special O
reference O
to O
cerebral B-Disease
haemorrhage I-Disease
, O
among O
240 O
patients O
with O
pathologically O
verified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
were O
investigated O
using O
the O
annuals O
of O
the O
pathological O
autopsy O
cases O
in O
japan O
from O
1981 O
to O
1985 O
. O

the O
leading O
causes O
of O
death B-Disease
were O
pneumonia B-Disease
and O
bronchitis B-Disease
( O
44 O
. O

1 O
% O
) O
, O
malignant O
neoplasms B-Disease
( O
11 O
. O

6 O
% O
) O
, O
heart B-Disease
diseases I-Disease
( O
4 O
. O

1 O
% O
) O
, O
cerebral B-Disease
infarction I-Disease
( O
3 O
. O

7 O
% O
) O
and O
septicaemia B-Disease
( O
3 O
. O

3 O
% O
) O
. O

cerebral B-Disease
haemorrhage I-Disease
was O
the O
11th O
most O
frequent O
cause O
of O
death B-Disease
, O
accounting O
for O
only O
0 O
. O

8 O
% O
of O
deaths B-Disease
among O
the O
patients O
, O
whereas O
it O
was O
the O
5th O
most O
common O
cause O
of O
death B-Disease
among O
the O
japanese O
general O
population O
in O
1985 O
. O

the O
low O
incidence O
of O
cerebral B-Disease
haemorrhage I-Disease
as O
a O
cause O
of O
death B-Disease
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
may O
reflect O
the O
hypotensive B-Disease
effect O
of O
levodopa O
and O
a O
hypotensive B-Disease
mechanism O
due O
to O
reduced O
noradrenaline O
levels O
in O
the O
parkinsonian B-Disease
brain O
. O

possible O
intramuscular O
midazolam O
- O
associated O
cardiorespiratory B-Disease
arrest I-Disease
and O
death B-Disease
. O

although O
generally O
consisted O
safe O
when O
given O
intramuscularly O
, O
intravenous O
administration O
is O
known O
to O
cause O
respiratory B-Disease
and I-Disease
cardiovascular I-Disease
depression I-Disease
. O

this O
report O
describes O
the O
first O
published O
case O
of O
cardiorespiratory B-Disease
arrest I-Disease
and O
death B-Disease
associated O
with O
intramuscular O
administration O
of O
midazolam O
. O

myasthenia B-Disease
gravis I-Disease
presenting O
as O
weakness O
after O
magnesium O
administration O
. O

we O
studied O
a O
patient O
with O
no O
prior O
history O
of O
neuromuscular B-Disease
disease I-Disease
who O
became O
virtually O
quadriplegic B-Disease
after O
parenteral O
magnesium O
administration O
for O
preeclampsia B-Disease
. O

while O
she O
was O
weak O
, O
2 O
- O
hz O
repetitive O
stimulation O
revealed O
a O
decrement O
without O
significant O
facilitation O
at O
rapid O
rates O
or O
after O
exercise O
, O
suggesting O
postsynaptic B-Disease
neuromuscular I-Disease
blockade I-Disease
. O

although O
paralysis B-Disease
after O
magnesium O
administration O
has O
been O
described O
in O
patients O
with O
known O
myasthenia B-Disease
gravis I-Disease
, O
it O
has O
not O
previously O
been O
reported O
to O
be O
the O
initial O
or O
only O
manifestation O
of O
the O
disease O
. O

patients O
who O
are O
unusually O
sensitive O
to O
the O
neuromuscular O
effects O
of O
magnesium O
should O
be O
suspected O
of O
having O
an O
underlying O
disorder B-Disease
of I-Disease
neuromuscular I-Disease
transmission I-Disease
. O

no O
hepatic O
preneoplastic O
nodules O
or O
hepatocellular B-Disease
carcinomas I-Disease
developed O
in O
rats O
fed O
the O
plain O
choline O
- O
supplemented O
diet O
, O
while O
one O
preneoplastic O
nodule O
and O
one O
hepatocellular B-Disease
carcinoma I-Disease
developed O
in O
two O
rats O
fed O
the O
same O
diet O
containing O
phenobarbital O
. O

the O
incidence O
of O
preneoplastic O
nodules O
and O
of O
hepatocellular B-Disease
carcinomas I-Disease
was O
10 O
% O
and O
37 O
% O
, O
respectively O
, O
in O
rats O
fed O
the O
plain O
choline O
- O
devoid O
diet O
, O
and O
17 O
% O
and O
30 O
% O
, O
in O
rats O
fed O
the O
phenobarbital O
- O
containing O
choline O
- O
devoid O
diet O
. O

liver B-Disease
enlargement I-Disease
and O
muscle B-Disease
wastage I-Disease
occurred O
in O
wistar O
rats O
following O
the O
subcutaneous O
administration O
of O
prednisolone O
. O

differential O
effects O
of O
gamma O
- O
hexachlorocyclohexane O
( O
lindane O
) O
on O
pharmacologically O
- O
induced O
seizures B-Disease
. O

gamma O
- O
hexachlorocyclohexane O
( O
gamma O
- O
hch O
) O
, O
the O
active O
ingredient O
of O
the O
insecticide O
lindane O
, O
has O
been O
shown O
to O
decrease O
seizure B-Disease
threshold O
to O
pentylenetrazol O
( O
ptz O
) O
3 O
h O
after O
exposure O
to O
gamma O
- O
hch O
and O
conversely O
increase O
threshold O
to O
ptz O
- O
induced O
seizures B-Disease
24 O
h O
after O
exposure O
to O
gamma O
- O
hch O
( O
vohland O
et O
al O
. O

1981 O
) O
. O

in O
this O
study O
, O
the O
severity O
of O
response O
to O
other O
seizure B-Disease
- O
inducing O
agents O
was O
tested O
in O
mice O
1 O
and O
24 O
h O
after O
intraperitoneal O
administration O
of O
80 O
mg O
/ O
kg O
gamma O
- O
hch O
. O

one O
hour O
after O
the O
administration O
of O
gamma O
- O
hch O
, O
the O
activity O
of O
seizure B-Disease
- O
inducing O
agents O
was O
increased O
, O
regardless O
of O
their O
mechanism O
, O
while O
24 O
h O
after O
gamma O
- O
hch O
a O
differential O
response O
was O
observed O
. O

seizure B-Disease
activity O
due O
to O
ptz O
and O
picrotoxin O
( O
ptx O
) O
was O
significantly O
decreased O
; O
however O
, O
seizure B-Disease
activity O
due O
to O
3 O
- O
mercaptopropionic O
acid O
( O
mpa O
) O
, O
bicuculline O
( O
bcc O
) O
, O
methyl O
6 O
, O
7 O
- O
dimethoxy O
- O
4 O
- O
ethyl O
- O
b O
- O
carboline O
- O
3 O
- O
carboxylate O
( O
dmcm O
) O
, O
or O
strychnine O
( O
str O
) O
was O
not O
different O
from O
control O
. O

the O
pharmacological O
challenge O
data O
suggest O
that O
tolerance O
may O
occur O
to O
seizure B-Disease
activity O
induced O
by O
ptz O
and O
ptx O
24 O
h O
after O
gamma O
- O
hch O
, O
since O
the O
response O
to O
only O
these O
two O
seizure B-Disease
- O
inducing O
agents O
is O
decreased O
. O

the O
in O
vitro O
data O
suggest O
that O
the O
site O
responsible O
for O
the O
decrease O
in O
seizure B-Disease
activity O
24 O
h O
after O
gamma O
- O
hch O
may O
be O
the O
gaba O
- O
a O
receptor O
- O
linked O
chloride O
channel O
. O

tolerance O
and O
antiviral O
effect O
of O
ribavirin O
in O
patients O
with O
argentine B-Disease
hemorrhagic I-Disease
fever I-Disease
. O

tolerance O
and O
antiviral O
effect O
of O
ribavirin O
was O
studied O
in O
6 O
patients O
with O
argentine B-Disease
hemorrhagic I-Disease
fever I-Disease
( O
ahf B-Disease
) O
of O
more O
than O
8 O
days O
of O
evolution O
. O

administration O
of O
ribavirin O
resulted O
in O
a O
neutralization O
of O
viremia B-Disease
and O
a O
drop O
of O
endogenous O
interferon O
titers O
. O

the O
average O
time O
of O
death B-Disease
was O
delayed O
. O

a O
reversible O
anemia B-Disease
was O
the O
only O
adverse O
effect O
observed O
. O

from O
these O
results O
, O
we O
conclude O
that O
ribavirin O
has O
an O
antiviral O
effect O
in O
advanced O
cases O
of O
ahf B-Disease
, O
and O
that O
anemia B-Disease
, O
the O
only O
secondary O
reaction O
observed O
, O
can O
be O
easily O
managed O
. O

the O
possible O
beneficial O
effect O
of O
ribavirin O
during O
the O
initial O
days O
of O
ahf B-Disease
is O
discussed O
. O

is O
the O
treatment O
of O
scabies B-Disease
hazardous O
? O
treatment O
for O
scabies B-Disease
is O
usually O
initiated O
by O
general O
practitioners O
; O
most O
consider O
lindane O
( O
gamma O
benzene O
hexachloride O
) O
the O
treatment O
of O
choice O
. O

evidence O
is O
accumulating O
that O
lindane O
can O
be O
toxic B-Disease
to I-Disease
the I-Disease
central I-Disease
nervous I-Disease
system I-Disease
and O
may O
be O
associated O
with O
aplastic B-Disease
anaemia I-Disease
. O

this O
literature O
review O
suggests O
that O
general O
practitioners O
should O
prescribe O
scabicides O
with O
increased O
caution O
for O
certain O
at O
- O
risk O
groups O
, O
and O
give O
adequate O
warnings O
regarding O
potential O
toxicity B-Disease
. O

the O
initial O
dose O
of O
amantadine O
depressed B-Disease
locomotor O
activity O
in O
all O
mouse O
strains O
studied O
with O
the O
balb O
/ O
c O
mice O
being O
the O
most O
sensitive O
. O

readministration O
of O
amantadine O
, O
after O
a O
drug O
- O
free O
overnight O
period O
, O
increased O
motility O
from O
respective O
saline O
control O
in O
all O
strains O
with O
exception O
of O
the O
balb O
/ O
c O
mice O
where O
suppression B-Disease
of I-Disease
motility I-Disease
occurred O
. O

the O
biochemical O
results O
of O
brain O
biogenic O
amines O
of O
balb O
/ O
c O
mouse O
strain O
suggest O
a O
probable O
decrease O
of O
catecholamine O
turnover O
rate O
and O
/ O
or O
metabolism O
by O
monoamine O
oxidase O
and O
a O
resulting O
increase O
in O
o O
- O
methylation O
of O
norepinephrine O
which O
may O
account O
for O
a O
behavioral B-Disease
depression I-Disease
caused O
by O
amantadine O
in O
the O
balb O
/ O
c O
mice O
. O

based O
on O
clinical O
data O
, O
indicating O
that O
chloroacetaldehyde O
( O
caa O
) O
is O
an O
important O
metabolite O
of O
oxazaphosphorine O
cytostatics O
, O
an O
experimental O
study O
was O
carried O
out O
in O
order O
to O
elucidate O
the O
role O
of O
caa O
in O
the O
development O
of O
hemorrhagic B-Disease
cystitis I-Disease
. O

the O
data O
demonstrate O
that O
caa O
after O
i O
. O

v O
. O

administration O
does O
not O
contribute O
to O
bladder B-Disease
damage I-Disease
. O

source O
of O
pain B-Disease
and O
primitive O
dysfunction O
in O
migraine B-Disease
: O
an O
identical O
site O
? O
twenty O
common O
migraine B-Disease
patients O
received O
a O
one O
sided O
frontotemporal O
application O
of O
nitroglycerin O
( O
10 O
patients O
) O
or O
placebo O
ointment O
( O
10 O
patients O
) O
in O
a O
double O
blind O
study O
. O

early O
onset O
migraine B-Disease
attacks O
were O
induced O
by O
nitroglycerin O
in O
seven O
out O
of O
10 O
patients O
versus O
no O
patient O
in O
the O
placebo O
group O
. O

subsequently O
20 O
migraine B-Disease
patients O
, O
who O
developed O
an O
early O
onset O
attack O
with O
frontotemporal O
nitroglycerin O
, O
received O
the O
drug O
in O
a O
second O
induction O
test O
at O
other O
body O
areas O
. O

no O
early O
onset O
migraine B-Disease
was O
observed O
. O

thus O
the O
migraine B-Disease
- O
inducing O
effect O
of O
nitroglycerin O
seems O
to O
depend O
on O
direct O
stimulation O
of O
the O
habitual O
site O
of O
pain B-Disease
, O
suggesting O
that O
the O
frontotemporal O
region O
is O
of O
crucial O
importance O
in O
the O
development O
of O
a O
migraine B-Disease
crisis O
. O

this O
is O
not O
consistent O
with O
a O
cns O
origin O
of O
migraine B-Disease
attack O
. O

hypersensitivity B-Disease
to O
carbamazepine O
presenting O
with O
a O
leukemoid B-Disease
reaction I-Disease
, O
eosinophilia B-Disease
, O
erythroderma B-Disease
, O
and O
renal B-Disease
failure I-Disease
. O

we O
report O
a O
patient O
in O
whom O
hypersensitivity B-Disease
to O
carbamazepine O
presented O
with O
generalized O
erythroderma B-Disease
, O
a O
severe O
leukemoid B-Disease
reaction I-Disease
, O
eosinophilia B-Disease
, O
hyponatremia B-Disease
, O
and O
renal B-Disease
failure I-Disease
. O

fluoxetine O
- O
induced O
akathisia B-Disease
: O
clinical O
and O
theoretical O
implications O
. O

five O
patients O
receiving O
fluoxetine O
for O
the O
treatment O
of O
obsessive B-Disease
compulsive I-Disease
disorder I-Disease
or O
major B-Disease
depression I-Disease
developed O
akathisia B-Disease
. O

the O
typical O
fluoxetine O
- O
induced O
symptoms O
of O
restlessness O
, O
constant O
pacing O
, O
purposeless O
movements O
of O
the O
feet O
and O
legs O
, O
and O
marked O
anxiety B-Disease
were O
indistinguishable O
from O
those O
of O
neuroleptic O
- O
induced O
akathisia B-Disease
. O

three O
patients O
who O
had O
experienced O
neuroleptic O
- O
induced O
akathisia B-Disease
in O
the O
past O
reported O
that O
the O
symptoms O
of O
fluoxetine O
- O
induced O
akathisia B-Disease
were O
identical O
, O
although O
somewhat O
milder O
. O

akathisia B-Disease
appeared O
to O
be O
a O
common O
side O
effect O
of O
fluoxetine O
and O
generally O
responded O
well O
to O
treatment O
with O
the O
beta O
- O
adrenergic O
antagonist O
propranolol O
, O
dose O
reduction O
, O
or O
both O
. O

the O
authors O
suggest O
that O
fluoxetine O
- O
induced O
akathisia B-Disease
may O
be O
caused O
by O
serotonergically O
mediated O
inhibition O
of O
dopaminergic O
neurotransmission O
and O
that O
the O
pathophysiology O
of O
fluoxetine O
- O
induced O
akathisia B-Disease
and O
tricyclic O
antidepressant O
- O
induced O
nan O
jitteriness O
nan O
may O
be O
identical O
. O

effect O
of O
converting O
enzyme O
inhibition O
on O
the O
course O
of O
adriamycin O
- O
induced O
nephropathy B-Disease
. O

the O
effect O
of O
the O
converting O
enzyme O
inhibitor O
( O
cei O
) O
enalapril O
was O
assessed O
in O
munich O
- O
wistar O
rats O
with O
established O
adriamycin O
nephrosis B-Disease
. O

rats O
were O
given O
a O
single O
dose O
of O
adriamycin O
and O
one O
month O
later O
divided O
into O
four O
groups O
matched O
for O
albuminuria B-Disease
, O
blood O
pressure O
, O
and O
plasma O
albumin O
concentration O
. O

these O
short O
- O
term O
studies O
showed O
that O
enalapril O
reduced O
arterial O
blood O
pressure O
( O
101 O
+ O
/ O
- O
2 O
vs O
. O

124 O
+ O
/ O
- O
3 O
mm O
hg O
, O
group O
2 O
vs O
. O

1 O
, O
p O
less O
than O
0 O
. O

5 O
) O
and O
glomerular O
capillary O
pressure O
( O
54 O
+ O
/ O
- O
1 O
vs O
. O

61 O
+ O
/ O
- O
2 O
mm O
hg O
, O
p O
less O
than O
0 O
. O

5 O
) O
without O
reducing O
albuminuria B-Disease
( O
617 O
+ O
/ O
- O
50 O
vs O
. O

570 O
+ O
/ O
- O
47 O
mg O
/ O
day O
) O
or O
gfr O
( O
1 O
. O

3 O
+ O
/ O
- O
0 O
. O

4 O
vs O
. O

1 O
. O

4 O
+ O
/ O
- O
0 O
. O

11 O
ml O
/ O
min O
) O
. O

groups O
3 O
and O
4 O
were O
studied O
at O
four O
and O
at O
six O
months O
to O
assess O
the O
effect O
of O
enalapril O
on O
progression O
of O
renal B-Disease
injury I-Disease
in O
adriamycin O
nephrosis B-Disease
. O

chronic O
enalapril O
treatment O
reduced O
blood O
pressure O
without O
reducing O
albuminuria B-Disease
in O
group O
4 O
. O

reduction O
in O
gfr O
was O
associated O
with O
the O
development O
of O
glomerular B-Disease
sclerosis I-Disease
in O
both O
treated O
and O
untreated O
rats O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
clotiazepam O
- O
induced O
acute O
hepatitis B-Disease
. O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
acute O
hepatitis B-Disease
with O
extensive B-Disease
hepatocellular I-Disease
necrosis I-Disease
, O
7 O
months O
after O
the O
onset O
of O
administration O
of O
clotiazepam O
, O
a O
thienodiazepine O
derivative O
. O

the O
administration O
of O
several O
benzodiazepines O
, O
chemically O
related O
to O
clotiazepam O
, O
did O
not O
interfere O
with O
recovery O
and O
did O
not O
induce O
any O
relapse O
of O
hepatitis B-Disease
. O

this O
observation O
shows O
that O
clotiazepam O
can O
induce O
acute O
hepatitis B-Disease
and O
suggests O
that O
there O
is O
no O
cross O
hepatotoxicity B-Disease
between O
clotiazepam O
and O
several O
benzodiazepines O
. O

5 O
- O
azacytidine O
potentiates O
initiation B-Disease
induced I-Disease
by I-Disease
carcinogens I-Disease
in O
rat O
liver O
. O

to O
test O
the O
validity O
of O
the O
hypothesis O
that O
hypomethylation O
of O
dna O
plays O
an O
important O
role O
in O
the O
initiation B-Disease
of I-Disease
carcinogenic I-Disease
process I-Disease
, O
5 O
- O
azacytidine O
( O
5 O
- O
azc O
) O
( O
10 O
mg O
/ O
kg O
) O
, O
an O
inhibitor O
of O
dna O
methylation O
, O
was O
given O
to O
rats O
during O
the O
phase O
of O
repair O
synthesis O
induced O
by O
the O
three O
carcinogens O
, O
benzo O
[ O
a O
] O
- O
pyrene O
( O
200 O
mg O
/ O
kg O
) O
, O
n O
- O
methyl O
- O
n O
- O
nitrosourea O
( O
60 O
mg O
/ O
kg O
) O
and O
1 O
, O
2 O
- O
dimethylhydrazine O
( O
1 O

, O
2 O
- O
dmh O
) O
( O
100 O
mg O
/ O
kg O
) O
. O

antihypertensive O
drugs O
and O
depression B-Disease
: O
a O
reappraisal O
. O

eighty O
- O
nine O
new O
referral O
hypertensive B-Disease
out O
- O
patients O
and O
46 O
new O
referral O
non O
- O
hypertensive B-Disease
chronically O
physically O
ill O
out O
- O
patients O
completed O
a O
mood O
rating O
scale O
at O
regular O
intervals O
for O
one O
year O
. O

the O
results O
showed O
a O
high O
prevalence O
of O
depression B-Disease
in O
both O
groups O
of O
patients O
, O
with O
no O
preponderance O
in O
the O
hypertensive B-Disease
group O
. O

hypertensive B-Disease
patients O
with O
psychiatric B-Disease
histories O
had O
a O
higher O
prevalence O
of O
depression B-Disease
than O
the O
comparison O
patients O
. O

this O
was O
accounted O
for O
by O
a O
significant O
number O
of O
depressions B-Disease
occurring O
in O
methyl O
dopa O
treated O
patients O
with O
psychiatric B-Disease
histories O
. O

chronic B-Disease
active I-Disease
hepatitis I-Disease
associated O
with O
diclofenac O
sodium O
therapy O
. O

although O
generally O
well O
- O
tolerated O
, O
asymptomatic O
abnormalities B-Disease
of I-Disease
liver I-Disease
function I-Disease
have O
been O
recorded O
and O
, O
less O
commonly O
, O
severe O
hepatitis B-Disease
induced O
by O
diclofenac O
. O

the O
patient O
described O
developed O
chronic B-Disease
active I-Disease
hepatitis I-Disease
after O
six O
months O
therapy O
with O
diclofenac O
sodium O
which O
progressed O
despite O
the O
withdrawal O
of O
the O
drug O
, O
a O
finding O
not O
previously O
reported O
. O

arterial O
hypertension B-Disease
as O
a O
complication O
of O
prolonged O
ketoconazole O
treatment O
. O

two O
of O
14 O
patients O
with O
cushing B-Disease
' I-Disease
s I-Disease
syndrome I-Disease
treated O
on O
a O
long O
- O
term O
basis O
with O
ketoconazole O
developed O
sustained O
hypertension B-Disease
. O

in O
both O
cases O
normal O
plasma O
and O
urinary O
free O
cortisol O
levels O
had O
been O
achieved O
following O
ketoconazole O
therapy O
, O
yet O
continuous O
blood O
pressure O
monitoring O
demonstrated O
hypertension B-Disease
31 O
( O
patient O
1 O
) O
and O
52 O
weeks O
( O
patient O
2 O
) O
after O
treatment O
. O

our O
findings O
show O
that O
long O
- O
term O
treatment O
with O
high O
doses O
of O
ketoconazole O
may O
induce O
enzyme O
blockade O
leading O
to O
mineralocorticoid O
- O
related O
hypertension B-Disease
. O

effects O
of O
an O
inhibitor O
of O
angiotensin O
converting O
enzyme O
( O
captopril O
) O
on O
pulmonary B-Disease
and I-Disease
renal I-Disease
insufficiency I-Disease
due O
to O
intravascular B-Disease
coagulation I-Disease
in O
the O
rat O
. O

induction O
of O
intravascular B-Disease
coagulation I-Disease
and O
inhibition O
of O
fibrinolysis O
by O
injection O
of O
thrombin O
and O
tranexamic O
acid O
( O
amca O
) O
in O
the O
rat O
gives O
rise O
to O
pulmonary B-Disease
and I-Disease
renal I-Disease
insufficiency I-Disease
resembling O
that O
occurring O
after O
trauma B-Disease
or O
sepsis B-Disease
in O
man O
. O

injection O
of O
captopril O
( O
1 O
mg O
/ O
kg O
) O
, O
an O
inhibitor O
of O
angiotensin O
converting O
enzyme O
( O
ace O
) O
, O
reduced O
both O
pulmonary B-Disease
and I-Disease
renal I-Disease
insufficiency I-Disease
in O
this O
rat O
model O
. O

renal B-Disease
damage I-Disease
as O
reflected O
by O
an O
increase O
in O
serum O
urea O
and O
in O
kidney O
weight O
was O
prevented O
by O
captopril O
. O

captopril O
may O
, O
by O
the O
same O
mechanism O
, O
reduce O
the O
increase O
in O
glomerular O
filtration O
that O
is O
known O
to O
occur O
after O
an O
injection O
of O
thrombin O
, O
thereby O
diminishing O
the O
aggregation O
of O
fibrin O
monomers O
in O
the O
glomeruli O
, O
with O
the O
result O
that O
less O
fibrin O
will O
be O
deposited O
and O
thus O
less O
kidney B-Disease
damage I-Disease
will O
be O
produced O
. O

stroke B-Disease
associated O
with O
cocaine O
use O
. O

we O
describe O
eight O
patients O
in O
whom O
cocaine O
use O
was O
related O
to O
stroke B-Disease
and O
review O
39 O
cases O
from O
the O
literature O
. O

stroke B-Disease
followed O
cocaine O
use O
by O
inhalation O
, O
intranasal O
, O
intravenous O
, O
and O
intramuscular O
routes O
. O

intracranial B-Disease
aneurysms I-Disease
or O
arteriovenous B-Disease
malformations I-Disease
were O
present O
in O
17 O
of O
32 O
patients O
studied O
angiographically O
or O
at O
autopsy O
; O
cerebral B-Disease
vasculitis I-Disease
was O
present O
in O
two O
patients O
. O

cerebral B-Disease
infarction I-Disease
occurred O
in O
10 O
patients O
( O
22 O
% O
) O
, O
intracerebral B-Disease
hemorrhage I-Disease
in O
22 O
( O
49 O
% O
) O
, O
and O
subarachnoid B-Disease
hemorrhage I-Disease
in O
13 O
( O
29 O
% O
) O
. O

these O
data O
indicate O
that O
( O
1 O
) O
the O
apparent O
incidence O
of O
stroke B-Disease
related O
to O
cocaine O
use O
is O
increasing O
; O
( O
2 O
) O
cocaine O
- O
associated O
stroke B-Disease
occurs O
primarily O
in O
young O
adults O
; O
( O
3 O
) O
stroke B-Disease
may O
follow O
any O
route O
of O
cocaine O
administration O
; O
( O
4 O
) O
stroke B-Disease
after O
cocaine O
use O
is O
frequently O
associated O
with O
intracranial B-Disease
aneurysms I-Disease
and O
arteriovenous B-Disease
malformations I-Disease
; O
and O
( O
5 O
) O
in O
cocaine O
- O
associated O
stroke B-Disease
, O
the O
frequency O
of O
intracranial B-Disease
hemorrhage I-Disease
exceeds O
that O
of O
cerebral B-Disease
infarction I-Disease
. O

a O
randomized O
comparison O
of O
labetalol O
and O
nitroprusside O
for O
induced O
hypotension B-Disease
. O

in O
a O
randomized O
study O
, O
labetalol O
- O
induced O
hypotension B-Disease
and O
nitroprusside O
- O
induced O
hypotension B-Disease
were O
compared O
in O
20 O
patients O
( O
10 O
in O
each O
group O
) O
scheduled O
for O
major O
orthopedic O
procedures O
. O

each O
patient O
was O
subjected O
to O
an O
identical O
anesthetic O
protocol O
and O
similar O
drug O
- O
induced O
reductions B-Disease
in I-Disease
mean I-Disease
arterial I-Disease
blood I-Disease
pressure I-Disease
( O
bp O
) O
( O
50 O
to O
55 O
mmhg O
) O
. O

nitroprusside O
infusion O
was O
associated O
with O
a O
significant O
( O
p O
less O
than O
0 O
. O

5 O
) O
increase B-Disease
in I-Disease
heart I-Disease
rate I-Disease
and I-Disease
cardiac I-Disease
output I-Disease
; O
rebound O
hypertension B-Disease
was O
observed O
in O
three O
patients O
after O
discontinuation O
of O
nitroprusside O
. O

sodium O
status O
influences O
chronic O
amphotericin O
b O
nephrotoxicity B-Disease
in O
rats O
. O

the O
nephrotoxic B-Disease
potential O
of O
amphotericin O
b O
( O
5 O
mg O
/ O
kg O
per O
day O
intraperitoneally O
for O
3 O
weeks O
) O
has O
been O
investigated O
in O
salt O
- O
depleted O
, O
normal O
- O
salt O
, O
and O
salt O
- O
loaded O
rats O
. O

flestolol O
produced O
a O
dose O
- O
dependent O
attenuation O
of O
isoproterenol O
- O
induced O
tachycardia B-Disease
. O

flestolol O
effectively O
reduced O
heart O
rate O
in O
patients O
with O
supraventricular B-Disease
tachyarrhythmia I-Disease
. O

in O
patients O
with O
unstable B-Disease
angina I-Disease
, O
flestolol O
infusion O
was O
found O
to O
be O
safe O
and O
effective O
in O
controlling O
chest B-Disease
pain I-Disease
. O

immunohistochemical O
, O
electron O
microscopic O
and O
morphometric O
studies O
of O
estrogen O
- O
induced O
rat O
prolactinomas B-Disease
after O
bromocriptine O
treatment O
. O

to O
clarify O
the O
effects O
of O
bromocriptine O
on O
prolactinoma B-Disease
cells O
in O
vivo O
, O
immunohistochemical O
, O
ultrastructural O
and O
morphometrical O
analyses O
were O
applied O
to O
estrogen O
- O
induced O
rat O
prolactinoma B-Disease
cells O
1 O
h O
and O
6 O
h O
after O
injection O
of O
bromocriptine O
( O
3 O
mg O
/ O
kg O
of O
body O
weight O
) O
. O

electron O
microscopy O
disclosed O
many O
secretory O
granules O
, O
slightly O
distorted O
rough O
endoplasmic O
reticulum O
, O
and O
partially O
dilated O
golgi O
cisternae O
in O
the O
prolactinoma B-Disease
cells O
. O

the O
prolactinoma B-Disease
cells O
at O
this O
time O
were O
well O
granulated O
, O
with O
vesiculated O
rough O
endoplasmic O
reticulum O
and O
markedly O
dilated O
golgi O
cisternae O
. O

electron O
microscopical O
immunohistochemistry O
revealed O
positive O
reaction O
products O
noted O
on O
the O
secretory O
granules O
, O
golgi O
cisternae O
, O
and O
endoplasmic O
reticulum O
of O
the O
untreated O
rat O
prolactinoma B-Disease
cells O
. O

however O
, O
only O
secretory O
granules O
showed O
the O
positive O
reaction O
products O
for O
prolactin O
6 O
h O
after O
bromocriptine O
treatment O
of O
the O
adenoma B-Disease
cells O
. O

sulfasalazine O
- O
induced O
lupus B-Disease
erythematosus I-Disease
. O

pneumonitis B-Disease
, O
bilateral O
pleural B-Disease
effusions I-Disease
, O
echocardiographic O
evidence O
of O
cardiac B-Disease
tamponade I-Disease
, O
and O
positive O
autoantibodies O
developed O
in O
a O
43 O
- O
year O
- O
old O
man O
, O
who O
was O
receiving O
long O
- O
term O
sulfasalazine O
therapy O
for O
chronic O
ulcerative B-Disease
colitis I-Disease
. O

it O
is O
suggested O
that O
the O
patient O
had O
sulfasalazine O
- O
induced O
lupus B-Disease
, O
which O
manifested O
with O
serositis B-Disease
and O
pulmonary O
parenchymal O
involvement O
in O
the O
absence O
of O
joint O
symptoms O
. O

physicians O
who O
use O
sulfasalazine O
to O
treat O
patients O
with O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
should O
be O
aware O
of O
the O
signs O
of O
sulfasalazine O
- O
induced O
lupus B-Disease
syndrome I-Disease
. O

chronic O
carbamazepine O
treatment O
in O
the O
rat O
: O
efficacy O
, O
toxicity B-Disease
, O
and O
effect O
on O
plasma O
and O
tissue O
folate O
concentrations O
. O

in O
the O
course O
of O
developing O
this O
model O
, O
a O
common O
vehicle O
, O
propylene O
glycol O
, O
by O
itself O
in O
high O
doses O
, O
was O
found O
to O
exhibit O
protective O
properties O
against O
induced O
seizures B-Disease
and O
inhibited O
weight B-Disease
gain I-Disease
. O

seizures B-Disease
induced O
by O
hexafluorodiethyl O
ether O
( O
hfde O
) O
were O
also O
found O
to O
be O
a O
more O
sensitive O
measure O
of O
protection O
by O
cbz O
than O
seizures B-Disease
induced O
by O
maximal O
electroshock O
( O
mes O
) O
. O

oral O
administration O
of O
cbz O
as O
an O
aqueous O
suspension O
every O
8 O
h O
at O
a O
dose O
of O
250 O
mg O
/ O
kg O
was O
continuously O
protective O
against O
hfde O
- O
induced O
seizures B-Disease
and O
was O
minimally O
toxic O
as O
measured O
by O
weight B-Disease
gain I-Disease
over O
8 O
weeks O
of O
treatment O
. O

dipyridamole O
- O
induced O
myocardial B-Disease
ischemia I-Disease
. O

angina B-Disease
and O
ischemic O
electrocardiographic O
changes O
occurred O
after O
administration O
of O
oral O
dipyridamole O
in O
four O
patients O
awaiting O
urgent O
myocardial O
revascularization O
procedures O
. O

to O
our O
knowledge O
, O
this O
has O
not O
previously O
been O
reported O
as O
a O
side O
effect O
of O
preoperative O
dipyridamole O
therapy O
, O
although O
dipyridamole O
- O
induced O
myocardial B-Disease
ischemia I-Disease
has O
been O
demonstrated O
to O
occur O
in O
animals O
and O
humans O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

epicardial O
coronary O
collateral O
vessels O
were O
demonstrated O
in O
all O
four O
patients O
; O
a O
coronary O
nan O
steal O
nan O
phenomenon O
may O
be O
the O
mechanism O
of O
the O
dipyridamole O
- O
induced O
ischemia B-Disease
observed O
. O

mean O
arterial O
pressure O
( O
as O
a O
percentage O
of O
control O
+ O
/ O
- O
sem O
) O
during O
randomized O
infusions O
of O
0 O
. O

3 O
, O
0 O
. O

1 O
, O
0 O
. O

3 O
, O
or O
1 O
. O

0 O
microgram O
/ O
kg O
/ O
min O
was O
99 O
+ O
/ O
- O
1 O
, O
95 O
+ O
/ O
- O
1 O
( O
p O
less O
than O
0 O
. O

5 O
) O
, O
93 O
+ O
/ O
- O
1 O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
or O
79 O
+ O
/ O
- O
6 O
% O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
respectively O
, O
but O
no O
tachycardia B-Disease
and O
no O
augmentation O
of O
the O
norepinephrine O
release O
rate O
( O
up O
to O
0 O
. O

3 O
microgram O
/ O
kg O
/ O
min O
) O
were O
observed O
, O
which O
is O
in O
contrast O
to O
comparable O
hypotension B-Disease
induced O
by O
hydralazine O
or O
nitroglycerin O
. O

nitroprusside O
- O
induced O
hypotension B-Disease
evokes O
acth O
secretion O
which O
is O
primarily O
mediated O
by O
enhanced O
secretion O
of O
immunoreactive O
corticotropin O
- O
releasing O
factor O
( O
ircrf O
) O
into O
the O
hypophysial O
- O
portal O
circulation O
. O

suppression O
of O
ircrf O
secretion O
in O
response O
to O
nitroprusside O
- O
induced O
hypotension B-Disease
is O
observed O
and O
occurs O
at O
a O
plasma O
corticosterone O
level O
between O
8 O
- O
12 O
micrograms O
/ O
dl O
. O

noradrenergic O
involvement O
in O
catalepsy B-Disease
induced O
by O
delta O
9 O
- O
tetrahydrocannabinol O
. O

these O
results O
indicate O
that O
noradrenergic O
neurons O
have O
an O
important O
role O
in O
the O
manifestation O
of O
catalepsy B-Disease
induced O
by O
thc O
, O
whereas O
dopaminergic O
neurons O
are O
important O
in O
catalepsy B-Disease
induced O
by O
haloperidol O
. O

reversibility O
of O
captopril O
- O
induced O
renal B-Disease
insufficiency I-Disease
after O
prolonged O
use O
in O
an O
unusual O
case O
of O
renovascular B-Disease
hypertension I-Disease
. O

we O
report O
a O
case O
of O
severe O
hypertension B-Disease
with O
an O
occluded O
renal O
artery O
to O
a O
solitary O
kidney O
, O
who O
developed O
sudden B-Disease
deterioration I-Disease
of I-Disease
renal I-Disease
function I-Disease
following O
treatment O
with O
captopril O
. O

this O
indicates O
reversibility O
in O
captopril O
- O
induced O
renal B-Disease
failure I-Disease
even O
after O
its O
prolonged O
use O
and O
suggests O
that O
no O
organic O
damage O
occurs O
to O
glomerular O
arterioles O
following O
chronic O
ace O
inhibition O
. O

myopathy B-Disease
, O
associated O
in O
some O
cases O
with O
myoglobinuria B-Disease
, O
and O
in O
2 O
cases O
with O
transient O
renal B-Disease
failure I-Disease
, O
has O
been O
rarely O
reported O
with O
lovastatin O
, O
especially O
in O
patients O
concomitantly O
treated O
with O
cyclosporin O
, O
gemfibrozil O
or O
niacin O
. O

as O
wider O
use O
confirms O
their O
safety O
profile O
, O
they O
will O
gain O
increasing O
importance O
in O
the O
therapeutic O
approach O
to O
hypercholesterolaemia B-Disease
and O
its O
consequences O
. O

by O
november O
1984 O
the O
committee O
on O
safety O
of O
medicines O
had O
received O
82 O
reports O
of O
possible O
hepatotoxicity B-Disease
associated O
with O
the O
drug O
, O
including O
five O
deaths B-Disease
. O

an O
analysis O
of O
the O
75 O
cases O
that O
had O
been O
adequately O
followed O
up O
suggested O
that O
16 O
, O
including O
three O
deaths B-Disease
, O
were O
probably O
related O
to O
treatment O
with O
the O
drug O
. O

the O
mean O
age O
of O
patients O
in O
the O
16 O
probable O
cases O
was O
57 O
. O

9 O
, O
with O
hepatotoxicity B-Disease
being O
more O
common O
in O
women O
. O

the O
average O
duration O
of O
treatment O
before O
the O
onset O
of O
jaundice B-Disease
was O
61 O
days O
. O

the O
results O
of O
serum O
liver O
function O
tests O
suggested O
hepatocellular B-Disease
injury I-Disease
in O
10 O
( O
63 O
% O
) O
; O
the O
rest O
showed O
a O
mixed O
pattern O
. O

in O
contrast O
, O
the O
results O
of O
histological O
examination O
of O
the O
liver O
often O
showed O
evidence O
of O
cholestasis B-Disease
. O

allergic O
manifestations O
such O
as O
rash B-Disease
and O
eosinophilia B-Disease
were O
rare O
. O

hepatitis B-Disease
was O
usually O
reversible O
when O
treatment O
was O
stopped O
, O
with O
the O
results O
of O
liver O
function O
tests O
returning O
to O
normal O
after O
an O
average O
of O
3 O
. O

1 O
months O
. O

in O
two O
of O
the O
three O
deaths B-Disease
probably O
associated O
with O
ketoconazole O
treatment O
the O
drug O
had O
been O
continued O
after O
the O
onset O
of O
jaundice B-Disease
and O
other O
symptoms O
of O
hepatitis B-Disease
. O

clinical O
and O
biochemical O
monitoring O
at O
regular O
intervals O
for O
evidence O
of O
hepatitis B-Disease
is O
advised O
during O
long O
term O
treatment O
with O
ketoconazole O
to O
prevent O
possible O
serious O
hepatic B-Disease
injury I-Disease
. O

glyburide O
- O
induced O
hepatitis B-Disease
. O

drug O
- O
induced O
hepatotoxicity B-Disease
, O
although O
common O
, O
has O
been O
reported O
only O
infrequently O
with O
sulfonylureas O
. O

for O
glyburide O
, O
a O
second O
- O
generation O
sulfonylurea O
, O
only O
two O
brief O
reports O
of O
hepatotoxicity B-Disease
exist O
. O

two O
patients O
with O
type B-Disease
ii I-Disease
diabetes I-Disease
mellitus I-Disease
developed O
an O
acute B-Disease
hepatitis I-Disease
- I-Disease
like I-Disease
syndrome I-Disease
soon O
after O
initiation O
of O
glyburide O
therapy O
. O

there O
was O
no O
serologic O
evidence O
of O
viral B-Disease
infection I-Disease
, O
and O
a O
liver O
biopsy O
sample O
showed O
a O
histologic O
pattern O
consistent O
with O
drug B-Disease
- I-Disease
induced I-Disease
hepatitis I-Disease
. O

glyburide O
can O
produce O
an O
acute B-Disease
hepatitis I-Disease
- I-Disease
like I-Disease
illness I-Disease
in O
some O
persons O
. O

intracranial O
pressure O
increases O
during O
alfentanil O
- O
induced O
rigidity B-Disease
. O

intracranial O
pressure O
( O
icp O
) O
was O
measured O
during O
alfentanil O
- O
induced O
rigidity B-Disease
in O
rats O
. O

in O
the O
five O
rats O
that O
developed O
somatic B-Disease
rigidity I-Disease
, O
icp O
and O
cvp O
increased O
significantly O
above O
baseline O
( O
delta O
icp O
7 O
. O

5 O
+ O
/ O
- O
1 O
. O

0 O
mmhg O
, O
delta O
cvp O
5 O
. O

9 O
+ O
/ O
- O
1 O
. O

3 O
mmhg O
) O
. O

these O
variables O
returned O
to O
baseline O
when O
rigidity B-Disease
was O
abolished O
with O
metocurine O
. O

these O
observations O
suggest O
that O
rigidity B-Disease
should O
be O
prevented O
when O
alfentanil O
, O
and O
, O
presumably O
, O
other O
opiates O
, O
are O
used O
in O
the O
anesthetic O
management O
of O
patients O
with O
icp O
problems O
. O

verapamil O
withdrawal O
as O
a O
possible O
cause O
of O
myocardial B-Disease
infarction I-Disease
in O
a O
hypertensive B-Disease
woman O
with O
a O
normal O
coronary O
angiogram O
. O

serious O
adverse O
effects O
are O
uncommon O
and O
mainly O
have O
been O
related O
to O
the O
depression B-Disease
of O
cardiac O
contractility O
and O
conduction O
, O
especially O
when O
the O
drug O
is O
combined O
with O
beta O
- O
blocking O
agents O
. O

we O
report O
a O
case O
in O
which O
myocardial B-Disease
infarction I-Disease
coincided O
with O
the O
introduction O
of O
captopril O
and O
the O
withdrawal O
of O
verapamil O
in O
a O
previously O
asymptomatic O
woman O
with O
severe O
hypertension B-Disease
. O

haemolytic B-Disease
- I-Disease
uraemic I-Disease
syndrome I-Disease
after O
treatment O
with O
metronidazole O
. O

this O
paper O
describes O
the O
clinical O
features O
of O
six O
children O
who O
developed O
the O
haemolytic B-Disease
- I-Disease
uraemic I-Disease
syndrome I-Disease
after O
treatment O
with O
metronidazole O
. O

while O
the O
involvement O
of O
metronidazole O
in O
the O
aetiology O
of O
the O
haemolytic B-Disease
- I-Disease
uraemic I-Disease
syndrome I-Disease
is O
not O
established O
firmly O
, O
the O
action O
of O
this O
drug O
in O
sensitizing O
tissues O
to O
oxidation O
injury O
and O
the O
reported O
evidence O
of O
oxidation O
changes O
in O
the O
haemolytic B-Disease
- I-Disease
uraemic I-Disease
syndrome I-Disease
suggest O
a O
possible O
link O
between O
metronidazole O
treatment O
and O
some O
cases O
of O
the O
haemolytic B-Disease
- I-Disease
uraemic I-Disease
syndrome I-Disease
. O

survival O
for O
patients O
with O
advanced O
head B-Disease
and I-Disease
neck I-Disease
carcinoma I-Disease
and O
esophageal B-Disease
carcinoma I-Disease
is O
poor O
with O
radiotherapy O
and O
/ O
or O
surgery O
. O

in O
the O
pre O
- O
treatment O
evaluation O
, O
signs O
of O
cardiovascular B-Disease
disease I-Disease
were O
found O
in O
33 O
patients O
( O
43 O
% O
) O
. O

the O
incidence O
of O
cardiotoxicity B-Disease
was O
not O
higher O
in O
patients O
with O
signs O
of O
cardiovascular B-Disease
disease I-Disease
than O
in O
those O
without O
in O
the O
pre O
- O
treatment O
evaluation O
. O

the O
most O
common O
signs O
of O
cardiotoxicity B-Disease
were O
chest B-Disease
pain I-Disease
, O
st O
- O
t O
wave O
changes O
and O
atrial B-Disease
fibrillation I-Disease
. O

this O
was O
followed O
by O
ventricular B-Disease
fibrillation I-Disease
in O
one O
patient O
and O
sudden B-Disease
death I-Disease
in O
another O
. O

it O
is O
concluded O
that O
patients O
on O
5 O
- O
fu O
treatment O
should O
be O
under O
close O
supervision O
and O
that O
the O
treatment O
should O
be O
discontinued O
if O
chest B-Disease
pain I-Disease
or O
tachyarrhythmia B-Disease
is O
observed O
. O

death B-Disease
from O
chemotherapy O
in O
gestational B-Disease
trophoblastic I-Disease
disease I-Disease
. O

multiple O
cytotoxic O
drug O
administration O
is O
the O
generally O
accepted O
treatment O
of O
patients O
with O
a O
high O
- O
risk O
stage O
of O
choriocarcinoma B-Disease
. O

within O
8 O
hours O
after O
initiation O
of O
therapy O
the O
patient O
died O
with O
a O
clinical O
picture O
resembling O
massive O
pulmonary B-Disease
obstruction I-Disease
due O
to O
choriocarcinomic O
tissue O
plugs O
, O
probably O
originating O
from O
the O
uterus O
. O

formation O
of O
these O
plugs O
was O
probably O
due O
to O
extensive O
tumor B-Disease
necrosis B-Disease
at O
the O
level O
of O
the O
walls O
of O
the O
major O
uterine O
veins O
, O
which O
resulted O
in O
an O
open O
exchange O
of O
tumor B-Disease
plugs O
to O
the O
vascular O
spaces O
; O
decrease O
in O
tumor B-Disease
tissue O
coherence O
secondary O
to O
chemotherapy O
may O
have O
further O
contributed O
to O
the O
formation O
of O
tumor B-Disease
emboli O
. O

in O
view O
of O
the O
close O
time O
association O
between O
the O
start O
of O
chemotherapy O
and O
the O
acute O
onset O
of O
massive O
embolism B-Disease
other O
explanations O
, O
such O
as O
spontaneous O
necrosis B-Disease
, O
must O
be O
considered O
less O
likely O
. O

patients O
with O
large O
pelvic B-Disease
tumor I-Disease
loads O
are O
, O
according O
to O
existing O
classifications O
, O
at O
high O
risk O
to O
die O
and O
to O
develop O
drug O
resistance O
. O

pulmonary O
shunt O
and O
cardiovascular O
responses O
to O
cpap O
during O
nitroprusside O
- O
induced O
hypotension B-Disease
. O

ten O
cm O
h2o O
cpap O
before O
nitroprusside O
infusion O
produced O
a O
further O
decrease B-Disease
in I-Disease
arterial I-Disease
blood I-Disease
pressure I-Disease
and O
significantly O
increased O
heart O
rate O
and O
decreased B-Disease
cardiac I-Disease
output I-Disease
and O
qs O
/ O
qt O
. O

nitroprusside O
caused O
significant O
decreases B-Disease
in I-Disease
arterial I-Disease
blood I-Disease
pressure I-Disease
and O
systemic O
vascular O
resistance O
and O
increases O
in O
heart O
rate O
, O
but O
did O
not O
change O
cardiac O
output O
or O
qs O
/ O
qt O
. O

during O
nitroprusside O
infusion O
low O
levels O
of O
cpap O
do O
not O
markedly O
alter O
cardiovascular O
dynamics O
, O
but O
high O
levels O
of O
cpap O
( O
10 O
cm O
h2o O
) O
, O
while O
decreasing O
qs O
/ O
qt O
, O
produce O
marked O
decreases B-Disease
in I-Disease
arterial I-Disease
blood I-Disease
pressure I-Disease
and I-Disease
cardiac I-Disease
output I-Disease
. O

systolic O
pressure O
variation O
is O
greater O
during O
hemorrhage B-Disease
than O
during O
sodium O
nitroprusside O
- O
induced O
hypotension B-Disease
in O
ventilated O
dogs O
. O

the O
systolic O
pressure O
variation O
( O
spv O
) O
, O
which O
is O
the O
difference O
between O
the O
maximal O
and O
minimal O
values O
of O
the O
systolic O
blood O
pressure O
( O
sbp O
) O
after O
one O
positive O
- O
pressure O
breath O
, O
was O
studied O
in O
ventilated O
dogs O
subjected O
to O
hypotension B-Disease
. O

mean O
arterial O
pressure O
was O
decreased O
to O
50 O
mm O
hg O
for O
30 O
minutes O
either O
by O
hemorrhage B-Disease
( O
hem B-Disease
, O
n O
= O
7 O
) O
or O
by O
continuous O
infusion O
of O
sodium O
nitroprusside O
( O
snp O
, O
n O
= O
7 O
) O
. O

during O
hem B-Disease
- O
induced O
hypotension B-Disease
the O
cardiac O
output O
was O
significantly O
lower O
and O
systemic O
vascular O
resistance O
higher O
compared O
with O
that O
in O
the O
snp O
group O
. O

the O
spv O
during O
hypotension B-Disease
was O
15 O
. O

7 O
+ O
/ O
- O
6 O
. O

7 O
mm O
hg O
in O
the O
hem B-Disease
group O
, O
compared O
with O
9 O
. O

1 O
+ O
/ O
- O
2 O
. O

0 O
mm O
hg O
in O
the O
snp O
group O
( O
p O
less O
than O
0 O
. O

2 O
) O
. O

the O
delta O
down O
, O
which O
is O
the O
measure O
of O
decrease O
of O
sbp O
after O
a O
mechanical O
breath O
, O
was O
20 O
. O

3 O
+ O
/ O
- O
8 O
. O

4 O
and O
10 O
. O

1 O
+ O
/ O
- O
3 O
. O

8 O
mm O
hg O
in O
the O
hem B-Disease
and O
snp O
groups O
, O
respectively O
, O
during O
hypotension B-Disease
( O
p O
less O
than O
0 O
. O

2 O
) O
. O

it O
is O
concluded O
that O
increases O
in O
the O
spv O
and O
the O
delta O
down O
are O
characteristic O
of O
a O
hypotensive B-Disease
state O
due O
to O
a O
predominant O
decrease O
in O
preload O
. O

they O
are O
thus O
more O
important O
during O
absolute O
hypovolemia B-Disease
than O
during O
deliberate O
hypotension B-Disease
. O

ventricular B-Disease
tachyarrhythmias I-Disease
during O
cesarean O
section O
after O
ritodrine O
therapy O
: O
interaction O
with O
anesthetics O
. O

this O
case O
illustrates O
that O
patients O
receiving O
ritodrine O
for O
preterm B-Disease
labor I-Disease
may O
risk O
interactions O
between O
the O
residual O
betamimetic O
effects O
of O
ritodrine O
and O
the O
effects O
of O
anesthetics O
during O
cesarean O
section O
. O

such O
interactions O
may O
result O
in O
serious O
cardiovascular B-Disease
complications I-Disease
even O
after O
cessation O
of O
an O
infusion O
of O
ritodrine O
. O

after O
delivery O
of O
the O
infant O
, O
there O
should O
be O
no O
contraindication O
to O
the O
use O
of O
an O
alpha O
- O
adrenergic O
vasopressor O
such O
as O
phenylephrine O
to O
treat O
hypotensive B-Disease
patients O
with O
tachycardia B-Disease
. O

verapamil O
- O
induced O
carbamazepine O
neurotoxicity B-Disease
. O

two O
patients O
with O
signs O
of O
carbamazepine O
neurotoxicity B-Disease
after O
combined O
treatment O
with O
verapamil O
showed O
complete O
recovery O
after O
discontinuation O
of O
the O
calcium O
entry O
blocker O
. O

paracetamol O
- O
associated O
coma B-Disease
, O
metabolic B-Disease
acidosis I-Disease
, O
renal B-Disease
and I-Disease
hepatic I-Disease
failure I-Disease
. O

a O
case O
of O
metabolic B-Disease
acidosis I-Disease
, O
acute B-Disease
renal I-Disease
failure I-Disease
and I-Disease
hepatic I-Disease
failure I-Disease
following O
paracetamol O
ingestion O
is O
presented O
. O

sexual B-Disease
dysfunction I-Disease
among O
patients O
with O
arthritis B-Disease
. O

the O
relationship O
of O
arthritis B-Disease
and O
sexual B-Disease
dysfunction I-Disease
was O
investigated O
among O
169 O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
, O
osteoarthritis B-Disease
and O
spondyloarthropathy B-Disease
, O
130 O
of O
whom O
were O
pair O
- O
matched O
to O
controls O
. O

assessments O
of O
marital O
happiness O
and O
depressed B-Disease
mood I-Disease
were O
also O
made O
using O
the O
ces O
- O
d O
and O
the O
azrin O
marital O
happiness O
scale O
( O
amhs O
) O
. O

sexual B-Disease
dysfunctions I-Disease
were O
found O
to O
be O
common O
among O
patients O
and O
controls O
, O
the O
majority O
in O
both O
groups O
reporting O
one O
or O
more O
dysfunctions O
. O

impotence B-Disease
was O
more O
common O
among O
male O
patients O
than O
controls O
and O
was O
found O
to O
be O
associated O
with O
co O
- O
morbidity O
and O
the O
taking O
of O
methotrexate O
. O

depressed B-Disease
mood I-Disease
was O
more O
common O
among O
patients O
and O
was O
associated O
with O
certain O
sexual O
difficulties O
, O
but O
not O
with O
impotence B-Disease
. O

marital O
unhappiness O
, O
as O
indicated O
by O
amhs O
scores O
, O
was O
not O
associated O
with O
arthritis B-Disease
but O
was O
associated O
with O
sexual B-Disease
dysfunction I-Disease
, O
sexual O
dissatisfaction O
and O
being O
female O
. O

does O
paracetamol O
cause O
urothelial B-Disease
cancer I-Disease
or O
renal B-Disease
papillary I-Disease
necrosis I-Disease
? O
the O
risk O
of O
developing O
renal B-Disease
papillary I-Disease
necrosis I-Disease
or O
cancer B-Disease
of I-Disease
the I-Disease
renal I-Disease
pelvis I-Disease
, I-Disease
ureter I-Disease
or I-Disease
bladder I-Disease
associated O
with O
consumption O
of O
either O
phenacetin O
or O
paracetamol O
was O
calculated O
from O
data O
acquired O
by O
questionnaire O
from O
381 O
cases O
and O
808 O
controls O
. O

the O
risk O
of O
renal B-Disease
papillary I-Disease
necrosis I-Disease
was O
increased O
nearly O
20 O
- O
fold O
by O
consumption O
of O
phenacetin O
, O
which O
also O
increased O
the O
risk O
for O
cancer B-Disease
of I-Disease
the I-Disease
renal I-Disease
pelvis I-Disease
and I-Disease
bladder I-Disease
but O
not O
for O
ureteric B-Disease
cancer I-Disease
. O

by O
contrast O
, O
we O
were O
unable O
to O
substantiate O
an O
increased O
risk O
from O
paracetamol O
consumption O
for O
renal B-Disease
papillary I-Disease
necrosis I-Disease
or O
any O
of O
these O
cancers B-Disease
although O
there O
was O
a O
suggestion O
of O
an O
association O
with O
cancer B-Disease
of I-Disease
the I-Disease
ureter I-Disease
. O

dapsone O
- O
associated O
heinz O
body O
hemolytic B-Disease
anemia I-Disease
in O
a O
cambodian O
woman O
with O
hemoglobin O
e O
trait O
. O

a O
cambodian O
woman O
with O
hemoglobin O
e O
trait O
( O
ae O
) O
and O
leprosy B-Disease
developed O
a O
heinz O
body O
hemolytic B-Disease
anemia I-Disease
while O
taking O
a O
dose O
of O
dapsone O
( O
50 O
mg O
/ O
day O
) O
not O
usually O
associated O
with O
clinical O
hemolysis B-Disease
. O

thus O
, O
ae O
rbcs O
appear O
to O
have O
an O
increased O
sensitivity O
to O
oxidant O
stress O
both O
in O
vitro O
and O
in O
vivo O
, O
since O
dapsone O
does O
not O
cause O
hemolytic B-Disease
anemia I-Disease
at O
this O
dose O
in O
hematologically O
normal O
individuals O
. O

given O
the O
influx O
of O
southeast O
asians O
into O
the O
united O
states O
, O
oxidant O
medications O
should O
be O
used O
with O
caution O
, O
especially O
if O
an O
infection B-Disease
is O
present O
, O
in O
individuals O
of O
ethnic O
backgrounds O
that O
have O
an O
increased O
prevalence O
of O
hemoglobin O
e O
. O

a O
47 O
- O
year O
- O
old O
patient O
suffering O
from O
coronary B-Disease
artery I-Disease
disease I-Disease
was O
admitted O
to O
the O
ccu O
in O
shock B-Disease
with O
iii O
. O

av B-Disease
block I-Disease
, O
severe O
hypotension B-Disease
, O
and O
impairment B-Disease
of I-Disease
ventricular I-Disease
function I-Disease
. O

therefore O
, O
patients O
belonging O
to O
the O
poor O
- O
metabolizer O
phenotype O
of O
sparteine O
/ O
debrisoquine O
polymorphism O
in O
drug O
metabolism O
, O
which O
constitutes O
6 O
. O

4 O
% O
of O
the O
german O
population O
, O
may O
experience O
adverse B-Disease
drug I-Disease
reactions I-Disease
when O
treated O
with O
standard O
doses O
of O
one O
of O
these O
drugs O
alone O
. O

nine O
patients O
exhibited O
mild O
to O
moderate O
extrapyramidal B-Disease
concomitant I-Disease
symptoms I-Disease
; O
no O
other O
side O
effects O
were O
observed O
. O

in O
the O
double O
blind O
study O
with O
haloperidol O
, O
both O
substances O
were O
found O
to O
be O
highly O
effective O
in O
the O
treatment O
of O
psychotic B-Disease
syndromes I-Disease
belonging I-Disease
predominantly I-Disease
to I-Disease
the I-Disease
schizophrenia I-Disease
group I-Disease
. O

prolonged O
cholestasis B-Disease
after O
troleandomycin O
- O
induced O
acute O
hepatitis B-Disease
. O

we O
report O
the O
case O
of O
a O
patient O
in O
whom O
troleandomycin O
- O
induced O
hepatitis B-Disease
was O
followed O
by O
prolonged O
anicteric O
cholestasis B-Disease
. O

jaundice B-Disease
occurred O
after O
administration O
of O
troleandomycin O
for O
7 O
days O
and O
was O
associated O
with O
hypereosinophilia B-Disease
. O

jaundice B-Disease
disappeared O
within O
3 O
months O
but O
was O
followed O
by O
prolonged O
anicteric O
cholestasis B-Disease
marked O
by O
pruritus B-Disease
and O
high O
levels O
of O
alkaline O
phosphatase O
and O
gammaglutamyltransferase O
activities O
. O

finally O
, O
pruritus B-Disease
disappeared O
within O
19 O
months O
, O
and O
liver O
tests O
returned O
to O
normal O
27 O
months O
after O
the O
onset O
of O
hepatitis B-Disease
. O

this O
observation O
demonstrates O
that O
prolonged O
cholestasis B-Disease
can O
follow O
troleandomycin O
- O
induced O
acute O
hepatitis B-Disease
. O

serial O
studies O
of O
auditory B-Disease
neurotoxicity I-Disease
in O
patients O
receiving O
deferoxamine O
therapy O
. O

visual B-Disease
and I-Disease
auditory I-Disease
neurotoxicity I-Disease
was O
previously O
documented O
in O
42 O
of O
89 O
patients O
with O
transfusion O
- O
dependent O
anemia B-Disease
who O
were O
receiving O
iron O
chelation O
therapy O
with O
daily O
subcutaneous O
deferoxamine O
. O

twenty O
- O
two O
patients O
in O
the O
affected O
group O
had O
abnormal B-Disease
audiograms I-Disease
with I-Disease
deficits I-Disease
mostly I-Disease
in I-Disease
the I-Disease
high I-Disease
frequency I-Disease
range I-Disease
of I-Disease
4 I-Disease
, I-Disease
0 I-Disease
to I-Disease
8 I-Disease
, I-Disease
0 I-Disease
hz I-Disease
and O
in O
the O
hearing O
threshold O
levels O
of O
30 O
to O
100 O
decibels O
. O

audiograms O
from O
15 O
patients O
remained O
abnormal O
and O
four O
patients O
required O
hearing O
aids O
because O
of O
permanent B-Disease
disability I-Disease
. O

since O
18 O
of O
the O
22 O
patients O
were O
initially O
receiving O
deferoxamine O
doses O
in O
excess O
of O
the O
commonly O
recommended O
50 O
mg O
/ O
kg O
per O
dose O
, O
therapy O
was O
restarted O
with O
lower O
doses O
, O
usually O
50 O
mg O
/ O
kg O
per O
dose O
or O
less O
depending O
on O
the O
degree O
of O
auditory B-Disease
abnormality I-Disease
, O
and O
with O
the O
exception O
of O
two O
cases O
no O
further O
toxicity B-Disease
was O
demonstrated O
. O

auditory O
deterioration O
and O
improvement O
, O
demonstrated O
serially O
in O
individual O
patients O
receiving O
and O
not O
receiving O
deferoxamine O
, O
respectively O
, O
provided O
convincing O
evidence O
for O
a O
cause O
- O
and O
- O
effect O
relation O
between O
deferoxamine O
administration O
and O
ototoxicity B-Disease
. O

with O
mild O
toxicity B-Disease
, O
a O
reduction O
to O
30 O
or O
40 O
mg O
/ O
kg O
per O
dose O
should O
result O
in O
a O
reversal O
of O
the O
abnormal O
results O
to O
normal O
within O
four O
weeks O
. O

in O
those O
with O
symptoms O
of O
hearing B-Disease
loss I-Disease
, O
the O
drug O
should O
be O
stopped O
for O
four O
weeks O
, O
and O
when O
the O
audiogram O
is O
stable O
or O
improved O
, O
therapy O
should O
be O
restarted O
at O
10 O
to O
25 O
mg O
/ O
kg O
per O
dose O
. O

serial O
audiograms O
should O
be O
performed O
every O
six O
months O
in O
those O
without O
problems O
and O
more O
frequently O
in O
young O
patients O
with O
normal O
serum O
ferritin O
values O
and O
in O
those O
with O
auditory B-Disease
dysfunction I-Disease
. O

lidocaine O
- O
induced O
cardiac B-Disease
asystole I-Disease
. O

intravenous O
administration O
of O
a O
single O
50 O
- O
mg O
bolus O
of O
lidocaine O
in O
a O
67 O
- O
year O
- O
old O
man O
resulted O
in O
profound O
depression B-Disease
of O
the O
activity O
of O
the O
sinoatrial O
and O
atrioventricular O
nodal O
pacemakers O
. O

the O
patient O
had O
no O
apparent O
associated O
conditions O
which O
might O
have O
predisposed O
him O
to O
the O
development O
of O
bradyarrhythmias B-Disease
; O
and O
, O
thus O
, O
this O
probably O
represented O
a O
TRUE O
idiosyncrasy O
to O
lidocaine O
. O

flurbiprofen O
in O
the O
treatment O
of O
juvenile B-Disease
rheumatoid I-Disease
arthritis I-Disease
. O

thirty O
- O
four O
patients O
with O
juvenile B-Disease
rheumatoid I-Disease
arthritis I-Disease
, O
who O
were O
treated O
with O
flurbiprofen O
at O
a O
maximum O
dose O
of O
4 O
mg O
/ O
kg O
/ O
day O
, O
had O
statistically O
significant O
decreases O
from O
baseline O
in O
6 O
arthritis B-Disease
indices O
after O
12 O
weeks O
of O
treatment O
. O

improvements O
were O
seen O
in O
the O
number O
of O
tender B-Disease
joints I-Disease
, O
the O
severity O
of O
swelling B-Disease
and O
tenderness B-Disease
, O
the O
time O
of O
walk O
50 O
feet O
, O
the O
duration O
of O
morning B-Disease
stiffness I-Disease
and O
the O
circumference O
of O
the O
left O
knee O
. O

the O
most O
frequently O
observed O
side O
effect O
was O
fecal B-Disease
occult I-Disease
blood I-Disease
( O
25 O
% O
of O
patients O
) O
; O
however O
, O
there O
was O
no O
other O
evidence O
of O
gastrointestinal B-Disease
( I-Disease
gi I-Disease
) I-Disease
bleeding I-Disease
in O
these O
patients O
. O

one O
patient O
was O
prematurely O
discontinued O
from O
the O
study O
for O
severe O
headache B-Disease
and O
abdominal B-Disease
pain I-Disease
. O

hyperkalemia B-Disease
associated O
with O
sulindac O
therapy O
. O

hyperkalemia B-Disease
has O
recently O
been O
recognized O
as O
a O
complication O
of O
nonsteroidal O
antiinflammatory O
agents O
( O
nsaid O
) O
such O
as O
indomethacin O
. O

we O
describe O
4 O
patients O
in O
whom O
hyperkalemia B-Disease
ranging O
from O
6 O
. O

1 O
to O
6 O
. O

9 O
meq O
/ O
l O
developed O
within O
3 O
to O
8 O
days O
of O
sulindac O
administration O
. O

as O
no O
other O
medications O
known O
to O
effect O
serum O
potassium O
had O
been O
given O
concomitantly O
, O
this O
course O
of O
events O
is O
suggestive O
of O
a O
cause O
- O
and O
- O
effect O
relationship O
between O
sulindac O
and O
hyperkalemia B-Disease
. O

drug O
- O
induced O
arterial O
spasm B-Disease
relieved O
by O
lidocaine O
. O

following O
major O
intracranial O
surgery O
in O
a O
35 O
- O
year O
- O
old O
man O
, O
sodium O
pentothal O
was O
intravenously O
infused O
to O
minimize O
cerebral B-Disease
ischaemia I-Disease
. O

intense O
vasospasm B-Disease
with O
threatened O
gangrene B-Disease
arose O
in O
the O
arm O
used O
for O
the O
infusion O
. O

since O
the O
cranial O
condition O
precluded O
use O
of O
more O
usual O
methods O
, O
lidocaine O
was O
given O
intra O
- O
arterially O
, O
with O
careful O
cardiovascular O
monitoring O
, O
to O
counteract O
the O
vasospasm B-Disease
. O

regional O
localization O
of O
the O
antagonism O
of O
amphetamine O
- O
induced O
hyperactivity B-Disease
by O
intracerebral O
calcitonin O
injections O
. O

the O
hematologic O
effects O
of O
cefonicid O
and O
cefazedone O
in O
the O
dog O
: O
a O
potential O
model O
of O
cephalosporin O
hematotoxicity B-Disease
in O
man O
. O

cephalosporin O
antibiotics O
cause O
a O
variety O
of O
hematologic B-Disease
disturbances I-Disease
in O
man O
, O
the O
pathogeneses O
and O
hematopathology O
of O
which O
remain O
poorly O
characterized O
. O

there O
is O
a O
need O
for O
a O
well O
- O
defined O
animal O
model O
in O
which O
these O
blood B-Disease
dyscrasias I-Disease
can O
be O
studied O
. O

in O
four O
subacute O
toxicity B-Disease
studies O
, O
the O
intravenous O
administration O
of O
cefonicid O
or O
cefazedone O
to O
beagle O
dogs O
caused O
a O
dose O
- O
dependent O
incidence O
of O
anemia B-Disease
, O
neutropenia B-Disease
, O
and O
thrombocytopenia B-Disease
after O
1 O
- O
3 O
months O
of O
treatment O
. O

a O
nonregenerative O
anemia B-Disease
was O
the O
most O
compromising O
of O
the O
cytopenias B-Disease
and O
occurred O
in O
approximately O
50 O
% O
of O
dogs O
receiving O
400 O
- O
500 O
mg O
/ O
kg O
cefonicid O
or O
540 O
- O
840 O
mg O
/ O
kg O
cefazedone O
. O

all O
three O
cytopenias B-Disease
were O
completely O
reversible O
following O
cessation O
of O
treatment O
; O
the O
time O
required O
for O
recovery O
of O
the O
erythron O
( O
approximately O
1 O
month O
) O
was O
considerably O
longer O
than O
that O
of O
the O
granulocytes O
and O
platelets O
( O
hours O
to O
a O
few O
days O
) O
. O

upon O
rechallenge O
with O
either O
cephalosporin O
, O
the O
hematologic B-Disease
syndrome I-Disease
was O
reproduced O
in O
most O
dogs O
tested O
; O
cefonicid O
( O
but O
not O
cefazedone O
) O
- O
treated O
dogs O
showed O
a O
substantially O
reduced O
induction O
period O
( O
15 O
+ O
/ O
- O
5 O
days O
) O
compared O
to O
that O
of O
the O
first O
exposure O
to O
the O
drug O
( O
61 O
+ O
/ O
- O
24 O
days O
) O
. O

this O
observation O
, O
along O
with O
the O
rapid O
rate O
of O
decline O
in O
red O
cell O
mass O
parameters O
of O
affected O
dogs O
, O
suggests O
that O
a O
hemolytic B-Disease
component O
complicated O
the O
red O
cell O
production O
problem O
and O
that O
multiple O
toxicologic O
mechanisms O
contributed O
to O
the O
cytopenia B-Disease
. O

we O
conclude O
that O
the O
administration O
of O
high O
doses O
of O
cefonicid O
or O
cefazedone O
to O
dogs O
can O
induce O
hematotoxicity B-Disease
similar O
to O
the O
cephalosporin O
- O
induced O
blood B-Disease
dyscrasias I-Disease
described O
in O
man O
and O
thus O
provides O
a O
useful O
model O
for O
studying O
the O
mechanisms O
of O
these O
disorders O
. O

cerebral O
blood O
flow O
and O
metabolism O
during O
isoflurane O
- O
induced O
hypotension B-Disease
in O
patients O
subjected O
to O
surgery O
for O
cerebral B-Disease
aneurysms I-Disease
. O

cerebral O
blood O
flow O
and O
cerebral O
metabolic O
rate O
for O
oxygen O
were O
measured O
during O
isoflurane O
- O
induced O
hypotension B-Disease
in O
10 O
patients O
subjected O
to O
craniotomy O
for O
clipping O
of O
a O
cerebral B-Disease
aneurysm I-Disease
. O

flow O
and O
metabolism O
were O
measured O
5 O
- O
13 O
days O
after O
the O
subarachnoid B-Disease
haemorrhage I-Disease
by O
a O
modification O
of O
the O
classical O
kety O
- O
schmidt O
technique O
using O
xenon O
- O
133 O
i O
. O

v O
. O

anaesthesia O
was O
maintained O
with O
an O
inspired O
isoflurane O
concentration O
of O
0 O
. O

75 O
% O
( O
plus O
67 O
% O
nitrous O
oxide O
in O
oxygen O
) O
, O
during O
which O
cbf O
and O
cmro2 O
were O
34 O
. O

3 O
+ O
/ O
- O
2 O
. O

1 O
ml O
/ O
100 O
g O
min O
- O
1 O
and O
2 O
. O

32 O
+ O
/ O
- O
0 O
. O

16 O
ml O
/ O
100 O
g O
min O
- O
1 O
at O
paco2 O
4 O
. O

1 O
+ O
/ O
- O
0 O
. O

1 O
kpa O
( O
mean O
+ O
/ O
- O
sem O
) O
. O

controlled O
hypotension B-Disease
to O
an O
average O
map O
of O
50 O
- O
55 O
mm O
hg O
was O
induced O
by O
increasing O
the O
dose O
of O
isoflurane O
, O
and O
maintained O
at O
an O
inspired O
concentration O
of O
2 O
. O

2 O
+ O
/ O
- O
0 O
. O

2 O
% O
. O

after O
the O
clipping O
of O
the O
aneurysm B-Disease
the O
isoflurane O
concentration O
was O
reduced O
to O
0 O
. O

75 O
% O
. O

there O
was O
a O
significant O
increase O
in O
cbf O
, O
although O
cmro2 O
was O
unchanged O
, O
compared O
with O
pre O
- O
hypotensive B-Disease
values O
. O

these O
changes O
might O
offer O
protection O
to O
brain O
tissue O
during O
periods O
of O
induced O
hypotension B-Disease
. O

triazolam O
- O
induced O
brief O
episodes O
of O
secondary O
mania B-Disease
in O
a O
depressed B-Disease
patient O
. O

large O
doses O
of O
triazolam O
repeatedly O
induced O
brief O
episodes O
of O
mania B-Disease
in O
a O
depressed B-Disease
elderly O
woman O
. O

features O
of O
organic B-Disease
mental I-Disease
disorder I-Disease
( O
delirium B-Disease
) O
were O
not O
present O
. O

manic B-Disease
excitement O
was O
coincident O
with O
the O
duration O
of O
action O
of O
triazolam O
. O

the O
correlation O
between O
neurotoxic B-Disease
esterase O
inhibition O
and O
mipafox O
- O
induced O
neuropathic B-Disease
damage I-Disease
in O
rats O
. O

the O
correlation O
between O
neuropathic B-Disease
damage I-Disease
and O
inhibition O
of O
neurotoxic B-Disease
esterase O
or O
neuropathy B-Disease
target O
enzyme O
( O
nte O
) O
was O
examined O
in O
rats O
acutely O
exposed O
to O
mipafox O
( O
n O
, O
n O
' O
- O
diisopropylphosphorodiamidofluoridate O
) O
, O
a O
neurotoxic B-Disease
organophosphate O
. O

these O
data O
were O
correlated O
with O
histologically O
scored O
cervical O
cord B-Disease
damage I-Disease
in O
a O
separate O
group O
of O
similarly O
dosed O
rats O
sampled O
14 O
- O
21 O
days O
post O
- O
exposure O
. O

in O
contrast O
, O
dosages O
of O
mipafox O
( O
less O
than O
or O
equal O
to O
5 O
mg O
/ O
kg O
) O
which O
inhibited O
mean O
nte O
activity O
in O
spinal O
cord O
less O
than O
or O
equal O
to O
61 O
% O
and O
brain O
less O
than O
or O
equal O
to O
60 O
% O
produced O
this O
degree O
of O
cord B-Disease
damage I-Disease
in O
only O
9 O
% O
of O
the O
animals O
. O

these O
data O
indicate O
that O
a O
critical O
percentage O
of O
nte O
inhibition O
in O
brain O
and O
spinal O
cord O
sampled O
shortly O
after O
mipafox O
exposure O
can O
predict O
neuropathic B-Disease
damage I-Disease
in O
rats O
several O
weeks O
later O
. O

allergic B-Disease
reaction I-Disease
to O
5 O
- O
fluorouracil O
infusion O
. O

an O
allergic B-Disease
reaction I-Disease
consisting O
of O
angioneurotic B-Disease
edema I-Disease
secondary O
to O
continuous O
infusion O
5 O
- O
fluorouracil O
occurred O
in O
a O
patient O
with O
recurrent O
carcinoma B-Disease
of I-Disease
the I-Disease
oral I-Disease
cavity I-Disease
, O
cirrhosis B-Disease
, O
and O
cisplatin O
- O
induced O
impaired B-Disease
renal I-Disease
function I-Disease
. O

oral O
diphenhydramine O
and O
prednisone O
were O
ineffective O
in O
preventing O
the O
recurrence O
of O
the O
allergic B-Disease
reaction I-Disease
. O

myasthenia B-Disease
gravis I-Disease
caused O
by O
penicillamine O
and O
chloroquine O
therapy O
for O
rheumatoid B-Disease
arthritis I-Disease
. O

we O
have O
described O
a O
unique O
patient O
who O
had O
reversible O
and O
dose O
- O
related O
myasthenia B-Disease
gravis I-Disease
after O
penicillamine O
and O
chloroquine O
therapy O
for O
rheumatoid B-Disease
arthritis I-Disease
. O

on O
the O
mechanisms O
of O
the O
development O
of O
tolerance O
to O
the O
muscular B-Disease
rigidity I-Disease
produced O
by O
morphine O
in O
rats O
. O

the O
development O
of O
tolerance O
to O
the O
muscular B-Disease
rigidity I-Disease
produced O
by O
morphine O
was O
studied O
in O
rats O
. O

saline O
- O
pretreated O
controls O
given O
a O
test O
dose O
of O
morphine O
( O
20 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
showed O
a O
pronounced O
rigidity B-Disease
recorded O
as O
tonic O
activity O
in O
the O
electromyogram O
. O

rats O
treated O
for O
11 O
days O
with O
morphine O
and O
withdrawn O
for O
36 O
- O
40 O
h O
showed O
differences O
in O
the O
development O
of O
tolerance O
: O
about O
half O
of O
the O
animals O
showed O
a O
rigidity B-Disease
after O
the O
test O
dose O
of O
morphine O
that O
was O
not O
significantly O
less O
than O
in O
the O
controls O
and O
were O
akinetic B-Disease
( O
a O
group O
) O
. O

the O
other O
rats O
showed O
a O
strong O
decrease O
in O
the O
rigidity B-Disease
and O
the O
occurrence O
of O
stereotyped O
( O
s O
) O
licking O
and O
/ O
or O
gnawing O
in O
presence O
of O
akinetic B-Disease
or O
hyperkinetic B-Disease
( O
k O
) O
behaviour O
( O
as O
/ O
ks O
group O
) O
, O
suggesting O
signs O
of O
dopaminergic O
activation O
. O

the O
rigidity B-Disease
was O
considerably O
decreased O
in O
both O
groups O
after O
20 O
days O
' O
treatment O
. O

in O
a O
further O
series O
of O
experiments O
, O
haloperidol O
( O
0 O
. O

2 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
was O
used O
in O
order O
to O
block O
the O
dopaminergic O
activation O
and O
to O
estimate O
the O
real O
degree O
of O
the O
tolerance O
to O
the O
rigidity B-Disease
without O
any O
dopaminergic O
interference O
. O

haloperidol O
enhanced O
the O
rigidity B-Disease
in O
the O
a O
group O
. O

the O
results O
suggest O
that O
rigidity B-Disease
, O
which O
is O
assumed O
to O
be O
due O
to O
an O
action O
of O
morphine O
in O
the O
striatum O
, O
can O
be O
antagonized O
by O
another O
process O
leading O
to O
dopaminergic O
activation O
in O
the O
striatum O
. O

the O
rapid O
alternations O
of O
rigidity B-Disease
and O
the O
signs O
of O
dopaminergic O
activation O
observed O
in O
the O
animals O
of O
the O
as O
/ O
ks O
group O
might O
be O
due O
to O
rapid O
shifts O
in O
the O
predominance O
of O
various O
da O
- O
innervated O
structures O
. O

a O
case O
of O
massive O
rhabdomyolysis B-Disease
following O
molindone O
administration O
. O

rhabdomyolysis B-Disease
is O
a O
potentially O
lethal O
syndrome O
that O
psychiatric B-Disease
patients O
seem O
predisposed O
to O
develop O
. O

the O
clinical O
signs O
and O
symptoms O
, O
typical O
laboratory O
features O
, O
and O
complications O
of O
rhabdomyolysis B-Disease
are O
presented O
. O

the O
case O
of O
a O
schizophrenic B-Disease
patient O
is O
reported O
to O
illustrate O
massive O
rhabdomyolysis B-Disease
and O
subsequent O
acute B-Disease
renal I-Disease
failure I-Disease
following O
molindone O
administration O
. O

compression B-Disease
neuropathy I-Disease
of I-Disease
the I-Disease
radial I-Disease
nerve I-Disease
due O
to O
pentazocine O
- O
induced O
fibrous B-Disease
myopathy I-Disease
. O

fibrous B-Disease
myopathy I-Disease
is O
a O
common O
, O
well O
- O
known O
side O
effect O
of O
repeated O
pentazocine O
injection O
. O

however O
, O
compression B-Disease
neuropathy I-Disease
due O
to O
fibrotic O
muscle O
affected O
by O
pentazocine O
- O
induced O
myopathy B-Disease
has O
not O
previously O
been O
reported O
. O

in O
a O
37 O
- O
year O
- O
old O
woman O
with O
documented O
pentazocine O
- O
induced O
fibrous B-Disease
myopathy I-Disease
of O
triceps O
and O
deltoid O
muscles O
bilaterally O
and O
a O
three O
- O
week O
history O
of O
right O
wrist O
drop O
, O
electrodiagnostic O
examination O
showed O
a O
severe O
but O
partial O
lesion O
of O
the O
right O
radial O
nerve O
distal O
to O
the O
branches O
to O
the O
triceps O
, O
in O
addition O
to O
the O
fibrous B-Disease
myopathy I-Disease
. O

recurrent O
reversible O
acute B-Disease
renal I-Disease
failure I-Disease
from O
amphotericin O
. O

a O
patient O
with O
cryptogenic O
cirrhosis B-Disease
and O
disseminated O
sporotrichosis B-Disease
developed O
acute B-Disease
renal I-Disease
failure I-Disease
immediately O
following O
the O
administration O
of O
amphotericin O
b O
on O
four O
separate O
occasions O
. O

the O
abruptness O
of O
the O
renal B-Disease
failure I-Disease
and O
its O
reversibility O
within O
days O
suggests O
that O
there O
was O
a O
functional O
component O
to O
the O
renal B-Disease
dysfunction I-Disease
. O

we O
propose O
that O
amphotericin O
, O
in O
the O
setting O
of O
reduced O
effective O
arterial O
volume O
, O
may O
activate O
tubuloglomerular O
feedback O
, O
thereby O
contributing O
to O
acute B-Disease
renal I-Disease
failure I-Disease
. O

cerebral B-Disease
infarction I-Disease
with O
a O
single O
oral O
dose O
of O
phenylpropanolamine O
. O

its O
prolonged O
use O
or O
overuse O
has O
been O
associated O
with O
seizures B-Disease
, O
intracerebral B-Disease
hemorrhage I-Disease
, O
neuropsychiatric B-Disease
symptoms I-Disease
, O
and O
nonhemorrhagic O
cerebral B-Disease
infarction I-Disease
. O

we O
report O
the O
case O
of O
a O
young O
woman O
who O
suffered O
a O
cerebral B-Disease
infarction I-Disease
after O
taking O
a O
single O
oral O
dose O
of O
ppa O
. O

remission O
induction O
of O
meningeal B-Disease
leukemia I-Disease
with O
high O
- O
dose O
intravenous O
methotrexate O
. O

twenty O
children O
with O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
who O
developed O
meningeal B-Disease
disease I-Disease
were O
treated O
with O
a O
high O
- O
dose O
intravenous O
methotrexate O
regimen O
that O
was O
designed O
to O
achieve O
and O
maintain O
csf O
methotrexate O
concentrations O
of O
10 O
( O
- O
5 O
) O
mol O
/ O
l O
without O
the O
need O
for O
concomitant O
intrathecal O
dosing O
. O

the O
most O
common O
toxicities B-Disease
encountered O
were O
transient O
serum O
transaminase O
and O
bilirubin O
elevations O
, O
neutropenia B-Disease
, O
and O
mucositis B-Disease
. O

one O
patient O
had O
focal O
seizures B-Disease
and O
transient B-Disease
hemiparesis I-Disease
but O
recovered O
completely O
. O

high O
- O
dose O
intravenous O
methotrexate O
is O
an O
effective O
treatment O
for O
the O
induction O
of O
remission O
after O
meningeal O
relapse O
in O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
. O

a O
synergistic O
effect O
of O
etoposide O
and O
cyclosporin O
a O
was O
observed O
in O
a O
patient O
with O
acute B-Disease
t I-Disease
- I-Disease
lymphocytic I-Disease
leukemia I-Disease
in O
relapse O
. O

the O
concomitant O
administration O
of O
etoposide O
and O
cyclosporin O
a O
resulted O
in O
eradication O
of O
hitherto O
refractory O
leukemic B-Disease
infiltration I-Disease
of O
bone O
marrow O
. O

severe O
side O
effects O
in O
terms O
of O
mental O
confusion B-Disease
and O
progressive O
hyperbilirubinemia B-Disease
, O
however O
, O
point O
to O
an O
enhancement O
not O
only O
of O
antineoplastic O
effects O
but O
also O
of O
toxicity B-Disease
in O
normal O
tissues O
. O

incidence O
of O
neoplasms B-Disease
in O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
exposed O
to O
different O
treatment O
regimens O
. O

immunosuppressive O
drugs O
have O
been O
used O
during O
the O
last O
30 O
years O
in O
treatment O
of O
patients O
with O
severe O
rheumatoid B-Disease
arthritis I-Disease
. O

there O
is O
evidence O
that O
all O
four O
immunosuppressive O
drugs O
can O
reduce O
synovitis B-Disease
, O
but O
disease O
activity O
almost O
always O
recurs O
after O
therapy O
is O
stopped O
. O

patients O
treated O
with O
alkylating O
agents O
have O
an O
increased O
risk O
of O
development O
of O
acute B-Disease
nonlymphocytic I-Disease
leukemia I-Disease
, O
and O
both O
alkylating O
agents O
and O
azathioprine O
are O
associated O
with O
the O
development O
of O
non B-Disease
- I-Disease
hodgkin I-Disease
' I-Disease
s I-Disease
lymphoma I-Disease
. O

cyclophosphamide O
therapy O
increases O
the O
risk O
of O
carcinoma B-Disease
of I-Disease
the I-Disease
bladder I-Disease
. O

there O
have O
been O
several O
long O
- O
term O
studies O
of O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
treated O
with O
azathioprine O
and O
cyclophosphamide O
and O
the O
incidence O
of O
most O
of O
the O
common O
cancers B-Disease
is O
not O
increased O
. O

data O
on O
the O
possible O
increased O
risk O
of O
malignancy B-Disease
in O
rheumatoid B-Disease
arthritis I-Disease
are O
still O
being O
collected O
, O
and O
until O
further O
information O
is O
available O
, O
the O
use O
of O
immunosuppressive O
drugs O
, O
particularly O
alkylating O
agents O
, O
in O
the O
treatment O
of O
rheumatoid B-Disease
arthritis I-Disease
should O
be O
reserved O
for O
patients O
with O
severe O
progressive O
disease O
or O
life O
- O
threatening O
complications O
. O

warfarin O
- O
induced O
iliopsoas O
hemorrhage B-Disease
with O
subsequent O
femoral B-Disease
nerve I-Disease
palsy I-Disease
. O

we O
present O
the O
case O
of O
a O
28 O
- O
year O
- O
old O
man O
on O
chronic O
warfarin O
therapy O
who O
sustained O
a O
minor O
muscle B-Disease
tear I-Disease
and O
developed O
increasing O
pain B-Disease
and O
a O
flexure O
contracture B-Disease
of O
the O
right O
hip O
. O

surgical O
exploration O
revealed O
an O
iliopsoas O
hematoma B-Disease
and O
femoral O
nerve B-Disease
entrapment I-Disease
, O
resulting O
in O
a O
femoral B-Disease
nerve I-Disease
palsy I-Disease
and O
partial B-Disease
loss I-Disease
of I-Disease
quadriceps I-Disease
functions I-Disease
. O

anticoagulant O
- O
induced O
femoral B-Disease
nerve I-Disease
palsy I-Disease
represents O
the O
most O
common O
form O
of O
warfarin O
- O
induced O
peripheral B-Disease
neuropathy I-Disease
; O
it O
is O
characterized O
by O
severe O
pain B-Disease
in O
the O
inguinal O
region O
, O
varying O
degrees O
of O
motor B-Disease
and I-Disease
sensory I-Disease
impairment I-Disease
, O
and O
flexure O
contracture B-Disease
of O
the O
involved O
extremity O
. O

pneumonitis O
with O
pleural B-Disease
and I-Disease
pericardial I-Disease
effusion I-Disease
and O
neuropathy B-Disease
during O
amiodarone O
therapy O
. O

a O
patient O
with O
sinuatrial B-Disease
disease I-Disease
and O
imB-Planted O
pacemaker O
was O
treated O
with O
amiodarone O
( O
maximum O
dose O
1000 O
mg O
, O
maintenance O
dose O
800 O
mg O
daily O
) O
for O
10 O
months O
, O
for O
control O
of O
supraventricular B-Disease
tachyarrhythmias I-Disease
. O

he O
developed O
pneumonitis B-Disease
, O
pleural B-Disease
and I-Disease
pericardial I-Disease
effusions I-Disease
, O
and O
a O
predominantly O
proximal B-Disease
motor I-Disease
neuropathy I-Disease
. O

review O
of O
this O
and O
previously O
reported O
cases O
indicates O
the O
need O
for O
early O
diagnosis O
of O
amiodarone O
pneumonitis B-Disease
, O
immediate O
withdrawal O
of O
amiodarone O
, O
and O
prompt O
but O
continued O
steroid O
therapy O
to O
ensure O
full O
recovery O
. O

amiodarone O
- O
induced O
sinoatrial B-Disease
block I-Disease
. O

we O
observed O
sinoatrial B-Disease
block I-Disease
due O
to O
chronic O
amiodarone O
administration O
in O
a O
5 O
- O
year O
- O
old O
boy O
with O
primary B-Disease
cardiomyopathy I-Disease
, O
wolff B-Disease
- I-Disease
parkinson I-Disease
- I-Disease
white I-Disease
syndrome I-Disease
and O
supraventricular B-Disease
tachycardia I-Disease
. O

reduction O
in O
the O
dosage O
of O
amiodarone O
resulted O
in O
the O
disappearance O
of O
the O
sinoatrial B-Disease
block I-Disease
and O
the O
persistence O
of O
asymptomatic O
sinus B-Disease
bradycardia I-Disease
. O

desipramine O
- O
induced O
delirium B-Disease
at O
nan O
subtherapeutic O
nan O
concentrations O
: O
a O
case O
report O
. O

an O
elderly O
patient O
treated O
with O
low O
dose O
desipramine O
developed O
a O
delirium B-Disease
while O
her O
plasma O
level O
was O
in O
the O
nan O
subtherapeutic O
nan O
range O
. O

delirium B-Disease
, O
which O
may O
be O
induced O
by O
tricyclic O
drug O
therapy O
in O
the O
elderly O
, O
can O
be O
caused O
by O
tricyclics O
with O
low O
anticholinergic O
potency O
. O

indomethacin O
- O
induced O
renal B-Disease
insufficiency I-Disease
: O
recurrence O
on O
rechallenge O
. O

we O
have O
reported O
a O
case O
of O
acute O
oliguric O
renal B-Disease
failure I-Disease
with O
hyperkalemia B-Disease
in O
a O
patient O
with O
cirrhosis B-Disease
, O
ascites B-Disease
, O
and O
cor B-Disease
pulmonale I-Disease
after O
indomethacin O
therapy O
. O

prompt O
restoration O
of O
renal O
function O
followed O
drug O
withdrawal O
, O
while O
re O
- O
exposure O
to O
a O
single O
dose O
of O
indomethacin O
caused O
recurrence O
of O
acute O
reversible O
oliguria B-Disease
. O

since O
nonsteroidal O
anti O
- O
inflammatory O
agents O
interfere O
with O
this O
compensatory O
mechanism O
and O
may O
cause O
acute B-Disease
renal I-Disease
failure I-Disease
, O
they O
should O
be O
used O
with O
caution O
in O
such O
patients O
. O

patterns O
of O
hepatic B-Disease
injury I-Disease
induced O
by O
methyldopa O
. O

twelve O
patients O
with O
liver B-Disease
disease I-Disease
related O
to O
methyldopa O
were O
seen O
between O
1967 O
and O
1977 O
. O

jaundice B-Disease
with O
tender O
hepatomegaly B-Disease
, O
usually O
preceded O
by O
symptoms O
of O
malaise O
, O
anorexia B-Disease
, O
nausea B-Disease
and O
vomiting B-Disease
, O
and O
associated O
with O
upper O
abdominal B-Disease
pain I-Disease
, O
was O
an O
invariable O
finding O
in O
all O
patients O
. O

biochemical O
liver O
function O
tests O
indicated O
hepatocellular O
necrosis B-Disease
and O
correlated O
with O
histopathological O
evidence O
of O
hepatic B-Disease
injury I-Disease
, O
the O
spectrum O
of O
which O
ranged O
from O
fatty B-Disease
change I-Disease
and O
focal O
hepatocellular O
necrosis B-Disease
to O
massive B-Disease
hepatic I-Disease
necrosis I-Disease
. O

most O
patients O
showed O
moderate O
to O
severe O
acute B-Disease
hepatitis I-Disease
or O
chronic B-Disease
active I-Disease
hepatitis I-Disease
with O
associated O
cholestasis B-Disease
. O

one O
patient O
died O
, O
having O
presented O
in O
hepatic B-Disease
failure I-Disease
, O
and O
another O
, O
who O
had O
been O
taking O
methyldopa O
for O
7 O
years O
, O
showed O
slower O
clinical O
and O
biochemical O
resolution O
over O
a O
period O
of O
several O
months O
. O

the O
remaining O
patient O
in O
the O
series O
developed O
fulminant B-Disease
hepatitis I-Disease
when O
the O
drug O
was O
accidentally O
recommenced O
1 O
year O
after O
a O
prior O
episode O
of O
methyldopa O
- O
induced O
hepatitis B-Disease
. O

in O
this O
latter O
patient O
, O
and O
in O
2 O
others O
, O
the O
causal O
relationship O
between O
methyldopa O
and O
hepatic B-Disease
dysfunction I-Disease
was O
proved O
with O
the O
recurrence O
of O
hepatitis B-Disease
within O
2 O
weeks O
of O
re O
- O
exposure O
to O
the O
drug O
. O

suxamethonium O
infusion O
rate O
and O
observed O
fasciculations B-Disease
. O

the O
infusion O
was O
discontinued O
either O
when O
there O
was O
no O
muscular O
response O
to O
tetanic B-Disease
stimulation O
of O
the O
ulnar O
nerve O
or O
when O
sch O
120 O
mg O
was O
exceeded O
. O

fasciculations B-Disease
in O
six O
areas O
of O
the O
body O
were O
scored O
from O
0 O
to O
3 O
and O
summated O
as O
a O
total O
fasciculation B-Disease
score O
. O

the O
times O
to O
first O
fasciculation B-Disease
, O
twitch B-Disease
suppression O
and O
tetanus B-Disease
suppression O
were O
inversely O
related O
to O
the O
infusion O
rates O
. O

fasciculations B-Disease
in O
the O
six O
areas O
and O
the O
total O
fasciculation B-Disease
score O
were O
related O
directly O
to O
the O
rate O
of O
infusion O
. O

total O
fasciculation B-Disease
scores O
in O
the O
30 O
- O
mg O
bolus O
group O
and O
the O
5 O
- O
mg O
s O
- O
1 O
and O
20 O
- O
mg O
s O
- O
1 O
infusion O
groups O
were O
not O
significantly O
different O
. O

treatment O
of O
psoriasis B-Disease
with O
azathioprine O
. O

azathioprine O
treatment O
benefited O
19 O
( O
66 O
% O
) O
out O
of O
29 O
patients O
suffering O
from O
severe O
psoriasis B-Disease
. O

minimal O
cholestasis B-Disease
was O
seen O
in O
two O
cases O
and O
portal O
fibrosis B-Disease
of O
a O
reversible O
degree O
in O
eight O
. O

liver O
biopsies O
should O
be O
undertaken O
at O
regular O
intervals O
if O
azathioprine O
therapy O
is O
continued O
so O
that O
structural O
liver B-Disease
damage I-Disease
may O
be O
detected O
at O
an O
early O
and O
reversible O
stage O
. O

angiosarcoma B-Disease
of I-Disease
the I-Disease
liver I-Disease
associated O
with O
diethylstilbestrol O
. O

angiosarcoma B-Disease
of I-Disease
the I-Disease
liver I-Disease
occurred O
in O
a O
76 O
- O
year O
- O
old O
man O
who O
had O
been O
treated O
for O
a O
well O
- O
differentiated O
adenocarcinoma B-Disease
of I-Disease
the I-Disease
liver I-Disease
with O
diethylstilbestrol O
for O
13 O
years O
. O

angiosarcoma B-Disease
was O
also O
present O
within O
pulmonary O
and O
renal O
arteries O
. O

the O
possibility O
that O
the O
intraarterial B-Disease
lesions I-Disease
might O
represent O
independent O
primary O
tumors B-Disease
is O
considered O
. O

galanthamine O
hydrobromide O
, O
an O
anticholinesterase O
drug O
capable O
of O
penetrating O
the O
blood O
- O
brain O
barrier O
, O
was O
used O
in O
a O
patient O
demonstrating O
central O
effects O
of O
scopolamine O
( O
hyoscine O
) O
overdosage B-Disease
. O

dizziness B-Disease
was O
less O
marked O
than O
sedation O
, O
but O
increased O
with O
the O
dose O
. O

there O
was O
pain B-Disease
on O
i O
. O

m O
. O

injection O
of O
flunitrazepam O
significantly O
more O
often O
than O
with O
isotonic O
saline O
. O

three O
infants O
, O
born O
of O
two O
mothers O
with O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
who O
received O
treatment O
with O
sulphasalazine O
throughout O
pregnancy O
, O
were O
found O
to O
have O
major O
congenital B-Disease
anomalies I-Disease
. O

in O
the O
singleton O
pregnancy O
, O
the O
mother O
had O
ulcerative B-Disease
colitis I-Disease
, O
and O
the O
infant O
, O
a O
male O
, O
had O
coarctation B-Disease
of I-Disease
the I-Disease
aorta I-Disease
and O
a O
ventricular B-Disease
septal I-Disease
defect I-Disease
. O

in O
the O
twin O
pregnancy O
, O
the O
mother O
had O
crohn B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

the O
first O
twin O
, O
a O
female O
, O
had O
a O
left O
potter B-Disease
- I-Disease
type I-Disease
iia I-Disease
polycystic I-Disease
kidney I-Disease
and O
a O
rudimentary B-Disease
left I-Disease
uterine I-Disease
cornu I-Disease
. O

the O
second O
twin O
, O
a O
male O
, O
had O
some O
features O
of O
potter B-Disease
' I-Disease
s I-Disease
facies I-Disease
, O
hypoplastic B-Disease
lungs I-Disease
, O
absent B-Disease
kidneys I-Disease
and I-Disease
ureters I-Disease
, O
and O
talipes B-Disease
equinovarus I-Disease
. O

thrombotic B-Disease
microangiopathy I-Disease
and O
renal B-Disease
failure I-Disease
associated O
with O
antineoplastic O
chemotherapy O
. O

five O
patients O
with O
carcinoma B-Disease
developed O
thrombotic B-Disease
microangiopathy I-Disease
( O
characterized O
by O
renal B-Disease
insufficiency I-Disease
, O
microangiopathic B-Disease
hemolytic I-Disease
anemia I-Disease
, O
and O
usually O
thrombocytopenia B-Disease
) O
after O
treatment O
with O
cisplatin O
, O
bleomycin O
, O
and O
a O
vinca O
alkaloid O
. O

one O
patient O
had O
thrombotic B-Disease
thrombocytopenic I-Disease
purpura I-Disease
, O
three O
the O
hemolytic B-Disease
- I-Disease
uremic I-Disease
syndrome I-Disease
, O
and O
one O
an O
apparent O
forme O
fruste O
of O
one O
of O
these O
disorders O
. O

histologic O
examination O
of O
the O
renal O
tissue O
showed O
evidence O
of O
intravascular B-Disease
coagulation I-Disease
, O
primarily O
affecting O
the O
small O
arteries O
, O
arterioles O
, O
and O
glomeruli O
. O

because O
each O
patient O
was O
tumor B-Disease
- O
free O
or O
had O
only O
a O
small O
tumor B-Disease
at O
the O
onset O
of O
this O
syndrome O
, O
the O
thrombotic B-Disease
microangiopathy I-Disease
may O
have O
been O
induced O
by O
chemotherapy O
. O

diagnosis O
of O
this O
potentially O
fatal O
complication O
may O
be O
delayed O
or O
missed O
if O
renal O
tissue O
or O
the O
peripheral O
blood O
smear O
is O
not O
examined O
, O
because O
renal B-Disease
failure I-Disease
may O
be O
ascribed O
to O
cisplatin O
nephrotoxicity B-Disease
and O
the O
anemia B-Disease
and O
thrombocytopenia B-Disease
to O
drug O
- O
induced O
bone B-Disease
marrow I-Disease
suppression I-Disease
. O

report O
on O
arrhythmia B-Disease
and O
other O
findings O
. O

the O
antiarrhythmic O
effects O
of O
the O
sustained O
release O
form O
of O
mexiletine O
( O
mexitil O
- O
perlongets O
) O
were O
evaluated O
in O
a O
double O
- O
blind O
placebo O
trial O
in O
630 O
patients O
with O
recent O
documented O
myocardial B-Disease
infarction I-Disease
. O

there O
were O
more O
deaths B-Disease
in O
the O
mexiletine O
group O
( O
7 O
. O

6 O
% O
) O
than O
in O
the O
placebo O
group O
( O
4 O
. O

8 O
% O
) O
; O
the O
difference O
was O
not O
statistically O
significant O
. O

previously O
recognized O
side O
effects O
, O
particularly O
tremor B-Disease
and O
gastrointestinal B-Disease
problems I-Disease
, O
were O
more O
frequent O
in O
the O
mexiletine O
group O
than O
in O
the O
placebo O
group O
. O

changes O
in O
heart O
size O
during O
long O
- O
term O
timolol O
treatment O
after O
myocardial B-Disease
infarction I-Disease
. O

the O
effect O
of O
long O
- O
term O
timolol O
treatment O
on O
heart O
size O
after O
myocardial B-Disease
infarction I-Disease
was O
evaluated O
by O
x O
- O
ray O
in O
a O
double O
- O
blind O
study O
including O
241 O
patients O
( O
placebo O
126 O
, O
timolol O
115 O
) O
. O

these O
differences O
may O
be O
caused O
by O
timolol O
- O
induced O
bradycardia B-Disease
and O
a O
compensatory O
increase O
in O
end O
- O
diastolic O
volume O
. O

in O
patients O
with O
cardiomegaly B-Disease
, O
the O
increase O
in O
heart O
size O
was O
similar O
in O
both O
groups O
. O

after O
re O
- O
infarction B-Disease
, O
heart O
size O
increased O
in O
the O
placebo O
group O
and O
remained O
unchanged O
in O
the O
timolol O
group O
. O

vitamin O
d3 O
toxicity B-Disease
in O
dairy O
cows O
. O

large O
parenteral O
doses O
of O
vitamin O
d3 O
( O
15 O
to O
17 O
. O

5 O
x O
10 O
( O
6 O
) O
iu O
vitamin O
d3 O
) O
were O
associated O
with O
prolonged O
hypercalcemia B-Disease
, O
hyperphosphatemia B-Disease
, O
and O
large O
increases O
of O
vitamin O
d3 O
and O
its O
metabolites O
in O
the O
blood O
plasma O
of O
nonlactating O
nonpregnant O
and O
pregnant O
jersey O
cows O
. O

none O
of O
the O
cows O
treated O
with O
vitamin O
d3 O
showed O
signs O
of O
milk B-Disease
fever I-Disease
during O
the O
peripartal O
period O
; O
however O
, O
22 O
% O
of O
the O
control O
cows O
developed O
clinical O
signs O
of O
milk B-Disease
fever I-Disease
during O
this O
period O
. O

signs O
of O
vitamin O
d3 O
toxicity B-Disease
were O
not O
observed O
in O
nonlactating O
nonpregnant O
cows O
; O
however O
, O
pregnant O
cows O
commonly O
developed O
severe O
signs O
of O
vitamin O
d3 O
toxicity B-Disease
and O
10 O
of O
17 O
cows O
died O
. O

because O
of O
the O
extreme O
toxicity B-Disease
of O
vitamin O
d3 O
in O
pregnant O
jersey O
cows O
and O
the O
low O
margin O
of O
safety O
between O
doses O
of O
vitamin O
d3 O
that O
prevent O
milk B-Disease
fever I-Disease
and O
doses O
that O
induce O
milk B-Disease
fever I-Disease
, O
we O
concluded O
that O
vitamin O
d3 O
cannot O
be O
used O
practically O
to O
prevent O
milk B-Disease
fever I-Disease
when O
injected O
several O
weeks O
prepartum O
. O

diseases B-Disease
of I-Disease
peripheral I-Disease
nerves I-Disease
as O
seen O
in O
the O
nigerian O
african O
. O

the O
anatomical O
and O
aetiological O
diagnoses O
of O
peripheral B-Disease
nerve I-Disease
disease I-Disease
excluding O
its O
primary O
benign O
and O
malignant O
disorders O
, O
as O
seen O
in O
358 O
nigerians O
are O
presented O
. O

sensori B-Disease
- I-Disease
motor I-Disease
neuropathy I-Disease
was O
the O
commonest O
presentation O
( O
50 O
% O
) O
. O

guillain B-Disease
- I-Disease
barr I-Disease
syndrome I-Disease
was O
the O
commonest O
identifiable O
cause O
( O
15 O
. O

6 O
% O
) O
, O
accounting O
for O
half O
of O
the O
cases O
with O
motor B-Disease
neuropathy I-Disease
. O

peripheral B-Disease
neuropathy I-Disease
due O
to O
nutritional B-Disease
deficiency I-Disease
of O
thiamine O
and O
riboflavin O
was O
common O
( O
10 O
. O

1 O
% O
) O
and O
presented O
mainly O
as O
sensory O
and O
sensori B-Disease
- I-Disease
motor I-Disease
neuropathy I-Disease
. O

diabetes B-Disease
mellitus I-Disease
was O
the O
major O
cause O
of O
autonomic B-Disease
neuropathy I-Disease
. O

isoniazid O
was O
the O
most O
frequent O
agent O
in O
drug O
- O
induced O
neuropathy B-Disease
. O

migraine B-Disease
( O
20 O
% O
) O
was O
not O
an O
uncommon O
cause O
of O
cranial B-Disease
neuropathy I-Disease
although O
malignancies B-Disease
arising O
from O
the O
reticuloendothelial O
system O
or O
related O
structures O
of O
the O
head O
and O
neck O
were O
more O
frequent O
( O
26 O
% O
) O
. O

in O
26 O
. O

5 O
% O
of O
all O
the O
cases O
, O
the O
aetiology O
of O
the O
neuropathy B-Disease
was O
undetermined O
. O

heredofamilial O
and O
connective B-Disease
tissue I-Disease
disorders I-Disease
were O
rare O
. O

some O
of O
the O
factors O
related O
to O
the O
clinical O
presentation O
and O
pathogenesis O
of O
the O
neuropathies B-Disease
are O
briefly O
discussed O
. O

reduction O
in O
caffeine O
toxicity B-Disease
by O
acetaminophen O
. O

because O
salicylates O
have O
been O
reported O
to O
augment O
the O
stimulatory O
effects O
of O
caffeine O
on O
the O
cns O
, O
attention O
was O
focused O
on O
the O
possibility O
that O
the O
presence O
of O
acetaminophen O
( O
52 O
micrograms O
/ O
ml O
) O
reduced O
the O
cns O
toxicity B-Disease
of O
caffeine O
. O

studies O
in O
dba O
/ O
2j O
mice O
showed O
that O
: O
1 O
) O
pretreatment O
with O
acetaminophen O
( O
100 O
mg O
/ O
kg O
) O
increased O
the O
interval O
between O
the O
administration O
of O
caffeine O
( O
300 O
to O
450 O
mg O
/ O
kg O
ip O
) O
and O
the O
onset O
of O
fatal O
convulsions B-Disease
by O
a O
factor O
of O
about O
two O
; O
and O
2 O
) O
pretreatment O
with O
acetaminophen O
( O
75 O
mg O
/ O
kg O
) O
reduced O
the O
incidence O
of O
audiogenic O
seizures B-Disease
produced O
in O
the O
presence O
of O
caffeine O
( O
12 O
. O

5 O
to O
75 O
mg O
/ O
kg O
ip O
) O
. O

the O
frequency O
of O
sound O
- O
induced O
seizures B-Disease
after O
12 O
. O

5 O
or O
25 O
mg O
/ O
kg O
caffeine O
was O
reduced O
from O
50 O
to O
5 O
% O
by O
acetaminophen O
. O

in O
the O
absence O
of O
caffeine O
, O
acetaminophen O
( O
up O
to O
300 O
mg O
/ O
kg O
) O
did O
not O
modify O
the O
seizures B-Disease
induced O
by O
maximal O
electroshock O
and O
did O
not O
alter O
the O
convulsant O
dose O
of O
pentylenetetrezol O
in O
mice O
( O
tests O
performed O
by O
the O
anticonvulsant O
screening O
project O
of O
nincds O
) O
. O

a O
double O
- O
blind O
study O
of O
the O
efficacy O
and O
safety O
of O
dothiepin O
hydrochloride O
in O
the O
treatment O
of O
major O
depressive B-Disease
disorder I-Disease
. O

in O
a O
6 O
- O
week O
double O
- O
blind O
parallel O
treatment O
study O
, O
dothiepin O
and O
amitriptyline O
were O
compared O
to O
placebo O
in O
the O
treatment O
of O
33 O
depressed B-Disease
outpatients O
. O

dothiepin O
and O
amitriptyline O
were O
equally O
effective O
in O
alleviating O
the O
symptoms O
of O
depressive B-Disease
illness I-Disease
, O
and O
both O
were O
significantly O
superior O
to O
placebo O
. O

the O
overall O
incidence O
of O
side O
effects O
and O
the O
frequency O
and O
severity O
of O
blurred B-Disease
vision I-Disease
, O
dry B-Disease
mouth I-Disease
, O
and O
drowsiness O
were O
significantly O
less O
with O
dothiepin O
than O
with O
amitriptyline O
. O

dothiepin O
thus O
was O
found O
to O
be O
an O
effective O
antidepressant O
drug O
associated O
with O
fewer O
side O
effects O
than O
amitriptyline O
in O
the O
treatment O
of O
depressed B-Disease
outpatients O
. O

behavioral O
effects O
of O
diazepam O
and O
propranolol O
in O
patients O
with O
panic B-Disease
disorder I-Disease
and O
agoraphobia B-Disease
. O

the O
effects O
of O
oral O
doses O
of O
diazepam O
( O
single O
dose O
of O
10 O
mg O
and O
a O
median O
dose O
of O
30 O
mg O
/ O
day O
for O
2 O
weeks O
) O
and O
propranolol O
( O
single O
dose O
of O
80 O
mg O
and O
a O
median O
dose O
of O
240 O
mg O
/ O
day O
for O
2 O
weeks O
) O
on O
psychological O
performance O
of O
patients O
with O
panic B-Disease
disorders I-Disease
and O
agoraphobia B-Disease
were O
investigated O
in O
a O
double O
- O
blind O
, O
randomized O
and O
crossover O
design O
. O

both O
drugs O
impaired B-Disease
immediate I-Disease
free I-Disease
recall I-Disease
but O
the O
decrease O
was O
greater O
for O
diazepam O
than O
propranolol O
. O

delayed B-Disease
free I-Disease
recall I-Disease
was I-Disease
also I-Disease
impaired I-Disease
but O
the O
two O
drugs O
did O
not O
differ O
. O

accumulation O
of O
drugs O
was O
not O
reflected O
in O
prolonged O
behavioral B-Disease
impairment I-Disease
. O

comparison O
of O
i O
. O

v O
. O

glycopyrrolate O
and O
atropine O
in O
the O
prevention O
of O
bradycardia B-Disease
and O
arrhythmias B-Disease
following O
repeated O
doses O
of O
suxamethonium O
in O
children O
. O

the O
effectiveness O
of O
administration O
of O
glycopyrrolate O
5 O
and O
10 O
micrograms O
kg O
- O
1 O
and O
atropine O
10 O
and O
20 O
micrograms O
kg O
- O
1 O
i O
. O

v O
. O

immediately O
before O
the O
induction O
of O
anaesthesia O
, O
to O
prevent O
arrhythmia B-Disease
and O
bradycardia B-Disease
following O
repeated O
doses O
of O
suxamethonium O
in O
children O
, O
was O
studied O
. O

a O
frequency O
of O
bradycardia B-Disease
of O
50 O
% O
was O
noted O
in O
the O
control O
group O
, O
but O
this O
was O
not O
significantly O
different O
from O
the O
frequency O
with O
the O
active O
drugs O
. O

bradycardia B-Disease
( O
defined O
as O
a O
decrease O
in O
heart O
rate O
to O
less O
than O
50 O
beat O
min O
- O
1 O
) O
was O
prevented O
when O
the O
larger O
dose O
of O
either O
active O
drug O
was O
used O
. O

veno B-Disease
- I-Disease
occlusive I-Disease
liver I-Disease
disease I-Disease
after O
dacarbazine O
therapy O
( O
dtic O
) O
for O
melanoma B-Disease
. O

a O
case O
of O
veno B-Disease
- I-Disease
occlusive I-Disease
disease I-Disease
of I-Disease
the I-Disease
liver I-Disease
with O
fatal O
outcome O
after O
dacarbazine O
( O
dtic O
) O
therapy O
for O
melanoma B-Disease
is O
reported O
. O

there O
was O
a O
fulminant O
clinical O
course O
from O
start O
of O
symptoms O
until O
death B-Disease
. O

at O
autopsy O
the O
liver O
was O
enlarged O
and O
firm O
with O
signs O
of O
venous B-Disease
congestion I-Disease
. O

small O
- O
and O
medium O
- O
sized O
hepatic O
veins O
were O
blocked O
by O
thrombosis B-Disease
. O

maternal O
lithium O
and O
neonatal O
ebstein B-Disease
' I-Disease
s I-Disease
anomaly I-Disease
: O
evaluation O
with O
cross O
- O
sectional O
echocardiography O
. O

in O
one O
infant O
, O
ebstein B-Disease
' I-Disease
s I-Disease
anomaly I-Disease
of O
the O
tricuspid O
valve O
was O
identified O
. O

in O
the O
other O
infant O
cross O
- O
sectional O
echocardiography O
provided O
reassurance O
that O
the O
infant O
did O
not O
have O
ebstein B-Disease
' I-Disease
s I-Disease
anomaly I-Disease
. O

cross O
- O
sectional O
echocardiographic O
screening O
of O
newborns O
exposed O
to O
lithium O
during O
gestation O
can O
provide O
highly O
accurate O
, O
noninvasive O
assessment O
of O
the O
presence O
or O
absence O
of O
lithium O
- O
induced O
cardiac B-Disease
malformations I-Disease
. O

effects O
of O
training O
on O
the O
extent O
of O
experimental O
myocardial B-Disease
infarction I-Disease
in O
aging O
rats O
. O

the O
effects O
of O
exercise O
on O
the O
severity O
of O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
were O
studied O
in O
female O
albino O
rats O
of O
20 O
, O
40 O
, O
60 O
and O
80 O
weeks O
of O
age O
. O

the O
occurrence O
of O
infarcts B-Disease
were O
confirmed O
by O
histological O
methods O
. O

studies O
dealing O
with O
myocardial B-Disease
infarction I-Disease
are O
more O
informative O
when O
dealt O
with O
age O
. O

effect O
of O
polyethylene O
glycol O
400 O
on O
adriamycin O
toxicity B-Disease
in O
mice O
. O

light O
microscopic O
analysis O
showed O
a O
significant O
protection O
against O
adr O
- O
induced O
cardiac B-Disease
morphological I-Disease
alterations I-Disease
. O

such O
treatment O
did O
not O
diminish O
the O
adr O
antitumor O
activity O
in O
l1210 B-Disease
leukemia I-Disease
and O
in O
ehrlich B-Disease
ascites I-Disease
tumor I-Disease
. O

um O
- O
272 O
( O
n O
, O
n O
- O
dimethylpropranolol O
) O
, O
a O
quaternary O
antiarrhythmic O
agent O
, O
was O
administered O
sublingually O
to O
dogs O
with O
ouabain O
- O
induced O
ventricular B-Disease
tachycardias I-Disease
. O

sublingual O
um O
- O
272 O
converted O
ventricular B-Disease
tachycardia I-Disease
to O
sinus O
rhythm O
in O
all O
5 O
dogs O
. O

early O
adjuvant O
adriamycin O
in O
superficial O
bladder B-Disease
carcinoma I-Disease
. O

a O
multicenter O
study O
was O
performed O
in O
110 O
patients O
with O
superficial O
transitional O
cell O
carcinoma B-Disease
of I-Disease
the I-Disease
bladder I-Disease
. O

adriamycin O
( O
50 O
mg O
/ O
50 O
ml O
) O
was O
administered O
intravesically O
within O
24 O
h O
after O
transurethral O
resection O
of O
ta O
- O
t1 O
( O
o O
- O
a O
) O
bladder B-Disease
tumors I-Disease
. O

in O
24 O
of O
these O
patients O
chemical O
cystitis B-Disease
was O
severe O
enough O
for O
them O
to O
drop O
out O
of O
the O
study O
. O

of O
these O
recurrences O
, O
27 O
were O
t1 O
tumors B-Disease
while O
five O
progressed O
to O
more O
highly O
invasive O
lesions O
. O

in O
patients O
that O
were O
free O
of O
recurrence O
during O
the O
first O
year O
, O
80 O
% O
remained O
tumor B-Disease
- O
free O
during O
the O
2 O
- O
to O
3 O
- O
year O
follow O
- O
up O
period O
. O

d O
- O
penicillamine O
- O
induced O
angiopathy B-Disease
in O
rats O
. O

the O
co O
- O
administration O
of O
aspirin O
with O
n O
- O
[ O
4 O
- O
( O
5 O
- O
nitro O
- O
2 O
- O
furyl O
) O
- O
2 O
- O
thiazolyl O
] O
- O
formamide O
( O
fanft O
) O
to O
rats O
resulted O
in O
a O
reduced O
incidence O
of O
fanft O
- O
induced O
bladder B-Disease
carcinomas I-Disease
but O
a O
concomitant O
induction O
of O
forestomach B-Disease
tumors I-Disease
. O

the O
present O
results O
are O
consistent O
with O
the O
carcinogenicity O
experiment O
suggesting O
that O
different O
mechanisms O
are O
involved O
in O
fanft O
carcinogenesis B-Disease
in O
the O
bladder O
and O
forestomach O
, O
and O
that O
aspirin O
' O
s O
effect O
on O
fanft O
in O
the O
forestomach O
is O
not O
due O
to O
an O
irritant O
effect O
associated O
with O
increased O
cell O
proliferation O
. O

a O
case O
of O
tardive B-Disease
dyskinesia I-Disease
caused O
by O
metoclopramide O
. O

abnormal B-Disease
involuntary I-Disease
movements I-Disease
appeared O
in O
the O
mouth O
, O
tongue O
, O
neck O
and O
abdomen O
of O
a O
64 O
- O
year O
- O
old O
male O
patient O
after O
he O
took O
metoclopramide O
for O
gastrointestinal B-Disease
disorder I-Disease
in O
a O
regimen O
of O
30 O
mg O
per O
day O
for O
a O
total O
of O
about O
260 O
days O
. O

when O
the O
metoclopramide O
administration O
was O
discontinued O
, O
the O
abnormal B-Disease
movements I-Disease
gradually O
improved O
to O
a O
considerable O
extent O
. O

attention O
to O
the O
possible O
induction O
of O
specific O
tardive B-Disease
dyskinesia I-Disease
is O
called O
for O
in O
the O
use O
of O
this O
drug O
. O

intra O
- O
arterial O
bcnu O
chemotherapy O
for O
treatment O
of O
malignant B-Disease
gliomas I-Disease
of O
the O
central O
nervous O
system O
. O

because O
of O
the O
rapid O
systemic O
clearance O
of O
bcnu O
( O
1 O
, O
3 O
- O
bis O
- O
( O
2 O
- O
chloroethyl O
) O
- O
1 O
- O
nitrosourea O
) O
, O
intra O
- O
arterial O
administration O
should O
provide O
a O
substantial O
advantage O
over O
intravenous O
administration O
for O
the O
treatment O
of O
malignant B-Disease
gliomas I-Disease
. O

twelve O
patients O
with O
grade O
iii O
or O
iv O
astrocytomas B-Disease
were O
treated O
after O
partial O
resection O
of O
the O
tumor B-Disease
without O
prior O
radiation O
therapy O
. O

after O
two O
to O
seven O
cycles O
of O
chemotherapy O
, O
nine O
patients O
showed O
a O
decrease O
in O
tumor B-Disease
size O
and O
surrounding O
edema B-Disease
on O
contrast O
- O
enhanced O
computerized O
tomography O
scans O
. O

twenty O
- O
four O
patients O
with O
recurrent O
grade O
i O
to O
iv O
astrocytomas B-Disease
, O
whose O
resection O
and O
irradiation O
therapy O
had O
failed O
, O
received O
two O
to O
eight O
courses O
of O
intra O
- O
arterial O
bcnu O
therapy O
. O

a O
delayed O
complication O
in O
nine O
patients O
has O
been O
unilateral O
loss B-Disease
of I-Disease
vision I-Disease
secondary O
to O
a O
retinal B-Disease
vasculitis I-Disease
. O

the O
frequency O
of O
visual B-Disease
loss I-Disease
decreased O
after O
the O
concentration O
of O
the O
ethanol O
diluent O
was O
lowered O
. O

provocation O
of O
postural O
hypotension B-Disease
by O
nitroglycerin O
in O
diabetic B-Disease
autonomic I-Disease
neuropathy I-Disease
? O
the O
effect O
of O
nitroglycerin O
on O
heart O
rate O
and O
systolic O
blood O
pressure O
was O
compared O
in O
5 O
normal O
subjects O
, O
12 O
diabetic B-Disease
subjects O
without O
autonomic B-Disease
neuropathy I-Disease
, O
and O
5 O
diabetic B-Disease
subjects O
with O
autonomic B-Disease
neuropathy I-Disease
. O

the O
magnitude O
and O
time O
course O
of O
the O
increase O
in O
heart O
rate O
and O
the O
decrease O
in O
systolic O
blood O
pressure O
after O
nitroglycerin O
were O
similar O
in O
the O
normal O
and O
diabetic B-Disease
subjects O
without O
autonomic B-Disease
neuropathy I-Disease
, O
whereas O
a O
lesser O
increase O
in O
heart O
rate O
and O
a O
greater O
decrease O
in O
systolic O
blood O
pressure O
occurred O
in O
the O
diabetic B-Disease
subjects O
with O
autonomic B-Disease
neuropathy I-Disease
. O

it O
is O
therefore O
suggested O
that O
caution O
should O
be O
exercised O
when O
prescribing O
vasodilator O
drugs O
in O
diabetic B-Disease
patients O
, O
particularly O
those O
with O
autonomic B-Disease
neuropathy I-Disease
. O

intrarenal O
infusion O
of O
noradrenaline O
caused O
hypertension B-Disease
at O
doses O
which O
did O
not O
do O
so O
when O
infused O
intravenously O
. O

these O
results O
suggest O
that O
hypertension B-Disease
after O
chronic O
intrarenal O
noradrenaline O
infusion O
is O
produced O
by O
relatively O
higher O
levels O
of O
circulating O
noradrenaline O
and O
by O
triggering O
of O
an O
additional O
intrarenal O
pressor O
mechanism O
. O

characterization O
of O
estrogen O
- O
induced O
adenohypophyseal B-Disease
tumors I-Disease
in O
the O
fischer O
344 O
rat O
. O

pituitary B-Disease
tumors I-Disease
were O
induced O
in O
f344 O
female O
rats O
by O
chronic O
treatment O
with O
diethylstilbestrol O
( O
des O
, O
8 O
- O
10 O
mg O
) O
imB-Planted O
subcutaneously O
in O
silastic O
capsules O
. O

the O
data O
extend O
the O
findings O
of O
other O
investigators O
, O
further O
establishing O
the O
des O
- O
induced O
tumor B-Disease
as O
a O
model O
for O
study O
of O
prl O
cellular O
control O
mechanisms O
. O

there O
was O
only O
one O
case O
of O
dementia B-Disease
possibly O
due O
to O
cimetidine O
( O
with O
a O
drug O
level O
of O
1 O
. O

9 O
microgram O
/ O
ml O
6 O
hr O
after O
a O
dose O
) O
in O
a O
group O
of O
13 O
patients O
without O
liver B-Disease
or I-Disease
kidney I-Disease
disease I-Disease
who O
had O
cimetidine O
levels O
above O
1 O
. O

25 O
microgram O
/ O
ml O
. O

thus O
, O
high O
cimetidine O
levels O
alone O
do O
not O
always O
induce O
dementia B-Disease
. O

a O
case O
is O
presented O
of O
a O
reversible O
intra B-Disease
- I-Disease
hisian I-Disease
block I-Disease
occurring O
under O
amiodarone O
treatment O
for O
atrial B-Disease
tachycardia I-Disease
in O
a O
patient O
without O
clear O
intraventricular B-Disease
conduction I-Disease
abnormalities I-Disease
. O

his O
bundle O
recordings O
showed O
an O
atrial B-Disease
tachycardia I-Disease
with O
intermittent O
exit O
block O
and O
greatly O
prolonged O
bh O
and O
hv O
intervals O
( O
40 O
and O
100 O
msec O
, O
respectively O
) O
. O

thirty O
days O
after O
amiodarone O
discontinuation O
, O
his O
bundle O
electrograms O
showed O
atrial B-Disease
flutter I-Disease
without O
intra O
- O
hisian O
or O
infra O
- O
hisian O
delay O
. O

development O
of O
clear B-Disease
cell I-Disease
adenocarcinoma I-Disease
in O
des O
- O
exposed O
offspring O
under O
observation O
. O

two O
cases O
of O
clear B-Disease
cell I-Disease
adenocarcinoma I-Disease
of I-Disease
the I-Disease
vagina I-Disease
detected O
at O
follow O
- O
up O
in O
young O
women O
exposed O
in O
utero O
to O
diethylstilbestrol O
are O
reported O
. O

one O
patient O
, O
aged O
23 O
, O
had O
been O
followed O
for O
2 O
years O
before O
carcinoma B-Disease
was O
diagnosed O
; O
the O
second O
patient O
, O
aged O
22 O
, O
had O
been O
seen O
on O
a O
regular O
basis O
for O
5 O
years O
, O
8 O
months O
. O

in O
both O
instances O
, O
suspicion O
of O
the O
presence O
of O
carcinoma B-Disease
was O
aroused O
by O
the O
palpation O
of O
a O
small O
nodule O
in O
the O
vaginal O
fornix O
. O

the O
possible O
role O
of O
low O
ph O
as O
well O
as O
total O
volume O
as O
potential O
factors O
in O
causing O
neurotoxicity B-Disease
was O
evaluated O
. O

of O
the O
20 O
animals O
that O
received O
subarachnoid O
injection O
of O
2 O
- O
chloroprocaine O
- O
ce O
seven O
( O
35 O
% O
) O
developed O
hind O
- O
limb O
paralysis B-Disease
. O

none O
of O
the O
animals O
that O
received O
bupivacaine O
, O
normal O
saline O
, O
or O
normal O
saline O
titrated O
to O
a O
ph O
3 O
. O

0 O
developed O
hind O
- O
limb O
paralysis B-Disease
. O

of O
the O
15 O
spinal O
cords O
of O
the O
animals O
that O
received O
2 O
- O
chloroprocaine O
- O
ce O
, O
13 O
showed O
subpial B-Disease
necrosis I-Disease
; O
the O
nerve O
roots O
and O
subarachnoid O
vessels O
were O
normal O
. O

procainamide O
- O
induced O
polymorphous O
ventricular B-Disease
tachycardia I-Disease
. O

seven O
cases O
of O
procainamide O
- O
induced O
polymorphous O
ventricular B-Disease
tachycardia I-Disease
are O
presented O
. O

in O
four O
patients O
, O
polymorphous O
ventricular B-Disease
tachycardia I-Disease
appeared O
after O
intravenous O
administration O
of O
200 O
to O
400 O
mg O
of O
procainamide O
for O
the O
treatment O
of O
sustained O
ventricular B-Disease
tachycardia I-Disease
. O

in O
the O
remaining O
three O
patients O
, O
procainamide O
was O
administered O
orally O
for O
treatment O
of O
chronic O
premature B-Disease
ventricular I-Disease
contractions I-Disease
or O
atrial B-Disease
flutter I-Disease
. O

these O
patients O
had O
q B-Disease
- I-Disease
t I-Disease
prolongation I-Disease
and O
recurrent O
syncope B-Disease
due O
to O
polymorphous O
ventricular B-Disease
tachycardia I-Disease
. O

in O
four O
patients O
, O
the O
arrhythmia B-Disease
was O
rapidly O
diagnosed O
and O
treated O
with O
disappearance O
of O
further O
episodes O
of O
the O
arrhythmia B-Disease
. O

in O
two O
patients O
, O
the O
arrhythmia B-Disease
degenerated O
into O
irreversible O
ventricular B-Disease
fibrillation I-Disease
and O
both O
patients O
died O
. O

in O
the O
seventh O
patient O
, O
a O
permanent O
ventricular O
pacemaker O
was O
inserted O
and O
, O
despite O
continuation O
of O
procainamide O
therapy O
, O
polymorphous O
ventricular B-Disease
tachycardia I-Disease
did O
not O
reoccur O
. O

these O
seven O
cases O
demonstrate O
that O
procainamide O
can O
produce O
an O
acquired O
prolonged B-Disease
q I-Disease
- I-Disease
t I-Disease
syndrome I-Disease
with O
polymorphous O
ventricular B-Disease
tachycardia I-Disease
. O

phenobarbitone O
- O
induced O
enlargement B-Disease
of I-Disease
the I-Disease
liver I-Disease
in O
the O
rat O
: O
its O
relationship O
to O
carbon O
tetrachloride O
- O
induced O
cirrhosis B-Disease
. O

the O
yield O
of O
severe O
cirrhosis B-Disease
of I-Disease
the I-Disease
liver I-Disease
( O
defined O
as O
a O
shrunken O
finely O
nodular O
liver O
with O
micronodular O
histology O
, O
ascites B-Disease
greater O
than O
30 O
ml O
, O
plasma O
albumin O
less O
than O
2 O
. O

2 O
g O
/ O
dl O
, O
splenomegaly B-Disease
2 O
- O
3 O
times O
normal O
, O
and O
testicular O
atrophy B-Disease
approximately O
half O
normal O
weight O
) O
after O
12 O
doses O
of O
carbon O
tetrachloride O
given O
intragastrically O
in O
the O
phenobarbitone O
- O
primed O
rat O
was O
increased O
from O
25 O
% O
to O
56 O
% O
by O
giving O
the O
initial O
nan O
calibrating O
nan O
dose O
of O
carbon O
tetrachloride O
at O
the O
peak O
of O
the O
phenobarbitone O
- O
induced O
enlargement B-Disease
of I-Disease
the I-Disease
liver I-Disease
. O

triamterene O
nephrolithiasis B-Disease
complicating O
dyazide O
therapy O
. O

a O
case O
of O
triamterene O
nephrolithiasis B-Disease
is O
reported O
in O
a O
man O
after O
4 O
years O
of O
hydrochlorothiazide O
- O
triamterene O
therapy O
for O
hypertension B-Disease
. O

factors O
affecting O
triamterene O
nephrolithiasis B-Disease
are O
discussed O
and O
2 O
previously O
reported O
cases O
are O
reviewed O
. O

busulfan O
- O
induced O
hemorrhagic B-Disease
cystitis I-Disease
. O

a O
case O
of O
a O
busulfan O
- O
induced O
hemorrhage B-Disease
cystitis I-Disease
is O
reported O
. O

the O
similarity O
between O
the O
histologic O
appearances O
of O
busulfan O
cystitis B-Disease
and O
both O
radiation O
and O
cyclophosphamide O
- O
induced O
cystitis B-Disease
is O
discussed O
and O
the O
world O
literature O
reviewed O
. O

in O
view O
of O
the O
known O
tendency O
of O
busulfan O
to O
induce O
cellular O
atypia O
and O
carcinoma B-Disease
in O
other O
sites O
, O
periodic O
urinary O
cytology O
is O
suggested O
in O
patients O
on O
long O
- O
term O
therapy O
. O

variant O
ventricular B-Disease
tachycardia I-Disease
in O
desipramine O
toxicity B-Disease
. O

we O
report O
a O
case O
of O
variant O
ventricular B-Disease
tachycardia I-Disease
induced O
by O
desipramine O
toxicity B-Disease
. O

unusual O
features O
of O
the O
arrhythmia B-Disease
are O
repetitive O
group O
beating O
, O
progressive O
shortening O
of O
the O
r O
- O
r O
interval O
, O
progressive O
widening O
of O
the O
qrs O
complex O
with O
eventual O
failure O
of O
intraventricular O
conduction O
, O
and O
changes O
in O
direction O
of O
the O
qrs O
axis O
. O

recognition O
of O
variant O
ventricular B-Disease
tachycardia I-Disease
is O
important O
because O
therapy O
differs O
from O
that O
of O
classic O
ventricular B-Disease
tachycardia I-Disease
. O

rebound O
hypertensive B-Disease
after O
sodium O
nitroprusside O
prevented O
by O
saralasin O
in O
rats O
. O

the O
role O
of O
the O
renin O
- O
- O
angiotensin O
system O
in O
the O
maintenance O
of O
blood O
pressure O
during O
halothane O
anesthesia O
and O
sodium O
nitroprusside O
( O
snp O
) O
- O
induced O
hypotension B-Disease
was O
evaluated O
. O

during O
the O
snp O
infusion O
the O
control O
animals O
demonstrated O
a O
progressive O
increase B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
to O
61 O
torr O
, O
whereas O
the O
saralasin O
- O
treated O
animals O
showed O
no O
change O
. O

this O
demonstrates O
the O
participation O
of O
the O
renin O
- O
- O
angiotensin O
system O
in O
antagonizing O
the O
combined O
hypotensive B-Disease
effects O
of O
halothane O
and O
snp O
. O

clinical O
nephrotoxicity B-Disease
of O
tobramycin O
and O
gentamicin O
. O

gentamicin O
sulfate O
and O
tobramycin O
sulfate O
continue O
to O
demonstrate O
ototoxicity B-Disease
and O
nephrotoxicity B-Disease
in O
both O
animal O
and O
clinical O
studies O
. O

in O
this O
study O
, O
62 O
patients O
with O
confirmed O
initial O
normal O
renal O
function O
and O
treated O
with O
2 O
to O
5 O
mg O
/ O
kg O
/ O
day O
of O
gentamicin O
sulfate O
or O
tobramycin O
sulfate O
for O
a O
minimum O
of O
seven O
days O
were O
followed O
up O
prospectively O
for O
the O
development O
of O
aminoglycoside O
- O
related O
renal B-Disease
failure I-Disease
, O
defined O
as O
at O
least O
a O
one O
- O
third O
reduction O
in O
renal O
function O
. O

in O
these O
62 O
patients O
, O
no O
other O
causes O
for O
renal B-Disease
failure I-Disease
could O
be O
identified O
. O

five O
of O
33 O
( O
15 O
% O
) O
of O
the O
tobramycin O
- O
treated O
patients O
and O
16 O
of O
29 O
( O
55 O
. O

2 O
% O
) O
of O
the O
gentamicin O
- O
treated O
patients O
had O
renal B-Disease
failure I-Disease
. O

thus O
, O
gentamicin O
was O
associated O
with O
renal B-Disease
failure I-Disease
more O
than O
three O
times O
as O
often O
as O
was O
tobramycin O
. O

metabolic O
involvement O
in O
adriamycin O
cardiotoxicity B-Disease
. O

the O
cardiotoxic B-Disease
effects O
of O
adriamycin O
were O
studied O
in O
mammalian O
myocardial O
cells O
in O
culture O
as O
a O
model O
system O
. O

age O
- O
dependent O
sensitivity O
of O
the O
rat O
to O
neurotoxic B-Disease
effects O
of O
streptomycin O
. O

abnormal B-Disease
movements I-Disease
and O
deafness B-Disease
occurred O
only O
in O
rats O
treated O
during O
the O
preweaning O
period O
; O
within O
this O
period O
the O
greatest O
sensitivities O
for O
these O
abnormalities O
occurred O
from O
2 O
to O
11 O
- O
17 O
and O
5 O
to O
11 O
days O
of O
age O
, O
respectively O
, O
indicating O
that O
the O
cochlea O
is O
more O
sensitive O
to O
streptomycin O
than O
the O
site O
( O
vestibular O
or O
central O
) O
responsible O
for O
the O
dyskinesias B-Disease
. O

late O
, O
late O
doxorubicin O
cardiotoxicity B-Disease
. O

cardiac B-Disease
toxicity I-Disease
is O
a O
major O
complication O
which O
limits O
the O
use O
of O
adriamycin O
as O
a O
chemotherapeutic O
agent O
. O

cardiomyopathy B-Disease
is O
frequent O
when O
the O
total O
dose O
exceeds O
600 O
mg O
/ O
m2 O
and O
occurs O
within O
one O
to O
six O
months O
after O
cessation O
of O
therapy O
. O

a O
patient O
is O
reported O
who O
developed O
progressive O
cardiomyopathy B-Disease
two O
and O
one O
- O
half O
years O
after O
receiving O
580 O
mg O
/ O
m2 O
which O
apparently O
represents O
late O
, O
late O
cardiotoxicity B-Disease
. O

attenuation O
of O
the O
lithium O
- O
induced O
diabetes B-Disease
- I-Disease
insipidus I-Disease
- I-Disease
like I-Disease
syndrome I-Disease
by O
amiloride O
in O
rats O
. O

the O
effect O
of O
amiloride O
on O
lithium O
- O
induced O
polydipsia B-Disease
and O
polyuria B-Disease
and O
on O
the O
lithium O
concentration O
in O
the O
plasma O
, O
brain O
, O
kidney O
, O
thyroid O
and O
red O
blood O
cells O
was O
investigated O
in O
rats O
, O
chronically O
treated O
with O
licl O
. O

in O
all O
the O
experiments O
, O
the O
attenuation O
of O
the O
lithium O
- O
induced O
diabetes B-Disease
- I-Disease
insipidus I-Disease
- I-Disease
like I-Disease
syndrome I-Disease
by O
amiloride O
was O
accompanied O
by O
a O
reduction O
of O
the O
ratio O
between O
the O
lithium O
concentration O
in O
the O
renal O
medulla O
and O
its O
levels O
in O
the O
blood O
and O
an O
elevation O
in O
the O
plasma O
potassium O
level O
. O

it O
is O
concluded O
that O
acute O
amiloride O
administration O
to O
lithium O
- O
treated O
patients O
suffering O
from O
polydipsia B-Disease
and O
polyuria B-Disease
might O
relieve O
these O
patients O
but O
prolonged O
amiloride O
supplementation O
would O
result O
in O
elevated O
lithium O
levels O
and O
might O
be O
hazardous O
. O

cardiovascular B-Disease
complications I-Disease
associated O
with O
terbutaline O
treatment O
for O
preterm B-Disease
labor I-Disease
. O

severe O
cardiovascular B-Disease
complications I-Disease
occurred O
in O
eight O
of O
160 O
patients O
treated O
with O
terbutaline O
for O
preterm B-Disease
labor I-Disease
. O

toxic B-Disease
hepatitis I-Disease
induced O
by O
antithyroid O
drugs O
: O
four O
cases O
including O
one O
with O
cross O
- O
reactivity O
between O
carbimazole O
and O
benzylthiouracil O
. O

objective O
: O
this O
study O
was O
conducted O
to O
assess O
the O
occurrence O
of O
hepatic B-Disease
adverse I-Disease
effects I-Disease
encountered O
with O
antithyroid O
drugs O
. O

methods O
: O
retrospective O
review O
of O
medical O
records O
of O
236 O
patients O
with O
hyperthyroidism B-Disease
admitted O
in O
our O
department O
( O
in O
- O
or O
out O
- O
patients O
) O
from O
1986 O
to O
1992 O
. O

results O
: O
four O
patients O
( O
1 O
. O

7 O
% O
) O
were O
identified O
with O
toxic B-Disease
hepatitis I-Disease
which O
could O
reasonably O
be O
attributed O
to O
the O
use O
of O
antithyroid O
agent O
. O

two O
patients O
had O
a O
cholestatic B-Disease
hepatitis I-Disease
induced O
by O
carbimazole O
( O
n O
omercazole O
) O
. O

two O
others O
had O
a O
mixed O
( O
cholestatic B-Disease
and O
cytolytic O
) O
hepatitis B-Disease
following O
carbimazole O
. O

one O
of O
the O
latter O
two O
patients O
further O
experienced O
a O
cytolytic O
hepatitis B-Disease
which O
appeared O
after O
benzylthiouracil O
( O
basd O
ne O
) O
had O
replaced O
carbimazole O
. O

biological O
features O
of O
hepatitis B-Disease
disappeared O
in O
all O
cases O
after O
cessation O
of O
the O
incriminated O
drug O
, O
while O
biliary O
, O
viral O
and O
immunological O
searches O
were O
negative O
. O

only O
2 O
patients O
of O
our O
retrospective O
study O
experienced O
a O
mild O
or O
severe O
neutropenia B-Disease
. O

conclusion O
: O
toxic B-Disease
hepatitis I-Disease
is O
a O
potential O
adverse O
effect O
of O
antithyroid O
drugs O
which O
warrants O
, O
as O
for O
haematological O
disturbances O
, O
a O
pre O
- O
therapeutic O
determination O
and O
a O
careful O
follow O
- O
up O
of O
relevant O
biological O
markers O
. O

moreover O
, O
hepatotoxicity B-Disease
may O
not O
be O
restricted O
to O
one O
class O
of O
antithyroid O
agents O
. O

dose O
- O
dependent O
bradycardia B-Disease
induced O
by O
verapamil O
was O
potentiated O
by O
lna O
, O
lca O
, O
and O
hca O
. O

pseudo O
- O
allergic B-Disease
reactions I-Disease
to O
corticosteroids O
: O
diagnosis O
and O
alternatives O
. O

a O
few O
minutes O
after O
administration O
of O
the O
drugs O
, O
they O
presented O
urticaria B-Disease
( O
patients O
1 O
and O
2 O
) O
and O
conjunctivitis B-Disease
( O
patient O
1 O
) O
. O

corticosteroids O
different O
from O
paramethasone O
also O
produced O
hypersensitivity B-Disease
reactions O
in O
these O
patients O
; O
however O
, O
a O
few O
of O
them O
were O
tolerated O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
a O
pseudo O
- O
allergy B-Disease
caused O
by O
paramethasone O
. O

study O
of O
the O
role O
of O
vitamin O
b12 O
and O
folinic O
acid O
supplementation O
in O
preventing O
hematologic O
toxicity B-Disease
of O
zidovudine O
. O

a O
prospective O
, O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
role O
of O
vitamin O
b12 O
and O
folinic O
acid O
supplementation O
in O
preventing O
zidovudine O
( O
zdv O
) O
- O
induced O
bone B-Disease
marrow I-Disease
suppression I-Disease
. O

seventy O
- O
five O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
( I-Disease
hiv I-Disease
) I-Disease
- I-Disease
infected I-Disease
patients O
with O
cd4 O
+ O
cell O
counts O
< O
500 O
/ O
mm3 O
were O
randomized O
to O
receive O
either O
zdv O
( O
500 O
mg O
daily O
) O
alone O
( O
group O
i O
, O
n O
= O
38 O
) O
or O
in O
combination O
with O
folinic O
acid O
( O
15 O
mg O
daily O
) O
and O
intramascular O
vitamin O
b12 O
( O
1000 O
micrograms O
monthly O
) O
( O
group O
ii O
, O
n O
= O
37 O
) O
. O

finally O
, O
15 O
patients O
were O
excluded O
from O
the O
study O
( O
noncompliance O
14 O
, O
death B-Disease
1 O
) O
; O
thus O
, O
60 O
patients O
( O
31 O
in O
group O
i O
and O
29 O
in O
group O
ii O
) O
were O
eligible O
for O
analysis O
. O

severe O
hematologic O
toxicity B-Disease
( O
neutrophil O
count O
< O
1000 O
/ O
mm3 O
and O
/ O
or O
hemoglobin O
< O
8 O
g O
/ O
dl O
) O
occurred O
in O
4 O
patients O
assigned O
to O
group O
i O
and O
7 O
assigned O
to O
group O
ii O
. O

there O
was O
no O
correlation O
between O
vitamin O
b12 O
or O
folate O
levels O
and O
development O
of O
myelosuppression B-Disease
. O

vitamin O
b12 O
and O
folinic O
acid O
supplementation O
of O
zdv O
therapy O
does O
not O
seem O
useful O
in O
preventing O
or O
reducing O
zdv O
- O
induced O
myelotoxicity B-Disease
in O
the O
overall O
treated O
population O
, O
although O
a O
beneficial O
effect O
in O
certain O
subgroups O
of O
patients O
cannot O
be O
excluded O
. O

controlled O
study O
in O
agoraphobia B-Disease
with O
panic B-Disease
disorder I-Disease
. O

the O
efficacy O
of O
alprazolam O
and O
placebo O
in O
panic B-Disease
disorder I-Disease
with O
agoraphobia B-Disease
, O
and O
the O
side O
- O
effect O
and O
adverse O
effect O
profiles O
of O
both O
drug O
groups O
were O
measured O
. O

method O
: O
in O
london O
and O
toronto O
154 O
patients O
who O
met O
dsm O
- O
iii O
criteria O
for O
panic B-Disease
disorder I-Disease
with O
agoraphobia B-Disease
were O
randomised O
to O
alprazolam O
or O
placebo O
. O

compared O
with O
placebo O
subjects O
, O
alprazolam O
patients O
developed O
more O
adverse O
reactions O
( O
21 O
% O
v O
. O

0 O
% O
) O
of O
depression B-Disease
, O
enuresis B-Disease
, O
disinhibition O
and O
aggression B-Disease
; O
and O
more O
side O
- O
effects O
, O
particularly O
sedation O
, O
irritability B-Disease
, O
impaired B-Disease
memory I-Disease
, O
weight B-Disease
loss I-Disease
and O
ataxia B-Disease
. O

crescentic O
fibrillary O
glomerulonephritis B-Disease
associated O
with O
intermittent O
rifampin O
therapy O
for O
pulmonary B-Disease
tuberculosis I-Disease
. O

this O
case O
study O
reveals O
an O
unusual O
finding O
of O
rapidly O
proliferative O
crescentic O
glomerulonephritis B-Disease
in O
a O
patient O
treated O
with O
rifampin O
who O
had O
no O
other O
identifiable O
causes O
for O
developing O
this O
disease O
. O

this O
patient O
underwent O
a O
10 O
- O
month O
regimen O
of O
rifampin O
and O
isoniazid O
for O
pulmonary B-Disease
tuberculosis I-Disease
and O
was O
discovered O
to O
have O
developed O
signs O
of O
severe O
renal B-Disease
failure I-Disease
five O
weeks O
after O
completion O
of O
therapy O
. O

renal O
biopsy O
revealed O
severe O
glomerulonephritis B-Disease
with O
crescents O
, O
electron O
dense O
fibrillar O
deposits O
and O
moderate O
lymphocytic O
interstitial O
infiltrate O
. O

other O
possible O
causes O
of O
rapidly O
progressive O
glomerulonephritis B-Disease
were O
investigated O
and O
ruled O
out O
. O

this O
report O
documents O
the O
unusual O
occurrence O
of O
rapidly O
progressive O
glomerulonephritis B-Disease
with O
crescents O
and O
fibrillar O
glomerulonephritis B-Disease
in O
a O
patient O
treated O
with O
rifampin O
. O

acute O
confusion B-Disease
induced O
by O
a O
high O
- O
dose O
infusion O
of O
5 O
- O
fluorouracil O
and O
folinic O
acid O
. O

a O
61 O
- O
year O
- O
old O
man O
was O
treated O
with O
combination O
chemotherapy O
incorporating O
cisplatinum O
, O
etoposide O
, O
high O
- O
dose O
5 O
- O
fluorouracil O
( O
2 O
, O
250 O
mg O
/ O
m2 O
/ O
24 O
hours O
) O
and O
folinic O
acid O
for O
an O
inoperable O
gastric B-Disease
adenocarcinoma I-Disease
. O

he O
developed O
acute O
neurologic O
symptoms O
of O
mental O
confusion B-Disease
, O
disorientation B-Disease
and O
irritability B-Disease
, O
and O
then O
lapsed O
into O
a O
deep O
coma B-Disease
, O
lasting O
for O
approximately O
40 O
hours O
during O
the O
first O
dose O
( O
day O
2 O
) O
of O
5 O
- O
fluorouracil O
and O
folinic O
acid O
infusion O
. O

because O
folinic O
acid O
was O
unlikely O
to O
be O
associated O
with O
this O
condition O
, O
neurotoxicity B-Disease
due O
to O
high O
- O
dose O
5 O
- O
fluorouracil O
was O
highly O
suspected O
. O

the O
pathogenesis O
of O
5 O
- O
fluorouracil O
neurotoxicity B-Disease
may O
be O
due O
to O
a O
krebs O
cycle O
blockade O
by O
fluoroacetate O
and O
fluorocitrate O
, O
thiamine O
deficiency O
, O
or O
dihydrouracil O
dehydrogenase O
deficiency O
. O

high O
- O
dose O
5 O
- O
fluorouracil O
/ O
folinic O
acid O
infusion O
therapy O
has O
recently O
become O
a O
popular O
regimen O
for O
various O
cancers B-Disease
. O

carbamazepine O
was O
switched O
to O
its O
10 O
- O
keto O
analogue O
oxcarbazepine O
among O
six O
difficult O
- O
to O
- O
treat O
schizophrenic B-Disease
or O
organic B-Disease
psychotic I-Disease
patients O
using O
concomitantly O
haloperidol O
, O
chlorpromazine O
or O
clozapine O
. O

this O
change O
resulted O
within O
2 O
- O
4 O
weeks O
in O
the O
50 O
- O
200 O
% O
increase O
in O
the O
plasma O
levels O
of O
these O
neuroleptics O
and O
the O
appearance O
of O
extrapyramidal B-Disease
symptoms I-Disease
. O

time O
course O
of O
lipid O
peroxidation O
in O
puromycin O
aminonucleoside O
- O
induced O
nephropathy B-Disease
. O

reactive O
oxygen O
species O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
acute O
puromycin O
aminonucleoside O
( O
pan O
) O
- O
induced O
nephropathy B-Disease
, O
with O
antioxidants O
significantly O
reducing O
the O
proteinuria B-Disease
. O

the O
temporal O
relationship O
between O
lipid O
peroxidation O
in O
the O
kidney O
and O
proteinuria B-Disease
was O
examined O
in O
this O
study O
. O

proteinuria B-Disease
was O
evident O
at O
day O
5 O
, O
peaked O
at O
day O
7 O
and O
persisted O
to O
day O
27 O
. O

this O
study O
supports O
the O
role O
of O
lipid O
peroxidation O
in O
mediating O
the O
proteinuric B-Disease
injury I-Disease
in O
pan O
nephropathy B-Disease
. O

composition O
of O
gall B-Disease
bladder I-Disease
stones I-Disease
associated O
with O
octreotide O
: O
response O
to O
oral O
ursodeoxycholic O
acid O
. O

octreotide O
, O
an O
effective O
treatment O
for O
acromegaly B-Disease
, O
induces O
gall B-Disease
bladder I-Disease
stones I-Disease
in O
13 O
- O
60 O
% O
of O
patients O
. O

because O
knowledge O
of O
stone O
composition O
is O
essential O
for O
studies O
of O
their O
pathogenesis O
, O
treatment O
, O
and O
prevention O
, O
this O
was O
investigated O
by O
direct O
and O
indirect O
methods O
in O
14 O
octreotide O
treated O
acromegalic B-Disease
patients O
with O
gall B-Disease
stones I-Disease
. O

chemical O
analysis O
of O
gall B-Disease
stones I-Disease
retrieved O
at O
cholecystectomy O
from O
two O
patients O
, O
showed O
that O
they O
contained O
71 O
% O
and O
87 O
% O
cholesterol O
by O
weight O
. O

after O
one O
year O
of O
treatment O
, O
five O
of O
the O
remaining O
nine O
patients O
showed O
either O
partial O
( O
n O
= O
3 O
) O
or O
complete O
( O
n O
= O
2 O
) O
gall B-Disease
stone I-Disease
dissolution O
, O
suggesting O
that O
their O
stones O
were O
cholesterol O
rich O
. O

this O
corresponds O
, O
by O
actuarial O
( O
life O
table O
) O
analysis O
, O
to O
a O
combined O
gall B-Disease
stone I-Disease
dissolution O
rate O
of O
58 O
. O

3 O
( O
15 O
. O

9 O
% O
) O
. O

in O
conclusion O
, O
octreotide O
induced O
gall B-Disease
stones I-Disease
are O
generally O
small O
, O
multiple O
, O
and O
cholesterol O
rich O
although O
, O
in O
common O
with O
spontaneous O
gall B-Disease
stone I-Disease
disease I-Disease
, O
at O
presentation O
some O
patients O
will O
have O
a O
blocked O
cystic O
duct O
and O
some O
gall B-Disease
stones I-Disease
containing O
calcium O
. O

erythema B-Disease
multiforme I-Disease
and O
hypersensitivity B-Disease
myocarditis I-Disease
caused O
by O
ampicillin O
. O

objective O
: O
to O
report O
a O
case O
of O
erythema B-Disease
multiforme I-Disease
and O
hypersensitivity B-Disease
myocarditis I-Disease
caused O
by O
ampicillin O
. O

case O
summary O
: O
a O
13 O
- O
year O
- O
old O
boy O
was O
treated O
with O
ampicillin O
and O
gentamicin O
because O
of O
suspected O
septicemia B-Disease
. O

medications O
were O
discontinued O
when O
erythema B-Disease
multiforme I-Disease
and O
congestive B-Disease
heart I-Disease
failure I-Disease
caused O
by O
myocarditis B-Disease
occurred O
. O

discussion O
: O
after O
most O
infections B-Disease
causing O
erythema B-Disease
multiforme I-Disease
and O
myocarditis B-Disease
were O
ruled O
out O
, O
a O
drug B-Disease
- I-Disease
induced I-Disease
allergic I-Disease
reaction I-Disease
was O
suspected O
. O

conclusions O
: O
hypersensitivity B-Disease
myocarditis I-Disease
is O
a O
rare O
and O
dangerous O
manifestation O
of O
allergy B-Disease
to O
penicillins O
. O

clomipramine O
- O
induced O
sleep B-Disease
disturbance I-Disease
does O
not O
impair O
its O
prolactin O
- O
releasing O
action O
. O

the O
present O
study O
was O
undertaken O
to O
examine O
the O
role O
of O
sleep B-Disease
disturbance I-Disease
, O
induced O
by O
clomipramine O
administration O
, O
on O
the O
secretory O
rate O
of O
prolactin O
( O
prl O
) O
in O
addition O
to O
the O
direct O
drug O
effect O
. O

as O
the O
relative O
increase O
in O
prl O
secretion O
expressed O
as O
a O
percentage O
of O
the O
mean O
did O
not O
significantly O
differ O
between O
the O
night O
and O
day O
time O
studies O
( O
46 O
+ O
/ O
- O
19 O
% O
vs O
34 O
+ O
/ O
- O
10 O
% O
) O
, O
it O
can O
be O
concluded O
that O
the O
observed O
sleep B-Disease
disturbance I-Disease
did O
not O
interfere O
with O
the O
drug O
action O
per O
se O
. O

there O
were O
13 O
cases O
of O
adverse O
reactions O
( O
0 O
. O

34 O
% O
) O
, O
ten O
of O
which O
were O
mild O
reactions O
such O
as O
nausea B-Disease
, O
exanthema B-Disease
, O
urtication B-Disease
, O
itchiness B-Disease
, O
and O
urgency O
to O
defecate O
, O
and O
did O
not O
require O
treatment O
. O

also O
recorded O
were O
one O
case O
of O
pain B-Disease
of O
the O
vein O
, O
which O
required O
treatment O
, O
and O
two O
cases O
of O
hypotension B-Disease
. O

the O
two O
hypotensive B-Disease
patients O
required O
treatment O
for O
shock B-Disease
. O

angioedema B-Disease
following O
the O
intravenous O
administration O
of O
metoprolol O
. O

a O
72 O
- O
year O
- O
old O
woman O
was O
admitted O
to O
the O
hospital O
with O
nan O
flash O
nan O
pulmonary B-Disease
edema I-Disease
, O
preceded O
by O
chest B-Disease
pain I-Disease
, O
requiring O
intubation O
. O

her O
medical O
history O
included O
coronary B-Disease
artery I-Disease
disease I-Disease
with O
previous O
myocardial B-Disease
infarctions I-Disease
, O
hypertension B-Disease
, O
and O
diabetes B-Disease
mellitus I-Disease
. O

a O
history O
of O
angioedema B-Disease
secondary O
to O
lisinopril O
therapy O
was O
elicited O
. O

during O
the O
first O
day O
of O
hospitalization O
( O
while O
intubated O
) O
, O
intravenous O
metoprolol O
was O
given O
, O
resulting O
in O
severe O
angioedema B-Disease
. O

the O
angioedema B-Disease
resolved O
after O
therapy O
with O
intravenous O
steroids O
and O
diphenhydramine O
hydrochloride O
. O

the O
major O
teratogenic O
outcome O
is O
arthrogryposis B-Disease
, O
presumably O
due O
to O
nicotinic O
receptor O
blockade O
. O

however O
, O
coniine O
has O
failed O
to O
produce O
arthrogryposis B-Disease
in O
rats O
or O
mice O
and O
is O
only O
weakly O
teratogenic O
in O
rabbits O
. O

both O
compounds O
caused O
deformations B-Disease
and O
lethality O
in O
a O
dose O
- O
dependent O
manner O
. O

the O
deformations B-Disease
caused O
by O
both O
coniine O
and O
nicotine O
sulfate O
were O
excessive B-Disease
flexion I-Disease
or I-Disease
extension I-Disease
of I-Disease
one I-Disease
or I-Disease
more I-Disease
toes I-Disease
. O

no O
histopathological O
alterations O
or O
differences O
in O
bone O
formation O
were O
seen O
in O
the O
limbs O
or O
toes O
of O
any O
chicks O
from O
any O
group O
; O
however O
, O
extensive O
cranial B-Disease
hemorrhage I-Disease
occurred O
in O
all O
nicotine O
sulfate O
- O
treated O
chicks O
. O

in O
summary O
, O
the O
chick O
embryo O
provides O
a O
reliable O
and O
simple O
experimental O
animal O
model O
of O
coniine O
- O
induced O
arthrogryposis B-Disease
. O

immediate O
allergic B-Disease
reactions I-Disease
to O
amoxicillin O
. O

a O
large O
group O
of O
patients O
with O
suspected O
allergic B-Disease
reactions I-Disease
to O
beta O
- O
lactam O
antibiotics O
was O
evaluated O
. O

a O
detailed O
clinical O
history O
, O
together O
with O
skin O
tests O
, O
rast O
( O
radioallergosorbent O
test O
) O
, O
and O
controlled O
challenge O
tests O
, O
was O
used O
to O
establish O
whether O
patients O
allergic B-Disease
to O
beta O
- O
lactam O
antibiotics O
had O
selective O
immediate O
allergic B-Disease
responses O
to O
amoxicillin O
( O
ax O
) O
or O
were O
cross O
- O
reacting O
with O
other O
penicillin O
derivatives O
. O

a O
total O
of O
177 O
patients O
were O
diagnosed O
as O
allergic B-Disease
to O
beta O
- O
lactam O
antibiotics O
. O

we O
selected O
the O
54 O
( O
30 O
. O

5 O
% O
) O
cases O
of O
immediate O
ax O
allergy B-Disease
with O
good O
tolerance O
of O
pg O
. O

anaphylaxis B-Disease
was O
seen O
in O
37 O
patients O
( O
69 O
% O
) O
, O
the O
other O
17 O
( O
31 O
% O
) O
having O
urticaria B-Disease
and O
/ O
or O
angioedema B-Disease
. O

all O
the O
patients O
were O
skin O
test O
negative O
to O
bpo O
; O
49 O
of O
51 O
( O
96 O
% O
) O
were O
also O
negative O
to O
mdm B-Disease
, O
and O
44 O
of O
46 O
( O
96 O
% O
) O
to O
pg O
. O

challenge O
tests O
with O
ax O
were O
performed O
in O
23 O
subjects O
( O
43 O
% O
) O
to O
establish O
the O
diagnosis O
of O
immediate O
allergic B-Disease
reaction I-Disease
to O
ax O
, O
and O
in O
15 O
cases O
( O
28 O
% O
) O
both O
skin O
test O
and O
rast O
for O
ax O
were O
negative O
. O

we O
describe O
the O
largest O
group O
of O
ax O
- O
allergic B-Disease
patients O
who O
have O
tolerated O
pg O
reported O
so O
far O
. O

reversal O
by O
phenylephrine O
of O
the O
beneficial O
effects O
of O
intravenous O
nitroglycerin O
in O
patients O
with O
acute B-Disease
myocardial I-Disease
infarction I-Disease
. O

nitroglycerin O
has O
been O
shown O
to O
reduce O
st O
- O
segment O
elevation O
during O
acute B-Disease
myocardial I-Disease
infarction I-Disease
, O
an O
effect O
potentiated O
in O
the O
dog O
by O
agents O
that O
reverse O
nitroglycerin O
- O
induced O
hypotension B-Disease
. O

ten O
patients O
with O
acute O
transmural O
myocardial B-Disease
infarctions I-Disease
received O
intravenous O
nitroglycerin O
, O
sufficient O
to O
reduce O
mean O
arterial O
pressure O
from O
107 O
+ O
/ O
- O
6 O
to O
85 O
+ O
/ O
- O
6 O
mm O
hg O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
for O
60 O
minutes O
. O

our O
results O
suggest O
that O
addition O
of O
phenylephrine O
to O
nitroglycerin O
is O
not O
beneficial O
in O
the O
treatment O
of O
patients O
with O
acute B-Disease
myocardial I-Disease
infarction I-Disease
. O

acetazolamide O
- O
induced O
nephrolithiasis B-Disease
: O
implications O
for O
treatment O
of O
neuromuscular B-Disease
disorders I-Disease
. O

carbonic O
anhydrase O
inhibitors O
can O
cause O
nephrolithiasis B-Disease
. O

we O
studied O
20 O
patients O
receiving O
long O
- O
term O
carbonic O
anhydrase O
inhibitor O
treatment O
for O
periodic O
paralysis B-Disease
and O
myotonia B-Disease
. O

three O
patients O
on O
acetazolamide O
( O
15 O
% O
) O
developed O
renal B-Disease
calculi I-Disease
. O

extracorporeal O
lithotripsy O
successfully O
removed O
a O
renal B-Disease
calculus I-Disease
in O
one O
patient O
and O
surgery O
removed O
a O
staghorn O
calculus B-Disease
in O
another O
, O
permitting O
continued O
treatment O
. O

nephrolithiasis B-Disease
is O
a O
complication O
of O
acetazolamide O
but O
does O
not O
preclude O
its O
use O
. O

effects O
of O
calcium O
channel O
blockers O
on O
bupivacaine O
- O
induced O
toxicity B-Disease
. O

the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
influence O
of O
calcium O
channel O
blockers O
on O
bupivacaine O
- O
induced O
acute O
toxicity B-Disease
. O

the O
convulsant O
activity O
of O
bupivacaine O
was O
not O
significantly O
modified O
but O
calcium O
channel O
blockers O
decreased O
the O
time O
of O
latency O
to O
obtain O
bupivacaine O
- O
induced O
convulsions B-Disease
; O
this O
effect O
was O
less O
pronounced O
with O
bepridil O
. O

epidural O
blood O
flow O
during O
prostaglandin O
e1 O
or O
trimethaphan O
induced O
hypotension B-Disease
. O

to O
evaluate O
the O
effect O
of O
prostaglandin O
e1 O
( O
pge1 O
) O
or O
trimethaphan O
( O
tmp O
) O
induced O
hypotension B-Disease
on O
epidural O
blood O
flow O
( O
ebf O
) O
during O
spinal O
surgery O
, O
ebf O
was O
measured O
using O
the O
heat O
clearance O
method O
in O
30 O
patients O
who O
underwent O
postero O
- O
lateral O
interbody O
fusion O
under O
isoflurane O
anaesthesia O
. O

the O
hypotensive B-Disease
drug O
was O
discontinued O
at O
the O
completion O
of O
the O
operative O
procedure O
. O

after O
starting O
pge1 O
or O
tmp O
, O
map O
and O
rate O
pressure O
product O
( O
rpp O
) O
decreased O
significantly O
compared O
with O
preinfusion O
values O
( O
p O
< O
0 O
. O

1 O
) O
, O
and O
the O
degree O
of O
hypotension B-Disease
due O
to O
pge1 O
remained O
constant O
until O
60 O
min O
after O
its O
discontinuation O
. O

these O
results O
suggest O
that O
pge1 O
may O
be O
preferable O
to O
tmp O
for O
hypotensive B-Disease
anaesthesia O
in O
spinal O
surgery O
because O
tmp O
decreased O
ebf O
. O

dup O
753 O
prevents O
the O
development O
of O
puromycin O
aminonucleoside O
- O
induced O
nephrosis B-Disease
. O

the O
appearance O
of O
nephrotic B-Disease
syndromes I-Disease
such O
as O
proteinuria B-Disease
, O
hypoalbuminemia B-Disease
, O
hypercholesterolemia B-Disease
and O
increase O
in O
blood O
nitrogen O
urea O
, O
induced O
in O
rats O
by O
injection O
of O
puromycin O
aminonucleoside O
was O
markedly O
inhibited O
by O
oral O
administration O
of O
dup O
753 O
( O
losartan O
) O
, O
a O
novel O
angiotensin O
ii O
receptor O
antagonist O
, O
at O
a O
dose O
of O
1 O
or O
2 O
mg O
/ O
kg O
per O
day O
. O

the O
results O
suggest O
a O
possible O
involvement O
of O
the O
renin O
- O
angiotensin O
system O
in O
the O
development O
of O
puromycin O
aminonucleoside O
- O
induced O
nephrosis B-Disease
. O

neuroplasticity O
of O
the O
adult O
primate O
auditory O
cortex O
following O
cochlear O
hearing B-Disease
loss I-Disease
. O

the O
purpose O
of O
this O
study O
was O
to O
determine O
if O
changes O
occur O
in O
this O
tonotopic O
organization O
following O
cochlear O
hearing B-Disease
loss I-Disease
. O

the O
region O
of O
cortex O
that O
represents O
the O
low O
frequencies O
was O
not O
obviously O
affected O
by O
the O
cochlear O
hearing B-Disease
loss I-Disease
. O

sodium O
bicarbonate O
alleviates O
penile B-Disease
pain I-Disease
induced O
by O
intracavernous O
injections O
for O
erectile B-Disease
dysfunction I-Disease
. O

in O
an O
attempt O
to O
determine O
whether O
penile B-Disease
pain I-Disease
associated O
with O
intracorporeal O
injections O
could O
be O
due O
to O
the O
acidity O
of O
the O
medication O
, O
we O
performed O
a O
randomized O
study O
comparing O
the O
incidence O
of O
penile B-Disease
pain I-Disease
following O
intracorporeal O
injections O
with O
or O
without O
the O
addition O
of O
sodium O
bicarbonate O
to O
the O
intracorporeal O
medications O
. O

a O
total O
of O
38 O
consecutive O
patients O
who O
presented O
to O
our O
clinic O
with O
impotence B-Disease
received O
0 O
. O

2 O
ml O
. O

of O
a O
combination O
of O
3 O
drugs O
: O
6 O
mg O
. O

papaverine O
, O
100 O
micrograms O
. O

phentolamine O
and O
10 O
micrograms O
. O

prostaglandin O
e1 O
with O
( O
ph O
7 O
. O

5 O
) O
or O
without O
( O
ph O
4 O
. O

17 O
) O
the O
addition O
of O
sodium O
bicarbonate O
( O
0 O
. O

3 O
meq O
. O

) O
. O

of O
the O
19 O
patients O
without O
sodium O
bicarbonate O
added O
to O
the O
medication O
11 O
( O
58 O
% O
) O
complained O
of O
penile B-Disease
pain I-Disease
due O
to O
the O
medication O
, O
while O
only O
1 O
of O
the O
19 O
men O
( O
5 O
% O
) O
who O
received O
sodium O
bicarbonate O
complained O
of O
penile B-Disease
pain I-Disease
. O

from O
these O
data O
we O
conclude O
that O
the O
penile B-Disease
pain I-Disease
following O
intracorporeal O
injections O
is O
most O
likely O
due O
to O
the O
acidity O
of O
the O
medication O
, O
which O
can O
be O
overcome O
by O
elevating O
the O
ph O
to O
a O
neutral O
level O
. O

the O
use O
and O
toxicity B-Disease
of O
didanosine O
( O
ddi O
) O
in O
hiv B-Disease
antibody I-Disease
- I-Disease
positive I-Disease
individuals O
intolerant O
to O
zidovudine O
( O
azt O
) O
seventy O
patients O
developed O
major O
opportunistic B-Disease
infections I-Disease
whilst O
on O
therapy O
; O
this O
was O
the O
first O
aids B-Disease
diagnosis O
in O
17 O
. O

only O
minor O
changes O
in O
cd4 O
+ O
lymphocyte O
subset O
count O
were O
observed O
in O
aids B-Disease
patients O
, O
although O
a O
more O
significant O
rise O
occurred O
in O
those O
with O
earlier O
stages O
of O
disease O
. O

the O
most O
common O
side O
- O
effect O
was O
diarrhoea B-Disease
, O
which O
resulted O
in O
cessation O
of O
therapy O
in O
19 O
individuals O
. O

peripheral B-Disease
neuropathy I-Disease
occurred O
in O
12 O
patients O
and O
pancreatitis B-Disease
in O
six O
. O

thirteen O
patients O
developed O
a O
raised O
serum O
amylase O
without O
abdominal B-Disease
pain I-Disease
. O

seven O
patients O
developed O
glucose B-Disease
tolerance I-Disease
curves I-Disease
characteristic O
of O
diabetes B-Disease
but O
these O
were O
mild O
, O
did O
not O
require O
treatment O
and O
returned O
to O
normal O
on O
ceasing O
didanosine O
. O

immunohistochemical O
studies O
with O
antibodies O
to O
neurofilament O
proteins O
on O
axonal B-Disease
damage I-Disease
in O
experimental O
focal O
lesions O
in O
rat O
. O

immunohistochemistry O
with O
monoclonal O
antibodies O
against O
neurofilament O
( O
nf O
) O
proteins O
of O
middle O
and O
high O
molecular O
weight O
class O
, O
nf O
- O
m O
and O
nf O
- O
h O
, O
was O
used O
to O
study O
axonal B-Disease
injury I-Disease
in O
the O
borderzone O
of O
focal O
lesions O
in O
rats O
. O

focal O
injury B-Disease
in I-Disease
the I-Disease
cortex I-Disease
was O
produced O
by O
infusion O
of O
lactate O
at O
acid O
ph O
or O
by O
stab O
caused O
by O
needle O
insertion O
. O

infarcts B-Disease
in I-Disease
substantia I-Disease
nigra I-Disease
pars I-Disease
reticulata I-Disease
were O
evoked O
by O
prolonged O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
. O

these O
immunohistochemical O
changes O
of O
nfs O
can O
serve O
as O
a O
marker O
for O
axonal B-Disease
damage I-Disease
in O
various O
experimental O
traumatic B-Disease
or O
ischemic O
lesions O
. O

pharmacokinetic O
and O
clinical O
studies O
in O
patients O
with O
cimetidine O
- O
associated O
mental O
confusion B-Disease
. O

15 O
cases O
of O
cimetidine O
- O
associated O
mental O
confusion B-Disease
have O
been O
reported O
. O

these O
6 O
patients O
had O
both O
renal B-Disease
and I-Disease
liver I-Disease
dysfunction I-Disease
( O
p O
less O
than O
0 O
. O

5 O
) O
, O
as O
well O
as O
cimetidine O
trough O
- O
concentrations O
of O
more O
than O
1 O
. O

25 O
microgram O
/ O
ml O
( O
p O
less O
than O
0 O
. O

5 O
) O
. O

patients O
likely O
to O
have O
both O
raised O
trough O
- O
concentrations O
and O
mental O
confusion B-Disease
are O
those O
with O
both O
severe O
renal B-Disease
and I-Disease
hepatic I-Disease
dysfunction I-Disease
. O

prospective O
study O
of O
the O
long O
- O
term O
effects O
of O
somatostatin O
analog O
( O
octreotide O
) O
on O
gallbladder O
function O
and O
gallstone B-Disease
formation O
in O
chinese O
acromegalic B-Disease
patients O
. O

this O
article O
reports O
the O
changes O
in O
gallbladder O
function O
examined O
by O
ultrasonography O
in O
20 O
chinese O
patients O
with O
active O
acromegaly B-Disease
treated O
with O
sc O
injection O
of O
the O
somatostatin O
analog O
octreotide O
in O
dosages O
of O
300 O
- O
1500 O
micrograms O
/ O
day O
for O
a O
mean O
of O
24 O
. O

2 O
+ O
/ O
- O
13 O
. O

9 O
months O
. O

during O
treatment O
with O
octreotide O
, O
17 O
patients O
developed O
sludge O
, O
10 O
had O
gallstones B-Disease
, O
and O
1 O
developed O
acute B-Disease
cholecystitis I-Disease
requiring O
surgery O
. O

in O
8 O
patients O
followed O
for O
24 O
weeks O
, O
gallbladder O
contractility O
remained O
depressed B-Disease
throughout O
therapy O
. O

after O
withdrawal O
of O
octreotide O
in O
10 O
patients O
without O
gallstones B-Disease
, O
8 O
patients O
assessed O
had O
return O
of O
normal O
gallbladder O
contractility O
within O
1 O
month O
. O

in O
8 O
of O
the O
remaining O
10 O
patients O
who O
developed O
gallstones B-Disease
during O
treatment O
, O
gallbladder O
contractility O
normalized O
in O
5 O
patients O
( O
3 O
of O
whom O
has O
disappearance O
of O
their O
stones O
within O
3 O
weeks O
) O
, O
and O
remained O
depressed B-Disease
in O
3 O
( O
2 O
of O
whom O
had O
stones O
present O
at O
6 O
months O
) O
. O

our O
results O
suggest O
that O
the O
suppression O
of O
gallbladder O
contractility O
is O
the O
cause O
of O
the O
successive O
formation O
of O
bile O
sludge O
, O
gallstones B-Disease
, O
and O
cholecystitis B-Disease
during O
octreotide O
therapy O
in O
chinese O
acromegalic B-Disease
patients O
. O

it O
is O
therefore O
very O
important O
to O
follow O
the O
changes O
of O
gallbladder O
function O
during O
long O
- O
term O
octreotide O
therapy O
of O
acromegalic B-Disease
patients O
. O

increase O
of O
parkinson B-Disease
disability I-Disease
after O
fluoxetine O
medication O
. O

depression B-Disease
is O
a O
major O
clinical O
feature O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

we O
report O
the O
increased O
amount O
of O
motor B-Disease
disability I-Disease
in O
four O
patients O
with O
idiopathic B-Disease
parkinson I-Disease
' I-Disease
s I-Disease
disease I-Disease
after O
exposure O
to O
the O
antidepressant O
fluoxetine O
. O

the O
possibility O
of O
a O
clinically O
relevant O
dopamine O
- O
antagonistic O
capacity O
of O
fluoxetine O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
patients O
must O
be O
considered O
. O

sinus B-Disease
arrest I-Disease
associated O
with O
continuous O
- O
infusion O
cimetidine O
. O

the O
administration O
of O
intermittent O
intravenous O
infusions O
of O
cimetidine O
is O
infrequently O
associated O
with O
the O
development O
of O
bradyarrhythmias B-Disease
. O

a O
40 O
- O
year O
- O
old O
man O
with O
leukemia B-Disease
and O
no O
history O
of O
cardiac B-Disease
disease I-Disease
developed O
recurrent O
, O
brief O
episodes O
of O
apparent O
sinus B-Disease
arrest I-Disease
while O
receiving O
continuous O
- O
infusion O
cimetidine O
50 O
mg O
/ O
hour O
. O

the O
arrhythmias B-Disease
were O
temporally O
related O
to O
cimetidine O
administration O
, O
disappeared O
after O
dechallenge O
, O
and O
did O
not O
recur O
during O
ranitidine O
treatment O
. O

this O
is O
the O
first O
reported O
case O
of O
sinus B-Disease
arrest I-Disease
associated O
with O
continuous O
- O
infusion O
cimetidine O
. O

phase O
ii O
trial O
of O
vinorelbine O
in O
metastatic O
squamous B-Disease
cell I-Disease
esophageal I-Disease
carcinoma I-Disease
. O

european O
organization O
for O
research O
and O
treatment O
of O
cancer B-Disease
gastrointestinal O
treat O
cancer B-Disease
cooperative O
group O
. O

purpose O
: O
to O
evaluate O
the O
response O
rate O
and O
toxic O
effects O
of O
vinorelbine O
( O
vnb O
) O
administered O
as O
a O
single O
agent O
in O
metastatic O
squamous B-Disease
cell I-Disease
esophageal I-Disease
carcinoma I-Disease
. O

thirty O
patients O
without O
prior O
chemotherapy O
and O
16 O
pretreated O
with O
cisplatin O
- O
based O
chemotherapy O
were O
assessable O
for O
toxicity B-Disease
and O
response O
. O

vnb O
was O
well O
tolerated O
and O
zero O
instances O
of O
who O
grade O
4 O
nonhematologic O
toxicity B-Disease
occurred O
. O

at O
least O
one O
episode O
of O
grade O
3 O
or O
4 O
granulocytopenia B-Disease
was O
seen O
in O
59 O
% O
of O
patients O
. O

a O
grade O
2 O
or O
3 O
infection B-Disease
occurred O
in O
16 O
% O
of O
patients O
, O
but O
no O
toxic O
deaths B-Disease
occurred O
. O

other O
side O
effects O
were O
rare O
, O
and O
peripheral B-Disease
neurotoxicity I-Disease
has O
been O
minor O
( O
26 O
% O
grade O
1 O
) O
. O

conclusion O
: O
these O
data O
indicate O
that O
vnb O
is O
an O
active O
agent O
in O
metastatic O
esophageal B-Disease
squamous I-Disease
cell I-Disease
carcinoma I-Disease
. O

given O
its O
excellent O
tolerance O
profile O
and O
low O
toxicity B-Disease
, O
further O
evaluation O
of O
vnb O
in O
combination O
therapy O
is O
warranted O
. O

the O
ocular B-Disease
hypotensive I-Disease
effects O
were O
statistically O
significant O
for O
apraclonidine O
- O
treated O
eyes O
throughout O
the O
study O
and O
also O
statistically O
significant O
for O
contralateral O
eyes O
from O
three O
hours O
after O
topical O
administration O
of O
1 O
% O
apraclonidine O
. O

decreases B-Disease
in I-Disease
systolic I-Disease
blood I-Disease
pressure I-Disease
were O
statistically O
, O
but O
not O
clinically O
, O
significant O
. O

conjunctival B-Disease
blanching I-Disease
and O
mydriasis B-Disease
were O
commonly O
found O
. O

while O
the O
elevations O
of O
the O
upper O
lid O
margin O
in O
most O
subjects O
were O
not O
more O
than O
2 O
mm O
and O
did O
not O
cause O
noticeable O
change O
in O
appearance O
, O
one O
subject O
suffered O
from O
mechanical O
entropion B-Disease
and O
marked O
corneal B-Disease
abrasion I-Disease
3 O
hours O
after O
instillation O
of O
the O
medication O
. O

thiopentone O
pretreatment O
for O
propofol O
injection O
pain B-Disease
in O
ambulatory O
patients O
. O

this O
study O
investigated O
propofol O
injection O
pain B-Disease
in O
patients O
undergoing O
ambulatory O
anaesthesia O
. O

loss B-Disease
of I-Disease
consciousness I-Disease
occurred O
in O
60 O
- O
90 O
sec O
. O

the O
vas O
scores O
for O
recall O
of O
pain B-Disease
in O
the O
recovery O
room O
were O
correlated O
with O
the O
vas O
scores O
during O
induction O
( O
r O
= O
0 O
. O

7045 O
; O
p O
< O
0 O
. O

1 O
) O
. O

we O
conclude O
that O
lidocaine O
reduces O
the O
incidence O
and O
severity O
of O
propofol O
injection O
pain B-Disease
in O
ambulatory O
patients O
whereas O
thiopentone O
only O
reduces O
its O
severity O
. O

persistent O
paralysis B-Disease
after O
prolonged O
use O
of O
atracurium O
in O
the O
absence O
of O
corticosteroids O
. O

reports O
of O
persistent O
paralysis B-Disease
after O
the O
discontinuance O
of O
these O
drugs O
have O
most O
often O
involved O
aminosteroid O
- O
based O
nmbas O
such O
as O
vecuronium O
bromide O
, O
especially O
when O
used O
in O
conjunction O
with O
corticosteroids O
. O

atracurium O
besylate O
, O
a O
short O
- O
acting O
benzylisoquinolinium O
nmba O
that O
is O
eliminated O
independently O
of O
renal O
or O
hepatic O
function O
, O
has O
also O
been O
associated O
with O
persistent O
paralysis B-Disease
, O
but O
only O
when O
used O
with O
corticosteroids O
. O

we O
report O
a O
case O
of O
atracurium O
- O
related O
paralysis B-Disease
persisting O
for O
approximately O
50 O
hours O
in O
a O
patient O
who O
was O
not O
treated O
with O
corticosteroids O
. O

a O
phase O
i O
/ O
ii O
study O
of O
paclitaxel O
plus O
cisplatin O
as O
first O
- O
line O
therapy O
for O
head B-Disease
and I-Disease
neck I-Disease
cancers I-Disease
: O
preliminary O
results O
. O

improved O
outcomes O
among O
patients O
with O
head B-Disease
and I-Disease
neck I-Disease
carcinomas I-Disease
require O
investigations O
of O
new O
drugs O
for O
induction O
therapy O
. O

preliminary O
results O
of O
an O
eastern O
cooperative O
oncology O
group O
study O
of O
single O
- O
agent O
paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
reported O
a O
37 O
% O
response O
rate O
in O
patients O
with O
head B-Disease
and I-Disease
neck I-Disease
cancer I-Disease
, O
and O
the O
paclitaxel O
/ O
cisplatin O
combination O
has O
been O
used O
successfully O
and O
has O
significantly O
improved O
median O
response O
duration O
in O
ovarian B-Disease
cancer I-Disease
patients O
. O

we O
initiated O
a O
phase O
i O
/ O
ii O
trial O
to O
determine O
the O
response O
and O
toxicity B-Disease
of O
escalating O
paclitaxel O
doses O
combined O
with O
fixed O
- O
dose O
cisplatin O
with O
granulocyte O
colony O
- O
stimulating O
factor O
support O
in O
patients O
with O
untreated O
locally O
advanced O
inoperable O
head B-Disease
and I-Disease
neck I-Disease
carcinoma I-Disease
. O

primary O
tumor B-Disease
sites O
were O
oropharynx O
, O
10 O
patients O
; O
hypopharynx O
, O
four O
; O
larynx O
, O
two O
; O
oral O
cavity O
, O
three O
; O
unknown O
primary O
, O
two O
; O
and O
nasal O
cavity O
and O
parotid O
gland O
, O
one O
each O
. O

of O
20 O
patients O
evaluable O
for O
toxicity B-Disease
, O
four O
had O
stage O
iii O
and O
16 O
had O
stage O
iv O
disease O
. O

the O
dose O
levels O
incorporate O
escalating O
paclitaxel O
doses O
, O
and O
intrapatient O
escalations O
within O
a O
given O
dose O
level O
are O
permitted O
if O
toxicity B-Disease
permits O
. O

alopecia B-Disease
, O
paresthesias B-Disease
, O
and O
arthralgias B-Disease
/ O
myalgias B-Disease
have O
occurred O
frequently O
, O
but O
with O
one O
exception O
( O
a O
grade O
3 O
myalgia B-Disease
) O
they O
have O
been O
grade O
1 O
or O
2 O
. O

no O
dose O
- O
limiting O
hematologic O
toxicity B-Disease
has O
been O
seen O
. O

paclitaxel O
/ O
cisplatin O
is O
an O
effective O
first O
- O
line O
regimen O
for O
locoregionally O
advanced O
head B-Disease
and I-Disease
neck I-Disease
cancer I-Disease
and O
continued O
study O
is O
warranted O
. O

improvement O
of O
levodopa O
- O
induced O
dyskinesia B-Disease
by O
propranolol O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

seven O
patients O
suffering O
from O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
with O
severely O
disabling O
dyskinesia B-Disease
received O
low O
- O
dose O
propranolol O
as O
an O
adjunct O
to O
the O
currently O
used O
medical O
treatment O
. O

there O
was O
a O
significant O
40 O
% O
improvement O
in O
the O
dyskinesia B-Disease
score O
without O
increase O
of O
parkinsonian B-Disease
motor B-Disease
disability I-Disease
. O

ballistic O
and O
choreic O
dyskinesia B-Disease
were O
markedly O
ameliorated O
, O
whereas O
dystonia B-Disease
was O
not O
. O

this O
study O
suggests O
that O
administration O
of O
low O
doses O
of O
beta O
- O
blockers O
may O
improve O
levodopa O
- O
induced O
ballistic O
and O
choreic O
dyskinesia B-Disease
in O
pd B-Disease
. O

habitual O
use O
of O
acetaminophen O
as O
a O
risk O
factor O
for O
chronic B-Disease
renal I-Disease
failure I-Disease
: O
a O
comparison O
with O
phenacetin O
. O

six O
epidemiologic O
studies O
in O
the O
united O
states O
and O
europe O
indicate O
that O
habitual O
use O
of O
phenacetin O
is O
associated O
with O
the O
development O
of O
chronic B-Disease
renal I-Disease
failure I-Disease
and O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
( O
esrd B-Disease
) O
, O
with O
a O
relative O
risk O
in O
the O
range O
of O
4 O
to O
19 O
. O

however O
, O
three O
case O
control O
studies O
, O
one O
each O
in O
north O
carolina O
, O
northern O
maryland O
, O
and O
west O
berlin O
, O
germany O
, O
showed O
that O
habitual O
use O
of O
acetaminophen O
is O
also O
associated O
with O
chronic B-Disease
renal I-Disease
failure I-Disease
and O
esrd B-Disease
, O
with O
a O
relative O
risk O
in O
the O
range O
of O
2 O
to O
4 O
. O

these O
studies O
suggest O
that O
both O
phenacetin O
and O
acetaminophen O
may O
contribute O
to O
the O
burden O
of O
esrd B-Disease
, O
with O
the O
risk O
of O
the O
latter O
being O
somewhat O
less O
than O
that O
of O
the O
former O
. O

this O
apparent O
difference O
in O
risk O
may O
not O
be O
due O
to O
differences O
in O
nephrotoxic B-Disease
potential O
of O
the O
drugs O
themselves O
. O

the O
possibility O
that O
habitual O
use O
of O
acetaminophen O
alone O
increases O
the O
risk O
of O
esrd B-Disease
has O
not O
been O
clearly O
demonstrated O
, O
but O
cannot O
be O
dismissed O
. O

acetaminophen O
- O
induced O
hypotension B-Disease
. O

the O
potential O
for O
acetaminophen O
to O
produce O
cardiovascular B-Disease
toxicities I-Disease
is O
very O
low O
. O

however O
, O
acetaminophen O
has O
been O
demonstrated O
to O
produce O
symptoms O
of O
anaphylaxis B-Disease
, O
including O
hypotension B-Disease
, O
in O
sensitive O
individuals O
. O

this O
article O
describes O
two O
critically B-Disease
ill I-Disease
patients O
in O
whom O
transient O
episodes O
of O
hypotension B-Disease
reproducibly O
developed O
after O
administration O
of O
acetaminophen O
. O

other O
symptoms O
of O
allergic B-Disease
reactions I-Disease
were O
not O
clinically O
detectable O
. O

the O
hypotensive B-Disease
episodes O
were O
severe O
enough O
to O
require O
vasopressor O
administration O
. O

the O
reports O
illustrate O
the O
need O
for O
clinicians O
to O
consider O
acetaminophen O
in O
patients O
with O
hypotension B-Disease
of O
unknown O
origin O
. O

reduction O
of O
heparan O
sulphate O
- O
associated O
anionic O
sites O
in O
the O
glomerular O
basement O
membrane O
of O
rats O
with O
streptozotocin O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
. O

heparan O
sulphate O
- O
associated O
anionic O
sites O
in O
the O
glomerular O
basement O
membrane O
were O
studied O
in O
rats O
8 O
months O
after O
induction O
of O
diabetes B-Disease
by O
streptozotocin O
and O
in O
age O
- O
adn O
sex O
- O
matched O
control O
rats O
, O
employing O
the O
cationic O
dye O
cuprolinic O
blue O
. O

the O
majority O
of O
anionic O
sites O
( O
74 O
% O
in O
diabetic B-Disease
and O
81 O
% O
in O
control O
rats O
) O
were O
found O
within O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
. O

a O
minority O
of O
anionic O
sites O
were O
scattered O
throughout O
the O
lamina O
densa O
and O
lamina O
rara O
interna O
, O
and O
were O
significantly O
smaller O
than O
those O
in O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
( O
p O
< O
0 O
. O

1 O
and O
p O
< O
0 O
. O

1 O
for O
diabetic B-Disease
and O
control O
rats O
, O
respectively O
) O
. O

diabetic B-Disease
rats O
progressively O
developed O
albuminuria B-Disease
reaching O
40 O
. O

3 O
( O
32 O
. O

2 O
- O
62 O
. O

0 O
) O
mg O
/ O
24 O
h O
after O
8 O
months O
in O
contrast O
to O
the O
control O
animals O
( O
0 O
. O

8 O
( O
0 O
. O

2 O
- O
0 O
. O

9 O
) O
mg O
/ O
24 O
h O
, O
p O
< O
0 O
. O

2 O
) O
. O

we O
conclude O
that O
in O
streptozotocin O
- O
diabetic B-Disease
rats O
with O
an O
increased O
urinary O
albumin O
excretion O
, O
a O
reduced O
heparan O
sulphate O
charge O
barrier O
/ O
density O
is O
found O
at O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
. O

mediation O
of O
enhanced O
reflex O
vagal O
bradycardia B-Disease
by O
l O
- O
dopa O
via O
central O
dopamine O
formation O
in O
dogs O
. O

in O
addition O
, O
reflex O
bradycardia B-Disease
caused O
by O
injected O
norepinephrine O
was O
significantly O
enhanced O
by O
l O
- O
dopa O
, O
dl O
- O
threo O
- O
dihydroxyphenylserine O
had O
no O
effect O
on O
blood O
pressure O
, O
heart O
rate O
or O
reflex O
responses O
to O
norepinephrine O
. O

fla O
- O
63 O
, O
a O
dopamine O
- O
beta O
- O
oxidase O
inhibitor O
, O
did O
not O
have O
any O
effect O
on O
the O
hypotension B-Disease
, O
bradycardia B-Disease
or O
reflex O
- O
enhancing O
effect O
of O
l O
- O
dopa O
. O

however O
, O
l O
- O
dopa O
restored O
the O
bradycardia B-Disease
caused O
by O
norepinephrine O
in O
addition O
to O
decreasing O
blood O
pressure O
and O
heart O
rate O
. O

5 O
- O
htp O
( O
5 O
mg O
/ O
kg O
i O
. O

v O
. O

) O
decreased O
blood O
pressure O
and O
heart O
rate O
and O
decreased O
the O
reflex O
bradycardia B-Disease
to O
norepinephrine O
. O

it O
is O
concluded O
that O
l O
- O
dopa O
enhances O
reflex O
bradycardia B-Disease
through O
central O
alpha O
- O
receptor O
stimulation O
. O

microangiopathic B-Disease
hemolytic I-Disease
anemia I-Disease
complicating O
fk506 O
( O
tacrolimus O
) O
therapy O
. O

we O
describe O
3 O
episodes O
of O
microangiopathic B-Disease
hemolytic I-Disease
anemia I-Disease
( O
maha B-Disease
) O
in O
2 O
solid O
organ O
recipients O
under O
fk506 O
( O
tacrolimus O
) O
therapy O
. O

in O
both O
cases O
, O
discontinuation O
of O
fk506 O
and O
treatment O
with O
plasma O
exchange O
, O
fresh O
frozen O
plasma O
replacement O
, O
corticosteroids O
, O
aspirin O
, O
and O
dipyridamole O
led O
to O
resolution O
of O
maha B-Disease
. O

in O
one O
patient O
, O
reintroduction O
of O
fk506 O
led O
to O
rapid O
recurrence O
of O
maha B-Disease
. O

fk506 O
- O
associated O
maha B-Disease
is O
probably O
rare O
but O
physicians O
must O
be O
aware O
of O
this O
severe O
complication O
. O

in O
our O
experience O
and O
according O
to O
the O
literature O
, O
fk506 O
does O
not O
seem O
to O
cross O
- O
react O
with O
cyclosporin O
a O
( O
cya O
) O
, O
an O
immuno O
- O
suppressive O
drug O
already O
known O
to O
induce O
maha B-Disease
. O

effect O
of O
some O
anticancer O
drugs O
and O
combined O
chemotherapy O
on O
renal B-Disease
toxicity I-Disease
. O

the O
nephrotoxic B-Disease
action O
of O
anticancer O
drugs O
such O
as O
nitrogranulogen O
( O
ng O
) O
, O
methotrexate O
( O
mtx O
) O
, O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
and O
cyclophosphamide O
( O
cy O
) O
administered O
alone O
or O
in O
combination O
[ O
mtx O
+ O
5 O
- O
fu O
+ O
cy O
( O
cmf O
) O
] O
was O
evaluated O
in O
experiments O
on O
wistar O
rats O
. O

cy O
caused O
hemorrhagic B-Disease
cystitis I-Disease
in O
40 O
% O
of O
rats O
, O
but O
it O
did O
not O
cause O
this O
complication O
when O
combined O
with O
5 O
- O
fu O
and O
mtx O
. O

our O
studies O
indicate O
that O
nephrotoxicity B-Disease
of O
mtx O
+ O
5 O
- O
fu O
+ O
cy O
administered O
jointly O
is O
lower O
than O
in O
monotherapy O
. O

compared O
with O
sham O
- O
operated O
controls O
, O
lesions O
significantly O
( O
p O
< O
0 O
. O

25 O
) O
blunted O
the O
early O
( O
< O
60 O
min O
) O
free O
- O
field O
locomotor B-Disease
hypoactivity I-Disease
caused O
by O
nicotine O
( O
0 O
. O

5 O
mg O
kg O
( O
- O
1 O
) O
, O
i O
. O

m O
. O

) O
, O
enhanced O
the O
later O
( O
60 O
- O
120 O
min O
) O
nicotine O
- O
induced O
hyperactivity B-Disease
, O
and O
raised O
spontaneous O
nocturnal O
activity O
. O

we O
conclude O
that O
the O
interpeduncular O
nucleus O
mediates O
nicotinic O
depression B-Disease
of O
locomotor O
activity O
and O
dampens O
nicotinic O
arousal O
mechanisms O
located O
elsewhere O
in O
the O
brain O
. O

lithium O
- O
associated O
cognitive B-Disease
and I-Disease
functional I-Disease
deficits I-Disease
reduced O
by O
a O
switch O
to O
divalproex O
sodium O
: O
a O
case O
series O
. O

background O
: O
lithium O
remains O
a O
first O
- O
line O
treatment O
for O
the O
acute O
and O
maintenance O
treatment O
of O
bipolar B-Disease
disorder I-Disease
. O

although O
much O
has O
been O
written O
about O
the O
management O
of O
the O
more O
common O
adverse O
effects O
of O
lithium O
, O
such O
as O
polyuria B-Disease
and O
tremor B-Disease
, O
more O
subtle O
lithium O
side O
effects O
such O
as O
cognitive B-Disease
deficits I-Disease
, O
loss B-Disease
of I-Disease
creativity I-Disease
, O
and O
functional B-Disease
impairments I-Disease
remain O
understudied O
. O

this O
report O
summarizes O
our O
experience O
in O
switching O
bipolar B-Disease
patients O
from O
lithium O
to O
divalproex O
sodium O
to O
alleviate O
such O
cognitive B-Disease
and I-Disease
functional I-Disease
impairments I-Disease
. O

results O
: O
we O
report O
seven O
cases O
where O
substitution O
of O
lithium O
, O
either O
fully O
or O
partially O
, O
with O
divalproex O
sodium O
was O
extremely O
helpful O
in O
reducing O
the O
cognitive B-Disease
, I-Disease
motivational I-Disease
, I-Disease
or I-Disease
creative I-Disease
deficits I-Disease
attributed O
to O
lithium O
in O
our O
bipolar B-Disease
patients O
. O

conclusion O
: O
in O
this O
preliminary O
report O
, O
divalproex O
sodium O
was O
a O
superior O
alternative O
to O
lithium O
in O
bipolar B-Disease
patients O
experiencing O
cognitive B-Disease
deficits I-Disease
, O
loss B-Disease
of I-Disease
creativity I-Disease
, O
and O
functional B-Disease
impairments I-Disease
. O

two O
groups O
of O
patients O
receiving O
tacrolimus O
were O
compared O
over O
a O
period O
of O
1 O
year O
, O
one O
group O
comprising O
hypertensive B-Disease
patients O
who O
were O
receiving O
nifedipine O
, O
and O
the O
other O
comprising O
nonhypertensive O
patients O
not O
receiving O
nifedipine O
. O

the O
observed O
positive O
impact O
of O
nifedipine O
on O
reducing O
the O
nephrotoxicity B-Disease
associated O
with O
tacrolimus O
in O
liver O
transB-Plant O
recipients O
should O
be O
an O
important O
factor O
in O
selecting O
an O
agent O
to O
treat O
hypertension B-Disease
in O
this O
population O
. O

alpha O
and O
beta O
coma B-Disease
in O
drug O
intoxication O
uncomplicated O
by O
cerebral B-Disease
hypoxia I-Disease
. O

four O
patients O
who O
were O
rendered O
comatose B-Disease
or O
stuporous B-Disease
by O
drug O
intoxication O
, O
but O
who O
were O
not O
hypoxic O
, O
are O
described O
. O

three O
patients O
received O
high O
doses O
of O
chlormethiazole O
for O
alcohol O
withdrawal B-Disease
symptoms I-Disease
, O
and O
one O
took O
a O
suicidal O
overdose B-Disease
of O
nitrazepam O
. O

the O
patient O
with O
nitrazepam O
overdose B-Disease
and O
two O
of O
those O
with O
chlormethiazole O
intoxication O
conformed O
to O
the O
criteria O
of O
' O
alpha O
coma B-Disease
' O
, O
showing O
non O
- O
reactive O
generalized O
or O
frontally O
predominant O
alpha O
activity O
in O
the O
eeg O
. O

all O
four O
recovered O
completely O
without O
neurological B-Disease
sequelae I-Disease
following O
the O
withdrawal O
of O
the O
offending O
agents O
. O

the O
similarities O
between O
the O
effects O
of O
structural O
lesions O
and O
pharmacological O
depression B-Disease
of O
the O
brain O
stem O
reticular O
formation O
are O
discussed O
. O

it O
is O
suggested O
that O
in O
both O
situations O
disturbed O
reticulo O
- O
thalamic O
interactions O
are O
important O
in O
the O
pathogenesis O
of O
alpha O
coma B-Disease
. O

it O
is O
concluded O
that O
when O
this O
electroencephalographic O
and O
behavioural O
picture O
is O
seen O
in O
drug O
intoxication O
, O
in O
the O
absence O
of O
significant O
hypoxaemia B-Disease
, O
a O
favourable O
outcome O
may O
be O
anticipated O
. O

magnetic O
resonance O
volumetry O
of O
the O
cerebellum O
in O
epileptic B-Disease
patients O
after O
phenytoin O
overdosages B-Disease
. O

the O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
relationship O
between O
phenytoin O
medication O
and O
cerebellar B-Disease
atrophy I-Disease
in O
patients O
who O
had O
experienced O
clinical O
intoxication O
. O

using O
linear O
regression O
we O
found O
that O
no O
correlation O
exists O
between O
seizure B-Disease
duration O
, O
elevation O
of O
phenytoin O
serum O
levels O
and O
cerebellar O
volume O
. O

we O
conclude O
that O
phenytoin O
overdosage B-Disease
does O
not O
necessarily O
result O
in O
cerebellar B-Disease
atrophy I-Disease
and O
it O
is O
unlikely O
that O
phenytoin O
medication O
was O
the O
only O
cause O
of O
cerebellar B-Disease
atrophy I-Disease
in O
the O
remaining O
patients O
. O

quantitative O
morphometric O
studies O
of O
the O
cerebellum O
provide O
valuable O
insights O
into O
the O
pathogenesis O
of O
cerebellar B-Disease
disorders I-Disease
. O

late O
recovery O
of O
renal O
function O
in O
a O
woman O
with O
the O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
. O

a O
case O
is O
reported O
of O
the O
hemolytic B-Disease
uremic I-Disease
syndrome I-Disease
( O
hus B-Disease
) O
in O
a O
woman O
taking O
oral O
contraceptives O
. O

she O
was O
treated O
with O
heparin O
, O
dipyridamole O
and O
hemodialysis O
; O
and O
after O
more O
than O
three O
months O
, O
her O
urinary O
output O
rose O
above O
500 O
ml O
; O
and O
six O
months O
after O
the O
onset O
of O
anuria B-Disease
, O
dialysis O
treatment O
was O
stopped O
. O

this O
case O
emphasizes O
the O
possibility O
that O
hus B-Disease
in O
adults O
is O
not O
invariably O
irreversible O
and O
that O
, O
despite O
prolonged O
oliguria B-Disease
, O
recovery O
of O
renal O
function O
can O
be O
obtained O
. O

therefore O
, O
in O
adult O
patients O
affected O
by O
hus B-Disease
, O
dialysis O
should O
not O
be O
discontinued O
prematurely O
; O
moreover O
, O
bilateral O
nephrectomy O
, O
for O
treatment O
of O
severe O
hypertension B-Disease
and O
microangiopathic B-Disease
hemolytic I-Disease
anemia I-Disease
, O
should O
be O
performed O
with O
caution O
. O

morphological O
features O
of O
encephalopathy B-Disease
after O
chronic O
administration O
of O
the O
antiepileptic O
drug O
valproate O
to O
rats O
. O

w O
. O

once O
daily O
to O
rats O
for O
1 O
, O
3 O
, O
6 O
, O
9 O
and O
12 O
months O
revealed O
neurological B-Disease
disorders I-Disease
indicating O
cerebellum B-Disease
damage I-Disease
( O
nan O
valproate O
encephalopathy B-Disease
nan O
) O
. O

lesions O
of O
the O
capillary O
included O
necrosis B-Disease
of O
endothelial O
cells O
. O

fragments O
of O
necrotic B-Disease
endothelial O
cells O
were O
in O
the O
vascular O
lumens O
and O
in O
these O
there O
was O
loosening O
and O
breaking O
of O
tight O
cellular O
junctions O
. O

the O
possible O
influence O
of O
the O
hepatic B-Disease
damage I-Disease
, O
mainly O
hyperammonemia B-Disease
, O
upon O
the O
development O
of O
valproate O
encephalopathy B-Disease
is O
discussed O
. O

fatal O
intracranial B-Disease
bleeding I-Disease
associated O
with O
prehospital O
use O
of O
epinephrine O
. O

we O
present O
a O
case O
of O
paramedic O
misjudgment O
in O
the O
execution O
of O
a O
protocol O
for O
the O
treatment O
of O
allergic B-Disease
reaction I-Disease
in O
a O
case O
of O
pulmonary B-Disease
edema I-Disease
with O
wheezing B-Disease
. O

the O
sudden O
onset O
of O
respiratory B-Disease
distress I-Disease
, O
rash B-Disease
, O
and O
a O
history O
of O
a O
new O
medicine O
led O
the O
two O
paramedics O
on O
the O
scene O
to O
administer O
subcutaneous O
epinephrine O
. O

subsequently O
, O
acute O
cardiac B-Disease
arrest I-Disease
and O
fatal O
subarachnoid B-Disease
hemorrhage I-Disease
occurred O
. O

epinephrine O
has O
a O
proven O
role O
in O
cardiac B-Disease
arrest I-Disease
in O
prehospital O
care O
; O
however O
, O
use O
by O
paramedics O
in O
patients O
with O
suspected O
allergic B-Disease
reaction I-Disease
and O
severe O
hypertension B-Disease
should O
be O
viewed O
with O
caution O
. O

role O
of O
activation O
of O
bradykinin O
b2 O
receptors O
in O
disruption O
of O
the O
blood O
- O
brain O
barrier O
during O
acute O
hypertension B-Disease
. O

cellular O
mechanisms O
which O
account O
for O
disruption O
the O
blood O
- O
brain O
barrier O
during O
acute O
hypertension B-Disease
are O
not O
clear O
. O

the O
goal O
of O
this O
study O
was O
to O
determine O
the O
role O
of O
synthesis O
/ O
release O
of O
bradykinin O
to O
activate O
b2 O
receptors O
in O
disruption O
of O
the O
blood O
- O
brain O
barrier O
during O
acute O
hypertension B-Disease
. O

permeability O
of O
the O
blood O
- O
brain O
barrier O
was O
quantitated O
by O
clearance O
of O
fluorescent O
- O
labeled O
dextran O
before O
and O
during O
phenylephrine O
- O
induced O
acute O
hypertension B-Disease
in O
rats O
treated O
with O
vehicle O
and O
hoe O
- O
140 O
( O
0 O
. O

1 O
microm O
) O
. O

these O
findings O
suggest O
that O
disruption O
of O
the O
blood O
- O
brain O
barrier O
during O
acute O
hypertension B-Disease
is O
not O
related O
to O
the O
synthesis O
/ O
release O
of O
bradykinin O
to O
activate O
b2 O
receptors O
. O

risk O
factors O
of O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
in O
preterm O
infants O
. O

among O
547 O
preterm O
infants O
of O
< O
or O
= O
34 O
weeks O
gestation O
born O
between O
1987 O
and O
1991 O
, O
8 O
children O
( O
1 O
. O

46 O
% O
) O
developed O
severe O
progressive O
and O
bilateral O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
. O

perinatal O
risk O
factors O
of O
infants O
with O
hearing B-Disease
loss I-Disease
were O
compared O
with O
those O
of O
two O
control O
groups O
matched O
for O
gestation O
and O
birth O
weight O
and O
for O
perinatal O
complications O
. O

our O
observations O
demonstrated O
an O
association O
of O
hearing B-Disease
loss I-Disease
with O
a O
higher O
incidence O
of O
perinatal O
complications O
. O

ototoxicity B-Disease
appeared O
closely O
related O
to O
a O
prolonged O
administration O
and O
higher O
total O
dose O
of O
ototoxic B-Disease
drugs O
, O
particularly O
aminoglycosides O
and O
furosemide O
. O

finally O
, O
we O
strongly O
recommend O
to O
prospectively O
and O
regularly O
perform O
audiologic O
assessment O
in O
sick O
preterm O
children O
as O
hearing B-Disease
loss I-Disease
is O
of O
delayed O
onset O
and O
in O
most O
cases O
bilateral O
and O
severe O
. O

seizure B-Disease
resulting O
from O
a O
venlafaxine O
overdose B-Disease
. O

objective O
: O
to O
report O
a O
case O
of O
venlafaxine O
overdose B-Disease
. O

case O
summary O
: O
a O
40 O
- O
year O
- O
old O
woman O
with O
major B-Disease
depression I-Disease
took O
an O
overdose B-Disease
of O
venlafaxine O
in O
an O
apparent O
suicide O
attempt O
. O

after O
the O
ingestion O
of O
26 O
venlafaxine O
50 O
- O
mg O
tablets O
, O
the O
patient O
experienced O
a O
witnessed O
generalized O
seizure B-Disease
. O

discussion O
: O
to O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
venlafaxine O
overdose B-Disease
that O
resulted O
in O
a O
generalized O
seizure B-Disease
. O

conclusions O
: O
the O
venlafaxine O
overdose B-Disease
in O
our O
patient O
resulted O
in O
a O
single O
episode O
of O
generalized O
seizure B-Disease
but O
elicited O
no O
further O
sequelae O
. O

combined O
effects O
of O
prolonged O
prostaglandin O
e1 O
- O
induced O
hypotension B-Disease
and O
haemodilution B-Disease
on O
human O
hepatic O
function O
. O

combined O
effects O
of O
prolonged O
prostaglandin O
e1 O
( O
pge1 O
) O
- O
induced O
hypotension B-Disease
and O
haemodilution B-Disease
on O
hepatic O
function O
were O
studied O
in O
30 O
patients O
undergoing O
hip O
surgery O
. O

the O
patients O
were O
randomly O
allocated O
to O
one O
of O
three O
groups O
; O
those O
in O
group O
a O
( O
n O
= O
10 O
) O
were O
subjected O
to O
controlled O
hypotension B-Disease
alone O
, O
those O
in O
group O
b O
( O
n O
= O
10 O
) O
to O
haemodilution B-Disease
alone O
and O
those O
in O
group O
c O
( O
n O
= O
10 O
) O
to O
both O
controlled O
hypotension B-Disease
and O
haemodilution B-Disease
. O

haemodilution B-Disease
in O
groups O
b O
and O
c O
was O
produced O
by O
withdrawing O
approximately O
1000 O
ml O
of O
blood O
and O
replacing O
it O
with O
the O
same O
amount O
of O
dextran O
solution O
, O
and O
final O
haematocrit O
values O
were O
21 O
or O
22 O
% O
. O

controlled O
hypotension B-Disease
in O
groups O
a O
and O
c O
was O
induced O
with O
pge1 O
to O
maintain O
mean O
arterial O
blood O
pressure O
at O
55 O
mmhg O
for O
180 O
min O
. O

in O
group O
c O
, O
akbr O
showed O
a O
significant O
decrease O
at O
120 O
min O
( O
- O
40 O
% O
) O
and O
at O
180 O
min O
( O
- O
49 O
% O
) O
after O
the O
start O
of O
hypotension B-Disease
and O
at O
60 O
min O
( O
- O
32 O
% O
) O
after O
recovery O
of O
normotension O
, O
and O
sgot O
, O
sgpt O
, O
ldh O
and O
total O
bilirubin O
showed O
significant O
increases O
after O
operation O
. O

the O
results O
suggest O
that O
a O
prolonged O
combination O
of O
more O
than O
120 O
min O
of O
pge1 O
- O
induced O
hypotension B-Disease
and O
moderate O
haemodilution B-Disease
would O
cause O
impairment B-Disease
of I-Disease
hepatic I-Disease
function I-Disease
. O

cardiovascular B-Disease
alterations I-Disease
in O
rat O
fetuses O
exposed O
to O
calcium O
channel O
blockers O
. O

preclinical O
toxicologic O
investigation O
suggested O
that O
a O
new O
calcium O
channel O
blocker O
, O
ro O
40 O
- O
5967 O
, O
induced O
cardiovascular B-Disease
alterations I-Disease
in O
rat O
fetuses O
exposed O
to O
this O
agent O
during O
organogenesis O
. O

the O
present O
study O
was O
designed O
to O
investigate O
the O
hypothesis O
that O
calcium O
channel O
blockers O
in O
general O
induce O
cardiovascular B-Disease
malformations I-Disease
indicating O
a O
pharmacologic O
class O
effect O
. O

pregnant O
rats O
were O
administered O
one O
of O
these O
calcium O
channel O
blockers O
during O
the O
period O
of O
cardiac O
morphogenesis O
and O
the O
offspring O
examined O
on O
day O
20 O
of O
gestation O
for O
cardiovascular B-Disease
malformations I-Disease
. O

a O
low O
incidence O
of O
cardiovascular B-Disease
malformations I-Disease
was O
observed O
after O
exposure O
to O
each O
of O
the O
four O
calcium O
channel O
blockers O
, O
but O
this O
incidence O
was O
statistically O
significant O
only O
for O
verapamil O
and O
nifedipine O
. O

atypical B-Disease
sensations I-Disease
following O
the O
use O
of O
subcutaneous O
sumatriptan O
are O
common O
, O
but O
of O
uncertain O
origin O
. O

two O
patients O
are O
presented O
with O
tingling B-Disease
or I-Disease
burning I-Disease
sensations I-Disease
limited O
to O
areas O
of O
heat O
exposure O
or O
sunburn B-Disease
. O

macula O
toxicity B-Disease
after O
intravitreal O
amikacin O
. O

background O
: O
although O
intravitreal O
aminoglycosides O
have O
substantially O
improved O
visual O
prognosis O
in O
endophthalmitis B-Disease
, O
macular O
infarction B-Disease
may O
impair O
full O
visual O
recovery O
. O

methods O
: O
we O
present O
a O
case O
of O
presumed O
amikacin O
retinal B-Disease
toxicity I-Disease
following O
treatment O
with O
amikacin O
and O
vancomycin O
for O
alpha O
- O
haemolytic O
streptococcal B-Disease
endophthalmitis I-Disease
. O

results O
: O
endophthalmitis B-Disease
resolved O
with O
improvement O
in O
visual O
acuity O
to O
6 O
/ O
24 O
at O
three O
months O
. O

fundus O
fluorescein O
angiography O
confirmed O
macular O
capillary O
closure O
and O
telangiectasis B-Disease
. O

conclusions O
: O
currently O
accepted O
intravitreal O
antibiotic O
regimens O
may O
cause O
retinal B-Disease
toxicity I-Disease
and O
macular O
ischaemia B-Disease
. O

treatment O
strategies O
aimed O
at O
avoiding O
retinal B-Disease
toxicity I-Disease
are O
discussed O
. O

the O
role O
of O
nicotine O
in O
smoking O
- O
related O
cardiovascular B-Disease
disease I-Disease
. O

nicotine O
activates O
the O
sympathetic O
nervous O
system O
and O
in O
this O
way O
could O
contribute O
to O
cardiovascular B-Disease
disease I-Disease
. O

animal O
studies O
and O
mechanistic O
studies O
indicate O
that O
nicotine O
could O
play O
a O
role O
in O
accelerating O
atherosclerosis B-Disease
, O
but O
evidence O
among O
humans O
is O
too O
inadequate O
to O
be O
definitive O
about O
such O
an O
effect O
. O

nicotine O
does O
not O
appear O
to O
enhance O
thrombosis B-Disease
among O
humans O
. O

iatrogenically O
induced O
intractable O
atrioventricular B-Disease
reentrant I-Disease
tachycardia I-Disease
after O
verapamil O
and O
catheter O
ablation O
in O
a O
patient O
with O
wolff B-Disease
- I-Disease
parkinson I-Disease
- I-Disease
white I-Disease
syndrome I-Disease
and O
idiopathic B-Disease
dilated I-Disease
cardiomyopathy I-Disease
. O

in O
a O
patient O
with O
wpw B-Disease
syndrome I-Disease
and O
idiopathic B-Disease
dilated I-Disease
cardiomyopathy I-Disease
, O
intractable O
atrioventricular B-Disease
reentrant I-Disease
tachycardia I-Disease
( O
avrt B-Disease
) O
was O
iatrogenically O
induced O
. O

qrs O
without O
preexcitation O
, O
caused O
by O
junctional O
escape O
beats O
after O
verapamil O
or O
unidirectional O
antegrade O
block O
of O
accessory O
pathway O
after O
catheter O
ablation O
, O
established O
frequent O
avrt B-Disease
attack O
. O

epidemic O
of O
liver B-Disease
disease I-Disease
caused O
by O
hydrochlorofluorocarbons O
used O
as O
ozone O
- O
sparing O
substitutes O
of O
chlorofluorocarbons O
. O

limited O
studies O
in O
animals O
indicate O
potential O
hepatotoxicity B-Disease
of O
some O
of O
these O
compounds O
. O

we O
investigated O
an O
epidemic O
of O
liver B-Disease
disease I-Disease
in O
nine O
industrial O
workers O
who O
had O
had O
repeated O
accidental O
exposure O
to O
a O
mixture O
of O
1 O
, O
1 O
- O
dichloro O
- O
2 O
, O
2 O
, O
2 O
- O
trifluoroethane O
( O
hcfc O
123 O
) O
and O
1 O
- O
chloro O
- O
1 O
, O
2 O
, O
2 O
, O
2 O
- O
tetrafluoroethane O
( O
hcfc O
124 O
) O
. O

both O
compounds O
are O
metabolised O
in O
the O
same O
way O
as O
1 O
- O
bromo O
- O
1 O
- O
chloro O
- O
2 O
, O
2 O
, O
2 O
- O
trifluoroethane O
( O
halothane O
) O
to O
form O
reactive O
trifluoroacetyl O
halide O
intermediates O
, O
which O
have O
been O
implicated O
in O
the O
hepatotoxicity B-Disease
of O
halothane O
. O

we O
aimed O
to O
test O
whether O
hcfcs O
123 O
and O
124 O
can O
result O
in O
serious O
liver B-Disease
disease I-Disease
. O

findings O
: O
the O
liver O
biopsy O
sample O
showed O
hepatocellular O
necrosis B-Disease
which O
was O
prominent O
in O
perivenular O
zone O
three O
and O
extended O
focally O
from O
portal O
tracts O
to O
portal O
tracts O
and O
centrilobular O
areas O
( O
bridging O
necrosis B-Disease
) O
. O

autoantibodies O
against O
p450 O
2E+01 O
or O
p58 O
, O
previously O
associated O
with O
halothane B-Disease
hepatitis I-Disease
, O
were O
detected O
in O
the O
serum O
of O
five O
affected O
workers O
. O

interpretation O
: O
repeated O
exposure O
of O
human O
beings O
to O
hcfcs O
123 O
and O
124 O
can O
result O
in O
serious O
liver B-Disease
injury I-Disease
in O
a O
large O
proportion O
of O
the O
exposed O
population O
. O

although O
the O
exact O
mechanism O
of O
hepatotoxicity B-Disease
of O
these O
agents O
is O
not O
known O
, O
the O
results O
suggest O
that O
trifluoroacetyl O
- O
altered O
liver O
proteins O
are O
involved O
. O

bile B-Disease
duct I-Disease
hamartoma I-Disease
occurring O
in O
association O
with O
long O
- O
term O
treatment O
with O
danazol O
. O

we O
report O
a O
case O
of O
bile B-Disease
duct I-Disease
hamartoma I-Disease
which O
developed O
in O
a O
patient O
who O
had O
been O
on O
long O
- O
term O
danazol O
treatment O
. O

if O
the O
patient O
develops O
a O
liver B-Disease
mass I-Disease
, O
because O
of O
non O
- O
specific O
clinical O
features O
and O
imaging O
appearances O
, O
biopsy O
may O
be O
the O
only O
way O
to O
achieve O
a O
definitive O
diagnosis O
. O

endocrine O
screening O
in O
1 O
, O
22 O
men O
with O
erectile B-Disease
dysfunction I-Disease
: O
clinical O
significance O
and O
cost O
- O
effective O
strategy O
. O

purpose O
: O
we O
reviewed O
the O
results O
of O
serum O
testosterone O
and O
prolactin O
determination O
in O
1 O
, O
22 O
patients O
referred O
because O
of O
erectile B-Disease
dysfunction I-Disease
and O
compared O
the O
data O
with O
history O
, O
results O
of O
physical O
examination O
, O
other O
etiological O
investigations O
and O
effects O
of O
endocrine O
therapy O
to O
refine O
the O
rules O
of O
cost O
- O
effective O
endocrine O
screening O
and O
to O
pinpoint O
actual O
responsibility O
for O
hormonal O
abnormalities O
. O

every O
patient O
was O
screened O
for O
testosterone O
and O
451 O
were O
screened O
for O
prolactin O
on O
the O
basis O
of O
low B-Disease
sexual I-Disease
desire I-Disease
, O
gynecomastia B-Disease
or O
testosterone O
less O
than O
4 O
ng O
. O

/ O
ml O
. O

prolactin O
results O
were O
compared O
with O
those O
of O
a O
previous O
personal O
cohort O
of O
1 O
, O
340 O
patients O
with O
erectile B-Disease
dysfunction I-Disease
and O
systematic O
prolactin O
determination O
. O

main O
clinical O
criteria O
tested O
regarding O
efficiency O
in O
hormone O
determination O
were O
low B-Disease
sexual I-Disease
desire I-Disease
, O
small O
testes O
and O
gynecomastia B-Disease
. O

endocrine O
therapy O
consisted O
of O
testosterone O
heptylate O
or O
human O
chorionic O
gonadotropin O
for O
hypogonadism B-Disease
and O
bromocriptine O
for O
hyperprolactinemia B-Disease
. O

two O
pituitary B-Disease
tumors I-Disease
were O
discovered O
after O
testosterone O
determination O
. O

most O
of O
the O
other O
low O
testosterone O
levels O
seemed O
to O
result O
from O
nonorganic O
hypothalamic B-Disease
dysfunction I-Disease
because O
of O
normal O
serum O
luteinizing O
hormone O
and O
prolactin O
and O
to O
have O
only O
a O
small O
role O
in O
erectile B-Disease
dysfunction I-Disease
( O
definite O
improvement O
in O
only O
16 O
of O
44 O
[ O
36 O
% O
] O
after O
androgen O
therapy O
, O
normal O
morning O
or O
nocturnal O
erections O
in O
30 O
% O
and O
definite O
vasculogenic O
contributions O
in O
42 O
% O
) O
. O

determining O
testosterone O
only O
in O
cases O
of O
low B-Disease
sexual I-Disease
desire I-Disease
or O
abnormal O
physical O
examination O
would O
have O
missed O
40 O
% O
of O
the O
cases O
with O
low O
testosterone O
, O
including O
37 O
% O
of O
those O
subsequently O
improved O
by O
androgen O
therapy O
. O

only O
1 O
prolactinoma B-Disease
was O
discovered O
. O

these O
data O
are O
lower O
than O
those O
we O
found O
during O
the O
last O
2 O
decades O
( O
overall O
prolactin O
greater O
than O
20 O
ng O
. O

/ O
ml O
. O

in O
1 O
. O

86 O
% O
of O
1 O
, O
821 O
patients O
, O
prolactinomas B-Disease
in O
7 O
, O
0 O
. O

38 O
% O
) O
. O

conclusions O
: O
low O
prevalences O
and O
effects O
of O
low O
testosterone O
and O
high O
prolactin O
in O
erectile B-Disease
dysfunction I-Disease
cannot O
justify O
their O
routine O
determination O
. O

however O
, O
cost O
- O
effective O
screening O
strategies O
recommended O
so O
far O
missed O
40 O
to O
50 O
% O
of O
cases O
improved O
with O
endocrine O
therapy O
and O
the O
pituitary B-Disease
tumors I-Disease
. O

we O
now O
advocate O
that O
before O
age O
50 O
years O
testosterone O
be O
determined O
only O
in O
cases O
of O
low B-Disease
sexual I-Disease
desire I-Disease
and O
abnormal O
physical O
examination O
but O
that O
it O
be O
measured O
in O
all O
men O
older O
than O
50 O
years O
. O

prolactin O
should O
be O
determined O
only O
in O
cases O
of O
low B-Disease
sexual I-Disease
desire I-Disease
, O
gynecomastia B-Disease
and O
/ O
or O
testosterone O
less O
than O
4 O
ng O
. O

/ O
ml O
. O

previous O
clinical O
studies O
have O
proposed O
that O
risperidone O
' O
s O
pharmacologic O
profile O
may O
produce O
improved O
efficacy O
for O
negative O
psychotic B-Disease
symptoms I-Disease
and O
decreased O
propensity O
for O
extrapyramidal O
side O
effects O
; O
features O
shared O
by O
so O
- O
called O
' O
atypical O
' O
neuroleptics O
. O

drug B-Disease
- I-Disease
induced I-Disease
parkinsonism I-Disease
was O
observed O
in O
subjects O
treated O
with O
risperidone O
( O
42 O
% O
) O
and O
haloperidol O
( O
29 O
% O
) O
and O
was O
observed O
at O
occupancy O
levels O
above O
60 O
% O
. O

treatment O
of O
previously O
treated O
metastatic O
breast B-Disease
cancer I-Disease
by O
mitoxantrone O
and O
48 O
- O
hour O
continuous O
infusion O
of O
high O
- O
dose O
5 O
- O
fu O
and O
leucovorin O
( O
mfl O
) O
: O
low O
palliative O
benefit O
and O
high O
treatment O
- O
related O
toxicity B-Disease
. O

for O
previously O
treated O
advanced O
breast B-Disease
cancer I-Disease
, O
there O
is O
no O
standard O
second O
- O
line O
therapy O
. O

from O
october O
1993 O
to O
november O
1995 O
, O
we O
treated O
13 O
patients O
with O
previously O
chemotherapy O
- O
treated O
metastatic O
breast B-Disease
cancer I-Disease
by O
mitoxantrone O
, O
12 O
mg O
/ O
m2 O
, O
on O
day O
1 O
and O
continuous O
infusion O
of O
5 O
- O
fu O
, O
3000 O
mg O
/ O
m2 O
, O
together O
with O
leucovorin O
, O
300 O
mg O
/ O
m2 O
, O
for O
48 O
h O
from O
day O
1 O
to O
2 O
. O

major O
toxicities B-Disease
were O
cardiotoxicity B-Disease
and O
leukopenia B-Disease
. O

eight O
patients O
were O
dead O
in O
the O
last O
follow O
- O
up O
; O
two O
of O
them O
died O
of O
treatment O
- O
related O
toxicity B-Disease
. O

the O
mfl O
regimen O
achieves O
little O
palliative O
benefit O
and O
induces O
severe O
toxicity B-Disease
at O
a O
fairly O
high O
rate O
. O

administration O
of O
this O
regimen O
to O
breast B-Disease
cancer I-Disease
patients O
who O
have O
been O
treated O
by O
chemotherapy O
and O
those O
with O
impaired B-Disease
heart I-Disease
function I-Disease
requires O
careful O
attention O
. O

ticlopidine O
- O
induced O
aplastic B-Disease
anemia I-Disease
: O
report O
of O
three O
chinese O
patients O
and O
review O
of O
the O
literature O
. O

in O
this O
study O
, O
three O
chinese O
patients O
with O
ticlopidine O
- O
induced O
aplastic B-Disease
anemia I-Disease
were O
reported O
and O
another O
13 O
patients O
in O
the O
english O
literature O
were O
reviewed O
. O

agranulocytosis B-Disease
occurred O
3 O
- O
20 O
weeks O
after O
initiation O
of O
ticlopidine O
, O
so O
frequent O
examination O
of O
white O
cell O
count O
during O
treatment O
is O
recommended O
. O

there O
seemed O
to O
be O
no O
direct O
correlation O
between O
the O
dose O
or O
duration O
used O
and O
the O
severity O
of O
bone B-Disease
marrow I-Disease
suppression I-Disease
. O

treatment O
for O
ticlopidine O
- O
induced O
aplastic B-Disease
anemia I-Disease
with O
colony O
- O
stimulating O
factors O
seemed O
to O
have O
little O
effect O
. O

upregulation O
of O
the O
expression O
of O
vasopressin O
gene O
in O
the O
paraventricular O
and O
supraoptic O
nuclei O
of O
the O
lithium O
- O
induced O
diabetes B-Disease
insipidus I-Disease
rat O
. O

the O
expression O
of O
arginine O
vasopressin O
( O
avp O
) O
gene O
in O
the O
paraventricular O
( O
pvn O
) O
and O
supraoptic O
nuclei O
( O
son O
) O
was O
investigated O
in O
rats O
with O
lithium O
( O
li O
) O
- O
induced O
polyuria B-Disease
, O
using O
in O
situ O
hybridization O
histochemistry O
and O
radioimmunoassay O
. O

the O
male O
wistar O
rats O
consuming O
a O
diet O
that O
contained O
licl O
( O
60 O
mmol O
/ O
kg O
) O
for O
4 O
weeks O
developed O
marked O
polyuria B-Disease
. O

these O
results O
suggest O
that O
dehydration B-Disease
and O
/ O
or O
the O
activation O
of O
visceral O
afferent O
inputs O
may O
contribute O
to O
the O
elevation O
of O
plasma O
avp O
and O
the O
upregulation O
of O
avp O
gene O
expression O
in O
the O
pvn O
and O
the O
son O
of O
the O
li O
- O
induced O
diabetes B-Disease
insipidus I-Disease
rat O
. O

( O
+ O
/ O
- O
) O
- O
pg O
- O
9 O
( O
10 O
- O
40 O
mg O
kg O
- O
1 O
i O
. O

p O
. O

) O
was O
able O
to O
prevent O
amnesia B-Disease
induced O
by O
scopolamine O
( O
1 O
mg O
kg O
- O
1 O
i O
. O

p O
. O

) O
and O
dicyclomine O
( O
2 O
mg O
kg O
- O
1 O
i O
. O

p O
. O

) O
in O
the O
mouse O
passive O
- O
avoidance O
test O
. O

affinity O
profiles O
of O
( O
+ O
/ O
- O
) O
- O
pg O
- O
9 O
for O
muscarinic O
receptor O
subtypes O
, O
determined O
by O
functional O
studies O
( O
rabbit O
vas O
deferens O
for O
m1 O
, O
guinea O
pig O
atrium O
for O
m2 O
, O
guinea O
pig O
ileum O
for O
m3 O
and O
immature O
guinea O
pig O
uterus O
for O
putative O
m4 O
) O
, O
have O
shown O
an O
m4 O
/ O
m1 O
selectivity O
ratio O
of O
10 O
. O

2 O
that O
might O
be O
responsible O
for O
the O
antinociception O
and O
the O
anti O
- O
amnesic B-Disease
effect O
induced O
by O
( O
+ O
/ O
- O
) O
- O
pg O
- O
9 O
through O
an O
increase O
in O
acetylcholine O
extracellular O
levels O
. O

the O
effect O
of O
different O
anaesthetic O
agents O
in O
hearing B-Disease
loss I-Disease
following O
spinal O
anaesthesia O
. O

the O
cause O
of O
hearing B-Disease
loss I-Disease
after O
spinal O
anaesthesia O
is O
unknown O
. O

up O
until O
now O
, O
the O
only O
factor O
studied O
has O
been O
the O
effect O
of O
the O
diameter O
of O
the O
spinal O
needle O
on O
post O
- O
operative O
sensorineural B-Disease
hearing I-Disease
loss I-Disease
. O

the O
aim O
of O
this O
study O
was O
to O
describe O
this O
hearing B-Disease
loss I-Disease
and O
to O
investigate O
other O
factors O
influencing O
the O
degree O
of O
hearing B-Disease
loss I-Disease
. O

patients O
given O
prilocaine O
were O
more O
likely O
to O
develop O
hearing B-Disease
loss I-Disease
( O
10 O
out O
of O
22 O
) O
than O
those O
given O
bupivacaine O
( O
4 O
out O
of O
22 O
) O
( O
p O
< O
0 O
. O

5 O
) O
. O

the O
average O
hearing B-Disease
loss I-Disease
for O
speech O
frequencies O
was O
about O
10 O
db O
after O
prilocaine O
and O
15 O
db O
after O
bupivacaine O
. O

none O
of O
the O
patients O
complained O
of O
subjective O
hearing B-Disease
loss I-Disease
. O

a O
transient O
neurological B-Disease
deficit I-Disease
following O
intrathecal O
injection O
of O
1 O
% O
hyperbaric O
bupivacaine O
for O
unilateral O
spinal O
anaesthesia O
. O

we O
describe O
a O
case O
of O
transient O
neurological B-Disease
deficit I-Disease
that O
occurred O
after O
unilateral O
spinal O
anaesthesia O
with O
8 O
mg O
of O
1 O
% O
hyperbaric O
bupivacaine O
slowly O
injected O
through O
a O
25 O
- O
gauge O
pencil O
- O
point O
spinal O
needle O
. O

the O
surgery O
and O
anaesthesia O
were O
uneventful O
, O
but O
3 O
days O
after O
surgery O
, O
the O
patient O
reported O
an O
area O
of O
hypoaesthesia O
over O
l3 O
- O
l4 O
dermatomes O
of O
the O
leg O
which O
had O
been O
operated O
on O
( O
loss B-Disease
of I-Disease
pinprick I-Disease
sensation I-Disease
) O
without O
reduction O
in O
muscular O
strength O
. O

however O
, O
we O
suggest O
that O
a O
low O
solution O
concentration O
should O
be O
preferred O
for O
unilateral O
spinal O
anaesthesia O
with O
a O
hyperbaric O
anaesthetic O
solution O
( O
if O
pencil O
- O
point O
needle O
and O
slow O
injection O
rate O
are O
employed O
) O
, O
in O
order O
to O
minimize O
the O
risk O
of O
a O
localized O
high O
peak O
anaesthetic O
concentration O
, O
which O
might O
lead O
to O
a O
transient O
neurological B-Disease
deficit I-Disease
. O

transient B-Disease
neurologic I-Disease
symptoms I-Disease
after O
spinal O
anesthesia O
: O
a O
lower O
incidence O
with O
prilocaine O
and O
bupivacaine O
than O
with O
lidocaine O
. O

background O
: O
recent O
evidence O
suggests O
that O
transient B-Disease
neurologic I-Disease
symptoms I-Disease
( O
tnss B-Disease
) O
frequently O
follow O
lidocaine O
spinal O
anesthesia O
but O
are O
infrequent O
with O
bupivacaine O
. O

accordingly O
, O
the O
present O
, O
prospective O
double O
- O
blind O
study O
compares O
prilocaine O
with O
lidocaine O
and O
bupivacaine O
with O
respect O
to O
duration O
of O
action O
and O
relative O
risk O
of O
tnss B-Disease
. O

in O
the O
evening O
of O
postoperative O
day O
1 O
, O
patients O
were O
evaluated O
for O
tnss B-Disease
by O
a O
physician O
unaware O
of O
the O
drug O
administered O
and O
the O
details O
of O
the O
anesthetic O
procedure O
. O

results O
: O
nine O
of O
30 O
patients O
receiving O
lidocaine O
experienced O
tnss B-Disease
, O
1 O
of O
30 O
patients O
receiving O
prilocaine O
( O
p O
= O
0 O
. O

3 O
) O
had O
them O
, O
and O
none O
of O
30 O
patients O
receiving O
bupivacaine O
had O
tnss B-Disease
. O

conclusions O
: O
prilocaine O
may O
be O
preferable O
to O
lidocaine O
for O
short O
surgical O
procedures O
because O
it O
has O
a O
similar O
duration O
of O
action O
but O
a O
lower O
incidence O
of O
tnss B-Disease
. O

suxamethonium O
- O
induced O
cardiac B-Disease
arrest I-Disease
and O
death B-Disease
following O
5 O
days O
of O
immobilization O
. O

the O
present O
report O
describes O
a O
case O
of O
cardiac B-Disease
arrest I-Disease
and O
subsequent O
death B-Disease
as O
a O
result O
of O
hyperkalaemia B-Disease
following O
the O
use O
of O
suxamethonium O
in O
a O
23 O
- O
year O
- O
old O
malawian O
woman O
. O

five O
days O
after O
the O
onset O
of O
the O
symptoms O
of O
meningitis B-Disease
, O
the O
patient O
aspirated O
stomach O
contents O
and O
needed O
endotracheal O
intubation O
. O

forty O
seconds O
after O
injection O
of O
suxamethonium O
, O
bradycardia B-Disease
and O
cardiac B-Disease
arrest I-Disease
occurred O
. O

apart O
from O
the O
reduction O
in O
the O
patient O
' O
s O
level O
of O
consciousness O
, O
there O
were O
no O
signs O
of O
motor O
neurone O
damage O
or O
of O
any O
of O
the O
other O
known O
predisposing O
conditions O
for O
hyperkalaemia B-Disease
following O
the O
administration O
of O
suxamethonium O
. O

it O
is O
postulated O
that O
her O
death B-Disease
was O
caused O
by O
hypersensitivity B-Disease
to O
suxamethonium O
, O
associated O
with O
her O
5 O
- O
day O
immobilization O
. O

acute O
hepatitis B-Disease
, O
autoimmune B-Disease
hemolytic I-Disease
anemia I-Disease
, O
and O
erythroblastocytopenia B-Disease
induced O
by O
ceftriaxone O
. O

an O
80 O
- O
yr O
- O
old O
man O
developed O
acute O
hepatitis B-Disease
shortly O
after O
ingesting O
oral O
ceftriaxone O
. O

although O
the O
transaminases O
gradually O
returned O
to O
baseline O
after O
withholding O
the O
beta O
lactam O
antibiotic O
, O
there O
was O
a O
gradual O
increase O
in O
serum O
bilirubin O
and O
a O
decrease O
in O
hemoglobin O
concentration O
caused O
by O
an O
autoimmune B-Disease
hemolytic I-Disease
anemia I-Disease
and O
erythroblastocytopenia B-Disease
. O

thyroxine O
abuse O
: O
an O
unusual O
case O
of O
thyrotoxicosis B-Disease
in O
pregnancy O
. O

eating B-Disease
disorders I-Disease
and O
the O
associated O
behavioural O
problems O
and O
drug B-Disease
abuse I-Disease
are O
uncommon O
in O
pregnancy O
. O

this O
case O
illustrates O
a O
number O
of O
problems O
that O
may O
be O
encountered O
in O
women O
with O
eating B-Disease
disorders I-Disease
in O
pregnancy O
, O
including O
prolonged O
and O
recurrent O
metabolic O
disturbances O
and O
diuretic O
abuse O
. O

in O
particular O
it O
illustrates O
the O
derangements O
of O
thyroid O
function O
seen O
in O
pregnant O
women O
with O
eating B-Disease
disorders I-Disease
and O
reminds O
us O
that O
when O
a O
cause O
for O
thyrotoxicosis B-Disease
remains O
obscure O
, O
thyroxine O
abuse O
should O
be O
considered O
and O
explored O
. O

in O
the O
acute O
experiment O
tri O
( O
given O
i O
. O

p O
. O

) O
does O
not O
antagonize O
the O
reserpine O
hypothermia B-Disease
in O
mice O
and O
does O
not O
potentiate O
the O
5 O
- O
hydroxytryptophan O
head O
twitches O
in O
rats O
. O

tri O
given O
repeatedly O
to O
rats O
increases O
the O
locomotor O
hyperactivity B-Disease
induced O
by O
d O
- O
amphetamine O
, O
quinpirole O
and O
( O
+ O
) O
- O
7 O
- O
hydroxy O
- O
dipropyloaminotetralin O
( O
dopamine O
d2 O
and O
d3 O
effects O
) O
. O

it O
increases O
the O
behaviour O
stimulation O
evoked O
by O
phenylephrine O
( O
given O
intraventricularly O
) O
in O
rats O
, O
evaluated O
in O
the O
open O
field O
test O
as O
well O
as O
the O
aggressiveness B-Disease
evoked O
by O
clonidine O
in O
mice O
, O
both O
these O
effects O
being O
mediated O
by O
an O
alpha1 O
- O
adrenergic O
receptor O
. O

pethidine O
- O
associated O
seizure B-Disease
in O
a O
healthy O
adolescent O
receiving O
pethidine O
for O
postoperative B-Disease
pain I-Disease
control O
. O

a O
healthy O
17 O
- O
year O
- O
old O
male O
received O
standard O
intermittent O
doses O
of O
pethidine O
via O
a O
patient O
- O
controlled O
analgesia O
( O
pca O
) O
pump O
for O
management O
of O
postoperative B-Disease
pain I-Disease
control O
. O

twenty O
- O
three O
h O
postoperatively O
he O
developed O
a O
brief O
self O
- O
limited O
seizure B-Disease
. O

no O
other O
risk O
factors O
for O
cns O
toxicity B-Disease
were O
identified O
. O

an O
increase B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
, O
accompanied O
by O
atrial B-Disease
fibrillation I-Disease
, O
agitation B-Disease
, O
incomprehensible B-Disease
shouts I-Disease
and O
loss B-Disease
of I-Disease
consciousness I-Disease
, O
was O
observed O
in O
an O
elderly O
, O
asa O
classification O
group O
ii O
, O
cardiovascularly O
medicated O
male O
, O
12 O
min O
after O
performance O
of O
axillary O
block O
with O
mepivacaine O
850 O
mg O
containing O
adrenaline O
0 O
. O

225 O
mg O
, O
for O
correction O
of O
dupuytren B-Disease
' I-Disease
s I-Disease
contracture I-Disease
. O

the O
block O
was O
successful O
and O
surgery O
was O
conducted O
as O
scheduled O
despite O
persisting O
atrial B-Disease
fibrillation I-Disease
. O

drug O
- O
associated O
acute O
- O
onset O
vanishing B-Disease
bile I-Disease
duct I-Disease
and O
stevens B-Disease
- I-Disease
johnson I-Disease
syndromes I-Disease
in O
a O
child O
. O

acute O
vanishing B-Disease
bile I-Disease
duct I-Disease
syndrome O
is O
a O
rare O
but O
established O
cause O
of O
progressive O
cholestasis B-Disease
in O
adults O
, O
is O
most O
often O
drug O
or O
toxin O
related O
, O
and O
is O
of O
unknown O
pathogenesis O
. O

stevens B-Disease
- I-Disease
johnson I-Disease
syndrome I-Disease
is O
a O
well O
- O
recognized O
immune O
complex O
- O
mediated O
hypersensitivity B-Disease
reaction O
that O
affects O
all O
age O
groups O
, O
is O
drug O
or O
infection B-Disease
induced O
, O
and O
has O
classic O
systemic O
, O
mucosal O
, O
and O
dermatologic O
manifestations O
. O

a O
previously O
healthy O
child O
who O
developed O
acute O
, O
severe O
, O
rapidly O
progressive O
vanishing B-Disease
bile I-Disease
duct I-Disease
syndrome I-Disease
shortly O
after O
stevens B-Disease
- I-Disease
johnson I-Disease
syndrome I-Disease
is O
described O
; O
this O
was O
temporally O
associated O
with O
ibuprofen O
use O
. O

despite O
therapy O
with O
ursodeoxycholic O
acid O
, O
prednisone O
, O
and O
then O
tacrolimus O
, O
her O
cholestatic B-Disease
disease I-Disease
was O
unrelenting O
, O
with O
cirrhosis B-Disease
shown O
by O
biopsy O
6 O
months O
after O
presentation O
. O

this O
case O
documents O
acute O
drug O
- O
related O
vanishing B-Disease
bile I-Disease
duct I-Disease
syndrome I-Disease
in O
the O
pediatric O
age O
group O
and O
suggests O
shared O
immune O
mechanisms O
in O
the O
pathogenesis O
of O
both O
stevens B-Disease
- I-Disease
johnson I-Disease
syndrome I-Disease
and O
vanishing B-Disease
bile I-Disease
duct I-Disease
syndrome I-Disease
. O

high O
incidence O
of O
primary B-Disease
pulmonary I-Disease
hypertension I-Disease
associated O
with O
appetite O
suppressants O
in O
belgium O
. O

primary B-Disease
pulmonary I-Disease
hypertension I-Disease
is O
a O
rare O
, O
progressive O
and O
incurable O
disease O
, O
which O
has O
been O
associated O
with O
the O
intake O
of O
appetite O
suppressant O
drugs O
. O

thirty O
- O
five O
patients O
with O
primary B-Disease
pulmonary I-Disease
hypertension I-Disease
and O
85 O
matched O
controls O
were O
recruited O
over O
32 O
months O
( O
1992 O
- O
1994 O
) O
in O
belgium O
. O

in O
8 O
patients O
the O
diagnosis O
of O
primary B-Disease
pulmonary I-Disease
hypertension I-Disease
was O
uncertain O
, O
5 O
of O
them O
had O
taken O
appetite O
suppressants O
. O

a O
policy O
of O
unrestricted O
prescription O
of O
appetite O
suppressants O
may O
lead O
to O
a O
high O
incidence O
of O
associated O
primary B-Disease
pulmonary I-Disease
hypertension I-Disease
. O

inappropriate O
use O
of O
carbamazepine O
and O
vigabatrin O
in O
typical O
absence B-Disease
seizures I-Disease
. O

carbamazepine O
and O
vigabatrin O
are O
contraindicated O
in O
typical O
absence B-Disease
seizures I-Disease
. O

frequency O
of O
absences O
increased O
in O
four O
children O
treated O
with O
carbamazepine O
and O
two O
of O
these O
developed O
myoclonic B-Disease
jerks I-Disease
, O
which O
resolved O
on O
withdrawal O
of O
carbamazepine O
. O

choreoathetoid B-Disease
movements I-Disease
associated O
with O
rapid O
adjustment O
to O
methadone O
. O

choreatiform B-Disease
hyperkinesias I-Disease
are O
known O
to O
be O
occasional O
movement B-Disease
abnormalities I-Disease
during O
intoxications O
with O
cocaine O
but O
not O
opiates O
. O

this O
is O
a O
case O
report O
of O
euphoria O
and O
choreoathetoid B-Disease
movements I-Disease
both O
transiently O
induced O
by O
rapid O
adjustment O
to O
the O
selective O
mu O
- O
opioid O
receptor O
agonist O
methadone O
in O
an O
inpatient O
previously O
abusing O
heroine O
and O
cocaine O
. O

conventional O
agents O
are O
associated O
with O
unwanted O
central O
nervous O
system O
effects O
, O
including O
extrapyramidal B-Disease
symptoms I-Disease
( O
eps B-Disease
) O
, O
tardive B-Disease
dyskinesia I-Disease
, O
sedation O
, O
and O
possible O
impairment O
of O
some O
cognitive O
measures O
, O
as O
well O
as O
cardiac O
effects O
, O
orthostatic B-Disease
hypotension I-Disease
, O
hepatic O
changes O
, O
anticholinergic O
side O
effects O
, O
sexual B-Disease
dysfunction I-Disease
, O
and O
weight B-Disease
gain I-Disease
. O

the O
newer O
atypical O
agents O
have O
a O
lower O
risk O
of O
eps B-Disease
, O
but O
are O
associated O
in O
varying O
degrees O
with O
sedation O
, O
cardiovascular O
effects O
, O
anticholinergic O
effects O
, O
weight B-Disease
gain I-Disease
, O
sexual B-Disease
dysfunction I-Disease
, O
hepatic O
effects O
, O
lowered O
seizure B-Disease
threshold O
( O
primarily O
clozapine O
) O
, O
and O
agranulocytosis B-Disease
( O
clozapine O
only O
) O
. O

a O
randomized O
, O
placebo O
- O
controlled O
dose O
- O
comparison O
trial O
of O
haloperidol O
for O
psychosis B-Disease
and O
disruptive B-Disease
behaviors I-Disease
in O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

objective O
: O
the O
goal O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
side O
effects O
of O
two O
doses O
of O
haloperidol O
and O
placebo O
in O
the O
treatment O
of O
psychosis B-Disease
and O
disruptive B-Disease
behaviors I-Disease
in O
patients O
with O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

method O
: O
in O
a O
6 O
- O
week O
random O
- O
assignment O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
( O
phase O
a O
) O
, O
haloperidol O
, O
2 O
- O
3 O
mg O
/ O
day O
( O
standard O
dose O
) O
, O
and O
haloperidol O
, O
0 O
. O

50 O
- O
0 O
. O

75 O
mg O
/ O
day O
( O
low O
dose O
) O
, O
were O
compared O
in O
71 O
outpatients O
with O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

results O
: O
for O
the O
60 O
patients O
who O
completed O
phase O
a O
, O
standard O
- O
dose O
haloperidol O
was O
efficacious O
and O
superior O
to O
both O
low O
- O
dose O
haloperidol O
and O
placebo O
for O
scores O
on O
the O
brief O
psychiatric O
rating O
scale O
psychosis B-Disease
factor O
and O
on O
psychomotor B-Disease
agitation I-Disease
. O

in O
phase O
a O
, O
extrapyramidal B-Disease
signs I-Disease
tended O
to O
be O
greater O
with O
the O
standard O
dose O
than O
in O
the O
other O
two O
conditions O
, O
primarily O
because O
of O
a O
subgroup O
( O
20 O
% O
) O
who O
developed O
moderate O
to O
severe O
signs O
. O

conclusions O
: O
the O
results O
indicated O
a O
favorable O
therapeutic O
profile O
for O
haloperidol O
in O
doses O
of O
2 O
- O
3 O
mg O
/ O
day O
, O
although O
a O
subgroup O
developed O
moderate O
to O
severe O
extrapyramidal B-Disease
signs I-Disease
. O

the O
narrow O
therapeutic O
window O
observed O
with O
haloperidol O
may O
also O
apply O
to O
other O
neuroleptics O
used O
in O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
patients O
with O
psychosis B-Disease
and O
disruptive B-Disease
behaviors I-Disease
. O

effects O
of O
acetylsalicylic O
acid O
, O
dipyridamole O
, O
and O
hydrocortisone O
on O
epinephrine O
- O
induced O
myocardial B-Disease
injury I-Disease
in O
dogs O
. O

a O
reproducible O
model O
for O
producing O
diffuse O
myocardial B-Disease
injury I-Disease
( O
epinephrine O
infusion O
) O
has O
been O
developed O
to O
study O
the O
cardioprotective O
effects O
of O
agents O
or O
maneuvers O
which O
might O
alter O
the O
evolution O
of O
acute O
myocardial B-Disease
infarction I-Disease
. O

results O
: O
the O
main O
pathologic O
diagnoses O
( O
some O
overlap O
) O
were O
acute O
rejection O
( O
ar O
; O
n O
= O
4 O
) O
, O
chronic O
rejection O
( O
cr O
; O
n O
= O
5 O
) O
, O
ar O
+ O
cr O
( O
n O
= O
4 O
) O
, O
recurrent O
iga B-Disease
nephropathy I-Disease
( O
n O
= O
5 O
) O
, O
normal O
findings O
( O
n O
= O
2 O
) O
, O
minimal O
- O
type O
chronic O
fk506 O
nephropathy B-Disease
( O
n O
= O
9 O
) O
, O
and O
mild O
- O
type O
fk506 O
nephropathy B-Disease
( O
n O
= O
11 O
) O
. O

of O
the O
nonepisode O
biopsies O
, O
7 O
and O
4 O
biopsies O
showed O
minimal O
- O
type O
and O
mild O
- O
type O
chronic O
fk506 O
nephropathy B-Disease
, O
respectively O
. O

chronic O
fk506 O
nephropathy B-Disease
consisted O
of O
rough O
and O
foamy O
tubular O
vacuolization O
( O
5 O
biopsies O
) O
, O
arteriolopathy O
( O
angiodegeneration O
of O
the O
arteriolar O
wall O
; O
20 O
biopsies O
) O
, O
focal B-Disease
segmental I-Disease
glomerulosclerosis I-Disease
( O
4 O
biopsies O
) O
and O
the O
striped O
form O
of O
interstitial B-Disease
fibrosis I-Disease
( O
11 O
biopsies O
) O
. O

the O
serum O
creatinine O
levels O
of O
patients O
in O
the O
mild O
- O
type O
chronic O
fk506 O
nephropathy B-Disease
group O
, O
which O
included O
7 O
episode O
biopsies O
, O
were O
statistically O
higher O
than O
those O
in O
the O
minimum O
- O
type O
chronic O
fk506 O
- O
nephropathy B-Disease
group O
( O
p O
< O
0 O
. O

1 O
) O
. O

conclusions O
: O
this O
study O
demonstrates O
that O
chronic O
fk506 O
nephropathy B-Disease
consists O
primarily O
of O
arteriolopathy O
manifesting O
as O
insudative O
hyalinosis O
of O
the O
arteriolar O
wall O
, O
and O
suggests O
that O
mild O
- O
type O
chronic O
fk506 O
nephropathy B-Disease
is O
a O
condition O
which O
may O
lead O
to O
deterioration O
of O
renal O
allograft O
function O
. O

different O
lobular O
distributions O
of O
altered O
hepatocyte O
tight O
junctions O
in O
rat O
models O
of O
intrahepatic B-Disease
and I-Disease
extrahepatic I-Disease
cholestasis I-Disease
. O

although O
hepatocyte O
tjs O
are O
impaired O
in O
cholestasis B-Disease
, O
attempts O
to O
localize O
the O
precise O
site O
of O
hepatocyte O
tj O
damage O
by O
freeze O
- O
fracture O
electron O
microscopy O
have O
produced O
limited O
information O
. O

we O
used O
rat O
models O
of O
intrahepatic B-Disease
cholestasis I-Disease
by O
ethinyl O
estradiol O
( O
ee O
) O
treatment O
and O
extrahepatic B-Disease
cholestasis I-Disease
by O
bile O
duct O
ligation O
( O
bdl O
) O
to O
precisely O
determine O
the O
site O
of O
tj O
damage O
. O

in O
the O
mouse O
passive O
- O
avoidance O
test O
, O
pg O
- O
9 O
( O
10 O
- O
30 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
, O
administered O
20 O
min O
before O
the O
training O
session O
, O
prevented O
amnesia B-Disease
induced O
by O
both O
the O
non O
selective O
antimuscarinic O
drug O
scopolamine O
and O
the O
m1 O
- O
selective O
antagonist O
s O
- O
( O
- O
) O
- O
et O
- O
126 O
. O

in O
the O
same O
experimental O
conditions O
, O
pg O
- O
9 O
( O
5 O
- O
20 O
microg O
per O
mouse O
, O
i O
. O

c O
. O

v O
. O

) O
was O
also O
able O
to O
prevent O
antimuscarine O
- O
induced O
amnesia B-Disease
, O
demonstrating O
a O
central O
localization O
of O
the O
activity O
. O

mechanisms O
of O
fk O
506 O
- O
induced O
hypertension B-Disease
in O
the O
rat O
. O

the O
clinical O
utility O
of O
fk O
506 O
is O
complicated O
by O
substantial O
hypertension B-Disease
and O
nephrotoxicity B-Disease
. O

to O
clarify O
the O
mechanisms O
of O
fk O
506 O
- O
induced O
hypertension B-Disease
, O
we O
studied O
the O
chronic O
effects O
of O
fk O
506 O
on O
the O
synthesis O
of O
endothelin O
- O
1 O
( O
et O
- O
1 O
) O
, O
the O
expression O
of O
mrna O
of O
et O
- O
1 O
and O
endothelin O
- O
converting O
enzyme O
- O
1 O
( O
ece O
- O
1 O
) O
, O
the O
endothelial O
nitric O
oxide O
synthase O
( O
enos O
) O
activity O
, O
and O
the O
expression O
of O
mrna O
of O
enos O
and O
c O
- O
type O
natriuretic O
peptide O
( O
cnp O
) O
in O
rat O
blood O
vessels O
. O

in O
addition O
, O
the O
effect O
of O
the O
specific O
endothelin O
type O
a O
receptor O
antagonist O
fr O
139317 O
on O
fk O
506 O
- O
induced O
hypertension B-Disease
in O
rats O
was O
studied O
. O

the O
administration O
of O
fr O
139317 O
( O
10 O
mg O
. O

kg O
- O
1 O
. O

d O
- O
1 O
) O
prevented O
fk O
506 O
- O
induced O
hypertension B-Disease
in O
rats O
. O

torsade B-Disease
de I-Disease
pointes I-Disease
ventricular B-Disease
tachycardia I-Disease
during O
low O
dose O
intermittent O
dobutamine O
treatment O
in O
a O
patient O
with O
dilated B-Disease
cardiomyopathy I-Disease
and O
congestive B-Disease
heart I-Disease
failure I-Disease
. O

the O
authors O
describe O
the O
case O
of O
a O
56 O
- O
year O
- O
old O
woman O
with O
chronic O
, O
severe O
heart B-Disease
failure I-Disease
secondary O
to O
dilated B-Disease
cardiomyopathy I-Disease
and O
absence O
of O
significant O
ventricular B-Disease
arrhythmias I-Disease
who O
developed O
qt B-Disease
prolongation I-Disease
and O
torsade B-Disease
de I-Disease
pointes I-Disease
ventricular B-Disease
tachycardia I-Disease
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2 O
. O

5 O
mcg O
/ O
kg O
per O
min O
) O
dobutamine O
. O

this O
report O
of O
torsade B-Disease
de I-Disease
pointes I-Disease
ventricular B-Disease
tachycardia I-Disease
during O
intermittent O
dobutamine O
supports O
the O
hypothesis O
that O
unpredictable O
fatal O
arrhythmias B-Disease
may O
occur O
even O
with O
low O
doses O
and O
in O
patients O
with O
no O
history O
of O
significant O
rhythm O
disturbances O
. O

after O
angiography O
by O
the O
venous O
route O
in O
patient O
n O
degree O
1 O
a O
biphasic O
reaction O
with O
an O
immediate O
reaction O
( O
dyspnea B-Disease
, O
loss B-Disease
of I-Disease
consciousness I-Disease
) O
and O
delayed O
macro B-Disease
- I-Disease
papular I-Disease
rash I-Disease
appeared O
, O
whilst O
patient O
n O
degree O
2 O
developed O
a O
generalised O
sensation O
of O
heat O
, O
persistent O
pain B-Disease
at O
the O
site O
of O
injection O
immediately O
and O
a O
generalised O
macro O
- O
papular O
reaction O
after O
24 O
hours O
. O

the O
positive O
skin O
tests O
are O
in O
favour O
of O
immunological O
reactions O
and O
may O
help O
in O
diagnosis O
of O
allergy B-Disease
in O
the O
patients O
. O

risk O
of O
transient O
hyperammonemic B-Disease
encephalopathy I-Disease
in O
cancer B-Disease
patients O
who O
received O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
with O
the O
complication O
of O
dehydration B-Disease
and O
infection B-Disease
. O

from O
1986 O
to O
1998 O
, O
29 O
cancer B-Disease
patients O
who O
had O
32 O
episodes O
of O
transient O
hyperammonemic B-Disease
encephalopathy I-Disease
related O
to O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
were O
identified O
. O

none O
of O
the O
patients O
had O
decompensated O
liver B-Disease
disease I-Disease
. O

onset O
of O
hyperammonemic B-Disease
encephalopathy I-Disease
varied O
from O
0 O
. O

5 O
to O
5 O
days O
( O
mean O
: O
2 O
. O

6 O
+ O
/ O
- O
1 O
. O

3 O
days O
) O
after O
the O
initiation O
of O
chemotherapy O
. O

among O
the O
32 O
episodes O
, O
26 O
( O
81 O
% O
) O
had O
various O
degrees O
of O
azotemia B-Disease
, O
18 O
( O
56 O
% O
) O
occurred O
during O
bacterial B-Disease
infections I-Disease
and O
14 O
( O
44 O
% O
) O
without O
infection B-Disease
occurred O
during O
periods O
of O
dehydration B-Disease
. O

higher O
plasma O
ammonium O
levels O
and O
more O
rapid O
onset O
of O
hyperammonemia B-Disease
were O
seen O
in O
18 O
patients O
with O
bacterial B-Disease
infections I-Disease
( O
p O
= O
0 O
. O

3 O
and O
0 O
. O

6 O
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
2600 O
or O
1800 O
mg O
/ O
m2 O
) O
of O
5 O
- O
fu O
( O
p O
= O
0 O
. O

1 O
and O
< O
0 O
. O

1 O
, O
respectively O
) O
. O

in O
conclusion O
, O
hyperammonemic B-Disease
encephalopathy I-Disease
can O
occur O
in O
patients O
receiving O
continuous O
infusion O
of O
5 O
- O
fu O
. O

azotemia B-Disease
, O
body O
fluid O
insufficiency O
and O
bacterial B-Disease
infections I-Disease
were O
frequently O
found O
in O
these O
patients O
. O

in O
the O
motor O
activity O
test O
measured O
with O
an O
animex O
- O
activity O
meter O
neither O
of O
the O
k O
( O
+ O
) O
- O
channel O
blockers O
affected O
morphine O
- O
induced O
hypoactivity B-Disease
, O
but O
both O
k O
( O
+ O
) O
- O
channel O
blockers O
prevented O
morphine O
- O
induced O
secondary O
hyperactivity B-Disease
. O

it O
is O
also O
suggested O
that O
the O
blockade O
of O
k O
( O
+ O
) O
- O
channels O
sensitive O
to O
these O
blockers O
is O
not O
sufficient O
to O
prevent O
morphine O
- O
induced O
hypoactivity B-Disease
whereas O
morphine O
- O
induced O
hyperactivity B-Disease
seems O
to O
be O
connected O
to O
both O
quinine O
- O
and O
4 O
- O
aminopyridine O
- O
sensitive O
k O
( O
+ O
) O
- O
channels O
. O

nociceptin O
/ O
orphanin O
fq O
and O
nocistatin O
on O
learning B-Disease
and I-Disease
memory I-Disease
impairment I-Disease
induced O
by O
scopolamine O
in O
mice O
. O

on O
the O
other O
hand O
, O
nocistatin O
is O
recently O
isolated O
from O
the O
same O
precursor O
as O
nociceptin O
and O
blocks O
nociceptin O
- O
induced O
allodynia B-Disease
and O
hyperalgesia B-Disease
. O

the O
present O
study O
was O
designed O
to O
investigate O
whether O
nociceptin O
/ O
orphanin O
fq O
and O
nocistatin O
could O
modulate O
impairment B-Disease
of I-Disease
learning I-Disease
and I-Disease
memory I-Disease
induced O
by O
scopolamine O
, O
a O
muscarinic O
cholinergic O
receptor O
antagonist O
, O
using O
spontaneous O
alternation O
of O
y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoidance O
tasks O
in O
mice O
. O

meloxicam O
- O
induced O
liver B-Disease
toxicity I-Disease
. O

we O
report O
the O
case O
of O
a O
female O
patient O
with O
rheumatoid B-Disease
arthritis I-Disease
who O
developed O
acute O
cytolytic O
hepatitis B-Disease
due O
to O
meloxicam O
. O

the O
acute O
cytolytic O
hepatitis B-Disease
occurred O
rapidly O
after O
meloxicam O
administration O
and O
was O
associated O
with O
the O
development O
of O
antinuclear O
antibodies O
suggesting O
a O
hypersensitivity B-Disease
mechanism O
. O

this O
first O
case O
of O
meloxicam O
related O
liver B-Disease
toxicity I-Disease
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
hepatic B-Disease
damage I-Disease
. O

induction O
of O
apoptosis O
by O
remoxipride O
metabolites O
in O
hl60 O
and O
cd34 O
+ O
/ O
cd19 O
- O
human O
bone O
marrow O
progenitor O
cells O
: O
potential O
relevance O
to O
remoxipride O
- O
induced O
aplastic B-Disease
anemia I-Disease
. O

the O
antipsychotic O
agent O
, O
remoxipride O
[ O
( O
s O
) O
- O
( O
- O
) O
- O
3 O
- O
bromo O
- O
n O
- O
[ O
( O
1 O
- O
ethyl O
- O
2 O
- O
pyrrolidinyl O
) O
methyl O
] O
- O
2 O
, O
6 O
- O
dimethoxybenz O
amide O
] O
has O
been O
associated O
with O
acquired O
aplastic B-Disease
anemia I-Disease
. O

no O
necrosis B-Disease
was O
observed O
in O
cells O
treated O
with O
ncq436 O
but O
ncq344 O
had O
a O
biphasic O
effect O
in O
both O
cell O
types O
, O
inducing O
apoptosis O
at O
lower O
concentrations O
and O
necrosis B-Disease
at O
higher O
concentrations O
. O

we O
propose O
that O
remoxipride O
and O
benzene O
may O
induce O
aplastic B-Disease
anemia I-Disease
via O
production O
of O
similar O
reactive O
metabolites O
and O
that O
the O
ability O
of O
ncq436 O
and O
ncq344 O
to O
induce O
apoptosis O
in O
hbmp O
cells O
may O
contribute O
to O
the O
mechanism O
underlying O
acquired O
aplastic B-Disease
anemia I-Disease
that O
has O
been O
associated O
with O
remoxipride O
. O

7e O
exhibits O
a O
high O
reversal O
of O
catalepsy B-Disease
induced O
by O
haloperidol O
indicating O
its O
atypical O
antipsychotic O
nature O
. O

sub O
- O
chronic O
inhibition O
of O
nitric O
- O
oxide O
synthesis O
modifies O
haloperidol O
- O
induced O
catalepsy B-Disease
and O
the O
number O
of O
nadph O
- O
diaphorase O
neurons O
in O
mice O
. O

rationale O
: O
ng O
- O
nitro O
- O
l O
- O
arginine O
( O
l O
- O
noarg O
) O
, O
an O
inhibitor O
of O
nitric O
- O
oxide O
synthase O
( O
nos O
) O
, O
induces O
catalepsy B-Disease
in O
mice O
. O

neuroleptic O
drugs O
such O
as O
haloperidol O
, O
which O
block O
dopamine O
receptors O
, O
also O
cause O
catalepsy B-Disease
in O
rodents O
. O

objectives O
: O
to O
investigate O
the O
effects O
of O
subchronic O
l O
- O
noarg O
treatment O
in O
haloperidol O
- O
induced O
catalepsy B-Disease
and O
the O
number O
of O
nos O
neurons O
in O
areas O
related O
to O
motor O
control O
. O

catalepsy B-Disease
was O
evaluated O
at O
the O
beginning O
and O
the O
end O
of O
the O
treatments O
. O

results O
: O
l O
- O
noarg O
sub O
- O
chronic O
administration O
produced O
tolerance O
of O
l O
- O
noarg O
and O
of O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

prolonged O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
occurs O
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
after O
both O
dobutamine O
and O
exercise O
induced O
myocardial B-Disease
ischaemia I-Disease
. O

objective O
: O
to O
determine O
whether O
pharmacological O
stress O
leads O
to O
prolonged O
but O
reversible O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
similar O
to O
that O
seen O
after O
exercise O
. O

design O
: O
a O
randomised O
crossover O
study O
of O
recovery O
time O
of O
systolic O
and O
diastolic O
left O
ventricular O
function O
after O
exercise O
and O
dobutamine O
induced O
ischaemia B-Disease
. O

subjects O
: O
10 O
patients O
with O
stable B-Disease
angina I-Disease
, O
angiographically O
proven O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
and O
normal O
left O
ventricular O
function O
. O

there O
was O
no O
difference O
in O
the O
maximum O
double O
product O
( O
p O
= O
0 O
. O

53 O
) O
or O
st O
depression B-Disease
( O
p O
= O
0 O
. O

63 O
) O
with O
either O
form O
of O
stress O
. O

conclusions O
: O
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
dobutamine O
induced O
ischaemia B-Disease
results O
in O
prolonged O
reversible O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
, O
presumed O
to O
be O
myocardial B-Disease
stunning I-Disease
, O
similar O
to O
that O
seen O
after O
exercise O
. O

dobutamine O
induced O
ischaemia B-Disease
could O
therefore O
be O
used O
to O
study O
the O
pathophysiology O
of O
this O
phenomenon O
further O
in O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

anorexigens O
and O
pulmonary B-Disease
hypertension I-Disease
in O
the O
united O
states O
: O
results O
from O
the O
surveillance O
of O
north O
american O
pulmonary B-Disease
hypertension I-Disease
. O

background O
: O
the O
use O
of O
appetite O
suppressants O
in O
europe O
has O
been O
associated O
with O
the O
development O
of O
primary B-Disease
pulmonary I-Disease
hypertension I-Disease
( O
pph B-Disease
) O
. O

materials O
and O
methods O
: O
we O
conducted O
a O
prospective O
surveillance O
study O
on O
patients O
diagnosed O
with O
pulmonary B-Disease
hypertension I-Disease
at O
12 O
large O
referral O
centers O
in O
north O
america O
. O

data O
collected O
on O
patients O
seen O
from O
september O
1 O
, O
1996 O
, O
to O
december O
31 O
, O
1997 O
, O
included O
the O
cause O
of O
the O
pulmonary B-Disease
hypertension I-Disease
and O
its O
severity O
. O

patients O
with O
no O
identifiable O
cause O
of O
pulmonary B-Disease
hypertension I-Disease
were O
classed O
as O
pph B-Disease
. O

results O
: O
five O
hundred O
seventy O
- O
nine O
patients O
were O
studied O
, O
205 O
with O
pph B-Disease
and O
374 O
with O
pulmonary B-Disease
hypertension I-Disease
from O
other O
causes O
( O
secondary O
pulmonary B-Disease
hypertension I-Disease
[ O
sph O
] O
) O
. O

however O
, O
of O
the O
medications O
surveyed O
, O
only O
the O
fenfluramines O
had O
a O
significant O
preferential O
association O
with O
pph B-Disease
as O
compared O
with O
sph O
( O
adjusted O
odds O
ratio O
for O
use O
> O
6 O
months O
, O
7 O
. O

5 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O

7 O
to O
32 O
. O

4 O
) O
. O

conclusion O
: O
the O
magnitude O
of O
the O
association O
with O
pph B-Disease
, O
the O
increase O
of O
association O
with O
increasing O
duration O
of O
use O
, O
and O
the O
specificity O
for O
fenfluramines O
are O
consistent O
with O
previous O
studies O
indicating O
that O
fenfluramines O
are O
causally O
related O
to O
pph B-Disease
. O

the O
high O
prevalence O
of O
anorexigen O
use O
in O
patients O
with O
sph O
also O
raises O
the O
possibility O
that O
these O
drugs O
precipitate O
pulmonary B-Disease
hypertension I-Disease
in O
patients O
with O
underlying O
conditions O
associated O
with O
sph O
. O

clinical O
aspects O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
and O
thrombosis B-Disease
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

heparin O
, O
first O
used O
to O
prevent O
the O
clotting O
of O
blood O
in O
vitro O
, O
has O
been O
clinically O
used O
to O
treat O
thrombosis B-Disease
for O
more O
than O
50 O
years O
. O

although O
several O
new O
anticoagulant O
drugs O
are O
in O
development O
, O
heparin O
remains O
the O
anticoagulant O
of O
choice O
to O
treat O
acute O
thrombotic B-Disease
episodes O
. O

bleeding B-Disease
is O
the O
primary O
untoward O
effect O
of O
heparin O
. O

major O
bleeding B-Disease
is O
of O
primary O
concern O
in O
patients O
receiving O
heparin O
therapy O
. O

however O
, O
additional O
important O
untoward O
effects O
of O
heparin O
therapy O
include O
heparin O
- O
induced O
thrombocytopenia B-Disease
, O
heparin O
- O
associated O
osteoporosis B-Disease
, O
eosinophilia B-Disease
, O
skin B-Disease
reactions I-Disease
, O
allergic B-Disease
reactions I-Disease
other O
than O
thrombocytopenia B-Disease
, O
alopecia B-Disease
, O
transaminasemia O
, O
hyperkalemia B-Disease
, O
hypoaldosteronism B-Disease
, O
and O
priapism B-Disease
. O

these O
side O
effects O
are O
relatively O
rare O
in O
a O
given O
individual O
, O
but O
given O
the O
extremely O
widespread O
use O
of O
heparin O
, O
some O
are O
quite O
common O
, O
particularly O
hitt B-Disease
and O
osteoporosis B-Disease
. O

a O
case O
of O
bilateral O
optic B-Disease
neuropathy I-Disease
in O
a O
patient O
on O
tacrolimus O
( O
fk506 O
) O
therapy O
after O
liver O
transB-Plantation O
. O

purpose O
: O
to O
report O
a O
case O
of O
bilateral O
optic B-Disease
neuropathy I-Disease
in O
a O
patient O
receiving O
tacrolimus O
( O
fk O
506 O
, O
prograf O
; O
fujisawa O
usa O
, O
inc O
, O
deerfield O
, O
illinois O
) O
for O
immunosuppression O
after O
orthotropic O
liver O
transB-Plantation O
. O

results O
: O
the O
patient O
had O
episodic O
deterioration O
of O
vision O
in O
both O
eyes O
, O
with O
clinical O
features O
resembling O
ischemic B-Disease
optic I-Disease
neuropathies I-Disease
. O

deterioration B-Disease
of I-Disease
vision I-Disease
occurred O
despite O
discontinuation O
of O
the O
tacrolimus O
. O

conclusion O
: O
tacrolimus O
and O
other O
immunosuppressive O
agents O
may O
be O
associated O
with O
optic B-Disease
nerve I-Disease
toxicity I-Disease
. O

hypercalcemia B-Disease
, O
arrhythmia B-Disease
, O
and O
mood O
stabilizers O
. O

recent O
findings O
in O
a O
bipolar B-Disease
patient O
receiving O
maintenance O
lithium O
therapy O
who O
developed O
hypercalcemia B-Disease
and O
severe O
bradyarrhythmia B-Disease
prompted O
the O
authors O
to O
conduct O
a O
retrospective O
study O
of O
bipolar B-Disease
patients O
with O
lithium O
- O
associated O
hypercalcemia B-Disease
. O

a O
printout O
of O
all O
cases O
of O
hypercalcemia B-Disease
that O
presented O
during O
a O
1 O
- O
year O
period O
was O
generated O
. O

after O
eliminating O
spurious O
hypercalcemias B-Disease
or O
those O
associated O
with O
intravenous O
fluids O
, O
the O
authors O
identified O
18 O
non O
- O
lithium O
- O
treated O
patients O
with O
hypercalcemias B-Disease
related O
to O
malignancies B-Disease
and O
other O
medical O
conditions O
( O
group O
a O
) O
and O
12 O
patients O
with O
lithium O
- O
associated O
hypercalcemia B-Disease
( O
group O
b O
) O
. O

thus O
, O
two O
control O
groups O
were O
generated O
: O
group O
c1 O
, O
which O
included O
age O
- O
and O
sex O
- O
comparable O
lithium O
- O
treated O
bipolar B-Disease
normocalcemic O
patients O
, O
and O
group O
c2 O
, O
which O
included O
bipolar B-Disease
normocalcemic O
patients O
treated O
with O
anticonvulsant O
mood O
stabilizers O
. O

patients O
with O
hypercalcemia B-Disease
resulting O
from O
medical O
diseases O
and O
bipolar B-Disease
patients O
with O
lithium O
- O
associated O
hypercalcemia B-Disease
had O
significantly O
higher O
frequencies O
of O
conduction O
defects O
. O

attenuation O
of O
nephrotoxicity B-Disease
by O
a O
novel O
lipid O
nanosphere O
( O
ns O
- O
718 O
) O
incorporating O
amphotericin O
b O
. O

ns O
- O
718 O
, O
a O
lipid O
nanosphere O
incorporating O
amphotericin O
b O
, O
is O
effective O
against O
pathogenic O
fungi O
and O
has O
low O
toxicity B-Disease
. O

we O
compared O
the O
toxicity B-Disease
of O
ns O
- O
718 O
with O
that O
of O
fungizone O
( O
amphotericin O
b O
- O
sodium O
deoxycholate O
; O
d O
- O
amb O
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin O
b O
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

histopathological O
examination O
of O
the O
kidney O
showed O
tubular B-Disease
necrosis I-Disease
in O
d O
- O
amb O
- O
treated O
rats O
but O
no O
change O
in O
ns O
- O
718 O
- O
treated O
rats O
. O

our O
in O
vitro O
and O
in O
vivo O
results O
suggest O
that O
incorporation O
of O
amphotericin O
b O
into O
lipid O
nanospheres O
of O
ns O
- O
718 O
attenuates O
the O
nephrotoxicity B-Disease
of O
amphotericin O
b O
. O

patterns O
of O
sulfadiazine O
acute B-Disease
nephrotoxicity I-Disease
. O

sulfadiazine O
acute B-Disease
nephrotoxicity I-Disease
is O
reviving O
specially O
because O
of O
its O
use O
in O
toxoplasmosis B-Disease
in O
hiv O
- O
positive O
patients O
. O

under O
treatment O
with O
sulfadiazine O
they O
developed O
oliguria B-Disease
, O
abdominal B-Disease
pain I-Disease
, O
renal B-Disease
failure I-Disease
and O
showed O
multiple O
radiolucent O
renal B-Disease
calculi I-Disease
in O
echography O
. O

a O
nephrostomy O
tube O
had O
to O
be O
placed O
in O
one O
of O
the O
patients O
for O
ureteral B-Disease
lithiasis I-Disease
in O
a O
single O
functional O
kidney O
. O

downbeat B-Disease
nystagmus I-Disease
associated O
with O
intravenous O
patient O
- O
controlled O
administration O
of O
morphine O
. O

implications O
: O
this O
case O
documents O
a O
patient O
who O
developed O
dizziness B-Disease
with O
downbeating B-Disease
nystagmus I-Disease
while O
receiving O
a O
relatively O
large O
dose O
of O
iv O
patient O
- O
controlled O
analgesia O
morphine O
. O

hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone O
and O
amiodarone O
in O
animals O
with O
a O
healed O
myocardial B-Disease
infarction I-Disease
. O

the O
hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone O
, O
a O
noniodinated O
compound O
structurally O
related O
to O
amiodarone O
, O
were O
compared O
with O
those O
of O
amiodarone O
after O
prolonged O
oral O
administration O
, O
both O
at O
rest O
and O
during O
sympathetic O
stimulation O
in O
conscious O
dogs O
with O
a O
healed O
myocardial B-Disease
infarction I-Disease
. O

both O
dronedarone O
and O
amiodarone O
significantly O
reduced O
the O
exercise O
- O
induced O
tachycardia B-Disease
and O
, O
at O
the O
highest O
dose O
, O
decreased O
the O
isoproterenol O
- O
induced O
tachycardia B-Disease
. O

consequently O
, O
dronedarone O
might O
be O
particularly O
suitable O
for O
the O
treatment O
and O
prevention O
of O
various O
clinical O
arrhythmias B-Disease
, O
without O
compromising O
the O
left O
ventricular O
function O
. O

phase O
2 O
trial O
of O
liposomal O
doxorubicin O
( O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
in O
platinum O
/ O
paclitaxel O
- O
refractory O
ovarian B-Disease
and I-Disease
fallopian I-Disease
tube I-Disease
cancers I-Disease
and O
primary O
carcinoma B-Disease
of I-Disease
the I-Disease
peritoneum I-Disease
. O

background O
: O
several O
studies O
have O
demonstrated O
liposomal O
doxorubicin O
( O
doxil O
) O
to O
be O
an O
active O
antineoplastic O
agent O
in O
platinum O
- O
resistant O
ovarian B-Disease
cancer I-Disease
, O
with O
dose O
limiting O
toxicity B-Disease
of O
the O
standard O
dosing O
regimen O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
) O
being O
severe O
erythrodysesthesia B-Disease
( O
nan O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
nan O
) O
and O
stomatitis B-Disease
. O

methods O
and O
materials O
: O
patients O
with O
ovarian B-Disease
or I-Disease
fallopian I-Disease
tube I-Disease
cancers I-Disease
or O
primary O
peritoneal B-Disease
carcinoma I-Disease
with O
platinum O
/ O
paclitaxel O
- O
refractory O
disease O
( O
stable O
or O
progressive O
disease O
following O
treatment O
with O
these O
agents O
or O
previous O
objective O
response O
< O
3 O
months O
in O
duration O
) O
were O
treated O
with O
liposomal O
doxorubicin O
at O
a O
dose O
of O
40 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
. O

six O
( O
12 O
% O
) O
and O
4 O
( O
8 O
% O
) O
patients O
experienced O
grade O
2 O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
and O
stomatitis B-Disease
, O
respectively O
( O
no O
episodes O
of O
grade O
3 O
) O
. O

one O
patient O
developed O
grade O
3 O
diarrhea B-Disease
requiring O
hospitalization O
for O
hydration O
. O

conclusion O
: O
this O
modified O
liposomal O
doxorubicin O
regimen O
results O
in O
less O
toxicity B-Disease
( O
stomatitis B-Disease
, O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
) O
than O
the O
standard O
fda O
- O
approved O
dose O
schedule O
. O

definite O
, O
although O
limited O
, O
antineoplastic O
activity O
is O
observed O
in O
patients O
with O
well O
- O
defined O
platinum O
- O
and O
paclitaxel O
- O
refractory O
ovarian B-Disease
cancer I-Disease
. O

efficacy O
of O
olanzapine O
in O
acute O
bipolar B-Disease
mania I-Disease
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
. O

background O
: O
we O
compared O
the O
efficacy O
and O
safety O
of O
olanzapine O
vs O
placebo O
for O
the O
treatment O
of O
acute O
bipolar B-Disease
mania I-Disease
. O

a O
total O
of O
115 O
patients O
with O
a O
dsm O
- O
iv O
diagnosis O
of O
bipolar B-Disease
disorder I-Disease
, O
manic B-Disease
or O
mixed O
, O
were O
randomized O
to O
olanzapine O
, O
5 O
to O
20 O
mg O
/ O
d O
( O
n O
= O
55 O
) O
, O
or O
placebo O
( O
n O
= O
60 O
) O
. O

the O
primary O
efficacy O
measure O
was O
the O
young O
- O
mania B-Disease
rating O
scale O
( O
y O
- O
mrs O
) O
total O
score O
. O

safety O
was O
assessed O
using O
adverse O
events O
, O
extrapyramidal B-Disease
symptom I-Disease
( O
eps B-Disease
) O
rating O
scales O
, O
laboratory O
values O
, O
electrocardiograms O
, O
vital O
signs O
, O
and O
weight O
change O
. O

there O
were O
no O
statistically O
significant O
differences O
in O
epss B-Disease
between O
groups O
. O

however O
, O
olanzapine O
- O
treated O
patients O
had O
a O
statistically O
significant O
greater O
mean O
( O
+ O
/ O
- O
sd O
) O
weight B-Disease
gain I-Disease
than O
placebo O
- O
treated O
patients O
( O
2 O
. O

1 O
+ O
/ O
- O
2 O
. O

8 O
vs O
0 O
. O

45 O
+ O
/ O
- O
2 O
. O

3 O
kg O
, O
respectively O
) O
and O
also O
experienced O
more O
treatment O
- O
emergent O
somnolence B-Disease
( O
21 O
patients O
[ O
38 O
. O

2 O
% O
] O
vs O
5 O
[ O
8 O
. O

3 O
% O
] O
, O
respectively O
) O
. O

conclusion O
: O
olanzapine O
demonstrated O
greater O
efficacy O
than O
placebo O
in O
the O
treatment O
of O
acute O
bipolar B-Disease
mania I-Disease
and O
was O
generally O
well O
tolerated O
. O

the O
effect O
of O
pupil B-Disease
dilation I-Disease
with O
tropicamide O
on O
vision O
and O
driving O
simulator O
performance O
. O

purpose O
: O
to O
assess O
the O
effect O
of O
pupil B-Disease
dilation I-Disease
on O
vision O
and O
driving O
ability O
. O

methods O
: O
a O
series O
of O
tests O
on O
various O
parameters O
of O
visual O
function O
and O
driving O
simulator O
performance O
were O
performed O
on O
12 O
healthy O
drivers O
, O
before O
and O
after O
pupil B-Disease
dilation I-Disease
using O
guttae O
tropicamide O
1 O
% O
. O

results O
: O
pupillary B-Disease
dilation I-Disease
resulted O
in O
a O
statistically O
significant O
deterioration O
in O
ct O
and O
hcva O
only O
. O

conclusions O
: O
pupillary B-Disease
dilation I-Disease
may O
lead O
to O
a O
decrease O
in O
vision O
and O
daylight O
driving O
performance O
in O
young O
people O
. O

a O
case O
of O
isotretinoin B-Disease
embryopathy I-Disease
with O
bilateral O
anotia B-Disease
and O
taussig B-Disease
- I-Disease
bing I-Disease
malformation I-Disease
. O

we O
report O
a O
newborn O
infant O
with O
multiple O
congenital O
anomalies O
( O
anotia B-Disease
and O
taussig B-Disease
- I-Disease
bing I-Disease
malformation I-Disease
) O
due O
to O
exposure O
to O
isotretinoin O
within O
the O
first O
trimester O
. O

effect O
of O
methoxamine O
on O
maximum O
urethral O
pressure O
in O
women O
with O
genuine O
stress B-Disease
incontinence I-Disease
: O
a O
placebo O
- O
controlled O
, O
double O
- O
blind O
crossover O
study O
. O

the O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
potential O
role O
for O
a O
selective O
alpha1 O
- O
adrenoceptor O
agonist O
in O
the O
treatment O
of O
urinary B-Disease
stress I-Disease
incontinence I-Disease
. O

half O
log O
incremental O
doses O
of O
intravenous O
methoxamine O
or O
placebo O
( O
saline O
) O
were O
administered O
to O
a O
group O
of O
women O
with O
genuine O
stress B-Disease
incontinence I-Disease
while O
measuring O
maximum O
urethral O
pressure O
( O
mup O
) O
, O
blood O
pressure O
, O
heart O
rate O
, O
and O
symptomatic O
side O
effects O
. O

methoxamine O
evoked O
non O
- O
significant O
increases O
in O
mup O
and O
diastolic O
blood O
pressure O
but O
caused O
a B-Disease
significant I-Disease
rise I-Disease
in I-Disease
systolic I-Disease
blood I-Disease
pressure I-Disease
and O
significant O
fall O
in O
heart O
rate O
at O
maximum O
dosage O
. O

systemic O
side O
effects O
including O
piloerection O
, O
headache B-Disease
, O
and O
cold O
extremities O
were O
experienced O
in O
all O
subjects O
. O

the O
results O
indicate O
that O
the O
clinical O
usefulness O
of O
direct O
, O
peripherally O
acting O
sub O
- O
type O
- O
selective O
alpha1 O
- O
adrenoceptor O
agonists O
in O
the O
medical O
treatment O
of O
stress B-Disease
incontinence I-Disease
may O
be O
limited O
by O
associated O
piloerection O
and O
cardiovascular O
side O
effects O
. O

hyperglycemic B-Disease
effect O
of O
amino O
compounds O
structurally O
related O
to O
caproate O
in O
rats O
. O

the O
chronic O
feeding O
of O
small O
amounts O
( O
0 O
. O

3 O
- O
3 O
% O
of O
diet O
weight O
) O
of O
certain O
amino O
derivatives O
of O
caproate O
resulted O
in O
hyperglycemia B-Disease
, O
an O
elevated O
glucose O
tolerance O
curve O
and O
, O
occasionally O
, O
glucosuria B-Disease
. O

toleration O
of O
high O
doses O
of O
angiotensin O
- O
converting O
enzyme O
inhibitors O
in O
patients O
with O
chronic O
heart B-Disease
failure I-Disease
: O
results O
from O
the O
atlas O
trial O
. O

background O
: O
treatment O
with O
angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitors O
reduces O
mortality O
and O
morbidity O
in O
patients O
with O
chronic O
heart B-Disease
failure I-Disease
( O
chf B-Disease
) O
, O
but O
most O
affected O
patients O
are O
not O
receiving O
these O
agents O
or O
are O
being O
treated O
with O
doses O
lower O
than O
those O
found O
to O
be O
efficacious O
in O
trials O
, O
primarily O
because O
of O
concerns O
about O
the O
safety O
and O
tolerability O
of O
these O
agents O
, O
especially O
at O
the O
recommended O
doses O
. O

the O
present O
study O
examines O
the O
safety O
and O
tolerability O
of O
high O
- O
compared O
with O
low O
- O
dose O
lisinopril O
in O
chf B-Disease
. O

patients O
with O
new O
york O
heart O
association O
classes O
ii O
to O
iv O
chf B-Disease
and O
left O
ventricular O
ejection O
fractions O
of O
no O
greater O
than O
0 O
. O

30 O
( O
n O
= O
3164 O
) O
were O
randomized O
and O
followed O
up O
for O
a O
median O
of O
46 O
months O
. O

we O
examined O
the O
occurrence O
of O
adverse O
events O
and O
the O
need O
for O
discontinuation O
and O
dose O
reduction O
during O
treatment O
, O
with O
a O
focus O
on O
hypotension B-Disease
and O
renal B-Disease
dysfunction I-Disease
. O

results O
: O
of O
405 O
patients O
not O
previously O
receiving O
an O
ace O
inhibitor O
, O
doses O
in O
only O
4 O
. O

2 O
% O
could O
not O
be O
titrated O
to O
the O
medium O
doses O
required O
for O
randomization O
because O
of O
symptoms O
possibly O
related O
to O
hypotension B-Disease
( O
2 O
. O

0 O
% O
) O
or O
because O
of O
renal B-Disease
dysfunction I-Disease
or O
hyperkalemia B-Disease
( O
2 O
. O

3 O
% O
) O
. O

subgroups O
presumed O
to O
be O
at O
higher O
risk O
for O
ace O
inhibitor O
intolerance O
( O
blood O
pressure O
, O
< O
120 O
mm O
hg O
; O
creatinine O
, O
> O
or O
= O
132 O
. O

6 O
micromol O
/ O
l O
[ O
> O
or O
= O
1 O
. O

5 O
mg O
/ O
dl O
] O
; O
age O
, O
> O
or O
= O
70 O
years O
; O
and O
patients O
with O
diabetes B-Disease
) O
generally O
tolerated O
the O
high O
- O
dose O
strategy O
. O

conclusions O
: O
these O
findings O
demonstrate O
that O
ace O
inhibitor O
therapy O
in O
most O
patients O
with O
chf B-Disease
can O
be O
successfully O
titrated O
to O
and O
maintained O
at O
high O
doses O
, O
and O
that O
more O
aggressive O
use O
of O
these O
agents O
is O
warranted O
. O

cocaine O
, O
ethanol O
, O
and O
cocaethylene O
cardiotoxity B-Disease
in O
an O
animal O
model O
of O
cocaine B-Disease
and I-Disease
ethanol I-Disease
abuse I-Disease
. O

objectives O
: O
simultaneous O
abuse B-Disease
of I-Disease
cocaine I-Disease
and I-Disease
ethanol I-Disease
affects O
12 O
million O
americans O
annually O
. O

their O
combined O
cardiac B-Disease
toxicity I-Disease
may O
be O
due O
to O
independent O
effects O
of O
each O
drug O
; O
however O
, O
they O
may O
also O
be O
due O
to O
cocaethylene O
( O
ce O
) O
, O
a O
cocaine O
metabolite O
formed O
only O
in O
the O
presence O
of O
ethanol O
. O

the O
purpose O
of O
this O
study O
was O
to O
delineate O
the O
role O
of O
ce O
in O
the O
combined O
cardiotoxicity B-Disease
of O
cocaine O
and O
ethanol O
in O
a O
model O
simulating O
their O
abuse O
. O

results O
: O
two O
of O
eight O
dogs O
in O
the O
c O
+ O
e O
group O
experienced O
cardiovascular B-Disease
collapse I-Disease
. O

peak O
ce O
levels O
were O
associated O
with O
a O
45 O
% O
( O
sd O
+ O
/ O
- O
22 O
% O
, O
95 O
% O
ci O
= O
22 O
% O
to O
69 O
% O
) O
decrease B-Disease
in I-Disease
cardiac I-Disease
output I-Disease
( O
p O
< O
0 O
. O

5 O
) O
, O
a O
56 O
% O
( O
sd O
+ O
/ O
- O
23 O
% O
, O
95 O
% O
ci O
= O
32 O
% O
to O
80 O
% O
) O
decrease O
in O
dp O
/ O
dt O
( O
max O
) O
( O
p O
< O
. O

6 O
) O
, O
and O
a O
23 O
% O
( O
sd O
+ O
/ O
- O
15 O
% O
, O
95 O
% O
ci O
= O
7 O
% O
to O
49 O
% O
) O
decrease O
in O
svo O
( O
2 O
) O
( O
p O
< O
0 O
. O

25 O
) O
. O

ventricular B-Disease
arrhythmias I-Disease
were O
primarily O
observed O
in O
the O
c O
+ O
e O
group O
, O
in O
which O
four O
of O
eight O
dogs O
experienced O
ventricular B-Disease
tachycardia I-Disease
. O

co O
- O
administration O
resulted O
in O
prolonged O
cardiac B-Disease
toxicity I-Disease
and O
was O
dysrhythmogenic O
. O

peak O
serum O
cocaethylene O
concentrations O
were O
associated O
with O
prolonged O
myocardial B-Disease
depression I-Disease
. O

worsening O
of O
parkinsonism B-Disease
after O
the O
use O
of O
veralipride O
for O
treatment O
of O
menopause O
: O
case O
report O
. O

we O
describe O
a O
female O
patient O
with O
stable O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
who O
has O
shown O
a O
marked O
worsening O
of O
her O
motor O
functions O
following O
therapy O
of O
menopause O
related O
symptoms O
with O
veralipride O
, O
as O
well O
as O
the O
improvement O
of O
her O
symptoms O
back O
to O
baseline O
after O
discontinuation O
of O
the O
drug O
. O

viracept O
and O
irregular B-Disease
heartbeat I-Disease
warning O
. O

a O
group O
of O
doctors O
in O
boston O
warn O
that O
the O
protease O
inhibitor O
viracept O
may O
cause O
an O
irregular B-Disease
heart I-Disease
beat I-Disease
, O
known O
as O
bradycardia B-Disease
, O
in O
people O
with O
hiv O
. O

bradycardia B-Disease
occurred O
in O
a O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
viracept O
in O
combination O
with O
other O
anti O
- O
hiv O
drugs O
. O

frequency O
of O
appearance O
of O
myeloperoxidase O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
mpo O
- O
anca O
) O
in O
graves B-Disease
' I-Disease
disease I-Disease
patients O
treated O
with O
propylthiouracil O
and O
the O
relationship O
between O
mpo O
- O
anca O
and O
clinical O
manifestations O
. O

objective O
: O
myeloperoxidase O
antineutrophil O
cytoplasmic O
antibody O
( O
mpo O
- O
anca O
) O
- O
positive O
vasculitis B-Disease
has O
been O
reported O
in O
patients O
with O
graves B-Disease
' I-Disease
disease I-Disease
who O
were O
treated O
with O
propylthiouracil O
( O
ptu O
) O
. O

nevertheless O
, O
there O
have O
been O
no O
studies O
on O
the O
temporal O
relationship O
between O
the O
appearance O
of O
mpo O
- O
anca O
and O
vasculitis B-Disease
during O
ptu O
therapy O
, O
or O
on O
the O
incidence O
of O
mpo O
- O
anca O
in O
untreated O
graves B-Disease
' I-Disease
disease I-Disease
patients O
. O

therefore O
, O
we O
sought O
to O
address O
these O
parameters O
in O
patients O
with O
graves B-Disease
' I-Disease
disease I-Disease
. O

patients O
: O
we O
investigated O
102 O
untreated O
patients O
with O
hyperthyroidism B-Disease
due O
to O
graves B-Disease
' I-Disease
disease I-Disease
for O
the O
presence O
of O
mpo O
- O
anca O
, O
and O
for O
the O
development O
vasculitis B-Disease
after O
starting O
ptu O
therapy O
. O

results O
: O
before O
treatment O
, O
the O
mpo O
- O
anca O
titres O
of O
all O
102 O
untreated O
graves B-Disease
' I-Disease
disease I-Disease
patients O
were O
within O
the O
reference O
range O
( O
below O
10 O
u O
/ O
ml O
) O
. O

in O
two O
of O
them O
, O
the O
mpo O
- O
anca O
titres O
transiently O
increased O
to O
12 O
. O

8 O
and O
15 O
. O

0 O
u O
/ O
ml O
, O
respectively O
, O
despite O
continued O
ptu O
therapy O
, O
but O
no O
vasculitic B-Disease
disorders I-Disease
developed O
. O

in O
the O
third O
patient O
, O
the O
mpo O
- O
anca O
titre O
increased O
to O
204 O
u O
/ O
ml O
and O
she O
developed O
a O
higher O
fever B-Disease
, O
oral B-Disease
ulcers I-Disease
and O
polyarthralgia B-Disease
, O
but O
the O
symptoms O
resolved O
2 O
weeks O
after O
stopping O
ptu O
therapy O
, O
and O
the O
mpo O
- O
anca O
titre O
decreased O
to O
20 O
. O

7 O
u O
/ O
ml O
by O
4 O
months O
after O
discontinuing O
ptu O
. O

conclusions O
: O
ptu O
therapy O
may O
be O
related O
to O
the O
appearance O
of O
mpo O
- O
anca O
, O
but O
mpo O
- O
anca O
does O
not O
appear O
to O
be O
closely O
related O
to O
vasculitis B-Disease
. O

prevalence O
of O
heart B-Disease
disease I-Disease
in O
asymptomatic O
chronic O
cocaine O
users O
. O

to O
determine O
the O
prevalence O
of O
heart B-Disease
disease I-Disease
in O
outpatient O
young O
asymptomatic O
chronic O
cocaine O
users O
, O
35 O
cocaine O
users O
and O
32 O
age O
- O
matched O
controls O
underwent O
resting O
and O
exercise O
electrocardiography O
( O
ecg O
) O
and O
doppler O
echocardiography O
. O

findings O
consistent O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
were O
detected O
in O
12 O
( O
34 O
% O
) O
patients O
and O
3 O
( O
9 O
% O
) O
controls O
( O
p O
= O
0 O
. O

1 O
) O
. O

finally O
, O
resting O
and O
peak O
exercise O
abnormal B-Disease
left I-Disease
ventricular I-Disease
filling I-Disease
was O
detected O
in O
38 O
and O
35 O
% O
of O
patients O
as O
compared O
to O
19 O
and O
9 O
% O
of O
controls O
, O
respectively O
( O
p O
= O
0 O
. O

11 O
and O
0 O
. O

2 O
, O
respectively O
) O
. O

we O
conclude O
that O
coronary B-Disease
artery I-Disease
or I-Disease
myocardial I-Disease
disease I-Disease
is O
common O
( O
38 O
% O
) O
in O
young O
asymptomatic O
chronic O
cocaine O
users O
. O

the O
cardioprotective O
effect O
of O
the O
ethanol O
extract O
of O
picrorrhiza O
kurroa O
rhizomes O
and O
roots O
( O
pk O
) O
on O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
with O
respect O
to O
lipid O
metabolism O
in O
serum O
and O
heart O
tissue O
has O
been O
investigated O
. O

oral O
pre O
- O
treatment O
with O
pk O
( O
80 O
mg O
kg O
( O
- O
1 O
) O
day O
( O
- O
1 O
) O
for O
15 O
days O
) O
significantly O
prevented O
the O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
and O
maintained O
the O
rats O
at O
near O
normal O
status O
. O

phase O
2 O
early O
afterdepolarization O
as O
a O
trigger O
of O
polymorphic O
ventricular B-Disease
tachycardia I-Disease
in O
acquired O
long B-Disease
- I-Disease
qt I-Disease
syndrome I-Disease
: O
direct O
evidence O
from O
intracellular O
recordings O
in O
the O
intact O
left O
ventricular O
wall O
. O

background O
: O
this O
study O
examined O
the O
role O
of O
phase O
2 O
early O
afterdepolarization O
( O
ead O
) O
in O
producing O
a O
trigger O
to O
initiate O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
with O
qt B-Disease
prolongation I-Disease
induced O
by O
dl O
- O
sotalol O
and O
azimilide O
. O

the O
contribution O
of O
transmural O
dispersion O
of O
repolarization O
( O
tdr O
) O
to O
transmural O
propagation O
of O
ead O
and O
the O
maintenance O
of O
tdp B-Disease
was O
also O
evaluated O
. O

dl O
- O
sotalol O
preferentially O
prolonged O
action O
potential O
duration O
( O
apd O
) O
in O
m O
cells O
dose O
- O
dependently O
( O
1 O
to O
100 O
micromol O
/ O
l O
) O
, O
leading O
to O
qt B-Disease
prolongation I-Disease
and O
an O
increase O
in O
tdr O
. O

although O
both O
dl O
- O
sotalol O
and O
azimilide O
rarely O
induced O
eads O
in O
canine O
left O
ventricles O
, O
they O
produced O
frequent O
eads O
in O
rabbits O
, O
in O
which O
more O
pronounced O
qt B-Disease
prolongation I-Disease
was O
seen O
. O

an O
increase O
in O
tdr O
by O
dl O
- O
sotalol O
facilitated O
transmural O
propagation O
of O
eads O
that O
initiated O
multiple O
episodes O
of O
spontaneous O
tdp B-Disease
in O
3 O
of O
6 O
rabbit O
left O
ventricles O
. O

conclusions O
: O
this O
study O
provides O
the O
first O
direct O
evidence O
from O
intracellular O
action O
potential O
recordings O
that O
phase O
2 O
ead O
can O
be O
generated O
from O
intact O
ventricular O
wall O
and O
produce O
a O
trigger O
to O
initiate O
the O
onset O
of O
tdp B-Disease
under O
qt B-Disease
prolongation I-Disease
. O

a O
pilot O
study O
to O
assess O
the O
safety O
of O
dobutamine O
stress O
echocardiography O
in O
the O
emergency O
department O
evaluation O
of O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

study O
objective O
: O
chest B-Disease
pain I-Disease
in O
the O
setting O
of O
cocaine O
use O
poses O
a O
diagnostic O
dilemma O
. O

dobutamine O
stress O
echocardiography O
( O
dse O
) O
is O
a O
widely O
available O
and O
sensitive O
test O
for O
evaluating O
cardiac O
ischemia B-Disease
. O

because O
of O
the O
theoretical O
concern O
regarding O
administration O
of O
dobutamine O
in O
the O
setting O
of O
cocaine O
use O
, O
we O
conducted O
a O
pilot O
study O
to O
assess O
the O
safety O
of O
dse O
in O
emergency O
department O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

patients O
were O
eligible O
for O
dse O
if O
they O
had O
used O
cocaine O
within O
24 O
hours O
preceding O
the O
onset O
of O
chest B-Disease
pain I-Disease
and O
had O
a O
normal O
ecg O
and O
tropinin O
i O
level O
. O

patients O
exhibiting O
signs O
of O
continuing O
cocaine O
toxicity B-Disease
were O
excluded O
from O
the O
study O
. O

two O
patients O
had O
inadequate O
resting O
images O
, O
one O
dse O
was O
terminated O
because O
of O
inferior O
hypokinesis B-Disease
, O
another O
dse O
was O
terminated O
because O
of O
a O
rate O
- O
related O
atrial O
conduction O
deficit O
, O
and O
1 O
patient O
did O
not O
reach O
the O
target O
heart O
rate O
. O

none O
of O
the O
patients O
experienced O
signs O
of O
exaggerated O
adrenergic O
response O
, O
which O
was O
defined O
as O
a O
systolic O
blood O
pressure O
of O
greater O
than O
200 O
mm O
hg O
or O
the O
occurrence O
of O
tachydysrhythmias B-Disease
( O
excluding O
sinus B-Disease
tachycardia I-Disease
) O
. O

conclusion O
: O
no O
exaggerated O
adrenergic O
response O
was O
detected O
when O
dobutamine O
was O
administered O
to O
patients O
with O
cocaine O
- O
related O
chest B-Disease
pain I-Disease
. O

prenatal O
cocaine O
exposure O
and O
cranial O
sonographic O
findings O
in O
preterm B-Disease
infants I-Disease
. O

purpose O
: O
prenatal O
cocaine O
exposure O
has O
been O
linked O
with O
subependymal O
hemorrhage B-Disease
and O
the O
formation O
of O
cysts B-Disease
that O
are O
detectable O
on O
cranial O
sonography O
in O
neonates O
born O
at O
term O
. O

we O
sought O
to O
determine O
if O
prenatal O
cocaine O
exposure O
increases O
the O
incidence O
of O
subependymal B-Disease
cysts I-Disease
in O
preterm B-Disease
infants I-Disease
. O

methods O
: O
we O
retrospectively O
reviewed O
the O
medical O
records O
and O
cranial O
sonograms O
obtained O
during O
a O
1 O
- O
year O
period O
on O
122 O
premature B-Disease
( I-Disease
< I-Disease
36 I-Disease
weeks I-Disease
of I-Disease
gestation I-Disease
) I-Disease
infants I-Disease
. O

infants O
were O
assigned O
to O
the O
cocaine O
- O
exposed O
group O
if O
there O
was O
a O
maternal O
history O
of O
cocaine B-Disease
abuse I-Disease
during O
pregnancy O
or O
if O
maternal O
or O
neonatal O
urine O
toxicology O
results O
were O
positive O
at O
the O
time O
of O
delivery O
. O

the O
incidence O
of O
subependymal B-Disease
cysts I-Disease
in O
the O
117 O
remaining O
infants O
was O
14 O
% O
( O
16 O
of O
117 O
) O
. O

the O
incidence O
of O
subependymal B-Disease
cysts I-Disease
in O
infants O
exposed O
to O
cocaine O
prenatally O
was O
44 O
% O
( O
8 O
of O
18 O
) O
compared O
with O
8 O
% O
( O
8 O
of O
99 O
) O
in O
the O
unexposed O
group O
( O
p O
< O
0 O
. O

1 O
) O
. O

conclusions O
: O
we O
found O
an O
increased O
incidence O
of O
subependymal B-Disease
cyst I-Disease
formation O
in O
preterm B-Disease
infants I-Disease
who O
were O
exposed O
to O
cocaine O
prenatally O
. O

thalidomide O
neuropathy B-Disease
in O
patients O
treated O
for O
metastatic O
prostate B-Disease
cancer I-Disease
. O

we O
prospectively O
evaluated O
thalidomide O
- O
induced O
neuropathy B-Disease
using O
electrodiagnostic O
studies O
. O

sixty O
- O
seven O
men O
with O
metastatic O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
in O
an O
open O
- O
label O
trial O
of O
oral O
thalidomide O
underwent O
neurologic O
examinations O
and O
nerve O
conduction O
studies O
( O
ncs O
) O
prior O
to O
and O
at O
3 O
- O
month O
intervals O
during O
treatment O
. O

six O
patients O
developed O
neuropathy B-Disease
. O

neuropathy B-Disease
may O
thus O
be O
a O
common O
complication O
of O
thalidomide O
in O
older O
patients O
. O

the O
snap O
index O
can O
be O
used O
to O
monitor O
peripheral B-Disease
neuropathy I-Disease
, O
but O
not O
for O
early O
detection O
. O

overexpression O
of O
copper O
/ O
zinc O
- O
superoxide O
dismutase O
protects O
from O
kanamycin O
- O
induced O
hearing B-Disease
loss I-Disease
. O

the O
participation O
of O
reactive O
oxygen O
species O
in O
aminoglycoside O
- O
induced O
ototoxicity B-Disease
has O
been O
deduced O
from O
observations O
that O
aminoglycoside O
- O
iron O
complexes O
catalyze O
the O
formation O
of O
superoxide O
radicals O
in O
vitro O
and O
that O
antioxidants O
attenuate O
ototoxicity B-Disease
in O
vivo O
. O

we O
therefore O
hypothesized O
that O
overexpression O
of O
cu O
/ O
zn O
- O
superoxide O
dismutase O
( O
h O
- O
sod1 O
) O
should O
protect O
transgenic O
mice O
from O
ototoxicity B-Disease
. O

the O
protection O
by O
overexpression O
of O
superoxide O
dismutase O
supports O
the O
hypothesis O
that O
oxidant O
stress O
plays O
a O
significant O
role O
in O
aminoglycoside O
- O
induced O
ototoxicity B-Disease
. O

fatty B-Disease
liver I-Disease
induced O
by O
tetracycline O
in O
the O
rat O
. O

dose O
- O
response O
relationships O
, O
biochemical O
mechanisms O
, O
and O
sex O
differences O
in O
the O
experimental O
fatty B-Disease
liver I-Disease
induced O
by O
tetracycline O
were O
studied O
in O
the O
intact O
rat O
and O
with O
the O
isolated O
perfused O
rat O
liver O
in O
vitro O
. O

with O
provision O
of O
adequate O
oleic O
acid O
as O
a O
substrate O
for O
the O
isolated O
perfused O
liver O
, O
a O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline O
and O
both O
accumulation O
of O
triglyceride O
in O
the O
liver O
and O
depression B-Disease
of O
output O
of O
triglyceride O
by O
livers O
from O
male O
and O
female O
rats O
. O

however O
, O
livers O
from O
female O
, O
and O
especially O
pregnant O
female O
rats O
, O
were O
strikingly O
resistant O
to O
the O
effects O
of O
tetracycline O
on O
depression B-Disease
of O
output O
of O
triglyceride O
under O
these O
experimental O
conditions O
. O

depressed O
hepatic O
secretion O
of O
triglyceride O
accounted O
only O
for O
30 O
to O
50 O
% O
of O
accumulated O
hepatic O
triglyceride O
, O
indicating O
that O
additional O
mechanisms O
must O
be O
involved O
in O
the O
production O
of O
the O
triglyceride O
- O
rich O
fatty B-Disease
liver I-Disease
in O
response O
to O
tetracycline O
. O

prednisone O
induces O
anxiety B-Disease
and O
glial O
cerebral O
changes O
in O
rats O
. O

objective O
: O
to O
assess O
whether O
prednisone O
( O
pdn O
) O
produces O
anxiety B-Disease
and O
/ O
or O
cerebral O
glial O
changes O
in O
rats O
. O

anxiety B-Disease
was O
assessed O
using O
an O
open O
field O
and O
elevated O
plus O
- O
maze O
devices O
. O

results O
: O
anxiety B-Disease
was O
documented O
in O
both O
groups O
of O
pdn O
treated O
rats O
compared O
with O
controls O
. O

conclusion O
: O
subacute O
exposure O
to O
pdn O
induced O
anxiety B-Disease
and O
reactivity O
of O
microglia O
. O

phase O
ii O
study O
of O
carboplatin O
and O
liposomal O
doxorubicin O
in O
patients O
with O
recurrent O
squamous B-Disease
cell I-Disease
carcinoma I-Disease
of I-Disease
the I-Disease
cervix I-Disease
. O

background O
: O
the O
activity O
of O
the O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
was O
tested O
in O
a O
phase O
ii O
study O
of O
patients O
with O
recurrent O
cervical B-Disease
carcinoma I-Disease
. O

methods O
: O
the O
combination O
of O
carboplatin O
( O
area O
under O
the O
concentration O
curve O
[ O
auc O
] O
, O
5 O
) O
and O
liposomal O
doxorubicin O
( O
doxil O
; O
starting O
dose O
, O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
was O
administered O
intravenously O
every O
28 O
days O
to O
37 O
patients O
with O
recurrent O
squamous B-Disease
cell I-Disease
cervical I-Disease
carcinoma I-Disease
to O
determine O
antitumor O
activity O
and O
toxicity B-Disease
profile O
. O

results O
: O
twenty O
- O
nine O
patients O
were O
assessable O
for O
response O
, O
and O
35 O
patients O
were O
assessable O
for O
toxicity B-Disease
. O

the O
main O
toxic O
effect O
was O
myelosuppression B-Disease
, O
with O
grade O
3 O
and O
4 O
neutropenia B-Disease
in O
16 O
patients O
, O
anemia B-Disease
in O
12 O
patients O
, O
thrombocytopenia B-Disease
in O
11 O
patients O
, O
and O
neutropenic B-Disease
fever I-Disease
in O
3 O
patients O
. O

grade O
> O
or O
= O
2 O
nonhematologic O
toxicity B-Disease
included O
nausea B-Disease
in O
17 O
patients O
, O
emesis B-Disease
in O
14 O
patients O
, O
fatigue B-Disease
in O
9 O
patients O
, O
mucositis B-Disease
and O
/ O
or O
stomatitis B-Disease
in O
8 O
patients O
, O
constipation B-Disease
in O
6 O
patients O
, O
weight B-Disease
loss I-Disease
in O
5 O
patients O
, O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
in O
2 O
patients O
, O
and O
skin B-Disease
reactions I-Disease
in O
3 O
patients O
. O

conclusions O
: O
the O
combination O
of O
carboplatin O
and O
liposomal O
doxorubicin O
has O
modest O
activity O
in O
patients O
with O
recurrent O
cervical B-Disease
carcinoma I-Disease
. O

antimicrobial O
- O
induced O
mania B-Disease
( O
antibiomania B-Disease
) O
: O
a O
review O
of O
spontaneous O
reports O
. O

the O
authors O
reviewed O
reported O
cases O
of O
antibiotic O
- O
induced O
manic B-Disease
episodes O
by O
means O
of O
a O
medline O
and O
psychlit O
search O
for O
reports O
of O
antibiotic O
- O
induced O
mania B-Disease
. O

twenty O
- O
one O
reports O
of O
antimicrobial O
- O
induced O
mania B-Disease
were O
found O
in O
the O
literature O
. O

cotrimoxazole O
, O
metronidazole O
, O
and O
erythromycin O
were O
involved O
in O
15 O
reported O
manic B-Disease
episodes O
. O

cases O
reported O
by O
the O
fda O
showed O
clarithromycin O
and O
ciprofloxacin O
to O
be O
the O
most O
frequently O
associated O
with O
the O
development O
of O
mania B-Disease
. O

patients O
have O
an O
increased O
risk O
of O
developing O
mania B-Disease
while O
being O
treated O
with O
antimicrobials O
. O

further O
research O
clearly O
is O
required O
to O
determine O
the O
incidence O
of O
antimicrobial O
- O
induced O
mania B-Disease
, O
the O
relative O
risk O
factors O
of O
developing O
an O
antimicrobial O
- O
induced O
manic B-Disease
episode O
among O
various O
demographic O
populations O
, O
and O
the O
incidence O
of O
patients O
who O
continue O
to O
have O
persistent O
affective O
disorders O
once O
the O
initial O
episode O
, O
which O
occurs O
while O
the O
patient O
is O
taking O
antibiotics O
, O
subsides O
. O

the O
authors O
elected O
to O
name O
this O
syndrome O
nan O
antibiomania B-Disease
. O

nan O
levodopa O
- O
induced O
ocular B-Disease
dyskinesias I-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

levodopa O
- O
induced O
ocular B-Disease
dyskinesias I-Disease
are O
very O
uncommon O
. O

usually O
they O
occur O
simultaneously O
with O
limb O
peak O
- O
dose O
choreatic B-Disease
dyskinesias I-Disease
. O

we O
report O
on O
a O
patient O
with O
leftward O
and O
upward O
deviations O
of O
gaze O
during O
the O
peak O
effect O
of O
levodopa O
, O
and O
hypothesize O
that O
a O
severe O
dopaminergic O
denervation O
in O
the O
caudate O
nucleus O
is O
needed O
for O
the O
appearance O
of O
these O
levodopa O
- O
induce O
ocular B-Disease
dyskinesias I-Disease
. O

a O
comparison O
of O
glyceryl O
trinitrate O
with O
diclofenac O
for O
the O
treatment O
of O
primary O
dysmenorrhea B-Disease
: O
an O
open O
, O
randomized O
, O
cross O
- O
over O
trial O
. O

primary O
dysmenorrhea B-Disease
is O
a O
syndrome O
characterized O
by O
painful O
uterine O
contractility O
caused O
by O
a O
hypersecretion O
of O
endometrial O
prostaglandins O
; O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
are O
the O
first O
choice O
for O
its O
treatment O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
efficacy O
of O
glyceryl O
trinitrate O
( O
gtn O
) O
, O
an O
no O
donor O
, O
in O
the O
resolution O
of O
primary O
dysmenorrhea B-Disease
in O
comparison O
with O
diclofenac O
( O
dcf O
) O
. O

a O
total O
of O
24 O
patients O
with O
the O
diagnosis O
of O
severe O
primary O
dysmenorrhea B-Disease
were O
studied O
during O
two O
consecutive O
menstrual O
cycles O
. O

the O
difference O
in O
pain B-Disease
intensity O
score O
( O
dpi O
) O
was O
the O
main O
outcome O
variable O
. O

however O
, O
dcf O
continued O
to O
be O
effective O
in O
reducing O
pelvic B-Disease
pain I-Disease
for O
two O
hours O
, O
whereas O
gtn O
scores O
remained O
more O
or O
less O
stable O
after O
30 O
min O
and O
significantly O
higher O
than O
those O
for O
dfc O
( O
after O
one O
hour O
: O
gtn O
, O
- O
12 O
. O

8 O
+ O
/ O
- O
17 O
. O

9 O
; O
dfc O
, O
- O
18 O
. O

9 O
+ O
/ O
- O
16 O
. O

6 O
and O
after O
two O
hours O
: O
gtn O
, O
- O
23 O
. O

7 O
+ O
/ O
- O
20 O
. O

5 O
; O
dfc O
, O
- O
59 O
. O

7 O
+ O
/ O
- O
17 O
. O

9 O
, O
p O
= O
0 O
. O

1 O
) O
. O

low B-Disease
back I-Disease
pain I-Disease
was O
also O
relieved O
by O
both O
drugs O
. O

headache B-Disease
was O
significantly O
increased O
by O
gtn O
but O
not O
by O
dcf O
. O

eight O
patients O
stopped O
using O
gtn O
because O
headache B-Disease
- O
- O
attributed O
to O
its O
use O
- O
- O
became O
intolerable O
. O

these O
findings O
indicate O
that O
gtn O
has O
a O
reduced O
efficacy O
and O
tolerability O
by O
comparison O
with O
dcf O
in O
the O
treatment O
of O
primary O
dysmenorrhea B-Disease
. O

temocapril O
, O
a O
long O
- O
acting O
non O
- O
sh O
group O
angiotensin O
converting O
enzyme O
inhibitor O
, O
modulates O
glomerular B-Disease
injury I-Disease
in O
chronic O
puromycin O
aminonucleoside O
nephrosis B-Disease
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
whether O
chronic O
administration O
of O
temocapril O
, O
a O
long O
- O
acting O
non O
- O
sh O
group O
angiotensin O
converting O
enzyme O
( O
ace O
) O
inhibitor O
, O
reduced O
proteinuria B-Disease
, O
inhibited O
glomerular O
hypertrophy B-Disease
and O
prevented O
glomerulosclerosis B-Disease
in O
chronic O
puromycin O
aminonucleoside O
( O
pan O
) O
- O
induced O
nephrotic B-Disease
rats O
. O

nephrosis B-Disease
was O
induced O
by O
injection O
of O
pan O
( O
15mg O
/ O
100g O
body O
weight O
) O
in O
male O
sprague O
- O
dawley O
( O
sd O
) O
rats O
. O

temocapril O
did O
not O
attenuate O
proteinuria B-Disease
at O
8 O
days O
, O
but O
it O
did O
markedly O
lower O
it O
from O
weeks O
4 O
to O
20 O
. O

the O
glomerulosclerosis B-Disease
index O
( O
gsi O
) O
was O
6 O
. O

21 O
% O
at O
4 O
weeks O
and O
respectively O
25 O
. O

35 O
% O
and O
30 O
. O

49 O
% O
at O
14 O
and O
20 O
weeks O
in O
the O
pan O
group O
. O

it O
appears O
that O
temocapril O
was O
effective O
in O
retarding O
renal O
progression O
and O
protected O
renal O
function O
in O
pan O
neprotic B-Disease
rats O
. O

pulmonary B-Disease
hypertension I-Disease
after O
ibuprofen O
prophylaxis O
in O
very O
preterm O
infants O
. O

we O
report O
three O
cases O
of O
severe O
hypoxaemia B-Disease
after O
ibuprofen O
administration O
during O
a O
randomised O
controlled O
trial O
of O
prophylactic O
treatment O
of O
patent B-Disease
ductus I-Disease
arteriosus I-Disease
with O
ibuprofen O
in O
premature O
infants O
born O
at O
less O
than O
28 O
weeks O
of O
gestation O
. O

hypoxaemia B-Disease
resolved O
quickly O
on O
inhaled O
nitric O
oxide O
therapy O
. O

we O
suggest O
that O
investigators O
involved O
in O
similar O
trials O
pay O
close O
attention O
to O
pulmonary O
pressure O
if O
hypoxaemia B-Disease
occurs O
after O
prophylactic O
administration O
of O
ibuprofen O
. O

hyponatremia B-Disease
and O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
anti I-Disease
- I-Disease
diuretic I-Disease
hormone I-Disease
reported O
with O
the O
use O
of O
vincristine O
: O
an O
over O
- O
representation O
of O
asians O
? O
purpose O
: O
this O
retrospective O
study O
used O
a O
pharmaceutical O
company O
' O
s O
global O
safety O
database O
to O
determine O
the O
reporting O
rate O
of O
hyponatremia B-Disease
and O
/ O
or O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
secretion I-Disease
of I-Disease
anti I-Disease
- I-Disease
diuretic I-Disease
hormone I-Disease
( O
siadh B-Disease
) O
among O
vincristine O
- O
treated O
patients O
and O
to O
explore O
the O
possibility O
of O
at O
- O
risk O
population O
subgroups O
. O

method O
: O
we O
searched O
the O
eli O
lilly O
and O
company O
' O
s O
computerized O
adverse O
event O
database O
for O
all O
reported O
cases O
of O
hyponatremia B-Disease
and O
/ O
or O
siadh B-Disease
as O
of O
1 O
november O
1999 O
that O
had O
been O
reported O
during O
the O
use O
of O
vincristine O
. O

results O
: O
a O
total O
of O
76 O
cases O
of O
hyponatremia B-Disease
and O
/ O
or O
siadh B-Disease
associated O
with O
vincristine O
use O
were O
identified O
. O

approximately O
75 O
% O
of O
the O
patients O
were O
receiving O
treatment O
for O
leukemia B-Disease
or O
lymphoma B-Disease
. O

conclusion O
: O
our O
data O
suggest O
that O
asian O
patients O
may O
be O
at O
increased O
risk O
of O
hyponatremia B-Disease
and O
/ O
or O
siadh B-Disease
associated O
with O
vincristine O
use O
. O

although O
the O
overall O
reported O
rate O
of O
siadh B-Disease
associated O
with O
vincristine O
is O
very O
low O
, O
physicians O
caring O
for O
asian O
oncology O
patients O
should O
be O
aware O
of O
this O
potential O
serious O
but O
reversible O
adverse O
event O
. O

delayed O
toxicity B-Disease
of O
cyclophosphamide O
on O
the O
bladder O
of O
dba O
/ O
2 O
and O
c57bl O
/ O
6 O
female O
mouse O
. O

early O
cy O
toxicity B-Disease
caused O
a O
typical O
haemorrhagic B-Disease
cystitis B-Disease
in O
both O
strains O
that O
was O
completely O
repaired O
in O
about O
7 O
- O
10 O
days O
. O

after O
30 O
days O
of O
cy O
injection O
ulcerous O
and O
non O
- O
ulcerous O
forms O
of O
chronic O
cystitis B-Disease
appeared O
in O
86 O
% O
of O
dba O
/ O
2 O
mice O
but O
only O
in O
4 O
% O
of O
c57bl O
/ O
6 O
mice O
. O

delayed O
cystitis B-Disease
was O
characterized O
by O
infiltration O
and O
transepithelial O
passage O
into O
the O
lumen O
of O
inflammatory O
cells O
and O
by O
frequent O
exfoliation O
of O
the O
urothelium O
. O

delayed O
cystitis B-Disease
still O
persisted O
in O
dba O
/ O
2 O
mice O
100 O
days O
after O
treatment O
. O

these O
results O
indicate O
that O
delayed O
toxicity B-Disease
of O
cy O
in O
female O
dba O
/ O
2 O
mice O
causes O
a O
bladder O
pathology O
that O
is O
not O
observed O
in O
c57bl O
/ O
6 O
mice O
. O

this O
pathology O
resembles O
interstitial B-Disease
cystitis I-Disease
in O
humans O
and O
could O
perhaps O
be O
used O
as O
an O
animal O
model O
for O
studies O
on O
the O
disease O
. O

high O
- O
dose O
5 O
- O
fluorouracil O
/ O
folinic O
acid O
in O
combination O
with O
three O
- O
weekly O
mitomycin O
c O
in O
the O
treatment O
of O
advanced O
gastric B-Disease
cancer I-Disease
. O

background O
: O
the O
24 O
- O
hour O
continuous O
infusion O
of O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
and O
folinic O
acid O
( O
fa O
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric B-Disease
cancer I-Disease
( O
agc B-Disease
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity B-Disease
. O

in O
a O
previous O
phase O
ii O
study O
with O
3 O
- O
weekly O
bolus O
5 O
- O
fu O
, O
fa O
and O
mitomycin O
c O
( O
mmc O
) O
we O
found O
a O
low O
toxicity B-Disease
rate O
and O
response O
rates O
comparable O
to O
those O
of O
regimens O
such O
as O
elf O
, O
fam O
or O
famtx O
, O
and O
a O
promising O
median O
overall O
survival O
. O

patients O
and O
methods O
: O
from O
february O
, O
1998 O
to O
september O
, O
2000 O
we O
recruited O
33 O
patients O
with O
agc B-Disease
to O
receive O
weekly O
24 O
- O
hour O
5 O
- O
fu O
2 O
, O
600 O
mg O
/ O
m O
( O
2 O
) O
preceded O
by O
2 O
- O
hour O
fa O
500 O
mg O
/ O
m O
( O
2 O
) O
for O
6 O
weeks O
, O
followed O
by O
a O
2 O
- O
week O
rest O
period O
. O

18 O
patients O
had O
a O
primary O
agc B-Disease
, O
and O
15 O
showed O
a O
relapsed O
agc B-Disease
. O

the O
worst O
toxicities B-Disease
( O
% O
) O
observed O
were O
( O
ctc O
- O
nci O
1 O
/ O
2 O
/ O
3 O
) O
: O
leukopenia B-Disease
45 O
. O

5 O
/ O
18 O
. O

2 O
/ O
6 O
. O

1 O
, O
thrombocytopenia B-Disease
33 O
. O

3 O
/ O
9 O
. O

1 O
/ O
6 O
. O

1 O
, O
vomitus B-Disease
24 O
. O

2 O
/ O
9 O
. O

1 O
/ O
0 O
, O
diarrhea B-Disease
36 O
. O

4 O
/ O
6 O
. O

1 O
/ O
3 O
. O

0 O
, O
stomatitis B-Disease
18 O
. O

2 O
/ O
9 O
. O

1 O
/ O
0 O
, O
hand B-Disease
- I-Disease
foot I-Disease
syndrome I-Disease
12 O
. O

1 O
/ O
0 O
/ O
0 O
. O

two O
patients O
developed O
hemolytic B-Disease
- I-Disease
uremic I-Disease
syndrome I-Disease
( O
hus B-Disease
) O
. O

conclusions O
: O
high O
- O
dose O
5 O
- O
fu O
/ O
fa O
/ O
mmc O
is O
an O
effective O
and O
well O
- O
tolerated O
outpatient O
regimen O
for O
agc B-Disease
( O
objective O
response O
rate O
54 O
. O

6 O
% O
) O
. O

it O
may O
serve O
as O
an O
alternative O
to O
cisplatin O
- O
containing O
regimens O
; O
however O
, O
it O
has O
to O
be O
considered O
that O
possibly O
hus B-Disease
may O
occur O
. O

persistent O
sterile O
leukocyturia B-Disease
is O
associated O
with O
impaired B-Disease
renal I-Disease
function I-Disease
in O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
type I-Disease
1 I-Disease
- I-Disease
infected I-Disease
children O
treated O
with O
indinavir O
. O

design O
: O
a O
prospective O
study O
to O
monitor O
indinavir O
- O
related O
nephrotoxicity B-Disease
in O
a O
cohort O
of O
30 O
human B-Disease
immunodeficiency I-Disease
virus I-Disease
type I-Disease
1 I-Disease
- I-Disease
infected I-Disease
children O
treated O
with O
indinavir O
. O

results O
: O
the O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia B-Disease
( O
> O
or O
= O
75 O
cells O
/ O
micro O
l O
in O
at O
least O
2 O
consecutive O
visits O
) O
after O
96 O
weeks O
was O
53 O
% O
. O

persistent O
sterile O
leukocyturia B-Disease
was O
frequently O
associated O
with O
a O
mild O
increase O
in O
the O
urine O
albumin O
/ O
creatinine O
ratio O
and O
by O
microscopic O
hematuria B-Disease
. O

children O
with O
persistent O
sterile O
leukocyturia B-Disease
more O
frequently O
had O
serum O
creatinine O
levels O
of O
50 O
% O
above O
normal O
than O
those O
children O
without O
persistent O
sterile O
leukocyturia B-Disease
. O

in O
children O
younger O
than O
5 O
. O

6 O
years O
, O
persistent O
sterile O
leukocyturia B-Disease
was O
significantly O
more O
frequent O
than O
in O
older O
children O
. O

a O
higher O
cumulative O
incidence O
of O
persistent O
leukocyturia B-Disease
was O
found O
in O
children O
with O
an O
area O
under O
the O
curve O
> O
19 O
mg O
/ O
l O
x O
h O
or O
a O
peak O
serum O
level O
of O
indinavir O
> O
12 O
mg O
/ O
l O
. O

in O
4 O
children O
, O
indinavir O
was O
discontinued O
because O
of O
nephrotoxicity B-Disease
. O

subsequently O
, O
the O
serum O
creatinine O
levels O
decreased O
, O
the O
urine O
albumin O
/ O
creatinine O
ratios O
returned O
to O
zero O
, O
and O
the O
leukocyturia B-Disease
disappeared O
within O
3 O
months O
. O

conclusions O
: O
children O
treated O
with O
indinavir O
have O
a O
high O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia B-Disease
. O

children O
with O
persistent O
sterile O
leukocyturia B-Disease
more O
frequently O
had O
an O
increase O
in O
serum O
creatinine O
levels O
of O
> O
50 O
% O
above O
normal O
. O

the O
impairment B-Disease
of I-Disease
the I-Disease
renal I-Disease
function I-Disease
in O
these O
children O
occurred O
in O
the O
absence O
of O
clinical O
symptoms O
of O
nephrolithiasis B-Disease
. O

indinavir O
- O
associated O
nephrotoxicity B-Disease
must O
be O
monitored O
closely O
, O
especially O
in O
children O
with O
risk O
factors O
such O
as O
persistent O
sterile O
leukocyturia B-Disease
, O
age O
< O
5 O
. O

6 O
years O
, O
an O
area O
under O
the O
curve O
of O
indinavir O
> O
19 O
mg O
/ O
l O
x O
h O
, O
and O
a O
c O
( O
max O
) O
> O
12 O
mg O
/ O
l O
. O

utility O
of O
troponin O
i O
in O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

baseline O
electrocardiogram O
abnormalities O
and O
market O
elevations O
not O
associated O
with O
myocardial B-Disease
necrosis I-Disease
make O
accurate O
diagnosis O
of O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
difficult O
in O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

objective O
: O
to O
assess O
outcomes O
based O
on O
troponin O
positivity O
in O
patients O
with O
cocaine O
chest B-Disease
pain I-Disease
admitted O
for O
exclusion O
of O
mi B-Disease
. O

methods O
: O
outcomes O
were O
examined O
in O
patients O
admitted O
for O
possible O
mi B-Disease
after O
cocaine O
use O
. O

outcomes O
included O
ck O
- O
mb O
mi B-Disease
( O
ck O
- O
mb O
> O
or O
= O
8 O
ng O
/ O
ml O
with O
a O
relative O
index O
[ O
( O
ck O
- O
mb O
x O
100 O
) O
/ O
total O
ck O
] O
> O
or O
= O
4 O
, O
cardiac B-Disease
death I-Disease
, O
and O
significant O
coronary B-Disease
disease I-Disease
( O
> O
or O
= O
50 O
% O
) O
. O

results O
: O
of O
the O
246 O
admitted O
patients O
, O
34 O
( O
14 O
% O
) O
met O
ck O
- O
mb O
criteria O
for O
mi B-Disease
and O
38 O
( O
16 O
% O
) O
had O
ctni O
elevations O
. O

three O
of O
the O
four O
patients O
without O
significant O
disease O
who O
had O
ctni O
elevations O
met O
ck O
- O
mb O
criteria O
for O
mi B-Disease
, O
and O
the O
other O
had O
a O
peak O
ck O
- O
mb O
level O
of O
13 O
ng O
/ O
ml O
. O

sensitivities O
, O
specificities O
, O
and O
positive O
and O
negative O
likelihood O
ratios O
for O
predicting O
cardiac B-Disease
death I-Disease
or O
significant O
disease O
were O
high O
for O
both O
ck O
- O
mb O
mi B-Disease
and O
ctni O
and O
were O
not O
significantly O
different O
. O

conclusions O
: O
most O
patients O
with O
ctni O
elevations O
meet O
ck O
- O
mb O
criteria O
for O
mi B-Disease
, O
as O
well O
as O
have O
a O
high O
incidence O
of O
underlying O
significant O
disease O
. O

troponin O
appears O
to O
have O
an O
equivalent O
diagnostic O
accuracy O
compared O
with O
ck O
- O
mb O
for O
diagnosing O
necrosis B-Disease
in O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
and O
suspected O
mi B-Disease
. O

acute O
interstitial B-Disease
nephritis I-Disease
due O
to O
nicergoline O
( O
sermion O
) O
. O

we O
report O
a O
case O
of O
acute O
interstitial B-Disease
nephritis I-Disease
( O
ain B-Disease
) O
due O
to O
nicergoline O
( O
sermion O
) O
. O

a O
50 O
- O
year O
- O
old O
patient O
admitted O
to O
our O
hospital O
for O
fever B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
. O

before O
admission O
, O
he O
had O
been O
taking O
nicergoline O
and O
bendazac O
lysine O
due O
to O
retinal B-Disease
vein I-Disease
occlusion I-Disease
at O
ophthalmologic O
department O
. O

thereafter O
, O
he O
experienced O
intermittent O
fever B-Disease
and O
skin B-Disease
rash I-Disease
. O

on O
admission O
, O
clinical O
symptoms O
( O
i O
. O

e O
. O

arthralgia B-Disease
and O
fever B-Disease
) O
and O
laboratory O
findings O
( O
i O
. O

e O
. O

eosinophilia B-Disease
and O
renal B-Disease
failure I-Disease
) O
suggested O
ain B-Disease
, O
and O
which O
was O
confirmed O
by O
pathologic O
findings O
on O
renal O
biopsy O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
nicergoline O
- O
associated O
ain B-Disease
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
complicated O
by O
massive O
intestinal O
bleeding B-Disease
in O
a O
patient O
with O
chronic B-Disease
renal I-Disease
failure I-Disease
. O

a O
patient O
with O
chronic B-Disease
renal I-Disease
failure I-Disease
( O
crf B-Disease
) O
developed O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
( O
nms B-Disease
) O
after O
administration O
of O
risperidone O
and O
levomepromazine O
. O

in O
addition O
to O
the O
typical O
symptoms O
of O
nms B-Disease
, O
massive O
intestinal O
bleeding B-Disease
was O
observed O
during O
the O
episode O
. O

this O
report O
suggests O
that O
nms B-Disease
in O
a O
patient O
with O
crf B-Disease
may O
be O
complicated O
by O
intestinal O
bleeding B-Disease
and O
needs O
special O
caution O
for O
this O
complication O
. O

adrenaline O
- O
induced O
hypertension B-Disease
was O
used O
to O
destroy O
the O
bbb O
, O
which O
was O
evaluated O
using O
triphenyltetrazolium O
( O
ttc O
) O
staining O
of O
the O
brain O
slices O
just O
after O
giving O
adrenaline O
for O
30 O
s O
. O

similar O
results O
were O
obtained O
in O
seizure B-Disease
- O
induced O
breakdown O
of O
bbb O
. O

carvedilol O
protects O
against O
doxorubicin O
- O
induced O
mitochondrial O
cardiomyopathy B-Disease
. O

several O
cytopathic O
mechanisms O
have O
been O
suggested O
to O
mediate O
the O
dose O
- O
limiting O
cumulative O
and O
irreversible O
cardiomyopathy B-Disease
caused O
by O
doxorubicin O
. O

recent O
evidence O
indicates O
that O
oxidative O
stress O
and O
mitochondrial B-Disease
dysfunction I-Disease
are O
key O
factors O
in O
the O
pathogenic O
process O
. O

the O
objective O
of O
this O
investigation O
was O
to O
test O
the O
hypothesis O
that O
carvedilol O
, O
a O
nonselective O
beta O
- O
adrenergic O
receptor O
antagonist O
with O
potent O
antioxidant O
properties O
, O
protects O
against O
the O
cardiac O
and O
hepatic O
mitochondrial O
bioenergetic O
dysfunction O
associated O
with O
subchronic O
doxorubicin O
toxicity B-Disease
. O

it O
is O
concluded O
that O
this O
protection O
by O
carvedilol O
against O
both O
the O
structural O
and O
functional O
cardiac O
tissue O
damage O
may O
afford O
significant O
clinical O
advantage O
in O
minimizing O
the O
dose O
- O
limiting O
mitochondrial B-Disease
dysfunction I-Disease
and O
cardiomyopathy B-Disease
that O
accompanies O
long O
- O
term O
doxorubicin O
therapy O
in O
cancer B-Disease
patients O
. O

cocaine O
- O
induced O
hyperactivity B-Disease
is O
more O
influenced O
by O
adenosine O
receptor O
agonists O
than O
amphetamine O
- O
induced O
hyperactivity B-Disease
. O

the O
influence O
of O
adenosine O
receptor O
agonists O
and O
antagonists O
on O
cocaine O
- O
and O
amphetamine O
- O
induced O
hyperactivity B-Disease
was O
examined O
in O
mice O
. O

all O
adenosine O
receptor O
agonists O
significantly O
decreased B-Disease
the I-Disease
locomotor I-Disease
activity I-Disease
in O
mice O
, O
and O
the O
effects O
were O
dose O
- O
dependent O
. O

similarly O
, O
all O
adenosine O
receptor O
agonists O
decreased O
amphetamine O
- O
induced O
hyperactivity B-Disease
, O
but O
at O
the O
higher O
doses O
than O
those O
which O
were O
active O
in O
cocaine O
- O
induced O
hyperactivity B-Disease
. O

our O
results O
have O
shown O
that O
all O
adenosine O
receptor O
agonists O
( O
a1 O
and O
a2 O
) O
reduce O
cocaine O
- O
and O
amphetamine O
- O
induced O
locomotor O
activity O
and O
indicate O
that O
cocaine O
- O
induced O
hyperactivity B-Disease
is O
more O
influenced O
by O
adenosine O
receptor O
agonists O
( O
particularly O
a1 O
receptors O
) O
than O
amphetamine O
- O
induced O
hyperactivity B-Disease
. O

amiodarone O
and O
the O
risk O
of O
bradyarrhythmia B-Disease
requiring O
permanent O
pacemaker O
in O
elderly O
patients O
with O
atrial B-Disease
fibrillation I-Disease
and O
prior O
myocardial B-Disease
infarction I-Disease
. O

objectives O
: O
the O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
amiodarone O
in O
patients O
with O
atrial B-Disease
fibrillation I-Disease
( O
af B-Disease
) O
increases O
the O
risk O
of O
bradyarrhythmia B-Disease
requiring O
a O
permanent O
pacemaker O
. O

background O
: O
reports O
of O
severe O
bradyarrhythmia B-Disease
during O
amiodarone O
therapy O
are O
infrequent O
and O
limited O
to O
studies O
assessing O
the O
therapy O
' O
s O
use O
in O
the O
management O
of O
patients O
with O
ventricular B-Disease
arrhythmias I-Disease
. O

methods O
: O
a O
study O
cohort O
of O
8 O
, O
770 O
patients O
age O
> O
or O
= O
65 O
years O
with O
a O
new O
diagnosis O
of O
af B-Disease
was O
identified O
from O
a O
provincewide O
database O
of O
quebec O
residents O
with O
a O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
between O
1991 O
and O
1999 O
. O

using O
a O
nested O
case O
- O
control O
design O
, O
477 O
cases O
of O
bradyarrhythmia B-Disease
requiring O
a O
permanent O
pacemaker O
were O
matched O
( O
1 O
: O
4 O
) O
to O
1 O
, O
908 O
controls O
. O

conclusions O
: O
this O
study O
suggests O
that O
the O
use O
of O
amiodarone O
in O
elderly O
patients O
with O
af B-Disease
and O
a O
previous O
mi B-Disease
increases O
the O
risk O
of O
bradyarrhythmia B-Disease
requiring O
a O
permanent O
pacemaker O
. O

nonsteroidal O
anti O
- O
inflammatory O
drug O
- O
induced O
cystitis B-Disease
is O
a O
poorly O
recognized O
and O
under O
- O
reported O
condition O
. O

conclusions O
: O
indomethacin O
resulted O
in O
histopathologic O
findings O
typical O
of O
interstitial B-Disease
cystitis I-Disease
, O
such O
as O
leaky O
bladder O
epithelium O
and O
mucosal O
mastocytosis B-Disease
. O

the O
TRUE O
incidence O
of O
nonsteroidal O
anti O
- O
inflammatory O
drug O
- O
induced O
cystitis B-Disease
in O
humans O
must O
be O
clarified O
by O
prospective O
clinical O
trials O
. O

an O
open O
- O
label O
phase O
ii O
study O
of O
low O
- O
dose O
thalidomide O
in O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
. O

the O
antiangiogenic O
effects O
of O
thalidomide O
have O
been O
assessed O
in O
clinical O
trials O
in O
patients O
with O
various O
solid O
and O
haematological B-Disease
malignancies I-Disease
. O

we O
undertook O
an O
open O
- O
label O
study O
using O
thalidomide O
100 O
mg O
once O
daily O
for O
up O
to O
6 O
months O
in O
20 O
men O
with O
androgen O
- O
independent O
prostate B-Disease
cancer I-Disease
. O

adverse O
effects O
included O
constipation B-Disease
, O
morning O
drowsiness B-Disease
, O
dizziness B-Disease
and O
rash B-Disease
, O
and O
resulted O
in O
withdrawal O
from O
the O
study O
by O
three O
men O
. O

evidence O
of O
peripheral B-Disease
sensory I-Disease
neuropathy I-Disease
was O
found O
in O
nine O
of O
13 O
men O
before O
treatment O
. O

in O
the O
seven O
men O
who O
completed O
six O
months O
on O
thalidomide O
, O
subclinical O
evidence O
of O
peripheral B-Disease
neuropathy I-Disease
was O
found O
in O
four O
before O
treatment O
, O
but O
in O
all O
seven O
at O
repeat O
testing O
. O

the O
findings O
indicate O
that O
thalidomide O
may O
be O
an O
option O
for O
patients O
who O
have O
failed O
other O
forms O
of O
therapy O
, O
provided O
close O
follow O
- O
up O
is O
maintained O
for O
development O
of O
peripheral B-Disease
neuropathy I-Disease
. O

central B-Disease
nervous I-Disease
system I-Disease
toxicity I-Disease
following O
the O
administration O
of O
levobupivacaine O
for O
lumbar O
plexus O
block O
: O
a O
report O
of O
two O
cases O
. O

background O
and O
objectives O
: O
central B-Disease
nervous I-Disease
system I-Disease
and I-Disease
cardiac I-Disease
toxicity I-Disease
following O
the O
administration O
of O
local O
anesthetics O
is O
a O
recognized O
complication O
of O
regional O
anesthesia O
. O

we O
describe O
2 O
cases O
of O
grand B-Disease
mal I-Disease
seizures I-Disease
following O
accidental O
intravascular O
injection O
of O
levobupivacaine O
. O

immediately O
after O
the O
administration O
of O
levobupivacaine O
0 O
. O

5 O
% O
with O
epinephrine O
2 O
. O

5 O
microgram O
/ O
ml O
, O
the O
patients O
developed O
grand B-Disease
mal I-Disease
seizures I-Disease
, O
despite O
negative O
aspiration O
for O
blood O
and O
no O
clinical O
signs O
of O
intravenous O
epinephrine O
administration O
. O

the O
seizures B-Disease
were O
successfully O
treated O
with O
sodium O
thiopental O
in O
addition O
to O
succinylcholine O
in O
1 O
patient O
. O

neither O
patient O
developed O
signs O
of O
cardiovascular B-Disease
toxicity I-Disease
. O

conclusions O
: O
although O
levobupivacaine O
may O
have O
a O
safer O
cardiac B-Disease
toxicity I-Disease
profile O
than O
racemic O
bupivacaine O
, O
if O
adequate O
amounts O
of O
levobupivacaine O
reach O
the O
circulation O
, O
it O
will O
result O
in O
convulsions B-Disease
. O

plasma O
concentrations O
sufficient O
to O
result O
in O
central B-Disease
nervous I-Disease
system I-Disease
toxicity I-Disease
did O
not O
produce O
manifestations O
of O
cardiac B-Disease
toxicity I-Disease
in O
these O
2 O
patients O
. O

amiodarone O
- O
induced O
torsade B-Disease
de I-Disease
pointes I-Disease
during O
bladder O
irrigation O
: O
an O
unusual O
presentation O
- O
- O
a O
case O
report O
. O

the O
authors O
present O
a O
case O
of O
early O
( O
within O
4 O
days O
) O
development O
of O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
associated O
with O
oral O
amiodarone O
therapy O
. O

consistent O
with O
other O
reports O
this O
case O
of O
tdp B-Disease
occurred O
in O
the O
context O
of O
multiple O
exacerbating O
factors O
including O
hypokalemia B-Disease
and O
digoxin O
excess O
. O

transient O
prolongation O
of O
the O
qt O
during O
bladder O
irrigation O
prompted O
the O
episode O
of O
tdp B-Disease
. O

it O
is O
well O
known O
that O
bradycardia B-Disease
exacerbates O
acquired O
tdp B-Disease
. O

the O
authors O
speculate O
that O
the O
increased O
vagal O
tone O
during O
bladder O
irrigation O
, O
a O
vagal O
maneuver O
, O
in O
the O
context O
of O
amiodarone O
therapy O
resulted O
in O
amiodarone O
- O
induced O
proarrhythmia B-Disease
. O

in O
the O
absence O
of O
amiodarone O
therapy O
, O
a O
second O
bladder O
irrigation O
did O
not O
induce O
tdp B-Disease
despite O
hypokalemia B-Disease
and O
hypomagnesemia B-Disease
. O

anaesthetic O
complications O
associated O
with O
myotonia B-Disease
congenita I-Disease
: O
case O
study O
and O
comparison O
with O
other O
myotonic B-Disease
disorders I-Disease
. O

myotonia B-Disease
congenita I-Disease
( O
mc B-Disease
) O
is O
caused O
by O
a O
defect O
in O
the O
skeletal O
muscle O
chloride O
channel O
function O
, O
which O
may O
cause O
sustained B-Disease
membrane I-Disease
depolarisation I-Disease
. O

we O
describe O
a O
previously O
healthy O
32 O
- O
year O
- O
old O
woman O
who O
developed O
a O
life O
- O
threatening O
muscle B-Disease
spasm I-Disease
and O
secondary O
ventilation O
difficulties O
following O
a O
preoperative O
injection O
of O
suxamethonium O
. O

the O
muscle B-Disease
spasms I-Disease
disappeared O
spontaneously O
and O
the O
surgery O
proceeded O
without O
further O
problems O
. O

when O
subsequently O
questioned O
, O
she O
reported O
minor O
symptoms O
suggesting O
a O
myotonic B-Disease
condition I-Disease
. O

myotonia B-Disease
was O
found O
on O
clinical O
examination O
and O
emg O
. O

the O
diagnosis O
mc B-Disease
was O
confirmed O
genetically O
. O

we O
give O
a O
brief O
overview O
of O
ion B-Disease
channel I-Disease
disorders I-Disease
including O
malignant B-Disease
hyperthermia I-Disease
and O
their O
anaesthetic O
considerations O
. O

respiratory O
pattern O
in O
a O
rat O
model O
of O
epilepsy B-Disease
. O

purpose O
: O
apnea B-Disease
is O
known O
to O
occur O
during O
seizures B-Disease
, O
but O
systematic O
studies O
of O
ictal O
respiratory O
changes O
in O
adults O
are O
few O
. O

here O
we O
sought O
to O
generate O
information O
with O
regard O
to O
the O
interictal O
period O
in O
animals O
with O
pilocarpine O
- O
induced O
epilepsy B-Disease
. O

methods O
: O
twelve O
rats O
( O
six O
chronically O
epileptic B-Disease
animals O
and O
six O
controls O
) O
were O
anesthetized O
, O
given O
tracheotomies O
, O
and O
subjected O
to O
hyperventilation B-Disease
or O
hypoventilation O
conditions O
. O

results O
: O
the O
hyperventilation B-Disease
maneuver O
caused O
a O
decrease O
in O
spontaneous O
ventilation O
in O
pilocarpine O
- O
treated O
and O
control O
rats O
. O

although O
ve O
had O
a O
similar O
decrease O
in O
both O
groups O
, O
in O
the O
epileptic B-Disease
group O
, O
the O
decrease O
in O
ve O
was O
due O
to O
a O
significant O
( O
p O
< O
0 O
. O

5 O
) O
increase O
in O
te O
peak O
in O
relation O
to O
that O
of O
the O
control O
animals O
. O

in O
the O
epileptic B-Disease
group O
, O
the O
increase O
in O
ve O
was O
mediated O
by O
a O
significant O
( O
p O
< O
0 O
. O

5 O
) O
decrease O
in O
te O
peak O
compared O
with O
the O
control O
group O
. O

we O
speculate O
on O
the O
possible O
relation O
of O
the O
current O
findings O
on O
treating O
different O
epilepsy B-Disease
- O
associated O
conditions O
. O

fatal O
myeloencephalopathy B-Disease
due O
to O
intrathecal O
vincristine O
administration O
. O

vincristine O
was O
accidentally O
given O
intrathecally O
to O
a O
child O
with O
leukaemia B-Disease
, O
producing O
sensory B-Disease
and I-Disease
motor I-Disease
dysfunction I-Disease
followed O
by O
encephalopathy B-Disease
and O
death O
. O

after O
determining O
the O
bupivacaine O
ad50 O
( O
the O
concentration O
of O
bupivacaine O
that O
caused O
50 O
% O
of O
all O
beating O
rat O
heart O
myocyte O
cultures O
to O
become O
arrhythmic B-Disease
) O
, O
we O
determined O
the O
effect O
of O
1 O
- O
hour O
progesterone O
hcl O
exposure O
on O
myocyte O
contractile O
rhythm O
. O

there O
was O
a O
significant O
decrease O
in O
the O
time O
to O
onset O
of O
arrhythmia B-Disease
as O
compared O
with O
control O
nonprogesterone O
- O
treated O
rats O
( O
6 O
. O

2 O
+ O
/ O
- O
1 O
. O

3 O
vs O
. O

30 O
. O

8 O
+ O
/ O
- O
2 O
. O

5 O
min O
, O
mean O
+ O
/ O
- O
se O
) O
. O

potentiation O
of O
bupivacaine O
arrhythmia B-Disease
in O
myocyte O
cultures O
suggests O
that O
this O
effect O
is O
at O
least O
partly O
mediated O
at O
the O
myocyte O
level O
. O

increased O
serum O
soluble O
fas O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
due O
to O
paracetamol O
overdose B-Disease
. O

background O
/ O
aims O
: O
experimental O
studies O
have O
suggested O
that O
apoptosis O
via O
the O
fas O
/ O
fas O
ligand O
signaling O
system O
may O
play O
an O
important O
role O
in O
the O
development O
of O
acute B-Disease
liver I-Disease
failure I-Disease
. O

the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
soluble O
form O
of O
fas O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
. O

methodology O
: O
serum O
levels O
of O
sfas O
( O
soluble O
fas O
) O
were O
measured O
by O
elisa O
in O
24 O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
and O
10 O
normal O
control O
subjects O
. O

serum O
levels O
of O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
and O
interferon O
- O
gamma O
were O
also O
determined O
by O
elisa O
. O

results O
: O
serum O
sfas O
was O
significantly O
increased O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
( O
median O
, O
26 O
. O

8 O
u O
/ O
ml O
; O
range O
, O
6 O
. O

9 O
- O
52 O
. O

7 O
u O
/ O
ml O
) O
compared O
to O
the O
normal O
controls O
( O
median O
, O
8 O
. O

6 O
u O
/ O
ml O
; O
range O
, O
6 O
. O

5 O
- O
12 O
. O

0 O
u O
/ O
ml O
, O
p O
< O
0 O
. O

1 O
) O
. O

levels O
were O
significantly O
greater O
in O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
due O
to O
paracetamol O
overdose B-Disease
( O
median O
, O
28 O
. O

7 O
u O
/ O
ml O
; O
range O
, O
12 O
. O

8 O
- O
52 O
. O

7 O
u O
/ O
ml O
, O
n O
= O
17 O
) O
than O
those O
due O
to O
non O
- O
a O
to O
e O
hepatitis B-Disease
( O
median O
, O
12 O
. O

5 O
u O
/ O
ml O
; O
range O
, O
6 O
. O

9 O
- O
46 O
. O

0 O
u O
/ O
ml O
, O
n O
= O
7 O
, O
p O
< O
0 O
. O

1 O
) O
. O

conclusions O
: O
the O
increased O
concentration O
of O
sfas O
in O
serum O
of O
patients O
with O
acute B-Disease
liver I-Disease
failure I-Disease
may O
reflect O
activation O
of O
fas O
- O
mediated O
apoptosis O
in O
the O
liver O
and O
this O
together O
with O
increased O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
may O
be O
an O
important O
factor O
in O
liver O
cell O
loss O
. O

bilateral O
subthalamic O
nucleus O
stimulation O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

high O
frequency O
stimulation O
of O
the O
subthalamic O
nucleus O
( O
stn O
) O
is O
known O
to O
ameliorate O
the O
signs O
and O
symptoms O
of O
advanced O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

method O
: O
twenty O
- O
three O
patients O
suffering O
from O
severe O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
stages O
iii O
- O
v O
on O
hoehn O
and O
yahr O
scale O
) O
and O
, O
particularly O
bradykinesia B-Disease
, O
rigidity B-Disease
, O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
underwent O
bilateral O
imB-Plantation O
of O
electrodes O
in O
the O
stn O
. O

preoperative O
and O
postoperative O
assessments O
of O
these O
patients O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
follow O
- O
up O
, O
in O
nan O
on O
nan O
and O
nan O
off O
nan O
drug O
conditions O
, O
was O
carried O
out O
using O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
, O
hoehn O
and O
yahr O
staging O
, O
england O
activities O
of O
daily O
living O
score O
and O
video O
recordings O
. O

results O
: O
after O
one O
year O
of O
electrical O
stimulation O
of O
the O
stn O
, O
the O
patients O
' O
scores O
for O
activities O
of O
daily O
living O
and O
motor O
examination O
scores O
( O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
parts O
ii O
and O
iii O
) O
off O
medication O
improved O
by O
62 O
% O
and O
61 O
% O
respectively O
( O
p O
< O
0 O
. O

5 O
) O
. O

the O
subscores O
for O
the O
akinesia B-Disease
, O
rigidity B-Disease
, O
tremor B-Disease
and O
gait O
also O
improved O
. O

conclusion O
: O
bilateral O
subthalamic O
nucleus O
stimulation O
is O
an O
effective O
treatment O
for O
advanced O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

the O
reduction O
in O
the O
levodopa O
dose O
is O
useful O
in O
controlling O
drug B-Disease
- I-Disease
induced I-Disease
dyskinesias I-Disease
. O

acute B-Disease
renal I-Disease
failure I-Disease
occurring O
during O
intravenous O
desferrioxamine O
therapy O
: O
recovery O
after O
haemodialysis O
. O

a O
patient O
with O
transfusion O
- O
dependent O
thalassemia B-Disease
was O
undergoing O
home O
intravenous O
desferrioxamine O
( O
dfx O
) O
treatment O
by O
means O
of O
a O
totally O
imB-Planted O
system O
because O
of O
his O
poor O
compliance O
with O
the O
nightly O
subcutaneous O
therapy O
. O

due O
to O
an O
accidental O
malfunctioning O
of O
the O
infusion O
pump O
, O
the O
patient O
was O
inadvertently O
administered O
a O
toxic O
dosage O
of O
the O
drug O
which O
caused O
renal B-Disease
insufficiency I-Disease
. O

given O
the O
progressive O
deterioration O
of O
the O
symptoms O
and O
of O
the O
laboratory O
values O
, O
despite O
adequate O
medical O
treatment O
, O
a O
decision O
was O
made O
to O
introduce O
haemodialytical O
therapy O
in O
order O
to O
remove O
the O
drug O
and O
therapy O
reduce O
the O
nephrotoxicity B-Disease
. O

from O
the O
results O
obtained O
, O
haemodialysis O
can O
therefore O
be O
suggested O
as O
a O
useful O
therapy O
in O
rare O
cases O
of O
progressive O
acute B-Disease
renal I-Disease
failure I-Disease
caused O
by O
desferrioxamine O
. O

ocular O
motility O
changes O
after O
subtenon O
carboplatin O
chemotherapy O
for O
retinoblastoma B-Disease
. O

background O
: O
focal O
subtenon O
carboplatin O
injections O
have O
recently O
been O
used O
as O
a O
presumably O
toxicity B-Disease
- O
free O
adjunct O
to O
systemic O
chemotherapy O
for O
intraocular O
retinoblastoma B-Disease
. O

objective O
: O
to O
report O
our O
clinical O
experience O
with O
abnormal B-Disease
ocular I-Disease
motility I-Disease
in O
patients O
treated O
with O
subtenon O
carboplatin O
chemotherapy O
. O

methods O
: O
we O
noted O
abnormal B-Disease
ocular I-Disease
motility I-Disease
in O
10 O
consecutive O
patients O
with O
retinoblastoma B-Disease
who O
had O
received O
subtenon O
carboplatin O
. O

during O
ocular O
manipulation O
under O
general O
anesthesia O
, O
we O
assessed O
their O
eyes O
by O
forced O
duction O
testing O
, O
comparing O
ocular O
motility O
after O
tumor B-Disease
control O
with O
ocular O
motility O
at O
diagnosis O
. O

results O
: O
limitation O
of O
ocular O
motility O
was O
detected O
in O
all O
12 O
eyes O
of O
10 O
patients O
treated O
for O
intraocular O
retinoblastoma B-Disease
with O
1 O
to O
6 O
injections O
of O
subtenon O
carboplatin O
as O
part O
of O
multimodality O
therapy O
. O

histopathological O
examination O
revealed O
many O
lipophages O
in O
the O
periorbital O
fat O
surrounding O
the O
optic O
nerve O
in O
1 O
eye O
, O
indicative O
of O
phagocytosis O
of O
previously O
existing O
fat O
cells O
and O
suggesting O
prior O
fat O
necrosis B-Disease
. O

the O
enucleations O
were O
technically O
difficult O
and O
hazardous O
for O
globe O
rupture B-Disease
because O
of O
extensive O
orbital O
soft O
tissue O
adhesions O
. O

conclusions O
: O
subtenon O
carboplatin O
chemotherapy O
is O
associated O
with O
significant O
fibrosis B-Disease
of O
orbital O
soft O
tissues O
, O
leading O
to O
mechanical O
restriction O
of O
eye O
movements O
and O
making O
subsequent O
enucleation O
difficult O
. O

subtenon O
carboplatin O
is O
not O
free O
of O
toxicity B-Disease
, O
and O
its O
use O
is O
best O
restricted O
to O
specific O
indications O
. O

ethambutol O
and O
optic B-Disease
neuropathy I-Disease
. O

purpose O
: O
to O
demonstrate O
the O
association O
between O
ethambutol O
and O
optic B-Disease
neuropathy I-Disease
. O

method O
: O
thirteen O
patients O
who O
developed O
optic B-Disease
neuropathy I-Disease
after O
being O
treated O
with O
ethambutol O
for O
tuberculosis B-Disease
of I-Disease
the I-Disease
lung I-Disease
or I-Disease
lymph I-Disease
node I-Disease
at O
siriraj O
hospital O
between O
1997 O
and O
2001 O
were O
retrospectively O
reviewed O
. O

results O
: O
all O
patients O
had O
optic B-Disease
neuropathy I-Disease
between O
1 O
to O
6 O
months O
( O
mean O
= O
2 O
. O

9 O
months O
) O
after O
starting O
ethambutol O
therapy O
at O
a O
dosage O
ranging O
from O
13 O
to O
20 O
mg O
/ O
kg O
/ O
day O
( O
mean O
= O
17 O
mg O
/ O
kg O
/ O
day O
) O
. O

of O
6 O
patients O
with O
irreversible O
visual B-Disease
impairment I-Disease
, O
4 O
patients O
had O
diabetes B-Disease
mellitus I-Disease
, O
glaucoma B-Disease
and O
a O
history O
of O
heavy O
smoking O
. O

conclusion O
: O
early O
recognition O
of O
optic B-Disease
neuropathy I-Disease
should O
be O
considered O
in O
patients O
with O
ethambutol O
therapy O
. O

a O
low O
dose O
and O
prompt O
discontinuation O
of O
the O
drug O
is O
recommended O
particularly O
in O
individuals O
with O
diabetes B-Disease
mellitus I-Disease
, O
glaucoma B-Disease
or O
who O
are O
heavy O
smokers O
. O

treatment O
of O
compensatory O
gustatory B-Disease
hyperhidrosis I-Disease
with O
topical O
glycopyrrolate O
. O

gustatory B-Disease
hyperhidrosis I-Disease
is O
facial O
sweating B-Disease
usually O
associated O
with O
the O
eating O
of O
hot O
spicy O
food O
or O
even O
smelling O
this O
food O
. O

all O
patients O
had O
gustatory B-Disease
hyperhidrosis I-Disease
, O
which O
interfered O
with O
their O
social O
activities O
, O
after O
transthroacic O
endoscopic O
sympathectomy O
, O
and O
which O
was O
associated O
with O
compensatory O
focal O
hyperhidrosis B-Disease
. O

after O
applying O
topical O
glycopyrrolate O
, O
the O
subjective O
effect O
was O
excellent O
( O
no O
sweating B-Disease
after O
eating O
hot O
spicy O
food O
) O
in O
10 O
patients O
( O
77 O
% O
) O
, O
and O
fair O
( O
clearly O
reduced O
sweating B-Disease
) O
in O
3 O
patients O
( O
23 O
% O
) O
. O

adverse O
effects O
included O
a O
mildly O
dry B-Disease
mouth I-Disease
and O
a O
sore B-Disease
throat I-Disease
in O
2 O
patients O
( O
2 O
% O
glycopyrrolate O
) O
, O
a O
light O
headache B-Disease
in O
1 O
patient O
( O
1 O
. O

5 O
% O
glycopyrrolate O
) O
. O

the O
topical O
application O
of O
a O
glycopyrrolate O
pad O
appeared O
to O
be O
safe O
, O
efficacious O
, O
well O
tolerated O
, O
and O
a O
convenient O
method O
of O
treatment O
for O
moderate O
to O
severe O
symptoms O
of O
gustatory B-Disease
hyperhidrosis I-Disease
in O
post O
transthoracic O
endoscopic O
sympathectomy O
or O
sympathicotomy O
patients O
, O
with O
few O
side O
effects O
. O

neuroleptic O
- O
associated O
hyperprolactinemia B-Disease
. O

six O
stable O
psychiatric O
outpatients O
with O
hyperprolactinemia B-Disease
and O
amenorrhea B-Disease
/ O
oligomenorrhea B-Disease
associated O
with O
their O
neuroleptic O
medications O
were O
treated O
with O
bromocriptine O
. O

daily O
dosages O
of O
5 O
- O
10 O
mg O
corrected O
the O
hyperprolactinemia B-Disease
and O
restored O
menstruation O
in O
four O
of O
the O
six O
patients O
. O

one O
woman O
, O
however O
, O
developed O
worsened O
psychiatric B-Disease
symptoms I-Disease
while O
taking O
bromocriptine O
, O
and O
it O
was O
discontinued O
. O

this O
suggests O
that O
bromocriptine O
should O
be O
further O
evaluated O
as O
potential O
therapy O
for O
neuroleptic O
- O
associated O
hyperprolactinemia B-Disease
and O
amenorrhea B-Disease
/ O
galactorrhea B-Disease
. O

ethacrynic O
acid O
- O
induced O
convulsions B-Disease
and O
brain O
neurotransmitters O
in O
mice O
. O

intracerebroventricular O
injection O
of O
ethacrynic O
acid O
( O
50 O
% O
convulsive B-Disease
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
ht O
) O
but O
suppressed O
the O
synthesis O
of O
gamma O
- O
aminobutyric O
acid O
and O
acetylcholine O
in O
mouse O
brain O
. O

in O
ethacrynic O
acid O
- O
induced O
convulsions B-Disease
, O
these O
neurotransmitter O
systems O
may O
be O
differentially O
modulated O
, O
probably O
through O
activation O
of O
glutaminergic O
neurons O
in O
the O
brain O
. O

moreover O
, O
0 O
. O

5 O
mg O
/ O
kg O
of O
this O
beta O
- O
carboline O
reduced O
markedly O
the O
increase O
of O
[ O
35s O
] O
tbps O
binding O
and O
the O
convulsions B-Disease
induced O
by O
isoniazid O
( O
200 O
mg O
/ O
kg O
s O
. O

c O
. O

) O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
recurrent O
myocardial B-Disease
infarction I-Disease
in O
a O
postpartum O
patient O
receiving O
bromocriptine O
. O

myocardial B-Disease
infarction I-Disease
in O
puerperium O
is O
infrequently O
reported O
. O

spasm B-Disease
, O
coronary O
dissection O
, O
or O
atheromatous O
etiology O
has O
been O
described O
. O

bromocriptine O
has O
been O
implicated O
in O
several O
previous O
case O
reports O
of O
myocardial B-Disease
infarction I-Disease
in O
the O
puerperium O
. O

asterixis B-Disease
induced O
by O
carbamazepine O
therapy O
. O

there O
are O
very O
few O
reports O
about O
asterixis B-Disease
as O
a O
side O
effect O
of O
treatment O
with O
psychopharmacologic O
agents O
. O

in O
this O
report O
we O
present O
four O
patients O
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis B-Disease
was O
triggered O
either O
by O
adding O
carbamazepine O
( O
cbz O
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O
. O

we O
consider O
asterixis B-Disease
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B-Disease
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium O
or O
clozapine O
are O
used O
in O
combination O
with O
cbz O
. O

pharmacodynamics O
of O
the O
hypotensive B-Disease
effect O
of O
levodopa O
in O
parkinsonian B-Disease
patients O
. O

blood O
pressure O
effects O
of O
i O
. O

v O
. O

levodopa O
were O
examined O
in O
parkinsonian B-Disease
patients O
with O
stable O
and O
fluctuating O
responses O
to O
levodopa O
. O

the O
magnitude O
of O
the O
hypotensive B-Disease
effect O
of O
levodopa O
was O
concentration O
dependent O
and O
was O
fit O
to O
an O
emax O
model O
in O
fluctuating O
responders O
. O

stable O
responders O
demonstrated O
a O
small O
hypotensive B-Disease
response O
. O

baseline O
blood O
pressures O
were O
higher O
in O
fluctuating O
patients O
; O
a O
higher O
baseline O
blood O
pressure O
correlated O
with O
greater O
hypotensive B-Disease
effects O
. O

phenylalanine O
, O
a O
large O
neutral O
amino O
acid O
( O
lnaa O
) O
competing O
with O
levodopa O
for O
transport O
across O
the O
blood O
- O
brain O
barrier O
, O
reduced O
the O
hypotensive B-Disease
and O
antiparkinsonian O
effects O
of O
levodopa O
. O

we O
conclude O
that O
levodopa O
has O
a O
central O
hypotensive B-Disease
action O
that O
parallels O
the O
motor O
effects O
in O
fluctuating O
patients O
. O

the O
hypotensive B-Disease
effect O
appears O
to O
be O
related O
to O
the O
higher O
baseline O
blood O
pressure O
we O
observed O
in O
fluctuating O
patients O
relative O
to O
stable O
patients O
. O

syndrome B-Disease
of I-Disease
inappropriate I-Disease
secretion I-Disease
of I-Disease
antidiuretic I-Disease
hormone I-Disease
after O
infusional O
vincristine O
. O

a O
77 O
- O
year O
- O
old O
woman O
with O
refractory O
multiple B-Disease
myeloma I-Disease
was O
treated O
with O
a O
4 O
- O
day O
continuous O
intravenous O
infusion O
of O
vincristine O
and O
doxorubicin O
and O
4 O
days O
of O
oral O
dexamethasone O
. O

nine O
days O
after O
her O
second O
cycle O
she O
presented O
with O
lethargy B-Disease
and O
weakness B-Disease
associated O
with O
hyponatremia B-Disease
. O

evaluation O
revealed O
the O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
secretion I-Disease
of I-Disease
antidiuretic I-Disease
hormone I-Disease
, O
which O
was O
attributed O
to O
the O
vincristine O
infusion O
. O

heart B-Disease
failure I-Disease
: O
to O
digitalise O
or O
not O
? O
in O
patients O
with O
atrial B-Disease
fibrillation I-Disease
digoxin O
is O
beneficial O
for O
ventricular O
rate O
control O
. O

for O
patients O
in O
sinus O
rhythm O
and O
heart B-Disease
failure I-Disease
the O
situation O
is O
less O
clear O
. O

also O
, O
digoxin O
has O
undesirable O
effects O
such O
as O
increasing O
peripheral O
resistance O
and O
myocardial O
demands O
, O
and O
causing O
arrhythmias B-Disease
. O

pooled O
analysis O
of O
the O
effects O
of O
other O
inotropic O
drugs O
shows O
an O
excess O
mortality O
and O
there O
is O
a O
possibility O
that O
digoxin O
may O
increase O
mortality O
after O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
. O

isradipine O
treatment O
for O
hypertension B-Disease
in O
general O
practice O
in O
hong O
kong O
. O

303 O
chinese O
patients O
with O
mild O
to O
moderate O
hypertension B-Disease
entered O
the O
study O
. O

the O
main O
side O
- O
effects O
were O
headache B-Disease
, O
dizziness B-Disease
, O
palpitation B-Disease
and O
flushing B-Disease
and O
these O
were O
not O
more O
frequent O
than O
reported O
in O
other O
studies O
with O
isradipine O
or O
with O
placebo O
. O

similar O
reductions O
occurred O
in O
standing O
blood O
pressure O
and O
there O
was O
no O
evidence O
of O
postural B-Disease
hypotension I-Disease
. O

the O
pharmacodynamic O
parameters O
assessed O
included O
induction O
and O
emergence O
times O
, O
respiratory O
and O
cardiovascular O
effects O
, O
and O
pain B-Disease
on O
injection O
. O

owing O
to O
a O
high O
incidence O
of O
thrombophlebitis B-Disease
, O
the O
study O
was O
terminated O
prematurely O
and O
only O
the O
data O
of O
the O
two O
parallel O
treatment O
groups O
( O
15 O
patients O
in O
each O
group O
) O
were O
analysed O
. O

pain B-Disease
on O
injection O
( O
80 O
vs O
. O

20 O
% O
, O
p O
< O
0 O
. O

1 O
) O
and O
thrombophlebitis B-Disease
( O
93 O
. O

3 O
vs O
. O

6 O
. O

6 O
% O
, O
p O
< O
0 O
. O

1 O
) O
occurred O
more O
frequently O
with O
am149 O
than O
with O
disoprivan O
. O

although O
both O
formulations O
had O
similar O
pharmacokinetic O
and O
pharmacodynamic O
profiles O
the O
new O
formulation O
is O
not O
suitable O
for O
clinical O
use O
due O
to O
the O
high O
incidence O
of O
thrombophlebitis B-Disease
produced O
. O

pure B-Disease
red I-Disease
cell I-Disease
aplasia I-Disease
, O
toxic B-Disease
dermatitis I-Disease
and O
lymphadenopathy B-Disease
in O
a O
patient O
taking O
diphenylhydantoin O
. O

a O
patient O
taking O
diphenylhydantoin O
for O
3 O
weeks O
developed O
a O
generalized O
skin B-Disease
rash I-Disease
, O
lymphadenopathy B-Disease
and O
pure B-Disease
red I-Disease
cell I-Disease
aplasia I-Disease
. O

skin B-Disease
rash I-Disease
is O
a O
well O
- O
known O
complication O
of O
diphenylhydantoin O
treatment O
as O
is O
benign O
and O
malignant O
lymphadenopathy B-Disease
. O

pure B-Disease
red I-Disease
cell I-Disease
aplasia I-Disease
associated O
with O
diphenylhydantoin O
medication O
has O
been O
reported O
in O
3 O
patients O
. O

in O
this O
patient O
the O
time O
relation O
between O
the O
ingestion O
of O
diphenylhydantoin O
and O
the O
occurrence O
of O
the O
skin B-Disease
rash I-Disease
, O
lymphadenopathy B-Disease
and O
pure B-Disease
red I-Disease
cell I-Disease
aplasia I-Disease
is O
very O
suggestive O
of O
a O
direct O
connection O
. O

in O
order O
to O
quantify O
the O
incidence O
of O
these O
cardiac O
events O
, O
we O
performed O
a O
meta O
- O
analysis O
of O
clinical O
trials O
comparing O
vnr O
with O
other O
chemotherapeutic O
agents O
in O
the O
treatment O
of O
various O
malignancies B-Disease
. O

randomized O
clinical O
trials O
comparing O
vnr O
with O
other O
drugs O
in O
the O
treatment O
of O
cancer B-Disease
were O
searched O
in O
medline O
, O
embase O
, O
evidence O
- O
based O
medicine O
reviews O
databases O
and O
the O
cochrane O
library O
from O
1987 O
to O
2002 O
. O

the O
risk O
of O
vnr O
cardiac O
events O
was O
similar O
to O
vindesine O
( O
vds O
) O
and O
other O
cardiotoxic B-Disease
drugs O
[ O
fluorouracil O
, O
anthracyclines O
, O
gemcitabine O
( O
gem O
) O
em O
leader O
] O
. O

even O
if O
it O
did O
not O
reach O
statistical O
significance O
because O
of O
a O
few O
number O
of O
cases O
, O
the O
risk O
was O
lower O
in O
trials O
excluding O
patients O
with O
cardiac O
history O
, O
and O
seemed O
to O
be O
higher O
in O
trials O
including O
patients O
with O
pre O
- O
existing O
cardiac B-Disease
diseases I-Disease
. O

mri O
findings O
of O
hypoxic O
cortical O
laminar O
necrosis B-Disease
in O
a O
child O
with O
hemolytic B-Disease
anemia I-Disease
crisis O
. O

we O
present O
magnetic O
resonance O
imaging O
findings O
of O
a O
5 O
- O
year O
- O
old O
girl O
who O
had O
a O
rapidly O
installing O
hemolytic B-Disease
anemia I-Disease
crisis O
induced O
by O
trimethoprim O
- O
sulfomethoxazole O
, O
resulting O
in O
cerebral B-Disease
anoxia I-Disease
leading O
to O
permanent O
damage O
. O

magnetic O
resonance O
imaging O
revealed O
cortical O
laminar O
necrosis B-Disease
in O
arterial O
border O
zones O
in O
both O
cerebral O
hemispheres O
, O
ischemic O
changes O
in O
subcortical O
white O
matter O
of O
left O
cerebral O
hemisphere O
, O
and O
in O
the O
left O
putamen O
. O

although O
cortical O
laminar O
necrosis B-Disease
is O
a O
classic O
entity O
in O
adulthood O
related O
to O
conditions O
of O
energy O
depletions O
, O
there O
are O
few O
reports O
available O
in O
children O
. O

the O
natural O
history O
of O
vigabatrin O
associated O
visual B-Disease
field I-Disease
defects I-Disease
in O
patients O
electing O
to O
continue O
their O
medication O
. O

purpose O
: O
to O
determine O
the O
natural O
history O
of O
visual B-Disease
field I-Disease
defects I-Disease
in O
a O
group O
of O
patients O
known O
to O
have O
vigabatrin O
- O
associated O
changes O
who O
elected O
to O
continue O
the O
medication O
because O
of O
good O
seizure B-Disease
control O
. O

following O
already O
published O
methodology O
( O
eye O
2002 O
; O
16 O
; O
567 O
- O
571 O
) O
monocular O
mean O
radial O
degrees O
( O
mrds O
) O
to O
the O
i O
/ O
4e O
isopter O
on O
goldmann O
perimetry O
was O
calculated O
for O
the O
right O
eye O
at O
the O
time O
of O
discovery O
of O
a O
visual B-Disease
field I-Disease
defect I-Disease
and O
again O
after O
not O
less O
than O
18 O
months O
follow O
- O
up O
. O

only O
one O
patient O
demonstrated O
a O
deterioration B-Disease
in I-Disease
visual I-Disease
field I-Disease
during O
the O
study O
period O
and O
discontinued O
treatment O
. O

conclusion O
: O
established O
visual B-Disease
field I-Disease
defects I-Disease
presumed O
to O
be O
due O
to O
vigabatrin O
therapy O
did O
not O
usually O
progress O
in O
spite O
of O
continuing O
use O
of O
the O
medication O
. O

these O
data O
give O
support O
to O
the O
hypothesis O
that O
the O
pathogenesis O
of O
vigabatrin O
- O
associated O
visual B-Disease
field I-Disease
defects I-Disease
may O
be O
an O
idiosyncratic O
adverse O
drug O
reaction O
rather O
than O
dose O
- O
dependent O
toxicity B-Disease
. O

induction O
of O
rosaceiform O
dermatitis B-Disease
during O
treatment O
of O
facial B-Disease
inflammatory I-Disease
dermatoses I-Disease
with O
tacrolimus O
ointment O
. O

background O
: O
tacrolimus O
ointment O
is O
increasingly O
used O
for O
anti O
- O
inflammatory O
treatment O
of O
sensitive O
areas O
such O
as O
the O
face O
, O
and O
recent O
observations O
indicate O
that O
the O
treatment O
is O
effective O
in O
steroid O
- O
aggravated O
rosacea B-Disease
and O
perioral B-Disease
dermatitis I-Disease
. O

we O
report O
on O
rosaceiform O
dermatitis B-Disease
as O
a O
complication O
of O
treatment O
with O
tacrolimus O
ointment O
. O

observations O
: O
six O
adult O
patients O
with O
inflammatory B-Disease
facial I-Disease
dermatoses I-Disease
were O
treated O
with O
tacrolimus O
ointment O
because O
of O
the O
ineffectiveness O
of O
standard O
treatments O
. O

within O
2 O
to O
3 O
weeks O
of O
initially O
effective O
and O
well O
- O
tolerated O
treatment O
, O
3 O
patients O
with O
a O
history O
of O
rosacea B-Disease
and O
1 O
with O
a O
history O
of O
acne B-Disease
experienced O
sudden O
worsening O
with O
pustular O
rosaceiform O
lesions O
. O

in O
1 O
patient O
with O
eyelid O
eczema B-Disease
, O
rosaceiform O
periocular B-Disease
dermatitis I-Disease
gradually O
appeared O
after O
3 O
weeks O
of O
treatment O
. O

in O
1 O
patient O
with O
atopic B-Disease
dermatitis I-Disease
, O
telangiectatic O
and O
papular B-Disease
rosacea I-Disease
insidiously O
appeared O
after O
5 O
months O
of O
treatment O
. O

conclusions O
: O
our O
observations O
suggest O
that O
the O
spectrum O
of O
rosaceiform O
dermatitis B-Disease
as O
a O
complication O
of O
treatment O
with O
tacrolimus O
ointment O
is O
heterogeneous O
. O

intravascular O
hemolysis B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
following O
intermittent O
rifampin O
therapy O
. O

renal B-Disease
failure I-Disease
is O
a O
rare O
complication O
associated O
with O
the O
use O
of O
rifampin O
. O

intravascular O
hemolysis B-Disease
leading O
to O
acute B-Disease
renal I-Disease
failure I-Disease
following O
rifampin O
therapy O
is O
extremely O
rare O
. O

two O
patients O
with O
leprosy B-Disease
who O
developed O
hemolysis B-Disease
and O
acute B-Disease
renal I-Disease
failure I-Disease
following O
rifampin O
are O
reported O
. O

we O
visualize O
, O
for O
the O
first O
time O
, O
the O
profile O
of O
structural B-Disease
deficits I-Disease
in I-Disease
the I-Disease
human I-Disease
brain I-Disease
associated O
with O
chronic O
methamphetamine O
( O
ma O
) O
abuse O
. O

studies O
of O
human O
subjects O
who O
have O
used O
ma O
chronically O
have O
revealed O
deficits O
in O
dopaminergic O
and O
serotonergic O
systems O
and O
cerebral O
metabolic B-Disease
abnormalities I-Disease
. O

using O
magnetic O
resonance O
imaging O
( O
mri O
) O
and O
new O
computational O
brain O
- O
mapping O
techniques O
, O
we O
determined O
the O
pattern O
of O
structural O
brain O
alterations O
associated O
with O
chronic O
ma O
abuse O
in O
human O
subjects O
and O
related O
these O
deficits O
to O
cognitive B-Disease
impairment I-Disease
. O

we O
used O
high O
- O
resolution O
mri O
and O
surface O
- O
based O
computational O
image O
analyses O
to O
map O
regional O
abnormalities B-Disease
in I-Disease
the I-Disease
cortex I-Disease
, I-Disease
hippocampus I-Disease
, I-Disease
white I-Disease
matter I-Disease
, I-Disease
and I-Disease
ventricles I-Disease
in O
22 O
human O
subjects O
who O
used O
ma O
and O
21 O
age O
- O
matched O
, O
healthy O
controls O
. O

on O
average O
, O
ma O
abusers O
had O
7 O
. O

8 O
% O
smaller O
hippocampal O
volumes O
than O
control O
subjects O
( O
p O
< O
0 O
. O

1 O
; O
left O
, O
p O
= O
0 O
. O

1 O
; O
right O
, O
p O
< O
0 O
. O

5 O
) O
and O
significant O
white O
- O
matter O
hypertrophy B-Disease
( O
7 O
. O

0 O
% O
; O
p O
< O
0 O
. O

1 O
) O
. O

mri O
- O
based O
maps O
suggest O
that O
chronic O
methamphetamine O
abuse O
causes O
a O
selective O
pattern O
of O
cerebral O
deterioration O
that O
contributes O
to O
impaired B-Disease
memory I-Disease
performance I-Disease
. O

prominent O
white O
- O
matter O
hypertrophy B-Disease
may O
result O
from O
altered O
myelination O
and O
adaptive O
glial O
changes O
, O
including O
gliosis B-Disease
secondary O
to O
neuronal B-Disease
damage I-Disease
. O

these O
brain O
substrates O
may O
help O
account O
for O
the O
symptoms O
of O
ma O
abuse O
, O
providing O
therapeutic O
targets O
for O
drug O
- O
induced O
brain B-Disease
injury I-Disease
. O

amiodarone O
, O
an O
efficacious O
and O
widely O
used O
antiarrhythmic O
agent O
, O
has O
been O
reported O
to O
cause O
hepatotoxicity B-Disease
in O
some O
patients O
. O

amiodarone O
induced O
hepatomegaly B-Disease
, O
hepatocyte O
microvesicular O
lipid O
accumulation O
, O
and O
a O
significant O
decrease O
in O
serum O
triglycerides O
and O
glucose O
. O

the O
absence O
of O
induction O
of O
these O
genes O
as O
well O
as O
hepatomegaly B-Disease
in O
pparalpha O
knockout O
[ O
pparalpha O
- O
/ O
- O
] O
mice O
indicated O
that O
the O
effects O
of O
amiodarone O
were O
dependent O
upon O
the O
presence O
of O
a O
functional O
pparalpha O
gene O
. O

compared O
to O
wild O
- O
type O
mice O
, O
treatment O
of O
pparalpha O
- O
/ O
- O
mice O
with O
amiodarone O
resulted O
in O
an O
increased O
rate O
and O
extent O
of O
total O
body O
weight B-Disease
loss I-Disease
. O

the O
inability O
of O
amiodarone O
to O
directly O
activate O
either O
human O
or O
mouse O
pparalpha O
transiently O
expressed O
in O
human O
hepg2 O
hepatoma B-Disease
cells O
indicates O
that O
the O
effects O
of O
amiodarone O
on O
the O
function O
of O
this O
receptor O
were O
indirect O
. O

these O
results O
provide O
important O
new O
mechanistic O
information O
regarding O
the O
hepatotoxic B-Disease
effects O
of O
amiodarone O
and O
indicate O
that O
pparalpha O
protects O
against O
amiodarone O
- O
induced O
hepatotoxicity B-Disease
. O

niacin O
extended O
- O
release O
/ O
lovastatin O
is O
a O
new O
combination O
product O
approved O
for O
treatment O
of O
primary O
hypercholesterolemia B-Disease
and O
mixed O
dyslipidemia B-Disease
. O

a O
total O
of O
4 O
, O
499 O
patients O
with O
dyslipidemia B-Disease
requiring O
drug O
intervention O
was O
enrolled O
at O
1 O
, O
81 O
sites O
. O

patients O
also O
received O
dietary O
counseling O
, O
educational O
materials O
, O
and O
reminders O
to O
call O
a O
toll O
- O
free O
number O
that O
provided O
further O
education O
about O
dyslipidemia B-Disease
and O
niacin O
extended O
- O
release O
/ O
lovastatin O
. O

primary O
end O
points O
were O
study O
compliance O
, O
increases O
in O
liver O
transaminases O
to O
> O
3 O
times O
the O
upper O
limit O
of O
normal O
, O
and O
clinical O
myopathy B-Disease
. O

flushing B-Disease
was O
the O
most O
common O
adverse O
event O
, O
reported O
by O
18 O
% O
of O
patients O
and O
leading O
to O
discontinuation O
by O
6 O
% O
. O

an O
increase O
of O
creatine O
phosphokinase O
to O
> O
5 O
times O
the O
upper O
limit O
of O
normal O
occurred O
in O
0 O
. O

24 O
% O
of O
patients O
, O
and O
no O
cases O
of O
drug O
- O
induced O
myopathy B-Disease
were O
observed O
. O

protective O
effect O
of O
terminalia O
chebula O
against O
experimental O
myocardial B-Disease
injury I-Disease
induced O
by O
isoproterenol O
. O

cardioprotective O
effect O
of O
ethanolic O
extract O
of O
terminalia O
chebula O
fruits O
( O
500 O
mg O
/ O
kg O
body O
wt O
) O
was O
examined O
in O
isoproterenol O
( O
200 O
mg O
/ O
kg O
body O
wt O
) O
induced O
myocardial B-Disease
damage I-Disease
in O
rats O
. O

histopathological O
examination O
was O
carried O
out O
to O
confirm O
the O
myocardial O
necrosis B-Disease
. O

a O
case O
of O
postoperative O
anxiety B-Disease
due O
to O
low O
dose O
droperidol O
used O
with O
patient O
- O
controlled O
analgesia O
. O

the O
diagnosis O
of O
droperidol O
- O
induced O
psychological B-Disease
disturbance I-Disease
was O
not O
made O
straight O
away O
although O
on O
subsequent O
close O
questioning O
the O
patient O
gave O
a O
very O
clear O
history O
. O

accurate O
patient O
history O
contributes O
to O
differentiating O
diabetes B-Disease
insipidus I-Disease
: O
a O
case O
study O
. O

the O
case O
discussed O
herein O
initially O
appeared O
to O
be O
neurogenic B-Disease
diabetes I-Disease
insipidus I-Disease
( O
di B-Disease
) O
secondary O
to O
a O
traumatic B-Disease
brain I-Disease
injury I-Disease
. O

the O
nursing O
staff O
, O
by O
reviewing O
the O
patient O
' O
s O
health O
history O
with O
his O
family O
, O
discovered O
a O
history O
of O
polydipsia B-Disease
and O
long O
- O
standing O
lithium O
use O
. O

lithium O
is O
implicated O
in O
drug O
- O
induced O
nephrogenic B-Disease
di I-Disease
, O
and O
because O
the O
patient O
had O
not O
received O
lithium O
since O
being O
admitted O
to O
the O
hospital O
, O
his O
treatment O
changed O
to O
focus O
on O
nephrogenic B-Disease
di I-Disease
. O

by O
combining O
information O
from O
the O
patient O
history O
, O
the O
physical O
examination O
, O
and O
radiologic O
and O
laboratory O
studies O
, O
the O
critical O
care O
team O
demonstrated O
that O
the O
patient O
had O
been O
self O
- O
treating O
his O
lithium O
- O
induced O
nephrogenic B-Disease
di I-Disease
and O
developed O
neurogenic B-Disease
di I-Disease
secondary O
to O
brain B-Disease
trauma I-Disease
. O

thus O
successful O
treatment O
required O
that O
nephrogenic O
and O
neurogenic B-Disease
di I-Disease
be O
treated O
concomitantly O
. O

factors O
contributing O
to O
ribavirin O
- O
induced O
anemia B-Disease
. O

background O
and O
aim O
: O
interferon O
and O
ribavirin O
combination O
therapy O
for O
chronic B-Disease
hepatitis I-Disease
c I-Disease
produces O
hemolytic B-Disease
anemia I-Disease
. O

this O
study O
was O
conducted O
to O
identify O
the O
factors O
contributing O
to O
ribavirin O
- O
induced O
anemia B-Disease
. O

methods O
: O
eighty O
- O
eight O
patients O
with O
chronic B-Disease
hepatitis I-Disease
c I-Disease
who O
received O
interferon O
- O
alpha O
- O
2b O
at O
a O
dose O
of O
6 O
mu O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin O
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

a O
hemoglobin O
concentration O
of O
< O
10 O
g O
/ O
dl O
was O
defined O
as O
ribavirin O
- O
induced O
anemia B-Disease
. O

results O
: O
ribavirin O
- O
induced O
anemia B-Disease
occurred O
in O
18 O
( O
20 O
. O

5 O
% O
) O
patients O
during O
treatment O
. O

a O
2 O
g O
/ O
dl O
decrease O
in O
hemoglobin O
concentrations O
in O
patients O
with O
anemia B-Disease
was O
observed O
at O
week O
2 O
after O
the O
start O
of O
treatment O
. O

a O
significant O
relationship O
was O
observed O
between O
the O
rate O
of O
reduction O
of O
hemoglobin O
concentrations O
at O
week O
2 O
and O
the O
severity O
of O
anemia B-Disease
( O
p O
< O
0 O
. O

1 O
) O
. O

zidovudine O
- O
induced O
hepatitis B-Disease
. O

a O
case O
of O
acute O
hepatitis B-Disease
induced O
by O
zidovudine O
in O
a O
38 O
- O
year O
- O
old O
patient O
with O
aids B-Disease
is O
presented O
. O

the O
mechanism O
whereby O
the O
hepatitis B-Disease
was O
induced O
is O
not O
known O
. O

physicians O
caring O
for O
patients O
with O
aids B-Disease
should O
be O
aware O
of O
this O
hitherto O
rarely O
reported O
complication O
. O

oxidative O
damage O
precedes O
nitrative O
damage O
in O
adriamycin O
- O
induced O
cardiac O
mitochondrial B-Disease
injury I-Disease
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
elevated O
reactive O
oxygen O
( O
ros O
) O
/ O
nitrogen O
species O
( O
rns O
) O
reported O
to O
be O
present O
in O
adriamycin O
( O
adr O
) O
- O
induced O
cardiotoxicity B-Disease
actually O
resulted O
in O
cardiomyocyte O
oxidative O
/ O
nitrative O
damage O
, O
and O
to O
quantitatively O
determine O
the O
time O
course O
and O
subcellular O
localization O
of O
these O
postulated O
damage O
products O
using O
an O
in O
vivo O
approach O
. O

our O
data O
showed O
adr O
induced O
4hne O
- O
protein O
adducts O
in O
mitochondria O
at O
the O
same O
time O
point O
as O
when O
mitochondrial B-Disease
injury I-Disease
initially O
appeared O
. O

these O
results O
document O
for O
the O
first O
time O
in O
vivo O
that O
mitochondrial B-Disease
oxidative I-Disease
damage I-Disease
precedes O
nitrative O
damage O
. O

the O
progressive O
nature O
of O
mitochondrial B-Disease
injury I-Disease
suggests O
that O
mitochondria O
, O
not O
other O
subcellular O
organelles O
, O
are O
the O
major O
site O
of O
intracellular O
injury O
. O

sotalol O
- O
induced O
coronary B-Disease
spasm I-Disease
in O
a O
patient O
with O
dilated B-Disease
cardiomyopathy I-Disease
associated O
with O
sustained O
ventricular B-Disease
tachycardia I-Disease
. O

a O
54 O
- O
year O
- O
old O
man O
with O
severe O
left O
ventricular B-Disease
dysfunction I-Disease
due O
to O
dilated B-Disease
cardiomyopathy I-Disease
was O
referred O
to O
our O
hospital O
for O
symptomatic O
incessant O
sustained O
ventricular B-Disease
tachycardia I-Disease
( O
vt B-Disease
) O
. O

after O
the O
administration O
of O
nifekalant O
hydrochloride O
, O
sustained O
vt B-Disease
was O
terminated O
. O

an O
alternate O
class O
iii O
agent O
, O
sotalol O
, O
was O
also O
effective O
for O
the O
prevention O
of O
vt B-Disease
. O

coronary B-Disease
vasospasm I-Disease
may O
be O
induced O
by O
the O
non O
- O
selective O
beta O
- O
blocking O
properties O
of O
sotalol O
. O

methods O
: O
the O
effect O
of O
pretreatment O
with O
trazodone O
on O
dexamphetamine O
- O
and O
apomorphine O
- O
induced O
oral B-Disease
stereotypies I-Disease
, O
on O
catalepsy B-Disease
induced O
by O
haloperidol O
and O
apomorphine O
( O
0 O
. O

5 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
, O
on O
ergometrine O
- O
induced O
wet O
dog O
shake O
( O
wds O
) O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
was O
studied O
in O
rats O
. O

we O
also O
investigated O
whether O
trazodone O
induces O
catalepsy B-Disease
in O
rats O
. O

results O
: O
trazodone O
at O
2 O
. O

5 O
- O
20 O
mg O
/ O
kg O
i O
. O

p O
. O

did O
not O
induce O
catalepsy B-Disease
, O
and O
did O
not O
antagonize O
apomorphine O
( O
1 O
. O

5 O
and O
3 O
mg O
/ O
kg O
) O
stereotypy O
and O
apomorphine O
( O
0 O
. O

5 O
mg O
/ O
kg O
) O
- O
induced O
catalepsy B-Disease
. O

however O
, O
pretreatment O
with O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
i O
. O

p O
. O

trazodone O
enhanced O
dexamphetamine O
stereotypy O
, O
and O
antagonized O
haloperidol O
catalepsy B-Disease
, O
ergometrine O
- O
induced O
wds O
behavior O
and O
fluoxetine O
- O
induced O
penile O
erections O
. O

trazodone O
at O
30 O
, O
40 O
and O
50 O
mg O
/ O
kg O
i O
. O

p O
. O

induced O
catalepsy B-Disease
and O
antagonized O
apomorphine O
and O
dexamphetamine O
stereotypies O
. O

we O
suggest O
that O
trazodone O
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
) O
, O
by O
blocking O
the O
5 O
- O
ht O
2c O
receptors O
, O
releases O
the O
nigrostriatal O
daergic O
neurons O
from O
tonic O
inhibition O
caused O
by O
5 O
- O
ht O
, O
and O
thereby O
potentiates O
dexamphetamine O
stereotypy O
and O
antagonizes O
haloperidol O
catalepsy B-Disease
. O

swallowing B-Disease
abnormalities I-Disease
and O
dyskinesia B-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

gastrointestinal B-Disease
abnormalities I-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
have O
been O
known O
for O
almost O
two O
centuries O
, O
but O
many O
aspects O
concerning O
their O
pathophysiology O
have O
not O
been O
completely O
clarified O
. O

the O
aim O
of O
this O
study O
was O
to O
characterize O
the O
oropharyngeal O
dynamics O
in O
pd B-Disease
patients O
with O
and O
without O
levodopa O
- O
induced O
dyskinesia B-Disease
. O

fifteen O
dyskinetic B-Disease
, O
12 O
nondyskinetic O
patients O
, O
and O
a O
control O
group O
were O
included O
. O

patients O
were O
asked O
about O
dysphagia B-Disease
and O
evaluated O
with O
the O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
parts O
ii O
and O
iii O
and O
the O
hoehn O
and O
yahr O
scale O
. O

nondyskinetic O
patients O
, O
but O
not O
the O
dyskinetic B-Disease
ones O
, O
showed O
less O
oropharyngeal O
swallowing O
efficiency O
( O
opse O
) O
for O
liquid O
food O
than O
controls O
( O
dunnett O
, O
p O
= O
0 O
. O

2 O
) O
. O

dyskinetic B-Disease
patients O
tended O
to O
have O
a O
greater O
opse O
than O
nondyskinetic O
( O
dunnett O
, O
p O
= O
0 O
. O

6 O
) O
. O

neither O
the O
report O
of O
dysphagia B-Disease
nor O
any O
of O
the O
pd B-Disease
severity O
parameters O
correlated O
to O
the O
videofluoroscopic O
variables O
. O

in O
the O
current O
study O
, O
dyskinetic B-Disease
patients O
performed O
better O
in O
swallowing O
function O
, O
which O
could O
be O
explained O
on O
the O
basis O
of O
a O
greater O
levodopa O
dose O
. O

our O
results O
suggest O
a O
role O
for O
levodopa O
in O
the O
oral O
phase O
of O
deglutition O
and O
confirm O
that O
dysphagia B-Disease
is O
not O
a O
good O
predictor O
of O
deglutition O
alterations O
in O
pd B-Disease
. O

inhibition O
of O
nuclear O
factor O
- O
kappab O
activation O
attenuates O
tubulointerstitial B-Disease
nephritis I-Disease
induced O
by O
gentamicin O
. O

background O
: O
animals O
treated O
with O
gentamicin O
can O
show O
residual O
areas O
of O
interstitial O
fibrosis B-Disease
in O
the O
renal O
cortex O
. O

the O
animals O
killed O
on O
day O
30 O
also O
presented O
fibrosis B-Disease
in O
the O
renal O
cortex O
despite O
the O
recovery O
of O
renal O
function O
. O

conclusions O
: O
these O
data O
show O
that O
inhibition O
of O
nf O
- O
kappab O
activation O
attenuates O
tubulointerstitial B-Disease
nephritis I-Disease
induced O
by O
gentamicin O
. O

glucose O
metabolism O
in O
patients O
with O
schizophrenia B-Disease
treated O
with O
atypical O
antipsychotic O
agents O
: O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
and O
minimal O
model O
analysis O
. O

background O
: O
while O
the O
incidence O
of O
new O
- O
onset O
diabetes B-Disease
mellitus I-Disease
may O
be O
increasing O
in O
patients O
with O
schizophrenia B-Disease
treated O
with O
certain O
atypical O
antipsychotic O
agents O
, O
it O
remains O
unclear O
whether O
atypical O
agents O
are O
directly O
affecting O
glucose O
metabolism O
or O
simply O
increasing O
known O
risk O
factors O
for O
diabetes B-Disease
. O

design O
: O
a O
cross O
- O
sectional O
design O
in O
stable O
, O
treated O
patients O
with O
schizophrenia B-Disease
evaluated O
using O
a O
frequently O
sampled O
intravenous O
glucose O
tolerance O
test O
and O
the O
bergman O
minimal O
model O
analysis O
. O

thirty O
- O
six O
nonobese O
subjects O
with O
schizophrenia B-Disease
or O
schizoaffective B-Disease
disorder I-Disease
, O
matched O
by O
body O
mass O
index O
and O
treated O
with O
either O
clozapine O
, O
olanzapine O
, O
or O
risperidone O
, O
were O
included O
in O
the O
analysis O
. O

main O
outcome O
measures O
: O
fasting O
plasma O
glucose O
and O
fasting O
serum O
insulin O
levels O
, O
insulin B-Disease
sensitivity I-Disease
index O
, O
homeostasis O
model O
assessment O
of O
insulin B-Disease
resistance I-Disease
, O
and O
glucose O
effectiveness O
. O

there O
was O
a O
significant O
difference O
in O
insulin B-Disease
sensitivity I-Disease
index O
among O
groups O
( O
f O
( O
33 O
) O
= O
10 O
. O

66 O
; O
p O
< O
. O

1 O
) O
( O
clozapine O
< O
olanzapine O
< O
risperidone O
) O
, O
with O
subjects O
who O
received O
clozapine O
and O
olanzapine O
exhibiting O
significant O
insulin B-Disease
resistance I-Disease
compared O
with O
subjects O
who O
were O
treated O
with O
risperidone O
( O
clozapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
- O
4 O
. O

29 O
; O
p O
< O
. O

1 O
; O
olanzapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
- O
3 O
. O

62 O
; O
p O
= O
. O

1 O
[ O
p O
< O
. O

1 O
] O
) O
. O

the O
homeostasis O
model O
assessment O
of O
insulin B-Disease
resistance I-Disease
also O
differed O
significantly O
among O
groups O
( O
f O
( O
33 O
) O
= O
4 O
. O

92 O
; O
p O
= O
. O

1 O
) O
( O
clozapine O
> O
olanzapine O
> O
risperidone O
) O
( O
clozapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
2 O
. O

94 O
; O
p O
= O
. O

6 O
; O
olanzapine O
vs O
risperidone O
, O
t O
( O
33 O
) O
= O
2 O
. O

42 O
; O
p O
= O
. O

2 O
) O
. O

conclusions O
: O
both O
nonobese O
clozapine O
- O
and O
olanzapine O
- O
treated O
groups O
displayed O
significant O
insulin B-Disease
resistance I-Disease
and O
impairment O
of O
glucose O
effectiveness O
compared O
with O
risperidone O
- O
treated O
subjects O
. O

patients O
taking O
clozapine O
and O
olanzapine O
must O
be O
examined O
for O
insulin B-Disease
resistance I-Disease
and O
its O
consequences O
. O

thoracic B-Disease
hematomyelia I-Disease
secondary O
to O
coumadin O
anticoagulant O
therapy O
: O
a O
case O
report O
. O

a O
case O
of O
thoracic B-Disease
hematomyelia I-Disease
secondary O
to O
anticoagulant O
therapy O
is O
presented O
. O

mania B-Disease
associated O
with O
fluoxetine O
treatment O
in O
adolescents O
. O

fluoxetine O
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
is O
gaining O
increased O
acceptance O
in O
the O
treatment O
of O
adolescent O
depression B-Disease
. O

generally O
safe O
and O
well O
tolerated O
by O
adults O
, O
fluoxetine O
has O
been O
reported O
to O
induce O
mania B-Disease
. O

the O
cases O
of O
five O
depressed B-Disease
adolescents O
, O
14 O
- O
16 O
years O
of O
age O
, O
who O
developed O
mania B-Disease
during O
pharmacotherapy O
with O
fluoxetine O
, O
are O
reported O
here O
. O

apparent O
risk O
factors O
for O
the O
development O
of O
mania B-Disease
or O
hypomania B-Disease
during O
fluoxetine O
pharmacotherapy O
in O
this O
population O
were O
the O
combination O
of O
attention B-Disease
- I-Disease
deficit I-Disease
hyperactivity I-Disease
disorder I-Disease
and O
affective O
instability O
; O
major O
depression B-Disease
with O
psychotic B-Disease
features O
; O
a O
family O
history O
of O
affective B-Disease
disorder I-Disease
, O
especially O
bipolar B-Disease
disorder I-Disease
; O
and O
a O
diagnosis O
of O
bipolar B-Disease
disorder I-Disease
. O

further O
study O
is O
needed O
to O
determine O
the O
optimal O
dosage O
and O
to O
identify O
risk O
factors O
that O
increase O
individual O
vulnerability O
to O
fluoxetine O
induced O
mania B-Disease
in O
adolescents O
. O

acute B-Disease
renal I-Disease
insufficiency I-Disease
after O
high O
- O
dose O
melphalan O
in O
patients O
with O
primary B-Disease
systemic I-Disease
amyloidosis I-Disease
during O
stem O
cell O
transB-Plantation O
. O

background O
: O
patients O
with O
primary B-Disease
systemic I-Disease
amyloidosis I-Disease
( O
al B-Disease
) O
have O
a O
poor O
prognosis O
. O

the O
authors O
have O
noted O
the O
development O
of O
acute B-Disease
renal I-Disease
insufficiency I-Disease
immediately O
after O
melphalan O
conditioning O
. O

methods O
: O
consecutive O
al B-Disease
patients O
who O
underwent O
pbsct O
were O
studied O
retrospectively O
. O

acute B-Disease
renal I-Disease
insufficiency I-Disease
( O
ari B-Disease
) O
after O
high O
- O
dose O
melphalan O
was O
defined O
by O
a O
minimum O
increase O
of O
0 O
. O

5 O
mg O
/ O
dl O
( O
44 O
micromol O
/ O
l O
) O
in O
the O
serum O
creatinine O
level O
that O
is O
greater O
than O
50 O
% O
of O
baseline O
immediately O
after O
conditioning O
. O

results O
: O
of O
the O
80 O
patients O
studied O
, O
ari B-Disease
developed O
in O
18 O
. O

8 O
% O
of O
the O
patients O
after O
high O
- O
dose O
melphalan O
. O

univariate O
analysis O
identified O
age O
, O
hypoalbuminemia B-Disease
, O
heavy O
proteinuria B-Disease
, O
diuretic O
use O
, O
and O
urine O
sediment O
score O
( O
> O
3 O
) O
as O
risk O
factors O
. O

patients O
who O
had O
ari B-Disease
after O
high O
- O
dose O
melphalan O
underwent O
dialysis O
more O
often O
( O
p O
= O
0 O
. O

7 O
) O
, O
and O
had O
a O
worse O
1 O
- O
year O
survival O
( O
p O
= O
0 O
. O

3 O
) O
. O

conclusion O
: O
the O
timing O
of O
renal B-Disease
injury I-Disease
strongly O
suggests O
melphalan O
as O
the O
causative O
agent O
. O

ongoing O
tubular B-Disease
injury I-Disease
may O
be O
a O
prerequisite O
for O
renal B-Disease
injury I-Disease
by O
melphalan O
as O
evidenced O
by O
the O
active O
urinary O
sediment O
. O

development O
of O
ari B-Disease
adversely O
affected O
the O
outcome O
after O
pbsct O
. O

effective O
preventive O
measures O
may O
help O
decrease O
the O
treatment O
mortality O
of O
pbsct O
in O
al B-Disease
patients O
. O

focal O
cerebral B-Disease
ischemia I-Disease
in O
rats O
: O
effect O
of O
phenylephrine O
- O
induced O
hypertension B-Disease
during O
reperfusion O
. O

after O
180 O
min O
of O
temporary O
middle B-Disease
cerebral I-Disease
artery I-Disease
occlusion I-Disease
in O
spontaneously O
hypertensive B-Disease
rats O
, O
the O
effect O
of O
phenylephrine O
- O
induced O
hypertension B-Disease
on O
ischemic B-Disease
brain I-Disease
injury I-Disease
and O
blood O
- O
brain O
barrier O
permeability O
was O
determined O
. O

blood O
pressure O
was O
manipulated O
by O
one O
of O
the O
following O
schedules O
during O
120 O
min O
of O
reperfusion O
: O
control O
, O
normotensive O
reperfusion O
; O
90 O
/ O
hypertension B-Disease
( O
90 O
/ O
htn B-Disease
) O
, O
blood O
pressure O
was O
increased O
by O
35 O
mm O
hg O
during O
the O
initial O
90 O
min O
of O
reperfusion O
only O
; O
15 O
/ O
hypertension B-Disease
( O
15 O
/ O
htn B-Disease
) O
, O
normotensive O
reperfusion O
for O
30 O
min O
followed O
by O
15 O
min O
of O
hypertension B-Disease
and O
75 O
min O
of O
normotension O
. O

part O
a O
, O
for O
eight O
rats O
in O
each O
group O
brain B-Disease
injury I-Disease
was O
evaluated O
by O
staining O
tissue O
using O
2 O
, O
3 O
, O
5 O
- O
triphenyltetrazolium O
chloride O
and O
edema B-Disease
was O
evaluated O
by O
microgravimetry O
. O

brain B-Disease
injury I-Disease
( O
percentage O
of O
the O
ischemic B-Disease
hemisphere I-Disease
) O
was O
less O
in O
the O
15 O
/ O
htn B-Disease
group O
( O
16 O
+ O
/ O
- O
6 O
, O
mean O
+ O
/ O
- O
sd O
) O
versus O
the O
90 O
/ O
htn B-Disease
group O
( O
30 O
+ O
/ O
- O
6 O
) O
, O
which O
was O
in O
turn O
less O
than O
the O
control O
group O
( O
42 O
+ O
/ O
- O
5 O
) O
. O

specific O
gravity O
was O
greater O
in O
the O
15 O
/ O
htn B-Disease
group O
( O
1 O
. O

43 O
+ O
/ O
- O
0 O
. O

2 O
) O
versus O
the O
90 O
/ O
htn B-Disease
( O
1 O
. O

36 O
+ O
/ O
- O
0 O
. O

3 O
) O
and O
control O
( O
1 O
. O

37 O
+ O
/ O
- O
0 O
. O

3 O
) O
groups O
. O

evans O
blue O
( O
mug O
g O
- O
1 O
of O
brain O
tissue O
) O
was O
greater O
in O
the O
90 O
/ O
htn B-Disease
group O
( O
24 O
. O

4 O
+ O
/ O
- O
6 O
. O

0 O
) O
versus O
the O
control O
group O
( O
12 O
. O

3 O
+ O
/ O
- O
4 O
. O

1 O
) O
, O
which O
was O
in O
turn O
greater O
than O
the O
15 O
/ O
htn B-Disease
group O
( O
7 O
. O

3 O
+ O
/ O
- O
3 O
. O

2 O
) O
. O

this O
study O
supports O
a O
hypothesis O
that O
during O
reperfusion O
, O
a O
short O
interval O
of O
hypertension B-Disease
decreases O
brain B-Disease
injury I-Disease
and O
edema B-Disease
; O
and O
that O
sustained O
hypertension B-Disease
increases O
the O
risk O
of O
vasogenic B-Disease
edema I-Disease
. O

people O
aged O
over O
75 O
in O
atrial B-Disease
fibrillation I-Disease
on O
warfarin O
: O
the O
rate O
of O
major O
hemorrhage B-Disease
and O
stroke B-Disease
in O
more O
than O
500 O
patient O
- O
years O
of O
follow O
- O
up O
. O

objectives O
: O
to O
determine O
the O
incidence O
of O
major O
hemorrhage B-Disease
and O
stroke B-Disease
in O
people O
aged O
76 O
and O
older O
with O
atrial B-Disease
fibrillation I-Disease
on O
adjusted O
- O
dose O
warfarin O
who O
had O
been O
recently O
been O
admitted O
to O
hospital O
. O

participants O
: O
two O
hundred O
thirty O
- O
five O
patients O
aged O
76 O
and O
older O
admitted O
to O
a O
major O
healthcare O
network O
between O
july O
1 O
, O
2001 O
, O
and O
june O
30 O
, O
2002 O
, O
with O
atrial B-Disease
fibrillation I-Disease
on O
warfarin O
were O
enrolled O
. O

measurements O
: O
information O
regarding O
major O
bleeding B-Disease
episodes O
, O
strokes B-Disease
, O
and O
warfarin O
use O
was O
obtained O
from O
patients O
, O
relatives O
, O
primary O
physicians O
, O
and O
medical O
records O
. O

there O
were O
53 O
major O
hemorrhages B-Disease
, O
for O
an O
annual O
rate O
of O
10 O
. O

0 O
% O
, O
including O
24 O
( O
45 O
. O

3 O
% O
) O
life O
- O
threatening O
and O
five O
( O
9 O
. O

4 O
% O
) O
fatal O
bleeds O
. O

the O
annual O
stroke B-Disease
rate O
after O
initiation O
of O
warfarin O
was O
2 O
. O

6 O
% O
. O

conclusion O
: O
the O
rate O
of O
major O
hemorrhage B-Disease
was O
high O
in O
this O
old O
, O
frail O
group O
, O
but O
excluding O
fatalities O
, O
resulted O
in O
no O
long O
- O
term O
sequelae O
, O
and O
the O
stroke B-Disease
rate O
on O
warfarin O
was O
low O
, O
demonstrating O
how O
effective O
warfarin O
treatment O
is O
. O

safety O
of O
celecoxib O
in O
patients O
with O
adverse O
skin B-Disease
reactions I-Disease
to O
acetaminophen O
( O
paracetamol O
) O
and O
nimesulide O
associated O
or O
not O
with O
common O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
. O

the O
rate O
of O
adverse O
hypersensitivity B-Disease
reactions O
to O
these O
agents O
is O
generally O
low O
. O

objective O
: O
we O
evaluated O
the O
tolerability O
of O
ce O
in O
a O
group O
of O
patients O
with O
documented O
history O
of O
adverse O
cutaneous B-Disease
reactions I-Disease
to O
p O
and O
n O
associated O
or O
not O
to O
classic O
nsaids O
. O

methods O
: O
we O
studied O
9 O
patients O
with O
hypersensitivity B-Disease
to O
p O
and O
n O
with O
or O
without O
associated O
reactions O
to O
classic O
nsaids O
. O

the O
diagnosis O
of O
p O
and O
n O
- O
induced O
skin B-Disease
reactions I-Disease
was O
based O
in O
vivo O
challenge O
. O

the O
challenge O
was O
considered O
positive O
if O
one O
or O
more O
of O
the O
following O
appeared O
: O
erythema B-Disease
, O
rush O
or O
urticaria B-Disease
- O
angioedema B-Disease
. O

only O
one O
patient O
developed O
a O
moderate O
angioedema B-Disease
of O
the O
lips O
. O

conclusion O
: O
only O
one O
hypersensitivity B-Disease
reaction O
to O
ce O
was O
documented O
among O
9 O
p O
and O
n O
- O
highly O
nsaids O
intolerant O
patients O
. O

case O
- O
control O
study O
of O
regular O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
use O
and O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
. O

background O
: O
studies O
on O
the O
association O
between O
the O
long O
- O
term O
use O
of O
aspirin O
and O
other O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
and O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
( O
esrd B-Disease
) O
have O
given O
conflicting O
results O
. O

in O
order O
to O
examine O
this O
association O
, O
a O
case O
- O
control O
study O
with O
incident O
cases O
of O
esrd B-Disease
was O
carried O
out O
. O

methods O
: O
the O
cases O
were O
all O
patients O
entering O
the O
local O
dialysis O
program O
because O
of O
esrd B-Disease
in O
the O
study O
area O
between O
june O
1 O
, O
1995 O
and O
november O
30 O
, O
1997 O
. O

they O
were O
classified O
according O
to O
the O
underlying O
disease O
, O
which O
had O
presumably O
led O
them O
to O
esrd B-Disease
. O

the O
risk O
of O
esrd B-Disease
associated O
with O
aspirin O
was O
related O
to O
the O
cumulated O
dose O
and O
duration O
of O
use O
, O
and O
it O
was O
particularly O
high O
among O
the O
subset O
of O
patients O
with O
vascular O
nephropathy B-Disease
as O
underlying O
disease O
[ O
2 O
. O

35 O
( O
1 O
. O

17 O
- O
4 O
. O

72 O
) O
] O
. O

conclusion O
: O
our O
data O
indicate O
that O
long O
- O
term O
use O
of O
nonaspirin O
analgesic O
drugs O
and O
nsaids O
is O
not O
associated O
with O
an O
increased O
risk O
of O
esrd B-Disease
. O

however O
, O
the O
chronic O
use O
of O
aspirin O
may O
increase O
the O
risk O
of O
esrd B-Disease
. O

two O
cases O
of O
amisulpride O
overdose B-Disease
: O
a O
cause O
for O
prolonged B-Disease
qt I-Disease
syndrome I-Disease
. O

two O
cases O
of O
deliberate O
self O
- O
poisoning B-Disease
with O
5 O
g O
and O
3 O
. O

6 O
g O
of O
amisulpride O
, O
respectively O
, O
are O
reported O
. O

in O
both O
cases O
, O
qt B-Disease
prolongation I-Disease
and O
hypocalcaemia B-Disease
were O
noted O
. O

the O
qt B-Disease
prolongation I-Disease
appeared O
to O
respond O
to O
administration O
of O
i O
. O

v O
. O

calcium O
gluconate O
. O

growth O
- O
associated O
protein O
43 O
expression O
in O
hippocampal O
molecular O
layer O
of O
chronic O
epileptic B-Disease
rats O
treated O
with O
cycloheximide O
. O

purpose O
: O
gap43 O
has O
been O
thought O
to O
be O
linked O
with O
mossy O
fiber O
sprouting O
( O
mfs O
) O
in O
various O
experimental O
models O
of O
epilepsy B-Disease
. O

to O
investigate O
how O
gap43 O
expression O
( O
gap43 O
- O
ir O
) O
correlates O
with O
mfs O
, O
we O
assessed O
the O
intensity O
( O
densitometry O
) O
and O
extension O
( O
width O
) O
of O
gap43 O
- O
ir O
in O
the O
inner O
molecular O
layer O
of O
the O
dentate O
gyrus O
( O
iml O
) O
of O
rats O
subject O
to O
status B-Disease
epilepticus I-Disease
induced O
by O
pilocarpine O
( O
pilo O
) O
, O
previously O
injected O
or O
not O
with O
cycloheximide O
( O
chx O
) O
, O
which O
has O
been O
shown O
to O
inhibit O
mfs O
. O

although O
some O
studies O
in O
experimental O
animals O
indicate O
clear O
pharmacological O
interactions O
between O
them O
, O
no O
studies O
have O
shown O
a O
specific O
interaction O
on O
anxiety B-Disease
responses O
. O

objectives O
: O
the O
present O
study O
investigates O
the O
effects O
of O
nicotine O
on O
anxiety B-Disease
induced O
by O
caffeine O
and O
another O
anxiogenic O
drug O
, O
pentylenetetrazole O
, O
in O
mice O
. O

the O
elevated O
plus O
- O
maze O
( O
epm O
) O
test O
was O
used O
to O
evaluate O
the O
effects O
of O
drugs O
on O
anxiety B-Disease
. O

nicotine O
( O
0 O
. O

25 O
mg O
/ O
kg O
) O
pretreatment O
blocked O
the O
caffeine O
- O
but O
not O
pentylenetetrazole O
- O
induced O
anxiety B-Disease
. O

conclusions O
: O
our O
results O
suggest O
that O
the O
antagonistic O
effect O
of O
nicotine O
on O
caffeine O
- O
induced O
anxiety B-Disease
is O
specific O
to O
caffeine O
, O
instead O
of O
a O
non O
- O
specific O
anxiolytic O
effect O
. O

background O
: O
hormone O
therapy O
( O
ht O
) O
is O
widely O
used O
for O
controlling O
menopausal B-Disease
symptoms I-Disease
. O

it O
has O
also O
been O
used O
for O
the O
management O
and O
prevention O
of O
cardiovascular B-Disease
disease I-Disease
, O
osteoporosis B-Disease
and O
dementia B-Disease
in O
older O
women O
but O
the O
evidence O
supporting O
its O
use O
for O
these O
indications O
is O
largely O
observational O
. O

objectives O
: O
to O
assess O
the O
effect O
of O
long O
- O
term O
ht O
on O
mortality O
, O
heart B-Disease
disease I-Disease
, O
venous B-Disease
thromboembolism I-Disease
, O
stroke B-Disease
, O
transient B-Disease
ischaemic I-Disease
attacks I-Disease
, O
breast B-Disease
cancer I-Disease
, O
colorectal B-Disease
cancer I-Disease
, O
ovarian B-Disease
cancer I-Disease
, O
endometrial B-Disease
cancer I-Disease
, O
gallbladder B-Disease
disease I-Disease
, O
cognitive O
function O
, O
dementia B-Disease
, O
fractures B-Disease
and O
quality O
of O
life O
. O

in O
relatively O
healthy O
women O
, O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thromboembolism I-Disease
or O
coronary O
event O
( O
after O
one O
year O
' O
s O
use O
) O
, O
stroke B-Disease
( O
after O
3 O
years O
) O
, O
breast B-Disease
cancer I-Disease
( O
after O
5 O
years O
) O
and O
gallbladder B-Disease
disease I-Disease
. O

long O
- O
term O
oestrogen O
- O
only O
ht O
also O
significantly O
increased O
the O
risk O
of O
stroke B-Disease
and O
gallbladder B-Disease
disease I-Disease
. O

overall O
, O
the O
only O
statistically O
significant O
benefits O
of O
ht O
were O
a O
decreased O
incidence O
of O
fractures B-Disease
and O
colon B-Disease
cancer I-Disease
with O
long O
- O
term O
use O
. O

among O
relatively O
healthy O
women O
over O
65 O
years O
taking O
continuous O
combined O
ht O
, O
there O
was O
a O
statistically O
significant O
increase O
in O
the O
incidence O
of O
dementia B-Disease
. O

among O
women O
with O
cardiovascular B-Disease
disease I-Disease
, O
long O
- O
term O
use O
of O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-Disease
thromboembolism I-Disease
. O

the O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B-Disease
thromboembolism I-Disease
in O
women O
taking O
combined O
continuous O
ht O
; O
their O
absolute O
risk O
remained O
very O
low O
. O

authors O
' O
conclusions O
: O
ht O
is O
not O
indicated O
for O
the O
routine O
management O
of O
chronic B-Disease
disease I-Disease
. O

drug B-Disease
- I-Disease
induced I-Disease
liver I-Disease
injury I-Disease
: O
an O
analysis O
of O
461 O
incidences O
submitted O
to O
the O
spanish O
registry O
over O
a O
10 O
- O
year O
period O
. O

background O
& O
aims O
: O
progress O
in O
the O
understanding O
of O
susceptibility O
factors O
to O
drug B-Disease
- I-Disease
induced I-Disease
liver I-Disease
injury I-Disease
( O
dili B-Disease
) O
and O
outcome O
predictability O
are O
hampered O
by O
the O
lack O
of O
systematic O
programs O
to O
detect O
bona O
fide O
cases O
. O

methods O
: O
a O
cooperative O
network O
was O
created O
in O
1994 O
in O
spain O
to O
identify O
all O
suspicions O
of O
dili B-Disease
following O
a O
prospective O
structured O
report O
form O
. O

the O
liver B-Disease
damage I-Disease
was O
characterized O
according O
to O
hepatocellular O
, O
cholestatic B-Disease
, O
and O
mixed O
laboratory O
criteria O
and O
to O
histologic O
criteria O
when O
available O
. O

results O
: O
since O
april O
1994 O
to O
august O
2004 O
, O
461 O
out O
of O
570 O
submitted O
cases O
, O
involving O
505 O
drugs O
, O
were O
deemed O
to O
be O
related O
to O
dili B-Disease
. O

indeed O
, O
the O
incidence O
of O
liver O
transB-Plantation O
and O
death O
in O
this O
group O
was O
11 O
. O

7 O
% O
if O
patients O
had O
jaundice B-Disease
at O
presentation O
, O
whereas O
the O
corresponding O
figure O
was O
3 O
. O

8 O
% O
in O
nonjaundiced O
patients O
( O
p O
< O
. O

4 O
) O
. O

factors O
associated O
with O
the O
development O
of O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
were O
female O
sex O
( O
or O
= O
25 O
; O
95 O
% O
ci O
: O
4 O
. O

1 O
- O
151 O
; O
p O
< O
. O

1 O
) O
, O
hepatocellular O
damage O
( O
or O
= O
7 O
. O

9 O
; O
95 O
% O
ci O
: O
1 O
. O

6 O
- O
37 O
; O
p O
< O
. O

9 O
) O
, O
and O
higher O
baseline O
plasma O
bilirubin O
value O
( O
or O
= O
1 O
. O

15 O
; O
95 O
% O
ci O
: O
1 O
. O

9 O
- O
1 O
. O

22 O
; O
p O
< O
. O

1 O
) O
. O

conclusions O
: O
patients O
with O
drug O
- O
induced O
hepatocellular O
jaundice B-Disease
have O
11 O
. O

7 O
% O
chance O
of O
progressing O
to O
death O
or O
transB-Plantation O
. O

amoxicillin O
- O
clavulanate O
stands O
out O
as O
the O
most O
common O
drug O
related O
to O
dili B-Disease
. O

morphological O
evaluation O
of O
the O
effect O
of O
d O
- O
ribose O
on O
adriamycin O
- O
evoked O
cardiotoxicity B-Disease
in O
rats O
. O

the O
influence O
of O
d O
- O
ribose O
on O
adriamycin O
- O
induced O
myocardiopathy B-Disease
in O
rats O
was O
studied O
. O

adriamycin O
in O
the O
cumulative O
dose O
of O
25 O
mg O
/ O
kg O
evoked O
fully O
developed O
cardiac B-Disease
toxicity I-Disease
. O

d O
- O
ribose O
in O
the O
multiple O
doses O
of O
200 O
mg O
/ O
kg O
did O
not O
influence O
adr O
cardiotoxicity B-Disease
. O

in O
vivo O
evidences O
suggesting O
the O
role O
of O
oxidative O
stress O
in O
pathogenesis O
of O
vancomycin O
- O
induced O
nephrotoxicity B-Disease
: O
protection O
by O
erdosteine O
. O

the O
aims O
of O
this O
study O
were O
to O
examine O
vancomycin O
( O
vcm O
) O
- O
induced O
oxidative O
stress O
that O
promotes O
production O
of O
reactive O
oxygen O
species O
( O
ros O
) O
and O
to O
investigate O
the O
role O
of O
erdosteine O
, O
an O
expectorant O
agent O
, O
which O
has O
also O
antioxidant O
properties O
, O
on O
kidney O
tissue O
against O
the O
possible O
vcm O
- O
induced O
renal B-Disease
impairment I-Disease
in O
rats O
. O

vcm O
administration O
to O
control O
rats O
significantly O
increased O
renal O
malondialdehyde O
( O
mda O
) O
and O
urinary O
n O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
nag O
, O
a O
marker O
of O
renal B-Disease
tubular I-Disease
injury I-Disease
) O
excretion O
but O
decreased O
superoxide O
dismutase O
( O
sod O
) O
and O
catalase O
( O
cat O
) O
activities O
. O

erdosteine O
showed O
histopathological O
protection O
against O
vcm O
- O
induced O
nephrotoxicity B-Disease
. O

there O
were O
a O
significant O
dilatation O
of O
tubular O
lumens O
, O
extensive O
epithelial O
cell O
vacuolization O
, O
atrophy B-Disease
, O
desquamation B-Disease
, O
and O
necrosis B-Disease
in O
vcm O
- O
treated O
rats O
more O
than O
those O
of O
the O
control O
and O
the O
erdosteine O
groups O
. O

it O
is O
concluded O
that O
oxidative O
tubular O
damage O
plays O
an O
important O
role O
in O
the O
vcm O
- O
induced O
nephrotoxicity B-Disease
and O
the O
modulation O
of O
oxidative O
stress O
with O
erdosteine O
reduces O
the O
vcm O
- O
induced O
kidney B-Disease
damage I-Disease
both O
at O
the O
biochemical O
and O
histological O
levels O
. O

gemfibrozil O
- O
lovastatin O
therapy O
for O
primary O
hyperlipoproteinemias B-Disease
. O

the O
specific O
aim O
of O
this O
retrospective O
, O
observational O
study O
was O
to O
assess O
safety O
and O
efficacy O
of O
long O
- O
term O
( O
21 O
months O
/ O
patient O
) O
, O
open O
- O
label O
, O
gemfibrozil O
- O
lovastatin O
treatment O
in O
80 O
patients O
with O
primary O
mixed O
hyperlipidemia B-Disease
( O
68 O
% O
of O
whom O
had O
atherosclerotic B-Disease
vascular I-Disease
disease I-Disease
) O
. O

myositis B-Disease
, O
attributable O
to O
the O
drug O
combination O
and O
symptomatic O
enough O
to O
discontinue O
it O
, O
occurred O
in O
3 O
% O
of O
patients O
, O
and O
in O
1 O
% O
with O
concurrent O
high O
creatine O
phosphokinase O
( O
769 O
u O
/ O
liter O
) O
; O
no O
patients O
had O
rhabdomyolysis B-Disease
or O
myoglobinuria B-Disease
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
does O
domperidone O
potentiate O
mirtazapine O
- O
associated O
restless B-Disease
legs I-Disease
syndrome I-Disease
? O
there O
is O
now O
evidence O
to O
suggest O
a O
central O
role O
for O
the O
dopaminergic O
system O
in O
restless B-Disease
legs I-Disease
syndrome I-Disease
( O
rls B-Disease
) O
. O

for O
example O
, O
the O
symptoms O
of O
rls B-Disease
can O
be O
dramatically O
improved O
by O
levodopa O
and O
dopamine O
agonists O
, O
whereas O
central O
dopamine O
d2 O
receptor O
antagonists O
can O
induce O
or O
aggravate O
rls B-Disease
symptoms O
. O

to O
our O
knowledge O
, O
there O
is O
no O
previous O
report O
regarding O
whether O
domperidone O
, O
a O
peripheral O
dopamine O
d2 O
receptor O
antagonist O
, O
can O
also O
induce O
or O
aggravate O
symptoms O
of O
rls B-Disease
. O

mirtazapine O
, O
the O
first O
noradrenergic O
and O
specific O
serotonergic O
antidepressant O
( O
nassa O
) O
, O
has O
been O
associated O
with O
rls B-Disease
in O
several O
recent O
publications O
. O

the O
authors O
report O
here O
a O
depressed O
patient O
comorbid O
with O
postprandial B-Disease
dyspepsia I-Disease
who O
developed O
rls B-Disease
after O
mirtazapine O
had O
been O
added O
to O
his O
domperidone O
therapy O
. O

our O
patient O
started O
to O
have O
symptoms O
of O
rls B-Disease
only O
after O
he O
had O
been O
treated O
with O
mirtazapine O
, O
and O
his O
rls B-Disease
symptoms O
resolved O
completely O
upon O
discontinuation O
of O
his O
mirtazapine O
. O

such O
a O
temporal O
relationship O
between O
the O
use O
of O
mirtazapine O
and O
the O
symptoms O
of O
rls B-Disease
in O
our O
patient O
did O
not O
support O
a O
potentiating O
effect O
of O
domperione O
on O
mirtazapine O
- O
associated O
rls B-Disease
. O

however O
, O
physicians O
should O
be O
aware O
of O
the O
possibility O
that O
mirtazapine O
can O
be O
associated O
with O
rls B-Disease
in O
some O
individuals O
, O
especially O
those O
receiving O
concomitant O
dopamine O
d2 O
receptor O
antagonists O
. O

antiandrogenic O
therapy O
can O
cause O
coronary B-Disease
arterial I-Disease
disease I-Disease
. O

aim O
: O
to O
study O
the O
change O
of O
lipid O
metabolism O
by O
antiandrogen O
therapy O
in O
patients O
with O
prostate B-Disease
cancer I-Disease
. O

materials O
and O
methods O
: O
we O
studied O
with O
a O
2 O
. O

5 O
years O
follow O
- O
up O
the O
changes O
in O
plasma O
cholesterols O
( O
c O
) O
, O
triglycerides O
( O
tg O
) O
, O
lipoproteins O
( O
lp O
) O
, O
and O
apolipoproteins O
( O
apo O
) O
b O
- O
100 O
, O
a O
- O
i O
, O
and O
a O
- O
ii O
pro O
fi O
les O
in O
24 O
patients O
of O
mean O
age O
60 O
years O
with O
low O
risk O
prostate B-Disease
cancer I-Disease
( O
stage O
: O
t1cn0m0 O
, O
gleason O
score O
: O
2 O
- O
5 O
) O
during O
treatment O
with O
cyproterone O
acetate O
( O
cpa O
) O
without O
surgical O
management O
or O
radiation O
therapy O
. O

after O
a O
period O
of O
2 O
. O

5 O
years O
on O
cpa O
treatment O
, O
four O
patients O
out O
of O
twenty O
- O
four O
were O
found O
to O
be O
affected O
by O
coronary B-Disease
heart I-Disease
disease I-Disease
. O

conclusions O
: O
ischaemic O
coronary B-Disease
arteriosclerosis I-Disease
with O
an O
incidence O
rate O
of O
16 O
. O

6 O
% O
as O
caused O
by O
prolonged O
cpa O
therapy O
is O
mediated O
through O
changes O
in O
hdl O
cholesterol O
, O
apo O
a O
- O
i O
and O
apo O
a O
- O
ii O
pro O
fi O
les O
, O
other O
than O
the O
well O
- O
known O
hyperglyceridemic B-Disease
effect I-Disease
caused O
by O
estrogen O
. O

5 O
- O
fluorouracil O
cardiotoxicity B-Disease
induced O
by O
alpha O
- O
fluoro O
- O
beta O
- O
alanine O
. O

cardiotoxicity B-Disease
is O
a O
rare O
complication O
occurring O
during O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
treatment O
for O
malignancies B-Disease
. O

we O
herein O
report O
the O
case O
of O
a O
70 O
- O
year O
- O
old O
man O
with O
5 O
- O
fu O
- O
induced O
cardiotoxicity B-Disease
, O
in O
whom O
a O
high O
serum O
level O
of O
alpha O
- O
fluoro O
- O
beta O
- O
alanine O
( O
fbal O
) O
was O
observed O
. O

the O
patient O
, O
who O
had O
unresectable O
colon B-Disease
cancer I-Disease
metastases O
to O
the O
liver O
and O
lung O
, O
was O
referred O
to O
us O
for O
chemotherapy O
from O
an O
affiliated O
hospital O
; O
he O
had O
no O
cardiac O
history O
. O

after O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5 O
- O
fu O
( O
1000 O
mg O
/ O
day O
) O
, O
during O
which O
precordial B-Disease
pain I-Disease
with O
right B-Disease
bundle I-Disease
branch I-Disease
block I-Disease
occurred O
concomitantly O
with O
a O
high O
serum O
fbal O
concentration O
of O
1955 O
ng O
/ O
ml O
. O

both O
the O
precordial B-Disease
pain I-Disease
and O
the O
electrocardiographic O
changes O
disappeared O
spontaneously O
after O
the O
discontinuation O
of O
5 O
- O
fu O
. O

as O
the O
precordial B-Disease
pain I-Disease
in O
this O
patient O
was O
considered O
to O
have O
been O
due O
to O
5 O
- O
fu O
- O
induced O
cardiotoxicity B-Disease
, O
the O
administration O
of O
5 O
- O
fu O
was O
abandoned O
. O

thereafter O
, O
no O
cardiac B-Disease
symptoms I-Disease
were O
observed O
. O

the O
experience O
of O
this O
case O
, O
together O
with O
a O
review O
of O
the O
literature O
, O
suggests O
that O
fbal O
is O
related O
to O
5 O
- O
fu O
- O
induced O
cardiotoxicity B-Disease
. O

s O
- O
1 O
may O
be O
administered O
safely O
to O
patients O
with O
5 O
- O
fu O
- O
induced O
cardiotoxicity B-Disease
. O

hepatocellular B-Disease
carcinoma I-Disease
in O
fanconi B-Disease
' I-Disease
s I-Disease
anemia I-Disease
treated O
with O
androgen O
and O
corticosteroid O
. O

the O
case O
of O
an O
11 O
- O
year O
- O
old O
boy O
is O
reported O
who O
was O
known O
to O
have O
fanconi B-Disease
' I-Disease
s I-Disease
anemia I-Disease
for O
3 O
years O
and O
was O
treated O
with O
androgens O
, O
corticosteroids O
and O
transfusions O
. O

two O
weeks O
before O
his O
death O
he O
was O
readmitted O
because O
of O
aplastic O
crisis O
with O
septicemia B-Disease
and O
marked O
abnormalities O
in O
liver O
function O
and O
died O
of O
hemorrhagic B-Disease
bronchopneumonia I-Disease
. O

at O
autopsy O
peliosis B-Disease
and O
multiple O
hepatic B-Disease
tumors I-Disease
were O
found O
which O
histologically O
proved O
to O
be O
well O
- O
differentiated O
hepatocellular B-Disease
carcinoma I-Disease
. O

this O
case O
contributes O
to O
the O
previous O
observations O
that O
non O
- O
metastasizing O
hepatic B-Disease
neoplasms I-Disease
and O
peliosis B-Disease
can O
develop O
in O
patients O
with O
androgen O
- O
and O
corticosteroid O
- O
treated O
fanconi B-Disease
' I-Disease
s I-Disease
anemia I-Disease
. O

the O
influence O
of O
the O
time O
interval O
between O
monoher O
and O
doxorubicin O
administration O
on O
the O
protection O
against O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
in O
mice O
. O

purpose O
: O
despite O
its O
well O
- O
known O
cardiotoxicity B-Disease
, O
the O
anthracyclin O
doxorubicin O
( O
dox O
) O
continues O
to O
be O
an O
effective O
and O
widely O
used O
chemotherapeutic O
agent O
. O

dox O
- O
induced O
cardiac B-Disease
damage I-Disease
presumably O
results O
from O
the O
formation O
of O
free O
radicals O
by O
dox O
. O

the O
semisynthetic O
flavonoid O
monohydroxyethylrutoside O
( O
monoher O
) O
showed O
cardioprotection O
against O
dox O
- O
induced O
cardiotoxicity B-Disease
through O
its O
radical O
scavenging O
and O
iron O
chelating O
properties O
. O

their O
cardiac O
tissues O
were O
processed O
for O
light O
microscopy O
, O
after O
which O
cardiomyocyte B-Disease
damage I-Disease
was O
evaluated O
according O
to O
billingham O
( O
in O
cancer B-Disease
treat O
rep O
62 O
( O
6 O
) O
: O
865 O
- O
872 O
, O
1978 O
) O
. O

microscopic O
evaluation O
revealed O
that O
treatment O
with O
dox O
alone O
induced O
significant O
cardiac B-Disease
damage I-Disease
in O
comparison O
to O
the O
saline O
control O
group O
( O
p O
< O
0 O
. O

1 O
) O
. O

clinical O
evaluation O
of O
adverse O
effects O
during O
bepridil O
administration O
for O
atrial B-Disease
fibrillation I-Disease
and I-Disease
flutter I-Disease
. O

background O
: O
bepridil O
hydrochloride O
( O
bpd O
) O
has O
attracted O
attention O
as O
an O
effective O
drug O
for O
atrial B-Disease
fibrillation I-Disease
( O
af B-Disease
) O
and O
atrial B-Disease
flutter I-Disease
( O
afl B-Disease
) O
. O

however O
, O
serious O
adverse O
effects O
, O
including O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
, O
have O
been O
reported O
. O

bpd O
was O
administered O
to O
459 O
patients O
( O
361 O
males O
, O
63 O
+ O
/ O
- O
12 O
years O
old O
) O
comprising O
378 O
af B-Disease
and O
81 O
afl B-Disease
cases O
. O

there O
was O
marked O
qt B-Disease
prolongation I-Disease
greater O
than O
0 O
. O

55 O
s O
in O
13 O
patients O
, O
bradycardia B-Disease
less O
than O
40 O
beats O
/ O
min O
in O
6 O
patients O
, O
dizziness B-Disease
and O
general O
fatigue B-Disease
in O
1 O
patient O
each O
. O

in O
4 O
of O
13 O
patients O
with O
qt B-Disease
prolongation I-Disease
, O
tdp B-Disease
occurred O
. O

the O
major O
triggering O
factors O
of O
tdp B-Disease
were O
hypokalemia B-Disease
and O
sudden O
decrease O
in O
heart O
rate O
. O

there O
were O
no O
differences O
in O
the O
clinical O
backgrounds O
of O
the O
patients O
with O
and O
without O
tdp B-Disease
other O
than O
lad O
and O
age O
, O
which O
were O
larger O
and O
older O
in O
the O
patients O
with O
tdp B-Disease
. O

enhanced O
isoproterenol O
- O
induced O
cardiac B-Disease
hypertrophy I-Disease
in O
transgenic O
rats O
with O
low O
brain O
angiotensinogen O
. O

lv B-Disease
hypertrophy I-Disease
induced O
by O
iso O
treatment O
was O
significantly O
higher O
in O
tgr O
than O
in O
sd O
rats O
( O
in O
g O
lv O
wt O
/ O
100 O
g O
body O
wt O
, O
0 O
. O

28 O
+ O
/ O
- O
0 O
. O

4 O
vs O
. O

0 O
. O

24 O
+ O
/ O
- O
0 O
. O

4 O
, O
respectively O
) O
. O

the O
greater O
lv B-Disease
hypertrophy I-Disease
in O
tgr O
rats O
was O
associated O
with O
more O
pronounced O
downregulation O
of O
beta O
- O
ar O
and O
upregulation O
of O
lv O
beta O
- O
ar O
kinase O
- O
1 O
mrna O
levels O
compared O
with O
those O
in O
sd O
rats O
. O

these O
results O
indicate O
that O
tgr O
are O
more O
sensitive O
to O
beta O
- O
ar O
agonist O
- O
induced O
cardiac B-Disease
inotropic I-Disease
response O
and O
hypertrophy B-Disease
, O
possibly O
due O
to O
chronically O
low O
sympathetic O
outflow O
directed O
to O
the O
heart O
. O

drug O
- O
induced O
long B-Disease
qt I-Disease
syndrome I-Disease
in O
injection O
drug O
users O
receiving O
methadone O
: O
high O
frequency O
in O
hospitalized O
patients O
and O
risk O
factors O
. O

background O
: O
drug O
- O
induced O
long B-Disease
qt I-Disease
syndrome I-Disease
is O
a O
serious O
adverse O
drug O
reaction O
. O

in O
the O
inpatient O
setting O
, O
the O
frequency O
of O
qt B-Disease
interval I-Disease
prolongation I-Disease
with O
methadone O
treatment O
, O
its O
dose O
dependence O
, O
and O
the O
importance O
of O
cofactors O
such O
as O
drug O
- O
drug O
interactions O
remain O
unknown O
. O

in O
addition O
to O
methadone O
dose O
, O
15 O
demographic O
, O
biological O
, O
and O
pharmacological O
variables O
were O
considered O
as O
potential O
risk O
factors O
for O
qt B-Disease
prolongation I-Disease
. O

six O
patients O
( O
3 O
. O

6 O
% O
) O
in O
the O
methadone O
group O
presented O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

multivariate O
regression O
analysis O
allowed O
attribution O
of O
31 O
. O

8 O
% O
of O
qtc O
variability O
to O
methadone O
dose O
, O
cytochrome O
p O
- O
450 O
3a4 O
drug O
- O
drug O
interactions O
, O
hypokalemia B-Disease
, O
and O
altered O
liver O
function O
. O

conclusions O
: O
qt B-Disease
interval I-Disease
prolongation I-Disease
in O
methadone O
maintenance O
patients O
hospitalized O
in O
a O
tertiary O
care O
center O
is O
a O
frequent O
finding O
. O

methadone O
dose O
, O
presence O
of O
cytochrome O
p O
- O
450 O
3a4 O
inhibitors O
, O
potassium O
level O
, O
and O
liver O
function O
contribute O
to O
qt B-Disease
prolongation I-Disease
. O

long B-Disease
qt I-Disease
syndrome I-Disease
can O
occur O
with O
low O
doses O
of O
methadone O
. O

mechanisms O
of O
hypertension B-Disease
induced O
by O
nitric O
oxide O
( O
no O
) O
deficiency O
: O
focus O
on O
venous O
function O
. O

loss O
of O
endothelial O
cell O
- O
derived O
nitric O
oxide O
( O
no O
) O
in O
hypertension B-Disease
is O
a O
hallmark O
of O
arterial B-Disease
dysfunction I-Disease
. O

experimental O
hypertension B-Disease
created O
by O
the O
removal O
of O
no O
, O
however O
, O
involves O
mechanisms O
in O
addition O
to O
decreased O
arterial O
vasodilator O
activity O
. O

we O
hypothesized O
that O
increased O
venous O
smooth O
muscle O
( O
venomotor O
) O
tone O
plays O
a O
role O
in O
nomega O
- O
nitro O
- O
l O
- O
arginine O
( O
lnna O
) O
hypertension B-Disease
through O
these O
mechanisms O
. O

mean O
circulatory O
filling O
pressure O
, O
an O
in O
vivo O
measure O
of O
venomotor O
tone O
, O
was O
not O
elevated O
in O
lnna O
hypertension B-Disease
at O
1 O
or O
2 O
weeks O
after O
lnna O
. O

similarly O
, O
ganglionic O
blockade O
with O
hexamethonium O
caused O
a O
significantly O
greater O
fall O
in O
lnna O
hypertensive B-Disease
rats O
( O
76 O
+ O
/ O
- O
9 O
mm O
hg O
) O
compared O
with O
control O
rats O
( O
35 O
+ O
/ O
- O
10 O
mm O
hg O
) O
. O

these O
data O
suggest O
that O
while O
no O
deficiency O
increases O
oxidative O
stress O
and O
sympathetic O
activity O
in O
both O
arterial O
and O
venous O
vessels O
, O
the O
impact O
on O
veins O
does O
not O
make O
a O
major O
contribution O
to O
this O
form O
of O
hypertension B-Disease
. O

association O
of O
drd2 O
polymorphisms O
and O
chlorpromazine O
- O
induced O
extrapyramidal B-Disease
syndrome I-Disease
in O
chinese O
schizophrenic B-Disease
patients O
. O

aim O
: O
extrapyramidal B-Disease
syndrome I-Disease
( O
eps B-Disease
) O
is O
most O
commonly O
affected O
by O
typical O
antipsychotic O
drugs O
that O
have O
a O
high O
affinity O
with O
the O
d2 O
receptor O
. O

recently O
, O
many O
research O
groups O
have O
reported O
on O
the O
positive O
relationship O
between O
the O
genetic O
variations O
in O
the O
drd2 O
gene O
and O
the O
therapeutic O
response O
in O
schizophrenia B-Disease
patients O
as O
a O
result O
of O
the O
role O
of O
variations O
in O
the O
receptor O
in O
modulating O
receptor O
expression O
. O

in O
this O
study O
, O
we O
evaluate O
the O
role O
drd2 O
plays O
in O
chlorpromazine O
- O
induced O
eps B-Disease
in O
schizophrenic B-Disease
patients O
. O

methods O
: O
we O
identified O
seven O
snp O
( O
single O
nucleotide O
polymorphism O
) O
( O
- O
141cins O
> O
del O
, O
taqib O
, O
taqid O
, O
ser311cys O
, O
rs6275 O
, O
rs6277 O
and O
taqia O
) O
in O
the O
drd2 O
gene O
in O
146 O
schizophrenic B-Disease
inpatients O
( O
59 O
with O
eps B-Disease
and O
87 O
without O
eps B-Disease
according O
to O
the O
simpson O
- O
angus O
scale O
) O
treated O
with O
chlorpromazine O
after O
8 O
weeks O
. O

conclusion O
: O
our O
results O
did O
not O
lend O
strong O
support O
to O
the O
view O
that O
the O
genetic O
variation O
of O
the O
drd2 O
gene O
plays O
a O
major O
role O
in O
the O
individually O
variable O
adverse O
effect O
induced O
by O
chlorpromazine O
, O
at O
least O
in O
chinese O
patients O
with O
schizophrenia B-Disease
. O

our O
results O
confirmed O
a O
previous O
study O
on O
the O
relationship O
between O
drd2 O
and O
eps B-Disease
in O
caucasians O
. O

physical O
training O
decreases O
susceptibility O
to O
subsequent O
pilocarpine O
- O
induced O
seizures B-Disease
in O
the O
rat O
. O

regular O
motor O
activity O
has O
many O
benefits O
for O
mental O
and O
physical O
condition O
but O
its O
implications O
for O
epilepsy B-Disease
are O
still O
controversial O
. O

in O
order O
to O
elucidate O
this O
problem O
, O
we O
have O
studied O
the O
effect O
of O
long O
- O
term O
physical O
activity O
on O
susceptibility O
to O
subsequent O
seizures B-Disease
. O

thereafter O
, O
seizures B-Disease
were O
induced O
by O
pilocarpine O
injections O
in O
trained O
and O
non O
- O
trained O
control O
groups O
. O

during O
the O
acute O
period O
of O
status B-Disease
epilepticus I-Disease
, O
we O
measured O
: O
( O
1 O
) O
the O
latency O
of O
the O
first O
motor O
sign O
, O
( O
2 O
) O
the O
intensity O
of O
seizures B-Disease
, O
( O
3 O
) O
the O
time O
when O
it O
occurred O
within O
the O
6 O
- O
h O
observation O
period O
, O
and O
( O
4 O
) O
the O
time O
when O
the O
acute O
period O
ended O
. O

all O
these O
behavioral O
parameters O
showed O
statistically O
significant O
changes O
suggesting O
that O
regular O
physical O
exercises O
decrease O
susceptibility O
to O
subsequently O
induced O
seizures B-Disease
and O
ameliorate O
the O
course O
of O
experimentally O
induced O
status B-Disease
epilepticus I-Disease
. O

tonic O
dopaminergic O
stimulation O
impairs B-Disease
associative I-Disease
learning I-Disease
in O
healthy O
subjects O
. O

administration O
of O
the O
dopamine O
precursor O
levodopa O
enhances O
learning O
in O
healthy O
subjects O
and O
stroke B-Disease
patients O
. O

the O
dopamine O
agonist O
significantly O
impaired B-Disease
novel I-Disease
word I-Disease
learning I-Disease
compared O
to O
placebo O
. O

thus O
, O
phasic O
signaling O
seems O
to O
be O
the O
critical O
mechanism O
by O
which O
dopamine O
enhances O
associative O
learning O
in O
healthy O
subjects O
and O
stroke B-Disease
patients O
. O

minocycline O
- O
induced O
vasculitis B-Disease
fulfilling O
the O
criteria O
of O
polyarteritis B-Disease
nodosa I-Disease
. O

a O
47 O
- O
year O
- O
old O
man O
who O
had O
been O
taking O
minocycline O
for O
palmoB-Plantar B-Disease
pustulosis I-Disease
developed O
fever B-Disease
, O
myalgias B-Disease
, O
polyneuropathy B-Disease
, O
and O
testicular B-Disease
pain I-Disease
, O
with O
elevated O
c O
- O
reactive O
protein O
( O
crp O
) O
. O

these O
manifestations O
met O
the O
american O
college O
of O
rheumatology O
1990 O
criteria O
for O
the O
classification O
of O
polyarteritis B-Disease
nodosa I-Disease
. O

to O
our O
knowledge O
, O
this O
is O
the O
second O
case O
of O
minocycline O
- O
induced O
vasculitis B-Disease
satisfying O
the O
criteria O
. O

differential O
diagnosis O
for O
drug O
- O
induced O
disease O
is O
invaluable O
even O
for O
patients O
with O
classical O
polyarteritis B-Disease
nodosa I-Disease
. O

intramuscular O
hepatitis B-Disease
b I-Disease
immune O
globulin O
combined O
with O
lamivudine O
in O
prevention O
of O
hepatitis B-Disease
b I-Disease
recurrence O
after O
liver O
transB-Plantation O
. O

background O
: O
combined O
hepatitis B-Disease
b I-Disease
immune O
globulin O
( O
hbig O
) O
and O
lamivudine O
in O
prophylaxis O
of O
the O
recurrence O
of O
hepatitis B-Disease
b I-Disease
after O
liver O
transB-Plantation O
has O
significantly O
improved O
the O
survival O
of O
hbsag O
positive O
patients O
. O

this O
study O
was O
undertaken O
to O
evaluate O
the O
outcomes O
of O
liver O
transB-Plantation O
for O
patients O
with O
hepatitis B-Disease
b I-Disease
virus O
( O
hbv O
) O
. O

methods O
: O
a O
retrospective O
chart O
analysis O
and O
a O
review O
of O
the O
organ O
transB-Plant O
database O
identified O
51 O
patients O
( O
43 O
men O
and O
8 O
women O
) O
transB-Planted O
for O
benign O
hbv O
- O
related O
cirrhotic B-Disease
diseases I-Disease
between O
june O
2002 O
and O
december O
2004 O
who O
had O
survived O
more O
than O
3 O
months O
. O

anticonvulsant O
effect O
of O
eslicarbazepine O
acetate O
( O
bia O
2 O
- O
93 O
) O
on O
seizures B-Disease
induced O
by O
microperfusion O
of O
picrotoxin O
in O
the O
hippocampus O
of O
freely O
moving O
rats O
. O

we O
have O
studied O
the O
effects O
of O
oral O
treatment O
with O
eslicarbazepine O
acetate O
on O
a O
whole O
- O
animal O
model O
in O
which O
partial O
seizures B-Disease
can O
be O
elicited O
repeatedly O
on O
different O
days O
without O
changes O
in O
threshold O
or O
seizure B-Disease
patterns O
. O

in O
the O
animals O
treated O
with O
threshold O
doses O
of O
picrotoxin O
, O
the O
average O
number O
of O
seizures B-Disease
was O
2 O
. O

3 O
+ O
/ O
- O
1 O
. O

2 O
, O
and O
average O
seizure B-Disease
duration O
was O
39 O
. O

5 O
+ O
/ O
- O
8 O
. O

4s O
. O

pre O
- O
treatment O
with O
a O
dose O
of O
30 O
mg O
/ O
kg O
2h O
before O
picrotoxin O
microperfusion O
prevented O
seizures B-Disease
in O
the O
75 O
% O
of O
the O
rats O
. O

lower O
doses O
( O
3 O
and O
10mg O
/ O
kg O
) O
did O
not O
suppress O
seizures B-Disease
, O
however O
, O
after O
administration O
of O
10mg O
/ O
kg O
, O
significant O
reductions O
in O
seizures B-Disease
duration O
( O
24 O
. O

3 O
+ O
/ O
- O
6 O
. O

8s O
) O
and O
seizure B-Disease
number O
( O
1 O
. O

6 O
+ O
/ O
- O
0 O
. O

34 O
) O
were O
found O
. O

acute B-Disease
renal I-Disease
failure I-Disease
associated O
with O
prolonged O
intake O
of O
slimming O
pills O
containing O
anthraquinones O
. O

nephropathy B-Disease
caused O
by O
chinese O
herbs O
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic O
acids O
. O

we O
report O
a O
23 O
- O
year O
- O
old O
woman O
who O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
following O
prolonged O
use O
of O
a O
proprietary O
chinese O
herbal O
slimming O
pill O
that O
contained O
anthraquinone O
derivatives O
, O
extracted O
from O
rhizoma O
rhei O
( O
rhubarb O
) O
. O

the O
renal B-Disease
injury I-Disease
was O
probably O
aggravated O
by O
the O
concomitant O
intake O
of O
a O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
diclofenac O
. O

renal O
pathology O
was O
that O
of O
hypocellular O
interstitial O
fibrosis B-Disease
. O

spontaneous O
renal O
recovery O
occurred O
upon O
cessation O
of O
the O
slimming O
pills O
, O
but O
mild O
interstitial O
fibrosis B-Disease
and O
tubular O
atrophy B-Disease
was O
still O
evident O
histologically O
4 O
months O
later O
. O

although O
a O
causal O
relationship O
between O
the O
use O
of O
an O
anthraquinone O
- O
containing O
herbal O
agent O
and O
renal B-Disease
injury I-Disease
remains O
to O
be O
proven O
, O
phytotherapy O
- O
associated O
interstitial O
nephropathy B-Disease
should O
be O
considered O
in O
patients O
who O
present O
with O
unexplained O
renal B-Disease
failure I-Disease
. O

chloroacetaldehyde O
as O
a O
sulfhydryl O
reagent O
: O
the O
role O
of O
critical O
thiol O
groups O
in O
ifosfamide O
nephropathy B-Disease
. O

chloroacetaldehyde O
( O
caa O
) O
is O
a O
metabolite O
of O
the O
alkylating O
agent O
ifosfamide O
( O
ifo O
) O
and O
putatively O
responsible O
for O
renal B-Disease
damage I-Disease
following O
anti O
- O
tumor B-Disease
therapy O
with O
ifo O
. O

toxicity B-Disease
of O
caa O
was O
determined O
by O
protein O
content O
, O
cell O
number O
, O
ldh O
release O
, O
trypan O
blue O
exclusion O
assay O
and O
caspase O
- O
3 O
activity O
. O

caa O
reduced O
hrptec O
cell O
number O
and O
protein O
, O
induced O
a O
loss O
in O
free O
intracellular O
thiols O
and O
an O
increase O
in O
necrosis B-Disease
markers O
. O

acidification O
, O
which O
slowed O
the O
reaction O
of O
caa O
with O
thiol O
donors O
, O
could O
also O
attenuate O
effects O
of O
caa O
on O
necrosis B-Disease
markers O
, O
thiol O
depletion O
and O
cysteine O
protease O
inhibition O
in O
living O
cells O
. O

thus O
, O
caa O
directly O
reacts O
with O
cellular O
protein O
and O
non O
- O
protein O
thiols O
, O
mediating O
its O
toxicity B-Disease
on O
hrptec O
. O

therefore O
, O
urinary O
acidification O
could O
be O
an O
option O
to O
prevent O
ifo O
nephropathy B-Disease
in O
patients O
. O

stereological O
methods O
reveal O
the O
robust O
size O
and O
stability O
of O
ectopic O
hilar O
granule O
cells O
after O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
in O
the O
adult O
rat O
. O

following O
status B-Disease
epilepticus I-Disease
in O
the O
rat O
, O
dentate O
granule O
cell O
neurogenesis O
increases O
greatly O
, O
and O
many O
of O
the O
new O
neurons O
appear O
to O
develop O
ectopically O
, O
in O
the O
hilar O
region O
of O
the O
hippocampal O
formation O
. O

it O
has O
been O
suggested O
that O
the O
ectopic O
hilar O
granule O
cells O
could O
contribute O
to O
the O
spontaneous O
seizures B-Disease
that O
ultimately O
develop O
after O
status B-Disease
epilepticus I-Disease
. O

to O
quantify O
this O
population O
, O
the O
total O
number O
of O
ectopic O
hilar O
granule O
cells O
was O
estimated O
using O
unbiased O
stereology O
at O
different O
times O
after O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
. O

the O
results O
indicate O
that O
the O
size O
of O
the O
hilar O
ectopic O
granule O
cell O
population O
after O
status B-Disease
epilepticus I-Disease
is O
substantial O
, O
and O
stable O
over O
time O
. O

interestingly O
, O
the O
size O
of O
the O
population O
appears O
to O
be O
correlated O
with O
the O
frequency O
of O
behavioral O
seizures B-Disease
, O
because O
animals O
with O
more O
ectopic O
granule O
cells O
in O
the O
hilus O
have O
more O
frequent O
behavioral O
seizures B-Disease
. O

the O
results O
provide O
new O
insight O
into O
the O
potential O
role O
of O
ectopic O
hilar O
granule O
cells O
in O
the O
pilocarpine O
model O
of O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
. O

a O
prospective O
, O
open O
- O
label O
trial O
of O
galantamine O
in O
autistic B-Disease
disorder I-Disease
. O

objective O
: O
post O
- O
mortem O
studies O
have O
reported O
abnormalities O
of O
the O
cholinergic O
system O
in O
autism B-Disease
. O

the O
purpose O
of O
this O
study O
was O
to O
assess O
the O
use O
of O
galantamine O
, O
an O
acetylcholinesterase O
inhibitor O
and O
nicotinic O
receptor O
modulator O
, O
in O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B-Disease
. O

methods O
: O
thirteen O
medication O
- O
free O
children O
with O
autism B-Disease
( O
mean O
age O
, O
8 O
. O

8 O
+ O
/ O
- O
3 O
. O

5 O
years O
) O
participated O
in O
a O
12 O
- O
week O
, O
open O
- O
label O
trial O
of O
galantamine O
. O

results O
: O
patients O
showed O
a O
significant O
reduction O
in O
parent O
- O
rated O
irritability B-Disease
and O
social O
withdrawal O
on O
the O
abc O
as O
well O
as O
significant O
improvements O
in O
emotional O
lability O
and O
inattention O
on O
the O
conners O
' O
parent O
rating O
scale O
- O
- O
revised O
. O

overall O
, O
galantamine O
was O
well O
- O
tolerated O
, O
with O
no O
significant O
adverse O
effects O
apart O
from O
headaches B-Disease
in O
one O
patient O
. O

conclusion O
: O
in O
this O
open O
trial O
, O
galantamine O
was O
well O
- O
tolerated O
and O
appeared O
to O
be O
beneficial O
for O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism B-Disease
, O
particularly O
aggression B-Disease
, O
behavioral B-Disease
dyscontrol I-Disease
, O
and O
inattention B-Disease
. O

randomized O
comparison O
of O
olanzapine O
versus O
risperidone O
for O
the O
treatment O
of O
first O
- O
episode O
schizophrenia B-Disease
: O
4 O
- O
month O
outcomes O
. O

objective O
: O
the O
authors O
compared O
4 O
- O
month O
treatment O
outcomes O
for O
olanzapine O
versus O
risperidone O
in O
patients O
with O
first O
- O
episode O
schizophrenia B-Disease
spectrum O
disorders O
. O

method O
: O
one O
hundred O
twelve O
subjects O
( O
70 O
% O
male O
; O
mean O
age O
= O
23 O
. O

3 O
years O
[ O
sd O
= O
5 O
. O

1 O
] O
) O
with O
first O
- O
episode O
schizophrenia B-Disease
( O
75 O
% O
) O
, O
schizophreniform B-Disease
disorder I-Disease
( O
17 O
% O
) O
, O
or O
schizoaffective B-Disease
disorder I-Disease
( O
8 O
% O
) O
were O
randomly O
assigned O
to O
treatment O
with O
olanzapine O
( O
2 O
. O

5 O
- O
20 O
mg O
/ O
day O
) O
or O
risperidone O
( O
1 O
- O
6 O
mg O
/ O
day O
) O
. O

negative O
symptom O
outcomes O
and O
measures O
of O
parkinsonism B-Disease
and O
akathisia B-Disease
did O
not O
differ O
between O
medications O
. O

extrapyramidal B-Disease
symptom I-Disease
severity O
scores O
were O
1 O
. O

4 O
( O
95 O
% O
ci O
= O
1 O
. O

2 O
- O
1 O
. O

6 O
) O
with O
risperidone O
and O
1 O
. O

2 O
( O
95 O
% O
ci O
= O
1 O
. O

0 O
- O
1 O
. O

4 O
) O
with O
olanzapine O
. O

significantly O
more O
weight B-Disease
gain I-Disease
occurred O
with O
olanzapine O
than O
with O
risperidone O
: O
the O
increase O
in O
weight O
at O
4 O
months O
relative O
to O
baseline O
weight O
was O
17 O
. O

3 O
% O
( O
95 O
% O
ci O
= O
14 O
. O

2 O
% O
- O
20 O
. O

5 O
% O
) O
with O
olanzapine O
and O
11 O
. O

3 O
% O
( O
95 O
% O
ci O
= O
8 O
. O

4 O
% O
- O
14 O
. O

3 O
% O
) O
with O
risperidone O
. O

both O
medications O
caused O
substantial O
rapid O
weight B-Disease
gain I-Disease
, O
but O
weight B-Disease
gain I-Disease
was O
greater O
with O
olanzapine O
. O

early O
paracentral O
visual B-Disease
field I-Disease
loss I-Disease
in O
patients O
taking O
hydroxychloroquine O
. O

thirty O
- O
five O
patients O
( O
13 O
. O

4 O
% O
) O
had O
visual B-Disease
field I-Disease
abnormalities I-Disease
, O
which O
were O
attributed O
to O
hydroxychloroquine O
treatment O
in O
4 O
patients O
( O
1 O
. O

5 O
% O
) O
. O

conclusions O
: O
the O
current O
study O
used O
a O
protocol O
of O
visual O
acuity O
and O
color O
vision O
assessment O
, O
funduscopy O
, O
and O
humphrey O
10 O
- O
2 O
visual O
field O
testing O
and O
shows O
that O
visual B-Disease
field I-Disease
defects I-Disease
appeared O
before O
any O
corresponding O
changes O
in O
any O
other O
tested O
clinical O
parameters O
; O
the O
defects O
were O
reproducible O
and O
the O
test O
parameters O
were O
reliable O
. O

peri O
- O
operative O
atrioventricular B-Disease
block I-Disease
as O
a O
result O
of O
chemotherapy O
with O
epirubicin O
and O
paclitaxel O
. O

a O
47 O
- O
year O
- O
old O
woman O
presented O
for O
mastectomy O
and O
immediate O
latissimus O
dorsi O
flap O
reconstruction O
having O
been O
diagnosed O
with O
carcinoma B-Disease
of I-Disease
the I-Disease
breast I-Disease
6 O
months O
previously O
. O

she O
was O
found O
to O
be O
bradycardic B-Disease
at O
pre O
- O
operative O
assessment O
but O
had O
no O
cardiac O
symptoms O
. O

second O
degree O
mobitz O
type O
ii O
atrioventricular B-Disease
block I-Disease
was O
diagnosed O
on O
electrocardiogram O
, O
and O
temporary O
transvenous O
ventricular O
pacing O
instituted O
in O
the O
peri O
- O
operative O
period O
. O

we O
discuss O
how O
evidence O
- O
based O
guidelines O
would O
not O
have O
been O
helpful O
in O
this O
case O
, O
and O
how O
chemotherapy O
can O
exhibit O
substantial O
cardiotoxicity B-Disease
that O
may O
develop O
over O
many O
years O
. O

objectives O
: O
the O
risk O
of O
acute B-Disease
myocardial I-Disease
infarction I-Disease
( O
ami B-Disease
) O
with O
cox O
- O
2 O
inhibitors O
may O
offset O
their O
gastrointestinal O
( O
gi O
) O
benefit O
compared O
with O
non O
- O
selective O
( O
ns O
) O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
. O

we O
aimed O
to O
compare O
the O
risks O
of O
hospitalization O
for O
ami B-Disease
and O
gi B-Disease
bleeding I-Disease
among O
elderly O
patients O
using O
cox O
- O
2 O
inhibitors O
, O
ns O
- O
nsaids O
and O
acetaminophen O
. O

among O
non O
- O
users O
of O
aspirin O
, O
the O
adjusted O
hazard O
ratios O
( O
95 O
% O
confidence O
interval O
) O
of O
hospitalization O
for O
ami B-Disease
/ O
gi O
vs O
the O
acetaminophen O
( O
with O
no O
aspirin O
) O
group O
were O
: O
rofecoxib O
1 O
. O

27 O
( O
1 O
. O

13 O
, O
1 O
. O

42 O
) O
, O
celecoxib O
0 O
. O

93 O
( O
0 O
. O

83 O
, O
1 O
. O

3 O
) O
, O
naproxen O
1 O
. O

59 O
( O
1 O
. O

31 O
, O
1 O
. O

93 O
) O
, O
diclofenac O
1 O
. O

17 O
( O
0 O
. O

99 O
, O
1 O
. O

38 O
) O
and O
ibuprofen O
1 O
. O

5 O
( O
0 O
. O

74 O
, O
1 O
. O

51 O
) O
. O

conclusion O
: O
among O
non O
- O
users O
of O
aspirin O
, O
naproxen O
seemed O
to O
carry O
the O
highest O
risk O
for O
ami B-Disease
/ O
gi B-Disease
bleeding I-Disease
. O

the O
ami B-Disease
/ O
gi O
toxicity B-Disease
of O
celecoxib O
was O
similar O
to O
that O
of O
acetaminophen O
and O
seemed O
to O
be O
better O
than O
those O
of O
rofecoxib O
and O
ns O
- O
nsaids O
. O

quinine O
- O
induced O
arrhythmia B-Disease
in O
a O
patient O
with O
severe B-Disease
malaria I-Disease
. O

it O
was O
reported O
that O
there O
was O
a O
case O
of O
severe B-Disease
malaria I-Disease
patient O
with O
jaundice B-Disease
who O
presented O
with O
arrhythmia B-Disease
( O
premature B-Disease
ventricular I-Disease
contraction I-Disease
) O
while O
getting O
quinine O
infusion O
was O
reported O
. O

a O
man O
, O
25 O
years O
old O
, O
was O
admitted O
to O
hospital O
with O
high O
fever B-Disease
, O
chill B-Disease
, O
vomiting B-Disease
, O
jaundice B-Disease
. O

on O
admission O
, O
laboratory O
examination O
showed O
plasmodium O
falciparum O
( O
+ O
+ O
+ O
+ O
) O
, O
total O
bilirubin O
8 O
. O

25 O
mg O
/ O
dl O
, O
conjugated O
bilirubin O
4 O
. O

36 O
mg O
/ O
dl O
, O
unconjugated O
bilirubin O
3 O
. O

89 O
mg O
/ O
dl O
, O
potassium O
3 O
. O

52 O
meq O
/ O
l O
patient O
was O
diagnosed O
as O
severe B-Disease
malaria I-Disease
with O
jaundice B-Disease
and O
got O
quinine O
infusion O
in O
dextrose O
5 O
% O
500 O
mg O
/ O
8 O
hour O
. O

on O
the O
second O
day O
the O
patient O
had O
vomitus B-Disease
, O
diarrhea B-Disease
, O
tinnitus B-Disease
, O
loss B-Disease
of I-Disease
hearing I-Disease
. O

after O
30 O
hours O
of O
quinine O
infusion O
the O
patient O
felt O
palpitation B-Disease
and O
electrocardiography O
( O
ecg O
) O
recording O
showed O
premature B-Disease
ventricular I-Disease
contraction I-Disease
( O
pvc B-Disease
) O
> O
5 O
x O
/ O
minute O
, O
trigemini O
, O
constant O
type O
- O
- O
sinoatrial B-Disease
block I-Disease
, O
positive O
u O
wave O
. O

three O
hours O
later O
the O
patient O
felt O
better O
, O
the O
frequency O
of O
pvc B-Disease
reduced O
to O
4 O
- O
5 O
x O
/ O
minute O
and O
on O
the O
third O
day O
ecg O
was O
normal O
, O
potassium O
level O
was O
3 O
. O

34 O
meq O
/ O
l O
. O

quinine O
, O
like O
quinidine O
, O
is O
a O
chincona O
alkaloid O
that O
has O
anti O
- O
arrhythmic B-Disease
property O
, O
although O
it O
also O
pro O
- O
arrhythmic B-Disease
that O
can O
cause O
various O
arrhythmias B-Disease
, O
including O
severe O
arrhythmia B-Disease
such O
as O
multiple O
pvc B-Disease
. O

administration O
of O
parenteral O
quinine O
must O
be O
done O
carefully O
and O
with O
good O
observation O
because O
of O
its O
pro O
- O
arrhythmic B-Disease
effect O
, O
especially O
in O
older O
patients O
who O
have O
heart B-Disease
diseases I-Disease
or O
patients O
with O
electrolyte B-Disease
disorder I-Disease
( O
hypokalemia B-Disease
) O
which O
frequently O
occurs O
due O
to O
vomiting B-Disease
and O
or O
diarrhea B-Disease
in O
malaria B-Disease
cases O
. O

penicillamine O
- O
related O
lichenoid B-Disease
dermatitis I-Disease
and O
utility O
of O
zinc O
acetate O
in O
a O
wilson B-Disease
disease I-Disease
patient O
with O
hepatic O
presentation O
, O
anxiety B-Disease
and O
spect O
abnormalities O
. O

wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
is O
an O
autosomal O
recessive O
disorder O
of O
hepatic O
copper O
metabolism O
with O
consequent O
copper O
accumulation O
and O
toxicity B-Disease
in O
many O
tissues O
and O
consequent O
hepatic B-Disease
, I-Disease
neurologic I-Disease
and I-Disease
psychiatric I-Disease
disorders I-Disease
. O

we O
report O
a O
case O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
with O
chronic B-Disease
liver I-Disease
disease I-Disease
; O
moreover O
, O
in O
our O
patient O
, O
presenting O
also O
with O
high O
levels O
of O
state O
anxiety B-Disease
without O
depression B-Disease
, O
99mtc O
- O
ecd O
- O
spect O
showed O
cortical O
hypoperfusion O
in O
frontal O
lobes O
, O
more O
marked O
on O
the O
left O
frontal O
lobe O
. O

during O
the O
follow O
- O
up O
of O
our O
patient O
, O
penicillamine O
was O
interrupted O
after O
the O
appearance O
of O
a O
lichenoid B-Disease
dermatitis I-Disease
, O
and O
zinc O
acetate O
permitted O
to O
continue O
the O
successful O
treatment O
of O
the O
patient O
without O
side O
- O
effects O
. O

in O
our O
case O
the O
therapy O
with O
zinc O
acetate O
represented O
an O
effective O
treatment O
for O
a O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
patient O
in O
which O
penicillamine O
- O
related O
side O
effects O
appeared O
. O

the O
safety O
of O
the O
zinc O
acetate O
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

since O
most O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
penicillamine O
- O
treated O
patients O
do O
not O
seem O
to O
develop O
this O
skin B-Disease
lesion I-Disease
, O
it O
could O
be O
conceivable O
that O
a O
specific O
genetic O
factor O
is O
involved O
in O
drug O
response O
. O

further O
studies O
are O
needed O
for O
a O
better O
clarification O
of O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
therapy O
, O
and O
in O
particular O
to O
differentiate O
specific O
therapies O
for O
different O
wilson B-Disease
' I-Disease
s I-Disease
disease I-Disease
phenotypes O
. O

a O
dramatic O
drop B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
following O
prehospital O
gtn O
administration O
. O

a O
male O
in O
his O
sixties O
with O
no O
history O
of O
cardiac O
chest B-Disease
pain I-Disease
awoke O
with O
chest B-Disease
pain I-Disease
following O
an O
afternoon O
sleep O
. O

several O
minutes O
after O
the O
gtn O
the O
patient O
experienced O
a O
sudden O
drop B-Disease
in I-Disease
blood I-Disease
pressure I-Disease
and O
heart O
rate O
, O
this O
was O
rectified O
by O
atropine O
sulphate O
and O
a O
fluid O
challenge O
. O

prehospital O
care O
providers O
who O
are O
managing O
any O
patient O
with O
a O
syncopal B-Disease
episode I-Disease
that O
fails O
to O
recover O
within O
a O
reasonable O
time O
frame O
should O
consider O
the O
bezold O
- O
jarisch O
reflex O
as O
the O
cause O
and O
manage O
the O
patient O
accordingly O
. O

chronic O
lesion O
of O
rostral O
ventrolateral O
medulla O
in O
spontaneously O
hypertensive B-Disease
rats O
. O

we O
studied O
the O
effects O
of O
chronic O
selective O
neuronal O
lesion O
of O
rostral O
ventrolateral O
medulla O
on O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
neurogenic O
tone O
in O
conscious O
, O
unrestrained O
spontaneously O
hypertensive B-Disease
rats O
. O

the O
trimethaphan O
- O
induced O
hypotension B-Disease
was O
accompanied O
by O
a O
significant O
bradycardia B-Disease
in O
lesioned O
rats O
( O
- O
32 O
+ O
/ O
- O
13 O
beats O
per O
minute O
) O
but O
a O
tachycardia B-Disease
in O
sham O
rats O
( O
+ O
33 O
+ O
/ O
- O
12 O
beats O
per O
minute O
) O
1 O
day O
postlesion O
. O

therefore O
, O
rostral O
ventrolateral O
medulla O
neurons O
appear O
to O
play O
a O
significant O
role O
in O
maintaining O
hypertension B-Disease
in O
conscious O
spontaneously O
hypertensive B-Disease
rats O
. O

spinal O
or O
suprabulbar O
structures O
could O
be O
responsible O
for O
the O
gradual O
recovery O
of O
the O
hypertension B-Disease
in O
the O
lesioned O
rats O
. O

acute B-Disease
encephalopathy I-Disease
and O
cerebral B-Disease
vasospasm I-Disease
after O
multiagent O
chemotherapy O
including O
peg O
- O
asparaginase O
and O
intrathecal O
cytarabine O
for O
the O
treatment O
of O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
. O

a O
7 O
- O
year O
- O
old O
girl O
with O
an O
unusual O
reaction O
to O
induction O
chemotherapy O
for O
precursor O
b O
- O
cell O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
( O
all B-Disease
) O
is O
described O
. O

the O
patient O
developed O
acute B-Disease
encephalopathy I-Disease
evidenced O
by O
behavioral O
changes O
, O
aphasia B-Disease
, O
incontinence B-Disease
, O
visual B-Disease
hallucinations I-Disease
, O
and O
right O
- O
sided O
weakness B-Disease
with O
diffuse O
cerebral B-Disease
vasospasm I-Disease
on O
magnetic O
resonance O
angiography O
after O
the O
administration O
of O
intrathecal O
cytarabine O
. O

comparison O
of O
valsartan O
/ O
hydrochlorothiazide O
combination O
therapy O
at O
doses O
up O
to O
320 O
/ O
25 O
mg O
versus O
monotherapy O
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
followed O
by O
long O
- O
term O
combination O
therapy O
in O
hypertensive B-Disease
adults O
. O

background O
: O
one O
third O
of O
patients O
treated O
for O
hypertension B-Disease
attain O
adequate O
blood O
pressure O
( O
bp O
) O
control O
, O
and O
multidrug O
regimens O
are O
often O
required O
. O

given O
the O
lifelong O
nature O
of O
hypertension B-Disease
, O
there O
is O
a O
need O
to O
evaluate O
the O
long O
- O
term O
efficacy O
and O
tolerability O
of O
higher O
doses O
of O
combination O
anti O
- O
hypertensive B-Disease
therapies O
. O

objective O
: O
this O
study O
investigated O
the O
efficacy O
and O
tolerability O
of O
valsartan O
( O
val O
) O
or O
hydrochlorothiazide O
( O
hctz O
) O
- O
monotherapy O
and O
higher O
- O
dose O
combinations O
in O
patients O
with O
essential B-Disease
hypertension I-Disease
. O

patients O
with O
essential B-Disease
hypertension I-Disease
( O
mean O
sitting O
diastolic O
bp O
[ O
msdbp O
] O
, O
> O
or O
= O
95 O
mm O
hg O
and O
< O
110 O
mm O
hg O
) O
were O
randomized O
to O
1 O
of O
8 O
treatment O
groups O
: O
val O
160 O
or O
320 O
mg O
; O
hctz O
12 O
. O

5 O
or O
25 O
mg O
; O
val O
/ O
hctz O
160 O
/ O
12 O
. O

5 O
, O
320 O
/ O
12 O
. O

5 O
, O
or O
320 O
/ O
25 O
mg O
; O
or O
placebo O
. O

the O
incidence O
of O
hypokalemia B-Disease
was O
lower O
with O
val O
/ O
hctz O
combinations O
( O
1 O
. O

8 O
% O
- O
6 O
. O

1 O
% O
) O
than O
with O
hctz O
monotherapies O
( O
7 O
. O

1 O
% O
- O
13 O
. O

3 O
% O
) O
. O

conclusions O
: O
in O
this O
study O
population O
, O
combination O
therapies O
with O
val O
/ O
hctz O
were O
associated O
with O
significantly O
greater O
bp O
reductions O
compared O
with O
either O
monotherapy O
, O
were O
well O
tolerated O
, O
and O
were O
associated O
with O
less O
hypokalemia B-Disease
than O
hctz O
alone O
. O

succimer O
chelation O
improves O
learning O
, O
attention O
, O
and O
arousal O
regulation O
in O
lead O
- O
exposed O
rats O
but O
produces O
lasting O
cognitive B-Disease
impairment I-Disease
in O
the O
absence O
of O
lead O
exposure O
. O

objectives O
: O
the O
present O
study O
was O
designed O
to O
answer O
these O
questions O
, O
using O
a O
rodent O
model O
of O
early O
childhood O
pb O
exposure O
and O
treatment O
with O
succimer O
, O
a O
widely O
used O
chelating O
agent O
for O
the O
treatment O
of O
pb B-Disease
poisoning I-Disease
. O

results O
: O
pb O
exposure O
produced O
lasting O
impairments B-Disease
in I-Disease
learning I-Disease
, I-Disease
attention I-Disease
, I-Disease
inhibitory I-Disease
control I-Disease
, I-Disease
and I-Disease
arousal I-Disease
regulation I-Disease
, O
paralleling O
the O
areas O
of O
dysfunction O
seen O
in O
pb O
- O
exposed O
children O
. O

in O
contrast O
, O
succimer O
treatment O
of O
rats O
not O
previously O
exposed O
to O
pb O
produced O
lasting O
and O
pervasive O
cognitive B-Disease
and I-Disease
affective I-Disease
dysfunction I-Disease
comparable O
in O
magnitude O
to O
that O
produced O
by O
the O
higher O
pb O
exposure O
regimen O
. O

conclusions O
: O
these O
are O
the O
first O
data O
, O
to O
our O
knowledge O
, O
to O
show O
that O
treatment O
with O
any O
chelating O
agent O
can O
alleviate O
cognitive B-Disease
deficits I-Disease
due O
to O
pb O
exposure O
. O

caffeine O
challenge O
test O
in O
panic B-Disease
disorder I-Disease
and O
depression B-Disease
with O
panic B-Disease
attacks I-Disease
. O

our O
aim O
was O
to O
observe O
if O
patients O
with O
panic B-Disease
disorder I-Disease
( O
pd B-Disease
) O
and O
patients O
with O
major B-Disease
depression I-Disease
with O
panic B-Disease
attacks I-Disease
( O
mdp B-Disease
) O
( O
diagnostic O
and O
statistical O
manual O
of O
mental B-Disease
disorders I-Disease
, O
fourth O
edition O
criteria O
) O
respond O
in O
a O
similar O
way O
to O
the O
induction O
of O
panic B-Disease
attacks I-Disease
by O
an O
oral O
caffeine O
challenge O
test O
. O

we O
randomly O
selected O
29 O
patients O
with O
pd B-Disease
, O
27 O
with O
mdp B-Disease
, O
25 O
with O
major B-Disease
depression I-Disease
without O
panic B-Disease
attacks I-Disease
( O
md B-Disease
) O
, O
and O
28 O
healthy O
volunteers O
. O

in O
a O
randomized O
double O
- O
blind O
experiment O
performed O
in O
2 O
occasions O
7 O
days O
apart O
, O
480 O
mg O
caffeine O
and O
a O
caffeine O
- O
free O
( O
placebo O
) O
solution O
were O
administered O
in O
a O
coffee O
form O
and O
anxiety B-Disease
scales O
were O
applied O
before O
and O
after O
each O
test O
. O

a O
total O
of O
58 O
. O

6 O
% O
( O
n O
= O
17 O
) O
of O
patients O
with O
pd B-Disease
, O
44 O
. O

4 O
% O
( O
n O
= O
12 O
) O
of O
patients O
with O
mdp B-Disease
, O
12 O
. O

0 O
% O
( O
n O
= O
3 O
) O
of O
patients O
with O
md B-Disease
, O
and O
7 O
. O

1 O
% O
( O
n O
= O
2 O
) O
of O
control O
subjects O
had O
a O
panic B-Disease
attack I-Disease
after O
the O
480 O
- O
mg O
caffeine O
challenge O
test O
( O
chi O
( O
2 O
) O
( O
3 O
) O
= O
16 O
. O

22 O
, O
p O
= O
. O

1 O
) O
. O

the O
patients O
with O
pd B-Disease
and O
mdp B-Disease
were O
more O
sensitive O
to O
caffeine O
than O
were O
patients O
with O
md B-Disease
and O
healthy O
volunteers O
. O

no O
panic B-Disease
attack I-Disease
was O
observed O
after O
the O
caffeine O
- O
free O
solution O
intake O
. O

the O
patients O
with O
md B-Disease
had O
a O
lower O
heart O
rate O
response O
to O
the O
test O
than O
all O
the O
other O
groups O
( O
2 O
- O
way O
analysis O
of O
variance O
, O
group O
by O
time O
interaction O
with O
greenhouse O
- O
geisser O
correction O
: O
f O
( O
3 O
, O
762 O
) O
= O
2 O
. O

85 O
, O
p O
= O
. O

26 O
) O
. O

our O
data O
suggest O
that O
there O
is O
an O
association O
between O
panic B-Disease
attacks I-Disease
, O
no O
matter O
if O
associated O
with O
pd B-Disease
or O
mdp B-Disease
, O
and O
hyperreactivity O
to O
an O
oral O
caffeine O
challenge O
test O
. O

mitral O
annuloplasty O
as O
a O
ventricular O
restoration O
method O
for O
the O
failing B-Disease
left I-Disease
ventricle I-Disease
: O
a O
pilot O
study O
. O

background O
and O
aim O
of O
the O
study O
: O
undersized O
mitral O
annuloplasty O
( O
map O
) O
is O
effective O
in O
patients O
with O
dilated B-Disease
cardiomyopathy I-Disease
and O
functional O
mitral B-Disease
regurgitation I-Disease
( O
mr B-Disease
) O
since O
, O
as O
well O
as O
addressing O
the O
mr B-Disease
, O
the O
map O
may O
also O
reshape O
the O
dilated O
left O
ventricular O
( O
lv O
) O
base O
. O

however O
, O
the O
direct O
benefits O
of O
this O
possible O
reshaping O
on O
lv O
function O
in O
the O
absence O
of O
underlying O
mr B-Disease
remain O
incompletely O
understood O
. O

the O
study O
aim O
was O
to O
identify O
these O
benefits O
in O
a O
canine O
model O
of O
acute O
heart B-Disease
failure I-Disease
. O

acute O
heart B-Disease
failure I-Disease
was O
induced O
by O
propranolol O
and O
volume O
loading O
after O
weaning O
from O
cardiopulmonary O
bypass O
; O
an O
absence O
of O
mr B-Disease
was O
confirmed O
by O
echocardiography O
. O

data O
were O
acquired O
at O
baseline O
, O
after O
induction O
of O
acute O
heart B-Disease
failure I-Disease
, O
and O
after O
map O
. O

conclusion O
: O
the O
data O
acquired O
suggest O
that O
isolated O
map O
may O
have O
certain O
benefits O
on O
lv O
dimension O
/ O
function O
in O
acute O
heart B-Disease
failure I-Disease
, O
even O
in O
the O
absence O
of O
mr B-Disease
. O

however O
, O
further O
investigations O
are O
warranted O
in O
a O
model O
of O
chronic O
heart B-Disease
failure I-Disease
. O

piperacillin O
/ O
tazobactam O
- O
induced O
seizure B-Disease
rapidly O
reversed O
by O
high O
flux O
hemodialysis O
in O
a O
patient O
on O
peritoneal O
dialysis O
. O

despite O
popular O
use O
of O
piperacillin O
, O
the O
dire O
neurotoxicity B-Disease
associated O
with O
piperacillin O
still O
goes O
unrecognized O
, O
leading O
to O
a O
delay O
in O
appropriate O
management O
. O

we O
report O
a O
57 O
- O
year O
- O
old O
woman O
with O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
capd O
) O
, O
who O
developed O
slurred O
speech O
, O
tremor B-Disease
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion B-Disease
, O
and O
2 O
episodes O
of O
generalized O
tonic B-Disease
- I-Disease
clonic I-Disease
seizure I-Disease
( O
gtcs B-Disease
) O
after O
5 O
doses O
of O
piperacillin O
/ O
tazobactam O
( O
2 O
g O
/ O
250 O
mg O
) O
were O
given O
for O
bronchiectasis B-Disease
with O
secondary B-Disease
infection I-Disease
. O

the O
laboratory O
data O
revealed O
normal O
plasma O
electrolyte O
and O
ammonia O
levels O
but O
leukocytosis B-Disease
. O

neurologic O
examinations O
showed O
dysarthria B-Disease
and O
bilateral O
babinski O
sign O
. O

despite O
the O
use O
of O
antiepileptic O
agents O
, O
another O
gtcs B-Disease
episode O
recurred O
after O
the O
sixth O
dose O
of O
piperacillin O
/ O
tazobactam O
. O

brain O
magnetic O
resonance O
imaging O
did O
not O
demonstrate O
acute O
infarction B-Disease
and O
organic B-Disease
brain I-Disease
lesions I-Disease
. O

piperacillin O
- O
induced O
encephalopathy B-Disease
should O
be O
considered O
in O
any O
uremic B-Disease
patients O
with O
unexplained O
neurological O
manifestations O
. O

capd O
is O
inefficient O
in O
removing O
piperacillin O
, O
whereas O
hemodialysis O
can O
rapidly O
terminate O
the O
piperacillin O
- O
induced O
encephalopathy B-Disease
. O

frequency O
of O
transient O
ipsilateral O
vocal B-Disease
cord I-Disease
paralysis I-Disease
in O
patients O
undergoing O
carotid O
endarterectomy O
under O
local O
anesthesia O
. O

temporary O
ipsilateral O
vocal B-Disease
nerve I-Disease
palsies I-Disease
due O
to O
local O
anesthetics O
have O
been O
described O
, O
however O
. O

such O
complications O
are O
most O
important O
in O
situations O
where O
there O
is O
a O
pre O
- O
existing O
contralateral O
paralysis B-Disease
. O

twelve O
patients O
( O
43 O
% O
) O
were O
found O
to O
have O
intraoperative O
ipsilateral O
vocal B-Disease
cord I-Disease
paralysis I-Disease
. O

there O
were O
no O
significant O
differences O
in O
operating O
time O
or O
volume O
or O
frequency O
of O
anesthetic O
administration O
in O
patients O
with O
temporary O
vocal B-Disease
cord I-Disease
paralysis I-Disease
compared O
with O
those O
without O
. O

conclusion O
: O
local O
anesthesia O
led O
to O
temporary O
ipsilateral O
vocal B-Disease
cord I-Disease
paralysis I-Disease
in O
almost O
half O
of O
these O
patients O
. O

because O
pre O
- O
existing O
paralysis B-Disease
is O
of O
a O
relevant O
frequency O
( O
up O
to O
3 O
% O
) O
, O
a O
preoperative O
evaluation O
of O
vocal O
cord O
function O
before O
carotid O
endarterectomy O
under O
local O
anesthesia O
is O
recommended O
to O
avoid O
intraoperative O
bilateral O
paralysis B-Disease
. O

in O
patients O
with O
preoperative O
contralateral O
vocal B-Disease
cord I-Disease
paralysis I-Disease
, O
surgery O
under O
general O
anesthesia O
should O
be O
considered O
. O

impaired B-Disease
fear I-Disease
recognition I-Disease
in O
regular O
recreational O
cocaine O
users O
. O

results O
: O
there O
were O
no O
group O
differences O
in O
psychopathology O
or O
nan O
eyes O
task O
nan O
performance O
, O
but O
the O
rc O
group O
, O
who O
otherwise O
had O
similar O
illicit O
substance O
use O
histories O
to O
the O
oc O
group O
, O
exhibited O
impaired B-Disease
fear I-Disease
recognition I-Disease
accuracy O
compared O
to O
the O
oc O
and O
cn O
groups O
. O

the O
selective O
deficit B-Disease
in I-Disease
fear I-Disease
recognition I-Disease
accuracy O
manifested O
by O
the O
rc O
group O
cannot O
be O
explained O
by O
the O
subacute O
effects O
of O
cocaine O
, O
or O
ecstasy O
, O
because O
recent O
and O
less O
recent O
users O
of O
these O
drugs O
within O
this O
group O
were O
similarly O
impaired O
. O

possible O
parallels O
between O
rc O
users O
and O
psychopaths B-Disease
with O
respect O
to O
impaired B-Disease
fear I-Disease
recognition I-Disease
, O
amygdala B-Disease
dysfunction I-Disease
, O
and O
etiology O
are O
discussed O
. O

damage B-Disease
of I-Disease
substantia I-Disease
nigra I-Disease
pars I-Disease
reticulata I-Disease
during O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
in O
the O
rat O
: O
immunohistochemical O
study O
of O
neurons O
, O
astrocytes O
and O
serum O
- O
protein O
extravasation O
. O

the O
substantia O
nigra O
has O
a O
gating O
function O
controlling O
the O
spread O
of O
epileptic B-Disease
seizure I-Disease
activity O
. O

additionally O
, O
in O
models O
of O
prolonged B-Disease
status I-Disease
epilepticus I-Disease
the O
pars O
reticulata O
of O
substantia O
nigra O
( O
snr O
) O
suffers O
from O
a O
massive O
lesion O
which O
may O
arise O
from O
a O
massive O
metabolic B-Disease
derangement I-Disease
and O
hyperexcitation O
developing O
in O
the O
activated O
snr O
. O

in O
this O
study O
, O
status B-Disease
epilepticus I-Disease
was O
induced O
by O
systemic O
injection O
of O
pilocarpine O
in O
rats O
. O

animals O
surviving O
20 O
, O
30 O
, O
40 O
, O
60 O
min O
, O
2 O
, O
3 O
, O
6 O
hours O
, O
1 O
, O
2 O
, O
and O
3 O
days O
after O
induction O
of O
status B-Disease
epilepticus I-Disease
were O
perfusion O
- O
fixed O
, O
and O
brains O
processed O
for O
immunohistochemical O
staining O
of O
snr O
. O

nissl O
- O
staining O
and O
antibodies O
against O
the O
neuron O
- O
specific O
calcium O
- O
binding O
protein O
, O
parvalbumin O
, O
served O
to O
detect O
neuronal B-Disease
damage I-Disease
in O
snr O
. O

immunohistochemical O
staining O
for O
serum O
- O
albumin O
and O
immunoglobulins O
in O
brain O
tissue O
was O
taken O
as O
indicator O
of O
blood O
- O
brain O
barrier O
disturbances O
and O
vasogenic B-Disease
edema I-Disease
formation O
. O

immunohistochemical O
staining O
indicated O
loss O
of O
gfap O
- O
staining O
already O
at O
30 O
min O
after O
induction O
of O
seizures B-Disease
in O
an O
oval O
focus O
situated O
in O
the O
center O
of O
snr O
while O
sparing O
medial O
and O
lateral O
aspects O
. O

by O
2 O
hours O
, O
parvalbumin O
- O
staining O
changed O
in O
the O
central O
snr O
indicating O
neuronal B-Disease
damage I-Disease
, O
and O
nissl O
- O
staining O
visualized O
some O
neuronal O
distortion O
. O

by O
6 O
h O
, O
vasogenic B-Disease
edema I-Disease
covered O
the O
lesioned B-Disease
snr I-Disease
. O

in O
a O
further O
group O
of O
animals O
surviving O
1 O
to O
5 O
days O
, O
conventional O
paraffin O
- O
sections O
confirmed O
the O
neuronal O
and O
glial O
damage B-Disease
of I-Disease
snr I-Disease
. O

both O
cell O
elements O
may O
suffer O
in O
common O
from O
metabolic O
disturbance O
and O
neurotransmitter B-Disease
dysfunction I-Disease
as O
occur O
during O
massive O
status B-Disease
epilepticus I-Disease
. O

neuroprotective O
effects O
of O
melatonin O
upon O
the O
offspring O
cerebellar O
cortex O
in O
the O
rat O
model O
of O
bcnu O
- O
induced O
cortical B-Disease
dysplasia I-Disease
. O

cortical B-Disease
dysplasia I-Disease
is O
a O
malformation O
characterized O
by O
defects O
in O
proliferation O
, O
migration O
and O
maturation O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
alterations O
in O
offspring O
rat O
cerebellum O
induced O
by O
maternal O
exposure O
to O
carmustine O
- O
[ O
1 O
, O
3 O
- O
bis O
( O
2 O
- O
chloroethyl O
) O
- O
1 O
- O
nitrosoure O
] O
( O
bcnu O
) O
and O
to O
investigate O
the O
effects O
of O
exogenous O
melatonin O
upon O
cerebellar O
bcnu O
- O
induced O
cortical B-Disease
dysplasia I-Disease
, O
using O
histological O
and O
biochemical O
analyses O
. O

histopathologically O
, O
typical O
findings O
were O
observed O
in O
the O
cerebella O
from O
the O
control O
groups O
, O
but O
the O
findings O
consistent O
with O
early O
embryonic O
development O
were O
noted O
in O
bcnu O
- O
exposed O
cortical B-Disease
dysplasia I-Disease
group O
. O

reduced O
cardiotoxicity B-Disease
of O
doxorubicin O
given O
in O
the O
form O
of O
n O
- O
( O
2 O
- O
hydroxypropyl O
) O
methacrylamide O
conjugates O
: O
and O
experimental O
study O
in O
the O
rat O
. O

a O
rat O
model O
was O
used O
to O
evaluate O
the O
general O
acute O
toxicity B-Disease
and O
the O
late O
cardiotoxicity B-Disease
of O
4 O
mg O
/ O
kg O
doxorubicin O
( O
dox O
) O
given O
either O
as O
free O
drug O
or O
in O
the O
form O
of O
three O
n O
- O
( O
2 O
- O
hydroxypropyl O
) O
methacrylamide O
( O
hpma O
) O
copolymer O
conjugates O
. O

throughout O
the O
study O
( O
20 O
weeks O
) O
, O
deaths O
related O
to O
cardiotoxicity B-Disease
were O
observed O
only O
in O
animals O
that O
received O
either O
free O
dox O
or O
the O
mixture O
of O
hpma O
copolymer O
and O
free O
dox O
; O
in O
these O
cases O
, O
histological O
investigations O
revealed O
marked O
changes O
in O
the O
heart O
that O
were O
consistent O
with O
dox O
- O
induced O
cardiotoxicity B-Disease
. O

corneal B-Disease
ulcers I-Disease
associated O
with O
aerosolized O
crack O
cocaine O
use O
. O

purpose O
: O
we O
report O
4 O
cases O
of O
corneal B-Disease
ulcers I-Disease
associated O
with O
drug B-Disease
abuse I-Disease
. O

the O
pathogenesis O
of O
these O
ulcers B-Disease
and O
management O
of O
these O
patients O
are O
also O
reviewed O
. O

methods O
: O
review O
of O
all O
cases O
of O
corneal B-Disease
ulcers I-Disease
associated O
with O
drug B-Disease
abuse I-Disease
seen O
at O
our O
institution O
from O
july O
2006 O
to O
december O
2006 O
. O

results O
: O
four O
patients O
with O
corneal B-Disease
ulcers I-Disease
associated O
with O
crack O
cocaine O
use O
were O
reviewed O
. O

all O
corneal B-Disease
ulcers I-Disease
were O
cultured O
, O
and O
the O
patients O
were O
admitted O
to O
the O
hospital O
for O
intensive O
topical O
antibiotic O
treatment O
. O

each O
patient O
received O
comprehensive O
health O
care O
, O
including O
medical O
and O
substance B-Disease
abuse I-Disease
consultations O
. O

the O
infections B-Disease
responded O
to O
antibiotic O
treatment O
. O

two O
patients O
needed O
a O
lateral O
tarsorrhaphy O
for O
persistent O
epithelial B-Disease
defects I-Disease
. O

conclusions O
: O
aerosolized O
crack O
cocaine O
use O
can O
be O
associated O
with O
the O
development O
of O
corneal B-Disease
ulcers I-Disease
. O

drug B-Disease
abuse I-Disease
provides O
additional O
challenges O
for O
management O
. O

not O
only O
treatment O
of O
their O
infections B-Disease
but O
also O
the O
overall O
poor O
health O
of O
the O
patients O
and O
increased O
risk O
of O
noncompliance O
need O
to O
be O
addressed O
. O

comprehensive O
care O
may O
provide O
the O
patient O
the O
opportunity O
to O
discontinue O
their O
substance B-Disease
abuse I-Disease
, O
improve O
their O
overall O
health O
, O
and O
prevent O
future O
corneal O
complications O
. O

topical O
0 O
. O

25 O
% O
capsaicin O
in O
chronic O
post B-Disease
- I-Disease
herpetic I-Disease
neuralgia I-Disease
: O
efficacy O
, O
predictors O
of O
response O
and O
long O
- O
term O
course O
. O

in O
order O
to O
evaluate O
the O
efficacy O
, O
time O
- O
course O
of O
action O
and O
predictors O
of O
response O
to O
topical O
capsaicin O
, O
39 O
patients O
with O
chronic O
post B-Disease
- I-Disease
herpetic I-Disease
neuralgia I-Disease
( O
phn B-Disease
) O
, O
median O
duration O
24 O
months O
, O
were O
treated O
with O
0 O
. O

25 O
% O
capsaicin O
cream O
for O
8 O
weeks O
. O

during O
therapy O
the O
patients O
rated O
their O
pain B-Disease
on O
a O
visual O
analogue O
scale O
( O
vas O
) O
and O
a O
verbal O
outcome O
scale O
. O

nineteen O
patients O
( O
48 O
. O

7 O
% O
) O
substantially O
improved O
after O
the O
8 O
- O
week O
trial O
; O
5 O
( O
12 O
. O

8 O
% O
) O
discontinued O
therapy O
due O
to O
side O
- O
effects O
such O
as O
intolerable O
capsaicin O
- O
induced O
burning O
sensations O
( O
4 O
) O
or O
mastitis B-Disease
( O
1 O
) O
; O
15 O
( O
38 O
. O

5 O
% O
) O
reported O
no O
benefit O
. O

treatment O
effect O
was O
not O
dependent O
on O
patient O
' O
s O
age O
, O
duration O
or O
localization O
of O
phn B-Disease
( O
trigeminal O
involvement O
was O
excluded O
) O
, O
sensory B-Disease
disturbance I-Disease
or O
pain B-Disease
character O
. O

if O
confirmed O
in O
controlled O
trials O
, O
the O
long O
- O
term O
results O
of O
this O
open O
, O
non O
- O
randomized O
study O
might O
indicate O
that O
the O
analgesic O
effect O
of O
capsaicin O
in O
phn B-Disease
is O
mediated O
by O
both O
interference O
with O
neuropeptide O
metabolism O
and O
morphological O
changes O
( O
perhaps O
degeneration O
) O
of O
nociceptive O
afferents O
. O

this O
study O
shows O
that O
mip O
synthase O
inhibition O
does O
not O
replicate O
or O
augment O
the O
effects O
of O
lithium O
in O
the O
inositol O
sensitive O
pilocarpine O
- O
induced O
seizures B-Disease
model O
. O

non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
- O
associated O
acute O
interstitial B-Disease
nephritis I-Disease
with O
granular O
tubular O
basement O
membrane O
deposits O
. O

acute B-Disease
tubulo I-Disease
- I-Disease
interstitial I-Disease
nephritis I-Disease
( O
atin B-Disease
) O
is O
an O
important O
cause O
of O
acute B-Disease
renal I-Disease
failure I-Disease
resulting O
from O
a O
variety O
of O
insults O
, O
including O
immune O
complex O
- O
mediated O
tubulo B-Disease
- I-Disease
interstitial I-Disease
injury I-Disease
, O
but O
drugs O
such O
as O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
are O
a O
far O
more O
frequent O
cause O
. O

overall O
, O
as O
an O
entity O
, O
atin B-Disease
remains O
under O
- O
diagnosed O
, O
as O
symptoms O
resolve O
spontaneously O
if O
the O
medication O
is O
stopped O
. O

we O
report O
on O
a O
14 O
- O
year O
- O
old O
boy O
who O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
2 O
weeks O
after O
aortic O
valve O
surgery O
. O

he O
was O
put O
on O
aspirin O
following O
surgery O
and O
took O
ibuprofen O
for O
fever B-Disease
for O
nearly O
a O
week O
prior O
to O
presentation O
. O

a O
kidney O
biopsy O
showed O
inflammatory O
infiltrate O
consistent O
with O
atin B-Disease
. O

his O
renal O
recovery O
and O
disappearance O
of O
proteinuria B-Disease
took O
a O
year O
. O

in O
conclusion O
, O
this O
is O
a O
first O
report O
of O
nsaids O
- O
associated O
atin B-Disease
, O
showing O
deposits O
of O
granular O
immune O
complex O
present O
only O
in O
the O
tbm O
and O
not O
in O
the O
glomeruli O
. O

rifampicin O
- O
associated O
segmental O
necrotizing O
glomerulonephritis B-Disease
in O
staphylococcal B-Disease
endocarditis I-Disease
. O

segmental O
necrotising O
glomerulonephritis B-Disease
has O
been O
reported O
as O
complication O
of O
rifampicin O
therapy O
in O
patients O
receiving O
treatment O
for O
tuberculosis B-Disease
. O

changing O
epidemiology O
of O
infections B-Disease
such O
as O
infective B-Disease
endocarditis I-Disease
( O
ie B-Disease
) O
has O
led O
to O
an O
increase O
in O
the O
use O
of O
rifampicin O
for O
staphylococcal B-Disease
infections I-Disease
. O

we O
describe O
a O
case O
of O
a O
patient O
with O
staphylococcal B-Disease
ie I-Disease
who O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
secondary O
to O
a O
segmental O
necrotising O
glomerulonephritis B-Disease
while O
being O
treated O
with O
rifampicin O
, O
and O
review O
the O
literature O
regarding O
this O
complication O
of O
rifampicin O
therapy O
. O

rate O
of O
ymdd O
motif O
mutants O
in O
lamivudine O
- O
untreated O
iranian O
patients O
with O
chronic B-Disease
hepatitis I-Disease
b I-Disease
virus I-Disease
infection I-Disease
. O

background O
: O
lamivudine O
is O
used O
for O
the O
treatment O
of O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
. O

recent O
studies O
show O
that O
the O
ymdd O
motif O
mutants O
( O
resistant O
hepatitis B-Disease
b I-Disease
virus O
) O
occur O
as O
natural O
genome O
variability O
in O
lamivudine O
- O
untreated O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
. O

in O
this O
study O
we O
aimed O
to O
determine O
the O
rate O
of O
ymdd O
motif O
mutants O
in O
lamivudine O
- O
untreated O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
in O
iran O
. O

patients O
and O
methods O
: O
a O
total O
of O
77 O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
who O
had O
not O
been O
treated O
with O
lamivudine O
were O
included O
in O
the O
study O
. O

conclusion O
: O
although O
the O
natural O
occurrence O
of O
ymdd O
motif O
mutants O
in O
lamivudine O
- O
untreated O
patients O
with O
chronic B-Disease
hepatitis I-Disease
b I-Disease
has O
been O
reported O
, O
these O
mutants O
were O
not O
detected O
in O
iranian O
lamivudine O
- O
untreated O
chronic B-Disease
hepatitis I-Disease
b I-Disease
patients O
. O

branch O
retinal B-Disease
vein I-Disease
occlusion I-Disease
and O
fluoxetine O
. O

a O
case O
of O
branch O
retinal B-Disease
vein I-Disease
occlusion I-Disease
associated O
with O
fluoxetine O
- O
induced O
secondary O
hypertension B-Disease
is O
described O
. O

although O
an O
infrequent O
complication O
of O
selective O
serotonin O
reuptake O
inhibitor O
therapy O
, O
it O
is O
important O
that O
ophthalmologists O
are O
aware O
that O
these O
agents O
can O
cause O
hypertension B-Disease
because O
this O
class O
of O
drugs O
is O
widely O
prescribed O
. O

the O
differential O
effects O
of O
bupivacaine O
and O
lidocaine O
on O
prostaglandin O
e2 O
release O
, O
cyclooxygenase O
gene O
expression O
and O
pain B-Disease
in O
a O
clinical O
pain B-Disease
model O
. O

background O
: O
in O
addition O
to O
blocking O
nociceptive O
input O
from O
surgical O
sites O
, O
long O
- O
acting O
local O
anesthetics O
might O
directly O
modulate O
inflammation B-Disease
. O

in O
the O
present O
study O
, O
we O
describe O
the O
proinflammatory O
effects O
of O
bupivacaine O
on O
local O
prostaglandin O
e2 O
( O
pge2 O
) O
production O
and O
cyclooxygenase O
( O
cox O
) O
gene O
expression O
that O
increases O
postoperative B-Disease
pain I-Disease
in O
human O
subjects O
. O

results O
: O
the O
bupivacaine O
/ O
rofecoxib O
group O
reported O
significantly O
less O
pain B-Disease
, O
as O
assessed O
by O
a O
visual O
analog O
scale O
, O
compared O
with O
the O
other O
three O
treatment O
groups O
over O
the O
first O
4 O
h O
. O

however O
, O
the O
bupivacaine O
/ O
placebo O
group O
reported O
significantly O
more O
pain B-Disease
at O
24 O
h O
and O
pge2 O
levels O
during O
the O
first O
4 O
h O
were O
significantly O
higher O
than O
the O
other O
three O
treatment O
groups O
. O

conclusions O
: O
these O
results O
suggest O
that O
bupivacaine O
stimulates O
cox O
- O
2 O
gene O
expression O
after O
tissue B-Disease
injury I-Disease
, O
which O
is O
associated O
with O
higher O
pge2 O
production O
and O
pain B-Disease
after O
the O
local O
anesthetic O
effect O
dissipates O
. O

p75ntr O
expression O
in O
rat O
urinary O
bladder O
sensory O
neurons O
and O
spinal O
cord O
with O
cyclophosphamide O
- O
induced O
cystitis B-Disease
. O

previous O
studies O
have O
examined O
the O
expression O
and O
regulation O
of O
tyrosine O
kinase O
receptors O
( O
trks O
) O
in O
micturition O
reflexes O
with O
urinary B-Disease
bladder I-Disease
inflammation I-Disease
. O

the O
present O
studies O
examine O
the O
expression O
and O
regulation O
of O
another O
receptor O
known O
to O
bind O
ngf O
, O
p75 O
( O
ntr O
) O
, O
after O
various O
durations O
of O
bladder B-Disease
inflammation I-Disease
induced O
by O
cyclophosphamide O
( O
cyp O
) O
. O

cyp O
- O
induced O
cystitis B-Disease
increased O
( O
p O
< O
or O
= O
0 O
. O

1 O
) O
p75 O
( O
ntr O
) O
expression O
in O
the O
superficial O
lateral O
and O
medial O
dorsal O
horn O
in O
l1 O
- O
l2 O
and O
l6 O
- O
s1 O
spinal O
segments O
. O

the O
number O
of O
p75 O
( O
ntr O
) O
- O
immunoreactive O
( O
- O
ir O
) O
cells O
in O
the O
lumbosacral O
dorsal O
root O
ganglia O
( O
drg O
) O
also O
increased O
( O
p O
< O
or O
= O
0 O
. O

5 O
) O
with O
cyp O
- O
induced O
cystitis B-Disease
( O
acute O
, O
intermediate O
, O
and O
chronic O
) O
. O

quantitative O
, O
real O
- O
time O
polymerase O
chain O
reaction O
also O
demonstrated O
significant O
increases O
( O
p O
< O
or O
= O
0 O
. O

1 O
) O
in O
p75 O
( O
ntr O
) O
mrna O
in O
drg O
with O
intermediate O
and O
chronic O
cyp O
- O
induced O
cystitis B-Disease
. O

in O
bladder O
afferent O
cells O
in O
drg O
, O
p75 O
( O
ntr O
) O
- O
ir O
was O
also O
increased O
( O
p O
< O
or O
= O
0 O
. O

1 O
) O
with O
cystitis B-Disease
. O

these O
studies O
demonstrate O
that O
p75 O
( O
ntr O
) O
expression O
in O
micturition O
reflexes O
is O
present O
constitutively O
and O
modified O
by O
bladder B-Disease
inflammation I-Disease
. O

the O
side O
effects O
of O
azathioprine O
include O
anemia B-Disease
, O
which O
has O
been O
attributed O
to O
bone O
marrow O
suppression O
. O

alternatively O
, O
anemia B-Disease
could O
result O
from O
accelerated O
suicidal O
erythrocyte O
death O
or O
eryptosis O
, O
which O
is O
characterized O
by O
exposure O
of O
phosphatidylserine O
( O
ps O
) O
at O
the O
erythrocyte O
surface O
and O
by O
cell O
shrinkage O
. O

conclusions O
: O
azathioprine O
triggers O
suicidal O
erythrocyte O
death O
, O
an O
effect O
presumably O
contributing O
to O
azathioprine O
- O
induced O
anemia B-Disease
. O

levetiracetam O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
suspected O
idiopathic B-Disease
epilepsy I-Disease
. O

objective O
: O
to O
assess O
pharmacokinetics O
, O
efficacy O
, O
and O
tolerability O
of O
oral O
levetiracetam O
administered O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
poorly O
controlled O
suspected O
idiopathic B-Disease
epilepsy I-Disease
. O

animals O
: O
12 O
cats O
suspected O
to O
have O
idiopathic B-Disease
epilepsy I-Disease
that O
was O
poorly O
controlled O
with O
phenobarbital O
or O
that O
had O
unacceptable O
adverse O
effects O
when O
treated O
with O
phenobarbital O
. O

seizure B-Disease
frequencies O
before O
and O
after O
initiation O
of O
levetiracetam O
treatment O
were O
compared O
, O
and O
adverse O
effects O
were O
recorded O
. O

median O
seizure B-Disease
frequency O
prior O
to O
treatment O
with O
levetiracetam O
( O
2 O
. O

1 O
seizures B-Disease
/ O
mo O
) O
was O
significantly O
higher O
than O
median O
seizure B-Disease
frequency O
after O
initiation O
of O
levetiracetam O
treatment O
( O
0 O
. O

42 O
seizures B-Disease
/ O
mo O
) O
, O
and O
7 O
of O
10 O
cats O
were O
classified O
as O
having O
responded O
to O
levetiracetam O
treatment O
( O
ie O
, O
reduction O
in O
seizure B-Disease
frequency O
of O
> O
or O
= O
50 O
% O
) O
. O

two O
cats O
had O
transient O
lethargy B-Disease
and O
inappetence B-Disease
. O

conclusions O
and O
clinical O
relevance O
: O
results O
suggested O
that O
levetiracetam O
is O
well O
tolerated O
in O
cats O
and O
may O
be O
useful O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
idiopathic B-Disease
epilepsy I-Disease
. O

serotonin O
reuptake O
inhibitors O
, O
paranoia B-Disease
, O
and O
the O
ventral O
basal O
ganglia O
. O

antidepressants O
have O
previously O
been O
associated O
with O
paranoid B-Disease
reactions O
in O
psychiatric O
patients O
. O

five O
cases O
of O
paranoid B-Disease
exacerbation O
with O
the O
serotonin O
reuptake O
inhibitors O
fluoxetine O
and O
amitriptyline O
are O
reported O
here O
. O

elements O
common O
to O
these O
cases O
included O
a O
history O
of O
paranoid B-Disease
symptomatology O
and O
the O
concomitant O
occurrence O
of O
depressive B-Disease
and I-Disease
psychotic I-Disease
symptoms I-Disease
. O

complicated O
depressive B-Disease
disorders I-Disease
( O
including O
atypicality O
of O
course O
and O
symptomatology O
, O
chronicity O
, O
psychosis B-Disease
, O
bipolarity O
, O
and O
secondary O
onset O
in O
the O
course O
of O
a O
primary O
psychosis B-Disease
) O
may O
present O
particular O
vulnerability O
to O
paranoid B-Disease
exacerbations O
associated O
with O
serotonin O
reuptake O
inhibitors O
. O

although O
the O
pharmacology O
and O
neurobiology O
of O
paranoia B-Disease
remain O
cryptic O
, O
several O
mechanisms O
, O
including O
5ht3 O
receptor O
- O
mediated O
dopamine O
release O
, O
beta O
- O
noradrenergic O
receptor O
downregulation O
, O
or O
gabab O
receptor O
upregulation O
acting O
in O
the O
vicinity O
of O
the O
ventral O
basal O
ganglia O
( O
possibly O
in O
lateral O
orbitofrontal O
or O
anterior O
cingulate O
circuits O
) O
, O
might O
apply O
to O
this O
phenomenon O
. O

these O
cases O
call O
attention O
to O
possible O
paranoid B-Disease
exacerbations O
with O
serotonin O
reuptake O
blockers O
in O
select O
patients O
and O
raise O
neurobiological O
considerations O
regarding O
paranoia B-Disease
. O

background O
: O
spinal O
anaesthesia O
is O
widely O
employed O
in O
clinical O
practice O
but O
has O
the O
main O
drawback O
of O
post O
- O
spinal O
block O
hypotension B-Disease
. O

results O
: O
three O
patients O
( O
8 O
. O

1 O
% O
) O
in O
the O
unilateral O
group O
and O
5 O
( O
13 O
. O

5 O
% O
) O
in O
the O
conventional O
group O
developed O
hypotension B-Disease
, O
p O
= O
0 O
. O

71 O
. O

four O
( O
10 O
. O

8 O
% O
) O
patients O
in O
the O
conventional O
group O
and O
1 O
( O
2 O
. O

7 O
% O
) O
in O
the O
unilateral O
group O
, O
p O
= O
0 O
. O

17 O
required O
epinephrine O
infusion O
to O
treat O
hypotension B-Disease
. O

spectrum O
of O
adverse O
events O
after O
generic O
haart O
in O
southern O
indian O
hiv B-Disease
- I-Disease
infected I-Disease
patients O
. O

to O
determine O
the O
incidence O
of O
clinically O
significant O
adverse O
events O
after O
long O
- O
term O
, O
fixed O
- O
dose O
, O
generic O
highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
use O
among O
hiv B-Disease
- I-Disease
infected I-Disease
individuals O
in O
south O
india O
, O
we O
examined O
the O
experiences O
of O
3154 O
hiv B-Disease
- I-Disease
infected I-Disease
individuals O
who O
received O
a O
minimum O
of O
3 O
months O
of O
generic O
haart O
between O
february O
1996 O
and O
december O
2006 O
at O
a O
tertiary O
hiv O
care O
referral O
center O
in O
south O
india O
. O

the O
most O
common O
adverse O
events O
and O
median O
cd4 O
at O
time O
of O
event O
were O
rash B-Disease
( O
15 O
. O

2 O
% O
; O
cd4 O
, O
285 O
cells O
/ O
microl O
) O
and O
peripheral B-Disease
neuropathy I-Disease
( O
9 O
. O

0 O
% O
and O
348 O
cells O
/ O
microl O
) O
. O

clinically O
significant O
anemia B-Disease
( O
hemoglobin O
< O
7 O
g O
/ O
dl O
) O
was O
observed O
in O
5 O
. O

4 O
% O
of O
patients O
( O
cd4 O
, O
165 O
cells O
/ O
microl O
) O
and O
hepatitis B-Disease
( O
clinical O
jaundice B-Disease
with O
alanine O
aminotransferase O
> O
5 O
times O
upper O
limits O
of O
normal O
) O
in O
3 O
. O

5 O
% O
of O
patients O
( O
cd4 O
, O
260 O
cells O
/ O
microl O
) O
. O

women O
were O
significantly O
more O
likely O
to O
experience O
lactic B-Disease
acidosis I-Disease
, O
while O
men O
were O
significantly O
more O
likely O
to O
experience O
immune B-Disease
reconstitution I-Disease
syndrome I-Disease
( O
p O
< O
0 O
. O

5 O
) O
. O

among O
the O
patients O
with O
1 O
year O
of O
follow O
- O
up O
, O
nvp O
therapy O
was O
significantly O
associated O
with O
developing O
rash B-Disease
and O
d4t O
therapy O
with O
developing O
peripheral B-Disease
neuropathy I-Disease
( O
p O
< O
0 O
. O

5 O
) O
. O

anemia B-Disease
and O
hepatitis B-Disease
often O
occur O
within O
12 O
weeks O
of O
initiating O
generic O
haart O
. O

frequent O
and O
early O
monitoring O
for O
these O
toxicities B-Disease
is O
warranted O
in O
developing O
countries O
where O
generic O
haart O
is O
increasingly O
available O
. O

thalidomide O
and O
sensory B-Disease
neurotoxicity I-Disease
: O
a O
neurophysiological O
study O
. O

background O
: O
recent O
studies O
confirmed O
a O
high O
incidence O
of O
sensory B-Disease
axonal I-Disease
neuropathy I-Disease
in O
patients O
treated O
with O
different O
doses O
of O
thalidomide O
. O

the O
study O
' O
s O
aims O
were O
to O
measure O
variations O
in O
sural O
nerve O
sensory O
action O
potential O
( O
sap O
) O
amplitude O
in O
patients O
with O
refractory O
cutaneous B-Disease
lupus I-Disease
erythematosus I-Disease
( O
cle B-Disease
) O
treated O
with O
thalidomide O
and O
use O
these O
findings O
to O
identify O
the O
neurotoxic B-Disease
potential O
of O
thalidomide O
and O
the O
recovery O
capacity O
of O
sensory O
fibres O
after O
discontinuation O
of O
treatment O
. O

patients O
and O
methods O
: O
clinical O
and O
electrophysiological O
data O
in O
12 O
female O
patients O
with O
cle B-Disease
during O
treatment O
with O
thalidomide O
and O
up O
to O
47 O
months O
after O
discontinuation O
of O
treatment O
were O
analysed O
. O

five O
patients O
complained O
of O
paresthesias B-Disease
and O
leg O
cramps B-Disease
. O

the O
threshold O
neurotoxic B-Disease
dosage O
is O
lower O
than O
previously O
reported O
. O

this O
electrophysiological O
parameter O
provides O
information O
about O
subclinical O
neurotoxic B-Disease
potential O
of O
thalidomide O
but O
is O
not O
helpful O
in O
predicting O
the O
appearance O
of O
sensory O
symptoms O
. O

five O
cases O
of O
encephalitis B-Disease
during O
treatment O
of O
loiasis B-Disease
with O
diethylcarbamazine O
. O

five O
cases O
of O
encephalitis B-Disease
following O
treatment O
with O
diethylcarbamazine O
( O
dec O
) O
were O
observed O
in O
congolese O
patients O
with O
loa O
loa O
filariasis B-Disease
. O

the O
relationship O
between O
the O
occurrence O
of O
encephalitis B-Disease
and O
the O
decrease O
in O
microfilaremia B-Disease
is O
evident O
. O

amiodarone O
- O
related O
pulmonary B-Disease
mass I-Disease
and O
unique O
membranous B-Disease
glomerulonephritis I-Disease
in O
a O
patient O
with O
valvular B-Disease
heart I-Disease
disease I-Disease
: O
diagnostic O
pitfall O
and O
new O
findings O
. O

amiodarone O
is O
an O
anti O
- O
arrhythmic B-Disease
drug O
for O
life O
- O
threatening O
tachycardia B-Disease
, O
but O
various O
adverse O
effects O
have O
been O
reported O
. O

reported O
herein O
is O
an O
autopsy O
case O
of O
valvular B-Disease
heart I-Disease
disease I-Disease
, O
in O
a O
patient O
who O
developed O
a O
lung B-Disease
mass I-Disease
( O
1 O
. O

5 O
cm O
in O
diameter O
) O
and O
proteinuria B-Disease
( O
2 O
. O

76 O
g O
/ O
day O
) O
after O
treatment O
with O
amiodarone O
for O
a O
long O
time O
. O

the O
lung B-Disease
mass I-Disease
was O
highly O
suspected O
to O
be O
lung B-Disease
cancer I-Disease
on O
ct O
and O
positron O
emission O
tomography O
, O
but O
histologically O
the O
lesion O
was O
composed O
of O
lymphoplasmacytic O
infiltrates O
in O
alveolar O
walls O
and O
intra O
- O
alveolar O
accumulation O
of O
foamy O
macrophages O
containing O
characteristic O
myelinoid O
bodies O
, O
indicating O
that O
it O
was O
an O
amiodarone O
- O
related O
lesion O
. O

in O
addition O
, O
the O
lung O
tissue O
had O
unevenly O
distributed O
hemosiderin B-Disease
deposition O
, O
and O
abnormally O
tortuous O
capillaries O
were O
seen O
in O
the O
mass O
and O
in O
heavily O
hemosiderotic B-Disease
lung O
portions O
outside O
the O
mass O
. O

autoimmune B-Disease
diseases I-Disease
, O
viral B-Disease
hepatitis I-Disease
, O
malignant O
neoplasms B-Disease
or O
other O
diseases O
with O
a O
known O
relationship O
to O
membranous B-Disease
glomerulonephritis I-Disease
were O
not O
found O
. O

the O
present O
case O
highlights O
the O
possibility O
that O
differential O
diagnosis O
between O
an O
amiodarone O
- O
related O
pulmonary B-Disease
lesion I-Disease
and O
a O
neoplasm B-Disease
can O
be O
very O
difficult O
radiologically O
, O
and O
suggests O
that O
membranous B-Disease
glomerulonephritis I-Disease
might O
be O
another O
possible O
complication O
of O
amiodarone O
treatment O
. O

risk O
of O
coronary B-Disease
artery I-Disease
disease I-Disease
associated O
with O
initial O
sulphonylurea O
treatment O
of O
patients O
with O
type B-Disease
2 I-Disease
diabetes I-Disease
: O
a O
matched O
case O
- O
control O
study O
. O

aims O
: O
this O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary B-Disease
artery I-Disease
disease I-Disease
( O
cad B-Disease
) O
associated O
with O
initial O
treatment O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
with O
different O
sulphonylureas O
. O

methods O
: O
in O
type B-Disease
2 I-Disease
diabetic I-Disease
patients O
, O
cases O
who O
developed O
cad B-Disease
were O
compared O
retrospectively O
with O
controls O
that O
did O
not O
. O

the O
20 O
- O
year O
risk O
of O
cad B-Disease
at O
diagnosis O
of O
diabetes B-Disease
, O
using O
the O
ukpds O
risk O
engine O
, O
was O
used O
to O
match O
cases O
with O
controls O
. O

results O
: O
the O
76 O
cases O
of O
cad B-Disease
were O
compared O
with O
152 O
controls O
. O

the O
hazard O
of O
developing O
cad B-Disease
( O
95 O
% O
ci O
) O
associated O
with O
initial O
treatment O
increased O
by O
2 O
. O

4 O
- O
fold O
( O
1 O
. O

3 O
- O
4 O
. O

3 O
, O
p O
= O
0 O
. O

4 O
) O
with O
glibenclamide O
; O
2 O
- O
fold O
( O
0 O
. O

9 O
- O
4 O
. O

6 O
, O
p O
= O
0 O
. O

99 O
) O
with O
glipizide O
; O
2 O
. O

9 O
- O
fold O
( O
1 O
. O

6 O
- O
5 O
. O

1 O
, O
p O
= O
0 O
. O

0 O
) O
with O
either O
, O
and O
was O
unchanged O
with O
metformin O
. O

conclusions O
: O
initiating O
treatment O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
with O
glibenclamide O
or O
glipizide O
is O
associated O
with O
increased O
risk O
of O
cad B-Disease
in O
comparison O
to O
gliclazide O
or O
glimepiride O
. O

reduced O
progression O
of O
adriamycin O
nephropathy B-Disease
in O
spontaneously O
hypertensive B-Disease
rats O
treated O
by O
losartan O
. O

background O
: O
the O
aim O
of O
the O
study O
was O
to O
investigate O
the O
antihypertensive O
effects O
of O
angiotensin O
ii O
type O
- O
1 O
receptor O
blocker O
, O
losartan O
, O
and O
its O
potential O
in O
slowing O
down O
renal B-Disease
disease I-Disease
progression O
in O
spontaneously O
hypertensive B-Disease
rats O
( O
shr O
) O
with O
adriamycin O
( O
adr O
) O
nephropathy B-Disease
. O

results O
: O
short O
- O
term O
losartan O
treatment O
, O
besides O
antihypertensive O
effect O
, O
improved O
glomerular O
filtration O
rate O
and O
ameliorated O
glomerulosclerosis B-Disease
resulting O
in O
decreased O
proteinuria B-Disease
. O

prolonged O
treatment O
with O
losartan O
showed O
further O
reduction O
of O
glomerulosclerosis B-Disease
associated O
with O
reduced O
progression O
of O
tubular O
atrophy B-Disease
and O
interstitial B-Disease
fibrosis I-Disease
, O
thus O
preventing O
heavy O
proteinuria B-Disease
and O
chronic B-Disease
renal I-Disease
failure I-Disease
. O

losartan O
reduced O
uraemia B-Disease
and O
increased O
urea O
clearance O
in O
advanced O
adr O
nephropathy B-Disease
in O
shr O
. O

histological O
examination O
showed O
that O
losartan O
could O
prevent O
tubular O
atrophy B-Disease
, O
interstitial O
infiltration O
and O
fibrosis B-Disease
in O
adr O
nephropathy B-Disease
. O

conclusion O
: O
losartan O
reduces O
the O
rate O
of O
progression O
of O
adr O
- O
induced O
focal B-Disease
segmental I-Disease
glomerulosclerosis I-Disease
to O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
in O
shr O
. O

postoperatively O
, O
a O
significantly O
higher O
incidence O
of O
seizures B-Disease
was O
found O
in O
group O
t O
( O
4 O
. O

6 O
% O
vs O
1 O
. O

2 O
% O
, O
p O
< O
0 O
. O

1 O
) O
. O

persistent O
atrial O
fibrillation O
( O
7 O
. O

9 O
% O
vs O
2 O
. O

3 O
% O
, O
p O
= O
0 O
. O

20 O
) O
and O
renal B-Disease
failure I-Disease
( O
9 O
. O

7 O
% O
vs O
1 O
. O

7 O
% O
, O
p O
= O
0 O
. O

2 O
) O
were O
also O
more O
common O
in O
group O
t O
, O
in O
the O
primary O
valve O
surgery O
subgroup O
. O

on O
the O
contrary O
, O
among O
primary O
coronary O
artery O
bypass O
surgery O
patients O
, O
there O
were O
more O
acute O
myocardial B-Disease
infarctions I-Disease
and O
renal B-Disease
dysfunction I-Disease
in O
group O
a O
( O
5 O
. O

8 O
% O
vs O
2 O
. O

0 O
% O
, O
p O
= O
0 O
. O

27 O
; O
22 O
. O

5 O
% O
vs O
15 O
. O

2 O
% O
, O
p O
= O
0 O
. O

36 O
, O
respectively O
) O
. O

delirium B-Disease
in O
an O
elderly O
woman O
possibly O
associated O
with O
administration O
of O
misoprostol O
. O

misoprostol O
has O
been O
associated O
with O
adverse O
reactions O
, O
including O
gastrointestinal O
symptoms O
, O
gynecologic O
problems O
, O
and O
headache B-Disease
. O

her O
delirium B-Disease
significantly O
improved O
after O
misoprostol O
was O
discontinued O
and O
her O
mental O
status O
returned O
to O
normal O
within O
a O
week O
. O

because O
no O
other O
factors O
related O
to O
this O
patient O
changed O
significantly O
, O
the O
delirium B-Disease
experienced O
by O
this O
patient O
possibly O
resulted O
from O
misoprostol O
therapy O
. O

the O
biological O
properties O
of O
the O
optical O
isomers O
of O
propranolol O
and O
their O
effects O
on O
cardiac B-Disease
arrhythmias I-Disease
. O

both O
isomers O
of O
propranolol O
were O
capable O
of O
preventing O
adrenaline O
- O
induced O
cardiac B-Disease
arrhythmias I-Disease
in O
cats O
anaesthetized O
with O
halothane O
, O
but O
the O
mean O
dose O
of O
( O
- O
) O
- O
propranolol O
was O
0 O
. O

9 O
+ O
/ O
- O
0 O
. O

2 O
mg O
/ O
kg O
whereas O
that O
of O
( O
+ O
) O
- O
propranolol O
was O
4 O
. O

2 O
+ O
/ O
- O
1 O
. O

2 O
mg O
/ O
kg O
. O

blockade O
of O
arrhythmias B-Disease
with O
both O
isomers O
was O
surmountable O
by O
increasing O
the O
dose O
of O
adrenaline O
. O

7 O
. O

both O
isomers O
of O
propranolol O
were O
also O
capable O
of O
reversing O
ventricular B-Disease
tachycardia I-Disease
caused O
by O
ouabain O
in O
anaesthetized O
cats O
and O
dogs O
. O

topotecan O
in O
combination O
with O
radiotherapy O
in O
unresectable O
glioblastoma B-Disease
: O
a O
phase O
2 O
study O
. O

improving O
glioblastoma B-Disease
multiforme I-Disease
( O
gbm B-Disease
) O
treatment O
with O
radio O
- O
chemotherapy O
remains O
a O
challenge O
. O

topotecan O
is O
an O
attractive O
option O
as O
it O
exhibits O
growth O
inhibition O
of O
human O
glioma B-Disease
as O
well O
as O
brain O
penetration O
. O

the O
present O
study O
assessed O
the O
combination O
of O
radiotherapy O
( O
60 O
gy O
/ O
30 O
fractions O
/ O
40 O
days O
) O
and O
topotecan O
( O
0 O
. O

9 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
on O
days O
1 O
- O
5 O
on O
weeks O
1 O
, O
3 O
and O
5 O
) O
in O
50 O
adults O
with O
histologically O
proven O
and O
untreated O
gbm B-Disease
. O

the O
incidence O
of O
non O
- O
hematological O
toxicities B-Disease
was O
low O
and O
grade O
3 O
- O
4 O
hematological O
toxicities B-Disease
were O
reported O
in O
20 O
patients O
( O
mainly O
lymphopenia B-Disease
and O
neutropenia B-Disease
) O
. O

however O
, O
while O
response O
and O
stabilization O
concerned O
one O
- O
third O
of O
the O
patients O
, O
the O
study O
did O
not O
show O
increased O
benefits O
in O
terms O
of O
survival O
in O
patients O
with O
unresectable O
gbm B-Disease
. O

long O
- O
term O
lithium O
therapy O
leading O
to O
hyperparathyroidism B-Disease
: O
a O
case O
report O
. O

we O
examined O
the O
case O
of O
a O
lithium O
- O
treated O
patient O
who O
had O
recurrent O
hypercalcemia B-Disease
to O
better O
understand O
the O
disease O
process O
. O

conclusion O
: O
primary B-Disease
hyperparathyroidism I-Disease
is O
a O
rare O
but O
potentially O
life O
- O
threatening O
side O
effect O
of O
long O
- O
term O
lithium O
therapy O
. O

practical O
implications O
: O
as O
much O
as O
15 O
% O
of O
lithium O
- O
treated O
patients O
become O
hypercalcemic B-Disease
. O

background O
: O
the O
purpose O
of O
this O
study O
was O
to O
compare O
surgical O
conditions O
, O
including O
the O
amount O
of O
intraoperative O
bleeding B-Disease
as O
well O
as O
intraoperative O
blood O
pressure O
, O
during O
functional O
endoscopic O
sinus O
surgery O
( O
fess O
) O
using O
flexible O
reinforced O
laryngeal O
mask O
airway O
( O
frlma O
) O
versus O
endotracheal O
tube O
( O
ett O
) O
in O
maintaining O
controlled O
hypotension B-Disease
anesthesia O
induced O
by O
propofol O
- O
remifentanil O
total O
i O
. O

v O
. O

anesthesia O
( O
tiva O
) O
. O

methods O
: O
sixty O
normotensive O
american O
society O
of O
anesthesiologists O
i O
- O
ii O
adult O
patients O
undergoing O
fess O
under O
controlled O
hypotension B-Disease
anesthesia O
caused O
by O
propofol O
- O
remifentanil O
- O
tiva O
were O
randomly O
assigned O
into O
two O
groups O
: O
group O
i O
, O
frlma O
; O
group O
ii O
, O
ett O
. O

hemorrhage B-Disease
was O
measured O
and O
the O
visibility O
of O
the O
operative O
field O
was O
evaluated O
according O
to O
a O
six O
- O
point O
scale O
. O

results O
: O
controlled O
hypotension B-Disease
was O
achieved O
within O
a O
shorter O
period O
using O
laryngeal O
mask O
using O
lower O
rates O
of O
remifentanil O
infusion O
and O
lower O
total O
dose O
of O
remifentanil O
. O

conclusion O
: O
in O
summary O
, O
our O
results O
indicate O
that O
airway O
management O
using O
frlma O
during O
controlled O
hypotension B-Disease
anesthesia O
provided O
better O
surgical O
conditions O
in O
terms O
of O
quality O
of O
operative O
field O
and O
blood O
loss O
and O
allowed O
for O
convenient O
induced O
hypotension B-Disease
with O
low O
doses O
of O
remifentanil O
during O
tiva O
in O
patients O
undergoing O
fess O
. O

nonalcoholic B-Disease
fatty I-Disease
liver I-Disease
disease I-Disease
during O
valproate O
therapy O
. O

valproic O
acid O
( O
vpa O
) O
is O
effective O
for O
the O
treatment O
of O
many O
types O
of O
epilepsy B-Disease
, O
but O
its O
use O
can O
be O
associated O
with O
an O
increase O
in O
body O
weight O
. O

we O
report O
a O
case O
of O
nonalcoholic B-Disease
fatty I-Disease
liver I-Disease
disease I-Disease
( O
nafld B-Disease
) O
arising O
in O
a O
child O
who O
developed O
obesity B-Disease
during O
vpa O
treatment O
. O

laboratory O
data O
revealed O
hyperinsulinemia B-Disease
with O
insulin B-Disease
resistance I-Disease
. O

after O
the O
withdrawal O
of O
vpa O
therapy O
, O
our O
patient O
showed O
a O
significant O
weight B-Disease
loss I-Disease
, O
a O
decrease O
of O
body O
mass O
index O
, O
and O
normalization O
of O
metabolic O
and O
endocrine O
parameters O
; O
moreover O
, O
ultrasound O
measurements O
showed O
a O
complete O
normalization O
. O

the O
present O
case O
suggests O
that O
obesity B-Disease
, O
hyperinsulinemia B-Disease
, O
insulin B-Disease
resistance I-Disease
, O
and O
long O
- O
term O
treatment O
with O
vpa O
may O
be O
all O
associated O
with O
the O
development O
of O
nafld B-Disease
; O
this O
side O
effect O
is O
reversible O
after O
vpa O
withdrawal O
. O

carbimazole O
induced O
anca B-Disease
positive I-Disease
vasculitis I-Disease
. O

anti O
- O
thyroid O
drugs O
, O
like O
carbimazole O
and O
propylthiouracil O
( O
ptu O
) O
are O
commonly O
prescribed O
for O
the O
treatment O
of O
hyperthyroidism B-Disease
. O

antineutrophil B-Disease
cytoplasmic I-Disease
antibody I-Disease
( I-Disease
anca I-Disease
) I-Disease
- I-Disease
- I-Disease
associated I-Disease
vasculitis I-Disease
is O
a O
potentially O
life O
- O
threatening O
adverse O
effect O
of O
antithyroidmedications O
. O

we O
report O
a O
patient O
with O
graves B-Disease
' I-Disease
disease I-Disease
who O
developed O
anca O
positive O
carbimazole O
induced O
vasculitis B-Disease
. O

the O
episode O
was O
characterized O
by O
a O
vasculitic B-Disease
skin B-Disease
rash I-Disease
associated O
with O
large O
joint O
arthritis B-Disease
, O
pyrexia B-Disease
and O
parotiditis B-Disease
but O
no O
renal O
or O
pulmonary O
involvement O
. O

he O
was O
referred O
to O
us O
for O
neurological O
evaluation O
because O
he O
had O
difficulty O
in O
getting O
up O
from O
squatting O
position O
and O
was O
suspected O
to O
have O
myositis B-Disease
. O

to O
the O
best O
of O
our O
knowledge O
this O
is O
the O
first O
anca O
positive O
carbimazole O
induced O
vasculitis B-Disease
case O
reported O
from O
india O
. O

background O
: O
coronary B-Disease
heart I-Disease
disease I-Disease
and O
cerebrovascular B-Disease
disease I-Disease
are O
leading O
causes O
of O
death O
in O
the O
united O
states O
. O

preventive O
services O
task O
force O
( O
uspstf O
) O
strongly O
recommended O
that O
clinicians O
discuss O
aspirin O
with O
adults O
who O
are O
at O
increased O
risk O
for O
coronary B-Disease
heart I-Disease
disease I-Disease
. O

purpose O
: O
to O
determine O
the O
benefits O
and O
harms O
of O
taking O
aspirin O
for O
the O
primary O
prevention O
of O
myocardial B-Disease
infarctions I-Disease
, O
strokes B-Disease
, O
and O
death O
. O

study O
selection O
: O
english O
- O
language O
randomized O
, O
controlled O
trials O
( O
rcts O
) O
; O
case O
- O
control O
studies O
; O
meta O
- O
analyses O
; O
and O
systematic O
reviews O
of O
aspirin O
versus O
control O
for O
the O
primary O
prevention O
of O
cardiovascular B-Disease
disease I-Disease
( O
cvd B-Disease
) O
were O
selected O
to O
answer O
the O
following O
questions O
: O
does O
aspirin O
decrease O
coronary O
heart O
events O
, O
strokes B-Disease
, O
death O
from O
coronary O
heart O
events O
or O
stroke B-Disease
, O
or O
all O
- O
cause O
mortality O
in O
adults O
without O
known O
cvd B-Disease
? O
does O
aspirin O
increase O
gastrointestinal B-Disease
bleeding I-Disease
or O
hemorrhagic B-Disease
strokes I-Disease
? O
data O
synthesis O
: O
new O
evidence O
from O
1 O
good O
- O
quality O
rct O
, O
1 O

good O
- O
quality O
meta O
- O
analysis O
, O
and O
2 O
fair O
- O
quality O
subanalyses O
of O
rcts O
demonstrates O
that O
aspirin O
use O
reduces O
the O
number O
of O
cvd B-Disease
events O
in O
patients O
without O
known O
cvd B-Disease
. O

men O
in O
these O
studies O
experienced O
fewer O
myocardial B-Disease
infarctions I-Disease
and O
women O
experienced O
fewer O
ischemic O
strokes B-Disease
. O

aspirin O
does O
not O
seem O
to O
affect O
cvd B-Disease
mortality O
or O
all O
- O
cause O
mortality O
in O
either O
men O
or O
women O
. O

the O
use O
of O
aspirin O
for O
primary O
prevention O
increases O
the O
risk O
for O
major O
bleeding B-Disease
events O
, O
primarily O
gastrointestinal B-Disease
bleeding I-Disease
events O
, O
in O
both O
men O
and O
women O
. O

men O
have O
an O
increased O
risk O
for O
hemorrhagic B-Disease
strokes I-Disease
with O
aspirin O
use O
. O

a O
new O
rct O
and O
meta O
- O
analysis O
suggest O
that O
the O
risk O
for O
hemorrhagic B-Disease
strokes I-Disease
in O
women O
is O
not O
statistically O
significantly O
increased O
. O

limitations O
: O
new O
evidence O
on O
aspirin O
for O
the O
primary O
prevention O
of O
cvd B-Disease
is O
limited O
. O

conclusion O
: O
aspirin O
reduces O
the O
risk O
for O
myocardial B-Disease
infarction I-Disease
in O
men O
and O
strokes B-Disease
in O
women O
. O

aspirin O
use O
increases O
the O
risk O
for O
serious O
bleeding B-Disease
events O
. O

reducing O
harm O
associated O
with O
anticoagulation O
: O
practical O
considerations O
of O
argatroban O
therapy O
in O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

argatroban O
is O
a O
hepatically O
metabolized O
, O
direct O
thrombin O
inhibitor O
used O
for O
prophylaxis O
or O
treatment O
of O
thrombosis B-Disease
in O
heparin O
- O
induced O
thrombocytopenia B-Disease
( O
hit B-Disease
) O
and O
for O
patients O
with O
or O
at O
risk O
of O
hit B-Disease
undergoing O
percutaneous O
coronary O
intervention O
( O
pci O
) O
. O

the O
objective O
of O
this O
review O
is O
to O
summarize O
practical O
considerations O
of O
argatroban O
therapy O
in O
hit B-Disease
. O

the O
us O
fda O
- O
recommended O
argatroban O
dose O
in O
hit B-Disease
is O
2 O
microg O
/ O
kg O
/ O
min O
( O
reduced O
in O
patients O
with O
hepatic B-Disease
impairment I-Disease
and O
in O
paediatric O
patients O
) O
, O
adjusted O
to O
achieve O
activated O
partial O
thromboplastin O
times O
( O
aptts O
) O
1 O
. O

5 O
- O
3 O
times O
baseline O
( O
not O
> O
100 O
seconds O
) O
. O

contemporary O
experiences O
indicate O
that O
reduced O
doses O
are O
also O
needed O
in O
patients O
with O
conditions O
associated O
with O
hepatic O
hypoperfusion O
, O
e O
. O

g O
. O

heart B-Disease
failure I-Disease
, O
yet O
are O
unnecessary O
for O
renal B-Disease
dysfunction I-Disease
, O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity B-Disease
. O

for O
pci O
, O
argatroban O
has O
not O
been O
investigated O
in O
hepatically O
impaired O
patients O
; O
dose O
adjustment O
is O
unnecessary O
for O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity B-Disease
, O
and O
lesser O
doses O
may O
be O
adequate O
with O
concurrent O
glycoprotein O
iib O
/ O
iiia O
inhibition O
. O

major O
bleeding B-Disease
with O
argatroban O
is O
0 O
- O
10 O
% O
in O
the O
non O
- O
interventional O
setting O
and O
0 O
- O
5 O
. O

8 O
% O
periprocedurally O
. O

improved O
familiarity O
of O
healthcare O
professionals O
with O
argatroban O
therapy O
in O
hit B-Disease
, O
including O
in O
special O
populations O
and O
during O
pci O
, O
may O
facilitate O
reduction O
of O
harm O
associated O
with O
hit B-Disease
( O
e O
. O

g O
. O

fewer O
thromboses O
) O
or O
its O
treatment O
( O
e O
. O

g O
. O

fewer O
argatroban O
medication O
errors O
) O
. O

rhabdomyolysis B-Disease
and O
brain O
ischemic B-Disease
stroke I-Disease
in O
a O
heroin O
- O
dependent O
male O
under O
methadone O
maintenance O
therapy O
. O

objective O
: O
there O
are O
several O
complications O
associated O
with O
heroin B-Disease
abuse I-Disease
, O
some O
of O
which O
are O
life O
- O
threatening O
. O

results O
: O
a O
33 O
- O
year O
- O
old O
man O
presented O
with O
rhabdomyolysis B-Disease
and O
cerebral O
ischemic B-Disease
stroke I-Disease
after O
intravenous O
heroin O
. O

he O
was O
found O
unconsciousness B-Disease
at O
home O
and O
was O
sent O
to O
our O
hospital O
. O

in O
the O
icu O
, O
we O
found O
rhabdomyolysis B-Disease
, O
acute B-Disease
renal I-Disease
failure I-Disease
and O
acute O
respiratory B-Disease
failure I-Disease
. O

after O
transfer O
to O
an O
internal O
ward O
, O
we O
noted O
aphasia B-Disease
and O
weakness B-Disease
of O
his O
left O
limbs O
. O

after O
mri O
, O
we O
found O
cerebral B-Disease
ischemic I-Disease
infarction I-Disease
. O

conclusion O
: O
those O
using O
methadone O
and O
heroin O
simultaneously O
may O
increase O
risk O
of O
rhabdomyolysis B-Disease
and O
ischemic B-Disease
stroke I-Disease
. O

hypotheses O
of O
heroin O
- O
related O
rhabdomyolysis B-Disease
and O
stroke B-Disease
in O
heroin O
abusers O
are O
discussed O
. O

increased O
vulnerability O
to O
6 O
- O
hydroxydopamine O
lesion O
and O
reduced O
development O
of O
dyskinesias B-Disease
in O
mice O
lacking O
cb1 O
cannabinoid O
receptors O
. O

treatment O
with O
l O
- O
dopa O
+ O
benserazide O
( O
12 O
weeks O
) O
resulted O
in O
less O
severe O
dyskinesias B-Disease
in O
cb1 O
ko O
than O
in O
wt O
mice O
. O

the O
results O
revealed O
that O
the O
lack O
of O
cannabinoid O
cb1 O
receptors O
increased O
the O
severity O
of O
motor O
impairment O
and O
da O
lesion O
, O
and O
reduced O
l O
- O
dopa O
- O
induced O
dyskinesias B-Disease
. O

these O
results O
suggest O
that O
activation O
of O
cb1 O
receptors O
offers O
neuroprotection O
against O
dopaminergic O
lesion O
and O
the O
development O
of O
l O
- O
dopa O
- O
induced O
dyskinesias B-Disease
. O

hepatocellular O
oxidant O
stress O
following O
intestinal O
ischemia B-Disease
- O
reperfusion B-Disease
injury I-Disease
. O

reperfusion O
of O
ischemic B-Disease
intestine O
results O
in O
acute O
liver B-Disease
dysfunction I-Disease
characterized O
by O
hepatocellular O
enzyme O
release O
into O
plasma O
, O
reduction O
in O
bile O
flow O
rate O
, O
and O
neutrophil O
sequestration O
within O
the O
liver O
. O

the O
pathophysiology O
underlying O
this O
acute O
hepatic B-Disease
injury I-Disease
is O
unknown O
. O

this O
study O
was O
undertaken O
to O
determine O
whether O
oxidants O
are O
associated O
with O
the O
hepatic B-Disease
injury I-Disease
and O
to O
determine O
the O
relative O
value O
of O
several O
indirect O
methods O
of O
assessing O
oxidant O
exposure O
in O
vivo O
. O

rats O
were O
subjected O
to O
a O
standardized O
intestinal O
ischemia B-Disease
- O
reperfusion B-Disease
injury I-Disease
. O

there O
was O
no O
change O
in O
hepatic O
tissue O
total O
glutathione O
following O
intestinal O
ischemia B-Disease
- O
reperfusion B-Disease
injury I-Disease
. O

animal O
model O
of O
mania B-Disease
induced O
by O
ouabain O
: O
evidence O
of O
oxidative O
stress O
in O
submitochondrial O
particles O
of O
the O
rat O
brain O
. O

the O
intracerebroventricular O
( O
icv O
) O
administration O
of O
ouabain O
( O
a O
na O
( O
+ O
) O
/ O
k O
( O
+ O
) O
- O
atpase O
inhibitor O
) O
in O
rats O
has O
been O
suggested O
to O
mimic O
some O
symptoms O
of O
human O
bipolar B-Disease
mania I-Disease
. O

clinical O
studies O
have O
shown O
that O
bipolar B-Disease
disorder I-Disease
may O
be O
related O
to O
mitochondrial B-Disease
dysfunction I-Disease
. O

our O
findings O
demonstrated O
that O
ouabain O
at O
10 O
( O
- O
2 O
) O
and O
10 O
( O
- O
3 O
) O
m O
induced O
hyperlocomotion B-Disease
in O
rats O
, O
and O
this O
response O
remained O
up O
to O
7 O
days O
following O
a O
single O
icv O
injection O
. O

in O
conclusion O
, O
ouabain O
- O
induced O
mania B-Disease
- O
like O
behavior O
may O
provide O
a O
useful O
animal O
model O
to O
test O
the O
hypothesis O
of O
the O
involvement O
of O
oxidative O
stress O
in O
bipolar B-Disease
disorder I-Disease
. O

liver O
transB-Plantation O
for O
acutely O
ill O
patients O
with O
fulminant B-Disease
liver I-Disease
failure I-Disease
carries O
high O
intraoperative O
and O
immediate O
postoperative O
risks O
. O

these O
are O
increased O
with O
the O
presence O
of O
concomitant O
acute B-Disease
kidney I-Disease
injury I-Disease
( O
aki B-Disease
) O
and O
intraoperative O
dialysis O
is O
sometimes O
required O
to O
allow O
the O
transB-Plant O
to O
proceed O
. O

the O
derangements O
in O
the O
procoagulant O
and O
anticoagulant O
pathways O
during O
fulminant B-Disease
liver I-Disease
failure I-Disease
can O
lead O
to O
difficulties O
with O
anticoagulation O
during O
dialysis O
, O
especially O
when O
continued O
in O
the O
operating O
room O
. O

systemic O
anticoagulation O
is O
unsafe O
and O
regional O
citrate O
anticoagulation O
in O
the O
absence O
of O
a O
functional O
liver O
carries O
the O
risk O
of O
citrate O
toxicity B-Disease
. O

we O
report O
a O
case O
of O
a O
40 O
- O
year O
- O
old O
female O
with O
acetaminophen O
- O
induced O
fulminant B-Disease
liver I-Disease
failure I-Disease
with O
associated O
aki B-Disease
who O
underwent O
intraoperative O
dialytic O
support O
during O
liver O
transB-Plantation O
anticoagulated O
with O
citrate O
dialysate O
during O
the O
entire O
procedure O
. O

the O
patient O
tolerated O
the O
procedure O
well O
without O
any O
signs O
of O
citrate O
toxicity B-Disease
and O
maintained O
adequate O
anticoagulation O
for O
patency O
of O
the O
dialysis O
circuit O
. O

citrate O
dialysate O
is O
a O
safe O
alternative O
for O
intradialytic O
support O
of O
liver O
transB-Plantation O
in O
fulminant B-Disease
liver I-Disease
failure I-Disease
. O

delirium B-Disease
in O
a O
patient O
with O
toxic O
flecainide O
plasma O
concentrations O
: O
the O
role O
of O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

objective O
: O
to O
describe O
a O
case O
of O
flecainide O
- O
induced O
delirium B-Disease
associated O
with O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine O
. O

case O
summary O
: O
a O
69 O
- O
year O
- O
old O
white O
female O
presented O
to O
the O
emergency O
department O
with O
a O
history O
of O
confusion B-Disease
and O
paranoia B-Disease
over O
the O
past O
several O
days O
. O

flecainide O
had O
been O
started O
2 O
weeks O
prior O
for O
atrial B-Disease
fibrillation I-Disease
. O

her O
delirium B-Disease
resolved O
3 O
days O
later O
. O

discussion O
: O
flecainide O
and O
pharmacologically O
similar O
agents O
that O
interact O
with O
sodium O
channels O
may O
cause O
delirium B-Disease
in O
susceptible O
patients O
. O

a O
medline O
search O
( O
1966 O
- O
january O
2009 O
) O
revealed O
one O
in O
vivo O
pharmacokinetic O
study O
on O
the O
interaction O
between O
flecainide O
, O
a O
cyp2d6 O
substrate O
, O
and O
paroxetine O
, O
a O
cyp2d6 O
inhibitor O
, O
as O
well O
as O
3 O
case O
reports O
of O
flecainide O
- O
induced O
delirium B-Disease
. O

according O
to O
the O
naranjo O
probability O
scale O
, O
flecainide O
was O
the O
probable O
cause O
of O
the O
patient O
' O
s O
delirium B-Disease
; O
the O
horn O
drug O
interaction O
probability O
scale O
indicates O
a O
possible O
pharmacokinetic O
drug O
interaction O
between O
flecainide O
and O
paroxetine O
. O

conclusions O
: O
supratherapeutic O
flecainide O
plasma O
concentrations O
may O
cause O
delirium B-Disease
. O

because O
toxicity B-Disease
may O
occur O
when O
flecainide O
is O
prescribed O
with O
paroxetine O
and O
other O
potent O
cyp2d6 O
inhibitors O
, O
flecainide O
plasma O
concentrations O
should O
be O
monitored O
closely O
with O
commencement O
of O
cyp2d6 O
inhibitors O
. O

efficacy O
of O
everolimus O
( O
rad001 O
) O
in O
patients O
with O
advanced O
nsclc B-Disease
previously O
treated O
with O
chemotherapy O
alone O
or O
with O
chemotherapy O
and O
egfr O
inhibitors O
. O

background O
: O
treatment O
options O
are O
scarce O
in O
pretreated O
advanced O
non B-Disease
- I-Disease
small I-Disease
- I-Disease
cell I-Disease
lung I-Disease
cancer I-Disease
( O
nsclc B-Disease
) O
patients O
. O

rad001 O
, O
an O
oral O
inhibitor O
of O
the O
mammalian O
target O
of O
rapamycin O
( O
mtor O
) O
, O
has O
shown O
phase O
i O
efficacy O
in O
nsclc B-Disease
. O

methods O
: O
stage O
iiib O
or O
iv O
nsclc B-Disease
patients O
, O
with O
two O
or O
fewer O
prior O
chemotherapy O
regimens O
, O
one O
platinum O
based O
( O
stratum O
1 O
) O
or O
both O
chemotherapy O
and O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitors O
( O
stratum O
2 O
) O
, O
received O
rad001 O
10 O
mg O
/ O
day O
until O
progression O
or O
unacceptable O
toxicity B-Disease
. O

analyses O
of O
markers O
associated O
with O
the O
mtor O
pathway O
were O
carried O
out O
on O
archival O
tumor B-Disease
from O
a O
subgroup O
using O
immunohistochemistry O
( O
ihc O
) O
and O
direct O
mutation O
sequencing O
. O

common O
> O
or O
= O
grade O
3 O
events O
were O
fatigue B-Disease
, O
dyspnea B-Disease
, O
stomatitis B-Disease
, O
anemia B-Disease
, O
and O
thrombocytopenia B-Disease
. O

pneumonitis B-Disease
, O
probably O
or O
possibly O
related O
, O
mainly O
grade O
1 O
/ O
2 O
, O
occurred O
in O
25 O
% O
. O

conclusions O
: O
rad001 O
10 O
mg O
/ O
day O
was O
well O
tolerated O
, O
showing O
modest O
clinical O
activity O
in O
pretreated O
nsclc B-Disease
. O

evaluation O
of O
rad001 O
plus O
standard O
therapy O
for O
metastatic O
nsclc B-Disease
continues O
. O

posttransB-Plant O
anemia B-Disease
: O
the O
role O
of O
sirolimus O
. O

posttransB-Plant O
anemia B-Disease
is O
a O
common O
problem O
that O
may O
hinder O
patients O
' O
quality O
of O
life O
. O

a O
variety O
of O
factors O
have O
been O
identified O
that O
increase O
the O
risk O
of O
posttransB-Plant O
anemia B-Disease
, O
of O
which O
the O
level O
of O
renal O
function O
is O
most O
important O
. O

sirolimus O
, O
a O
mammalian O
target O
of O
rapamycin O
inhibitor O
, O
has O
been O
implicated O
as O
playing O
a O
special O
role O
in O
posttransB-Plant O
anemia B-Disease
. O

this O
review O
considers O
anemia B-Disease
associated O
with O
sirolimus O
, O
including O
its O
presentation O
, O
mechanisms O
, O
and O
management O
. O

coronary O
computerized O
tomography O
angiography O
for O
rapid O
discharge O
of O
low O
- O
risk O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
. O

background O
: O
most O
patients O
presenting O
to O
emergency O
departments O
( O
eds O
) O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
are O
admitted O
for O
at O
least O
12 O
hours O
and O
receive O
a O
nan O
rule O
out O
acute B-Disease
coronary I-Disease
syndrome I-Disease
nan O
protocol O
, O
often O
with O
noninvasive O
testing O
prior O
to O
discharge O
. O

it O
is O
unclear O
whether O
a O
coronary O
cta O
strategy O
would O
be O
efficacious O
in O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
, O
as O
coronary B-Disease
vasospasm I-Disease
may O
account O
for O
some O
of O
the O
ischemia B-Disease
. O

we O
studied O
whether O
a O
negative O
coronary O
cta O
in O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
could O
identify O
a O
subset O
safe O
for O
discharge O
. O

methods O
: O
we O
prospectively O
evaluated O
the O
safety O
of O
coronary O
cta O
for O
low O
- O
risk O
patients O
who O
presented O
to O
the O
ed O
with O
cocaineassociated O
chest B-Disease
pain I-Disease
( O
self O
- O
reported O
or O
positive O
urine O
test O
) O
. O

patients O
with O
negative O
coronary O
cta O
( O
maximal O
stenosis B-Disease
less O
than O
50 O
% O
) O
were O
discharged O
. O

the O
main O
outcome O
was O
30 O
- O
day O
cardiovascular O
death O
or O
myocardial B-Disease
infarction I-Disease
. O

results O
: O
a O
total O
of O
59 O
patients O
with O
cocaine O
- O
associated O
chest B-Disease
pain I-Disease
were O
evaluated O
. O

six O
patients O
had O
coronary B-Disease
stenosis I-Disease
> O
or O
= O
50 O
% O
. O

during O
the O
30 O
- O
day O
follow O
- O
up O
period O
, O
no O
patients O
died O
of O
a O
cardiovascular O
event O
( O
0 O
% O
; O
95 O
% O
ci O
, O
0 O
- O
6 O
. O

1 O
% O
) O
and O
no O
patient O
sustained O
a O
nonfatal O
myocardial B-Disease
infarction I-Disease
( O
0 O
% O
; O
95 O
% O
ci O
, O
0 O
- O
6 O
. O

1 O
% O
) O
. O

conclusions O
: O
although O
cocaine O
- O
associated O
myocardial B-Disease
ischemia I-Disease
can O
result O
from O
coronary O
vasoconstriction O
, O
patients O
with O
cocaine O
associated O
chest B-Disease
pain I-Disease
, O
a O
non O
- O
ischemic B-Disease
ecg O
, O
and O
a O
timi O
risk O
score O
< O
2 O
may O
be O
safely O
discharged O
from O
the O
ed O
after O
a O
negative O
coronary O
cta O
with O
a O
low O
risk O
of O
30 O
- O
day O
adverse O
events O
. O

bilateral O
haemorrhagic B-Disease
infarction I-Disease
of I-Disease
the I-Disease
globus I-Disease
pallidus I-Disease
after O
cocaine O
and O
alcohol O
intoxication O
. O

cocaine O
is O
a O
risk O
factor O
for O
both O
ischemic B-Disease
and I-Disease
haemorrhagic I-Disease
stroke I-Disease
. O

we O
present O
the O
case O
of O
a O
31 O
- O
year O
- O
old O
man O
with O
bilateral O
ischemia B-Disease
of I-Disease
the I-Disease
globus I-Disease
pallidus I-Disease
after O
excessive O
alcohol O
and O
intranasal O
cocaine O
use O
. O

drug O
- O
related O
globus B-Disease
pallidus I-Disease
infarctions I-Disease
are O
most O
often O
associated O
with O
heroin O
. O

bilateral O
basal B-Disease
ganglia I-Disease
infarcts I-Disease
after O
the O
use O
of O
cocaine O
, O
without O
concurrent O
heroin O
use O
, O
have O
never O
been O
reported O
. O

in O
our O
patient O
, O
transient O
cardiac B-Disease
arrhythmia I-Disease
or O
respiratory B-Disease
dysfunction I-Disease
related O
to O
cocaine O
and O
/ O
or O
ethanol O
use O
were O
the O
most O
likely O
causes O
of O
cerebral B-Disease
hypoperfusion I-Disease
. O

late O
fulminant O
posterior B-Disease
reversible I-Disease
encephalopathy I-Disease
syndrome I-Disease
after O
liver O
transB-Plant O
. O

objectives O
: O
posterior B-Disease
leukoencephalopathy I-Disease
due O
to O
calcineurin O
- O
inhibitor O
- O
related O
neurotoxicity B-Disease
is O
a O
rare O
but O
severe O
complication O
that O
results O
from O
treatment O
with O
immunosuppressive O
agents O
( O
primarily O
those O
administered O
after O
a O
liver O
or O
kidney O
transB-Plant O
) O
. O

case O
: O
we O
report O
the O
case O
of O
a O
46 O
- O
year O
- O
old O
woman O
who O
received O
a O
liver O
transB-Plant O
in O
our O
center O
as O
treatment O
for O
alcoholic B-Disease
cirrhosis I-Disease
and O
in O
whom O
either O
a O
fulminant O
course O
of O
posterior B-Disease
leukoencephalopathy I-Disease
or O
posterior B-Disease
reversible I-Disease
encephalopathy I-Disease
syndrome I-Disease
developed O
110 O
days O
after O
transB-Plant O
. O

conclusions O
: O
posterior B-Disease
reversible I-Disease
encephalopathy I-Disease
syndrome I-Disease
after O
liver O
transB-Plant O
is O
rare O
. O

prolonged O
hypothermia B-Disease
as O
a O
bridge O
to O
recovery O
for O
cerebral B-Disease
edema I-Disease
and O
intracranial B-Disease
hypertension I-Disease
associated O
with O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
. O

background O
: O
to O
review O
evidence O
- O
based O
treatment O
options O
in O
patients O
with O
cerebral B-Disease
edema I-Disease
complicating O
fulminant B-Disease
hepatic I-Disease
failure I-Disease
( O
fhf B-Disease
) O
and O
discuss O
the O
potential O
applications O
of O
hypothermia B-Disease
. O

method O
: O
case O
- O
based O
observations O
from O
a O
medical O
intensive O
care O
unit O
( O
micu O
) O
in O
a O
tertiary O
care O
facility O
in O
a O
27 O
- O
year O
- O
old O
female O
with O
fhf B-Disease
from O
acetaminophen O
and O
resultant O
cerebral B-Disease
edema I-Disease
. O

results O
: O
our O
patient O
was O
admitted O
to O
the O
micu O
after O
being O
found O
unresponsive O
with O
presumed O
toxicity B-Disease
from O
acetaminophen O
which O
was O
ingested O
over O
a O
2 O
- O
day O
period O
. O

initial O
evaluation O
confirmed O
fhf B-Disease
from O
acetaminophen O
and O
cerebral B-Disease
edema I-Disease
. O

the O
patient O
was O
treated O
with O
hyperosmolar O
therapy O
, O
hyperventilation B-Disease
, O
sedation O
, O
and O
chemical O
paralysis B-Disease
. O

we O
then O
initiated O
therapeutic O
hypothermia B-Disease
which O
was O
continued O
for O
5 O
days O
. O

at O
re O
- O
warming O
, O
patient O
had O
resolution O
of O
her O
cerebral B-Disease
edema I-Disease
and O
intracranial B-Disease
hypertension I-Disease
. O

conclusion O
: O
in O
patients O
with O
fhf B-Disease
and O
cerebral B-Disease
edema I-Disease
from O
acetaminophen O
overdose B-Disease
, O
prolonged O
therapeutic O
hypothermia B-Disease
could O
potentially O
be O
used O
as O
a O
life O
saving O
therapy O
and O
a O
bridge O
to O
hepatic O
and O
neurological O
recovery O
. O

a O
clinical O
trial O
of O
hypothermia B-Disease
in O
patients O
with O
this O
condition O
is O
warranted O
. O

binasal B-Disease
visual I-Disease
field I-Disease
defects I-Disease
are O
not O
specific O
to O
vigabatrin O
. O

this O
study O
investigated O
the O
visual B-Disease
defects I-Disease
associated O
with O
the O
antiepileptic O
drug O
vigabatrin O
( O
vgb O
) O
. O

two O
hundred O
four O
people O
with O
epilepsy B-Disease
were O
grouped O
on O
the O
basis O
of O
antiepileptic O
drug O
therapy O
( O
current O
, O
previous O
, O
or O
no O
exposure O
to O
vgb O
) O
. O

groups O
were O
matched O
with O
respect O
to O
age O
, O
gender O
, O
and O
seizure B-Disease
frequency O
. O

bilateral B-Disease
visual I-Disease
field I-Disease
abnormalities I-Disease
are O
common O
in O
the O
treated O
epilepsy B-Disease
population O
, O
irrespective O
of O
drug O
history O
. O

assessment O
by O
conventional O
static O
perimetry O
may O
neither O
be O
sufficiently O
sensitive O
nor O
specific O
to O
reliably O
identify O
retinal B-Disease
toxicity I-Disease
associated O
with O
vgb O
. O

smoking O
of O
crack O
cocaine O
as O
a O
risk O
factor O
for O
hiv B-Disease
infection I-Disease
among O
people O
who O
use O
injection O
drugs O
. O

background O
: O
little O
is O
known O
about O
the O
possible O
role O
that O
smoking O
crack O
cocaine O
has O
on O
the O
incidence O
of O
hiv B-Disease
infection I-Disease
. O

given O
the O
increasing O
use O
of O
crack O
cocaine O
, O
we O
sought O
to O
examine O
whether O
use O
of O
this O
illicit O
drug O
has O
become O
a O
risk O
factor O
for O
hiv B-Disease
infection I-Disease
. O

to O
determine O
whether O
the O
risk O
of O
hiv B-Disease
seroconversion I-Disease
among O
daily O
smokers O
of O
crack O
cocaine O
changed O
over O
time O
, O
we O
used O
cox O
proportional O
hazards O
regression O
and O
divided O
the O
study O
into O
3 O
periods O
: O
may O
1 O
, O
1996 O
- O
nov O
. O

of O
these O
, O
137 O
acquired O
hiv B-Disease
infection I-Disease
during O
follow O
- O
up O
. O

after O
adjusting O
for O
potential O
confounders O
, O
we O
found O
that O
the O
risk O
of O
hiv B-Disease
seroconversion I-Disease
among O
participants O
who O
were O
daily O
smokers O
of O
crack O
cocaine O
increased O
over O
time O
( O
period O
1 O
: O
hazard O
ratio O
[ O
hr O
] O
1 O
. O

3 O
, O
95 O
% O
confidence O
interval O
[ O
ci O
] O
0 O
. O

57 O
- O
1 O
. O

85 O
; O
period O
2 O
: O
hr O
1 O
. O

68 O
, O
95 O
% O
ci O
1 O
. O

1 O
- O
2 O
. O

80 O
; O
and O
period O
3 O
: O
hr O
2 O
. O

74 O
, O
95 O
% O
ci O
1 O
. O

6 O
- O
7 O
. O

11 O
) O
. O

interpretation O
: O
smoking O
of O
crack O
cocaine O
was O
found O
to O
be O
an O
independent O
risk O
factor O
for O
hiv B-Disease
seroconversion I-Disease
among O
people O
who O
were O
injection O
drug O
users O
. O

fluoxetine O
improves O
the O
memory B-Disease
deficits I-Disease
caused O
by O
the O
chemotherapy O
agent O
5 O
- O
fluorouracil O
. O

cancer B-Disease
patients O
who O
have O
been O
treated O
with O
systemic O
adjuvant O
chemotherapy O
have O
described O
experiencing O
deteriorations O
in O
cognition O
. O

liver O
- O
specific O
ablation O
of O
integrin O
- O
linked O
kinase O
in O
mice O
results O
in O
enhanced O
and O
prolonged O
cell O
proliferation O
and O
hepatomegaly B-Disease
after O
phenobarbital O
administration O
. O

decreased O
expression O
of O
na O
/ O
k O
- O
atpase O
, O
nhe3 O
, O
nbc1 O
, O
aqp1 O
and O
oat O
in O
gentamicin O
- O
induced O
nephropathy B-Disease
. O

the O
present O
study O
was O
aimed O
to O
determine O
whether O
there O
is O
an O
altered O
regulation O
of O
tubular O
transporters O
in O
gentamicin O
- O
induced O
nephropathy B-Disease
. O

gentamicin O
- O
induced O
nephropathy B-Disease
may O
at O
least O
in O
part O
be O
causally O
related O
with O
a O
decreased O
expression O
of O
na O
( O
+ O
) O
/ O
k O
( O
+ O
) O
- O
atpase O
, O
nhe3 O
, O
nbc1 O
, O
aqp1 O
and O
oat O
. O

acute B-Disease
renal I-Disease
failure I-Disease
after O
high O
- O
dose O
methotrexate O
therapy O
in O
a O
patient O
with O
ileostomy O
. O

high O
- O
dose O
methotrexate O
( O
hd O
- O
mtx O
) O
is O
an O
important O
treatment O
for O
burkitt B-Disease
lymphoma I-Disease
, O
but O
can O
cause O
hepatic B-Disease
and I-Disease
renal I-Disease
toxicity I-Disease
when O
its O
clearance O
is O
delayed O
. O

we O
report O
a O
case O
of O
acute B-Disease
renal I-Disease
failure I-Disease
after O
hd O
- O
mtx O
therapy O
in O
a O
patient O
with O
ileostomy O
, O
the O
patient O
was O
a O
3 O
- O
year O
- O
old O
boy O
who O
had O
received O
a O
living O
- O
related O
liver O
transB-Plantation O
for O
congenital O
biliary B-Disease
atresia I-Disease
. O

at O
day O
833 O
after O
the O
transB-Plantation O
, O
he O
was O
diagnosed O
with O
ptld B-Disease
( O
post B-Disease
- I-Disease
transB-Plantation I-Disease
lymphoproliferative I-Disease
disorder I-Disease
, O
burkitt B-Disease
- I-Disease
type I-Disease
malignant I-Disease
lymphoma I-Disease
) O
. O

subsequent O
hd O
- O
mtx O
therapy O
caused O
acute B-Disease
renal I-Disease
failure I-Disease
that O
required O
continuous O
hemodialysis O
. O

we O
supposed O
that O
intravascular O
hypovolemia B-Disease
due O
to O
substantial O
drainage O
from O
the O
ileostoma O
caused O
acute B-Disease
prerenal I-Disease
failure I-Disease
. O

longitudinal O
association O
of O
alcohol O
use O
with O
hiv B-Disease
disease I-Disease
progression O
and O
psychological O
health O
of O
women O
with O
hiv O
. O

we O
evaluated O
the O
association O
of O
alcohol O
consumption O
and O
depression B-Disease
, O
and O
their O
effects O
on O
hiv B-Disease
disease I-Disease
progression O
among O
women O
with O
hiv O
. O

the O
participants O
had O
physical O
examination O
, O
medical O
record O
extraction O
, O
and O
venipuncture O
, O
cd4 O
+ O
t O
- O
cell O
counts O
determination O
, O
measurement O
of O
depression B-Disease
symptoms O
( O
using O
the O
self O
- O
report O
center O
for O
epidemiological O
studies O
- O
depression B-Disease
scale O
) O
, O
and O
alcohol O
use O
assessment O
at O
enrollment O
, O
and O
semiannually O
until O
march O
2000 O
. O

the O
association O
between O
alcohol O
consumption O
and O
depression B-Disease
was O
significant O
( O
p O
< O
0 O
. O

1 O
) O
. O

depression B-Disease
had O
a O
significant O
negative O
effect O
on O
cd4 O
+ O
t O
- O
cell O
counts O
over O
time O
regardless O
of O
art O
use O
. O

our O
findings O
suggest O
that O
alcohol O
consumption O
has O
a O
direct O
association O
with O
depression B-Disease
. O

moreover O
, O
depression B-Disease
is O
associated O
with O
hiv B-Disease
disease I-Disease
progression O
. O

chemokine O
ccl2 O
and O
its O
receptor O
ccr2 O
are O
increased O
in O
the O
hippocampus O
following O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
. O

background O
: O
neuroinflammation B-Disease
occurs O
after O
seizures B-Disease
and O
is O
implicated O
in O
epileptogenesis O
. O

ccr2 O
is O
a O
chemokine O
receptor O
for O
ccl2 O
and O
their O
interaction O
mediates O
monocyte O
infiltration O
in O
the O
neuroinflammatory B-Disease
cascade O
triggered O
in O
different O
brain O
pathologies O
. O

in O
this O
work O
ccr2 O
and O
ccl2 O
expression O
were O
examined O
following O
status B-Disease
epilepticus I-Disease
( O
se B-Disease
) O
induced O
by O
pilocarpine O
injection O
. O

methods O
: O
se B-Disease
was O
induced O
by O
pilocarpine O
injection O
. O

five O
days O
after O
se B-Disease
, O
ccr2 O
staining O
in O
neurons O
and O
glial O
cells O
was O
examined O
using O
imunohistochemical O
analyses O
. O

results O
: O
increased O
ccr2 O
was O
observed O
in O
the O
hippocampus O
after O
se B-Disease
. O

seizures B-Disease
also O
resulted O
in O
alterations O
to O
the O
cell O
types O
expressing O
ccr2 O
. O

increased O
numbers O
of O
neurons O
that O
expressed O
ccr2 O
was O
observed O
following O
se B-Disease
. O

microglial O
cells O
were O
more O
closely O
apposed O
to O
the O
ccr2 O
- O
labeled O
cells O
in O
se B-Disease
rats O
. O

in O
addition O
, O
rats O
that O
experienced O
se B-Disease
exhibited O
ccr2 O
- O
labeling O
in O
populations O
of O
hypertrophied B-Disease
astrocytes O
, O
especially O
in O
ca1 O
and O
dentate O
gyrus O
. O

examination O
of O
ccl2 O
expression O
showed O
that O
it O
was O
elevated O
in O
the O
hippocampus O
following O
se B-Disease
. O

conclusion O
: O
the O
data O
show O
that O
ccr2 O
and O
ccl2 O
are O
up O
- O
regulated O
in O
the O
hippocampus O
after O
pilocarpine O
- O
induced O
se B-Disease
. O

seizures B-Disease
also O
result O
in O
changes O
to O
ccr2 O
receptor O
expression O
in O
neurons O
and O
astrocytes O
. O

these O
changes O
might O
be O
involved O
in O
detrimental O
neuroplasticity O
and O
neuroinflammatory B-Disease
changes O
that O
occur O
following O
seizures B-Disease
. O

the O
present O
study O
aimed O
to O
explore O
the O
effect O
of O
mt O
induction O
on O
carmustine O
( O
bcnu O
) O
- O
induced O
hippocampal O
cognitive B-Disease
dysfunction I-Disease
in O
rats O
. O

the O
obtained O
data O
revealed O
that O
bcnu O
administration O
resulted O
in O
deterioration B-Disease
of I-Disease
learning I-Disease
and I-Disease
short I-Disease
- I-Disease
term I-Disease
memory I-Disease
( O
stm O
) O
, O
as O
measured O
by O
using O
radial O
arm O
water O
maze O
, O
accompanied O
with O
decreased O
hippocampal O
glutathione O
reductase O
( O
gr O
) O
activity O
and O
reduced O
glutathione O
( O
gsh O
) O
content O
. O

also O
, O
bcnu O
administration O
increased O
serum O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
( O
tnfalpha O
) O
, O
hippocampal O
mt O
and O
malondialdehyde O
( O
mda O
) O
contents O
as O
well O
as O
caspase O
- O
3 O
activity O
in O
addition O
to O
histological O
alterations O
. O

in O
conclusion O
, O
mt O
induction O
halts O
bcnu O
- O
induced O
hippocampal O
toxicity B-Disease
as O
it O
prevented O
gr O
inhibition O
and O
gsh O
depletion O
and O
counteracted O
the O
increased O
levels O
of O
tnfalpha O
, O
mda O
and O
caspase O
- O
3 O
activity O
with O
subsequent O
preservation O
of O
cognition O
. O

fatal O
carbamazepine O
induced O
fulminant B-Disease
eosinophilic I-Disease
( O
hypersensitivity B-Disease
) O
myocarditis B-Disease
: O
emphasis O
on O
anatomical O
and O
histological O
characteristics O
, O
mechanisms O
and O
genetics O
of O
drug B-Disease
hypersensitivity I-Disease
and O
differential O
diagnosis O
. O

a O
frequently O
fatal O
, O
although O
exceptionally O
rare O
side O
effect O
of O
carbamazepine O
is O
necrotizing O
eosinophilic O
( O
hypersensitivity B-Disease
) O
myocarditis B-Disease
. O

we O
report O
a O
case O
of O
hypersensitivity B-Disease
myocarditis B-Disease
secondary O
to O
administration O
of O
carbamazepine O
. O

acute O
hypersensitivity B-Disease
myocarditis B-Disease
was O
not O
suspected O
clinically O
, O
and O
the O
diagnosis O
was O
made O
post O
- O
mortem O
. O

clinically O
, O
death O
was O
due O
to O
cardiogenic B-Disease
shock I-Disease
. O

to O
best O
of O
our O
knowledge O
this O
is O
the O
second O
case O
of O
fatal O
carbamazepine O
induced O
myocarditis B-Disease
reported O
in O
english O
literature O
. O

neuropsychiatric O
behaviors O
in O
the O
mptp O
marmoset O
model O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

objectives O
: O
neuropsychiatric O
symptoms O
are O
increasingly O
recognised O
as O
a O
significant O
problem O
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
. O

the O
levodopa O
- O
treated O
mptp O
- O
lesioned O
marmoset O
was O
used O
as O
a O
model O
of O
neuropsychiatric B-Disease
symptoms I-Disease
in O
pd B-Disease
patients O
. O

here O
we O
compare O
the O
time O
course O
of O
levodopa O
- O
induced O
motor O
fluctuations O
and O
neuropsychiatric B-Disease
- I-Disease
like I-Disease
behaviors I-Disease
to O
determine O
the O
relationship O
between O
duration O
of O
treatment O
and O
onset O
of O
symptoms O
. O

methods O
: O
marmosets O
were O
administered O
1 O
- O
methyl O
- O
4 O
- O
phenyl O
- O
1 O
, O
2 O
, O
3 O
, O
6 O
- O
tetrahydropyridine O
( O
2 O
. O

0 O
mg O
/ O
kg O
s O
. O

c O
. O

) O
for O
five O
days O
, O
resulting O
in O
stable O
parkinsonism B-Disease
. O

animals O
were O
evaluated O
for O
parkinsonian B-Disease
disability I-Disease
, O
dyskinesia B-Disease
and O
on O
- O
time O
( O
motor O
fluctuations O
) O
and O
neuropsychiatric B-Disease
- I-Disease
like I-Disease
behaviors I-Disease
on O
day O
0 O
( O
prior O
to O
levodopa O
) O
and O
on O
days O
1 O
, O
7 O
, O
13 O
, O
27 O
and O
30 O
of O
treatment O
using O
post O
hoc O
dvd O
analysis O
by O
a O
trained O
rater O
, O
blind O
to O
the O
treatment O
day O
. O

results O
: O
the O
neuropsychiatric B-Disease
- I-Disease
like I-Disease
behavior I-Disease
rating O
scale O
demonstrated O
high O
interrater O
reliability O
between O
three O
trained O
raters O
of O
differing O
professional O
backgrounds O
. O

as O
anticipated O
, O
animals O
exhibited O
a O
progressive O
increase O
in O
levodopa O
- O
induced O
motor O
fluctuations O
, O
dyskinesia B-Disease
and O
wearing O
- O
off O
, O
that O
correlated O
with O
the O
duration O
of O
levodopa O
therapy O
. O

in O
contrast O
, O
levodopa O
- O
induced O
neuropsychiatric B-Disease
- I-Disease
like I-Disease
behaviors I-Disease
were O
present O
on O
day O
1 O
of O
levodopa O
treatment O
and O
their O
severity O
did O
not O
correlate O
with O
duration O
of O
treatment O
. O

conclusions O
: O
the O
data O
suggest O
that O
neuropsychiatric B-Disease
disorders I-Disease
in O
pd B-Disease
are O
more O
likely O
an O
interaction O
between O
levodopa O
and O
the O
disease O
state O
than O
a O
consequence O
of O
sensitisation O
to O
repeated O
dopaminergic O
therapy O
. O

contrast O
medium O
nephrotoxicity B-Disease
after O
renal O
artery O
and O
coronary O
angioplasty O
. O

background O
: O
renal B-Disease
dysfunction I-Disease
induced O
by O
iodinated O
contrast O
medium O
( O
cm O
) O
administration O
can O
minimize O
the O
benefit O
of O
the O
interventional O
procedure O
in O
patients O
undergoing O
renal O
angioplasty O
( O
ptra O
) O
. O

purpose O
: O
to O
compare O
the O
susceptibility O
to O
nephrotoxic B-Disease
effect O
of O
cm O
in O
patients O
undergoing O
ptra O
with O
that O
of O
patients O
submitted O
to O
percutaneous O
coronary O
intervention O
( O
pci O
) O
. O

conclusion O
: O
in O
this O
preliminary O
study O
patients O
submitted O
to O
ptra O
showed O
a O
lower O
susceptibility O
to O
renal B-Disease
damage I-Disease
induced O
by O
cm O
administration O
than O
pci O
patients O
. O

the O
effectiveness O
of O
ptra O
on O
renal O
function O
seems O
to O
be O
barely O
influenced O
by O
cm O
toxicity B-Disease
. O

we O
conclude O
that O
an O
h1 O
antagonist O
may O
be O
useful O
in O
preventing O
hypotension B-Disease
caused O
by O
iv O
cimetidine O
, O
since O
the O
vasodilating O
activity O
of O
cimetidine O
is O
mediated O
, O
in O
part O
, O
through O
the O
h1 O
receptor O
. O

medical O
and O
psychiatric O
outcomes O
for O
patients O
transB-Planted O
for O
acetaminophen O
- O
induced O
acute B-Disease
liver I-Disease
failure I-Disease
: O
a O
case O
- O
control O
study O
. O

background O
: O
acetaminophen O
- O
induced O
hepatotoxicity B-Disease
is O
the O
most O
common O
cause O
of O
acute B-Disease
liver I-Disease
failure I-Disease
( O
alf B-Disease
) O
in O
the O
uk O
. O

aims O
and O
methods O
: O
we O
compared O
the O
severity O
of O
pretransB-Plant O
illness O
, O
psychiatric O
co O
- O
morbidity O
, O
medical O
and O
psychosocial O
outcomes O
of O
all O
patients O
who O
had O
undergone O
liver O
transB-Plantation O
( O
lt O
) O
emergently O
between O
1999 O
- O
2004 O
for O
acetaminophen O
- O
induced O
alf B-Disease
( O
n O
= O
36 O
) O
with O
age O
- O
and O
sex O
- O
matched O
patients O
undergoing O
emergent O
lt O
for O
non O
- O
acetaminophen O
- O
induced O
alf B-Disease
( O
n O
= O
35 O
) O
and O
elective O
lt O
for O
chronic B-Disease
liver I-Disease
disease I-Disease
( O
cld B-Disease
, O
n O
= O
34 O
) O
. O

results O
: O
acetaminophen O
- O
induced O
alf B-Disease
patients O
undergoing O
lt O
had O
a O
greater O
severity O
of O
pre O
- O
lt O
illness O
reflected O
by O
higher O
acute O
physiology O
and O
chronic O
health O
evaluation O
ii O
scores O
and O
requirement O
for O
organ O
support O
compared O
with O
the O
other O
two O
groups O
. O

twenty O
( O
56 O
% O
) O
acetaminophen O
- O
induced O
alf B-Disease
patients O
had O
a O
formal O
psychiatric O
diagnosis O
before O
lt O
( O
non O
- O
acetaminophen O
- O
induced O
alf B-Disease
= O
0 O
/ O
35 O
, O
cld B-Disease
= O
2 O
/ O
34 O
; O
p O
< O
0 O
. O

1 O
for O
all O
) O
and O
nine O
( O
25 O
% O
) O
had O
a O
previous O
suicide O
attempt O
. O

during O
follow O
- O
up O
( O
median O
5 O
years O
) O
, O
there O
were O
no O
significant O
differences O
in O
rejection O
( O
acute O
and O
chronic O
) O
, O
graft O
failure O
or O
survival O
between O
the O
groups O
( O
acetaminophen O
- O
induced O
alf B-Disease
1 O
year O
87 O
% O
, O
5 O
years O
75 O
% O
; O
non O
- O
acetaminophen O
- O
induced O
alf B-Disease
88 O
% O
, O
78 O
% O
; O
cld B-Disease
93 O
% O
, O
82 O
% O
: O
p O
> O
0 O
. O

6 O
log O
rank O
) O
. O

two O
acetaminophen O
- O
induced O
alf B-Disease
patients O
reattempted O
suicide O
post O
- O
lt O
( O
one O
died O
8 O
years O
post O
- O
lt O
) O
. O

conclusions O
: O
despite O
a O
high O
prevalence O
of O
psychiatric O
disturbance O
, O
outcomes O
for O
patients O
transB-Planted O
emergently O
for O
acetaminophen O
- O
induced O
alf B-Disease
were O
comparable O
to O
those O
transB-Planted O
for O
non O
- O
acetaminophen O
- O
induced O
alf B-Disease
and O
electively O
for O
cld B-Disease
. O

antithrombotic O
drug O
use O
, O
cerebral B-Disease
microbleeds I-Disease
, O
and O
intracerebral B-Disease
hemorrhage I-Disease
: O
a O
systematic O
review O
of O
published O
and O
unpublished O
studies O
. O

background O
and O
purpose O
: O
cerebral B-Disease
microbleeds I-Disease
( O
mb B-Disease
) O
are O
potential O
risk O
factors O
for O
intracerebral B-Disease
hemorrhage I-Disease
( O
ich B-Disease
) O
, O
but O
it O
is O
unclear O
if O
they O
are O
a O
contraindication O
to O
using O
antithrombotic O
drugs O
. O

insights O
could O
be O
gained O
by O
pooling O
data O
on O
mb B-Disease
frequency O
stratified O
by O
antithrombotic O
use O
in O
cohorts O
with O
ich B-Disease
and O
ischemic B-Disease
stroke I-Disease
( O
is B-Disease
) O
/ O
transient B-Disease
ischemic I-Disease
attack I-Disease
( O
tia B-Disease
) O
. O

methods O
: O
we O
performed O
a O
systematic O
review O
of O
published O
and O
unpublished O
data O
from O
cohorts O
with O
stroke B-Disease
or O
tia B-Disease
to O
compare O
the O
presence O
of O
mb B-Disease
in O
: O
( O
1 O
) O
antithrombotic O
users O
vs O
nonantithrombotic O
users O
with O
ich B-Disease
; O
( O
2 O
) O
antithrombotic O
users O
vs O
nonusers O
with O
is B-Disease
/ O
tia B-Disease
; O
and O
( O
3 O
) O
ich B-Disease
vs O
ischemic B-Disease
events O
stratified O
by O
antithrombotic O
use O
. O

we O
also O
analyzed O
published O
and O
unpublished O
follow O
- O
up O
data O
to O
determine O
the O
risk O
of O
ich B-Disease
in O
antithrombotic O
users O
with O
mb B-Disease
. O

results O
: O
in O
a O
pooled O
analysis O
of O
1460 O
ich B-Disease
and O
3817 O
is B-Disease
/ O
tia B-Disease
, O
mb B-Disease
were O
more O
frequent O
in O
ich B-Disease
vs O
is B-Disease
/ O
tia B-Disease
in O
all O
treatment O
groups O
, O
but O
the O
excess O
increased O
from O
2 O
. O

8 O
( O
odds O
ratio O
; O
range O
, O
2 O
. O

3 O
- O
3 O
. O

5 O
) O
in O
nonantithrombotic O
users O
to O
5 O
. O

7 O
( O
range O
, O
3 O
. O

4 O
- O
9 O
. O

7 O
) O
in O
antiplatelet O
users O
and O
8 O
. O

0 O
( O
range O
, O
3 O
. O

5 O
- O
17 O
. O

8 O
) O
in O
warfarin O
users O
( O
p O
difference O
= O
0 O
. O

1 O
) O
. O

there O
was O
also O
an O
excess O
of O
mb B-Disease
in O
warfarin O
users O
vs O
nonusers O
with O
ich B-Disease
( O
or O
, O
2 O
. O

7 O
; O
95 O
% O
ci O
, O
1 O
. O

6 O
- O
4 O
. O

4 O
; O
p O
< O
0 O
. O

1 O
) O
but O
none O
in O
warfarin O
users O
with O
is B-Disease
/ O
tia B-Disease
( O
or O
, O
1 O
. O

3 O
; O
95 O
% O
ci O
, O
0 O
. O

9 O
- O
1 O
. O

7 O
; O
p O
= O
0 O
. O

33 O
; O
p O
difference O
= O
0 O
. O

1 O
) O
. O

there O
was O
a O
smaller O
excess O
of O
mb B-Disease
in O
antiplatelet O
users O
vs O
nonusers O
with O
ich B-Disease
( O
or O
, O
1 O
. O

7 O
; O
95 O
% O
ci O
, O
1 O
. O

3 O
- O
2 O
. O

3 O
; O
p O
< O
0 O
. O

1 O
) O
, O
but O
findings O
were O
similar O
for O
antiplatelet O
users O
with O
is B-Disease
/ O
tia B-Disease
( O
or O
, O
1 O
. O

4 O
; O
95 O
% O
ci O
, O
1 O
. O

2 O
- O
1 O
. O

7 O
; O
p O
< O
0 O
. O

1 O
; O
p O
difference O
= O
0 O
. O

25 O
) O
. O

in O
pooled O
follow O
- O
up O
data O
for O
768 O
antithrombotic O
users O
, O
presence O
of O
mb B-Disease
at O
baseline O
was O
associated O
with O
a O
substantially O
increased O
risk O
of O
subsequent O
ich B-Disease
( O
or O
, O
12 O
. O

1 O
; O
95 O
% O
ci O
, O
3 O
. O

4 O
- O
42 O
. O

5 O
; O
p O
< O
0 O
. O

1 O
) O
. O

conclusions O
: O
the O
excess O
of O
mb B-Disease
in O
warfarin O
users O
with O
ich B-Disease
compared O
to O
other O
groups O
suggests O
that O
mb B-Disease
increase O
the O
risk O
of O
warfarin O
- O
associated O
ich B-Disease
. O

studies O
of O
synergy O
between O
morphine O
and O
a O
novel O
sodium O
channel O
blocker O
, O
cnsb002 O
, O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic B-Disease
pain I-Disease
. O

objective O
: O
this O
study O
determined O
the O
antihyperalgesic O
effect O
of O
cnsb002 O
, O
a O
sodium O
channel O
blocker O
with O
antioxidant O
properties O
given O
alone O
and O
in O
combinations O
with O
morphine O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic B-Disease
pain I-Disease
. O

design O
: O
dose O
response O
curves O
for O
nonsedating O
doses O
of O
morphine O
and O
cnsb002 O
given O
intraperitoneally O
alone O
and O
together O
in O
combinations O
were O
constructed O
for O
antihyperalgesic O
effect O
using O
paw O
withdrawal O
from O
noxious O
heat O
in O
two O
rat O
pain B-Disease
models O
: O
carrageenan O
- O
induced O
paw O
inflammation B-Disease
and O
streptozotocin O
( O
stz O
) O
- O
induced O
diabetic B-Disease
neuropathy I-Disease
. O

the O
doses O
calculated O
to O
cause O
50 O
% O
reversal O
of O
hyperalgesia B-Disease
( O
ed50 O
) O
were O
7 O
. O

54 O
( O
1 O
. O

81 O
) O
and O
4 O
. O

83 O
( O
1 O
. O

54 O
) O
in O
the O
carrageenan O
model O
and O
44 O
. O

18 O
( O
1 O
. O

37 O
) O
and O
9 O
. O

14 O
( O
1 O
. O

24 O
) O
in O
the O
stz O
- O
induced O
neuropathy B-Disease
model O
for O
cnsb002 O
and O
morphine O
, O
respectively O
( O
mg O
/ O
kg O
; O
mean O
, O
sem O
) O
. O

the O
ed50 O
values O
for O
morphine O
when O
given O
in O
combination O
with O
cnsb002 O
( O
5 O
mg O
/ O
kg O
) O
were O
less O
than O
the O
maximum O
nonsedating O
dose O
: O
0 O
. O

56 O
( O
1 O
. O

55 O
) O
in O
the O
carrageenan O
model O
and O
1 O
. O

37 O
( O
1 O
. O

23 O
) O
in O
the O
neuropathy B-Disease
model O
( O
mg O
/ O
kg O
; O
mean O
, O
sem O
) O
. O

the O
antinociception O
after O
morphine O
( O
3 O
. O

2 O
mg O
/ O
kg O
) O
was O
increased O
by O
co O
- O
administration O
with O
cnsb002 O
from O
28 O
. O

0 O
and O
31 O
. O

7 O
% O
to O
114 O
. O

6 O
and O
56 O
. O

9 O
% O
reversal O
of O
hyperalgesia B-Disease
in O
the O
inflammatory O
and O
neuropathic B-Disease
models O
, O
respectively O
( O
p O
< O
0 O
. O

1 O
; O
one O
- O
way O
analysis O
of O
variance O
- O
significantly O
greater O
than O
either O
drug O
given O
alone O
) O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
: O
a O
practical O
review O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
( O
hit B-Disease
) O
remains O
under O
- O
recognized O
despite O
its O
potentially O
devastating O
outcomes O
. O

thrombosis B-Disease
and O
thrombocytopenia B-Disease
that O
follow O
comprise O
the O
2 O
hallmark O
traits O
of O
hit B-Disease
, O
with O
the O
former O
largely O
responsible O
for O
significant O
vascular O
complications O
. O

the O
prevalence O
of O
hit B-Disease
varies O
among O
several O
subgroups O
, O
with O
greater O
incidence O
in O
surgical O
as O
compared O
with O
medical O
populations O
. O

hit B-Disease
must O
be O
acknowledged O
for O
its O
intense O
predilection O
for O
thrombosis B-Disease
and O
suspected O
whenever O
thrombosis B-Disease
occurs O
after O
heparin O
exposure O
. O

the O
treatment O
of O
hit B-Disease
mandates O
an O
immediate O
cessation O
of O
all O
heparin O
exposure O
and O
the O
institution O
of O
an O
antithrombotic O
therapy O
, O
most O
commonly O
using O
a O
direct O
thrombin O
inhibitor O
. O

current O
nan O
diagnostic O
nan O
tests O
, O
which O
primarily O
include O
functional O
and O
antigenic O
assays O
, O
have O
more O
of O
a O
confirmatory O
than O
diagnostic O
role O
in O
the O
management O
of O
hit B-Disease
. O

direct O
thrombin O
inhibitors O
are O
appropriate O
, O
evidence O
- O
based O
alternatives O
to O
heparin O
in O
patients O
with O
a O
history O
of O
hit B-Disease
, O
who O
need O
to O
undergo O
percutaneous O
coronary O
intervention O
. O

as O
heparin O
remains O
one O
of O
the O
most O
frequently O
used O
medications O
today O
with O
potential O
for O
hit B-Disease
with O
every O
heparin O
exposure O
, O
a O
close O
vigilance O
of O
platelet O
counts O
must O
be O
practiced O
whenever O
heparin O
is O
initiated O
. O

abductor O
paralysis B-Disease
after O
botox O
injection O
for O
adductor B-Disease
spasmodic I-Disease
dysphonia I-Disease
. O

objectives O
/ O
hypothesis O
: O
botulinum O
toxin O
( O
botox O
) O
injections O
into O
the O
thyroarytenoid O
muscles O
are O
the O
current O
standard O
of O
care O
for O
adductor B-Disease
spasmodic I-Disease
dysphonia I-Disease
( O
adsd B-Disease
) O
. O

reported O
adverse O
effects O
include O
a O
period O
of O
breathiness O
, O
throat B-Disease
pain I-Disease
, O
and O
difficulty O
with O
swallowing O
liquids O
. O

here O
we O
report O
multiple O
cases O
of O
bilateral O
abductor O
paralysis B-Disease
following O
botox O
injections O
for O
adsd B-Disease
, O
a O
complication O
previously O
unreported O
. O

methods O
: O
patients O
that O
received O
botox O
injections O
for O
spasmodic B-Disease
dysphonia I-Disease
between O
january O
2000 O
and O
october O
2009 O
were O
evaluated O
. O

patients O
with O
adsd B-Disease
were O
identified O
. O

for O
patients O
with O
bilateral O
abductor O
paralysis B-Disease
, O
age O
, O
sex O
, O
paralytic O
botox O
dose O
, O
prior O
botox O
dose O
, O
and O
course O
following O
paralysis B-Disease
were O
noted O
. O

results O
: O
from O
a O
database O
of O
452 O
patients O
receiving O
botox O
, O
352 O
patients O
had O
been O
diagnosed O
with O
adsd B-Disease
. O

of O
these O
352 O
patients O
, O
eight O
patients O
suffered O
bilateral O
abductor O
paralysis B-Disease
, O
and O
two O
suffered O
this O
complication O
twice O
. O

most O
patients O
had O
received O
treatments O
prior O
to O
abductor O
paralysis B-Disease
and O
continued O
receiving O
after O
paralysis B-Disease
. O

the O
incidence O
of O
abductor O
paralysis B-Disease
after O
botox O
injection O
for O
adsd B-Disease
was O
0 O
. O

34 O
% O
. O

conclusions O
: O
bilateral O
abductor O
paralysis B-Disease
is O
a O
rare O
complication O
of O
botox O
injections O
for O
adsd B-Disease
, O
causing O
difficulty O
with O
breathing O
upon O
exertion O
. O

the O
likely O
mechanism O
of O
paralysis B-Disease
is O
diffusion O
of O
botox O
around O
the O
muscular O
process O
of O
the O
arytenoid O
to O
the O
posterior O
cricoarytenoid O
muscles O
. O

the O
paralysis B-Disease
is O
temporary O
, O
and O
watchful O
waiting O
with O
restriction O
of O
activity O
is O
the O
recommended O
management O
. O

mitochondrial B-Disease
impairment I-Disease
contributes O
to O
cocaine O
- O
induced O
cardiac B-Disease
dysfunction I-Disease
: O
prevention O
by O
the O
targeted O
antioxidant O
mitoq O
. O

the O
goal O
of O
this O
study O
was O
to O
assess O
mitochondrial O
function O
and O
ros O
production O
in O
an O
experimental O
model O
of O
cocaine O
- O
induced O
cardiac B-Disease
dysfunction I-Disease
. O

we O
hypothesized O
that O
cocaine B-Disease
abuse I-Disease
may O
lead O
to O
altered O
mitochondrial O
function O
that O
in O
turn O
may O
cause O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
. O

this O
uncoupling O
effect O
on O
oxidative O
phosphorylation O
was O
not O
detectable O
after O
short O
- O
term O
exposure O
to O
cocaine O
, O
suggesting O
that O
these O
mitochondrial B-Disease
abnormalities I-Disease
were O
a O
late O
rather O
than O
a O
primary O
event O
in O
the O
pathological O
response O
to O
cocaine O
. O

mitoq O
, O
a O
mitochondrial O
- O
targeted O
antioxidant O
, O
was O
shown O
to O
completely O
prevent O
these O
mitochondrial B-Disease
abnormalities I-Disease
as O
well O
as O
cardiac B-Disease
dysfunction I-Disease
characterized O
here O
by O
a O
diastolic B-Disease
dysfunction I-Disease
studied O
with O
a O
conductance O
catheter O
to O
obtain O
pressure O
- O
volume O
data O
. O

taken O
together O
, O
these O
results O
extend O
previous O
studies O
and O
demonstrate O
that O
cocaine O
- O
induced O
cardiac B-Disease
dysfunction I-Disease
may O
be O
due O
to O
a O
mitochondrial B-Disease
defect I-Disease
. O

trimethoprim O
- O
induced O
immune O
hemolytic B-Disease
anemia I-Disease
in O
a O
pediatric O
oncology O
patient O
presenting O
as O
an O
acute O
hemolytic O
transfusion O
reaction O
. O

a O
10 O
- O
year O
- O
old O
male O
with O
acute B-Disease
leukemia I-Disease
presented O
with O
post O
- O
chemotherapy O
anemia B-Disease
. O

during O
red O
cell O
transfusion O
, O
he O
developed O
hemoglobinuria B-Disease
. O

drug O
- O
induced O
immune O
hemolytic B-Disease
anemia I-Disease
was O
suspected O
because O
of O
positive O
direct O
antiglobulin O
test O
, O
negative O
eluate O
, O
and O
microspherocytes O
on O
smear O
pre O
- O
and O
post O
- O
transfusion O
. O

other O
causes O
of O
anemia B-Disease
should O
be O
considered O
in O
patients O
with O
worse O
- O
than O
- O
expected O
anemia B-Disease
after O
chemotherapy O
. O

furthermore O
, O
hemolysis B-Disease
during O
transfusion O
is O
not O
always O
a O
transfusion O
reaction O
. O

verapamil O
stimulation O
test O
in O
hyperprolactinemia B-Disease
: O
loss O
of O
prolactin O
response O
in O
anatomic O
or O
functional O
stalk O
effect O
. O

aim O
: O
verapamil O
stimulation O
test O
was O
previously O
investigated O
as O
a O
tool O
for O
differential O
diagnosis O
of O
hyperprolactinemia B-Disease
, O
but O
with O
conflicting O
results O
. O

macroprolactinemia B-Disease
was O
never O
considered O
in O
those O
previous O
studies O
. O

here O
, O
we O
aimed O
to O
re O
- O
investigate O
the O
diagnostic O
value O
of O
verapamil O
in O
a O
population O
who O
were O
all O
screened O
for O
macroprolactinemia B-Disease
. O

prolactin O
responses O
to O
verapamil O
in O
65 O
female O
patients O
( O
age O
: O
29 O
. O

9 O
+ O
/ O
- O
8 O
. O

1 O
years O
) O
with O
hyperprolactinemia B-Disease
were O
tested O
in O
a O
descriptive O
, O
matched O
case O
- O
control O
study O
. O

results O
: O
verapamil O
significantly O
increased O
prl O
levels O
in O
healthy O
controls O
( O
n O
. O

8 O
, O
prl O
: O
183 O
% O
) O
, O
macroprolactinoma B-Disease
( O
n O
. O

8 O
, O
prl O
: O
7 O
% O
) O
, O
microprolactinoma B-Disease
( O
n O
. O

19 O
, O
prl O
: O
21 O
% O
) O
, O
macroprolactinemia B-Disease
( O
n O
. O

23 O
, O
prl O
: O
126 O
% O
) O
, O
but O
not O
in O
pseudoprolactinoma B-Disease
( O
n O
. O

8 O
, O
prl O
: O
0 O
. O

8 O
% O
) O
, O
and O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
( O
n O
. O

7 O
, O
prl O
: O
3 O
% O
) O
. O

roc O
curve O
analysis O
revealed O
that O
unresponsiveness O
to O
verapamil O
defined O
as O
prl O
< O
7 O
% O
, O
discriminated O
anatomical O
or O
functional O
stalk O
effect O
( O
sensitivity O
: O
74 O
% O
, O
specificity O
: O
73 O
% O
, O
auc O
: O
0 O
. O

855 O
+ O
/ O
- O
0 O
. O

4 O
, O
p O
< O
0 O
. O

1 O
, O
ci O
: O
0 O
. O

768 O
- O
0 O
. O

942 O
) O
associated O
with O
pseudoprolactinoma B-Disease
or O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
, O
respectively O
. O

conclusion O
: O
verapamil O
responsiveness O
is O
not O
a O
reliable O
finding O
for O
the O
differential O
diagnosis O
of O
hyperprolactinemia B-Disease
. O

however O
, O
verapamil O
unresponsiveness O
discriminates O
stalk O
effect O
( O
i O
. O

e O
. O

, O
anatomically O
or O
functionally O
inhibited O
dopaminergic O
tonus O
) O
from O
other O
causes O
of O
hyperprolactinemia B-Disease
with O
varying O
degrees O
of O
responsiveness O
. O

blockade O
of O
endothelial O
- O
mesenchymal O
transition O
by O
a O
smad3 O
inhibitor O
delays O
the O
early O
development O
of O
streptozotocin O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
. O

objective O
: O
a O
multicenter O
, O
controlled O
trial O
showed O
that O
early O
blockade O
of O
the O
renin O
- O
angiotensin O
system O
in O
patients O
with O
type B-Disease
1 I-Disease
diabetes I-Disease
and O
normoalbuminuria O
did O
not O
retard O
the O
progression O
of O
nephropathy B-Disease
, O
suggesting O
that O
other O
mechanism O
( O
s O
) O
are O
involved O
in O
the O
pathogenesis O
of O
early O
diabetic B-Disease
nephropathy I-Disease
( O
diabetic B-Disease
nephropathy I-Disease
) O
. O

we O
have O
previously O
demonstrated O
that O
endothelial O
- O
mesenchymal O
- O
transition O
( O
endomt O
) O
contributes O
to O
the O
early O
development O
of O
renal O
interstitial O
fibrosis B-Disease
independently O
of O
microalbuminuria O
in O
mice O
with O
streptozotocin O
( O
stz O
) O
- O
induced O
diabetes B-Disease
. O

in O
the O
present O
study O
, O
we O
hypothesized O
that O
blocking O
endomt O
reduces O
the O
early O
development O
of O
diabetic B-Disease
nephropathy I-Disease
. O

blocking O
studies O
using O
receptor O
for O
age O
sirna O
and O
a O
specific O
inhibitor O
of O
smad3 O
( O
sis3 O
) O
were O
performed O
in O
mmecs O
and O
in O
stz O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
in O
tie2 O
- O
cre O
; O
loxp O
- O
egfp O
mice O
. O

immunoprecipitation O
/ O
western O
blotting O
showed O
that O
smad3 O
was O
activated O
by O
ages O
but O
was O
inhibited O
by O
sis3 O
in O
mmecs O
and O
in O
stz O
- O
induced O
diabetic B-Disease
nephropathy I-Disease
. O

confocal O
microscopy O
and O
real O
- O
time O
pcr O
further O
demonstrated O
that O
sis3 O
abrogated O
endomt O
, O
reduced O
renal O
fibrosis B-Disease
, O
and O
retarded O
progression O
of O
nephropathy B-Disease
. O

conclusions O
: O
endomt O
is O
a O
novel O
pathway O
leading O
to O
early O
development O
of O
diabetic B-Disease
nephropathy I-Disease
. O

blockade O
of O
endomt O
by O
sis3 O
may O
provide O
a O
new O
strategy O
to O
retard O
the O
progression O
of O
diabetic B-Disease
nephropathy I-Disease
and O
other O
diabetes B-Disease
complications I-Disease
. O

cytostatic O
and O
anti O
- O
angiogenic O
effects O
of O
temsirolimus O
in O
refractory O
mantle B-Disease
cell I-Disease
lymphoma I-Disease
. O

mantle B-Disease
cell I-Disease
lymphoma I-Disease
( O
mcl B-Disease
) O
is O
a O
rare O
and O
aggressive O
type O
of O
b B-Disease
- I-Disease
cell I-Disease
non I-Disease
- I-Disease
hodgkin I-Disease
' I-Disease
s I-Disease
lymphoma I-Disease
. O

however O
, O
a O
38 O
% O
remission O
rate O
has O
been O
recently O
reported O
in O
refractory O
mcl B-Disease
treated O
with O
temsirolimus O
, O
a O
mtor O
inhibitor O
. O

here O
we O
had O
the O
opportunity O
to O
study O
a O
case O
of O
refractory O
mcl B-Disease
who O
had O
tumor B-Disease
regression O
two O
months O
after O
temsirolimus O
treatment O
, O
and O
a O
progression O
- O
free O
survival O
of O
10 O
months O
. O

comparison O
of O
the O
two O
biopsies O
showed O
that O
temsirolimus O
inhibited O
tumor B-Disease
cell O
proliferation O
through O
cell O
cycle O
arrest O
, O
but O
did O
not O
induce O
any O
change O
in O
the O
number O
of O
apoptotic O
tumor B-Disease
cells O
. O

apart O
from O
this O
cytostatic O
effect O
, O
temsirolimus O
had O
an O
antiangiogenic O
effect O
with O
decrease O
of O
tumor B-Disease
microvessel O
density O
and O
of O
vegf O
expression O
. O

moreover O
, O
numerous O
patchy O
, O
well O
- O
limited O
fibrotic O
areas O
, O
compatible O
with O
post O
- O
necrotic B-Disease
tissue O
repair O
, O
were O
found O
after O
6 O
- O
month O
temsirolimus O
therapy O
. O

thus O
, O
temsirolimus O
reduced O
tumor B-Disease
burden O
through O
associated O
cytostatic O
and O
anti O
- O
angiogenic O
effects O
. O

this O
dual O
effect O
of O
temsirolimus O
on O
tumor B-Disease
tissue O
could O
contribute O
to O
its O
recently O
reported O
efficiency O
in O
refractory O
mcl B-Disease
resistant O
to O
conventional O
chemotherapy O
. O

acute B-Disease
renal I-Disease
failure I-Disease
due O
to O
rifampicin O
. O

a O
23 O
- O
year O
- O
old O
male O
patient O
with O
bacteriologically O
proven O
pulmonary B-Disease
tuberculosis I-Disease
was O
treated O
with O
the O
various O
regimens O
of O
antituberculosis O
drugs O
for O
nearly O
15 O
months O
. O

rifampicin O
was O
administered O
thrice O
as O
one O
of O
the O
3 O
- O
4 O
drug O
regimen O
and O
each O
time O
he O
developed O
untoward O
side O
effects O
like O
nausea B-Disease
, O
vomiting B-Disease
and O
fever B-Disease
with O
chills O
and O
rigors O
. O

syncope B-Disease
caused O
by O
hyperkalemia B-Disease
during O
use O
of O
a O
combined O
therapy O
with O
the O
angiotensin O
- O
converting O
enzyme O
inhibitor O
and O
spironolactone O
. O

a O
76 O
year O
- O
old O
woman O
with O
a O
history O
of O
coronary O
artery O
bypass O
grafting O
and O
prior O
myocardial B-Disease
infarction I-Disease
was O
transferred O
to O
the O
emergency O
room O
with O
loss B-Disease
of I-Disease
consciousness I-Disease
due O
to O
marked O
bradycardia B-Disease
caused O
by O
hyperkalemia B-Disease
. O

the O
cause O
of O
hyperkalemia B-Disease
was O
considered O
to O
be O
several O
doses O
of O
spiranolactone O
, O
an O
aldosterone O
antagonist O
, O
in O
addition O
to O
the O
long O
- O
term O
intake O
of O
ramipril O
, O
an O
ace O
inhibitor O
. O

clinicians O
should O
be O
alert O
to O
the O
possibility O
of O
hyperkalemia B-Disease
, O
especially O
in O
elderly O
patients O
using O
ace O
/ O
arb O
in O
combination O
with O
potassium O
sparing O
agents O
and O
who O
have O
mild O
renal B-Disease
disturbance I-Disease
. O

diffuse O
skeletal O
pain B-Disease
after O
administration O
of O
alendronate O
. O

background O
: O
osteoporosis B-Disease
is O
caused O
by O
bone O
resorption O
in O
excess O
of O
bone O
formation O
, O
and O
bisphosphonates O
, O
are O
used O
to O
inhibit O
bone O
resorption O
. O

alendronate O
, O
a O
biphosphonate O
, O
is O
effective O
for O
both O
the O
treatment O
and O
prevention O
of O
osteoporosis B-Disease
in O
postmenopausal O
women O
. O

musculoskeletal B-Disease
pain I-Disease
may O
be O
an O
important O
side O
effect O
in O
these O
patients O
. O

we O
presented O
a O
patient O
admitted O
to O
our O
out O
- O
patient O
clinic O
with O
diffuse O
skeletal O
pain B-Disease
after O
three O
consecutive O
administration O
of O
alendronate O
. O

conclusion O
: O
we O
conclude O
that O
patients O
with O
osteoporosis B-Disease
can O
report O
pain B-Disease
, O
and O
bisphosphonate O
- O
related O
pain B-Disease
should O
also O
be O
considered O
before O
ascribing O
this O
complaint O
to O
osteoporosis B-Disease
. O

cerebrospinal O
fluid O
penetration O
of O
high O
- O
dose O
daptomycin O
in O
suspected O
staphylococcus O
aureus O
meningitis B-Disease
. O

objective O
: O
to O
report O
a O
case O
of O
methicillin O
- O
sensitive O
staphylococcus O
aureus O
( O
mssa O
) O
bacteremia B-Disease
with O
suspected O
mssa O
meningitis B-Disease
treated O
with O
high O
- O
dose O
daptomycin O
assessed O
with O
concurrent O
serum O
and O
cerebrospinal O
fluid O
( O
csf O
) O
concentrations O
. O

case O
summary O
: O
a O
54 O
- O
year O
- O
old O
male O
presented O
to O
the O
emergency O
department O
with O
generalized O
weakness B-Disease
and O
presumed O
health O
- O
care O
- O
associated O
pneumonia B-Disease
shown O
on O
chest O
radiograph O
. O

on O
day O
8 O
, O
the O
patient O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
( O
serum O
creatinine O
1 O
. O

9 O
mg O
/ O
dl O
, O
increased O
from O
1 O
. O

2 O
mg O
/ O
dl O
the O
previous O
day O
and O
0 O
. O

8 O
mg O
/ O
dl O
on O
admission O
) O
. O

the O
patient O
' O
s O
glasgow O
coma O
score O
was O
3 O
, O
with O
normal O
findings O
shown O
on O
computed O
tomography O
scan O
of O
the O
head O
72 O
hours O
following O
an O
episode O
of O
cardiac B-Disease
arrest I-Disease
on O
day O
10 O
. O

the O
patient O
experienced O
relapsing O
mssa O
bacteremia B-Disease
on O
day O
9 O
, O
increasing O
the O
suspicion O
for O
a O
central O
nervous O
system O
( O
cns O
) O
infection B-Disease
. O

nafcillin O
was O
discontinued O
and O
daptomycin O
9 O
mg O
/ O
kg O
daily O
was O
initiated O
for O
suspected O
meningitis B-Disease
and O
was O
continued O
until O
the O
patient O
' O
s O
death O
on O
day O
16 O
. O

discussion O
: O
daptomycin O
was O
initiated O
in O
our O
patient O
secondary O
to O
possible O
nafcillin O
- O
induced O
acute O
interstitial B-Disease
nephritis I-Disease
and O
relapsing O
bacteremia B-Disease
. O

conclusions O
: O
high O
- O
dose O
daptomycin O
may O
be O
an O
alternative O
option O
for O
mssa O
bacteremia B-Disease
with O
or O
without O
a O
cns O
source O
in O
patients O
who O
have O
failed O
or O
cannot O
tolerate O
standard O
therapy O
. O

further O
clinical O
evaluation O
in O
patients O
with O
confirmed O
meningitis B-Disease
is O
warranted O
. O

the O
role O
of O
nitric O
oxide O
in O
convulsions B-Disease
induced O
by O
lindane O
in O
rats O
. O

it O
evokes O
convulsions B-Disease
mainly O
trough O
the O
blockage O
of O
gaba O
( O
a O
) O
receptors O
. O

nitric O
oxide O
( O
no O
) O
, O
gaseous O
neurotransmitter O
, O
has O
contradictor O
role O
in O
epileptogenesis O
due O
to O
opposite O
effects O
of O
l O
- O
arginine O
, O
precursor O
of O
no O
syntheses O
( O
nos O
) O
, O
and O
l O
- O
name O
( O
nos O
inhibitor O
) O
observed O
in O
different O
epilepsy B-Disease
models O
. O

the O
aim O
of O
the O
current O
study O
was O
to O
determine O
the O
effects O
of O
no O
on O
the O
behavioral O
and O
eeg O
characteristics O
of O
lindane O
- O
induced O
epilepsy B-Disease
in O
male O
wistar O
albino O
rats O
. O

the O
administration O
of O
l O
- O
arginine O
( O
600 O
, O
800 O
and O
1000 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
in O
dose O
- O
dependent O
manner O
significantly O
increased O
convulsion B-Disease
incidence O
and O
severity O
and O
shortened O
latency O
time O
to O
first O
convulsion B-Disease
elicited O
by O
lower O
lindane O
dose O
( O
4 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
. O

on O
the O
contrary O
, O
pretreatment O
with O
l O
- O
name O
( O
500 O
, O
700 O
and O
900 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
decreased O
convulsion B-Disease
incidence O
and O
severity O
and O
prolonged O
latency O
time O
to O
convulsion B-Disease
following O
injection O
with O
a O
convulsive B-Disease
dose O
of O
lindane O
( O
8 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
. O

these O
results O
support O
the O
conclusion O
that O
no O
plays O
a O
role O
of O
endogenous O
convulsant O
in O
rat O
model O
of O
lindane O
seizures B-Disease
. O

severe O
polyneuropathy B-Disease
and O
motor O
loss O
after O
intrathecal O
thiotepa O
combination O
chemotherapy O
: O
description O
of O
two O
cases O
. O

two O
cases O
of O
severe O
delayed O
neurologic B-Disease
toxicity I-Disease
related O
to O
the O
administration O
of O
intrathecal O
( O
it O
) O
combination O
chemotherapy O
including O
thiotepa O
( O
tspa O
) O
are O
presented O
. O

both O
cases O
developed O
axonal B-Disease
neuropathy I-Disease
with O
motor O
predominance O
in O
the O
lower O
extremities O
1 O
and O
6 O
months O
after O
it O
chemotherapy O
was O
administered O
. O

neurologic B-Disease
toxicities I-Disease
have O
been O
described O
with O
it O
- O
methotrexate O
, O
it O
- O
cytosine O
arabinoside O
and O
it O
- O
tspa O
. O

to O
our O
knowledge O
, O
however O
, O
axonal B-Disease
neuropathy I-Disease
following O
administration O
of O
these O
three O
agents O
has O
not O
been O
previously O
described O
. O

in O
spite O
of O
the O
fact O
that O
tspa O
is O
a O
useful O
it O
agent O
, O
its O
combination O
with O
mtx O
, O
ara O
- O
c O
and O
radiotherapy O
could O
cause O
severe O
neurotoxicity B-Disease
. O

vasodilation O
of O
large O
and O
small O
coronary O
vessels O
and O
hypotension B-Disease
induced O
by O
cromakalim O
and O
pinacidil O
were O
not O
affected O
by O
prior O
combined O
beta O
adrenergic O
and O
muscarinic O
receptors O
blockade O
but O
drug O
- O
induced O
tachycardia B-Disease
was O
abolished O
. O

mefenamic O
acid O
- O
induced O
neutropenia B-Disease
and O
renal B-Disease
failure I-Disease
in O
elderly O
females O
with O
hypothyroidism B-Disease
. O

we O
report O
mefenamic O
acid O
- O
induced O
non O
- O
oliguric O
renal B-Disease
failure I-Disease
and O
severe O
neutropenia B-Disease
occurring O
simultaneously O
in O
two O
elderly O
females O
. O

the O
neutropenia B-Disease
was O
due O
to O
maturation O
arrest O
of O
the O
myeloid O
series O
in O
one O
patient O
. O

both O
patients O
were O
also O
hypothyroid B-Disease
, O
but O
it O
is O
not O
clear O
whether O
this O
was O
a O
predisposing O
factor O
to O
the O
development O
of O
these O
adverse O
reactions O
. O

however O
, O
it O
would O
seem O
prudent O
not O
to O
use O
mefenamic O
acid O
in O
hypothyroid B-Disease
patients O
until O
the O
hypothyroidism B-Disease
has O
been O
corrected O
. O

etiology O
of O
hypercalcemia B-Disease
in O
hemodialysis O
patients O
on O
calcium O
carbonate O
therapy O
. O

fourteen O
of O
39 O
dialysis O
patients O
( O
36 O
% O
) O
became O
hypercalcemic B-Disease
after O
switching O
to O
calcium O
carbonate O
as O
their O
principal O
phosphate O
binder O
. O

in O
order O
to O
identify O
risk O
factors O
associated O
with O
the O
development O
of O
hypercalcemia B-Disease
, O
indirect O
parameters O
of O
intestinal O
calcium O
reabsorption O
and O
bone O
turnover O
rate O
in O
these O
14 O
patients O
were O
compared O
with O
results O
in O
14 O
eucalcemic O
patients O
matched O
for O
age O
, O
sex O
, O
length O
of O
time O
on O
dialysis O
, O
and O
etiology O
of O
renal B-Disease
disease I-Disease
. O

in O
addition O
to O
experiencing O
hypercalcemic B-Disease
episodes O
with O
peak O
calcium O
values O
of O
2 O
. O

7 O
to O
3 O
. O

8 O
mmol O
/ O
l O
( O
10 O
. O

7 O
to O
15 O
. O

0 O
mg O
/ O
dl O
) O
, O
patients O
in O
the O
hypercalcemic B-Disease
group O
exhibited O
a O
significant O
increase O
in O
the O
mean O
calcium O
concentration O
obtained O
during O
6 O
months O
before O
the O
switch O
, O
compared O
with O
the O
mean O
value O
obtained O
during O
the O
7 O
months O
of O
observation O
after O
the O
switch O
( O
2 O
. O

4 O
+ O
/ O
- O
0 O
. O

3 O
to O
2 O
. O

5 O
+ O
/ O
- O
0 O
. O

3 O
mmol O
/ O
l O
[ O
9 O
. O

7 O
+ O
/ O
- O
0 O
. O

2 O
to O
10 O
. O

2 O
+ O
/ O
- O
0 O
. O

1 O
mg O
/ O
dl O
] O
, O
p O
= O
0 O
. O

6 O
) O
. O

late O
- O
onset O
scleroderma B-Disease
renal I-Disease
crisis I-Disease
induced O
by O
tacrolimus O
and O
prednisolone O
: O
a O
case O
report O
. O

scleroderma B-Disease
renal I-Disease
crisis I-Disease
( O
src B-Disease
) O
is O
a O
rare O
complication O
of O
systemic B-Disease
sclerosis I-Disease
( O
ssc B-Disease
) O
but O
can O
be O
severe O
enough O
to O
require O
temporary O
or O
permanent O
renal O
replacement O
therapy O
. O

moderate O
to O
high O
dose O
corticosteroid O
use O
is O
recognized O
as O
a O
major O
risk O
factor O
for O
src B-Disease
. O

furthermore O
, O
there O
have O
been O
reports O
of O
thrombotic B-Disease
microangiopathy I-Disease
precipitated O
by O
cyclosporine O
in O
patients O
with O
ssc B-Disease
. O

in O
this O
article O
, O
we O
report O
a O
patient O
with O
src B-Disease
induced O
by O
tacrolimus O
and O
corticosteroids O
. O

the O
aim O
of O
this O
work O
is O
to O
call O
attention O
to O
the O
risk O
of O
tacrolimus O
use O
in O
patients O
with O
ssc B-Disease
. O

methyldopa O
- O
induced O
hemolytic B-Disease
anemia I-Disease
in O
a O
15 O
year O
old O
presenting O
as O
near O
- O
syncope B-Disease
. O

methyldopa O
causes O
an O
autoimmune B-Disease
hemolytic I-Disease
anemia I-Disease
in O
a O
small O
percentage O
of O
patients O
who O
take O
the O
drug O
. O

we O
report O
a O
case O
of O
methyldopa O
- O
induced O
hemolytic B-Disease
anemia I-Disease
in O
a O
15 O
- O
year O
- O
old O
boy O
who O
presented O
to O
the O
emergency B-Disease
department I-Disease
with O
near O
- O
syncope B-Disease
. O

the O
boy O
had O
been O
treated O
with O
intravenous O
methyldopa O
during O
a O
trauma B-Disease
admission O
seven O
weeks O
prior O
to O
presentation O
. O

a O
brief O
review O
of O
autoimmune O
and O
drug O
- O
induced O
hemolytic B-Disease
anemias I-Disease
is O
provided O
. O

the O
risk O
and O
associated O
factors O
of O
methamphetamine O
psychosis B-Disease
in O
methamphetamine O
- O
dependent O
patients O
in O
malaysia O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
determine O
the O
risk O
of O
lifetime O
and O
current O
methamphetamine O
- O
induced O
psychosis B-Disease
in O
patients O
with O
methamphetamine O
dependence O
. O

the O
association O
between O
psychiatric O
co O
- O
morbidity O
and O
methamphetamine O
- O
induced O
psychosis B-Disease
was O
also O
studied O
. O

patients O
with O
the O
diagnosis O
of O
methamphetamine O
based O
on O
dsm O
- O
iv O
were O
interviewed O
using O
the O
mini O
international O
neuropsychiatric O
interview O
( O
m O
. O

i O
. O

n O
. O

i O
. O

) O
for O
methamphetamine O
- O
induced O
psychosis B-Disease
and O
other O
axis O
i O
psychiatric B-Disease
disorders I-Disease
. O

results O
: O
of O
292 O
subjects O
, O
47 O
. O

9 O
% O
of O
the O
subjects O
had O
a O
past O
history O
of O
psychotic B-Disease
symptoms I-Disease
and O
13 O
. O

0 O
% O
of O
the O
patients O
were O
having O
current O
psychotic B-Disease
symptoms I-Disease
. O

co O
- O
morbid O
major O
depressive B-Disease
disorder I-Disease
( O
or O
= O
7 O
. O

18 O
, O
95 O
ci O
= O
2 O
. O

612 O
- O
19 O
. O

708 O
) O
, O
bipolar B-Disease
disorder I-Disease
( O
or O
= O
13 O
. O

807 O
, O
95 O
ci O
= O
5 O
. O

194 O
- O
36 O
. O

706 O
) O
, O
antisocial B-Disease
personality I-Disease
disorder I-Disease
( O
or O
= O
12 O
. O

619 O
, O
95 O
ci O
= O
6 O
. O

702 O
- O
23 O
. O

759 O
) O
and O
heavy O
methamphetamine O
uses O
were O
significantly O
associated O
with O
lifetime O
methamphetamine O
- O
induced O
psychosis B-Disease
after O
adjusted O
for O
other O
factors O
. O

major B-Disease
depressive I-Disease
disorder I-Disease
( O
or O
= O
2 O
. O

870 O
, O
ci O
= O
1 O
. O

154 O
- O
7 O
. O

142 O
) O
and O
antisocial B-Disease
personality I-Disease
disorder I-Disease
( O
or O
= O
3 O
. O

299 O
, O
95 O
ci O
= O
1 O
. O

375 O
- O
7 O
. O

914 O
) O
were O
the O
only O
factors O
associated O
with O
current O
psychosis B-Disease
. O

conclusion O
: O
there O
was O
a O
high O
risk O
of O
psychosis B-Disease
in O
patients O
with O
methamphetamine O
dependence O
. O

it O
was O
associated O
with O
co O
- O
morbid O
affective B-Disease
disorder I-Disease
, O
antisocial B-Disease
personality I-Disease
, O
and O
heavy O
methamphetamine O
use O
. O

it O
is O
recommended O
that O
all O
cases O
of O
methamphetamine O
dependence O
should O
be O
screened O
for O
psychotic B-Disease
symptoms I-Disease
. O

cerebellar O
sensory O
processing O
alterations O
impact O
motor O
cortical O
plasticity O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
: O
clues O
from O
dyskinetic B-Disease
patients O
. O

the O
plasticity O
of O
primary O
motor O
cortex O
( O
m1 O
) O
in O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
( O
lids B-Disease
) O
is O
severely O
impaired O
. O

this O
study O
demonstrates O
that O
the O
deficient O
sensorimotor O
m1 O
plasticity O
in O
16 O
patients O
with O
lids B-Disease
could O
be O
reinstated O
by O
a O
single O
session O
of O
real O
inhibitory O
cerebellar O
stimulation O
but O
not O
sham O
stimulation O
. O

the O
benefit O
of O
inhibitory O
cerebellar O
stimulation O
on O
lids B-Disease
is O
known O
. O

to O
explore O
whether O
this O
benefit O
is O
linked O
to O
the O
restoration O
of O
sensorimotor O
plasticity O
of O
m1 O
, O
we O
conducted O
an O
additional O
study O
looking O
at O
changes O
in O
lids B-Disease
and O
pas O
- O
induced O
plasticity O
after O
10 O
sessions O
of O
either O
bilateral O
, O
real O
inhibitory O
cerebellar O
stimulation O
or O
sham O
stimulation O
. O

these O
results O
suggest O
that O
alterations O
in O
cerebellar O
sensory O
processing O
function O
, O
occurring O
secondary O
to O
abnormal O
basal O
ganglia O
signals O
reaching O
it O
, O
may O
be O
an O
important O
element O
contributing O
to O
the O
maladaptive O
sensorimotor O
plasticity O
of O
m1 O
and O
the O
emergence O
of O
abnormal B-Disease
involuntary I-Disease
movements I-Disease
. O

the O
long O
- O
term O
safety O
of O
danazol O
in O
women O
with O
hereditary B-Disease
angioedema I-Disease
. O

we O
therefore O
investigated O
the O
long O
- O
term O
safety O
of O
danazol O
by O
performing O
a O
retrospective O
chart O
review O
of O
60 O
female O
patients O
with O
hereditary B-Disease
angioedema I-Disease
treated O
with O
danazol O
for O
a O
continuous O
period O
of O
6 O
months O
or O
longer O
. O

menstrual B-Disease
abnormalities I-Disease
( O
79 O
% O
) O
, O
weight B-Disease
gain I-Disease
( O
60 O
% O
) O
, O
muscle B-Disease
cramps I-Disease
/ O
myalgias B-Disease
( O
40 O
% O
) O
, O
and O
transaminase O
elevations O
( O
40 O
% O
) O
were O
the O
most O
common O
adverse O
reactions O
. O

the O
function O
of O
p2x3 O
receptor O
and O
nk1 O
receptor O
antagonists O
on O
cyclophosphamide O
- O
induced O
cystitis B-Disease
in O
rats O
. O

purpose O
: O
the O
purpose O
of O
the O
study O
is O
to O
explore O
the O
function O
of O
p2x3 O
and O
nk1 O
receptors O
antagonists O
on O
cyclophosphamide O
( O
cyp O
) O
- O
induced O
cystitis B-Disease
in O
rats O
. O

spontaneous O
pain B-Disease
behaviors O
following O
the O
administration O
of O
cyp O
were O
observed O
. O

results O
: O
cyclophosphamide O
treatment O
increased O
the O
spontaneous O
pain B-Disease
behaviors O
scores O
. O

histological O
changes O
evident O
in O
model O
and O
intervention O
groups O
rats O
' O
bladder O
included O
edema B-Disease
, O
vasodilation O
, O
and O
infiltration O
of O
inflammatory O
cells O
. O

conclusions O
: O
in O
cyp O
- O
induced O
cystitis B-Disease
, O
the O
expression O
of O
p2x3 O
and O
nk1 O
receptors O
increased O
in O
urothelium O
and O
/ O
or O
suburothelium O
. O

patient O
tolerance O
study O
of O
topical O
chlorhexidine O
diphosphanilate O
: O
a O
new O
topical O
agent O
for O
burns B-Disease
. O

effective O
topical O
antimicrobial O
agents O
decrease O
infection B-Disease
and O
mortality O
in O
burn B-Disease
patients O
. O

chlorhexidine O
phosphanilate O
( O
chp O
) O
, O
a O
new O
broad O
- O
spectrum O
antimicrobial O
agent O
, O
has O
been O
evaluated O
as O
a O
topical O
burn B-Disease
wound O
dressing O
in O
cream O
form O
, O
but O
preliminary O
clinical O
trials O
reported O
that O
it O
was O
painful O
upon O
application O
. O

twenty O
- O
nine O
burn B-Disease
patients O
, O
each O
with O
two O
similar O
burns B-Disease
which O
could O
be O
separately O
treated O
, O
were O
given O
pairs O
of O
treatments O
at O
successive O
12 O
- O
h O
intervals O
over O
a O
3 O
- O
day O
period O
. O

one O
burn B-Disease
site O
was O
treated O
with O
each O
of O
four O
different O
chp O
concentrations O
, O
from O
0 O
. O

25 O
per O
cent O
to O
2 O
per O
cent O
, O
their O
vehicle O
, O
and O
1 O
per O
cent O
silver O
sulphadiazine O
( O
agsd O
) O
cream O
, O
an O
antimicrobial O
agent O
frequently O
used O
for O
topical O
treatment O
of O
burn B-Disease
wounds O
. O

there O
was O
a O
direct O
relationship O
between O
chp O
concentration O
and O
patients O
' O
ratings O
of O
pain B-Disease
on O
an O
analogue O
scale O
. O

the O
0 O
. O

25 O
per O
cent O
chp O
cream O
was O
closest O
to O
agsd O
in O
pain B-Disease
tolerance O
; O
however O
, O
none O
of O
the O
treatments O
differed O
statistically O
from O
agsd O
or O
from O
each O
other O
. O

acute O
hepatitis B-Disease
associated O
with O
clopidogrel O
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

drug O
- O
induced O
hepatotoxicity B-Disease
is O
a O
common O
cause O
of O
acute O
hepatitis B-Disease
, O
and O
the O
recognition O
of O
the O
responsible O
drug O
may O
be O
difficult O
. O

we O
describe O
a O
case O
of O
clopidogrel O
- O
related O
acute O
hepatitis B-Disease
. O

reports O
about O
cases O
of O
hepatotoxicity B-Disease
due O
to O
clopidogrel O
are O
increasing O
in O
the O
last O
few O
years O
, O
after O
the O
increased O
use O
of O
this O
drug O
. O

in O
conclusion O
, O
we O
believe O
that O
physicians O
should O
carefully O
consider O
the O
risk O
of O
drug O
- O
induced O
hepatic B-Disease
injury I-Disease
when O
clopidogrel O
is O
prescribed O
. O

bortezomib O
and O
dexamethasone O
as O
salvage O
therapy O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple B-Disease
myeloma I-Disease
: O
analysis O
of O
long O
- O
term O
clinical O
outcomes O
. O

bortezomib O
( O
bort O
) O
- O
dexamethasone O
( O
dex O
) O
is O
an O
effective O
therapy O
for O
relapsed O
/ O
refractory O
( O
r O
/ O
r O
) O
multiple B-Disease
myeloma I-Disease
( O
mm B-Disease
) O
. O

this O
retrospective O
study O
investigated O
the O
combination O
of O
bort O
( O
1 O
. O

3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
4 O
, O
8 O
, O
and O
11 O
every O
3 O
weeks O
) O
and O
dex O
( O
20 O
mg O
on O
the O
day O
of O
and O
the O
day O
after O
bort O
) O
as O
salvage O
treatment O
in O
85 O
patients O
with O
r O
/ O
r O
mm B-Disease
after O
prior O
autologous O
stem O
cell O
transB-Plantation O
or O
conventional O
chemotherapy O
. O

the O
most O
relevant O
adverse O
event O
was O
peripheral B-Disease
neuropathy I-Disease
, O
which O
occurred O
in O
78 O
% O
of O
the O
patients O
( O
grade O
ii O
, O
38 O
% O
; O
grade O
iii O
, O
21 O
% O
) O
and O
led O
to O
treatment O
discontinuation O
in O
6 O
% O
. O

bort O
- O
dex O
was O
an O
effective O
salvage O
treatment O
for O
mm B-Disease
patients O
, O
particularly O
for O
those O
in O
first O
relapse O
. O

pubertal O
exposure O
to O
bisphenol O
a O
increases O
anxiety B-Disease
- O
like O
behavior O
and O
decreases O
acetylcholinesterase O
activity O
of O
hippocampus O
in O
adult O
male O
mice O
. O

acetylcholinesterase O
( O
ache O
) O
is O
a O
regulatory O
enzyme O
which O
is O
involved O
in O
anxiety B-Disease
- O
like O
behavior O
. O

results O
from O
our O
behavioral O
phenotyping O
indicated O
that O
anxiety B-Disease
- O
like O
behavior O
was O
increased O
in O
mice O
exposed O
to O
bpa O
. O

our O
findings O
showed O
that O
pubertal O
bpa O
exposure O
increased O
anxiety B-Disease
- O
like O
behavior O
, O
which O
may O
be O
associated O
with O
decreased O
ache O
activity O
of O
the O
hippocampus O
in O
adult O
male O
mice O
. O

further O
studies O
are O
necessary O
to O
investigate O
the O
cholinergic O
signaling O
of O
the O
hippocampus O
in O
pbe O
induced O
anxiety B-Disease
- O
like O
behaviors O
. O

biochemical O
effects O
of O
solidago O
virgaurea O
extract O
on O
experimental O
cardiotoxicity B-Disease
. O

cardiovascular B-Disease
diseases I-Disease
( O
cvds B-Disease
) O
are O
the O
major O
health O
problem O
of O
advanced O
as O
well O
as O
developing O
countries O
of O
the O
world O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
the O
solidago O
virgaurea O
extract O
on O
isoproterenol O
- O
induced O
cardiotoxicity B-Disease
in O
rats O
. O

nan O
real O
- O
world O
nan O
data O
on O
the O
efficacy O
and O
safety O
of O
lenalidomide O
and O
dexamethasone O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple B-Disease
myeloma I-Disease
who O
were O
treated O
according O
to O
the O
standard O
clinical O
practice O
: O
a O
study O
of O
the O
greek O
myeloma B-Disease
study O
group O
. O

lenalidomide O
and O
dexamethasone O
( O
rd O
) O
is O
a O
standard O
of O
care O
for O
relapsed O
/ O
refractory O
multiple B-Disease
myeloma I-Disease
( O
rrmm B-Disease
) O
, O
but O
there O
is O
limited O
published O
data O
on O
its O
efficacy O
and O
safety O
in O
the O
nan O
real O
world O
nan O
( O
rw O
) O
, O
according O
to O
the O
international O
society O
of O
pharmacoeconomics O
and O
outcomes O
research O
definition O
. O

we O
studied O
212 O
rrmm B-Disease
patients O
who O
received O
rd O
in O
rw O
. O

adverse O
events O
were O
reported O
in O
68 O
. O

9 O
% O
of O
patients O
( O
myelosuppression B-Disease
in O
49 O
. O

4 O
% O
) O
and O
12 O
. O

7 O
% O
of O
patients O
needed O
hospitalization O
. O

peripheral B-Disease
neuropathy I-Disease
was O
observed O
only O
in O
2 O
. O

5 O
% O
of O
patients O
and O
deep B-Disease
vein I-Disease
thrombosis I-Disease
in O
5 O
. O

7 O
% O
. O

our O
study O
confirms O
that O
rd O
is O
effective O
and O
safe O
in O
rrmm B-Disease
in O
the O
rw O
; O
it O
produces O
durable O
responses O
especially O
in O
patients O
who O
continue O
on O
treatment O
till O
progression O
and O
improves O
humoral O
immunity O
even O
in O
patients O
with O
stable O
disease O
. O

it O
is O
characterized O
by O
its O
intense O
urotoxic O
action O
, O
leading O
to O
hemorrhagic B-Disease
cystitis I-Disease
. O

mesna O
significantly O
reduces O
ifo O
' O
s O
genotoxicity B-Disease
, O
while O
when O
administered O
in O
high O
concentrations O
it O
acts O
in O
an O
inhibitory O
fashion O
on O
the O
cytostatic O
action O
of O
the O
drug O
. O

risk O
factors O
and O
predictors O
of O
levodopa O
- O
induced O
dyskinesia B-Disease
among O
multiethnic O
malaysians O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

chronic O
pulsatile O
levodopa O
therapy O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
leads O
to O
the O
development O
of O
motor O
fluctuations O
and O
dyskinesia B-Disease
. O

we O
studied O
the O
prevalence O
and O
predictors O
of O
levodopa O
- O
induced O
dyskinesia B-Disease
among O
multiethnic O
malaysian O
patients O
with O
pd B-Disease
. O

methods O
: O
this O
is O
a O
cross O
- O
sectional O
study O
involving O
95 O
patients O
with O
pd B-Disease
on O
uninterrupted O
levodopa O
therapy O
for O
at O
least O
6 O
months O
. O

the O
predictors O
of O
dyskinesia B-Disease
were O
determined O
using O
multivariate O
logistic O
regression O
analysis O
. O

dyskinesia B-Disease
was O
present O
in O
44 O
% O
( O
n O
= O
42 O
) O
with O
median O
levodopa O
therapy O
of O
3 O
years O
. O

eighty O
- O
one O
percent O
of O
patients O
with O
dyskinesia B-Disease
had O
clinical O
fluctuations O
. O

patients O
with O
dyskinesia B-Disease
had O
lower O
onset O
age O
( O
p O
< O
0 O
. O

1 O
) O
, O
longer O
duration O
of O
levodopa O
therapy O
( O
p O
< O
0 O
. O

1 O
) O
, O
longer O
disease O
duration O
( O
p O
< O
0 O
. O

1 O
) O
, O
higher O
total O
daily O
levodopa O
dose O
( O
p O
< O
0 O
. O

1 O
) O
, O
and O
higher O
total O
updrs O
scores O
( O
p O
= O
0 O
. O

5 O
) O
than O
patients O
without O
dyskinesia B-Disease
. O

the O
three O
significant O
predictors O
of O
dyskinesia B-Disease
were O
duration O
of O
levodopa O
therapy O
, O
onset O
age O
, O
and O
total O
daily O
levodopa O
dose O
. O

conclusions O
: O
the O
prevalence O
of O
levodopa O
- O
induced O
dyskinesia B-Disease
in O
our O
patients O
was O
44 O
% O
. O

dose O
- O
dependent O
neurotoxicity B-Disease
of O
high O
- O
dose O
busulfan O
in O
children O
: O
a O
clinical O
and O
pharmacological O
study O
. O

busulfan O
is O
known O
to O
be O
neurotoxic B-Disease
in O
animals O
and O
humans O
, O
but O
its O
acute O
neurotoxicity B-Disease
remains O
poorly O
characterized O
in O
children O
. O

we O
report O
here O
a O
retrospective O
study O
of O
123 O
children O
( O
median O
age O
, O
6 O
. O

5 O
years O
) O
receiving O
high O
- O
dose O
busulfan O
in O
combined O
chemotherapy O
before O
bone O
marrow O
transB-Plantation O
for O
malignant O
solid O
tumors B-Disease
, O
brain B-Disease
tumors I-Disease
excluded O
. O

ninety O
- O
six O
patients O
were O
not O
given O
anticonvulsive O
prophylaxis O
; O
7 O
( O
7 O
. O

5 O
% O
) O
developed O
seizures B-Disease
during O
the O
4 O
days O
of O
the O
busulfan O
course O
or O
within O
24 O
h O
after O
the O
last O
dosing O
. O

when O
the O
total O
busulfan O
dose O
was O
taken O
into O
account O
, O
there O
was O
a O
significant O
difference O
in O
terms O
of O
neurotoxicity B-Disease
incidence O
among O
patients O
under O
16 O
mg O
/ O
kg O
( O
1 O
of O
57 O
, O
1 O
. O

7 O
% O
) O
and O
patients O
under O
600 O
mg O
/ O
m2 O
( O
6 O
of O
39 O
, O
15 O
. O

4 O
% O
) O
( O
p O
less O
than O
0 O
. O

2 O
) O
. O

twenty O
- O
seven O
patients O
were O
given O
a O
600 O
- O
mg O
/ O
m2 O
busulfan O
total O
dose O
with O
continuous O
i O
. O

v O
. O

infusion O
of O
clonazepam O
; O
none O
had O
any O
neurological B-Disease
symptoms I-Disease
. O

busulfan O
levels O
were O
measured O
by O
a O
gas O
chromatographic O
- O
mass O
spectrometry O
assay O
in O
the O
plasma O
and O
cerebrospinal O
fluid O
of O
9 O
children O
without O
central B-Disease
nervous I-Disease
system I-Disease
disease I-Disease
under O
600 O
mg O
/ O
m2 O
busulfan O
with O
clonazepam O
: O
busulfan O
cerebrospinal O
fluid O
: O
plasma O
ratio O
was O
1 O
. O

39 O
. O

this O
study O
shows O
that O
busulfan O
neurotoxicity B-Disease
is O
dose O
- O
dependent O
in O
children O
and O
efficiently O
prevented O
by O
clonazepam O
. O

a O
busulfan O
dose O
calculated O
on O
the O
basis O
of O
body O
surface O
area O
, O
resulting O
in O
higher O
doses O
in O
young O
children O
, O
was O
followed O
by O
increased O
neurotoxicity B-Disease
, O
close O
to O
neurotoxicity B-Disease
incidence O
observed O
in O
adults O
. O

an O
unexpected O
diagnosis O
in O
a O
renal O
- O
transB-Plant O
patient O
with O
proteinuria B-Disease
treated O
with O
everolimus O
: O
al B-Disease
amyloidosis B-Disease
. O

proteinuria B-Disease
is O
an O
expected O
complication O
in O
transB-Plant O
patients O
treated O
with O
mammalian O
target O
of O
rapamycin O
inhibitors O
( O
mtor O
- O
i O
) O
. O

however O
, O
clinical O
suspicion O
should O
always O
be O
supported O
by O
histological O
evidence O
in O
order O
to O
investigate O
potential O
alternate O
diagnoses O
such O
as O
acute O
or O
chronic O
rejection O
, O
interstitial O
fibrosis B-Disease
and O
tubular O
atrophy B-Disease
, O
or O
recurrent O
or O
de O
novo O
glomerulopathy B-Disease
. O

in O
this O
case O
we O
report O
the O
unexpected O
diagnosis O
of O
amyloidosis B-Disease
in O
a O
renal O
- O
transB-Plant O
patient O
with O
pre O
- O
transB-Plant O
monoclonal O
gammapathy O
of O
undetermined O
significance O
who O
developed O
proteinuria B-Disease
after O
conversion O
from O
tacrolimus O
to O
everolimus O
. O

long O
- O
term O
oral O
galactose O
treatment O
prevents O
cognitive B-Disease
deficits I-Disease
in O
male O
wistar O
rats O
treated O
intracerebroventricularly O
with O
streptozotocin O
. O

basic O
and O
clinical O
research O
has O
demonstrated O
that O
dementia B-Disease
of O
sporadic O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
sad O
) O
type O
is O
associated O
with O
dysfunction O
of O
the O
insulin O
- O
receptor O
( O
ir O
) O
system O
followed O
by O
decreased O
glucose O
transport O
via O
glucose O
transporter O
glut4 O
and O
decreased O
glucose O
metabolism O
in O
brain O
cells O
. O

exclusively O
parenteral O
daily O
injections O
of O
galactose O
induce O
memory B-Disease
deterioration I-Disease
in O
rodents O
and O
are O
used O
to O
generate O
animal O
aging O
model O
, O
but O
the O
effects O
of O
oral O
galactose O
treatment O
on O
cognitive O
functions O
have O
never O
been O
tested O
. O

we O
have O
investigated O
the O
effects O
of O
continuous O
daily O
oral O
galactose O
( O
200 O
mg O
/ O
kg O
/ O
day O
) O
treatment O
on O
cognitive B-Disease
deficits I-Disease
in O
streptozotocin O
- O
induced O
( O
stz O
- O
icv O
) O
rat O
model O
of O
sad O
, O
tested O
by O
morris O
water O
maze O
and O
passive O
avoidance O
test O
, O
respectively O
. O

one O
month O
of O
oral O
galactose O
treatment O
initiated O
immediately O
after O
the O
stz O
- O
icv O
administration O
, O
successfully O
prevented O
development O
of O
the O
stz O
- O
icv O
- O
induced O
cognitive B-Disease
deficits I-Disease
. O

oral O
galactose O
exposure O
might O
have O
beneficial O
effects O
on O
learning O
and O
memory O
ability O
and O
could O
be O
worth O
investigating O
for O
improvement O
of O
cognitive B-Disease
deficits I-Disease
associated O
with O
glucose B-Disease
hypometabolism I-Disease
in O
ad B-Disease
. O

an O
investigation O
of O
the O
pattern O
of O
kidney B-Disease
injury I-Disease
in O
hiv O
- O
positive O
persons O
exposed O
to O
tenofovir O
disoproxil O
fumarate O
: O
an O
examination O
of O
a O
large O
population O
database O
( O
mhra O
database O
) O
. O

reports O
that O
satisfy O
defined O
criteria O
were O
classified O
as O
acute B-Disease
kidney I-Disease
injury I-Disease
, O
kidney B-Disease
tubular I-Disease
dysfunction I-Disease
and O
fanconi B-Disease
syndrome I-Disease
. O

of O
the O
407 O
yellow O
card O
records O
analysed O
, O
106 O
satisfied O
criteria O
for O
tdf O
- O
related O
kidney B-Disease
disease I-Disease
, O
of O
which O
53 O
( O
50 O
% O
) O
had O
features O
of O
kidney B-Disease
tubular I-Disease
dysfunction I-Disease
, O
35 O
( O
33 O
% O
) O
were O
found O
to O
have O
features O
of O
glomerular B-Disease
dysfunction I-Disease
and O
18 O
( O
17 O
% O
) O
had O
fanconi B-Disease
syndrome I-Disease
. O

the O
incidence O
of O
hospitalisation O
for O
tdf O
kidney O
adverse O
effects O
was O
high O
, O
particularly O
amongst O
patients O
with O
features O
of O
fanconi B-Disease
syndrome I-Disease
. O

incidence O
of O
postoperative B-Disease
delirium I-Disease
is O
high O
even O
in O
a O
population O
without O
known O
risk O
factors O
. O

purpose O
: O
postoperative B-Disease
delirium I-Disease
is O
a O
recognized O
complication O
in O
populations O
at O
risk O
. O

the O
aim O
of O
this O
study O
is O
to O
assess O
the O
prevalence O
of O
early O
postoperative B-Disease
delirium I-Disease
in O
a O
population O
without O
known O
risk O
factors O
admitted O
to O
the O
icu O
for O
postoperative O
monitoring O
after O
elective O
major O
surgery O
. O

exclusion O
criteria O
were O
any O
preexisting O
predisposing O
factor O
for O
delirium B-Disease
or O
other O
potentially O
confounding O
neurological B-Disease
dysfunctions I-Disease
. O

patients O
were O
assessed O
daily O
using O
the O
confusion B-Disease
assessment O
method O
for O
the O
icu O
scale O
for O
3 O
days O
after O
the O
surgical O
procedure O
. O

early O
postoperative B-Disease
delirium I-Disease
incidence O
risk O
factors O
were O
then O
assessed O
through O
three O
different O
multiple O
regression O
models O
. O

results O
: O
according O
to O
the O
confusion O
assessment O
method O
for O
the O
icu O
scale O
, O
28 O
% O
of O
patients O
were O
diagnosed O
with O
early O
postoperative B-Disease
delirium I-Disease
. O

the O
use O
of O
thiopentone O
was O
significantly O
associated O
with O
an O
eight O
- O
fold O
- O
higher O
risk O
for O
delirium B-Disease
compared O
to O
propofol O
( O
57 O
. O

1 O
% O
vs O
. O

7 O
. O

1 O
% O
, O
rr O
= O
8 O
. O

0 O
, O
x2 O
= O
4 O
. O

256 O
; O
df O
= O
1 O
; O
0 O
. O

5 O
< O
p O
< O
0 O
. O

2 O
) O
. O

conclusion O
: O
in O
this O
study O
early O
postoperative B-Disease
delirium I-Disease
was O
found O
to O
be O
a O
very O
common O
complication O
after O
major O
surgery O
, O
even O
in O
a O
population O
without O
known O
risk O
factors O
. O

a O
single O
neurotoxic B-Disease
dose O
of O
methamphetamine O
induces O
a O
long O
- O
lasting O
depressive B-Disease
- O
like O
behaviour O
in O
mice O
. O

methamphetamine O
( O
meth O
) O
triggers O
a O
disruption O
of O
the O
monoaminergic O
system O
and O
meth O
abuse O
leads O
to O
negative O
emotional O
states O
including O
depressive B-Disease
symptoms I-Disease
during O
drug O
withdrawal O
. O

however O
, O
it O
is O
currently O
unknown O
if O
the O
acute O
toxic O
dosage O
of O
meth O
also O
causes O
a O
long O
- O
lasting O
depressive B-Disease
phenotype O
and O
persistent O
monoaminergic O
deficits O
. O

thus O
, O
we O
now O
assessed O
the O
depressive B-Disease
- O
like O
behaviour O
in O
mice O
at O
early O
and O
long O
- O
term O
periods O
following O
a O
single O
high O
meth O
dose O
( O
30 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
. O

this O
depressive B-Disease
- O
like O
profile O
induced O
by O
meth O
was O
accompanied O
by O
a O
marked O
depletion O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
neurotransmission O
, O
indicated O
by O
a O
reduction O
in O
the O
levels O
of O
dopamine O
, O
dopac O
and O
hva O
, O
tyrosine O
hydroxylase O
and O
serotonin O
, O
observed O
at O
both O
3 O
and O
49 O
days O
post O
- O
administration O
. O

in O
parallel O
, O
another O
neurochemical O
feature O
of O
depression B-Disease
- O
- O
astroglial O
dysfunction O
- O
- O
was O
unaffected O
in O
the O
cortex O
and O
the O
striatal O
levels O
of O
the O
astrocytic O
protein O
marker O
, O
glial O
fibrillary O
acidic O
protein O
, O
were O
only O
transiently O
increased O
at O
3 O
days O
. O

these O
findings O
demonstrate O
for O
the O
first O
time O
that O
a O
single O
high O
dose O
of O
meth O
induces O
long O
- O
lasting O
depressive B-Disease
- O
like O
behaviour O
in O
mice O
associated O
with O
a O
persistent O
disruption O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
homoeostasis O
. O

linezolid O
- O
induced O
optic B-Disease
neuropathy I-Disease
. O

we O
describe O
a O
case O
of O
progressive O
loss B-Disease
of I-Disease
vision I-Disease
associated O
with O
linezolid O
therapy O
. O

a O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second O
- O
line O
anti O
- O
tuberculous O
drugs O
including O
linezolid O
and O
ethambutol O
for O
extensively B-Disease
drug I-Disease
- I-Disease
resistant I-Disease
tuberculosis I-Disease
( O
xdr B-Disease
- I-Disease
tb I-Disease
) O
presented O
to O
us O
with O
painless O
progressive O
loss B-Disease
of I-Disease
vision I-Disease
in O
both O
eyes O
. O

color O
vision O
was O
defective O
and O
fundus O
examination O
revealed O
optic B-Disease
disc I-Disease
edema I-Disease
in O
both O
eyes O
. O

ethambutol O
- O
induced O
toxic B-Disease
optic I-Disease
neuropathy I-Disease
was O
suspected O
and O
tablet O
ethambutol O
was O
withdrawn O
. O

deterioration B-Disease
of I-Disease
vision I-Disease
occurred O
despite O
withdrawal O
of O
ethambutol O
. O

resuscitation O
with O
lipid O
, O
epinephrine O
, O
or O
both O
in O
levobupivacaine O
- O
induced O
cardiac B-Disease
toxicity I-Disease
in O
newborn O
piglets O
. O

background O
: O
the O
optimal O
dosing O
regimens O
of O
lipid O
emulsion O
, O
epinephrine O
, O
or O
both O
are O
not O
yet O
determined O
in O
neonates O
in O
cases O
of O
local O
anaesthetic O
systemic O
toxicity B-Disease
( O
last O
) O
. O

methods O
: O
newborn O
piglets O
received O
levobupivacaine O
until O
cardiovascular B-Disease
collapse I-Disease
occurred O
. O

standard O
cardiopulmonary O
resuscitation O
was O
started O
and O
electrocardiogram O
( O
ecg O
) O
was O
monitored O
for O
ventricular B-Disease
tachycardia I-Disease
, O
fibrillation B-Disease
, O
or O
qrs O
prolongation O
. O

incidence O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
type I-Disease
ii I-Disease
and O
postoperative O
recovery O
of O
platelet O
count O
in O
liver O
graft O
recipients O
: O
a O
retrospective O
cohort O
analysis O
. O

background O
: O
thrombocytopenia B-Disease
in O
patients O
with O
end B-Disease
- I-Disease
stage I-Disease
liver I-Disease
disease I-Disease
is O
a O
common O
disorder O
caused O
mainly O
by O
portal B-Disease
hypertension I-Disease
, O
low O
levels O
of O
thrombopoetin O
, O
and O
endotoxemia B-Disease
. O

the O
impact O
of O
immune O
- O
mediated O
heparin O
- O
induced O
thrombocytopenia B-Disease
type I-Disease
ii I-Disease
( O
hit B-Disease
type I-Disease
ii I-Disease
) O
as O
a O
cause O
of O
thrombocytopenia B-Disease
after O
liver O
transB-Plantation O
is O
not O
yet O
understood O
, O
with O
few O
literature O
citations O
reporting O
contradictory O
results O
. O

the O
aim O
of O
our O
study O
was O
to O
demonstrate O
the O
perioperative O
course O
of O
thrombocytopenia B-Disease
after O
liver O
transB-Plantation O
and O
determine O
the O
occurrence O
of O
clinical O
hit B-Disease
type I-Disease
ii I-Disease
. O

method O
: O
we O
retrospectively O
evaluated O
the O
medical O
records O
of O
205 O
consecutive O
adult O
patients O
who O
underwent O
full O
- O
size O
liver O
transB-Plantation O
between O
january O
2006 O
and O
december O
2010 O
due O
to O
end B-Disease
- I-Disease
stage I-Disease
or I-Disease
malignant I-Disease
liver I-Disease
disease I-Disease
. O

preoperative O
platelet O
count O
, O
postoperative O
course O
of O
platelets O
, O
and O
clinical O
signs O
of O
hit B-Disease
type I-Disease
ii I-Disease
were O
analyzed O
. O

results O
: O
a O
total O
of O
155 O
( O
75 O
. O

6 O
% O
) O
of O
205 O
patients O
had O
thrombocytopenia B-Disease
before O
transB-Plantation O
, O
significantly O
influenced O
by O
model O
of O
end B-Disease
- I-Disease
stage I-Disease
liver I-Disease
disease I-Disease
score O
and O
liver B-Disease
cirrhosis I-Disease
. O

regarding O
hit B-Disease
ii I-Disease
, O
there O
were O
four O
( O
1 O
. O

95 O
% O
) O
patients O
with O
a O
background O
of O
hit B-Disease
type I-Disease
ii I-Disease
. O

conclusions O
: O
the O
incidence O
of O
hit B-Disease
in O
patients O
with O
end B-Disease
- I-Disease
stage I-Disease
hepatic I-Disease
failure I-Disease
is O
, O
with O
about O
1 O
. O

95 O
% O
, O
rare O
. O

for O
further O
reduction O
of O
hit B-Disease
type I-Disease
ii I-Disease
, O
the O
use O
of O
intravenous O
heparin O
should O
be O
avoided O
and O
the O
prophylactic O
anticoagulation O
should O
be O
performed O
with O
low O
- O
molecular O
- O
weight O
heparin O
after O
normalization O
of O
platelet O
count O
. O

takotsubo B-Disease
syndrome I-Disease
( O
or O
apical B-Disease
ballooning I-Disease
syndrome I-Disease
) O
secondary O
to O
zolmitriptan O
. O

takotsubo B-Disease
syndrome I-Disease
( O
ts B-Disease
) O
, O
also O
known O
as O
broken B-Disease
heart I-Disease
syndrome I-Disease
, O
is O
characterized O
by O
left O
ventricle O
apical O
ballooning O
with O
elevated O
cardiac O
biomarkers O
and O
electrocardiographic O
changes O
suggestive O
of O
an O
acute B-Disease
coronary I-Disease
syndrome I-Disease
( O
ie O
, O
st O
- O
segment O
elevation O
, O
t O
wave O
inversions O
, O
and O
pathologic O
q O
waves O
) O
. O

we O
report O
a O
case O
of O
54 O
- O
year O
- O
old O
woman O
with O
medical O
history O
of O
mitral B-Disease
valve I-Disease
prolapse I-Disease
and O
migraines B-Disease
, O
who O
was O
admitted O
to O
the O
hospital O
for O
substernal O
chest B-Disease
pain I-Disease
and O
electrocardiogram O
demonstrated O
1 O
/ O
2 O
mm O
st O
- O
segment O
elevation O
in O
leads O
ii O
, O
iii O
, O
avf O
, O
v5 O
, O
and O
v6 O
and O
positive O
troponin O
i O
. O

emergent O
coronary O
angiogram O
revealed O
normal O
coronary O
arteries O
with O
moderately O
reduced O
left O
ventricular O
ejection O
fraction O
with O
wall O
motion O
abnormalities O
consistent O
with O
ts B-Disease
. O

detailed O
history O
obtained O
retrospectively O
revealed O
that O
the O
patient O
took O
zolmitriptan O
sparingly O
only O
when O
she O
had O
migraines B-Disease
. O

but O
before O
this O
event O
, O
she O
was O
taking O
zolmitriptan O
2 O
- O
3 O
times O
daily O
for O
several O
days O
because O
of O
a O
persistent O
migraine B-Disease
headache I-Disease
. O

there O
was O
no O
evidence O
of O
any O
recent O
stress O
or O
status B-Disease
migrainosus I-Disease
. O

extensive O
literature O
search O
revealed O
multiple O
cases O
of O
coronary B-Disease
artery I-Disease
vasospasm I-Disease
secondary O
to O
zolmitriptan O
, O
but O
none O
of O
the O
cases O
were O
associated O
with O
ts B-Disease
. O

depression B-Disease
, O
impulsiveness B-Disease
, O
sleep O
, O
and O
memory O
in O
past O
and O
present O
polydrug O
users O
of O
3 O
, O
4 O
- O
methylenedioxymethamphetamine O
( O
mdma O
, O
ecstasy O
) O
. O

participants O
completed O
a O
drug O
history O
questionnaire O
, O
beck O
depression B-Disease
inventory O
, O
barratt O
impulsiveness B-Disease
scale O
, O
pittsburgh O
sleep O
quality O
index O
, O
and O
wechsler O
memory O
scale O
- O
revised O
which O
, O
in O
total O
, O
provided O
13 O
psychometric O
measures O
. O

conclusions O
: O
given O
this O
record O
of O
impaired B-Disease
memory I-Disease
and O
clinically O
significant O
levels O
of O
depression B-Disease
, O
impulsiveness B-Disease
, O
and O
sleep B-Disease
disturbance I-Disease
, O
the O
prognosis O
for O
the O
current O
generation O
of O
ecstasy O
users O
is O
a O
major O
cause O
for O
concern O
. O

association O
of O
common O
genetic O
variants O
of O
homer1 O
gene O
with O
levodopa O
adverse O
effects O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
patients O
. O

levodopa O
is O
the O
most O
effective O
symptomatic O
therapy O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
but O
its O
chronic O
use O
could O
lead O
to O
chronic O
adverse O
outcomes O
, O
such O
as O
motor O
fluctuations O
, O
dyskinesia B-Disease
and O
visual B-Disease
hallucinations I-Disease
. O

a O
total O
of O
205 O
patients O
with O
idiopathic B-Disease
parkinson I-Disease
' I-Disease
s I-Disease
disease I-Disease
were O
investigated O
. O

the O
rs4704559 O
g O
allele O
was O
associated O
with O
a O
lower O
prevalence O
of O
dyskinesia B-Disease
( O
prevalence O
ratio O
( O
pr O
) O
= O
0 O
. O

615 O
, O
95 O
% O
confidence O
interval O
( O
ci O
) O
0 O
. O

426 O
- O
0 O
. O

887 O
, O
p O
= O
0 O
. O

9 O
) O
and O
visual B-Disease
hallucinations I-Disease
( O
pr O
= O
0 O
. O

515 O
, O
95 O
% O
ci O
0 O
. O

295 O
- O
0 O
. O

899 O
, O
p O
= O
0 O
. O

20 O
) O
. O

crocin O
reduced O
inhibition O
of O
erk O
activation O
and O
diazinon O
- O
induced O
hyperlipemia B-Disease
and O
increased O
levels O
of O
ldlr O
transcript O
. O

conclusions O
: O
crocin O
may O
be O
considered O
as O
a O
novel O
protective O
agent O
in O
diazinon O
- O
induced O
hyperlipemia B-Disease
through O
modulating O
of O
erk O
pathway O
and O
increase O
of O
ldlr O
expression O
. O

gem O
- O
p O
chemotherapy O
is O
active O
in O
the O
treatment O
of O
relapsed O
hodgkin B-Disease
lymphoma I-Disease
. O

hodgkin B-Disease
lymphoma I-Disease
( O
hl B-Disease
) O
is O
a O
relatively O
chemosensitive O
malignancy B-Disease
. O

regimens O
commonly O
used O
often O
require O
inpatient O
administration O
and O
can O
be O
difficult O
to O
deliver O
due O
to O
toxicity B-Disease
. O

gemcitabine O
and O
cisplatin O
have O
activity O
in O
hl B-Disease
, O
non O
- O
overlapping O
toxicity B-Disease
with O
first O
- O
line O
chemotherapeutics O
, O
and O
may O
be O
delivered O
in O
an O
outpatient O
setting O
. O

in O
this O
retrospective O
single O
- O
centre O
analysis O
, O
patients O
with O
relapsed O
or O
refractory O
hl B-Disease
treated O
with O
gemcitabine O
1 O
, O
0 O
mg O
/ O
m O
( O
2 O
) O
day O
( O
d O
) O
1 O
, O
d8 O
and O
d15 O
; O
methylprednisolone O
1 O
, O
0 O
mg O
d1 O
- O
5 O
; O
and O
cisplatin O
100 O
mg O
/ O
m O
( O
2 O
) O
d15 O
, O
every O
28 O
days O
( O
gem O
- O
p O
) O
were O
included O
. O

demographic O
, O
survival O
, O
response O
and O
toxicity B-Disease
data O
were O
recorded O
. O

the O
most O
common O
grade O
3 O
/ O
4 O
toxicities B-Disease
were O
haematological O
: O
neutropenia B-Disease
54 O
% O
and O
thrombocytopenia B-Disease
51 O
% O
. O

gem O
- O
p O
is O
a O
salvage O
chemotherapy O
with O
relatively O
high O
response O
rates O
, O
leading O
to O
successful O
transB-Plantation O
in O
appropriate O
patients O
, O
in O
the O
treatment O
of O
relapsed O
or O
refractory O
hl B-Disease
. O

rationale O
: O
ecstasy O
( O
mdma O
) O
is O
a O
psychostimulant O
drug O
which O
is O
increasingly O
associated O
with O
psychobiological B-Disease
dysfunction I-Disease
. O

results O
: O
both O
user O
groups O
exhibited O
significantly O
greater O
levels O
of O
anxiety B-Disease
and O
depression B-Disease
than O
nonusers O
. O

conclusions O
: O
the O
increases O
in O
anxiety B-Disease
and O
depression B-Disease
are O
in O
line O
with O
previous O
observations O
in O
recreational O
ecstasy O
- O
polydrug O
users O
. O

ifosfamide O
related O
encephalopathy B-Disease
: O
the O
need O
for O
a O
timely O
eeg O
evaluation O
. O

background O
: O
ifosfamide O
is O
an O
alkylating O
agent O
useful O
in O
the O
treatment O
of O
a O
wide O
range O
of O
cancers B-Disease
including O
sarcomas B-Disease
, O
lymphoma B-Disease
, O
gynecologic B-Disease
and I-Disease
testicular I-Disease
cancers I-Disease
. O

encephalopathy B-Disease
has O
been O
reported O
in O
10 O
- O
40 O
% O
of O
patients O
receiving O
high O
- O
dose O
iv O
ifosfamide O
. O

objective O
: O
to O
highlight O
the O
role O
of O
electroencephalogram O
( O
eeg O
) O
in O
the O
early O
detection O
and O
management O
of O
ifosfamide O
related O
encephalopathy B-Disease
. O

methods O
: O
retrospective O
chart O
review O
including O
clinical O
data O
and O
eeg O
recordings O
was O
done O
on O
five O
patients O
, O
admitted O
to O
md O
anderson O
cancer B-Disease
center O
between O
years O
2009 O
and O
2012 O
, O
who O
developed O
ifosfamide O
related O
acute O
encephalopathy B-Disease
. O

results O
: O
all O
five O
patients O
experienced O
symptoms O
of O
encephalopathy B-Disease
soon O
after O
( O
within O
12 O
h O
- O
2 O
days O
) O
receiving O
ifosfamide O
. O

two O
patients O
developed O
generalized O
convulsions B-Disease
while O
one O
patient O
developed O
continuous O
non B-Disease
- I-Disease
convulsive I-Disease
status I-Disease
epilepticus I-Disease
( O
ncse B-Disease
) O
that O
required O
icu O
admission O
and O
intubation O
. O

conclusions O
: O
severity O
of O
ifosfamide O
related O
encephalopathy B-Disease
correlates O
with O
eeg O
changes O
. O

we O
suggest O
a O
timely O
eeg O
evaluation O
for O
patients O
receiving O
ifosfamide O
who O
develop O
features O
of O
encephalopathy B-Disease
. O

incidence O
of O
contrast O
- O
induced O
nephropathy B-Disease
in O
hospitalised O
patients O
with O
cancer B-Disease
. O

objectives O
: O
to O
determine O
the O
frequency O
of O
and O
possible O
factors O
related O
to O
contrast O
- O
induced O
nephropathy B-Disease
( O
cin O
) O
in O
hospitalised O
patients O
with O
cancer B-Disease
. O

patients O
with O
risk O
factors O
for O
acute B-Disease
renal I-Disease
failure I-Disease
were O
excluded O
. O

cin O
was O
significantly O
more O
after O
treatment O
with O
bevacizumab O
/ O
irinotecan O
( O
p O
= O
0 O
. O

21 O
) O
and O
in O
patients O
with O
hypertension B-Disease
( O
p O
= O
0 O
. O

44 O
) O
. O

cin O
developed O
4 O
. O

5 O
- O
times O
more O
frequently O
in O
patients O
with O
cancer B-Disease
who O
had O
undergone O
recent O
chemotherapy O
. O

hypertension B-Disease
and O
the O
combination O
of O
bevacizumab O
/ O
irinotecan O
may O
be O
additional O
risk O
factors O
for O
cin O
development O
. O

contrast O
- O
induced O
nephropathy B-Disease
( O
cin O
) O
is O
a O
concern O
for O
oncological O
patients O
undergoing O
ct O
. O

. O

hypertension B-Disease
and O
treatment O
with O
bevacizumab O
appear O
to O
be O
additional O
risk O
factors O
. O

syndrome B-Disease
of I-Disease
inappropriate I-Disease
antidiuretic I-Disease
hormone I-Disease
secretion O
associated O
with O
desvenlafaxine O
. O

objective O
: O
to O
report O
a O
case O
of O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
anti I-Disease
- I-Disease
diuretic I-Disease
hormone I-Disease
( O
siadh B-Disease
) O
secretion O
associated O
with O
desvenlafaxine O
. O

case O
summary O
: O
a O
57 O
- O
year O
old O
female O
with O
hyponatraemia B-Disease
. O

her O
medications O
included O
desvenlafaxine O
, O
and O
symptoms O
included O
nausea B-Disease
, O
anxiety B-Disease
and O
confusion B-Disease
. O

the O
serum O
sodium O
at O
this O
time O
was O
120 O
mmol O
/ O
l O
, O
serum O
osmolality O
was O
263 O
mosmol O
/ O
kg O
, O
urine O
osmolality O
410 O
mosmol O
/ O
kg O
and O
urine O
sodium O
63 O
mmol O
/ O
l O
, O
consistent O
with O
a O
diagnosis O
of O
siadh B-Disease
. O

discussion O
: O
siadh B-Disease
has O
been O
widely O
reported O
with O
a O
range O
of O
antidepressants O
. O

this O
case O
report O
suggests O
that O
desvenlafaxine O
might O
cause O
clinically O
significant O
hyponatremia B-Disease
. O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
the O
potential O
for O
antidepressants O
to O
cause O
hyponatremia B-Disease
, O
and O
take O
appropriate O
corrective O
action O
where O
necessary O
. O

oxidative O
stress O
on O
cardiotoxicity B-Disease
after O
treatment O
with O
single O
and O
multiple O
doses O
of O
doxorubicin O
. O

the O
mechanism O
of O
doxorubicin O
( O
dox O
) O
- O
induced O
cardiotoxicity B-Disease
remains O
controversial O
. O

single O
dose O
of O
dox O
was O
associated O
with O
increased O
cardiac B-Disease
disarrangement I-Disease
, O
necrosis B-Disease
, O
and O
dna O
damage O
( O
strand O
breaks O
( O
sbs O
) O
and O
oxidized O
pyrimidines O
) O
and O
decreased O
tap O
. O

the O
chronological O
study O
showed O
an O
effect O
of O
a O
cumulative O
dose O
on O
body O
weight O
( O
r O
= O
- O
0 O
. O

99 O
, O
p O
= O
0 O
. O

11 O
) O
, O
necrosis B-Disease
( O
r O
= O
1 O
. O

0 O
, O
p O
= O
0 O
. O

4 O
) O
, O
tap O
( O
r O
= O
0 O
. O

95 O
, O
p O
= O
0 O
. O

49 O
) O
, O
and O
dna O
sbs O
( O
r O
= O
- O
0 O
. O

95 O
, O
p O
= O
0 O
. O

49 O
) O
. O

dna O
sbs O
damage O
was O
negatively O
associated O
with O
tap O
( O
r O
= O
- O
0 O
. O

98 O
, O
p O
= O
0 O
. O

18 O
) O
, O
and O
necrosis B-Disease
( O
r O
= O
- O
0 O
. O

97 O
, O
p O
= O
0 O
. O

27 O
) O
. O

our O
results O
suggest O
that O
oxidative O
damage O
is O
associated O
with O
acute O
cardiotoxicity B-Disease
induced O
by O
a O
single O
dose O
of O
dox O
only O
. O

thus O
, O
different O
mechanisms O
may O
be O
involved O
in O
acute O
toxicity B-Disease
versus O
chronic O
toxicity B-Disease
. O

tacrolimus O
- O
related O
seizure B-Disease
after O
pediatric O
liver O
transB-Plantation O
- O
- O
a O
single O
- O
center O
experience O
. O

to O
identify O
the O
risk O
factors O
for O
new O
- O
onset O
seizures B-Disease
after O
pediatric O
lt O
and O
to O
assess O
their O
clinical O
implications O
and O
long O
- O
term O
prognosis O
. O

patients O
were O
divided O
into O
seizures B-Disease
group O
and O
a O
non O
- O
seizures B-Disease
group O
. O

seizures B-Disease
occurred O
in O
four O
children O
, O
an O
incidence O
of O
14 O
. O

8 O
% O
. O

all O
exhibited O
generalized O
tonic B-Disease
- I-Disease
clonic I-Disease
seizures I-Disease
within O
the O
first O
two O
wk O
after O
lt O
. O

univariate O
analysis O
showed O
that O
the O
risk O
factors O
associated O
with O
seizures B-Disease
after O
pediatric O
lt O
included O
gender O
, O
pediatric O
end B-Disease
- I-Disease
stage I-Disease
liver I-Disease
disease I-Disease
score O
before O
surgery O
, O
child O
- O
pugh O
score O
before O
surgery O
, O
serum O
total O
bilirubin O
after O
surgery O
, O
and O
trough O
tac O
level O
. O

multivariate O
analysis O
showed O
that O
trough O
tac O
level O
was O
the O
only O
independent O
risk O
factor O
associated O
with O
the O
seizures B-Disease
. O

all O
children O
who O
experienced O
seizures B-Disease
survived O
with O
good O
graft O
function O
and O
remained O
seizure B-Disease
- O
free O
without O
anti O
- O
epileptic B-Disease
drugs O
over O
a O
mean O
follow O
- O
up O
period O
of O
33 O
. O

7 O
+ O
14 O
. O

6 O
months O
. O

high O
trough O
tac O
level O
was O
the O
predominant O
factor O
that O
contributed O
to O
seizures B-Disease
in O
the O
early O
post O
- O
operative O
period O
after O
pediatric O
lt O
. O

high O
peld O
and O
child O
- O
pugh O
scores O
before O
lt O
and O
high O
post O
- O
operative O
serum O
tbil O
may O
be O
contributory O
risk O
factors O
for O
tac O
- O
related O
seizures B-Disease
. O

furthermore O
, O
apigenin O
did O
not O
prevent O
the O
amnesia B-Disease
induced O
by O
scopolamine O
( O
1mg O
/ O
kg O
, O
i O
. O

p O
. O

, O
30 O
min O
before O
the O
acquisition O
) O
. O

in O
the O
saline O
treated O
group O
, O
the O
first O
significant O
decline O
in O
passive O
avoidance O
response O
was O
observed O
at O
four O
weeks O
, O
and O
complete O
memory B-Disease
loss I-Disease
was O
found O
five O
weeks O
after O
the O
acquisition O
of O
the O
passive O
avoidance O
task O
. O

histamine O
antagonists O
and O
d O
- O
tubocurarine O
- O
induced O
hypotension B-Disease
in O
cardiac O
surgical O
patients O
. O

we O
have O
previously O
reported O
that O
cck O
- O
8 O
significantly O
alleviated O
morphine O
- O
induced O
amnesia B-Disease
and O
reversed O
spine O
density O
decreases O
in O
the O
ca1 O
region O
of O
the O
hippocampus O
in O
morphine O
- O
treated O
animals O
. O

the O
present O
results O
demonstrate O
that O
cck O
- O
8 O
attenuates O
the O
effect O
of O
morphine O
on O
hippocampal O
ltp O
through O
cck2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
cck O
- O
8 O
on O
morphine O
- O
induced O
memory B-Disease
impairment I-Disease
. O

glial O
activation O
and O
post O
- O
synaptic O
neurotoxicity B-Disease
: O
the O
key O
events O
in O
streptozotocin O
( O
icv O
) O
induced O
memory B-Disease
impairment I-Disease
in O
rats O
. O

in O
the O
present O
study O
the O
role O
of O
glial O
activation O
and O
post O
synaptic O
toxicity B-Disease
in O
icv O
streptozotocin O
( O
stz O
) O
induced O
memory B-Disease
impaired I-Disease
rats O
was O
explored O
. O

in O
experiment O
set O
up O
1 O
: O
memory B-Disease
deficit I-Disease
was O
found O
in O
morris O
water O
maze O
test O
on O
14 O
- O
16 O
days O
after O
stz O
( O
icv O
; O
3mg O
/ O
kg O
) O
administration O
. O

stz O
causes O
increased O
expression O
of O
gfap O
, O
cd11b O
and O
tnf O
- O
a O
indicating O
glial O
activation O
and O
neuroinflammation B-Disease
. O

stz O
also O
significantly O
increased O
the O
level O
of O
ros O
, O
nitrite O
, O
ca O
( O
2 O
+ O
) O
and O
reduced O
the O
mitochondrial O
activity O
in O
synaptosomal O
preparation O
illustrating O
free O
radical O
generation O
and O
excitotoxicity B-Disease
. O

stz O
treatment O
showed O
decrease O
expression O
of O
post O
synaptic O
markers O
camkiia O
and O
psd O
- O
95 O
, O
while O
, O
expression O
of O
pre O
synaptic O
markers O
( O
synaptophysin O
and O
snap O
- O
25 O
) O
remains O
unaltered O
indicating O
selective O
post O
synaptic O
neurotoxicity B-Disease
. O

oral O
treatment O
with O
memantine O
( O
10mg O
/ O
kg O
) O
and O
ibuprofen O
( O
50 O
mg O
/ O
kg O
) O
daily O
for O
13 O
days O
attenuated O
stz O
induced O
glial O
activation O
, O
apoptotic O
cell O
death O
and O
post O
synaptic O
neurotoxicity B-Disease
in O
rat O
brain O
. O

collective O
data O
indicates O
that O
neuroinflammatory B-Disease
process O
and O
oxidative O
stress O
occurs O
earlier O
to O
apoptosis O
and O
does O
not O
affect O
memory O
function O
. O

present O
study O
clearly O
suggests O
that O
glial O
activation O
and O
post O
synaptic O
neurotoxicity B-Disease
are O
the O
key O
factors O
in O
stz O
induced O
memory B-Disease
impairment I-Disease
and O
neuronal O
cell O
death O
. O

comparison O
of O
effects O
of O
isotonic O
sodium O
chloride O
with O
diltiazem O
in O
prevention O
of O
contrast O
- O
induced O
nephropathy B-Disease
. O

introduction O
and O
objective O
: O
contrast O
- O
induced O
nephropathy B-Disease
( O
cin O
) O
significantly O
increases O
the O
morbidity O
and O
mortality O
of O
patients O
. O

among O
a O
total O
of O
60 O
patients O
included O
in O
the O
study O
, O
16 O
patients O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
( O
arf B-Disease
) O
on O
the O
second O
day O
after O
contrast O
material O
was O
injected O
( O
26 O
. O

6 O
% O
) O
. O

the O
number O
of O
patients O
who O
developed O
arf B-Disease
on O
the O
second O
day O
after O
the O
injection O
in O
the O
first O
group O
was O
five O
( O
25 O
% O
) O
, O
in O
the O
second O
group O
was O
six O
( O
30 O
% O
) O
and O
the O
third O
group O
was O
five O
( O
25 O
% O
) O
( O
p O
> O
0 O
. O

5 O
) O
. O

neurocognitive O
and O
neuroradiologic O
central O
nervous O
system O
late O
effects O
in O
children O
treated O
on O
pediatric O
oncology O
group O
( O
pog O
) O
p9605 O
( O
standard O
risk O
) O
and O
p9201 O
( O
lesser O
risk O
) O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
protocols O
( O
accl0131 O
) O
: O
a O
methotrexate O
consequence O
? O
concerns O
about O
long O
- O
term O
methotrexate O
( O
mtx O
) O
neurotoxicity B-Disease
in O
the O
1990s O
led O
to O
modifications O
in O
intrathecal O
( O
it O
) O
therapy O
, O
leucovorin O
rescue O
, O
and O
frequency O
of O
systemic O
mtx O
administration O
in O
children O
with O
acute B-Disease

lymphoblastic I-Disease
leukemia I-Disease
. O

in O
this O
study O
, O
neurocognitive O
outcomes O
and O
neuroradiologic O
evidence O
of O
leukoencephalopathy B-Disease
were O
compared O
in O
children O
treated O
with O
intense O
central O
nervous O
system O
( O
cns O
) O
- O
directed O
therapy O
( O
p9605 O
) O
versus O
those O
receiving O
fewer O
cns O
- O
directed O
treatment O
days O
during O
intensive O
consolidation O
( O
p9201 O
) O
. O

a O
total O
of O
66 O
children O
from O
16 O
pediatric O
oncology O
group O
institutions O
with O
nan O
standard O
- O
risk O
nan O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
, O
1 O
. O

0 O
to O
9 O
. O

99 O
years O
at O
diagnosis O
, O
without O
evidence O
of O
cns O
leukemia B-Disease
at O
diagnosis O
were O
enrolled O
on O
accl0131 O
: O
28 O
from O
p9201 O
and O
38 O
from O
p9605 O
. O

significantly O
more O
p9605 O
patients O
developed O
leukoencephalopathy B-Disease
compared O
with O
p9201 O
patients O
( O
68 O
% O
, O
95 O
% O
confidence O
interval O
49 O
% O
- O
83 O
% O
vs O
. O

22 O
% O
, O
95 O
% O
confidence O
interval O
5 O
% O
- O
44 O
% O
; O
p O
= O
0 O
. O

1 O
) O
identified O
as O
late O
as O
7 O
. O

7 O
years O
after O
the O
end O
of O
treatment O
. O

children O
on O
both O
studies O
had O
significant O
attention B-Disease
problems I-Disease
, O
but O
p9605 O
children O
scored O
below O
average O
on O
more O
neurocognitive O
measures O
than O
those O
treated O
on O
p9201 O
( O
82 O
% O
, O
14 O
/ O
17 O
measures O
vs O
. O

24 O
% O
, O
4 O
/ O
17 O
measures O
) O
. O

tranexamic O
acid O
overdosage O
- O
induced O
generalized O
seizure B-Disease
in O
renal B-Disease
failure I-Disease
. O

we O
report O
a O
45 O
- O
year O
- O
old O
lady O
with O
chronic B-Disease
kidney I-Disease
disease I-Disease
stage O
4 O
due O
to O
chronic O
tubulointerstial B-Disease
disease I-Disease
. O

she O
was O
admitted O
to O
our O
center O
for O
severe O
anemia B-Disease
due O
to O
menorrhagia B-Disease
and O
deterioration B-Disease
of I-Disease
renal I-Disease
function I-Disease
. O

tranexamic O
acid O
( O
tna O
) O
1 O
g O
8 O
- O
hourly O
was O
administered O
to O
her O
to O
control O
bleeding B-Disease
per O
vaginum O
. O

two O
hours O
after O
the O
sixth O
dose O
of O
tna O
, O
she O
had O
an O
episode O
of O
generalized O
tonic B-Disease
clonic I-Disease
convulsions I-Disease
. O

investigations O
of O
the O
patient O
revealed O
no O
biochemical O
or O
structural O
central O
nervous B-Disease
system I-Disease
abnormalities I-Disease
that O
could O
have O
provoked O
the O
convulsions B-Disease
. O

she O
had O
no O
further O
episodes O
of O
convulsion B-Disease
till O
dis O
- O
charge O
and O
during O
the O
two O
months O
of O
follow O
- O
up O
. O

thus O
, O
the O
precipitating O
cause O
of O
convulsions B-Disease
was O
believed O
to O
be O
an O
overdose B-Disease
of O
tna O
. O

pre O
- O
treatment O
of O
bupivacaine O
- O
induced O
cardiovascular B-Disease
depression I-Disease
using O
different O
lipid O
formulations O
of O
propofol O
. O

background O
: O
pre O
- O
treatment O
with O
lipid O
emulsions O
has O
been O
shown O
to O
increase O
lethal O
doses O
of O
bupivacaine O
, O
and O
the O
lipid O
content O
of O
propofol O
may O
alleviate O
bupivacaine O
- O
induced O
cardiotoxicity B-Disease
. O

the O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
propofol O
in O
intralipid O
or O
medialipid O
emulsions O
on O
bupivacaine O
- O
induced O
cardiotoxicity B-Disease
. O

we O
recorded O
time O
to O
first O
dysrhythmia B-Disease
occurrence O
, O
respective O
times O
to O
25 O
% O
and O
50 O
% O
reduction O
of O
the O
heart O
rate O
( O
hr O
) O
and O
mean O
arterial O
pressure O
, O
and O
time O
to O
asystole B-Disease
and O
total O
amount O
of O
bupivacaine O
consumption O
. O

blood O
and O
tissue O
samples O
were O
collected O
following O
asystole B-Disease
. O

results O
: O
the O
time O
to O
first O
dysrhythmia B-Disease
occurrence O
, O
time O
to O
25 O
% O
and O
50 O
% O
reductions O
in O
hr O
, O
and O
time O
to O
asystole B-Disease
were O
longer O
in O
group O
p O
than O
the O
other O
groups O
. O

conclusion O
: O
we O
conclude O
that O
pre O
- O
treatment O
with O
propofol O
in O
intralipid O
, O
compared O
with O
propofol O
in O
medialipid O
or O
saline O
, O
delayed O
the O
onset O
of O
bupivacaine O
- O
induced O
cardiotoxic B-Disease
effects O
as O
well O
as O
reduced O
plasma O
bupivacaine O
levels O
. O

drug B-Disease
- I-Disease
induced I-Disease
acute I-Disease
liver I-Disease
injury I-Disease
within O
12 O
hours O
after O
fluvastatin O
therapy O
. O

although O
statins O
are O
generally O
well O
- O
tolerated O
drugs O
, O
recent O
cases O
of O
drug B-Disease
- I-Disease
induced I-Disease
liver I-Disease
injury I-Disease
associated O
with O
their O
use O
have O
been O
reported O
. O

a O
52 O
- O
year O
- O
old O
chinese O
man O
reported O
with O
liver B-Disease
damage I-Disease
, O
which O
appeared O
12 O
hours O
after O
beginning O
treatment O
with O
fluvastatin O
. O

patient O
presented O
with O
complaints O
of O
increasing O
nausea B-Disease
, O
anorexia B-Disease
, O
and O
upper O
abdominal B-Disease
pain I-Disease
. O

therefore O
, O
when O
prescribing O
statins O
, O
the O
possibility O
of O
hepatic B-Disease
damage I-Disease
should O
be O
taken O
into O
account O
. O

fluconazole O
associated O
agranulocytosis B-Disease
and O
thrombocytopenia B-Disease
. O

case O
: O
we O
describe O
a O
second O
case O
of O
fluconazole O
associated O
agranulocytosis B-Disease
with O
thrombocytopenia B-Disease
and O
recovery O
upon O
discontinuation O
of O
therapy O
. O

this O
case O
highlights O
that O
drug O
- O
induced O
blood B-Disease
dyscrasias I-Disease
can O
occur O
unexpectedly O
as O
a O
result O
of O
treatment O
with O
a O
commonly O
used O
drug O
thought O
to O
be O
nan O
safe O
nan O
. O

conclusion O
: O
according O
to O
naranjo O
' O
s O
algorithm O
the O
likelihood O
that O
our O
patient O
' O
s O
agranulocytosis B-Disease
and O
thrombocytopenia B-Disease
occurred O
as O
a O
result O
of O
therapy O
with O
fluconazole O
is O
probable O
, O
with O
a O
total O
of O
six O
points O
. O

in O
particular O
the O
temporal O
relationship O
of O
bone B-Disease
marrow I-Disease
suppression I-Disease
to O
the O
initiation O
of O
fluconazole O
and O
the O
abatement O
of O
symptoms O
that O
rapidly O
reversed O
immediately O
following O
discontinuation O
. O

two O
- O
dimensional O
speckle O
tracking O
echocardiography O
combined O
with O
high O
- O
sensitive O
cardiac O
troponin O
t O
in O
early O
detection O
and O
prediction O
of O
cardiotoxicity B-Disease
during O
epirubicine O
- O
based O
chemotherapy O
. O

aims O
: O
to O
investigate O
whether O
alterations O
of O
myocardial B-Disease
strain I-Disease
and O
high O
- O
sensitive O
cardiac O
troponin O
t O
( O
ctnt O
) O
could O
predict O
future O
cardiac B-Disease
dysfunction I-Disease
in O
patients O
after O
epirubicin O
exposure O
. O

methods O
: O
seventy O
- O
five O
patients O
with O
non B-Disease
- I-Disease
hodgkin I-Disease
lymphoma I-Disease
treated O
with O
epirubicin O
were O
studied O
. O

cardiotoxicity B-Disease
was O
defined O
as O
a O
reduction O
of O
the O
lvef O
of O
> O
5 O
% O
to O
< O
55 O
% O
with O
symptoms O
of O
heart B-Disease
failure I-Disease
or O
an O
asymptomatic O
reduction O
of O
the O
lvef O
of O
> O
10 O
% O
to O
< O
55 O
% O
. O

results O
: O
fourteen O
patients O
( O
18 O
. O

67 O
% O
) O
developed O
cardiotoxicity B-Disease
after O
treatment O
. O

a O
> O
15 O
. O

9 O
% O
decrease O
in O
gls O
[ O
sensitivity O
, O
86 O
% O
; O
specificity O
, O
75 O
% O
; O
area O
under O
the O
curve O
( O
auc O
) O
= O
0 O
. O

815 O
; O
p O
= O
0 O
. O

1 O
] O
and O
a O
> O
0 O
. O

4 O
ng O
/ O
ml O
elevation O
in O
ctnt O
( O
sensitivity O
, O
79 O
% O
; O
specificity O
, O
64 O
% O
; O
auc O
= O
0 O
. O

757 O
; O
p O
= O
0 O
. O

5 O
) O
from O
baseline O
to O
the O
third O
cycle O
of O
chemotherapy O
predicted O
later O
cardiotoxicity B-Disease
. O

the O
decrease O
in O
gls O
remained O
the O
only O
independent O
predictor O
of O
cardiotoxicity B-Disease
( O
p O
= O
0 O
. O

0 O
) O
. O

conclusions O
: O
gls O
combined O
with O
ctnt O
may O
provide O
a O
reliable O
and O
non O
- O
invasive O
method O
to O
predict O
cardiac B-Disease
dysfunction I-Disease
in O
patients O
receiving O
anthracycline O
- O
based O
chemotherapy O
. O

prevention O
of O
etomidate O
- O
induced O
myoclonus B-Disease
: O
which O
is O
superior O
: O
fentanyl O
, O
midazolam O
, O
or O
a O
combination O
? O
background O
: O
in O
this O
retrospective O
comparative O
study O
, O
we O
aimed O
to O
compare O
the O
effectiveness O
of O
fentanyl O
, O
midazolam O
, O
and O
a O
combination O
of O
fentanyl O
and O
midazolam O
to O
prevent O
etomidate O
- O
induced O
myoclonus B-Disease
. O

myoclonic B-Disease
movements I-Disease
are O
evaluated O
, O
which O
were O
observed O
and O
graded O
according O
to O
clinical O
severity O
during O
the O
2 O
minutes O
after O
etomidate O
injection O
. O

the O
severity O
of O
pain B-Disease
due O
to O
etomidate O
injection O
, O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
adverse O
effects O
were O
also O
evaluated O
. O

results O
: O
study O
results O
showed O
that O
myoclonus B-Disease
incidence O
was O
85 O
% O
, O
40 O
% O
, O
70 O
% O
, O
and O
25 O
% O
in O
group O
np O
, O
group O
f O
, O
group O
m O
, O
and O
group O
fm O
, O
respectively O
, O
and O
were O
significantly O
lower O
in O
group O
f O
and O
group O
fm O
. O

conclusions O
: O
we O
conclude O
that O
pretreatment O
with O
fentanyl O
or O
combination O
of O
fentanyl O
and O
midazolam O
was O
effective O
in O
preventing O
etomidate O
- O
induced O
myoclonus B-Disease
. O

lindane O
( O
gamma O
- O
hexachlorocyclohexane O
) O
is O
an O
organochlorine O
insecticide O
with O
known O
neurotoxic B-Disease
effects O
. O

we O
studied O
the O
effect O
of O
lindane O
( O
150 O
mg O
/ O
kg O
) O
on O
the O
gabaergic O
and O
dopaminergic O
systems O
by O
measuring O
the O
concentration O
of O
gaba O
, O
dopamine O
and O
its O
metabolites O
in O
7 O
brain O
areas O
at O
the O
onset O
of O
seizures B-Disease
. O

all O
animals O
suffered O
tonic O
convulsions B-Disease
at O
18 O
. O

3 O
+ O
/ O
- O
1 O
. O

4 O
min O
after O
lindane O
administration O
. O

cholestatic B-Disease
presentation O
of O
yellow O
phosphorus O
poisoning B-Disease
. O

yellow O
phosphorus O
, O
a O
component O
of O
certain O
pesticide O
pastes O
and O
fireworks O
, O
is O
well O
known O
to O
cause O
hepatotoxicity B-Disease
. O

poisoning B-Disease
with O
yellow O
phosphorus O
classically O
manifests O
with O
acute B-Disease
hepatitis I-Disease
leading O
to O
acute B-Disease
liver I-Disease
failure I-Disease
which O
may O
need O
liver O
transB-Plantation O
. O

we O
present O
a O
case O
of O
yellow O
phosphorus O
poisoning B-Disease
in O
which O
a O
patient O
presented O
with O
florid O
clinical O
features O
of O
cholestasis B-Disease
highlighting O
the O
fact O
that O
cholestasis B-Disease
can O
rarely O
be O
a O
presenting O
feature O
of O
yellow O
phosphorus O
hepatotoxicity B-Disease
. O

vasovagal B-Disease
syncope I-Disease
and O
severe O
bradycardia B-Disease
following O
intranasal O
dexmedetomidine O
for O
pediatric O
procedural O
sedation O
. O

we O
report O
syncope B-Disease
and O
bradycardia B-Disease
in O
an O
11 O
- O
year O
- O
old O
girl O
following O
administration O
of O
intranasal O
dexmedetomidine O
for O
sedation O
for O
a O
voiding O
cystourethrogram O
. O

the O
primary O
abnormality O
found O
was O
persistent O
bradycardia B-Disease
, O
and O
she O
was O
admitted O
to O
the O
hospital O
for O
telemetric O
observation O
. O

the O
bradycardia B-Disease
lasted O
~ O
2 O
h O
, O
and O
further O
cardiac O
workup O
revealed O
no O
underlying O
abnormality O
. O

paradoxical O
severe O
agitation B-Disease
induced O
by O
add O
- O
on O
high O
- O
doses O
quetiapine O
in O
schizo B-Disease
- I-Disease
affective I-Disease
disorder I-Disease
. O

we O
report O
the O
case O
of O
a O
35 O
- O
year O
- O
old O
patient O
suffering O
from O
schizo B-Disease
- I-Disease
affective I-Disease
disorder I-Disease
since O
the O
age O
of O
19 O
years O
, O
treated O
by O
a O
combination O
of O
first O
- O
generation O
antipsychotics O
, O
zuclopenthixol O
( O
100 O
mg O
/ O
day O
) O
and O
lithium O
( O
1200 O
mg O
/ O
day O
) O
( O
serum O
lithium O
= O
0 O
. O

85 O
meq O
/ O
l O
) O
. O

this O
patient O
had O
no O
associated O
personality B-Disease
disorder I-Disease
( O
particularly O
no O
antisocial B-Disease
disorder I-Disease
) O
and O
no O
substance B-Disease
abuse I-Disease
disorder I-Disease
. O

within O
the O
48 O
h O
following O
the O
gradual O
introduction O
of O
quetiapine O
( O
up O
to O
600 O
mg O
/ O
day O
) O
, O
the O
patient O
presented O
severe O
agitation B-Disease
without O
an O
environmental O
explanation O
, O
contrasting O
with O
the O
absence O
of O
a O
history O
of O
aggressiveness B-Disease
or O
personality B-Disease
disorder I-Disease
. O

the O
diagnoses O
of O
manic B-Disease
shift O
and O
akathisia B-Disease
were O
dismissed O
. O

the O
withdrawal O
and O
the O
gradual O
reintroduction O
of O
quetiapine O
2 O
weeks O
later O
, O
which O
led O
to O
another O
severe O
agitation B-Disease
, O
enabled O
us O
to O
attribute O
the O
agitation B-Disease
specifically O
to O
quetiapine O
. O

antioxidant O
effects O
of O
bovine O
lactoferrin O
on O
dexamethasone O
- O
induced O
hypertension B-Disease
in O
rat O
. O

dexamethasone O
- O
( O
dex O
- O
) O
induced O
hypertension B-Disease
is O
associated O
with O
enhanced O
oxidative O
stress O
. O

in O
this O
study O
, O
we O
investigated O
the O
effect O
of O
chronic O
administration O
of O
lf O
on O
oxidative O
stress O
and O
hypertension B-Disease
upon O
dex O
administration O
. O

lf O
lowered O
( O
p O
< O
0 O
. O

1 O
) O
and O
dose O
dependently O
prevented O
( O
p O
< O
0 O
. O

1 O
) O
dex O
- O
induced O
hypertension B-Disease
. O

lf O
prevented O
body O
weight B-Disease
loss I-Disease
and O
significantly O
reduced O
the O
elevated O
plasma O
h2o2 O
and O
increased O
frap O
values O
. O

chronic O
administration O
of O
lf O
strongly O
reduced O
the O
blood O
pressure O
and O
production O
of O
ros O
and O
improved O
antioxidant O
capacity O
in O
dex O
- O
induced O
hypertension B-Disease
, O
suggesting O
the O
role O
of O
inhibition O
of O
oxidative O
stress O
as O
another O
mechanism O
of O
antihypertensive O
action O
of O
lf O
. O

the O
association O
between O
tranexamic O
acid O
and O
convulsive B-Disease
seizures B-Disease
after O
cardiac O
surgery O
: O
a O
multivariate O
analysis O
in O
11 O
529 O
patients O
. O

because O
of O
a O
lack O
of O
contemporary O
data O
regarding O
seizures B-Disease
after O
cardiac O
surgery O
, O
we O
undertook O
a O
retrospective O
analysis O
of O
prospectively O
collected O
data O
from O
11 O
529 O
patients O
in O
whom O
cardiopulmonary O
bypass O
was O
used O
from O
january O
2004 O
to O
december O
2010 O
. O

a O
convulsive B-Disease
seizure B-Disease
was O
defined O
as O
a O
transient O
episode O
of O
disturbed O
brain O
function O
characterised O
by O
abnormal B-Disease
involuntary I-Disease
motor I-Disease
movements I-Disease
. O

multivariate O
regression O
analysis O
was O
performed O
to O
identify O
independent O
predictors O
of O
postoperative O
seizures B-Disease
. O

a O
total O
of O
100 O
( O
0 O
. O

9 O
% O
) O
patients O
developed O
postoperative O
convulsive B-Disease
seizures B-Disease
. O

generalised B-Disease
and I-Disease
focal I-Disease
seizures I-Disease
were O
identified O
in O
68 O
and O
32 O
patients O
, O
respectively O
. O

the O
median O
( O
iqr O
[ O
range O
] O
) O
time O
after O
surgery O
when O
the O
seizure B-Disease
occurred O
was O
7 O
( O
6 O
- O
12 O
[ O
1 O
- O
216 O
] O
) O
h O
and O
8 O
( O
6 O
- O
11 O
[ O
4 O
- O
18 O
] O
) O
h O
, O
respectively O
. O

independent O
predictors O
of O
postoperative O
seizures B-Disease
included O
age O
, O
female O
sex O
, O
redo O
cardiac O
surgery O
, O
calcification O
of O
ascending O
aorta O
, O
congestive B-Disease
heart I-Disease
failure I-Disease
, O
deep O
hypothermic B-Disease
circulatory O
arrest O
, O
duration O
of O
aortic O
cross O
- O
clamp O
and O
tranexamic O
acid O
. O

when O
tested O
in O
a O
multivariate O
regression O
analysis O
, O
tranexamic O
acid O
was O
a O
strong O
independent O
predictor O
of O
seizures B-Disease
( O
or O
14 O
. O

3 O
, O
95 O
% O
ci O
5 O
. O

5 O
- O
36 O
. O

7 O
; O
p O
< O
0 O
. O

1 O
) O
. O

patients O
with O
convulsive B-Disease
seizures B-Disease
had O
2 O
. O

5 O
times O
higher O
in O
- O
hospital O
mortality O
rates O
and O
twice O
the O
length O
of O
hospital O
stay O
compared O
with O
patients O
without O
convulsive B-Disease
seizures B-Disease
. O

mean O
( O
iqr O
[ O
range O
] O
) O
length O
of O
stay O
in O
the O
intensive O
care O
unit O
was O
115 O
( O
49 O
- O
228 O
[ O
32 O
- O
481 O
] O
) O
h O
in O
patients O
with O
convulsive B-Disease
seizures B-Disease
compared O
with O
26 O
( O
22 O
- O
69 O
[ O
14 O
- O
1080 O
] O
) O
h O
in O
patients O
without O
seizures B-Disease
( O
p O
< O
0 O
. O

1 O
) O
. O

convulsive B-Disease
seizures B-Disease
are O
a O
serious O
postoperative B-Disease
complication I-Disease
after O
cardiac O
surgery O
. O

as O
tranexamic O
acid O
is O
the O
only O
modifiable O
factor O
, O
its O
administration O
, O
particularly O
in O
doses O
exceeding O
80 O
mg O
. O

kg O
( O
- O
1 O
) O
, O
should O
be O
weighed O
against O
the O
risk O
of O
postoperative O
seizures B-Disease
. O

dysfunctional B-Disease
overnight I-Disease
memory I-Disease
consolidation O
in O
ecstasy O
users O
. O

previous O
studies O
indicate O
that O
ecstasy O
users O
have O
marked O
and O
persistent O
neurocognitive O
and O
sleep B-Disease
- I-Disease
related I-Disease
impairments I-Disease
. O

ecstasy O
users O
demonstrated O
impaired B-Disease
overnight I-Disease
memory I-Disease
consolidation O
, O
a O
finding O
that O
was O
more O
pronounced O
following O
associative O
interference O
. O

we O
suggest O
that O
ecstasy O
- O
associated O
dysfunction O
in O
fronto O
- O
temporal O
circuitry O
may O
underlie O
overnight O
consolidation O
memory B-Disease
impairments I-Disease
in O
regular O
ecstasy O
users O
. O

normoammonemic O
encephalopathy B-Disease
: O
solely O
valproate O
induced O
or O
multiple O
mechanisms O
? O
a O
77 O
- O
year O
- O
old O
woman O
presented O
with O
subacute O
onset O
progressive O
confusion B-Disease
, O
aggression B-Disease
, O
auditory B-Disease
hallucinations I-Disease
and O
delusions B-Disease
. O

in O
the O
preceding O
months O
, O
the O
patient O
had O
a O
number O
of O
admissions O
with O
transient O
unilateral O
hemiparesis B-Disease
with O
facial O
droop O
, O
and O
had O
been O
started O
on O
valproate O
for O
presumed O
hemiplegic B-Disease
migraine I-Disease
. O

eeg O
undertaken O
during O
inpatient O
stay O
showed O
changes O
consistent O
with O
encephalopathy B-Disease
, O
and O
low O
titre O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptor O
antibodies O
were O
present O
in O
this O
patient O
. O

the O
possible O
aetiologies O
of O
valproate O
- O
induced O
encephalopathy B-Disease
and O
nmda O
receptor O
- O
associated O
encephalitis B-Disease
present O
a O
diagnostic O
dilemma O
. O

cerebellar B-Disease
and I-Disease
oculomotor I-Disease
dysfunction I-Disease
induced O
by O
rapid O
infusion O
of O
pethidine O
. O

pethidine O
is O
an O
opioid O
that O
gains O
its O
popularity O
for O
the O
effective O
pain B-Disease
control O
through O
acting O
on O
the O
opioid O
- O
receptors O
. O

however O
, O
rapid O
pain B-Disease
relief O
sometimes O
brings O
about O
unfavourable O
side O
effects O
that O
largely O
limit O
its O
clinical O
utility O
. O

common O
side O
effects O
include O
nausea B-Disease
, O
vomiting B-Disease
and O
hypotension B-Disease
. O

in O
patients O
with O
impaired B-Disease
renal I-Disease
and I-Disease
liver I-Disease
function I-Disease
, O
and O
those O
who O
need O
long O
- O
term O
pain B-Disease
control O
, O
pethidine O
may O
cause O
excitatory O
central O
nervous O
system O
( O
cns O
) O
effects O
through O
its O
neurotoxic B-Disease
metabolite O
, O
norpethidine O
, O
resulting O
in O
irritability B-Disease
and O
seizure B-Disease
attack O
. O

in O
this O
case O
report O
, O
we O
highlight O
opioid O
' O
s O
inhibitory O
side O
effects O
on O
the O
cerebellar O
structure O
that O
causes O
dysmetria B-Disease
, O
dysarthria B-Disease
, O
reduced O
smooth O
pursuit O
gain O
and O
decreased O
saccadic O
velocity O
. O

baboon B-Disease
syndrome I-Disease
induced O
by O
ketoconazole O
. O

a O
27 O
- O
year O
- O
old O
male O
patient O
presented O
with O
a O
maculopapular B-Disease
eruption I-Disease
on O
the O
flexural O
areas O
and O
buttocks O
after O
using O
oral O
ketoconazole O
. O

the O
patient O
was O
diagnosed O
with O
drug O
- O
induced O
baboon B-Disease
syndrome I-Disease
based O
on O
his O
history O
, O
which O
included O
prior O
sensitivity O
to O
topical O
ketoconazole O
, O
a O
physical O
examination O
, O
and O
histopathological O
findings O
. O

baboon B-Disease
syndrome I-Disease
is O
a O
drug O
- O
or O
contact O
allergen O
- O
related O
maculopapular B-Disease
eruption I-Disease
that O
typically O
involves O
the O
flexural O
and O
gluteal O
areas O
. O

to O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
ketoconazole O
- O
induced O
baboon B-Disease
syndrome I-Disease
in O
the O
english O
literature O
. O

a O
case O
of O
sudden B-Disease
cardiac I-Disease
death I-Disease
due O
to O
pilsicainide O
- O
induced O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

an O
84 O
- O
year O
- O
old O
male O
received O
oral O
pilsicainide O
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
his O
paroxysmal O
atrial B-Disease
fibrillation I-Disease
to O
a O
sinus O
rhythm O
; O
the O
patient O
developed O
sudden B-Disease
cardiac I-Disease
death I-Disease
two O
days O
later O
. O

the O
holter O
electrocardiogram O
, O
which O
was O
worn O
by O
chance O
, O
revealed O
torsade B-Disease
de I-Disease
pointes I-Disease
with O
gradually O
prolonged O
qt O
intervals O
. O

although O
the O
patient O
' O
s O
renal O
function O
was O
not O
highly O
impaired O
and O
the O
dose O
of O
pilsicainide O
was O
low O
, O
the O
plasma O
concentration O
of O
pilsicainide O
may O
have O
been O
high O
, O
which O
can O
produce O
torsades B-Disease
de I-Disease
pointes I-Disease
in O
the O
octogenarian O
. O

although O
the O
oral O
administration O
of O
class O
ic O
drugs O
, O
including O
pilsicainide O
, O
is O
effective O
to O
terminate O
atrial B-Disease
fibrillation I-Disease
, O
careful O
consideration O
must O
be O
taken O
before O
giving O
these O
drugs O
to O
octogenarians O
. O

all O
- O
trans O
retinoic O
acid O
- O
induced O
inflammatory O
myositis B-Disease
in O
a O
patient O
with O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
. O

all O
- O
trans O
retinoic O
acid O
( O
atra O
) O
, O
a O
component O
of O
standard O
therapy O
for O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
( O
apl B-Disease
) O
, O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

only O
a O
handful O
of O
cases O
of O
atra O
- O
induced O
myositis B-Disease
in O
children O
have O
been O
reported O
, O
and O
none O
in O
the O
radiology O
literature O
. O

we O
present O
such O
a O
case O
in O
a O
15 O
- O
year O
- O
old O
boy O
with O
apl B-Disease
, O
where O
recognition O
of O
imaging O
findings O
played O
a O
crucial O
role O
in O
making O
the O
diagnosis O
and O
facilitated O
prompt O
, O
effective O
treatment O
. O

tolerability O
of O
lomustine O
in O
combination O
with O
cyclophosphamide O
in O
dogs O
with O
lymphoma B-Disease
. O

this O
retrospective O
study O
describes O
toxicity B-Disease
associated O
with O
a O
protocol O
of O
lomustine O
( O
ccnu O
) O
and O
cyclophosphamide O
( O
ctx O
) O
in O
dogs O
with O
lymphoma B-Disease
. O

neutropenia B-Disease
was O
the O
principal O
toxic O
effect O
, O
and O
the O
overall O
frequency O
of O
grade O
4 O
neutropenia B-Disease
after O
the O
first O
treatment O
of O
ccnu O
/ O
ctx O
was O
30 O
% O
( O
95 O
% O
confidence O
interval O
, O
19 O
- O
43 O
% O
) O
. O

the O
mean O
body O
weight O
of O
dogs O
with O
grade O
4 O
neutropenia B-Disease
( O
19 O
. O

7 O
kg O
+ O
13 O
. O

4 O
kg O
) O
was O
significantly O
less O
than O
the O
mean O
body O
weight O
of O
dogs O
that O
did O
not O
develop O
grade O
4 O
neutropenia B-Disease
( O
31 O
. O

7 O
kg O
+ O
12 O
. O

4 O
kg O
; O
p O
= O
. O

5 O
) O
. O

one O
dog O
( O
3 O
% O
) O
developed O
hematologic O
changes O
suggestive O
of O
hepatotoxicity B-Disease
. O

no O
dogs O
had O
evidence O
of O
either O
renal B-Disease
toxicity I-Disease
or O
hemorrhagic B-Disease
cystitis I-Disease
. O

on O
the O
basis O
of O
the O
findings O
reported O
herein O
, O
a O
dose O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
ccnu O
combined O
with O
250 O
mg O
/ O
m O
( O
2 O
) O
of O
ctx O
( O
divided O
over O
5 O
days O
) O
q O
4 O
wk O
is O
tolerable O
in O
tumor B-Disease
- O
bearing O
dogs O
. O

nelarabine O
neurotoxicity B-Disease
with O
concurrent O
intrathecal O
chemotherapy O
: O
case O
report O
and O
review O
of O
literature O
. O

severe O
nelarabine O
neurotoxicity B-Disease
in O
a O
patient O
who O
received O
concurrent O
intrathecal O
( O
it O
) O
chemotherapy O
is O
reported O
. O

a O
37 O
- O
year O
- O
old O
caucasian O
woman O
with O
a O
history O
of O
t B-Disease
- I-Disease
cell I-Disease
lymphoblastic I-Disease
lymphoma I-Disease
was O
admitted O
for O
relapsed O
disease O
. O

she O
developed O
relapsed O
disease O
10 O
months O
later O
with O
leukemic B-Disease
involvement O
. O

at O
the O
time O
of O
treatment O
, O
she O
was O
on O
continuous O
renal O
replacement O
therapy O
due O
to O
sequelae O
of O
tumor B-Disease
lysis I-Disease
syndrome I-Disease
( O
tls B-Disease
) O
. O

predominantly O
sensory O
, O
though O
also O
motor O
and O
autonomic O
, O
peripheral B-Disease
neuropathy I-Disease
started O
in O
her O
feet O
, O
ascended O
proximally O
to O
the O
mid O
- O
thoracic O
region O
, O
and O
eventually O
included O
her O
distal O
upper O
extremities O
. O

her O
neuropathy B-Disease
stabilized O
and O
showed O
slight O
improvement O
and O
ultimately O
received O
an O
unrelated O
, O
reduced O
- O
intensity O
allogeneic O
transB-Plant O
while O
in O
complete O
remission O
, O
but O
relapsed O
disease O
10 O
weeks O
later O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
severe O
neurotoxicity B-Disease
caused O
by O
nelarabine O
in O
a O
patient O
who O
received O
concurrent O
it O
chemotherapy O
. O

valproate O
- O
induced O
hyperammonemic B-Disease
encephalopathy B-Disease
in O
a O
renal O
transB-Planted O
patient O
. O

neurological B-Disease
complications I-Disease
after O
renal O
transB-Plantation O
constitute O
an O
important O
cause O
of O
morbidity O
and O
mortality O
. O

valproate O
- O
induced O
hyperammonemic B-Disease
encephalopathy B-Disease
is O
an O
uncommon O
but O
serious O
effect O
of O
valproate O
treatment O
. O

here O
, O
we O
describe O
the O
case O
of O
a O
15 O
- O
year O
- O
old O
girl O
who O
was O
on O
a O
long O
- O
term O
therapy O
with O
valproate O
due O
to O
epilepsy B-Disease
and O
revealed O
impaired B-Disease
consciousness I-Disease
with O
hyperammonemia B-Disease
12 O
days O
after O
renal O
transB-Plantation O
. O

necrotising B-Disease
fasciitis I-Disease
after O
bortezomib O
and O
dexamethasone O
- O
containing O
regimen O
in O
an O
elderly O
patient O
of O
waldenstrom B-Disease
macroglobulinaemia I-Disease
. O

bortezomib O
and O
high O
- O
dose O
dexamethasone O
- O
containing O
regimens O
are O
considered O
to O
be O
generally O
tolerable O
with O
few O
severe O
bacterial B-Disease
infections I-Disease
in O
patients O
with O
b O
- O
cell O
malignancies B-Disease
. O

we O
report O
a O
case O
of O
a O
76 O
- O
year O
- O
old O
man O
with O
waldenstrom B-Disease
macroglobulinaemia I-Disease
who O
suffered O
necrotising B-Disease
fasciitis I-Disease
without O
neutropenia B-Disease
after O
the O
combination O
treatment O
with O
bortezomib O
, O
high O
- O
dose O
dexamethasone O
and O
rituximab O
. O

physicians O
should O
recognise O
the O
possibility O
of O
fatal O
bacterial B-Disease
infections I-Disease
related O
to O
bortezomib O
plus O
high O
- O
dose O
dexamethasone O
in O
elderly O
patients O
, O
and O
we O
believe O
this O
case O
warrants O
further O
investigation O
. O

an O
integrated O
characterization O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
in O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

many O
efficacious O
cancer B-Disease
treatments O
cause O
significant O
cardiac O
morbidity O
, O
yet O
biomarkers O
or O
functional O
indices O
of O
early O
damage O
, O
which O
would O
allow O
monitoring O
and O
intervention O
, O
are O
lacking O
. O

in O
this O
study O
, O
we O
have O
utilized O
a O
rat O
model O
of O
progressive O
doxorubicin O
( O
dox O
) O
- O
induced O
cardiomyopathy B-Disease
, O
applying O
multiple O
approaches O
, O
including O
cardiac O
magnetic O
resonance O
imaging O
( O
mri O
) O
, O
to O
provide O
the O
most O
comprehensive O
characterization O
to O
date O
of O
the O
timecourse O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
underlying O
this O
toxicity B-Disease
. O

electron O
microscopy O
of O
the O
myocardium O
revealed O
subcellular B-Disease
degeneration I-Disease
and O
marked O
mitochondrial O
changes O
after O
a O
single O
dose O
. O

histopathological O
analysis O
revealed O
progressive O
cardiomyocyte B-Disease
degeneration I-Disease
, O
hypertrophy B-Disease
/ O
cytomegaly O
, O
and O
extensive O
vacuolation O
after O
two O
doses O
. O

extensive O
replacement O
fibrosis B-Disease
( O
quantified O
by O
sirius O
red O
staining O
) O
developed O
during O
the O
off O
- O
dosing O
period O
. O

functional O
indices O
assessed O
by O
cardiac O
mri O
( O
including O
left O
ventricular O
ejection O
fraction O
( O
lvef O
) O
, O
cardiac O
output O
, O
and O
e O
/ O
a O
ratio O
) O
declined O
progressively O
, O
reaching O
statistical O
significance O
after O
two O
doses O
and O
culminating O
in O
nan O
clinical O
nan O
lv B-Disease
dysfunction I-Disease
by O
12 O
weeks O
. O

troponin O
i O
levels O
positively O
correlated O
with O
delayed O
and O
peak O
gadolinium O
contrast O
enhancement O
, O
histopathological O
grading O
, O
and O
diastolic B-Disease
dysfunction I-Disease
. O

in O
summary O
, O
subcellular O
cardiomyocyte B-Disease
degeneration I-Disease
was O
the O
earliest O
marker O
, O
followed O
by O
progressive O
functional O
decline O
and O
histopathological O
manifestations O
. O

however O
, O
all O
indices O
predated O
nan O
clinical O
nan O
lv B-Disease
dysfunction I-Disease
and O
thus O
warrant O
further O
evaluation O
as O
predictive O
biomarkers O
. O

intradermal O
glutamate O
and O
capsaicin O
injections O
: O
intra O
- O
and O
interindividual O
variability O
of O
provoked O
hyperalgesia B-Disease
and O
allodynia B-Disease
. O

intradermal O
injections O
of O
glutamate O
and O
capsaicin O
are O
attractive O
to O
use O
in O
human O
experimental O
pain B-Disease
models O
because O
hyperalgesia B-Disease
and O
allodynia B-Disease
mimic O
isolated O
aspects O
of O
clinical O
pain B-Disease
disorders I-Disease
. O

magnitudes O
of O
secondary O
pinprick O
hyperalgesia B-Disease
and O
brush O
- O
evoked O
allodynia B-Disease
were O
investigated O
using O
von O
frey O
filaments O
( O
gauges O
10 O
, O
15 O
, O
60 O
and O
100 O
g O
) O
and O
brush O
strokes O
. O

areas O
of O
secondary B-Disease
hyperalgesia I-Disease
and O
allodynia B-Disease
were O
quantified O
immediately O
after O
injection O
and O
after O
15 O
, O
30 O
and O
60 O
min O
. O

secondary O
pinprick O
hyperalgesia B-Disease
was O
observed O
as O
a O
marked O
increase O
in O
the O
visual O
analogue O
scale O
( O
vas O
) O
response O
to O
von O
frey O
gauges O
60 O
and O
100 O
g O
( O
p O
< O
0 O
. O

1 O
) O
after O
glutamate O
injection O
. O

for O
capsaicin O
, O
secondary O
pinprick O
hyperalgesia B-Disease
was O
detected O
with O
all O
von O
frey O
gauges O
( O
p O
< O
0 O
. O

1 O
) O
. O

capsaicin O
injection O
was O
reproducible O
for O
secondary B-Disease
hyperalgesia I-Disease
( O
icc O
> O
0 O
. O

70 O
) O
and O
allodynia B-Disease
( O
icc O
> O
0 O
. O

71 O
) O
. O

intra O
- O
individual O
variability O
was O
generally O
lower O
for O
the O
vas O
response O
to O
von O
frey O
and O
brush O
compared O
with O
areas O
of O
secondary B-Disease
hyperalgesia I-Disease
and O
allodynia B-Disease
. O

in O
conclusion O
, O
glutamate O
and O
capsaicin O
yield O
reproducible O
hyperalgesic B-Disease
and O
allodynic B-Disease
responses O
, O
and O
the O
present O
model O
is O
well O
suited O
for O
basic O
research O
, O
as O
well O
as O
for O
assessing O
the O
modulation O
of O
central O
phenomena O
. O

ocular O
- O
specific O
er O
stress O
reduction O
rescues O
glaucoma B-Disease
in O
murine O
glucocorticoid O
- O
induced O
glaucoma B-Disease
. O

administration O
of O
glucocorticoids O
induces O
ocular B-Disease
hypertension I-Disease
in O
some O
patients O
. O

if O
untreated O
, O
these O
patients O
can O
develop O
a O
secondary O
glaucoma B-Disease
that O
resembles O
primary B-Disease
open I-Disease
- I-Disease
angle I-Disease
glaucoma I-Disease
( O
poag B-Disease
) O
. O

the O
underlying O
pathology O
of O
glucocorticoid O
- O
induced O
glaucoma B-Disease
is O
not O
fully O
understood O
, O
due O
in O
part O
to O
lack O
of O
an O
appropriate O
animal O
model O
. O

here O
, O
we O
developed O
a O
murine O
model O
of O
glucocorticoid O
- O
induced O
glaucoma B-Disease
that O
exhibits O
glaucoma B-Disease
features O
that O
are O
observed O
in O
patients O
. O

treatment O
of O
wt O
mice O
with O
topical O
ocular O
0 O
. O

1 O
% O
dexamethasone O
led O
to O
elevation O
of O
intraocular O
pressure O
( O
iop O
) O
, O
functional O
and O
structural O
loss O
of O
retinal B-Disease
ganglion I-Disease
cells O
, O
and O
axonal B-Disease
degeneration I-Disease
, O
resembling O
glucocorticoid O
- O
induced O
glaucoma B-Disease
in O
human O
patients O
. O

furthermore O
, O
dexamethasone O
- O
induced O
ocular B-Disease
hypertension I-Disease
was O
associated O
with O
chronic O
er O
stress O
of O
the O
trabecular O
meshwork O
( O
tm O
) O
. O

dexamethasone O
induced O
the O
transcriptional O
factor O
chop O
, O
a O
marker O
for O
chronic O
er O
stress O
, O
in O
the O
anterior O
segment O
tissues O
, O
and O
chop O
deletion O
reduced O
er O
stress O
in O
these O
tissues O
and O
prevented O
dexamethasone O
- O
induced O
ocular B-Disease
hypertension I-Disease
. O

furthermore O
, O
reduction O
of O
er O
stress O
in O
the O
tm O
with O
sodium O
4 O
- O
phenylbutyrate O
prevented O
dexamethasone O
- O
induced O
ocular B-Disease
hypertension I-Disease
in O
wt O
mice O
. O

our O
data O
indicate O
that O
er O
stress O
contributes O
to O
glucocorticoid O
- O
induced O
ocular B-Disease
hypertension I-Disease
and O
suggest O
that O
reducing O
er O
stress O
has O
potential O
as O
a O
therapeutic O
strategy O
for O
treating O
glucocorticoid O
- O
induced O
glaucoma B-Disease
. O

effects O
of O
ginsenosides O
on O
opioid O
- O
induced O
hyperalgesia B-Disease
in O
mice O
. O

opioid O
- O
induced O
hyperalgesia B-Disease
( O
oih B-Disease
) O
is O
characterized O
by O
nociceptive O
sensitization O
caused O
by O
the O
cessation O
of O
chronic O
opioid O
use O
. O

oih B-Disease
can O
limit O
the O
clinical O
use O
of O
opioid O
analgesics O
and O
complicate O
withdrawal O
from O
opioid B-Disease
addiction I-Disease
. O

in O
this O
study O
, O
we O
investigated O
the O
effects O
of O
re O
, O
rg1 O
, O
and O
rb1 O
ginsenosides O
, O
the O
bioactive O
components O
of O
ginseng O
, O
on O
oih B-Disease
. O

oih B-Disease
was O
achieved O
in O
mice O
after O
subcutaneous O
administration O
of O
morphine O
for O
7 O
consecutive O
days O
three O
times O
per O
day O
. O

re O
( O
300 O
mg O
/ O
kg O
) O
inhibited O
oih B-Disease
in O
both O
the O
thermal O
sensitivity O
test O
and O
the O
acetic O
acid O
- O
induced O
writhing O
test O
. O

however O
, O
the O
rg1 O
and O
rb1 O
ginsenosides O
failed O
to O
prevent O
oih B-Disease
in O
either O
test O
. O

furthermore O
, O
rg1 O
showed O
a O
tendency O
to O
aggravate O
oih B-Disease
in O
the O
acetic O
acid O
- O
induced O
writhing O
test O
. O

our O
data O
suggested O
that O
the O
ginsenoside O
re O
, O
but O
not O
rg1 O
or O
rb1 O
, O
may O
contribute O
toward O
reversal O
of O
oih B-Disease
. O

the O
primary O
outcome O
of O
this O
study O
was O
a O
composite O
of O
severe O
hypotension B-Disease
( O
mean O
arterial O
pressure O
< O
60 O
mm O
hg O
) O
and O
bradycardia B-Disease
( O
heart O
rate O
< O
50 O
beats O
/ O
min O
) O
during O
sedative O
infusion O
. O

when O
analyzed O
separately O
, O
no O
differences O
could O
be O
found O
in O
the O
prevalence O
of O
severe O
hypotension B-Disease
or O
bradycardia B-Disease
in O
either O
the O
unmatched O
or O
matched O
cohorts O
. O

conclusions O
: O
severe O
hypotension B-Disease
and O
bradycardia B-Disease
occur O
at O
similar O
prevalence O
in O
neurocritical O
care O
patients O
who O
receive O
dexmedetomidine O
or O
propofol O
. O

providers O
should O
similarly O
consider O
the O
likelihood O
of O
hypotension B-Disease
or O
bradycardia B-Disease
before O
starting O
either O
sedative O
. O

hydroxytyrosol O
ameliorates O
oxidative O
stress O
and O
mitochondrial B-Disease
dysfunction I-Disease
in O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
in O
rats O
with O
breast B-Disease
cancer I-Disease
. O

oxidative O
stress O
is O
involved O
in O
several O
processes O
including O
cancer B-Disease
, O
aging O
and O
cardiovascular B-Disease
disease I-Disease
, O
and O
has O
been O
shown O
to O
potentiate O
the O
therapeutic O
effect O
of O
drugs O
such O
as O
doxorubicin O
. O

doxorubicin O
causes O
significant O
cardiotoxicity B-Disease
characterized O
by O
marked O
increases O
in O
oxidative O
stress O
and O
mitochondrial B-Disease
dysfunction I-Disease
. O

herein O
, O
we O
investigate O
whether O
doxorubicin O
- O
associated O
chronic O
cardiac B-Disease
toxicity I-Disease
can O
be O
ameliorated O
with O
the O
antioxidant O
hydroxytyrosol O
in O
rats O
with O
breast B-Disease
cancer I-Disease
. O

thirty O
- O
six O
rats O
bearing O
breast B-Disease
tumors I-Disease
induced O
chemically O
were O
divided O
into O
4 O
groups O
: O
control O
, O
hydroxytyrosol O
( O
0 O
. O

5mg O
/ O
kg O
, O
5days O
/ O
week O
) O
, O
doxorubicin O
( O
1mg O
/ O
kg O
/ O
week O
) O
, O
and O
doxorubicin O
plus O
hydroxytyrosol O
. O

cardiac B-Disease
disturbances I-Disease
at O
the O
cellular O
and O
mitochondrial O
level O
, O
mitochondrial O
electron O
transport O
chain O
complexes O
i O
- O
iv O
and O
apoptosis O
- O
inducing O
factor O
, O
and O
oxidative O
stress O
markers O
have O
been O
analyzed O
. O

hydroxytyrosol O
improved O
the O
cardiac B-Disease
disturbances I-Disease
enhanced O
by O
doxorubicin O
by O
significantly O
reducing O
the O
percentage O
of O
altered O
mitochondria O
and O
oxidative O
damage O
. O

this O
study O
demonstrates O
that O
hydroxytyrosol O
protect O
rat O
heart B-Disease
damage I-Disease
provoked O
by O
doxorubicin O
decreasing O
oxidative O
damage O
and O
mitochondrial O
alterations O
. O

amiodarone O
- O
induced O
myxoedema B-Disease
coma I-Disease
. O

a O
62 O
- O
year O
- O
old O
man O
was O
found O
to O
have O
bradycardia B-Disease
, O
hypothermia B-Disease
and O
respiratory B-Disease
failure I-Disease
3 O
weeks O
after O
initiation O
of O
amiodarone O
therapy O
for O
atrial B-Disease
fibrillation I-Disease
. O

the O
only O
two O
cases O
of O
amiodarone O
- O
induced O
myxoedema B-Disease
coma I-Disease
in O
the O
literature O
report O
patient O
death O
despite O
supportive O
therapy O
and O
thyroid O
hormone O
replacement O
. O

this O
case O
represents O
the O
most O
thoroughly O
investigated O
case O
of O
amiodarone O
- O
induced O
myxoedema B-Disease
coma I-Disease
with O
a O
history O
significant O
for O
subclinical O
thyroid B-Disease
disease I-Disease
. O

use O
of O
argatroban O
and O
catheter O
- O
directed O
thrombolysis B-Disease
with O
alteplase O
in O
an O
oncology O
patient O
with O
heparin O
- O
induced O
thrombocytopenia B-Disease
with O
thrombosis B-Disease
. O

purpose O
: O
the O
case O
of O
an O
oncology O
patient O
who O
developed O
heparin O
- O
induced O
thrombocytopenia B-Disease
with O
thrombosis B-Disease
( O
hitt B-Disease
) O
and O
was O
treated O
with O
argatroban O
plus O
catheter O
- O
directed O
thrombolysis B-Disease
( O
cdt O
) O
with O
alteplase O
is O
presented O
. O

summary O
: O
a O
63 O
- O
year O
- O
old O
caucasian O
man O
with O
renal O
amyloidosis B-Disease
undergoing O
peripheral O
blood O
stem O
cell O
collection O
for O
an O
autologous O
stem O
cell O
transB-Plant O
developed O
extensive O
bilateral O
upper B-Disease
- I-Disease
extremity I-Disease
deep I-Disease
venous I-Disease
thrombosis I-Disease
( O
dvt B-Disease
) O
and O
pulmonary B-Disease
embolism I-Disease
secondary O
to O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

after O
one O
week O
of O
therapy O
, O
he O
was O
transferred O
to O
the O
intensive O
care O
unit O
with O
cardiopulmonary O
compromise O
related O
to O
superior B-Disease
vena I-Disease
cava I-Disease
( I-Disease
svc I-Disease
) I-Disease
syndrome I-Disease
. O

a O
percutaneous O
mechanical O
thrombectomy O
and O
cdt O
with O
alteplase O
were O
attempted O
, O
but O
the O
procedure O
was O
aborted O
due O
to O
epistaxis B-Disease
. O

the O
epistaxis B-Disease
resolved O
the O
next O
day O
, O
and O
the O
patient O
was O
restarted O
on O
argatroban O
. O

although O
the O
patient O
recovered O
, O
he O
experienced O
permanent O
vision B-Disease
and I-Disease
hearing I-Disease
loss I-Disease
, O
as O
well O
as O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
. O

conclusion O
: O
a O
63 O
- O
year O
- O
old O
man O
with O
renal O
amyloidosis B-Disease
and O
svc B-Disease
syndrome I-Disease
secondary O
to O
hitt B-Disease
was O
successfully O
treated O
with O
argatroban O
and O
cdt O
with O
alteplase O
. O

effects O
of O
dehydroepiandrosterone O
in O
amphetamine O
- O
induced O
schizophrenia B-Disease
models O
in O
mice O
. O

objective O
: O
to O
examine O
the O
effects O
of O
dehydroepiandrosterone O
( O
dhea O
) O
on O
animal O
models O
of O
schizophrenia B-Disease
. O

amphetamine O
( O
3 O
mg O
/ O
kg O
ip O
) O
induced O
hyper B-Disease
locomotion O
, O
apomorphine O
( O
1 O
. O

5 O
mg O
/ O
kg O
subcutaneously O
[ O
sc O
] O
) O
induced O
climbing O
, O
and O
haloperidol O
( O
1 O
. O

5 O
mg O
/ O
kg O
sc O
) O
induced O
catalepsy B-Disease
tests O
were O
used O
as O
animal O
models O
of O
schizophrenia B-Disease
. O

statistical O
analysis O
was O
carried O
out O
using O
kruskal O
- O
wallis O
test O
for O
hyper B-Disease
locomotion O
, O
and O
one O
- O
way O
anova O
for O
climbing O
and O
catalepsy B-Disease
tests O
. O

there O
was O
a O
significant O
difference O
between O
groups O
in O
the O
haloperidol O
- O
induced O
catalepsy B-Disease
test O
( O
p O
< O
0 O
. O

5 O
) O
. O

conclusion O
: O
we O
observed O
that O
dhea O
reduced O
locomotor O
activity O
and O
increased O
catalepsy B-Disease
at O
both O
doses O
, O
while O
it O
had O
no O
effect O
on O
climbing O
behavior O
. O

we O
suggest O
that O
dhea O
displays O
typical O
neuroleptic O
- O
like O
effects O
, O
and O
may O
be O
used O
in O
the O
treatment O
of O
schizophrenia B-Disease
. O

availability O
of O
human O
induced O
pluripotent O
stem O
cell O
- O
derived O
cardiomyocytes O
in O
assessment O
of O
drug O
potential O
for O
qt B-Disease
prolongation I-Disease
. O

however O
, O
there O
is O
no O
report O
showing O
that O
this O
technique O
can O
be O
used O
to O
predict O
multichannel O
blocker O
potential O
for O
qt B-Disease
prolongation I-Disease
. O

the O
aim O
of O
this O
study O
is O
to O
show O
that O
fpd O
from O
mea O
( O
multielectrode O
array O
) O
of O
hips O
- O
cms O
can O
detect O
qt B-Disease
prolongation I-Disease
induced O
by O
multichannel O
blockers O
. O

finally O
, O
the O
ikr O
blockers O
, O
terfenadine O
and O
citalopram O
, O
which O
are O
reported O
to O
cause O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
in O
clinical O
practice O
, O
produced O
early O
afterdepolarization O
( O
ead O
) O
. O

this O
study O
also O
shows O
that O
this O
assay O
can O
help O
detect O
ead O
for O
drugs O
with O
tdp B-Disease
potential O
. O

dermal O
developmental O
toxicity B-Disease
of O
n O
- O
phenylimide O
herbicides O
in O
rats O
. O

background O
: O
s O
- O
53482 O
and O
s O
- O
23121 O
are O
n O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality B-Disease
, O
teratogenicity B-Disease
( O
mainly O
ventricular B-Disease
septal I-Disease
defects I-Disease
and O
wavy O
ribs O
) O
, O
and O
growth B-Disease
retardation I-Disease
in O
rats O
in O
conventional O
oral O
developmental O
toxicity B-Disease
studies O
. O

our O
objective O
in O
this O
study O
was O
to O
investigate O
whether O
the O
compounds O
induce O
developmental O
toxicity B-Disease
via O
the O
dermal O
route O
, O
which O
is O
more O
relevant O
to O
occupational O
exposure O
, O
hence O
better O
addressing O
human O
health O
risks O
. O

results O
: O
dermal O
exposure O
of O
rats O
to O
s O
- O
53482 O
at O
300 O
mg O
/ O
kg O
produced O
patterns O
of O
developmental O
toxicity B-Disease
similar O
to O
those O
resulting O
from O
oral O
exposure O
. O

toxicity B-Disease
included O
embryolethality B-Disease
, O
teratogenicity B-Disease
, O
and O
growth B-Disease
retardation I-Disease
. O

dermal O
administration O
of O
s O
- O
23121 O
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic B-Disease
death I-Disease
and O
ventricular B-Disease
septal I-Disease
defect I-Disease
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
s O
- O
23121 O
. O

conclusions O
: O
based O
on O
the O
results O
, O
s O
- O
53482 O
and O
s O
- O
23121 O
were O
teratogenic B-Disease
when O
administered O
dermally O
to O
pregnant O
rats O
as O
were O
the O
compounds O
administered O
orally O
. O

rates O
of O
renal B-Disease
toxicity I-Disease
in O
cancer B-Disease
patients O
receiving O
cisplatin O
with O
and O
without O
mannitol O
. O

one O
of O
the O
major O
complications O
of O
cisplatin O
use O
is O
dose O
- O
limiting O
nephrotoxicity B-Disease
. O

there O
are O
many O
strategies O
to O
prevent O
this O
toxicity B-Disease
, O
including O
the O
use O
of O
mannitol O
as O
a O
nephroprotectant O
in O
combination O
with O
hydration O
. O

objective O
: O
we O
aimed O
to O
evaluate O
the O
rates O
of O
cisplatin O
- O
induced O
nephrotoxicity B-Disease
in O
cancer B-Disease
patients O
receiving O
single O
- O
agent O
cisplatin O
with O
and O
without O
mannitol O
. O

data O
were O
collected O
on O
adult O
cancer B-Disease
patients O
receiving O
single O
- O
agent O
cisplatin O
as O
an O
outpatient O
from O
january O
2011 O
to O
september O
2012 O
. O

the O
primary O
outcome O
was O
acute B-Disease
kidney I-Disease
injury I-Disease
( O
aki B-Disease
) O
. O

results O
: O
we O
evaluated O
143 O
patients O
who O
received O
single O
- O
agent O
cisplatin O
; O
97 O
. O

2 O
% O
of O
patients O
had O
head B-Disease
and I-Disease
neck I-Disease
cancer I-Disease
as O
their O
primary O
malignancy B-Disease
. O

patients O
who O
did O
not O
receive O
mannitol O
were O
more O
likely O
to O
develop O
nephrotoxicity B-Disease
: O
odds O
ratio O
[ O
or O
] O
= O
2 O
. O

646 O
( O
95 O
% O
ci O
= O
1 O
. O

8 O
, O
6 O
. O

944 O
; O
p O
= O
0 O
. O

48 O
) O
. O

patients O
who O
received O
the O
100 O
mg O
/ O
m O
( O
2 O
) O
dosing O
and O
patients O
who O
had O
a O
history O
of O
hypertension B-Disease
also O
had O
a O
higher O
likelihood O
of O
developing O
nephrotoxicity B-Disease
: O
or O
= O
11 O
. O

494 O
( O
95 O
% O
ci O
= O
4 O
. O

149 O
, O
32 O
. O

258 O
; O
p O
< O
0 O
. O

1 O
) O
and O
or O
= O
3 O
. O

219 O
( O
95 O
% O
ci O
= O
1 O
. O

228 O
, O
8 O
. O

439 O
; O
p O
= O
0 O
. O

17 O
) O
, O
respectively O
. O

conclusions O
: O
when O
limited O
quantities O
of O
mannitol O
are O
available O
, O
it O
should O
preferentially O
be O
given O
to O
patients O
at O
particularly O
high O
risk O
of O
nephrotoxicity B-Disease
. O

our O
analysis O
suggests O
that O
those O
patients O
receiving O
the O
dosing O
schedule O
of O
100 O
mg O
/ O
m O
( O
2 O
) O
cisplatin O
every O
3 O
weeks O
and O
those O
with O
hypertension B-Disease
are O
at O
the O
greatest O
risk O
of O
nephrotoxicity B-Disease
and O
would O
benefit O
from O
the O
addition O
of O
mannitol O
. O

metformin O
protects O
against O
seizures B-Disease
, O
learning B-Disease
and I-Disease
memory I-Disease
impairments I-Disease
and O
oxidative O
damage O
induced O
by O
pentylenetetrazole O
- O
induced O
kindling O
in O
mice O
. O

cognitive B-Disease
impairment I-Disease
, O
the O
most O
common O
and O
severe O
comorbidity O
of O
epilepsy B-Disease
, O
greatly O
diminishes O
the O
quality O
of O
life O
. O

however O
, O
current O
therapeutic O
interventions O
for O
epilepsy B-Disease
can O
also O
cause O
untoward O
cognitive O
effects O
. O

thus O
, O
there O
is O
an O
urgent O
need O
for O
new O
kinds O
of O
agents O
targeting O
both O
seizures B-Disease
and O
cognition B-Disease
deficits I-Disease
. O

oxidative O
stress O
is O
considered O
to O
play O
an O
important O
role O
in O
epileptogenesis O
and O
cognitive B-Disease
deficits I-Disease
, O
and O
antioxidants O
have O
a O
putative O
antiepileptic O
potential O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
ameliorative O
effects O
of O
metformin O
on O
seizures B-Disease
, O
cognitive B-Disease
impairment I-Disease
and O
brain O
oxidative O
stress O
markers O
observed O
in O
pentylenetetrazole O
- O
induced O
kindling O
animals O
. O

we O
found O
that O
metformin O
suppressed O
the O
progression O
of O
kindling O
, O
ameliorated O
the O
cognitive B-Disease
impairment I-Disease
and O
decreased O
brain O
oxidative O
stress O
. O

thus O
the O
present O
study O
concluded O
that O
metformin O
may O
be O
a O
potential O
agent O
for O
the O
treatment O
of O
epilepsy B-Disease
as O
well O
as O
a O
protective O
medicine O
against O
cognitive B-Disease
impairment I-Disease
induced O
by O
seizures B-Disease
. O

p53 O
inhibition O
exacerbates O
late O
- O
stage O
anthracycline O
cardiotoxicity B-Disease
. O

aims O
: O
doxorubicin O
( O
dox O
) O
is O
an O
effective O
anti O
- O
cancer B-Disease
therapeutic O
, O
but O
is O
associated O
with O
both O
acute O
and O
late O
- O
stage O
cardiotoxicity B-Disease
. O

children O
are O
particularly O
sensitive O
to O
dox O
- O
induced O
heart B-Disease
failure I-Disease
. O

here O
, O
the O
impact O
of O
p53 O
inhibition O
on O
acute O
vs O
. O

late O
- O
stage O
dox O
cardiotoxicity B-Disease
was O
examined O
in O
a O
juvenile O
model O
. O

furthermore O
, O
these O
data O
suggest O
an O
explanation O
as O
to O
how O
p53 O
inhibition O
can O
result O
in O
cardioprotection O
during O
drug O
treatment O
and O
, O
paradoxically O
, O
enhanced O
cardiotoxicity B-Disease
long O
after O
the O
cessation O
of O
drug O
treatment O
. O

metronidazole O
- O
induced O
encephalopathy B-Disease
: O
an O
uncommon O
scenario O
. O

we O
present O
a O
case O
where O
a O
patient O
developed O
features O
of O
encephalopathy B-Disease
following O
prolonged O
metronidazole O
intake O
. O

the O
diagnosis O
of O
metronidazole O
toxicity B-Disease
was O
made O
by O
the O
mri O
findings O
and O
supported O
clinically O
. O

aconitine O
- O
induced O
ca2 O
+ O
overload O
causes O
arrhythmia B-Disease
and O
triggers O
apoptosis O
through O
p38 O
mapk O
signaling O
pathway O
in O
rats O
. O

emerging O
evidence O
indicates O
that O
voltage O
- O
dependent O
na O
( O
+ O
) O
channels O
have O
pivotal O
roles O
in O
the O
cardiotoxicity B-Disease
of O
aconitine O
. O

however O
, O
no O
reports O
are O
available O
on O
the O
role O
of O
ca O
( O
2 O
+ O
) O
in O
aconitine O
poisoning B-Disease
. O

in O
this O
study O
, O
we O
explored O
the O
importance O
of O
pathological O
ca O
( O
2 O
+ O
) O
signaling O
in O
aconitine O
poisoning B-Disease
in O
vitro O
and O
in O
vivo O
. O

we O
found O
that O
ca O
( O
2 O
+ O
) O
overload O
lead O
to O
accelerated O
beating O
rhythm O
in O
adult O
rat O
ventricular O
myocytes O
and O
caused O
arrhythmia B-Disease
in O
conscious O
freely O
moving O
rats O
. O

to O
investigate O
effects O
of O
aconitine O
on O
myocardial B-Disease
injury I-Disease
, O
we O
performed O
cytotoxicity B-Disease
assay O
in O
neonatal O
rat O
ventricular O
myocytes O
( O
nrvms O
) O
, O
as O
well O
as O
measured O
lactate O
dehydrogenase O
level O
in O
the O
culture O
medium O
of O
nrvms O
and O
activities O
of O
serum O
cardiac O
enzymes O
in O
rats O
. O

the O
results O
showed O
that O
aconitine O
resulted O
in O
myocardial B-Disease
injury I-Disease
and O
reduced O
nrvms O
viability O
dose O
- O
dependently O
. O

hence O
, O
our O
results O
suggest O
that O
aconitine O
significantly O
aggravates O
ca O
( O
2 O
+ O
) O
overload O
and O
causes O
arrhythmia B-Disease
and O
finally O
promotes O
apoptotic O
development O
via O
phosphorylation O
of O
p38 O
mitogen O
- O
activated O
protein O
kinase O
. O

chronic O
treatment O
with O
metformin O
suppresses O
toll O
- O
like O
receptor O
4 O
signaling O
and O
attenuates O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
following O
myocardial B-Disease
infarction I-Disease
. O

acute O
treatment O
with O
metformin O
has O
a O
protective O
effect O
in O
myocardial B-Disease
infarction I-Disease
by O
suppression O
of O
inflammatory O
responses O
due O
to O
activation O
of O
amp O
- O
activated O
protein O
kinase O
( O
ampk O
) O
. O

in O
the O
present O
study O
, O
the O
effect O
of O
chronic O
pre O
- O
treatment O
with O
metformin O
on O
cardiac B-Disease
dysfunction I-Disease
and O
toll O
- O
like O
receptor O
4 O
( O
tlr4 O
) O
activities O
following O
myocardial B-Disease
infarction I-Disease
and O
their O
relation O
with O
ampk O
were O
assessed O
. O

isoproterenol O
( O
100mg O
/ O
kg O
) O
was O
injected O
subcutaneously O
on O
the O
13th O
and O
14th O
days O
to O
induce O
acute B-Disease
myocardial I-Disease
infarction I-Disease
. O

the O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
was O
significantly O
lower O
in O
the O
groups O
treated O
with O
25 O
and O
50mg O
/ O
kg O
of O
metformin O
. O

metfromin O
markedly O
lowered O
isoproterenol O
- O
induced O
elevation O
in O
the O
levels O
of O
tlr4 O
mrna O
, O
myeloid O
differentiation O
protein O
88 O
( O
myd88 O
) O
, O
tumor B-Disease
necrosis B-Disease
factor O
- O
alpha O
( O
tnf O
- O
a O
) O
, O
and O
interleukin O
6 O
( O
il O
- O
6 O
) O
in O
the O
heart O
tissues O
. O

chronic O
pre O
- O
treatment O
with O
metformin O
reduces O
post O
- O
myocardial B-Disease
infarction I-Disease
cardiac O
dysfunction O
and O
suppresses O
inflammatory O
responses O
, O
possibly O
through O
inhibition O
of O
tlr4 O
activities O
. O

two O
cases O
of O
propylthiouracil O
- O
associated O
acute O
hepatitis B-Disease
, O
one O
case O
of O
fatal O
methimazole O
- O
associated O
hepatocellular B-Disease
necrosis I-Disease
and O
one O
case O
of O
propylthiouracil O
- O
associated O
lupus B-Disease
- I-Disease
like I-Disease
syndrome I-Disease
are O
described O
. O

it O
is O
concluded O
that O
in O
most O
circumstances O
131i O
is O
the O
therapy O
of O
choice O
for O
hyperthyroidism B-Disease
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
induced O
by O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
in O
a O
japanese O
patient O
with O
huntington B-Disease
' I-Disease
s I-Disease
disease I-Disease
at O
the O
terminal O
stage O
of O
recurrent O
breast B-Disease
cancer I-Disease
. O

we O
herein O
describe O
the O
case O
of O
an O
81 O
- O
year O
- O
old O
japanese O
woman O
with O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride O
( O
75 O
mg O
/ O
day O
) O
and O
tetrabenazine O
( O
12 O
. O

5 O
mg O
/ O
day O
) O
for O
huntington B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

she O
also O
had O
advanced O
breast B-Disease
cancer I-Disease
when O
the O
combination O
therapy O
was O
initiated O
. O

to O
the O
best O
of O
our O
knowledge O
, O
the O
occurrence O
of O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
due O
to O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
has O
not O
been O
previously O
reported O
. O

a O
metoprolol O
- O
terbinafine O
combination O
induced O
bradycardia B-Disease
. O

to O
report O
a O
sinus B-Disease
bradycardia I-Disease
induced O
by O
metoprolol O
and O
terbinafine O
drug O
- O
drug O
interaction O
and O
its O
management O
. O

a O
63 O
year O
- O
old O
caucasian O
man O
on O
metoprolol O
200 O
mg O
/ O
day O
for O
stable O
coronary B-Disease
artery I-Disease
disease I-Disease
was O
prescribed O
a O
90 O
- O
day O
course O
of O
oral O
terbinafine O
250 O
mg O
/ O
day O
for O
onychomycosis B-Disease
. O

on O
the O
49th O
day O
of O
terbinafine O
therapy O
, O
he O
was O
brought O
to O
the O
emergency O
room O
for O
a O
decrease O
of O
his O
global O
health O
status O
, O
confusion B-Disease
and O
falls O
. O

the O
electrocardiogram O
revealed O
a O
37 O
beats O
/ O
min O
sinus B-Disease
bradycardia I-Disease
. O

a O
score O
of O
7 O
on O
the O
naranjo O
adverse B-Disease
drug I-Disease
reaction I-Disease
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
patient O
' O
s O
sinus B-Disease
bradycardia I-Disease
and O
the O
drug O
interaction O
between O
metoprolol O
and O
terbinafine O
. O

by O
inhibiting O
the O
cytochrome O
p450 O
2d6 O
, O
terbinafine O
had O
decreased O
metoprolol O
' O
s O
clearance O
, O
leading O
in O
metoprolol O
accumulation O
which O
has O
resulted O
in O
clinically O
significant O
sinus B-Disease
bradycardia I-Disease
. O

optochiasmatic O
and O
peripheral B-Disease
neuropathy I-Disease
due O
to O
ethambutol O
overtreatment O
. O

ethambutol O
is O
known O
to O
cause O
optic B-Disease
neuropathy I-Disease
and O
, O
more O
rarely O
, O
axonal O
polyneuropathy B-Disease
. O

we O
characterize O
the O
clinical O
, O
neurophysiological O
, O
and O
neuroimaging O
findings O
in O
a O
72 O
- O
year O
- O
old O
man O
who O
developed O
visual B-Disease
loss I-Disease
and O
paresthesias B-Disease
after O
11 O
weeks O
of O
exposure O
to O
a O
supratherapeutic O
dose O
of O
ethambutol O
. O

this O
case O
demonstrates O
the O
selective O
vulnerability O
of O
the O
anterior O
visual O
pathways O
and O
peripheral O
nerves O
to O
ethambutol O
toxicity B-Disease
. O

testosterone O
ameliorates O
streptozotocin O
- O
induced O
memory B-Disease
impairment I-Disease
in O
male O
rats O
. O

aim O
: O
to O
study O
the O
effects O
of O
testosterone O
on O
streptozotocin O
( O
stz O
) O
- O
induced O
memory B-Disease
impairment I-Disease
in O
male O
rats O
. O

administration O
of O
flutamide O
, O
letrozole O
or O
tamoxifen O
significantly O
impaired B-Disease
the I-Disease
memory I-Disease
in O
intact O
rats O
, O
and O
significantly O
attenuated O
the O
testosterone O
replacement O
in O
improving O
stz O
- O
and O
castration O
- O
induced O
memory B-Disease
impairment I-Disease
. O

conclusion O
: O
testosterone O
administration O
ameliorates O
stz O
- O
and O
castration O
- O
induced O
memory B-Disease
impairment I-Disease
in O
male O
wistar O
rats O
. O

behavioral O
and O
neurochemical O
studies O
in O
mice O
pretreated O
with O
garcinielliptone O
fc O
in O
pilocarpine O
- O
induced O
seizures B-Disease
. O

it O
is O
widely O
used O
in O
folk O
medicine O
to O
treat O
skin B-Disease
diseases I-Disease
in O
both O
humans O
and O
animals O
as O
well O
as O
the O
seed O
decoction O
has O
been O
used O
to O
treat O
diarrheas B-Disease
and O
inflammatory B-Disease
diseases I-Disease
. O

the O
present O
study O
aimed O
to O
evaluate O
the O
gfc O
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg O
/ O
kg O
on O
seizure B-Disease
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino O
acid O
( O
r O
- O
aminobutyric O
acid O
( O
gaba O
) O
, O
glutamine O
, O
aspartate O
and O
glutathione O
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
ache O
) O
activity O
in O
mice O
hippocampus O
after O
seizures B-Disease
. O

gfc O
produced O
an O
increased O
latency O
to O
first O
seizure B-Disease
, O
at O
doses O
25mg O
/ O
kg O
( O
20 O
. O

12 O
+ O
2 O
. O

20 O
min O
) O
, O
50mg O
/ O
kg O
( O
20 O
. O

95 O
+ O
2 O
. O

21 O
min O
) O
or O
75 O
mg O
/ O
kg O
( O
23 O
. O

43 O
+ O
1 O
. O

99 O
min O
) O
when O
compared O
with O
seized O
mice O
. O

the O
results O
indicate O
that O
gfc O
can O
exert O
anticonvulsant O
activity O
and O
reduce O
the O
frequency O
of O
installation O
of O
pilocarpine O
- O
induced O
status B-Disease
epilepticus I-Disease
, O
as O
demonstrated O
by O
increase O
in O
latency O
to O
first O
seizure B-Disease
and O
decrease O
in O
mortality O
rate O
of O
animals O
. O

standard O
operating O
procedures O
for O
antibiotic O
therapy O
and O
the O
occurrence O
of O
acute B-Disease
kidney I-Disease
injury I-Disease
: O
a O
prospective O
, O
clinical O
, O
non O
- O
interventional O
, O
observational O
study O
. O

introduction O
: O
acute B-Disease
kidney I-Disease
injury I-Disease
( O
aki B-Disease
) O
occurs O
in O
7 O
% O
of O
hospitalized O
and O
66 O
% O
of O
intensive O
care O
unit O
( O
icu O
) O
patients O
. O

the O
aim O
of O
this O
study O
was O
to O
investigate O
, O
whether O
there O
is O
an O
association O
between O
adherence O
to O
guidelines O
( O
standard O
operating O
procedures O
( O
sop O
) O
) O
for O
potentially O
nephrotoxic B-Disease
antibiotics O
and O
the O
occurrence O
of O
aki B-Disease
. O

aki B-Disease
was O
defined O
according O
to O
rifle O
criteria O
. O

development O
of O
aki B-Disease
was O
compared O
between O
groups O
with O
exact O
chi2 O
- O
test O
and O
multivariate O
logistic O
regression O
analysis O
( O
two O
- O
sided O
p O
< O
0 O
. O

5 O
) O
. O

aki B-Disease
occurred O
significantly O
more O
often O
in O
lag O
with O
36 O
% O
versus O
21 O
% O
in O
hag O
( O
p O
= O
0 O
. O

35 O
) O
. O

basic O
characteristics O
were O
comparable O
, O
except O
an O
increased O
rate O
of O
soft O
tissue O
infections B-Disease
in O
lag O
. O

multivariate O
analysis O
revealed O
an O
odds O
ratio O
of O
2 O
. O

5 O
- O
fold O
for O
lag O
to O
develop O
aki B-Disease
compared O
with O
hag O
( O
95 O
% O
confidence O
interval O
1 O
. O

195 O
to O
5 O
. O

124 O
, O
p O
= O
0 O
. O

39 O
) O
. O

conclusion O
: O
low O
adherence O
to O
sops O
for O
potentially O
nephrotoxic B-Disease
antibiotics O
was O
associated O
with O
a O
higher O
occurrence O
of O
aki B-Disease
. O

rhabdomyolysis B-Disease
in O
a O
hepatitis B-Disease
c I-Disease
virus I-Disease
infected I-Disease
patient O
treated O
with O
telaprevir O
and O
simvastatin O
. O

a O
46 O
- O
year O
old O
man O
with O
a O
chronic O
hepatitis B-Disease
c I-Disease
virus I-Disease
infection I-Disease
received O
triple O
therapy O
with O
ribavirin O
, O
pegylated O
interferon O
and O
telaprevir O
. O

one O
month O
after O
starting O
the O
antiviral O
therapy O
, O
the O
patient O
was O
admitted O
to O
the O
hospital O
because O
he O
developed O
rhabdomyolysis B-Disease
. O

at O
admission O
simvastatin O
and O
all O
antiviral O
drugs O
were O
discontinued O
because O
toxicity B-Disease
due O
to O
a O
drug O
- O
drug O
interaction O
was O
suspected O
. O

simvastatin O
plasma O
concentration O
increased O
30 O
times O
in O
this O
patient O
and O
statin O
induced O
muscle B-Disease
toxicity I-Disease
is O
related O
to O
the O
concentration O
of O
the O
statin O
in O
blood O
. O

combination O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
vtd O
) O
as O
a O
consolidation O
therapy O
after O
autologous O
stem O
cell O
transB-Plantation O
for O
symptomatic O
multiple B-Disease
myeloma I-Disease
in O
japanese O
patients O
. O

consolidation O
therapy O
for O
patients O
with O
multiple B-Disease
myeloma I-Disease
( O
mm B-Disease
) O
has O
been O
widely O
adopted O
to O
improve O
treatment O
response O
following O
autologous O
stem O
cell O
transB-Plantation O
. O

in O
this O
study O
, O
we O
retrospectively O
analyzed O
the O
safety O
and O
efficacy O
of O
combination O
regimen O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
vtd O
) O
as O
consolidation O
therapy O
in O
24 O
japanese O
patients O
with O
newly O
diagnosed O
mm B-Disease
. O

grade O
3 O
- O
4 O
neutropenia B-Disease
and O
thrombocytopenia B-Disease
were O
documented O
in O
four O
and O
three O
patients O
( O
17 O
and O
13 O
% O
) O
, O
respectively O
, O
but O
drug O
dose O
reduction O
due O
to O
cytopenia B-Disease
was O
not O
required O
in O
any O
case O
. O

peripheral B-Disease
neuropathy I-Disease
was O
common O
( O
63 O
% O
) O
, O
but O
severe O
grade O
3 O
- O
4 O
peripheral B-Disease
neuropathy I-Disease
was O
not O
observed O
. O

conversion O
to O
sirolimus O
ameliorates O
cyclosporine O
- O
induced O
nephropathy B-Disease
in O
the O
rat O
: O
focus O
on O
serum O
, O
urine O
, O
gene O
, O
and O
protein O
renal O
expression O
biomarkers O
. O

protocols O
of O
conversion O
from O
cyclosporin O
a O
( O
csa O
) O
to O
sirolimus O
( O
srl O
) O
have O
been O
widely O
used O
in O
immunotherapy O
after O
transB-Plantation O
to O
prevent O
csa O
- O
induced O
nephropathy B-Disease
, O
but O
the O
molecular O
mechanisms O
underlying O
these O
protocols O
remain O
nuclear O
. O

renal B-Disease
lesions I-Disease
were O
analyzed O
in O
hematoxylin O
and O
eosin O
, O
periodic O
acid O
- O
schiff O
, O
and O
masson O
' O
s O
trichrome O
stains O
. O

srl O
- O
treated O
rats O
presented O
proteinuria B-Disease
and O
ngal O
( O
serum O
and O
urinary O
) O
as O
the O
best O
markers O
of O
renal B-Disease
impairment I-Disease
. O

short O
csa O
treatment O
presented O
slight O
or O
even O
absent O
kidney B-Disease
lesions I-Disease
and O
tgf O
- O
b O
, O
nf O
- O
kb O
, O
mtor O
, O
pcna O
, O
tp53 O
, O
kim O
- O
1 O
, O
and O
ctgf O
as O
relevant O
gene O
and O
protein O
changes O
. O

prolonged O
csa O
exposure O
aggravated O
renal B-Disease
damage I-Disease
, O
without O
clear O
changes O
on O
the O
traditional O
markers O
, O
but O
with O
changes O
in O
serums O
tgf O
- O
b O
and O
il O
- O
7 O
, O
tbars O
clearance O
, O
and O
kidney O
tgf O
- O
b O
and O
mtor O
. O

conversion O
to O
srl O
prevented O
csa O
- O
induced O
renal B-Disease
damage I-Disease
evolution O
( O
absent O
/ O
mild O
grade O
lesions O
) O
, O
while O
ngal O
( O
serum O
versus O
urine O
) O
seems O
to O
be O
a O
feasible O
biomarker O
of O
csa O
replacement O
to O
srl O
. O

kinin O
b2 O
receptor O
deletion O
and O
blockage O
ameliorates O
cisplatin O
- O
induced O
acute B-Disease
renal I-Disease
injury I-Disease
. O

cisplatin O
treatment O
has O
been O
adopted O
in O
some O
chemotherapies O
; O
however O
, O
this O
drug O
can O
induce O
acute B-Disease
kidney I-Disease
injury I-Disease
due O
its O
ability O
to O
negatively O
affect O
renal O
function O
, O
augment O
serum O
levels O
of O
creatinine O
and O
urea O
, O
increase O
the O
acute B-Disease
tubular I-Disease
necrosis I-Disease
score O
and O
up O
- O
regulate O
cytokines O
( O
e O
. O

g O
. O

, O
il O
- O
1b O
and O
tnf O
- O
a O
) O
. O

the O
kinin O
b2 O
receptor O
has O
been O
associated O
with O
the O
inflammation B-Disease
process O
, O
as O
well O
as O
the O
regulation O
of O
cytokine O
expression O
, O
and O
its O
deletion O
resulted O
in O
an O
improvement O
in O
the O
diabetic B-Disease
nephropathy I-Disease
status O
. O

to O
examine O
the O
role O
of O
the O
kinin O
b2 O
receptor O
in O
cisplatin O
- O
induced O
acute B-Disease
kidney I-Disease
injury I-Disease
, O
kinin O
b2 O
receptor O
knockout O
mice O
were O
challenged O
with O
cisplatin O
. O

b2 O
receptor O
- O
deficient O
mice O
were O
less O
sensitive O
to O
this O
drug O
than O
the O
wt O
mice O
, O
as O
shown O
by O
reduced O
weight B-Disease
loss I-Disease
, O
better O
preservation O
of O
kidney O
function O
, O
down O
regulation O
of O
inflammatory O
cytokines O
and O
less O
acute B-Disease
tubular I-Disease
necrosis I-Disease
. O

thus O
, O
our O
data O
suggest O
that O
the O
kinin O
b2 O
receptor O
is O
involved O
in O
cisplatin O
- O
induced O
acute B-Disease
kidney I-Disease
injury I-Disease
by O
mediating O
the O
necrotic B-Disease
process O
and O
the O
expression O
of O
inflammatory O
cytokines O
, O
thus O
resulting O
in O
declined O
renal O
function O
. O

these O
results O
highlight O
the O
kinin O
b2 O
receptor O
antagonist O
treatment O
in O
amelioration O
of O
nephrotoxicity B-Disease
induced O
by O
cisplatin O
therapy O
. O

safety O
and O
efficacy O
of O
fluocinolone O
acetonide O
intravitreal O
imB-Plant O
( O
0 O
. O

59 O
mg O
) O
in O
birdshot B-Disease
retinochoroidopathy I-Disease
. O

purpose O
: O
to O
report O
the O
treatment O
outcomes O
of O
the O
fluocinolone O
acetonide O
intravitreal O
imB-Plant O
( O
0 O
. O

59 O
mg O
) O
in O
patients O
with O
birdshot B-Disease
retinochoroidopathy I-Disease
whose O
disease O
is O
refractory O
or O
intolerant O
to O
conventional O
immunomodulatory O
therapy O
. O

methods O
: O
a O
retrospective O
case O
series O
involving O
11 O
birdshot B-Disease
retinochoroidopathy I-Disease
patients O
( O
11 O
eyes O
) O
. O

disease O
activity O
markers O
, O
including O
signs O
of O
ocular O
inflammation B-Disease
, O
evidence O
of O
retinal B-Disease
vasculitis I-Disease
, O
swedish O
interactive O
threshold O
algorithm O
- O
short O
wavelength O
automated O
perimetry O
humphrey O
visual O
field O
analysis O
, O
electroretinographic O
parameters O
, O
and O
optical O
coherence O
tomography O
were O
recorded O
. O

data O
on O
occurrence O
of O
cataract B-Disease
and O
raised B-Disease
intraocular I-Disease
pressure I-Disease
were O
collected O
in O
all O
eyes O
. O

results O
: O
intraocular O
inflammation B-Disease
was O
present O
in O
54 O
. O

5 O
, O
9 O
. O

9 O
, O
11 O
. O

1 O
, O
and O
0 O
% O
of O
patients O
at O
baseline O
, O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
after O
receiving O
the O
imB-Plant O
, O
respectively O
. O

active O
vasculitis B-Disease
was O
noted O
in O
36 O
. O

3 O
% O
patients O
at O
baseline O
and O
0 O
% O
at O
3 O
years O
of O
follow O
- O
up O
. O

more O
than O
20 O
% O
( O
47 O
. O

61 O
- O
67 O
. O

2 O
% O
) O
reduction O
in O
central O
retinal O
thickness O
was O
noted O
in O
all O
patients O
with O
cystoid B-Disease
macular I-Disease
edema I-Disease
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
and O
3 O
years O
postimB-Plant O
. O

adverse O
events O
included O
increased B-Disease
intraocular I-Disease
pressure I-Disease
( O
54 O
. O

5 O
% O
) O
and O
cataract B-Disease
formation O
( O
100 O
% O
) O
. O

conclusion O
: O
the O
data O
suggest O
that O
fluocinolone O
acetonide O
imB-Plant O
( O
0 O
. O

59 O
mg O
) O
helps O
to O
control O
inflammation B-Disease
in O
otherwise O
treatment O
- O
refractory O
cases O
of O
birdshot B-Disease
retinochoroidopathy I-Disease
. O

it O
is O
associated O
with O
significant O
side O
effects O
of O
cataract B-Disease
and O
ocular B-Disease
hypertension I-Disease
requiring O
treatment O
. O

optimal O
precurarizing O
dose O
of O
rocuronium O
to O
decrease O
fasciculation B-Disease
and O
myalgia B-Disease
following O
succinylcholine O
administration O
. O

background O
: O
succinylcholine O
commonly O
produces O
frequent O
adverse O
effects O
, O
including O
muscle B-Disease
fasciculation I-Disease
and O
myalgia B-Disease
. O

the O
current O
study O
identified O
the O
optimal O
dose O
of O
rocuronium O
to O
prevent O
succinylcholine O
- O
induced O
fasciculation B-Disease
and O
myalgia B-Disease
and O
evaluated O
the O
influence O
of O
rocuronium O
on O
the O
speed O
of O
onset O
produced O
by O
succinylcholine O
. O

all O
patients O
received O
succinylcholine O
1 O
. O

5 O
mg O
/ O
kg O
at O
2 O
minutes O
after O
the O
precurarization O
, O
and O
were O
assessed O
the O
incidence O
and O
severity O
of O
fasciculations B-Disease
, O
while O
myalgia B-Disease
was O
assessed O
at O
24 O
hours O
after O
surgery O
. O

results O
: O
the O
incidence O
and O
severity O
of O
visible O
muscle B-Disease
fasciculation I-Disease
was O
significantly O
less O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
( O
p O
< O
0 O
. O

1 O
) O
. O

those O
of O
myalgia B-Disease
tend O
to O
decrease O
according O
to O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
, O
but O
there O
was O
no O
significance O
( O
p O
= O
0 O
. O

72 O
) O
. O

conclusions O
: O
precurarization O
with O
0 O
. O

4 O
mg O
/ O
kg O
rocuronium O
was O
the O
optimal O
dose O
considering O
the O
reduction O
in O
the O
incidence O
and O
severity O
of O
fasciculation B-Disease
and O
myalgia B-Disease
with O
acceptable O
onset O
time O
, O
and O
the O
safe O
and O
effective O
precurarization O
. O

absence O
of O
pkc O
- O
alpha O
attenuates O
lithium O
- O
induced O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
. O

lithium O
, O
an O
effective O
antipsychotic O
, O
induces O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
( O
ndi B-Disease
) O
in O
40 O
% O
of O
patients O
. O

targeting O
an O
alternative O
signaling O
pathway O
, O
such O
as O
pkc O
- O
mediated O
signaling O
, O
may O
be O
an O
effective O
method O
of O
treating O
lithium O
- O
induced O
polyuria B-Disease
. O

our O
data O
show O
that O
ablation O
of O
pkca O
preserves O
aqp2 O
and O
ut O
- O
a1 O
protein O
expression O
and O
localization O
in O
lithium O
- O
induced O
ndi B-Disease
, O
and O
prevents O
the O
development O
of O
the O
severe O
polyuria B-Disease
associated O
with O
lithium O
therapy O
. O

is O
dysguesia B-Disease
going O
to O
be O
a O
rare O
or O
a O
common O
side O
- O
effect O
of O
amlodipine O
? O
a O
very O
rare O
side O
- O
effect O
of O
amlodipine O
is O
dysguesia B-Disease
. O

we O
report O
a O
case O
about O
a O
female O
with O
essential O
hypertension B-Disease
on O
drug O
treatment O
with O
amlodipine O
developed O
loss B-Disease
of I-Disease
taste I-Disease
sensation I-Disease
. O

we O
conclude O
that O
amlodipine O
can O
cause O
dysguesia B-Disease
. O

here O
, O
we O
describe O
the O
clinical O
presentation O
and O
review O
the O
relevant O
literature O
on O
amlodipine O
and O
dysguesia B-Disease
. O

rhabdomyolysis B-Disease
in O
association O
with O
simvastatin O
and O
dosage O
increment O
in O
clarithromycin O
. O

this O
particular O
case O
is O
of O
interest O
as O
rhabdomyolysis B-Disease
only O
occurred O
after O
an O
increase O
in O
the O
dose O
of O
clarithromycin O
. O

the O
patient O
developed O
raised O
cardiac O
biomarkers O
without O
any O
obvious O
cardiac O
issues O
, O
a O
phenomenon O
that O
has O
been O
linked O
to O
rhabdomyolysis B-Disease
previously O
. O

to O
date O
, O
there O
has O
been O
no O
reported O
effect O
of O
rhabdomyolysis B-Disease
on O
the O
structure O
and O
function O
of O
cardiac O
muscle O
. O

clinicians O
need O
to O
be O
aware O
of O
prescribing O
concomitant O
medications O
that O
increase O
the O
risk O
of O
myopathy B-Disease
or O
inhibit O
the O
cyp3a4 O
enzyme O
. O

our O
case O
suggests O
that O
troponin O
elevation O
could O
be O
associated O
with O
statin O
induced O
rhabdomyolysis B-Disease
, O
which O
may O
warrant O
further O
studies O
. O

characterization O
of O
a O
novel O
bche O
nan O
silent O
nan O
allele O
: O
point O
mutation O
( O
p O
. O

val204asp O
) O
causes O
loss O
of O
activity O
and O
prolonged O
apnea B-Disease
with O
suxamethonium O
. O

butyrylcholinesterase B-Disease
deficiency I-Disease
is O
characterized O
by O
prolonged O
apnea B-Disease
after O
the O
use O
of O
muscle O
relaxants O
( O
suxamethonium O
or O
mivacurium O
) O
in O
patients O
who O
have O
mutations O
in O
the O
bche O
gene O
. O

delayed O
anemia B-Disease
after O
treatment O
with O
injectable O
artesunate O
in O
the O
democratic O
republic O
of O
the O
congo O
: O
a O
manageable O
issue O
. O

cases O
of O
delayed O
hemolytic B-Disease
anemia I-Disease
have O
been O
described O
after O
treatment O
with O
injectable O
artesunate O
, O
the O
current O
world O
health O
organization O
( O
who O
) O
- O
recommended O
first O
- O
line O
drug O
for O
the O
treatment O
of O
severe O
malaria B-Disease
. O

a O
total O
of O
350 O
patients O
( O
215 O
[ O
61 O
. O

4 O
% O
] O
< O
5 O
years O
of O
age O
and O
135 O
[ O
38 O
. O

6 O
% O
] O
> O
5 O
years O
of O
age O
) O
were O
followed O
- O
up O
after O
treatment O
with O
injectable O
artesunate O
for O
severe O
malaria B-Disease
in O
hospitals O
and O
health O
centers O
of O
the O
democratic O
republic O
of O
the O
congo O
. O

all O
cases O
of O
delayed O
anemia B-Disease
were O
clinically O
manageable O
and O
resolved O
within O
one O
month O
. O

regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
and O
apoptotic O
pathways O
by O
betaine O
attenuates O
isoproterenol O
- O
induced O
acute O
myocardial B-Disease
injury I-Disease
in O
rats O
. O

the O
present O
study O
was O
designed O
to O
investigate O
the O
cardioprotective O
effects O
of O
betaine O
on O
acute O
myocardial B-Disease
ischemia I-Disease
induced O
experimentally O
in O
rats O
focusing O
on O
regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
stat3 O
) O
and O
apoptotic O
pathways O
as O
the O
potential O
mechanism O
underlying O
the O
drug O
effect O
. O

acute O
myocardial B-Disease
ischemic I-Disease
injury I-Disease
was O
induced O
in O
rats O
by O
subcutaneous O
injection O
of O
isoproterenol O
( O
85 O
mg O
/ O
kg O
) O
, O
for O
two O
consecutive O
days O
. O

oral O
administration O
of O
betaine O
( O
200 O
and O
400 O
mg O
/ O
kg O
) O
significantly O
reduced O
the O
level O
of O
cardiac O
marker O
enzyme O
in O
the O
serum O
and O
prevented O
left O
ventricular B-Disease
remodeling I-Disease
. O

the O
protective O
role O
of O
betaine O
on O
myocardial B-Disease
damage I-Disease
was O
further O
confirmed O
by O
histopathological O
examination O
. O

in O
summary O
, O
our O
results O
showed O
that O
betaine O
pretreatment O
attenuated O
isoproterenol O
- O
induced O
acute O
myocardial B-Disease
ischemia I-Disease
via O
the O
regulation O
of O
stat3 O
and O
apoptotic O
pathways O
. O

quetiapine O
- O
induced O
neutropenia B-Disease
in O
a O
bipolar B-Disease
patient O
with O
hepatocellular B-Disease
carcinoma I-Disease
. O

objective O
: O
quetiapine O
is O
a O
dibenzothiazepine O
derivative O
, O
similar O
to O
clozapine O
, O
which O
has O
the O
highest O
risk O
of O
causing O
blood B-Disease
dyscrasias I-Disease
, O
especially O
neutropenia B-Disease
. O

a O
case O
of O
a O
patient O
with O
hepatocellular B-Disease
carcinoma I-Disease
that O
developed O
neutropenia B-Disease
after O
treatment O
with O
quetiapine O
is O
described O
here O
. O

case O
report O
: O
a O
62 O
- O
year O
- O
old O
taiwanese O
widow O
with O
bipolar B-Disease
disorder I-Disease
was O
diagnosed O
with O
hepatocellular B-Disease
carcinoma I-Disease
at O
age O
60 O
. O

she O
developed O
leucopenia B-Disease
after O
being O
treated O
with O
quetiapine O
. O

conclusions O
: O
although O
neutropenia B-Disease
is O
not O
a O
common O
side O
effect O
of O
quetiapine O
, O
physicians O
should O
be O
cautious O
about O
its O
presentation O
and O
associated O
risk O
factors O
. O

hepatic B-Disease
dysfunction I-Disease
may O
be O
one O
of O
the O
possible O
risk O
factors O
, O
and O
concomitant O
fever B-Disease
may O
be O
a O
diagnostic O
marker O
for O
adverse O
reaction O
to O
quetiapine O
. O

lateral O
antebrachial O
cutaneous O
neuropathy B-Disease
after O
steroid O
injection O
at O
lateral O
epicondyle O
. O

background O
and O
objectives O
: O
this O
report O
aimed O
to O
present O
a O
case O
of O
lateral O
antebrachial O
cutaneous O
neuropathy B-Disease
( O
lacnp O
) O
that O
occurred O
after O
a O
steroid O
injection O
in O
the O
lateral O
epicondyle O
to O
treat O
lateral B-Disease
epicondylitis I-Disease
in O
a O
40 O
- O
year O
- O
old O
woman O
. O

material O
and O
method O
: O
a O
40 O
- O
year O
- O
old O
woman O
presented O
with O
decreased O
sensation O
and O
paresthesia B-Disease
over O
her O
right O
lateral O
forearm O
; O
the O
paresthesia B-Disease
had O
occurred O
after O
a O
steroid O
injection O
in O
the O
right O
lateral O
epicondyle O
3 O
months O
before O
. O

her O
sensation O
of O
light O
touch O
and O
pain B-Disease
was O
diminished O
over O
the O
lateral O
side O
of O
the O
right O
forearm O
and O
wrist O
area O
. O

conclusion O
: O
this O
report O
describes O
the O
case O
of O
a O
woman O
with O
lacnp O
that O
developed O
after O
a O
steroid O
injection O
for O
the O
treatment O
of O
lateral B-Disease
epicondylitis I-Disease
. O

curcumin O
prevents O
maleate O
- O
induced O
nephrotoxicity B-Disease
: O
relation O
to O
hemodynamic O
alterations O
, O
oxidative O
stress O
, O
mitochondrial O
oxygen O
consumption O
and O
activity O
of O
respiratory O
complex O
i O
. O

the O
potential O
protective O
effect O
of O
the O
dietary O
antioxidant O
curcumin O
( O
120 O
mg O
/ O
kg O
/ O
day O
for O
6 O
days O
) O
against O
the O
renal B-Disease
injury I-Disease
induced O
by O
maleate O
was O
evaluated O
. O

tubular O
proteinuria B-Disease
and O
oxidative O
stress O
were O
induced O
by O
a O
single O
injection O
of O
maleate O
( O
400 O
mg O
/ O
kg O
) O
in O
rats O
. O

maleate O
- O
induced O
renal B-Disease
injury I-Disease
included O
increase O
in O
renal O
vascular O
resistance O
and O
in O
the O
urinary O
excretion O
of O
total O
protein O
, O
glucose O
, O
sodium O
, O
neutrophil O
gelatinase O
- O
associated O
lipocalin O
( O
ngal O
) O
and O
n O
- O
acetyl O
b O
- O
d O
- O
glucosaminidase O
( O
nag O
) O
, O
upregulation O
of O
kidney B-Disease
injury I-Disease
molecule O
( O
kim O
) O
- O
1 O
, O
decrease O
in O
renal O
blood O
flow O
and O
claudin O
- O
2 O
expression O
besides O
of O
necrosis B-Disease
and O
apoptosis O
of O
tubular O
cells O
on O
24 O
h O
. O

it O
is O
concluded O
that O
curcumin O
is O
able O
to O
attenuate O
in O
vivo O
maleate O
- O
induced O
nephropathy B-Disease
and O
in O
vitro O
cell O
damage O
. O

anticonvulsant O
actions O
of O
mk O
- O
801 O
on O
the O
lithium O
- O
pilocarpine O
model O
of O
status B-Disease
epilepticus I-Disease
in O
rats O
. O

mk O
- O
801 O
, O
a O
noncompetitive O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptor O
antagonist O
, O
was O
tested O
for O
anticonvulsant O
effects O
in O
rats O
using O
two O
seizure B-Disease
models O
, O
coadministration O
of O
lithium O
and O
pilocarpine O
and O
administration O
of O
a O
high O
dose O
of O
pilocarpine O
alone O
. O

first O
, O
pretreatment O
with O
mk O
- O
801 O
produced O
an O
effective O
and O
dose O
- O
dependent O
anticonvulsant O
action O
with O
the O
lithium O
- O
pilocarpine O
model O
but O
not O
with O
rats O
treated O
with O
pilocarpine O
alone O
, O
suggesting O
that O
different O
biochemical O
mechanisms O
control O
seizures B-Disease
in O
these O
two O
models O
. O

second O
, O
the O
anticonvulsant O
effect O
of O
mk O
- O
801 O
in O
the O
lithium O
- O
pilocarpine O
model O
only O
occurred O
after O
initial O
periods O
of O
seizure B-Disease
activity O
. O

third O
, O
although O
it O
is O
relatively O
easy O
to O
block O
seizures B-Disease
induced O
by O
lithium O
and O
pilocarpine O
by O
administration O
of O
anticonvulsants O
prior O
to O
pilocarpine O
, O
it O
is O
more O
difficult O
to O
terminate O
ongoing O
status B-Disease
epilepticus I-Disease
and O
block O
the O
lethality O
of O
the O
seizures B-Disease
. O

administration O
of O
mk O
- O
801 O
30 O
or O
60 O
min O
after O
pilocarpine O
, O
i O
. O

e O
. O

, O
during O
status B-Disease
epilepticus I-Disease
, O
gradually O
reduced O
electrical O
and O
behavioral O
seizure B-Disease
activity O
and O
greatly O
enhanced O
the O
survival O
rate O
. O

these O
results O
suggest O
that O
activation O
of O
nmda O
receptors O
plays O
an O
important O
role O
in O
status B-Disease
epilepticus I-Disease
and O
brain B-Disease
damage I-Disease
in O
the O
lithium O
- O
pilocarpine O
model O
. O

this O
was O
further O
supported O
by O
results O
showing O
that O
nonconvulsive O
doses O
of O
nmda O
and O
pilocarpine O
were O
synergistic O
, O
resulting O
in O
status B-Disease
epilepticus I-Disease
and O
subsequent O
mortality O
. O

continuous O
infusion O
tobramycin O
combined O
with O
carbenicillin O
for O
infections B-Disease
in O
cancer B-Disease
patients O
. O

the O
cure O
rate O
of O
infections B-Disease
in O
cancer B-Disease
patients O
is O
adversely O
affected O
by O
neutropenia B-Disease
( O
less O
than O
1 O
, O
0 O
/ O
mm3 O
) O
. O

in O
particular O
, O
patients O
with O
severe O
neutropenia B-Disease
( O
less O
than O
100 O
/ O
mm3 O
) O
have O
shown O
a O
poor O
response O
to O
antibiotics O
. O

to O
overcome O
the O
adverse O
effects O
of O
neutropenia B-Disease
, O
tobramycin O
was O
given O
by O
continuous O
infusion O
and O
combined O
with O
intermittent O
carbenicillin O
. O

there O
were O
125 O
infectious O
episodes O
in O
116 O
cancer B-Disease
patients O
receiving O
myelosuppressive O
chemotherapy O
. O

pneumonia B-Disease
was O
the O
most O
common O
infection B-Disease
and O
61 O
% O
of O
59 O
episodes O
were O
cured O
. O

gram O
- O
negative O
bacilli O
were O
the O
most O
common O
causative O
organisms O
and O
69 O
% O
of O
these O
infections B-Disease
were O
cured O
. O

the O
most O
common O
pathogen O
was O
klebsiella O
pneumoniae B-Disease
and O
this O
, O
together O
with O
escherichia O
coli O
and O
pseudomonas O
aeruginosa O
, O
accounted O
for O
74 O
% O
of O
all O
gram B-Disease
- I-Disease
negative I-Disease
bacillary I-Disease
infections I-Disease
. O

response O
was O
not O
influenced O
by O
the O
initial O
neutrophil O
count O
, O
with O
a O
62 O
% O
cure O
rate O
for O
39 O
episodes O
associated O
with O
severe O
neutropenia B-Disease
. O

azotemia B-Disease
was O
the O
major O
side O
effect O
recognized O
, O
and O
it O
occurred O
in O
11 O
% O
of O
episodes O
. O

major O
azotemia B-Disease
( O
serum O
creatinine O
greater O
than O
2 O
. O

5 O
mg O
/ O
dl O
or O
bun O
greater O
than O
50 O
mg O
/ O
dl O
) O
occurred O
in O
only O
2 O
% O
. O

azotemia B-Disease
was O
not O
related O
to O
duration O
of O
therapy O
or O
serum O
tobramycin O
concentration O
. O

this O
antibiotic O
regimen O
showed O
both O
therapeutic O
efficacy O
and O
acceptable O
renal B-Disease
toxicity I-Disease
for O
these O
patients O
. O

incidence O
of O
solid O
tumours B-Disease
among O
pesticide O
applicators O
exposed O
to O
the O
organophosphate O
insecticide O
diazinon O
in O
the O
agricultural O
health O
study O
: O
an O
updated O
analysis O
. O

objective O
: O
diazinon O
, O
a O
common O
organophosphate O
insecticide O
with O
genotoxic O
properties O
, O
was O
previously O
associated O
with O
lung B-Disease
cancer I-Disease
in O
the O
agricultural O
health O
study O
( O
ahs O
) O
cohort O
, O
but O
few O
other O
epidemiological O
studies O
have O
examined O
diazinon O
- O
associated O
cancer B-Disease
risk O
. O

we O
used O
updated O
diazinon O
exposure O
and O
cancer B-Disease
incidence O
information O
to O
evaluate O
solid O
tumour B-Disease
risk O
in O
the O
ahs O
. O

methods O
: O
male O
pesticide O
applicators O
in O
iowa O
and O
north O
carolina O
reported O
lifetime O
diazinon O
use O
at O
enrolment O
( O
1993 O
- O
1997 O
) O
and O
follow O
- O
up O
( O
1998 O
- O
2005 O
) O
; O
cancer B-Disease
incidence O
was O
assessed O
through O
2010 O
( O
north O
carolina O
) O
/ O
2011 O
( O
iowa O
) O
. O

among O
applicators O
with O
usage O
information O
sufficient O
to O
evaluate O
exposure O
- O
response O
patterns O
, O
we O
used O
poisson O
regression O
to O
estimate O
adjusted O
rate O
ratios O
( O
rrs O
) O
and O
95 O
% O
ci O
for O
cancer B-Disease
sites O
with O
> O
10 O
exposed O
cases O
for O
both O
lifetime O
( O
lt O
) O
exposure O
days O
and O
intensity O
- O
weighted O
( O
iw O
) O
lifetime O
exposure O
days O
( O
accounting O
for O
factors O
impacting O
exposure O
) O
. O

results O
: O
we O
observed O
elevated O
lung B-Disease
cancer I-Disease
risks O
( O
n O
= O
283 O
) O
among O
applicators O
with O
the O
greatest O
number O
of O
lt O
( O
rr O
= O
1 O
. O

60 O
; O
95 O
% O
ci O
1 O
. O

11 O
to O
2 O
. O

31 O
; O
ptrend O
= O
0 O
. O

2 O
) O
and O
iw O
days O
of O
diazinon O
use O
( O
rr O
= O
1 O
. O

41 O
; O
95 O
% O
ci O
0 O
. O

98 O
to O
2 O
. O

4 O
; O
ptrend O
= O
0 O
. O

8 O
) O
. O

kidney B-Disease
cancer I-Disease
( O
n O
= O
94 O
) O
risks O
were O
non O
- O
significantly O
elevated O
( O
rrlt O
days O
= O
1 O
. O

77 O
; O
95 O
% O
ci O
0 O
. O

90 O
to O
3 O
. O

51 O
; O
ptrend O
= O
0 O
. O

9 O
; O
rriw O
days O
1 O
. O

37 O
; O
95 O
% O
ci O
0 O
. O

64 O
to O
2 O
. O

92 O
; O
ptrend O
= O
0 O
. O

50 O
) O
, O
as O
were O
risks O
for O
aggressive O
prostate B-Disease
cancer I-Disease
( O
n O
= O
656 O
) O
. O

conclusions O
: O
our O
updated O
evaluation O
of O
diazinon O
provides O
additional O
evidence O
of O
an O
association O
with O
lung B-Disease
cancer I-Disease
risk O
. O

newly O
identified O
links O
to O
kidney B-Disease
cancer I-Disease
and O
associations O
with O
aggressive O
prostate B-Disease
cancer I-Disease
require O
further O
evaluation O
. O

associations O
of O
ozone O
and O
pm2 O
. O

5 O
concentrations O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
among O
participants O
in O
the O
agricultural O
health O
study O
. O

objective O
: O
this O
study O
describes O
associations O
of O
ozone O
and O
fine O
particulate O
matter O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
observed O
among O
farmers O
in O
north O
carolina O
and O
iowa O
. O

methods O
: O
we O
used O
logistic O
regression O
to O
determine O
the O
associations O
of O
these O
pollutants O
with O
self O
- O
reported O
, O
doctor O
- O
diagnosed O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

results O
: O
we O
observed O
positive O
associations O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
with O
ozone O
( O
odds O
ratio O
= O
1 O
. O

39 O
; O
95 O
% O
ci O
: O
0 O
. O

98 O
to O
1 O
. O

98 O
) O
and O
fine O
particulate O
matter O
( O
odds O
ratio O
= O
1 O
. O

34 O
; O
95 O
% O
ci O
: O
0 O
. O

93 O
to O
1 O
. O

93 O
) O
in O
north O
carolina O
but O
not O
in O
iowa O
. O

conclusions O
: O
the O
plausibility O
of O
an O
effect O
of O
ambient O
concentrations O
of O
these O
pollutants O
on O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
risk O
is O
supported O
by O
experimental O
data O
demonstrating O
damage O
to O
dopaminergic O
neurons O
at O
relevant O
concentrations O
. O

low O
functional O
programming O
of O
renal O
at2r O
mediates O
the O
developmental O
origin O
of O
glomerulosclerosis B-Disease
in O
adult O
offspring O
induced O
by O
prenatal O
caffeine O
exposure O
. O

unassigned O
: O
our O
previous O
study O
has O
indicated O
that O
prenatal O
caffeine O
exposure O
( O
pce O
) O
could O
induce O
intrauterine B-Disease
growth I-Disease
retardation I-Disease
( O
iugr B-Disease
) O
of O
offspring O
. O

recent O
research O
suggested O
that O
iugr B-Disease
is O
a O
risk O
factor O
for O
glomerulosclerosis B-Disease
. O

however O
, O
whether O
pce O
could O
induce O
glomerulosclerosis B-Disease
and O
its O
underlying O
mechanisms O
remain O
unknown O
. O

this O
study O
aimed O
to O
demonstrate O
the O
induction O
to O
glomerulosclerosis B-Disease
in O
adult O
offspring O
by O
pce O
and O
its O
intrauterine O
programming O
mechanisms O
. O

a O
rat O
model O
of O
iugr B-Disease
was O
established O
by O
pce O
, O
male O
fetuses O
and O
adult O
offspring O
at O
the O
age O
of O
postnatal O
week O
24 O
were O
euthanized O
. O

the O
results O
revealed O
that O
the O
adult O
offspring O
kidneys O
in O
the O
pce O
group O
exhibited O
glomerulosclerosis B-Disease
as O
well O
as O
interstitial B-Disease
fibrosis I-Disease
, O
accompanied O
by O
elevated O
levels O
of O
serum O
creatinine O
and O
urine O
protein O
. O

these O
results O
demonstrated O
that O
pce O
could O
induce O
dysplasia B-Disease
of I-Disease
fetal I-Disease
kidneys I-Disease
as O
well O
as O
glomerulosclerosis B-Disease
of O
adult O
offspring O
, O
and O
the O
low O
functional O
programming O
of O
renal O
at2r O
might O
mediate O
the O
developmental O
origin O
of O
adult O
glomerulosclerosis B-Disease
. O

1 O
, O
3 O
- O
butadiene O
, O
cml B-Disease
and O
the O
t O
( O
9 O
: O
22 O
) O
translocation O
: O
a O
reality O
check O
. O

unassigned O
: O
epidemiological O
studies O
of O
1 O
, O
3 O
- O
butadiene O
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic B-Disease
myeloid I-Disease
leukemia I-Disease
( O
cml B-Disease
) O
. O

cml B-Disease
has O
a O
well O
- O
documented O
association O
with O
ionizing O
radiation O
, O
but O
reports O
of O
associations O
with O
chemical O
exposures O
have O
been O
questioned O
. O

ionizing O
radiation O
is O
capable O
of O
inducing O
the O
requisite O
cml B-Disease
- O
associated O
t O
( O
9 O
: O
22 O
) O
translocation O
( O
philadelphia B-Disease
chromosome I-Disease
) O
in O
appropriate O
cells O
in O
vitro O
but O
, O
thus O
far O
, O
chemicals O
have O
not O
shown O
this O
capacity O
. O

cancer B-Disease
incidence O
and O
metolachlor O
use O
in O
the O
agricultural O
health O
study O
: O
an O
update O
. O

environmental O
protection O
agency O
based O
on O
increased O
liver B-Disease
neoplasms I-Disease
in O
female O
rats O
. O

we O
evaluated O
cancer B-Disease
incidence O
through O
2010 O
/ O
2011 O
( O
nc O
/ O
ia O
) O
for O
49 O
, O
616 O
applicators O
, O
53 O
% O
of O
whom O
reported O
ever O
using O
metolachlor O
. O

we O
used O
poisson O
regression O
to O
evaluate O
relations O
between O
two O
metrics O
of O
metolachlor O
use O
( O
lifetime O
days O
, O
intensity O
- O
weighted O
lifetime O
days O
) O
and O
cancer B-Disease
incidence O
. O

we O
saw O
no O
association O
between O
metolachlor O
use O
and O
incidence O
of O
all O
cancers B-Disease
combined O
( O
n O
= O
5 O
, O
701 O
with O
a O
5 O
- O
year O
lag O
) O
or O
most O
site O
- O
specific O
cancers B-Disease
. O

for O
liver B-Disease
cancer I-Disease
, O
in O
analyses O
restricted O
to O
exposed O
workers O
, O
elevations O
observed O
at O
higher O
categories O
of O
use O
were O
not O
statistically O
significant O
. O

a O
similar O
pattern O
was O
observed O
for O
follicular B-Disease
cell I-Disease
lymphoma I-Disease
, O
but O
no O
other O
lymphoma B-Disease
subtypes O
. O

an O
earlier O
suggestion O
of O
increased O
lung B-Disease
cancer I-Disease
risk O
at O
high O
levels O
of O
metolachlor O
use O
in O
this O
cohort O
was O
not O
confirmed O
in O
this O
update O
. O

this O
suggestion O
of O
an O
association O
between O
metolachlor O
and O
liver B-Disease
cancer I-Disease
among O
pesticide O
applicators O
is O
a O
novel O
finding O
and O
echoes O
observation O
of O
increased O
liver B-Disease
neoplasms I-Disease
in O
some O
animal O
studies O
. O

however O
, O
our O
findings O
for O
both O
liver B-Disease
cancer I-Disease
and O
follicular O
cell O
lymphoma B-Disease
warrant O
follow O
- O
up O
to O
better O
differentiate O
effects O
of O
metolachlor O
use O
from O
other O
factors O
. O

there O
is O
considerable O
interest O
in O
identifying O
the O
molecular O
mechanisms O
that O
relate O
early O
- O
life O
ias O
exposure O
to O
the O
development O
of O
these O
latent O
diseases O
, O
particularly O
in O
relationship O
to O
cancer B-Disease
. O

objectives O
: O
this O
work O
summarizes O
research O
on O
the O
molecular O
mechanisms O
that O
underlie O
the O
increased O
risk O
of O
cancer B-Disease
development O
in O
adulthood O
that O
is O
associated O
with O
early O
- O
life O
ias O
exposure O
. O

discussion O
: O
epigenetic O
reprogramming O
that O
imparts O
functional O
changes O
in O
gene O
expression O
, O
the O
development O
of O
cancer B-Disease
stem O
cells O
, O
and O
immunomodulation O
are O
plausible O
underlying O
mechanisms O
by O
which O
early O
- O
life O
ias O
exposure O
elicits O
latent O
carcinogenic O
effects O
. O

conclusions O
: O
evidence O
is O
mounting O
that O
relates O
early O
- O
life O
ias O
exposure O
and O
cancer B-Disease
development O
later O
in O
life O
. O

nifedipine O
induced O
bradycardia B-Disease
in O
a O
patient O
with O
autonomic B-Disease
neuropathy I-Disease
. O

an O
80 O
year O
old O
diabetic B-Disease
male O
with O
evidence O
of O
peripheral B-Disease
and I-Disease
autonomic I-Disease
neuropathy I-Disease
was O
admitted O
with O
chest B-Disease
pain I-Disease
. O

he O
was O
found O
to O
have O
atrial B-Disease
flutter I-Disease
at O
a O
ventricular O
rate O
of O
70 O
/ O
min O
which O
slowed O
down O
to O
30 O
- O
40 O
/ O
min O
when O
nifedipine O
( O
60 O
mg O
) O
in O
3 O
divided O
doses O
, O
during O
which O
he O
was O
paced O
at O
a O
rate O
of O
70 O
/ O
min O
. O

this O
is O
inconsistent O
with O
the O
well O
- O
established O
finding O
that O
nifedipine O
induces O
tachycardia B-Disease
in O
normally O
innervated O
hearts O
. O

however O
, O
in O
hearts O
deprived O
of O
compensatory O
sympathetic O
drive O
, O
it O
may O
lead O
to O
bradycardia B-Disease
. O

haloperidol O
failed O
to O
prevent O
amphetamine O
- O
induced O
seizures B-Disease
, O
but O
did O
lower O
the O
mortality O
rate O
at O
most O
doses O
tested O
. O

haloperidol O
decreased O
the O
incidence O
of O
cocaine O
- O
induced O
seizures B-Disease
at O
the O
two O
highest O
doses O
, O
but O
the O
lowering O
of O
the O
mortality O
rate O
did O
not O
reach O
statistical O
significance O
at O
any O
dose O
. O

these O
data O
suggest O
a O
protective O
role O
for O
the O
central O
dopamine O
blocker O
haloperidol O
against O
death O
from O
high O
- O
dose O
amphetamine O
exposure O
without O
reducing O
the O
incidence O
of O
seizures B-Disease
. O

in O
contrast O
, O
haloperidol O
demonstrated O
an O
ability O
to O
reduce O
cocaine O
- O
induced O
seizures B-Disease
without O
significantly O
reducing O
mortality O
. O

autoradiographic O
evidence O
of O
estrogen O
binding O
sites O
in O
nuclei O
of O
diethylstilbesterol O
induced O
hamster O
renal B-Disease
carcinomas I-Disease
. O

estrogen O
binding O
sites O
were O
demonstrated O
by O
autoradiography O
in O
one O
transB-Plantable O
and O
five O
primary O
diethylstilbesterol O
induced O
renal B-Disease
carcinomas I-Disease
in O
three O
hamsters O
. O

radiolabelling O
, O
following O
the O
in O
vivo O
injection O
of O
3h O
- O
17 O
beta O
estradiol O
, O
was O
increased O
only O
over O
the O
nuclei O
of O
tumor B-Disease
cells O
; O
stereologic O
analysis O
revealed O
a O
4 O
. O

5 O
- O
to O
6 O
. O

7 O
- O
times O
higher O
concentration O
of O
reduced O
silver O
grains O
over O
nuclei O
than O
cytoplasm O
of O
these O
cells O
. O

this O
is O
the O
first O
published O
report O
documenting O
the O
preferential O
in O
vivo O
binding O
of O
estrogen O
to O
nuclei O
of O
cells O
in O
estrogen O
induced O
hamster O
renal B-Disease
carcinomas I-Disease
. O

bradycardia B-Disease
due O
to O
biperiden O
. O

in O
a O
38 O
- O
year O
- O
old O
male O
patient O
suffering O
from O
a O
severe O
postzosteric B-Disease
trigeminal B-Disease
neuralgia I-Disease
, O
intravenous O
application O
of O
10 O
mg O
biperiden O
lactate O
led O
to O
a O
long O
- O
lasting O
paradoxical O
reaction O
characterized O
by O
considerable O
bradycardia B-Disease
, O
dysarthria B-Disease
, O
and O
dysphagia B-Disease
. O

bradycardia B-Disease
induced O
by O
biperiden O
is O
attributed O
to O
the O
speed O
of O
injection O
and O
to O
a O
dose O
- O
related O
dual O
effect O
of O
atropine O
- O
like O
drugs O
on O
muscarine O
receptors O
. O

deliberate O
hypotension B-Disease
induced O
by O
labetalol O
with O
halothane O
, O
enflurane O
or O
isoflurane O
for O
middle O
- O
ear O
surgery O
. O

the O
feasibility O
of O
using O
labetalol O
, O
an O
alpha O
- O
and O
beta O
- O
adrenergic O
blocking O
agent O
, O
as O
a O
hypotensive B-Disease
agent O
in O
combination O
with O
inhalation O
anaesthetics O
( O
halothane O
, O
enflurane O
or O
isoflurane O
) O
was O
studied O
in O
23 O
adult O
patients O
undergoing O
middle O
- O
ear O
surgery O
. O

the O
mean O
h O
concentration O
during O
hypotension B-Disease
in O
the O
inspiratory O
gas O
was O
0 O
. O

7 O
+ O
/ O
- O
0 O
. O

1 O
vol O
% O
, O
the O
mean O
e O
concentration O
1 O
. O

6 O
+ O
/ O
- O
0 O
. O

2 O
vol O
% O
, O
and O
the O
mean O
i O
concentration O
1 O
. O

0 O
+ O
/ O
- O
0 O
. O

1 O
vol O
% O
. O

during O
hypotension B-Disease
, O
the O
heart O
rate O
was O
stable O
without O
tachy B-Disease
- I-Disease
or I-Disease
bradycardia I-Disease
. O

the O
operating O
conditions O
regarding O
bleeding B-Disease
were O
estimated O
in O
a O
double O
- O
blind O
manner O
, O
and O
did O
not O
differ O
significantly O
between O
the O
groups O
. O

during O
hypotension B-Disease
, O
the O
serum O
creatinine O
concentration O
rose O
significantly O
in O
all O
groups O
from O
the O
values O
before O
hypotension B-Disease
and O
returned O
postoperatively O
to O
the O
initial O
level O
in O
the O
other O
groups O
, O
except O
the O
isoflurane O
group O
. O

after O
hypotension B-Disease
there O
was O
no O
rebound O
phenomenon O
in O
either O
blood O
pressure O
or O
heart O
rate O
. O

these O
results O
indicate O
that O
labetalol O
induces O
easily O
adjustable O
hypotension B-Disease
without O
compensatory O
tachycardia B-Disease
and O
rebound O
hypertension B-Disease
. O

convulsion B-Disease
following O
intravenous O
fluorescein O
angiography O
. O

tonic B-Disease
- I-Disease
clonic I-Disease
seizures I-Disease
followed O
intravenous O
fluorescein O
injection O
for O
fundus O
angiography O
in O
a O
47 O
- O
year O
- O
old O
male O
. O

acc O
- O
9653 O
and O
phenytoin O
sodium O
have O
equivalent O
anticonvulsant O
activity O
against O
seizures B-Disease
induced O
by O
maximal O
electroshock O
( O
mes O
) O
in O
mice O
following O
i O
. O

p O
. O

, O
oral O
, O
or O
i O
. O

v O
. O

administration O
. O

acc O
- O
9653 O
and O
phenytoin O
sodium O
have O
similar O
antiarrhythmic O
activity O
against O
ouabain O
- O
induced O
ventricular B-Disease
tachycardia I-Disease
in O
anesthetized O
dogs O
. O

the O
total O
doses O
of O
acc O
- O
9653 O
or O
phenytoin O
sodium O
necessary O
to O
convert O
the O
arrhythmia B-Disease
to O
a O
normal O
sinus O
rhythm O
were O
24 O
+ O
/ O
- O
6 O
and O
14 O
+ O
/ O
- O
3 O
mg O
/ O
kg O
, O
respectively O
. O

only O
phenytoin O
sodium O
displayed O
in O
vitro O
antiarrhythmic O
activity O
against O
strophanthidin O
- O
induced O
arrhythmias B-Disease
in O
guinea O
pig O
right O
atria O
. O

acute O
toxicity B-Disease
studies O
of O
acc O
- O
9653 O
and O
phenytoin O
sodium O
were O
carried O
out O
in O
mice O
, O
rats O
, O
rabbits O
, O
and O
dogs O
by O
i O
. O

v O
. O

, O
i O
. O

m O
. O

, O
and O
i O
. O

p O
. O

routes O
of O
administration O
. O

tachyphylaxis O
to O
systemic O
but O
not O
to O
airway O
responses O
during O
prolonged O
therapy O
with O
high O
dose O
inhaled O
salbutamol O
in O
asthmatics B-Disease
. O

high O
doses O
of O
inhaled O
salbutamol O
produce O
substantial O
improvements O
in O
airway O
response O
in O
patients O
with O
asthma B-Disease
, O
and O
are O
associated O
with O
dose O
- O
dependent O
systemic O
beta O
- O
adrenoceptor O
responses O
. O

twelve O
asthmatic B-Disease
patients O
( O
fev1 O
, O
81 O
+ O
/ O
- O
4 O
% O
predicted O
) O
, O
requiring O
only O
occasional O
inhaled O
beta O
- O
agonists O
as O
their O
sole O
therapy O
, O
were O
given O
a O
14 O
- O
day O
treatment O
with O
high O
dose O
inhaled O
salbutamol O
( O
hds O
) O
, O
4 O
, O
0 O
micrograms O
daily O
, O
low O
dose O
inhaled O
salbutamol O
( O
lds O
) O
, O
800 O
micrograms O
daily O
, O
or O
placebo O
( O
pi O
) O
by O
metered O
- O
dose O
inhaler O
in O
a O
double O
- O
blind O
, O
randomized O
crossover O
design O
. O

at O
the O
end O
of O
each O
14 O
- O
day O
treatment O
, O
a O
dose O
- O
response O
curve O
( O
drc O
) O
was O
performed O
, O
and O
airway O
( O
fev1 O
, O
fef25 O
- O
75 O
) O
chronotropic O
( O
hr O
) O
, O
tremor B-Disease
, O
and O
metabolic O
( O
k O
, O
glu O
) O
responses O
were O
measured O
at O
each O
step O
( O
from O
100 O
to O
4 O
, O
0 O
micrograms O
) O
. O

frequency O
and O
severity O
of O
subjective O
adverse O
effects O
were O
also O
reduced O
after O
hds O
: O
tremor B-Disease
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
palpitations B-Disease
( O
p O
less O
than O
0 O
. O

1 O
) O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
phenytoin O
induced O
fatal O
hepatic B-Disease
injury I-Disease
. O

a O
61 O
year O
old O
female O
developed O
fatal O
hepatic B-Disease
failure I-Disease
after O
phenytoin O
administration O
. O

a O
typical O
multisystem O
clinical O
pattern O
precedes O
the O
manifestations O
of O
hepatic B-Disease
injury I-Disease
. O

the O
hematologic O
, O
biochemical O
and O
pathologic O
features O
indicate O
a O
mixed O
hepatocellular B-Disease
damage I-Disease
due O
to O
drug B-Disease
hypersensitivity I-Disease
. O

we O
studied O
mortality O
after O
pertussis B-Disease
immunization O
in O
the O
mouse O
. O

without O
treatment O
, O
73 O
of O
92 O
animals O
( O
80 O
% O
) O
died O
after O
injection O
of O
bovine O
serum O
albumin O
( O
bsa O
) O
on O
day O
+ O
7 O
of O
pertussis B-Disease
immunization O
. O

blockade O
of O
histamine O
h1 O
receptors O
may O
reduce O
mortality O
in O
pertussis B-Disease
immunization O
- O
induced O
encephalopathy B-Disease
in O
mice O
. O

support O
for O
adrenaline O
- O
hypertension B-Disease
hypothesis O
: O
18 O
hour O
pressor O
effect O
after O
6 O
hours O
adrenaline O
infusion O
. O

these O
findings O
are O
strong O
support O
for O
the O
adrenaline O
- O
hypertension B-Disease
hypothesis O
in O
man O
. O

effect O
of O
alkylxanthines O
on O
gentamicin O
- O
induced O
acute B-Disease
renal I-Disease
failure I-Disease
in O
the O
rat O
. O

adenosine O
antagonists O
have O
been O
previously O
shown O
to O
be O
of O
benefit O
in O
some O
ischaemic B-Disease
and O
nephrotoxic B-Disease
models O
of O
acute B-Disease
renal I-Disease
failure I-Disease
( O
arf B-Disease
) O
. O

in O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines O
with O
different O
potencies O
as O
adenosine O
antagonists O
8 O
- O
phenyltheophylline O
, O
theophylline O
and O
enprofylline O
, O
were O
examined O
in O
rats O
developing O
acute B-Disease
renal I-Disease
failure I-Disease
after O
4 O
daily O
injections O
of O
gentamicin O
( O
200 O
mg O
kg O
- O
1 O
) O
. O

renal O
function O
was O
assessed O
by O
biochemical O
( O
plasma O
urea O
and O
creatinine O
) O
, O
functional O
( O
urine O
analysis O
and O
[ O
3h O
] O
inulin O
and O
[ O
14c O
] O
p O
- O
aminohippuric O
acid O
clearances O
) O
and O
morphological O
( O
degree O
of O
necrosis B-Disease
) O
indices O
. O

the O
lack O
of O
any O
consistent O
protective O
effect O
noted O
with O
the O
alkylxanthines O
tested O
in O
the O
present O
study O
indicates O
that O
adenosine O
plays O
little O
, O
if O
any O
, O
pathophysiological O
role O
in O
gentamicin O
- O
induced O
arf B-Disease
. O

a O
total O
of O
261 O
adverse O
ocular O
reactions O
occurred O
in O
237 O
patients O
who O
received O
isotretinoin O
, O
a O
commonly O
used O
drug O
in O
the O
treatment O
of O
severe O
cystic O
acne B-Disease
. O

blepharoconjunctivitis B-Disease
, O
subjective O
complaints O
of O
dry B-Disease
eyes I-Disease
, O
blurred B-Disease
vision I-Disease
, O
contact O
lens O
intolerance O
, O
and O
photodermatitis B-Disease
are O
reversible O
side O
effects O
. O

more O
serious O
ocular O
adverse O
reactions O
include O
papilledema B-Disease
, O
pseudotumor B-Disease
cerebri I-Disease
, O
and O
white O
or O
gray O
subepithelial O
corneal B-Disease
opacities I-Disease
; O
all O
of O
these O
are O
reversible O
if O
the O
drug O
is O
discontinued O
. O

isotretinoin O
is O
contraindicated O
in O
pregnancy O
because O
of O
the O
many O
reported O
congenital B-Disease
abnormalities I-Disease
after O
maternal O
use O
( O
including O
microphthalmos B-Disease
, O
orbital O
hypertelorism B-Disease
, O
and O
optic B-Disease
nerve I-Disease
hypoplasia I-Disease
) O
. O

procaterol O
and O
terbutaline O
in O
bronchial B-Disease
asthma I-Disease
. O

procaterol O
, O
a O
new O
beta O
- O
2 O
adrenoceptor O
stimulant O
, O
was O
studied O
in O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
trial O
in O
patients O
with O
bronchial B-Disease
asthma I-Disease
. O

both O
anti O
- O
asthmatic B-Disease
and O
tremorgenic B-Disease
effects O
of O
procaterol O
were O
dose O
- O
related O
. O

subacute O
effects O
of O
propranolol O
and O
b O
24 O
/ O
76 O
on O
isoproterenol O
- O
induced O
rat O
heart B-Disease
hypertrophy I-Disease
in O
correlation O
with O
blood O
pressure O
. O

the O
studies O
were O
performed O
using O
an O
experimental O
model O
of O
isoproterenol O
- O
induced O
heart B-Disease
hypertrophy I-Disease
in O
rats O
. O

a O
correlation O
of O
the O
blood O
pressure O
was O
neither O
found O
in O
the O
development O
nor O
in O
the O
attempt O
to O
suppress O
the O
development O
of O
heart B-Disease
hypertrophy I-Disease
with O
the O
two O
beta O
- O
receptor O
blockers O
. O

both O
beta O
- O
blockers O
influenced O
the O
development O
of O
hypertrophy B-Disease
to O
a O
different O
, O
but O
not O
reproducible O
extent O
. O

it O
was O
possible O
to O
suppress O
the O
increased O
ornithine O
decarboxylase O
activity O
with O
both O
beta O
- O
blockers O
in O
hypertrophied B-Disease
hearts I-Disease
, O
but O
there O
was O
no O
effect O
on O
the O
heart O
mass O
. O

neither O
propranolol O
nor O
b O
24 O
/ O
76 O
could O
stop O
the O
changes O
in O
the O
characteristic O
myosin O
isoenzyme O
pattern O
of O
the O
hypertrophied B-Disease
rat O
heart O
. O

thus O
, O
the O
investigations O
did O
not O
provide O
any O
evidence O
that O
the O
beta O
- O
receptor O
blockers O
propranolol O
and O
b O
24 O
/ O
76 O
have O
the O
potency O
to O
prevent O
isoproterenol O
from O
producing O
heart B-Disease
hypertrophy I-Disease
. O

increased O
anxiogenic O
effects O
of O
caffeine O
in O
panic B-Disease
disorders I-Disease
. O

the O
effects O
of O
oral O
administration O
of O
caffeine O
( O
10 O
mg O
/ O
kg O
) O
on O
behavioral O
ratings O
, O
somatic O
symptoms O
, O
blood O
pressure O
and O
plasma O
levels O
of O
3 O
- O
methoxy O
- O
4 O
- O
hydroxyphenethyleneglycol O
( O
mhpg O
) O
and O
cortisol O
were O
determined O
in O
17 O
healthy O
subjects O
and O
21 O
patients O
meeting O
dsm O
- O
iii O
criteria O
for O
agoraphobia B-Disease
with O
panic B-Disease
attacks I-Disease
or O
panic B-Disease
disorder I-Disease
. O

caffeine O
produced O
significantly O
greater O
increases O
in O
subject O
- O
rated O
anxiety B-Disease
, O
nervousness O
, O
fear O
, O
nausea B-Disease
, O
palpitations B-Disease
, O
restlessness B-Disease
, O
and O
tremors B-Disease
in O
the O
patients O
compared O
with O
healthy O
subjects O
. O

seventy O
- O
one O
percent O
of O
the O
patients O
reported O
that O
the O
behavioral O
effects O
of O
caffeine O
were O
similar O
to O
those O
experienced O
during O
panic B-Disease
attacks I-Disease
. O

because O
caffeine O
is O
an O
adenosine O
receptor O
antagonist O
, O
these O
results O
suggest O
that O
some O
panic B-Disease
disorder I-Disease
patients O
may O
have O
abnormalities B-Disease
in I-Disease
neuronal I-Disease
systems I-Disease
involving O
adenosine O
. O

patients O
with O
anxiety B-Disease
disorders I-Disease
may O
benefit O
by O
avoiding O
caffeine O
- O
containing O
foods O
and O
beverages O
. O

comparison O
of O
the O
effect O
of O
oxitropium O
bromide O
and O
of O
slow O
- O
release O
theophylline O
on O
nocturnal O
asthma B-Disease
. O

the O
effects O
of O
a O
new O
inhaled O
antimuscarinic O
drug O
, O
oxitropium O
bromide O
, O
and O
of O
a O
slow O
- O
release O
theophylline O
preparation O
upon O
nocturnal O
asthma B-Disease
were O
compared O
in O
a O
placebo O
- O
controlled O
double O
- O
blind O
study O
. O

no O
subject O
reported O
side O
effects O
of O
oxitropium O
, O
as O
compared O
to O
three O
subjects O
reporting O
nausea B-Disease
, O
vomiting B-Disease
and O
tremors B-Disease
after O
theophylline O
. O

oxitropium O
proves O
to O
be O
a O
valuable O
alternative O
to O
theophylline O
in O
nocturnal O
asthma B-Disease
, O
since O
it O
is O
equally O
potent O
, O
safer O
and O
does O
not O
require O
the O
titration O
of O
dosage O
. O

penicillin O
anaphylaxis B-Disease
. O

a O
case O
of O
oral O
penicillin O
anaphylaxis B-Disease
is O
described O
, O
and O
the O
terminology O
, O
occurrence O
, O
clinical O
manifestations O
, O
pathogenesis O
, O
prevention O
, O
and O
treatment O
of O
anaphylaxis B-Disease
are O
reviewed O
. O

emergency O
physicians O
should O
be O
aware O
of O
oral O
penicillin O
anaphylaxis B-Disease
in O
order O
to O
prevent O
its O
occurrence O
by O
prescribing O
the O
antibiotic O
judiciously O
and O
knowledgeably O
and O
to O
offer O
optimal O
medical O
therapy O
once O
this O
life O
- O
threatening O
reaction O
has O
begun O
. O

reversible O
valproic O
acid O
- O
induced O
dementia B-Disease
: O
a O
case O
report O
. O

reversible O
valproic O
acid O
- O
induced O
dementia B-Disease
was O
documented O
in O
a O
21 O
- O
year O
- O
old O
man O
with O
epilepsy B-Disease
who O
had O
a O
3 O
- O
year O
history O
of O
insidious O
progressive O
decline O
in O
global O
cognitive O
abilities O
documented O
by O
serial O
neuropsychological O
studies O
. O

possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
cns O
) O
toxic O
effect O
of O
valproic O
acid O
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
cns O
toxic O
effect O
mediated O
through O
valproic O
acid O
- O
induced O
hyperammonemia B-Disease
. O

reversal O
of O
scopolamine O
- O
induced O
amnesia B-Disease
of O
passive O
avoidance O
by O
pre O
- O
and O
post O
- O
training O
naloxone O
. O

in O
a O
series O
of O
five O
experiments O
, O
the O
modulating O
role O
of O
naloxone O
on O
a O
scopolamine O
- O
induced O
retention B-Disease
deficit I-Disease
in O
a O
passive O
avoidance O
paradigm O
was O
investigated O
in O
mice O
. O

scopolamine O
, O
but O
not O
methyl O
scopolamine O
( O
1 O
and O
3 O
mg O
/ O
kg O
) O
, O
induced O
an O
amnesia B-Disease
as O
measured O
by O
latency O
and O
duration O
parameters O
. O

naloxone O
( O
0 O
. O

3 O
, O
1 O
, O
3 O
, O
and O
10 O
mg O
/ O
kg O
) O
injected O
prior O
to O
training O
attenuated O
the O
retention B-Disease
deficit I-Disease
with O
a O
peak O
of O
activity O
at O
3 O
mg O
/ O
kg O
. O

post O
- O
training O
administration O
of O
naloxone O
( O
3 O
mg O
/ O
kg O
) O
as O
a O
single O
or O
as O
a O
split O
dose O
also O
attenuated O
the O
scopolamine O
- O
induced O
amnesia B-Disease
. O

control O
experiments O
indicated O
that O
neither O
an O
increase O
in O
pain B-Disease
sensitivity O
( O
pre O
- O
training O
naloxone O
) O
nor O
an O
induced O
aversive O
state O
( O
post O
- O
training O
naloxone O
) O
appear O
to O
be O
responsible O
for O
the O
influence O
of O
naloxone O
on O
the O
scopolamine O
- O
induced O
retention B-Disease
deficit I-Disease
. O

electron O
microscopic O
investigations O
of O
the O
cyclophosphamide O
- O
induced O
lesions B-Disease
of I-Disease
the I-Disease
urinary I-Disease
bladder I-Disease
of O
the O
rat O
and O
their O
prevention O
by O
mesna O
. O

fully O
developed O
cyclophosphamide O
- O
induced O
cystitis B-Disease
is O
characterized O
by O
nearly O
complete O
detachment O
of O
the O
urothelium O
, O
severe O
submucosal O
edema B-Disease
owing O
to O
damage O
to O
the O
microvascular O
bed O
and O
focal O
muscle O
necroses B-Disease
. O

subsequent O
breaks O
in O
the O
lateral O
cell O
membranes O
of O
the O
superficial O
cells O
and O
in O
all O
the O
plasma O
membranes O
of O
the O
intermediate O
and O
basal O
cells O
, O
intercellular O
and O
intracellular O
edema B-Disease
and O
disintegration O
of O
the O
desmosomes O
and O
hemidesmosomes O
lead O
to O
progressive O
degeneration O
and O
detachment O
of O
the O
epithelial O
cells O
with O
exposure O
and O
splitting O
of O
the O
basal O
membrane O
. O

increase O
in O
intragastric O
pressure O
during O
suxamethonium O
- O
induced O
muscle B-Disease
fasciculations I-Disease
in O
children O
: O
inhibition O
by O
alfentanil O
. O

the O
incidence O
and O
intensity O
of O
muscle B-Disease
fasciculations I-Disease
caused O
by O
suxamethonium O
were O
significantly O
greater O
in O
the O
control O
than O
in O
the O
alfentanil O
group O
. O

the O
intragastric O
pressure O
during O
muscle B-Disease
fasciculations I-Disease
was O
significantly O
higher O
in O
the O
control O
group O
( O
16 O
+ O
/ O
- O
0 O
. O

7 O
( O
sem O
) O
cm O
h2o O
) O
than O
in O
the O
alfentanil O
group O
( O
7 O
. O

7 O
+ O
/ O
- O
1 O
. O

5 O
( O
sem O
) O
cm O
h2o O
) O
. O

the O
increase O
in O
intragastric O
pressure O
was O
directly O
related O
to O
the O
intensity O
of O
muscle B-Disease
fasciculations I-Disease
( O
regression O
line O
: O
y O
= O
0 O
. O

5 O
+ O
4 O
. O

78x O
with O
r O
of O
0 O
. O

78 O
) O
. O

it O
is O
concluded O
that O
intragastric O
pressure O
increases O
significantly O
during O
muscle B-Disease
fasciculations I-Disease
caused O
by O
suxamethonium O
in O
healthy O
children O
. O

alfentanil O
50 O
micrograms O
kg O
- O
1 O
effectively O
inhibits O
the O
incidence O
and O
intensity O
of O
suxamethonium O
- O
induced O
muscle B-Disease
fasciculations I-Disease
; O
moreover O
, O
intragastric O
pressure O
remains O
at O
its O
control O
value O
. O

acute O
insulin O
treatment O
normalizes O
the O
resistance O
to O
the O
cardiotoxic B-Disease
effect O
of O
isoproterenol O
in O
streptozotocin O
diabetic B-Disease
rats O
. O

a O
morphometric O
study O
of O
isoproterenol O
induced O
myocardial O
fibrosis B-Disease
. O

the O
acute O
effect O
of O
insulin O
treatment O
on O
the O
earlier O
reported O
protective O
effect O
of O
streptozotocin O
diabetes B-Disease
against O
the O
cardiotoxic B-Disease
effect O
of O
high O
doses O
of O
isoproterenol O
( O
iso O
) O
was O
investigated O
in O
rats O
. O

thirty O
to O
135 O
min O
after O
the O
injection O
of O
crystalline O
insulin O
, O
iso O
was O
given O
subcutaneously O
and O
when O
iso O
induced O
fibrosis B-Disease
in O
the O
myocardium O
was O
morphometrically O
analyzed O
7 O
days O
later O
, O
a O
highly O
significant O
correlation O
( O
r O
= O
0 O
. O

83 O
, O
2 O
p O
= O
0 O
. O

6 O
) O
to O
the O
slope O
of O
the O
fall O
in O
blood O
glucose O
after O
insulin O
treatment O
appeared O
. O

the O
myocardial O
content O
of O
catecholamines O
was O
estimated O
in O
these O
8 O
day O
diabetic B-Disease
rats O
. O

the O
rapid O
reversion O
after O
insulin O
treatment O
excludes O
the O
possibility O
that O
streptozotocin O
in O
itself O
causes O
the O
iso O
resistance O
and O
points O
towards O
a O
direct O
insulin O
effect O
on O
myocardial O
catecholamine O
sensitivity O
in O
diabetic B-Disease
rats O
. O

the O
phenomenon O
described O
might O
elucidate O
pathogenetic O
mechanisms O
behind O
toxic O
myocardial O
cell O
degeneration O
and O
may O
possibly O
have O
relevance O
for O
acute O
cardiovascular O
complications O
in O
diabetic B-Disease
patients O
. O

differential O
effects O
of O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
on O
seizures B-Disease
produced O
by O
pilocarpine O
in O
rats O
. O

the O
muscarinic O
cholinergic O
agonist O
pilocarpine O
induces O
in O
rats O
seizures B-Disease
and O
status B-Disease
epilepticus I-Disease
followed O
by O
widespread O
damage O
to O
the O
forebrain O
. O

the O
present O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
5 O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
, O
sodium O
salicylate O
, O
phenylbutazone O
, O
indomethacin O
, O
ibuprofen O
and O
mefenamic O
acid O
, O
on O
seizures B-Disease
produced O
by O
pilocarpine O
. O

indomethacin O
, O
1 O
- O
10 O
mg O
/ O
kg O
, O
and O
ibuprofen O
, O
10 O
- O
100 O
mg O
/ O
kg O
, O
failed O
to O
modulate O
seizures B-Disease
produced O
by O
pilocarpine O
. O

mefenamic O
acid O
, O
26 O
( O
22 O
- O
30 O
) O
mg O
/ O
kg O
, O
prevented O
seizures B-Disease
and O
protected O
rats O
from O
seizure B-Disease
- O
related O
brain B-Disease
damage I-Disease
induced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

these O
results O
indicate O
that O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
differentially O
modulate O
the O
threshold O
for O
pilocarpine O
- O
induced O
seizures B-Disease
. O

acute B-Disease
neurologic I-Disease
dysfunction I-Disease
after O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B-Disease
glioma I-Disease
. O

etoposide O
( O
vp O
- O
16 O
- O
213 O
) O
has O
been O
used O
in O
the O
treatment O
of O
many O
solid O
tumors B-Disease
and O
hematologic B-Disease
malignancies I-Disease
. O

when O
used O
in O
high O
doses O
and O
in O
conjunction O
with O
autologous O
bone O
marrow O
transB-Plantation O
, O
this O
agent O
has O
activity O
against O
several O
treatment O
- O
resistant O
cancers B-Disease
including O
malignant B-Disease
glioma I-Disease
. O

in O
six O
of O
eight O
patients O
( O
75 O
% O
) O
who O
we O
treated O
for O
recurrent O
or O
resistant O
glioma B-Disease
, O
sudden O
severe O
neurologic B-Disease
deterioration I-Disease
occurred O
. O

significant O
clinical O
manifestations O
have O
included O
confusion B-Disease
, O
papilledema B-Disease
, O
somnolence B-Disease
, O
exacerbation O
of O
motor B-Disease
deficits I-Disease
, O
and O
sharp O
increase O
in O
seizure B-Disease
activity O
. O

in O
all O
patients O
, O
computerized O
tomographic O
( O
ct O
) O
brain O
scans O
demonstrated O
stability O
in O
tumor B-Disease
size O
and O
peritumor O
edema B-Disease
when O
compared O
with O
pretransB-Plant O
scans O
. O

this O
complication O
appears O
to O
represent O
a O
significant O
new O
toxicity B-Disease
of O
high O
- O
dose O
etoposide O
therapy O
for O
malignant B-Disease
glioma I-Disease
. O

progressive O
bile B-Disease
duct I-Disease
injury I-Disease
after O
thiabendazole O
administration O
. O

a O
27 O
- O
yr O
- O
old O
man O
developed O
jaundice B-Disease
2 O
wk O
after O
exposure O
to O
thiabendazole O
. O

cholestasis B-Disease
persisted O
for O
3 O
yr O
, O
at O
which O
time O
a O
liver O
transB-Plant O
was O
performed O
. O

prominent O
fibrosis B-Disease
and O
hepatocellular O
regeneration O
were O
also O
present O
; O
however O
, O
the O
lobular O
architecture O
was O
preserved O
. O

this O
case O
represents O
an O
example O
of O
nan O
idiosyncratic O
nan O
drug B-Disease
- I-Disease
induced I-Disease
liver I-Disease
damage I-Disease
in O
which O
the O
primary O
target O
of O
injury O
is O
the O
bile O
duct O
. O

an O
autoimmune O
pathogenesis O
of O
the O
bile B-Disease
duct I-Disease
destruction I-Disease
is O
suggested O
. O

increasing O
recognition O
of O
the O
importance O
of O
calcium O
in O
the O
pathogenesis O
of O
cardiovascular B-Disease
disease I-Disease
has O
stimulated O
research O
into O
the O
use O
of O
calcium O
channel O
blocking O
agents O
for O
treatment O
of O
a O
variety O
of O
cardiovascular B-Disease
diseases I-Disease
. O

as O
the O
first O
dihydropyridine O
available O
for O
use O
in O
the O
united O
states O
, O
nifedipine O
controls O
angina B-Disease
and O
hypertension B-Disease
with O
minimal O
depression O
of O
cardiac O
function O
. O

once O
or O
twice O
daily O
dosage O
possible O
with O
nitrendipine O
and O
nisoldipine O
offers O
a O
convenient O
administration O
schedule O
, O
which O
encourages O
patient O
compliance O
in O
long O
- O
term O
therapy O
of O
hypertension B-Disease
. O

the O
coronary O
vasodilating O
properties O
of O
nisoldipine O
have O
led O
to O
the O
investigation O
of O
this O
agent O
for O
use O
in O
angina B-Disease
. O

selectivity O
for O
the O
cerebrovascular O
bed O
makes O
nimodipine O
potentially O
useful O
in O
the O
treatment O
of O
subarachnoid B-Disease
hemorrhage I-Disease
, O
migraine B-Disease
headache I-Disease
, O
dementia B-Disease
, O
and O
stroke B-Disease
. O

in O
general O
, O
the O
dihydropyridine O
calcium O
channel O
blockers O
are O
usually O
well O
tolerated O
, O
with O
headache B-Disease
, O
facial O
flushing B-Disease
, O
palpitations B-Disease
, O
edema B-Disease
, O
nausea B-Disease
, O
anorexia B-Disease
, O
and O
dizziness B-Disease
being O
the O
more O
common O
adverse O
effects O
. O

the O
enhancement O
of O
aminonucleoside O
nephrosis B-Disease
by O
the O
co O
- O
administration O
of O
protamine O
. O

an O
experimental O
model O
of O
focal B-Disease
segmental I-Disease
glomerular I-Disease
sclerosis I-Disease
( O
fsgs B-Disease
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin O
- O
aminonucleoside O
( O
amns O
) O
and O
protamine O
sulfate O
( O
ps O
) O
. O

they O
developed O
nephrotic B-Disease
syndrome I-Disease
and O
finally O
renal B-Disease
failure I-Disease
. O

their O
glomeruli O
showed O
changes O
of O
progressive O
fsgs B-Disease
. O

therefore O
, O
it O
is O
suggested O
that O
the O
administration O
of O
ps O
enhances O
the O
toxicity B-Disease
of O
amns O
on O
the O
glomerulus O
and O
readily O
produces O
progressive O
fsgs B-Disease
in O
rats O
resulting O
in O
the O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
. O

theophylline O
neurotoxicity B-Disease
in O
pregnant O
rats O
. O

the O
purpose O
of O
this O
investigation O
was O
to O
determine O
whether O
the O
neurotoxicity B-Disease
of O
theophylline O
is O
altered O
in O
advanced O
pregnancy O
. O

sprague O
- O
dawley O
rats O
that O
were O
20 O
days O
pregnant O
and O
nonpregnant O
rats O
of O
the O
same O
age O
and O
strain O
received O
infusions O
of O
aminophylline O
until O
onset O
of O
maximal O
seizures B-Disease
which O
occurred O
after O
28 O
and O
30 O
minutes O
respectively O
. O

fetal O
serum O
concentrations O
at O
onset O
of O
seizures B-Disease
in O
the O
mother O
were O
similar O
to O
maternal O
brain O
and O
csf O
concentrations O
and O
correlated O
significantly O
with O
the O
former O
. O

it O
is O
concluded O
that O
advanced O
pregnancy O
has O
a O
negligible O
effect O
on O
the O
neurotoxic B-Disease
response O
to O
theophylline O
in O
rats O
. O

hyperkalemia B-Disease
induced O
by O
indomethacin O
and O
naproxen O
and O
reversed O
by O
fludrocortisone O
. O

we O
have O
described O
a O
patient O
with O
severe O
rheumatoid B-Disease
arthritis I-Disease
and O
a O
history O
of O
mefenamic O
acid O
nephropathy B-Disease
in O
whom O
hyperkalemia B-Disease
and O
inappropriate O
hypoaldosteronism B-Disease
were O
caused O
by O
both O
indomethacin O
and O
naproxen O
, O
without O
major O
decline O
in O
renal O
function O
. O

it O
is O
likely O
that O
preexisting O
renal B-Disease
disease I-Disease
predisposed O
this O
patient O
to O
type B-Disease
iv I-Disease
renal I-Disease
tubular I-Disease
acidosis I-Disease
with O
prostaglandin O
synthetase O
inhibitors O
. O

because O
he O
was O
unable O
to O
discontinue O
nonsteroidal O
anti O
- O
inflammatory O
drug O
therapy O
, O
fludrocortisone O
was O
added O
, O
correcting O
the O
hyperkalemia B-Disease
and O
allowing O
indomethacin O
therapy O
to O
be O
continued O
safely O
. O

hypotension B-Disease
as O
a O
manifestation O
of O
cardiotoxicity B-Disease
in O
three O
patients O
receiving O
cisplatin O
and O
5 O
- O
fluorouracil O
. O

cardiac O
symptoms O
, O
including O
hypotension B-Disease
, O
developed O
in O
three O
patients O
with O
advanced O
colorectal B-Disease
carcinoma I-Disease
while O
being O
treated O
with O
cisplatin O
( O
cddp O
) O
and O
5 O
- O
fluorouracil O
( O
5 O
- O
fu O
) O
. O

in O
two O
patients O
, O
hypotension B-Disease
was O
associated O
with O
severe O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
. O

the O
presentation O
and O
cardiac O
evaluation O
( O
hemodynamic O
, O
echocardiographic O
, O
and O
scintigraphic O
) O
of O
these O
patients O
suggest O
new O
manifestations O
of O
5 O
- O
fu O
cardiotoxicity B-Disease
that O
may O
be O
influenced O
by O
cddp O
. O

fatal O
aplastic B-Disease
anemia I-Disease
in O
a O
patient O
treated O
with O
carbamazepine O
. O

a O
case O
of O
fatal O
aplastic B-Disease
anemia I-Disease
due O
to O
carbamazepine O
treatment O
in O
an O
epileptic B-Disease
woman O
is O
reported O
. O

despite O
concerns O
of O
fatal O
bone B-Disease
marrow I-Disease
toxicity I-Disease
due O
to O
carbamazepine O
, O
this O
is O
only O
the O
fourth O
documented O
and O
published O
report O
. O

participation O
of O
a O
bulbospinal O
serotonergic O
pathway O
in O
the O
rat O
brain O
in O
clonidine O
- O
induced O
hypotension B-Disease
and O
bradycardia B-Disease
. O

the O
clonidine O
- O
induced O
hypotension B-Disease
was O
antagonized O
by O
prior O
spinal O
transection O
, O
but O
not O
bilateral O
vagotomy O
. O

on O
the O
other O
hand O
, O
the O
clonidine O
- O
induced O
bradycardia B-Disease
was O
antagonized O
by O
prior O
bilateral O
vagotomy O
, O
but O
not O
spinal O
transection O
. O

furthermore O
, O
selective O
destruction O
of O
the O
spinal O
5 O
- O
ht O
nerves O
, O
produced O
by O
bilateral O
spinal O
injection O
of O
5 O
, O
7 O
- O
dihydroxytryptamine O
, O
reduced O
the O
magnitude O
of O
the O
vasodepressor O
or O
the O
bradycardiac B-Disease
responses O
to O
clonidine O
microinjected O
into O
the O
area O
near O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
in O
rats O
. O

the O
data O
indicate O
that O
a O
bulbospinal O
serotonergic O
pathway O
is O
involved O
in O
development O
of O
clonidine O
- O
induced O
hypotension B-Disease
and O
bradycardia B-Disease
. O

the O
induced O
hypotension B-Disease
is O
brought O
about O
by O
a O
decrease O
in O
sympathetic O
efferent O
activity O
, O
whereas O
the O
induced O
bradycardia B-Disease
was O
due O
to O
an O
increase O
in O
vagal O
efferent O
activity O
. O

hypertension B-Disease
in O
neuroblastoma B-Disease
induced O
by O
imipramine O
. O

hypertension B-Disease
is O
a O
well O
- O
known O
finding O
in O
some O
patients O
with O
neuroblastoma B-Disease
. O

we O
report O
the O
occurrence O
of O
severe O
hypertension B-Disease
( O
blood O
pressure O
190 O
/ O
160 O
) O
in O
a O
4 O
- O
year O
- O
old O
girl O
with O
neuroblastoma B-Disease
who O
was O
given O
imipramine O
to O
control O
a O
behavior B-Disease
disorder I-Disease
. O

it O
was O
determined O
later O
that O
this O
patient O
' O
s O
tumor B-Disease
was O
recurring O
at O
the O
time O
of O
her O
hypertensive B-Disease
episode O
. O

since O
she O
had O
no O
blood O
pressure O
elevation O
at O
initial O
diagnosis O
and O
none O
following O
discontinuation O
of O
the O
imipramine O
( O
when O
she O
was O
in O
florid O
relapse O
) O
, O
we O
believe O
that O
this O
drug O
rather O
than O
her O
underlying O
disease O
alone O
caused O
her O
hypertension B-Disease
. O

from O
this O
experience O
, O
we O
urge O
extreme O
caution O
in O
the O
use O
of O
tricyclic O
antidepressants O
in O
children O
with O
active O
neuroblastoma B-Disease
. O

rechallenge O
of O
patients O
who O
developed O
oral B-Disease
candidiasis I-Disease
or O
hoarseness B-Disease
with O
beclomethasone O
dipropionate O
. O

of O
158 O
asthmatic B-Disease
patients O
who O
were O
placed O
on O
inhaled O
beclomethasone O
, O
15 O
( O
9 O
. O

5 O
% O
) O
developed O
either O
hoarseness B-Disease
( O
8 O
) O
, O
oral O
thrush B-Disease
( O
6 O
) O
, O
or O
both O
( O
1 O
) O
. O

these O
included O
five O
cases O
who O
developed O
hoarseness B-Disease
and O
three O
who O
developed O
candidiasis B-Disease
. O

oral O
thrush B-Disease
did O
not O
recur O
, O
but O
60 O
% O
( O
3 O
/ O
5 O
) O
of O
patients O
with O
hoarseness B-Disease
had O
recurrence O
. O

we O
conclude O
that O
patients O
may O
be O
restarted O
on O
inhaled O
beclomethasone O
when O
clinically O
indicated O
; O
however O
, O
because O
of O
the O
high O
recurrence O
rate O
, O
patients O
who O
develop O
hoarseness B-Disease
should O
not O
be O
re O
- O
challenged O
. O

concomitant O
use O
of O
oral O
prednisone O
and O
topical O
beclomethasone O
may O
increase O
the O
risk O
of O
developing O
hoarseness B-Disease
or O
candidiasis B-Disease
. O

cyclophosphamide O
cardiotoxicity B-Disease
: O
an O
analysis O
of O
dosing O
as O
a O
risk O
factor O
. O

at O
these O
high O
doses O
of O
cya O
, O
serious O
cardiotoxicity B-Disease
may O
occur O
, O
but O
definitive O
risk O
factors O
for O
the O
development O
of O
such O
cardiotoxicity B-Disease
have O
not O
been O
described O
. O

since O
chemotherapeutic O
agent O
toxicity B-Disease
generally O
correlates O
with O
dose O
per O
body O
surface O
area O
, O
we O
retrospectively O
calculated O
the O
dose O
of O
cya O
in O
patients O
transB-Planted O
at O
our O
institution O
to O
determine O
whether O
the O
incidence O
of O
cya O
cardiotoxicity B-Disease
correlated O
with O
the O
dose O
per O
body O
surface O
area O
. O

eighty O
patients O
who O
were O
to O
receive O
cya O
50 O
mg O
/ O
kg O
/ O
d O
for O
four O
days O
as O
preparation O
for O
marrow O
grafting O
underwent O
a O
total O
of O
84 O
transB-Plants O
for O
aplastic B-Disease
anemia I-Disease
, O
wiskott B-Disease
- I-Disease
aldrich I-Disease
syndrome I-Disease
, O
or O
severe B-Disease
combined I-Disease
immunodeficiency I-Disease
syndrome I-Disease
. O

fourteen O
of O
84 O
( O
17 O
% O
) O
patients O
had O
symptoms O
and O
signs O
consistent O
with O
cya O
cardiotoxicity B-Disease
within O
ten O
days O
of O
receiving O
1 O
to O
4 O
doses O
of O
cya O
. O

six O
of O
the O
14 O
patients O
died O
with O
congestive B-Disease
heart I-Disease
failure I-Disease
. O

cardiotoxicity B-Disease
that O
was O
thought O
to O
be O
related O
to O
cya O
occurred O
in O
1 O
/ O
32 O
( O
3 O
% O
) O
of O
patients O
in O
group O
1 O
and O
in O
13 O
/ O
52 O
( O
25 O
% O
) O
patients O
in O
group O
2 O
( O
p O
less O
than O
0 O
. O

25 O
) O
. O

congestive B-Disease
heart I-Disease
failure I-Disease
caused O
or O
contributed O
to O
death O
in O
0 O
/ O
32 O
patients O
in O
group O
1 O
v O
6 O
/ O
52 O
( O
12 O
% O
) O
of O
patients O
in O
group O
2 O
( O
p O
less O
than O
0 O
. O

25 O
) O
. O

we O
conclude O
that O
the O
cya O
cardiotoxicity B-Disease
correlates O
with O
cya O
dosage O
as O
calculated O
by O
body O
surface O
area O
, O
and O
that O
patients O
with O
aplastic B-Disease
anemia I-Disease
and O
immunodeficiencies B-Disease
can O
be O
effectively O
prepared O
for O
bone O
marrow O
grafting O
at O
a O
cya O
dose O
of O
1 O
. O

55 O
g O
/ O
m2 O
/ O
d O
for O
four O
days O
with O
a O
lower O
incidence O
of O
cardiotoxicity B-Disease
than O
patients O
whose O
cya O
dosage O
is O
calculated O
based O
on O
weight O
. O

this O
study O
reaffirms O
the O
principle O
that O
drug O
toxicity B-Disease
correlates O
with O
dose O
per O
body O
surface O
area O
. O

studies O
of O
risk O
factors O
for O
aminoglycoside O
nephrotoxicity B-Disease
. O

the O
epidemiology O
of O
aminoglycoside O
- O
induced O
nephrotoxicity B-Disease
is O
not O
fully O
understood O
. O

experimental O
studies O
in O
healthy O
human O
volunteers O
indicate O
aminoglycosides O
cause O
proximal O
tubular O
damage O
in O
most O
patients O
, O
but O
rarely O
, O
if O
ever O
, O
cause O
glomerular B-Disease
or I-Disease
tubular I-Disease
dysfunction I-Disease
. O

clinical O
trials O
of O
aminoglycosides O
in O
seriously O
ill O
patients O
indicate O
that O
the O
relative O
risk O
for O
developing O
acute B-Disease
renal I-Disease
failure I-Disease
during O
therapy O
ranges O
from O
8 O
to O
10 O
and O
that O
the O
attributable O
risk O
is O
70 O
% O
to O
80 O
% O
. O

further O
analysis O
of O
these O
data O
suggests O
that O
the O
duration O
of O
therapy O
, O
plasma O
aminoglycoside O
levels O
, O
liver B-Disease
disease I-Disease
, O
advanced O
age O
, O
high O
initial O
estimated O
creatinine O
clearance O
and O
, O
possibly O
, O
female O
gender O
all O
increase O
the O
risk O
for O
nephrotoxicity B-Disease
. O

other O
causes O
of O
acute B-Disease
renal I-Disease
failure I-Disease
, O
such O
as O
shock B-Disease
, O
appear O
to O
have O
an O
additive O
effect O
. O

these O
models O
may O
also O
be O
useful O
in O
developing O
insights O
into O
the O
pathophysiology O
of O
aminoglycoside O
- O
induced O
nephrotoxicity B-Disease
. O

the O
effect O
of O
clonidine O
, O
naphazoline O
and O
xylometazoline O
on O
analgesia O
induced O
by O
morphine O
, O
codeine O
, O
fentanyl O
and O
pentazocine O
, O
and O
on O
cataleptic B-Disease
effect O
of O
morphine O
, O
codine O
and O
fentanyl O
was O
studied O
in O
rats O
. O

it O
was O
found O
that O
three O
drugs O
stimulating O
central O
na O
receptors O
failed O
to O
affect O
the O
analgesic O
ed50 O
of O
all O
antinociceptive O
agents O
and O
they O
enhanced O
catalepsy B-Disease
induced O
by O
morphine O
and O
fentanyl O
. O

codeine O
catalepsy B-Disease
was O
increased O
by O
clonidine O
and O
decreased O
by O
naphazoline O
and O
xylometazoline O
. O

flurothyl O
seizure B-Disease
thresholds O
in O
mice O
treated O
neonatally O
with O
a O
single O
injection O
of O
monosodium O
glutamate O
( O
msg O
) O
: O
evaluation O
of O
experimental O
parameters O
in O
flurothyl O
seizure B-Disease
testing O
. O

monosodium O
glutamate O
( O
msg O
) O
administration O
to O
neonatal O
rodents O
produces O
convulsions B-Disease
and O
results O
in O
numerous O
biochemical O
and O
behavioral O
deficits O
. O

these O
studies O
were O
undertaken O
to O
determine O
if O
neonatal O
administration O
of O
msg O
produced O
permanent O
alterations O
in O
seizure B-Disease
susceptibility O
, O
since O
previous O
investigations O
were O
inconclusive O
. O

a O
flurothyl O
ether O
seizure B-Disease
screening O
technique O
was O
used O
to O
evaluate O
seizure B-Disease
susceptibility O
in O
adult O
mice O
that O
received O
neonatal O
injections O
of O
msg O
( O
4 O
mg O
/ O
g O
and O
1 O
mg O
/ O
g O
) O
. O

msg O
treatment O
resulted O
in O
significant O
reductions O
in O
whole O
brain O
weight O
but O
did O
not O
alter O
seizure B-Disease
threshold O
. O

a O
naloxone O
( O
5 O
mg O
/ O
kg O
) O
challenge O
was O
also O
ineffective O
in O
altering O
the O
seizure B-Disease
thresholds O
of O
either O
control O
of O
msg O
- O
treated O
mice O
. O

flurothyl O
ether O
produced O
hypothermia B-Disease
which O
was O
correlated O
with O
the O
duration O
of O
flurothyl O
exposure O
; O
however O
, O
the O
relationship O
of O
hypothermia B-Disease
to O
seizure B-Disease
induction O
was O
unclear O
. O

flurothyl O
seizure B-Disease
testing O
proved O
to O
be O
a O
rapid O
and O
reliable O
technique O
with O
which O
to O
evaluate O
seizure B-Disease
susceptibility O
. O

susceptibility O
to O
seizures B-Disease
produced O
by O
pilocarpine O
in O
rats O
after O
microinjection O
of O
isoniazid O
or O
gamma O
- O
vinyl O
- O
gaba O
into O
the O
substantia O
nigra O
. O

pilocarpine O
, O
given O
intraperitoneally O
to O
rats O
, O
reproduces O
the O
neuropathological O
sequelae O
of O
temporal B-Disease
lobe I-Disease
epilepsy I-Disease
and O
provides O
a O
relevant O
animal O
model O
for O
studying O
mechanisms O
of O
buildup O
of O
convulsive B-Disease
activity O
and O
pathways O
operative O
in O
the O
generalization O
and O
propagation O
of O
seizures B-Disease
within O
the O
forebrain O
. O

in O
the O
present O
study O
, O
the O
effects O
of O
manipulating O
the O
activity O
of O
the O
gamma O
- O
aminobutyric O
acid O
( O
gaba O
) O
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
on O
seizures B-Disease
produced O
by O
pilocarpine O
in O
rats O
, O
were O
investigated O
. O

in O
animals O
pretreated O
with O
microinjections O
of O
isoniazid O
, O
150 O
micrograms O
, O
an O
inhibitor O
of O
activity O
of O
the O
gaba O
- O
synthesizing O
enzyme O
, O
l O
- O
glutamic O
acid O
decarboxylase O
, O
into O
the O
substantia O
nigra O
pars O
reticulata O
( O
snr O
) O
, O
bilaterally O
, O
non O
- O
convulsant O
doses O
of O
pilocarpine O
, O
100 O
and O
200 O
mg O
/ O
kg O
, O
resulted O
in O
severe O
motor O
limbic O
seizures B-Disease
and O
status B-Disease
epilepticus I-Disease
. O

electroencephalographic O
and O
behavioral O
monitoring O
revealed O
a O
profound O
reduction O
of O
the O
threshold O
for O
pilocarpine O
- O
induced O
convulsions B-Disease
. O

morphological O
analysis O
of O
frontal O
forebrain O
sections O
with O
light O
microscopy O
revealed O
seizure B-Disease
- O
related O
damage O
to O
the O
hippocampal O
formation O
, O
thalamus O
, O
amygdala O
, O
olfactory O
cortex O
, O
substantia O
nigra O
and O
neocortex O
, O
which O
is O
typically O
observed O
with O
pilocarpine O
in O
doses O
exceeding O
350 O
mg O
/ O
kg O
. O

bilateral O
intrastriatal O
injections O
of O
isoniazid O
did O
not O
augment O
seizures B-Disease
produced O
by O
pilocarpine O
, O
200 O
mg O
/ O
kg O
. O

application O
of O
an O
irreversible O
inhibitor O
of O
gaba O
transaminase O
, O
gamma O
- O
vinyl O
- O
gaba O
( O
d O
, O
l O
- O
4 O
- O
amino O
- O
hex O
- O
5 O
- O
enoic O
acid O
) O
, O
5 O
micrograms O
, O
into O
the O
snr O
, O
bilaterally O
, O
suppressed O
the O
appearance O
of O
electrographic O
and O
behavioral O
seizures B-Disease
produced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

this O
treatment O
was O
also O
sufficient O
to O
protect O
animals O
from O
the O
occurrence O
of O
brain B-Disease
damage I-Disease
. O

microinjections O
of O
gamma O
- O
vinyl O
- O
gaba O
, O
5 O
micrograms O
, O
into O
the O
dorsal O
striatum O
, O
bilaterally O
, O
failed O
to O
prevent O
the O
development O
of O
convulsions B-Disease
produced O
by O
pilocarpine O
, O
380 O
mg O
/ O
kg O
. O

the O
results O
demonstrate O
that O
the O
threshold O
for O
pilocarpine O
- O
induced O
seizures B-Disease
in O
rats O
is O
subjected O
to O
the O
regulation O
of O
the O
gaba O
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
. O

human O
and O
canine O
ventricular O
vasoactive O
intestinal O
polypeptide O
: O
decrease O
with O
heart B-Disease
failure I-Disease
. O

myocardial O
levels O
of O
vip O
were O
assayed O
before O
and O
after O
the O
development O
of O
heart B-Disease
failure I-Disease
in O
two O
canine O
models O
. O

in O
the O
first O
, O
cobalt O
cardiomyopathy B-Disease
was O
induced O
in O
eight O
dogs O
; O
vip O
( O
by O
radioimmunoassay O
) O
decreased O
from O
35 O
+ O
/ O
- O
11 O
pg O
/ O
mg O
protein O
( O
mean O
+ O
/ O
- O
sd O
) O
to O
5 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
p O
less O
than O
0 O
. O

5 O
) O
. O

in O
six O
dogs O
with O
doxorubicin O
- O
induced O
heart B-Disease
failure I-Disease
, O
vip O
decreased O
from O
31 O
+ O
/ O
- O
7 O
to O
11 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
p O
less O
than O
0 O
. O

5 O
) O
. O

in O
addition O
, O
vip O
content O
of O
left O
ventricular O
muscle O
of O
resected O
failing O
hearts O
in O
10 O
patients O
receiving O
a O
heart O
transB-Plant O
was O
compared O
with O
the O
papillary O
muscles O
in O
14 O
patients O
( O
five O
with O
rheumatic B-Disease
disease I-Disease
, O
nine O
with O
myxomatous B-Disease
degeneration I-Disease
) O
receiving O
mitral O
valve O
prostheses O
. O

the O
lowest O
myocardial O
vip O
concentration O
was O
found O
in O
the O
hearts O
of O
patients O
with O
coronary B-Disease
disease I-Disease
( O
one O
patient O
receiving O
a O
transB-Plant O
and O
three O
receiving O
mitral O
prostheses O
) O
( O
6 O
. O

3 O
+ O
/ O
- O
1 O
. O

9 O
pg O
/ O
mg O
protein O
) O
. O

the O
hearts O
without O
coronary B-Disease
artery I-Disease
disease I-Disease
( O
average O
ejection O
fraction O
of O
this O
group O
62 O
% O
+ O
/ O
- O
10 O
% O
) O
had O
a O
vip O
concentration O
of O
14 O
. O

1 O
+ O
/ O
- O
7 O
. O

9 O
pg O
/ O
mg O
protein O
, O
and O
this O
was O
greater O
than O
in O
hearts O
of O
the O
patients O
with O
coronary B-Disease
disease I-Disease
and O
the O
hearts O
of O
patients O
receiving O
a O
transB-Plant O
( O
p O
less O
than O
0 O
. O

5 O
) O
. O

non O
- O
invasive O
detection O
of O
coronary B-Disease
artery I-Disease
disease I-Disease
by O
body O
surface O
electrocardiographic O
mapping O
after O
dipyridamole O
infusion O
. O

electrocardiographic O
changes O
after O
dipyridamole O
infusion O
( O
0 O
. O

568 O
mg O
/ O
kg O
/ O
4 O
min O
) O
were O
studied O
in O
41 O
patients O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
and O
compared O
with O
those O
after O
submaximal O
treadmill O
exercise O
by O
use O
of O
the O
body O
surface O
mapping O
technique O
. O

patients O
were O
divided O
into O
three O
groups O
; O
19 O
patients O
without O
myocardial B-Disease
infarction I-Disease
( O
non O
- O
mi B-Disease
group O
) O
, O
14 O
with O
anterior B-Disease
infarction I-Disease
( O
ant B-Disease
- I-Disease
mi I-Disease
) O
and O
eight O
with O
inferior B-Disease
infarction I-Disease
( O
inf B-Disease
- I-Disease
mi I-Disease
) O
. O

after O
dipyridamole O
, O
ischemic B-Disease
st O
- O
segment O
depression B-Disease
( O
0 O
. O

5 O
mv O
or O
more O
) O
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
mi B-Disease
group O
, O
29 O
% O
of O
the O
ant B-Disease
- I-Disease
mi I-Disease
group O
, O
63 O
% O
of O
the O
inf B-Disease
- I-Disease
mi I-Disease
group O
and O
61 O
% O
of O
the O
total O
population O
. O

exercise O
- O
induced O
st O
depression B-Disease
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
mi B-Disease
group O
, O
43 O
% O
of O
the O
ant B-Disease
- I-Disease
mi I-Disease
group O
, O
38 O
% O
of O
the O
inf B-Disease
- I-Disease
mi I-Disease
group O
and O
61 O
% O
of O
the O
total O
. O

for O
individual O
patients O
, O
there O
were O
no O
obvious O
differences O
between O
the O
body O
surface O
distribution O
of O
st O
depression B-Disease
in O
both O
tests O
. O

the O
data O
suggest O
that O
the O
dipyridamole O
- O
induced O
myocardial B-Disease
ischemia I-Disease
is O
caused O
by O
the O
inhomogenous O
distribution O
of O
myocardial O
blood O
flow O
. O

we O
conclude O
that O
the O
dipyridamole O
ecg O
test O
is O
as O
useful O
as O
the O
exercise O
ecg O
test O
for O
the O
assessment O
of O
coronary B-Disease
artery I-Disease
disease I-Disease
. O

bradycardia B-Disease
after O
high O
- O
dose O
intravenous O
methylprednisolone O
therapy O
. O

in O
5 O
consecutive O
patients O
with O
rheumatoid B-Disease
arthritis I-Disease
who O
received O
intravenous O
high O
- O
dose O
methylprednisolone O
( O
mp O
) O
therapy O
( O
1 O
g O
daily O
for O
2 O
or O
3 O
consecutive O
days O
) O
, O
a O
decline O
in O
pulse O
rate O
was O
observed O
, O
most O
pronounced O
on O
day O
4 O
. O

in O
one O
of O
the O
5 O
patients O
the O
bradycardia B-Disease
was O
associated O
with O
complaints O
of O
substernal O
pressure O
. O

electrocardiographic O
registrations O
showed O
sinus B-Disease
bradycardia I-Disease
in O
all O
cases O
. O

high O
- O
dose O
mp O
may O
be O
contraindicated O
in O
patients O
with O
known O
heart B-Disease
disease I-Disease
. O

two O
cases O
of O
downbeat B-Disease
nystagmus I-Disease
and O
oscillopsia B-Disease
associated O
with O
carbamazepine O
. O

downbeat B-Disease
nystagmus I-Disease
is O
often O
associated O
with O
structural O
lesions O
at O
the O
craniocervical O
junction O
, O
but O
has O
occasionally O
been O
reported O
as O
a O
manifestation O
of O
metabolic O
imbalance O
or O
drug O
intoxication O
. O

we O
recorded O
the O
eye O
movements O
of O
two O
patients O
with O
reversible O
downbeat B-Disease
nystagmus I-Disease
related O
to O
carbamazepine O
therapy O
. O

the O
nystagmus B-Disease
of O
both O
patients O
resolved O
after O
reduction O
of O
the O
serum O
carbamazepine O
levels O
. O

in O
patients O
with O
downbeat B-Disease
nystagmus I-Disease
who O
are O
taking O
anticonvulsant O
medications O
, O
consideration O
should O
be O
given O
to O
reduction O
in O
dose O
before O
further O
investigation O
is O
undertaken O
. O

improvement O
by O
denopamine O
( O
ta O
- O
64 O
) O
of O
pentobarbital O
- O
induced O
cardiac B-Disease
failure I-Disease
in O
the O
dog O
heart O
- O
lung O
preparation O
. O

the O
efficacy O
of O
denopamine O
, O
an O
orally O
active O
beta O
1 O
- O
adrenoceptor O
agonist O
, O
in O
improving O
cardiac B-Disease
failure I-Disease
was O
assessed O
in O
dog O
heart O
- O
lung O
preparations O
. O

no O
arrhythmias B-Disease
were O
induced O
by O
these O
doses O
of O
denopamine O
. O

the O
results O
warrant O
clinical O
trials O
of O
denopamine O
in O
the O
treatment O
of O
cardiac B-Disease
failure I-Disease
. O

clonazepam O
monotherapy O
for O
epilepsy B-Disease
in O
childhood O
. O

sixty O
patients O
( O
age O
- O
range O
one O
month O
to O
14 O
years O
) O
with O
other O
types O
of O
epilepsy B-Disease
than O
infantile B-Disease
spasms I-Disease
were O
treated O
with O
clonazepam O
. O

disappearance O
of O
seizures B-Disease
and O
normalization O
of O
abnormal O
eeg O
with O
disappearance O
of O
seizures B-Disease
were O
recognized O
in O
77 O
% O
and O
50 O
% O
, O
respectively O
. O

seizures B-Disease
disappeared O
in O
71 O
% O
of O
the O
patients O
with O
generalized O
seizures B-Disease
and O
89 O
% O
of O
partial O
seizures B-Disease
. O

the O
incidence O
of O
side O
effects O
such O
as O
drowsiness B-Disease
and O
ataxia B-Disease
was O
only O
5 O
% O
. O

a O
postmarketing O
surveillance O
study O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
a O
fixed O
- O
ratio O
combination O
containing O
10 O
mg O
of O
timolol O
maleate O
and O
25 O
mg O
of O
hydrochlorothiazide O
, O
administered O
twice O
daily O
for O
one O
month O
to O
hypertensive B-Disease
patients O
. O

the O
antihypertensive O
effect O
of O
the O
drug O
was O
greater O
in O
patients O
with O
more O
severe O
hypertension B-Disease
. O

overall O
, O
1 O
, O
453 O
patients O
experienced O
a O
total O
of O
2 O
, O
658 O
adverse O
events O
, O
the O
most O
common O
being O
fatigue B-Disease
, O
dizziness B-Disease
, O
and O
weakness B-Disease
. O

salicylate O
nephropathy B-Disease
in O
the O
gunn O
rat O
: O
potential O
role O
of O
prostaglandins O
. O

we O
examined O
the O
potential O
role O
of O
prostaglandins O
in O
the O
development O
of O
analgesic O
nephropathy B-Disease
in O
the O
gunn O
strain O
of O
rat O
. O

the O
homozygous O
gunn O
rats O
have O
unconjugated O
hyperbilirubinemia B-Disease
due O
to O
the O
absence O
of O
glucuronyl O
transferase O
, O
leading O
to O
marked O
bilirubin O
deposition O
in O
renal O
medulla O
and O
papilla O
. O

these O
rats O
are O
also O
highly O
susceptible O
to O
develop O
papillary B-Disease
necrosis I-Disease
with O
analgesic O
administration O
. O

the O
changes O
in O
renal O
prostaglandin O
synthesis O
were O
accompanied O
by O
evidence O
of O
renal B-Disease
damage I-Disease
in O
aspirin O
- O
treated O
jj O
but O
not O
jj O
rats O
as O
evidenced O
by O
: O
increased O
incidence O
and O
severity O
of O
hematuria B-Disease
( O
p O
less O
than O
0 O
. O

1 O
) O
; O
increased O
serum O
creatinine O
( O
p O
less O
than O
0 O
. O

5 O
) O
; O
and O
increase O
in O
outer O
medullary O
histopathologic O
lesions O
( O
p O
less O
than O
0 O
. O

5 O
compared O
to O
either O
sham O
- O
treated O
jj O
or O
aspirin O
- O
treated O
jj O
) O
. O

these O
results O
suggest O
that O
enhanced O
prostaglandin O
synthesis O
contributes O
to O
maintenance O
of O
renal O
function O
and O
morphological O
integrity O
, O
and O
that O
inhibition O
of O
prostaglandin O
synthesis O
may O
lead O
to O
pathological B-Disease
renal I-Disease
medullary I-Disease
lesions I-Disease
and O
deterioration B-Disease
of I-Disease
renal I-Disease
function I-Disease
. O

prophylactic O
lidocaine O
in O
the O
early O
phase O
of O
suspected O
myocardial B-Disease
infarction I-Disease
. O

four O
hundred O
two O
patients O
with O
suspected O
myocardial B-Disease
infarction I-Disease
seen O
within O
6 O
hours O
of O
the O
onset O
of O
symptoms O
entered O
a O
double O
- O
blind O
randomized O
trial O
of O
lidocaine O
vs O
placebo O
. O

during O
the O
1 O
hour O
after O
administration O
of O
the O
drug O
the O
incidence O
of O
ventricular B-Disease
fibrillation I-Disease
or O
sustained O
ventricular B-Disease
tachycardia I-Disease
among O
the O
204 O
patients O
with O
acute O
myocardial B-Disease
infarction I-Disease
was O
low O
, O
1 O
. O

5 O
% O
. O

lidocaine O
, O
given O
in O
a O
300 O
mg O
dose O
intramuscularly O
followed O
by O
100 O
mg O
intravenously O
, O
did O
not O
prevent O
sustained O
ventricular B-Disease
tachycardia I-Disease
, O
although O
there O
was O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
warning O
arrhythmias B-Disease
between O
15 O
and O
45 O
minutes O
after O
the O
administration O
of O
lidocaine O
( O
p O
less O
than O
0 O
. O

5 O
) O
. O

the O
average O
plasma O
lidocaine O
level O
10 O
minutes O
after O
administration O
for O
patients O
without O
a O
myocardial B-Disease
infarction I-Disease
was O
significantly O
higher O
than O
that O
for O
patients O
with O
an O
acute O
infarction B-Disease
. O

during O
the O
1 O
- O
hour O
study O
period O
, O
the O
incidence O
of O
central O
nervous O
system O
side O
effects O
was O
significantly O
greater O
in O
the O
lidocaine O
group O
, O
hypotension B-Disease
occurred O
in O
11 O
patients O
, O
nine O
of O
whom O
had O
received O
lidocaine O
, O
and O
four O
patients O
died O
from O
asystole B-Disease
, O
three O
of O
whom O
had O
had O
lidocaine O
. O

we O
cannot O
advocate O
the O
administration O
of O
lidocaine O
prophylactically O
in O
the O
early O
hours O
of O
suspected O
myocardial B-Disease
infarction I-Disease
. O

evidence O
for O
a O
cholinergic O
role O
in O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

experiments O
in O
mice O
tested O
previous O
evidence O
that O
activation O
of O
cholinergic O
systems O
promotes O
catalepsy B-Disease
and O
that O
cholinergic O
mechanisms O
need O
to O
be O
intact O
for O
full O
expression O
of O
neuroleptic O
- O
induced O
catalepsy B-Disease
. O

large O
doses O
of O
the O
cholinomimetic O
, O
pilocarpine O
, O
could O
induce O
catalepsy B-Disease
when O
peripheral O
cholinergic O
receptors O
were O
blocked O
. O

low O
doses O
of O
pilocarpine O
caused O
a O
pronounced O
enhancement O
of O
the O
catalepsy B-Disease
that O
was O
induced O
by O
the O
dopaminergic O
blocker O
, O
haloperidol O
. O

a O
muscarinic O
receptor O
blocker O
, O
atropine O
, O
disrupted O
haloperidol O
- O
induced O
catalepsy B-Disease
. O

intracranial O
injection O
of O
an O
acetylcholine O
- O
synthesis O
inhibitor O
, O
hemicholinium O
, O
prevented O
the O
catalepsy B-Disease
that O
is O
usually O
induced O
by O
haloperidol O
. O

these O
findings O
suggest O
the O
hypothesis O
that O
the O
catalepsy B-Disease
that O
is O
produced O
by O
neuroleptics O
such O
as O
haloperidol O
is O
actually O
mediated O
by O
intrinsic O
central O
cholinergic O
systems O
. O

alternatively O
, O
activation O
of O
central O
cholinergic O
systems O
could O
promote O
catalepsy B-Disease
by O
suppression O
of O
dopaminergic O
systems O
. O

cardiovascular B-Disease
dysfunction I-Disease
and O
hypersensitivity B-Disease
to O
sodium O
pentobarbital O
induced O
by O
chronic O
barium O
chloride O
ingestion O
. O

barium O
- O
supplemented O
long O
- O
evans O
hooded O
rats O
were O
characterized O
by O
a O
persistent O
hypertension B-Disease
that O
was O
evident O
after O
1 O
month O
of O
barium O
( O
100 O
micrograms O
/ O
ml O
mineral O
fortified O
water O
) O
treatment O
. O

analysis O
of O
in O
vivo O
myocardial O
excitability O
, O
contractility O
, O
and O
metabolic O
characteristics O
at O
16 O
months O
revealed O
other O
significant O
barium O
- O
induced O
disturbances B-Disease
within I-Disease
the I-Disease
cardiovascular I-Disease
system I-Disease
. O

the O
most O
distinctive O
aspect O
of O
the O
barium O
effect O
was O
a O
demonstrated O
hypersensitivity B-Disease
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
. O

overall O
, O
the O
altered O
cardiac O
contractility O
and O
excitability O
characteristics O
, O
the O
myocardial O
metabolic B-Disease
disturbances I-Disease
, O
and O
the O
hypersensitivity B-Disease
of O
the O
cardiovascular O
system O
to O
sodium O
pentobarbital O
suggest O
the O
existence O
of O
a O
heretofore O
undescribed O
cardiomyopathic B-Disease
disorder I-Disease
induced O
by O
chronic O
barium O
exposure O
. O

propranolol O
antagonism O
of O
phenylpropanolamine O
- O
induced O
hypertension B-Disease
. O

phenylpropanolamine O
( O
ppa O
) O
overdose B-Disease
can O
cause O
severe O
hypertension B-Disease
, O
intracerebral B-Disease
hemorrhage I-Disease
, O
and O
death O
. O

we O
studied O
the O
efficacy O
and O
safety O
of O
propranolol O
in O
the O
treatment O
of O
ppa O
- O
induced O
hypertension B-Disease
. O

left O
ventricular O
function O
( O
assessed O
by O
echocardiography O
) O
showed O
that O
ppa O
increased O
the O
stroke B-Disease
volume O
30 O
% O
( O
from O
62 O
. O

5 O
+ O
/ O
- O
20 O
. O

9 O
to O
80 O
. O

8 O
+ O
/ O
- O
22 O
. O

4 O
ml O
) O
, O
the O
ejection O
fraction O
9 O
% O
( O
from O
64 O
% O
+ O
/ O
- O
10 O
% O
to O
70 O
% O
+ O
/ O
- O
7 O
% O
) O
, O
and O
cardiac O
output O
14 O
% O
( O
from O
3 O
. O

6 O
+ O
/ O
- O
0 O
. O

6 O
to O
4 O
. O

1 O
+ O
/ O
- O
1 O
. O

0 O
l O
/ O
min O
) O
. O

mesangial O
function O
and O
glomerular B-Disease
sclerosis I-Disease
in O
rats O
with O
aminonucleoside O
nephrosis B-Disease
. O

the O
possible O
relationship O
between O
mesangial B-Disease
dysfunction I-Disease
and O
development O
of O
glomerular B-Disease
sclerosis I-Disease
was O
studied O
in O
the O
puromycin O
aminonucleoside O
( O
pan O
) O
model O
. O

after O
4 O
weeks O
the O
pan O
rats O
were O
severely O
proteinuric B-Disease
( O
190 O
+ O
/ O
- O
80 O
mg O
/ O
24 O
hr O
) O
, O
and O
all O
rats O
were O
given O
colloidal O
carbon O
( O
cc O
) O
intravenously O
. O

at O
5 O
months O
glomerular B-Disease
sclerosis I-Disease
was O
found O
in O
7 O
. O

6 O
+ O
/ O
- O
3 O
. O

4 O
% O
of O
the O
glomeruli O
of O
pan O
rats O
; O
glomeruli O
of O
the O
controls O
were O
normal O
. O

glomeruli O
with O
sclerosis B-Disease
contained O
significantly O
more O
cc O
than O
non O
- O
sclerotic O
glomeruli O
in O
the O
same O
kidneys O
. O

since O
mesangial O
cc O
clearance O
from O
the O
mesangium O
did O
not O
change O
during O
chronic O
pan O
treatment O
, O
we O
conclude O
that O
this O
preferential O
cc O
localization O
within O
the O
lesions O
is O
caused O
by O
an O
increased O
cc O
uptake O
shortly O
after O
injection O
in O
apparent O
vulnerable O
areas O
where O
sclerosis B-Disease
will O
develop O
subsequently O
. O

similar O
to O
the O
remnant O
kidney O
model O
in O
pan O
nephrosis B-Disease
the O
development O
of O
glomerular B-Disease
sclerosis I-Disease
may O
be O
related O
to O
nan O
mesangial O
overloading O
. O

nan O
relationship O
between O
nicotine O
- O
induced O
seizures B-Disease
and O
hippocampal O
nicotinic O
receptors O
. O

using O
mice O
derived O
from O
a O
classical O
f2 O
and O
backcross O
genetic O
design O
, O
a O
relationship O
between O
nicotine O
- O
induced O
seizures B-Disease
and O
alpha O
- O
bungarotoxin O
nicotinic O
receptor O
concentration O
was O
found O
. O

mice O
sensitive O
to O
the O
convulsant O
effects O
of O
nicotine O
had O
greater O
alpha O
- O
bungarotoxin O
binding O
in O
the O
hippocampus O
than O
seizure B-Disease
insensitive O
mice O
. O

the O
binding O
sites O
from O
seizure B-Disease
sensitive O
and O
resistant O
mice O
were O
equally O
affected O
by O
treatment O
with O
dithiothreitol O
, O
trypsin O
or O
heat O
. O

thus O
it O
appears O
that O
the O
difference O
between O
seizure B-Disease
sensitive O
and O
insensitive O
animals O
may O
be O
due O
to O
a O
difference O
in O
hippocampal O
nicotinic O
receptor O
concentration O
as O
measured O
with O
alpha O
- O
bungarotoxin O
binding O
. O

the O
role O
of O
p O
- O
aminophenol O
in O
acetaminophen O
- O
induced O
nephrotoxicity B-Disease
: O
effect O
of O
bis O
( O
p O
- O
nitrophenyl O
) O
phosphate O
on O
acetaminophen O
and O
p O
- O
aminophenol O
nephrotoxicity B-Disease
and O
metabolism O
in O
fischer O
344 O
rats O
. O

acetaminophen O
( O
apap O
) O
produces O
proximal O
tubular B-Disease
necrosis I-Disease
in O
fischer O
344 O
( O
f344 O
) O
rats O
. O

the O
purpose O
of O
this O
study O
was O
to O
determine O
if O
pap O
formation O
is O
a O
requisite O
step O
in O
apap O
- O
induced O
nephrotoxicity B-Disease
. O

therefore O
, O
the O
effect O
of O
bis O
( O
p O
- O
nitrophenyl O
) O
phosphate O
( O
bnpp O
) O
, O
an O
acylamidase O
inhibitor O
, O
on O
apap O
and O
pap O
nephrotoxicity B-Disease
and O
metabolism O
was O
determined O
. O

pretreatment O
of O
animals O
with O
bnpp O
prior O
to O
apap O
or O
pap O
administration O
resulted O
in O
marked O
reduction O
of O
apap O
( O
900 O
mg O
/ O
kg O
) O
nephrotoxicity B-Disease
but O
not O
pap O
nephrotoxicity B-Disease
. O

therefore O
, O
the O
bnpp O
- O
induced O
reduction O
in O
apap O
- O
induced O
nephrotoxicity B-Disease
appears O
to O
be O
due O
to O
inhibition O
of O
apap O
deacetylation O
. O

it O
is O
concluded O
that O
pap O
formation O
, O
in O
vivo O
, O
accounts O
, O
at O
least O
in O
part O
, O
for O
apap O
- O
induced O
renal B-Disease
tubular I-Disease
necrosis I-Disease
. O

morphine O
- O
induced O
seizures B-Disease
in O
newborn O
infants O
. O

two O
neonates O
suffered O
from O
generalized O
seizures B-Disease
during O
the O
course O
of O
intravenous O
morphine O
sulfate O
for O
post O
- O
operative O
analgesia O
. O

they O
received O
morphine O
in O
doses O
of O
32 O
micrograms O
/ O
kg O
/ O
hr O
and O
40 O
micrograms O
/ O
kg O
/ O
hr O
larger O
than O
a O
group O
of O
10 O
neonates O
who O
received O
6 O
- O
24 O
micrograms O
/ O
kg O
/ O
hr O
and O
had O
no O
seizures B-Disease
. O

other O
known O
reasons O
for O
seizures B-Disease
were O
ruled O
out O
and O
the O
convulsions B-Disease
stopped O
a O
few O
hours O
after O
cessation O
of O
morphine O
and O
did O
not O
reoccur O
in O
the O
subsequent O
8 O
months O
. O

indomethacin O
induced O
hypotension B-Disease
in O
sodium O
and O
volume O
depleted O
rats O
. O

four O
types O
of O
experimental O
arrhythmia B-Disease
are O
used O
- O
- O
with O
bacl2 O
, O
with O
chloroform O
- O
adrenaline O
, O
with O
strophantine O
g O
and O
with O
aconitine O
. O

the O
compound O
manifests O
antiarrhythmic O
activity O
in O
all O
models O
of O
experimental O
arrhythmia B-Disease
used O
, O
causing O
greatest O
inhibition O
on O
the O
arrhythmia B-Disease
induced O
by O
chloroform O
- O
adrenaline O
( O
in O
90 O
per O
cent O
) O
and O
with O
bacl2 O
( O
in O
84 O
per O
cent O
) O
. O

recurrent O
subarachnoid B-Disease
hemorrhage I-Disease
associated O
with O
aminocaproic O
acid O
therapy O
and O
acute B-Disease
renal I-Disease
artery I-Disease
thrombosis I-Disease
. O

epsilon O
aminocaproic O
acid O
( O
eaca O
) O
has O
been O
used O
to O
prevent O
rebleeding O
in O
patients O
with O
subarachnoid B-Disease
hemorrhage I-Disease
( O
sah B-Disease
) O
. O

although O
this O
agent O
does O
decrease O
the O
frequency O
of O
rebleeding O
, O
several O
reports O
have O
described O
thrombotic B-Disease
complications O
of O
eaca O
therapy O
. O

these O
complications O
have O
included O
clinical O
deterioration O
and O
intracranial B-Disease
vascular I-Disease
thrombosis I-Disease
in O
patients O
with O
sah B-Disease
, O
arteriolar O
and O
capillary O
fibrin O
thrombi B-Disease
in O
patients O
with O
fibrinolytic O
syndromes O
treated O
with O
eaca O
, O
or O
other O
thromboembolic B-Disease
phenomena I-Disease
. O

since O
intravascular O
fibrin O
thrombi B-Disease
are O
often O
observed O
in O
patients O
with O
fibrinolytic O
disorders O
, O
eaca O
should O
not O
be O
implicated O
in O
the O
pathogenesis O
of O
fibrin O
thrombi B-Disease
in O
patients O
with O
disseminated B-Disease
intravascular I-Disease
coagulation I-Disease
or O
other O
nan O
consumption B-Disease
coagulopathies I-Disease
. O

nan O
this O
report O
describes O
subtotal O
infarction B-Disease
of O
the O
kidney O
due O
to O
thrombosis B-Disease
of I-Disease
a I-Disease
normal I-Disease
renal I-Disease
artery I-Disease
. O

this O
occlusion O
occurred O
after O
eaca O
therapy O
in O
a O
patient O
with O
sah B-Disease
and O
histopathological O
documentation O
of O
recurrent O
sah B-Disease
. O

the O
corresponding O
clinical O
event O
was O
characterized O
by O
marked O
hypertension B-Disease
and O
abrupt O
neurological O
deterioration O
. O

effect O
of O
vincristine O
sulfate O
on O
pseudomonas B-Disease
infections I-Disease
in O
monkeys O
. O

leukocytosis B-Disease
was O
observed O
in O
all O
monkeys O
. O

intravenous O
or O
intratracheal O
inoculation O
of O
2 O
. O

0 O
to O
2 O
. O

5 O
mg O
of O
vincristine O
sulfate O
was O
followed O
by O
leukopenia B-Disease
in O
4 O
to O
5 O
days O
. O

intravenous O
inoculation O
of O
4 O
. O

2 O
x O
10 O
( O
10 O
) O
to O
7 O
. O

8 O
x O
10 O
( O
10 O
) O
pyocin O
type O
6 O
pseudomonas O
organisms O
in O
monkeys O
given O
vincristine O
sulfate O
4 O
days O
previously O
resulted O
in O
fatal O
infection B-Disease
in O
11 O
of O
14 O
monkeys O
, O
whereas O
none O
of O
four O
receiving O
pseudomonas O
alone O
died O
. O

these O
studies O
suggest O
that O
an O
antimetabolite O
- O
induced O
leukopenia B-Disease
predisposes O
to O
severe O
pseudomonas O
sepsis B-Disease
and O
that O
such O
monkeys O
may O
serve O
as O
a O
biological O
model O
for O
study O
of O
comparative O
efficacy O
of O
antimicrobial O
agents O
. O

modification O
by O
propranolol O
of O
cardiovascular O
effects O
of O
induced O
hypoglycaemia B-Disease
. O

the O
cardiovascular O
effects O
of O
hypoglycaemia B-Disease
, O
with O
and O
without O
beta O
- O
blockade O
, O
were O
compared O
in O
fourteen O
healthy O
men O
. O

in O
the O
insulin O
- O
group O
the O
period O
of O
hypoglycaemia B-Disease
was O
associated O
with O
an O
increase O
in O
heart O
- O
rate O
and O
a O
fall O
in O
diastolic O
blood O
- O
pressure O
. O

hypertension B-Disease
in O
diabetics B-Disease
prone O
to O
hypoglycaemia B-Disease
attacks O
should O
not O
be O
treated O
with O
beta O
- O
blockers O
because O
these O
drugs O
may O
cause O
a O
sharp O
rise O
in O
blood O
- O
pressure O
in O
such O
patients O
. O

we O
conclude O
that O
previously O
reported O
hypoglycemia B-Disease
, O
hyperbilirubinemia B-Disease
, O
polycythemia B-Disease
, O
neonatal B-Disease
apnea I-Disease
, O
and O
bradycardia B-Disease
are O
not O
invariable O
and O
cannot O
be O
statistically O
correlated O
with O
chronic O
propranolol O
therapy O
. O

growth B-Disease
retardation I-Disease
, O
however O
, O
appears O
to O
be O
significant O
in O
both O
of O
our O
series O
. O

high O
doses O
caused O
an O
apparent O
central O
excitation O
, O
most O
clearly O
seen O
as O
clonic O
convulsions B-Disease
, O
superimposed O
on O
general O
depression B-Disease
. O

following O
a O
lethal O
dose O
, O
death O
was O
always O
associated O
with O
convulsions B-Disease
. O

comparing O
the O
relative O
sensitivity O
to O
central O
depression B-Disease
and O
excitation O
revealed O
that O
rats O
were O
least O
likely O
to O
have O
convulsions B-Disease
at O
doses O
that O
did O
not O
first O
cause O
loss B-Disease
of I-Disease
consciousness I-Disease
, O
while O
cats O
most O
clearly O
showed O
marked O
central O
excitatory O
actions O
. O

signs O
of O
fzp O
toxocity B-Disease
in O
cats O
included O
excessive O
salivation B-Disease
, O
extreme O
apprehensive O
behavior O
, O
retching O
, O
muscle B-Disease
tremors I-Disease
and O
convulsions B-Disease
. O

as O
a O
function O
of O
dose O
, O
fzp O
first O
protected O
against O
convulsions B-Disease
and O
death O
. O

at O
higher O
doses O
, O
however O
, O
convulsions B-Disease
again O
emerged O
. O

these O
doses O
of O
fzp O
were O
lower O
than O
those O
that O
would O
alone O
cause O
convulsions B-Disease
. O

these O
results O
may O
be O
relevant O
to O
the O
use O
of O
fzp O
in O
clinical O
situations O
in O
which O
there O
is O
increased O
neural O
excitability O
, O
such O
as O
epilepsy B-Disease
or O
sedative O
- O
hypnotic O
drug O
withdrawal O
. O

use O
of O
propranolol O
in O
the O
treatment O
of O
idiopathic B-Disease
orthostatic I-Disease
hypotension I-Disease
. O

five O
patients O
with O
idiopathic B-Disease
orthostatic I-Disease
hypotension I-Disease
who O
had O
physiologic O
and O
biochemical O
evidence O
of O
severe O
autonomic O
dysfunction O
were O
included O
in O
the O
study O
. O

they O
all O
exhibited O
markedly O
reduced O
plasma O
catecholamines O
and O
plasma O
renin O
activity O
in O
both O
recumbent O
and O
upright O
positions O
and O
had O
marked O
hypersensitivity B-Disease
to O
the O
pressor O
effects O
of O
infused O
norepinephrine O
. O

in O
1 O
patient O
, O
marked O
hypertension B-Disease
was O
induced O
by O
propranolol O
and O
the O
drug O
had O
to O
be O
withdrawn O
. O

the O
studies O
suggest O
that O
propranolol O
is O
a O
useful O
drug O
in O
selected O
patients O
with O
severe O
idiopathic B-Disease
orthostatic I-Disease
hypotension I-Disease
. O

the O
investigation O
was O
discontinued O
after O
18 O
patients O
because O
of O
the O
frequency O
and O
intensity O
of O
side O
- O
effects O
, O
particularly O
pain B-Disease
and O
myoclonia B-Disease
, O
which O
caused O
the O
technique O
to O
be O
abandoned O
in O
two O
cases O
. O

it O
is O
considered O
unlikely O
that O
etomidate O
will O
prove O
to O
be O
the O
hypnotic O
of O
choice O
for O
a O
totally O
intravenous O
anesthetic O
technique O
in O
adults O
because O
of O
the O
high O
incidence O
of O
myoclonia B-Disease
after O
prolonged O
administration O
. O

we O
compared O
the O
effects O
of O
single O
doses O
of O
50 O
mg O
atenolol O
( O
cardioselective O
) O
, O
40 O
mg O
propranolol O
( O
nonselective O
) O
, O
and O
placebo O
on O
both O
exercise O
- O
and O
isoproterenol O
- O
induced O
tachycardia B-Disease
in O
two O
experiments O
involving O
nine O
normal O
subjects O
. O

the O
effects O
on O
isoproterenol O
tachycardia B-Disease
were O
determined O
before O
and O
after O
atropine O
( O
0 O
. O

4 O
mg O
/ O
kg O
iv O
) O
. O

these O
data O
are O
consistent O
with O
the O
hypothesis O
that O
exercise O
- O
induced O
tachycardia B-Disease
results O
largely O
from O
beta O
1 O
- O
receptor O
activation O
that O
is O
blocked O
by O
both O
cardioselective O
and O
nonselective O
drugs O
, O
whereas O
isoproterenol O
activates O
both O
beta O
1 O
- O
and O
beta O
2 O
- O
receptors O
so O
that O
after O
cardioselective O
blockade O
there O
remains O
a O
beta O
2 O
- O
component O
that O
can O
be O
blocked O
with O
a O
nonselective O
drug O
. O

hormones O
and O
risk O
of O
breast B-Disease
cancer I-Disease
. O

mastodynia B-Disease
was O
reported O
by O
21 O
patients O
, O
and O
physical O
examination O
revealed O
a O
light O
increase O
in O
breast O
firmness O
in O
12 O
women O
and O
a O
moderate O
increase O
in O
breast O
nodularity O
in O
2 O
women O
. O

themography O
confirmed O
the O
existence O
of O
an O
excessive O
breast O
stimulation O
in O
1 O
women O
who O
complained O
of O
moderate O
mastodynia B-Disease
and O
in O
5 O
of O
the O
7 O
women O
who O
complained O
of O
severe O
mastodynia B-Disease
. O

early O
infections B-Disease
in O
kidney O
, O
heart O
, O
and O
liver O
transB-Plant O
recipients O
on O
cyclosporine O
. O

eighty O
- O
one O
renal O
, O
seventeen O
heart O
, O
and O
twenty O
- O
four O
liver O
transB-Plant O
patients O
were O
followed O
for O
infection B-Disease
. O

the O
randomized O
aza O
patients O
had O
more O
overall O
infections B-Disease
( O
p O
less O
than O
0 O
. O

5 O
) O
and O
more O
nonviral O
infections B-Disease
( O
p O
less O
than O
0 O
. O

2 O
) O
than O
the O
randomized O
cyclosporine O
patients O
. O

heart O
and O
liver O
patients O
had O
more O
infections B-Disease
than O
cyclosporine O
renal O
patients O
but O
fewer O
infections B-Disease
than O
the O
aza O
renal O
patients O
. O

there O
were O
no O
infectious O
deaths O
in O
renal O
transB-Plant O
patients O
on O
cyclosporine O
or O
aza O
, O
but O
infection B-Disease
played O
a O
major O
role O
in O
3 O
out O
of O
6 O
cardiac O
transB-Plant O
deaths O
and O
in O
8 O
out O
of O
9 O
liver O
transB-Plant O
deaths O
. O

renal O
patients O
on O
cyclosporine O
had O
the O
fewest O
bacteremias B-Disease
. O

analysis O
of O
site O
of O
infection B-Disease
showed O
a O
preponderance O
of O
abdominal B-Disease
infections I-Disease
in O
liver O
patients O
, O
intrathoracic O
infections B-Disease
in O
heart O
patients O
, O
and O
urinary B-Disease
tract I-Disease
infections I-Disease
in O
renal O
patients O
. O

pulmonary O
infections B-Disease
were O
less O
common O
in O
cyclosporine O
- O
treated O
renal O
patients O
than O
in O
aza O
- O
treated O
patients O
( O
p O
less O
than O
0 O
. O

5 O
) O
. O

aza O
patients O
had O
significantly O
more O
staphylococcal B-Disease
infections I-Disease
than O
all O
other O
transB-Plant O
groups O
( O
p O
less O
than O
0 O
. O

5 O
) O
, O
and O
systemic O
fungal B-Disease
infections I-Disease
occurred O
only O
in O
the O
liver O
transB-Plant O
group O
. O

of O
the O
cyclosporine O
patients O
, O
15 O
% O
had O
symptoms O
related O
to O
cmv B-Disease
infection I-Disease
. O

serological O
evidence O
for O
epstein B-Disease
barr I-Disease
virus I-Disease
infection I-Disease
was O
found O
in O
20 O
% O
of O
65 O
cyclosporine O
patients O
studied O
. O

three O
had O
associated O
symptoms O
, O
and O
one O
developed O
a O
lymphoma B-Disease
. O

structure O
- O
activity O
and O
dose O
- O
effect O
relationships O
of O
the O
antagonism O
of O
picrotoxin O
- O
induced O
seizures B-Disease
by O
cholecystokinin O
, O
fragments O
and O
analogues O
of O
cholecystokinin O
in O
mice O
. O

intraperitoneal O
administration O
of O
cholecystokinin O
octapeptide O
sulphate O
ester O
( O
cck O
- O
8 O
- O
se O
) O
and O
nonsulphated O
cholecystokinin O
octapeptide O
( O
cck O
- O
8 O
- O
ns O
) O
enhanced O
the O
latency O
of O
seizures B-Disease
induced O
by O
picrotoxin O
in O
mice O
. O

the O
peptide O
cck O
- O
5 O
- O
8 O
had O
weak O
anticonvulsant O
activity O
in O
comparison O
to O
the O
octapeptides O
, O
3 O
. O

2 O
mumol O
/ O
kg O
and O
larger O
doses O
of O
the O
reference O
drug O
, O
diazepam O
, O
totally O
prevented O
picrotoxin O
- O
induced O
seizures B-Disease
and O
mortality O
. O

vasopressin O
as O
a O
possible O
contributor O
to O
hypertension B-Disease
. O

the O
role O
of O
vasopressin O
as O
a O
pressor O
agent O
to O
the O
hypertensive B-Disease
process O
was O
examined O
. O

vasopressin O
plays O
a O
major O
role O
in O
the O
pathogenesis O
of O
doca O
- O
salt O
hypertension B-Disease
, O
since O
the O
elevation O
of O
blood O
pressure O
was O
not O
substantial O
in O
the O
rats O
with O
lithium O
- O
treated O
diabetes B-Disease
insipidus I-Disease
after O
doca O
- O
salt O
treatment O
. O

furthermore O
, O
the O
pressor O
action O
of O
vasopressin O
appears O
to O
be O
important O
in O
the O
development O
of O
this O
model O
of O
hypertension B-Disease
, O
since O
the O
enhanced O
pressor O
responsiveness O
to O
the O
hormone O
was O
observed O
in O
the O
initial O
stage O
of O
hypertension B-Disease
. O

increased O
secretion O
of O
vasopressin O
from O
neurohypophysis O
also O
promotes O
the O
function O
of O
the O
hormone O
as O
a O
pathogenetic O
factor O
in O
hypertension B-Disease
. O

however O
, O
the O
role O
of O
vasopressin O
remains O
to O
be O
determined O
in O
human O
essential O
hypertension B-Disease
. O

toxic B-Disease
hepatitis I-Disease
induced O
by O
disulfiram O
in O
a O
non O
- O
alcoholic O
. O

a O
reversible O
toxic B-Disease
liver I-Disease
damage I-Disease
was O
observed O
in O
a O
non O
- O
alcoholic O
woman O
treated O
with O
disulfiram O
. O

atrial B-Disease
thrombosis I-Disease
involving O
the O
heart O
of O
f O
- O
344 O
rats O
ingesting O
quinacrine O
hydrochloride O
. O

rats O
treated O
with O
500 O
ppm O
quinacrine O
hydrochloride O
in O
the O
diet O
all O
developed O
a O
high O
incidence O
of O
left O
atrial B-Disease
thrombosis I-Disease
. O

the O
lesion O
was O
associated O
with O
cardiac B-Disease
hypertrophy I-Disease
and O
dilatation O
and O
focal O
myocardial B-Disease
degeneration I-Disease
. O

rats O
died O
from O
cardiac B-Disease
hypertrophy I-Disease
with O
severe O
acute O
and O
chronic O
congestion O
of O
the O
lungs O
, O
liver O
, O
and O
other O
organs O
. O

seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine O
hydrochloride O
and O
1 O
, O
0 O
ppm O
sodium O
nitrite O
simultaneously O
in O
the O
diet O
had O
thrombosis B-Disease
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial B-Disease
thrombosis I-Disease
. O

alternating B-Disease
sinus I-Disease
rhythm I-Disease
and O
intermittent O
sinoatrial B-Disease
block I-Disease
induced O
by O
propranolol O
. O

alternating B-Disease
sinus I-Disease
rhythm I-Disease
and O
intermittent O
sinoatrial B-Disease
( I-Disease
s I-Disease
- I-Disease
a I-Disease
) I-Disease
block I-Disease
was O
observed O
in O
a O
57 O
- O
year O
- O
old O
woman O
, O
under O
treatment O
for O
angina B-Disease
with O
80 O
mg O
propranolol O
daily O
. O

following O
these O
basic O
sinus O
cycles O
, O
alternating B-Disease
rhythm I-Disease
started O
with O
the O
longer O
p O
- O
p O
interval O
. O

in O
one O
recording O
a O
short O
period O
of O
regular O
sinus O
rhythm O
with O
intermittent O
2 O
/ O
1 O
s B-Disease
- I-Disease
a I-Disease
block I-Disease
was O
observed O
. O

the O
abnormal O
rhythm O
disappeared O
with O
the O
withdrawal O
of O
propranolol O
and O
when O
the O
drug O
was O
restarted O
a O
2 O
/ O
1 O
s B-Disease
- I-Disease
a I-Disease
block I-Disease
was O
seen O
. O

this O
was O
accepted O
as O
evidence O
for O
propranolol O
being O
the O
cause O
of O
this O
conduction B-Disease
disorder I-Disease
. O

antitumor O
effect O
, O
cardiotoxicity B-Disease
, O
and O
nephrotoxicity B-Disease
of O
doxorubicin O
in O
the O
igm O
solid O
immunocytoma B-Disease
- O
bearing O
lou O
/ O
m O
/ O
wsl O
rat O
. O

antitumor O
activity O
, O
cardiotoxicity B-Disease
, O
and O
nephrotoxicity B-Disease
induced O
by O
doxorubicin O
were O
studied O
in O
lou O
/ O
m O
/ O
wsl O
inbred O
rats O
each O
bearing O
a O
transB-Plantable O
solid O
igm O
immunocytoma B-Disease
. O

animals O
with O
a O
tumor B-Disease
( O
diameter O
, O
15 O
. O

8 O
+ O
/ O
- O
3 O
. O

3 O
mm O
) O
were O
treated O
with O
iv O
injections O
of O
doxorubicin O
on O
5 O
consecutive O
days O
, O
followed O
by O
1 O
weekly O
injection O
for O
7 O
weeks O
( O
dose O
range O
, O
0 O
. O

15 O
- O
4 O
. O

0 O
mg O
/ O
kg O
body O
wt O
) O
. O

tumor B-Disease
regression O
was O
observed O
with O
0 O
. O

5 O
mg O
doxorubicin O
/ O
kg O
. O

complete O
disappearance O
of O
the O
tumor B-Disease
was O
induced O
with O
1 O
. O

0 O
mg O
doxorubicin O
/ O
kg O
. O

histologic O
evidence O
of O
cardiotoxicity B-Disease
scored O
as O
grade O
iii O
was O
only O
observed O
at O
a O
dose O
of O
1 O
. O

0 O
mg O
doxorubicin O
/ O
kg O
. O

light O
microscopic O
evidence O
of O
renal B-Disease
damage I-Disease
was O
seen O
above O
a O
dose O
of O
0 O
. O

5 O
mg O
doxorubicin O
/ O
kg O
, O
which O
resulted O
in O
albuminuria B-Disease
and O
very O
low O
serum O
albumin O
levels O
. O

ascites B-Disease
and O
hydrothorax B-Disease
were O
observed O
simultaneously O
. O

the O
same O
experiments O
were O
performed O
with O
non O
- O
tumor B-Disease
- O
bearing O
rats O
, O
in O
which O
no O
major O
differences O
were O
observed O
. O

in O
conclusion O
, O
antitumor O
activity O
, O
cardiotoxicity B-Disease
, O
and O
nephrotoxicity B-Disease
were O
studied O
simultaneously O
in O
the O
same O
lou O
/ O
m O
/ O
wsl O
rat O
. O

albuminuria B-Disease
due O
to O
renal B-Disease
damage I-Disease
led O
to O
extremely O
low O
serum O
albumin O
levels O
, O
so O
ascites B-Disease
and O
hydrothorax B-Disease
were O
not O
necessarily O
a O
consequence O
of O
the O
observed O
cardiomyopathy B-Disease
. O

intraoperative O
bradycardia B-Disease
and O
hypotension B-Disease
associated O
with O
timolol O
and O
pilocarpine O
eye O
drops O
. O

a O
69 O
- O
yr O
- O
old O
man O
, O
who O
was O
concurrently O
being O
treated O
with O
pilocarpine O
nitrate O
and O
timolol O
maleate O
eye O
drops O
, O
developed O
a O
bradycardia B-Disease
and O
became O
hypotensive B-Disease
during O
halothane O
anaesthesia O
. O

it O
is O
postulated O
that O
this O
action O
may O
have O
been O
enhanced O
during O
halothane O
anaesthesia O
with O
resultant O
bradycardia B-Disease
and O
hypotension B-Disease
. O

succinylcholine O
apnoea B-Disease
: O
attempted O
reversal O
with O
anticholinesterases O
. O

anticholinesterases O
were O
administered O
in O
an O
attempt O
to O
antagonize O
prolonged O
neuromuscular B-Disease
blockade I-Disease
following O
the O
administration O
of O
succinylcholine O
in O
a O
patient O
later O
found O
to O
be O
homozygous O
for O
atypical O
plasma O
cholinesterase O
. O

it O
is O
concluded O
that O
anticholinesterases O
are O
only O
partially O
effective O
in O
restoring O
neuromuscular O
function O
in O
succinylcholine O
apnoea B-Disease
despite O
muscle O
twitch O
activity O
typical O
of O
phase O
ii O
block O
. O

our O
findings O
suggest O
that O
the O
changes O
leading O
to O
an O
alteration O
of O
myocardial O
dynamic O
imaging O
with O
i O
- O
131 O
ha O
are O
not O
the O
initiating O
factor O
in O
doxorubicin O
cardiotoxicity B-Disease
. O

hemodynamics O
and O
myocardial O
metabolism O
under O
deliberate O
hypotension B-Disease
. O

coronary O
blood O
flow O
, O
cardiac O
work O
and O
metabolism O
were O
studied O
in O
dogs O
under O
sodium O
nitroprusside O
( O
snp O
) O
and O
trimetaphan O
( O
tmp O
) O
deliberate O
hypotension B-Disease
( O
20 O
% O
and O
40 O
% O
mean O
pressure O
decrease O
from O
baseline O
) O
. O

regarding O
the O
effects O
of O
drug O
- O
induced O
hypotension B-Disease
on O
coronary O
blood O
flow O
, O
aortic O
and O
coronary O
sinus O
metabolic O
data O
( O
ph O
, O
po2 O
, O
pco2 O
) O
we O
could O
confirm O
that O
nitroprusside O
hypotension B-Disease
could O
be O
safely O
used O
to O
30 O
% O
mean O
blood O
pressure O
decrease O
from O
control O
, O
trimetaphan O
hypotension B-Disease
to O
20 O
% O
mean O
blood O
pressure O
decrease O
. O

cardiac O
work O
was O
significantly O
reduced O
during O
snp O
hypotension B-Disease
. O

the O
hyperactivity B-Disease
induced O
by O
d O
- O
amphetamine O
( O
10 O
mumol O
/ O
kg O
) O
was O
significantly O
reduced O
by O
dsp4 O
pretreatment O
. O

however O
, O
the O
increased O
rearings O
and O
the O
amphetamine O
- O
induced O
stereotypies B-Disease
were O
not O
blocked O
by O
pretreatment O
with O
dsp4 O
. O

the O
reduction O
of O
amphetamine O
hyperactivity B-Disease
induced O
by O
dsp4 O
was O
blocked O
by O
pretreatment O
with O
the O
noradrenaline O
- O
uptake O
blocking O
agent O
, O
desipramine O
, O
which O
prevents O
the O
neurotoxic B-Disease
action O
of O
dsp4 O
. O

accelerated B-Disease
junctional I-Disease
rhythms I-Disease
during O
oral O
verapamil O
therapy O
. O

this O
study O
examined O
the O
frequency O
of O
atrioventricular O
( O
av O
) O
dissociation O
and O
accelerated B-Disease
junctional I-Disease
rhythms I-Disease
in O
59 O
patients O
receiving O
oral O
verapamil O
. O

accelerated B-Disease
junctional I-Disease
rhythms I-Disease
and O
av O
dissociation O
were O
frequent O
in O
patients O
with O
supraventricular B-Disease
tachyarrhythmias I-Disease
, O
particularly O
av O
nodal O
reentry O
. O

in O
patients O
with O
various O
chest B-Disease
pain I-Disease
syndromes O
, O
verapamil O
neither O
increased O
the O
frequency O
of O
junctional O
rhythms O
nor O
suppressed O
their O
role O
as O
escape O
rhythms O
under O
physiologically O
appropriate O
circumstances O
. O

five O
phenotypic O
characteristics O
- O
- O
locomotor O
activity O
, O
righting O
ability O
, O
clonic B-Disease
seizure I-Disease
induction O
, O
stress O
- O
induced O
lethality O
, O
death O
without O
external O
stress O
- O
- O
were O
scored O
at O
various O
caffeine O
doses O
in O
drug O
- O
naive O
animals O
under O
empirically O
optimized O
, O
rigidly O
constant O
experimental O
conditions O
. O

in O
the O
same O
animals O
the O
occurrence O
of O
clonic B-Disease
seizures I-Disease
was O
scored O
as O
to O
time O
of O
onset O
and O
severity O
for O
20 O
min O
after O
drug O
administration O
. O

when O
these O
proceeded O
to O
tonic B-Disease
seizures I-Disease
, O
death O
occurred O
in O
less O
than O
20 O
min O
. O

animals O
surviving O
for O
20 O
min O
were O
immediately O
stressed O
by O
a O
swim O
test O
in O
25 O
degrees O
c O
water O
, O
and O
death O
- O
producing O
tonic B-Disease
seizures I-Disease
were O
scored O
for O
2 O
min O
. O

these O
results O
indicate O
that O
behavioral O
toxicity B-Disease
testing O
of O
alkylxanthines O
in O
a O
single O
mouse O
strain O
may O
be O
misleading O
and O
suggest O
that O
toxic O
responses O
of O
the O
central O
nervous O
system O
to O
this O
class O
of O
compounds O
are O
genetically O
influenced O
in O
mammals O
. O

treatment O
of O
ovarian B-Disease
cancer I-Disease
with O
a O
combination O
of O
cis O
- O
platinum O
, O
adriamycin O
, O
cyclophosphamide O
and O
hexamethylmelamine O
. O

during O
the O
last O
2 O
1 O
/ O
2 O
years O
, O
38 O
patients O
with O
ovarian B-Disease
cancer I-Disease
were O
treated O
with O
a O
combination O
of O
cisplatinum O
( O
cpdd O
) O
, O
50 O
mg O
/ O
m2 O
, O
adriamycin O
, O
30 O
mg O
/ O
m2 O
, O
cyclophosphamide O
, O
300 O
mg O
/ O
m2 O
, O
on O
day O
1 O
; O
and O
hexamethylmelamine O
( O
hmm O
) O
, O
6 O
mg O
/ O
kg O
daily O
, O
for O
14 O
days O
. O

hematologic B-Disease
toxicity I-Disease
was O
moderate O
and O
with O
reversible O
anemia B-Disease
developing O
in O
71 O
% O
of O
patients O
. O

hmm O
gastrointestinal B-Disease
toxicity I-Disease
necessitated O
discontinuation O
of O
the O
drug O
in O
5 O
patients O
. O

severe O
nephrotoxicity B-Disease
was O
observed O
in O
2 O
patients O
but O
was O
reversible O
. O

nontraumatic O
dissecting B-Disease
aneurysm I-Disease
of O
the O
basilar O
artery O
. O

a O
case O
of O
nontraumatic O
dissecting B-Disease
aneurysm I-Disease
of O
the O
basilar O
artery O
in O
association O
with O
hypertension B-Disease
, O
smoke O
, O
and O
oral O
contraceptives O
is O
reported O
in O
a O
young O
female O
patient O
with O
a O
locked B-Disease
- I-Disease
in I-Disease
syndrome I-Disease
. O

a O
method O
for O
the O
measurement O
of O
tremor B-Disease
, O
and O
a O
comparison O
of O
the O
effects O
of O
tocolytic O
beta O
- O
mimetics O
. O

a O
method O
permitting O
measurement O
of O
finger O
tremor B-Disease
as O
a O
displacement O
- O
time O
curve O
is O
described O
, O
using O
a O
test O
system O
with O
simple O
amplitude O
calibration O
. O

by O
means O
of O
a O
computer O
program O
, O
periods O
and O
amplitudes O
of O
tremor B-Disease
oscillations O
were O
calculated O
and O
classified O
. O

at O
therapeutic O
doses O
both O
substances O
raised O
the O
mean O
tremor B-Disease
amplitude O
to O
about O
three O
times O
the O
control O
level O
. O

after O
the O
end O
of O
fenoterol O
- O
hydrobromide O
infusion O
, O
tremor B-Disease
amplitudes O
decreased O
significantly O
faster O
than O
those O
following O
ritodrin O
- O
hcl O
infusion O
. O

propylthiouracil O
- O
induced O
hepatic B-Disease
damage I-Disease
. O

two O
cases O
of O
propylthiouracil O
- O
induced O
liver B-Disease
damage I-Disease
have O
been O
observed O
. O

the O
first O
case O
is O
of O
an O
acute O
type O
of O
damage O
, O
proven O
by O
rechallenge O
; O
the O
second O
presents O
a O
clinical O
and O
histologic O
picture O
resembling O
chronic B-Disease
active I-Disease
hepatitis I-Disease
, O
with O
spontaneous O
remission O
. O

studies O
on O
the O
bradycardia B-Disease
induced O
by O
bepridil O
. O

bepridil O
, O
a O
novel O
active O
compound O
for O
prophylactic O
treatment O
of O
anginal B-Disease
attacks I-Disease
, O
induced O
persistent O
bradycardia B-Disease
and O
a O
non O
- O
specific O
anti O
- O
tachycardial B-Disease
effect O
, O
the O
mechanisms O
of O
which O
were O
investigated O
in O
vitro O
and O
in O
vivo O
. O

hepatitis B-Disease
and O
renal B-Disease
tubular I-Disease
acidosis I-Disease
after O
anesthesia O
with O
methoxyflurane O
. O

a O
69 O
- O
year O
- O
old O
man O
operated O
for O
acute B-Disease
cholecystitis I-Disease
under O
methoxyflurane O
anesthesia O
developed O
postoperatively O
a O
hepatic B-Disease
insufficiency I-Disease
syndrome I-Disease
and O
renal B-Disease
tubular I-Disease
acidosis I-Disease
. O

massive O
bleeding B-Disease
appeared O
during O
surgery O
which O
lasted O
for O
six O
hours O
. O

pituitary O
response O
to O
luteinizing O
hormone O
- O
releasing O
hormone O
during O
haloperidol O
- O
induced O
hyperprolactinemia B-Disease
. O

during O
the O
course O
of O
haloperidol O
infusions O
, O
significant O
hyperprolactinemia B-Disease
was O
found O
, O
together O
with O
an O
abolished O
pituitary O
response O
to O
lh O
- O
rh O
, O
as O
compared O
with O
responses O
of O
control O
subjects O
. O

antirifampicin O
antibodies O
in O
acute O
rifampicin O
- O
associated O
renal B-Disease
failure I-Disease
. O

5 O
patients O
with O
acute B-Disease
renal I-Disease
failure I-Disease
( O
3 O
with O
thrombopenia B-Disease
and O
hemolysis B-Disease
) O
induced O
by O
the O
reintroduction O
of O
rifampicin O
are O
described O
. O

antibodies O
suggested O
to O
be O
of O
the O
igm O
class O
were O
detected O
in O
all O
3 O
patients O
with O
hematological B-Disease
disorders I-Disease
. O

the O
pattern O
of O
non O
- O
specific O
acute B-Disease
tubular I-Disease
necrosis I-Disease
found O
in O
the O
2 O
biopsied O
patients O
, O
indistinguishable O
from O
that O
of O
ischemic O
origin O
, O
raised O
the O
possibility O
of O
a O
vascular O
- O
mediated O
damage O
. O

cardiovascular O
effects O
of O
hypotension B-Disease
induced O
by O
adenosine O
triphosphate O
and O
sodium O
nitroprusside O
on O
dogs O
with O
denervated O
hearts O
. O

adenosine O
triphosphate O
( O
atp O
) O
and O
sodium O
nitroprusside O
( O
snp O
) O
are O
administered O
to O
patients O
to O
induce O
and O
control O
hypotension B-Disease
during O
anesthesia O
. O

before O
, O
during O
and O
after O
induced O
hypotension B-Disease
, O
we O
measured O
major O
cardiovascular O
parameters O
. O

hypotension B-Disease
induced O
by O
atp O
was O
accompanied O
by O
significant O
decreases O
in O
mean O
pulmonary O
arterial O
pressure O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
central O
venous O
pressure O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
total O
peripheral O
resistance O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
rate O
pressure O
product O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
total O
body O
oxygen O
consumption O
( O
p O
less O
than O
0 O
. O

5 O
) O
, O
and O
heart O
rate O
( O
p O
less O
than O
0 O
. O

1 O
) O
; O
all O
these O
variables O
returned O
normal O
within O
30 O
min O
after O
atp O
was O
stopped O
. O

during O
hypotension B-Disease
produced O
by O
snp O
similar O
decreases O
were O
observed O
in O
mean O
pulmonary O
arterial O
pressure O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
central O
venous O
pressure O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
total O
peripheral O
resistance O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
rate O
pressure O
product O
( O
p O
less O
than O
0 O
. O

1 O
) O
, O
and O
oxygen O
content O
difference O
between O
arterial O
and O
mixed O
venous O
blood O
( O
p O
less O
than O
0 O
. O

5 O
) O
, O
while O
heart O
rate O
( O
p O
less O
than O
0 O
. O

1 O
) O
and O
cardiac O
output O
( O
p O
less O
than O
0 O
. O

5 O
) O
were O
increased O
. O

the O
dimer O
- O
x O
group O
had O
a O
higher O
incidence O
of O
nausea B-Disease
and O
dizziness B-Disease
. O

the O
endografine O
group O
had O
a O
higher O
incidence O
of O
abdominal B-Disease
pain I-Disease
. O

hexabrix O
and O
vasurix O
polyvidone O
are O
considered O
the O
best O
contrast O
media O
for O
hysterosalpingography O
and O
perhaps O
because O
of O
its O
low O
toxicity B-Disease
hexabrix O
should O
be O
preferred O
. O

post O
- O
suxamethonium O
pains B-Disease
in O
nigerian O
surgical O
patients O
. O

contrary O
to O
an O
earlier O
report O
by O
coxon O
, O
scoline O
pain B-Disease
occurs O
in O
african O
negroes O
. O

about O
62 O
% O
of O
the O
out O
- O
patients O
developed O
scoline O
pain B-Disease
as O
compared O
with O
about O
26 O
% O
among O
the O
in O
- O
patients O
. O

the O
abolition O
of O
muscle O
fasciculations B-Disease
( O
by O
0 O
. O

075mg O
/ O
kg O
dose O
of O
fazadinium O
) O
did O
not O
influence O
the O
occurrence O
of O
scoline O
pain B-Disease
. O

neither O
the O
type O
of O
induction O
agent O
( O
althesin O
or O
thiopentone O
) O
nor O
the O
salt O
preparation O
of O
suxamethonium O
used O
( O
chloride O
or O
bromide O
) O
, O
affected O
the O
incidence O
of O
scoline O
pain B-Disease
. O

invasive O
carcinoma B-Disease
of I-Disease
the I-Disease
renal I-Disease
pelvis I-Disease
following O
cyclophosphamide O
therapy O
for O
nonmalignant O
disease O
. O

a O
47 O
- O
year O
- O
old O
woman O
with O
right O
hydroureteronephrosis B-Disease
due O
to O
ureterovesical O
junction O
obstruction O
had O
gross O
hematuria B-Disease
after O
being O
treated O
for O
five O
years O
wtih O
cyclophosphamide O
for O
cerebral B-Disease
vasculitis I-Disease
. O

a O
right O
nephroureterectomy O
was O
required O
for O
control O
of O
bleeding B-Disease
. O

the O
pathology O
specimen O
contained O
clinically O
occult O
invasive O
carcinoma B-Disease
of I-Disease
the I-Disease
renal I-Disease
pelvis I-Disease
. O

although O
the O
ability O
of O
cyclophosphamide O
to O
cause O
hemorrhagic B-Disease
cystitis I-Disease
and O
urine O
cytologic O
abnormalities O
indistinguishable O
from O
high O
grade O
carcinoma B-Disease
is O
well O
known O
, O
it O
is O
less O
widely O
appreciated O
that O
it O
is O
also O
associated O
with O
carcinoma B-Disease
of I-Disease
the I-Disease
urinary I-Disease
tract I-Disease
. O

twenty O
carcinomas B-Disease
of I-Disease
the I-Disease
urinary I-Disease
bladder I-Disease
and O
one O
carcinoma B-Disease
of I-Disease
the I-Disease
prostate I-Disease
have O
been O
reported O
in O
association O
with O
its O
use O
. O

the O
present O
case O
is O
the O
first O
carcinoma B-Disease
of I-Disease
the I-Disease
renal I-Disease
pelvis I-Disease
reported O
in O
association O
with O
cyclophosphamide O
treatment O
. O

it O
is O
the O
third O
urinary B-Disease
tract I-Disease
cancer I-Disease
reported O
in O
association O
with O
cyclophosphamide O
treatment O
for O
nonmalignant O
disease O
. O

the O
association O
of O
the O
tumor B-Disease
with O
preexisting O
hydroureteronephrosis B-Disease
suggests O
that O
stasis O
prolonged O
and O
intensified O
exposure O
of O
upper O
urinary O
tract O
epithelium O
to O
cyclophosphamide O
. O

patients O
who O
are O
candidates O
for O
long O
- O
term O
cyclophosphamide O
treatment O
should O
be O
routinely O
evaluated O
for O
obstructive B-Disease
uropathy I-Disease
. O

medial O
changes O
in O
arterial O
spasm B-Disease
induced O
by O
l O
- O
norepinephrine O
. O

in O
the O
media O
of O
the O
saphenous O
artery O
and O
its O
distal O
branch O
, O
vasoconstriction O
induced O
by O
l O
- O
norepinephrine O
produced O
many O
cell O
- O
to O
- O
cell O
hernias B-Disease
within O
15 O
minutes O
. O

the O
experimental O
data O
are O
discussed O
in O
relation O
to O
medial O
changes O
observed O
in O
other O
instances O
of O
arterial O
spasm B-Disease
. O

bilateral O
retinal B-Disease
artery I-Disease
and I-Disease
choriocapillaris I-Disease
occlusion I-Disease
following O
the O
injection O
of O
long O
- O
acting O
corticosteroid O
suspensions O
in O
combination O
with O
other O
drugs O
: O
i O
. O

two O
well O
- O
documented O
cases O
of O
bilateral O
retinal B-Disease
artery I-Disease
and I-Disease
choriocapillaris I-Disease
occlusions I-Disease
with O
blindness B-Disease
following O
head O
and O
neck O
soft O
- O
tissue O
injection O
with O
methylprednisolone O
acetate O
in O
combination O
with O
lidocaine O
, O
epinephrine O
, O
or O
penicillin O
are O
reported O
. O

the O
acute O
observations O
included O
hazy O
sensorium O
, O
superior O
gaze O
palsy B-Disease
, O
pupillary B-Disease
abnormalities I-Disease
, O
and O
conjunctival O
hemorrhages B-Disease
with O
edema B-Disease
. O

follow O
- O
up O
changes O
showed O
marked O
visual B-Disease
loss I-Disease
, O
constricted O
visual O
fields O
, O
optic O
nerve O
pallor O
, O
vascular O
attenuation O
, O
and O
chorioretinal B-Disease
atrophy I-Disease
. O

abnormalities O
of O
the O
pupil O
and O
visual O
- O
evoked O
potential O
in O
quinine O
amblyopia B-Disease
. O

total O
blindness B-Disease
with O
a O
transient O
tonic B-Disease
pupillary I-Disease
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
developed O
in O
a O
54 O
- O
year O
- O
old O
man O
after O
the O
use O
of O
quinine O
sulfate O
for O
leg B-Disease
cramps I-Disease
. O

a O
transient O
tonic B-Disease
pupillary I-Disease
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
in O
quinine O
toxicity B-Disease
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O
. O

suxamethonium O
- O
induced O
jaw B-Disease
stiffness I-Disease
and O
myalgia B-Disease
associated O
with O
atypical O
cholinesterase O
: O
case O
report O
. O

in O
response O
to O
this O
a O
marked O
jaw B-Disease
stiffness I-Disease
occurred O
which O
lasted O
for O
two O
minutes O
and O
the O
anaesthesia O
were O
terminated O
. O

four O
hours O
of O
apnoea B-Disease
ensued O
and O
he O
suffered O
generalized O
severe O
myalgia B-Disease
lasting O
for O
one O
week O
. O

the O
case O
shows O
that O
prolonged B-Disease
jaw I-Disease
rigidity I-Disease
and O
myalgia B-Disease
may O
occur O
after O
suxamethonium O
in O
patients O
with O
atypical O
cholinesterase O
despite O
pretreatment O
with O
pancuronium O
. O

indomethacin O
- O
induced O
hyperkalemia B-Disease
in O
three O
patients O
with O
gouty B-Disease
arthritis I-Disease
. O

we O
describe O
three O
patients O
in O
whom O
severe O
, O
life O
- O
threatening O
hyperkalemia B-Disease
and O
renal B-Disease
insufficiency I-Disease
developed O
after O
treatment O
of O
acute O
gouty B-Disease
arthritis I-Disease
with O
indomethacin O
. O

this O
complication O
may O
result O
from O
an O
inhibition O
of O
prostaglandin O
synthesis O
and O
consequent O
hyporeninemic B-Disease
hypoaidosteronism I-Disease
. O

careful O
attention O
to O
renal O
function O
and O
potassium O
balance O
in O
patients O
receiving O
indomethacin O
or O
other O
nonsteroidal O
anti O
- O
inflammatory O
agents O
, O
particularly O
in O
those O
patients O
with O
diabetes B-Disease
mellitus I-Disease
or O
preexisting O
renal B-Disease
disease I-Disease
, O
will O
help O
prevent O
this O
potentially O
serious O
complication O
. O

venous O
pain B-Disease
occurred O
in O
68 O
% O
of O
patients O
and O
50 O
% O
had O
redness O
, O
pain B-Disease
or O
swelling B-Disease
related O
to O
the O
injection O
site O
, O
in O
some O
cases O
lasting O
up O
to O
three O
weeks O
after O
anaesthesia O
. O

skeletal O
movements O
occurred O
in O
50 O
% O
of O
patients O
; O
30 O
% O
experienced O
respiratory B-Disease
upset I-Disease
, O
one O
sufficiently O
severe O
to O
necessitate O
abandoning O
the O
technique O
. O

nausea B-Disease
and O
vomiting B-Disease
occurred O
in O
40 O
% O
and O
25 O
% O
had O
disturbing O
emergence O
psychoses B-Disease
. O

levodopa O
- O
induced O
dyskinesias B-Disease
are O
improved O
by O
fluoxetine O
. O

we O
evaluated O
the O
severity O
of O
motor B-Disease
disability I-Disease
and O
dyskinesias B-Disease
in O
seven O
levodopa O
- O
responsive O
patients O
with O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
after O
an O
acute O
challenge O
with O
the O
mixed O
dopamine O
agonist O
, O
apomorphine O
, O
before O
and O
after O
the O
administration O
of O
fluoxetine O
( O
20 O
mg O
twice O
per O
day O
) O
for O
11 O
+ O
/ O
- O
1 O
days O
. O

after O
fluoxetine O
treatment O
, O
there O
was O
a O
significant O
47 O
% O
improvement O
( O
p O
< O
0 O
. O

5 O
) O
of O
apomorphine O
- O
induced O
dyskinesias B-Disease
without O
modification O
of O
parkinsonian B-Disease
motor B-Disease
disability I-Disease
. O

the O
dyskinesias B-Disease
were O
reduced O
predominantly O
in O
the O
lower O
limbs O
during O
the O
onset O
and O
disappearance O
of O
dystonic B-Disease
dyskinesias I-Disease
( O
onset O
- O
and O
end O
- O
of O
- O
dose O
dyskinesias B-Disease
) O
and O
in O
the O
upper O
limbs O
during O
choreic B-Disease
mid I-Disease
- I-Disease
dose I-Disease
dyskinesias I-Disease
. O

the O
results O
suggest O
that O
increased O
brain O
serotoninergic O
transmission O
with O
fluoxetine O
may O
reduce O
levodopa O
- O
or O
dopamine O
agonist O
- O
induced O
dyskinesias B-Disease
without O
aggravating O
parkinsonian B-Disease
motor B-Disease
disability I-Disease
. O

a O
large O
population O
- O
based O
follow O
- O
up O
study O
of O
trimethoprim O
- O
sulfamethoxazole O
, O
trimethoprim O
, O
and O
cephalexin O
for O
uncommon O
serious O
drug B-Disease
toxicity I-Disease
. O

we O
conducted O
a O
population O
- O
based O
45 O
- O
day O
follow O
- O
up O
study O
of O
232 O
, O
390 O
people O
who O
were O
prescribed O
trimethoprim O
- O
sulfamethoxazole O
( O
tmp O
- O
smz O
) O
, O
266 O
, O
951 O
prescribed O
trimethoprim O
alone O
, O
and O
196 O
, O
397 O
prescribed O
cephalexin O
, O
to O
estimate O
the O
risk O
of O
serious O
liver B-Disease
, I-Disease
blood I-Disease
, I-Disease
skin I-Disease
, I-Disease
and I-Disease
renal I-Disease
disorders I-Disease
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

the O
risk O
of O
clinically O
important O
idiopathic O
liver B-Disease
disease I-Disease
was O
similar O
for O
persons O
prescribed O
tmp O
- O
smz O
( O
5 O
. O

2 O
/ O
100 O
, O
0 O
) O
and O
those O
prescribed O
trimethoprim O
alone O
( O
3 O
. O

8 O
/ O
100 O
, O
0 O
) O
. O

only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
tmp O
- O
smz O
; O
of O
seven O
with O
erythema B-Disease
multiforme I-Disease
and O
stevens B-Disease
- I-Disease
johnson I-Disease
syndrome I-Disease
, O
four O
were O
exposed O
to O
tmp O
- O
smz O
. O

the O
one O
case O
of O
toxic B-Disease
epidermal I-Disease
necrolysis I-Disease
occurred O
in O
a O
patient O
who O
took O
cephalexin O
. O

finally O
, O
only O
five O
cases O
of O
acute O
parenchymal O
renal B-Disease
disease I-Disease
occurred O
, O
none O
likely O
to O
be O
caused O
by O
a O
study O
drug O
. O

clinical O
safety O
of O
lidocaine O
in O
patients O
with O
cocaine O
- O
associated O
myocardial B-Disease
infarction I-Disease
. O

study O
objective O
: O
to O
evaluate O
the O
safety O
of O
lidocaine O
in O
the O
setting O
of O
cocaine O
- O
induced O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
. O

participants O
: O
patients O
with O
cocaine O
- O
associated O
mi B-Disease
who O
received O
lidocaine O
in O
the O
emergency O
department O
. O

results O
: O
of O
29 O
patients O
who O
received O
lidocaine O
in O
the O
setting O
of O
cocaine O
- O
associated O
mi B-Disease
, O
no O
patient O
died O
; O
exhibited O
bradydysrhythmias B-Disease
, O
ventricular B-Disease
tachycardia I-Disease
, O
or O
ventricular B-Disease
fibrillation I-Disease
; O
or O
experienced O
seizures B-Disease
after O
administration O
of O
lidocaine O
( O
95 O
% O
confidence O
interval O
, O
0 O
% O
to O
11 O
% O
) O
. O

conclusion O
: O
despite O
theoretical O
concerns O
that O
lidocaine O
may O
enhance O
cocaine O
toxicity B-Disease
, O
the O
use O
of O
lidocaine O
in O
patients O
with O
cocaine O
- O
associated O
mi B-Disease
was O
not O
associated O
with O
significant O
cardiovascular B-Disease
or I-Disease
central I-Disease
nervous I-Disease
system I-Disease
toxicity I-Disease
. O

experimental O
progressive O
muscular B-Disease
dystrophy I-Disease
and O
its O
treatment O
with O
high O
doses O
anabolizing O
agents O
. O

we O
are O
still O
a O
long O
way O
from O
discovering O
an O
unequivocal O
pathogenetic O
interpretation O
of O
progressive O
muscular B-Disease
dystrophy I-Disease
in O
man O
. O

myopathy B-Disease
due O
to O
lack O
of O
vitamin O
e O
and O
myopathy B-Disease
induced O
by O
certain O
viruses O
have O
much O
in O
common O
anatomically O
and O
pathologically O
with O
the O
human O
form O
. O

the O
authors O
induced O
myodystrophy B-Disease
in O
the O
rat O
by O
giving O
it O
a O
diet O
lacking O
in O
vitamin O
e O
. O

it O
is O
thus O
confirmed O
that O
the O
histological O
characteristics O
of O
myopathic B-Disease
rat O
muscle O
induced O
experimentally O
are O
extraordinarily O
similar O
to O
those O
of O
human O
myopathy B-Disease
as O
confirmed O
during O
biopsies O
performed O
at O
the O
orthopaedic O
traumatological O
centre O
, O
florence O
. O

the O
encouraging O
results O
obtained O
in O
various O
authoratative O
departments O
in O
myopathic B-Disease
patients O
by O
using O
anabolizing O
steroids O
have O
encouraged O
the O
authors O
to O
investigate O
the O
beneficial O
effects O
of O
one O
anabolizing O
agent O
( O
dianabol O
, O
ciba O
) O
at O
high O
doses O
in O
rats O
rendered O
myopathic B-Disease
by O
a O
diet O
deficient O
in O
vitamin O
e O
. O

in O
this O
way O
they O
obtained O
appreciable O
changes O
in O
body O
weight O
( O
increased O
from O
50 O
to O
70 O
g O
after O
forty O
days O
at O
a O
dose O
of O
5 O
mg O
per O
day O
of O
anabolizing O
agent O
) O
, O
but O
most O
of O
all O
they O
found O
histological O
changes O
due O
to O
nan O
regenerative O
nan O
changes O
in O
the O
muscle O
tissue O
, O
which O
however O
maintained O
its O
myopathic B-Disease
characteristics O
in O
the O
control O
animals O
that O
were O
not O
treated O
with O
the O
anabolizing O
agent O
. O

the O
authors O
conclude O
by O
affirming O
the O
undoubted O
efficacy O
of O
the O
anabolizing O
steroids O
in O
experimental O
myopathic B-Disease
disease I-Disease
, O
but O
they O
have O
reservations O
as O
to O
the O
transfer O
of O
the O
results O
into O
the O
human O
field O
, O
where O
high O
dosage O
cannot O
be O
carried O
out O
continuously O
because O
of O
the O
effects O
of O
the O
drug O
on O
virility O
; O
because O
the O
tissue O
injury O
too O
often O
occurs O
at O
an O
irreversible O
stage O
vis O
- O
a O
- O
vis O
the O
nan O
regeneration O
nan O
of O
the O
muscle O
tissue O
; O
and O
finally O
because O
the O
dystrophic O
injurious O
agent O
is O
certainly O
not O
the O
lack O
of O
vitamin O
e O
but O
something O
as O
yet O
unknown O
. O

paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
by O
3 O
- O
hour O
infusion O
was O
combined O
with O
carboplatin O
in O
a O
phase O
i O
/ O
ii O
study O
directed O
to O
patients O
with O
non B-Disease
- I-Disease
small I-Disease
cell I-Disease
lung I-Disease
cancer I-Disease
. O

the O
225 O
mg O
/ O
m2 O
level O
was O
expanded O
for O
the O
phase O
ii O
study O
since O
the O
highest O
level O
achieved O
( O
250 O
mg O
/ O
m2 O
) O
required O
modification O
because O
of O
nonhematologic O
toxicities B-Disease
( O
arthralgia B-Disease
and O
sensory B-Disease
neuropathy I-Disease
) O
. O

toxicities B-Disease
were O
compared O
with O
a O
cohort O
of O
patients O
in O
a O
phase O
i O
trial O
of O
paclitaxel O
alone O
at O
identical O
dose O
levels O
. O

carboplatin O
did O
not O
appear O
to O
add O
to O
the O
hematologic B-Disease
toxicities I-Disease
observed O
, O
and O
the O
paclitaxel O
/ O
carboplatin O
combination O
could O
be O
dosed O
every O
3 O
weeks O
. O

the O
dose O
- O
dependent O
effect O
of O
misoprostol O
on O
indomethacin O
- O
induced O
renal B-Disease
dysfunction I-Disease
in O
well O
compensated O
cirrhosis B-Disease
. O

misoprostol O
( O
200 O
micrograms O
) O
has O
been O
shown O
to O
acutely O
counteract O
the O
indomethacin O
- O
induced O
renal B-Disease
dysfunction I-Disease
in O
well O
compensated O
cirrhotic B-Disease
patients O
. O

parameters O
of O
renal O
hemodynamics O
and O
tubular O
sodium O
and O
water O
handling O
were O
assessed O
by O
clearance O
techniques O
in O
26 O
well O
compensated O
cirrhotic B-Disease
patients O
before O
and O
after O
an O
oral O
combination O
of O
50 O
mg O
of O
indomethacin O
and O
various O
doses O
of O
misoprostol O
. O

however O
, O
until O
this O
apparent O
ability O
of O
200 O
micrograms O
of O
misoprostol O
to O
prevent O
the O
adverse O
effects O
of O
indomethacin O
on O
renal O
function O
is O
confirmed O
with O
chronic O
frequent O
dosing O
, O
it O
would O
be O
prudent O
to O
avoid O
nonsteroidal O
anti O
- O
inflammatory O
therapy O
in O
patients O
with O
cirrhosis B-Disease
. O

increased O
frequency O
and O
severity O
of O
angio B-Disease
- I-Disease
oedema I-Disease
related O
to O
long O
- O
term O
therapy O
with O
angiotensin O
- O
converting O
enzyme O
inhibitor O
in O
two O
patients O
. O

adverse O
reactions O
to O
drugs O
are O
well O
recognized O
as O
a O
cause O
of O
acute O
or O
chronic O
urticaria B-Disease
, O
and O
angio B-Disease
- I-Disease
oedema I-Disease
. O

angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitors O
, O
used O
to O
treat O
hypertension B-Disease
and O
congestive B-Disease
heart I-Disease
failure I-Disease
, O
were O
introduced O
in O
europe O
in O
the O
middle O
of O
the O
eighties O
, O
and O
the O
use O
of O
these O
drugs O
has O
increased O
progressively O
. O

soon O
after O
the O
introduction O
of O
ace O
inhibitors O
, O
acute O
bouts O
of O
angio B-Disease
- I-Disease
oedema I-Disease
were O
reported O
in O
association O
with O
the O
use O
of O
these O
drugs O
. O

we O
wish O
to O
draw O
attention O
to O
the O
possibility O
of O
adverse O
reactions O
to O
ace O
inhibitors O
after O
long O
- O
term O
use O
and O
in O
patients O
with O
pre O
- O
existing O
angio B-Disease
- I-Disease
oedema I-Disease
. O

myoclonus B-Disease
associated O
with O
lorazepam O
therapy O
in O
very O
- O
low O
- O
birth O
- O
weight O
infants O
. O

three O
young O
infants O
, O
all O
of O
birth O
weight O
< O
1 O
, O
500 O
g O
, O
experienced O
myoclonus B-Disease
following O
the O
intravenous O
administration O
of O
lorazepam O
. O

the O
potential O
neurotoxic B-Disease
effects O
of O
the O
drug O
( O
and O
its O
vehicle O
) O
in O
this O
population O
are O
discussed O
. O

transvenous O
right O
ventricular O
pacing O
during O
cardiopulmonary O
resuscitation O
of O
pediatric O
patients O
with O
acute O
cardiomyopathy B-Disease
. O

we O
describe O
the O
cardiopulmonary O
resuscitation O
efforts O
on O
five O
patients O
who O
presented O
in O
acute O
circulatory B-Disease
failure I-Disease
from O
myocardial B-Disease
dysfunction I-Disease
. O

three O
patients O
had O
acute O
viral O
myocarditis B-Disease
, O
one O
had O
a O
carbamazepine O
- O
induced O
acute O
eosinophilic B-Disease
myocarditis I-Disease
, O
and O
one O
had O
cardiac O
hemosiderosis O
resulting O
in O
acute O
cardiogenic B-Disease
shock I-Disease
. O

an O
introducer O
sheath O
, O
a O
pacemaker O
, O
and O
sterile O
pacing O
wires O
were O
made O
readily O
available O
for O
the O
patients O
, O
should O
the O
need O
arise O
to O
terminate O
resistant O
cardiac O
dysrhythmias B-Disease
. O

all O
patients O
developed O
cardiocirculatory O
arrest O
associated O
with O
extreme O
hypotension B-Disease
and O
dysrhythmias B-Disease
within O
the O
first O
48 O
hours O
of O
their O
admission O
to O
the O
pediatric O
intensive O
care O
unit O
( O
picu O
) O
. O

these O
patients O
had O
a O
second O
event O
of O
cardiac B-Disease
arrest I-Disease
, O
resulting O
in O
death O
, O
within O
10 O
to O
60 O
minutes O
. O

we O
conclude O
that O
cardiac O
pacing O
during O
resuscitative O
efforts O
in O
pediatric O
patients O
suffering O
from O
acute O
myocardial B-Disease
dysfunction I-Disease
may O
not O
have O
long O
- O
term O
value O
in O
and O
of O
itself O
; O
however O
, O
if O
temporary O
hemodynamic O
stability O
is O
achieved O
by O
this O
procedure O
, O
it O
may O
provide O
additional O
time O
needed O
to O
institute O
other O
therapeutic O
modalities O
. O

efficacy O
and O
safety O
of O
granisetron O
, O
a O
selective O
5 O
- O
hydroxytryptamine O
- O
3 O
receptor O
antagonist O
, O
in O
the O
prevention O
of O
nausea B-Disease
and O
vomiting B-Disease
induced O
by O
high O
- O
dose O
cisplatin O
. O

purpose O
: O
to O
assess O
the O
antiemetic O
effects O
and O
safety O
profile O
of O
four O
different O
doses O
of O
granisetron O
( O
kytril O
; O
smithkline O
beecham O
pharmaceuticals O
, O
philadelphia O
, O
pa O
) O
when O
administered O
as O
a O
single O
intravenous O
( O
iv O
) O
dose O
for O
prophylaxis O
of O
cisplatin O
- O
induced O
nausea B-Disease
and O
vomiting B-Disease
. O

patients O
were O
observed O
on O
an O
inpatient O
basis O
for O
18 O
to O
24 O
hours O
, O
and O
vital O
signs O
, O
nausea B-Disease
, O
vomiting B-Disease
, O
retching O
, O
and O
appetite O
were O
assessed O
. O

results O
: O
after O
granisetron O
doses O
of O
5 O
, O
10 O
, O
20 O
, O
and O
40 O
micrograms O
/ O
kg O
, O
a O
major O
response O
( O
< O
or O
= O
two O
vomiting B-Disease
or O
retching O
episodes O
, O
and O
no O
antiemetic O
rescue O
) O
was O
recorded O
in O
23 O
% O
, O
57 O
% O
, O
58 O
% O
, O
and O
60 O
% O
of O
patients O
, O
respectively O
, O
and O
a O
complete O
response O
( O
no O
vomiting B-Disease
or O
retching O
, O
and O
no O
antiemetic O
rescue O
) O
in O
18 O
% O
, O
41 O
% O
, O
40 O
% O
, O
and O
47 O
% O
of O
patients O
, O
respectively O
. O

there O
was O
a O
statistically O
longer O
time O
to O
first O
episode O
of O
nausea B-Disease
( O
p O
= O
. O

15 O
) O
and O
vomiting B-Disease
( O
p O
= O
. O

1 O
) O
, O
and O
fewer O
patients O
were O
administered O
additional O
antiemetic O
medication O
in O
the O
10 O
- O
micrograms O
/ O
kg O
dosing O
groups O
than O
in O
the O
5 O
- O
micrograms O
/ O
kg O
dosing O
group O
. O

headache B-Disease
was O
the O
most O
frequently O
reported O
adverse O
event O
( O
20 O
% O
) O
. O

conclusion O
: O
a O
single O
10 O
- O
, O
20 O
- O
, O
or O
40 O
- O
micrograms O
/ O
kg O
dose O
of O
granisetron O
was O
effective O
in O
controlling O
vomiting B-Disease
in O
57 O
% O
to O
60 O
% O
of O
patients O
who O
received O
cisplatin O
at O
doses O
greater O
than O
81 O
mg O
/ O
m2 O
and O
totally O
prevented O
vomiting B-Disease
in O
40 O
% O
to O
47 O
% O
of O
patients O
. O

objective O
: O
to O
report O
two O
cases O
of O
a O
possible O
adverse O
interaction O
between O
clonidine O
and O
verapamil O
resulting O
in O
atrioventricular B-Disease
( I-Disease
av I-Disease
) I-Disease
block I-Disease
in O
both O
patients O
and O
severe O
hypotension B-Disease
in O
one O
patient O
. O

case O
summaries O
: O
a O
54 O
- O
year O
- O
old O
woman O
with O
hyperaldosteronism B-Disease
was O
treated O
with O
verapamil O
480 O
mg O
/ O
d O
and O
spironolactone O
100 O
mg O
/ O
d O
. O

after O
the O
addition O
of O
a O
minimal O
dose O
of O
clonidine O
( O
0 O
. O

15 O
mg O
bid O
) O
, O
she O
developed O
complete O
av B-Disease
block I-Disease
and O
severe O
hypotension B-Disease
, O
which O
resolved O
upon O
cessation O
of O
all O
medications O
. O

after O
the O
addition O
of O
clonidine O
0 O
. O

15 O
mg O
bid O
she O
developed O
complete O
av B-Disease
block I-Disease
, O
which O
resolved O
after O
all O
therapy O
was O
stopped O
. O

s O
- O
312 O
, O
s O
- O
312 O
- O
d O
, O
but O
not O
s O
- O
312 O
- O
l O
, O
l O
- O
type O
calcium O
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic B-Disease
tonic I-Disease
convulsions I-Disease
in O
dba O
/ O
2 O
mice O
; O
and O
their O
ed50 O
values O
were O
18 O
. O

4 O
( O
12 O
. O

8 O
- O
27 O
. O

1 O
) O
mg O
/ O
kg O
, O
p O
. O

o O
. O

and O
15 O
. O

0 O
( O
10 O
. O

2 O
- O
23 O
. O

7 O
) O
mg O
/ O
kg O
, O
p O
. O

o O
. O

, O
respectively O
, O
while O
that O
of O
flunarizine O
was O
34 O
. O

0 O
( O
26 O
. O

0 O
- O
44 O
. O

8 O
) O
mg O
/ O
kg O
, O
p O
. O

o O
. O

although O
moderate O
anticonvulsant O
effects O
of O
s O
- O
312 O
- O
d O
in O
higher O
doses O
were O
observed O
against O
the O
clonic O
convulsions B-Disease
induced O
by O
pentylenetetrazole O
( O
85 O
mg O
/ O
kg O
, O
s O
. O

c O
. O

) O
or O
bemegride O
( O
40 O
mg O
/ O
kg O
, O
s O
. O

c O
. O

) O
, O
no O
effects O
were O
observed O
in O
convulsions B-Disease
induced O
by O
n O
- O
methyl O
- O
d O
- O
aspartate O
, O
picrotoxin O
, O
or O
electroshock O
in O
slc O
: O
ddy O
mice O
. O

s O
- O
312 O
- O
d O
may O
be O
useful O
in O
the O
therapy O
of O
certain O
types O
of O
human O
epilepsy B-Disease
. O

transmural O
myocardial B-Disease
infarction I-Disease
with O
sumatriptan O
. O

we O
describe O
a O
47 O
- O
year O
- O
old O
woman O
with O
an O
acute O
myocardial B-Disease
infarction I-Disease
after O
administration O
of O
sumatriptan O
6 O
mg O
subcutaneously O
for O
cluster B-Disease
headache I-Disease
. O

the O
patient O
had O
no O
history O
of O
underlying O
ischaemic B-Disease
heart I-Disease
disease I-Disease
or O
prinzmetal B-Disease
' I-Disease
s I-Disease
angina I-Disease
. O

flumazenil O
induces O
seizures B-Disease
and O
death O
in O
mixed O
cocaine O
- O
diazepam O
intoxications O
. O

study O
hypothesis O
: O
administration O
of O
the O
benzodiazepine O
antagonist O
flumazenil O
may O
unmask O
seizures B-Disease
in O
mixed O
cocaine O
- O
benzodiazepine O
intoxication O
. O

animal O
behavior O
, O
seizures B-Disease
( O
time O
to O
and O
incidence O
) O
, O
death O
( O
time O
to O
and O
incidence O
) O
, O
and O
cortical O
eeg O
tracings O
were O
recorded O
. O

this O
resulted O
in O
100 O
% O
developing O
seizures B-Disease
and O
death O
. O

this O
resulted O
in O
no O
overt O
or O
eeg O
- O
detectable O
seizures B-Disease
and O
a O
50 O
% O
incidence O
of O
death O
. O

this O
resulted O
in O
an O
increased O
incidence O
of O
seizures B-Disease
, O
90 O
% O
( O
p O
< O
. O

1 O
) O
, O
and O
death O
, O
100 O
% O
( O
p O
< O
or O
= O
. O

1 O
) O
, O
compared O
with O
group O
4 O
. O

this O
also O
resulted O
in O
an O
increased O
incidence O
of O
seizures B-Disease
, O
90 O
% O
( O
p O
< O
or O
= O
. O

1 O
) O
, O
and O
death O
, O
90 O
% O
( O
p O
< O
or O
= O
. O

5 O
) O
, O
compared O
with O
group O
4 O
. O

conclusion O
: O
flumazenil O
can O
unmask O
seizures B-Disease
and O
increase O
the O
incidence O
of O
death O
in O
a O
model O
of O
combined O
cocaine O
- O
diazepam O
intoxications O
. O

mechanisms O
for O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
- O
mediated O
nephropathy B-Disease
in O
rats O
. O

studies O
were O
performed O
to O
examine O
the O
mechanisms O
for O
the O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin O
( O
gm O
) O
- O
mediated O
nephropathy B-Disease
. O

administration O
of O
gm O
at O
40 O
mg O
/ O
kg O
sc O
for O
13 O
days O
to O
rats O
induced O
a O
significant O
reduction O
in O
renal O
blood O
flow O
( O
rbf O
) O
and O
inulin O
clearance O
( O
cin O
) O
as O
well O
as O
marked O
tubular B-Disease
damage I-Disease
. O

a O
significant O
reduction O
in O
urinary O
guanosine O
3 O
' O
, O
5 O
' O
- O
cyclic O
monophosphate O
( O
cgmp O
) O
excretion O
and O
a O
significant O
increase O
in O
renal O
cortical O
renin O
and O
endothelin O
- O
1 O
contents O
were O
also O
observed O
in O
gm O
- O
mediated O
nephropathy B-Disease
. O

sod O
did O
not O
attenuate O
the O
tubular B-Disease
damage I-Disease
. O

in O
contrast O
, O
dmtu O
significantly O
reduced O
the O
tubular B-Disease
damage I-Disease
and O
lipid O
peroxidation O
, O
but O
it O
did O
not O
affect O
renal O
hemodynamics O
and O
vasoactive O
substances O
. O

these O
results O
suggest O
that O
1 O
) O
both O
sod O
and O
dmtu O
have O
protective O
effects O
on O
gm O
- O
mediated O
nephropathy B-Disease
, O
2 O
) O
the O
mechanisms O
for O
the O
protective O
effects O
differ O
for O
sod O
and O
dmtu O
, O
and O
3 O
) O
superoxide O
anions O
play O
a O
critical O
role O
in O
gm O
- O
induced O
renal O
vasoconstriction O
. O

cephalothin O
- O
induced O
immune O
hemolytic B-Disease
anemia I-Disease
. O

a O
patient O
with O
renal B-Disease
disease I-Disease
developed O
coombs O
- O
positive O
hemolytic B-Disease
anemia I-Disease
while O
receiving O
cephalothin O
therapy O
. O

careful O
investigation O
of O
drug O
- O
induced O
hemolytic B-Disease
anemias I-Disease
reveals O
the O
complexity O
of O
the O
immune O
mechanisms O
involved O
. O

assessment O
of O
cardiomyocyte O
dna O
synthesis O
during O
hypertrophy B-Disease
in O
adult O
mice O
. O

the O
ability O
of O
cardiomyocytes O
to O
synthesize O
dna O
in O
response O
to O
experimentally O
induced O
cardiac B-Disease
hypertrophy I-Disease
was O
assessed O
in O
adult O
mice O
. O

no O
dna O
synthesis O
, O
as O
assessed O
by O
autoradiographic O
analysis O
of O
isolated O
cardiomyocytes O
, O
was O
observed O
in O
control O
or O
hypertrophic B-Disease
hearts I-Disease
. O

to O
determine O
whether O
the O
capacity O
for O
reactive O
dna O
synthesis O
was O
also O
subject O
to O
genetic O
regulation O
, O
cardiac B-Disease
hypertrophy I-Disease
was O
induced O
in O
the O
strains O
of O
mice O
comprising O
the O
extremes O
of O
the O
nuclear O
number O
survey O
. O

these O
data O
indicate O
that O
adult O
mouse O
atrial O
and O
ventricular O
cardiomyocytes O
do O
not O
synthesize O
dna O
in O
response O
to O
isoproterenol O
- O
induced O
cardiac B-Disease
hypertrophy I-Disease
. O

central O
cardiovascular O
effects O
of O
avp O
and O
anp O
in O
normotensive O
and O
spontaneously O
hypertensive B-Disease
rats O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
compare O
influence O
of O
central O
arginine O
vasopressin O
( O
avp O
) O
and O
of O
atrial O
natriuretic O
peptide O
( O
anp O
) O
on O
control O
of O
arterial O
blood O
pressure O
( O
map O
) O
and O
heart O
rate O
( O
hr O
) O
in O
normotensive O
( O
wky O
) O
and O
spontaneously O
hypertensive B-Disease
( O
shr O
) O
rats O
. O

sensitivity O
of O
cardiac O
component O
of O
baroreflex O
( O
ccb O
) O
, O
expressed O
as O
a O
slope O
of O
the O
regression O
line O
was O
determined O
from O
relationships O
between O
systolic O
arterial O
pressure O
( O
sap O
) O
and O
hr O
period O
( O
hrp O
) O
during O
phenylephrine O
( O
phe O
) O
- O
induced O
hypertension B-Disease
and O
sodium O
nitroprusside O
( O
sn O
) O
- O
induced O
hypotension B-Disease
. O

ccb O
was O
reduced O
in O
wky O
and O
shr O
after O
lv O
administration O
of O
avp O
during O
sn O
- O
induced O
hypotension B-Disease
. O

cutaneous O
exposure O
to O
warfarin O
- O
like O
anticoagulant O
causing O
an O
intracerebral B-Disease
hemorrhage I-Disease
: O
a O
case O
report O
. O

a O
case O
of O
intercerebral O
hematoma B-Disease
due O
to O
warfarin O
- O
induced O
coagulopathy B-Disease
is O
presented O
. O

percutaneous O
absorption O
of O
warfarin O
causing O
coagulopathy B-Disease
, O
reported O
three O
times O
in O
the O
past O
, O
is O
a O
significant O
risk O
if O
protective O
measures O
, O
such O
as O
gloves O
, O
are O
not O
used O
. O

an O
adverse O
drug O
interaction O
with O
piroxicam O
, O
which O
she O
took O
occasionally O
, O
may O
have O
exacerbated O
the O
coagulopathy B-Disease
. O

indications O
for O
transB-Plantation O
were O
idiopathic B-Disease
cardiomyopathy I-Disease
( O
52 O
% O
) O
, O
congenital B-Disease
heart I-Disease
disease I-Disease
( O
35 O
% O
) O
with O
and O
without O
prior O
repair O
( O
71 O
% O
and O
29 O
% O
, O
respectively O
) O
, O
hypertrophic B-Disease
cardiomyopathy I-Disease
( O
5 O
% O
) O
, O
valvular B-Disease
heart I-Disease
disease I-Disease
( O
3 O
% O
) O
, O
and O
doxorubicin O
cardiomyopathy B-Disease
( O
5 O
% O
) O
. O

there O
have O
been O
no O
deaths O
related O
to O
rejection O
or O
infection B-Disease
. O

freedom O
from O
serious O
infections B-Disease
was O
83 O
% O
at O
1 O
month O
and O
65 O
% O
at O
1 O
year O
. O

cytomegalovirus B-Disease
infections I-Disease
were O
treated O
successfully O
with O
ganciclovir O
in O
11 O
patients O
. O

twenty O
- O
one O
patients O
( O
60 O
% O
) O
have O
undergone O
annual O
catheterizations O
and O
no O
sign O
of O
graft O
atherosclerosis B-Disease
has O
been O
observed O
. O

seizures B-Disease
occurred O
in O
five O
patients O
( O
14 O
% O
) O
and O
hypertension B-Disease
was O
treated O
in O
10 O
patients O
( O
28 O
% O
) O
. O

no O
patient O
was O
disabled O
and O
no O
lymphoproliferative B-Disease
disorder I-Disease
was O
observed O
. O

( O
abstract O
truncated O
at O
250 O
words O
) O
delirium B-Disease
during O
fluoxetine O
treatment O
. O

in O
some O
cases O
, O
a O
high O
serum O
concentration O
of O
citalopram O
( O
> O
600 O
nmol O
/ O
l O
) O
in O
elderly O
patients O
has O
been O
associated O
with O
increased O
somnolence B-Disease
and O
movement B-Disease
difficulties I-Disease
. O

widespread O
cognitive B-Disease
disorders I-Disease
, O
such O
as O
delirium B-Disease
, O
have O
not O
been O
previously O
linked O
with O
high O
blood O
levels O
of O
ssris O
. O

in O
this O
report O
, O
we O
describe O
a O
patient O
with O
acute O
hyperkinetic B-Disease
delirium B-Disease
connected O
with O
a O
high O
serum O
total O
fluoxetine O
( O
fluoxetine O
plus O
desmethylfluoxetine O
) O
concentration O
. O

pulmonary B-Disease
edema I-Disease
and O
shock B-Disease
after O
high O
- O
dose O
aracytine O
- O
c O
for O
lymphoma B-Disease
; O
possible O
role O
of O
tnf O
- O
alpha O
and O
paf O
. O

four O
out O
of O
23 O
consecutive O
patients O
treated O
with O
high O
- O
dose O
ara O
- O
c O
for O
lymphomas B-Disease
in O
our O
institution O
developed O
a O
strikingly O
similar O
syndrome O
during O
the O
perfusion O
. O

it O
was O
characterized O
by O
the O
onset O
of O
fever B-Disease
, O
diarrhea B-Disease
, O
shock B-Disease
, O
pulmonary B-Disease
edema I-Disease
, O
acute B-Disease
renal I-Disease
failure I-Disease
, O
metabolic B-Disease
acidosis I-Disease
, O
weight B-Disease
gain I-Disease
and O
leukocytosis B-Disease
. O

thorough O
bacteriological O
screening O
failed O
to O
provide O
evidence O
of O
infection B-Disease
. O

as O
tnf O
and O
paf O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock B-Disease
and O
adult B-Disease
respiratory I-Disease
distress I-Disease
syndrome I-Disease
, O
we O
hypothesize O
that O
high O
- O
dose O
ara O
- O
c O
may O
be O
associated O
with O
cytokine O
release O
. O

protective O
effect O
of O
clentiazem O
against O
epinephrine O
- O
induced O
cardiac B-Disease
injury I-Disease
in O
rats O
. O

we O
investigated O
the O
effects O
of O
clentiazem O
, O
a O
1 O
, O
5 O
- O
benzothiazepine O
calcium O
antagonist O
, O
on O
epinephrine O
- O
induced O
cardiomyopathy B-Disease
in O
rats O
. O

with O
2 O
- O
week O
chronic O
epinephrine O
infusion O
, O
16 O
of O
30 O
rats O
died O
within O
4 O
days O
, O
and O
severe O
ischemic B-Disease
lesions I-Disease
and O
fibrosis B-Disease
of O
the O
left O
ventricles O
were O
observed O
. O

treatment O
with O
clentiazem O
prevented O
epinephrine O
- O
induced O
death O
( O
p O
< O
. O

5 O
) O
, O
and O
attenuated O
the O
ventricular O
ischemic B-Disease
lesions I-Disease
and O
fibrosis B-Disease
, O
in O
a O
dose O
- O
dependent O
manner O
. O

in O
conclusion O
, O
clentiazem O
attenuated O
epinephrine O
- O
induced O
cardiac B-Disease
injury I-Disease
, O
possibly O
through O
its O
effect O
on O
the O
adrenergic O
pathway O
. O

kaliuretic O
effect O
of O
l O
- O
dopa O
treatment O
in O
parkinsonian B-Disease
patients O
. O

hypokalemia B-Disease
, O
sometimes O
severe O
, O
was O
observed O
in O
some O
l O
- O
dopa O
- O
treated O
parkinsonian B-Disease
patients O
. O

the O
influence O
of O
l O
- O
dopa O
on O
the O
renal O
excretion O
of O
potassium O
was O
studied O
in O
3 O
patients O
with O
hypokalemia B-Disease
and O
in O
5 O
normokalemic O
patients O
by O
determination O
of O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
, O
plasma O
concentration O
of O
potassium O
and O
sodium O
as O
well O
as O
urinary O
excretion O
of O
potassium O
, O
sodium O
and O
aldosterone O
. O

cocaine O
induced O
myocardial B-Disease
ischemia I-Disease
. O

we O
report O
a O
case O
of O
myocardial B-Disease
ischemia I-Disease
induced O
by O
cocaine O
. O

the O
ischemia B-Disease
probably O
induced O
by O
coronary B-Disease
artery I-Disease
spasm I-Disease
was O
reversed O
by O
nitroglycerin O
and O
calcium O
blocking O
agents O
. O

doxorubicin O
- O
induced O
cardiotoxicity B-Disease
monitored O
by O
ecg O
in O
freely O
moving O
mice O
. O

in O
laboratory O
animals O
, O
histology O
is O
most O
commonly O
used O
to O
study O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
. O

after O
sacrifice O
the O
hearts O
of O
doxorubicin O
- O
treated O
animals O
were O
enlarged O
and O
the O
atria O
were O
hypertrophic B-Disease
. O

as O
this O
schedule O
exerted O
more O
toxicity B-Disease
than O
needed O
to O
investigate O
protective O
agents O
, O
the O
protection O
of O
icrf O
- O
187 O
was O
determined O
using O
a O
dose O
schedule O
with O
lower O
general O
toxicity B-Disease
( O
6 O
weekly O
doses O
of O
4 O
mg O
/ O
kg O
doxorubicin O
given O
i O
. O

v O
. O

plus O
2 O
weeks O
of O
observation O
) O
. O

the O
results O
indicate O
that O
this O
new O
model O
is O
very O
sensitive O
and O
enables O
monitoring O
of O
the O
development O
of O
cardiotoxicity B-Disease
with O
time O
. O

these O
findings O
result O
in O
a O
model O
that O
allows O
the O
testing O
of O
protectors O
against O
doxorubicin O
- O
induced O
cardiotoxicity B-Disease
as O
demonstrated O
by O
the O
protection O
provided O
by O
icrf O
- O
187 O
. O

since O
bupivacaine O
and O
epinephrine O
may O
both O
precipitate O
dysrhythmias B-Disease
, O
circulating O
bupivacaine O
during O
regional O
anesthesia O
could O
potentiate O
dysrhythmogenic O
effects O
of O
epinephrine O
. O

we O
therefore O
examined O
whether O
bupivacaine O
alters O
the O
dysrhythmogenicity O
of O
subsequent O
administration O
of O
epinephrine O
in O
conscious O
, O
healthy O
dogs O
and O
in O
anesthetized O
dogs O
with O
myocardial B-Disease
infarction I-Disease
. O

seventeen O
animals O
responded O
with O
ventricular B-Disease
tachycardia I-Disease
( O
vt B-Disease
) O
within O
3 O
min O
. O

vt B-Disease
appeared O
in O
fewer O
dogs O
and O
at O
a O
later O
time O
, O
and O
there O
were O
more O
sinoatrial O
beats O
and O
less O
ectopies O
. O

one O
day O
after O
experimental O
myocardial B-Disease
infarction I-Disease
, O
six O
additional O
halothane O
- O
anesthetized O
dogs O
received O
4 O
micrograms O
. O

kg O
- O
1 O
. O

min O
- O
1 O
epinephrine O
until O
vt B-Disease
appeared O
. O

bupivacaine O
antagonizes O
epinephrine O
dysrhythmogenicity O
in O
conscious O
dogs O
susceptible O
to O
vt B-Disease
and O
in O
anesthetized O
dogs O
with O
spontaneous O
postinfarct O
dysrhythmias B-Disease
. O

milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
induced O
by O
1 O
, O
25 O
( O
oh O
) O
2d O
in O
a O
patient O
with O
hypoparathyroidism B-Disease
. O

milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic B-Disease
ulcer I-Disease
disease I-Disease
with O
large O
amounts O
of O
calcium O
and O
alkali O
. O

although O
with O
current O
ulcer B-Disease
therapy O
( O
h O
- O
2 O
blockers O
, O
omeprazole O
, O
and O
sucralfate O
) O
, O
the O
frequency O
of O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
has O
decreased O
significantly O
, O
the O
classic O
triad O
of O
hypercalcemia B-Disease
, O
alkalosis B-Disease
, O
and O
renal B-Disease
impairment I-Disease
remains O
the O
hallmark O
of O
the O
syndrome O
. O

milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
can O
present O
serious O
and O
occasionally O
life O
- O
threatening O
illness O
unless O
diagnosed O
and O
treated O
appropriately O
. O

this O
article O
presents O
a O
patient O
with O
hypoparathyroidism B-Disease
who O
was O
treated O
with O
calcium O
carbonate O
and O
calcitriol O
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
. O

this O
illustrates O
intravenous O
pamidronate O
as O
a O
valuable O
therapeutic O
tool O
when O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
presents O
as O
hypercalcemic B-Disease
emergency I-Disease
. O

famotidine O
- O
associated O
delirium B-Disease
. O

famotidine O
is O
a O
histamine O
h2 O
- O
receptor O
antagonist O
used O
in O
inpatient O
settings O
for O
prevention O
of O
stress O
ulcers B-Disease
and O
is O
showing O
increasing O
popularity O
because O
of O
its O
low O
cost O
. O

although O
all O
of O
the O
currently O
available O
h2 O
- O
receptor O
antagonists O
have O
shown O
the O
propensity O
to O
cause O
delirium B-Disease
, O
only O
two O
previously O
reported O
cases O
have O
been O
associated O
with O
famotidine O
. O

the O
authors O
report O
on O
six O
cases O
of O
famotidine O
- O
associated O
delirium B-Disease
in O
hospitalized O
patients O
who O
cleared O
completely O
upon O
removal O
of O
famotidine O
. O

encephalopathy B-Disease
during O
amitriptyline O
therapy O
: O
are O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
and O
serotonin B-Disease
syndrome I-Disease
spectrum O
disorders O
? O
this O
report O
describes O
a O
case O
of O
encephalopathy B-Disease
developed O
in O
the O
course O
of O
amitriptyline O
therapy O
, O
during O
a O
remission O
of O
unipolar B-Disease
depression I-Disease
. O

this O
patient O
could O
have O
been O
diagnosed O
as O
having O
either O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
( O
nms B-Disease
) O
or O
serotonin B-Disease
syndrome I-Disease
( O
ss B-Disease
) O
. O

the O
nms B-Disease
- O
like O
encephalopathy B-Disease
that O
develops O
in O
association O
with O
the O
use O
of O
antidepressants O
indicates O
that O
nms B-Disease
and O
ss B-Disease
are O
spectrum O
disorders O
induced O
by O
drugs O
with O
both O
antidopaminergic O
and O
serotonergic O
effects O
. O

genetic O
separation O
of O
tumor B-Disease
growth O
and O
hemorrhagic B-Disease
phenotypes O
in O
an O
estrogen O
- O
induced O
tumor B-Disease
. O

chronic O
administration O
of O
estrogen O
to O
the O
fischer O
344 O
( O
f344 O
) O
rat O
induces O
growth O
of O
large O
, O
hemorrhagic B-Disease
pituitary B-Disease
tumors I-Disease
. O

ten O
weeks O
of O
diethylstilbestrol O
( O
des O
) O
treatment O
caused O
female O
f344 O
rat O
pituitaries O
to O
grow O
to O
an O
average O
of O
109 O
. O

2 O
+ O
/ O
- O
6 O
. O

3 O
mg O
( O
mean O
+ O
/ O
- O
se O
) O
versus O
11 O
. O

3 O
+ O
/ O
- O
1 O
. O

4 O
mg O
for O
untreated O
rats O
, O
and O
to O
become O
highly O
hemorrhagic B-Disease
. O

surprisingly O
, O
the O
f1 O
hybrid O
tumors B-Disease
were O
not O
hemorrhagic B-Disease
and O
had O
hemoglobin O
content O
and O
outward O
appearance O
identical O
to O
that O
of O
bn O
. O

however O
, O
while O
des O
- O
induced O
pituitary O
growth O
exhibited O
quantitative O
, O
additive O
inheritance O
, O
the O
hemorrhagic B-Disease
phenotype O
exhibited O
recessive O
, O
epistatic O
inheritance O
. O

only O
5 O
of O
the O
160 O
f2 O
pituitaries O
exhibited O
the O
hemorrhagic B-Disease
phenotype O
; O
36 O
of O
the O
160 O
f2 O
pituitaries O
were O
in O
the O
f344 O
range O
of O
mass O
, O
but O
31 O
of O
these O
were O
not O
hemorrhagic B-Disease
, O
indicating O
that O
the O
hemorrhagic B-Disease
phenotype O
is O
not O
merely O
a O
consequence O
of O
extensive O
growth O
. O

the O
hemorrhagic B-Disease
f2 O
pituitaries O
were O
all O
among O
the O
most O
massive O
, O
indicating O
that O
some O
of O
the O
genes O
regulate O
both O
phenotypes O
. O

increased O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
in O
bladder O
afferent O
pathways O
following O
chronic O
bladder B-Disease
irritation I-Disease
. O

immunocytochemical O
techniques O
were O
used O
to O
examine O
alterations O
in O
the O
expression O
of O
neuronal O
nitric O
oxide O
synthase O
( O
nos O
) O
in O
bladder O
pathways O
following O
acute O
and O
chronic O
irritation B-Disease
of I-Disease
the I-Disease
urinary I-Disease
tract I-Disease
of O
the O
rat O
. O

chemical O
cystitis B-Disease
was O
induced O
by O
cyclophosphamide O
( O
cyp O
) O
which O
is O
metabolized O
to O
acrolein O
, O
an O
irritant O
eliminated O
in O
the O
urine O
. O

effects O
of O
a O
new O
calcium O
antagonist O
, O
cd O
- O
832 O
, O
on O
isoproterenol O
- O
induced O
myocardial B-Disease
ischemia I-Disease
in O
dogs O
with O
partial O
coronary B-Disease
stenosis I-Disease
. O

effects O
of O
cd O
- O
832 O
on O
isoproterenol O
( O
iso O
) O
- O
induced O
myocardial B-Disease
ischemia I-Disease
were O
studied O
in O
dogs O
with O
partial O
coronary B-Disease
stenosis I-Disease
of O
the O
left O
circumflex O
coronary O
artery O
and O
findings O
were O
compared O
with O
those O
for O
nifedipine O
or O
diltiazem O
. O

in O
the O
presence O
of O
coronary B-Disease
artery I-Disease
stenosis I-Disease
, O
3 O
- O
min O
periods O
of O
intracoronary O
iso O
infusion O
( O
10 O
ng O
/ O
kg O
/ O
min O
) O
increased O
heart O
rate O
and O
maximal O
rate O
of O
left O
ventricular O
pressure O
rise O
, O
which O
resulted O
in O
a O
decrease O
in O
percentage O
segmental O
shortening O
and O
st O
- O
segment O
elevation O
of O
the O
epicardial O
electrocardiogram O
. O

after O
the O
control O
iso O
infusion O
with O
stenosis B-Disease
was O
performed O
, O
equihypotensive O
doses O
of O
cd O
- O
832 O
( O
3 O
and O
10 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
, O
nifedipine O
( O
1 O
and O
3 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
9 O
) O
or O
diltiazem O
( O
10 O
and O
30 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
were O
infused O
5 O
min O
before O
and O
during O
the O
second O
and O
third O
iso O
infusion O
. O

in O
contrast O
to O
nifedipine O
, O
cd O
- O
832 O
( O
10 O
micrograms O
/ O
kg O
/ O
min O
) O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
32 O
+ O
/ O
- O
12 O
% O
to O
115 O
+ O
/ O
- O
26 O
% O
of O
the O
control O
value O
( O
p O
< O
. O

1 O
) O
and O
st O
- O
segment O
elevation O
from O
5 O
. O

6 O
+ O
/ O
- O
1 O
. O

0 O
mv O
to O
1 O
. O

6 O
+ O
/ O
- O
1 O
. O

3 O
mv O
( O
p O
< O
. O

1 O
) O
at O
3 O
min O
after O
iso O
infusion O
with O
stenosis B-Disease
. O

diltiazem O
( O
30 O
micrograms O
/ O
kg O
/ O
min O
) O
also O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
34 O
+ O
/ O
- O
14 O
% O
to O
63 O
+ O
/ O
- O
18 O
% O
of O
the O
control O
value O
( O
p O
< O
. O

5 O
) O
and O
st O
- O
segment O
elevation O
from O
4 O
. O

7 O
+ O
/ O
- O
0 O
. O

7 O
mv O
to O
2 O
. O

1 O
+ O
/ O
- O
0 O
. O

7 O
mv O
( O
p O
< O
. O

1 O
) O
at O
3 O
min O
after O
iso O
infusion O
with O
stenosis B-Disease
. O

these O
data O
show O
that O
cd O
- O
832 O
improves O
myocardial B-Disease
ischemia I-Disease
during O
iso O
infusion O
with O
stenosis B-Disease
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
cd O
- O
832 O
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
cd O
- O
832 O
. O

the O
effect O
of O
recombinant O
human O
insulin O
- O
like O
growth O
factor O
- O
i O
on O
chronic O
puromycin O
aminonucleoside O
nephropathy B-Disease
in O
rats O
. O

we O
recently O
demonstrated O
that O
recombinant O
hgh O
exacerbates O
renal O
functional O
and O
structural O
injury O
in O
chronic O
puromycin O
aminonucleoside O
( O
pan O
) O
nephropathy B-Disease
, O
an O
experimental O
model O
of O
glomerular B-Disease
disease I-Disease
. O

therefore O
, O
we O
examined O
whether O
recombinant O
human O
( O
rh O
) O
igf O
- O
i O
is O
a O
safer O
alternative O
for O
the O
treatment O
of O
growth B-Disease
failure I-Disease
in O
rats O
with O
chronic O
pan O
nephropathy B-Disease
. O

the O
glomerulopathy B-Disease
was O
induced O
by O
seven O
serial O
injections O
of O
pan O
over O
12 O
wk O
. O

rhigf O
- O
i O
improved O
weight O
gain O
by O
14 O
% O
( O
p O
< O
0 O
. O

5 O
) O
, O
without O
altering O
hematocrit O
or O
blood O
pressure O
in O
rats O
with O
renal B-Disease
disease I-Disease
. O

urinary O
protein O
excretion O
was O
unaltered O
by O
rhigf O
- O
i O
treatment O
in O
rats O
with O
chronic O
pan O
nephropathy B-Disease
. O

after O
12 O
wk O
, O
the O
inulin O
clearance O
was O
higher O
in O
rhigf O
- O
i O
- O
treated O
rats O
, O
0 O
. O

48 O
+ O
/ O
- O
0 O
. O

8 O
versus O
0 O
. O

24 O
+ O
/ O
- O
0 O
. O

6 O
ml O
/ O
min O
/ O
100 O
g O
of O
body O
weight O
in O
untreated O
pan O
nephropathy B-Disease
animals O
, O
p O
< O
0 O
. O

5 O
. O

the O
improvement O
in O
gfr O
was O
not O
associated O
with O
enhanced O
glomerular B-Disease
hypertrophy I-Disease
or O
increased O
segmental O
glomerulosclerosis B-Disease
, O
tubulointerstitial B-Disease
injury I-Disease
, O
or O
renal O
cortical O
malondialdehyde O
content O
. O

in O
rats O
with O
pan O
nephropathy B-Disease
, O
administration O
of O
rhigf O
- O
i O
increased O
igf O
- O
i O
and O
gh O
receptor O
gene O
expression O
, O
without O
altering O
the O
steady O
state O
level O
of O
igf O
- O
i O
receptor O
mrna O
. O

in O
normal O
rats O
with O
intact O
kidneys O
, O
rhigf O
- O
i O
administration O
( O
n O
= O
4 O
) O
did O
not O
alter O
weight O
gain O
, O
blood O
pressure O
, O
proteinuria B-Disease
, O
gfr O
, O
glomerular O
planar O
area O
, O
renal O
cortical O
malondialdehyde O
content O
, O
or O
glomerular O
or O
tubulointerstitial B-Disease
damage I-Disease
, O
compared O
with O
untreated O
animals O
( O
n O
= O
4 O
) O
. O

we O
conclude O
that O
: O
1 O
) O
administration O
of O
rhigf O
- O
i O
improves O
growth O
and O
gfr O
in O
rats O
with O
chronic O
pan O
nephropathy B-Disease
and O
2 O
) O
unlike O
rhgh O
, O
long O
- O
term O
use O
of O
rhigf O
- O
i O
does O
not O
worsen O
renal O
functional O
and O
structural O
injury O
in O
this O
disease O
model O
. O

nefiracetam O
( O
dm O
- O
9384 O
) O
reverses O
apomorphine O
- O
induced O
amnesia B-Disease
of O
a O
passive O
avoidance O
response O
: O
delayed O
emergence O
of O
the O
memory O
retention O
effects O
. O

nefiracetam O
is O
a O
novel O
pyrrolidone O
derivative O
which O
attenuates O
scopolamine O
- O
induced O
learning B-Disease
and I-Disease
post I-Disease
- I-Disease
training I-Disease
consolidation I-Disease
deficits I-Disease
. O

given O
that O
apomorphine O
inhibits O
passive O
avoidance O
retention O
when O
given O
during O
training O
or O
in O
a O
defined O
10 O
- O
12h O
post O
- O
training O
period O
, O
we O
evaluated O
the O
ability O
of O
nefiracetam O
to O
attenuate O
amnesia B-Disease
induced O
by O
dopaminergic O
agonism O
. O

however O
, O
administration O
of O
nefiracetam O
during O
training O
completely O
reversed O
the O
amnesia B-Disease
induced O
by O
apomorphine O
at O
the O
10h O
post O
- O
training O
time O
and O
the O
converse O
was O
also O
TRUE O
. O

phenytoin O
encephalopathy B-Disease
as O
probable O
idiosyncratic O
reaction O
: O
case O
report O
. O

a O
case O
of O
phenytoin O
( O
dph O
) O
encephalopathy B-Disease
with O
increasing O
seizures B-Disease
and O
eeg O
and O
mental O
changes O
is O
described O
. O

the O
encephalopathy B-Disease
was O
probably O
an O
idiosyncratic O
and O
not O
toxic O
or O
allergic O
reaction O
. O

in O
fact O
the O
concentration O
of O
free O
dph O
was O
normal O
, O
the O
patient O
presented O
a O
retarded O
morbilliform O
rash B-Disease
during O
dph O
treatment O
, O
the O
protidogram O
was O
normal O
, O
and O
an O
intradermic O
dph O
injection O
had O
no O
local O
effect O
. O

the O
authors O
conclude O
that O
in O
a O
patient O
starting O
dph O
treatment O
an O
unexpected O
increase O
in O
seizures B-Disease
, O
with O
eeg O
and O
mental O
changes O
occurring O
simultaneously O
, O
should O
alert O
the O
physician O
to O
the O
possible O
need O
for O
eliminating O
dph O
from O
the O
therapeutic O
regimen O
, O
even O
if O
plasma O
concentrations O
are O
low O
. O

prevention O
and O
treatment O
of O
endometrial B-Disease
disease I-Disease
in O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

the O
treatment O
regimens O
are O
described O
in O
74 O
patients O
with O
endometrial B-Disease
disease I-Disease
among O
850 O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

cystic O
hyperplasia B-Disease
was O
associated O
with O
unopposed O
oestrogen O
therapy O
without O
progestagen O
. O

two O
courses O
of O
21 O
days O
of O
5 O
mg O
norethisterone O
daily O
caused O
reversion O
to O
normal O
in O
all O
57 O
cases O
of O
cystic O
hyperplasia B-Disease
and O
6 O
of O
the O
8 O
cases O
of O
atypical O
hyperplasia B-Disease
. O

4 O
cases O
of O
endometrial B-Disease
carcinoma I-Disease
referred O
from O
elsewhere O
demonstrated O
the O
problems O
of O
inappropriate O
and O
unsupervised O
unopposed O
oestrogen O
therapy O
and O
the O
difficulty O
in O
distinguishing O
severe O
hyperplasia B-Disease
from O
malignancy B-Disease
. O

cyclical O
low O
- O
dose O
oestrogen O
therapy O
with O
7 O
- O
- O
13 O
days O
of O
progestagen O
does O
not O
seem O
to O
increase O
the O
risk O
of O
endometrial B-Disease
hyperplasia I-Disease
or O
carcinoma B-Disease
. O

effects O
of O
exercise O
on O
the O
severity O
of O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
. O

the O
effect O
of O
exercise O
on O
the O
severity O
of O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
was O
studied O
in O
male O
rats O
. O

the O
results O
indicated O
that O
exercise O
reduced O
the O
mortality O
associated O
with O
the O
effects O
of O
large O
dosages O
of O
isoproterenol O
but O
had O
little O
on O
the O
severity O
of O
the O
infarction B-Disease
. O

human O
corticotropin O
- O
releasing O
hormone O
and O
thyrotropin O
- O
releasing O
hormone O
modulate O
the O
hypercapnic B-Disease
ventilatory O
response O
in O
humans O
. O

the O
results O
indicate O
an O
additive O
effect O
of O
both O
releasing O
hormones O
on O
the O
hypercapnic B-Disease
ventilatory O
response O
in O
humans O
, O
presumably O
independent O
of O
central O
chemosensitivity O
. O

lamivudine O
is O
effective O
in O
suppressing O
hepatitis B-Disease
b I-Disease
virus O
dna O
in O
chinese O
hepatitis O
b O
surface O
antigen O
carriers O
: O
a O
placebo O
- O
controlled O
trial O
. O

lamivudine O
is O
a O
novel O
2 O
' O
, O
3 O
' O
- O
dideoxy O
cytosine O
analogue O
that O
has O
potent O
inhibitory O
effects O
on O
hepatitis B-Disease
b I-Disease
virus O
replication O
in O
vitro O
and O
in O
vivo O
. O

all O
36 O
patients O
receiving O
lamivudine O
had O
a O
decrease O
in O
hepatitis B-Disease
b I-Disease
virus O
( O
hbv O
) O
dna O
values O
of O
> O
90 O
% O
( O
p O
< O
. O

1 O
compared O
with O
placebo O
) O
. O

there O
was O
no O
change O
in O
the O
hepatitis B-Disease
b I-Disease
e O
antigen O
status O
or O
in O
aminotransferase O
levels O
. O

population O
- O
based O
study O
of O
risk O
of O
venous B-Disease
thromboembolism I-Disease
associated O
with O
various O
oral O
contraceptives O
. O

background O
: O
four O
studies O
published O
since O
december O
, O
1995 O
, O
reported O
that O
the O
incidence O
of O
venous B-Disease
thromboembolism I-Disease
( O
vte B-Disease
) O
was O
higher O
in O
women O
who O
used O
oral O
contraceptives O
( O
ocs O
) O
containing O
the O
third O
- O
generation O
progestagens O
gestodene O
or O
desogestrel O
than O
in O
users O
of O
ocs O
containing O
second O
- O
generation O
progestagens O
. O

the O
aim O
of O
our O
study O
was O
to O
re O
- O
examine O
the O
association O
between O
risk O
of O
vte B-Disease
and O
oc O
use O
with O
a O
different O
study O
design O
and O
analysis O
to O
avoid O
some O
of O
the O
bias O
and O
confounding O
of O
the O
earlier O
studies O
. O

all O
women O
who O
had O
a O
recorded O
diagnosis O
of O
deep B-Disease
- I-Disease
vein I-Disease
thrombosis I-Disease
, O
venous B-Disease
thrombosis I-Disease
not O
otherwise O
specified O
, O
or O
pulmonary O
embolus O
during O
the O
study O
period O
, O
and O
who O
had O
been O
treated O
with O
an O
anticoagulant O
were O
identified O
as O
potential O
cases O
of O
vte B-Disease
. O

we O
did O
a O
cohort O
analysis O
to O
estimate O
and O
compare O
incidence O
of O
vte B-Disease
in O
users O
of O
the O
main O
oc O
preparations O
, O
and O
a O
nested O
case O
- O
control O
study O
to O
calculate O
the O
odds O
ratios O
of O
vte B-Disease
associated O
with O
use O
of O
different O
types O
of O
oc O
, O
after O
adjustment O
for O
potential O
confounding O
factors O
. O

findings O
: O
85 O
women O
met O
the O
inclusion O
criteria O
for O
vte B-Disease
, O
two O
of O
whom O
were O
users O
of O
progestagen O
- O
only O
ocs O
. O

of O
the O
83 O
cases O
of O
vte B-Disease
associated O
with O
use O
of O
combined O
ocs O
, O
43 O
were O
recorded O
as O
deep B-Disease
- I-Disease
vein I-Disease
thrombosis I-Disease
, O
35 O
as O
pulmonary O
thrombosis B-Disease
, O
and O
five O
as O
venous B-Disease
thrombosis I-Disease
not O
otherwise O
specified O
. O

the O
crude O
rate O
of O
vte B-Disease
per O
10 O
, O
0 O
woman O
- O
years O
was O
4 O
. O

10 O
in O
current O
users O
of O
any O
oc O
, O
3 O
. O

10 O
in O
users O
of O
second O
- O
generation O
ocs O
, O
and O
4 O
. O

96 O
in O
users O
of O
third O
- O
generation O
preparations O
. O

after O
adjustment O
for O
age O
, O
the O
rate O
ratio O
of O
vte B-Disease
in O
users O
of O
third O
- O
generation O
relative O
to O
second O
- O
generation O
ocs O
was O
1 O
. O

68 O
( O
95 O
% O
ci O
1 O
. O

4 O
- O
2 O
. O

75 O
) O
. O

logistic O
regression O
showed O
no O
significant O
difference O
in O
the O
risk O
of O
vte B-Disease
between O
users O
of O
third O
- O
generation O
and O
second O
- O
generation O
ocs O
. O

among O
users O
of O
third O
- O
generation O
progestagens O
, O
the O
risk O
of O
vte B-Disease
was O
higher O
in O
users O
of O
desogestrel O
with O
20 O
g O
ethinyloestradiol O
than O
in O
users O
of O
gestodene O
or O
desogestrel O
with O
30 O
g O
ethinyloestradiol O
. O

with O
all O
second O
- O
generation O
ocs O
as O
the O
reference O
, O
the O
odds O
ratios O
for O
vte B-Disease
were O
3 O
. O

49 O
( O
1 O
. O

21 O
- O
10 O
. O

12 O
) O
for O
desogestrel O
plus O
20 O
g O
ethinyloestradiol O
and O
1 O
. O

18 O
( O
0 O
. O

66 O
- O
2 O
. O

17 O
) O
for O
the O
other O
third O
- O
generation O
progestagens O
. O

mk O
- O
801 O
augments O
pilocarpine O
- O
induced O
electrographic O
seizure B-Disease
but O
protects O
against O
brain B-Disease
damage I-Disease
in O
rats O
. O

the O
authors O
examined O
the O
anticonvulsant O
effects O
of O
mk O
- O
801 O
on O
the O
pilocarpine O
- O
induced O
seizure B-Disease
model O
. O

intraperitoneal O
injection O
of O
pilocarpine O
( O
400 O
mg O
/ O
kg O
) O
induced O
tonic B-Disease
and I-Disease
clonic I-Disease
seizure I-Disease
. O

scopolamine O
( O
10 O
mg O
/ O
kg O
) O
and O
pentobarbital O
( O
5 O
mg O
/ O
kg O
) O
prevented O
development O
of O
pilocarpine O
- O
induced O
behavioral O
seizure B-Disease
but O
mk O
- O
801 O
( O
0 O
. O

5 O
mg O
/ O
kg O
) O
did O
not O
. O

an O
electrical O
seizure B-Disease
measured O
with O
hippocampal O
eeg O
appeared O
in O
the O
pilocarpine O
- O
treated O
group O
. O

scopolamine O
and O
pentobarbital O
blocked O
the O
pilocarpine O
- O
induced O
electrographic O
seizure B-Disease
, O
mk O
- O
801 O
treatment O
augmented O
the O
electrographic O
seizure B-Disease
induced O
by O
pilocarpine O
. O

brain B-Disease
damage I-Disease
was O
assessed O
by O
examining O
the O
hippocampus O
microscopically O
. O

pilocarpine O
produced O
neuronal B-Disease
death I-Disease
in O
the O
hippocampus O
, O
which O
showed O
pyknotic O
changes O
. O

pentobarbital O
, O
scopolamine O
and O
mk O
- O
801 O
protected O
the O
brain B-Disease
damage I-Disease
by O
pilocarpine O
, O
though O
in O
the O
mk O
- O
801 O
- O
treated O
group O
, O
the O
pyramidal O
cells O
of O
hippocampus O
appeared O
darker O
than O
normal O
. O

these O
results O
indicate O
that O
status B-Disease
epilepticus I-Disease
induced O
by O
pilocarpine O
is O
initiated O
by O
cholinergic O
overstimulation O
and O
propagated O
by O
glutamatergic O
transmission O
, O
the O
elevation O
of O
which O
may O
cause O
brain B-Disease
damage I-Disease
through O
an O
excitatory O
nmda O
receptor O
- O
mediated O
mechanism O
. O

paclitaxel O
, O
5 O
- O
fluorouracil O
, O
and O
folinic O
acid O
in O
metastatic O
breast B-Disease
cancer I-Disease
: O
bre O
- O
26 O
, O
a O
phase O
ii O
trial O
. O

5 O
- O
fluorouracil O
plus O
folinic O
acid O
and O
paclitaxel O
( O
taxol O
; O
bristol O
- O
myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
are O
effective O
salvage O
therapies O
for O
metastatic O
breast B-Disease
cancer I-Disease
patients O
. O

paclitaxel O
and O
5 O
- O
fluorouracil O
have O
additive O
cytotoxicity B-Disease
in O
mcf O
- O
7 O
cell O
lines O
. O

we O
performed O
a O
phase O
ii O
trial O
of O
paclitaxel O
175 O
mg O
/ O
m2 O
over O
3 O
hours O
on O
day O
i O
followed O
by O
folinic O
acid O
300 O
mg O
over O
1 O
hour O
before O
5 O
- O
fluorouracil O
350 O
mg O
/ O
m2 O
on O
days O
1 O
to O
3 O
every O
28 O
days O
( O
tfl O
) O
in O
women O
with O
metastatic O
breast B-Disease
cancer I-Disease
. O

analysis O
is O
reported O
on O
37 O
patients O
with O
a O
minimum O
of O
6 O
months O
follow O
- O
up O
who O
received O
a O
total O
of O
192 O
cycles O
of O
tfl O
: O
nine O
cycles O
( O
5 O
% O
) O
were O
associated O
with O
grade O
3 O
/ O
4 O
neutropenia B-Disease
requiring O
hospitalization O
; O
seven O
( O
4 O
% O
) O
cycles O
in O
two O
patients O
required O
granulocyte O
colony O
- O
stimulating O
factor O
due O
to O
neutropenia B-Disease
; O
no O
patient O
required O
platelet O
transfusions O
. O

grade O
3 O
/ O
4 O
nonhematologic O
toxicities B-Disease
were O
uncommon O
. O

tfl O
is O
an O
active O
, O
well O
- O
tolerated O
regimen O
in O
metastatic O
breast B-Disease
cancer I-Disease
. O

efficacy O
and O
proarrhythmia B-Disease
with O
the O
use O
of O
d O
, O
l O
- O
sotalol O
for O
sustained O
ventricular B-Disease
tachyarrhythmias I-Disease
. O

this O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades B-Disease
de I-Disease
pointes I-Disease
, O
and O
the O
presumable O
risk O
factors O
for O
torsades B-Disease
de I-Disease
pointes I-Disease
in O
patients O
treated O
with O
d O
, O
l O
- O
sotalol O
for O
sustained O
ventricular B-Disease
tachyarrhythmias I-Disease
. O

eighty O
- O
one O
consecutive O
patients O
( O
54 O
with O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
and O
20 O
with O
dilated B-Disease
cardiomyopathy I-Disease
) O
with O
inducible O
sustained O
ventricular B-Disease
tachycardia I-Disease
or O
ventricular B-Disease
fibrillation I-Disease
received O
oral O
d O
, O
l O
- O
sotalol O
to O
prevent O
induction O
of O
the O
ventricular B-Disease
tachyarrhythmia I-Disease
. O

those O
patients O
in O
whom O
d O
, O
l O
- O
sotalol O
prevented O
induction O
of O
ventricular B-Disease
tachycardia I-Disease
or O
ventricular B-Disease
fibrillation I-Disease
were O
discharged O
with O
the O
drug O
and O
followed O
up O
on O
an O
outpatient O
basis O
for O
21 O
+ O
/ O
- O
18 O
months O
. O

induction O
of O
the O
ventricular B-Disease
tachyarrhythmia I-Disease
was O
prevented O
by O
oral O
d O
, O
l O
- O
sotalol O
in O
35 O
( O
43 O
% O
) O
patients O
; O
the O
ventricular B-Disease
tachyarrhythmia I-Disease
remained O
inducible O
in O
40 O
( O
49 O
% O
) O
patients O
; O
and O
two O
( O
2 O
. O

5 O
% O
) O
patients O
did O
not O
tolerate O
even O
40 O
mg O
of O
d O
, O
l O
- O
sotalol O
once O
daily O
. O

four O
( O
5 O
% O
) O
patients O
had O
from O
torsades B-Disease
de I-Disease
pointes I-Disease
during O
the O
initial O
oral O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

neither O
ecg O
[ O
sinus O
- O
cycle O
length O
( O
scl O
) O
, O
qt O
or O
qtc O
interval O
, O
or O
u O
wave O
] O
nor O
clinical O
parameters O
identified O
patients O
at O
risk O
for O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

however O
, O
the O
oral O
dose O
of O
d O
, O
l O
- O
sotalol O
was O
significantly O
lower O
in O
patients O
with O
torsades B-Disease
de I-Disease
pointes I-Disease
( O
200 O
+ O
/ O
- O
46 O
vs O
. O

328 O
+ O
/ O
- O
53 O
mg O
/ O
day O
; O
p O
= O
0 O
. O

17 O
) O
. O

risk O
factors O
associated O
with O
the O
development O
of O
torsades B-Disease
de I-Disease
pointes I-Disease
were O
the O
appearance O
of O
an O
u O
wave O
( O
p O
= O
0 O
. O

49 O
) O
, O
female O
gender O
( O
p O
= O
0 O
. O

15 O
) O
, O
and O
significant O
dose O
- O
corrected O
changes O
of O
scl O
, O
qt O
interval O
, O
and O
qtc O
interval O
( O
p O
< O
0 O
. O

5 O
) O
. O

during O
follow O
- O
up O
, O
seven O
( O
20 O
% O
) O
patients O
had O
a O
nonfatal O
ventricular B-Disease
tachycardia I-Disease
recurrence O
, O
and O
two O
( O
6 O
% O
) O
patients O
died O
suddenly O
. O

one O
female O
patient O
with O
stable O
cardiac B-Disease
disease I-Disease
had O
recurrent O
torsades B-Disease
de I-Disease
pointes I-Disease
after O
2 O
years O
of O
successful O
treatment O
with O
d O
, O
l O
- O
sotalol O
. O

torsades B-Disease
de I-Disease
pointes I-Disease
occurred O
early O
during O
treatment O
even O
with O
low O
doses O
of O
oral O
d O
, O
l O
- O
sotalol O
. O

pronounced O
changes O
in O
the O
surface O
ecg O
( O
cycle O
length O
, O
qt O
, O
and O
qtc O
) O
in O
relation O
to O
the O
dose O
of O
oral O
d O
, O
l O
- O
sotalol O
might O
identify O
a O
subgroup O
of O
patients O
with O
an O
increased O
risk O
for O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

other O
ecg O
parameters O
before O
the O
application O
of O
d O
, O
l O
- O
sotalol O
did O
not O
identify O
patients O
at O
increased O
risk O
for O
torsades B-Disease
de I-Disease
pointes I-Disease
. O

recurrence O
rates O
of O
ventricular B-Disease
tachyarrhythmias I-Disease
are O
high O
despite O
complete O
suppression O
of O
the O
arrhythmia B-Disease
during O
programmed O
stimulation O
. O

chronic O
hyperprolactinemia B-Disease
and O
changes O
in O
dopamine O
neurons O
. O

the O
purpose O
of O
this O
study O
was O
to O
induce O
hyperprolactinemia B-Disease
in O
rats O
for O
extended O
periods O
of O
time O
and O
examine O
its O
effects O
on O
dopaminergic O
systems O
in O
the O
brain O
. O

hyperprolactinemia B-Disease
was O
induced O
by O
treatment O
with O
haloperidol O
, O
a O
dopamine O
receptor O
antagonist O
, O
and O
palkovits O
' O
microdissection O
technique O
in O
combination O
with O
high O
- O
performance O
liquid O
chromatography O
was O
used O
to O
measure O
neurotransmitter O
concentrations O
in O
several O
areas O
of O
the O
brain O
. O

after O
6 O
months O
of O
hyperprolactinemia B-Disease
, O
dopamine O
( O
da O
) O
concentrations O
in O
the O
median O
eminence O
( O
me O
) O
increased O
by O
84 O
% O
over O
the O
control O
group O
. O

nine O
months O
of O
hyperprolactinemia B-Disease
produced O
a O
50 O
% O
increase O
in O
da O
concentrations O
in O
the O
me O
over O
the O
control O
group O
. O

however O
, O
da O
response O
was O
lost O
if O
a O
9 O
- O
month O
long O
haloperidol O
- O
induced O
hyperprolactinemia B-Disease
was O
followed O
by O
a O
1 O
1 O
/ O
2 O
month O
- O
long O
extremely O
high O
increase O
in O
serum O
prl O
levels O
produced O
by O
imB-Plantation O
of O
mmq O
cells O
under O
the O
kidney O
capsule O
. O

there O
was O
no O
change O
in O
the O
levels O
of O
da O
, O
norepinephrine O
( O
ne O
) O
, O
serotonin O
( O
5 O
- O
ht O
) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
( O
an O
) O
, O
medial O
preoptic O
area O
( O
mpa O
) O
, O
caudate O
putamen O
( O
cp O
) O
, O
substantia O
nigra O
( O
sn O
) O
, O
and O
zona O
incerta O
( O
zi O
) O
, O
except O
for O
a O
decrease O
in O
5 O
- O
hydroxyindoleacetic O
acid O
( O
5 O
- O
hiaa O
) O
in O
the O
an O
after O
6 O
- O
months O
of O
hyperprolactinemia B-Disease
and O
an O
increase O
in O

da O
concentrations O
in O
the O
an O
after O
9 O
- O
months O
of O
hyperprolactinemia B-Disease
. O

these O
results O
demonstrate O
that O
hyperprolactinemia B-Disease
specifically O
affects O
tida O
neurons O
and O
these O
effects O
vary O
, O
depending O
on O
the O
duration O
and O
intensity O
of O
hyperprolactinemia B-Disease
. O

treatment O
- O
related O
disseminated O
necrotizing O
leukoencephalopathy B-Disease
with O
characteristic O
contrast O
enhancement O
of O
the O
white O
matter O
. O

this O
report O
describes O
unique O
contrast O
enhancement O
of O
the O
white O
matter O
on O
t1 O
- O
weighted O
magnetic O
resonance O
images O
of O
two O
patients O
with O
disseminated O
necrotizing O
leukoencephalopathy B-Disease
, O
which O
developed O
from O
acute B-Disease
lymphoblastic I-Disease
leukemia I-Disease
treated O
with O
high O
- O
dose O
methotrexate O
. O

necropsy O
of O
the O
first O
case O
revealed O
loss B-Disease
of I-Disease
myelination I-Disease
and O
necrosis B-Disease
of O
the O
white O
matter O
. O

possible O
mechanisms O
causing O
such O
a O
leukoencephalopathy B-Disease
are O
discussed O
. O

thrombotic B-Disease
complications O
in O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
during O
all O
- O
trans O
- O
retinoic O
acid O
therapy O
. O

a O
case O
of O
acute B-Disease
renal I-Disease
failure I-Disease
, O
due O
to O
occlusion B-Disease
of I-Disease
renal I-Disease
vessels I-Disease
in O
a O
patient O
with O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
( O
apl B-Disease
) O
treated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
atra O
) O
and O
tranexamic O
acid O
has O
been O
described O
recently O
. O

we O
report O
a O
case O
of O
acute B-Disease
renal I-Disease
failure I-Disease
in O
an O
apl B-Disease
patient O
treated O
with O
atra O
alone O
. O

this O
case O
further O
supports O
the O
concern O
about O
thromboembolic B-Disease
complications O
associated O
with O
atra O
therapy O
in O
apl B-Disease
patients O
. O

the O
patients O
, O
a O
43 O
- O
year O
- O
old O
man O
, O
presented O
all O
the O
signs O
and O
symptoms O
of O
apl B-Disease
and O
was O
included O
in O
a O
treatment O
protocol O
with O
atra O
. O

after O
10 O
days O
of O
treatment O
, O
he O
developed O
acute B-Disease
renal I-Disease
failure I-Disease
that O
was O
completely O
reversible O
after O
complete O
remission O
of O
apl B-Disease
was O
achieved O
and O
therapy O
discontinued O
. O

we O
conclude O
that O
atra O
is O
a O
valid O
therapeutic O
choice O
for O
patients O
with O
apl B-Disease
, O
although O
the O
procoagulant O
tendency O
is O
not O
completely O
corrected O
. O

thrombotic B-Disease
events O
, O
however O
, O
could O
be O
avoided O
by O
using O
low O
- O
dose O
heparin O
. O

pupillary O
changes O
associated O
with O
the O
development O
of O
stimulant O
- O
induced O
mania B-Disease
: O
a O
case O
report O
. O

a O
30 O
- O
year O
- O
old O
cocaine O
- O
dependent O
man O
who O
was O
a O
subject O
in O
a O
study O
evaluating O
the O
anticraving O
efficacy O
of O
the O
stimulant O
medication O
diethylpropion O
( O
dep O
) O
became O
manic B-Disease
during O
his O
second O
week O
on O
the O
study O
drug O
. O

pupillometric O
changes O
while O
on O
dep O
, O
especially O
changes O
in O
the O
total O
power O
of O
pupillary B-Disease
oscillation I-Disease
, O
were O
dramatically O
different O
than O
those O
observed O
in O
the O
eight O
other O
study O
subjects O
who O
did O
not O
become O
manic B-Disease
. O

the O
large O
changes O
in O
total O
power O
of O
pupillary B-Disease
oscillation I-Disease
occurred O
a O
few O
days O
before O
the O
patient O
became O
fully O
manic B-Disease
. O

such O
medication O
- O
associated O
changes O
in O
the O
total O
power O
of O
pupillary B-Disease
oscillation I-Disease
might O
be O
of O
utility O
in O
identifying O
persons O
at O
risk O
for O
manic B-Disease
- O
like O
adverse O
effects O
during O
the O
medical O
use O
of O
psychomotor O
stimulants O
or O
sympathomimetic O
agents O
. O

the O
baby O
died O
of O
cerebral B-Disease
and I-Disease
pulmonary I-Disease
hemorrhage I-Disease
. O

the O
baby O
showed O
warfarin O
- O
induced O
embryopathy B-Disease
with O
nasal B-Disease
hypoplasia I-Disease
and O
stippled B-Disease
epiphyses I-Disease
( O
chondrodysplasia B-Disease
punctata I-Disease
) O
. O

nasal B-Disease
hypoplasia I-Disease
with O
or O
without O
stippled B-Disease
epiphyses I-Disease
has O
now O
been O
reported O
in O
11 O
infants O
born O
to O
mothers O
treated O
with O
warfarin O
during O
the O
first O
trimester O
, O
and O
a O
causal O
association O
is O
probable O
. O

objective O
: O
we O
wanted O
to O
test O
whether O
assessment O
of O
both O
a O
central O
pain B-Disease
- O
related O
signal O
( O
chemo O
- O
somatosensory O
evoked O
potential O
, O
cssep O
) O
and O
a O
concomitantly O
recorded O
peripheral O
signal O
( O
negative O
mucosal O
potential O
, O
nmp O
) O
allows O
for O
separation O
of O
central O
and O
peripheral O
effects O
of O
nsaids O
. O

for O
this O
purpose O
, O
experimental O
conditions O
were O
created O
in O
which O
nsaids O
had O
previously O
been O
observed O
to O
produce O
effects O
on O
phasic O
and O
tonic O
pain B-Disease
by O
either O
central O
or O
peripheral O
mechanisms O
. O

phasic O
pain B-Disease
was O
applied O
by O
means O
of O
short O
pulses O
of O
co2 O
to O
the O
nasal O
mucosa O
( O
stimulus O
duration O
500 O
ms O
, O
interval O
approximately O
60 O
s O
) O
, O
and O
tonic O
pain B-Disease
was O
induced O
in O
the O
nasal O
cavity O
by O
means O
of O
dry O
air O
of O
controlled O
temperature O
, O
humidity O
and O
flow O
rate O
( O
22 O
degrees O
c O
, O
0 O
% O
relative O
humidity O
, O
145 O
ml O
. O

s O
- O
1 O
) O
. O

both O
csseps O
as O
central O
and O
nmps O
as O
peripheral O
correlates O
of O
pain B-Disease
were O
obtained O
in O
response O
to O
the O
co2 O
stimuli O
. O

additionally O
, O
the O
subjects O
rated O
the O
intensity O
of O
both O
phasic O
and O
tonic O
pain B-Disease
by O
means O
of O
visual O
analogue O
scales O
. O

results O
: O
as O
described O
earlier O
, O
administration O
of O
ibuprofen O
was O
followed O
by O
a O
decrease O
in O
tonic O
pain B-Disease
but O
- O
relative O
to O
placebo O
- O
an O
increase O
in O
correlates O
of O
phasic O
pain B-Disease
, O
indicating O
a O
specific O
effect O
of O
ibuprofen O
on O
the O
interaction O
between O
the O
pain B-Disease
stimuli O
under O
these O
special O
experimental O
conditions O
. O

the O
major O
advantage O
of O
this O
pain B-Disease
model O
is O
the O
possibility O
of O
obtaining O
peripheral O
pain B-Disease
- O
related O
activity O
directly O
using O
a O
non O
- O
invasive O
technique O
in O
humans O
. O

effect O
of O
d O
- O
glucarates O
on O
basic O
antibiotic O
- O
induced O
renal B-Disease
damage I-Disease
in O
rats O
. O

dehydrated B-Disease
rats O
regularly O
develop O
acute B-Disease
renal I-Disease
failure I-Disease
following O
single O
injection O
of O
aminoglycoside O
antibiotics O
combined O
with O
dextran O
or O
of O
antibiotics O
only O
. O

oral O
administration O
of O
2 O
, O
5 O
- O
di O
- O
o O
- O
acetyl O
- O
d O
- O
glucaro O
- O
1 O
, O
4 O
- O
6 O
, O
3 O
- O
dilactone O
protected O
rats O
against O
renal B-Disease
failure I-Disease
induced O
by O
kanamycin O
- O
dextran O
. O

d O
- O
glucarates O
were O
effective O
against O
renal B-Disease
damage I-Disease
induced O
by O
peptide O
antibiotics O
as O
well O
as O
various O
aminoglycoside O
antibitocis O
. O

with O
a O
d O
- O
glucarate O
of O
a O
fixed O
size O
of O
dose O
, O
approximately O
the O
same O
degree O
of O
protection O
was O
obtained O
against O
renal B-Disease
damages I-Disease
induced O
by O
different O
basic O
antibiotics O
despite O
large O
disparities O
in O
administration O
doses O
of O
different O
antibiotics O
. O

d O
- O
glucarates O
had O
the O
ability O
to O
prevent O
renal B-Disease
damage I-Disease
but O
not O
to O
cure O
it O
. O

rats O
excreted O
acidic O
urine O
when O
they O
were O
spared O
from O
renal B-Disease
lesions I-Disease
by O
monosaccharides O
. O

the O
reduction O
effect O
of O
d O
- O
glucarates O
against O
nephrotoxicity B-Disease
of O
basic O
antibiotics O
was O
discussed O
. O

acute O
severe O
depression B-Disease
following O
peri O
- O
operative O
ondansetron O
. O

a O
41 O
- O
year O
- O
old O
woman O
with O
a O
strong O
history O
of O
postoperative B-Disease
nausea I-Disease
and I-Disease
vomiting I-Disease
presented O
for O
abdominal O
hysterectomy O
3 O
months O
after O
a O
previous O
anaesthetic O
where O
ondansetron O
prophylaxis O
had O
been O
used O
. O

she O
had O
developed O
a O
severe O
acute O
major B-Disease
depression I-Disease
disorder I-Disease
almost O
immediately O
thereafter O
, O
possibly O
related O
to O
the O
use O
of O
a O
serotonin O
antagonist O
. O

nine O
years O
before O
she O
had O
experienced O
a O
self O
- O
limited O
puerperal O
depressive B-Disease
episode I-Disease
. O

anaesthesia O
with O
a O
propofol O
infusion O
and O
avoidance O
of O
serotonin O
antagonists O
provided O
a O
nausea B-Disease
- O
free O
postoperative O
course O
without O
exacerbation O
of O
the O
depression B-Disease
disorder I-Disease
. O

hypertensive B-Disease
response O
during O
dobutamine O
stress O
echocardiography O
. O

among O
3 O
, O
129 O
dobutamine O
stress O
echocardiographic O
studies O
, O
a O
hypertensive B-Disease
response O
, O
defined O
as O
systolic O
blood O
pressure O
( O
bp O
) O
> O
or O
= O
220 O
mm O
hg O
and O
/ O
or O
diastolic O
bp O
> O
or O
= O
110 O
mm O
hg O
, O
occurred O
in O
30 O
patients O
( O
1 O
% O
) O
. O

patients O
with O
this O
response O
more O
often O
had O
a O
history O
of O
hypertension B-Disease
and O
had O
higher O
resting O
systolic O
and O
diastolic O
bp O
before O
dobutamine O
infusion O
. O

continuously O
nebulized O
albuterol O
in O
severe O
exacerbations O
of O
asthma B-Disease
in O
adults O
: O
a O
case O
- O
controlled O
study O
. O

a O
retrospective O
, O
case O
- O
controlled O
analysis O
comparing O
patients O
admitted O
to O
a O
medical O
intensive O
care O
unit O
with O
severe O
exacerbations O
of O
asthma B-Disease
who O
received O
continuously O
nebulized O
albuterol O
( O
cna O
) O
versus O
intermittent O
albuterol O
( O
ina O
) O
treatments O
is O
reported O
. O

forty O
matched O
pairs O
of O
patients O
with O
asthma B-Disease
are O
compared O
. O

the O
incidence O
of O
cardiac B-Disease
dysrhythmias I-Disease
was O
similar O
between O
groups O
. O

symptomatic O
hypokalemia B-Disease
did O
not O
occur O
. O

paraplegia B-Disease
following O
intrathecal O
methotrexate O
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

a O
patient O
who O
developed O
paraplegia B-Disease
following O
the O
intrathecal O
instillation O
of O
methotrexate O
is O
discribed O
. O

the O
following O
factors O
appear O
to O
predispose O
to O
the O
development O
of O
this O
complication O
: O
abnormal O
cerebrospinal O
dynamics O
related O
to O
the O
presence O
of O
central B-Disease
nervous I-Disease
system I-Disease
leukemia I-Disease
, O
and O
epidural O
cerebrospinal O
leakage O
; O
elevated O
cerebrospinal O
fluid O
methothexate O
concentration O
related O
to O
abnormal O
cerebrospinal O
fluid O
dynamics O
and O
to O
inappropriately O
high O
methotrexate O
doses O
based O
on O
body O
surface O
area O
calculations O
in O
older O
children O
and O
adults O
; O
the O
presence O
of O
neurotoxic B-Disease
preservatives O
in O
commercially O
available O
methotrexate O
preparations O
and O
diluents O
; O
and O
the O
use O
of O

methotrexate O
diluents O
of O
unphysiologic O
ph O
, O
ionic O
content O
and O
osmolarity O
. O

the O
role O
of O
methotrexate O
contaminants O
, O
local O
folate B-Disease
deficiency I-Disease
, O
and O
cranial O
irradiation O
in O
the O
pathogenesis O
of O
intrathecal O
methotrexate O
toxicity B-Disease
is O
unclear O
. O

the O
incidence O
of O
neurotoxicity B-Disease
may O
be O
reduced O
by O
employing O
lower O
doses O
of O
methotrexate O
in O
the O
presence O
of O
central B-Disease
nervous I-Disease
system I-Disease
leukemia I-Disease
, O
in O
older O
children O
and O
adults O
, O
and O
in O
the O
presence O
of O
epidural O
leakage O
. O

periodic O
monitoring O
of O
cerebruspinal O
fluid O
methotrexate O
levels O
may O
be O
predictive O
of O
the O
development O
of O
serious O
neurotoxicity B-Disease
. O

hyperosmolar B-Disease
nonketotic I-Disease
coma I-Disease
precipitated O
by O
lithium O
- O
induced O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
. O

a O
45 O
- O
year O
- O
old O
man O
, O
with O
a O
10 O
- O
year O
history O
of O
manic B-Disease
depression I-Disease
treated O
with O
lithium O
, O
was O
admitted O
with O
hyperosmolar B-Disease
, I-Disease
nonketotic I-Disease
coma I-Disease
. O

he O
gave O
a O
five O
- O
year O
history O
of O
polyuria B-Disease
and O
polydipsia B-Disease
, O
during O
which O
time O
urinalysis O
had O
been O
negative O
for O
glucose O
. O

after O
recovery O
from O
hyperglycaemia B-Disease
, O
he O
remained O
polyuric B-Disease
despite O
normal O
blood O
glucose O
concentrations O
; O
water O
deprivation O
testing O
indicated O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
, O
likely O
to O
be O
lithium O
- O
induced O
. O

we O
hypothesize O
that O
when O
this O
man O
developed O
type B-Disease
2 I-Disease
diabetes I-Disease
, O
chronic O
polyuria B-Disease
due O
to O
nephrogenic B-Disease
diabetes I-Disease
insipidus I-Disease
was O
sufficient O
to O
precipitate O
hyperosmolar O
dehydration B-Disease
. O

background O
: O
in O
dogs O
, O
a O
large O
amount O
of O
intravenous O
cocaine O
causes O
a O
profound O
deterioration B-Disease
of I-Disease
left I-Disease
ventricular I-Disease
( I-Disease
lv I-Disease
) I-Disease
systolic I-Disease
function I-Disease
and O
an O
increase O
in O
lv O
end O
- O
diastolic O
pressure O
. O

methods O
and O
results O
: O
in O
20 O
patients O
( O
14 O
men O
and O
6 O
women O
aged O
39 O
to O
72 O
years O
) O
referred O
for O
cardiac O
catheterization O
for O
the O
evaluation O
of O
chest B-Disease
pain I-Disease
, O
we O
measured O
heart O
rate O
, O
systemic O
arterial O
pressure O
, O
lv O
pressure O
and O
its O
first O
derivative O
( O
dp O
/ O
dt O
) O
, O
and O
lv O
volumes O
and O
ejection O
fraction O
before O
and O
during O
the O
final O
2 O
to O
3 O
minutes O
of O
a O
15 O
- O
minute O
intracoronary O
infusion O
of O
saline O
( O
n O
= O
10 O
, O
control O
subjects O
) O
or O
cocaine O
hydrochloride O
1 O
mg O
/ O
min O
( O
n O
= O
10 O
) O
. O

conclusions O
: O
in O
humans O
, O
the O
intracoronary O
infusion O
of O
cocaine O
sufficient O
in O
amount O
to O
achieve O
a O
high O
drug O
concentration O
in O
coronary O
sinus O
blood O
causes O
a O
deterioration B-Disease
of I-Disease
lv I-Disease
systolic I-Disease
and I-Disease
diastolic I-Disease
performance I-Disease
. O

recorded O
were O
dose O
- O
limiting O
adverse O
events O
: O
hyper B-Disease
- I-Disease
or I-Disease
hypotension I-Disease
( O
three O
) O
, O
severe O
abdominal B-Disease
pain I-Disease
( O
0 O
) O
, O
vomiting B-Disease
( O
0 O
) O
and O
retained B-Disease
placenta I-Disease
( O
four O
) O
. O

serious O
adverse O
events O
occurred O
in O
seven O
women O
: O
six O
cases O
with O
blood B-Disease
loss I-Disease
> O
or O
= O
1000 O
ml O
, O
four O
cases O
of O
manual O
placenta O
removal O
, O
five O
cases O
of O
additional O
oxytocics O
administration O
and O
five O
cases O
of O
blood O
transfusion O
. O

maximum O
blood B-Disease
loss I-Disease
was O
greatest O
at O
the O
upper O
and O
lower O
dose O
levels O
, O
and O
lowest O
in O
the O
70 O
- O
125 O
microg O
dose O
range O
. O

four O
out O
of O
six O
cases O
with O
blood B-Disease
loss I-Disease
> O
or O
= O
1000 O
ml O
occurred O
in O
the O
200 O
microg O
group O
. O

heparin O
- O
induced O
thrombocytopenia B-Disease
, O
paradoxical O
thromboembolism B-Disease
, O
and O
other O
side O
effects O
of O
heparin O
therapy O
. O

important O
untoward O
effects O
of O
heparin O
therapy O
including O
heparin O
- O
induced O
thrombocytopenia B-Disease
, O
heparin O
- O
associated O
osteoporosis B-Disease
, O
eosinophilia B-Disease
, O
skin B-Disease
reactions I-Disease
, O
allergic B-Disease
reactions I-Disease
other O
than O
thrombocytopenia B-Disease
and O
alopecia B-Disease
will O
be O
discussed O
in O
this O
article O
. O

nonopaque O
crystal O
deposition O
causing O
ureteric B-Disease
obstruction I-Disease
in O
patients O
with O
hiv O
undergoing O
indinavir O
therapy O
. O

objective O
: O
we O
describe O
the O
unique O
ct O
features O
of O
ureteric B-Disease
calculi I-Disease
in O
six O
hiv B-Disease
- I-Disease
infected I-Disease
patients O
receiving O
indinavir O
, O
the O
most O
commonly O
used O
hiv O
protease O
inhibitor O
, O
which O
is O
associated O
with O
an O
increased O
incidence O
of O
urolithiasis B-Disease
. O

conclusion O
: O
ureteric B-Disease
obstruction I-Disease
caused O
by O
precipitated O
indinavir O
crystals O
may O
be O
difficult O
to O
diagnose O
with O
unenhanced O
ct O
. O

images O
may O
need O
to O
be O
obtained O
using O
i O
. O

v O
. O

contrast O
material O
to O
enable O
diagnosis O
of O
ureteric B-Disease
stones I-Disease
or I-Disease
obstruction I-Disease
in O
patients O
with O
hiv B-Disease
infection I-Disease
who O
receive O
indinavir O
therapy O
. O

ischemic B-Disease
colitis I-Disease
and O
sumatriptan O
use O
. O

cases O
have O
been O
published O
of O
coronary B-Disease
vasospasm I-Disease
, O
myocardial B-Disease
ischemia I-Disease
, O
and O
myocardial B-Disease
infarction I-Disease
occurring O
after O
sumatriptan O
use O
. O

we O
report O
on O
the O
development O
of O
8 O
serious O
cases O
of O
ischemic B-Disease
colitis I-Disease
in O
patients O
with O
migraine B-Disease
treated O
with O
sumatriptan O
. O

51 O
patients O
with O
medically O
refractory O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
underwent O
stereotactic O
posteromedial O
pallidotomy O
between O
august O
1993 O
and O
february O
1997 O
for O
treatment O
of O
bradykinesia B-Disease
, O
rigidity B-Disease
, O
and O
l O
- O
dopa O
- O
induced O
dyskinesias B-Disease
. O

clinical O
assessment O
as O
well O
as O
blinded O
ratings O
of O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
( O
updrs O
) O
scores O
were O
carried O
out O
pre O
- O
and O
postoperatively O
. O

85 O
percent O
of O
patients O
with O
dyskinesias B-Disease
were O
relieved O
of O
symptoms O
, O
regardless O
of O
whether O
the O
pallidotomies O
were O
performed O
with O
the O
gamma O
knife O
or O
radiofrequency O
methods O
. O

about O
2 O
/ O
3 O
of O
the O
patients O
in O
both O
gamma O
knife O
and O
radiofrequency O
groups O
showed O
improvements O
in O
bradykinesia B-Disease
and O
rigidity B-Disease
, O
although O
when O
considered O
as O
a O
group O
neither O
the O
gamma O
knife O
nor O
the O
radiofrequency O
group O
showed O
statistically O
significant O
improvements O
in O
updrs O
scores O
. O

one O
patient O
in O
the O
gamma O
knife O
group O
( O
3 O
. O

4 O
% O
) O
developed O
a O
homonymous B-Disease
hemianopsia I-Disease
9 O
months O
following O
treatment O
and O
5 O
patients O
( O
27 O
. O

7 O
% O
) O
in O
the O
radiofrequency O
group O
became O
transiently O
confused O
postoperatively O
. O

gamma O
knife O
pallidotomy O
is O
as O
effective O
as O
radiofrequency O
pallidotomy O
in O
controlling O
certain O
of O
the O
symptoms O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

it O
may O
be O
the O
only O
practical O
technique O
available O
in O
certain O
patients O
, O
such O
as O
those O
who O
take O
anticoagulants O
, O
have O
bleeding B-Disease
diatheses O
or O
serious O
systemic O
medical O
illnesses O
. O

this O
response O
was O
significantly O
reduced O
by O
the O
intravenous O
( O
i O
. O

v O
. O

) O
injection O
of O
guanethidine O
( O
5 O
mg O
) O
, O
hexamethonium O
( O
10 O
mg O
) O
or O
phentolamine O
( O
5 O
mg O
) O
, O
and O
conversely O
, O
potentiated O
by O
i O
. O

v O
. O

desmethylimipramine O
( O
0 O
. O

3 O
mg O
) O
, O
while O
propranolol O
( O
0 O
. O

5 O
mg O
) O
i O
. O

v O
. O

selectively O
inhibited O
the O
enlargement B-Disease
of I-Disease
pulse I-Disease
pressure I-Disease
and O
the O
tachycardia B-Disease
following O
i O
. O

c O
. O

carbachol O
( O
1 O
mug O
) O
. O

neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
and O
methylphenidate O
. O

a O
1 O
- O
year O
- O
old O
female O
presented O
with O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
probably O
caused O
by O
methylphenidate O
. O

she O
had O
defects O
in O
the O
supratentorial O
brain O
including O
the O
basal O
ganglia O
and O
the O
striatum O
( O
multicystic B-Disease
encephalomalacia I-Disease
) O
due O
to O
severe O
perinatal O
hypoxic B-Disease
- I-Disease
ischemic I-Disease
encephalopathy I-Disease
, O
which O
was O
considered O
to O
be O
a O
possible O
predisposing O
factor O
causing O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
. O

this O
is O
the O
first O
reported O
patient O
with O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
probably O
caused O
by O
methylphenidate O
. O

this O
study O
shows O
that O
17alpha O
- O
ethinylestradiol O
( O
ee O
) O
- O
induced O
intrahepatic B-Disease
cholestasis I-Disease
in O
rats O
is O
associated O
with O
selective O
inhibition O
of O
the O
neutral O
pathway O
of O
bile O
salt O
( O
bs O
) O
synthesis O
. O

glibenclamide O
- O
sensitive O
hypotension B-Disease
produced O
by O
helodermin O
assessed O
in O
the O
rat O
. O

helodermin O
produced O
hypotension B-Disease
in O
a O
dose O
- O
dependent O
manner O
with O
approximately O
similar O
potency O
and O
duration O
to O
vip O
. O

hypotension B-Disease
induced O
by O
both O
peptides O
was O
significantly O
attenuated O
by O
glibenclamide O
, O
which O
abolished O
a O
levcromakalim O
- O
produced O
decrease O
in O
arterial O
blood O
pressure O
. O

oxyhemoglobin O
did O
not O
affect O
helodermin O
- O
induced O
hypotension B-Disease
, O
whereas O
it O
shortened O
the O
duration O
of O
acetylcholine O
( O
ach O
) O
- O
produced O
hypotension B-Disease
. O

these O
findings O
suggest O
that O
helodermin O
- O
produced O
hypotension B-Disease
is O
partly O
attributable O
to O
the O
activation O
of O
glibenclamide O
- O
sensitive O
k O
+ O
channels O
( O
k O
( O
atp O
) O
channels O
) O
, O
which O
presumably O
exist O
on O
arterial O
smooth O
muscle O
cells O
. O

edrf O
( O
endothelium O
- O
derived O
relaxing O
factor O
) O
/ O
nitric O
oxide O
does O
not O
seem O
to O
play O
an O
important O
role O
in O
the O
peptide O
- O
produced O
hypotension B-Disease
. O

long O
- O
term O
efficacy O
and O
adverse O
event O
of O
nifedipine O
sustained O
- O
release O
tablets O
for O
cyclosporin O
a O
- O
induced O
hypertension B-Disease
in O
patients O
with O
psoriasis B-Disease
. O

thirteen O
psoriatic B-Disease
patients O
with O
hypertension B-Disease
during O
the O
course O
of O
cyclosporin O
a O
therapy O
were O
treated O
for O
25 O
months O
with O
a O
calcium O
channel O
blocker O
, O
sustained O
- O
release O
nifedipine O
, O
to O
study O
the O
clinical O
antihypertensive O
effects O
and O
adverse O
events O
during O
treatment O
with O
both O
drugs O
. O

seven O
of O
the O
13 O
patients O
had O
exhibited O
a O
subclinical O
hypertensive B-Disease
state O
before O
cyclosporin O
a O
therapy O
. O

the O
adverse O
events O
during O
combined O
therapy O
with O
cyclosporin O
a O
and O
nifedipine O
included O
an O
increase O
in O
blood O
urea O
nitrogen O
levels O
in O
9 O
of O
the O
13 O
patients O
and O
development O
of O
gingival B-Disease
hyperplasia I-Disease
in O
2 O
of O
the O
13 O
patients O
. O

our O
findings O
indicate O
that O
sustained O
- O
release O
nifedipine O
is O
useful O
for O
hypertensive B-Disease
psoriatic B-Disease
patients O
under O
long O
- O
term O
treatment O
with O
cyclosporin O
a O
, O
but O
that O
these O
patients O
should O
be O
monitored O
for O
gingival B-Disease
hyperplasia I-Disease
. O

22 O
- O
oxacalcitriol O
suppresses O
secondary B-Disease
hyperparathyroidism I-Disease
without O
inducing O
low B-Disease
bone I-Disease
turnover I-Disease
in O
dogs O
with O
renal B-Disease
failure I-Disease
. O

background O
: O
calcitriol O
therapy O
suppresses O
serum O
levels O
of O
parathyroid O
hormone O
( O
pth O
) O
in O
patients O
with O
renal B-Disease
failure I-Disease
but O
has O
several O
drawbacks O
, O
including O
hypercalcemia B-Disease
and O
/ O
or O
marked O
suppression B-Disease
of I-Disease
bone I-Disease
turnover I-Disease
, O
which O
may O
lead O
to O
adynamic B-Disease
bone I-Disease
disease I-Disease
. O

this O
study O
was O
undertaken O
to O
determine O
the O
effects O
of O
oct O
on O
serum O
pth O
levels O
and O
bone O
turnover O
in O
states O
of O
normal O
or O
impaired B-Disease
renal I-Disease
function I-Disease
. O

results O
: O
in O
nx O
dogs O
, O
oct O
significantly O
decreased O
serum O
pth O
levels O
soon O
after O
the O
induction O
of O
renal B-Disease
insufficiency I-Disease
. O

in O
long O
- O
standing O
secondary B-Disease
hyperparathyroidism I-Disease
, O
oct O
( O
0 O
. O

3 O
microg O
/ O
kg O
) O
stabilized O
serum O
pth O
levels O
during O
the O
first O
months O
. O

these O
effects O
were O
accompanied O
by O
episodes O
of O
hypercalcemia B-Disease
and O
hyperphosphatemia B-Disease
. O

in O
nx O
dogs O
, O
oct O
reversed O
abnormal O
bone O
formation O
, O
such O
as O
woven B-Disease
osteoid I-Disease
and O
fibrosis B-Disease
, O
but O
did O
not O
significantly O
alter O
the O
level O
of O
bone O
turnover O
. O

conclusions O
: O
these O
results O
indicate O
that O
even O
though O
oct O
does O
not O
completely O
prevent O
the O
occurrence O
of O
hypercalcemia B-Disease
in O
experimental O
dogs O
with O
renal B-Disease
insufficiency I-Disease
, O
it O
may O
be O
of O
use O
in O
the O
management O
of O
secondary B-Disease
hyperparathyroidism I-Disease
because O
it O
does O
not O
induce O
low B-Disease
bone I-Disease
turnover I-Disease
and O
, O
therefore O
, O
does O
not O
increase O
the O
risk O
of O
adynamic B-Disease
bone I-Disease
disease I-Disease
. O

hypotension B-Disease
, O
bradycardia B-Disease
, O
and O
asystole B-Disease
after O
high O
- O
dose O
intravenous O
methylprednisolone O
in O
a O
monitored O
patient O
. O

we O
report O
a O
case O
of O
hypotension B-Disease
, O
bradycardia B-Disease
, O
and O
asystole B-Disease
after O
intravenous O
administration O
of O
high O
- O
dose O
methylprednisolone O
in O
a O
73 O
- O
year O
- O
old O
patient O
who O
underwent O
electrocardiographic O
( O
ecg O
) O
monitoring O
throughout O
the O
episode O
. O

there O
was O
a O
history O
of O
ischemic B-Disease
cardiac B-Disease
disease I-Disease
9 O
years O
earlier O
. O

the O
patient O
was O
admitted O
with O
a O
pulmonary B-Disease
- I-Disease
renal I-Disease
syndrome I-Disease
with O
hemoptysis B-Disease
, O
rapidly O
progressive O
renal B-Disease
failure I-Disease
, O
and O
hypoxemia B-Disease
that O
required O
mechanical O
ventilation O
in O
the O
intensive O
care O
unit O
. O

the O
ecg O
showed O
a O
junctional O
rhythm O
without O
ventricular B-Disease
arrhythmia I-Disease
. O

this O
study O
reviews O
the O
current O
proposed O
mechanisms O
of O
sudden B-Disease
death I-Disease
after O
a O
high O
dose O
of O
intravenous O
methylprednisolone O
( O
ivmp O
) O
. O

rapid O
infusion O
and O
underlying O
cardiac B-Disease
disease I-Disease
were O
important O
risk O
factors O
in O
the O
case O
reported O
here O
, O
and O
the O
authors O
discount O
ventricular B-Disease
arrhythmia I-Disease
as O
the O
main O
mechanism O
. O

worsening O
of O
levodopa O
- O
induced O
dyskinesias B-Disease
by O
motor O
and O
mental O
tasks O
. O

ten O
patients O
who O
had O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
with O
disabling O
dyskinesia B-Disease
were O
included O
in O
this O
study O
to O
evaluate O
the O
role O
of O
mental O
( O
mental O
calculation O
) O
and O
motor O
( O
flexion O
/ O
extension O
of O
right O
fingers O
, O
flexion O
/ O
extension O
of O
left O
fingers O
, O
flexion O
/ O
extension O
of O
the O
neck O
, O
speaking O
aloud O
) O
tasks O
on O
the O
worsening O
of O
peak O
- O
dose O
dyskinesia B-Disease
following O
administration O
of O
an O
effective O
single O
dose O
of O
apomorphine O
. O

compared O
with O
the O
score O
at O
rest O
( O
1 O
. O

3 O
+ O
/ O
- O
0 O
. O

3 O
) O
, O
a O
significant O
aggravation O
of O
the O
dyskinesia B-Disease
score O
was O
observed O
during O
speaking O
aloud O
( O
5 O
. O

2 O
+ O
/ O
- O
1 O
. O

1 O
, O
p O
< O
0 O
. O

5 O
) O
, O
movements O
of O
right O
( O
4 O
. O

5 O
+ O
/ O
- O
1 O
. O

0 O
, O
p O
< O
0 O
. O

5 O
) O
and O
left O
( O
3 O
. O

7 O
+ O
/ O
- O
0 O
. O

8 O
, O
p O
< O
0 O
. O

5 O
) O
fingers O
, O
movements O
of O
the O
neck O
( O
5 O
. O

1 O
+ O
/ O
- O
1 O
. O

0 O
, O
p O
< O
0 O
. O

5 O
) O
, O
and O
mental O
calculation O
( O
3 O
. O

1 O
+ O
/ O
- O
1 O
. O

0 O
, O
p O
< O
0 O
. O

5 O
) O
. O

these O
results O
suggest O
that O
activation O
tasks O
such O
as O
nan O
speaking O
aloud O
nan O
could O
be O
used O
for O
objective O
assessment O
of O
dyskinesia B-Disease
severity O
. O

background O
: O
although O
an O
indicator O
of O
renal B-Disease
tubular I-Disease
dysfunction I-Disease
, O
an O
increased O
urinary O
n O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
nag O
) O
activity O
might O
reflect O
increased O
lysosomal O
activity O
in O
renal O
tubular O
cells O
. O

methods O
: O
puromycin O
aminonucleoside O
( O
pan O
) O
was O
administered O
to O
sprague O
dawley O
rats O
to O
induce O
proteinuria B-Disease
. O

peak O
urine O
nag O
activity O
and O
a O
change O
in O
nag O
isoenzyme O
pattern O
coincided O
with O
both O
the O
peak O
proteinuria B-Disease
and O
the O
reduction O
in O
intracellular O
protein O
and O
nag O
droplets O
( O
day O
six O
onwards O
) O
. O

cauda B-Disease
equina I-Disease
syndrome I-Disease
after O
spinal O
anaesthesia O
with O
hyperbaric O
5 O
% O
lignocaine O
: O
a O
review O
of O
six O
cases O
of O
cauda B-Disease
equina I-Disease
syndrome I-Disease
reported O
to O
the O
swedish O
pharmaceutical O
insurance O
1993 O
- O
1997 O
. O

six O
cases O
of O
cauda B-Disease
equina I-Disease
syndrome I-Disease
with O
varying O
severity O
were O
reported O
to O
the O
swedish O
pharmaceutical O
insurance O
during O
the O
period O
1993 O
- O
1997 O
. O

three O
of O
the O
cases O
were O
most O
likely O
caused O
by O
direct O
neurotoxicity B-Disease
of O
hyperbaric O
5 O
% O
lignocaine O
. O

in O
the O
other O
3 O
cases O
, O
direct O
neurotoxicity B-Disease
was O
also O
probable O
, O
but O
unfortunately O
radiological O
investigations O
were O
not O
done O
to O
definitely O
exclude O
a O
compressive O
aetiology O
. O

all O
cases O
sustained O
permanent O
neurological B-Disease
deficits I-Disease
. O

systemic O
toxicity B-Disease
following O
administration O
of O
sirolimus O
( O
formerly O
rapamycin O
) O
for O
psoriasis B-Disease
: O
association O
of O
capillary B-Disease
leak I-Disease
syndrome I-Disease
with O
apoptosis O
of O
lesional O
lymphocytes O
. O

after O
2 O
individuals O
with O
psoriasis B-Disease
developed O
a O
capillary B-Disease
leak I-Disease
syndrome I-Disease
following O
treatment O
with O
oral O
sirolimus O
lesional O
skin O
cells O
and O
activated O
peripheral O
blood O
cells O
were O
analyzed O
for O
induction O
of O
apoptosis O
. O

observations O
: O
a O
keratome O
skin O
specimen O
from O
1 O
patient O
with O
sirolimus O
- O
induced O
capillary B-Disease
leak I-Disease
syndrome I-Disease
had O
a O
2 O
. O

3 O
- O
fold O
increase O
in O
percentage O
of O
apoptotic O
cells O
( O
to O
48 O
% O
) O
compared O
with O
an O
unaffected O
sirolimus O
- O
treated O
patient O
with O
psoriasis B-Disease
( O
21 O
% O
) O
. O

activated O
peripheral O
blood O
t O
cells O
from O
patients O
with O
psoriasis B-Disease
tended O
to O
exhibit O
greater O
spontaneous O
or O
dexamethasone O
- O
induced O
apoptosis O
than O
did O
normal O
t O
cells O
, O
particularly O
in O
the O
presence O
of O
sirolimus O
. O

conclusions O
: O
severe O
adverse O
effects O
of O
sirolimus O
include O
fever B-Disease
, O
anemia B-Disease
, O
and O
capillary B-Disease
leak I-Disease
syndrome I-Disease
. O

because O
patients O
with O
severe O
psoriasis B-Disease
may O
develop O
capillary B-Disease
leak I-Disease
from O
various O
systemic O
therapies O
, O
clinical O
monitoring O
is O
advisable O
for O
patients O
with O
inflammatory B-Disease
diseases I-Disease
who O
are O
treated O
with O
immune O
modulators O
. O

these O
were O
evaluated O
with O
respect O
to O
the O
duration O
of O
lithium O
therapy O
, O
age O
, O
sex O
, O
and O
family O
history O
( O
whether O
or O
not O
the O
patient O
had O
a O
first O
- O
degree O
relative O
with O
thyroid B-Disease
disease I-Disease
) O
. O

patients O
: O
one O
hundred O
and O
one O
patients O
( O
28 O
men O
and O
73 O
women O
) O
with O
bipolar B-Disease
disorder I-Disease
receiving O
lithium O
maintenance O
therapy O
ranging O
from O
1 O
year O
' O
s O
to O
32 O
years O
' O
duration O
. O

the O
control O
group O
consisted O
of O
82 O
patients O
with O
no O
psychiatric B-Disease
or O
endocrinological O
diagnoses O
from O
the O
hospital O
' O
s O
out O
- O
patient O
clinics O
. O

results O
: O
hypothyroidism B-Disease
developed O
in O
40 O
patients O
, O
excluding O
8 O
patients O
who O
were O
hypothyroid B-Disease
at O
baseline O
. O

all O
patients O
having O
first O
- O
degree O
relatives O
affected O
by O
thyroid B-Disease
illness I-Disease
had O
accelerated O
onset O
of O
hypothyroidism B-Disease
( O
3 O
. O

7 O
years O
after O
onset O
of O
lithium O
therapy O
) O
compared O
with O
patients O
without O
a O
family O
history O
( O
8 O
. O

6 O
years O
after O
onset O
of O
lithium O
therapy O
) O
. O

women O
over O
60 O
years O
of O
age O
were O
more O
often O
affected O
by O
hypothyroidism B-Disease
than O
women O
under O
60 O
years O
of O
age O
( O
34 O
. O

6 O
% O
versus O
31 O
. O

9 O
% O
) O
. O

conclusions O
: O
familial O
thyroid B-Disease
illness I-Disease
is O
a O
risk O
factor O
for O
hypothyroidism B-Disease
and O
hypercalcemia B-Disease
during O
lithium O
therapy O
. O

severe O
immune O
hemolytic B-Disease
anemia I-Disease
associated O
with O
prophylactic O
use O
of O
cefotetan O
in O
obstetric O
and O
gynecologic O
procedures O
. O

second O
- O
and O
third O
- O
generation O
cephalosporins O
, O
especially O
cefotetan O
, O
are O
increasingly O
associated O
with O
severe O
, O
sometimes O
fatal O
immune O
hemolytic B-Disease
anemia I-Disease
. O

we O
noticed O
that O
10 O
of O
our O
35 O
cases O
of O
cefotetan O
- O
induced O
hemolytic B-Disease
anemias I-Disease
were O
in O
patients O
who O
had O
received O
cefotetan O
prophylactically O
for O
obstetric O
and O
gynecologic O
procedures O
. O

eight O
of O
these O
cases O
of O
severe O
immune O
hemolytic B-Disease
anemia I-Disease
are O
described O
. O

effects O
of O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
on O
hemostasis O
in O
patients O
with O
aneurysmal B-Disease
subarachnoid I-Disease
hemorrhage I-Disease
. O

patients O
with O
aneurysmal B-Disease
subarachnoid I-Disease
hemorrhage I-Disease
( O
sah B-Disease
) O
were O
randomized O
to O
receive O
either O
ketoprofen O
, O
100 O
mg O
, O
three O
times O
a O
day O
( O
ketoprofen O
group O
, O
n O
= O
9 O
) O
or O
a O
weak O
nsaid O
, O
acetaminophen O
, O
1 O
g O
, O
three O
times O
a O
day O
( O
acetaminophen O
group O
, O
n O
= O
9 O
) O
starting O
immediately O
after O
the O
diagnosis O
of O
aneurysmal B-Disease
sah B-Disease
. O

maximal O
platelet B-Disease
aggregation I-Disease
induced O
by O
6 O
microm O
of O
adenosine O
diphosphate O
decreased O
after O
administration O
of O
ketoprofen O
. O

in O
contrast O
, O
maximal O
platelet B-Disease
aggregation I-Disease
increased O
in O
the O
acetaminophen O
group O
on O
the O
third O
postoperative O
day O
as O
compared O
with O
the O
pretreatment O
platelet B-Disease
aggregation I-Disease
results O
( O
p O
< O
. O

5 O
) O
. O

one O
patient O
in O
the O
ketoprofen O
group O
developed O
a O
postoperative O
intracranial O
hematoma B-Disease
. O

ketoprofen O
but O
not O
acetaminophen O
impaired O
platelet O
function O
in O
patients O
with O
sah B-Disease
. O

if O
ketoprofen O
is O
used O
before O
surgery O
on O
cerebral O
artery B-Disease
aneurysms I-Disease
, O
it O
may O
pose O
an O
additional O
risk O
factor O
for O
hemorrhage B-Disease
. O

nitric O
oxide O
synthase O
expression O
in O
the O
course O
of O
lead O
- O
induced O
hypertension B-Disease
. O

we O
recently O
showed O
elevated O
reactive O
oxygen O
species O
( O
ros O
) O
, O
reduced O
urinary O
excretion O
of O
no O
metabolites O
( O
nox O
) O
, O
and O
increased O
no O
sequestration O
as O
nitrotyrosine O
in O
various O
tissues O
in O
rats O
with O
lead O
- O
induced O
hypertension B-Disease
. O

this O
study O
was O
designed O
to O
discern O
whether O
the O
reduction O
in O
urinary O
nox O
in O
lead O
- O
induced O
hypertension B-Disease
is O
, O
in O
part O
, O
due O
to O
depressed O
no O
synthase O
( O
nos O
) O
expression O
. O

vitamin O
e O
supplementation O
ameliorated O
hypertension B-Disease
, O
lowered O
plasma O
mda O
concentration O
, O
and O
raised O
urinary O
nox O
excretion O
while O
significantly O
lowering O
vascular O
, O
but O
not O
renal O
, O
tissue O
enos O
and O
inos O
expression O
. O

in O
conclusion O
, O
lead O
- O
induced O
hypertension B-Disease
in O
this O
model O
was O
associated O
with O
a O
compensatory O
upregulation O
of O
renal O
and O
vascular O
enos O
and O
inos O
expression O
. O

this O
is O
, O
in O
part O
, O
due O
to O
ros O
- O
mediated O
no O
inactivation O
, O
lead O
- O
associated O
inhibition O
of O
nos O
activity O
, O
and O
perhaps O
stimulatory O
actions O
of O
increased O
shear O
stress O
associated O
with O
hypertension B-Disease
. O

glyceryl O
trinitrate O
induces O
attacks O
of O
migraine B-Disease
without I-Disease
aura I-Disease
in O
sufferers O
of O
migraine B-Disease
with I-Disease
aura I-Disease
. O

migraine B-Disease
with I-Disease
aura I-Disease
and O
migraine B-Disease
without I-Disease
aura I-Disease
have O
the O
same O
pain B-Disease
phase O
, O
thus O
indicating O
that O
migraine B-Disease
with I-Disease
aura I-Disease
and O
migraine B-Disease
without I-Disease
aura I-Disease
share O
a O
common O
pathway O
of O
nociception O
. O

in O
recent O
years O
, O
increasing O
evidence O
has O
suggested O
that O
the O
messenger O
molecule O
nitric O
oxide O
( O
no O
) O
is O
involved O
in O
pain B-Disease
mechanisms O
of O
migraine B-Disease
without I-Disease
aura I-Disease
. O

in O
order O
to O
clarify O
whether O
the O
same O
is O
TRUE O
for O
migraine B-Disease
with I-Disease
aura I-Disease
, O
in O
the O
present O
study O
we O
examined O
the O
headache B-Disease
response O
to O
intravenous O
infusion O
of O
glyceryl O
trinitrate O
( O
gtn O
) O
( O
0 O
. O

5 O
microg O
/ O
kg O
/ O
min O
for O
20 O
min O
) O
in O
12 O
sufferers O
of O
migraine B-Disease
with I-Disease
aura I-Disease
. O

the O
specific O
aim O
was O
to O
elucidate O
whether O
an O
aura O
and O
/ O
or O
an O
attack O
of O
migraine B-Disease
without I-Disease
aura I-Disease
could O
be O
induced O
. O

headache B-Disease
was O
more O
severe O
in O
migraineurs B-Disease
than O
in O
the O
controls O
during O
and O
immediately O
after O
gtn O
infusion O
( O
p O
= O
0 O
. O

37 O
) O
as O
well O
as O
during O
the O
following O
11 O
h O
( O
p O
= O
0 O
. O

8 O
) O
. O

in O
the O
controls O
, O
the O
gtn O
- O
induced O
headache B-Disease
gradually O
disappeared O
, O
whereas O
in O
migraineurs B-Disease
peak O
headache B-Disease
intensity O
occurred O
at O
a O
mean O
time O
of O
240 O
min O
post O
- O
infusion O
. O

at O
this O
time O
the O
induced O
headache B-Disease
in O
6 O
of O
12 O
migraineurs B-Disease
fulfilled O
the O
diagnostic O
criteria O
for O
migraine B-Disease
without I-Disease
aura I-Disease
of O
the O
international O
headache B-Disease
society O
. O

the O
results O
therefore O
suggest O
that O
no O
is O
involved O
in O
the O
pain B-Disease
mechanisms O
of O
migraine B-Disease
with I-Disease
aura I-Disease
. O

since O
cortical O
spreading O
depression B-Disease
has O
been O
shown O
to O
liberate O
no O
in O
animals O
, O
this O
finding O
may O
help O
our O
understanding O
of O
the O
coupling O
between O
cortical O
spreading O
depression B-Disease
and O
headache B-Disease
in O
migraine B-Disease
with I-Disease
aura I-Disease
. O

rapid O
reversal O
of O
life O
- O
threatening O
diltiazem O
- O
induced O
tetany B-Disease
with O
calcium O
chloride O
. O

we O
describe O
a O
patient O
who O
developed O
tetany B-Disease
with O
sudden O
respiratory B-Disease
arrest I-Disease
after O
the O
infusion O
of O
intravenous O
diltiazem O
. O

the O
administration O
of O
calcium O
chloride O
rapidly O
resolved O
the O
patient O
' O
s O
tetany B-Disease
with O
prompt O
recovery O
of O
respiratory O
function O
, O
averting O
the O
need O
for O
more O
aggressive O
airway O
management O
and O
ventilatory O
support O
. O

the O
emergency O
physician O
should O
be O
aware O
that O
life O
- O
threatening O
tetany B-Disease
may O
accompany O
the O
administration O
of O
intravenous O
diltiazem O
and O
that O
calcium O
chloride O
may O
be O
a O
rapid O
and O
effective O
remedy O
. O

predictors O
of O
decreased B-Disease
renal I-Disease
function I-Disease
in O
patients O
with O
heart B-Disease
failure I-Disease
during O
angiotensin O
- O
converting O
enzyme O
inhibitor O
therapy O
: O
results O
from O
the O
studies O
of O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
( O
solvd O
) O
background O
: O
although O
angiotensin O
- O
converting O
enzyme O
inhibitor O
therapy O
reduces O
mortality O
rates O
in O
patients O
with O
congestive B-Disease
heart I-Disease
failure I-Disease
( O
chf B-Disease
) O
, O
it O
may O
also O
cause O
decreased B-Disease
renal I-Disease
function I-Disease
. O

objective O
: O
to O
quantify O
specific O
clinical O
predictors O
of O
reduction B-Disease
in I-Disease
renal I-Disease
function I-Disease
in O
patients O
with O
chf B-Disease
who O
are O
prescribed O
angiotensin O
- O
converting O
enzyme O
inhibitor O
therapy O
. O

method O
: O
we O
analyzed O
data O
from O
the O
studies O
of O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
( O
solvd O
) O
, O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
of O
enalapril O
for O
the O
treatment O
of O
chf B-Disease
. O

decreased B-Disease
renal I-Disease
function I-Disease
was O
defined O
as O
a O
rise O
in O
serum O
creatinine O
> O
/ O
= O
0 O
. O

5 O
mg O
/ O
dl O
( O
44 O
micromol O
/ O
l O
) O
from O
baseline O
. O

we O
used O
time O
- O
to O
- O
event O
analysis O
to O
identify O
potential O
predictors O
of O
decrease O
in O
renal O
function O
including O
age O
, O
baseline O
ejection O
fraction O
, O
baseline O
creatinine O
, O
low O
systolic O
blood O
pressure O
( O
< O
100 O
mm O
hg O
) O
, O
history O
of O
hypertension B-Disease
, O
diabetes B-Disease
, O
and O
use O
of O
antiplatelet O
, O
diuretic O
, O
and O
beta O
- O
blocker O
therapy O
. O

results O
: O
patients O
randomly O
assigned O
to O
enalapril O
had O
a O
33 O
% O
greater O
likelihood O
of O
decreased B-Disease
renal I-Disease
function I-Disease
than O
controls O
( O
p O
= O
. O

3 O
) O
. O

by O
multivariate O
analysis O
, O
in O
both O
the O
placebo O
and O
enalapril O
groups O
older O
age O
, O
diuretic O
therapy O
, O
and O
diabetes B-Disease
were O
associated O
with O
decreased B-Disease
renal I-Disease
function I-Disease
, O
whereas O
beta O
- O
blocker O
therapy O
and O
higher O
ejection O
fraction O
were O
renoprotective O
. O

older O
age O
was O
associated O
with O
a O
greater O
risk O
of O
developing O
decreased B-Disease
renal I-Disease
function I-Disease
in O
both O
groups O
, O
but O
significantly O
more O
so O
in O
the O
enalapril O
group O
( O
enalapril O
: O
risk O
ratio O
[ O
rr O
] O
1 O
. O

42 O
per O
10 O
years O
, O
95 O
% O
confidence O
interval O
[ O
ci O
] O
1 O
. O

32 O
- O
1 O
. O

52 O
with O
enalapril O
; O
placebo O
: O
rr O
1 O
. O

18 O
, O
95 O
% O
ci O
1 O
. O

12 O
- O
1 O
. O

25 O
) O
. O

diuretic O
therapy O
was O
likewise O
associated O
with O
a O
greater O
risk O
of O
decreased B-Disease
renal I-Disease
function I-Disease
in O
the O
enalapril O
group O
( O
rr O
1 O
. O

89 O
, O
95 O
% O
ci O
1 O
. O

70 O
- O
2 O
. O

8 O
) O
than O
in O
the O
placebo O
group O
( O
rr O
1 O
. O

35 O
, O
95 O
% O
ci O
1 O
. O

9 O
- O
1 O
. O

66 O
) O
. O

conversely O
, O
enalapril O
had O
a O
relative O
renoprotective O
effect O
( O
rr O
1 O
. O

33 O
, O
95 O
% O
ci O
1 O
. O

13 O
- O
1 O
. O

53 O
) O
compared O
with O
placebo O
( O
rr O
1 O
. O

96 O
, O
95 O
% O
ci O
1 O
. O

57 O
- O
2 O
. O

44 O
) O
in O
patients O
with O
diabetes B-Disease
. O

a O
lower O
risk O
of O
renal B-Disease
impairment I-Disease
was O
seen O
in O
both O
groups O
with O
beta O
- O
blocker O
therapy O
( O
rr O
0 O
. O

70 O
, O
95 O
% O
ci O
0 O
. O

57 O
- O
0 O
. O

85 O
) O
and O
higher O
baseline O
ejection O
fraction O
( O
rr O
0 O
. O

93 O
per O
5 O
% O
increment O
, O
95 O
% O
ci O
0 O
. O

91 O
- O
0 O
. O

96 O
) O
. O

conclusions O
: O
enalapril O
use O
caused O
a O
33 O
% O
increase O
in O
the O
risk O
of O
decreased B-Disease
renal I-Disease
function I-Disease
in O
patients O
with O
chf B-Disease
. O

diabetes B-Disease
was O
associated O
with O
an O
increased O
risk O
of O
renal B-Disease
impairment I-Disease
in O
all O
patients O
with O
chf B-Disease
, O
but O
this O
risk O
was O
reduced O
in O
the O
enalapril O
group O
compared O
with O
the O
placebo O
group O
. O

hypomania B-Disease
- O
like O
syndrome O
induced O
by O
olanzapine O
. O

we O
report O
a O
female O
patient O
with O
a O
diagnosis O
of O
a O
not O
otherwise O
specified O
psychotic B-Disease
disorder I-Disease
( O
dsm O
- O
iv O
) O
who O
developed O
hypomania B-Disease
shortly O
after O
the O
introduction O
of O
olanzapine O
treatment O
. O

acetazolamide O
- O
induced O
gerstmann B-Disease
syndrome I-Disease
. O

acute O
confusion B-Disease
induced O
by O
acetazolamide O
is O
a O
well O
known O
adverse O
drug O
reaction O
in O
patients O
with O
renal B-Disease
impairment I-Disease
. O

we O
report O
a O
case O
of O
acetazolamide O
- O
induced O
gerstmann B-Disease
syndrome I-Disease
in O
a O
patient O
with O
normal O
renal O
function O
, O
to O
highlight O
predisposing O
factors O
that O
are O
frequently O
overlooked O
. O

vasopressin O
in O
the O
treatment O
of O
milrinone O
- O
induced O
hypotension B-Disease
in O
severe O
heart B-Disease
failure I-Disease
. O

the O
use O
of O
phosphodiesterase O
inhibitors O
such O
as O
milrinone O
in O
the O
treatment O
of O
severe O
heart B-Disease
failure I-Disease
is O
frequently O
restricted O
because O
they O
cause O
vasodilation O
and O
hypotension B-Disease
. O

in O
patients O
with O
decompensated O
heart B-Disease
failure I-Disease
with O
hypotension B-Disease
after O
treatment O
with O
milrinone O
, O
low O
doses O
of O
vasopressin O
restored O
blood O
pressure O
without O
inhibiting O
the O
inotropic O
effect O
of O
milrinone O
. O

indications O
for O
early O
conversion O
were O
neurotoxicity B-Disease
( O
20 O
) O
, O
( B-Disease
insulin I-Disease
- I-Disease
dependent I-Disease
) I-Disease
diabetes I-Disease
mellitus I-Disease
( O
iddm B-Disease
) O
( O
5 O
) O
, O
nephrotoxicity B-Disease
( O
3 O
) O
, O
gastrointestinal B-Disease
( I-Disease
gi I-Disease
) I-Disease
toxicity I-Disease
( O
6 O
) O
, O
and O
cardiomyopathy B-Disease
( O
1 O
) O
, O
and O
for O
late O
conversion O
were O
neurotoxicity B-Disease
( O
15 O
) O
, O
iddm B-Disease
( O
12 O
) O
, O
nephrotoxicity B-Disease
( O
3 O
) O
, O
gi B-Disease
toxicity I-Disease
( O
5 O
) O
, O
hepatotoxicity B-Disease
( O
6 O
) O
, O
post B-Disease
- I-Disease
transB-Plant I-Disease

lmphoproliferate I-Disease
disease I-Disease
( O
ptld B-Disease
) O
( O
2 O
) O
, O
cardiomyopathy B-Disease
( O
1 O
) O
, O
hemolytic B-Disease
anemia I-Disease
( O
1 O
) O
, O
and O
pruritus B-Disease
( O
1 O
) O
. O

ocular O
manifestations O
of O
juvenile B-Disease
rheumatoid I-Disease
arthritis I-Disease
. O

we O
followed O
210 O
cases O
of O
juvenile B-Disease
rheumatoid I-Disease
arthritis I-Disease
closely O
for O
eleven O
years O
. O

thirty O
- O
six O
of O
the O
210 O
patients O
( O
17 O
. O

2 O
% O
) O
developed O
iridocyclitis B-Disease
. O

iridocyclitis B-Disease
was O
seen O
most O
frequently O
in O
young O
female O
patients O
( O
0 O
to O
4 O
years O
) O
with O
the O
monoarticular O
or O
pauciatricular O
form O
of O
the O
arthritis B-Disease
. O

however O
, O
30 O
% O
of O
the O
patients O
developed O
uveitis B-Disease
after O
16 O
years O
of O
age O
. O

although O
61 O
% O
of O
patients O
had O
a O
noncontributory O
ocular O
history O
on O
entry O
, O
42 O
% O
had O
active O
uveitis B-Disease
on O
entry O
. O

our O
approach O
was O
effective O
in O
detecting O
uveitis B-Disease
in O
new O
cases O
and O
exacerbations O
of O
uveitis B-Disease
in O
established O
cases O
. O

forty O
- O
four O
percent O
of O
patients O
with O
uveitis B-Disease
had O
one O
or O
more O
identifiable O
signs O
or O
symptoms O
, O
such O
as O
red O
eye O
, O
ocular B-Disease
pain I-Disease
, O
decreased B-Disease
visual I-Disease
acuity I-Disease
, O
or O
photophobia B-Disease
, O
in O
order O
of O
decreasing O
frequency O
. O

even O
after O
early O
detection O
and O
prompt O
treatment O
, O
41 O
% O
of O
cases O
of O
uveitis B-Disease
did O
not O
respond O
to O
more O
than O
six O
months O
of O
intensive O
topical O
treatment O
with O
corticosteroids O
and O
mydriatics O
. O

despite O
this O
, O
there O
was O
a O
dramatic O
decrease O
in O
the O
50 O
% O
incidence O
of O
blinding O
complications O
of O
uveitis B-Disease
cited O
in O
earlier O
studies O
. O

cataract B-Disease
and O
band B-Disease
keratopathy I-Disease
occurred O
in O
only O
22 O
and O
13 O
% O
of O
our O
group O
, O
respectively O
. O

we O
used O
chloroquine O
or O
hydroxychloroquine O
in O
173 O
of O
210 O
cases O
and O
found O
only O
one O
case O
of O
chorioretinopathy B-Disease
attributable O
to O
these O
drugs O
. O

systemically O
administered O
corticosteroids O
were O
used O
in O
75 O
of O
210 O
cases O
; O
a O
significant O
number O
of O
posterior O
subcapsular O
cataracts B-Disease
was O
found O
. O

typical O
keratoconjunctivitis B-Disease
sicca O
developed O
in O
three O
of O
the O
uveitis B-Disease
cases O
. O

this O
association O
with O
uveitis B-Disease
and O
jra O
was O
not O
noted O
previously O
. O

surgical O
treatment O
of O
cataracts B-Disease
, O
band B-Disease
keratopathy I-Disease
, O
and O
glaucoma B-Disease
achieved O
uniformly O
discouraging O
results O
. O

cyclophosphamide O
- O
induced O
cystitis B-Disease
in O
freely O
- O
moving O
conscious O
rats O
: O
behavioral O
approach O
to O
a O
new O
model O
of O
visceral B-Disease
pain I-Disease
. O

purpose O
: O
to O
develop O
a O
model O
of O
visceral B-Disease
pain I-Disease
in O
rats O
using O
a O
behavioral O
approach O
. O

cyclophosphamide O
( O
cp O
) O
, O
an O
antitumoral O
agent O
known O
to O
produce O
toxic O
effects O
on O
the O
bladder O
wall O
through O
its O
main O
toxic O
metabolite O
acrolein O
, O
was O
used O
to O
induce O
cystitis B-Disease
. O

morphine O
dose O
- O
dependently O
reversed O
these O
behavioral B-Disease
disorders I-Disease
. O

at O
the O
time O
of O
administration O
of O
morphine O
, O
histological O
modifications O
of O
the O
bladder O
wall O
, O
such O
as O
chorionic O
and O
muscle O
layer O
edema B-Disease
, O
were O
observed O
. O

conclusions O
: O
overall O
, O
these O
results O
indicate O
that O
this O
experimental O
model O
of O
cp O
- O
induced O
cystitis B-Disease
may O
be O
an O
interesting O
new O
behavioral O
model O
of O
inflammatory O
visceral B-Disease
pain I-Disease
, O
allowing O
a O
better O
understanding O
of O
these O
painful B-Disease
syndromes I-Disease
and O
thus O
a O
better O
therapeutic O
approach O
to O
them O
. O

prednisolone O
- O
induced O
muscle B-Disease
dysfunction I-Disease
is O
caused O
more O
by O
atrophy B-Disease
than O
by O
altered O
acetylcholine O
receptor O
expression O
. O

on O
day O
8 O
, O
the O
nerve O
- O
evoked O
peak O
twitch O
tensions O
, O
tetanic B-Disease
tensions O
, O
and O
fatigability O
, O
and O
the O
dose O
- O
response O
curves O
of O
d O
- O
tubocurarine O
in O
the O
tibialis O
cranialis O
muscle O
were O
measured O
in O
vivo O
and O
related O
to O
muscle O
mass O
or O
expression O
of O
achrs O
. O

the O
evoked O
peak O
twitch O
and O
tetanic B-Disease
tensions O
were O
less O
in O
the O
p100 O
group O
than O
in O
the O
p10 O
or O
s O
groups O
, O
however O
, O
tension O
per O
milligram O
of O
muscle O
mass O
was O
greater O
in O
the O
p100 O
group O
than O
in O
the O
s O
group O
. O

our O
results O
suggest O
that O
the O
neuromuscular B-Disease
dysfunction I-Disease
after O
prednisolone O
is O
dose O
- O
dependent O
, O
and O
derives O
primarily O
from O
muscle B-Disease
atrophy I-Disease
and O
derives O
less O
so O
from O
changes O
in O
achr O
expression O
. O

we O
suggest O
that O
the O
observed O
effects O
are O
dose O
- O
dependent O
and O
derive O
primarily O
from O
muscle B-Disease
atrophy I-Disease
and O
derive O
less O
from O
changes O
in O
acetylcholine O
receptor O
expression O
. O

apomorphine O
: O
an O
underutilized O
therapy O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

apomorphine O
was O
the O
first O
dopaminergic O
drug O
ever O
used O
to O
treat O
symptoms O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

while O
powerful O
antiparkinsonian O
effects O
had O
been O
observed O
as O
early O
as O
1951 O
, O
the O
potential O
of O
treating O
fluctuating O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
by O
subcutaneous O
administration O
of O
apomorphine O
has O
only O
recently O
become O
the O
subject O
of O
systematic O
study O
. O

in O
addition O
, O
there O
is O
convincing O
clinical O
evidence O
that O
monotherapy O
with O
continuous O
subcutaneous O
apomorphine O
infusions O
is O
associated O
with O
marked O
reductions O
of O
preexisting O
levodopa O
- O
induced O
dyskinesias B-Disease
. O

the O
main O
side O
effects O
of O
subcutaneous O
apomorphine O
treatment O
are O
related O
to O
cutaneous O
tolerability O
problems O
, O
whereas O
sedation O
and O
psychiatric B-Disease
complications O
play O
a O
lesser O
role O
. O

given O
the O
marked O
degree O
of O
efficacy O
of O
subcutaneous O
apomorphine O
treatment O
in O
fluctuating O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
this O
approach O
seems O
to O
deserve O
more O
widespread O
clinical O
use O
. O

objective O
: O
the O
pharmacological O
response O
to O
drugs O
that O
act O
on O
the O
cholinergic O
system O
of O
the O
iris O
has O
been O
used O
to O
predict O
deficits O
in O
central O
cholinergic O
functioning O
due O
to O
diseases O
such O
as O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
yet O
correlations O
between O
central O
and O
peripheral O
responses O
have O
not O
been O
properly O
studied O
. O

outcome O
measures O
: O
pupil O
size O
at O
time O
points O
after O
administration O
of O
tropicamide O
and O
pilocarpine O
; O
scopolamine O
- O
induced O
impairment B-Disease
in I-Disease
word I-Disease
recall I-Disease
. O

compared O
with O
the O
young O
group O
, O
the O
elderly O
group O
had O
greater O
scopolamine O
- O
induced O
impairment B-Disease
in I-Disease
word I-Disease
recall I-Disease
60 O
, O
90 O
and O
120 O
minutes O
after O
administration O
( O
p O
< O
0 O
. O

5 O
) O
. O

pain B-Disease
responses O
in O
methadone O
- O
maintained O
opioid O
abusers O
. O

providing O
pain B-Disease
management O
for O
known O
opioid O
abusers O
is O
a O
challenging O
clinical O
task O
, O
in O
part O
because O
little O
is O
known O
about O
their O
pain B-Disease
experience O
and O
analgesic O
requirements O
. O

this O
study O
was O
designed O
to O
describe O
pain B-Disease
tolerance O
and O
analgesic O
response O
in O
a O
sample O
of O
opioid B-Disease
addicts I-Disease
stabilized O
in O
methadone O
- O
maintenance O
( O
mm O
) O
treatment O
( O
n O
= O
60 O
) O
in O
comparison O
to O
matched O
nondependent O
control O
subjects O
( O
n O
= O
60 O
) O
. O

by O
using O
a O
placebo O
- O
controlled O
, O
two O
- O
way O
factorial O
design O
, O
tolerance O
to O
cold O
- O
pressor O
( O
cp O
) O
pain B-Disease
was O
examined O
, O
both O
before O
and O
after O
oral O
administration O
of O
therapeutic O
doses O
of O
common O
opioid O
( O
hydromorphone O
2 O
mg O
) O
and O
nonsteroidal O
anti O
- O
inflammatory O
( O
ketorolac O
10 O
mg O
) O
analgesic O
agents O
. O

results O
showed O
that O
mm O
individuals O
were O
significantly O
less O
tolerant O
of O
cp O
pain B-Disease
than O
control O
subjects O
, O
replicating O
previous O
work O
. O

these O
data O
indicate O
that O
mm O
opioid O
abusers O
represent O
a O
pain B-Disease
- I-Disease
intolerant I-Disease
subset O
of O
clinical O
patients O
. O

their O
complaints O
of O
pain B-Disease
should O
be O
evaluated O
seriously O
and O
managed O
aggressively O
. O

high O
- O
dose O
methylprednisolone O
may O
do O
more O
harm O
for O
spinal B-Disease
cord I-Disease
injury I-Disease
. O

because O
of O
the O
national O
acute O
spinal B-Disease
cord I-Disease
injury I-Disease
studies O
( O
nascis O
) O
, O
high O
- O
dose O
methylprednisolone O
became O
the O
standard O
of O
care O
for O
the O
acute O
spinal B-Disease
cord I-Disease
injury I-Disease
. O

in O
the O
nascis O
, O
there O
was O
no O
mention O
regarding O
the O
possibility O
of O
acute O
corticosteroid O
myopathy B-Disease
that O
high O
- O
dose O
methylprednisolone O
may O
cause O
. O

we O
hypothesize O
that O
it O
may O
cause O
some O
damage B-Disease
to I-Disease
the I-Disease
muscle I-Disease
of O
spinal B-Disease
cord I-Disease
injury I-Disease
patients O
. O

further O
, O
steroid O
myopathy B-Disease
recovers O
naturally O
and O
the O
neurological O
improvement O
shown O
in O
the O
nascis O
may O
be O
just O
a O
recording O
of O
this O
natural O
motor O
recovery O
from O
the O
steroid O
myopathy B-Disease
, O
instead O
of O
any O
protection O
that O
methylprednisolone O
offers O
to O
the O
spinal B-Disease
cord I-Disease
injury I-Disease
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
discussion O
considering O
the O
possibility O
that O
the O
methylprednisolone O
recommended O
by O
nascis O
may O
cause O
acute O
corticosteroid O
myopathy B-Disease
. O

background O
: O
the O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
effects O
of O
rapa O
conversion O
in O
patients O
undergoing O
cyclosporine O
( O
csa O
) O
or O
tacrolimus O
( O
tac O
) O
toxicity B-Disease
. O

the O
indications O
for O
switch O
were O
chronic O
csa O
or O
tac O
nephrotoxicity B-Disease
( O
12 O
) O
, O
acute O
csa O
or O
tac O
toxicity B-Disease
( O
3 O
) O
, O
severe O
facial B-Disease
dysmorphism I-Disease
( O
2 O
) O
, O
posttransB-Plant B-Disease
lymphoproliferative I-Disease
disorder I-Disease
( O
ptld B-Disease
) O
in O
remission O
( O
2 O
) O
, O
and O
hepatotoxicity B-Disease
in O
1 O
. O

results O
: O
in O
the O
12 O
patients O
switched O
because O
of O
chronic O
nephrotoxicity B-Disease
there O
was O
a O
significant O
decrease O
in O
serum O
creatinine O
[ O
233 O
+ O
/ O
- O
34 O
to O
210 O
+ O
/ O
- O
56 O
micromol O
/ O
liter O
( O
p O
< O
0 O
. O

5 O
) O
at O
6 O
months O
] O
. O

facial B-Disease
dysmorphism I-Disease
improved O
in O
two O
patients O
. O

no O
relapse O
of O
ptld B-Disease
was O
observed O
. O

five O
patients O
developed O
pneumonia B-Disease
( O
two O
pneumocystis B-Disease
carinii I-Disease
pneumonia I-Disease
, O
one O
infectious B-Disease
mononucleosis I-Disease
with O
polyclonal O
ptld B-Disease
lung O
infiltrate O
) O
and O
two O
had O
bronchiolitis B-Disease
obliterans I-Disease
. O

rapa O
was O
discontinued O
in O
four O
patients O
, O
because O
of O
pneumonia B-Disease
in O
two O
, O
ptld B-Disease
in O
one O
, O
and O
oral O
aphtous B-Disease
ulcers I-Disease
in O
one O
. O

however O
, O
when O
converting O
patients O
to O
rapa O
drug O
levels O
should O
be O
monitored O
to O
avoid O
over O
- O
immunosuppression O
and O
adequate O
antiviral O
and O
pneumocystis B-Disease
carinii I-Disease
pneumonia I-Disease
prophylaxis O
should O
be O
given O
. O

electro O
- O
oculography O
, O
electroretinography O
, O
visual O
evoked O
potentials O
, O
and O
multifocal O
electroretinography O
in O
patients O
with O
vigabatrin O
- O
attributed O
visual B-Disease
field I-Disease
constriction I-Disease
. O

purpose O
: O
symptomatic O
visual B-Disease
field I-Disease
constriction I-Disease
thought O
to O
be O
associated O
with O
vigabatrin O
has O
been O
reported O
. O

the O
current O
study O
investigated O
the O
visual O
fields O
and O
visual O
electrophysiology O
of O
eight O
patients O
with O
known O
vigabatrin O
- O
attributed O
visual B-Disease
field I-Disease
loss I-Disease
, O
three O
of O
whom O
were O
reported O
previously O
. O

results O
: O
seven O
patients O
showed O
marked O
visual B-Disease
field I-Disease
constriction I-Disease
with O
some O
sparing O
of O
the O
temporal O
visual O
field O
. O

conclusion O
: O
marked O
visual B-Disease
field I-Disease
constriction I-Disease
appears O
to O
be O
associated O
with O
vigabatrin O
therapy O
. O

myocardial B-Disease
ischemia I-Disease
due O
to O
coronary B-Disease
artery I-Disease
spasm I-Disease
during O
dobutamine O
stress O
echocardiography O
. O

dobutamine O
stress O
echocardiography O
( O
dse O
) O
is O
a O
useful O
and O
safe O
provocation O
test O
for O
myocardial B-Disease
ischemia I-Disease
. O

until O
now O
, O
the O
test O
has O
been O
focused O
only O
on O
the O
organic O
lesion O
in O
the O
coronary O
artery O
, O
and O
positive O
dse O
has O
indicated O
the O
presence O
of O
significant O
fixed O
coronary B-Disease
artery I-Disease
stenosis I-Disease
. O

the O
aim O
of O
the O
present O
study O
is O
to O
examine O
whether O
myocardial B-Disease
ischemia I-Disease
due O
to O
coronary B-Disease
spasm I-Disease
is O
induced O
by O
dobutamine O
. O

we O
performed O
dse O
on O
51 O
patients O
with O
coronary B-Disease
spastic I-Disease
angina I-Disease
but O
without O
significant O
fixed O
coronary B-Disease
artery I-Disease
stenosis I-Disease
. O

all O
patients O
had O
anginal B-Disease
attacks O
at O
rest O
with O
st O
elevation O
on O
the O
electrocardiogram O
( O
variant B-Disease
angina I-Disease
) O
. O

coronary O
spasm O
was O
induced O
by O
intracoronary O
injection O
of O
acetylcholine O
, O
and O
no O
fixed O
coronary B-Disease
artery I-Disease
stenosis I-Disease
was O
documented O
on O
angiograms O
in O
all O
patients O
. O

all O
7 O
patients O
( O
13 O
. O

7 O
% O
) O
had O
chest B-Disease
pain I-Disease
during O
asynergy O
, O
and O
both O
chest B-Disease
pain I-Disease
and O
electrocardiographic O
changes O
were O
preceded O
by O
asynergy O
. O

these O
findings O
indicate O
that O
dobutamine O
can O
provoke O
coronary B-Disease
spasm I-Disease
in O
some O
patients O
with O
coronary B-Disease
spastic I-Disease
angina I-Disease
. O

when O
dse O
is O
performed O
to O
evaluate O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
not O
only O
fixed O
coronary B-Disease
stenosis I-Disease
, O
but O
also O
coronary B-Disease
spasm I-Disease
should O
be O
considered O
as O
a O
genesis O
of O
asynergy O
. O

effect O
of O
intravenous O
metoprolol O
or O
intravenous O
metoprolol O
plus O
glucagon O
on O
dobutamine O
- O
induced O
myocardial B-Disease
ischemia I-Disease
. O

conclusion O
: O
during O
dobutamine O
stress O
testing O
, O
metoprolol O
attenuates O
or O
eliminates O
evidence O
of O
myocardial B-Disease
ischemia I-Disease
. O

the O
objective O
of O
this O
study O
was O
to O
explore O
the O
functional O
anatomy O
of O
the O
globus O
pallidus O
internus O
( O
gpi O
) O
by O
studying O
the O
effects O
of O
unilateral O
pallidotomy O
on O
parkinsonian B-Disease
' O
off O
' O
signs O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
( O
lid B-Disease
) O
. O

we O
found O
significant O
positive O
correlations O
between O
the O
preoperative O
levodopa O
responsiveness O
of O
motor O
signs O
and O
the O
levodopa O
responsiveness O
of O
scores O
in O
timed O
tests O
( O
core O
assessment O
program O
for O
intracerebral O
transB-Plantations O
) O
in O
the O
contralateral O
limbs O
and O
the O
improvement O
in O
these O
scores O
after O
surgery O
, O
whereas O
there O
was O
no O
correlation O
with O
the O
improvement O
in O
lid B-Disease
. O

we O
also O
found O
a O
highly O
significant O
correlation O
( O
p O
: O
< O
0 O
. O

1 O
, O
r O
= O
0 O
. O

8 O
) O
between O
the O
volume O
of O
the O
ventral O
lesion O
in O
the O
gpi O
and O
the O
improvement O
in O
lid B-Disease
in O
the O
contralateral O
limbs O
, O
whereas O
there O
was O
no O
correlation O
between O
the O
ventral O
volume O
and O
the O
improvement O
in O
parkinsonian B-Disease
' O
off O
' O
signs O
. O

the O
volumes O
of O
the O
total O
lesion O
cylinder O
and O
the O
dorsal O
lesion O
did O
not O
correlate O
with O
the O
outcome O
of O
either O
dyskinesias B-Disease
or O
parkinsonian B-Disease
' O
off O
' O
signs O
. O

the O
differential O
predictive O
value O
of O
levodopa O
responsiveness O
for O
the O
outcome O
of O
parkinsonian B-Disease
' O
off O
' O
signs O
and O
lid B-Disease
and O
the O
different O
correlations O
of O
ventral O
lesion O
volume O
with O
dyskinesias B-Disease
and O
parkinsonian B-Disease
' O
off O
' O
signs O
indicate O
that O
different O
anatomical O
or O
pathophysiological O
substrates O
may O
be O
responsible O
for O
the O
generation O
of O
parkinsonian B-Disease
' O
off O
' O
signs O
and O
dyskinesias B-Disease
. O

whereas O
cells O
in O
a O
wider O
area O
of O
the O
gpi O
may O
be O
implicated O
in O
parkinsonism B-Disease
, O
the O
ventral O
gpi O
seems O
to O
be O
crucial O
for O
the O
manifestation O
of O
lid B-Disease
. O

we O
suggest O
that O
our O
observations O
are O
additional O
proof O
of O
the O
functional O
somatotopy O
of O
the O
systems O
within O
the O
gpi O
that O
mediate O
parkinsonism B-Disease
and O
dyskinesias B-Disease
, O
especially O
along O
the O
dorsoventral O
trajectory O
used O
in O
pallidotomy O
. O

screening O
for O
stimulant O
use O
in O
adult O
emergency O
department O
seizure B-Disease
patients O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
determine O
the O
prevalence O
of O
positive O
plasma O
drug O
screening O
for O
cocaine O
or O
amphetamine O
in O
adult O
emergency O
department O
seizure B-Disease
patients O
. O

methods O
: O
this O
prospective O
study O
evaluated O
consecutive O
eligible O
seizure B-Disease
patients O
who O
had O
a O
plasma O
sample O
collected O
as O
part O
of O
their O
clinical O
evaluation O
. O

patient O
demographics O
, O
history O
of O
underlying O
drug O
or O
alcohol O
- O
related O
seizure B-Disease
disorder O
, O
estimated O
time O
from O
seizure B-Disease
to O
sample O
collection O
, O
history O
or O
suspicion O
of O
cocaine B-Disease
or I-Disease
amphetamine I-Disease
abuse I-Disease
, O
results O
of O
clinical O
urine O
testing O
for O
drugs O
of O
abuse O
, O
and O
assay O
results O
were O
recorded O
without O
patient O
identifiers O
. O

positive O
test O
results O
were O
more O
common O
in O
patient O
visits O
where O
there O
was O
a O
history O
or O
suspicion O
of O
cocaine B-Disease
or I-Disease
amphetamine I-Disease
abuse I-Disease
( O
p O
< O
0 O
. O

5 O
) O
. O

conclusions O
: O
during O
this O
study O
period O
, O
routine O
plasma O
screening O
for O
cocaine O
and O
amphetamines O
in O
adult O
seizure B-Disease
patients O
had O
a O
low O
yield O
. O

as O
a O
result O
, O
routine O
plasma O
screening O
would O
yield O
few O
cases O
of O
stimulant O
drug O
in O
which O
there O
was O
neither O
a O
history O
nor O
suspicion O
of O
drug B-Disease
abuse I-Disease
in O
this O
population O
. O

contribution O
of O
sodium O
valproate O
to O
the O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
secretion I-Disease
of I-Disease
antidiuretic I-Disease
hormone I-Disease
. O

we O
report O
the O
case O
of O
a O
62 O
- O
year O
- O
old O
man O
who O
was O
administered O
sodium O
valproate O
( O
vpa O
) O
and O
who O
subsequently O
developed O
the O
syndrome B-Disease
of I-Disease
inappropriate I-Disease
secretion I-Disease
of I-Disease
antidiuretic I-Disease
hormone I-Disease
( O
siadh B-Disease
) O
. O

he O
had O
been O
taking O
vpa O
for O
treatment O
of O
idiopathic O
generalized O
tonic B-Disease
- I-Disease
clonic I-Disease
convulsions I-Disease
since O
he O
was O
56 O
years O
old O
. O

we O
consider O
this O
episode O
of O
siadh B-Disease
to O
be O
the O
result O
of O
a O
combination O
of O
factors O
including O
a O
weakness B-Disease
of I-Disease
the I-Disease
central I-Disease
nervous I-Disease
system I-Disease
and O
the O
long O
- O
term O
administration O
of O
vpa O
. O

association O
of O
nitric O
oxide O
production O
and O
apoptosis O
in O
a O
model O
of O
experimental O
nephropathy B-Disease
. O

we O
have O
studied O
the O
role O
of O
no O
and O
its O
association O
with O
apoptosis O
in O
an O
experimental O
model O
of O
nephrotic B-Disease
syndrome I-Disease
induced O
by O
a O
single O
injection O
of O
adriamycin O
( O
adr O
) O
. O

rats O
were O
stratified O
into O
control O
groups O
and O
adr O
- O
induced O
nephropathy B-Disease
groups O
. O

results O
: O
histopathological O
examination O
of O
the O
kidneys O
of O
rats O
treated O
with O
adr O
revealed O
focal O
areas O
of O
mesangial B-Disease
proliferation I-Disease
and O
mild O
tubulointerstitial B-Disease
inflammation I-Disease
. O

they O
also O
had O
significantly O
higher O
levels O
of O
proteinuria B-Disease
compared O
with O
control O
and O
treatment O
groups O
( O
p O
< O
0 O
. O

5 O
) O
. O

urine O
nitrite O
levels O
were O
significantly O
increased O
in O
the O
adr O
- O
nephropathy B-Disease
group O
( O
p O
< O
0 O
. O

5 O
) O
. O

in O
the O
iprk O
phenylephrine O
and O
acetylcholine O
related O
responses O
were O
significantly O
impaired O
in O
the O
adr O
- O
nephropathy B-Disease
group O
. O

however O
, O
in O
the O
adr O
- O
nephropathy B-Disease
group O
, O
numerous O
apoptotic O
cells O
were O
identified O
in O
the O
tubulointerstitial O
areas O
. O

conclusion O
: O
we O
suggest O
that O
interactions O
between O
no O
and O
apoptosis O
are O
important O
in O
the O
pathogenesis O
of O
the O
adr O
- O
induced O
nephrosis B-Disease
. O

dual O
effects O
of O
melatonin O
on O
barbiturate O
- O
induced O
narcosis B-Disease
in O
rats O
. O

melatonin O
affects O
the O
circadian O
sleep O
/ O
wake O
cycle O
, O
but O
it O
is O
not O
clear O
whether O
it O
may O
influence O
drug O
- O
induced O
narcosis B-Disease
. O

melatonin O
pre O
- O
treatment O
affected O
in O
a O
dual O
manner O
barbiturate O
narcosis B-Disease
, O
however O
, O
no O
dose O
- O
effect O
correlation O
was O
found O
. O

in O
particular O
, O
low O
doses O
reduced O
the O
latency O
to O
and O
prolonged O
the O
duration O
of O
barbiturate O
narcosis B-Disease
. O

in O
contrast O
, O
the O
highest O
dose O
of O
melatonin O
( O
50 O
mg O
/ O
kg O
) O
caused O
a O
paradoxical O
increase O
in O
the O
latency O
and O
produced O
a O
sustained O
reduction O
of O
the O
duration O
of O
narcosis B-Disease
, O
and O
a O
reduction O
in O
mortality O
rate O
. O

melatonin O
0 O
. O

5 O
and O
5 O
mg O
/ O
kg O
influenced O
the O
duration O
but O
not O
the O
latency O
of O
ketamine O
- O
or O
diazepam O
- O
induced O
narcosis B-Disease
. O

thus O
, O
the O
dual O
action O
of O
melatonin O
on O
pharmacological O
narcosis B-Disease
seems O
to O
be O
specific O
for O
the O
barbiturate O
mechanism O
of O
action O
. O

reduced O
cardiotoxicity B-Disease
and O
preserved O
antitumor O
efficacy O
of O
liposome O
- O
encapsulated O
doxorubicin O
and O
cyclophosphamide O
compared O
with O
conventional O
doxorubicin O
and O
cyclophosphamide O
in O
a O
randomized O
, O
multicenter O
trial O
of O
metastatic O
breast B-Disease
cancer I-Disease
. O

purpose O
: O
to O
determine O
whether O
myocet O
( O
liposome O
- O
encapsulated O
doxorubicin O
; O
the O
liposome O
company O
, O
elan O
corporation O
, O
princeton O
, O
nj O
) O
in O
combination O
with O
cyclophosphamide O
significantly O
reduces O
doxorubicin O
cardiotoxicity B-Disease
while O
providing O
comparable O
antitumor O
efficacy O
in O
first O
- O
line O
treatment O
of O
metastatic O
breast B-Disease
cancer I-Disease
( O
mbc B-Disease
) O
. O

patients O
and O
methods O
: O
two O
hundred O
ninety O
- O
seven O
patients O
with O
mbc B-Disease
and O
no O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomized O
to O
receive O
either O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
myocet O
( O
m O
) O
or O
conventional O
doxorubicin O
( O
a O
) O
, O
in O
combination O
with O
600 O
mg O
/ O
m O
( O
2 O
) O
of O
cyclophosphamide O
( O
c O
) O
, O
every O
3 O
weeks O
until O
disease O
progression O
or O
unacceptable O
toxicity B-Disease
. O

cardiotoxicity B-Disease
was O
defined O
by O
reductions O
in O
left O
- O
ventricular O
ejection O
fraction O
, O
assessed O
by O
serial O
multigated O
radionuclide O
angiography O
scans O
, O
or O
congestive B-Disease
heart I-Disease
failure I-Disease
( O
chf B-Disease
) O
. O

antitumor O
efficacy O
was O
assessed O
by O
objective O
tumor B-Disease
response O
rates O
( O
world O
health O
organization O
criteria O
) O
, O
time O
to O
progression O
, O
and O
survival O
. O

results O
: O
six O
percent O
of O
mc O
patients O
versus O
21 O
% O
( O
including O
five O
cases O
of O
chf B-Disease
) O
of O
ac O
patients O
developed O
cardiotoxicity B-Disease
( O
p O
= O
. O

2 O
) O
. O

mc O
patients O
also O
experienced O
less O
grade O
4 O
neutropenia B-Disease
. O

conclusion O
: O
myocet O
improves O
the O
therapeutic O
index O
of O
doxorubicin O
by O
significantly O
reducing O
cardiotoxicity B-Disease
and O
grade O
4 O
neutropenia B-Disease
and O
provides O
comparable O
antitumor O
efficacy O
, O
when O
used O
in O
combination O
with O
cyclophosphamide O
as O
first O
- O
line O
therapy O
for O
mbc B-Disease
. O

the O
role O
of O
nitrergic O
system O
in O
lidocaine O
- O
induced O
convulsion B-Disease
in O
the O
mouse O
. O

the O
effects O
of O
n O
- O
nitro O
- O
l O
- O
arginine O
- O
methyl O
ester O
( O
l O
- O
name O
) O
a O
nitric O
oxide O
( O
no O
) O
synthase O
inhibitor O
and O
l O
- O
arginine O
, O
a O
no O
precursor O
, O
were O
investigated O
on O
lidocaine O
- O
induced O
convulsions B-Disease
. O

l O
- O
name O
( O
100 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
and O
diazepam O
( O
2 O
mg O
/ O
kg O
) O
significantly O
decreased O
the O
incidence O
of O
lidocaine O
( O
50 O
mg O
/ O
kg O
) O
- O
induced O
convulsions B-Disease
. O

in O
contrast O
, O
the O
l O
- O
arginine O
treatment O
increased O
the O
incidence O
of O
lidocaine O
( O
80 O
mg O
/ O
kg O
, O
i O
. O

p O
. O

) O
- O
induced O
convulsions B-Disease
significantly O
. O

these O
results O
may O
suggest O
that O
no O
is O
a O
proconvulsant O
mediator O
in O
lidocaine O
- O
induced O
convulsions B-Disease
. O

erythropoietin O
restores O
the O
anemia B-Disease
- O
induced O
reduction O
in O
cyclophosphamide O
cytotoxicity B-Disease
in O
rat O
tumors B-Disease
. O

the O
aim O
of O
this O
study O
was O
to O
examine O
the O
impact O
of O
anemia B-Disease
prevention O
by O
recombinant O
human O
erythropoietin O
( O
rhuepo O
) O
treatment O
on O
the O
cytotoxicity B-Disease
of O
cyclophosphamide O
in O
solid O
experimental O
tumors B-Disease
. O

anemia B-Disease
was O
induced O
using O
a O
single O
dose O
of O
carboplatin O
( O
50 O
mg O
/ O
kg O
i O
. O

v O
. O

) O
resulting O
in O
a O
long O
- O
lasting O
reduction O
( O
30 O
% O
) O
of O
the O
hemoglobin O
concentration O
. O

in O
a O
second O
group O
, O
the O
development O
of O
anemia B-Disease
was O
prevented O
by O
rhuepo O
( O
1000 O
iu O
/ O
kg O
) O
administered O
s O
. O

c O
. O

three O
times O
/ O
week O
starting O
7 O
days O
before O
carboplatin O
application O
. O

four O
days O
after O
carboplatin O
treatment O
, O
tumors B-Disease
( O
ds O
- O
sarcoma B-Disease
of O
the O
rat O
) O
were O
imB-Planted O
s O
. O

c O
. O

onto O
the O
hind O
food O
dorsum O
. O

neither O
carboplatin O
nor O
rhuepo O
treatment O
influenced O
tumor B-Disease
growth O
rate O
per O
se O
. O

when O
tumors B-Disease
were O
treated O
with O
a O
single O
dose O
of O
cyclophosphamide O
( O
60 O
mg O
/ O
kg O
i O
. O

p O
. O

) O
5 O
days O
after O
imB-Plantation O
, O
a O
growth O
delay O
with O
a O
subsequent O
regrowth O
of O
the O
tumors B-Disease
was O
observed O
. O

in O
the O
anemia B-Disease
group O
, O
the O
growth O
delay O
was O
significantly O
shorter O
compared O
with O
nonanemic O
controls O
( O
13 O
. O

3 O
days O
versus O
8 O
. O

6 O
days O
) O
. O

in O
the O
group O
where O
anemia B-Disease
was O
prevented O
by O
rhuepo O
treatment O
, O
growth O
delay O
was O
comparable O
with O
that O
of O
nonanemic O
controls O
( O
13 O
. O

3 O
days O
) O
. O

these O
results O
suggest O
that O
chemotherapy O
- O
induced O
anemia B-Disease
reduces O
cytotoxicity B-Disease
of O
cyclophosphamide O
in O
tumors B-Disease
, O
whereas O
correction O
of O
anemia B-Disease
by O
rhuepo O
treatment O
( O
epoetin O
alpha O
) O
increases O
the O
sensitivity O
, O
probably O
as O
a O
result O
of O
an O
improved O
oxygen O
supply O
to O
tumor B-Disease
tissue O
. O

fatal O
haemorrhagic B-Disease
myocarditis I-Disease
secondary O
to O
cyclophosphamide O
therapy O
. O

haemorrhagic B-Disease
myocarditis I-Disease
is O
a O
rare O
but O
important O
complication O
of O
cyclophosphamide O
therapy O
. O

effects O
of O
verapamil O
on O
atrial B-Disease
fibrillation I-Disease
and O
its O
electrophysiological O
determinants O
in O
dogs O
. O

background O
: O
atrial B-Disease
tachycardia I-Disease
- O
induced O
remodeling O
promotes O
the O
occurrence O
and O
maintenance O
of O
atrial B-Disease
fibrillation I-Disease
( O
af B-Disease
) O
and O
decreases O
l O
- O
type O
ca O
( O
2 O
+ O
) O
current O
. O

there O
is O
also O
a O
clinical O
suggestion O
that O
acute O
l O
- O
type O
ca O
( O
2 O
) O
channel O
blockade O
can O
promote O
af B-Disease
, O
consistent O
with O
an O
af B-Disease
promoting O
effect O
of O
ca O
( O
2 O
+ O
) O
channel O
inhibition O
. O

methods O
: O
to O
evaluate O
the O
potential O
mechanisms O
of O
af B-Disease
promotion O
by O
ca O
( O
2 O
+ O
) O
channel O
blockers O
, O
we O
administered O
verapamil O
to O
morphine O
- O
chloralose O
anesthetized O
dogs O
. O

epicardial O
mapping O
with O
240 O
epicardial O
electrodes O
was O
used O
to O
evaluate O
activation O
during O
af B-Disease
. O

results O
: O
verapamil O
caused O
af B-Disease
promotion O
in O
six O
dogs O
, O
increasing O
mean O
duration O
of O
af B-Disease
induced O
by O
burst O
pacing O
, O
from O
8 O
+ O
/ O
- O
4 O
s O
( O
mean O
+ O
/ O
- O
s O
. O

e O
. O

) O
to O
95 O
+ O
/ O
- O
39 O
s O
( O
p O
< O
0 O
. O

1 O
vs O
. O

control O
) O
at O
a O
loading O
dose O
of O
0 O
. O

1 O
mg O
/ O
kg O
and O
228 O
+ O
/ O
- O
101 O
s O
( O
p O
< O
0 O
. O

5 O
vs O
. O

control O
) O
at O
a O
dose O
of O
0 O
. O

2 O
mg O
/ O
kg O
. O

in O
these O
experiments O
, O
verapamil O
shortened O
mean O
effective O
refractory O
period O
( O
erp O
) O
from O
122 O
+ O
/ O
- O
5 O
to O
114 O
+ O
/ O
- O
4 O
ms O
( O
p O
< O
0 O
. O

2 O
) O
at O
a O
cycle O
length O
of O
300 O
ms O
, O
decreased O
erp O
heterogeneity O
( O
from O
15 O
+ O
/ O
- O
1 O
to O
10 O
+ O
/ O
- O
1 O
% O
, O
p O
< O
0 O
. O

5 O
) O
, O
heterogeneously O
accelerated O
atrial O
conduction O
and O
decreased O
the O
cycle O
length O
of O
af B-Disease
( O
94 O
+ O
/ O
- O
4 O
to O
84 O
+ O
/ O
- O
3 O
ms O
, O
p O
< O
0 O
. O

5 O
) O
. O

diltiazem O
did O
not O
affect O
erp O
, O
af B-Disease
cycle O
length O
or O
af B-Disease
duration O
, O
but O
produced O
conduction O
acceleration O
similar O
to O
that O
caused O
by O
verapamil O
( O
n O
= O
5 O
) O
. O

in O
the O
presence O
of O
autonomic O
blockade O
, O
verapamil O
failed O
to O
promote O
af B-Disease
and O
increased O
, O
rather O
than O
decreasing O
, O
refractoriness O
. O

epicardial O
mapping O
suggested O
that O
verapamil O
promoted O
af B-Disease
by O
increasing O
the O
number O
of O
simultaneous O
wavefronts O
reflected O
by O
separate O
zones O
of O
reactivation O
in O
each O
cycle O
. O

conclusions O
: O
verapamil O
promotes O
af B-Disease
in O
normal O
dogs O
by O
promoting O
multiple O
circuit O
reentry O
, O
an O
effect O
dependent O
on O
intact O
autonomic O
tone O
and O
not O
shared O
by O
diltiazem O
. O

calcitonin O
gene O
- O
related O
peptide O
levels O
during O
nitric O
oxide O
- O
induced O
headache B-Disease
in O
patients O
with O
chronic O
tension B-Disease
- I-Disease
type I-Disease
headache I-Disease
. O

it O
has O
been O
proposed O
that O
nitric O
oxide O
( O
no O
) O
induced O
headache B-Disease
in O
primary B-Disease
headaches I-Disease
may O
be O
associated O
with O
release O
of O
calcitonin O
gene O
- O
related O
peptide O
( O
cgrp O
) O
. O

in O
the O
present O
study O
we O
aimed O
to O
investigate O
plasma O
levels O
of O
cgrp O
during O
headache B-Disease
induced O
by O
the O
no O
donor O
glyceryl O
trinitrate O
( O
gtn O
) O
in O
16 O
patients O
with O
chronic O
tension B-Disease
- I-Disease
type I-Disease
headache I-Disease
and O
16 O
healthy O
controls O
. O

the O
subjects O
were O
randomly O
allocated O
to O
receive O
0 O
. O

5 O
microg O
/ O
kg O
/ O
min O
gtn O
or O
placebo O
over O
20 O
min O
on O
two O
headache B-Disease
- O
free O
days O
. O

both O
patients O
and O
controls O
developed O
significantly O
stronger O
immediate O
headache B-Disease
on O
the O
gtn O
day O
than O
on O
the O
placebo O
day O
and O
the O
headache B-Disease
was O
significantly O
more O
pronounced O
in O
patients O
than O
in O
controls O
. O

the O
present O
study O
indicates O
that O
no O
- O
induced O
immediate O
headache B-Disease
is O
not O
associated O
with O
release O
of O
cgrp O
. O

fluconazole O
- O
induced O
torsade B-Disease
de I-Disease
pointes I-Disease
. O

objective O
: O
to O
present O
a O
case O
of O
fluconazole O
- O
associated O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
and O
discuss O
fluconazole O
' O
s O
role O
in O
causing O
tdp B-Disease
. O

case O
summary O
: O
a O
68 O
- O
year O
- O
old O
white O
woman O
with O
candida O
glabrata O
isolated O
from O
a O
presacral O
abscess O
developed O
tdp B-Disease
eight O
days O
after O
commencing O
oral O
fluconazole O
the O
patient O
had O
no O
other O
risk O
factors O
for O
tdp B-Disease
, O
including O
coronary B-Disease
artery I-Disease
disease I-Disease
, O
cardiomyopathy B-Disease
, O
congestive B-Disease
heart I-Disease
failure I-Disease
, O
and O
electrolyte O
abnormalities O
there O
was O
a O
temporal O
association O
between O
the O
initiation O
of O
fluconazole O
and O
tdp B-Disease
. O

the O
tdp B-Disease
resolved O
when O
fluconazole O
was O
discontinued O
; O
however O
, O
the O
patient O
continued O
to O
have O
premature B-Disease
ventricular I-Disease
contractions I-Disease
and O
nonsustained O
ventricular B-Disease
tachycardia I-Disease
( O
nsvt B-Disease
) O
until O
six O
days O
after O
drug O
cessation O
discussion O
: O
use O
of O
the O
naranjo O
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
use O
of O
fluconazole O
and O
the O
development O
of O
tdp B-Disease
. O

the O
possible O
mechanism O
is O
depression B-Disease
of O
rapidly O
activating O
delayed O
rectifier O
potassium O
currents O
. O

in O
our O
patient O
, O
there O
was O
no O
other O
etiology O
identified O
that O
could O
explain O
qt B-Disease
prolongation I-Disease
or O
tdp B-Disease
the O
complete O
disappearance O
of O
nsvt B-Disease
and O
premature B-Disease
ventricular I-Disease
contractions I-Disease
followed O
by O
normalization O
of O
qt O
interval O
after O
the O
drug O
was O
stopped O
strongly O
suggests O
fluconazole O
as O
the O
etiology O
. O

conclusions O
: O
clinicians O
should O
be O
aware O
that O
fluconazole O
, O
even O
at O
low O
doses O
, O
may O
cause O
prolongation B-Disease
of I-Disease
the I-Disease
qt I-Disease
interval I-Disease
, O
leading O
to O
tdp B-Disease
. O

serial O
electrocardiographic O
monitoring O
may O
be O
considered O
when O
fluconazole O
is O
administered O
in O
patients O
who O
are O
at O
risk O
for O
ventricular B-Disease
arrhythmias I-Disease
. O

cutaneous B-Disease
leucocytoclastic I-Disease
vasculitis I-Disease
associated O
with O
oxacillin O
. O

a O
67 O
- O
year O
- O
old O
man O
who O
was O
treated O
with O
oxacillin O
for O
one O
week O
because O
of O
staphylococcus B-Disease
aureus I-Disease
bacteremia I-Disease
, O
developed O
renal B-Disease
failure I-Disease
and O
diffuse O
, O
symmetric O
, O
palpable O
purpuric B-Disease
lesions I-Disease
on O
his O
feet O
. O

necrotic B-Disease
blisters I-Disease
were O
noted O
on O
his O
fingers O
. O

skin O
biopsies O
showed O
findings O
diagnostic O
of O
leucocytoclastic B-Disease
vasculitis I-Disease
. O

the O
rash B-Disease
disappeared O
after O
three O
weeks O
and O
renal O
function O
returned O
to O
normal O
. O

leucocytoclastic B-Disease
vasculitis I-Disease
presents O
as O
palpable O
purpura B-Disease
of O
the O
lower O
extremities O
often O
accompanied O
by O
abdominal B-Disease
pain I-Disease
, O
arthralgia B-Disease
, O
and O
renal B-Disease
involvement I-Disease
. O

etiologic O
factors O
or O
associated O
disorders O
include O
infections B-Disease
, O
medications O
, O
collagen B-Disease
vascular I-Disease
disease I-Disease
and O
neoplasia B-Disease
. O

oxacillin O
should O
be O
included O
among O
the O
drugs O
that O
can O
cause O
leucocytoclastic B-Disease
vasculitis I-Disease
. O

the O
renal O
pathology O
in O
a O
case O
of O
lithium O
- O
induced O
diabetes B-Disease
insipidus I-Disease
. O

a O
case O
of O
lithium O
- O
induced O
diabetes B-Disease
insipidus I-Disease
is O
reported O
. O

cholestatic B-Disease
jaundice I-Disease
associated O
with O
the O
use O
of O
metformin O
. O

we O
report O
a O
patient O
who O
developed O
cholestatic B-Disease
jaundice I-Disease
shortly O
after O
initiation O
of O
treatment O
with O
metformin O
hydrochloride O
. O

a O
percutaneous O
liver O
biopsy O
was O
obtained O
showing O
marked O
cholestasis B-Disease
, O
with O
portal O
edema B-Disease
, O
ductular O
proliferation O
, O
and O
acute O
inflammation B-Disease
. O

metformin O
hydrochloride O
was O
discontinued O
, O
and O
the O
patient O
' O
s O
jaundice B-Disease
resolved O
slowly O
over O
a O
period O
of O
several O
months O
. O

given O
the O
onset O
of O
his O
jaundice B-Disease
2 O
wk O
after O
the O
initiation O
of O
metformin O
, O
we O
believe O
that O
this O
case O
represents O
an O
example O
of O
metformin O
- O
associated O
hepatotoxicity B-Disease
, O
the O
first O
such O
case O
reported O
. O

systemic O
toxicity B-Disease
and O
resuscitation O
in O
bupivacaine O
- O
, O
levobupivacaine O
- O
, O
or O
ropivacaine O
- O
infused O
rats O
. O

we O
compared O
the O
systemic O
toxicity B-Disease
of O
bupivacaine O
, O
levobupivacaine O
, O
and O
ropivacaine O
in O
anesthetized O
rats O
. O

when O
asystole B-Disease
was O
recorded O
, O
drug O
infusion O
was O
stopped O
and O
a O
resuscitation O
sequence O
was O
begun O
. O

the O
cumulative O
doses O
of O
levobupivacaine O
and O
ropivacaine O
that O
produced O
seizures B-Disease
were O
similar O
and O
were O
larger O
than O
those O
of O
bupivacaine O
. O

the O
cumulative O
doses O
of O
levobupivacaine O
that O
produced O
dysrhythmias B-Disease
and O
asystole B-Disease
were O
smaller O
than O
the O
corresponding O
doses O
of O
ropivacaine O
, O
but O
they O
were O
larger O
than O
those O
of O
bupivacaine O
. O

we O
conclude O
that O
the O
systemic O
toxicity B-Disease
of O
levobupivacaine O
is O
intermediate O
between O
that O
of O
ropivacaine O
and O
bupivacaine O
when O
administered O
at O
the O
same O
rate O
and O
that O
ropivacaine O
- O
induced O
cardiac B-Disease
arrest I-Disease
appears O
to O
be O
more O
susceptible O
to O
treatment O
than O
that O
induced O
by O
bupivacaine O
or O
levobupivacaine O
. O

amphotericin O
b O
- O
induced O
seizures B-Disease
in O
a O
patient O
with O
aids B-Disease
. O

objective O
: O
to O
report O
a O
case O
of O
multiple O
episodes O
of O
seizure B-Disease
activity O
in O
an O
aids B-Disease
patent O
following O
amphotericin O
b O
infusion O
. O

case O
summary O
: O
a O
46 O
- O
year O
- O
old O
african O
- O
american O
man O
experienced O
recurrent O
grand B-Disease
mal I-Disease
seizures I-Disease
during O
intravenous O
infusion O
of O
amphotericin O
b O
, O
then O
petit O
mal O
seizures B-Disease
as O
the O
infusion O
was O
stopped O
and O
the O
drug O
concentrations O
decreased O
with O
time O
. O

despite O
administration O
of O
phenytoin O
and O
lorazepam O
, O
the O
seizures B-Disease
persisted O
and O
occurred O
only O
during O
amphotercin O
b O
administration O
. O

discussion O
: O
aids B-Disease
and O
cryptococcal B-Disease
meningitis I-Disease
, O
both O
of O
which O
the O
patient O
had O
, O
can O
potentially O
cause O
seizures B-Disease
. O

the O
patient O
had O
a O
history O
of O
alcohol B-Disease
abuse I-Disease
; O
alcohol O
intake O
as O
well O
as O
withdrawal O
can O
also O
cause O
seizures B-Disease
. O

didanosine O
also O
has O
a O
potential O
for O
inducing O
seizures B-Disease
. O

however O
, O
these O
other O
potential O
causes O
of O
seizure B-Disease
were O
ruled O
out O
. O

the O
time O
course O
of O
events O
suggested O
that O
amphotericin O
b O
was O
the O
cause O
of O
the O
seizures B-Disease
in O
this O
aids B-Disease
patient O
. O

conclusions O
: O
amphotericin O
b O
seems O
to O
be O
the O
probable O
cause O
of O
the O
seizures B-Disease
. O

to O
date O
, O
only O
three O
cases O
of O
seizures B-Disease
associated O
with O
amphotericin O
b O
have O
been O
reported O
in O
the O
literature O
, O
but O
healthcare O
providers O
should O
be O
aware O
of O
the O
potential O
for O
this O
rare O
adverse O
effect O
. O

although O
these O
drugs O
are O
highly O
effective O
and O
represent O
the O
mainstay O
of O
transB-Plant O
immunosuppression O
, O
they O
are O
associated O
with O
acute O
and O
chronic O
nephrotoxicity B-Disease
. O

acute O
nephrotoxicity B-Disease
, O
which O
occurs O
in O
the O
early O
period O
after O
transB-Plantation O
, O
leads O
to O
a O
higher O
rate O
of O
dialysis O
, O
and O
chronic O
nephrotoxicity B-Disease
may O
eventually O
result O
in O
graft O
loss O
. O

acute O
and O
chronic O
nephrotoxicity B-Disease
is O
becoming O
more O
common O
as O
the O
use O
of O
marginal O
kidneys O
for O
transB-Plantation O
increases O
. O

two O
recently O
available O
immunosuppressive O
agents O
, O
mycophenolate O
mofetil O
and O
sirolimus O
( O
rapamycin O
) O
, O
have O
no O
nephrotoxicity B-Disease
. O

tolerability O
of O
nimesulide O
and O
paracetamol O
in O
patients O
with O
nsaid O
- O
induced O
urticaria B-Disease
/ O
angioedema B-Disease
. O

in O
this O
study O
we O
investigated O
tolerability O
and O
reliability O
of O
nimesulide O
and O
paracetamol O
in O
a O
very O
large O
number O
of O
patients O
with O
an O
exclusive O
well O
- O
documented O
history O
of O
nsaid O
- O
induced O
urticaria B-Disease
/ O
angioedema B-Disease
. O

a O
single O
- O
placebo O
- O
controlled O
oral O
challenge O
procedure O
with O
nimesulide O
or O
paracetamol O
was O
applied O
to O
829 O
patients O
with O
a O
history O
of O
nsaid O
- O
induced O
urticaria B-Disease
/ O
angioedema B-Disease
. O

furthermore O
, O
18 O
. O

28 O
% O
of O
patients O
with O
a O
history O
of O
chronic O
urticaria B-Disease
and O
11 O
. O

8 O
% O
of O
subjects O
with O
an O
history O
of O
nsaid O
- O
induced O
urticaria B-Disease
/ O
angioedema B-Disease
or O
angioedema B-Disease
alone O
( O
with O
or O
without O
chronic O
urticaria B-Disease
) O
resulted O
to O
be O
intolerant O
to O
alternative O
drugs O
. O

taken O
together O
, O
our O
results O
confirm O
the O
good O
tolerability O
of O
nimesulide O
and O
paracetamol O
in O
patients O
who O
experienced O
urticaria B-Disease
/ O
angioedema B-Disease
caused O
by O
nsaids O
. O

however O
, O
the O
risk O
of O
reaction O
to O
these O
alternative O
study O
drugs O
is O
statistically O
increased O
by O
a O
history O
of O
chronic O
urticaria B-Disease
and O
, O
above O
all O
, O
by O
a O
history O
of O
nsaid O
- O
induced O
angioedema B-Disease
. O

comparison O
of O
aqueous O
and O
gellan O
ophthalmic O
timolol O
with O
placebo O
on O
the O
24 O
- O
hour O
heart O
rate O
response O
in O
patients O
on O
treatment O
for O
glaucoma B-Disease
. O

purpose O
: O
topical O
beta O
- O
blocker O
treatment O
is O
routine O
therapy O
in O
the O
management O
of O
patients O
with O
glaucoma B-Disease
. O

design O
: O
this O
trial O
evaluated O
the O
effect O
of O
placebo O
, O
0 O
. O

5 O
% O
aqueous O
timolol O
( O
timolol O
solution O
) O
and O
a O
0 O
. O

5 O
% O
timolol O
suspension O
that O
forms O
a O
gel O
on O
application O
to O
the O
conjunctiva O
( O
timolol O
gellan O
) O
on O
the O
24 O
- O
hour O
heart O
rate O
in O
patients O
currently O
being O
treated O
for O
glaucoma B-Disease
to O
quantify O
the O
reduction O
in O
mean O
heart O
rate O
. O

methods O
: O
forty O
- O
three O
caucasian O
patients O
with O
primary O
open B-Disease
- I-Disease
angle I-Disease
glaucoma I-Disease
or O
ocular B-Disease
hypertension I-Disease
with O
a O
mean O
( O
+ O
/ O
- O
sd O
) O
age O
of O
63 O
( O
+ O
/ O
- O
8 O
) O
years O
were O
randomized O
and O
crossed O
over O
in O
a O
double O
- O
masked O
manner O
to O
14 O
days O
of O
treatment O
with O
placebo O
( O
morning O
and O
evening O
in O
both O
eyes O
) O
, O
timolol O
solution O
( O
morning O
and O
evening O
in O
both O
eyes O
) O
, O
or O
timolol O
gellan O
( O
morning O
in O
both O
eyes O
with O
placebo O
in O
the O
evening O
) O
. O

these O
data O
quantify O
the O
modest O
bradycardia B-Disease
associated O
with O
ophthalmic O
beta O
- O
blocker O
therapy O
in O
a O
typical O
patient O
population O
on O
therapy O
for O
glaucoma B-Disease
. O

management O
strategies O
for O
ribavirin O
- O
induced O
hemolytic B-Disease
anemia I-Disease
in O
the O
treatment O
of O
hepatitis B-Disease
c I-Disease
: O
clinical O
and O
economic O
implications O
. O

objectives O
: O
recently O
published O
studies O
have O
demonstrated O
increased O
efficacy O
and O
cost O
- O
effectiveness O
of O
combination O
therapy O
with O
interferon O
and O
alpha O
- O
2b O
/ O
ribavirin O
compared O
with O
interferon O
- O
alpha O
monotherapy O
in O
the O
treatment O
of O
chronic B-Disease
hepatitis I-Disease
c I-Disease
( O
chc B-Disease
) O
. O

combination O
therapy O
is O
associated O
with O
a O
clinically O
important O
adverse O
effect O
: O
ribavirin O
- O
induced O
hemolytic B-Disease
anemia I-Disease
( O
riha B-Disease
) O
. O

the O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
direct O
health O
- O
care O
costs O
and O
management O
of O
riha B-Disease
during O
treatment O
of O
chc B-Disease
in O
a O
clinical O
trial O
setting O
. O

methods O
: O
a O
systematic O
literature O
review O
was O
conducted O
to O
synthesize O
information O
on O
the O
incidence O
and O
management O
of O
riha B-Disease
. O

decision O
- O
analytic O
techniques O
were O
used O
to O
estimate O
the O
cost O
of O
treating O
riha B-Disease
. O

results O
: O
riha B-Disease
, O
defined O
as O
a O
reduction O
in O
hemoglobin O
to O
less O
than O
100 O
g O
/ O
l O
, O
occurs O
in O
approximately O
7 O
% O
to O
9 O
% O
of O
patients O
treated O
with O
combination O
therapy O
. O

the O
standard O
of O
care O
for O
management O
of O
riha B-Disease
is O
reduction O
or O
discontinuation O
of O
the O
ribavirin O
dosage O
. O

we O
estimated O
the O
direct O
cost O
of O
treating O
clinically O
significant O
riha B-Disease
to O
be O
170 O
per O
patient O
receiving O
combination O
therapy O
per O
48 O
- O
week O
treatment O
course O
( O
range O
68 O
- O
692 O
) O
. O

conclusions O
: O
the O
direct O
cost O
of O
treating O
clinically O
significant O
riha B-Disease
is O
1 O
% O
( O
170 O
/ O
16 O
, O
459 O
) O
of O
drug O
treatment O
costs O
. O

questions O
remain O
about O
the O
optimal O
dose O
of O
ribavirin O
and O
the O
incidence O
of O
riha B-Disease
in O
a O
real O
- O
world O
population O
. O

despite O
these O
uncertainties O
, O
this O
initial O
evaluation O
of O
the O
direct O
cost O
of O
treating O
riha B-Disease
provides O
an O
estimate O
of O
the O
cost O
and O
management O
implications O
of O
this O
clinically O
important O
adverse O
effect O
. O

background O
: O
preclinical O
studies O
of O
intrathecal O
adenosine O
suggest O
it O
may O
be O
effective O
in O
the O
treatment O
of O
acute B-Disease
and I-Disease
chronic I-Disease
pain I-Disease
in O
humans O
, O
and O
preliminary O
studies O
in O
volunteers O
and O
patients O
with O
a O
swedish O
formulation O
of O
adenosine O
suggests O
it O
may O
be O
effective O
in O
hypersensitivity B-Disease
states O
but O
not O
with O
acute O
noxious O
stimulation O
. O

the O
purpose O
of O
this O
study O
was O
to O
screen O
for O
efficacy O
of O
a O
different O
formulation O
of O
adenosine O
marketed O
in O
the O
us O
, O
using O
both O
acute O
noxious O
stimulation O
and O
capsaicin O
- O
evoked O
mechanical O
hypersensitivity B-Disease
. O

cerebrospinal O
fluid O
was O
obtained O
for O
pharmacokinetic O
analysis O
, O
and O
pain B-Disease
ratings O
in O
response O
to O
acute O
heat O
stimuli O
and O
areas O
of O
mechanical B-Disease
hyperalgesia I-Disease
and O
allodynia B-Disease
after O
intradermal O
capsaicin O
injection O
were O
determined O
. O

results O
: O
adenosine O
produced O
no O
effect O
on O
pain B-Disease
report O
to O
acute O
noxious O
thermal O
or O
chemical O
stimulation O
but O
reduced O
mechanical B-Disease
hyperalgesia I-Disease
and O
allodynia B-Disease
from O
intradermal O
capsaicin O
injection O
for O
at O
least O
24 O
h O
. O

conclusions O
: O
these O
results O
show O
selective O
inhibition O
by O
intrathecal O
adenosine O
of O
hypersensitivity B-Disease
, O
presumed O
to O
reflect O
central O
sensitization O
in O
humans O
after O
peripheral O
capsaicin O
injection O
. O

the O
long O
- O
lasting O
effect O
is O
consistent O
with O
that O
observed O
in O
preliminary O
reports O
of O
patients O
with O
chronic O
neuropathic B-Disease
pain I-Disease
and O
is O
not O
due O
to O
prolonged O
residence O
of O
adenosine O
in O
cerebrospinal O
fluid O
. O

delayed O
- O
onset O
heparin O
- O
induced O
thrombocytopenia B-Disease
. O

background O
: O
heparin O
- O
induced O
thrombocytopenia B-Disease
presents O
5 O
to O
12 O
days O
after O
heparin O
exposure O
, O
with O
or O
without O
arterial B-Disease
or I-Disease
venous I-Disease
thromboemboli I-Disease
. O

delayed O
recognition O
and O
treatment O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
contribute O
to O
poor O
patient O
outcomes O
. O

objective O
: O
to O
describe O
and O
increase O
awareness O
of O
a O
clinical O
scenario O
in O
which O
the O
onset O
or O
manifestations O
of O
heparin O
- O
induced O
thrombocytopenia B-Disease
are O
delayed O
. O

patients O
: O
14 O
patients O
seen O
over O
a O
3 O
- O
year O
period O
in O
whom O
heparin O
- O
induced O
thrombocytopenia B-Disease
became O
apparent O
on O
delayed O
presentation O
with O
thromboembolic B-Disease
complications O
. O

measurements O
: O
platelet O
counts O
, O
onset O
of O
objectively O
determined O
thromboembolism B-Disease
, O
results O
of O
heparin O
- O
induced O
platelet O
factor O
4 O
antibody O
tests O
, O
and O
outcomes O
. O

results O
: O
patients O
went O
home O
after O
hospitalizations O
that O
had O
included O
heparin O
exposure O
- O
- O
in O
most O
cases O
, O
with O
no O
thrombocytopenia B-Disease
recognized O
- O
- O
only O
to O
return O
to O
the O
hospital O
( O
median O
, O
day O
14 O
) O
with O
thromboembolic B-Disease
complications O
. O

thromboemboli B-Disease
were O
venous O
( O
12 O
patients O
, O
7 O
with O
pulmonary B-Disease
emboli I-Disease
) O
or O
arterial O
( O
4 O
patients O
) O
or O
both O
. O

conclusions O
: O
delayed O
- O
onset O
heparin O
- O
induced O
thrombocytopenia B-Disease
is O
increasingly O
being O
recognized O
. O

to O
avoid O
disastrous O
outcomes O
, O
physicians O
must O
consider O
heparin O
- O
induced O
thrombocytopenia B-Disease
whenever O
a O
recently O
hospitalized O
patient O
returns O
with O
thromboembolism B-Disease
; O
therapy O
with O
alternative O
anticoagulants O
, O
not O
heparin O
, O
should O
be O
initiated O
. O

treatment O
of O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
with O
a O
dopamine O
agonist O
in O
children O
. O

background O
: O
risperidone O
, O
a O
potent O
antagonist O
of O
both O
serotonergic O
( O
5ht2a O
) O
and O
dopaminergic O
d2 O
receptors O
is O
associated O
with O
hyperprolactinemia B-Disease
in O
adults O
and O
children O
. O

chronically O
elevated O
prolactin O
levels O
in O
children O
with O
prolactinomas B-Disease
may O
be O
associated O
with O
arrested O
growth O
and O
development O
resulting O
in O
either O
delayed B-Disease
puberty I-Disease
or O
short O
stature O
. O

these O
possibilities O
stress O
the O
importance O
of O
developing O
a O
safe O
and O
effective O
approach O
to O
drug O
- O
induced O
hyperprolactinemia B-Disease
in O
youth O
. O

we O
report O
the O
successful O
treatment O
of O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
with O
cabergoline O
in O
youth O
. O

methods O
: O
we O
undertook O
a O
retrospective O
case O
review O
of O
four O
children O
with O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
treated O
with O
cabergoline O
. O

results O
: O
four O
males O
( O
age O
6 O
- O
11 O
years O
) O
with O
diagnostic O
and O
statistical O
manual O
of O
mental B-Disease
disorders I-Disease
( O
fourth O
edition O
) O
bipolar B-Disease
disorder I-Disease
or O
psychoses B-Disease
, O
with O
risperidone O
- O
induced O
elevations O
in O
serum O
prolactin O
levels O
( O
57 O
. O

5 O
- O
129 O
ng O
/ O
ml O
, O
normal O
5 O
- O
15 O
ng O
/ O
ml O
) O
, O
were O
treated O
with O
cabergoline O
( O
mean O
dose O
2 O
. O

13 O
+ O
/ O
- O
0 O
. O

9 O
mg O
/ O
week O
) O
. O

conclusions O
: O
cabergoline O
may O
be O
useful O
for O
the O
treatment O
of O
risperidone O
- O
induced O
hyperprolactinemia B-Disease
in O
youth O
; O
however O
, O
further O
research O
is O
needed O
. O

acute O
cholestatic B-Disease
hepatitis I-Disease
after O
exposure O
to O
isoflurane O
. O

objective O
: O
to O
report O
a O
case O
of O
acute O
cholestatic B-Disease
hepatitis I-Disease
following O
exposure O
to O
the O
inhalational O
anesthetic O
isoflurane O
. O

case O
summary O
: O
a O
70 O
- O
year O
- O
old O
healthy O
woman O
from O
iraq O
developed O
acute O
cholestatic B-Disease
hepatitis I-Disease
3 O
weeks O
following O
repair O
of O
the O
right O
rotator O
cuff O
under O
general O
anesthesia O
. O

there O
was O
no O
evidence O
for O
viral O
, O
autoimmune O
, O
or O
metabolic O
causes O
of O
hepatitis B-Disease
. O

no O
other O
medications O
were O
involved O
except O
for O
dipyrone O
for O
analgesia B-Disease
. O

discussion O
: O
the O
clinical O
and O
histologic O
picture O
of O
this O
case O
resembles O
halothane B-Disease
hepatitis I-Disease
, O
which O
has O
a O
significant O
mortality O
rate O
. O

conclusions O
: O
isoflurane O
, O
a O
common O
anesthetic O
agent O
, O
can O
cause O
severe O
cholestatic B-Disease
hepatitis I-Disease
. O

torsade B-Disease
de I-Disease
pointes I-Disease
induced O
by O
metoclopramide O
in O
an O
elderly O
woman O
with O
preexisting O
complete O
left B-Disease
bundle I-Disease
branch I-Disease
block I-Disease
. O

there O
is O
a O
growing O
list O
of O
drugs O
implicated O
in O
acquired O
long B-Disease
qt I-Disease
syndrome I-Disease
and O
torsade B-Disease
de I-Disease
pointes I-Disease
. O

we O
report O
on O
a O
92 O
- O
year O
- O
old O
woman O
with O
preexisting O
complete O
left B-Disease
bundle I-Disease
branch I-Disease
block I-Disease
who O
developed O
torsade B-Disease
de I-Disease
pointes I-Disease
after O
intravenous O
and O
oral O
administration O
of O
metoclopramide O
. O

this O
patient O
also O
developed O
torsade B-Disease
de I-Disease
pointes I-Disease
when O
cisapride O
and O
erythromycin O
were O
given O
simultaneously O
. O

this O
is O
the O
first O
documentation O
that O
metoclopramide O
provokes O
torsade B-Disease
de I-Disease
pointes I-Disease
clinically O
. O

metoclopramide O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
risk O
of O
torsade B-Disease
de I-Disease
pointes I-Disease
. O

dopamine O
( O
da O
) O
, O
through O
d1 O
/ O
d2 O
receptor O
- O
mediated O
signaling O
, O
plays O
a O
major O
role O
in O
the O
control O
of O
epileptic B-Disease
seizures I-Disease
arising O
in O
the O
limbic O
system O
. O

excitotoxicity B-Disease
leading O
to O
neuronal O
cell O
death O
in O
the O
affected O
areas O
is O
a O
major O
consequence O
of O
seizures B-Disease
at O
the O
cellular O
level O
. O

in O
this O
respect O
, O
little O
is O
known O
about O
the O
role O
of O
da O
receptors O
in O
the O
occurrence O
of O
epilepsy B-Disease
- O
induced O
neuronal O
cell O
death O
. O

here O
we O
analyze O
the O
occurrence O
of O
seizures B-Disease
and O
neurotoxicity B-Disease
in O
d2r O
- O
/ O
- O
mice O
treated O
with O
the O
cholinergic O
agonist O
pilocarpine O
. O

importantly O
, O
d2r O
- O
/ O
- O
mice O
develop O
seizures B-Disease
at O
doses O
of O
both O
drugs O
that O
are O
not O
epileptogenic O
for O
wt O
littermates O
and O
show O
greater O
neurotoxicity B-Disease
. O

however O
, O
pilocarpine O
- O
induced O
seizures B-Disease
result O
in O
a O
more O
widespread O
neuronal O
death O
in O
both O
wt O
and O
d2r O
- O
/ O
- O
brains O
in O
comparison O
to O
ka O
. O

thus O
, O
the O
absence O
of O
d2r O
lowers O
the O
threshold O
for O
seizures B-Disease
induced O
by O
both O
glutamate O
and O
acetylcholine O
. O

moreover O
, O
the O
dopaminergic O
control O
of O
epilepsy B-Disease
- O
induced O
neurodegeneration B-Disease
seems O
to O
be O
mediated O
by O
distinct O
interactions O
of O
d2r O
signaling O
with O
these O
two O
neurotransmitters O
. O

steroid O
structure O
and O
pharmacological O
properties O
determine O
the O
anti O
- O
amnesic B-Disease
effects O
of O
pregnenolone O
sulphate O
in O
the O
passive O
avoidance O
task O
in O
rats O
. O

moreover O
, O
pregs O
is O
able O
to O
reverse O
the O
amnesic B-Disease
- O
like O
effects O
of O
nmdar O
and O
gaba O
( O
a O
) O
r O
ligands O
. O

the O
memory O
- O
enhancing O
effects O
of O
pregs O
and O
its O
analogs O
were O
tested O
in O
the O
passive O
avoidance O
task O
using O
the O
model O
of O
scopolamine O
- O
induced O
amnesia B-Disease
. O

moreover O
, O
enantioselectivity O
was O
demonstrated O
by O
the O
ability O
of O
natural O
pregs O
to O
be O
an O
order O
of O
magnitude O
more O
effective O
than O
its O
synthetic O
enantiomer O
in O
reversing O
scopolamine O
- O
induced O
amnesia B-Disease
. O

activation O
of O
poly O
( O
adp O
- O
ribose O
) O
polymerase O
contributes O
to O
development O
of O
doxorubicin O
- O
induced O
heart B-Disease
failure I-Disease
. O

increased O
oxidative O
stress O
is O
a O
major O
factor O
implicated O
in O
the O
cardiotoxicity B-Disease
of O
doxorubicin O
( O
dox O
) O
, O
a O
widely O
used O
antitumor O
anthracycline O
antibiotic O
. O

thus O
, O
we O
hypothesized O
that O
the O
activation O
of O
parp O
may O
contribute O
to O
the O
dox O
- O
induced O
cardiotoxicity B-Disease
. O

using O
a O
dual O
approach O
of O
parp O
- O
1 O
suppression O
, O
by O
genetic O
deletion O
or O
pharmacological O
inhibition O
with O
the O
phenanthridinone O
parp O
inhibitor O
pj34 O
, O
we O
now O
demonstrate O
the O
role O
of O
parp O
in O
the O
development O
of O
cardiac B-Disease
dysfunction I-Disease
induced O
by O
dox O
. O

treatment O
with O
a O
pj34 O
significantly O
improved O
cardiac B-Disease
dysfunction I-Disease
and O
increased O
the O
survival O
of O
the O
animals O
. O

thus O
, O
parp O
activation O
contributes O
to O
the O
cardiotoxicity B-Disease
of O
dox O
. O

parp O
inhibitors O
may O
exert O
protective O
effects O
against O
the O
development O
of O
severe O
cardiac B-Disease
complications I-Disease
associated O
with O
the O
dox O
treatment O
. O

spironolactone O
: O
is O
it O
a O
novel O
drug O
for O
the O
prevention O
of O
amphotericin O
b O
- O
related O
hypokalemia B-Disease
in O
cancer B-Disease
patients O
? O
objective O
: O
nephrotoxicity B-Disease
is O
the O
major O
adverse O
effect O
of O
amphotericin O
b O
( O
amb O
) O
, O
often O
limiting O
administration O
of O
full O
dosage O
. O

selective O
distal O
tubular O
epithelial O
toxicity B-Disease
seems O
to O
be O
responsible O
for O
the O
profound O
potassium O
wasting O
that O
is O
a O
major O
clinical O
side O
effect O
of O
treatment O
with O
amb O
. O

potassium O
depletion O
also O
potentiates O
the O
tubular O
toxicity B-Disease
of O
amb O
. O

this O
study O
was O
designed O
to O
assess O
the O
ability O
of O
spironolactone O
to O
reduce O
potassium O
requirements O
and O
to O
prevent O
hypokalemia B-Disease
in O
neutropenic B-Disease
patients O
on O
amb O
treatment O
. O

methods O
: O
in O
this O
study O
26 O
patients O
with O
various O
hematological B-Disease
disorders I-Disease
were O
randomized O
to O
receive O
either O
intravenous O
amb O
alone O
or O
amb O
and O
oral O
spironolactone O
100 O
mg O
twice O
daily O
when O
developing O
a O
proven O
or O
suspected O
fungal B-Disease
infection I-Disease
. O

conclusion O
: O
this O
study O
showed O
that O
spironolactone O
can O
reduce O
potassium O
requirements O
and O
prevent O
hypokalemia B-Disease
by O
reducing O
urinary O
potassium O
loss O
in O
neutropenic B-Disease
patients O
on O
amb O
treatment O
. O

erectile B-Disease
dysfunction I-Disease
occurs O
following O
substantia O
nigra O
lesions O
in O
the O
rat O
. O

lesions O
of O
the O
substantia O
nigra O
are O
therefore O
associated O
with O
erectile B-Disease
dysfunction I-Disease
in O
rats O
and O
may O
serve O
as O
a O
model O
to O
study O
erectile B-Disease
dysfunction I-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

nicotine O
potentiation O
of O
morphine O
- O
induced O
catalepsy B-Disease
in O
mice O
. O

in O
the O
present O
study O
, O
effects O
of O
nicotine O
on O
catalepsy B-Disease
induced O
by O
morphine O
in O
mice O
have O
been O
investigated O
. O

morphine O
but O
not O
nicotine O
induced O
a O
dose O
- O
dependent O
catalepsy B-Disease
. O

intraperitoneal O
administration O
of O
atropine O
, O
naloxone O
, O
mecamylamine O
, O
and O
hexamethonium O
to O
mice O
reduced O
catalepsy B-Disease
induced O
by O
a O
combination O
of O
morphine O
with O
nicotine O
. O

intracerebroventricular O
injection O
of O
atropine O
, O
hexamethonium O
, O
and O
naloxone O
also O
decreased O
catalepsy B-Disease
induced O
by O
morphine O
plus O
nicotine O
. O

it O
was O
concluded O
that O
morphine O
catalepsy B-Disease
can O
be O
elicited O
by O
opioid O
and O
cholinergic O
receptors O
, O
and O
the O
potentiation O
of O
morphine O
induced O
by O
nicotine O
may O
also O
be O
mediated O
through O
cholinergic O
receptor O
mechanisms O
. O

force O
overflow O
and O
levodopa O
- O
induced O
dyskinesias B-Disease
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

we O
assessed O
force O
coordination O
of O
the O
hand O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
and O
its O
relationship O
to O
motor O
complications O
of O
levodopa O
therapy O
, O
particularly O
to O
levodopa O
- O
induced O
dyskinesias B-Disease
( O
lid B-Disease
) O
. O

we O
studied O
two O
groups O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
patients O
with O
( O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
+ O
lid B-Disease
, O
n O
= O
23 O
) O
and O
without O
levodopa O
- O
induced O
dyskinesias B-Disease
( O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
- O
lid B-Disease
, O
n O
= O
10 O
) O
, O
and O
age O
- O
matched O
healthy O
controls O
. O

the O
motor O
score O
of O
the O
unified O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
rating O
scale O
, O
a O
dyskinesia B-Disease
score O
and O
force O
in O
a O
grip O
- O
lift O
paradigm O
were O
assessed O
on O
and O
off O
levodopa O
. O

a O
pathological O
increase O
of O
forces O
was O
seen O
in O
on O
- O
state O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
+ O
lid B-Disease
only O
. O

in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
+ O
lid B-Disease
, O
the O
force O
involved O
in O
pressing O
down O
the O
object O
before O
lifting O
was O
significantly O
increased O
by O
levodopa O
( O
by O
61 O
% O
, O
p O
< O
0 O
. O

5 O
) O
. O

in O
contrast O
, O
no O
excessive O
force O
was O
found O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
- O
lid B-Disease
. O

peak O
grip O
force O
in O
on O
- O
state O
was O
140 O
% O
( O
p O
< O
0 O
. O

5 O
) O
higher O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
+ O
lid B-Disease
than O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
- O
lid B-Disease
, O
while O
static O
grip O
force O
was O
increased O
by O
138 O
% O
( O
p O
< O
0 O
. O

1 O
) O
between O
groups O
. O

severity O
of O
peak O
- O
dose O
dyskinesias B-Disease
was O
strongly O
correlated O
with O
grip O
force O
in O
on O
- O
state O
( O
r O
= O
0 O
. O

79 O
with O
peak O
force O
, O
p O
< O
0 O
. O

1 O
) O
. O

force O
excess O
was O
only O
observed O
in O
patients O
with O
lid B-Disease
and O
motor O
fluctuations O
. O

a O
close O
relationship O
was O
seen O
between O
the O
overshooting O
of O
forces O
and O
dyskinesias B-Disease
in O
the O
on O
- O
drug O
condition O
. O

we O
postulate O
that O
both O
lid B-Disease
and O
grip O
force O
excess O
share O
common O
pathophysiological O
mechanisms O
related O
to O
motor O
fluctuations O
. O

this O
study O
focuses O
on O
behavioral O
syndromes O
that O
may O
used O
as O
models O
for O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
, O
or O
tardive B-Disease
dyskinesia I-Disease
, O
and O
its O
response O
after O
glutamatergic O
blockage O
. O

reserpine O
( O
1 O
mg O
/ O
kg O
) O
, O
administered O
once O
every O
other O
day O
for O
4 O
days O
, O
produced O
increases O
in O
orofacial B-Disease
dyskinesia I-Disease
, O
tongue O
protrusion O
and O
vacuous O
chewing O
in O
mice O
, O
which O
are O
signs O
indicative O
of O
tardive B-Disease
dyskinesia I-Disease
. O

reserpine O
also O
produced O
tremor B-Disease
and O
catalepsy B-Disease
, O
which O
are O
signs O
suggestive O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
. O

mk O
- O
801 O
( O
0 O
. O

1 O
mg O
/ O
kg O
) O
, O
administered O
30 O
min O
before O
the O
observation O
test O
, O
prevented O
the O
vacuous O
chewing O
movements O
, O
tongue O
protrusions O
and O
catalepsy B-Disease
induced O
by O
reserpine O
. O

however O
, O
mk O
- O
801 O
injection O
produced O
a O
significant O
increase O
of O
tremor B-Disease
in O
reserpine O
- O
treated O
mice O
. O

reserpine O
( O
1 O
mg O
/ O
kg O
) O
, O
administered O
90 O
min O
before O
the O
test O
and O
followed O
by O
apomophine O
injection O
( O
0 O
. O

1 O
mg O
/ O
kg O
) O
5 O
min O
before O
the O
test O
, O
did O
not O
produce O
oral B-Disease
dyskinesia I-Disease
in O
mice O
. O

on O
the O
other O
hand O
, O
reserpine O
induced O
increases O
in O
tremor B-Disease
and O
catalepsy B-Disease
compared O
to O
control O
mice O
. O

mk O
- O
801 O
( O
0 O
. O

1 O
mg O
/ O
kg O
) O
administration O
attenuated O
the O
catalepsy B-Disease
and O
tremor B-Disease
induced O
by O
reserpine O
. O

pretreatment O
with O
reserpine O
( O
1 O
mg O
/ O
kg O
) O
24 O
h O
before O
the O
observation O
test O
produced O
increases O
in O
vacuous O
chewing O
movements O
and O
tongue O
protrusion O
, O
as O
well O
as O
increases O
in O
tremor B-Disease
and O
catalepsy B-Disease
, O
whereas O
mk O
- O
801 O
( O
0 O
. O

1 O
mg O
/ O
kg O
) O
injection O
90 O
min O
before O
the O
test O
reversed O
the O
effects O
of O
reserpine O
. O

these O
results O
show O
that O
reserpine O
produces O
different O
and O
abnormal B-Disease
movements I-Disease
, O
which O
are O
related O
to O
dose O
and O
schedule O
employed O
and O
can O
be O
considered O
as O
parkinsonian B-Disease
- O
like O
and O
tardive B-Disease
dsykinesia I-Disease
signs O
. O

the O
glutamatergic O
blockage O
produced O
by O
nmda O
can O
restore O
these O
signs O
, O
such O
as O
vacuous O
chewing O
movements O
, O
tongue O
protrusions O
, O
catalepsy B-Disease
and O
tremor B-Disease
according O
to O
the O
employed O
model O
. O

risperidone O
- O
associated O
, O
benign O
transient O
visual B-Disease
disturbances I-Disease
in O
schizophrenic B-Disease
patients O
with O
a O
past O
history O
of O
lsd O
abuse O
. O

two O
schizophrenic B-Disease
patients O
, O
who O
had O
a O
prior O
history O
of O
lsd O
abuse O
and O
who O
had O
previously O
developed O
eps B-Disease
with O
classic O
antipsychotics O
, O
were O
successfully O
treated O
with O
risperidone O
. O

they O
both O
reported O
short O
episodes O
of O
transient O
visual B-Disease
disturbances I-Disease
, O
which O
appeared O
immediately O
after O
starting O
treatment O
with O
risperidone O
. O

this O
imagery O
resembled O
visual B-Disease
disturbances I-Disease
previously O
experienced O
as O
nan O
flashbacks O
nan O
related O
to O
prior O
lsd O
consumption O
. O

risperidone O
administration O
was O
continued O
and O
the O
visual B-Disease
disturbances I-Disease
gradually O
wore O
off O
. O

during O
a O
six O
- O
month O
follow O
- O
up O
period O
, O
there O
was O
no O
recurrence O
of O
visual B-Disease
disturbances I-Disease
. O

topiramate O
- O
induced O
nephrolithiasis B-Disease
. O

topiramate O
is O
a O
recently O
developed O
antiepileptic O
medication O
that O
is O
becoming O
more O
widely O
prescribed O
because O
of O
its O
efficacy O
in O
treating O
refractory B-Disease
seizures I-Disease
. O

urologists O
should O
be O
aware O
that O
this O
medication O
can O
cause O
metabolic B-Disease
acidosis I-Disease
in O
patients O
secondary O
to O
inhibition O
of O
carbonic O
anhydrase O
. O

these O
factors O
can O
lead O
to O
the O
development O
of O
calcium O
phosphate O
nephrolithiasis B-Disease
. O

we O
report O
the O
first O
two O
cases O
of O
topiramate O
- O
induced O
nephrolithiasis B-Disease
in O
the O
urologic O
literature O
. O

diazepam O
, O
unless O
contraindicated O
or O
risky O
, O
remains O
the O
only O
necessary O
complementary O
drug O
to O
ketamine O
as O
it O
buffers O
its O
cardiovascular O
response O
and O
decreases O
the O
duration O
and O
intensity O
of O
operative O
and O
postoperative O
hallucinations B-Disease
. O

local O
anaesthetic O
blocks O
were O
useful O
in O
decreasing O
the O
requirement O
for O
postoperative O
analgesia B-Disease
. O

intravenous O
ribavirin O
treatment O
for O
severe O
adenovirus B-Disease
disease I-Disease
in O
immunocompromised O
children O
. O

the O
incidence O
of O
severe O
adenovirus B-Disease
disease I-Disease
in O
pediatrics O
is O
increasing O
in O
association O
with O
growing O
numbers O
of O
immunocompromised O
children O
, O
where O
case O
fatality O
rates O
as O
high O
as O
50 O
% O
to O
80 O
% O
have O
been O
reported O
. O

there O
are O
no O
approved O
antiviral O
agents O
with O
proven O
efficacy O
for O
the O
treatment O
of O
severe O
adenovirus B-Disease
disease I-Disease
, O
nor O
are O
there O
any O
prospective O
randomized O
, O
controlled O
trials O
of O
potentially O
useful O
anti O
- O
adenovirus O
therapies O
. O

apparent O
clinical O
success O
in O
the O
treatment O
of O
severe O
adenovirus B-Disease
disease I-Disease
is O
limited O
to O
a O
few O
case O
reports O
and O
small O
series O
. O

ribavirin O
is O
licensed O
in O
aerosol O
form O
for O
the O
treatment O
of O
respiratory B-Disease
syncytial I-Disease
virus I-Disease
infection I-Disease
, O
and O
orally O
in O
combination O
with O
interferon O
to O
treat O
hepatitis B-Disease
c I-Disease
. O

intravenous O
ribavirin O
is O
the O
treatment O
of O
choice O
for O
infection B-Disease
with I-Disease
hemorrhagic I-Disease
fever I-Disease
viruses I-Disease
. O

the O
most O
common O
adverse O
effect O
of O
intravenous O
ribavirin O
is O
reversible O
mild O
anemia B-Disease
. O

the O
use O
of O
cidofovir O
in O
severe O
adenovirus B-Disease
infection I-Disease
has O
been O
limited O
by O
adverse O
effects O
, O
the O
most O
significant O
of O
which O
is O
nephrotoxicity B-Disease
. O

objective O
: O
we O
report O
our O
experience O
with O
intravenous O
ribavirin O
therapy O
for O
severe O
adenovirus B-Disease
disease I-Disease
in O
a O
series O
of O
immunocompromised O
children O
and O
review O
the O
literature O
. O

design O
/ O
methods O
: O
we O
retrospectively O
reviewed O
the O
medical O
records O
of O
5 O
children O
treated O
with O
intravenous O
ribavirin O
for O
documented O
severe O
adenovirus B-Disease
disease I-Disease
. O

two O
patients O
developed O
adenovirus O
hemorrhagic B-Disease
cystitis I-Disease
after O
cardiac O
and O
bone O
marrow O
transB-Plants O
, O
respectively O
. O

an O
additional O
3 O
children O
developed O
adenovirus B-Disease
pneumonia I-Disease
; O
2 O
were O
neonates O
, O
1 O
of O
whom O
had O
partial O
digeorge B-Disease
syndrome I-Disease
. O

results O
: O
complete O
clinical O
recovery O
followed O
later O
by O
viral O
clearance O
was O
observed O
in O
2 O
children O
: O
the O
cardiac O
transB-Plant O
recipient O
with O
adenovirus O
hemorrhagic B-Disease
cystitis I-Disease
and O
the O
immunocompetent O
neonate O
with O
adenovirus B-Disease
pneumonia I-Disease
. O

the O
remaining O
3 O
children O
died O
of O
adenovirus B-Disease
disease I-Disease
. O

use O
of O
cidofovir O
in O
1 O
child O
was O
associated O
with O
progressive B-Disease
renal I-Disease
failure I-Disease
and O
neutropenia B-Disease
. O

discussion O
: O
our O
series O
of O
patients O
is O
representative O
of O
the O
spectrum O
of O
immunocompromised O
children O
at O
greatest O
risk O
for O
severe O
adenovirus B-Disease
disease I-Disease
, O
namely O
solid O
- O
organ O
and O
bone O
marrow O
transB-Plant O
recipients O
, O
neonates O
, O
and O
children O
with O
immunodeficiency B-Disease
. O

although O
intravenous O
ribavirin O
was O
not O
effective O
for O
all O
children O
with O
severe O
adenovirus B-Disease
disease I-Disease
in O
this O
series O
or O
in O
the O
literature O
, O
therapy O
is O
unlikely O
to O
be O
of O
benefit O
if O
begun O
late O
in O
the O
course O
of O
the O
infection B-Disease
. O

early O
identification O
, O
eg O
by O
polymerase O
chain O
reaction O
of O
those O
patients O
at O
risk O
of O
disseminated O
adenovirus B-Disease
disease I-Disease
may O
permit O
earlier O
antiviral O
treatment O
and O
better O
evaluation O
of O
therapeutic O
response O
. O

conclusions O
: O
two O
of O
5 O
children O
with O
severe O
adenovirus B-Disease
disease I-Disease
treated O
with O
intravenous O
ribavirin O
recovered O
. O

the O
availability O
of O
newer O
rapid O
diagnostic O
techniques O
, O
such O
as O
polymerase O
chain O
reaction O
, O
may O
make O
earlier O
, O
more O
effective O
treatment O
of O
adenovirus B-Disease
infection I-Disease
possible O
. O

given O
the O
seriousness O
and O
increasing O
prevalence O
of O
adenovirus B-Disease
disease I-Disease
in O
certain O
hosts O
, O
especially O
children O
, O
a O
large O
, O
multicenter O
clinical O
trial O
of O
potentially O
useful O
anti O
- O
adenoviral O
therapies O
, O
such O
as O
intravenous O
ribavirin O
, O
is O
clearly O
required O
to O
demonstrate O
the O
most O
effective O
and O
least O
toxic O
therapy O
. O

delayed O
asystolic B-Disease
cardiac B-Disease
arrest I-Disease
after O
diltiazem O
overdose B-Disease
; O
resuscitation O
with O
high O
dose O
intravenous O
calcium O
. O

a O
51 O
year O
old O
man O
took O
a O
mixed O
overdose B-Disease
including O
1 O
. O

8 O
- O
3 O
. O

6 O
g O
of O
diltiazem O
, O
paracetamol O
, O
aspirin O
, O
isosorbide O
nitrate O
, O
and O
alcohol O
. O

he O
initially O
presented O
to O
hospital O
after O
six O
hours O
with O
mild O
hypotension B-Disease
and O
was O
treated O
with O
activated O
charcoal O
and O
intravenous O
fluids O
. O

eighteen O
hours O
after O
the O
overdose B-Disease
he O
had O
two O
generalised O
tonic B-Disease
- I-Disease
clonic I-Disease
seizures I-Disease
. O

the O
patient O
remained O
unresponsive O
with O
junctional O
bradycardia B-Disease
, O
unrecordable O
blood O
pressure O
, O
and O
then O
became O
asystolic B-Disease
. O

this O
case O
suggests O
there O
is O
a O
role O
for O
aggressive O
high O
dose O
intravenous O
calcium O
therapy O
in O
severe O
diltiazem O
overdose B-Disease
, O
particularly O
with O
the O
onset O
of O
asystole B-Disease
. O

it O
should O
be O
considered O
early O
in O
cases O
of O
cardiac B-Disease
arrest I-Disease
after O
diltiazem O
overdose B-Disease
. O

the O
case O
also O
highlights O
the O
problems O
with O
delayed O
toxicity B-Disease
when O
whole O
bowel O
irrigation O
is O
not O
administered O
. O

data O
to O
establish O
the O
thromboembolic B-Disease
risk O
were O
incomplete O
. O

the O
incidence O
rate O
of O
thromboembolism B-Disease
was O
0 O
. O

9 O
% O
for O
all O
the O
studies O
and O
0 O
. O

5 O
, O
0 O
, O
20 O
, O
and O
0 O
% O
in O
groups O
a O
, O
b O
, O
c O
, O
and O
d O
, O
respectively O
; O
for O
hemorrhage B-Disease
, O
the O
overall O
rate O
was O
3 O
. O

4 O
% O
( O
3 O
. O

8 O
, O
2 O
. O

6 O
, O
10 O
, O
and O
0 O
% O
for O
the O
respective O
groups O
) O
. O

cardiac B-Disease
arrest I-Disease
after O
intravenous O
metoclopramide O
- O
a O
case O
of O
five O
repeated O
injections O
of O
metoclopramide O
causing O
five O
episodes O
of O
cardiac B-Disease
arrest I-Disease
. O

we O
describe O
a O
patient O
where O
intravenous O
injection O
of O
metoclopramide O
was O
immediately O
followed O
by O
asystole B-Disease
repeatedly O
. O

after O
interviewing O
the O
attending O
nurses O
and O
reviewing O
the O
written O
documentation O
, O
it O
is O
clear O
that O
every O
administration O
of O
metoclopramide O
was O
immediately O
( O
within O
s O
) O
followed O
by O
asystole B-Disease
. O

the O
asystole B-Disease
lasted O
15 O
- O
30 O
s O
on O
four O
occasions O
, O
on O
one O
occasion O
it O
lasted O
2 O
min O
. O

we O
interpret O
this O
as O
episodes O
of O
cardiac B-Disease
arrest I-Disease
caused O
by O
metoclopramide O
. O

immunohistochemical O
study O
on O
inducible O
type O
of O
nitric O
oxide O
( O
inos O
) O
, O
basic O
fibroblast O
growth O
factor O
( O
bfgf O
) O
and O
tumor B-Disease
growth O
factor O
- O
beta1 O
( O
tgf O
- O
beta1 O
) O
in O
arteritis B-Disease
induced O
in O
rats O
by O
fenoldopam O
and O
theophylline O
, O
vasodilators O
. O

arteritis B-Disease
induced O
in O
rats O
by O
vasodilators O
, O
fenoldopam O
and O
theophylline O
, O
was O
examined O
immunohistochemically O
for O
expressions O
of O
inducible O
type O
of O
nitric O
oxide O
synthase O
( O
inos O
) O
, O
basic O
fibroblast O
growth O
factor O
( O
bfgf O
) O
and O
tumor B-Disease
growth O
factor O
- O
beta1 O
( O
tgf O
- O
beta1 O
) O
. O

these O
results O
suggest O
that O
the O
peak O
expression O
of O
inos O
antigen O
was O
followed O
by O
that O
of O
bfgf O
antigen O
, O
and O
bfgf O
may O
have O
a O
suppressive O
effect O
on O
inos O
expression O
in O
these O
rat O
arteritis B-Disease
models O
. O

haloperidol O
( O
1 O
mg O
/ O
kg O
ip O
) O
induced O
parkinsonian B-Disease
- O
like O
muscle B-Disease
rigidity I-Disease
, O
measured O
as O
an O
increased O
resistance O
of O
a O
rat O
' O
s O
hind O
foot O
to O
passive O
flexion O
and O
extension O
at O
the O
ankle O
joint O
. O

aida O
in O
doses O
of O
7 O
. O

5 O
- O
15 O
microg O
/ O
0 O
. O

5 O
microl O
diminished O
the O
haloperidol O
- O
induced O
muscle B-Disease
rigidity I-Disease
. O

the O
present O
results O
may O
suggest O
that O
the O
blockade O
of O
striatal O
mglur1 O
, O
but O
not O
the O
stimulation O
of O
group O
ii O
mglurs O
, O
may O
ameliorate O
parkinsonian B-Disease
muscle B-Disease
rigidity I-Disease
. O

a O
phase O
ii O
study O
of O
thalidomide O
in O
advanced O
metastatic O
renal B-Disease
cell I-Disease
carcinoma I-Disease
. O

objectives O
: O
to O
evaluate O
the O
toxicity B-Disease
and O
activity O
of O
thalidomide O
in O
patients O
with O
advanced O
metastatic O
renal B-Disease
cell I-Disease
cancer I-Disease
and O
to O
measure O
changes O
of O
one O
angiogenic O
factor O
, O
vascular O
endothelial O
growth O
factor O
( O
vegf O
) O
165 O
, O
with O
therapy O
. O

results O
: O
24 O
patients O
were O
evaluable O
for O
response O
with O
one O
partial O
response O
of O
11 O
months O
duration O
of O
a O
patient O
with O
hepatic O
and O
pulmonary O
metastases B-Disease
( O
4 O
% O
) O
, O
one O
minor O
response O
, O
and O
2 O
patients O
stable O
for O
over O
6 O
months O
. O

somnolence B-Disease
and O
constipation B-Disease
were O
prominent O
toxicities B-Disease
and O
most O
patients O
could O
not O
tolerate O
the O
1200 O
mg O
/ O
day O
dose O
level O
. O

conclusion O
: O
these O
results O
are O
consistent O
with O
a O
low O
level O
of O
activity O
of O
thalidomide O
in O
renal B-Disease
cell I-Disease
carcinoma I-Disease
. O

the O
dose O
- O
response O
relationship O
, O
if O
any O
, O
of O
thalidomide O
for O
renal B-Disease
cell I-Disease
carcinoma I-Disease
is O
unclear O
. O

can O
lidocaine O
reduce O
succinylcholine O
induced O
postoperative B-Disease
myalgia I-Disease
? O
this O
study O
was O
undertaken O
to O
determine O
the O
effect O
of O
lidocaine O
pretreatment O
on O
reduction O
of O
succinylcholine O
- O
induced O
myalgia B-Disease
in O
patients O
undergoing O
general O
anesthesia O
for O
gynecological O
surgery O
. O

following O
administration O
of O
these O
agents O
, O
the O
presence O
, O
and O
degree O
of O
fasciculation B-Disease
were O
assessed O
visually O
on O
a O
four O
point O
scale O
by O
one O
investigator O
who O
was O
blinded O
to O
the O
drug O
administered O
. O

twenty O
- O
four O
hours O
later O
, O
any O
myalgia B-Disease
experienced O
was O
assessed O
according O
to O
a O
structured O
questionaire O
and O
graded O
by O
a O
four O
point O
scale O
by O
one O
investigator O
blinded O
to O
the O
intraoperative O
management O
. O

the O
results O
indicate O
that O
muscle B-Disease
fasciculation I-Disease
was O
not O
found O
in O
group O
pr O
while O
the O
patients O
in O
group O
ls O
had O
a O
lower O
incidence O
of O
muscle B-Disease
fasciculation I-Disease
than O
those O
in O
group O
ps O
( O
p O
< O
0 O
. O

1 O
) O
. O

at O
24 O
h O
, O
the O
incidence O
of O
myalgia B-Disease
was O
higher O
in O
group O
ps O
than O
in O
group O
ls O
and O
pr O
( O
p O
< O
0 O
. O

5 O
) O
. O

a O
correlation O
was O
not O
found O
between O
the O
incidence O
of O
myalgia B-Disease
and O
the O
occurrence O
of O
muscle B-Disease
fasciculation I-Disease
. O

in O
conclusion O
, O
where O
succinylcholine O
is O
used O
, O
lidocaine O
is O
proven O
to O
be O
the O
useful O
pretreatment O
agent O
for O
the O
reduction O
of O
postoperative B-Disease
myalgia I-Disease
. O

reduced O
sodium O
channel O
density O
, O
altered O
voltage O
dependence O
of O
inactivation O
, O
and O
increased O
susceptibility O
to O
seizures B-Disease
in O
mice O
lacking O
sodium O
channel O
beta O
2 O
- O
subunits O
. O

beta2 O
( O
- O
/ O
- O
) O
mice O
displayed O
increased O
susceptibility O
to O
seizures B-Disease
, O
as O
indicated O
by O
reduced O
latency O
and O
threshold O
for O
pilocarpine O
- O
induced O
seizures B-Disease
, O
but O
seemed O
normal O
in O
other O
neurological O
tests O
. O

acute B-Disease
liver I-Disease
failure I-Disease
with O
concurrent O
bupropion O
and O
carbimazole O
therapy O
. O

objective O
: O
to O
report O
a O
case O
of O
fatal O
liver B-Disease
failure I-Disease
possibly O
associated O
with O
concurrent O
use O
of O
bupropion O
and O
carbimazole O
. O

case O
summary O
: O
a O
41 O
- O
year O
- O
old O
chinese O
man O
with O
a O
history O
of O
hyperthyroidism B-Disease
had O
been O
treated O
with O
carbimazole O
and O
propranolol O
for O
the O
past O
5 O
years O
. O

he O
developed O
acute B-Disease
liver I-Disease
failure I-Disease
with O
rapid O
deterioration O
of O
renal O
function O
. O

liver O
biopsy O
showed O
evidence O
of O
nonspecific O
drug B-Disease
- I-Disease
induced I-Disease
acute I-Disease
liver I-Disease
injury I-Disease
. O

his O
condition O
was O
further O
complicated O
by O
sepsis B-Disease
and O
coagulopathy B-Disease
. O

the O
likelihood O
that O
bupropion O
induced O
hepatotoxicity B-Disease
in O
our O
patient O
was O
possible O
, O
based O
on O
the O
naranjo O
probability O
scale O
. O

discussion O
: O
although O
there O
is O
increasing O
evidence O
of O
hepatotoxicity B-Disease
induced O
by O
bupropion O
, O
this O
is O
the O
first O
case O
of O
fatality O
that O
could O
have O
resulted O
from O
acute B-Disease
liver I-Disease
failure I-Disease
in O
a O
patient O
receiving O
bupropion O
while O
on O
concomitant O
treatment O
with O
carbimazole O
. O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
the O
possibility O
of O
acute B-Disease
liver I-Disease
insult I-Disease
induced O
by O
bupropion O
given O
concurrently O
with O
other O
hepatotoxic B-Disease
drugs O
. O

the O
etiology O
of O
pyeloureteritis B-Disease
cystica I-Disease
has O
long O
been O
attributed O
to O
chronic O
infection B-Disease
and O
inflammation B-Disease
. O

there O
is O
no O
evidence O
of O
antecedent O
or O
concurrent O
infection B-Disease
in O
this O
patient O
. O

the O
disease O
occurred O
subsequent O
to O
the O
initiation O
of O
heparin O
therapy O
for O
suspected O
pelvic O
thrombophlebitis B-Disease
and O
cleared O
rapidly O
subsequent O
to O
its O
discontinuation O
. O

the O
rate O
of O
resolution O
of O
the O
radiographic O
findings O
may O
be O
helpful O
in O
distinguishing O
between O
TRUE O
pyeloureteritis B-Disease
cystica I-Disease
and O
submucosal B-Disease
hemorrhage I-Disease
. O

nephrotoxic B-Disease
effects O
in O
high O
- O
risk O
patients O
undergoing O
angiography O
. O

background O
: O
the O
use O
of O
iodinated O
contrast O
medium O
can O
result O
in O
nephropathy B-Disease
. O

whether O
iso O
- O
osmolar O
contrast O
medium O
is O
less O
nephrotoxic B-Disease
than O
low O
- O
osmolar O
contrast O
medium O
in O
high O
- O
risk O
patients O
is O
uncertain O
. O

methods O
: O
we O
conducted O
a O
randomized O
, O
double O
- O
blind O
, O
prospective O
, O
multicenter O
study O
comparing O
the O
nephrotoxic B-Disease
effects O
of O
an O
iso O
- O
osmolar O
, O
dimeric O
, O
nonionic O
contrast O
medium O
, O
iodixanol O
, O
with O
those O
of O
a O
low O
- O
osmolar O
, O
nonionic O
, O
monomeric O
contrast O
medium O
, O
iohexol O
. O

the O
study O
involved O
129 O
patients O
with O
diabetes B-Disease
with O
serum O
creatinine O
concentrations O
of O
1 O
. O

5 O
to O
3 O
. O

5 O
mg O
per O
deciliter O
who O
underwent O
coronary O
or O
aortofemoral O
angiography O
. O

conclusions O
: O
nephropathy B-Disease
induced O
by O
contrast O
medium O
may O
be O
less O
likely O
to O
develop O
in O
high O
- O
risk O
patients O
when O
iodixanol O
is O
used O
rather O
than O
a O
low O
- O
osmolar O
, O
nonionic O
contrast O
medium O
. O

protective O
effect O
of O
edaravone O
against O
streptomycin O
- O
induced O
vestibulotoxicity B-Disease
in O
the O
guinea O
pig O
. O

this O
study O
investigated O
alleviation O
of O
streptomycin O
- O
induced O
vestibulotoxicity B-Disease
by O
edaravone O
in O
guinea O
pigs O
. O

edaravone O
, O
a O
free O
radical O
scavenger O
, O
has O
potent O
free O
radical O
quenching O
action O
and O
is O
used O
in O
clinical O
practice O
to O
treat O
cerebral B-Disease
infarction I-Disease
. O

these O
results O
suggest O
that O
edaravone O
suppresses O
streptomycin O
- O
induced O
vestibulotoxicity B-Disease
. O

levodopa O
- O
induced O
oromandibular O
dystonia B-Disease
in O
progressive B-Disease
supranuclear I-Disease
palsy I-Disease
. O

levodopa O
- O
induced O
dyskinesias B-Disease
have O
been O
reported O
in O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
and O
multiple B-Disease
system I-Disease
atrophy I-Disease
. O

cranial O
dystonias B-Disease
are O
rare O
in O
patients O
with O
progressive B-Disease
supranuclear I-Disease
palsy I-Disease
( O
psp B-Disease
) O
. O

in O
this O
report O
we O
describe O
an O
unusual O
case O
of O
reversible O
levodopa O
- O
induced O
oromandibular B-Disease
dystonia I-Disease
( O
omd B-Disease
) O
in O
a O
psp B-Disease
patient O
to O
highlight O
the O
importance O
of O
recognizing O
this O
drug O
related O
complication O
in O
the O
management O
of O
psp B-Disease
, O
and O
discuss O
the O
possible O
underlying O
pathophysiology O
. O

case O
report O
: O
dexatrim O
( O
phenylpropanolamine O
) O
as O
a O
cause O
of O
myocardial B-Disease
infarction I-Disease
. O

its O
use O
has O
been O
associated O
with O
hypertensive B-Disease
episodes O
and O
hemorrhagic B-Disease
strokes I-Disease
in O
younger O
women O
. O

several O
reports O
have O
linked O
the O
abuse O
of O
ppa O
with O
myocardial B-Disease
injury I-Disease
, O
especially O
when O
overdose B-Disease
is O
involved O
. O

we O
report O
here O
the O
first O
case O
of O
dexatrim O
( O
ppa O
) O
- O
induced O
myocardial B-Disease
injury I-Disease
in O
a O
young O
woman O
who O
was O
using O
it O
at O
recommended O
doses O
for O
weight O
control O
. O

in O
addition O
, O
we O
review O
the O
7 O
other O
cases O
of O
ppa O
related O
myocardial B-Disease
injury I-Disease
that O
have O
been O
reported O
so O
far O
. O

differential O
diagnosis O
of O
high O
serum O
creatine O
kinase O
levels O
in O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
. O

we O
report O
the O
clinical O
and O
bioptic O
findings O
for O
a O
57 O
- O
year O
- O
old O
woman O
with O
severe O
chloroquine O
- O
induced O
myopathy B-Disease
. O

since O
1989 O
, O
she O
had O
been O
suffering O
from O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
( O
sle B-Disease
) O
with O
renal B-Disease
involvement I-Disease
and O
undergone O
periods O
of O
treatment O
with O
azathioprine O
and O
cyclophosphamide O
. O

additional O
therapy O
with O
chloroquine O
( O
cq O
) O
was O
started O
because O
of O
arthralgia B-Disease
. O

myositis B-Disease
was O
suspected O
, O
and O
the O
patient O
was O
treated O
with O
steroids O
. O

the O
ck O
increase O
persisted O
, O
however O
, O
and O
she O
developed O
progressive O
muscular B-Disease
weakness I-Disease
and O
muscular B-Disease
atrophy I-Disease
. O

the O
neurological O
and O
electrophysiological O
findings O
were O
not O
typical O
of O
myositis B-Disease
. O

thus O
, O
muscle O
biopsy O
of O
the O
deltoid O
muscle O
was O
performed O
in O
order O
to O
exclude O
polymyositis B-Disease
or O
toxic O
myopathy B-Disease
. O

as O
it O
revealed O
chloroquine O
- O
induced O
myopathy B-Disease
, O
medication O
was O
stopped O
. O

discriminating O
between O
primary O
sle B-Disease
- O
induced O
affection B-Disease
of I-Disease
the I-Disease
musculoskeletal I-Disease
system I-Disease
and O
drug O
- O
induced O
side O
effects O
is O
important O
for O
appropriate O
treatment O
of O
sle B-Disease
patients O
. O

seizure B-Disease
associated O
with O
sleep B-Disease
deprivation I-Disease
and O
sustained O
- O
release O
bupropion O
. O

this O
case O
report O
describes O
a O
generalized O
seizure B-Disease
associated O
with O
sustained O
- O
release O
bupropion O
use O
and O
sleep B-Disease
deprivation I-Disease
. O

after O
5 O
weeks O
of O
bupropion O
use O
, O
the O
subject O
experienced O
a O
generalized O
tonic O
clonic O
seizure B-Disease
after O
staying O
up O
nearly O
all O
night O
packing O
and O
moving O
to O
a O
new O
residence O
. O

the O
patient O
had O
no O
other O
risk O
factors O
for O
seizures B-Disease
. O

we O
suggest O
that O
sleep B-Disease
deprivation I-Disease
may O
add O
to O
the O
risk O
of O
bupropion O
- O
associated O
seizures B-Disease
. O

postoperative B-Disease
myalgia I-Disease
after O
succinylcholine O
: O
no O
evidence O
for O
an O
inflammatory O
origin O
. O

a O
common O
side O
effect O
associated O
with O
succinylcholine O
is O
postoperative B-Disease
myalgia I-Disease
. O

the O
pathogenesis O
of O
this O
myalgia B-Disease
is O
still O
unclear O
; O
inflammation B-Disease
has O
been O
suggested O
but O
without O
convincing O
evidence O
. O

we O
designed O
the O
present O
study O
to O
investigate O
whether O
an O
inflammatory O
reaction O
contributes O
to O
this O
myalgia B-Disease
. O

the O
incidence O
and O
severity O
of O
succinylcholine O
- O
associated O
myalgia B-Disease
was O
determined O
in O
64 O
patients O
pretreated O
with O
saline O
or O
dexamethasone O
before O
succinylcholine O
( O
n O
= O
32 O
for O
each O
) O
. O

incidence O
and O
severity O
of O
myalgia B-Disease
did O
not O
differ O
significantly O
between O
the O
two O
groups O
: O
15 O
patients O
in O
the O
dexamethasone O
group O
complained O
of O
myalgia B-Disease
compared O
with O
18 O
patients O
in O
the O
saline O
group O
, O
and O
severe O
myalgia B-Disease
was O
reported O
by O
five O
patients O
and O
three O
patients O
, O
respectively O
( O
not O
significant O
) O
. O

at O
48 O
h O
after O
surgery O
, O
12 O
patients O
in O
both O
groups O
still O
suffered O
from O
myalgia B-Disease
( O
not O
significant O
) O
. O

in O
addition O
, O
interleukin O
- O
6 O
( O
il O
- O
6 O
) O
as O
an O
early O
marker O
of O
inflammation B-Disease
was O
assessed O
in O
a O
subgroup O
of O
10 O
patients O
pretreated O
with O
saline O
. O

we O
found O
an O
increase O
of O
il O
- O
6 O
for O
only O
three O
patients O
, O
but O
only O
one O
patient O
reported O
myalgia B-Disease
; O
no O
relationship O
between O
myalgia B-Disease
and O
the O
increase O
of O
il O
- O
6 O
was O
found O
. O

in O
conclusion O
, O
there O
is O
no O
evidence O
for O
an O
inflammatory O
origin O
of O
succinylcholine O
- O
associated O
myalgia B-Disease
. O

implications O
: O
administration O
of O
dexamethasone O
before O
succinylcholine O
was O
not O
effective O
in O
decreasing O
the O
incidence O
or O
the O
severity O
of O
succinylcholine O
- O
induced O
postoperative B-Disease
myalgia I-Disease
. O

furthermore O
, O
there O
was O
no O
significant O
relationship O
between O
postoperative B-Disease
myalgia I-Disease
and O
time O
course O
of O
interleukin O
- O
6 O
concentrations O
, O
a O
marker O
of O
inflammation B-Disease
. O

pretreatment O
with O
dexamethasone O
is O
not O
justified O
to O
prevent O
postoperative B-Disease
myalgia I-Disease
after O
succinylcholine O
. O

effect O
of O
lindane O
on O
hepatic O
and O
brain O
cytochrome O
p450s O
and O
influence O
of O
p450 O
modulation O
in O
lindane O
induced O
neurotoxicity B-Disease
. O

induction O
studies O
have O
further O
shown O
that O
while O
pretreatment O
of O
3 O
- O
methylcholanthrene O
( O
mc O
) O
, O
an O
inducer O
of O
p4501a1 O
/ O
1a2 O
, O
did O
not O
produce O
any O
significant O
effect O
in O
the O
incidence O
of O
lindane O
induced O
convulsions B-Disease
, O
pretreatment O
with O
phenobarbital O
( O
pb O
) O
, O
an O
inducer O
of O
p450 O
2b1 O
/ O
2b2 O
or O
ethanol O
, O
an O
inducer O
of O
p450 O
2E+01 O
catalysed O
reactions O
, O
significantly O
increased O
the O
incidence O
of O
lindane O
induced O
convulsions B-Disease
. O

similarly O
, O
when O
the O
p450 O
- O
mediated O
metabolism O
of O
lindane O
was O
blocked O
by O
cobalt O
chloride O
incidence O
of O
convulsions B-Disease
was O
increased O
in O
animals O
treated O
with O
lindane O
indicating O
that O
lindane O
per O
se O
or O
its O
metabolites O
formed O
by O
pb O
or O
ethanol O
inducible O
p450 O
isoenzymes O
are O
involved O
in O
its O
neurobehavioral O
toxicity B-Disease
. O

absolute O
and O
attributable O
risk O
of O
venous B-Disease
thromboembolism I-Disease
in O
women O
on O
combined O
cyproterone O
acetate O
and O
ethinylestradiol O
. O

objective O
: O
to O
achieve O
absolute O
risk O
estimates O
of O
venous B-Disease
thromboembolism I-Disease
( O
vte B-Disease
) O
among O
women O
on O
cyproterone O
acetate O
plus O
ethinylestradiol O
( O
cpa O
/ O
ee O
) O
, O
and O
among O
women O
on O
combined O
oral O
contraceptives O
( O
cocs O
) O
. O

methods O
: O
from O
the O
danish O
national O
register O
of O
patients O
( O
nrp O
) O
, O
1996 O
to O
1998 O
, O
the O
records O
of O
1 O
. O

1 O
million O
danish O
women O
, O
ages O
15 O
to O
44 O
years O
, O
were O
searched O
for O
evidence O
of O
vte B-Disease
. O

results O
: O
during O
the O
time O
frame O
of O
the O
study O
, O
330 O
women O
were O
found O
to O
have O
had O
vte B-Disease
while O
on O
cocs O
. O

the O
corresponding O
absolute O
risk O
of O
vte B-Disease
was O
3 O
. O

4 O
( O
range O
, O
3 O
. O

1 O
- O
3 O
. O

8 O
) O
per O
10 O
0 O
women O
years O
among O
the O
women O
on O
cocs O
, O
4 O
. O

2 O
( O
range O
, O
3 O
. O

2 O
- O
5 O
. O

2 O
) O
per O
10 O
0 O
women O
years O
among O
women O
on O
levonorgestrel O
- O
containing O
cocs O
, O
and O
3 O
. O

1 O
( O
range O
, O
1 O
. O

3 O
- O
4 O
. O

9 O
) O
per O
10 O
0 O
women O
years O
among O
the O
women O
on O
cpa O
/ O
ee O
. O

conclusion O
: O
our O
results O
suggest O
the O
absolute O
risk O
of O
vte B-Disease
among O
danish O
women O
on O
cocs O
is O
similar O
to O
that O
among O
women O
taking O
cpa O
/ O
ee O
. O

background O
: O
analysis O
of O
the O
literature O
for O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
nsaids O
) O
suggests O
that O
a O
low O
incidence O
of O
developmental B-Disease
anomalies I-Disease
occurs O
in O
rats O
given O
nsaids O
on O
specific O
days O
during O
organogenesis O
. O

aspirin O
( O
acetylsalicylic O
acid O
[ O
asa O
] O
) O
, O
an O
irreversible O
cyclooxygenase O
1 O
and O
2 O
inhibitor O
, O
induces O
developmental B-Disease
anomalies I-Disease
when O
administered O
to O
wistar O
rats O
on O
gestational O
day O
( O
gd O
) O
9 O
, O
10 O
, O
or O
11 O
( O
kimmel O
ca O
, O
wilson O
jg O
, O
schumacher O
hj O
. O

teratology O
4 O
: O
15 O
- O
24 O
, O
1971 O
) O
. O

objectives O
of O
the O
current O
study O
were O
to O
compare O
results O
between O
sprague O
- O
dawley O
( O
sd O
) O
and O
wistar O
strains O
when O
asa O
is O
administered O
on O
gd O
9 O
, O
10 O
, O
or O
11 O
; O
to O
compare O
the O
malformation O
patterns O
following O
single O
and O
multiple O
dosings O
during O
organogenesis O
in O
sd O
rats O
; O
and O
to O
test O
the O
hypothesis O
that O
maternal O
gastrointestinal B-Disease
toxicity I-Disease
confounds O
the O
detection O
of O
low O
incidence O
malformations B-Disease
with O
asa O
when O
a O
multiple O
dosing O
paradigm O
is O
used O
. O

results O
: O
the O
literature O
evaluation O
suggested O
that O
nsaids O
induce O
ventricular B-Disease
septal I-Disease
defects I-Disease
( O
vsds B-Disease
) O
and O
midline B-Disease
defects I-Disease
( O
mds B-Disease
) O
in O
rats O
and O
diaphragmatic B-Disease
hernia I-Disease
( O
dh B-Disease
) O
, O
mds B-Disease
, O
and O
vsds B-Disease
in O
rabbits O
( O
cook O
jc O
et O
al O
. O

, O
2003 O
) O
; O
hence O
, O
the O
present O
study O
focused O
on O
these O
malformations B-Disease
, O
even O
though O
asa O
induces O
several O
other O
low O
- O
incidence O
malformations B-Disease
. O

in O
single O
dose O
studies O
, O
dh B-Disease
, O
md B-Disease
, O
and O
vsd B-Disease
were O
induced O
on O
gds O
9 O
and O
10 O
. O

vsd B-Disease
also O
was O
noted O
following O
treatment O
on O
gd O
11 O
. O

in O
contrast O
, O
dh B-Disease
and O
md B-Disease
were O
noted O
in O
the O
multiple O
dose O
study O
design O
only O
in O
the O
high O
- O
dose O
group O
, O
and O
vsd B-Disease
was O
noted O
across O
all O
dose O
groups O
. O

conclusions O
: O
high O
concordance O
in O
major O
developmental B-Disease
anomalies I-Disease
between O
wistar O
and O
sd O
rats O
were O
noted O
with O
the O
exception O
of O
vsd B-Disease
in O
the O
sd O
rats O
and O
hydrocephalus B-Disease
in O
the O
wistar O
rats O
. O

variations O
and O
malformations B-Disease
were O
similar O
when O
asa O
was O
administered O
as O
a O
single O
dose O
or O
during O
the O
period O
of O
organogenesis O
( O
gds O
6 O
to O
17 O
) O
. O

it O
was O
also O
evident O
that O
, O
by O
titrating O
the O
dose O
to O
achieve O
a O
maximum O
tolerated O
dose O
, O
malformations B-Disease
that O
normally O
occur O
at O
low O
incidence O
, O
as O
reported O
from O
previous O
single O
dose O
studies O
, O
could O
also O
be O
induced O
with O
asa O
given O
at O
multiple O
doses O
. O

the O
most O
common O
adverse O
effects O
were O
nausea B-Disease
and O
vomiting B-Disease
in O
the O
flumazenil O
group O
and O
nausea B-Disease
and O
injection O
- O
site O
pain B-Disease
in O
the O
placebo O
group O
. O

methylphenidate O
- O
induced O
obsessive B-Disease
- I-Disease
compulsive I-Disease
symptoms I-Disease
in O
an O
elderly O
man O
. O

an O
82 O
- O
year O
- O
old O
man O
with O
treatment B-Disease
- I-Disease
resistant I-Disease
depression I-Disease
and O
early O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
was O
started O
on O
methylphenidate O
. O

significant O
obsessive B-Disease
- I-Disease
compulsive I-Disease
behavior I-Disease
ensued O
but O
diminished O
over O
several O
weeks O
when O
methylphenidate O
was O
replaced O
by O
fluvoxamine O
. O

the O
patient O
had O
no O
prior O
psychiatric B-Disease
history O
, O
but O
he O
had O
a O
sister O
with O
obsessive B-Disease
- I-Disease
compulsive I-Disease
disorder I-Disease
. O

ciprofloxacin O
- O
induced O
acute O
interstitial B-Disease
nephritis I-Disease
and O
autoimmune B-Disease
hemolytic I-Disease
anemia I-Disease
. O

ciprofloxacin O
has O
been O
associated O
with O
several O
side O
effects O
including O
interstitial B-Disease
nephritis I-Disease
and O
hemolytic B-Disease
anemia I-Disease
. O

in O
this O
report O
, O
we O
describe O
a O
case O
of O
ciprofloxacin O
- O
induced O
interstitial B-Disease
nephritis I-Disease
and O
autoimmune B-Disease
hemolytic I-Disease
anemia I-Disease
. O

hemolytic B-Disease
anemia I-Disease
improved O
after O
stopping O
the O
drug O
and O
initiation O
of O
steroid O
therapy O
. O

unfortunately O
, O
acute O
interstitial B-Disease
nephritis I-Disease
was O
irreversible O
and O
the O
patient O
developed O
end B-Disease
- I-Disease
stage I-Disease
renal I-Disease
disease I-Disease
. O

potential O
deleterious O
effect O
of O
furosemide O
in O
radiocontrast O
nephropathy B-Disease
. O

the O
purpose O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
furosemide O
in O
addition O
to O
intravenous O
fluids O
in O
the O
prevention O
of O
radiocontrast O
nephropathy B-Disease
. O

18 O
patients O
, O
referred O
to O
a O
radiocontrast O
study O
, O
considered O
at O
risk O
because O
of O
preexisting O
renal B-Disease
insufficiency I-Disease
, O
were O
enrolled O
in O
a O
prospective O
, O
randomized O
, O
controlled O
trial O
, O
performed O
at O
the O
secondary O
care O
center O
of O
a O
1 O
, O
100 O
- O
bed O
private O
university O
hospital O
. O

renal B-Disease
function I-Disease
significantly I-Disease
deteriorated I-Disease
in O
the O
group O
pretreated O
with O
furosemide O
( O
p O
< O
0 O
. O

5 O
by O
anova O
) O
, O
with O
a O
rise O
in O
serum O
creatinine O
from O
145 O
+ O
/ O
- O
13 O
to O
182 O
+ O
/ O
- O
16 O
mumol O
/ O
l O
at O
24 O
h O
, O
while O
no O
change O
occurred O
in O
the O
control O
group O
( O
from O
141 O
+ O
/ O
- O
6 O
to O
142 O
+ O
/ O
- O
7 O
mumol O
/ O
l O
) O
. O

renal B-Disease
failure I-Disease
was O
associated O
with O
weight B-Disease
loss I-Disease
in O
the O
furosemide O
- O
treated O
group O
. O

furosemide O
may O
be O
deleterious O
in O
the O
prevention O
of O
radiocontrast O
nephropathy B-Disease
. O

progestational O
agents O
and O
blood B-Disease
coagulation I-Disease
. O

thromboembolic B-Disease
and O
other O
complications O
of O
oral O
contraceptive O
therapy O
in O
relationship O
to O
pretreatment O
levels O
of O
blood B-Disease
coagulation I-Disease
factors O
: O
summary O
report O
of O
a O
ten O
- O
year O
study O
. O

significant O
increases O
in O
certain O
factors O
of O
the O
blood B-Disease
coagulation I-Disease
and O
fibrinolysin O
systems O
( O
factors O
i O
, O
ii O
, O
vii O
, O
viii O
, O
ix O
, O
and O
x O
and O
plasminogen O
) O
were O
observed O
in O
the O
treated O
groups O
. O

all O
four O
had O
an O
abnormal O
blood B-Disease
coagulation I-Disease
profile O
, O
suggesting O
nan O
hypercoagulability B-Disease
nan O
before O
initiation O
of O
therapy O
. O

one O
of O
these O
patients O
developed O
a O
myocardial B-Disease
infarction I-Disease
before O
receiving O
any O
medication O
, O
shortly O
after O
the O
base O
- O
line O
values O
were O
obtained O
. O

one O
patient O
developed O
retinopathy B-Disease
19 O
months O
after O
she O
began O
therapy O
, O
and O
another O
developed O
thrombophlebitis B-Disease
after O
27 O
months O
of O
therapy O
. O

the O
fourth O
patient O
developed O
thrombophlebitis B-Disease
14 O
days O
after O
initiation O
of O
contraceptive O
therapy O
. O

previous O
studies O
suggested O
the O
possiblility O
of O
increased O
propensity O
for O
thromboembolic B-Disease
episodes I-Disease
in O
patients O
possessing O
the O
a O
antigen O
. O

orthostatic B-Disease
hypotension I-Disease
occurs O
following O
alpha O
2 O
- O
adrenoceptor O
blockade O
in O
chronic O
prazosin O
- O
pretreated O
conscious O
spontaneously O
hypertensive B-Disease
rats O
. O

studies O
were O
performed O
to O
evaluate O
whether O
chronic O
prazosin O
treatment O
alters O
the O
alpha O
2 O
- O
adrenoceptor O
function O
for O
orthostatic O
control O
of O
arterial O
blood O
pressure O
in O
conscious O
spontaneously O
hypertensive B-Disease
rats O
( O
shr O
) O
. O

orthostatic B-Disease
hypotension I-Disease
was O
determined O
by O
the O
average O
decrease O
( O
% O
) O
in O
mean O
arterial O
pressure O
( O
map O
femoral O
) O
over O
the O
60 O
- O
s O
tilt O
period O
. O

however O
, O
the O
head O
- O
up O
tilt O
induced O
orthostatic B-Disease
hypotension I-Disease
in O
the O
shr O
treated O
with O
prazosin O
( O
- O
16 O
% O
map O
, O
n O
= O
6 O
) O
, O
but O
not O
in O
the O
shr O
treated O
with O
rauwolscine O
( O
less O
than O
+ O
2 O
% O
map O
, O
n O
= O
6 O
) O
. O

head O
- O
up O
tilts O
in O
these O
rats O
did O
not O
produce O
orthostatic B-Disease
hypotension I-Disease
when O
performed O
either O
prior O
to O
or O
after O
acute O
dosing O
of O
prazosin O
( O
0 O
. O

1 O
mg O
kg O
- O
1 O
i O
. O

p O
. O

) O
. O

the O
pressor O
responses O
and O
bradycardia B-Disease
to O
the O
alpha O
1 O
- O
agonist O
cirazoline O
( O
0 O
. O

6 O
and O
2 O
micrograms O
kg O
- O
1 O
i O
. O

v O
. O

) O
, O
the O
alpha O
2 O
- O
agonist O
abbott O
- O
53693 O
( O
1 O
and O
3 O
micrograms O
kg O
- O
1 O
i O
. O

v O
. O

) O
, O
and O
noradrenaline O
( O
0 O
. O

1 O
and O
1 O
. O

0 O
micrograms O
kg O
- O
1 O
i O
. O

v O
. O

) O
were O
determined O
in O
conscious O
shr O
with O
and O
without O
chronic O
prazosin O
pretreatment O
. O

both O
the O
pressor O
and O
bradycardia B-Disease
effects O
of O
cirazoline O
were O
abolished O
in O
chronic O
prazosin O
treated O
shr O
( O
n O
= O
4 O
) O
as O
compared O
to O
the O
untreated O
shr O
( O
n O
= O
4 O
) O
. O

on O
the O
other O
hand O
, O
the O
pressor O
effects O
of O
abbott O
- O
53693 O
were O
similar O
in O
both O
groups O
of O
shr O
, O
but O
the O
accompanying O
bradycardia B-Disease
was O
greater O
in O
shr O
with O
chronic O
prazosin O
treatment O
than O
without O
such O
treatment O
. O

furthermore O
, O
the O
bradycardia B-Disease
that O
accompanied O
the O
noradrenaline O
- O
induced O
pressor O
effect O
in O
shr O
was O
similar O
with O
and O
without O
chronic O
prazosin O
treatment O
despite O
a O
47 O
- O
71 O
% O
reduction O
of O
the O
pressor O
effect O
in O
chronic O
alpha O
1 O
- O
receptor O
blocked O
shr O
. O

( O
abstract O
truncated O
at O
400 O
words O
) O
hemolytic B-Disease
- I-Disease
uremic I-Disease
syndrome I-Disease
associated O
with O
ingestion O
of O
quinine O
. O

hemolytic B-Disease
- I-Disease
uremic I-Disease
syndrome I-Disease
following O
quinine O
ingestion O
is O
a O
newly O
described O
phenomenon O
, O
with O
just O
two O
previous O
descriptions O
of O
4 O
cases O
in O
the O
literature O
. O

quinine O
- O
associated O
hemolytic B-Disease
- I-Disease
uremic I-Disease
syndrome I-Disease
probably O
occurs O
more O
often O
than O
is O
recognized O
. O

amnestic B-Disease
syndrome I-Disease
associated O
with O
propranolol O
toxicity B-Disease
: O
a O
case O
report O
. O

an O
elderly O
woman O
developed O
an O
alzheimer B-Disease
- O
like O
subacute O
dementia B-Disease
as O
a O
result O
of O
propranolol O
toxicity B-Disease
. O

there O
is O
evidence O
that O
cerebral O
reactions O
to O
drug O
toxicity B-Disease
can O
exhibit O
patterns O
that O
suggest O
highly O
selective O
involvement O
of O
functional O
subdivisions O
of O
the O
brain O
. O

cefotetan O
- O
induced O
immune O
hemolytic B-Disease
anemia I-Disease
. O

immune O
hemolytic B-Disease
anemia I-Disease
due O
to O
a O
drug O
- O
adsorption O
mechanism O
has O
been O
described O
primarily O
in O
patients O
receiving O
penicillins O
and O
first O
- O
generation O
cephalosporins O
. O

we O
describe O
a O
patient O
who O
developed O
anemia B-Disease
while O
receiving O
intravenous O
cefotetan O
. O

these O
observations O
, O
in O
conjunction O
with O
clinical O
and O
laboratory O
evidence O
of O
extravascular O
hemolysis B-Disease
, O
are O
consistent O
with O
drug O
- O
induced O
hemolytic B-Disease
anemia I-Disease
, O
possibly O
involving O
both O
drug O
- O
adsorption O
and O
autoantibody O
formation O
mechanisms O
. O

use O
of O
dexamethasone O
with O
mesna O
for O
the O
prevention O
of O
ifosfamide O
- O
induced O
hemorrhagic B-Disease
cystitis I-Disease
. O

aim O
: O
hemorrhagic B-Disease
cystitis I-Disease
( O
hc B-Disease
) O
is O
a O
limiting O
side O
- O
effect O
of O
chemotherapy O
with O
ifosfamide O
( O
ifs O
) O
. O

in O
the O
study O
presented O
here O
, O
we O
investigated O
the O
use O
of O
dexamethasone O
in O
combination O
with O
mesna O
for O
the O
prevention O
of O
ifs O
- O
induced O
hc B-Disease
. O

cystitis B-Disease
was O
evaluated O
24 O
h O
after O
its O
induction O
by O
the O
changes O
in O
bladder O
wet O
weight O
and O
by O
macroscopic O
and O
microscopic O
analysis O
. O

conclusion O
: O
dexamethasone O
in O
combination O
with O
mesna O
was O
efficient O
in O
blocking O
ifs O
- O
induced O
hc B-Disease
. O

however O
, O
the O
replacement O
of O
last O
two O
doses O
of O
mesna O
with O
saline O
or O
all O
of O
the O
mesna O
doses O
with O
dexamethasone O
did O
not O
prevent O
hc B-Disease
. O

all O
- O
trans O
- O
retinoic O
acid O
- O
induced O
erythema B-Disease
nodosum I-Disease
in O
patients O
with O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
. O

erythema B-Disease
nodosum I-Disease
associated O
with O
all O
- O
trans O
- O
retinoic O
acid O
( O
atra O
) O
for O
acute B-Disease
promyelocytic I-Disease
leukemia I-Disease
( O
apl B-Disease
) O
is O
very O
rare O
. O

we O
describe O
four O
patients O
with O
classic O
apl B-Disease
who O
developed O
erythema B-Disease
nodosum I-Disease
during O
atra O
therapy O
. O

fever B-Disease
and O
subsequent O
multiple O
painful B-Disease
erythematous B-Disease
nodules I-Disease
over O
extremities O
developed O
on O
d11 O
, O
d16 O
, O
d17 O
, O
and O
d19 O
, O
respectively O
, O
after O
atra O
therapy O
. O

the O
skin O
biopsy O
taken O
from O
each O
patient O
was O
consistent O
with O
erythema B-Disease
nodosum I-Disease
. O

fever B-Disease
subsided O
rapidly O
and O
the O
skin O
lesions O
regressed O
completely O
. O

atra O
seemed O
to O
be O
the O
most O
possible O
etiology O
of O
erythema B-Disease
nodosum I-Disease
in O
our O
patients O
. O

short O
- O
term O
use O
of O
steroid O
is O
very O
effective O
in O
atra O
- O
induced O
erythema B-Disease
nodosum I-Disease
. O

loreclezole O
( O
5 O
mg O
/ O
kg O
) O
exerted O
a O
significant O
protective O
action O
in O
amygdala O
- O
kindled O
rats O
, O
reducing O
both O
seizure B-Disease
and O
afterdischarge O
durations O
. O

mitochondrial O
dna O
and O
its O
respiratory O
chain O
products O
are O
defective O
in O
doxorubicin O
nephrosis B-Disease
. O

background O
: O
doxorubicin O
induces O
a O
self O
- O
perpetuating O
nephropathy B-Disease
characterized O
by O
early O
glomerular B-Disease
and I-Disease
late I-Disease
- I-Disease
onset I-Disease
tubular I-Disease
lesions I-Disease
in O
rats O
. O

we O
investigated O
the O
potential O
role O
of O
mitochondrial B-Disease
injury I-Disease
in O
the O
onset O
of O
these O
lesions O
. O

glomerular B-Disease
and I-Disease
tubular I-Disease
injury I-Disease
was O
monitored O
and O
correlated O
to O
the O
activity O
or O
expression O
of O
respiratory O
chain O
components O
. O

results O
: O
the O
' O
long O
- O
term O
' O
group O
had O
significant O
glomerular B-Disease
and I-Disease
tubular I-Disease
lesions I-Disease
, O
depressed O
activities O
of O
mtdna O
- O
encoded O
nadh O
dehydrogenase O
and O
cytochrome O
- O
c O
oxidase O
( O
cox O
) O
and O
increased O
citrate O
synthase O
activity O
. O

in O
' O
short O
- O
term O
' O
rats O
, O
there O
were O
fewer O
tubular B-Disease
lesions I-Disease
, O
but O
similar O
numbers O
of O
glomerular B-Disease
lesions I-Disease
activity O
. O

among O
all O
animals O
, O
glomerular B-Disease
and I-Disease
tubular I-Disease
injury I-Disease
were O
inversely O
correlated O
with O
mtdna O
levels O
, O
mtdna O
- O
encoded O
respiratory O
chain O
activities O
and O
with O
the O
expression O
of O
the O
mtdna O
- O
encoded O
respiratory O
chain O
subunit O
cox O
- O
i O
. O

conclusions O
: O
these O
results O
suggest O
an O
important O
role O
for O
quantitative O
and O
qualitative O
mtdna O
alterations O
through O
the O
reduction O
of O
mtdna O
- O
encoded O
respiratory O
chain O
function O
and O
induction O
of O
superoxide O
in O
doxorubicin O
- O
induced O
renal B-Disease
lesions I-Disease
. O

a O
randomized O
, O
placebo O
- O
controlled O
, O
crossover O
study O
of O
ephedrine O
for O
ssri O
- O
induced O
female O
sexual B-Disease
dysfunction I-Disease
. O

the O
objective O
of O
this O
study O
was O
to O
determine O
whether O
ephedrine O
, O
an O
alpha O
- O
and O
beta O
- O
adrenergic O
agonist O
previously O
shown O
to O
enhance O
genital O
blood O
flow O
in O
women O
, O
has O
beneficial O
effects O
in O
reversing O
antidepressant O
- O
induced O
sexual B-Disease
dysfunction I-Disease
. O

nineteen O
sexually B-Disease
dysfunctional I-Disease
women O
receiving O
either O
fluoxetine O
, O
sertraline O
, O
or O
paroxetine O
participated O
in O
an O
eight O
- O
week O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
study O
of O
the O
effects O
of O
ephedrine O
( O
50 O
mg O
) O
on O
self O
- O
report O
measures O
of O
sexual O
desire O
, O
arousal O
, O
orgasm O
, O
and O
sexual O
satisfaction O
. O

does O
hormone O
therapy O
for O
the O
treatment O
of O
breast B-Disease
cancer I-Disease
have O
a O
detrimental B-Disease
effect I-Disease
on I-Disease
memory I-Disease
and I-Disease
cognition I-Disease
? O
this O
pilot O
study O
examines O
whether O
hormone O
therapy O
for O
breast B-Disease
cancer I-Disease
affects O
cognition O
. O

patients O
participating O
in O
a O
randomised O
trial O
of O
anastrozole O
, O
tamoxifen O
alone O
or O
combined O
( O
atac O
) O
( O
n O
= O
94 O
) O
and O
a O
group O
of O
women O
without O
breast B-Disease
cancer I-Disease
( O
n O
= O
35 O
) O
completed O
a O
battery O
of O
neuropsychological O
measures O
. O

the O
results O
showed O
specific O
impairments O
in O
processing O
speed O
and O
verbal O
memory O
in O
women O
receiving O
hormonal O
therapy O
for O
the O
treatment O
of O
breast B-Disease
cancer I-Disease
. O

doxorubicin O
is O
an O
anti O
- O
tumor B-Disease
agent O
that O
represses O
cardiac O
- O
specific O
gene O
expression O
and O
induces O
myocardial O
cell O
apoptosis O
. O

these O
findings O
demonstrate O
that O
overexpression O
of O
p300 O
protects O
cardiac O
myocytes O
from O
doxorubicin O
- O
induced O
apoptosis O
and O
reduces O
the O
extent O
of O
acute O
heart B-Disease
failure I-Disease
in O
adult O
mice O
in O
vivo O
. O

methimazole O
- O
induced O
cholestatic B-Disease
jaundice I-Disease
. O

a O
43 O
- O
year O
- O
old O
woman O
had O
severe O
jaundice B-Disease
and O
itching B-Disease
1 O
month O
after O
receiving O
methimazole O
( O
10 O
mg O
tid O
) O
and O
propranolol O
( O
20 O
mg O
tid O
) O
for O
treatment O
of O
hyperthyroidism B-Disease
. O

the O
patient O
continued O
treatment O
for O
another O
4 O
days O
after O
the O
appearance O
of O
jaundice B-Disease
until O
she O
finished O
both O
medications O
. O

when O
seen O
at O
the O
emergency O
department O
2 O
weeks O
later O
, O
she O
still O
had O
severe O
icterus B-Disease
, O
pruritus B-Disease
, O
and O
hyperbilirubinemia B-Disease
, O
formed O
mainly O
of O
the O
conjugated O
fraction O
. O

methimazole O
- O
induced O
cholestasis B-Disease
was O
diagnosed O
, O
and O
propranolol O
therapy O
was O
resumed O
. O

in O
rare O
cases O
within O
the O
first O
few O
weeks O
of O
therapy O
, O
this O
drug O
can O
cause O
severe O
and O
reversible O
cholestatic B-Disease
jaundice I-Disease
. O

atrial B-Disease
fibrillation I-Disease
following O
chemotherapy O
for O
stage O
iiie O
diffuse O
large O
b O
- O
cell O
gastric B-Disease
lymphoma I-Disease
in O
a O
patient O
with O
myotonic B-Disease
dystrophy I-Disease
( O
steinert B-Disease
' I-Disease
s I-Disease
disease I-Disease
) O
. O

the O
authors O
describe O
the O
unusual O
association O
between O
diffuse O
b O
- O
cell O
gastric B-Disease
lymphoma I-Disease
and O
myotonic B-Disease
dystrophy I-Disease
, O
the O
most O
common O
form O
of O
adult O
muscular B-Disease
dystrophy I-Disease
, O
and O
sudden O
atrial B-Disease
fibrillation I-Disease
following O
one O
cycle O
of O
doxorubicin O
- O
based O
chemotherapy O
in O
the O
same O
patient O
. O

atrial B-Disease
fibrillation I-Disease
or O
other O
cardiac B-Disease
arrhythmias I-Disease
are O
unusual O
complications O
in O
patients O
treated O
with O
chemotherapy O
. O

the O
cardiac B-Disease
toxicity I-Disease
intrinsically O
associated O
with O
the O
aggressive O
chemotherapy O
employed O
could O
function O
as O
a O
triggering O
factor O
for O
the O
arrhythmia B-Disease
in O
the O
predisposed O
myocardium O
of O
this O
patient O
. O

hypersensitivity B-Disease
immune O
reaction O
as O
a O
mechanism O
for O
dilevalol O
- O
associated O
hepatitis B-Disease
. O

objective O
: O
to O
assess O
lymphocyte O
reactivity O
to O
dilevalol O
and O
to O
serum O
containing O
putative O
ex O
vivo O
dilevalol O
antigens O
or O
metabolites O
in O
a O
case O
of O
dilevalol O
- O
induced O
liver B-Disease
injury I-Disease
. O

patient O
: O
a O
58 O
- O
year O
- O
old O
woman O
with O
a O
clinical O
diagnosis O
of O
dilevalol O
- O
induced O
liver B-Disease
injury I-Disease
. O

conclusions O
: O
the O
methodology O
used O
allowed O
the O
detection O
of O
lymphocyte O
sensitization O
to O
sera O
containing O
ex O
vivo O
- O
prepared O
dilevalol O
antigens O
, O
suggesting O
the O
involvement O
of O
an O
immunologic O
mechanism O
in O
dilevalol O
- O
induced O
liver B-Disease
injury I-Disease
. O

increased O
expression O
and O
apical O
targeting O
of O
renal O
enac O
subunits O
in O
puromycin O
aminonucleoside O
- O
induced O
nephrotic B-Disease
syndrome I-Disease
in O
rats O
. O

nephrotic B-Disease
syndrome I-Disease
is O
often O
accompanied O
by O
sodium O
retention O
and O
generalized O
edema B-Disease
. O

after O
7 O
days O
, O
pan O
treatment O
induced O
significant O
proteinuria B-Disease
, O
hypoalbuminemia B-Disease
, O
decreased O
urinary O
sodium O
excretion O
, O
and O
extensive O
ascites B-Disease
. O

in O
conclusion O
, O
the O
increased O
or O
sustained O
expression O
of O
enac O
subunits O
combined O
with O
increased O
apical O
targeting O
in O
the O
dct2 O
, O
connecting O
tubule O
, O
and O
collecting O
duct O
are O
likely O
to O
play O
a O
role O
in O
the O
sodium O
retention O
associated O
with O
pan O
- O
induced O
nephrotic B-Disease
syndrome I-Disease
. O

a O
resurgence O
of O
interest O
in O
the O
surgical O
treatment O
of O
parkinson B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
pd B-Disease
) O
came O
with O
the O
rediscovery O
of O
posteroventral O
pallidotomy O
by O
laitinen O
in O
1985 O
. O

laitinen O
' O
s O
procedure O
improved O
most O
symptoms O
in O
drug O
- O
resistant O
pd B-Disease
, O
which O
engendered O
wide O
interest O
in O
the O
neurosurgical O
community O
. O

according O
to O
the O
literature O
pallidotomy O
improves O
the O
nan O
on O
nan O
symptoms O
of O
pd B-Disease
, O
such O
as O
dyskinesias B-Disease
, O
as O
well O
as O
the O
nan O
off O
nan O
symptoms O
, O
such O
as O
rigidity B-Disease
, O
bradykinesia B-Disease
, O
and O
on O
- O
off O
fluctuations O
. O

pallidal O
stimulation O
improves O
bradykinesia B-Disease
and O
rigidity B-Disease
to O
a O
minor O
extent O
; O
however O
, O
its O
strength O
seems O
to O
be O
in O
improving O
levodopa O
- O
induced O
dyskinesias B-Disease
. O

stimulation O
often O
produces O
an O
improvement O
in O
the O
hyper B-Disease
- I-Disease
or I-Disease
dyskinetic I-Disease
upper O
limbs O
, O
but O
increases O
the O
nan O
freezing O
nan O
phenomenon O
in O
the O
lower O
limbs O
at O
the O
same O
time O
. O

effects O
of O
the O
cyclooxygenase O
- O
2 O
specific O
inhibitor O
valdecoxib O
versus O
nonsteroidal O
antiinflammatory O
agents O
and O
placebo O
on O
cardiovascular O
thrombotic B-Disease
events O
in O
patients O
with O
arthritis B-Disease
. O

there O
have O
been O
concerns O
that O
the O
risk O
of O
cardiovascular O
thrombotic B-Disease
events O
may O
be O
higher O
with O
cyclooxygenase O
( O
cox O
) O
- O
2 O
- O
specific O
inhibitors O
than O
nonselective O
nonsteroidal O
antiinflammatory O
drugs O
( O
nsaids O
) O
. O

we O
evaluated O
cardiovascular O
event O
data O
for O
valdecoxib O
, O
a O
new O
cox O
- O
2 O
- O
specific O
inhibitor O
in O
approximately O
8000 O
patients O
with O
osteoarthritis B-Disease
and O
rheumatoid B-Disease
arthritis I-Disease
treated O
with O
this O
agent O
in O
randomized O
clinical O
trials O
. O

the O
incidence O
of O
cardiovascular O
thrombotic B-Disease
events O
( O
cardiac O
, O
cerebrovascular O
and O
peripheral O
vascular O
, O
or O
arterial O
thrombotic B-Disease
) O
was O
determined O
by O
analyzing O
pooled O
valdecoxib O
( O
10 O
- O
80 O
mg O
daily O
) O
, O
nonselective O
nsaid O
( O
diclofenac O
75 O
mg O
bid O
, O
ibuprofen O
800 O
mg O
tid O
, O
or O
naproxen O
500 O
mg O
bid O
) O
and O
placebo O
data O
from O
10 O
randomized O
osteoarthritis B-Disease
and O
rheumatoid B-Disease
arthritis I-Disease
trials O
that O
were O
6 O
- O
52 O
weeks O
in O
duration O
. O

crude O
and O
exposure O
- O
adjusted O
incidences O
of O
thrombotic B-Disease
events O
were O
similar O
for O
valdecoxib O
, O
nsaids O
, O
and O
placebo O
. O

the O
risk O
of O
serious O
thrombotic B-Disease
events O
was O
also O
similar O
for O
each O
valdecoxib O
dose O
. O

thrombotic B-Disease
risk O
was O
consistently O
higher O
for O
users O
of O
aspirin O
users O
than O
nonusers O
of O
aspirin O
( O
placebo O
, O
1 O
. O

4 O
% O
vs O
. O

0 O
% O
; O
valdecoxib O
, O
1 O
. O

7 O
% O
vs O
. O

0 O
. O

2 O
% O
; O
nsaids O
, O
1 O
. O

9 O
% O
vs O
. O

0 O
. O

5 O
% O
) O
. O

short O
- O
and O
intermediate O
- O
term O
treatment O
with O
therapeutic O
( O
10 O
or O
20 O
mg O
daily O
) O
and O
supratherapeutic O
( O
40 O
or O
80 O
mg O
daily O
) O
valdecoxib O
doses O
was O
not O
associated O
with O
an O
increased O
incidence O
of O
thrombotic B-Disease
events O
relative O
to O
nonselective O
nsaids O
or O
placebo O
in O
osteoarthritis B-Disease
and O
rheumatoid B-Disease
arthritis I-Disease
patients O
in O
controlled O
clinical O
trials O
. O

hypersensitivity B-Disease
myocarditis B-Disease
complicating O
hypertrophic B-Disease
cardiomyopathy I-Disease
heart O
. O

the O
present O
report O
describes O
a O
case O
of O
eosinophilic B-Disease
myocarditis I-Disease
complicating O
hypertrophic B-Disease
cardiomyopathy I-Disease
. O

the O
47 O
- O
year O
- O
old O
female O
patient O
, O
known O
to O
have O
hypertrophic B-Disease
cardiomyopathy I-Disease
, O
was O
admitted O
with O
biventricular B-Disease
failure I-Disease
and O
managed O
aggressively O
with O
dobutamine O
infusion O
and O
other O
drugs O
while O
being O
assessed O
for O
heart O
transB-Plantation O
. O

on O
transthoracic O
echocardiogram O
, O
she O
had O
moderate O
left B-Disease
ventricular I-Disease
dysfunction I-Disease
with O
regional O
variability O
and O
moderate O
mitral B-Disease
regurgitation I-Disease
. O

the O
recipient O
' O
s O
heart O
showed O
the O
features O
of O
apical O
hypertrophic B-Disease
cardiomyopathy I-Disease
and O
myocarditis B-Disease
with O
abundant O
eosinophils O
. O

myocarditis B-Disease
is O
rare O
and O
eosinophilic B-Disease
myocarditis I-Disease
is O
rarer O
. O

it O
is O
likely O
that O
the O
hypersensitivity B-Disease
( O
eosinophilic B-Disease
) O
myocarditis B-Disease
was O
related O
to O
dobutamine O
infusion O
therapy O
. O

eosinophilic B-Disease
myocarditis I-Disease
has O
been O
reported O
with O
an O
incidence O
of O
2 O
. O

4 O
% O
to O
7 O
. O

2 O
% O
in O
exB-Planted O
hearts O
and O
may O
be O
related O
to O
multidrug O
therapy O
. O

time O
trends O
in O
warfarin O
- O
associated O
hemorrhage B-Disease
. O

the O
annual O
incidence O
of O
warfarin O
- O
related O
bleeding B-Disease
at O
brigham O
and O
women O
' O
s O
hospital O
increased O
from O
0 O
. O

97 O
/ O
1 O
, O
0 O
patient O
admissions O
in O
the O
first O
time O
period O
( O
january O
1995 O
to O
october O
1998 O
) O
to O
1 O
. O

19 O
/ O
1 O
, O
0 O
patient O
admissions O
in O
the O
second O
time O
period O
( O
november O
1998 O
to O
august O
2002 O
) O
of O
this O
study O
. O

the O
proportion O
of O
patients O
with O
major O
and O
intracranial B-Disease
bleeding I-Disease
increased O
from O
20 O
. O

2 O
% O
and O
1 O
. O

9 O
% O
, O
respectively O
, O
in O
the O
first O
time O
period O
, O
to O
33 O
. O

3 O
% O
and O
7 O
. O

8 O
% O
, O
respectively O
, O
in O
the O
second O
. O

yohimbine O
treatment O
of O
sexual B-Disease
side I-Disease
effects I-Disease
induced O
by O
serotonin O
reuptake O
blockers O
. O

background O
: O
preclinical O
and O
clinical O
studies O
suggest O
that O
yohimbine O
facilitates O
sexual O
behavior O
and O
may O
be O
helpful O
in O
the O
treatment O
of O
male B-Disease
impotence I-Disease
. O

a O
single O
case O
report O
suggests O
that O
yohimbine O
may O
be O
used O
to O
treat O
the O
sexual B-Disease
side I-Disease
effects I-Disease
of O
clomipramine O
. O

this O
study O
evaluated O
yohimbine O
as O
a O
treatment O
for O
the O
sexual B-Disease
side I-Disease
effects I-Disease
caused O
by O
serotonin O
reuptake O
blockers O
. O

method O
: O
six O
patients O
with O
either O
obsessive B-Disease
compulsive I-Disease
disorder I-Disease
, O
trichotillomania B-Disease
, O
anxiety B-Disease
, O
or O
affective B-Disease
disorders I-Disease
who O
suffered O
sexual B-Disease
side I-Disease
effects I-Disease
after O
treatment O
with O
serotonin O
reuptake O
blockers O
were O
given O
yohimbine O
on O
a O
p O
. O

r O
. O

n O
. O

basis O
in O
an O
open O
clinical O
trial O
. O

side O
effects O
of O
yohimbine O
included O
excessive O
sweating O
, O
increased O
anxiety B-Disease
, O
and O
a O
wound O
- O
up O
feeling O
in O
some O
patients O
. O

conclusion O
: O
the O
results O
of O
this O
study O
indicate O
that O
yohimbine O
may O
be O
an O
effective O
treatment O
for O
the O
sexual B-Disease
side I-Disease
effects I-Disease
caused O
by O
serotonin O
reuptake O
blockers O
. O

hemorrhagic B-Disease
cystitis I-Disease
complicating O
bone O
marrow O
transB-Plantation O
. O

hemorrhagic B-Disease
cystitis I-Disease
is O
a O
potentially O
serious O
complication O
of O
high O
- O
dose O
cyclophosphamide O
therapy O
administered O
before O
bone O
marrow O
transB-Plantation O
. O

in O
an O
attempt O
to O
obviate O
the O
inconvenience O
of O
bladder O
irrigation O
, O
we O
conducted O
a O
feasibility O
trial O
of O
uroprophylaxis O
with O
mesna O
, O
which O
neutralizes O
the O
hepatic O
metabolite O
of O
cyclophosphamide O
that O
causes O
hemorrhagic B-Disease
cystitis I-Disease
. O

of O
97 O
patients O
who O
received O
standard O
prophylaxis O
, O
4 O
had O
symptomatic O
hemorrhagic B-Disease
cystitis I-Disease
. O

in O
contrast O
, O
two O
of O
four O
consecutive O
patients O
who O
received O
mesna O
uroprophylaxis O
before O
allogeneic O
bone O
marrow O
transB-Plantation O
had O
severe O
hemorrhagic B-Disease
cystitis I-Disease
for O
at O
least O
2 O
weeks O
. O

because O
of O
this O
suboptimal O
result O
, O
we O
resumed O
the O
use O
of O
bladder O
irrigation O
and O
forced O
hydration O
to O
minimize O
the O
risk O
of O
hemorrhagic B-Disease
cystitis I-Disease
. O

consensus O
statement O
concerning O
cardiotoxicity B-Disease
occurring O
during O
haematopoietic O
stem O
cell O
transB-Plantation O
in O
the O
treatment O
of O
autoimmune B-Disease
diseases I-Disease
, O
with O
special O
reference O
to O
systemic B-Disease
sclerosis I-Disease
and O
multiple B-Disease
sclerosis I-Disease
. O

autologous O
haematopoietic O
stem O
cell O
transB-Plantation O
is O
now O
a O
feasible O
and O
effective O
treatment O
for O
selected O
patients O
with O
severe O
autoimmune B-Disease
diseases I-Disease
. O

this O
is O
primarily O
due O
to O
complications O
related O
to O
either O
the O
stage O
of O
the O
disease O
at O
transB-Plant O
or O
due O
to O
infections B-Disease
. O

the O
number O
of O
deaths O
related O
to O
cardiac B-Disease
toxicity I-Disease
is O
low O
. O

however O
, O
caution O
is O
required O
when O
cyclophosphamide O
or O
anthracyclines O
such O
as O
mitoxantrone O
are O
used O
in O
patients O
with O
a O
possible O
underlying O
heart B-Disease
damage I-Disease
, O
for O
example O
, O
systemic B-Disease
sclerosis I-Disease
patients O
. O

the O
object O
of O
the O
meeting O
was O
to O
analyse O
existing O
data O
, O
both O
published O
or O
available O
, O
in O
the O
european O
group O
for O
blood O
and O
marrow O
transB-Plantation O
autoimmune B-Disease
disease I-Disease
database O
, O
and O
to O
propose O
a O
safe O
approach O
to O
such O
patients O
. O

does O
supplemental O
vitamin O
c O
increase O
cardiovascular B-Disease
disease I-Disease
risk O
in O
women O
with O
diabetes B-Disease
? O
these O
observations O
led O
us O
to O
hypothesize O
that O
a O
high O
intake O
of O
vitamin O
c O
in O
diabetic B-Disease
persons O
might O
promote O
atherosclerosis B-Disease
. O

objective O
: O
the O
objective O
was O
to O
examine O
the O
relation O
between O
vitamin O
c O
intake O
and O
mortality O
from O
cardiovascular B-Disease
disease I-Disease
. O

design O
: O
we O
studied O
the O
relation O
between O
vitamin O
c O
intake O
and O
mortality O
from O
total O
cardiovascular B-Disease
disease I-Disease
( O
n O
= O
281 O
) O
, O
coronary B-Disease
artery I-Disease
disease I-Disease
( O
n O
= O
175 O
) O
, O
and O
stroke B-Disease
( O
n O
= O
57 O
) O
in O
1923 O
postmenopausal O
women O
who O
reported O
being O
diabetic B-Disease
at O
baseline O
. O

diet O
was O
assessed O
with O
a O
food O
- O
frequency O
questionnaire O
at O
baseline O
, O
and O
subjects O
initially O
free O
of O
coronary B-Disease
artery I-Disease
disease I-Disease
were O
prospectively O
followed O
for O
15 O
y O
. O

results O
: O
after O
adjustment O
for O
cardiovascular B-Disease
disease I-Disease
risk O
factors O
, O
type O
of O
diabetes B-Disease
medication O
used O
, O
duration O
of O
diabetes B-Disease
, O
and O
intakes O
of O
folate O
, O
vitamin O
e O
, O
and O
beta O
- O
carotene O
, O
the O
adjusted O
relative O
risks O
of O
total O
cardiovascular B-Disease
disease I-Disease
mortality O
were O
1 O
. O

0 O
, O
0 O
. O

97 O
, O
1 O
. O

11 O
, O
1 O
. O

47 O
, O
and O
1 O
. O

84 O
( O
p O
for O
trend O
< O
0 O
. O

1 O
) O
across O
quintiles O
of O
total O
vitamin O
c O
intake O
from O
food O
and O
supplements O
. O

adjusted O
relative O
risks O
of O
coronary B-Disease
artery I-Disease
disease I-Disease
were O
1 O
. O

0 O
, O
0 O
. O

81 O
, O
0 O
. O

99 O
, O
1 O
. O

26 O
, O
and O
1 O
. O

91 O
( O
p O
for O
trend O
= O
0 O
. O

1 O
) O
and O
of O
stroke B-Disease
were O
1 O
. O

0 O
, O
0 O
. O

52 O
, O
1 O
. O

23 O
, O
2 O
. O

22 O
, O
and O
2 O
. O

57 O
( O
p O
for O
trend O
< O
0 O
. O

1 O
) O
. O

vitamin O
c O
intake O
was O
unrelated O
to O
mortality O
from O
cardiovascular B-Disease
disease I-Disease
in O
the O
nondiabetic O
subjects O
at O
baseline O
. O

conclusion O
: O
a O
high O
vitamin O
c O
intake O
from O
supplements O
is O
associated O
with O
an O
increased O
risk O
of O
cardiovascular B-Disease
disease I-Disease
mortality O
in O
postmenopausal O
women O
with O
diabetes B-Disease
. O

optical O
coherence O
tomography O
can O
measure O
axonal O
loss O
in O
patients O
with O
ethambutol O
- O
induced O
optic B-Disease
neuropathy I-Disease
. O

purpose O
: O
to O
map O
and O
identify O
the O
pattern O
, O
in O
vivo O
, O
of O
axonal B-Disease
degeneration I-Disease
in O
ethambutol O
- O
induced O
optic B-Disease
neuropathy I-Disease
using O
optical O
coherence O
tomography O
( O
oct O
) O
. O

ethambutol O
is O
an O
antimycobacterial O
agent O
often O
used O
to O
treat O
tuberculosis B-Disease
. O

a O
serious O
complication O
of O
ethambutol O
is O
an O
optic B-Disease
neuropathy I-Disease
that O
impairs O
visual O
acuity O
, O
contrast O
sensitivity O
, O
and O
color O
vision O
. O

however O
, O
early O
on O
, O
when O
the O
toxic O
optic B-Disease
neuropathy I-Disease
is O
mild O
and O
partly O
reversible O
, O
the O
funduscopic O
findings O
are O
often O
subtle O
and O
easy O
to O
miss O
. O

methods O
: O
three O
subjects O
with O
a O
history O
of O
ethambutol O
( O
emb O
) O
- O
induced O
optic B-Disease
neuropathy I-Disease
of O
short O
- O
, O
intermediate O
- O
, O
and O
long O
- O
term O
visual B-Disease
deficits I-Disease
were O
administered O
a O
full O
neuro O
- O
ophthalmologic O
examination O
including O
visual O
acuity O
, O
color O
vision O
, O
contrast O
sensitivity O
, O
and O
fundus O
examination O
. O

in O
all O
subjects O
with O
history O
of O
emb O
- O
induced O
optic B-Disease
neuropathy I-Disease
, O
there O
was O
a O
mean O
loss O
of O
72 O
% O
nerve O
fiber O
layer O
thickness O
in O
the O
temporal O
quadrant O
( O
patient O
a O
, O
with O
eventual O
recovery O
of O
visual O
acuity O
and O
fields O
, O
58 O
% O
loss O
; O
patient O
b O
, O
with O
intermediate O
visual B-Disease
deficits I-Disease
, O
68 O
% O
loss O
; O
patient O
c O
, O
with O
chronic O
visual B-Disease
deficits I-Disease
, O
90 O
% O
loss O
) O
, O
with O
an O
average O
mean O
optic O
nerve O
thickness O
of O
26 O
+ O
/ O
- O
16 O
microm O
. O

in O
both O
sets O
( O
four O
) O
of O
eyes O
of O
the O
subjects O
with O
persistent O
visual B-Disease
deficits I-Disease
( O
patients O
b O
and O
c O
) O
, O
there O
was O
an O
average O
loss O
of O
79 O
% O
of O
nerve O
fiber O
thickness O
in O
the O
temporal O
quadrant O
. O

conclusions O
: O
the O
oct O
results O
in O
these O
patients O
with O
emb O
- O
induced O
optic B-Disease
neuropathy I-Disease
show O
considerable O
loss O
especially O
of O
the O
temporal O
fibers O
. O

this O
is O
consistent O
with O
prior O
histopathological O
studies O
that O
show O
predominant O
loss O
of O
parvo O
- O
cellular O
axons O
( O
or O
small O
- O
caliber O
axons O
) O
within O
the O
papillo O
- O
macular O
bundle O
in O
toxic O
or O
hereditary O
optic B-Disease
neuropathies I-Disease
. O

oct O
can O
be O
a O
valuable O
tool O
in O
the O
quantitative O
analysis O
of O
optic B-Disease
neuropathies I-Disease
. O

additionally O
, O
in O
terms O
of O
management O
of O
emb O
- O
induced O
optic B-Disease
neuropathy I-Disease
, O
it O
is O
important O
to O
properly O
manage O
ethambutol O
dosing O
in O
patients O
with O
renal B-Disease
impairment I-Disease
and O
to O
achieve O
proper O
transition O
to O
a O
maintenance O
dose O
once O
an O
appropriate O
loading O
dose O
has O
been O
reached O
. O

hypoxia B-Disease
in O
renal B-Disease
disease I-Disease
with O
proteinuria B-Disease
and O
/ O
or O
glomerular O
hypertension B-Disease
. O

in O
this O
study O
, O
we O
developed O
a O
new O
hypoxia B-Disease
- O
responsive O
reporter O
vector O
using O
a O
hypoxia B-Disease
- O
responsive O
element O
of O
the O
5 O
' O
vascular O
endothelial O
growth O
factor O
untranslated O
region O
and O
generated O
a O
novel O
hypoxia B-Disease
- O
sensing O
transgenic O
rat O
. O

we O
then O
applied O
this O
animal O
model O
to O
the O
detection O
of O
tubulointerstitial O
hypoxia B-Disease
in O
the O
diseased B-Disease
kidney I-Disease
. O

with O
this O
model O
, O
we O
were O
able O
to O
identify O
diffuse O
cortical O
hypoxia B-Disease
in O
the O
puromycin O
aminonucleoside O
- O
induced O
nephrotic B-Disease
syndrome I-Disease
and O
focal O
and O
segmental O
hypoxia B-Disease
in O
the O
remnant O
kidney O
model O
. O

expression O
of O
the O
hypoxia B-Disease
- O
responsive O
transgene O
increased O
throughout O
the O
observation O
period O
, O
reaching O
2 O
. O

2 O
- O
fold O
at O
2 O
weeks O
in O
the O
puromycin O
aminonucleoside O
model O
and O
2 O
. O

6 O
- O
fold O
at O
4 O
weeks O
in O
the O
remnant O
kidney O
model O
, O
whereas O
that O
of O
vascular O
endothelial O
growth O
factor O
showed O
a O
mild O
decrease O
, O
reflecting O
distinct O
behaviors O
of O
the O
two O
genes O
. O

the O
degree O
of O
hypoxia B-Disease
showed O
a O
positive O
correlation O
with O
microscopic O
tubulointerstitial B-Disease
injury I-Disease
in O
both O
models O
. O

finally O
, O
we O
identified O
the O
localization O
of O
proliferating O
cell O
nuclear O
antigen O
- O
positive O
, O
ed O
- O
1 O
- O
positive O
, O
and O
terminal O
dutp O
nick O
- O
end O
labeled O
- O
positive O
cells O
in O
the O
hypoxic B-Disease
cortical O
area O
in O
the O
remnant O
kidney O
model O
. O

we O
propose O
here O
a O
possible O
pathological O
tie O
between O
chronic O
tubulointerstitial O
hypoxia B-Disease
and O
progressive O
glomerular B-Disease
diseases I-Disease
. O

adequate O
timing O
of O
ribavirin O
reduction O
in O
patients O
with O
hemolysis B-Disease
during O
combination O
therapy O
of O
interferon O
and O
ribavirin O
for O
chronic B-Disease
hepatitis I-Disease
c I-Disease
. O

background O
: O
hemolytic B-Disease
anemia I-Disease
is O
one O
of O
the O
major O
adverse O
events O
of O
the O
combination O
therapy O
of O
interferon O
and O
ribavirin O
. O

because O
of O
ribavirin O
- O
related O
hemolytic B-Disease
anemia I-Disease
, O
dose O
reduction O
is O
a O
common O
event O
in O
this O
therapy O
. O

in O
this O
clinical O
retrospective O
cohort O
study O
we O
have O
examined O
the O
suitable O
timing O
of O
ribavirin O
reduction O
in O
patients O
with O
hemolysis B-Disease
during O
combination O
therapy O
. O

methods O
: O
thirty O
- O
seven O
of O
160 O
patients O
who O
had O
hcv O
- O
genotype O
1b O
, O
had O
high O
virus O
load O
, O
and O
received O
24 O
- O
week O
combination O
therapy O
developed O
anemia B-Disease
with O
hemoglobin O
level O
< O
10 O
g O
/ O
dl O
or O
anemia B-Disease
- O
related O
signs O
during O
therapy O
. O

however O
, O
10 O
of O
37 O
patients O
with O
reduction O
of O
ribavirin O
could O
not O
continue O
combination O
therapy O
because O
their O
< O
8 O
. O

5 O
g O
/ O
dl O
hemoglobin O
values O
decreased O
to O
or O
anemia B-Disease
- O
related O
severe O
side O
effects O
occurred O
( O
group O
b O
) O
. O

aging O
process O
of O
epithelial O
cells O
of O
the O
rat O
prostate O
lateral O
lobe O
in O
experimental O
hyperprolactinemia B-Disease
induced O
by O
haloperidol O
. O

the O
aim O
of O
the O
study O
was O
to O
examine O
the O
influence O
of O
hyperprolactinemia B-Disease
, O
induced O
by O
haloperidol O
( O
hal O
) O
on O
age O
related O
morphology O
and O
function O
changes O
of O
epithelial O
cells O
in O
rat O
prostate O
lateral O
lobe O
. O

light O
microscopy O
visualized O
the O
following O
: O
hypertrophy B-Disease
and O
epithelium O
hyperplasia B-Disease
of O
the O
glandular O
ducts O
, O
associated O
with O
increased O
pcna O
expression O
. O

relation O
of O
perfusion O
defects O
observed O
with O
myocardial O
contrast O
echocardiography O
to O
the O
severity O
of O
coronary B-Disease
stenosis I-Disease
: O
correlation O
with O
thallium O
- O
201 O
single O
- O
photon O
emission O
tomography O
. O

it O
has O
been O
previously O
shown O
that O
myocardial O
contrast O
echocardiography O
is O
a O
valuable O
technique O
for O
delineating O
regions O
of O
myocardial O
underperfusion O
secondary O
to O
coronary B-Disease
occlusion I-Disease
and O
to O
critical O
coronary B-Disease
stenoses I-Disease
in O
the O
presence O
of O
hyperemic B-Disease
stimulation O
. O

the O
aim O
of O
this O
study O
was O
to O
determine O
whether O
myocardial O
contrast O
echocardiography O
performed O
with O
a O
stable O
solution O
of O
sonicated O
albumin O
could O
detect O
regions O
of O
myocardial O
underperfusion O
resulting O
from O
various O
degrees O
of O
coronary B-Disease
stenosis I-Disease
. O

during O
a O
transient O
( O
20 O
- O
s O
) O
coronary B-Disease
occlusion I-Disease
, O
a O
perfusion O
defect O
was O
observed O
with O
contrast O
echocardiography O
in O
14 O
of O
the O
15 O
dogs O
in O
which O
the O
occlusion O
was O
produced O
. O

during O
dipyridamole O
- O
induced O
hyperemia B-Disease
, O
12 O
of O
the O
16 O
dogs O
with O
a O
partial O
coronary B-Disease
stenosis I-Disease
had O
a O
visible O
area O
of O
hypoperfusion O
by O
contrast O
echocardiography O
. O

the O
four O
dogs O
without O
a O
perfusion O
defect O
had O
a O
stenosis O
that O
resulted O
in O
a O
mild O
( O
0 O
% O
to O
50 O
% O
) O
reduction O
in O
dipyridamole O
- O
induced O
hyperemia B-Disease
. O

thallium O
- O
201 O
spect O
demonstrated O
a O
perfusion O
defect O
in O
all O
14 O
dogs O
analyzed O
during O
dipyridamole O
- O
induced O
hyperemia B-Disease
; O
the O
size O
of O
the O
perfusion O
defect O
correlated O
with O
the O
anatomic O
area O
at O
risk O
( O
r O
= O
0 O
. O

58 O
; O
p O
less O
than O
0 O
. O

3 O
) O
and O
with O
the O
perfusion O
defect O
by O
contrast O
echocardiography O
( O
r O
= O
0 O
. O

58 O
; O
p O
less O
than O
0 O
. O

3 O
) O
. O

thus O
, O
myocardial O
contrast O
echocardiography O
can O
be O
used O
to O
visualize O
and O
quantitate O
the O
amount O
of O
jeopardized O
myocardium O
during O
moderate O
to O
severe O
degrees O
of O
coronary B-Disease
stenosis I-Disease
. O

the O
activation O
of O
spinal O
n O
- O
methyl O
- O
d O
- O
aspartate O
receptors O
may O
contribute O
to O
degeneration O
of O
spinal O
motor O
neurons O
induced O
by O
neuraxial O
morphine O
after O
a O
noninjurious O
interval O
of O
spinal B-Disease
cord I-Disease
ischemia I-Disease
. O

we O
investigated O
the O
relationship O
between O
the O
degeneration O
of O
spinal O
motor O
neurons O
and O
activation O
of O
n O
- O
methyl O
- O
d O
- O
aspartate O
( O
nmda O
) O
receptors O
after O
neuraxial O
morphine O
following O
a O
noninjurious O
interval O
of O
aortic B-Disease
occlusion I-Disease
in O
rats O
. O

spinal B-Disease
cord I-Disease
ischemia I-Disease
was O
induced O
by O
aortic B-Disease
occlusion I-Disease
for O
6 O
min O
with O
a O
balloon O
catheter O
. O

second O
, O
we O
investigated O
the O
effect O
of O
it O
mk O
- O
801 O
( O
30 O
mug O
) O
on O
the O
histopathologic O
changes O
in O
the O
spinal O
cord O
after O
morphine O
- O
induced O
spastic B-Disease
paraparesis I-Disease
. O

it O
mk O
- O
801 O
significantly O
reduced O
the O
number O
of O
dark O
- O
stained O
alpha O
- O
motoneurons O
after O
morphine O
- O
induced O
spastic B-Disease
paraparesis I-Disease
compared O
with O
the O
saline O
group O
. O

these O
data O
indicate O
that O
it O
morphine O
induces O
spastic B-Disease
paraparesis I-Disease
with O
a O
concomitant O
increase O
in O
csf O
glutamate O
, O
which O
is O
involved O
in O
nmda O
receptor O
activation O
. O

we O
suggest O
that O
opioids O
may O
be O
neurotoxic B-Disease
in O
the O
setting O
of O
spinal B-Disease
cord I-Disease
ischemia I-Disease
via O
nmda O
receptor O
activation O
. O

acute O
low B-Disease
back I-Disease
pain I-Disease
during O
intravenous O
administration O
of O
amiodarone O
: O
a O
report O
of O
two O
cases O
. O

amiodarone O
represents O
an O
effective O
antiarrhythmic O
drug O
for O
cardioversion O
of O
recent O
- O
onset O
atrial B-Disease
fibrillation I-Disease
( O
af B-Disease
) O
and O
maintenance O
of O
sinus O
rhythm O
. O

we O
briefly O
describe O
two O
patients O
suffering O
from O
recent O
- O
onset O
atrial B-Disease
fibrillation I-Disease
, O
who O
experienced O
an O
acute O
devastating O
low B-Disease
back I-Disease
pain I-Disease
a O
few O
minutes O
after O
initiation O
of O
intravenous O
amiodarone O
loading O
. O

quantitative O
drug O
levels O
in O
stimulant O
psychosis B-Disease
: O
relationship O
to O
symptom O
severity O
, O
catecholamines O
and O
hyperkinesia B-Disease
. O

to O
examine O
the O
relationship O
between O
quantitative O
stimulant O
drug O
levels O
, O
catecholamines O
, O
and O
psychotic B-Disease
symptoms I-Disease
, O
nineteen O
patients O
in O
a O
psychiatric B-Disease
emergency O
service O
with O
a O
diagnosis O
of O
amphetamine O
- O
or O
cocaine O
- O
induced O
psychosis B-Disease
were O
interviewed O
, O
and O
plasma O
and O
urine O
were O
collected O
for O
quantitative O
assays O
of O
stimulant O
drug O
and O
catecholamine O
metabolite O
levels O
. O

methamphetamine O
or O
amphetamine O
levels O
were O
related O
to O
several O
psychopathology O
scores O
and O
the O
global O
hyperkinesia B-Disease
rating O
. O

hva O
levels O
were O
related O
to O
global O
hyperkinesia B-Disease
but O
not O
to O
psychopathology O
ratings O
. O

although O
many O
other O
factors O
such O
as O
sensitization O
may O
play O
a O
role O
, O
intensity O
of O
stimulant O
- O
induced O
psychotic B-Disease
symptoms I-Disease
and O
stereotypies B-Disease
appears O
to O
be O
at O
least O
in O
part O
dose O
- O
related O
. O

pheochromocytoma B-Disease
unmasked O
by O
amisulpride O
and O
tiapride O
. O

objective O
: O
to O
describe O
the O
unmasking O
of O
pheochromocytoma B-Disease
in O
a O
patient O
treated O
with O
amisulpride O
and O
tiapride O
. O

case O
summary O
: O
a O
42 O
- O
year O
- O
old O
white O
man O
developed O
acute O
hypertension B-Disease
with O
severe O
headache B-Disease
and O
vomiting B-Disease
2 O
hours O
after O
the O
first O
doses O
of O
amisulpride O
100 O
mg O
and O
tiapride O
100 O
mg O
. O

abdominal O
ultrasound O
showed O
an O
adrenal O
mass O
, O
and O
postoperative O
histologic O
examination O
confirmed O
the O
diagnosis O
of O
pheochromocytoma B-Disease
. O

discussion O
: O
drug O
- O
induced O
symptoms O
of O
pheochromocytoma B-Disease
are O
often O
associated O
with O
the O
use O
of O
substituted O
benzamide O
drugs O
, O
but O
the O
underlying O
mechanism O
is O
unknown O
. O

in O
our O
case O
, O
use O
of O
the O
naranjo O
probability O
scale O
indicated O
a O
possible O
relationship O
between O
the O
hypertensive B-Disease
crisis O
and O
amisulpride O
and O
tiapride O
therapy O
. O

conclusions O
: O
as O
of O
march O
24 O
, O
2005 O
, O
this O
is O
the O
first O
reported O
case O
of O
amisulpride O
- O
and O
tiapride O
- O
induced O
hypertensive B-Disease
crisis O
in O
a O
patient O
with O
pheochromocytoma B-Disease
. O

minor O
neurological B-Disease
dysfunction I-Disease
, O
cognitive O
development O
, O
and O
somatic O
development O
at O
the O
age O
of O
3 O
to O
7 O
years O
after O
dexamethasone O
treatment O
in O
very O
- O
low O
birth O
- O
weight O
infants O
. O

the O
objective O
of O
this O
study O
was O
to O
assess O
minor O
neurological B-Disease
dysfunction I-Disease
, O
cognitive O
development O
, O
and O
somatic O
development O
after O
dexamethasone O
therapy O
in O
very O
- O
low O
- O
birthweight O
infants O
. O

exclusion O
criteria O
were O
asphyxia B-Disease
, O
malformations B-Disease
, O
major O
surgical O
interventions O
, O
small O
for O
gestational O
age O
, O
intraventricular O
haemorrhage B-Disease
grades O
iii O
and O
iv O
, O
periventricular B-Disease
leukomalacia I-Disease
, O
and O
severe O
psychomotor B-Disease
retardation I-Disease
. O

each O
child O
was O
examined O
by O
a O
neuropediatrician O
for O
minor O
neurological B-Disease
dysfunctions I-Disease
and O
tested O
by O
a O
psychologist O
for O
cognitive O
development O
with O
a O
kaufman O
assessment O
battery O
for O
children O
and O
a O
draw O
- O
a O
- O
man O
test O
. O

after O
dexamethasone O
treatment O
, O
children O
showed O
a O
higher O
rate O
of O
minor O
neurological B-Disease
dysfunctions I-Disease
. O

valproic O
acid O
i O
: O
time O
course O
of O
lipid O
peroxidation O
biomarkers O
, O
liver B-Disease
toxicity I-Disease
, O
and O
valproic O
acid O
metabolite O
levels O
in O
rats O
. O

to O
determine O
whether O
there O
was O
a O
temporal O
relationship O
between O
vpa O
- O
associated O
oxidative O
stress O
and O
hepatotoxicity B-Disease
, O
adult O
male O
sprague O
- O
dawley O
rats O
were O
treated O
ip O
with O
vpa O
( O
500 O
mg O
/ O
kg O
) O
or O
0 O
. O

9 O
% O
saline O
( O
vehicle O
) O
once O
daily O
for O
2 O
, O
4 O
, O
7 O
, O
10 O
, O
or O
14 O
days O
. O

liver B-Disease
toxicity I-Disease
was O
evaluated O
based O
on O
serum O
levels O
of O
alpha O
- O
glutathione O
s O
- O
transferase O
( O
alpha O
- O
gst O
) O
and O
by O
histology O
. O

serum O
alpha O
- O
gst O
levels O
were O
significantly O
elevated O
by O
day O
4 O
, O
which O
corresponded O
to O
hepatotoxicity B-Disease
as O
shown O
by O
the O
increasing O
incidence O
of O
inflammation B-Disease
of O
the O
liver O
capsule O
, O
necrosis B-Disease
, O
and O
steatosis B-Disease
throughout O
the O
study O
. O

overall O
, O
these O
findings O
indicate O
that O
vpa O
treatment O
results O
in O
oxidative O
stress O
, O
as O
measured O
by O
levels O
of O
15 O
- O
f O
( O
2t O
) O
- O
isop O
, O
which O
precedes O
the O
onset O
of O
necrosis B-Disease
, O
steatosis B-Disease
, O
and O
elevated O
levels O
of O
serum O
alpha O
- O
gst O
. O

assessment O
of O
perinatal O
hepatitis B-Disease
b I-Disease
and O
rubella B-Disease
prevention O
in O
new O
hampshire O
delivery O
hospitals O
. O

objective O
: O
to O
evaluate O
current O
performance O
on O
recommended O
perinatal O
hepatitis B-Disease
b I-Disease
and O
rubella B-Disease
prevention O
practices O
in O
new O
hampshire O
. O

assessment O
was O
done O
on O
the O
following O
: O
prenatal O
screening O
for O
hepatitis B-Disease
b I-Disease
and O
rubella B-Disease
, O
administration O
of O
the O
hepatitis B-Disease
b I-Disease
vaccine O
birth O
dose O
to O
all O
infants O
, O
administration O
of O
hepatitis B-Disease
b I-Disease
immune O
globulin O
to O
infants O
who O
were O
born O
to O
hepatitis O
b O
surface O
antigen O
- O
positive O
mothers O
, O
rubella B-Disease
immunity O
, O
and O
administration O
of O
in O
- O
hospital O
postpartum O
rubella B-Disease
vaccine O
to O
rubella B-Disease
nonimmune O
women O
. O

results O
: O
prenatal O
screening O
rates O
for O
hepatitis B-Disease
b I-Disease
( O
98 O
. O

8 O
% O
) O
and O
rubella B-Disease
( O
99 O
. O

4 O
% O
) O
were O
high O
. O

hepatitis B-Disease
b I-Disease
vaccine O
birth O
dose O
was O
administered O
to O
76 O
. O

2 O
% O
of O
all O
infants O
. O

all O
infants O
who O
were O
born O
to O
hepatitis O
b O
surface O
antigen O
- O
positive O
mothers O
also O
received O
hepatitis B-Disease
b I-Disease
immune O
globulin O
. O

multivariate O
logistic O
regression O
showed O
that O
the O
month O
of O
delivery O
and O
infant O
birth O
weight O
were O
independent O
predictors O
of O
hepatitis B-Disease
b I-Disease
vaccination O
. O

women O
who O
were O
born O
between O
1971 O
and O
1975 O
had O
the O
highest O
rate O
of O
rubella B-Disease
nonimmunity O
( O
9 O
. O

5 O
% O
) O
. O

in O
- O
hospital O
postpartum O
rubella B-Disease
vaccine O
administration O
was O
documented O
for O
75 O
. O

6 O
% O
of O
nonimmune O
women O
. O

conclusion O
: O
this O
study O
documents O
good O
compliance O
in O
new O
hampshire O
' O
s O
birthing O
hospitals O
with O
national O
guidelines O
for O
perinatal O
hepatitis B-Disease
b I-Disease
and O
rubella B-Disease
prevention O
and O
highlights O
potential O
areas O
for O
improvement O
. O

succinylcholine O
- O
induced O
masseter B-Disease
muscle I-Disease
rigidity I-Disease
during O
bronchoscopic O
removal O
of O
a O
tracheal O
foreign O
body O
. O

masseter B-Disease
muscle I-Disease
rigidity I-Disease
during O
general O
anesthesia O
is O
considered O
an O
early O
warning O
sign O
of O
a O
possible O
episode O
of O
malignant B-Disease
hyperthermia I-Disease
. O

the O
decision O
whether O
to O
continue O
or O
discontinue O
the O
procedure O
depends O
on O
the O
urgency O
of O
the O
surgery O
and O
severity O
of O
masseter B-Disease
muscle I-Disease
rigidity I-Disease
. O

here O
, O
we O
describe O
a O
case O
of O
severe O
masseter B-Disease
muscle I-Disease
rigidity I-Disease
( O
jaw B-Disease
of I-Disease
steel I-Disease
) O
after O
succinylcholine O
( O
sch O
) O
administration O
during O
general O
anesthetic O
management O
for O
rigid O
bronchoscopic O
removal O
of O
a O
tracheal O
foreign O
body O
. O

anesthesia O
was O
continued O
uneventfully O
with O
propofol O
infusion O
while O
all O
facilities O
were O
available O
to O
detect O
and O
treat O
malignant B-Disease
hyperthermia I-Disease
. O

dexrazoxane O
protects O
against O
myelosuppression B-Disease
from O
the O
dna O
cleavage O
- O
enhancing O
drugs O
etoposide O
and O
daunorubicin O
but O
not O
doxorubicin O
. O

purpose O
: O
the O
anthracyclines O
daunorubicin O
and O
doxorubicin O
and O
the O
epipodophyllotoxin O
etoposide O
are O
potent O
dna O
cleavage O
- O
enhancing O
drugs O
that O
are O
widely O
used O
in O
clinical O
oncology O
; O
however O
, O
myelosuppression B-Disease
and O
cardiac B-Disease
toxicity I-Disease
limit O
their O
use O
. O

dexrazoxane O
( O
icrf O
- O
187 O
) O
is O
recommended O
for O
protection O
against O
anthracycline O
- O
induced O
cardiotoxicity B-Disease
. O

experimental O
design O
: O
because O
of O
their O
widespread O
use O
, O
the O
hematologic B-Disease
toxicity I-Disease
following O
coadministration O
of O
dexrazoxane O
and O
these O
three O
structurally O
different O
dna O
cleavage O
enhancers O
was O
investigated O
: O
sensitivity O
of O
human O
and O
murine O
blood O
progenitor O
cells O
to O
etoposide O
, O
daunorubicin O
, O
and O
doxorubicin O
+ O
/ O
- O
dexrazoxane O
was O
determined O
in O
granulocyte O
- O
macrophage O
colony O
forming O
assays O
. O

results O
: O
nontoxic O
doses O
of O
dexrazoxane O
reduced O
myelosuppression B-Disease
and O
weight B-Disease
loss I-Disease
from O
daunorubicin O
and O
etoposide O
in O
mice O
and O
antagonized O
their O
antiproliferative O
effects O
in O
the O
colony O
assay O
; O
however O
, O
dexrazoxane O
neither O
reduced O
myelosuppression B-Disease
, O
weight B-Disease
loss I-Disease
, O
nor O
the O
in O
vitro O
cytotoxicity B-Disease
from O
doxorubicin O
. O

clinical O
trials O
in O
patients O
with O
brain O
metastases B-Disease
combining O
dexrazoxane O
and O
high O
doses O
of O
etoposide O
is O
ongoing O
with O
the O
aim O
of O
improving O
efficacy O
without O
aggravating O
hematologic B-Disease
toxicity I-Disease
. O

assessment O
of O
the O
onset O
and O
persistence O
of O
amnesia B-Disease
during O
procedural O
sedation O
with O
propofol O
. O

the O
mean O
highest O
bis O
score O
corresponding O
to O
the O
inability B-Disease
to I-Disease
repeat I-Disease
words I-Disease
was O
81 O
. O

5 O
( O
95 O
% O
ci O
= O
78 O
. O

1 O
to O
84 O
. O

8 O
) O
. O

furthermore O
, O
patients O
had O
no O
recall O
of O
words O
repeated O
prior O
to O
procedural O
sedation O
in O
bis O
ranges O
associated O
with O
recall O
after O
procedural O
sedation O
, O
suggestive O
of O
retrograde B-Disease
amnesia I-Disease
. O

amiodarone O
pulmonary B-Disease
toxicity I-Disease
. O

amiodarone O
is O
an O
effective O
antiarrhythmic O
agent O
whose O
utility O
is O
limited O
by O
many O
side O
- O
effects O
, O
the O
most O
problematic O
being O
pneumonitis B-Disease
. O

the O
pulmonary B-Disease
toxicity I-Disease
of O
amiodarone O
is O
thought O
to O
result O
from O
direct O
injury O
related O
to O
the O
intracellular O
accumulation O
of O
phospholipid O
and O
t O
cell O
- O
mediated O
hypersensitivity B-Disease
pneumonitis I-Disease
. O

the O
clinical O
and O
radiographic O
features O
of O
amiodarone O
- O
induced O
pulmonary B-Disease
toxicity I-Disease
are O
characteristic O
but O
nonspecific O
. O

the O
diagnosis O
depends O
on O
exclusion O
of O
other O
entities O
, O
such O
as O
heart B-Disease
failure I-Disease
, O
infection B-Disease
, O
and O
malignancy B-Disease
. O

two O
prodrugs O
of O
potent O
and O
selective O
glur5 O
kainate O
receptor O
antagonists O
actives O
in O
three O
animal O
models O
of O
pain B-Disease
. O

their O
ester O
prodrugs O
6 O
and O
8 O
were O
orally O
active O
in O
three O
models O
of O
pain B-Disease
: O
reversal O
of O
formalin O
- O
induced O
paw O
licking O
, O
carrageenan O
- O
induced O
thermal B-Disease
hyperalgesia I-Disease
, O
and O
capsaicin O
- O
induced O
mechanical B-Disease
hyperalgesia I-Disease
. O

possible O
azithromycin O
- O
associated O
hiccups B-Disease
. O

objective O
: O
to O
report O
a O
case O
of O
persistent O
hiccups B-Disease
associated O
by O
azithromycin O
therapy O
. O

case O
summary O
: O
a O
76 O
- O
year O
- O
old O
man O
presented O
with O
persistent O
hiccups B-Disease
after O
beginning O
azithromycin O
for O
the O
treatment O
of O
pharyngitis B-Disease
. O

hiccups B-Disease
were O
persistent O
and O
exhausting O
. O

discontinuation O
of O
azithromycin O
and O
therapy O
with O
baclofen O
finally O
resolved O
hiccups B-Disease
. O

no O
organic O
cause O
of O
hiccups B-Disease
was O
identified O
despite O
extensive O
investigation O
. O

discussion O
: O
pharmacotherapeutic O
agents O
have O
been O
uncommonly O
associated O
with O
hiccups B-Disease
. O

corticosteroids O
( O
dexamethasone O
and O
methylprednisolone O
) O
, O
benzodiazepines O
( O
midazolam O
) O
and O
general O
anaesthesia O
have O
been O
the O
specific O
agents O
mentioned O
most O
frequently O
in O
the O
literature O
as O
being O
associated O
with O
the O
development O
of O
hiccups B-Disease
. O

few O
cases O
of O
drug O
- O
induced O
hiccups B-Disease
have O
been O
reported O
related O
to O
macrolide O
antimicrobials O
. O

using O
the O
naranjo O
adverse O
effect O
reaction O
probability O
scale O
this O
event O
could O
be O
classified O
as O
possible O
( O
score O
5 O
points O
) O
, O
mostly O
because O
of O
the O
close O
temporal O
sequence O
, O
previous O
reports O
on O
this O
reaction O
with O
other O
macrolides O
and O
the O
absence O
of O
any O
alternative O
explanation O
for O
hiccups B-Disease
. O

our O
hypothesis O
is O
that O
a O
vagal O
mechanism O
mediated O
by O
azithromycin O
could O
be O
the O
pathogenesis O
of O
hiccups B-Disease
in O
our O
patient O
. O

conclusions O
: O
diagnosis O
of O
drug O
- O
induced O
hiccups B-Disease
is O
difficult O
and O
often O
achieved O
only O
by O
a O
process O
of O
elimination O
. O

however O
, O
macrolide O
antimicrobials O
have O
been O
reported O
to O
be O
associated O
with O
hiccups B-Disease
and O
vagal O
mechanism O
could O
explain O
the O
development O
of O
this O
side O
- O
effect O
. O

calcium O
carbonate O
toxicity B-Disease
: O
the O
updated O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
; O
report O
of O
3 O
cases O
and O
review O
of O
the O
literature O
. O

objective O
: O
to O
describe O
3 O
patients O
with O
calcium O
carbonate O
- O
induced O
hypercalcemia B-Disease
and O
gain O
insights O
into O
the O
cause O
and O
management O
of O
the O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
. O

methods O
: O
we O
report O
the O
clinical O
and O
laboratory O
data O
in O
3 O
patients O
who O
presented O
with O
severe O
hypercalcemia B-Disease
( O
corrected O
serum O
calcium O
> O
or O
= O
14 O
mg O
/ O
dl O
) O
and O
review O
the O
pertinent O
literature O
on O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
. O

results O
: O
the O
3 O
patients O
had O
acute B-Disease
renal I-Disease
insufficiency I-Disease
, O
relative O
metabolic B-Disease
alkalosis I-Disease
, O
and O
low O
parathyroid O
hormone O
( O
pth O
) O
, O
pth O
- O
related O
peptide O
, O
and O
1 O
, O
25 O
- O
dihydroxyvitamin O
d O
concentrations O
. O

the O
2 O
patients O
with O
the O
higher O
serum O
calcium O
concentrations O
received O
pamidronate O
intravenously O
( O
60 O
and O
30 O
mg O
, O
respectively O
) O
, O
which O
caused O
severe O
hypocalcemia B-Disease
. O

in O
addition O
to O
our O
highlighted O
cases O
, O
we O
review O
the O
history O
, O
classification O
, O
pathophysiologic O
features O
, O
and O
treatment O
of O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
and O
summarize O
the O
cases O
reported O
from O
early O
1995 O
to O
november O
2003 O
. O

conclusion O
: O
milk B-Disease
- I-Disease
alkali I-Disease
syndrome I-Disease
may O
be O
a O
common O
cause O
of O
unexplained O
hypercalcemia B-Disease
and O
can O
be O
precipitated O
by O
small O
amounts O
of O
orally O
ingested O
calcium O
carbonate O
in O
susceptible O
persons O
. O

pamidronate O
treatment O
is O
associated O
with O
considerable O
risk O
for O
hypocalcemia B-Disease
, O
even O
in O
cases O
of O
initially O
severe O
hypercalcemia B-Disease
. O

warfarin O
- O
induced O
leukocytoclastic B-Disease
vasculitis I-Disease
. O

leukocytoclastic B-Disease
vasculitis I-Disease
( O
lv B-Disease
) O
is O
primarily O
a O
cutaneous B-Disease
small I-Disease
vessel I-Disease
vasculitis I-Disease
, O
though O
systemic O
involvement O
may O
be O
encountered O
. O

we O
report O
4 O
patients O
with O
late O
- O
onset O
lv B-Disease
probably O
due O
to O
warfarin O
. O

all O
4 O
patients O
presented O
with O
skin B-Disease
eruptions I-Disease
that O
developed O
after O
receiving O
warfarin O
for O
several O
years O
. O

the O
results O
of O
skin B-Disease
lesion I-Disease
biopsies O
were O
available O
in O
3 O
patients O
, O
confirming O
lv B-Disease
cutaneous I-Disease
lesions I-Disease
resolved O
in O
all O
patients O
after O
warfarin O
was O
discontinued O
. O

lv B-Disease
may O
be O
a O
late O
- O
onset O
adverse O
reaction O
associated O
with O
warfarin O
therapy O
. O

cocaine O
- O
induced O
brainstem O
seizures B-Disease
and O
behavior O
. O

the O
abnormal O
behaviors O
were O
yawning O
, O
retrocollis O
, O
hyperactivity B-Disease
, O
hypersensitivity B-Disease
, O
nan O
beating O
drum O
nan O
behavior O
, O
squealing O
, O
head O
bobbing O
, O
circling O
, O
sniffing O
, O
abnormal O
posturing O
, O
and O
facial O
twitching O
. O

hypersensitivity B-Disease
to O
various O
auditory O
, O
tactile O
, O
and O
visual O
stimulation O
was O
present O
and O
shifts O
in O
the O
brainstem O
ambient O
power O
spectral O
frequency O
occurred O
in O
response O
to O
tactile O
stimulation O
. O

rtms O
of O
supplementary O
motor O
area O
modulates O
therapy O
- O
induced O
dyskinesias B-Disease
in O
parkinson B-Disease
disease I-Disease
. O

the O
neural O
mechanisms O
and O
circuitry O
involved O
in O
levodopa O
- O
induced O
dyskinesia B-Disease
are O
unclear O
. O

using O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rtms O
) O
over O
the O
supplementary O
motor O
area O
( O
sma O
) O
in O
a O
group O
of O
patients O
with O
advanced O
parkinson B-Disease
disease I-Disease
, O
the O
authors O
investigated O
whether O
modulation O
of O
sma O
excitability O
may O
result O
in O
a O
modification O
of O
a O
dyskinetic B-Disease
state O
induced O
by O
continuous O
apomorphine O
infusion O
. O

rtms O
at O
1 O
hz O
was O
observed O
to O
markedly O
reduce O
drug B-Disease
- I-Disease
induced I-Disease
dyskinesias I-Disease
, O
whereas O
5 O
- O
hz O
rtms O
induced O
a O
slight O
but O
not O
significant O
increase O
. O

intracavitary O
chemotherapy O
( O
paclitaxel O
/ O
carboplatin O
liquid O
crystalline O
cubic O
phases O
) O
for O
recurrent O
glioblastoma B-Disease
- O
- O
clinical O
observations O
. O

human O
malignant O
brain B-Disease
tumors I-Disease
have O
a O
poor O
prognosis O
in O
spite O
of O
surgery O
and O
radiation O
therapy O
. O

for O
human O
glioblastoma B-Disease
recurrences O
, O
the O
feasibility O
, O
safety O
, O
and O
short O
- O
term O
effects O
of O
a O
surgical O
intracavitary O
application O
of O
paclitaxel O
and O
carboplatin O
encapsulated O
by O
liquid O
crystalline O
cubic O
phases O
are O
examined O
in O
a O
pilot O
study O
. O

a O
total O
of O
12 O
patients O
with O
a O
recurrence O
of O
a O
glioblastoma B-Disease
multiforme O
underwent O
re O
- O
resection O
and O
received O
an O
intracavitary O
application O
of O
paclitaxel O
and O
carboplatin O
cubic O
phases O
in O
different O
dosages O
. O

six O
of O
the O
patients O
received O
more O
than O
15 O
mg O
paclitaxel O
and O
suffered O
from O
moderate O
to O
severe O
brain B-Disease
edema I-Disease
, O
while O
the O
remaining O
patients O
received O
only O
a O
total O
of O
15 O
mg O
paclitaxel O
. O

in O
the O
latter O
group O
, O
brain B-Disease
edema I-Disease
was O
markedly O
reduced O
and O
dealt O
medically O
. O

intracavitary O
chemotherapy O
in O
recurrent O
glioblastoma B-Disease
using O
cubic O
phases O
is O
feasible O
and O
safe O
, O
yet O
the O
clinical O
benefit O
remains O
to O
be O
examined O
in O
a O
clinical O
phase O
ii O
study O
. O

lamotrigine O
associated O
with O
exacerbation O
or O
de O
novo O
myoclonus B-Disease
in O
idiopathic B-Disease
generalized I-Disease
epilepsies I-Disease
. O

five O
patients O
with O
idiopathic B-Disease
generalized I-Disease
epilepsies I-Disease
( O
ige B-Disease
) O
treated O
with O
lamotrigine O
( O
ltg O
) O
experienced O
exacerbation O
or O
de O
novo O
appearance O
of O
myoclonic B-Disease
jerks I-Disease
( O
mj B-Disease
) O
. O

in O
three O
patients O
, O
ltg O
exacerbated O
mj B-Disease
in O
a O
dose O
- O
dependent O
manner O
with O
early O
aggravation O
during O
titration O
. O

mj B-Disease
disappeared O
when O
ltg O
dose O
was O
decreased O
by O
25 O
to O
50 O
% O
. O

in O
two O
patients O
, O
ltg O
exacerbated O
mj B-Disease
in O
a O
delayed O
but O
more O
severe O
manner O
, O
with O
myoclonic B-Disease
status I-Disease
that O
only O
ceased O
after O
ltg O
withdrawal O
. O

absence O
of O
acute O
cerebral O
vasoconstriction O
after O
cocaine O
- O
associated O
subarachnoid B-Disease
hemorrhage I-Disease
. O

introduction O
: O
cocaine O
use O
has O
been O
associated O
with O
neurovascular B-Disease
complications I-Disease
, O
including O
arterial O
vasoconstriction O
and O
vasculitis B-Disease
. O

information O
on O
these O
effects O
could O
be O
obtained O
from O
angiograms O
of O
patients O
with O
cocaine O
- O
associated O
subarachnoid B-Disease
hemorrhage I-Disease
( O
sah B-Disease
) O
who O
underwent O
angiography O
shortly O
after O
cocaine O
use O
. O

methods O
: O
we O
screened O
patients O
with O
sah B-Disease
retrospectively O
and O
identified O
those O
with O
positive O
urine O
toxicology O
for O
cocaine O
or O
its O
metabolites O
. O

quantitative O
arterial O
diameter O
measurements O
from O
angiograms O
of O
these O
patients O
were O
compared O
to O
measurements O
from O
control O
patients O
with O
sah B-Disease
who O
were O
matched O
for O
factors O
known O
to O
influence O
arterial O
diameter O
. O

conclusion O
: O
no O
quantitative O
evidence O
for O
narrowing O
of O
large O
cerebral O
arteries O
or O
qualitative O
angiographic O
evidence O
for O
distal O
narrowing O
or O
vasculitis B-Disease
could O
be O
found O
in O
patients O
who O
underwent O
angiography O
after O
aneurysmal B-Disease
sah B-Disease
associated O
with O
cocaine O
use O
. O

methamphetamine O
causes O
alterations O
in O
the O
map O
kinase O
- O
related O
pathways O
in O
the O
brains O
of O
mice O
that O
display O
increased O
aggressiveness B-Disease
. O

aggressive B-Disease
behaviors I-Disease
have O
been O
reported O
in O
patients O
who O
suffer O
from O
some O
psychiatric B-Disease
disorders I-Disease
, O
and O
are O
common O
in O
methamphetamine O
( O
meth O
) O
abusers O
. O

herein O
, O
we O
report O
that O
multiple O
( O
but O
not O
single O
) O
injections O
of O
meth O
significantly O
increased O
aggressiveness B-Disease
in O
male O
cd O
- O
1 O
mice O
. O

this O
increase O
in O
aggressiveness B-Disease
was O
not O
secondary O
to O
meth O
- O
induced O
hyperactivity B-Disease
. O

these O
findings O
suggest O
that O
alterations O
in O
map O
kinase O
- O
related O
pathways O
in O
the O
prefronto O
- O
striatal O
circuitries O
might O
be O
involved O
in O
the O
manifestation O
of O
aggressive B-Disease
behaviors I-Disease
in O
mice O
. O

amisulpride O
related O
tic B-Disease
- I-Disease
like I-Disease
symptoms I-Disease
in O
an O
adolescent O
schizophrenic B-Disease
. O

tic B-Disease
disorders I-Disease
can O
be O
effectively O
treated O
by O
atypical O
antipsychotics O
such O
as O
risperidone O
, O
olanzapine O
and O
ziprasidone O
. O

however O
, O
there O
are O
two O
case O
reports O
that O
show O
tic B-Disease
- I-Disease
like I-Disease
symptoms I-Disease
, O
including O
motor O
and O
phonic O
variants O
, O
occurring O
during O
treatment O
with O
quetiapine O
or O
clozapine O
. O

we O
present O
a O
15 O
- O
year O
- O
old O
girl O
schizophrenic B-Disease
who O
developed O
frequent O
involuntary B-Disease
eye I-Disease
- I-Disease
blinking I-Disease
movements I-Disease
after O
5 O
months O
of O
amisulpride O
treatment O
( O
1000 O
mg O
per O
day O
) O
. O

the O
tic B-Disease
- I-Disease
like I-Disease
symptoms I-Disease
resolved O
completely O
after O
we O
reduced O
the O
dose O
of O
amisulpride O
down O
to O
800 O
mg O
per O
day O
. O

however O
, O
her O
psychosis B-Disease
recurred O
after O
the O
dose O
reduction O
. O

no O
more O
tic B-Disease
- I-Disease
like I-Disease
symptoms I-Disease
or O
other O
side O
effects O
have O
been O
reported O
. O

together O
with O
previously O
reported O
cases O
, O
our O
patient O
suggests O
that O
tic B-Disease
- I-Disease
like I-Disease
symptoms I-Disease
might O
occur O
in O
certain O
vulnerable O
individuals O
during O
treatment O
with O
atypical O
antipsychotics O
such O
as O
quetiapine O
, O
clozapine O
, O
or O
amisulpride O
. O

chloroquine O
related O
complete O
heart B-Disease
block I-Disease
with O
blindness B-Disease
: O
case O
report O
. O

a O
27 O
- O
year O
old O
african O
woman O
with O
history O
of O
regular O
chloroquine O
ingestion O
presented O
with O
progressive O
deterioration B-Disease
of I-Disease
vision I-Disease
, O
easy O
fatiguability B-Disease
, O
dyspnoea B-Disease
, O
dizziness B-Disease
progressing O
to O
syncopal B-Disease
attacks I-Disease
. O

ophthalmological O
assessment O
revealed O
features O
of O
chloroquine O
retinopathy B-Disease
, O
cardiac O
assessment O
revealed O
features O
of O
heart B-Disease
failure I-Disease
and O
a O
complete O
heart B-Disease
block I-Disease
with O
right B-Disease
bundle I-Disease
branch I-Disease
block I-Disease
pattern O
. O

the O
heart B-Disease
block I-Disease
was O
treated O
by O
pacemaker O
insertion O
and O
the O
heart B-Disease
failure I-Disease
resolved O
spontaneously O
following O
chloroquine O
discontinuation O
. O

she O
however O
remains O
blind B-Disease
. O

although O
suprofen O
has O
been O
associated O
with O
the O
development O
of O
acute B-Disease
renal I-Disease
failure I-Disease
in O
greater O
than O
100 O
subjects O
, O
the O
mechanism O
of O
damage O
remains O
unclear O
. O

the O
direct O
nephrotoxic B-Disease
effects O
of O
a O
single O
dose O
of O
15 O
mg O
of O
suprofen O
were O
compared O
in O
the O
recirculating O
isolated O
rat O
kidney O
perfused O
with O
cell O
- O
free O
buffer O
with O
or O
without O
the O
addition O
of O
5 O
mg O
/ O
dl O
of O
uric O
acid O
. O

in O
summary O
, O
suprofen O
causes O
acute B-Disease
declines I-Disease
in I-Disease
renal I-Disease
function I-Disease
, O
most O
likely O
by O
directly O
altering O
the O
intrarenal O
distribution O
of O
uric O
acid O
. O

microinjection O
of O
ritanserin O
into O
the O
ca1 O
region O
of O
hippocampus O
improves O
scopolamine O
- O
induced O
amnesia B-Disease
in O
adult O
male O
rats O
. O

the O
effect O
of O
ritanserin O
( O
5 O
- O
ht2 O
antagonist O
) O
on O
scopolamine O
( O
muscarinic O
cholinergic O
antagonist O
) O
- O
induced O
amnesia B-Disease
in O
morris O
water O
maze O
( O
mwm O
) O
was O
investigated O
. O

our O
findings O
show O
that O
microinjection O
of O
ritanserin O
into O
the O
ca1 O
region O
of O
the O
hippocampus O
improves O
the O
scopolamine O
- O
induced O
amnesia B-Disease
. O

ptu O
- O
associated O
vasculitis B-Disease
in O
a O
girl O
with O
turner B-Disease
syndrome I-Disease
and O
graves B-Disease
' I-Disease
disease I-Disease
. O

palpable O
purpura B-Disease
is O
a O
concerning O
clinical O
finding O
in O
pediatric O
patients O
and O
can O
have O
many O
causes O
, O
including O
infectious O
and O
autoimmune O
processes O
. O

a O
rare O
cause O
, O
drug O
- O
induced O
vasculitis B-Disease
, O
may O
result O
from O
the O
production O
of O
antineutrophil O
cytoplasmic O
antibodies O
( O
ancas O
) O
in O
response O
to O
a O
medication O
. O

we O
report O
a O
girl O
with O
turner B-Disease
syndrome I-Disease
and O
graves B-Disease
' I-Disease
disease I-Disease
who O
presented O
with O
palpable O
purpuric B-Disease
lesions I-Disease
. O

the O
diagnosis O
of O
propylthiouracil O
( O
ptu O
) O
- O
associated O
vasculitis B-Disease
was O
made O
by O
observation O
of O
consistent O
clinical O
features O
, O
the O
detection O
of O
elevated O
ana O
and O
anca O
in O
the O
blood O
, O
and O
the O
observed O
clinical O
resolution O
of O
symptoms O
following O
withdrawal O
of O
ptu O
. O

subsequent O
treatment O
of O
persistent O
hyperthyroidism B-Disease
with O
radioablation O
did O
not O
result O
in O
an O
exacerbation O
of O
the O
vasculitis B-Disease
, O
a O
complication O
described O
in O
prior O
case O
reports O
. O

daidzein O
activates O
choline O
acetyltransferase O
from O
mc O
- O
ixc O
cells O
and O
improves O
drug O
- O
induced O
amnesia B-Disease
. O

the O
choline O
acetyltransferase O
( O
chat O
) O
activator O
, O
which O
enhances O
cholinergic O
transmission O
via O
an O
augmentation O
of O
the O
enzymatic O
production O
of O
acetylcholine O
( O
ach O
) O
, O
is O
an O
important O
factor O
in O
the O
treatment O
of O
alzheimer B-Disease
' I-Disease
s I-Disease
disease I-Disease
( O
ad B-Disease
) O
. O

in O
order O
to O
investigate O
the O
effects O
of O
daidzein O
from O
pueraria O
thunbergiana O
on O
scopolamine O
- O
induced O
impairments B-Disease
of I-Disease
learning I-Disease
and I-Disease
memory I-Disease
, O
we O
conducted O
a O
series O
of O
in O
vivo O
tests O
. O

administration O
of O
daidzein O
( O
4 O
. O

5 O
mg O
/ O
kg O
body O
weight O
) O
to O
mice O
was O
shown O
significantly O
to O
reverse O
scopolamine O
- O
induced O
amnesia B-Disease
, O
according O
to O
the O
results O
of O
a O
y O
- O
maze O
test O
. O

these O
results O
indicate O
that O
daidzein O
might O
play O
a O
role O
in O
acetylcholine O
biosynthesis O
as O
a O
chat O
activator O
, O
and O
that O
it O
also O
ameliorates O
scopolamine O
- O
induced O
amnesia B-Disease
. O

urinary O
symptoms O
and O
quality O
of O
life O
changes O
in O
thai O
women O
with O
overactive B-Disease
bladder I-Disease
after O
tolterodine O
treatment O
. O

objectives O
: O
to O
study O
the O
urinary O
symptoms O
and O
quality O
of O
life O
changes O
in O
thai O
women O
with O
overactive B-Disease
bladder I-Disease
( O
oab B-Disease
) O
after O
tolterodine O
treatment O
. O

material O
and O
method O
: O
thirty O
women O
( O
aged O
30 O
- O
77 O
years O
) O
diagnosed O
as O
having O
oab B-Disease
at O
the O
gynecology O
clinic O
, O
king O
chulalongkorn O
memorial O
hospital O
from O
january O
to O
april O
2004 O
were O
included O
in O
the O
present O
study O
. O

the O
number O
of O
nocturia B-Disease
episodes O
decreased O
from O
5 O
. O

4 O
+ O
/ O
- O
4 O
. O

2 O
to O
1 O
. O

1 O
+ O
/ O
- O
1 O
. O

0 O
times O
per O
night O
. O

the O
most O
common O
side O
effect O
was O
dry B-Disease
month I-Disease
in O
5 O
cases O
( O
16 O
. O

7 O
% O
) O
with O
2 O
cases O
reporting O
a O
moderate O
degree O
and O
1 O
case O
with O
severe O
degree O
. O

only O
one O
case O
( O
3 O
. O

3 O
% O
) O
withdrew O
from O
the O
present O
study O
due O
to O
a O
severe O
dry B-Disease
mouth I-Disease
. O

conclusion O
: O
tolterodine O
was O
well O
tolerated O
and O
its O
effects O
improved O
the O
quality O
of O
life O
in O
thai O
women O
with O
oab B-Disease
. O

remifentanil O
pretreatment O
reduces O
myoclonus B-Disease
after O
etomidate O
. O

study O
objective O
: O
the O
aim O
of O
the O
study O
was O
to O
compare O
the O
effect O
of O
pretreatment O
with O
remifentanil O
1 O
microg O
/ O
kg O
and O
the O
effect O
of O
gender O
on O
the O
incidence O
of O
myoclonus B-Disease
after O
anesthesia O
induction O
with O
etomidate O
. O

measurements O
: O
myoclonus B-Disease
was O
recorded O
with O
a O
scale O
of O
0 O
to O
3 O
. O

the O
grade O
of O
sedation O
( O
none O
, O
mild O
, O
moderate O
, O
severe O
) O
, O
nausea B-Disease
, O
pruritus B-Disease
, O
and O
apnea B-Disease
were O
recorded O
after O
injection O
of O
both O
drugs O
. O

main O
results O
: O
the O
incidence O
of O
myoclonus B-Disease
was O
significantly O
lower O
in O
the O
remifentanil O
group O
( O
6 O
. O

7 O
% O
) O
than O
in O
the O
placebo O
group O
( O
70 O
% O
) O
( O
p O
< O
0 O
. O

1 O
) O
. O

none O
of O
the O
patients O
experienced O
sedation O
, O
apnea B-Disease
, O
nausea B-Disease
, O
or O
pruritus B-Disease
after O
injection O
of O
both O
drugs O
. O

in O
the O
placebo O
group O
, O
male O
patients O
were O
associated O
with O
significantly O
increased O
incidence O
of O
myoclonus B-Disease
after O
etomidate O
administration O
. O

conclusion O
: O
pretreatment O
with O
remifentanil O
1 O
microg O
/ O
kg O
reduced O
myoclonus B-Disease
after O
etomidate O
induction O
without O
side O
effects O
such O
as O
sedation O
, O
apnea B-Disease
, O
nausea B-Disease
, O
or O
pruritus B-Disease
. O

men O
experience O
increased O
incidence O
of O
myoclonus B-Disease
than O
women O
after O
etomidate O
administration O
. O

although O
3 O
, O
4 O
- O
methylenedioxymethamphetamine O
( O
mdma O
or O
ecstasy O
) O
has O
been O
shown O
to O
damage O
brain O
serotonin O
( O
5 O
- O
ht O
) O
neurons O
in O
animals O
and O
possibly O
humans O
, O
little O
is O
known O
about O
the O
long O
- O
term O
consequences O
of O
mdma O
- O
induced O
5 O
- O
ht O
neurotoxic B-Disease
lesions I-Disease
on O
functions O
in O
which O
5 O
- O
ht O
is O
involved O
, O
such O
as O
cognitive O
function O
. O

in O
contrast O
, O
no O
evidence O
of O
memory B-Disease
impairment I-Disease
was O
observed O
in O
moderate O
mdma O
users O
. O

while O
the O
use O
of O
mdma O
in O
quantities O
that O
may O
be O
considered O
nan O
moderate O
nan O
is O
not O
associated O
with O
impaired B-Disease
memory I-Disease
functioning I-Disease
, O
heavy O
use O
of O
mdma O
use O
may O
lead O
to O
long O
lasting O
memory B-Disease
impairments I-Disease
. O

role O
of O
mangiferin O
on O
biochemical O
alterations O
and O
antioxidant O
status O
in O
isoproterenol O
- O
induced O
myocardial B-Disease
infarction I-Disease
in O
rats O
. O

( O
anacardiaceae O
) O
, O
on O
isoproterenol O
( O
isph O
) O
- O
induced O
myocardial B-Disease
infarction I-Disease
( O
mi B-Disease
) O
in O
rats O
through O
its O
antioxidative O
mechanism O
. O

subcutaneous O
injection O
of O
isph O
( O
200 O
mg O
/ O
kg O
body O
weight O
in O
1 O
ml O
saline O
) O
to O
rats O
for O
2 O
consecutive O
days O
caused O
myocardial B-Disease
damage I-Disease
in O
rat O
heart O
, O
which O
was O
determined O
by O
the O
increased O
activity O
of O
serum O
lactate O
dehydrogenase O
( O
ldh O
) O
and O
creatine O
phosphokinase O
isoenzymes O
( O
ck O
- O
mb O
) O
, O
increased O
uric O
acid O
level O
and O
reduced O
plasma O
iron O
binding O
capacity O
. O

the O
protective O
role O
of O
mangiferin O
was O
analyzed O
by O
triphenyl O
tetrazolium O
chloride O
( O
ttc O
) O
test O
used O
for O
macroscopic O
enzyme O
mapping O
assay O
of O
the O
ischemic B-Disease
myocardium I-Disease
. O

the O
heart O
tissue O
antioxidant O
enzymes O
such O
as O
superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
, O
glutathione O
transferase O
and O
glutathione O
reductase O
activities O
, O
non O
- O
enzymic O
antioxidants O
such O
as O
cerruloplasmin O
, O
vitamin O
c O
, O
vitamin O
e O
and O
glutathione O
levels O
were O
altered O
in O
mi B-Disease
rats O
. O

upon O
pretreatment O
with O
mangiferin O
( O
100 O
mg O
/ O
kg O
body O
weight O
suspended O
in O
2 O
ml O
of O
dimethyl O
sulphoxide O
) O
given O
intraperitoneally O
for O
28 O
days O
to O
mi B-Disease
rats O
protected O
the O
above O
- O
mentioned O
parameters O
to O
fall O
from O
the O
normal O
levels O
. O

activities O
of O
heart O
tissue O
enzymic O
antioxidants O
and O
serum O
non O
- O
enzymic O
antioxidants O
levels O
rose O
significantly O
upon O
mangiferin O
administration O
as O
compared O
to O
isph O
- O
induced O
mi B-Disease
rats O
. O

from O
the O
present O
study O
it O
is O
concluded O
that O
mangiferin O
exerts O
a O
beneficial O
effect O
against O
isph O
- O
induced O
mi B-Disease
due O
to O
its O
antioxidant O
potential O
, O
which O
regulated O
the O
tissues O
defense O
system O
against O
cardiac B-Disease
damage I-Disease
. O

randomised O
clinical O
trials O
and O
observational O
studies O
have O
shown O
an O
increased O
risk O
of O
myocardial B-Disease
infarction I-Disease
, O
stroke B-Disease
, O
hypertension B-Disease
and O
heart B-Disease
failure I-Disease
during O
treatment O
with O
cyclooxygenase O
inhibitors O
. O

diagnostic O
markers O
such O
as O
n O
- O
terminal O
pro O
brain O
natriuretic O
peptide O
( O
nt O
- O
probnp O
) O
or O
high O
- O
sensitive O
c O
- O
reactive O
protein O
might O
help O
in O
the O
early O
identification O
of O
patients O
at O
risk O
, O
thus O
avoiding O
the O
occurrence O
of O
serious O
cardiovascular B-Disease
toxicity I-Disease
. O

pilocarpine O
seizures B-Disease
cause O
age O
- O
dependent O
impairment B-Disease
in I-Disease
auditory I-Disease
location I-Disease
discrimination I-Disease
. O

children O
who O
have O
status B-Disease
epilepticus I-Disease
have O
continuous O
or O
rapidly O
repeating O
seizures B-Disease
that O
may O
be O
life O
- O
threatening O
and O
may O
cause O
life O
- O
long O
changes O
in O
brain O
and O
behavior O
. O

the O
extent O
to O
which O
status B-Disease
epilepticus I-Disease
causes O
deficits B-Disease
in I-Disease
auditory I-Disease
discrimination I-Disease
is O
unknown O
. O

a O
naturalistic O
auditory O
location O
discrimination O
method O
was O
used O
to O
evaluate O
this O
question O
using O
an O
animal O
model O
of O
status B-Disease
epilepticus I-Disease
. O

pilocarpine O
on O
either O
day O
induced O
status B-Disease
epilepticus I-Disease
; O
status B-Disease
epilepticus I-Disease
at O
p45 O
resulted O
in O
ca3 O
cell O
loss O
and O
spontaneous O
seizures B-Disease
, O
whereas O
p20 O
rats O
had O
no O
cell O
loss O
or O
spontaneous O
seizures B-Disease
. O

in O
status B-Disease
epilepticus I-Disease
( O
p20 O
) O
rats O
, O
acquisition O
of O
the O
sound O
- O
source O
location O
discrimination O
was O
moderately O
impaired O
. O

status B-Disease
epilepticus I-Disease
( O
p45 O
) O
rats O
failed O
to O
acquire O
either O
sound O
- O
source O
location O
or O
sound O
- O
silence O
discriminations O
. O

status B-Disease
epilepticus I-Disease
in O
rat O
causes O
an O
age O
- O
dependent O
, O
long O
- O
term O
impairment B-Disease
in I-Disease
auditory I-Disease
discrimination I-Disease
. O

this O
impairment O
may O
explain O
one O
cause O
of O
impaired B-Disease
auditory I-Disease
location I-Disease
discrimination I-Disease
in O
humans O
. O

nerve O
growth O
factor O
and O
prostaglandins O
in O
the O
urine O
of O
female O
patients O
with O
overactive B-Disease
bladder I-Disease
. O

we O
investigated O
changes O
in O
urinary O
ngf O
and O
pgs O
in O
women O
with O
oab B-Disease
. O

materials O
and O
methods O
: O
the O
study O
groups O
included O
65 O
women O
with O
oab B-Disease
and O
20 O
without O
bladder O
symptoms O
who O
served O
as O
controls O
. O

in O
addition O
, O
correlations O
between O
urinary O
ngf O
and O
pg O
, O
and O
urodynamic O
parameters O
in O
patients O
with O
oab B-Disease
were O
examined O
. O

results O
: O
urinary O
ngf O
, O
pge2 O
and O
pgf2alpha O
were O
significantly O
increased O
in O
patients O
with O
oab B-Disease
compared O
with O
controls O
( O
p O
< O
0 O
. O

5 O
) O
. O

however O
, O
urinary O
pgi2 O
was O
not O
different O
between O
controls O
and O
patients O
with O
oab B-Disease
. O

in O
patients O
with O
oab B-Disease
urinary O
pge2 O
positively O
correlated O
with O
volume O
at O
first O
desire O
to O
void O
and O
maximum O
cystometric O
capacity O
( O
p O
< O
0 O
. O

5 O
) O
. O

urinary O
ngf O
, O
pgf2alpha O
and O
pgi2 O
did O
not O
correlate O
with O
urodynamic O
parameters O
in O
patients O
with O
oab B-Disease
. O

conclusions O
: O
ngf O
and O
pgs O
have O
important O
roles O
in O
the O
development O
of O
oab B-Disease
symptoms O
in O
female O
patients O
. O

urinary O
levels O
of O
these O
factors O
may O
be O
used O
as O
markers O
to O
evaluate O
oab B-Disease
symptoms O
. O

definition O
and O
management O
of O
anemia B-Disease
in O
patients O
infected B-Disease
with I-Disease
hepatitis I-Disease
c I-Disease
virus I-Disease
. O

chronic B-Disease
infection I-Disease
with I-Disease
hepatitis I-Disease
c I-Disease
virus I-Disease
( O
hcv O
) O
can O
progress O
to O
cirrhosis B-Disease
, O
hepatocellular B-Disease
carcinoma I-Disease
, O
and O
end B-Disease
- I-Disease
stage I-Disease
liver I-Disease
disease I-Disease
. O

the O
current O
best O
treatment O
for O
hcv B-Disease
infection I-Disease
is O
combination O
therapy O
with O
pegylated O
interferon O
and O
ribavirin O
. O

although O
this O
regimen O
produces O
sustained O
virologic O
responses O
( O
svrs O
) O
in O
approximately O
50 O
% O
of O
patients O
, O
it O
can O
be O
associated O
with O
a O
potentially O
dose O
- O
limiting O
hemolytic B-Disease
anemia I-Disease
. O

hemoglobin O
concentrations O
decrease O
mainly O
as O
a O
result O
of O
ribavirin O
- O
induced O
hemolysis B-Disease
, O
and O
this O
anemia B-Disease
can O
be O
problematic O
in O
patients O
with O
hcv B-Disease
infection I-Disease
, O
especially O
those O
who O
have O
comorbid O
renal B-Disease
or I-Disease
cardiovascular I-Disease
disorders I-Disease
. O

in O
general O
, O
anemia B-Disease
can O
increase O
the O
risk O
of O
morbidity O
and O
mortality O
, O
and O
may O
have O
negative O
effects O
on O
cerebral O
function O
and O
quality O
of O
life O
. O

although O
ribavirin O
- O
associated O
anemia B-Disease
can O
be O
reversed O
by O
dose O
reduction O
or O
discontinuation O
, O
this O
approach O
compromises O
outcomes O
by O
significantly O
decreasing O
svr O
rates O
. O

recombinant O
human O
erythropoietin O
has O
been O
used O
to O
manage O
ribavirin O
- O
associated O
anemia B-Disease
but O
has O
other O
potential O
disadvantages O
. O

viramidine O
, O
a O
liver O
- O
targeting O
prodrug O
of O
ribavirin O
, O
has O
the O
potential O
to O
maintain O
the O
virologic O
efficacy O
of O
ribavirin O
while O
decreasing O
the O
risk O
of O
hemolytic B-Disease
anemia I-Disease
in O
patients O
with O
chronic B-Disease
hepatitis I-Disease
c I-Disease
. O

this O
study O
examined O
the O
utility O
of O
biometry O
for O
detecting O
alcohol O
- O
related O
fetal O
growth B-Disease
impairment I-Disease
. O

analyses O
of O
covariance O
were O
used O
to O
determine O
whether O
there O
were O
differences O
between O
groups O
after O
controlling O
for O
influences O
of O
gestational O
age O
and O
drug B-Disease
abuse I-Disease
. O

any O
alcohol O
consumption O
postpregnancy O
recognition O
among O
the O
heavy O
drinkers O
resulted O
in O
reduced B-Disease
cerebellar I-Disease
growth I-Disease
as O
well O
as O
decreased B-Disease
cranial I-Disease
to I-Disease
body I-Disease
growth I-Disease
in O
comparison O
with O
women O
who O
either O
quit O
drinking O
or O
who O
were O
nondrinkers O
. O

ethambutol O
- O
associated O
optic B-Disease
neuropathy I-Disease
. O

introduction O
: O
ethambutol O
is O
used O
in O
the O
treatment O
of O
tuberculosis B-Disease
, O
which O
is O
still O
prevalent O
in O
southeast O
asia O
, O
and O
can O
be O
associated O
with O
permanent O
visual B-Disease
loss I-Disease
. O

we O
report O
3 O
cases O
which O
presented O
with O
bitemporal B-Disease
hemianopia I-Disease
. O

clinical O
picture O
: O
three O
patients O
with O
ethambutol O
- O
associated O
toxic O
optic B-Disease
neuropathy I-Disease
are O
described O
. O

all O
3 O
patients O
had O
loss B-Disease
of I-Disease
central I-Disease
visual I-Disease
acuity I-Disease
, I-Disease
colour I-Disease
vision I-Disease
( I-Disease
ishihara I-Disease
) I-Disease
and I-Disease
visual I-Disease
field I-Disease
. O

the O
visual B-Disease
field I-Disease
loss I-Disease
had O
a O
bitemporal O
flavour O
, O
suggesting O
involvement O
of O
the O
optic O
chiasm O
. O

outcome O
: O
all O
3 O
patients O
had O
some O
permanent O
loss B-Disease
of I-Disease
visual I-Disease
function I-Disease
. O

conclusions O
: O
ethambutol O
usage O
is O
associated O
with O
permanent O
visual B-Disease
loss I-Disease
and O
should O
be O
avoided O
if O
possible O
or O
used O
with O
caution O
and O
proper O
ophthalmological O
follow O
- O
up O
. O

possible O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
related O
to O
concomitant O
treatment O
with O
paroxetine O
and O
alprazolam O
. O

a O
74 O
- O
year O
- O
old O
man O
with O
depressive B-Disease
symptoms I-Disease
was O
admitted O
to O
a O
psychiatric B-Disease
hospital O
due O
to O
insomnia B-Disease
, O
loss B-Disease
of I-Disease
appetite I-Disease
, O
exhaustion O
, O
and O
agitation B-Disease
. O

on O
the O
10th O
day O
of O
paroxetine O
and O
alprazolam O
treatment O
, O
the O
patient O
exhibited O
marked O
psychomotor B-Disease
retardation I-Disease
, O
disorientation O
, O
and O
severe O
muscle B-Disease
rigidity I-Disease
with O
tremors B-Disease
. O

the O
patient O
had O
a O
fever B-Disease
( O
38 O
. O

2 O
degrees O
c O
) O
, O
fluctuating O
blood O
pressure O
( O
between O
165 O
/ O
90 O
and O
130 O
/ O
70 O
mg O
mm O
hg O
) O
, O
and O
severe O
extrapyramidal B-Disease
symptoms I-Disease
. O

7 O
days O
later O
, O
the O
fever B-Disease
disappeared O
and O
the O
patient O
' O
s O
serum O
cpk O
levels O
were O
normalized O
( O
175 O
iu O
/ O
l O
) O
. O

this O
patient O
presented O
with O
symptoms O
of O
neuroleptic B-Disease
malignant I-Disease
syndrome I-Disease
( O
nms B-Disease
) O
, O
thus O
demonstrating O
that O
nms B-Disease
- O
like O
symptoms O
can O
occur O
after O
combined O
paroxetine O
and O
alprazolam O
treatment O
. O

the O
adverse O
drug O
reaction O
score O
obtained O
by O
the O
naranjo O
algorithm O
was O
6 O
in O
our O
case O
, O
indicating O
a O
probable O
relationship O
between O
the O
patient O
' O
s O
nms B-Disease
- O
like O
adverse O
symptoms O
and O
the O
combined O
treatment O
used O
in O
this O
case O
. O

several O
risk O
factors O
for O
nms B-Disease
should O
be O
noted O
in O
elderly O
depressive B-Disease
patients O
whose O
symptoms O
often O
include O
dehydration B-Disease
, O
agitation B-Disease
, O
malnutrition B-Disease
, O
and O
exhaustion O
. O

careful O
therapeutic O
intervention O
is O
necessary O
in O
cases O
involving O
elderly O
patients O
who O
suffer O
from O
depression B-Disease
. O

down O
- O
regulation O
of O
norepinephrine O
transporter O
function O
induced O
by O
chronic O
administration O
of O
desipramine O
linking O
to O
the O
alteration O
of O
sensitivity O
of O
local O
- O
anesthetics O
- O
induced O
convulsions B-Disease
and O
the O
counteraction O
by O
co O
- O
administration O
with O
local O
anesthetics O
. O

alterations O
of O
norepinephrine O
transporter O
( O
net O
) O
function O
by O
chronic O
inhibition O
of O
net O
in O
relation O
to O
sensitization O
to O
seizures B-Disease
induce O
by O
cocaine O
and O
local O
anesthetics O
were O
studied O
in O
mice O
. O

daily O
administration O
of O
desipramine O
increased O
the O
incidence O
of O
appearance O
of O
lidocaine O
- O
induced O
convulsions B-Disease
and O
decreased O
that O
of O
cocaine O
- O
induced O
convulsions B-Disease
. O

co O
- O
administration O
of O
lidocaine O
with O
desipramine O
reversed O
the O
changes O
of O
convulsive B-Disease
activity O
of O
lidocaine O
and O
cocaine O
induced O
by O
repeated O
administration O
of O
desipramine O
. O

these O
results O
suggest O
that O
down O
- O
regulation O
of O
hippocampal O
net O
induced O
by O
chronic O
administration O
of O
desipramine O
may O
be O
relevant O
to O
desipramine O
- O
induced O
sensitization O
of O
lidocaine O
convulsions B-Disease
. O

desipramine O
- O
induced O
sensitization O
of O
lidocaine O
seizures B-Disease
may O
have O
a O
mechanism O
distinct O
from O
kindling O
resulting O
from O
repeated O
administration O
of O
cocaine O
. O

atorvastatin O
prevented O
and O
reversed O
dexamethasone O
- O
induced O
hypertension B-Disease
in O
the O
rat O
. O

to O
assess O
the O
antioxidant O
effects O
of O
atorvastatin O
( O
atorva O
) O
on O
dexamethasone O
( O
dex O
) O
- O
induced O
hypertension B-Disease
, O
60 O
male O
sprague O
- O
dawley O
rats O
were O
treated O
with O
atorva O
30 O
mg O
/ O
kg O
/ O
day O
or O
tap O
water O
for O
15 O
days O
. O

atorva O
reversed O
dex O
- O
induced O
hypertension B-Disease
( O
129 O
+ O
/ O
- O
0 O
. O

6 O
mmhg O
, O
vs O
. O

135 O
+ O
/ O
- O
0 O
. O

6 O
mmhg O
p O
' O
< O
0 O
. O

5 O
) O
and O
decreased O
plasma O
superoxide O
( O
7931 O
+ O
/ O
- O
392 O
. O

8 O
dex O
, O
1187 O
+ O
/ O
- O
441 O
. O

2 O
atorva O
+ O
dex O
, O
p O
< O
0 O
. O

1 O
) O
. O

thus O
, O
atorvastatin O
prevented O
and O
reversed O
dexamethasone O
- O
induced O
hypertension B-Disease
in O
the O
rat O
. O

peripheral B-Disease
neuropathy I-Disease
caused O
by O
high O
- O
dose O
cytosine O
arabinoside O
treatment O
in O
a O
patient O
with O
acute B-Disease
myeloid I-Disease
leukemia I-Disease
. O

the O
central O
nervous O
system O
toxicity B-Disease
of O
high O
- O
dose O
cytosine O
arabinoside O
is O
well O
recognized O
, O
but O
the O
toxicity B-Disease
of O
cytosine O
arabinoside O
in O
the O
peripheral O
nervous O
system O
has O
been O
infrequently O
reported O
. O

a O
49 O
- O
year O
- O
old O
japanese O
man O
was O
diagnosed O
with O
acute B-Disease
myeloid I-Disease
leukemia I-Disease
. O

the O
first O
course O
of O
high O
- O
dose O
cytosine O
arabinoside O
resulted O
in O
no O
unusual O
symptoms O
, O
but O
on O
day O
21 O
of O
the O
second O
course O
of O
treatment O
, O
the O
patient O
complained O
of O
numbness B-Disease
in O
his O
right O
foot O
. O

electromyogram O
and O
nerve O
- O
conduction O
studies O
showed O
peripheral B-Disease
neuropathy I-Disease
in O
both O
peroneal O
nerves O
. O

this O
neuropathy B-Disease
was O
gradually O
resolving O
; O
however O
, O
after O
the O
patient O
received O
allogeneic O
bone O
marrow O
transB-Plantation O
, O
the O
symptoms O
worsened O
, O
with O
the O
development O
of O
graft B-Disease
- I-Disease
versus I-Disease
- I-Disease
host I-Disease
disease I-Disease
, O
and O
the O
symptoms O
subsequently O
responded O
to O
methylprednisolone O
. O

although O
the O
mechanisms O
of O
peripheral B-Disease
neuropathy I-Disease
are O
still O
unclear O
, O
high O
- O
dose O
cytosine O
arabinoside O
is O
a O
therapy O
that O
is O
potentially O
toxic O
to O
the O
peripheral O
nervous O
system O
, O
and O
auto O
/ O
alloimmunity O
may O
play O
an O
important O
role O
in O
these O
mechanisms O
. O

effect O
of O
alpha O
- O
tocopherol O
and O
deferoxamine O
on O
methamphetamine O
- O
induced O
neurotoxicity B-Disease
. O

methamphetamine O
( O
ma O
) O
- O
induced O
dopaminergic O
neurotoxicity B-Disease
is O
believed O
to O
be O
associated O
with O
the O
increased O
formation O
of O
free O
radicals O
. O

this O
study O
examined O
the O
effect O
of O
alpha O
- O
tocopherol O
( O
alpha O
- O
tc O
) O
, O
a O
scavenger O
of O
reactive O
oxygen O
species O
, O
and O
deferoxamine O
( O
dfo O
) O
, O
an O
iron O
chelator O
, O
on O
the O
ma O
- O
induced O
neurotoxicity B-Disease
. O

alpha O
- O
tc O
and O
dfo O
attenuated O
the O
ma O
- O
induced O
hyperthermia B-Disease
as O
well O
as O
the O
alterations O
in O
the O
locomotor O
activity O
. O

this O
suggests O
that O
alpha O
- O
tc O
and O
dfo O
ameliorate O
the O
ma O
- O
induced O
neuronal B-Disease
damage I-Disease
by O
decreasing O
the O
level O
of O
oxidative O
stress O
. O

blockade O
of O
both O
d O
- O
1 O
and O
d O
- O
2 O
dopamine O
receptors O
may O
induce O
catalepsy B-Disease
in O
mice O
. O

the O
catalepsy B-Disease
induced O
by O
dopamine O
antagonists O
has O
been O
tested O
and O
the O
possible O
dopamine O
subtypes O
involved O
in O
catalepsy B-Disease
was O
determined O
. O

dopamine O
antagonist O
fluphenazine O
, O
d O
- O
1 O
antagonist O
sch O
23390 O
or O
d O
- O
2 O
antagonist O
sulpiride O
induced O
catalepsy B-Disease
. O

combination O
of O
sch O
23390 O
with O
sulpiride O
did O
not O
induce O
catalepsy B-Disease
potentiation O
. O

d O
- O
1 O
agonist O
skf O
38393 O
or O
d O
- O
2 O
agonist O
quinpirole O
decreased O
the O
catalepsy B-Disease
induced O
by O
fluphenazine O
, O
sch O
23390 O
or O
sulpiride O
. O

combination O
of O
skf O
38393 O
with O
quinpirole O
did O
not O
cause O
potentiated O
inhibitory O
effect O
on O
catalepsy B-Disease
induced O
by O
dopamine O
antagonists O
. O

the O
data O
may O
indicate O
that O
although O
d O
- O
2 O
receptor O
blockade O
is O
involved O
in O
catalepsy B-Disease
, O
the O
d O
- O
1 O
receptor O
may O
plan O
a O
role O
. O

sustained O
clinical O
improvement O
of O
a O
patient O
with O
decompensated O
hepatitis B-Disease
b I-Disease
virus O
- O
related O
cirrhosis B-Disease
after O
treatment O
with O
lamivudine O
monotherapy O
. O

hepatitis B-Disease
b I-Disease
virus I-Disease
( I-Disease
hbv I-Disease
) I-Disease
infection I-Disease
, O
which O
causes O
liver B-Disease
cirrhosis I-Disease
and O
hepatocellular B-Disease
carcinoma I-Disease
, O
remains O
a O
major O
health O
problem O
in O
asian O
countries O
. O

in O
this O
report O
, O
we O
encountered O
a O
patient O
with O
decompensated O
hbv O
- O
related O
cirrhosis B-Disease
who O
exhibited O
the O
dramatic O
improvements O
after O
antiviral O
therapy O
. O

the O
administration O
of O
lamivudine O
to O
patients O
with O
hbv O
- O
related O
cirrhosis B-Disease
, O
like O
our O
present O
case O
, O
should O
be O
considered O
as O
an O
initial O
medical O
therapeutic O
option O
, O
especially O
in O
countries O
where O
liver O
transB-Plantation O
is O
not O
reliably O
available O
. O

antiarrhythmic O
effects O
of O
optical O
isomers O
of O
cibenzoline O
on O
canine O
ventricular B-Disease
arrhythmias I-Disease
. O

antiarrhythmic O
effects O
of O
( O
+ O
) O
- O
cibenzoline O
and O
( O
- O
) O
- O
cibenzoline O
were O
examined O
using O
two O
canine O
ventricular B-Disease
arrhythmia I-Disease
models O
. O

digitalis O
arrhythmia B-Disease
, O
which O
is O
suppressed O
by O
na O
channel O
blockers O
, O
was O
induced O
by O
intermittent O
intravenous O
( O
i O
. O

v O
. O

) O
injection O
of O
ouabain O
in O
pentobarbital O
- O
anesthetized O
dogs O
. O

adrenaline B-Disease
arrhythmia I-Disease
, O
which O
is O
suppressed O
by O
ca O
channel O
blockers O
, O
was O
induced O
by O
adrenaline O
infusion O
in O
halothane O
- O
anesthetized O
dogs O
. O

ten O
and O
5 O
mg O
/ O
kg O
i O
. O

v O
. O

( O
+ O
) O
- O
cibenzoline O
suppressed O
digitalis O
- O
and O
adrenaline O
- O
induced O
arrhythmias B-Disease
, O
respectively O
. O

the O
minimum O
effective O
plasma O
concentrations O
of O
( O
+ O
) O
- O
cibenzoline O
for O
digitalis O
- O
and O
adrenaline O
- O
induced O
arrhythmias B-Disease
were O
1 O
. O

4 O
+ O
/ O
- O
0 O
. O

4 O
and O
2 O
. O

0 O
+ O
/ O
- O
0 O
. O

6 O
micrograms O
/ O
ml O
, O
respectively O
( O
mean O
+ O
/ O
- O
sd O
, O
n O
= O
6 O
) O
. O

a O
lower O
dose O
of O
1 O
mg O
/ O
kg O
i O
. O

v O
. O

of O
( O
- O
) O
- O
cibenzoline O
suppressed O
the O
digitalis O
- O
induced O
arrhythmia B-Disease
, O
whereas O
5 O
mg O
/ O
kg O
i O
. O

v O
. O

was O
needed O
to O
suppress O
adrenaline O
- O
induced O
arrhythmias B-Disease
. O

the O
minimum O
effective O
plasma O
concentrations O
of O
( O
- O
) O
- O
cibenzoline O
for O
digitalis O
- O
and O
adrenaline O
- O
induced O
arrhythmia B-Disease
were O
0 O
. O

6 O
+ O
/ O
- O
0 O
. O

4 O
and O
0 O
. O

7 O
+ O
/ O
- O
0 O
. O

1 O
micrograms O
/ O
ml O
, O
respectively O
( O
mean O
+ O
/ O
- O
sd O
, O
n O
= O
6 O
) O
. O

passage O
of O
mannitol O
into O
the O
brain O
around O
gliomas B-Disease
: O
a O
potential O
cause O
of O
rebound O
phenomenon O
. O

aim O
: O
widespread O
use O
of O
mannitol O
to O
reduce O
brain B-Disease
edema I-Disease
and O
lower O
elevated B-Disease
icp I-Disease
in O
brain B-Disease
tumor I-Disease
patients O
continues O
to O
be O
afflicted O
by O
the O
so O
- O
called O
rebound O
phenomenon O
. O

as O
a O
contribution O
to O
this O
issue O
we O
decided O
to O
research O
the O
possible O
passage O
of O
mannitol O
into O
the O
brain O
after O
administration O
to O
21 O
brain B-Disease
tumor I-Disease
patients O
. O

methods O
: O
mannitol O
( O
18 O
% O
solution O
; O
1 O
g O
/ O
kg O
) O
was O
administered O
as O
a O
bolus O
to O
patients O
( O
ten O
had O
malignant B-Disease
glioma I-Disease
, O
seven O
brain O
metastases B-Disease
and O
four O
meningioma B-Disease
) O
about O
30 O
minutes O
before O
craniotomy O
. O

during O
resection O
, O
a O
sample O
of O
the O
surrounding O
edematous B-Disease
white O
matter O
was O
taken O
at O
the O
same O
time O
as O
a O
10 O
ml O
venous O
blood O
sample O
. O

results O
: O
in O
most O
glioma B-Disease
patients O
, O
mannitol O
concentrations O
in O
white O
matter O
were O
2 O
to O
6 O
times O
higher O
than O
in O
plasma O
( O
mean O
3 O
. O

5 O
times O
) O
. O

in O
meningioma B-Disease
and O
metastases B-Disease
patients O
plasma O
concentrations O
of O
mannitol O
were O
higher O
than O
white O
matter O
concentrations O
except O
in O
three O
cases O
with O
infiltration O
by O
neoplastic O
cells O
. O

conclusions O
: O
the O
results O
of O
our O
study O
show O
that O
even O
after O
a O
single O
bolus O
, O
mannitol O
may O
leak O
through O
the O
altered O
bbb O
near O
gliomas B-Disease
, O
reversing O
the O
initial O
plasma O
- O
to O
- O
blood O
osmotic O
gradient O
, O
aggravating O
peritumoral O
edema B-Disease
and O
promoting O
rebound O
of O
icp O
. O

placebo O
- O
level O
incidence O
of O
extrapyramidal B-Disease
symptoms I-Disease
( O
eps B-Disease
) O
with O
quetiapine O
in O
controlled O
studies O
of O
patients O
with O
bipolar B-Disease
mania I-Disease
. O

objectives O
: O
to O
evaluate O
extrapyramidal B-Disease
symptoms I-Disease
( O
eps B-Disease
) O
, O
including O
akathisia B-Disease
, O
with O
quetiapine O
in O
patients O
with O
bipolar B-Disease
mania I-Disease
. O

extrapyramidal B-Disease
symptoms I-Disease
were O
evaluated O
using O
the O
simpson O
- O
angus O
scale O
( O
sas O
) O
, O
the O
barnes O
akathisia O
rating O
scale O
( O
bars O
) O
, O
adverse O
event O
reports O
and O
anticholinergic O
drug O
usage O
. O

results O
: O
the O
incidence O
of O
eps B-Disease
- O
related O
adverse O
events O
, O
including O
akathisia B-Disease
, O
was O
no O
different O
with O
quetiapine O
monotherapy O
( O
12 O
. O

9 O
% O
) O
than O
with O
placebo O
( O
13 O
. O

1 O
% O
) O
. O

similarly O
, O
eps B-Disease
- O
related O
adverse O
events O
with O
qtp O
+ O
li O
/ O
dvp O
( O
21 O
. O

4 O
% O
) O
were O
no O
different O
than O
with O
pbo O
+ O
li O
/ O
dvp O
( O
19 O
. O

2 O
% O
) O
. O

adverse O
events O
related O
to O
eps B-Disease
occurred O
in O
59 O
. O

6 O
% O
of O
patients O
treated O
with O
haloperidol O
( O
n O
= O
99 O
) O
monotherapy O
, O
whereas O
26 O
. O

5 O
% O
of O
patients O
treated O
with O
lithium O
( O
n O
= O
98 O
) O
monotherapy O
experienced O
adverse O
events O
related O
to O
eps B-Disease
. O

the O
incidence O
of O
akathisia B-Disease
was O
low O
and O
similar O
with O
quetiapine O
monotherapy O
( O
3 O
. O

3 O
% O
) O
and O
placebo O
( O
6 O
. O

1 O
% O
) O
, O
and O
with O
qtp O
+ O
li O
/ O
dvp O
( O
3 O
. O

6 O
% O
) O
and O
pbo O
+ O
li O
/ O
dvp O
( O
4 O
. O

9 O
% O
) O
. O

lithium O
was O
associated O
with O
a O
significantly O
higher O
incidence O
( O
p O
< O
0 O
. O

5 O
) O
of O
tremor B-Disease
( O
18 O
. O

4 O
% O
) O
than O
quetiapine O
( O
5 O
. O

6 O
% O
) O
; O
cerebellar O
tremor B-Disease
, O
which O
is O
a O
known O
adverse O
effect O
of O
lithium O
, O
may O
have O
contributed O
to O
the O
elevated O
rate O
of O
tremor B-Disease
in O
patients O
receiving O
lithium O
therapy O
. O

haloperidol O
induced O
a O
significantly O
higher O
incidence O
( O
p O
< O
0 O
. O

1 O
) O
of O
akathisia B-Disease
( O
33 O
. O

3 O
% O
versus O
5 O
. O

9 O
% O
) O
, O
tremor B-Disease
( O
30 O
. O

3 O
% O
versus O
7 O
. O

8 O
% O
) O
, O
and O
extrapyramidal B-Disease
syndrome I-Disease
( O
35 O
. O

4 O
% O
versus O
5 O
. O

9 O
% O
) O
than O
quetiapine O
. O

conclusions O
: O
in O
bipolar B-Disease
mania I-Disease
, O
the O
incidence O
of O
eps B-Disease
, O
including O
akathisia B-Disease
, O
with O
quetiapine O
therapy O
is O
similar O
to O
that O
with O
placebo O
. O

is O
phenytoin O
administration O
safe O
in O
a O
hypothermic B-Disease
child O
? O
a O
male O
neonate O
with O
a O
chiari B-Disease
malformation I-Disease
and O
a O
leaking O
myelomeningocoele O
underwent O
ventriculoperitoneal O
shunt O
insertion O
followed O
by O
repair O
of O
myelomeningocoele O
. O

during O
anaesthesia O
and O
surgery O
, O
he O
inadvertently O
became O
moderately O
hypothermic B-Disease
. O

intravenous O
phenytoin O
was O
administered O
during O
the O
later O
part O
of O
the O
surgery O
for O
seizure B-Disease
prophylaxis O
. O

following O
phenytoin O
administration O
, O
the O
patient O
developed O
acute O
severe O
bradycardia B-Disease
, O
refractory O
to O
atropine O
and O
adrenaline O
. O

the O
cardiac O
depressant O
actions O
of O
phenytoin O
and O
hypothermia B-Disease
can O
be O
additive O
. O

administration O
of O
phenytoin O
in O
the O
presence O
of O
hypothermia B-Disease
may O
lead O
to O
an O
adverse O
cardiac O
event O
in O
children O
. O

valproate O
- O
induced O
chorea B-Disease
and O
encephalopathy B-Disease
in O
atypical O
nonketotic B-Disease
hyperglycinemia I-Disease
. O

nonketotic B-Disease
hyperglycinemia I-Disease
is O
a O
disorder B-Disease
of I-Disease
amino I-Disease
acid I-Disease
metabolism I-Disease
in O
which O
a O
defect O
in O
the O
glycine O
cleavage O
system O
leads O
to O
an O
accumulation O
of O
glycine O
in O
the O
brain O
and O
other O
body O
compartments O
. O

in O
the O
classical O
form O
it O
presents O
as O
neonatal O
apnea B-Disease
, O
intractable O
seizures B-Disease
, O
and O
hypotonia B-Disease
, O
followed O
by O
significant O
psychomotor B-Disease
retardation I-Disease
. O

an O
important O
subset O
of O
children O
with O
nonketotic B-Disease
hyperglycinemia I-Disease
are O
atypical O
variants O
who O
present O
in O
a O
heterogeneous O
manner O
. O

this O
report O
describes O
a O
patient O
with O
mild O
language B-Disease
delay I-Disease
and O
mental B-Disease
retardation I-Disease
, O
who O
was O
found O
to O
have O
nonketotic B-Disease
hyperglycinemia I-Disease
following O
her O
presentation O
with O
acute O
encephalopathy B-Disease
and O
chorea B-Disease
shortly O
after O
initiation O
of O
valproate O
therapy O
. O

delayed O
institution O
of O
hypertension B-Disease
during O
focal O
cerebral B-Disease
ischemia I-Disease
: O
effect O
on O
brain B-Disease
edema I-Disease
. O

the O
effect O
of O
induced O
hypertension B-Disease
instituted O
after O
a O
2 O
- O
h O
delay O
following O
middle B-Disease
cerebral I-Disease
artery I-Disease
occlusion I-Disease
( O
mcao B-Disease
) O
on O
brain B-Disease
edema I-Disease
formation O
and O
histochemical O
injury O
was O
studied O
. O

under O
isoflurane O
anesthesia O
, O
the O
mca O
of O
14 O
spontaneously O
hypertensive B-Disease
rats O
was O
occluded O
. O

in O
the O
hypertensive B-Disease
group O
( O
n O
= O
7 O
) O
, O
the O
map O
was O
elevated O
by O
25 O
- O
30 O
mm O
hg O
beginning O
2 O
h O
after O
mcao B-Disease
. O

four O
hours O
after O
mcao B-Disease
, O
the O
rats O
were O
killed O
and O
the O
brains O
harvested O
. O

the O
brains O
were O
sectioned O
along O
coronal O
planes O
spanning O
the O
distribution O
of O
ischemia B-Disease
produced O
by O
mcao B-Disease
. O

specific O
gravity O
( O
sg O
) O
was O
determined O
in O
the O
subcortex O
and O
in O
two O
sites O
in O
the O
cortex O
( O
core O
and O
periphery O
of O
the O
ischemic B-Disease
territory O
) O
. O

the O
extent O
of O
neuronal B-Disease
injury I-Disease
was O
determined O
by O
2 O
, O
3 O
, O
5 O
- O
triphenyltetrazolium O
staining O
. O

in O
the O
ischemic B-Disease
core O
, O
there O
was O
no O
difference O
in O
sg O
in O
the O
subcortex O
and O
cortex O
in O
the O
two O
groups O
. O

in O
the O
periphery O
of O
the O
ischemic B-Disease
territory O
, O
sg O
in O
the O
cortex O
was O
greater O
( O
less O
edema B-Disease
accumulation O
) O
in O
the O
hypertensive B-Disease
group O
( O
1 O
. O

41 O
+ O
/ O
- O
0 O
. O

1 O
vs O
1 O
. O

39 O
+ O
/ O
- O
0 O
. O

1 O
, O
p O
less O
than O
0 O
. O

5 O
) O
. O

the O
area O
of O
histochemical O
injury O
( O
as O
a O
percent O
of O
the O
cross O
- O
sectional O
area O
of O
the O
hemisphere O
) O
was O
less O
in O
the O
hypertensive B-Disease
group O
( O
33 O
+ O
/ O
- O
3 O
% O
vs O
21 O
+ O
/ O
- O
2 O
% O
, O
p O
less O
than O
0 O
. O

5 O
) O
. O

the O
data O
indicate O
that O
phenylephrine O
- O
induced O
hypertension B-Disease
instituted O
2 O
h O
after O
mcao B-Disease
does O
not O
aggravate O
edema B-Disease
in O
the O
ischemic B-Disease
core O
, O
that O
it O
improves O
edema B-Disease
in O
the O
periphery O
of O
the O
ischemic B-Disease
territory O
, O
and O
that O
it O
reduces O
the O
area O
of O
histochemical O
neuronal B-Disease
dysfunction I-Disease
. O

behavioral O
measures O
included O
locomotion O
, O
irritability B-Disease
, O
copulation O
, O
partner O
preference O
, O
and O
aggression B-Disease
. O

animals O
were O
tested O
for O
aggression B-Disease
in O
their O
home O
cage O
, O
both O
with O
and O
without O
physical O
provocation O
( O
mild O
tail O
pinch O
) O
. O

chronic O
exposure O
to O
pcpa O
alone O
significantly O
decreased O
locomotor O
activity O
and O
increased O
irritability B-Disease
but O
had O
no O
effect O
on O
sexual O
behavior O
, O
partner O
preference O
, O
or O
aggression B-Disease
. O

t O
alone O
had O
no O
effect O
on O
locomotion O
, O
irritability B-Disease
, O
or O
sexual O
behavior O
but O
increased O
partner O
preference O
and O
aggression B-Disease
. O

based O
on O
these O
data O
, O
it O
can O
be O
speculated O
that O
pubertal O
aas O
users O
with O
low O
central O
5 O
- O
ht O
may O
be O
especially O
prone O
to O
exhibit O
aggressive B-Disease
behavior I-Disease
. O

earlier O
studies O
have O
demonstrated O
that O
antagonism O
of O
sigma1 O
receptors O
attenuates O
the O
convulsive B-Disease
, O
lethal O
, O
locomotor O
stimulatory O
and O
rewarding O
actions O
of O
cocaine O
in O
mice O
. O

in O
behavioral O
studies O
, O
pretreatment O
of O
swiss O
webster O
mice O
with O
umb24 O
or O
( O
+ O
/ O
- O
) O
- O
sm O
21 O
significantly O
attenuated O
cocaine O
- O
induced O
convulsions B-Disease
and O
locomotor O
activity O
, O
but O
not O
lethality O
. O

cardiac B-Disease
arrest I-Disease
in O
a O
child O
with O
cerebral B-Disease
palsy I-Disease
undergoing O
sevoflurane O
induction O
of O
anesthesia O
after O
preoperative O
clonidine O
. O

we O
present O
a O
case O
of O
a O
5 O
- O
year O
- O
old O
child O
with O
cerebral B-Disease
palsy I-Disease
and O
seizure B-Disease
disorder I-Disease
, O
receiving O
clonidine O
for O
restlessness B-Disease
, O
who O
presented O
for O
placement O
of O
a O
baclofen O
pump O
. O

without O
the O
knowledge O
of O
the O
medical O
personnel O
, O
the O
patient O
' O
s O
mother O
administered O
three O
doses O
of O
clonidine O
during O
the O
evening O
before O
and O
morning O
of O
surgery O
to O
reduce O
anxiety B-Disease
. O

during O
induction O
of O
anesthesia O
, O
the O
patient O
developed O
bradycardia B-Disease
and O
hypotension B-Disease
requiring O
cardiac O
resuscitation O
. O

there O
are O
no O
previous O
reports O
of O
clonidine O
- O
associated O
cardiac B-Disease
arrest I-Disease
in O
a O
child O
undergoing O
induction O
of O
anesthesia O
. O

angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
inhibitor O
- O
associated O
angioedema B-Disease
of O
the O
stomach O
and O
small O
intestine O
: O
a O
case O
report O
. O

this O
is O
a O
case O
report O
on O
a O
45 O
- O
year O
old O
african O
- O
american O
female O
with O
newly O
diagnosed O
hypertension B-Disease
, O
who O
was O
started O
on O
a O
combination O
pill O
of O
amlodipine O
/ O
benazapril O
10 O
/ O
5 O
mg O
. O

the O
very O
next O
day O
, O
she O
presented O
at O
the O
emergency O
room O
( O
er O
) O
with O
abdominal B-Disease
pain I-Disease
, O
nausea B-Disease
and O
vomiting B-Disease
. O

angiotensin O
- O
converting O
enzyme O
inhibitor O
( O
acei O
) O
- O
induced O
angioedema B-Disease
was O
suspected O
, O
and O
anti O
- O
hypertensive B-Disease
medications O
were O
discontinued O
. O

her O
symptoms O
improved O
within O
the O
next O
24 O
hours O
, O
and O
repeat O
ct O
after O
72 O
hours O
revealed O
marked O
improvement O
in O
stomach O
and O
small O
bowel O
thickening O
and O
resolution O
of O
ascites B-Disease
. O

the O
recognition O
of O
angiotensin O
- O
converting O
enzyme O
( O
ace O
) O
and O
angiotensin O
receptor O
blocker O
( O
arb O
) O
intestinal B-Disease
angioedema I-Disease
constitutes O
a O
challenge O
to O
primary O
care O
physicians O
, O
internists O
, O
emergency O
room O
personal O
and O
surgeons O
. O

carbamazepine O
- O
induced O
cardiac B-Disease
dysfunction I-Disease
. O

a O
patient O
with O
sinus O
bradycardia B-Disease
and O
atrioventricular B-Disease
block I-Disease
, O
induced O
by O
carbamazepine O
, O
prompted O
an O
extensive O
literature O
review O
of O
all O
previously O
reported O
cases O
. O

from O
the O
analysis O
of O
these O
cases O
, O
two O
distinct O
forms O
of O
carbamazepine O
- O
associated O
cardiac B-Disease
dysfunction I-Disease
emerged O
. O

one O
patient O
group O
developed O
sinus B-Disease
tachycardias I-Disease
in O
the O
setting O
of O
a O
massive O
carbamazepine O
overdose B-Disease
. O

the O
second O
group O
consisted O
almost O
exclusively O
of O
elderly O
women O
who O
developed O
potentially O
life O
- O
threatening O
bradyarrhythmias B-Disease
or O
atrioventricular B-Disease
conduction I-Disease
delay I-Disease
, O
associated O
with O
either O
therapeutic O
or O
modestly O
elevated O
carbamazepine O
serum O
levels O
. O

because O
carbamazepine O
is O
widely O
used O
in O
the O
treatment O
of O
many O
neurologic O
and O
psychiatric B-Disease
conditions O
, O
the O
recognition O
of O
the O
latter O
syndrome O
has O
important O
implications O
for O
the O
use O
of O
this O
drug O
in O
elderly O
patients O
. O

detection O
of O
abnormal O
cardiac O
adrenergic O
neuron O
activity O
in O
adriamycin O
- O
induced O
cardiomyopathy B-Disease
with O
iodine O
- O
125 O
- O
metaiodobenzylguanidine O
. O

using O
a O
rat O
model O
of O
adriamycin O
- O
induced O
cardiomyopathy B-Disease
, O
we O
tested O
the O
hypothesis O
that O
abnormal O
cardiac O
adrenergic O
neuron O
activity O
may O
appear O
and O
be O
exacerbated O
dose O
- O
dependently O
in O
adriamycin O
cardiomyopathy B-Disease
. O

the O
degree O
of O
vacuolar B-Disease
degeneration I-Disease
of I-Disease
myocardial I-Disease
cells I-Disease
was O
analyzed O
in O
relation O
to O
the O
duration O
of O
adriamycin O
treatment O
( O
2 O
mg O
/ O
kg O
, O
once O
a O
week O
) O
. O

the O
appearance O
of O
impaired O
cardiac O
adrenergic O
neuron O
activity O
in O
the O
presence O
of O
slight O
myocardial B-Disease
impairment I-Disease
( O
scattered O
or O
focal O
vacuolar B-Disease
degeneration I-Disease
) O
indicates O
that O
mibg O
scintigraphy O
may O
be O
a O
useful O
method O
for O
detection O
of O
adriamycin O
- O
induced O
cardiomyopathy B-Disease
. O

syncope B-Disease
and O
qt B-Disease
prolongation I-Disease
among O
patients O
treated O
with O
methadone O
for O
heroin O
dependence O
in O
the O
city O
of O
copenhagen O
. O

prolongation O
of O
the O
qt O
interval O
in O
the O
ecg O
of O
patients O
with O
torsade B-Disease
de I-Disease
pointes I-Disease
( O
tdp B-Disease
) O
has O
been O
reported O
in O
methadone O
users O
. O
